BSAVA
BRITISHSMALLANIMAL
BSAvAManual of
VETERINARYASSOCIATION
CanineandFeline
Oncology
third edition
Edited by
Jane M.Dobson
and B. Duncan X. Lascelles
小尾巴宠物健康中心http://ltahc.laobao.co m
Contents
Listofcontributors
V
Foreword
vi
Preface
viii
1
Introduction:cancerincatsanddogs
1
JaneM.Dobson
2
Howtomakeadiagnosis
6
TimothyJ.ScaseandJaneM.Dobson
3
Clinical stagingand theTNMclassification
20
JaneM.Dobson
4
Paraneoplasticsyndromes
30
RichardMellanby
5
Whentotreatanimalswithcancer
40
BernardE.Rollin
6
Principlesofoncologicalsurgery
44
KieriJermynandB.DuncanX.Lascelles
7
Principlesofchemotherapy
60
SusanE.LanaandJaneM.Dobson
8
Principlesofradiationtherapy
80
AmyF.PruittandDonaldE.Thrall
9
Therapiesofthefuture
91
StuartC.Helfand
10
Principlesofnutritionforthecancerpatient
102
KorinnE.Saker
11
Reliefofchroniccancerpain
111
BrianJ.TrumpatoriandB.DuncanX.Lascelles
12
Tumours ofskin and subcutaneoustissues
130
LauraBlackwood
13
Tumoursoftheskeletalsystem
159
WilliamS.Dernell
14
Softtissuesarcomas
178
NicholasBacon
15
Tumoursofthedigestivetract
a
Oraltumours
191
B.DuncanX.Lascelles
ili
b
Tumoursofthesalivaryglands
202
BrianJ.TrumpatoriandRichardA.S.White
C
Tumoursoftheoesophagus
206
BrianJ.TrumpatoriandRichardA.S.White
d
Tumoursofthestomach
209
JonathanBrayandRetoNeiger
e
Tumoursofthesmallintestines
212
B.DuncanX.LascellesandRichardA.S.White
f
Tumoursofthecolonandrectum
216
JonathanBray
g
Tumoursoftheperianalregion
223
JonathanBray
h
Tumoursoftheliver
229
JonathanBray
Tumoursoftheexocrinepancreas
235
BrianJ.Trumpatori andRetoNeiger
16
Tumoursof themammaryglands
237
HenrikvonEuler
17
Tumoursoftheurogenitalsystem
248
RobertN.WhiteandMalcolmJ.Brearley
18
Tumours of therespiratory system and thoracic cavity
265
B.DuncanX.LascellesandRobertN.White
19
Tumoursof the haemopoietic system and spleen
Tumoursofthehaemopoieticsystem
285
a
DavidM.Vail
b
Tumoursofthespleen
304
JaneM.Dobson
20
Endocrinetumours
309
J.CatharineR.Scott-Moncrieff
21
Tumoursofthenervoussystem
329
ChristopherMariani
22
Oculartumours
341
DavidGould
Index
354
Contributors
NicholasJ.BaconMA VetMBCertVRCertSASDiplomate ECVSDiplomateACVSMRCVS
Clinical AssistantProfessorinSurgical Oncology,Department ofSmallAnimal Clinical Sciences,
CollegeofVeterinaryMedicine,UniversityofFlorida,Gainesville,FL32610-0126,USA
Laura Blackwood BVMSPhDMVMCertVRDiplomate ECVIM-CA(Oncology)MRCVS
SeniorLecturerinOncology,SmallAnimalTeachingHospital,UniversityofLiverpool
LeahurstCampus,ChesterHighRoad,Neston,WirralCH647TE
JonathanBrayMVScMAcvScCertSASDiplomateECVSMRcvs
EuropeanandRCvSSpecialist inSmallAnimalSurgery
CentreforCompanionAnimalHealth,InstituteofVeterinary,AnimalandBiomedicalSciences，
MasseyUniversity,PalmerstonNorth4471,NewZealand
MalcolmJ.BrearleyMAVetMBMSc(ClinOnc)DiplomateECVIM-CA(Oncology)FRCVS
EuropeanandRcvSSpecialistinVeterinaryOncology
MadingleyRoad,CambridgeCB3OES
WilliamS.Dernell DVMMSDiplomateAcvs
WashingtonStateUniversity,POBox646610,Pulman,WA99164-6610,USA
DavidGouldBSc(Hons)BVM&SPhDDVOphthal DiplomateECVOMRCVS
RCVSandEuropeanVeterinarySpecialist inOphthalmology
Hitchin,HertsSG53HR
StuartC.HelfandDvMDiplomateACvIM(OncologyandSmallAnimal InternalMedicine)
Corvallis,OR97331,USA
KieriJermynBVScCertSASMRcVS
Sciences,NorthCarolineStateniversity,4700HillsboroughStreet,Raleigh,NC7606,A
SusanE.LanaDVMMSDiplomateAcVIM
AssociateProfessor,AnimalCancerCenter,DepartmentofClinicalSciences,
ColoradoStateUniversity,FortCollins,CO80523,USA
B.DuncanX.LascellesBScBVScPhDCertVADSAS(ST)DiplomateECVSDiplomateACVSMRCVS
ComparativePainResearchLaboratoryandSurgerySection,DepartmentofClinicalSciences,
CollegeofVeterinaryMedicine,NorthCarolinaStateUniversity，4700HillsboroughStreet
Raleigh,NC27606,USA
ChristopherL.MarianiDvMPhDDiplomateACviM(Neurology)
AssistantProfessorofNeurology,DepartmentofClinicalSciences,CollegeofVeterinaryMedicine，
4700HillsboroughStreet,NorthCarolinaStateUniversity,Raleigh,NC7606,USA
Richard MellanbyBSc(Hons) BVMSPhDDSAMDiplomateECVIM-CAMRCVS
TheRoyal(Dick)SchoolofVeterinaryStudies,TheUniversityofEdinburgh,EasterBush,
MidlothianEH259RG
RetoNeigerDrMedVetPhDDiplomateACVIMDiplomateECVIM-CA
KlinikfurKleintiere,Justus-LiebigUniversitatGiessen,FrankfurterStrasse126
35392Giessen,Germany
AmyF.PruittDVMPhDDiplomateACVR(RadiationOncology)
CollegeofVeterinaryMedicine,NorthCarolinaStateUniversity,4700HillsboroughStreet,Raleigh
NC27606,USA
Bernard E.Rollin
UniversityDistinguishedProfessor,ProfessorofPhilosophy,ProfessorofAnimalSciences,
ProfessorofBiomedicalSciences,UniversityBioethicist,DepartmentofPhilosophy,
ColoradoStateUniversity,FortCollins,CO80523-1781,USA
KorinnSakerDvMDiplomateAcvN
NorthCarolinaStateUniversity4700HillsboroughStreet,Raleigh,NC27606,UA
TimothyJ.ScaseBScBVM&SPhDDipACVPMRCVS
Director,BridgePathologyLtd,CourtyardHouse,26OakfieldRoad,Bristol BS82AT
J.CatharineR.Scott-MoncrieffMAVetMBMSDiplomateACVIM(SAInternal Medicine)DiplomateECVIM-CA
Professor,SmallAnimalInternalMedicine,SchoolofVeterinaryMedicine,PurdueUniversity
LynnHall,625HarrisonStreet,WestLafayette,IN47907-2026,USA
DonaldE.Thrall DVMPhDDiplomateACVR(Radiology,RadiationOncology)
Professor,DepartmentofMolecularBiomedicalSciences,CollegeofVeterinaryMedicine,North
CarolinaStateUniversity,4700HillsboroughStreet,Raleigh,NC7606,UA
BrianJ.TrumpatoriDvMDiplomateAcvs
VeterinarySpecialtyHospitalof theCarolinas,6405TryonRoad#100,Cary,NC27518,USA
DavidM.Vail DVMDiplomateACVIM(Oncology)
ProfessorofOncology,Director,CenterforClinicalTrialsandResearch,SchoolofVeterinaryMedicine
UniversityofWisconsin-Madison,2015LindenDrive,Madison,WI53706,USA
HenrikvonEulerDVMMScPhDDiplomateECVIM-CA(Oncology)
AssociateProfessor,SmallAnimalInternalMedicine,HeadofCenterofClinicalComparative
Oncology(C3O),DepartmentofClinicalSciences,SwedishUniversityofAgriculturalSciences
(SLU),POBox7054,75007Uppsala,Sweden
RichardA.S.WhiteBVetMedPhDDSASDVRDiplomateACVSDiplomateECVSFRCVS
VeterinaryOncology
DickWhiteReferrals,StationFarm,SixMileBottom,NewmarketCB8oUH
RobertN.WhiteBSc(Hons)BVetMed CertVADSAS(SoftTissue)DiplomateECVSMRCVS
RCVSSpecialistinSmallAnimalSoftTissueSurgery;EuropeanSpecialistinSmallAnimalSurgery
Foreword
Canceristheleadingcauseofdeathindogs(andlikelycats)inmost
countries.AsmanyastwooutofthreeGoldenRetrieversandformer
racingGreyhoundsintheUSdieofcancer.However,cancer,unlike
chronickidneyorheartdiseases,istheonlycommonchronicdisease
insmallanimalswhere arelativelyearly diagnosisfrequentlyleadsto
excellentqualityoflife.
Thisneweditionof theverywell knownandwidelyusedBSAVAManual
ofCanineandFelineOncologyisagreatcontributiontotheliterature,
providingeasy-to-understand,practitioner-orientedinformationin
aclearandconcisematter.Anall-starcastofseasonedclinicians
andinvestigators,leadbyDrsDobsonandLascelles,bothexcellent
clinicians,providesthelatestoncancerdiagnosisandtreatment,inan
informationiseasytofind.
Chaptersaresuccinct,yettheyprovidevaluableright-to-the-point
information,easilyappliedtotheclinicalcasethepractitionerisreading
about.
TheinclusionofchapterssuchasBernieRollin'sWhentotreatanimals
withcancerprovidesanextradimensionrarelyfoundinclinicallyoriented
books.Thechapteronpainmanagement,by two of themain authorities
inthefield,shouldbeoftremendousvaluetothepracticingveterinarian.
Inbrief,a'must-have'foranyveterinarystudentorpractitionerinterested
in small animal oncology.Practitionersfrequently inquire as towhat
isatthetopofmylist!
C.GuillermoCoutoDvMDiplomateACVIM
TheOhioStateUniversityVeterinaryMedicalCenter
vii
Preface
Inthis,thethirdeditionofthewellestablishedBSAVAManualofCanine
andFelineOncology,wehavesoughttomarrythebestoftheoldwith
thenew.Aselectionofnewinternationalauthoritiesinfieldsof oncology
haveupdated orrewrittenthemajorityof chapters,withaviewtomaking
thisneweditionevenmorepracticalanduser-friendlywhilstkeeping
thecontentattheforefrontofveterinaryoncology-reflectingsomeof
thesignificantadvancesinthisfieldoverthepast8years.
TheoveralllayoutoftheManualremainsthesame,andwillbefamiliar
tothosewhohavebeenusingthesecondeditionintheirpractice.
However,therapidlychangingfieldofveterinaryoncologydemands
thatthisManualreflectthedynamismofthesubjectandtheincreasing
interestinthesubjectinpractice.
The first few chapters(on making a diagnosis) havebeenrearranged
newtothisedition,wehaveincludedtheveryimportantdiscussionof
Whentotreat,includingdiscussionoftheinterplaybetweentherapy，
qualityoflifeandeuthanasiadecisions.Vitaltothesuccessofcancer
therapyaretheprinciplesofsurgery,chemotherapy,radiationtherapy,
and havebeenthoroughlyupdated andexpanded.
Therehasbeenasignificantamountofnewinformationproducedsince
thelasteditionregardingtreatmentmodalitiesforvarioustumours.
Accordingly,thechaptersdealingwithoncologyofvariousbodysystems
guidingthecliniciantothemosteffectivetherapies.Throughoutthe
Manualwehavetriedtoillustratethehaptersarefullywithappropria
and clinicallyusefultables,flowdiagrams,drawingsandimages.
Wehopeyoufindthisneweditionusefultoyouinyourworkin
mostrewardingofdisciplines.
JaneDobson
DuncanLascelles
October2010
vii
Introduction: cancer in cats
and dogs
Jane M.Dobson
Introduction
1.Geneticallyaltered cell
Canceris a majorhealth concernincatsanddogs.It
isestimatedthatoneinfourcatsanddogswilldie
fromcancerorcancer-relateddisease.
Acell withinanormalpopulation sustainsageneticmutationthat
Whatis cancer?
increasesitstendencytoproliferatewhenitwouldnormallyrest.
Cancer'isanumbrellatermthatdescribesaseem-
2.Hyperplasia
inglydiverserangeofconditions(Figure 1.1).
Term
Definition
LiterallyswellingTendstobeusedgenerically to
describe anymass and canbequalified asbenignor
malignant
Thealteredcellprliferatesitsprogenycontinuetolooknormalbut
Neoplasia
Literally'newgrowth'.Correctscientifictermforthe
pathological process of abnormal cell growth
alsoproliferate.Overtimeoneof thesecellssuffersanothermutation
which drivesfurtheruncontrolled cellgrowth.
Cancer
Refers tomalignant tumours orneoplasms
3.Dysplasia
Oncology
The studyof all of the above
1.1
Terms and definitions.
Featuresthattheseconditionshaveincommon
aretheuncontrolledgrowthandproliferationofhost
cells，oftentothedetrimentofthehostitself.Itis
occurringcancersarisefromthetransformationofa
Theprogenyof thiscellstartoappearabnormal inshapeandin
singleprecursororstem cell(Figure 1.2).Although
orientation.Overtimeanothermutationoccursthatalterscell
theeventsthatleadtothisneoplastictransformation
behaviour.
arenotfullyunderstood,it isknownthatthebasic
changeisrelatedtodisruptionofthenormalgenetic
4.In situ cancer
mechanismsthatcontrolcellgrowth/divisionand
cellulardifferentiation.Canceris thusagenetic
diseaseofsomaticcells.
Thekeyfeaturesofcancerareasfollows.
Cancercellproliferationisuncontrolledand
occursindependentlyoftherequirementfornew
cells.
Theprocessofcellulardifferentiationisimpaired
incancercells:theyareoften'immature'.
Theprogenyof themutatedcellbecome stillmore abnormal in
Twoclassesofgenes,whosenormal functionis
point thetumourhasnotbecomeinvasiveandisstillcontainedby
tocontrol theintricatesequenceofeventsbywhich
thebasementmembrane.
acellgrows and divides,play major roles in
1.2
triggering cancer:
Tumourdevelopment.(continues)
Chapter1
1Introduction:cancerincatsanddogs
5.Invasive cancer
Furthermutationsincludinglossof
adhesionfactors,allowthetumour
tobecomeinvasivethroughthe
basementmembrane and into
adjacent tissues.Invasionofblood
or lymphaticvesselsmayresult in
metastasis.
1.2
(continued)Tumourdevelopment.
Proto-oncogenes,whoseaberrantorexcessive
What causes these genetic
actionpromotesneoplasticgrowth,oftenby
changes?
drivingover-productionofgrowthfactorsor
causingover-stimulationofcellulargrowth
Although there are some germ line genetic abnor-
stimulatorypathways
malitiesthatconferanincreasedriskofcancer(see
Tumoursuppressorgenes,whosenormal
below),theaetiologyof mostcancersisprobably
actionpreventsproliferationofgenetically
multifactorial.S
Spontaneousgenetic abnormalities
damagedcells.Wheninactivatedbymutations
occurincellsthroughoutlife;inadditionthereare
thereisaresultinglossofsuppressorproteins
someexternalagentsthatmaydamageDNAand
andafailuretostopinappropriategrowth;and
lead togeneticmutations:
geneticallydamagedcellsareallowedtomultiply.
Viruses(e.g.retroviruses)
Alteredformsofotherclassesofgenesmaypar-
Radiation(e.g.therapeutic,diagnosticor
backgroundenvironmental)
ticipateincarcinogenesis,forexamplebyenablingthe
Ultraviolet light(e.g.skincancerrelated to
celltobecome invasiveorcapableofmetastasis.
Thus,thedevelopmentof cancerdependsnotona
sunburn)
Chemical carcinogens(e.g.aromatic amines,
singlegeneticmutationbutonaseriesofmutations
thataccumulateoveraperiodof time.Itisthoughtthat
azo dyes,alkylating agents).
at leastsixgeneticalterationsarenecessaryfordevel-
Heritablecancer
opmentof mostcancers(Hanahan and Weinberg,
Insomecasestheremayalsobeaninherited,genetic
2000).Asaresultof these mutations the cancercell
predispositiontosomecancers,whereanabnormal
acquiresthecapabilitiesoutlined inFigure1.3.
geneispresentinthegermline.Forexample:
Familialbreastcancerinwomenhasbeen
Acquired capability
Example of mechanism
associatedwithmutationsof thegenesBRCA1
Self-sufficiency in
Rasgenestransmit stimulatorysignalsfrom
(chromosome 17)and BRCA2(chromosome13).
growth signals
growthfactorreceptors;hyperactive,mutant
TheLi-Fraumenifamilieswithp53(a tumour
rasproteinsarefound inabout25%ofall
suppressorgene)mutationsareassociatedwith
humancancers
breastcancer,leukaemia,gliomas,adrenocortical
Insensitivity to
Evasionofactionsof transforminggrowth
carcinomas andsofttissuesarcomas.
anti-growth signals
factorbeta（TGF-β)asubstance thatcan
stopgrowth of normal cellsthrough
Whilstbreedpredispositionsforcancerindogs
inactivationofcellsurfacereceptorsorloss
arewelldocumented(seebelow),thegeneticbasis
of p15gene
forthesehasyet tobeelucidated.
Limitless potentialto
Activationof theenzymetelomeraseconfers
Inthemajorityofcancersasequenceofseveral
replicate
an immortal phenotype oncancercells
suchgeneticeventsorinteractions,oftenoccurring
Evasion of apoptosis
Inactivatingmutationsintumoursuppressor
overanumberofyears,maybenecessarybefore
neoplastictransformationoccursanda‘cancer
genes,e.g.p53
develops.
Sustained
Productionorinductionof vascular
angiogenesis
endothelial growth factor(VEGF)
Prevalenceofcancer
Tissue invasion and
Alteredbindingspecificitiesofcadherins
metastasis
cellularadhesionmolecules and integrins
ThehumanpopulationoftheUKisestimatedtobe
around60million,inwhichtherearearound289,000
1.3
Acquired capabilitiesof cancer cells.
newcasesofcancerdiagnosedeachyear(onenew
Chapter 1Introduction:cancer in cats and dogs
Mammarycarcinoma
Osteosarcoma
Lymphoma
Softissue sarcoma
Mastcelltumour
Adenoma
Lipoma
Key
Malignant
Histiocytoma
Benign
0
50
100
150
200
250
300
350
400
Standardized incidencerate(per100,000dogsperyear)
1.4
Incidenceofspecifictypesof canineneoplasia.
caseevery2minutes).AccordingtoCancer
Comparative aspects
ResearchUK,in2006intheUKtherewere154,162
cancer deaths,representing roughly one in four
Manyspontaneouslyoccurringcancersincatsand
(27%)ofall human deaths.Such is theimportance
dogssharesimilarcharacteristicsandbehaviourto
and impactofcancerinthehumanpopulation.
theirhumancounterpartsbuttheirnaturalhistoryis
Cancerisalsoanimportantdiseaseincompan-
shorter,duetoanimals'
shorterlifespans.
ionanimals:it isoneof themajorcausesofdeath
Companionanimalsmaybeconsideredassentinel
reported ininsured dogs（Bonnett et al.,1997;
species,sharingtheirenvironmentandlifestylewith
Michell,1999)and ingeriatriccats.Accuratefigures
their owners.It isinterestingto compare theinci-
fortheincidenceof tumoursincatsanddogsare
denceofhumancancerwiththatseenincompanion
hard tocomebybutastudyof insureddogsin the
animals,as there arebothsome striking similarities
UKshowedthatskinandsofttissueswerethemost
anddifferences.
commonsitesfortumourdevelopment,withastand-
Breastcanceristhemostcommonmalignancyin
ardizedannualincidencerateof1437per100,000
womenandthemammaryglandisacommonsite
dogs,followed bymammary,urogenital,lymphoid,
fortumourdevelopmentinbitches,thoughtheriskis
endocrine,alimentary and oropharyngeal sites.
reduced inbitchesspayedatayoungage,demon-
Caninecutaneoushistiocytomawasthemostcom-
strating the importanceofendogenoushormones
mon singletumourtype,followed bylipoma,aden-
inthe developmentof thisdisease.However,carcin-
oma,mast cell tumour,soft tissue sarcoma and
omasof theprostate,averycommoncondition in
lymphoma(Figure1.4)(Dobson et al.,2002).
menandalsoassociatedwithhormonal stimulation,
Veryfewepidemiologicalstudiesoftheinci-
arerelativelyrareindogsandoccurwithequalfre-
denceofcancerincatshavebeenpublished,but
quencyinentireandneuteredanimals.Carcinomas
clinicalobservationsuggeststhatthefrequencyof
ofthelungand large bowel,the most common
benignskinandsofttissuetumoursismuchlower
human tumours excluding breast and prostate，do
thanindogs.Lymphoidtumoursappeartobebyfar
notfeaturehighlyinthecanineorfelinepopulation，
themost common malignancy in cats,accounting
whereas soft tissue sarcomas,rareinhumans,are
fornearly30%ofalltumoursinonestudy,followed
relativelycommoninbothspecies.
by tumours of the skin(22%),mammarygland
Spontaneouscancersarealsogoodmodelsfor
(16%),connective tissue and alimentary system
humandiseaseintermsof therapy.Withcatsand
(Dorn et al.,1968).
dogs,theirbodysize ismoreakinto thatofhumans
In theabsenceofreliabletumourregistries,it is
thanthatofmiceorrats,andtheirshorterlifespan
difficulttoknowwhethertheprevalenceofcancerin
meansthattherapeutictrialsmaybeconductedand
dogsandcatsis actuallyincreasing,buta numberof
completedinamuchshortertimeframe thanispos-
factorsmaycontributetoanincrease inthediagnosis
sible inhumanpatients.Animalsbearing spontane-
ofcancerincatsand dogs.Asaresultof improve-
ouslyoccurringneoplasms are thus apotential
ments inhealthandwelfare,animalsareliving longer
ology,pathogenesis and genetics,and alsorepre-
Advancesinveterinarymedicine,particularlydiagnos-
sentpotential modelsfortherapeutictrails.
ticsandhigherexpectationsof thepet-owningpublic,
Indogsthereareseveralgoodmodelsof
arelikelytoresult in anincreasedrateofdiagnosis.
predictablemetastaticdisease:
3
chapter1Introduction:cancerin catsand dogs
Osteosarcomainlarge-breeddogs:with
Farlessispublishedaboutbreedpredilectionsin
amputation alone,average survival timeis36
cats.Siamesecatsappeartohaveapredilectionfor
months;failure'is duetodevelopment of
lymphoma.Early-onset mediastinal lymphoma has
pulmonarymetastaticdisease in90%ofpatients
beenreportedinFeLV-negativeSiamese-type
Oralmalignantmelanoma,anaggressiveand
breeds,suggestingapossiblegeneticpredisposition
highlymetastaticdisease:theprimarytumour
to thiscondition.Siamesecatshavebeenreported
maybecontrolledbysurgery/radiotherapy,giving
torespondmorefavourablythanotherbreedsto
averagesurvivaltimesintheorderof6months,
chemotherapeutictreatmentoflymphoma（Teskeet
withfailureduetometastasis
al.,2002).
Splenichaemangiosarcoma:following
splenectomy,averagesurvivaltimesarelessthan
6months,duetodevelopmentofmetastases.
Treatmentofcancer
Incatsthemajorityoforalandpharyngeal
Thelast20yearshaveseenmanychangesinthe
tumoursaresquamouscellcarcinomaandsimilarto
attitude and approach of thepet-owningpublic and
humanhead-and-neck cancers.These tumours
oftheveterinaryprofessiontothediagnosisand
respondpoorly toconventional therapy(especially
treatmentof cancerincatsanddogs,withtheresult
whenlingual)andintheabsenceofaneffective
thatthedemandforbothbasicandspecialisttreat-
meansoftherapythesefelinepatientswouldbe
mentofanimalswithcancerhascontinually
idealcandidatesfornewapproaches.
increased.However,whileknowledgeofthebasic
diseaseprocesshasadvancedhugelyinthepast
twodecades,thishasyet tomakeamajorimpacton
Breedpredilections
theclinicalmanagementofcancerinpetanimals.
Thus surgery,radiotherapy and chemotherapy
Indogsitiswellrecognizedthatdifferencesexist
remainforthetimebeingthemainweaponsinthe
betweendifferentbreedsregardingtheirriskof
fightagainstcancer.
developingcertaintypesofcancer,buttherearefew
Surgeryisand
remainsthemosteffective
large-scaleepidemiologicalstudiesontheincidence
methodoftreatmentformany'solid'tumourssuchas
ofdifferenttypesofcancerinthecaninepopulation
mast cell tumours,low-grade sarcomasandlow-
anditsvariationbetweenbreeds.Inastudyofrates
gradecarcinomas.Thedevelopmentofsurgical
andcausesof deathininsureddogsinSweden，
techniquestoallowadequatemarginsofexcisionfor
Bonnettet al.(1997)found that the Bernese
suchtumourscanfrequentlyresultinsurgicalcure.
MountainDog,！
Irish
Wolfhound,Flat-coated
Theincreasingavailabilityofradiotherapyfacili-
Retriever,BoxerandStBernardwerethefivebreeds
ties,firstlyinNorthAmericaandthenintheUKand
withthehighestmortalityfromtumour-relateddeath.
Europe,hasled toanincreasing applicationof radi-
In Denmark,Bernese Mountain Dog,Flat-coated
ation,eitherasaprimary treatmentforbrainand
Retriever,GoldenRetrieverandRottweilerwerethe
nasal tumours,for example,or in conjunctionwith
topfourbreeds,withover20%of deathsduetocan-
surgeryforthemoreinvasivemastcelltumours
cer(Proschowskyetal.,2003).
andsarcomas
Thesepopulation-basedstudiesprovideuseful
Chemotherapyremainsthetreatmentofchoice
indicatorstobreedsatriskofcancer,butshouldnot
forsystemicdiseases,particularlylymphoma,andis
beregardedascompletelydefinitive.Theoutcome
increasinglyusedasanadjuncttosurgeryforthose
oftendependsonthestructureofthepopulation at
tumourswithahighriskofmetastasis.Withthe
riskwithrespecttobreed,whichexplainsthediffer-
exceptionofosteosarcoma,however,thelatterindi-
encesfound instudiesfromdifferentcountries.
cationhasyettobevalidatedbycleardemonstration
However,thefactthatthereareundoubtedlybreed-
ofefficacyincontrolledclinical trials.
relatedpredispositionstodevelopmentofcancer
hasimportantimplicationsinunderstanding the aeti-
ologyof cancer,asit suggestsapossiblegenetic，
Future directions
heritablecomponent.
Somebreedsofdoghavebeenassociatedwith
New technologyishaving animpactontheveteri-
specifictypesof tumour,suchasBerneseMountain
naryapproachto thecancerpatient.Intermsof
Dog(systemicand malignanthistiocytosis)andIrish
diagnostics,the use of monoclonal antibodies to
Wolfhound (osteosarcoma);others,such as Boxer,
immunophenotypetumourssuchaslymphoma and
GoldenRetrieverandRottweiler,areassociatedwith
leukaemiahasbeenshowntobeofprognostic
ahigherriskof tumoursingeneral.Thisobservation
value,andimmunocytochemistryhasbecomemore
alsohasimportant geneticimplications,suggesting
widelyused inthediagnosisandclassificationofthis
thatthesituationinsomebreedsmaybelikethe
andotherformsofcancer.Increasedavailabilityof
rarehumanLi-Fraumenisyndromewhereagerm
advancedimagingtechniquessuchasadvanced
linemutation ina tumour suppressor gene(p53)
resultsinahereditarypredispositiontocertainforms
neticresonanceimagingisstarting torevolutionize
ofcancer（TaboriandMalkin,2008);whereasother
theabilitytodetectanddeterminethetrueextentof
breedsmayhaveamorespecificgeneticabnormal-
some tumours,allowingbetterplanning forsurgical
ityleadingtoaparticulartypeoftumour.
approaches andradiotherapy.
chapter1Introduction:cancerincats and dogs
Somenovelmethodsoftreatmenthavebecome
somecarryingradiopharmaceuticals,areindevelop-
available.For example,photodynamic therapyis
ment fortreatmentofB-cellymphoma.
beingusedforthetreatmentofsuperficialsquamous
Whilstthereismuchtobelearntfromcompara-
cellcarcinomasandotherheadandnecktumours.A
tiveoncology,theseadvancescannotbedirectly
novelimmunesystemmodulator,imiquimod,which
translatedintoveterinarymedicine.Forrational
possessesbothantiviralandanti-tumouractivity,has
applicationofsuchtargetedcytostatictreatmentsin
beenusedwithvariabledegreesofsuccess
in
veterinarycancermedicinethetargetsneedtobe
humanpatients withcutaneous tumours,including
defined,andsoresearchisrequiredtodetermine
basalandsquamouscellcarcinomaandepithelio-
whichcellsurfacereceptorsareexpressedindiffer-
trophiclymphoma,andhasalsobeenused inveteri-
enttumoursandwhatsignallingpathwaysarefunc-
narypractice.
tionalordysfunctional intheneoplasticcells.Work
Inrecentyearsmuchmoretargetedmethodsof
alreadyinprogressintheseareasoffersapromising
cancertherapyhavemetwithsuccessinhuman
startto anexcitingfuture.
medicine,such as the smallmolecule tyrosine
kinase inhibitor imatinib(Gleevec,Novartis),which
targetscellswithactivatingmutationsinKITfortreat-
Referencesandfurtherreading
mentofchronicmyeloidleukaemiaandgastrointesti-
nalstromal tumours(GiSTs).Ithasbeen shown that
BonnettBNEgenvallA,OlsonPandHedhammarA（1997）Mortalityin
20-30%ofcaninemastcell tumourshavemutations
insuredSwedishdogs:ratesandcausesofdeathinvarious
breeds.VeterinaryRecord141,40-44
inthejuxtamembraneregionofc-kit,implicatingKIT
Dobson JM,Samuel S,Milstein H,RogersKand Wood JLN(2002)
tyrosinekinaseinthepathogenesisof
fthese
Canineneoplasiain theUK:estimatesofincidenceratesfroma
populationof insureddogs.Journal of SmallAnimalPractice43
tumours.Tyrosinekinase inhibitorshavebeenshown
240-246
tohavesomeefficacyinthetreatmentofnon-resect-
Dorn CR,TaylorDO,Schneider,HibbardHHandKlauberMR（1968）
ablemast celltumours in dogs(Londonet al.,2003;
Surveyofanimal neoplasms inAlameda and Contra Costa
counties,California.ll.Cancer morbidityin dogs and catsfrom
Hahn et al.,2008)and twosuchagents-masitinib
AlamedaCounty.Journalof theNationalCancerInstitute40,307-
(Masivet,AB Science)and toceranib phosphate
318
(Palladia,Pfizer)-haverecentlybeenauthorized for
HanahanD and Weinberg RA(200o)The hallmarks of cancer.Cell100,
treatmentofcaninemastcelltumours.
57-70
HahnKA,Oglivie G,DevauchellePetal.(2008）Masitinib is safeand
Specificgrowthfactorreceptors
areanother
effectiveforthetreatmentofcaninemastcelltumours.Journalof
VeterinaryInternalMedicine22,1301-1309
London C,Hannah AL,Zadovoskaya R et al.(2003） Phase Idose
Theantibodytargetingthehumanepidermalgrowth
escalating studyof Su11654,asmallmoleculereceptortyrosine
factor receptor (HER-2),“Herceptin',has proven to
kinase inhibitor,indogswith spontaneousmalignancies.Clinical
beeffectiveinthetreatmentofHER-2-positive
CancerResearch9,2755-2768
Michell AR（1999)Longevity of British breedsof dog and its
breastcancer.Antibodieshavealsobeendeveloped
relationshipswith sex,size,
cardiovascularvariablesanddisease.
totargetotherreceptorsinvolvedwithcellsignalling:
VeterinaryRecord145,625-629
CD20isatransmembraneproteinthatregulates
Proschowsky HF,Rugbjerg H and Ersboll AK (2003) Morbidity of
purebreddogsinDenmark.PreventiveVeterinaryMedicine5853-
earlystepsintheactivationofcellcycleinitiationand
62
differentiation.The antigen is expressed onmost
TaboriUandMalkinD（2008）Riskstratificationincancerpredisposition
B-cell non-Hodgkin'slymphomasbut isnotfound on
syndromes:lessonslearned fromnovelmoleculardevelopmentsin
Li-Fraumenisyndrome.CancerResearch68,2053-2057
stemcells,pro-Bcells,normalplasma cellsorother
Teske E,van Straten G,van Noort R and Rutteman GR （2002)
normal tissues.Rituximab,ananti-humanCD20 anti-
Chemotherapy
with
cyclophosphamide，
vincristineand
prednisolone(CoP)incatswithmalignant lymphoma:newresults
body,isapprovedfortreatmentofB-celllymphoma
withanoldprotocol.JournalofVeterinaryInternalMedicine16.
inadults.Furtherhumanizedanti-CD20antibodies,
179-186
5
How to make a diagnosis
TimothyJ.Scaseand JaneM.Dobson
Introduction
Cytology
Obtaininganaccuratepathologicaldiagnosisisan
Cytologicalexaminationoftissuesamplesisaquick
essentialrequirementforoptimizing thetreatment
andsimpletechnique,requiringaminimumofequip-
oftheindividualcancerpatientandforprovidingthe
ment,thatcaneasilybeperformed inthegeneral
clientwithanassessmentoflikelycancerbehaviour
practicesetting.Manycommercialclinicalpathology
andlikelyprognosis.Anaccuratediagnosisprovides
laboratorieswillreportoncytologicalsamplesand,
arationalstartingpointforselecting thebesttreat-
withpractice,mostveterinary surgeons shouldbe
mentforthecancerpatient.Withoutanaccurate
abletousecytologytodiscriminatebetweenreactive
pathological diagnosis,thecliniciancanonlyrelyon
andneoplasticlesionsandeventodiagnosesome
empiricalevidencetodecidehowbesttotreatthe
particularlycharacteristictumours,suchasMCTs.
patient.Atthemostbasiclevel,differentiationofneo
Fine-needleaspiratesorimpressionsmearsfrom
plasiafromnon-neoplasticdiseaseislikelytogreatly
solidtumoursandthecytologicalexaminationofthe
increasethechanceoftherapysuccess.
cellularcontentoffluidscollectedfromorgansorbody
Withtheincreasingsophisticationoftechniques
cavitiescanprovideagreatdealofinformationabout
availabletothediagnosticpathologist,thereismuch
thelesionandinmostcaseswillenabledifferentiation
greaterpotentialforobtaininganaccuratediagnosis
betweeninflammatoryandneoplasticprocesses.In
fromsubmittedtissuesamples.lt isalsoexpectedthat,
thehandsofanexperiencedclinicalpathologist,itcan
withtherefinementofdiagnostictechniques,method-
beahighlyrewardingdiagnostictechniquethatcan
ologiesandclassificationschemes,therequirementto
obtainanaccurateandhighlyspecificdiagnosisfor
sequent diagnosticor therapeuticdecision（Figure
treatmentandprognosiswillincreasein thefuture.
2.1).In inexperienced hands,however,orif the sam-
Thischapterdiscussestheoptimumstrategies
plesaretakenusingpoortechniqueorhandled in-
pretapathologyreportandwhattoexpectfromthe
atworst,misleadingandresult inthewrongdiagnos-
pathologistintermsofdiagnosticquality,margin
ticortherapeuticchoicesbeingmade.
examinationandspecialstains.Allofthesefactors
canincreaseordecreasethelikelihoodofachieving
thetruepathologicaldiagnosis，andfromtherethe
Cellpopulation
morelikelyitisthatrationaltherapiescanbechosen.
Choosing thecorrectbiopsymodalityforanypar-
ticulartumourtypecanpresentachallengetothe
clinicianwhentryingtooptimizethecost/benefitratio
Onecell type
Multiple cell
of theextentofanyinvestigationsintothetumour
predominates
typespresent
priorto treatment.In some cases,ifanexcisional
biopsyischosenastheprimarydiagnosticmodality
andifabenigntumourhasbeenexcisedwithcom-
Inflammatoryor
plete tumour-free surgical margins,the diagnostic
reactivetissue
andtreatmentmodalityhavebeenthesameandno
moneywill havebeenused inthediagnosticwork-up
of thecase.However,if histopathologyshowsamast
celltumour(MCT)or soft tissue sarcoma thathas
Spindle
Round
been incompletelyremoved,the best chanceof
Epithelial
cells
cells
surgical cure hasbeen lost.Thus inmany casesthe
clinicianwillwishtohavesomeideaastowhat
tumourtypetheyaredealingwithpriortofurther
biopsy or treatment.In many cases,choosing an
Applycriteriaformalignancy
aspirateorsmearasthefirstdiagnosticprocedure
willenablerationaldecisionmakingforchoosingthe
2.1
Decision treeforcytological diagnosis.
subsequentdiagnosticmodality.
6
Chapter2Howtomakeadiagnosis
Themorphologyofneoplasticcellswillalsooften
Cytologycannotbeusedto'grade'mosttumours,
provideanindicationofthelikelynatureofatumour
asgradingislargelydependentonconsideration
and its degreeof malignancy(Figures2.2and 2.3).
oftherelationshipoftheneoplasticcellswiththe
surroundingnormaltissues,andotherfactorssuch
Cytological features
asthemitoticrate,thedegreeof inflammationand
necrosis,allofwhichcanbedifficultorimpossible
Cell population
Pleomorphism
toassessoncytologicalexaminationalone
Presence of mitoses,especially abnormal or
Sometumours,suchasmammarytumours,have
bizarreforms
averycomplexarchitectureandexaminationof
Cellular features
Largecellsize/giant cells(anisocytosis)
histological tissuesectionsisrequiredtomakea
Poorlyientatdnastil
diagnosis.Inthesecases,cytologyismuchless
High nuclear to cytoplasmicratio
useful,asit maynotbeabletodistinguish
Nuclearfeatures
Largenuclearsizenuclearpleomorphism
betweendifferentmammarytumourtypes
(anisokaryosis)
(Figures2.4and 2.5).
Multiplenuclei(oftenof variable size)
Hyperchromaticnuclei with clumpingor
stippling of chromatin
Prominent andoftenmultiplenucleoliof
variable size and shape
Histological features
Cellularfeatures
Asabove
Tumour architecture
Lackofstructuralorganizationofcellsinto
recognizableform
Relationship with
Invasionof cellsintoadjacent normal tissues
adjacent tissues
Evidenceof
Tumourcellsinvading orpresent within
metastaticbehaviour
lymphaticsorvenules
2.2
Cytological andhistological featuresof
malignancy.(Adapted fromMorris andDobson,
2001,withpermissionof thepublisher)
(b)
2.4
Mastcelltumour.(a) Histological sectionfroma
welldifferentiatedMCT,showinghomogenous
sheetsof mastcells;tumourarchitectureisnotimportant
indiagnosis.（H&E,X20objective)（b)Afine-needle
aspiratefromsuchatumourislikelytoyieldasimilar
populationof tumourcells.(Giemsa,X40objective)
2.3
Criteria formalignancy:aclusterofcellsfrom
anaspirate of aprostaticcarcinoma.Thecells
are displaying marked anisocytosis and anisokaryosis.In
somecellsthenucleartocytoplasmicratioisincreased.
There arebi-and evenmultinucleated cells.Thenuclei
containprominent,oftenmultiple,nucleoli.(Modified
Wright'sstain,original magnificationX1000)
techniqueintheinvestigationofneoplasia,butit is
importanttobeawareofitslimitations:
Cytologyoftenwill notprovideadefinitivetumour
diagnosis.Forinstance,insomesolidtumours,
neoplasticcellsmaynotexfoliatesufficientlyto
2.5
Incontrast toFigure2.4,thishistological section
provideenoughcellsfordiagnosis.Thismay
fromamixedmammarytumourshowsthe
occurwithanytumoursthatproduce
architecturalarrangementof thecells,forminglobulesand
considerablestromalcomponents,suchasa
ducts.Thisis an important aspect of diagnosis and cannot
fibromaorosteoma
berepresentedcytologically.(Giemsa,X20objective)
7
Chapter2Howtomakeadiagnosis
Cytologytechniques
Thismightbeparticularlyimportantwherethe
fluid-filledstructureisclosetoajointorbody
Impressionsmears
cavity(forinstance,aspirationofaperinealmass
Impressionsmearscanbeperformedwiththemass
thatcouldrepresentaperinealhernia),where
insitu,orusingbiopsyspecimensfrom themass.
thereisapossibilityofcommunicationbetween
1.Pat thecleanlyincisedsurfacedrywithgauze
themassandabodycavity.
(sterilitydependentonwhethertheimpression
2.Prepare a needle(20-25G,starting with 1-inch
smearistakeninsituornot)toremoveexcess
23G)and syringe(5-10ml).Insert the needle
blood that would otherwiseswamp thecytology
intothemassandrepositionusingastabbing
preparation.
actionthreetofivetimes.Thiscanbedoneeither
2.Daba cleanglassslide onto thecutsurfaceif the
withnegativepressuregeneratedbypullingback
massisinsitu,ordabthecutfaceofasampleon
onthesyringeplunger,orwithnonegative
toa slide(Figure2.6),and allowto air dry.
pressure.Insome cases,excessive negative
pressureontheaspiratedcellscanresultincell
of thesample.
2.6
Making animpression smear.
Toincreasethelikelihoodofadiagnosticprepa-
rationbeingachieved,multipleslidesshouldbepre-
pared.Multipleimpressions canbeplacedona
(a)
singleslideif thesurfaceareaof thetissueissmall.
Performingimpressionsmearsfromthetissue in-
housepriortosubmissionofabiopsyforhistological
examinationcanberewardingforthepractitioner,as
itenablesdirectcorrelationofthein-housecytologi-
caldiagnosiswiththefinalhistologicaldiagnosisand
allowsthepractitionertopitthemselvesagainstthe
pathologist.
Fine-needleaspiration
Fine-needle aspiration(FNA;Figure2.7) is the cyto-
(b)
logicaltechniqueofchoiceforthosesituationswhere
aprovisionaldiagnosisisrequiredpriortoincisional/
excisionalbiopsyorwhereanaspiratecanbe
obtainedviaimaging-guidedtechniquesratherthan
requiring surgical intervention,suchaswhensam-
plinganintra-abdominalmassusingultrasound
guidance.FNAisfrequentlyusedfordiagnosisand
stagingof lymphoma,as theneoplasticcellsexfoli-
atewellanditisusuallydiagnosticwithoutresorting
tomoreinvasivesurgical biopsytechniques.
1.Preparethe skin.Inmost cases,theskin doesnot
furwithalcohol.InthosecaseswheretheFNA
samplemightbecultured,itisgoodpracticeto
(c)
clipandpreparetheskinasforasurgicalbiopsy,
2.7
FNA techniquefora subcutaneousnodule.
inordertoreducethepossibilityofcontaminating
(a)Thelesionislocatedandheldfirmlywhile
thesamplewithcutaneousmicroorganisms.In
theneedleisinserted.(b)Anair-filledsyringe is
somecases,wherea fluctuantmassisbeing
connectedtothehubof theneedleand thecontents
blown ontoa clean glass slide.(c)Asecondcleanglass
aspirated,itissimilarlyprudenttopreparethe
slideisplacedgentlyontopof thesample,allowing the
skinfurtherinordertoreducethechanceof
filmtospreadbetweentheslideswhicharethengently
contaminationof thefluidwithinthemass/cavity.
drawnapart.Seetextforfull details.
8
Chapter2Howtomakeadiagnosis
3.Release anypressureonthe syringeplungerand
withdrawtheneedleandattachedsyringefrom
thepatient.Detachthesyringefromtheneedle
hub(anyaspirated cellswill beinthehub/
needle).Airisdrawn intothesyringe.Reattach
thesyringetotheneedlehub.
4.Placea clean slide onahorizontal surface,and
presstheplungerdownfirmlytoexpelthe
needle/needle-hubcontentsontothe slide.A
singleFNAmaybeenoughtomaketwoorthree
slidepreparations.
5.Tomake thesmears,and toprevent the
preparationbeingtoothicktoexamine
microscopically,placeasecondcleanslideat
rightanglesontopofthefirstandsmoothlyand
gentlysmearouttotheedge.Noextrapressure
2.9
Cytospinpreparationofpleural fluid froma cat
shouldbeexertedontheslidebeyondthat
withamediastinal mass.(Giemsa,X100
requiredtomoveitovertheslidebeneath.
objective)
Excessivepressurewillresult inextensive
ruptureoftheaspiratedcellsandrenderthe
Bonemarrowsampling
preparationimpossible tointerpret(Figure 2.8).
6.
Thesmearsarethenairdriedpriortosubmission
Aspiration:Specializedneedleswithstyletstopre-
or in-house staining.
ventcorticalboneblocking theendof theneedleare
required forbonemarrow aspiration.TheKlima
needle（Figure2.10)isoneexamplebutothertypes
(e.g.Jamshidi;seeFigure2.13)and disposablever-
sionsare available.
2.8
Poorsmearing technique:thestringyblue
streaksreflectDNAmaterial fromrupturedcells.
2.10
Klimaneedleforbonemarrowaspiration.
(ModifiedWright'sstain,originalmagnificationX400)
(CourtesyofClinicalPathologyLaboratory,Departmentof
Inthedog,bonemarrowcanbecollected from
VeterinaryMedicine,UniversityofCambridge)
anyofthelargerlongbones,thepelvisortheribs.
Differentclinicianshave theirpreferredapproaches:
Cytospinsofbodyfluids/effusions
thedorsalwingoftheileumisaneasysitetosample
Foranybodycavity,orindeedanyfluid-filledmass,
provided thepatientisnotoverweight(Figure2.11);
cytologicalexaminationofcellsexfoliatingintothe
otherpeoplepreferthecranialaspectoftheproximal
fluidmayenableadiagnosistobemadeandinpar-
humerus.Inthecatthefemurisusuallythepreferred
ticularmayprovideevidenceforthepresenceor
siteandtheprocedureisoftenperformedunder
absenceofaneoplasticprocess.Asthecellsare
general anaesthetic.
oftenpresentatlowdensitywithinthefluid,acon-
centrating techniqueisusuallyrequiredinorder to
1.In thedog:withthepatientsedated andlocal
provideenoughcellsonaslidetomakeaconfident
anaestheticinfiltrated intothesurroundingskin,
diagnosis.Thisismosteasilyachievedbyusinga
muscleandperiosteum,inserttheKlimaneedle
cytospinmachine-aspecializedcentrifugewhere
(withstyletinplace)intothedorsalwingof the
oneormoredropsofthefluidareplaced inaholder
iliaccrest using a twisting action(Figure 2.12.a).
attached toaglassslide,and the cells areprecipi-
2.
Oncetheneedleisdeeplyseatedwithinthe
tatedontotheslidebythespinningof thecentrifuge
bone,removethestylet,connecta10mlsyringe
arm.Oncethearmhasstopped spinning,theslideis
and applysuction,resultinginasampleofbone
detachedandlefttoairdryandthecytospinprepar-
marrowbubblinginto thesyringe(Figure2.12b).
ation is stained routinely(Figure2.9).In most cases
3.
Withdrawthesyringeandneedlefromtheboneas
cytospinpreparationswillbeperformedatadiag-
oneunit and applydropsofbonemarrowto5-10
nosticlaboratoryratherthaninapracticelaboratory.
cleanglassslidespositionedatabout45degrees
9
Chapter2Howtomakeadiagnosis
smearismade(somepeopleadvocateuseof
anticoagulants,e.g.ACD,inthe syringepriorto
suction,butintheauthors'experience tiltingthe
slidesallowsexcessbloodtorunoff,thus
preventinghaemodilutionofthesample,and
promptandadeptsmearinggivesgoodresults).
Thesampleisthenairdriedandsenttothe
laboratoryforfixationandstaining.
Biopsy:Thesameapproachandpositioningmay
beusedwithaJamshidineedle（Figure2.13)to
collectacoreofbonemarrow.Thiswillrequirefixa-
tioninformalinandprocessingbystandardhisto-
logical methods.
2.11
Bone marrowsampling sites.(1)The dorsal
wingof theiliaccrestisoneof themost
common sites used inmedium to largedogs.(2)The
femurmaybesampledviathetrochantericfossa(dog
andcat,anaesthesia required).(3)The caudal ischium
2.13
maybemoreeasilylocatedinoverweightdogs.
Jamshidibiopsyneedle.
Submissionofcytologicalspecimens
It isimperativethatcytologicalspecimens,inparticu-
larsmears,donotcomeintocontactwithformalin
fumes.Exposuretoformalinmarkedlydecreasesthe
intensity and microscopic appearance of standard
cytologicalstains,rendering examination of the
smearsalmostimpossible.Thisismostlyaproblem
whencytologicalpreparationsandhistologicalspeci-
mensaresubmitted in thesamepackaging toa
(a)
(b)
C
diagnosticpathologylaboratory.lf atallpossible,the
cytologicalpreparationsshouldbesentto thelabo-
ratoryinseparatepackagingtopreventformalin
exposure,aseventightlyclosedspecimencontain-
erscontainingformalincanemitsmallamountsof
formalinfumes,sufficienttodestroythecytological
detailonthesmears.
(d)
Bonemarrowaspirationtechnique.(a)The
Surgical biopsy techniques
2.12
needle isinserted,usinga twisting action.
(b)Bone marrowbubblesinto the syringe.(c) Globules of
Histologicalexaminationofabiopsysampleis the
fatandflecksofmarrowarevisibleinthesample.
mostaccuratemethodofcancerdiagnosisandis
(d)Making thesmear.Seetextforfulldetails.
likelytoleadtoamoredefinitivediagnosisthansam-
pling for cytological diagnosis alone.In general,
tovertical.Thisallowstheexcessbloodtorun
larger tissue specimenswillbeobtained,enabling
downtheslide,thusreducingthehaemodilutionof
theneoplasticcellstobeobservedwiththesur-
thesample.Inagoodsampleof bonemarrow,it
rounding tissue architecture.This alsohas the
shouldbepossibletoseeglobulesof fatand
advantage thathistological examination of the
flecksof marrow(Figure2.12c).
tumourmayallowidentificationofinvasivefeatures,
4.Use a second clean glass slide,drawn
suchasinvasionofbloodvesselsorlymphatics,and
perpendicularlyacrossthefirst,tomakethe
mayallowgradingof thetumour.Inmanycases,the
smear(Figure2.12d).Speed isimportanthereto
smallerthesampleoftissuesubmittedforexamina-
preventthemarrowfromclottingbeforethe
tion,thegreaterthechanceofthetissuesections
10
Chapter2Howtomakeadiagnosis
beingnon-representative,orof thepathologistbeing
2.
Press thecircularbladeof thepunch(Figure
unabletomakeanaccuratediagnosis.Thisisone
2.15)ontothesurfaceofthelesionandrotate
reasonwhypost-mortemexaminationistheultimate
undergentlepressure totherequireddepthto
diagnosticmodality.
collectacylindricalspecimenwithinthepunch.
Oneormoresuturesmayberequiredtoclose
Excisionalversusincisional biopsy
thewound.
Inthemajorityofcasesitisusefultodeterminethe
likelytypeandgradeoftumourpriortodefinitivesur-
gery,sothatthedefinitivesurgical approachcanbe
optimized.Anincisional biopsy is thereforemost
appropriateinmanycases,suchaswhenapproach-
ingalarge cutaneousorsubcutaneousmass,ora
mass ina surgicallychallenginglocation.However,
biopsyprior tosurgeryisnotnecessary if prior
knowledgeoftumourtypeandgradewillnotaffect
the surgical approach,e.g.with splenic,renal or
caninemammarytumours.
Thevarietyofbiopsytechniquesthatmaybe
usedtocollecttumoursamplesincludes:
Punch
Needlecore
2.15
Skin biopsy punch.
oTru-cut(soft tissue)
oJamshidi(bone)
Grab
Thepunchdoesnotpenetratedeeplyinto the
Incisional
lesionandsocare shouldbetaken tocollect
Excisional.
representativetissueincaseswherethere isnecro-
Selectionoftechniquewilldepend uponthesize,
sisorinflammatorytissue（e.g.oral tumours).
Additionally,ifgoingthroughtheskintoretrievea
siteandnature ofthesuspected tumour.Careful
thought shouldbe given to thebiopsyprocedure in
samplefrom a subcutaneousmass,caremustbe
takentoensurethatthepunchbiopsyinstrument
ordertoensurethatarepresentativesampleoftis-
doesnot justfillwith skin.In thisscenario,itisbest
sueiscollected,withoutpredisposingtolocaltumour
tomakeasmall incisiontoallowtheinstrumentto
dissemination
orcompromising
futuretherapy
reachthemass.
(Figure 2.14).
Needlecorebiopsy
Objective
Considerations
Needlecorebiopsyis suitable for collectingsmall
Procurea
Avoidsuilrationr
coresoftissuefromsolidsofttissuelesionsthatcan
representative
inflammation ornecrosis
be located and fixed for sampling.This technique
sampleof the
Ensureadequatedepthofbiopsyparticularly
canbeusedwithultrasoundguidanceforsampling
tumour
fororal tumours
intra-abdominal(andcertainintrathoracic)lesions.
Trytoincludetumour/normaltissueboundary
in thebiopsy sample
1.Clipandsurgicallyprepare theskinoverthe
Procedure should
Minimize handlingof tumourbyadequate
lesion.Thepatientshouldbesedatedandlocal
notpredispose to
surgicalexposure
anaestheticinfiltratedintotheskinandsofttissue
local tumour
Ensure adequate haemostasis
in theregion of thelesion.
recurrence or local
Minimizetrauma to tumourandnormaltissues
2.TheTru-cutbiopsy needle(Figure 2.16)is most
dissemination
Avoid contaminationof normal tissueby
commonlyused.Sometypesaremanually
surgical instruments
operated:followingintroductionof theneedleinto
Donot
Anybiopsyprocedureshouldbesitedwell
thelesion,thecentralcoreisadvancedfurther
compromise
withinthemarginsoffutureexcisionah
intothelesionandrotatedtocollecttissueinthe
subsequent
biopsytract will potentiallybecontaminated
therapy
withtumourcells
specimennotch.Theoutersleeve isthen
advanced,trapping thetissueinthenotch.The
2.14
Biopsyconsiderations.(AdaptedfromMorrisand
needleiswithdrawnandopenedforcollectionof
Dobson,2001,withpermissionof thepublisher)
thebiopsysample.Spring-loadedversionsof the
Tru-cut'needleperformthisprocedure
Punchbiopsy
automaticallyandareparticularlyuseful,asthey
Punchbiopsyissuitableforcollectingsamplesfrom
allowtheoperatortohaveonehandfreeto
superficial lesions(e.g.skinoranyexternal relatively
stabilize the lesion.
superficial tumour).It canalsobeused at lapar-
otomyfororganssuchasliverorspleen.
The Tru-cutneedle is not usually sufficiently
robusttosamplebonylesions.Specializedneedles
1.Clipandsurgicallyprepare the site and infiltrate
(e.g.Jamshidi,seeFigure 2.13)are available for this
local anaestheticintotheareatobesampled.
purpose,as described in Chapter13.
11
Chapter2Howtomakeadiagnosis
(a)
(b)
(c)
2.17
Grabbiopsyequipment.
affecting theorgan.Indeed,duetothenatureofthe
biopsytechniqueand thesizeof thebiopsycupthat
(d)
mayneedtobeusedinarestrictedspace（for
instance,when biopsyingthe urethra),the samples
meaningfulhistopathologicaldiagnosisverydifficult
toachieve.
(e)
Submissionofhistologicalsamples
2.16
Needlecorebiopsy.(a)Tru-cut needle.
Thewholesampleshouldbesentinformalinwher-
（b)Withthestyletretracted,theneedleis
everpossible,asthis allowstheassessmentof the
advancedintothelesion.(e)Thestyletisadvanced to
exposethespecimennotch,whichisthenrotated to
entire tumourspecimen,including surgical margins.
collect tissue.(d)The outersleeveisadvanced tocover
For complex specimens,the tissue orientation
thesample.(e)Thesample isremoved from thenotch.
shouldbemarkedifimportant.Ifit isnecessaryto
(b-dreproducedfrom theBSAVAGuide toProceduresin
send part of a large tissue mass (e.g.spleen),a
SmallAnimalPractice)
numberofrepresentativeportionsfromtheperiphery
of themassshouldbesent,avoidingareasofhaem-
orrhageornecrosis.It isimportanttoensureahigh
Graborpinchbiopsy
ratioof formalinvolume to tissuevolume(e.g.10:1)
Graborpinchbiopsyissuitableforcollectingsam-
andnottoforcebigsamplesintosmallcontainers.
plesfrommucosal surfaces(e.g.respiratory,alimen-
lIfonlypartofthetumourisbeing submitted,
tary and urogenital systems).Thistechnique isoften
necroticorhaemorrhagicareas(e.g.thecentreofan
used inconjunctionwithendoscopy,allowing visual-
ulceratedmammaryglandmassor thecentreofa
izationofthesurfacetobesampled.Mostendo-
suspected splenichaemangiosarcoma)shouldbe
scopes areequippedwithbiopsy cups(Figure 2.17),
avoided，astheseareasoftenlacksufficientcellular
whichcollectmucosalsamples throughabiting
detailforadiagnosistobemade.
action.General anaesthesiaisusuallyrequired.
If very small samples are to be submitted (e.g.
Whilstallowingaccesstoholloworgansystems
endoscopicbiopsies),it isimperative toavoid
inarelativelynon-invasivemanner,thedisadvantage
artefactsthatareintroducedduringcollectionofthe
ofthegraborpinchbiopsytechniqueliesin the
specimens.For instance,crush artefacts obscure
superficial nature of the samples collected,which
cellulardetailwithinthesections,asallthenuclei
maynotbe trulyrepresentativeof thepathology
andcytoplasmaresqueezedoutofthedamaged
12
Chapter2Howtomakeadiagnosis
cells.Otherartefactstobeavoidedarethosecaused
bycautery,especiallyatimportanttumourmargins.
Theaccuracyofthediagnosiswillbemuch
greaterwheretheclinicianprovidesfurtherinforma-
tionabout the case,including signalment,lesion
locationandorientation(whereappropriate)andany
Embed the entire tissueinwax andcutat5umsections:
importantclinicaldetailssuchasevidenceofmeta-
e.g.2cmwouldyield about4000sections.
stasis,presenceofinvasionbasedonimagingstud-
ies,etc.The pathologist should thenbe able to
provideanaccuratediagnosisandprognostically
usefulinformationsuchastumourgrade,presence
ofvascular/lymphaticinvasion,andextentofsurgical
excision.Wherethere isuncertaintyinthediagnosis,
The otherextreme:asingle sectionthroughthemass.
itisusefulforthepathologisttoprovidedetailsofthe
degreeofuncertaintyandthelikelydifferentialdiag-
nosis.Thepathologistmayrecommendfurtherdiag-
nostic orprognostic assays,suchas undertaking
differenthistochemicalstainsorthrough theuseof
immunohistochemicalstaining.
Surgical margins
Theevaluationofsurgicalmarginsasanindicatorof
theeffectivenessofsurgicalexcisioncanoftenpre-
senta challengetoclinicians,pathologistsand his-
tologytechnicians.Becausetheentiretissuecannot
beeasilyexamined,the evaluationrepresentsa
trade-offbetweenwhatismostpracticalandwhatis
mostcost-effectiveforanindividualcase.Fon
instance,if theentirespecimenofanellipticalpiece
ofskinmeasuring3x2x1cmwascutinto5micro-
metre sections,it would take approximately4000
Apragmaticchoicebetweenthetwoextremes.
histologicalsectionstoexaminetheentiretissue
(Figure2.18).Consequentlyanypracticalevaluation
ofsurgicalmarginsinvolvessomepragmatismand
degreeofjudgementastowhichof themanyorien-
tationsorplanesofsectionsarethemostlikelyto
provide the information.
Inhumanmedicine,ithasbeenrecognizedthatit
isveryimportanttohaveapathologistinvolvedin
theevaluationanddissectionofagrossspecimen
rightfromitsinitialreceiptintothelaboratory.This
The choiceinsomeveterinarylaboratories:cruciate
sections.
shouldenablethemostappropriatesectionstobe
takenforsubsequentmicroscopicevaluation.
Therearesetguidelinesforhowtissuespeci-
mensshouldbeexaminedandprocessedinhuman
medicine,provided by,for instance，the Royal
CollegeofPathologistsintheUKandtheCollegeof
AmericanPathologistsintheUS.Yeteveninhuman
medicinethereisadegreeofcontroversyabouthow
besttotakethemarginsfromanygiventissueor
tumourtype,andindeedforsometissuestheguide-
Alternativeforskin ellipses-includes shavemargins.
linesaremuchlessstringent thanforothers.
Themeaningful interpretationof thesurgicalmar-
2.18
Optionsfortheevaluationof surgical margins.
ginsofatumourmassbythehistopathologistis
unfortunatelynotquiteasstraightforwardasmight
beimagined.Themostreliablewayforthesubmit-
colouredmarginsindicatedwillalsohelpthelabora-
tingcliniciantobeassured thatthepathologistis
torytechniciantrimming thespecimen.Paintingthe
examiningthe‘true'surgical marginsofaspecimen
specimenisthemostreliablemethodofmargin
isforthosemarginstobemarked.Thereareanum-
identificationandtheuseofdifferentcolourstopaint
berofdifferentwaysthatthiscanbedone.
differentsurgicalmarginscanenablespecificmar-
Ink
ginstobeidentified andindividuallyassessed.
Thecutsurgicalmarginsof theunfixedspecimen
Therearemanydifferenttypesandcoloursof
canbepaintedusingoneormoredifferentinks.
commerciallyavailablesurgical inks,butthecheap-
Drawingadiagramonthesubmissionformwiththe
estandeasiestmethodistouseoneormore
13
Chapter2Howtomakeadiagnosis
differentcoloursof Indianink.Inordertoinkthemar-
withasoftbrushorcotton-buds,ratherthan
gins (Figure 2.19):
beingimmersedintheink,asotherwiseinkcan
percolatethroughsmallfissuresinthetissueand
Patthetissuedrywithpapertowelstoremove
result ininkaccumulatingonthe tissuethatisnot
the surface blood.
actually themargin.
2.Paint thetissuewithundiluted Indianinkoverthe
3.Immersethepainted tissue in10%aceticacid
marginsurfacesasappropriate(forinstance,
(e.g.whitevinegar)tostopitbeingwashedaway
overthesubcutaneousfatoverthedeepborder
intheformalin.
ofaskintumour).The tissueshouldbepainted
4.Pat thetissuewithapapertoweltoremovethe
excessink/aceticacidandthenplaceitinto
formalinforsubmissiontothelaboratory.
For the pathologists at the microscope,prior
inkingofthetissuescanmakeahugedifferenceto
howeasyitisidentifythe‘real'surgicalmarginsfrom
false margins.
Suture-tagging
Suturescanbeplacedattheappropriatemargins
that areofparticularimportance(e.g.a margin that
grosslyisclose tonormal tissue,oratananatomi-
(a)
callyimportantsite).Thismethodworkslesswell for
broadtumourfrontsorverylargespecimens,or
wheremultiplesurgicalmarginsarebeingassessed.
Becausethesutureshavetoberemovedpriorto
processing,it isoftenimpossibletoidentifythe spe-
cificmarginsagainonthewettissueshouldfurther
sectionsberequested.
Separatesurgicalmargins
Marginal tissueistakenfromthetissuebedthatis
leftbehindintheanimalandthistissueissubmitted
separatelyasrepresenting thetissuemargins.
Particularlyfor large samples,thisisaverygood
wayofsubmittingmargins.It reducesthechancesof
processing/trimming errors,allowsthe surgeon to
submitthemostanatomicallyrelevantmarginsand
mayalsobecheaper,asfewerblocksmayneedto
beprocessed.In addition,whendone incombina-
tionwiththestandard‘cruciate’sections through
themain tumour mass,useful measurements can
stillbeobtainedfor thetissuemargin/tumour
margindistance.
At thediagnosticlaboratory,the tissue willbe
removedfromthefixativeandappropriatesamples
takenforprocessing andsubsequenthistological
examination.Inmostveterinarydiagnosticlaborato-
riesexaminationofmarginsmaynotbeasthorough
asit is inhumanmedicine.Indeed,in themajority of
commercial diagnosticpractices,trimming ofgross
tissueswillbeperformedbyatechnicianratherthan
apathologist.The‘standard’method for tissues,
whereitcanbedone,istotake‘cruciate'sections
(north,east,south,west)(Figure 2.20)such that
marginscanbeassessedaroundthetissue.
However,thisprocessdoesnotworkparticularlywell
inallcases.Therefore,peripheral or tangential
'shave'sectionsmaybemorerepresentativeofthe
tissuemarginsinthesecases,aided bypre-fixation
2.19
(a)Atypicalellipseofskinfromanexcisional
inking.Thisisparticularlyappropriatewherethere
biopsy of a subcutaneous mass.(b) The
subcutaneoustissuesaredriedwithpapertowelsand
arelarge specimens,specimensfromanatomically
paintedwithindianink.(e)Thetissuesarethen dippedin
complexsites(head/neck),tissuesfromanextremity
aceticacid(whitevinegar)toprecipitate theinkonto the
(forinstance,the earpinna or tail)or tissue from a
tissue surface.
tubular organ(forinstance the intestine).
14
Chapter2Howtomakeadiagnosis
Manypathologistsarenowusingamorestand-
ardizedformatthathasbeenpromotedbytheArmed
ForcesInstituteofPathologistsandtheAmericanand
EuropeanCollegesofVeterinaryPathology.This
descriptivetechniquemirrorsthediagnosticprocess
thatapathologistwillgo through.Moreimportantly,it
provideslargeamountsof informationonthetumour
specimeninarelativelyconciseform,withthemajor-
ityofthemostclinicallyrelevantinformationbeing
presented at thebeginning(Figure 2.21).Theaimof
theapproachisbothtoconveythedescriptiveinfor-
mationthatenablesadefinitivehistologicaldiagnosis
Grosstumourspecimenshowingcruciate
tobe made(e.g.peripheralnerve sheathtumour) and
2.20
sectionsformargins.Typical full-thickness
toconvey clinicallyimportantinformation(e.g.degree
cruciatesectionsaretaken,and thetissuesamplesare
of differentiation).
placedintocassettespriortoprocessingintoparaffin
By reading the histological description,the
blocks.
cliniciancanformamentalpictureofthelesion.In
particular，agooddescriptionshouldincludeboth
Interpretation of tumour
qualitativeandquantitativedetailthatshouldenable
descriptions
diagnosticallyandprognosticallyuseful information
tobegleaned fromit.Forinstance,enumeration of
Aswithanyotherdiagnosticmodality,theclinician
themitoticindexisprognosticallyrelevantincanine
shouldread thepathologyreportcritically,i.e.does
cutaneousMCTs;wheretermssuchasbriskmitotic
thehistologicaldiagnosisfittheclinicalpicture?
activity'or'smallnumbersofmitoses'areused,itcan
Therearetwomaintypesoftechniquethatpatho-
beimpossibletoobtainthisinformation.
logists use to describe tumours.The first,which is
Insome cases,if there is insufficient tissue
mostwidelyused intheUK,isafree-formdescription.
availableforexaminationitcanbeverydifficultfora
This method,althoughoftenmore flowing,does not
pathologisttoreachadefinitivediagnosisaboutthe
alwaysprovidesufficientinformationforaclinicianto
tissue.Otherproblemsfacingthepathologistinclude
beabletoassessthedegreeofdifferentiation,ade-
orientationofthetissuesample,artefactsintroduced
quacy of margins,etc.It is oneof the mainreasons
bycrushingofsmallsamples,and thermocauteryof
thatoncologistsmightrequestasecond opinion.
the tissue edges.
Line
Description
Significance
Line1:Subgross
Includessubgrosstissuelocation;sizeshapecell
Themostmortantlineof thedescriptiongivingsomeof the
description
density;expansile orinfiltrative;encapsulatedor
mostclinicallyrelevantnformatonornstancesitnfltratig
non-encapsulated;welldemarcatedorpoorly
demarcated;fullyexcisedornotfullyexcised
marginstumour-free?
Line2:Patterns of
Thepatternsinwhich thetumourcellsarearrangede..
Describeswhetherthetumourisofepithelialmesenchymalr
cells and types of
nests,packetlobulescords（carcinoma);acinitbule
roundcelorigin.Providesa large amountof potentiallyuseful
stroma
（adenocarcnoma);streambundes,asciclesstrifrm
prognosticand therapeuticinformation
patterns(sarcoma);sheets,cords（round celltumour).
Theamount and type of stroma are also assessed
Line 3:Cytological
ndividulelluaaureudinga
Thislineandthefollowinglinesgivesomeindicationastothe
features
cytoplasmfeatures
degreeofdifferentiationof theneoplasticcell.nmanycases,
thelesswellthetumourisdifferentiated,theworsetheprognoss
Line 4:Nuclear
Detailsofnuclearshape,izechromatinpattrns,
Largeirrulaulwithveryrminntulliareof
features
nucleoli features
feature of aggressivetumours
Line5:Unique
Examples:presence of multinucleatedcells;degreeof
Ingeneral,thehigherthedegreeofcellularandnuclear
features
anisokaryosis(variationinnuclearsize）oranisocytosis
pleomorphism,thelesswelldifferentiatedthetumour
(variation in cellsize)
Line6:Mitotic
Usuallyexpressedasnumbersofmitoticfiguresperhigh
Thehigherthemitoticrate,themorequicklytheneoplasticcells
activity
powerfield（HPF)orper3,5or10HPFs
areproliferating.Ahighmitoticrateisoftenassociatedwithmore
aggressive tumourbehaviour
Line7:Evidence of
Evidenceofcapsulanvasinvasulanvasn
Ingeneralthemoreinvasiveandinfitrativethetmour,themore
malignancy
lymphaticinvasion,necrosis,haemorrhage
likelyit isthat thetumourhasalreadymetastasizedorwillrecur
locally
Line8:Anything
Anyotherpathologicalfeaturerelated to,orunrelatedto
Manytumourswillresult inpathologicalchangeswithin the
else
the neoplasticprocess,e.g.ulcerationorperitumoral
adacentiss.gilammatnadacensur
inflammation
adjacent skeletal muscle
2.21
Standardizedpathologyreportformat.
15
Chapter2Howtomakeadiagnosis
Immunohistochemistry
Inpracticetherearemanyfactorsthatcanaffect
thequality andquantityof IHCstaining.Forinstance,
Immunohistochemistry(IHC)canenable thepatholo-
tissuesthatareinadequatelyfixedinformalinwill
gisttoconfirmahistologicaldiagnosismadefroma
oftenshowveryhighlevelsofbackgroundstaining,
standardstainedsectionandtodeterminethecellof
whichcanmakeitverydifficulttoassessthetrue
originofpoorlydifferentiatedtumours.Inaddition,it
stainingcharacteristicsandraisesthepossibilityof
canbeusedtoaid in tumourprognostication.This
falsepositiveresults.Conversely,tissuesthathave
canprovidetheclinicianwithuseful informationfor
beenexposedtoformalinforextendedperiodsof
decidingonthebesttreatmentforthetumourandfor
timemaylosetheirabilitytobindsomeantibodies,
helpingtopredicthowthetumourislikelytobehave.
therebycreatingfalsenegativeresults.Fixationarte-
Asthenumberofantibodiesthatcanbesuccessfully
factsaresomeofthereasonsthatcontrolsareso
employedinveterinarydiagnosticpathologyisgrow-
essentialfortheinterpretationofIHCstainingresults.
ing,IHCis increasinglybeing seen asan essential
Figure2.23listssomeofthetumourmarkers
partof thepathologist'sandclinician'sarmoury.
thatarecommonlyidentifiedusingIHC.Incancer
Thetechniqueinvolvesthedetectionofantigen-
diagnostics,themainuseof IHChasbeentoaidthe
specificantibodiesbindingtotheirantigentargetsin
pathologistindeterminingthecellortissueoforigin
atissuesection.Aninsolublecolouredprecipitate
of theneoplasticcellpopulation.Thishassignificant
formsattheantigen-antibodybindingsiteandisvis-
practicalapplication:it canbeverydifficultto
ualizedusingamicroscope.Positiveandnegative
determinetheexactcelloforiginforsomepoorly
controlsareusedtoaidinterpretationandforquality
controlpurposes.Theextremelyselectivenatureof
Marker
Significance and usage
antibodybindingtoitsligandisutilizedtoidentifythe
(antigen)
extentandcellularlocalizationofexpressionofthe
antibody,andits targetantigenwithinatissue
Vimentin
Identifies allmesenchymal cells.Oftenused to
helpconfirm diagnosisof a tumourof
(Figure2.22).
mesenchymalorigine.gallsarcomasarepositive
for vimentin whereasmost carcinomas are
negative
Chromogen
Cytokeratin
Identifiesmostepithelialcells.Oftenused tohelp
andenzyme
confirm diagnosisofa tumourofepithelial origin,
e.g.most carcinomas arepositive forcytokeratin
Secondary antibody
whereas sarcomas are almost alwaysnegative
CD3
Amarkerof T-cellorigin.TogetherwithCD79a,
used tohelp distinguish betweenT-and B-cell
Primaryantibody
lymphomas,andessential inhelping toapply the
Tissue section
WHO-REALlymphoma classification system
Antigen
CD79a
Amarkerof B-cellorigin.Used ina similarmanner
Slide
to CD3.Most plasma cells do not express CD79a,
makingit of lessuseindiagnosingplasmacytomas
2.22
Thebasicprinciple of immunohistochemistry.
CD18
Amarkerof leucocytes.Very useful inhelping to
diagnosetumours of monocyte/macrophage
originuchashistiocytisarcomas
ThemainstepsinperformingIHCareasfollows:
Desmin
Amarkerof muscle origin.lsexpressed inmost
1.A tissuesection isincubatedwithaspecific
tumours of smoothmuscle or striatedmuscle
dilutionofaprimaryantibodythathasbeen
origin
developedtobindtoasingletissueantigen(such
S100
Amarkerof neuroectoderm origin.lsexpressed in
asa particularprotein,orpart thereof).
anumrfdiffrenttumousludingeriphrl
2.Asecondaryantibodythatislinked toa marker
nerve sheathtumours,melanomas,
enzyme(usuallyhorseradishperoxidase) is
chondrosarcomas
incubatedwiththetissueandtheprimary
Glial fibillary
Amarkerof glialoriginUsedforconfirmingthe
antibody.Thissecondary antibodywillbindtothe
acid protein
diagnosis of gliomas
non-antigen-bindingendoftheprimaryantibody
(GFAP)
molecule(forexample,itmightbearabbit
CD117 (KIT)
Amarkerofmastcelloriginorinterstitialcellsof
antibodythatwillbindspecificallytoall mouse
Cajal
antibodies).
Mac387
Amarkerof macrophages.Canbeused tohelp
3.Asubstrateisadded tothefinal mixture,which
distinguishhistiocytictumoursfromgranulomatous
undergoesacolourchangeandprecipitateson
inflammation
tothetissuesectionwhenitisactivatedbythe
Synaptophysin
Amarkerof neuroendocrine cells
enzymeboundtothesecondaryantibody.
4.Thesectionsarethencounterstainedwith
MelanA
Aspecificmarkerofmelanocytediferentiation.
haematoxylin,coverslippedandexaminedunder
Canbeused tohelp confirma diagnosis of
amicroscope.Specificpositive staining is
amelanoticmelanoma
identifiedwherethereisstainingofthecellsby
2.23
Tumourmarkerscommonlyidentified using
thecolouredenzymesubstrate.
immunohistochemistry.
16
Chapter2How tomakeadiagnosis
differentiatedtumoursbasedonroutinelightmicro-
that theabsenceofpositivestainingusing otherIHC
scopyalone,andwithoutIHCtheamountofinfor-
markerscannotbeinterpreted.
mationthatcanbegleanedfromexaminationofthe
Inordertoclassify tumoursfurther,arange of
specimensmaybegreatlylimited.
tissue-specificproteinscanbetargetedusingspe-
cificantiseraraisedagainst them.Forinstance,the
intermediatefilamentproteins,thegeneraltissueof
intermediatefilamentproteindesmincanbeusedto
origincanusuallybeidentified andthetumourclass-
confirmamuscleoriginof thetumourtissue.Then,
ifiedintothebroadcategoriesofepithelial/glandular
usingantibodiesagainstarangeofdifferentactins
versusmesenchymal.Ingeneral,theformertumour
andmyoglobin,itispossibletocharacterize the
typesoftenmetastasizevialymphaticsandfre-
celloforiginassmoothmuscle,skeletal muscleor
quentlyearlyinthecourseofdisease,whilstthelat-
cardiacmuscle.
tertypeoftenmetastasizeshaematogenouslyand
Ingeneral,themostuseful informationfor the
lateroninthediseasecourse.Antibodypanelscan
alsohelptodistinguishmesenchymaltumoursfrom
providedbypanelsofantibodiesthatenabledistinc-
thegeneralcategoryof‘roundcell tumours'，which
tionbetweentwotumoursthat,althoughthey
arelikelytohaveadifferentbiologicalbehaviourand
appeargrosslyandmicroscopicallysimilar,arelikely
tobesensitivetodifferenttreatmentprotocols.Inter-
tohaveverydifferentbiologicalbehavioursor
mediatefilamentsofavarietyofdifferentspecific
responses to therapies.
tissuetypesarefoundinallcellsandrangefrom8to
However,itshouldbenotedthatingeneralwhen
10nmindiameter.Forinstance,cytokeratinsare
tumourappearsverypoorlydifferentiated
expressedbycellsofepithelialoriginandvimentinis
microscopically,itislikelythat,whateverthecellof
expressedbymesenchymal cells,withonlysome
origin,theresponseto therapy andprognosiswillbe
celltypes (e.g.mesothelium)expressing both.
poor.Indeed，whenneoplasticcellsareverypoorly
Vimentinisparticularlyusefulbecause,asallmes-
differentiated,theycanoftenexhibit aberrant
enchymalcells express it,all tissues would be
expressionofcellularproteins,suchthatitbecomes
expectedtocontainsomevimentin-positivecells
verydifficulttoidentifythecelloforiginwithcertainty.
withinthem.Itthereforeactsasausefulcontrolto
SomeexampleswhereIHCwouldbeveryuseful
assessfixationartefacts:ifnovimentin staining is
tohelptodistinguishtumoursofdifferentprognosis/
identified,itislikelythatthetissueisover-fixed,and
treatment optionsaregiveninFigures2.24and2.25.
Histological differential diagnosis
Response to antibodies
Amelanoticmelanomaversusfibrosarcomain
Amelanoticmelanoma:
Fibrosarcoma:
oralcavity
S100+,MelanA+
S100-,MelanA-
Osteosarcoma versusfibrosarcoma
Osteosarcoma:
Fibrosarcoma:
osteocalcin+
osteocalcin-
Synovial sarcomaversushistiocyticsarcoma
Synovial sarcoma:
Histiocyticsarcoma:
vimentin+,cytokeratin+，CD18
vimentin+,cytokeratin-,CD18+
Nasal carcinoma versus lymphoma
Carcinoma:
Lymphoma:
cytokeratin+,CD18-,CD79a-,CD3-
cytokeratin-,CD18+，CD79a/CD3±
2.24
Examplesof useof immunohistochemistry indistinguishingcertain tumours.
Histologicalsectionsshowing
2.25
IHCstaining ofahistiocytic
sarcoma for:(a)vimentin;
(b)cytokeratin;(c)lysosyme;
(d)CD18.Notethatthetumouris
negativeforcytokeratin.
(b)
(d)
17
Chapter 2How to make a diagnosis
Tumourmarkersandtargetedtreatment
moleculesof thestain.Anincrease inthenumberof
TheHolyGrailofcancertherapyistoidentify
AgNORproteinsindicatesanincreaseddemandfor
tumour-specifictargetsthatwillallowtumourcellsto
ribosomalbiogenesisandthereforeahighermeta-
be targeted andkilled,leavingnormal,non-neoplas-
bolicactivity.HighAgNORcountsareassociatedwith
ticcells unharmed.IHC plays a vitalrole ina
ashortercellcycleandthereforeahigherrateofcell
researchsettingtoaididentificationofnoveltargets;
proliferation.AgNORcountsareindependentprog-
andinadiagnosticsettingitisoftenthetoolof
nosticfactorsinmanyhumantumours.Incompanion
choicetodeterminewhether theindividualcaseis
animal species,theyarepredictiveofsurvivaltimes
likelytobenefitfromsuchtargetedtherapy.ltisrou-
incanine lymphoma and canine MCTs.However,
onlyrecentlyhavethetechniquesforAgNORstaining
theextentofHER-2/Neuexpressioninbreastcancer
andquantificationbeenstandardized,makingcom-
toidentifythosewomenwhowouldbenefitfromanti-
parisonsbetweendifferentstudiesdifficult.
HER-2/Neu antibody therapy (i.e.Herceptin).This
proteinis similarlyexpressedinsome canine and
Ki67
felinemammarytumoursanditispossiblethat,
Thisis anunidentifiedantigen towhich themonoclo-
shouldthedrugeverbecomeaffordable,it mightbe
nal antibody MIB-1binds.Ki67 is a very large
ofpotentialuse inaveterinarysetting.Similarly,
nuclearproteinthatisexpressedexclusivelybycells
detectionofoestrogenreceptorexpressioninmam-
during the cellcycle;therefore,ifacell isexpressing
marytumourscanbeusedtopredictwhether the
Ki67,itisactivelyreplicating.Ki67providesameas-
patientwillbenefit fromanti-oestrogentherapy.
ureof thegrowthfractionof a cellpopulation.lt isan
IncanineMCTs,theexpressionof thereceptor
independentprognosticfactorinmanyhuman
tyrosine kinase KIT(CD117)may help to predict
tumoursandithasbeenshowntobeanindepend-
responsetoanewclassofsmall-moleculetyrosine
entprognosticfactorincanineMCTs.Ingeneral,the
kinase inhibitors.KIT is expressed by normal mast
greatertheproliferationindexofamastcelltumour,
cells,but is variably expressed inneoplasticmast
themorelikelyit istorecurlocallyandtometasta-
cells.Thoseindividual MCTsthatexpressminimal or
size,and hence theworse theprognosis.
undetectablelevelsofKITandothersimilarreceptor
tyrosinekinaseswouldbepredictedtorespondless
PCNA
favourablytothisclassof drugs,comparedwiththose
Proliferating cellnuclear antigen(PCNA) is the delta
thatexpresshighlevelsof thedrugtarget.Although
subunitofDNApolymerase1.PCNAexpression is
relativeKiTexpressionlevelscanbedeterminedby
determinedbyimmunohistochemistry.PCNAcounts
IHC,IHC cannot be used to identify whether KIT
areexpressedasthenumberofpositivelystaining
mutations are present.Rather,molecularmethods
nucleiasapercentage ofallneoplasticnuclei
suchasPCRandnucleotidesequencing arerequired
counted.It is anindependentprognosticfactorina
toidentifythepresenceorabsenceofmutations.
numberofhumantumours,buttheroleforit asa
prognosticmarkerincanineandfelinetumoursis
Tumourgrading
still unclear.
Thespecifichistological/immunohistochemicaldiag-
nosisitself is likelytogive themost importantprog-
Summary
nostic information for the clinician.For instance，a
Withtheincreasedsophisticationofclinicaloncology
diagnosisoflymphomaversussofttissuesarcomais
incatsanddogs,obtaininganaccuratediagnosis
likelytoresultinverydifferenttreatmentsandadif-
priortoembarkingontherapyisbecomingofever
ferentprognosis.However,identifying variousfea-
greater importance.In mostcases thiswillentail
turesof different subtypesof the same tumour(e.g.
low-gradeversushigh-gradesofttissuesarcomas;
obtainingatissuebiopsyorcytologysampleand
submittingittoaqualifiedveterinarypathologist.The
gradeIversusgradeIlMCTs)canalsobeusedto
mannerinwhichthesesamplesaretaken,and the
directtherapyandtopredictprognosis.Tumourgrad-
associatedinformationthattheclinicianprovidesto
ingcanbefurtheraugmentedbyassessmentofa
thepathologist,cangreatly enhance orpotentially
varietyofothermarkersofpotentialprognosticbene-
fit,suchasbymeasurementofproliferationmarkers.
detractfromthediagnosisthatcanbemadebased
onthosesamples.Thereforeit isofutmostimpor-
Proliferationmarkers
tance(ifvaluableresources,timeandexpenseare
Oneofthehallmarksofaneoplasticmassisun-
nottobewasted)thatthoughtisputintodeciding
controlledgrowth.Severaldifferent techniquesof
whatsamplingmodalitywillprovidethebestcost
measuringcellproliferationhavebeendeveloped,
benefitbalanceforthepatientand theclient.
themostrobustandreliableofwhicharebasedon
Itisincumbentonthepathologisttoexaminethe
histochemical stains(AgNORs)and immunohisto-
samplesinsuchawayastoprovidetheclinician
chemical stains(PCNA,Ki67).
withthemostaccurateandprognosticallyrelevant
information.Inthisway，ahighlyfruitfulrelationship
AgNORs
canbedevelopedbetweenclinicianandpathologist,
Argyrophilicnucleolarorganizingregions(AgNORs)
suchthatpatientcareisoptimizedandthetissue
areloopsofDNAthatcontainribosomalgenes,andit
samplesobtainedcanbeutilizedandanalysedto
istheNOR-associatedproteinsthatbind thesilver
theirfullpotential.
18
Chapter2Howtomakeadiagnosis
Thereareanincreasingrangeofimmunohisto-
thearsenalofdrugsthatmightberationallyapplied
chemicalstainingtechniquesthatcanbeusedwith
toveterinarycancerpatients.
canineandfeline tissueandmuchresearchisbeing
undertakentousethesetechniquestodistinguish
previouslyindistinguishabletumours.Byusingthese
Referencesandfurtherreading
techniques,it isbecoming increasinglypossibleto
providemoreaccurateprognosticinformationtoclin-
icians,enablingthem tomake thebest treatment
Disease4thednMosbyEIsevier,St.ouis
decisionsfortheirpatients.Inaddition,itislikelythat
Meuten DJ(2002）Tumors inDomesticAnimals,4thedn.lowaState
applicationofthesetechniqueswillhelptoidentify
Press,Ames,lowa
MorrisJand Dobson JM(2001)SmallAnimalOncology.Blackwell
newtherapeutictargets,whichwillfurtherincrease
poxo
19
clinical staging and the TNM
classification
Jane M.Dobson
Introduction
tumours,theirpatternsoflocal growthandmecha-
nismsof metastasis.Although it is not theremit of
Thediagnosticevaluationofthepatientisofpara-
thischaptertodelveintothefinedetailoftumour
mountimportanceinthemanagementofcancer.
biology，anunderstandingof thebasicpathological
The initial approach to anypatientwithsuspected
behaviouroftumoursisaprerequisitetotheprocess
cancermustbedesignedtoachievethefollowing
of clinical staging.
objectivestotheextentthatisappropriateforthe
individual owner:
Tumourbiology
Tomakeahistological/cytologicaldiagnosis
Togradethedisease
Theprocessesthatleadtotumourdevelopmentare
Todeterminetheextentofthediseaseintermsof
describedbrieflyinChapter1.Twoimportantfacts
bothlocalanddistantspread
mustbeborneinmind:
Toinvestigateandtreatanytumour-relatedor
concurrentcomplicationsthatmightaffectthe
A tumourdoesmostofitsgrowingbeforeitcan
overallprognosisorthepatient'sabilityto
bedetected
toleratetherapy.
Thecellsthatmakeupatumourmassarenot
identical.
Chapter2discussesmethodsfortumourdiagno-
sisand histologicalgrading,butthestageorextent
A tumourcannotbedetectedbypalpation,radio-
ofthetumourisequallyimportantindetermining
treatment andprognosis.Thestage ofcancer
atdiagnosisisapowerfulpredictorofsurvival
inweight,bywhichtimeitcontainsapproximately
andoftendictatestreatmentselection.Thischapter
108-109cells（Figure 3.1).
coverstechniquestoevaluatethecancerpatientas
Cancercells continuallymodifytheirproperties
awholeanddiscusseswhatmaybegainedfrom
during theprocessofgrowth,largelythroughsmall
suchcomprehensiveapproaches.Paraneoplastic
mutations occurring during cell division.Hence，
syndromesareaddressed inChapter4.
although thecellsinthetumourmassmayshare
Appropriateclinicalstagingislargelyinformedby
somefeaturesof theoriginalprecursorcell,theymay
aknowledgeofthebiologicalbehaviourofmalignant
bedifferentinotherproperties,suchasthe abilityto
3.1
1012
Tumourgrowthand
clinical detection.
cells
Firstpalpable(1cmmass)
tumour
Firstdetectableby
radiography(0.5cmmass)
106
Numberof
0
Time
20
Chapter3ClinicalstagingandtheTNMclassification
metastasizeor tometabolize a cytotoxic drug.This
thetumour,intermsofrelationshiptoadjacentnor-
variationisimportantintherapybecausedifferent
mal tissues,mitoticrate,cellularandnuclearcharac-
cellswithinthetumourmassmaybeinherentlymore
teristics,is therefore important in prognosis(see
orlesssensitivetocytotoxicdrugsortoradiation.
Chapter2).
Tumourbehaviour
Featuresofmalignancy
Tumoursaretraditionallyclassifiedasbeingbenign
Clinically,the most important features of malig-
or
malignant,according totheir
growthand
nancy are invasion and metastasis (Figure 3.3)
behaviouralcharacteristics(Figure3.2).
Theseare closelyalliedprocesses,as inmany
Althoughthisdivisionisusefulfordescriptivepur-
cases invasionisthe first step on theroadto
poses,inreality tumours displaya spectrumof
metastasis.Invasionandmetastasis are very
behaviour,rangingfromtrulybenigntohighlymalig-
complex processes,the geneticand biochemical
nant.Some (e.g.low-grade spindle cell tumours)
basisofwhicharestillnotfullyunderstood.Itis
havelocalcharacteristicsofmalignancybutrarely
knownthatcell-celladhesion molecules(notably
metastasize.Others(e.g.mast celltumours(MCTs))
membersofthecadherinfamily)andintegrins
candisplayawidespectrumofbehaviourranging
(whichlinkcellstoextracellular matrixsubstances)
frombenigntomalignant.
areinvolved in the process,as is proteolytic
Histologically,a number ofmorphological fea-
remodelling of the extracellular matrix,which
turesofatumourcanbeusedtopredictitslikely
allowstumourcellstomovethroughconnective
behaviour.Thehistologicalappearanceorgradeof
tissuebarriers.
Characteristic
Benign
Malignant
Rateof growth
Relatively slow.Growthmayceaseinsomecases
Oftenrapid.Rarelyceasesgrowing
Mannerof growth
Expansive.Usuallywelldefinedboundarybetween
Invasive.Poorlydefinedborders;tumourcellsextend intoand
neoplasticand normal tissues.Maybecome encapsulated
maybescattered throughoutadjacentnormaltissues
Effects on adjacent
Oftenminimal.May cause pressure necrosis and
Oftenserious.Tumourgrowthandinvasionresultindestructionof
tissues
anatomicaldeformity
adjacentormaltissuesmanifestasulcerationofsuerfical
tissues,lysis of bone
Metastasis
Does not occur
Metastasizebylymphaticand haematogenousroutes and
transcoelomicspread
Effect onhost
Oftenminimalbutcanbelife-threateningif tumour
Oftenlife-threateningbyvirtueofdestructivenatureofgrowthand
develops inavital organ(e.g.brain)
metastatic dissemination to other(vital) organs
3.2
Characteristicsof benignversusmalignant tumours.
1.Cancercellsbreachbasement membrane and
detachfromprimary site.
3.3
Invasion andmetastasis.(continues)
21
chapter3ClinicalstagingandtheTNMclassification
2.Cancercellspenetratethe
3.Cancercellscirculatevia the
4.Cancer cells lodge ina
basementmembrane of local
bloodstreamorlymph.
vessel,adhere to and
blood or lymphatic vessel.
penetrate capillary wall.
5.Cancer cells invade adjacent tissue and
dividetocreatesecondarytumour.
3.3
(continued) Invasionandmetastasis.
Invasion
frompreviouspathologicalstudiesoftumourinva-
Fromthe clinical perspective，tumour invasioninto
sion.Forexample,therequirementforwidemargins
thewallofaholloworganorintoadjacenttissue
ofresectionforgradeIlMCTsiswelldocumented.A
compartmentsdictatestheextentofsurgicalmargin
recentstudyof23cutaneousMCTs showed that
requiredtoeffectcompleteremovalandthusthe
75%of20gradelltumourswerecompletelyexcised
feasibilityofa surgicalcure(Figure3.4).
at1cmandallwerecompletelyexcisedat2cm
Unfortunately,intheclinicalsetting itisverydiffi-
(Simpson et al.,2004).The authorsconcluded that a
culttoassessthepathological invasivenessofapar-
2cmlateralmarginandadeepmarginofonefascial
ticular tumour prior to surgical resection;thus,in
planeappeartobeadequateforcompleteexcision
clinicalpracticeitisusual torelyondatagenerated
ofgradeIandgradelltumoursandsubsequently
a
b
3.4
Microscopiccomparisonofwelldefinedversusinvasivetumours.(a)Welldefinedcomplexmammaryadenoma
froman8-year-oldfemaleStaffordshireBullTerrier.Theblackarrowsshowthecleardemarcationbetweentumour
andsurroundingnormal tissue.Theredarrowshowsnormal mammarygland.(b)Aninvasiveanalsacglandcarcinoma
froma6-year-oldCockerSpaniel.Incontrastto（a),thereisnoclearboundarybetweentumourandnormal tissue,and
lobulesof tumourcellsareseeninvadingtheadjacentconnective tissue(blackarrows).(H&E,originalmagnificationX40)
(lmagescourtesyofDrFernandoConstantino-Casas,DepartmentofVeterinaryMedicine,UniversityofCambridge)
22
Chapter3Clinical staging and the TNM classification
confirmedthisinaseparateprospectivestudyin16
Staginghasseveral purposes:
dogs(Fulcheretal.,2006).Veterinary-specificdata
To define the local,regional and distant extent of
onothertumourtypesisrelativelysparse.
disease
Metastasis
Tohelptodeterminetheoptimumtreatment
Theabilityofmalignanttumourstospreadtoand
Toprovideabaselineagainstwhichresponseto
growindistantorgansistheirmostseriousandlife-
treatmentcanbeassessed
threatening characteristic.Cancermetastases are
Toprovideprognosticinformation.
thecauseof 90%ofhumancancerdeaths.The
Cancer staging can be divided intoa clinical
mechanismsinvolved in theprocessofmetastasis
stageandapathologicalstage:
arenotfullyunderstood.Inordertoformameta-
staticgrowth,acancercellmustdetachfromthepri-
Clinicalstageisbasedonallof theinformation
marytumour,invadeandmoveintothevasculature
obtainedbyphysical examination,imaging,
to traveltoa newlocation,aggregatewithplatelets
endoscopy,biopsy,etc.,priortosurgery
andfibrintoarrestatthenewsite,extravasateinto
Pathologicalstageaddsadditional information
surroundingparenchymaandestablishgrowth(see
gainedbymicroscopicexaminationofthetumour
Figure3.3).During thisprocess the cellmustevade
byapathologist;thisisapostoperativestaging.
hostdefencemechanismsandsurviveinthecircula-
tion.Current theories suggest that only certain
Clinicalstageandpathologicalstageshouldbe
regardedascomplementary.It isnotunusual for
clonesofcellswithinatumourdevelopalltheabili-
theretobea differencebetweentheclinicalstageof
tiesrequiredformetastasisbutthattheseclones
probablyariseanddisseminateintheearlystagesof
adiseaseand thepathologicalstage,becauseitis
not possible to detectmicroscopic tumour exten-
thattumour'sgrowth,oftenpriorto thedetection of
theprimarytumour.
sionsordepositsbygrossexaminationorwiththe
Tumoursmaymetastasizeviathelymphaticroute
imagingtoolsavailabletotheclinician.Thepatho-
logicalstageisusuallyconsidered the‘truerstage
tolocalandregional lymphnodes,orviathehaem-
asitisinformedbydirect(microscopic)visualization
atogenousroute,allowing secondarytumoursto
of thetumour,whereasclinical stagingislimitedby
developinanybodyorgan.Thesetwosystemsare
thefactthattheinformationisgainedbyindirect
widelyinterconnectedandmanytumoursusethese
observationofa tumourthatisstillinsitu.However,
connectionstospreadthroughthebody.Tumoursmay
pathological staging canalsobeproblematic,asit
alsodisseminatethroughbodycavitiesviahaemor-
rhageoreffusionsandmaybespreadoninstruments.
reliesonthepresenceofmalignantcellsinthesec-
Inhumans,differenttypesofcancershowdifferent
tionsoftissuesexaminedandonthevisualskillsof
thepathologisttoidentifymaybeoneortwocancer
targetorganspecificityformetastasis.Forexample:
cellsmixedwithhealthycellsona slide.New,more
Prostatic carcinoma:bone
sensitive, methods using molecular screening
.
Breastcarcinoma:bone,brain,adrenal,lung,liver
(reverse transcriptionpolymerase chainreaction,
Cutaneousmelanoma:liver,brain,bowel.
RT-PCR)for cancer-specific proteins are being
developedforuseinhumanpatients.
Insmall animals,thelungs arethemostcommon
Manyclinical staging systems
havebeen
siteforthedevelopmentofhaematogenoussecond-
describedforuseinhumanandveterinarypatients
arytumours butother sites,including liver,spleen,
withcancersatvarioussitesinthebody.Theideal
kidneys,skin andbone,shouldnotbeoverlooked.
stagingsystemshouldbe:easytouseandremem-
ber;reproducible;not subject tointer-orintra-
CarcinomasandMCTsusuallymetastasizefirst
observervariation;andbasedonprognostically
bythelymphaticroute,beforedisseminating
importantfactors.TheWorldHealthOrganization's
morewidely.
TNMClassificationofTumoursinDomesticAnimals
Sarcomas(soft tissue andbone)and melanomas
(Owen,1980)isoneofthemostwidelyusedand
metastasizebythehaematogenousroute.
adapted inveterinarymedicine.Althoughitmaynot
However,tumoursdonotalwaysfollowexpected
beappropriateornecessaryforthepractitionerto
use the TNMor other staging nomenclature,the
patternsofbehaviourandsomemayspreadbyboth
basicprincipleofdetermining theextentofatumour
lymphaticandhaematogenousroutes.
intermsoflocalinvasionandnodalanddistant
metastasisisvital tothework-upofanycancercase.
Clinicalstagingofcancer
Theclinicalstagedescribestheanatomicalextentof
TNM classification
a tumour at a setpoint in time,i.e.it defineshow
TheTNMsystemisbasedontheanatomicalextent
muchthecancerhasspread.Theclinical stageoften
of spread (Figure 3.5):
takesaccountof thesizeofa tumour,howdeeplyit
haspenetratedthewallof anorganorotheradjacent
Treferstotheextentoftheprimarytumour
tissues,whether it has metastasized to local or
Nreferstotheextentofnodalmetastasis
regionallymphnodesandhowmanyareaffected,
Mreferstothepresenceorabsenceofdistant
andwhetherithasspreadtomoredistantorgans.
metastasis.
23
Chapter3Clinicalstagingand theTNMclassification
T-primary tumour
headandneckandsofttissuesarcomashaslargely
beensupersededbymagneticresonanceimaging
X1
Primary tumour cannot be assessed
(seebelow).
TO
No evidenceof primary tumour
Ultrasonography:Ultrasoundexaminationhasan
Tis
Carcinomainsitu
importantroleinevaluationof the site,size and
T1-4
Increasing sizeand localextentof primarytumour
extentofanytumourmassineitherbodycavity.Itis
N-regional lymph nodes
organsandlesionsand incaseswithpleuralorperi-
Nx
Regional nodes cannot be assessed
tonealeffusions.Itcanalsobeusedtoassesssoft
NO
No regional nodemetastasis
tissuemassesonlimbsandintheneck.Inallthese
Increasinginvolvementof regionalnodes
situationsultrasound isverysensitiveatlocating
N1-3
lesionsand inassessing theirextentandrelationship
M-distant metastasis
withadjacentstructures;however,it isnotspecific
Mx
Distantmetastasiscannot be assessed
fortheaetiologyofthelesionandcannotdifferenti-
No distantmetastasis
ateneoplastic fromnon-neoplasticlesions,
nor
MO
benignfrommalignant.Cytologyorhistologyarestill
M1
Distantmetastasispresent
requiredtomake thediagnosis;andfine-needle
3.5
TheTNM system.Two classificationscan be
aspirationorneedlebiopsysamplescanbecol-
describedforeachsite:clinical(TNM)and
lectedfromlesionsunderultrasoundguidance.
pathological(pTNM).
inassessmentoftumoursaffectingorganssuchas
Clinicalassessmentoftheprimary
thealimentarysystemandurogenitalsystemasit
tumour（T)
allowsvisualizationofthelayersofmuscleforming
Certainphysicalfeaturesoftheprimarymassmay
thewallsoftheseorgansand thuscangiveinform-
giveimportantcluesastoitsdegreeofmalignancy,
ationonthedepthofpenetrationofthetumour
feasibilityoftreatmentandprognosis.A thorough
(Figure 3.6).
assessmentoftheprimarymassisobviouslyof
paramountimportanceinplanningsurgery.
Physicalexamination
BLADDE
Thesizeof theprimarymassisimportant.Forexam-
ple,inmammarytumours,those<3cmindiameter
generallycarryamorefavourableprognosisthan
largerones(see Chapter16).
Thedegreeofinfiltrationorinvasionofadjacent
normal tissuesby theprimary tumourreflectsits
malignancyandaffectsbothtreatmentandprogno-
NECK
sisfor local recurrence.Thismaybeassessed by
featuressuchashowwellcircumscribedthemass
appears,thedegreeofmobility,fixationof thelesion
inoneormoreplanes,adhesiontoadjacentstruc-
tures,orulcerationofoverlyingskinorepithelium.
3.6
Ultrasoundimageofabladdertumour
Thesefeaturesshouldbeassessedandrecorded
(arrowed)showinglayersof thebladderwall.
aspartoftheinitialexaminationofthecancer
patient.Forsuperficial softtissue tumours,physical
examinationmaybeallthatisrequiredforassess-
Computed tomography:CTusesionizingradiation
mentoftheprimarytumour.Fortumoursatcertain
butimagesareacquiredperpendiculartothebody
sites,（e.g.head and neck),close to or involving
orbodypart.Spiral CTscannersallowthese images
bone,orinvolving hollow organs,further investiga-
tobereformattedinhighdetailwithgreatly
tionsmaybe indicated.Endoscopy enablesvisual
increasedtissuedefinitionincomparisonwithradio-
assessmentof theextent of tumours of theupper
graphy.CTishighlysensitiveforfinebonedetail,but
andloweralimentarysystem,upperrespiratorysys-
softtissuedefinitionisnotasgoodaswithmagnetic
tem(intranasal)andbladder.Abiopsysamplemay
resonanceimaging(MRI) and forthisreason,ingen-
betakenat thesame time.
eral,CTisusedmorefordetectionofmetastaticdis-
Diagnosticimaging
this alsodependsuponavailabilitycostand time.CT
isconsiderablyquickerthanMRlandpatientsdonot
Radiography:Radiographyof，forexample,intra-
alwaysneedtobeanaesthetized.CT-guidedbiopsy
oraltumours,intranasaltumoursortumoursaffecting
can be performed on,forexample,lung masses,
digitsallowsassessmentofthedegreeofbony
which cannotbeimagedusingultrasound.In some
destructionandthustheinvasivenessofthetumour.
centresCTispreferredforradiationplanning,asthe
Whilstradiographyisrelativelylowcostandreadily
available,itsuseforstagingprimarytumoursofthe
mentplanningcomputerprograms.
24
Chapter3
Clinicalstagingand theTNMclassification
Magneticresonanceimaging:MRIproduces
3.8
images intransverse,sagittaland dorsal planes.It
providesexcellentsofttissuedetailandanatomical
T1andT2
definition,butdoesnotprovideanydetailofcortical
weighteddorsal
bone.Itisparticularlysensitiveforimagingthebrain
sectionsfroma
dogwithanasal
（Figure3.7)andspinalcord(andhaslargely
tumourinvading
replacedmyelographyinhumanmedicine)butisalso
themaxillary
veryusefulforpre-treatmentassessmentofsofttis-
bone.
sue sarcomas and intranasal tumours（Figure 3.8)
(seealsorelevant chapters).MRI canbe used for
imagingprimary tumoursof the headandneck,
spine,dorsum and pelvis but,because of the need
for theareaofinteresttoremainstillduringacquis-
itionof images,itisusedlessfrequentlyforimaging
lesionsofthechestandabdomeninsmallanimals.
Gatingsystemscanbeappliedtonegatemovement
artefact,butCTispreferableforimagingtumoursof
theseregions.
Clinicalassessmentoflocalandregional
lymphnodes(N)
Lymphnodemetastasisismostcommon
in
carcinomas,melanomasandmastcelltumours;soft
tissue sarcomasmayoccasionallymetastasizeby
thisroute.Theclinicianshould befamiliarwith the
principallymphnodesandpatternsoflymphatic
drainage(Figure3.9).
Physicalexamination
The size，shape,texture and mobility oflocaland
regional lymphnodesshouldbeassessed aspartof
theinitialpatient appraisal.Grossenlargement,irreg-
ularity,firmnessandfixationareallfeaturesindicative
ofneoplasticinvolvement.Amoresubtlelymphadeno-
pathymayindicateasmallmetastaticdepositormay
ariseasaresultofreactivehyperplasia.
MRI transverseandsagittalsectionsof thebrain
Anydegreeoflymphadenopathy
3.7
shouldbe
inadogwithpituitarymacroadenoma.
investigatedfurtherbycollectionoffine-needle
25
Chapter3Clinical stagingand theTNMclassification
3.9
Parotid
Medialretropharyngeal
Principal lymphnodesand
Lumbar-iliac
lymphaticdrainageinthe
Mediastinal
dog.
Mandibular
Prescapular
Superficial
inguinal
Axillary
Popliteal
Sternal
aspiratesandcytology.Arguably,aspiratesshouldbe
metastases.ltcanalsoprovidegoodsofttissuedefi-
collectedfromevenapparentlynormal lymphnodes
nitionofabdominal lymphnodesandcanbeusedto
fromregionsdraininghighlymalignanttumourssuch
guidefine-needleaspirationorneedlebiopsy,orsur-
asmalignantmelanoma.
gical investigation atexploratorylaparotomy.
Interpretationoflymphnodecytologycanbe
challenging in some cases,particularly in MCTs
Magneticresonanceimaging:Because of cost
becausemastcellscanbefound inlymphnode
thelengthoftimerequiredtoacquireimages,the
aspiratesfromnormalanimals.Currentrecommen-
need foranaesthesiaand gating,MRl isnot the
dationsarethatmetastasisofanMCTtoalymph
methodofchoiceforevaluationofthoracicor
nodemaybediagnosedoncytologyifmastcells
abdominal lymphnodes.
represent>3%of the cellpopulation(Duncan,1999).
However,using this criterion,up to25%ofnormal
Clinicalassessmentofdistant
dogswould thenbediagnosedwithametastatic
metastasis (M)
MCT（Bookbinder et al.,1992);therefore,results
Malignanttumoursmayspreadvia thehaemato-
fromlymphnodesdrainingamastcelltumourmust
genousroute,giving risetometastasesindistant
betreated withcaution.Conversely,afine-needle-
organs.Softtissuesarcomas,
osteosarcomas
aspirate‘negative'formastcellsdoesnotcompletely
(OSAs)and malignantmelanoma characteristically
excludethepossibilityofmetastasis.Excisionand
metastasizeinthiswaybutsomecarcinomasand
histopathologyisthemostsecuremethodforevalua-
MCTsalsospreadvia theblood todistantsites.
tionof lymphnodesdrainingMCTs(seeChapter12))
Althoughthelungsarethemostcommonsitefor
thedevelopmentofmetastasesinsmallanimals,
Imaging
otherpotentialsitesformetastaticspreadshouldnot
beoverlooked.Theseinclude:
Radiography:Whilstradiographyisusefulfor
screeningforenlargementofintrathoracicorintra-
Skin
abdominal lymphnodes,it canonlydetect gross
Bones
changes in lymph node size,and other imaging
Brainandspinalcord
methodsaresuperiorforstaginglymphnodes.
Internalorgans,pleen,liver,kidneys,heart.
Ultrasonography:Ultrasonography is a very sensi-
Thedetectionofmetastases isproblematic:
tivemethodfordetectingabdominallymphadeno-
tumoursonlybecomelargeenoughtodetectata
pathy.Itallowsguidedfine-needleaspiratestobe
relativelylatestage
intheirdevelopmentand
collectedforcytology,andmeasurementoflymph
micrometastasesthatarebelowthethresholdof
nodesforinitial stagingandtreatmentmonitoring.lt
detectionofimagingtechniquesmaybepresent.
islessusefulforassessmentof thoraciclymph-
adenopathybecauseof thelimitationsof air-filledlung.
Physicalexamination
Athoroughhistorymayrevealsignsindicativeofa
Computed tomography:CTismoresensitive than
wider problem;forexample,weightloss,anorexia，
radiographyfordetectionofmediastinallymphadeno-
lethargyorpyrexiamayraise thesuspicionof
pathyandwouldbethemethodofchoicefor
metastatic disease.Clinical findings such as skin
assessmentof ananimalwithalungmass,asit is
nodules,hepatosplenomegaly or bone pain would
alsomoresensitivefordetectionofpulmonary
warrantfurtherinvestigations.
26
Chapter3Clinicalstagingand theTNMclassification
Tosomedegreethesearchformetastatic
magesize.512x512
WL:-312WW:1632
tumourand itsknownmetastaticbehaviour.Anall-
encompassing
'met.
check'is
probably
not
appropriateforeverycancerpatient.
Imaging
Radiography:Routine thoracicradiographyisa
standardscreeningprocessfortumours thatmeta-
stasize via thehaematogenous route(e.g.OSA,
haemangiosarcoma,malignant melanoma,mam-
marycarcinomaandothercarcinomas-
thyroid,
bladder)as thelungs areone of the first sitesfor
developmentofmetastases.Radiographyisnota
verysensitivemeans
ofdetecting
pulmonary
masses.Sensitivitycanbeoptimized by:
Reducingmovementblur
Makingtheexposureonmaximuminflation
Taking appropriateviews.
MadehOsi
3.10
CTtransversesectionofcaninethorax,showing
Rightandleftlateralthoracicradiographsarethe
multiple pulmonarymetastases.(Image
minimumrequirementforscreeningforpulmonary
courtesyofPaddyMannion,CambridgeRadiology
metastases,as contrastisoptimized in theupper,
Referrals)
air-filledlung,whilstthepartial compressionof the
lowerlungmayobscureasofttissuenodule.
Whetherathirddorsoventralorventrodorsalview
lesionsbut,aswithotherimagingtechniques,itdoes
addstosensitivityisdebatable,thoughonestudyof
notprovideahistologicalorcytologicaldiagnosis
caninehaemangiosarcoma suggested that obtaining
(Fife etal.,2004).
threeviewssignificantlyreducedthefalsenegative
rate(Holt et al.,1992).Even thenan apparently clear
Magneticresonance imaging:Although whole-
thoracicradiographdoesnotruleoutthepresence
bodyMRI isusedinstaginghumancancerpatients,
of metastases.
itsroleinveterinarymedicineismoredirectedat
Whilstsurveyabdominalradiographsareoften
staging theprimarytumour thanassessing the
notveryhelpful inassessingmetastaticdiseasein
patientformetastases.
organssuchastheliverandspleen,surveyskeletal
filmsmaybeusefulforthosetumoursthatmeta-
Nuclear medicine (scintigraphy):The useof
stasizetoorinvolvebone(e.g.multiplemyeloma).
radioactivepharmaceuticalsthatlocalizetothearea
ofinteresttoassessorganfunctionandextentof
Ultrasonography:Ultrasound isverysensitiveat
disease iswellestablishedinhumanmedicinebut
detectinglesionsintheliver,spleenandkidneysbut,
littleusedinveterinarysmallanimalmedicine.The
asabove,isnotspecificforthenatureofthelesion
mostcommonlyusedradioisotopeis99mtechnetium,
andoftencannotdistinguishbenignnodularhyper-
becauseit hasashorthalf-lifeand iseasilyboundto
plasia frommore aggressive disease.Ultrasono-
localizingpharmaceuticalssuchasthebone-seeking
graphymaybeusedtoguidefine-needleaspiration
methylene diphosphonate(MDP).This combination
from suspiciouslesions,but thediagnosticyield is
(99mTcMDP)isa sensitiveandnon-invasivemethod
oftenlow.
ofevaluatingtheskeletoninanimalssuspectedof
Contrast-enhancedultrasonographyusingmicro-
havingorbeingatriskfrombonemetastases,such
bubblecontrastmediahasbeenusedtoimprove
asdogswithOSA（seeChapter13)
characterizationbetweenbenignandmalignantfocal
ormultifocal lesions in the spleen(Rossi et al.,2008).
Otherinvestigations
Computed tomography:CTismoresensitive than
Routinebloodsampling
maybeindicatedwhenthethoracicradiograph
Assessmentofhaematologicalandbiochemical
appearanceisequivocalorinthecaseoftumours
parametersmaybeperformedformanyreasonsin
withahighriskofpulmonarymetastases(e.g.OSA),
theanimalcancerpatientandcanformpartofthe
asithasbeenshowntobesuperiortoradiography
staging process.For example,in haematological
fordetectionofpulmonarymetastaticneoplasia
malignanciesitisimportanttoknowthedegreeof
(Nemanic etal.,2006)(Figure 3.10)
involvementintheperipheralbloodandthepres-
CTmayalsobeusedforassessmentofabdomi-
ence of any cytopenias(see Chapter 19).Some
nal organs.Contrast-enhanced CThasbeen shown
tumoursare associatedwithparaneoplastic syn-
toprovidesignificantdifferencesinimagingcharac-
dromessuchashypercalcaemiaandhypoglycaemia
teristicsbetweenbenignandmalignant splenic
(see Chapter4).
27
Chapter3Clinicalstagingand theTNMclassification
Bonemarrowaspiration
Bonemarrowaspirationisparticularlyusefulinthe
meansotherthanradicalsurgeryandeventhen
carrya poorprognosis(see Chapter18).
cies(lymphoma,myeloma and leukaemia).
Clinical stageisparticularlyimportantinclinical
Someauthoritiesalsorecommendthatbone
studies,especiallytrialsofanewdrugortherapy
marrowevaluationisnecessaryforclinicalstagingof
whereitisessentialthatlikeiscomparedwithlike.
MCTs.Althoughsystemicmastocytosishas been
Forexample,anewtreatmentforScCofthenasal
reported indogs(OKeefeetal.,1987)thisisarare
planumincatswouldnotbegivenfairassessmentif
conditionandthevastmajorityofdogswithcuta-
allcatsreceivingthenewtherapyboreT4tumours
neousMCTsdonothave circulating mast cellsor
andoutcomewascomparedwithcatswithTisand
evidenceofbonemarrowinfiltration.Consequently,
T1tumourswhoreceivedstandardtherapy.
in theauthorsopinionsuchinvestigationsarenot
warrantedintheevaluationofdogswithsolitary
cutaneousMCTs.
Summary
Figure3.13summarizesclinical stagingprocedures
Exampleofaclinicalstaging system
and indications.
Theprinciplesofclinicalstagingareofpara-
An exampleof theclinical staging systemfor
mountimportanceingeneralclinicalpractice,where
tumoursof theskin,appliedtosquamouscellcarci-
knowledgeofthelikelybehaviourofdifferenttumour
noma(ScC)of thenasalplanuminthecat,isshown
typesformsthebasisforselectionofclinical investi-
inFigures3.11 and 3.12.
gations.Clinicalstagingandstage grouping are
Tis,T1and T2
tumoursmaybetreated
includedwhererelevantinthefollowingchaptersfor
specifictumoursandbodysystems.
Tgroup
Description
Tis
Pre-invasive carcinoma（carcinoma in situ)（Figure3.12a)
T1
Tumourcmmaximaldiameteruperficialorexophytic（Figure3.12b）
T2
Tumour25cmmaximaldiameterorwithminimalinvasionirrespectiveofsize
T3
Tumour>5cm，orwithinvasionof the subcutisirrespective of size（Figure3.12c)
T4
Invasonfthrstruture.faciamuslrtilarbone（Fgur.
3.11
Clinical stagingsystemfortumoursofepidermal origin(Owen,1980)
3.12
Clinical
stagingof
SCC of the nasal
planuminacat.
(a)Tis:pre-invasive
carcinoma in situ.
(b)T1:superficial/
exophytic,<2cm）.
(c)T3:invasionof the
subcutis.(d)T4:
invadingother
structures.
(a)
(c)
(d)
28
Chapter3ClinicalstagingandtheTNMclassification
Technique
Indication
Physicalexamination
andassessment of nodalanddistantmetastasis
Radiography
T-Primary sitewheretumoursareadjacentoorinvolvingbone
N-Screening forthoracicand abdominal lymphadenopathy
M-Rightandleft lateral thoracicradiographsforallmalignanttumourslikelytometastasizetothelungs
Ultrasonography
T-Primarytumours f sftissuesabominal organs
N-Abdominallymphnodes
cell tumoursandgastrointestinal tumours
CT
T-Primary lung masses(also N and M)
N-Thoracic and abdominal lymphadenopathy
MRI
Scintigraphy
M-Assessmentof bonemetastasis.Evaluationofectopicormetastaticthyroid tumours
Haematology/biochemistry
May helpin staging haemopoieticmalignancies
Bonemarrowaspiration/biopsy
Importantinstaginghaemopoieticmalignancies
3.13
Summaryof clinical stagingprocedures and indications.
Referencesandfurtherreading
thoracicradiographsandpostmortemfindingsindogs with
hemangiosarcoma:77 cases （1984-1989).Journal of the
Bookbinder PF,Butt MT and Harvey HJ（1992）Determination of the
AmericanVeterinaryMedicalAssociation200.1535-1539
NemanicS,LondonCAand Wisner ER(2006)Comparisonof thoracic
numberofmastcellsinlymphnode,bonemarrowandbuffycoat
cytologicalspecimensindogs.Journalof theAmericanVeterinary
radiographs and single breath-hold helicalCT for detectionof
pulmonarynodulesindogswithmetastaticneoplasia.Journalof
MedicalAssociation200,1648-1650
VeterinaryInternaMedicine20,508-515
Duncan J （1999)The lymph nodes.In:Diagnostic Cytology and
O'Keefe DA,Couto GC,Burke-Schwartz Cand Jacobs RM（1987)
Haematologyof theDogandCat2ndedned.RLCowelletalp
Systemicmastocytosisin16dogs.JournalofVeterinary Internal
9-103,MosbySt.Louis
Medicine1,75-80
FifeWD,Samil VF,Drost WT,Matton JS and Hoshaw-Woodard S
OwenLN(198o)TNMClassificationofTumoursinDomesticAnimals.
(2004)Comparison betweenmalignant and non-malignant splenic
massesin dogs using contrast-enhancedcomputed tomography.
WorldHealthOrganization,Geneva
RossiF,LeoneVF,VignoliM,Laddaga EandTerragniR(2008）Useof
VeterinaryRadiologyandUItrasound45289-297
contrast-enhancedultrasound forcharacterizationof focalsplenic
FulcherRP,LudwogLL,BergmanPJetal.(2006）Evaluationofawo-
lesions.VeterinaryRadiologyandUltrasound49.154-164
centimetrelateralsurgicalmarginforexcisionofgradeIandgrade
Simpson AM,Ludwig LL,Newman SJ et al.(2004） Evaluation of
I cutaneousmastcell tumoursindogs.Journalof theAmerican
surgical marginsrequired forcomplete excisionof cutaneousmast
VeterinaryMedicalAssociation228210-215
Holt D,Van WinkleT,Schelling Cet al.(1992)Correlationbetween
Association224,236-240
29
RichardMellanby
Introduction
Multiplemyeloma
Leukaemia
Paraneoplasticsyndromes result fromindirect
Thymoma
effectsof tumoursduetotheproductionandrelease
Malignantmelanoma.
ofbiologicallyactivesubstancessuchashormones,
growthfactorsandcytokines.Paraneoplasticsyn-
Cats
dromesareanextremelyimportantconsiderationin
Incats,lymphomaandsquamouscellcarcinomaare
themanagementofmalignanciesinsmallanimal
themostcommontumourtypesassociatedwith
patientsforavarietyofreasons;thepresenceof
hypercalcaemia.Otherfelinetumourtypesreported
clinicalsignsrelated to the paraneoplasticsyn-
tobeassociatedwithhypercalcaemiainclude:
dromemaybethefirstindicationthatananimalhas
anunderlying neoplasia,and recurrence of the
Leukaemia
·
Osteosarcoma
paraneoplasticsyndromemaybetheearliestindica-
tionthat thetumourhasrecurredfollowingtreat-
。
Bronchiogeniccarcinoma
ment.Inaddition,paraneoplasticsyndromesmaybe
Fibrosarcoma
Undifferentiatedsarcoma.
evenmortalitythantheprimarytumouritselfand
Incontrasttodogs,adenocarcinomaof the apo-
consequentlymayhaveimportantprognosticimpli-
crineglandhasrarelybeendiagnosedincats
cationsand/ormayalterthetherapeuticapproachto
(Mellanby etal.,2002).
theunderlyingmalignancy.
Paraneoplasticsyndromestendtobeclassified
Clinicalsigns
accordingtothebodysystemwhichismostaffected.
Althoughtheraisedplasmacalciumconcentrationin
Thischapterwillreviewparaneoplasticsyndromes
manydogsandcatswithmalignancy-relatedhyper-
involving theendocrine,haematological/haemo-
calcaemia can cause significant clinical signs，in
static,gastrointestinal,renal,cutaneous andneuro-
othercasestheclinicalsignsmayberelatedpre-
muscularbodysystemsandwillbrieflydiscussother
dominantlytotheunderlyingneoplasia.Forexample,
lesscommonlyobservedparaneoplasticsyndromes.
tenesmusindogswithadenocarcinomaoftheapo-
crineglandof theanal sacisacommonpresenting
complaint.Hypercalcaemiaindogstendstocause
Endocrine system
inappetence,polydipsia,polyuriaandvomitinginthe
Hypercalcaemia
majorityofcases,withmuscleweaknessortwitching
Hypercalcaemiaisoneofthemostcommonparaneo-
occurringina minority.
plasticsyndromesdiagnosed insmallanimalpatients.
Oneof themostimportanteffectsofhypercalcae-
miaistheinhibitionofantidiuretichormone,which
Althoughparathyroidadenomasarewellrecognized
inbothdogsandcatsasacauseofhypercalcaemia
leadstoaninabilitytoconcentrateurineandcauses
duetoexcessiveproductionofparathyroidhormone,
non-parathyroidtumoursmorecommonlycause
isosthenuricorhyposthenuric.lf theanimal failsto
malignancy-associatedhypercalcaemiaincompanion
drinkenoughwatertocompensatefortheincreased
urinary water loss,dehydrationwilldevelop,with
animals.Thetumoursthatareassociatedwithhyper-
calcaemia differslightlybetweendogsandcats.
resultantprerenalazotaemia.Longstandinghyper-
calcaemia,especiallyifaccompaniedbyhyperphos-
phataemia,mayresultinrenaltubulardamageand
Dogs
Thetwomostcommontumoursassociatedwith
soanintrinsicrenal azotaemia.Consequently,it is
hypercalcaemiainthedogarelymphomaandadeno-
difficulttodistinguishprerenalfromrenalazotaemia
carcinomaoftheapocrineglandoftheanalsac,but
inanimalswithhypercalcaemia,sinceinbothsitua-
hypercalcaemiahasbeenassociatedwithawide
tionstheurinespecificgravitywillbelowered.
Incatswithhypercalcaemiathesignsaremore
rangeofothercanine tumours,including:
non-specific.Inappetence isrecorded in mostcases,
Carcinomassuchasnasal,mammary,bronchial
withpolydipsiaandvomitingoccurringlesscom-
andsquamouscellneoplasms
monly thanindogs.
30
Chapter4Paraneoplasticsyndromes
Parathyroidhormone-relatedprotein
PTHrp concentrationwithin thereferencerange
Themainhormonesinvolvedintheregulationof
(Mellanbyetal.,2006).
calciummetabolisminhealthyanimalsare:
Arangeofothercytokinesandhormoneshave
Parathyroidhormone
beenimplicatedincausinghypercalcaemia-associ-
ated malignancy,suchas ectopic production of
1,25-dihydroxyvitaminD（1,25（OH）D)
1,25（OH）Dandinterleukin-1,butlittleobjectivework
Calcitonin.
hasbeendoneinthisareaindogsandcatswith
However,a fourthhormone,namelyparathyroid
spontaneoustumours.Parathyroidhormonetendsto
hormone-relatedprotein(PTHrp),hasbeen demon-
bewithinorbelow thereferencerangeinanimals
stratedtoplayanimportantroleincalciummetabo-
withmalignancy-relatedhypercalcaemiaandraised
lism,particularlyinmalignantconditionsinhumans
plasmaPTHrpconcentrations.
andcompanionanimals（Rosoletal.,1992;
Mellanbyet al.,2006).PTHrphasa similarstructure
PTHrpassay:Atwo-siteimmunoradiometricPTHrp
andfunctiontoparathyroidhormoneandcauses
assayhasbeenclinicallyvalidatedforbothdogsand
hypercalcaemiabyincreasingboneresorptionand
cats(Figure 4.1)(Bolliger et al.,2002;Mellanby et
renal tubularresorptionofcalcium.Incontrast to
al.,2006).Theassayuses twodifferentantibodiesto
hypercalcaemiaassociatedwithprimaryhyperpara-
humanPTHrp that arespecificfordifferentwell
thyroidism,whichistypicallydue to theexcessive
definedregionsofthePTHrpmolecule.Thetwo-site
productionofparathyroidhormonebyaparathyroid
assaysaregenerallyconsideredtobesuperiorto
adenoma（Feldman etal.,2005),thepathogenesis
assaysthatdetectonlyoneregionof thePTHrpmol-
ofhypercalcaemiaassociatedwithmalignanciesis
ecule,since the two-siteassaysare morelikely to
usuallydue toectopicproductionofPTHrp.Dogs
measureintactPTHrpratherthanPTHrpfragments.
withhypercalcaemiaassociatedwithchronicrenal
Aradioimmunoassayhasalsobeenvalidatedinthe
failureorprimaryhyperparathyroidismduetoapara-
dog,but this assayis not currentlycommercially
thyroidadenomadonothavearaisedPTHrpcon-
available(Rosolet al.,1992).
centration(Mellanby et al.,2006).
PTHrpisalabileproteinandcarehastobetaken
PTHrpcausesanincreaseinbothtotalandion-
inthetransportationof thesampletothelaboratory;it
izedcalciumconcentrations.Thereisnocorrelation
isadvisabletodiscussspecificrequirementswiththe
betweenPTHrpconcentrationand thedegreeof
laboratory.Theusualrequirementis tocollect the
hypercalcaemia (either ionized or total calcium).
sampleintoEDTA,separatetheplasmaimmediately
However,it is importanttoacknowledge thathyper-
andstorefrozen（-20°Cisadequateforshort-term
calcaemiaassociatedwithmalignancyisnotinvari-
shortage).Thefrozenplasma shouldbedeliveredto
ablycausedbyectopicproductionofPTHrpbythe
thelaboratoryinspecialfreezerpacks,whichare
tumour,sinceaminorityofcaseshaveaplasma
usuallysuppliedbythelaboratory.
20-
18-
16
14
12
10
8
9
roid
4
P
2-
、
0
Control
Lymphoma
Lymphoma
Anal sac
PHP
CRF
-N
-H
carc.
4.1
PTHrpconcentrationsin:healthydogs(Control);dogswithlymphoma thatwerenormocalcaemic(Lymphoma-
N)andhypercalcaemic(Lymphoma-H);dogswithhypercalcaemiaassociatedwithanadenocarcinomaof the
apocrinegland(Analsaccarc.);hypercalcaemicdogswithprimaryhyperparathyroidismcausedbyaparathyroid
adenoma(PHP);anddogswithhypercalcaemia and chronicrenal failure(CRF).The dotted linerepresentsthe upperlimit
of thereferencerange.Normaldogs andhypercalcaemicdogswithanon-malignant diseaserarelyhaveelevatedPTHrp
concentrations.Incontrast,dogswithhypercalcaemiacausedbyneoplasiaoften(butnotinvariably)haveelevatedplasma
PTHrp concentrations.(Data from Mellanby et al.,2006).
31
Chapter4Paraneoplasticsyndromes
Diagnosis
Allhypercalcaemicanimalsshouldhavetheir
Thediagnosisofhypercalcaemia-associatedmalig-
peripheral lymphnodescarefullypalpatedanddogs
nancyisusuallystraightforward,basedontheclini-
shouldhavearectalexaminationtoassessfor
calpresentation and haematology,biochemistry,
thepresenceofanalsacmassesandsublumbar
urinalysisanddiagnosticimagingresults.
An
lymphadenopathy.Inaddition,inanimalswithhyper-
approachtotheevaluationofthehypercalcaemic
calcaemiawheretheunderlyingcauseisnotimme-
patient(Figure4.2)isdetailedintheBSAVAManual
diatelyapparentbasedonclinicalexamination,
ofCanineandFelineClinicalPathology;differential
haematology,biochemistry,urinalysisand fine-nee-
diagnosesforhypercalcaemiainthedogandthecat
dleaspiration/biopsyof lymphnodesormasses,fur-
arelisted inFigure 4.3.
Lookforneoplasia/lymphoproliferativedisease
Clinicalexamination(checkanalsacs)
Aspirate/biopsysampletakenfromanyenlargedorfirmlymphnodes
Haematologyprofile-cytopeniassuggestbonemarrowdisease
otherabdominal mass?
±ScanliverandspleenandtakeFNAif infiltratesuspected
Bonemarrowaspirate
Neoplasiadetected?
No
Yes
ACTHstimulationtest
Hypercalcaemiaof
Flat lineNormal
malignancy
Hypoadrenocorticism
PTHelevated?
Yes
No
Azotaemia?
PTHrPelevated?
No
Yes
Yes
No
Ultrasonography
iCaelevated?
Continuesearch
1,25（OH）D3or
ofneckand
fortumour
25(OH)D
exploratory
Yes
elevated?
surgery
No
Yes
Parathyroidnodule
Renalfailure
Granulomatouslesions
detected:primary
orothercausesof
hyperparathyroidism
hypervitaminosisD
4.2
Adiagnosticapproachtohypercalcaemia.(ReproducedfromBSAvAManualofCanineandFelineClinical
Pathology,2ndedn)
Dogs
Cats
Malignancy:
Malignancy:
Lymphoma
Lymphoma
Adenocarcinoma of theapocrinegland
.
Squamous cell carcinoma
Miscellaneoustumours（e.gvariouscarcinomasmuliplemyelomaeukami
Miscellaneous tumours(e.g.variouscarcinomas,leukaemia,
Hypoadrenocorticism
various sarcomas)
Chronicrenal failure
Chronicrenal failure
Primaryhyperparathyroidism
Primaryhyperparathyroidism
Less common causes:
Granulomatousdisease
HypervitaminosisD
Juvenile dog
4.3
Differentialdiagnosesforhypercalcaemiaindogsandcats.
32
Chapter4Paraneoplasticsyndromes
andabdominalradiographs/ultrasonographyisadvis-
pathogenesisofthelowplasmaglucoseconcentra-
able.AnACTHstimulationtestshouldbeundertaken
tionisoftenunclear.Severaltheorieshavebeenpro-
ifhypoadrenocorticismissuspected.Plasmaelectro-
posed,suchashypersecretionofinsulinor
phoresisshouldbeconsideredifmultiplemyelomais
insulin-like substances,glucoseutilizationbya large
suspected.MeasurementofPTH,PTHrpandvitamin
tumourmassandfailureofcompensatorymecha-
Dmetabolitescanalsobehelpful in thediagnostic
nisms.Hypersecretionof insulin bynon-islet cell
evaluationofhypercalcaemicpatients.
tumoursisanunlikelyexplanation,sincethemajority
ofdogswithhypoglycaemiaassociatedwithnon-islet
Treatment
celltumourstypicallyhavelowornormalinsulin
Themanagement of hypercalcaemia associatedwith
concentrations.Ectopic productionof insulin-like
malignancyisinvariablybasedontreatmentofthe
factorsis a more plausible explanation,which is
underlyingneoplasia.However,supportive measures
supportedby thecasereport of a dogwith hypogly-
areimportantduringthediagnosticevaluationpro-
caemiaassociatedwithaleiomyomaofthegastric
cess,particularlyindogswithelevatedcalciumand
wallthathadelevatedserumandintra-tumourcon-
phosphateconcentrationswhoareatriskofmeta-
centrationsof insulin-likegrowthfactorll-likepeptide
staticmineralizationofsofttissuesandirreversible
(Boari et al.,1995).
renal damage.
Correctionoffluiddeficitsandsalinediuresisare
Clinical signs
themainstay of therapy.Rehydrationwith intra-
Hypoglycaemia causes a range of clinical signs that
venousfluidsattwoorthreetimesmaintenance
include:
(0.9%sodium chloride)and then continuing the
·
Weakness
aggressivefluidtherapyoncerehydratedisadvis-
·
Lethargy
ableinanefforttoreducethecalciumconcentration
·
Inappetence
and topreserverenalfunction.Furosemideisalso
·
Ataxia
usedtopromotediuresisoncethefluiddeficitshave
·
Blindnessand seizures.
beencorrected.Glucocorticoidsmayincreasethe
urinaryexcretionofcalciumbutmakethediagnosis
Treatment
ofsomediseases,especiallylymphoproliferative dis-
Initialtreatment isbasedoncorrectionofthehypo-
orders,more difficult and so should notbe used
glycaemicstatebyfeedingcomplexcarbohydrates
beforeafinaldefinitivediagnosishasbeenmade.
ororaladministrationofsyrupscontainingglucose/
Salmoncalcitoninhasbeenusedtotreathyper-
dextrose.Intravenousadministration ofglucose-
calcaemiaindogs,but its short half-life,high inci-
containingfluidsmaybeadvisableiffeedingisnot
denceofsideeffectsandhighcosthavelimitedits
practicalorisineffective.Glucagon andglucose in-
clinical use (Dougherty et al.,1990).Bisphospho-
fusionscould alsobeconsideredforrefractorycases.
natesdecreaseosteoclastactivityandfunctionand
Definitivetreatmentofnon-isletcelltumournor-
canbeusedtotreathypercalcaemia,particularlyin
mallyrequiressurgicalexcisionofthetumour.Low-
casesofmalignancy-relatedhypercalcaemiawhere
doseglucocorticoidscanbevaluableinthepalliative
thetumourisnotamenabletotreatment(Milneret
al.,2004).The bisphosphonate pamidronate has
sion is notpossible.
Althoughnotwidelyused,streptozocinhasbeen
hypercalcaemia in dogs (Hostutler etal.,2005).The
administered tomanagecanine insulinomasmedi-
oralbisphosphonateclodronatehasalsobeenused
cally(Mooreetal.,2002)
totreathypercalcaemicdogswithunresectable
tumours(Gould,2001).
Miscellaneousendocrineparaneoplastic
syndromes
Hypoglycaemia
Hypoglycaemiaisawellrecognizedparaneoplastic
Hyperadrenocorticism
syndrome indogsand cats.Insulinoma,which is
Hyperadrenocorticismsecondarytoectopicproduc-
aninsulin-secreting isletcellneoplasmof thepan-
tionofACTH isawelldescribedparaneoplasticsyn-
creas,is the most common cause of malignancy-
dromeinhumans.Thissyndromeisassociatedwith
increasedACTHconcentrationsresultinginpersis-
associatedhypoglycaemia.Arangeofnon-isletcell
tumourshave alsobeen associated withhypogly-
tentlyraisedplasma cortisol concentrations,which
caemia,including:
producesclinical signs suchaspolydipsia,polyuria
andpolyphagia.Thediagnosisisbasedontheiden-
Hepatocellularcarcinoma
tificationofaconsistentlyincreasedplasmaACTH
Leiomyoma
concentrationintheabsenceofhypothalamic,pitui-
Leiomyosarcoma
taryandadrenalneoplasiaandtheidentificationofa
Haemangiosarcoma
primaryneuroendocrine tumour.Thisconditionhas
Multiplemyeloma
beeninfrequentlyrecognizedincompanionanimals
Renal adenocarcinoma
(Galac et al.,2005).
Hepatoma.
SIADH
The aetiology of thehypoglycaemia in insulinoma
Thesyndromeofinappropriatesecretionofanti-
isexcessivesecretionof insulin,whereasinnon-islet
diuretichormone(SIADH)is alsoawellrecognized
celltumoursassociatedwithhypoglycaemia the
paraneoplasticsyndromeinhumans,leading to
33
chapter4Paraneoplasticsyndromes
hyponatraemia,serumhyposmolalityand urine
Myelophthisis
hyperosmolalityintheabsenceofabnormalitiesin
Inanimalswithmyelophthisis,bonemarrowinvasion
renal,adrenalandthyroidfunction.Thisparaneo-
bytumourcellscandirectlyreducetheproductionof
plasticsyndromeisextremelyuncommonincom-
red blood cells.This is most commonly seen in
panionanimalsbutshouldbeconsideredinpatients
myelo-and lymphoproliferativedisorders.
withappropriatelaboratoryabnormalities.
Microangiopathichaemolyticanaemia
Microangiopathichaemolysisoccurswhenredblood
Haematological/haemostatic
cellsarefragmentedwithinbloodvessels
by
complications
intravascularfibrinstrands,forexampleinanimals
Anaemia
withsplenichaemangiosarcoma(seeChapter19).
Anaemiaisoneofthemostcommonparaneoplastic
Erythrocytosis(polycythaemia)
syndromesdiagnosed incompanionanimals.The
clinicalsignificanceofmalignancy-associatedanae-
Paraneoplasticerythrocytosisisrarelydiagnosedin
companionanimals.Incontrasttoprimaryerythro-
miacanbehighlyvariablebutinmanycasesitcan
cytosis,whichisaprimarydisorderoftheerythroid
haveamarkednegativeimpactonqualityof life,
responsetotreatmentandsurvival.Forexample,
celllines,paraneoplasticerythrocytosisoccursdue
toinappropriatelyelevatederythropoietinconcen-
dogswithlymphomaandanaemiaatthetimeof
trations.Thismaybeduetoectopicproductionof
diagnosiswerefoundtohaveashortersurvivaltime
thandogs thatwere notanaemic(Milleretal.,2009).
excessiverenalproductionoferythropoietin
Anaemiamaydevelopincompanionanimalswitha
in
malignancythroughvariousmechanisms,including
responsetohypoxia.Polycythaemialeadstoan
the following.
signs such as neurological signs,polydipsia,poly-
Anaemiaofchronicdisease
uriaandretinopathies.Paraneoplasticerythrocyt-
Anaemiaofchronicdiseaseiscommonlyobserved
osisistreatedbysurgicalexcisionof thetumour.
indogs andcatswithneoplasticdiseases.Itis char-
Phlebotomycanbeauseful temporaryadjunctive
acterizedbyreducederythrocytelifespan,leadingto
therapy.
amildtomoderatenormocytic,normochromic,non-
regenerativeanaemia.Itcanoccursecondarytoa
Leucocytosis
Increasedperipheral granulocytosiswithout evi-
widerangeoftumoursandtheaetiologyispoorly
understood;disorderedironmetabolismis widely
denceofinfectionorleukaemiaoccursinfrequently
consideredtobeanimportantfactorinthedevelop-
mentofanaemiaofchronicdisease.
leucocytesarenormallymatureneutrophilsandclini-
cal signsarerarelyobserved.Paraneoplasticneutro-
Immune-mediatedhaemolyticanaemia
philicleucocytosishasbeenreportedindogswith
Immune-mediatedhaemolyticanaemiaisalsoawell
renal carcinoma,lymphoma,fibrosarcomaand pul-
recognizedparaneoplastic syndrome(Figure 4.4).It
monarycarcinoma.The diagnosisismadebyexclu-
ismostcommonlyassociatedwithlymphoidmalig-
sionofothercausesofneutrophiliaandresolutionof
nanciesandlessfrequentlywithsolidtumours.
theleucocytosisfollowingsuccessfultreatmentof
the tumour.
Paraneoplasticeosinophiliahasbeenrarely
reportedincompanionanimals.ltmaybedifficultto
distinguishparaneoplasticeosinophiliafromeosino-
philicleukaemia andhypereosinophilicsyndrome.
Thrombocytopenia
Thrombocytopenia
Iis
commonly
observedin
companionanimalswithneoplasiaandcandevelop
throughvariousmechanisms,including:
。
Decreasedplateletconsumption
·
Increasedsequestration
Increased consumption
Pallor(shownherebythemucous membranes)
Immune-mediatedplateletdestruction.
4.4
isacommonclinicalfindingindogswith
malignancy-associated immune-mediatedhaemolytic
Theclinicalsignificanceofthethrombocytopenia
anaemia.
varieswidely，dependingontheseverityofthe
thrombocytopenia,theunderlying tumourandcon-
Chronicblood loss
currentillnesses.Severe thrombocytopenia can
Anaemiamayresultfrombloodlossduetoaprimary
resultinclinicalsignssuchaspetechiaeandecchy-
gastrointestinal tumour.Itmayalsooccursecondar-
moses(Figure 4.5).The therapyofchoice forpara-
ilyduetogastrointestinalulcerationinanimalswith
neoplasticthrombocytopeniaisdefinitivetreatment
mastcelltumoursorgastrinomas.
of theunderlyingtumour.
34
Chapter4Paraneoplasticsyndromes
Pancytopenia
Pancytopeniaisawellrecognizedcomplicationof
chemotherapybutcanalsooccurasaparaneoplas-
ticsyndrome.Thebest describedsyndrome isin
oestrogen-producingSertolicell tumours,whichcan
resultinanaemia,thrombocytopenia and leucopenia.
Themechanismofoestrogen-relatedmyelotoxicosis
isincompletelyunderstoodandmaybeduetothe
oestrogen-inducedproductionofamyelopoiesis
inhibitoryfactor.Theprognosisfordogswithmyelo-
toxocitysecondarytoanoestrogen-producingSertoli
celltumour tendstobepoor;pancytopenia canper-
sistevenwithsuccessfulremovalof theprimary
tumourandsupportivecare.
4.5
Thrombocytosis
Severe
Thrombocytosisis anunusualparaneoplasticsyn-
thrombocytopenia
dromeandhasbeendescribedinanimalswitha
canresultin
clinical signs such
rangeoftumours,includingosteosarcoma,leukaemia
as(a)petechiae
andsquamouscellcarcinoma.Itcanbeassociated
and/or(b)
withthromboticorhaemorrhagictendenciesbutin
ecchymoses.
mostcasesisnotassociatedwithanyclinical signs.
Coagulation disorders
Disseminatedintravascularcoagulation(Dic)isthe
mostcommonmalignancy-relatedcoagulationdis-
orderindogs andcats.The diagnosis ofDiCis
madeonthebasisofclinicalsignsofacoagulopathy
withlaboratoryfindingsofthrombocytopenia,hypo-
fibrinogenaemia,increasedfibrindegradationprod-
uctsandprolongedactivatedpartialthromboplastin
time(Figures4.6and4.7).Awidevarietyof tumours
hasbeenassociatedwithDiC,mostnotablyhaem-
angiosarcomas indogs.TreatmentofDiCisfre-
quentlychallengingandprognosisispoor.
4.6
History:Age,breedx
Diagnostic
Currenttherapy
approachto
thepatient
witha
Clinical examination:
bleeding
disorder.
Natureandseverityof bleed
(Redrawn after
Dobson and
Gorman,
Assess haemostasis:
1993)
cloting time (WB/ACT)
Wholeblood/activated
Normal WB/ACT
ProlongedWB/ACT
Hae
Assessclottingpathways:
OSPT-extrinsic
APTT-intrinsic
Erythrocytosis or
Thrombocytopenia
Clotting defects
Hyperviscosity
Primaryorsecondary?
Coumarinpoisoning
syndrome
qulation
Inherited facto
Antiplateletantibody
Assess FDPs,anti-
deficiencies
Stopanycytotoxic
thrombinlllandfibrinogen
Severeliver disease
treatment
35
Chapter4Paraneoplasticsyndromes
4.7
Endotoxins
Trauma
Neoplasms
Summaryof thepathways
Heatshock
Anaphylaxis
Necrosis
involved inDIC.（Redrawn
Viruses
Haemolysis
afterDobson and Gorman,
1993)
Endothelialinjury
Tissue thromboplastinreleas
Thrombin
Intravascularcoagulation
Circulatingthrombi
Consumptionofplateletsand
coagulationfactors
Fibrinolysis/FDPs
Microvascularthrombosis
Thromboembolicdisease
Bleeding diathesis
Renal failure
Ischaemia
Petechiae
Gastrointestinal ulceration
Ecchymoses
Gastrointestinal bleeding
Epistaxis
Pulmonary emboli
Neurological defectcoma
Bleeds intojoints,bodycavities
Intracranial haemorrhage
Hyperproteinaemia
Renal system
Paraneoplastichyperproteinaemiacanoccurincats
Companion animals with a protein-losing nephro-
ordogsdiagnosedwithmultiplemyeloma,leukaemia
andlymphoma,resultingfromexcessiveproduction
pathyconfirmedbyconcurrentevaluationofurine
of immunoglobulin(seeChapter 19).Increased con-
sedimentandurinaryprotein:creatinineratioshould
centrationsofimmunoglobulinscanleadtoclinical
signsassociatedwithserumhyperviscosity,suchas
since tumour-relatedimmunecomplexesmaybe
retinopathies,ataxia,altered demeanour and sei-
depositedin theglomeruliresultinginexcessive
zures.Abnormalitiesincoagulationmayalsooccur
urinaryproteinloss.Ashighlightedinthesectionon
duetopoorplateletaggregationoralteredfunction
ofcoagulationfactors.
neoplastichypercalcaemiacanbedamagingtorenal
functionparticularlyif thehypercalcaemicstateis
associatedwithconcurrenthyperphosphataemia.
Gastrointestinal system
Gastrointestinal ulcerationisawellrecognizedcom-
Cutaneous system
plicationofprimarygastrointestinaltumoursindogs
Asmallnumber
ofcutaneous
paraneoplastic
and cats.lt can alsooccurasaparaneoplastic syn-
syndromes
havebeenreported
incompanion
dromesecondarytomastcellneoplasia.Malignant
animals（Turek,2003).
mastcell tumoursmay secrete histamine,heparin
andproteolyticenzymes,withhyperhistaminaemia
Nodulardermatofibrosis
regardedasthemainfactorcontributingtogastro-
Nodulardermatofibrosisischaracterizedbythe
intestinalulceration.Histamine isapotentsecreta-
developmentofmultiplefirmandwellcircumscribed
gogue and acts on H-2receptors in the parietal cells,
cutaneous nodules
in
associationwithrenal
leadingtoincreasedgastricacidsecretion
and
cystadenocarcinoma orcystadenoma.lt ismostcom-
potentiallygastrointestinal ulceration.Histaminemay
monlydiagnosedinmiddle-agedGermanShepherd
alsostimulateintestinalmotilityandbloodflow.
Dogswherethediseaseisinheritedinanautosomal
Consequently，gastroprotectanttreatmentshouldbe
dominantpattern.Thecutaneousnodulesareoften
considered in dogs with mast cell tumours,partic-
non-pruritic,located in the dermis or subcutis,and
ularlyinpatientswithclinicalsigns suggestiveof
arefreelymoveable.Theytendtobelocatedprimarily
gastrointestinal ulceration(seeChapter12).Gastrin-
ontheextremitiesbutthecutaneouslesionscanbe
omasarerarepancreaticislettumoursthatsecrete
diffuse.Histologically,thenodulesconsistofirregular
excessiveamounts ofgastrin,whichcanlead to
bundlesofdense,welldifferentiatedcollagenfibresn
vomiting,lethargyandabdominalpain.
the dermisorsubcutis.
36
Chapter4Paraneoplasticsyndromes
Mostaffecteddogspresentwiththeprimarycom-
carcinomaandlesscommonlywithbiliarycarcin-
plaint ofnon-painful cutaneousnodules,butsigns of
oma.In the majority of cases,the disease has
renalpathologysuchashaematuriamayalsobepre-
alreadymetastasizedatthetimeofdiagnosis;how-
sent.Thereisnoeffectivetherapyfortheunderlying
ever,successfulresolutionofparaneoplasticalope
tumour.Palliativetreatmentbysurgicalexcisionof
ciahasbeenreportedinacatfollowingsurgical
cutaneousnodulesthatareulceratedorinterfering
resection of apancreaticmass(Taskeret al.,1999).
withlocomotionmaybewarrantedinsomecases.
Paraneoplasticexfoliativedermatitis
Superficialnecrolyticdermatitis(SND)
Paraneoplasticexfoliativedermatitishas
been
SND,alsotermednecrolyticmigratoryerythemaor
reportedincatsinassociationwiththymoma.Feline
hepatocutaneous syndrome,isa welldescribed
thymoma-associatedexfoliativedermatitisbegins
cutaneousparaneoplasticsyndromeincompanion
asnon-pruriticscalingandmilderythemaonthe
animals.The skinlesions associatedwithSND
headandpinnae,whichmayprogresstoageneral
includeerythema,crusting,exudation,ulcerationand
distribution.Crustsandulcersmaydevelopin
alopecia on thefeet,pressurepoints such as the
somecases.
elbow and hocks,flank,perineal area,muzzle
Successfultreatmentofparaneoplasticexfoliative
(Figure 4.8),facialmucocutaneous junction and/or
dermatitishasbeenreported
followingsurgical
oralcavity.Hyperkeratosisandfissuringoffoodpads
excisionof thymoma(Forster-VanHijfte etal.,1997).
occur inmanyanimals.Histopathologicalexamina-
Canine paraneoplastic alopecia
tionrevealsepidermalparakeratosis,oedemaand
Bilateralsymmetricalflankalopeciamayoccurasa
necrosisofkeratinocytes inthestratumspinosum
and hyperplasticbasal cells.
paraneoplasticsyndromeindogswithtesticular
tumours.TheseareoftenSertoli celltumoursand
thealopeciaiswidelyconsideredtobesecondaryto
hyperoestrogenism.
Canineparaneoplasticpemphigus
Paraneoplasticpemphigushasbeenreportedina
7-year-oldBouvierdesFlandreswithmediastinal
lymphomawhichpresentedwitherosiveandulcer-
ativeoral lesions(Lemmensetal.,1998)
Neuromuscular system
Myastheniagravis
Myastheniagravisisawellrecognizedneuromus-
cularparaneoplasticsyndrome incompanionani-
mals.Antibodiestoacetylcholinereceptorsare
commonlydetectedindogswithmyastheniagravis,
whichresultinafailureoftransmissionacrossthe
neuromuscular junction.Myasthenia gravis often
occursasaparaneoplasticsyndromeindogswith
thymoma,buthasalsobeenreported tooccurin
associationwithosteosarcomaandbileduct
carcinoma.
Typicalclinicalsignsincludeintermittentmildto
severe muscular weakness,exercise intolerance,
dysphagia,megaoesophagus andaspirationpneu-
monia.Detectionof
circulatingautoantibodies
againsttheacetylcholinereceptorandimprovement
Superficialnecrolyticdermatitis:skinlesionsof
ofexercisetolerancefollowingadministrationof
4.8
crusting andexudation affectingthemuzzleand
edrophoniumissupportiveofadiagnosisofmyas-
themucocutaneousjunctionsof theeyelid.
thenia gravis.Surgicalremoval of the underlying
tumouris the treatmentofchoice,butmyasthenia
UnderlyingconditionsindogswithSNDinclude
gravisdoesnotinvariablyresolveevenwithsuccess-
glucagon-secreting pancreatic tumours,hepatic
fulexcisionof thethymoma.
diseaseanddiabetesmellitus.Thepathogenesisof
SNDisunclear,thoughit hasbeenpostulatedthat
Peripheralneuropathy
hypoaminoacidaemiaisimportant.
Peripheralneuropathyhasbeenreportedinassocia-
tionwitharangeoftumours,includingmultiplemye-
Felineparaneoplasticalopecia
loma,lymphomaandvariouscarcinomasand
Felineparaneoplasticalopeciapresentsasnon-
sarcomas.Clinicalsignsareweaknessandprogres-
pruritic progressive symmetrical alopecia,which
siveparaparesis to tetraparesis,characterized by
lowermotorneurondysfunction.
37
Chapter4Paraneoplasticsyndromes
Miscellaneous conditions
presenceofaconcurrentdisordersuchasan
infectionoradversedrugreaction,butitmayalso
Hypertrophicosteopathy
occurasagenuineparaneoplastic syndrome.The
Hypertrophicosteopathyindogsisawelldescribed
prevalenceoffeverasagenuineparaneoplastic
conditionthathasbeenassociatedwithawidevari-
disorderisunknownindogsandcats.Animalswitha
etyofmalignantdiseases,includingprimary and
neoplasticprocessandafevershouldbecarefully
metastatic lung tumours,oesophageal tumours,
assessedforthepresenceofaninflammatoryor
rhabdomyosarcomaofthebladder,nephroblastomas
infectiousprocessand thentreated appropriately.
and livercarcinoma.lt canalsooccasionallybe
associatedwithnon-malignantconditions.
Cancercachexia
Itis characterized by progressive periosteal
Cancer cachexia,definedasloss of bothlean
hyperostosisthatoccursonthebonesofdistal
musclemassandadiposetissuedespiteadequate
extremitiesandoccasionallyonotherlongbonesof
nutritional intake,isanimportant and arguablythe
the appendicularskeleton(Figure4.9)
mostcommonparaneoplasticsyndromediagnosed
indogsandcats.Canceranorexiareferstoweight
lossduetopoornutritionalintake.
Recentstudieshavefoundthat,atthetimeof
diagnosis,over 20%ofdogswithneoplasia had
lostmorethan10%of theirbodyweight.Inaddition,
15%hadevidenceofclinicallyrelevantmuscle
wasting(Micheletal.,2004).Inastudyofcatswith
neoplasms,93%had evidence of muscle wastage
and44%hadabodyconditionscoreof lessthan
5/9（Baez et al.,2007).Importantly,this study
alsodemonstratedthatcatswithabodycondition
scoreoflessthan5hadashortermediansurvival
periodcomparedwithcatswithabodycondition
scoreof5ormore.
Referencesandfurtherreading
Anderson GM,Lane1,FischerJ.andLopezA(1999）Hypercalcemia
andparathyroidhormone-relatedproteininadogwith
undiferentiatednasalcarcinoma.CanadianVeterinaryJournal40,
341-342
BaezJL,Michel KE,SorenmoKand ShoferFS(2007)Aprospective
4.9
Radiographsof thelowerlimbsdemonstrating
investigation of the prevalence andprognostic significanceof
periosteal newbonecharacteristicof
hypertrophicosteopathy.
JournalofFelineMedicineandSurgery9411417
BattagliaL,PetterinoC,ZappulliVandCastagnaroM(2005)Hypo-
glycaemia as a paraneoplasticsyndrome associated with renal
Thecausesofthisconditionremain ill-defined，
adenocarcinomainadog.VeterinaryResearchCommunications
thoughincreasedperipheralbloodflowtothedistal
29,671-675
Battersby IA,Murphy KF,Tasker S and Papasoulitis K (2006)
extremitiesstimulatingconnectivetissueandperi-
Retrospectivestudyoffeverindogs:laboratorytestingdiagnoses
ostealproliferationhavelongbeenconsideredto
andinfluenceofpriortreatment.JournalofSmallAnimalPractice
be important.Thismaybeduetoincreasedvagal
47,370-376
BeaudryD,Knapp DW.MontgomeryTetal.（1995)Hypoglycemiain
tone,since hypertrophicosteopathy canresolve
fourdogswithsmoothmuscletumors.JournalofVeterinary
followingvagotomy.
InternalMedicine9,415-418
The clinical signs ofhypertrophic osteopathy are
BennettPF,DeNicola DB.BonneyP,Glickman NWandKnapp DW
(2002)Canine anal sacadenocarcinomas:clinical presentation and
typicallylamenessandreluctancetomovetogether
responsetotherapy.JournalofVeterinaryInternalMedicine16,
withswollenandpainfuldistalextremities,butclinical
100-104
BoariA,Barreca A，Bestetti GE,MinutoF and Venturoli M（1995)
signsmayalsoberelatedtotheprimaryneoplastic
Hypoglycaemia inadogwithaleiomyomaof thegastricwall
disease.Diagnosisisbasedonidentificationof typi-
producinganinsuli-likegrowthfactorllikepeptideEuropean
calperiostealreactiononradiographsoftheappen-
JournalofEndocrinology132,744-750
BolligerAPGrahamPA,RichardVetal.(2002）Detectionofparathyroid
dicularskeleton;thepatientshould thenbefollowed
hormone-relatedprotein in catswithhumoral hypercalcemiaof
upbyadditionaldiagnosticteststoidentifythepri-
malignancy.VeterinaryClinicalPathology31.38
marylesion.Therapyisbasedontreatmentofthe
CaywoodDD,KlausnerS,OLearyTPetal.（1988）Pancreaticinsulin-
secretingneoplasms:clinical,diagnostic,andprognosticfeaturesin
primarylesioninconjunctionwithanalgesiaand
73dogs.Journalof theAmericanAnimalHospitalAssociation24
supportivecareforthepainassociatedwiththeskel-
577-584
etal changes.
andhypoglycaemia inacaseof lymphaticleukaemia inthe dog.
Hypertrophic
osteopathyhasonlybeenrarely
VeterinaryRecord94,602-603
reported incats.
gammopathyinadogwithplasmacelldyscrasia.Journalofthe
Pyrexia
AmericanVeterinaryMedicalAssociation180,1345-1348
DobsonJMandGormanNT(1993)CancerChemotherapy inSmall
Fevercanoccurincompanionanimalswithavariety
AnimalPractice.BlackwellScientificPublications,Oxford
Dougherty SA,Center SA and Dzanis DA(19go) Salmon calcitonin as
of tumours.Typically,the pyrexia occurs due tothe
adjunct treatment forvitaminD toxicosisina dog.Journalof the
38
Chapter4Paraneoplasticsyndromes
AmericanVeterinaryMedicalAssociation196.1269-1272
Mellanby RJ,Craig R.Evans Hand Herrtage ME (2006)Plasma
DunnKJand DunnJK（1998)Diagnostic investigationsof 101dogs
parathyroid hormonerelatedproteinconcentrationsin dogswith
withpyrexiaofunknownorigin.JournalofSmallAnimalPractice
calciummetabolismdisorders.VeterinaryRecord159833-838
39,574-580
MichelKE,SorenmoKand ShoferFS(2004）Evaluation of body
ElliottJ,Dobson JM,Dunn JK,Herrtage MEandJacksonKF（1991）
Hypercalcaemia inthe dog:a studyof40cases.Journal of Small
oncologyservice.JournalofVeterinaryInternalMedicine1869
AnimalPractice32,564571
695
Feldman EC,HoarB,Pollard Rand Nelson RW(2005)Pretreatment
MillerAG,Morely PS,RaoS et al.(2009)Anemia isassociated with
clinicalandlaboratoryfindingsindogs
withprimary
decreasedsurvival time indogswithlymphoma.Journalof
VeterinaryInternalMedicine23,116-122
AmericanVeterinaryMedicalAssociation227,756-761
Milner RJ.Farese J,Henry CJet al.(2004)Bisphosphonates and
FoleyP,ShawD,Runyon C,McConkey S and Ikede B(20oo) Serum
cancer.JournalofVeterinaryIntrnalMedicine18,597-604
parathyroidhormone-relatedproteinconcentrationinadogwitha
Moore AS,Nelson RW,Henry CJ et al.(2002) Streptozocin for
thymoma andpersistent hypercalcemia.Canadian Veterinary
Journal41,867-870
1999).JournaloftheAmericanVeterinaryMedicalAssociation221
Forster-Van Hijfte MA,Curtis CF and White RN(1997) Resolution of
811-818
exfoliativedermatitisandMalasseziapachydermatisovergrowthin
Pressler BM,Rotstein DS,LawJMet al.(2002)Hypercalcemia and
acataftersurgicalthymomaresection.JournalofSmallAnimal
highparathyroidhormonerelatedproteinconcentrationassociated
Practice38,451-454
withmalignantmelanoma inadog.JournaloftheAmerican
GalacS,KooistraHS,VoorhoutGetal.(2005）Hyperadrenocorticismin
VeterinaryMedicalAssociation221263-240
adogduetoectopicsecretionofadrenocorticotropichormone.
Rosol TJ,Nagode LA,Couto CGet al.(1992)Parathyroid hormone
DomesticAnimalEndocrinology28,338-348
（PTH-relprtTHand5dihyrxitamini
Gaschen FP and Teske E(2005)Paraneoplastic syndromes.In:
with cancer-associated hypercalcemia.Endocrinology131,1157-
TextbookofSmallAnimal Medicine,edSJEttingerandEC
1164
Feldmanp.789795.lsevierSaundersStouisMissouri
Savary KC,Price GSandVaden SL(200o)Hypercalcemia in cats:a
Gould SM(2001)The long term useofclodronate to controlhumoral
retrospective studyof71cases(1991-1997).Journalof Veterinary
InternalMediine14,184-189
CongressProceedings,p.73
Sherding RG,Wilson GP and Kociba GJ （1981）Bone marow
HostutlerRA,ChewDJ,JaegerJQetal.2005)Usesandeffectiveness
hypoplasiaineight dogswithSertolicellstumors.Journalof the
ofpamidronatedisodiumfor treatmentofdogsandcatswith
AmericanVeterinaryMedicalAssociation178497-501
hypercalcaemia.JournalofVeterinaryInternalMedicine192933
Skely BJ and Mellanby RJ (2005)Electrolyte disorders.In:BSAVA
Kleiter M,Hirt R,Kirtz G and Day MJ (2001)Hypercalcaemia
Manualof Clinical Pathology.2ndedn,ed.EVilliers andL
associatedwithchroniclymphocyticleukaemiainaGiant
Blackwoodpp.113-134.BSAVAPublications,Gloucester
Schnauzer.AustralianVeterinarJournal79335338
Strombeck DR,Krum S,Meyers D and Kappesser RM （1976)
Leifer CE,Peterson ME,Matus RE and Patnaik AK （1985)
Hypoglycemia andhypoinsulinemia associatedwithhepatomaina
Hypoglycemiaassociatedwithnonisletcelltumorin13dogs.
dog.Journalof theAmericanVeterinaryMedicalAssociation169.
JournaloftheAmericanVeterinaryMedicalAssociation186,53-55
811-812
LemmensP,de BruinAanddeMeulemeesterJ(1998)Paraneoplastic
Tasker S, Grifon DJ, Nuttal TJ and Hill PB （1999)Resolution of
pemphigusinadog.VeterinaryDermatology9,127-134
paraneoplasticalopeciafollowingsurgicalremovalofapancreatic
MatusRE,LeiferCE,MacEwenEGandHurvitzAl（1986)Prognostic
TurekMM(2003）Cutaneousparaneoplasticsyndromesindogsand
carcinomainacat.JournalofSmallAnimalPractice40,16-19
factorsformultiplemyelomainthedog.Journalof the American
VeterinaryMedicalAssociation188,1288-1292
cats:areviwofthlitratureVetrinaryDermatology14279-296
MellanbyRJ,FoaleR,FriendEetal.(2002)Anal sacadenocarcinoma
Weiss DJ,Evanson OA and SykesJ（1999)Aretrospective studyof
inacat.JournalofFelineMedicineandSurgery4,205-207
caninepancytopenia.VeterinaryClinicalPathology28,83-88
39
When to treat animals with
cancer
Bernard E.Rollin
Trendsinhumanmedicine
Palliativecareandeuthanasia
‘Palliativecare’wasforgotteninthezealtopreserve
The2othcenturymarkedthetransmutationof
life.Asrecentlyas1991，it was reportedthat
humanmedicinefromafieldperceivingitselfascon-
although90%ofcancerpainwasmanageablewith
stitutingabalancebetweenartandsciencetoone
availablemodalities,80%wasnot controlled（Ferrell
farmorefirmlyensconced inthesciences.Muchof
andRhiner,1991).In the same vein,hospice wasa
thiswas to the good,as the Flexner Report pro-
conceptdevelopedalmostwhollybynurses,notsci-
duced in the US noted（Flexner,1910).Thus,for
entificphysicians,tohelptopreservepatientquality
example,medicinemovedfromasituationof‘medi-
of life.Asonenursingdeanstated,Physiciansworry
calanarchism'withabewilderingarrayoftherapeutic
aboutcure;nursesworryaboutcare'Ifpainwas
modalitiescompetingforpatientallegiance-homeo-
ignoredasscientificallyunreal,whathopewasthere
pathy,hydrotherapy,naturopathy and thelike-toa
forothernegativesequelaetotreatment,suchas
moreuniformbodyofdiagnosticandtreatment
lossofdignity?As thevastand international move-
modalitiesrooted(atleasttheoretically)inscience
mentinfavourofassisted suicideattests(laws in
andempiricalverification.
Belgium,theNetherlandsandOregon,theworkofDr
Kevorkian,pleasfordeathwithdignity)itbecame
Prolongationoflife
clearthatmanyifnotmostpatientsfearpain,andthe
Thetransitionofmedicinefromartintosciencewas
sufferinganddegradationthatextremepaininflicts
not without costs.As medicine became‘applied
onpatientsandfamilies,morethantheyfeardeath.
biology'or‘biomedical science'，certainkeyaspects
Itwastherecognitionofthispointthatledtothe
of traditionalmedicineweresuppressed.Forexam-
organizationofauniqueconferenceoneuthanasia
ple,asrational treatments for diseases suchas
in1980inNewYork,sponsoredjointlybythe
canceremerged,physicians marked their success
ColumbusUniversityCollegeofPhysiciansand
Surgeonsand theAnimal MedicalCenter,amajor
byempiricalparameters.Notableamongthese
measureswasadditionallifegarneredbywayof
veterinaryhospital.Theideaoftheplannerswasthat
the treatments.Such a scoring system,however,
thepowerofeuthanasiaasanultimatemodalityfor
alleviationofsufferingwaswellrecognizedinveteri-
entailedaneglectofqualityoflifeconsiderations.
Whilechemotherapyorradiationdidindeedprolong
narymedicine,butinsufficiently soinhuman medi-
cine.Thiswaswellillustratedbytheconundrumthat
lifeinmanyinstances,medicine failedtoask at
whatcost.Qualitative considerations,suchas the
apersonwhofailstoeuthanizeasufferinganimal is
perceivedsocietallyasmorallyblameworthy,whilea
patient'ssubjectiveexperience,becameinvisibleto
personwhohelpsa sufferinggrandmother,begging
scientificmedicinein thefaceoftheassumption
todie,toendherlifeisalsoseenasblameworthy.
thatmorelifewasalwaysbetter-avictoryagainst
The organizers felt that as companion animals
thedisease.
becomeincreasinglyperceivedas‘membersofthe
Social,cultural,idiosyncratic and moral dimen-
family'andlesslikelivestock,themoralimperativeto
sionsofaperson-featuresessentialtobeingaper-
endsufferingmighttransfertohumanmedicine.
son-cametobeseenasirrelevanttothetaskof
medicine,orasmysticalormetaphysicalandthere-
foreoutsidethephysician'spurview.Thusphysicians
Trendsinveterinarymedicine
toooftentreatedillnessesasbodilymalfunctions
andsawnoneedtobemorethanpoliteandcompe-
As the ensuing three decades evidenced,what
tentapplied scientists.Agreatdealhas,ofcourse，
subsequentlytookplacesocietallywasironically
beenwrittenaboutthetendencyofphysicianstofor-
theopposite:veterinarymedicinebecamemore
getthatpatientsarepersonsandtodesignate
likehumanmedicineinthefaceofanimalsassum-
patientsby suchlocutionsas‘thekidneyinroom
inggreaterfamilialsignificanceasobjectsoflove，
422'or‘theosteosarcoma'Whatisinterestingto
andthusmovedawayfromeuthanasiaasapower-
medicineasasciencearetherepeatable,universal
ful tool for alleviating suffering.Thisoccurred by
featuresofbodies,nottheindividualityofpeople
virtueofanumberofsynergisticandmutuallyre-
(Rollin,1987).
inforcingfactors.
40
Chapter5Whentotreatanimalswithcancer
·In thefirstplace,intheUSmore thanhalfof
likelyineffectivetreatmentsarepursued.Ofcourse,
marriagesend indivorce.TheUKhasthehighest
thesamecateringtoanowner'sunwillingnesstolet
divorcerateinEurope.Manydivorced
gocanoccuringeneralveterinarypractice.
professionalswithchildrenliveinurban
Thus,paradoxically,theriseof loveforcompan-
environments,wherethebestjobsaretobe
ionanimalscanresultinnewsourcesofuncon-
found,wheretheyareseparatedfromextended
trolledsuffering,buttressing thedictumthatloving
familyandmakingfriendsisnotoriouslydifficult.
somethingisnotsufficientinitsownrighttoassure
Thustheanimalassumesgreaterprominencein
thatoneprovidesthebelovedwithgoodcare.
people'semotional lives,withupwardsof85%of
theUSpublicaffirmingthattheiranimalsare
Roleoftheveterinarysurgeon
membersof thefamily'(HarrisInteractive,2007).
In theauthor'sexperience,thevastmajorityofveteri-
Thisstrongemotional bondwaswell illustrated
narysurgeons,particularlycompanionanimalpracti-
duringHurricaneKatrina,wherepeoplerefused
tioners,embracetheviewoftheveterinarysurgeon
rescuewhentoldtheycouldnotbringtheirpets.
asideallyanalogoustoapaediatricianratherthana
Therehasbeenanexplosioninveterinary
garagemechanic.That is,in the case of competing
specialtypracticesofferinghigh-level complicated
obligationssuchastheownerelectingtoprolong
andaggressivetreatment.
sufferingbypursuinguselesstherapies,theveteri-
At thesametime,manycompanionanimal
narysurgeon'sprimaryobligationistotheanimal
ownerswillfighttheiranimal'scanceras
and itswellbeing,nottotheowner.
aggressivelyastheywouldfighttheirown.For
Platosagelymadethispointwithregardtothe
suchpeople,euthanasia isalast-resortoption.
shepherd:in one's capacity as shepherd,one's
primaryroleis tocareforthesheep.Whatone
Insomesenses,thesefactors are salubrious.For
earnsdoingthisoccursinone'scapacityaswage-
example,thecostoftreatmentisfarlessofadeter-
earner,whichisconnectedbutsubordinatetothe
renttotreatinganimaldiseasethanitoncewas;
shepherdrole
thereforemanyanimalswhowouldhistoricallyhave
Obviously,given thatanimalsarethe propertyof
beeneuthanizednowregainextendedandgood
owners,veterinarysurgeonsarenotinapositionto
quality lives.It is inthefieldofoncologythat thisis
dictatetreatmentsor,morerelevanttothisdiscus-
mostapparent.
sion,euthanasia to end suffering.Furthermore,we
But there isan offsetting negative side,again
liveinasocietyinwhichmedicalpaternalismisa
produced by converging factors.First of all,many
dirtyword,andpatientorclientautonomyisatrendy
academiconcologists arealsoresearchers,who
slogan.Nonetheless,apowerfulelementofpaternal-
admirablyutilizesickcompanionanimalsin their
ismisaliveand thriving,andcanbedeployedto
research,rather thancreating diseaseinhealthy
goodeffectbyveterinarysurgeons.
animals.Whilethisapproachisinherentlylaudable,
Thatelementisapractitioner'sAesculapian
italsoengenderssome untoward effects,mainly
authority,thesingularauthoritypossessedbyphysi-
thetendencytoprolongtreatmentforreasonsserv-
ing the science,not the individual animal.This
medicalprofessionals（Rollin,2002).To deploy such
obviouslyplaysintonaturalownerreluctance
authorityonbehalfoftheanimaltoendsuffering is,
toeuthanize,sometimes resulting inextended
in the author'sview,not onlypermissiblebut obliga
unnecessarysuffering.
toryundercertaincircumstances.Whenclientsask,
Secondly,some clientssimplycannotacceptthe
What would you do if it were your dog， Doctor?”,
need toeuthanizetheirbestfriend”or“familymem-
theyareappealingtothepractitioner'sAesculapian
ber'.Theresult is a willingness to‘try anything'tosave
authority.Thusthe dictum(sometimespronounced in
theanimal,howeverfargoneorsufferingitmaybe.A
veterinarycircles)thatapractitioner shouldnever
particularlyperniciousconsequenceofthisisthepro-
suggestoradvocateeuthanasia,lesttheclientlater
liferationofevidentiallybaseless,unproven'comple-
blame theveterinary surgeonforkilling'theirbeloved
mentary'and'alternative'therapies.Suchmodalities
animal,should categoricallyberejected.
rangefrom‘Bachfloweressences'tohomeopathy
which,if true,invalidatesbasicprinciplesofmodern
Mentallifeoftheanimal
chemistry.Whetherpractitionersofalternativemedi-
Inextricablyboundupwithsuccessfuldeploymentof
cinearetruebelieversoraresimplybilkingthegull-
suchauthorityregardingtheneedforeuthanasiato
ible,accesstotheInternetassures thatdesperate
alleviateuntreatedoruntreatablesufferingis the
clientscanfindaninexhaustiblenumberofallegedly
issueofexplainingtoclientssomefundamentaldif-
therapeuticmodalitiesthattheywishtopursue.
ferencesbetweenhumanandanimalmentallife
Aparticularlydangerouscorollarytosuchan
thathavemajorandradicallydistinctimplications
attitudecanberepresentedbyhospicesfordying
forqualityoflifeinpeopleversuscompanionani-
animals.Insomecases,whereanownerwishesto
mals.Human thoughtis irreduciblytiedtolanguage,
pursuepalliativecareandlegitimatetreatmentforthe
whichallowsingressionintomodesof thought
canceranimal andhasmoneybutnotimetoprovide
closedtoanimals.Humanscanthinkinvery
care,thepethospicecanfulfilavaluablefunction.But
abstract terms (e.g.mathematics and logic);in
justasoften,thehospicecanallowtheownerto
negativeterms(therearenodragonsinthelibrary');
dodgetheissueofeuthanasiaforuntreatedor
inconditionalterms（if itdoesrain,wewillhold
untreatablesufferingwhileendlessnewunprovenand
graduation indoors');infutureterms(1wish toretire
41
Chapter5Whentotreatanimalswithcancer
inIceland someday");in universal terms(all trian-
betweenthehumanandanimalmindandchoose
gleshave three sides');in fictional terms（writing
thepossibilityoflifeprolongationatanyqualitative
novels);incounter-factual terms(ifDarwinhadnot
cost.Itisatthispointthatthemorallyresponsible
discoverednaturalselection,someone elsewould
veterinarysurgeonisthrustintotheirroleasanimal
have').These are all madepossiblebybeing able to
advocate,speaking forwhatmatterstothe animal.
structure thought linguistically,whichin turnallows
linguisticsyntax totranscendthoughtrootedin
Qualityoflife
immediateexperience.
Thebestwaytoaccomplishthissortofadvocacyis
Therichnessandmoralrelevanceofanimalmen-
tosetupthetypeofrelationshipwithaclientfrom
tal life shouldnotbe denied.There is,however,a
theoutsetthathasbothpartiesagreeingtokeepthe
strikingdissimilaritybetweenhumansandanimals
bestinterestsof theanimal inviewastheparamount
facinglife-threateningillnesses,evenasthetoolsof
goalof treatment.Inthisway,the cliniciancan
medicinedealingwithsuchcrisesconvergeinthe
educate theclientonthenatureofanimal mentation,
twoareas.Humancognitionissuchthatitcanvalue
suffering,and what matters to the animal.Such
long-termfuture goals and endure short-run nega-
educationshouldbeginalongwithtreatment,as
tiveexperiencesforthesakeofachievingthem.
shouldtheveterinarysurgeon'sclaimforadvocacy
Examplesareplentiful.Manypeopleundergovolun-
fortheanimal'squalityoflife.Qualityoflife
taryfoodrestriction,andtheunpleasantexperience
considerationsshouldbeintroducedatthebeginning
attendantinitswake,forthesakeofloweringblood
ofarelationshipwiththeclient,notsuddenlysprung
pressure,orlooking good inabikinias summer
onthemwhentreatment isover.Theclient（who,
approaches.Theymemorizevolumesofboring
afterall,knowstheanimalbetterthantheveterinary
materialforthesakeofgainingadmissiontoveteri-
surgeon)shouldbeencouragedfromthebeginning
naryormedicalschool.Theyenduretheexcruciating
tohelptodefinequalityof lifeforthatanimal.
painofcosmeticsurgeryinordertolookbetter.And
Beginningwiththeonsetof treatmentforcancer,
theysimilarlyendurechemotherapy,radiation,dialy-
theveterinarysurgeonshouldobtainfromtheclient
sis,physical therapy and transplants to achieve
a list,aslongaspossible,ofwhat makestheanimal
longerlifeandabetterqualityof lifethantheywould
happyorunhappy，and how theyknow.This list,
havewithoutit,or,insomecases,merelytoprolong
writtendownaspartofthemedicalrecord，can
thelengthoflifetoseetheirchildrengraduate,orto
servetoremindownersoftheirowncriteriafor
completeanopus,orfulfilsomeothergoal.
qualityoflifeatthepointwheretreatmentisfailing,
However,thereisnoevidence,eitherempiricalor
whenwishful thinkingandessentiallyselfishdesires
conceptual,thatanimalshavethecapabilitytoweigh
mayreplaceobjectivity.Iusedthismethodwitha
futurebenefitsorpossibilitiesagainstcurrentmisery.
friendwhoaskedmehowtojudgewhenitwastime
Totreatcompanionanimalsmorallyandwith
foreuthanasiaandhowtoavoidcompromisinghis
respect,theirmentational limitsneedtobekeptin
animal'squalityof lifebyoverlyprolongingtreatment.
mind.Paramountinimportanceistheextreme
Helaterthankedmeandtoldmethat,wasitnotfor
unlikelihood thattheycanunderstandtheconcepts
hisownencodednotesdefiningtheanimal'squality
of“life’anddeath’in themselves,rather than the
of lifewhiletheanimalwasstillwell,hewouldhave
painsandpleasureassociatedwithlifeordeath.To
rationalizedtryingavarietyofmodalitiesthatwould
theanimalmind,inarealsensethereisonlyquality
havegreatlyimpairedtheanimal'squalityoflife.
of life,i.e.whetheritsexperientialcontent ispleasant
Unquestionably,hesaid,denialwouldhavedistorted
orunpleasantinallofthemodesitiscapableof-
his perceptionbut forhisown reflective,codified
boredoroccupied,fearfulornotfearful,lonelyor
deliberationsonthatanimal'squalityoflifewhich,
enjoying companionship，painful or not,hungry or
not,thirstyornot,etc.Thereisnoreason tobelieve
eveninextremis,wasimpossibletoignore.
TheBritishVeterinaryAssociation,inconjunction
thatananimalcangraspthenotionofextendedlife,
withtheUniversitiesFederationforAnimalWelfare,
letalonechoosetotradecurrentsufferingforit.
heldagroundbreakingseminarin2006onqualityof
Thisinturn demandsarealisticassessment,
，as
lifeinanimals.Intheend,itisessentialthatveterinary
faraspossible,of what animals are experiencing.An
medicineshouldlearnfrom themistakesofhuman
animalcannotweighbeingtreatedforcanceragainst
medicineandnotsacrificequalityoflifeforquantity.
thesuffering thatthisentails.Ananimalcannot
Thischapterisdesignedtoassistveterinarysur-
affirmorevenconceiveofadesiretoendurecurrent
geonsinoptimizingqualityof lifeforcancerpatients,
suffering forthesakeoffuturelife;cannotchooseto
throughtreatment andsupport.Intreating andsup-
losea legtoprecludemetastasis.lt mustberemem-
beredthat ananimal isitspain,forit isincapable of
porting their cancer patients,veterinary surgeons
anticipatingorevenhopingforcessationof thatpain.
haveadutytobeanadvocatefortheanimal,andto
assessthecurrentsituationfromtheperspectiveof
Thuswhenlife-threateningillnessesafflictcompan-
ionanimals,itisnotaxiomaticthattheybetreatedat
theanimal.
whateverqualitative,experientialcostthatmay
involve.Theownermayconsiderthesufferingthata
treatmentmodalityentailstobeasmallpricefor
Referencesandfurtherreading
extra life,buttheanimalneithervaluesnorcompre-
FerrellBRand RhinerM(1991)High-tech comfort:ethereal issues in
hendsextralife'，letalonethetrade-offthisrequires.
cancerpainmanagementforthe1990s.JournalofClinical Ethics
The owner,in turn,may ignore the difference
2,108-115
42
Chapter5Whentotreatanimalswithcancer
FlexnerA(1910)MedicalEducationintheUnitedStates andCanada.
CaseStudiesnPatientManagemented.indlyandPWatn,
CarnegeFoundatinforHighrEdcatinrnctnwesy
pp.232-267.BSAVAPublications,Gloucester
HarrisInteractiveInc.(2007）PetsareMembersof theFamily’andTwo-
RameyDWandRollinBE(2004)Complementary andAlternative
ThirdsofPetOwnersBuyTheirPetsHolidayPresents.HarrisPoll
MedicineConsidered.Blackwell,Ames,lowa
#120,December4，2007,www.harrisinteractive.com/harris-_pol/
RollinBE（1987)Therights of the dying person.In:Principlesof
index.asp?PID=840
Thanatologyed.AHKutscherAGCarrandLGKutscherpp.109
MarksRMandSacherEJ(1973)Undertreatmentof medical patients
133.ColumbiaUniversityPress,NewYork
withnarcoticanalgesia.Annalsof InternalMedicine78,173-181
Rollin BE(2002)The use and abuse of Aesculapian authority in
PoltonG(2010)Patients with neoplasticdisease.In:BSAVA Manualof
CanineandFelineRehabilitionSupportiveandPallitiveCare：
Association220,1144-1149
43
Principles of oncologi
surgery
KieriJermynandB.DuncanX.Lascelles
Introduction
Completepatientevaluationisnecessaryto
determinetheoptionsforsurgicalintervention.
Oncological surgery isprobably themost interesting
Whenindicated,theaimof surgerymustbe
andmultifacetedsurgeryaveterinarysurgeoncan
clearlyrecognized,i.e.curativeintent,
carryout.It encompasses aspectsofsoft tissue,
cytoreductiveorpalliative.
Alternativetreatmentoptions,oradecisionnotto
acomprehensiveknowledgeofanatomyandrecon-
treat(seeChapter5),mustbefullyassessed
structiveproceduresforresultantdeficits.Boundaries
fromapracticalandprognosticstandpoint,both
arecontinuallybeingpushedforwardonthesurgical
individuallyandincombinationwithsurgery.
proceduresthatcanbeemployedtotreatlocalized
Theownermustbefullyinformedof theintentof
cancerinsmall animals.However,ifoncological sur-
surgery,theadjunctivetherapiesavailableand
gery istobe effective and successful,therearecer-
thelikelyprognosis.
tainprinciplesthatmustbeadhered to,andtheseare
outlined inthischapter.
Primarysurgery
Comparedwithothertreatmentmodalities,surgery
Theopportunityforthemostfavourableoutcome
oflocalizedtumoursprovidesthepossibilityforan
existswhenemploying surgeryforthefirst time;revi-
immediate cure,is not carcinogenic,isnotimmuno-
sion surgeries are less successful.The greatest
suppressiveanddoesnothavelocal toxiceffects.
chanceofacurelieswiththeprimarysurgeryfora
Withsensibleandappropriateanaestheticandan-
numberofreasons:
algesicprotocolsandadherencetotheprinciplesof
Untreatedtumourstendtohavemorenormal
anaesthesiaandsurgerycanbeminimizedanda
surroundinganatomy,whichfacilitatessurgical
successfuloutcomerealized.
removal
Inordertocarryoutsuccessfuloncologicalsur-
Recurrenttumoursmayhaveseededto
gery,surgeonsrequiremorethanacomprehensive
previouslynon-involvedtissueplanes,hence
knowledgeofanatomy,physiologyandresectionand
increasingtherequiredresection
reconstructiontechniquesforthespecificareaor
Themostactiveandinvasivepartsofthetumour
organinvolved.Athoroughunderstandingofgeneral
areat theperiphery,wherethebloodsupplyis
tumourbiology，the specificcharacteristics ofthe
greatest,andsubtotalresectionmaythusleave
neoplasm involved,the stage of disease,and thus
behind themostaggressivecomponentsof the
prognosisandtheadjunctivetherapiesthatmaybe
tumour
appropriate,isessentialineachcase.
Patientswithrecurrenceoftenhavesignificant
anatomicaldisruptionandlessnormaltissue
Thedecision tousesurgery
availableforclosure.
Surgeryinoncologyismainlyusedtofacilitatediag-
Preoperativeplanning
nosisandfortreatmentoflocalizedneoplasia.Prior
Tooptimizethelikelihoodofsuccessfulsurgery,itis
necessarytodefinepreciselytheroleoftheproce-
tocontemplatingsurgicalmanagementofacancer,
thepatientandtreatmentoptionsmustbefully
durewhilstgivingdueconsiderationtotherecon-
appraisedtodeterminethemosteffective approach.
structiveaspects.Many tumourresectionsresult in
substantial tissuedeficits.Apprehensionaboutnot
Thecancermustbecharacterized(typeand
beingabletoclosethesubsequentdefectisa
grade).Asurgicalprocedure(biopsy)maybe
potentdeterrenttofollowingexcisionguidelinesrig-
involved inthisprocess(seeChapters2and3)
orously(Figure 6.1).Ideally,one individual should
Thelocoregionalandsystemicextentof the
removethetumour,adheringtotheoncologicalprin-
disease(stage)mustbeassessed using
cipleson themarginsrequired,anda secondindi-
appropriateinvestigations,suchasphysical
vidualshouldthenperform thereconstruction.This
examination,bloodevaluations,radiography,
israrelyfeasibleandhencethesurgeonmustgive
ultrasonography,oradvancedimagingmodalities
fullconsiderationtothereconstructionpriorto
(see Chapter 3).
embarkingontheexcision.
44
Chapter6Principlesofoncologicalsurgery
6.1
The sarcoma in this
catrequiredwide
resectionmargins,including
full-thicknessresectionof the
bodywall.Apprehensionabout
closing theresultingdefect
(almostcompleteresectionof
theventral bodywall)could
resultinthesurgeon's
compromisingtheresection
marginsinfavourofbeingable
toclose thedefectmoreeasily.
Preoperativeplanningoftheanaestheticand
analgesicregimenandthepostoperativecarewill
minimizeperioperativemorbidity.
Revisionsurgery
Aspreviously stated,thefirstsurgeryhasthebest
chanceofasuccessfuloutcome.Excisedtissue
marginsareexaminedhistologicallyandfurthersur-
gerymaybeindicatedifthemarginsarepositivefor
tumour cells ornarrow(presenceof tumour cells
veryclose tothemargin).Managementof incom-
pletelyorcloselyexcisedtumoursrequiresthatthe
entireexistingsurgicalscarandanydrainagesites
areconsidered'contaminated'.Thesurgicalmargins
(a)
indicatedarethenthesameasfortheinitialsurgery.
Usuallythisresultsinamuchwiderresectionthan
the original surgery(Figure 6.2).
Theroleofoncologicalsurgery
Oncological surgerymayhavethefollowingpurposes:
Prophylacticsurgery
Diagnosisandstagingof neoplasticdisease
Definitiveexcision
Cytoreductionofthetumourmass
Palliativesurgery
Dealingwithemergencies
Support surgery
(b)
Surgicaltreatmentofmetastaticdisease.
6.2
Managementofanincompletelyexcisedgradell
mastcell tumour.(a)The entire surgicalscar
Prophylacticsurgery
and anyadherent tissuemustbeconsideredcontaminated.
Prophylacticoncological surgerycanbedefinedas
(b)Thesurgical marginsindicatedforrevisionsurgeryon
surgery thatresultsinareductionofeither the antici-
thistumourresultedinamuchwiderresectionand
patedincidencerateofaparticulartumourtype,or
subsequent tissuedeficit thantheoriginal surgery.
therateofrecurrenceofaneoplasticdiseaseafter
therapy.Thereareseveralcommonexamplesofpro-
expectedinentirebitches(Schneider etal.,1969).
phylacticsurgeryinsmall animal surgery.
Thisrelativeriskrisesquicklybeyondthefirstoes-
trus.Theincidenceis25%ofthatwhichmightbe
Mammarytumoursinthebitch
expectedinintactbitchesforbitchesspayedafterthe
Ovariohysterectomyperformedpriortothefirstsea-
secondseason.Therelativeriskforqueensis9%
sonisknowntoreducetheincidenceofmalignant
and14%,respectively.Bytheageof2years,littleor
mammarytumoursto0.05%ofthatwhichmightbe
nocancer-sparingeffectcanbeexpected inbitches.
45
Chapter 6Principles of oncological surgery
Oestrogenreceptorand/orprogesteronereceptor
Dermal squamouscell carcinomainthecat
expressionhasbeendemonstratedinbothbenign
Exposureofunpigmentedskintoultravioletradiation
(70%)and malignant (50%)mammary tumours.
canresultinthedevelopmentofsquamouscellcarc-
Expressionofprogesteronereceptorsappearsto
inoma(SCC).Often thisispreceded by the develop-
occurmorefrequentlyinbenigntumoursandmaybe
ment ofacrustingerythematouspigmented
ofpositiveprognosticsignificance.Evenlate-stage
premalignant lesion.The removal of this,together
ovariectomycanreducetheriskforbenigntumours.
withany susceptibleunpigmentedarea(e.g.resec-
Therealsoappearstobeahistological continuumin
tionofthecompletepinnaandverticalauralcanal;
theprogressionofcaninemammarytumoursfrom
nasal planum amputation)ishighly successful inpre-
benigntomalignant,whichwould argueforprophy-
ventingthedevelopmentofSCC(seealsoChapters
lacticremovalofbenignneoplasms(seeChapter16
12 and 18).
formoreinformation).
Colorectaltumoursinthedog
Benignvaginaltumoursinthebitch
Upto18%ofbenignpolypoidlesionsandcarcinoma
Ovariectomyisaneffectivemeansofpreventing
insituofthecolonandrectumhavedemonstrated
boththedevelopmentandtherecurrenceofbenign
potential toundergomalignant transformation into
andpossiblymalignantvaginaltumoursinthebitch,
carcinoma.Earlywidelocalresectionoftheselesions
andthisprocedureshouldbeconsideredanintegral
isabletopreventsomeformsofrectalcancer.
partof thesurgicalmanagementof thisdisease
alongwithlocalexcision(Figure6.3).Malignantvagi-
Trauma/chronicinflammation
nal tumoursarenotashormonallyinfluencedas
Chronicinflammationcanlead tomutations that
benign tumours(see alsoChapter17).
resultintissuesundergoingneoplastictransforma-
tion.Thisprocessmayplayaroleindevelopmentof
6.3
digital SCCfollowing chronic subungual infection/
inflammation,auralsebaceouscelladenocarcinoma
Localresectionof
andfelineinjectionsitesarcomas,tonamea few.
avaginal
ThecurrentrecommendationfromtheVaccine-
leiomyoma
Tumour
followingan
AssociatedFelineSarcomaTaskForceisthat
episiotomy
masses thatoccuratsitesfollowingvaccination
approach.
shouldbetreatedbysurgicalexcisionifthelesionis
Ovariectomyisan
stillevidentmorethan3monthsaftervaccination,if
importantpartof
itis>2cmorifitisincreasinginsizemorethan4
the approachto
thesetumoursto
weeksfollowingvaccineadministration.
prevent
Diagnosis and staging
recurrence.
Obtainingadiagnosisandclinicalstagingof sus-
pectedneoplasiaareofparamountimportancebefore
determiningtreatmentoptions.Thehistopathological
diagnosiswill influenceprognosisandhelptoestab-
lishthemost appropriaterecommendationsforsurgi-
caland adjunctive therapy(Figure 6.4).Thiswillassist
theveterinarysurgeonandownerinmakingdecisions
abouthowtoprogress.Withtheexceptionoftruly
bestbespeculativeandcanrarelybejustified，evenn
Testiculartumoursinthedog
thehandsof anexperiencedoncologist.
Theincidenceoftesticularneoplasiaissignificantly
greater(byabout14times)inanundescended tes-
Biopsytechnique
ticleover the incidence inanormaldog.This
Thereisavarietyofbiopsy techniques（seealso
meansthatabout50%ofcryptorchidtesticleswill
Chapter2):
developneoplasticlesions.Neoplasiaisalsomore
commonthanexpectedinthedescendedtesticleof
Cytology(fluidandexfoliativecellrecovery,fine
cryptorchiddogs,probablydue togeneticfactors
needle aspiration(FNA),impression smears)
thatpredisposetothedevelopmentofneoplasia.
Needlecorebiopsy(Tru-cut,Menghini or
Sertolicell tumours(60%ofcryptorchid tumours)
Jamshiditypeneedles)
andseminomasarethemostfrequenttumourtypes
Incisional biopsy(surgicallyremovedpinch,
associatedwithcryptorchidism.Bilateralelective
punch or wedge samples)
orchidectomypreventsthedevelopmentofsuch
Excisionalbiopsy('complete'postsurgical
tumoursin at-riskpatients.
specimen).
Castrationofthenon-cryptorchidmaledogwill
alsohelptopreventperianaladenomasandtesticu-
Thetypeofbiopsyprocedurechosenwilldepend
lar cancer.Although castration doesnotappear to
ontheinformationthattheclinicianrequires.lfthe
precipitatedevelopmentofprostaticneoplasiain
detectionof individualneoplasticcellsis sufficient,
dogs,it mayfavourtumourprogression.
cytological techniques willsuffice(e.g.formast cell
46
Chapter 6Principles of oncological surgery
Tumour presentation
Reason forperformingbiopsypriorto surgery
Subcutaneousmass on the
Twopossiblediagnosesarealipomaandaperipheralnerve sheathtumour(spindlecellsarcoma)The surgeries
lateral thorax/abdomenofa
requiredtogainacurearevastlydiferentTheprognosisforthetwotumoursisverydifferentandtheprognosisfor
6op
differinggradesofnervesheathtumoursisalsoverydifferent.GradeItumourscanbecuredbywidesurgical
treatmentstrategyRemovalof thewholemasstoobtainadiagnosismaywellresultinamoredificult surgerybeing
requiredlaterwithlesschanceofcompleteresection
Alarge cranialmediastinal
mass
thymomabest treatedbysurgery
A2cm diametermass on
Thedistinctionbetweenperipheralodontogenicfibroma（anepulis）andosteosarcomaisimportant.Theepulisrequires
therostralmandibleof adog
prognosis.However,theprognosisforamandibularosteosarcomaismuchbetterthanforanamelanoticmelanoma
6.4
Someexamplesofwhenbiopsyshouldbeperformedpriortosurgery.
tumours(MCTs).However,ifa stromal tumour is
Adequateexposureisnecessaryforboth
suspected (e.g.a sarcoma),the tissuearchitecture
incisional andexcisionbiopsiestoensure
willneedtobeexaminedandneedlecoreorinci-
minimaldisruptionofthetumourandadjacent
sionalbiopsytechniqueswillbetheminimum
tissues.
requirement.Also,if tumoursare tobe graded，
needlecoreorincisionaltechniquesaregenerally
Useofbiopsy
indicated.Tumourtypeandgradeareusually
Inthemajorityof instances,preoperativebiopsyis
requiredtohelptodirectthesurgeontowardsthe
indicatedbecausethekindorextentoftreatmentwill
requisiteorrecommendedresectionmargins.Often
bealteredbyknowledgeofthetumourtype（Figure
arelativelynon-invasiveorsimpleprocedureisused
6.4).Thebiopsyreportwillprovideinformationon
)
diagnosisand,where appropriate,grades thatare
mentofothertechniquesuntilsufficientisknown
majorprognosticdeterminantsand thisprovidesthe
abouttheneoplasmtoallowformulationofthemost
cornerstone for subsequent surgical planning.For
effectivesurgical and adjunctivetherapyprotocol.
example,softtissue sarcomas,oral fibrosarcomas
Toavoidcompromisingfuturetreatment,afew
andMCTs(intermediatetohighgrade)haveahigh
generalprinciplesofbiopsyshouldbeobserved.
rateoflocalrecurrenceafterconservativeresection
andthusrequireremovalwithmuchwidermargins
Thebiopsysiteshouldbepositionedwithinthe
thanbenignorotherlow-gradetumours.Permanent
probablesurgicalorradiationfield.
localtumourcontrol andsurvivalarepositivelycorre-
Thebiopsyincisionshouldbeassmall asis
lated,andpreoperativeknowledgeofthetumourtype
required,andorientedsoasnottoincreasethe
will helpinplanningthecorrectdefinitivesurgeryand
sizeofthesubsequenttreatmentarea
thusachievingalocal cure.
unnecessarily(usually along skintension lines).
In someinstances,however,priorknowledgeof
Forexample,biopsyincisionsonlimbsshouldbe
thetumourtypewillnotalterthesurgicaltreatment
orientedparalleltothelongaxisof thelimb.
plan.Examplesofthisincludelobectomyforasoli-
Specimensshouldbehandledcarefully.Useof
tarylungmassandsplenectomyforlocalizedsplenic
electrocauterytoobtainthesamplewilldistort
neoplasia.Inmanyinstancesofaggressivelydestruc-
tissuearchitectureandmakeitunreadablebythe
tivebonylesionsthetreatmentplanwillinclude
pathologist.Electrocauterymaybeused
amputation,regardlessof the diagnosis.Conversely,
afterwardsforhaemostasis.
theabilitytoobtainadiagnosticcytologywiththe
Multiplesamplesshouldbeobtainedifpossible
and fromdifferentareasofthelesion.Thetumour
andcomputedtomography)inaminimallyinvasive
shouldbecarefullyexaminedpriortobiopsy,and
fashionis improving.For example,imaging-guided
areasofinflammationandnecrosisavoided,as
FNAcanmakeapositivediagnosisin89%of
theunderlying neoplastic processmaybe
osteosarcomas（Brittetal.,2007)and65%of intra-
maskedbysecondarytissuechanges.Oftenthe
thoraciclesions(Zekas et al.,2005).lf thebiopsy is
bestareaforbiopsyisthejunctionofnormal and
asdifficult as thepostulatedcurative surgery,such
abnormaltissue.Importantexceptionstothisare
asistruefortheremovalofbraintumours,informa-
primarybonetumours;astheyoftenhavean
tionaboutthetumourtypeshouldbeobtainedafter
extensivereactiveprocesssurroundingthe
surgicalremoval.
primarylesion,samplesshouldbeobtainedfrom
Insomeinstances,usuallydrivenbyownersand
thecentre.
oftenonfinancialgrounds,masses areremoved
Thebiopsyshouldresultinminimalriskoflocal
withoutanypreoperativeknowledgeofwhatthe
disseminationoftheneoplasticdisease.
massis.Examplesincludeolddogsbotheredby
Uninvolvedanatomicalplanesandcompartments
ulcerated cutaneous masses.Communication isof
shouldnotbebreachedandfresh
paramountimportanceinthesecases:theowner
instrumentationshouldbeusedforeachsite
mustunderstandthat thesurgerybeingcarried
sampled.
outmaynotbeappropriatefor thismass,could
47
Chapter6Principles of oncological surgery
impactfuturetreatmentoptionsandmaynoteffect
mass.These marginswillhave beendecided on
alocalcure.
priortosurgeryonthebasisofthebiopsy
Itisimportanttorememberthattumourtissue
information.Theincisionshouldalsoallowadequate
itself oftenhasa poor orabsentnerve supply and so
accesstothetumourtoavoidroughhandlingand
biopsysamplesrepresentativeoftheneoplastic
fragmentationoftheneoplastictissue.
processcanbeobtainedusingonlytheminimumof
sedationandlocalanalgesia;generalanaesthesiais
The surgical margin
notnecessarilyrequired.Theargumentthatitisjust
Thechoiceofthemarginatsurgerywillprofoundly
asmuchhassletogetthebiopsyastochopitoff'is
affect the success of the surgeryasacurative proce-
sometimesused againstprocuring abiopsy.Thisis
dure.The apparentlynormal tissue surrounding
not true.
malignanttumoursisfrequentlyinfiltratedbyneo-
plasticcells.Generally,thegreater thelikelihoodof
Definitiveexcision
localinfiltration,thewiderthesurgical marginmust
Thisreferstotheuseofsurgeryasthesoletreat-
bebecauseofthepropensityfor local,unappreci-
ment,withoutadjunctiveradiotherapyorchemo-
ated spread (Figure6.5).Themagnitudeof grossly
therapy,toachieve anoutright cure-curative
normaltissuetakenwiththeobvious‘primary'mass
intent.Surgical excisionremains thedominant
willdependonthehistologicaltypeandgradeof
modalityofcurative therapy.Thisispossiblewith
tumour,againemphasizingtheneedforestablishing
localizedandoccasionallywithregionallyconfined
thisinformationbybiopsypreoperatively.Thetumour
neoplasticdisease.Thegoal iscompleteremoval of
andadjacenttissuesneedtobeconsideredthree-
allneoplastictissue,withclearnegative margins
dimensionallywithrespecttomargindetermination,
andmaximumpreservationoffunction,inonesur-
peripheral/circumferentialanddeep,allofwhichare
gery.Realistically,the definitive surgery probably
equallyimportant.
doesnotremoveeverylasttumourcell;instead,the
Althoughmarginsareusuallydescribedinterms
animal'sownlocalimmunedefencemechanism
ofa specifiedmeasurable distance,consideration
maywell‘mop up'theremainingneoplasticcells.
shouldalsobegiventothebiologicalbehaviourof
However,thisprocessshouldnotbereliedonto
thetumourinquestion.Themosteffectivenatural
correctcompromisedsurgical technique.Theinci-
barrierstothespreadofcancerarecollagen-rich
sion,thesurgicalexposure andthesurgicalmargin
relatively
avascular
tissues,
including fascia,
arethemostimportantaspectsofadefinitive
tendons,ligamentsand cartilage.Fat,subcutaneous
surgery.
tissue,muscle and other parenchymatous organs
offerrelativelylittleresistancetoinvadingneoplastic
The incision andsurgical exposure
cells.Peripheralmarginsarefrequentlyreferredtoin
Theplacingoftheincisionshouldtakeintoaccount
termsofmetricmeasurementsanddeepmarginsin
theneedtoresectanyscarsthatarearesultof
termsofmetricmeasurementsorfascialplanes.
previous surgeryor sites of biopsy.Suchscars
Fixationof thetumour toadjacentstructuresor
shouldbeafforded thesamemarginsasthebulkof
fascialplanesmandatesremovalof theadherent
thetumourduetocontaminationfromtheprimary
areaincontinuitywiththetumour.
Tumour type and grade
Required margins to give'good
Depth of resection needed
chance of cleanresection
Peripheralodontogenicfibroma（POF)and
0.5cm
Throughtissueinalldirections.Somesurgeonswill
ameloblastoma(epulides)
scrape'thePOFfrom bone（they donot invade
bone)butthiscanbeassociatedwithrecurrence
Oral basal cell carcinoma(epulis)
1cm
Throughtissueinalldirections
Grade I(low grade)MCT
1cm
Downtoandincluding themuscleorfascial plane
belowthetumour
GradeIsoftissuesarcomas(spindlecellsarcomas)
Osteosarcomasthathavenotinvadedsoft tissues
WelldifferentiateddermalSCC
Grade ll(intermediate grade)MCTs
2cm
Downto andincluding themuscleorfascial plane
belowthe tumour;or tissue inall directions(fororal
Mostmalignant oraltumours(fibrosarcoma,
(snon
osteosarcomasquamouscellsarcoma
IntermediateorpoorlydifferentiateddermalSCC
6.5
completeresection.
48
Chapter6Principlesofoncologicalsurgery
Figure6.6outlinessomenaturalbarriers to
Intuitivelythiscouldbeexpectedtoinfluencethe
tumourspreadatdifferentlocationsinthebody.
sizeof appropriatemargins and,indeed,hasbeen
Thesearetakenintoconsiderationwhendecidingon
demonstratedtobecorrectformelanomainhuman
the appropriateextentofresection.
patients,whereanatomicalsite and thicknessare
There is substantialevidence tosupport the
independentpredictorsofoutcome.Currentmargin
theorythata‘positivesurgicalmargin'（presenceof
recommendationsformelanomaaresite-andsize-
tumourcellsat theedgeof theexcised tissue)hasa
dependentandvaryfrom1to2cmtoreflectthis
negative impact onlocalrecurrence rates,risk of
(Zitelli et al., 1997).
metastaticdisease,length ofdisease-freeinterval
Theabilitytoappreciateaccuratelytheextentof
anddisease-related death.Equally,marginsexces-
thegrossdisease(particularlywhereitisnotpossi-
bletopalpatetheentiretumourexternally)and
ityoflife.Significantdebateremainsastothe
henceobtainadequatesurgical marginsissubstan-
optimalexcisionmargins.Excessivelywidemargins
tiallyimprovedbyuseofadvancedimagingmodal-
contribute toincreaseddurationofhospitalization,
ities(Wallacket al.,2002).Attempting toachievea
cost,increasedcosmeticdisfigurementandwound
negativesurgicalmargininthecaseofmetastatec-
complications.lfmarginsaretoonarrowtherewillbe
tomystillappearstobeimportant,assomestudies
increased incidenceofrecurrence,metastasisand
havedemonstratedanimpactonriskofdisease
mortality.Surgeonsaimforamarginthatiswide
recurrenceandsurvivaltimes.
enoughtoremovethetumourcompletelyforan
Theextentofthesurgicalmargincanbe
acceptablepercentageof timeandnarrowenoughto
categorizedanatomicallyas:
minimizeremovalofexcessivenormaltissue.
OnestudyinMCTsevaluated thepresenceof
Localexcision
tumourcellsinexcisedtissueatlocationsof1,2and
Widelocalexcision
3cm from theprimarymass(Simpson etal.,2004).
Radical local excision.
Forlow-gradelesions,allwerecompletelyexcised at
adistanceof1cm;intermediategradesachieved
Localexcision:Thisistheremovalofthegross
75%completeexcisionat1cmand100%at2cm.
tumourwiththeminimalamountofsurroundingnor-
Anotherstudydemonstrated91%completeexcision
maltissue.Thisoftenmeansremovalofthetumour
oflow-andintermediate-gradeMCTsatadistance
throughitsnaturalcapsuleorimmediateboundaries,
of2cmwithnolocalrecurrenceduringthefollow-up
usually
leaving
residualmicroscopicdisease.
period(Fulcheretal.,2006).Evenwithhistologically
Althoughanadditionalmarginofnormaltissueis
complete excision,local recurrence is stillpossible
usuallyremoved,therearesomeinstanceswhenit
(Weisseetal.,2002).Thelikelihoodofrecurrence
isdesirablenottoexceedtheboundaryofthe
followingmarginalexcisionvarieswithtumourtype
tumour,soastopreservevitalsurroundingtissue
andhistologicalgrade.
(e.g.removaloffelinethyroid tumourswithpreserva-
Itisalsowellrecognizedthattheprognosisfor
tionoftheparathyroid tissue,orremovalofcentral
certaintumoursisimpactedbytumoursizeandana-
nervoussystemtumourswithpreservationofsur-
tomical location,forexamplewithMCTsandSCCs.
roundingneuronal tissue).
Areaof thebody
Fascial ormusclestructure that canberemoved andmayactasa ventral barrierto tumour spread
Antebrachium
Antebrachial fascia covering the antebrachialmuscles
Head
Fasciacovering the temporalismuscles
Lateral thorax
Latissimusdorsimuscle.Althoughthemuscledoesnotneed tobe suturedbacktogether,dead space shouldbecarefullyclosed
toprevent seroma formation
Lateralabdomen
Abdominal muscles(e.g.external abdominal oblique).Once twoof the threemain abdominal muscleshavebeenresected,the
deficit shouldbeclosed orreinforced
Ventral abdomen
Rectussheath.Deficitsintherectussheathshouldeclosedif theycannotbeclosedfurtherdeepmuscleshouldberesected
to allowappositionof theedgesof therectussheath
Dorsum
Fasciaoverthedorsalspinalandparalumbarmuscles.lf tumoursareattachedtofasciathatisinturnattachedtospinous
processesof vertebraethesespinousprocesses shouldberemoved
Cruralregion
Thereisnofascial sheathcomparabletothatintheforelimb.Althoughlocally thefascia overmusclessuchasthecranialtibial
musclecanberesectedandperiosteumusedasadeepmargin,tumoursin thisareaoftencanonlybecytoreducedwithout
amputation
Lateral thigh
Fasciaovethicpsemorishissinmatlyassociatedwitthebicesmorimsclandsuallmarinsaregaied
partialresectionof thebicepsfemorismuscle
Examplesofnaturalbarrierstotumourspread.If thetumourhasinfiltratedthroughthislayer,itnolongeractsas
6.6
abarrierandtheresectionmustgotobelowthenextuninvolvedfascialmusclelayer.
49
Chapter6Principlesof oncological surgery
Tumourtypessuitableforlocalexcisionare:
Lipoma
Histiocytoma
Sebaceousadenoma
Thyroid adenoma.
Widelocalexcision:Whenasignificantpredeter-
minedmarginofsurroundingtissueisremoved
togetherwith theprimarymass,the excision is
termedwidelocal excision'.Again,preoperative
knowledgeof thetumourtypeandgradeisessential
fordecidingonthatappropriatemargin.Figure6.5
givessomeguidelinesastotheresectionmargins
required,andhowtheydifferforvarioustumour
types and grades.
6.8
Requiredresectionmarginsoftenseemvery
Anatomicalconsiderationsmaydictatewhetherit
large.Thisskintumourhas3cmmargins
ispossibletoresectthemasswiththeappropriate
marked out.
margin;ifnotpossible,considerationshouldbegiven
totheuseofsuitableadjunctivetherapy.Veryoften,
spreadoftumourcells;thisisremovedwiththe
especiallyonthelimbs,theappropriatedepthof sur-
tumourandactsasthe‘deepmargin'.Thefasciais
gicalmargincannotbeobtainedwithoutsignificant
removedoverthesameareaastheskinresection.lf
functional consequence.In thesecircumstancesuse
thereisanyadhesionof thefasciatotheunderlying
ismadeof theknownbiologyof tumours.Acollagen-
muscleortissue,thenextlayerdownshouldbe
richfascialplane(e.g.a musclesheath oraponeuro-
removedalso.Preoperativeevaluationistherefore
sis)mayactasanaturalboundarytotumourspread.
essential to planfor such findings.Otherexamplesof
Figure6.7showshowgradeandfascialplane
naturalbarrierstospreadoftumoursareindicatedin
involvementaltertheresectionrequired.Thisformof
Figure6.6;removalofindicatedstructuresdoesnot
surgery(widelocalresection)isprobably themost
compromisefunction.
difficultbecauseitissotemptingtotakelesstissue
thanmayberequiredinordertopreservetissuefor
Radical localexcision,supraradical excision,
closure.Therequiredmargins,whenmeasuredoutin
compartmental
excision
and
amputation:
thepatient,canoftenappearverylarge(Figure6.8).
Removalofthetumourwithanatomicallyextensive
Preoperativeplanningisessential inthesecases.
marginsoftissue,includingfascialplanesthatare
Forexample,foragradeIlMCT,thesuggested
undisturbedbytheprimarygrowthofthetumour,is
marginofexcisionis2cm.Ontheantebrachiumofa
termedradical local,supraradicalorcompartmental
dog,2cmdeepwouldtakethesurgeondownto
excision.Sarcomas,inparticular,extend along fas-
bone,oreven intobone.However,the thickantebra
cialplanesratherthanthroughthemandthispattern
chialfascialsheathactsasabarriertotheventral
ofgrowthdictatesremovaloftheentireanatomical
6.7
Thedegreeof localtissue
Gradel
infiltrationvarieswiththe
tumourgrade.Thecentraltumour
massisthegrosslyvisibleand
palpablepart.Invisibletothenaked
Skin
eyearestrands,ortentacles,of
neoplastictissuepenetrating out
intonormal tissue.It is thisinfiltration
Fascial
thatdeterminestherequired
Splanes
marginsofresection,and the
degreeof infiltrationvarieswith
tumourtype andgrade.Tumour
GradeIll
grade isgenerallydesignatedasI,I
orlllwithlllusuallybeingthemost
aggressive.Othertermsusedare
low,intermediateandhighgrade
Involved
andwelldifferentiatedthroughto
fascial
poorlydifferentiated.xindicatesthe
plane
necessaryperipheral or
Uninvolved
circumferential margin(usuallya
metricmeasurement)andythe
fascial
deepmargin(usuallymeasured in
plane
termsoffascialplanes,alsocanbe
measured metrically).
Gross disease
Microscopicdisease
Surgical incision
50
Chapter 6Principles of oncological surgery
compartmentratherthansimplywidemarginsoftis-
5.Whetherthesurgeonhastherequisite skill,
sue.Oneexampleof thisistheresectionofasingle
facilitiesandcomfortleveltoperformthe
musclegroupforsmalltumoursinvolvingmuscle
procedureorwillofferreferral
bellieswheretheouterfascialplaneshavenotbeen
Whattheowners'expectationsareandwhether
breached.Resectiontocleanfascialplanesonall
theycanbemetormodified.
sidesnecessitatesremovalofallbloodvessels,
nervesandlymphaticsthatliewithintheaffected
Dissectiontechnique
compartment.Inthelimbs,muscleswiththeirassoci-
Ascalpeloffersorprovidestheleasttraumaticform
atedfascialcapsulescompriseindividualcompart-
oftissueseparationandisrecommendedfortheskin
ments.Otherexamplesof
compartmentai
or
incisionand incisionsintohollowviscera.Scissors
supraradicalresectionsinclude:
andswabsshouldbeusedfortheseparationoffas-
cialplanes,theseparationofadhesionsand inbody
Removalofthewholepinnaandverticalear
cavitieswhereuseofascalpelmaybedangerous.
canalforresectionofScCofthepinna
Bloodvesselsshouldbeidentifiedandligatedor
Resectionofthecompletemandibleandits
cauterizedpriortotransection,andtissuesshouldbe
muscleattachmentsfortreatmentofmandibular
placedundermoderatetensionas thedissectionis
chondro-orosteosarcomas(OSAs)
carriedouttofacilitatetheidentificationoffascial
Amputation of a limbforappendicular OSA
planes and tumourmargins.
Hemipelvectomyforhighhindlimbtumours
Removalof thescapulaand associatedmuscles
Reductionoftumourcellcontaminationwithin
for scapulartumours.
surgicalfield
Therearemanyreportsoftumourseedingafter
Examplesofradicalresectionsinclude:
biopsyorsurgicalproceduresinhumanpatients,and
veterinarycasesofsurgicallyinducedtumourseed-
·Excisionoftheeyelidsandorbitalcontentsfor
inghavealsobeenidentified.Thepseudocapsule
removalof invasiveSCCsoftheeyelid
aroundmanytumours,especiallysarcomas,hasvia
Totalorpartialorbitectomyforthetreatmentof
bletumourcellsonits surface.Manipulation and
periorbitaltumours
surgicalexposureofthepseudocapsulepromote
Radicalchestwallresectionorabdominalwall
tumourspreadviaexfoliatedcells.
resectionfortheremovalofsarcomas
Although it is tempting tograsp a tumour using
Radicalresectionsofthenasalplanumand
traumatictissueforceps,thismayleadtotissuefrag-
rostralmaxilla.
mentation and disseminationof neoplasticcells;stay
sutures,placed in normal surroundingtissuebeing
Formarginsequallingorexceeding3cm,surgery
resected,arethebestwaytomanipulateatumour.
ofteninvolvesresectionof largecompartmentsof tis-
Inbodycavities,neoplasmsshouldbeisolatedfrom
suesuchasamputation,hemipelvectomy,extensive
maxillofacialsurgery,orabdominal andchest wall
minimizecontaminationofnormaltissuebyexfoli-
resections.Higher-gradetumoursoftentravelexten-
ated tumourcells.
sivelyalongfascialplanes;hencesurgeriessuchas
Itisoftenhelpful toapproachtumoursasif they
amputationareindicatedratherthanlocalresection.
were abscessesorinfected tissue,and the tech-
Examplesoftumoursthatrequireradicalexcision
niquesandprecautionsusedtopreventspreadof
(3cm,downtoandincludinganuninvolvedmuscle
bacteriawillalsohelptominimizethespreadofneo-
orfascialplanebelow thetumour)include
the
plasticcellsthroughinadvertent tumourviolation.
following,but these are onlyguidelines and
However,therearesomedifferences.Withrespectto
unfortunatelydonotguaranteecompleteresectionof
adhesionsbetweenneoplastictissueandadjacent
the tumour:
structures,theseadhesionsrepresentdirecttumour
invasioninupto57%ofcases,and thetumourand
GradeIll(highgrade) MCTs
theadhesionsshouldberemovedenblocwhenever
?
Grade Il andIllsofttissuesarcomas(spindlecell
possible.Seededtumourcellsappeartoadhere to
sarcomas)
normaltissueviaspecificcellsurfacereceptors,and
OSAsthathaveinvadedsofttissues
routinewoundorcavitylavagefollowingremovalis
Felinevaccine-associatedsarcomas.
oflittlebenefitintermsof‘washingoutremaining
tumour cells.However,remaining tumour cells are
In summary,inordertoformulateasurgicalplan
not likely tobe spread by lavage;thus,lavage isrec-
the surgeonmust establish:
ommendedtoeffectremovalofbloodclots,foreign
material,necrotic tissue fragments and any unat-
1.Thelocal,regionalandsystemicextentof the
tachedtumourcells.Inhumanpatientswithinadvert-
tumourinthepatient
entcontaminationofthesurgicalsitefollowingsoft
2.
Themarginsrequiredforattempteddefinitive
tissue sarcomaresection,itispossible toachieve
excision
similaroutcomeswhencomparedwiththosewithout
3.Howthosemarginswill translateanatomicallyon
contamination,butre-excisionandwound irrigation
tothepatientintheareaofthetumour
is necessary (Virkus et al.,2002).Gloves,instru-
4.The impact on the patient and the anticipated
mentsanddrapesshouldbechangedaftertumour
postoperativecare
excisionand lavage,astumourcellswill adhere to
51
Chapter6Principles of oncological surgery
theseinanimateobjectsandpotentiallybeseededto
practiceislikelytobecomemorecommonplace
tissuesasclosureiscarriedout.Glovesandequip-
(Pereira et al.,2008;Tang et al.,2009).
mentshouldalsobechangedwhenperformingmul-
Lymphnodesareonlyminimallyeffectivebarriers
tipleproceduresinthesamepatient,toavoid
tothepassageoftumourcellsand theirfunctionis
mechanical contamination.
probablyoneofimmunologicalsurveillanceand
immuneediting,ratherthanfiltrationoftumourcells.
Avoidanceofwoundcomplications
Theimmunologicalresponseofregionallymph
Localcellulardefencemechanismsand immuno-
nodesappearstobemoreeffectiveearlyoninthe
modulationmaywellbeveryimportantinthe
courseofdisease.Local lymphnode metastasis
removalofresidualtumourcells.Thedevelopmentof
iscommonformalignantmelanomasandmost
haematomas,seromasor sepsiswill interferewith
carcinomas,of intermediatefrequencyforsarcomas,
thisfunctionandtheseshouldbeavoidedbymeticu-
respiratory tumours,cutaneous carcinomas and
loushaemostasis,effectiveclosureofdeadspace
MCTs,andrarefornervoussystemtumours,skeletal
andappropriateuseofdrainsandperioperativeanti-
tumours,nasaltumoursandmostendocrinetumours
biotics.Theuseofdrainsissomewhatcontroversial
(e.g.thyroid carcinoma).Removing lymph nodes
amongstveterinaryoncological surgeons,especially
mayinterferewithlocalimmunedefencemecha-
if theresectionhasbeenincomplete.Thereispoten-
nismsinthepostoperativeperiod.There isalsoa
tialforseedingoftumourcellsalongthetissues
potentialincreaseinsurgicalmorbidityrelatedtothe
where thedrainisplaced（thismaybedecreased
moreextensive surgicalprocedure.
withtheuseof activeversuspassivedrains),making
Thepracticeofroutinelyremovingthe'sentinel
further surgery or adjunctive therapyverymuch
orregional lymphnodesinbothhumansandanim-
moredifficult if there isrecurrence.Theauthor[KJ]
alsprophylacticallyisamatterofcontinuedcontro-
doesusedrains,butpositionstheirexitsclosetothe
versybutisgenerallynolongerrecommended
incisionsoasnottocompromisefurtheradjunctive
(Krag,2000).
therapythatmaybeneeded.
Ingeneral,althoughdecisionsmustbemadeon
a case-by-casebasis,currentrecommendations are
Vascularocclusiontechniques
thenon-destructivebiopsy(FNA)ofgrosslynormal
Vascularsupplytothetumour,andvenousandlym-
localnodes,andremovalof thenodeinthefollowing
phaticdrainagefromit,shouldbeligatedasearly
situations:
aspossibleduringsurgery.Thepredominantreason
forvascularocclusionisimprovedintraoperative
Thenodeishistologicallyproven tocontain
haemostasisandvisualizationbutitisofnotable
tumourcells
importancewheretheprobabilityofcellexfoliationis
Thenodeappearsgrosslyabnormal atsurgery
high,such as fortumours ofectodermal origin(e.g.
Thenodeisintimatelyassociatedwiththetissue
SCCs,MCTs).
beingremovedandsurgical marginsdictateits
removal(e.g.aspartofacompartmental
Managementoflocal lymphnodes
resectionsuchastheinguinal lymphnodeduring
Theflowoflymphisdirectional;lymphnodesthat
mastectomy)
arethefirsttoreceivedrainagefromanygivenloca-
Thenodeissufficientlylargeand/orlocatedin
tionarecalled'sentinel'lymphnodes.Sentinel lymph
suchanareaastocausesomedegreeof
nodeshavebeenmapped inhumansusingcontrast,
functionalimpairmentassociatedwithspace
dyesandradioactivetracers;inhumanpatientsitis
occupation.
the‘sentinel'lymphnodesthataretargetedfor
biopsytostagedisease,orforremovalinthetreat-
Onecasewherelocallymphnoderemovalis
ment of disease （Krag,2000).Once the marker is
probablybeneficialistheremovalofthemedialiliac
injected,thefirstsentinel lymphnodeisidentified
lymphnodes(oftenerroneouslyreferred toasthe
and biopsy isperformed.lf thatnodeisnegativefor
sublumbarlymphnodes)inpatientswithmetastatic
thecancer,furtherdissectionisavoided;if thesenti-
apocrineoranalsacglandadenocarcinomasofthe
nel nodeispositive,furtherdissectionisperformed.
perineum.Removalof thesepositivelymphnodes
Inveterinarymedicinesuchstudiesarelimited
doesnotresultinacure,butcanhelptoalleviatethe
andoncologistsusuallyrefertotheregionallymph
paraneoplasticsyndromeofhypercalcaemiaandmay
nodes.Thesenodes should be sampled(usuallyvia
helptopreventlargebowelobstruction.It isrecom-
FNA)asacomponentofroutineoncologicalstaging,
mended that,incritical areas（retropharyngeal,hilar,
asitisnotpossible todetermine thepresence,or
mesenteric),lymphnodes thathave eroded through
absence,ofmicrometastasis throughmere palp-
thecapsuleandbecomeadherenttosurroundingtis-
ation.This isespeciallyimportantifthe decision
suesarenotremoved,becauseattemptingtodothis
regardingtheuseofadjunctivetherapyisdependent
wouldcausesignificantharmtothepatient.
nodes.Tumourgradeandsurvival havebeenlinked
Reconstructionoftheresulting deficit
withthepresenceofmicrometastasisinthelymph
Thereisoftenagreattemptationtocompromise
nodes,as detected by cytological assessment
excisionmarginsthroughalackofconfidencein
(WithrowandVail,2007;Kricketal.,2009).Further
one'sabilitytoreconstructtheresultingdeficit.This
studies,using contrast-enhanced imaging modali-
compromisemayresultinfailureofasinglesurgical
ties,arestartingtochart theselymphnodes and this
procedurethatcouldhaveproducedacure.ltmay
52
Chapter6Principlesof oncological surgery
alsoresultindeathofananimalthatshouldhave
deadspace.Gastro-omentalpedicleflapscanalso
beencured.ltistheresectionoftumoursinvolving
beusedtoprovideasourceofextra tissueinthe
theskinandassociatedstructuresthatoftenresults
reconstructionofhollowviscerasuchasthebladder.
insubstantial deficits,andavarietyof techniques
Skinexpanderscanpotentiallybeusedtoaugment
areavailabletodealwiththesedeficits(seeBSAVA
skinintheareaofatumourpriortoresection.
ManualofCanineandFelineWoundManagement
andReconstruction).
Myocutaneous flaps:Thesemaybeharvested
asmuscleflapsorcombinedmuscleandskinflaps
Primaryskinclosure:Thisis thecoaptationofthe
forclosureandsupportoflargerstructuraldefects
woundedgesatthetimeoftheinitialsurgerywithout
suchasthoseinvolvingthoracicwall(Halfacreeet
theneedforextensiveskin-releasingtechniques.Itis
al.,2007).
usedmainlyintheclosureofsmallerdeficitsor
wherethereisalotoflooseskin.Towel clampsmay
Meshimplants:Thesecanbeusedontheirown,or
beusedtemporarilytohelptoalignskinedgesand
combinedwithomentaltransfertechniques,topro-
stretchskin,and‘walking’suturesshouldbeusedto
videascaffoldforreconstructionofthethoracicand
bringskinedgestogethergradually.Therearemany
abdominalwall(Matthiesenetal.,1992;Liptaketal.,
othertension-releasing techniquesthatcanbeused
2008)(Figure6.10).Cutaneousreconstruction tech-
tofacilitateprimaryskinclosureandinoncological
niquesarethenused toclosetheskin.Asanalter-
surgeryfullconsiderationshouldbegivento these
nativetotheuseofmeshtoreconstructthethoracic
priortoplanningextensiveflaptechniques.
wallafterresections,diaphragmatic advancement
withorwithoutcaudallunglobectomycanbeused
Secondaryskinhealing:Thisistheclosureofthe
toobviatethenecessitytoreconstructathoracicwall
woundbythenaturalprocessesofwoundcontracture
(Matthiesen etal.,1992).
andepithelialization.It isparticularlysuitedtocontam-
inatedwoundsorwherethereconstructionofthe
woundisprohibitedbythelackofsurroundingskin.
Pedicleflapclosureoftheskin:Thisisclosureof
woundsusing slidingflapsofskin,e.g.localplasty
techniques,skinmeshing,advancementflaps,rota-
tionflapsand transpositionflaps.Italsoincludes
theuseofaxial（Figure6.9)orislandflaps.Such
techniquescanbeusedimmediatelyaftertheexci-
sional surgery.
Meshbeingusedtoreconstruct thebodywall
6.10
defectcreated inFigure6.2.
6.9
Completedcaudalsupericial epigastricaxial
Closureconsiderations
patternflapbeingused inadogtocloseaskin
Theoncologicalsurgeonshouldbefamiliarwithall of
deficitresultingfromtumourresection.
theabovetechniques.Asuitableclosure technique
shouldbeplannedpriortoresectionofthetumour.
Freeskingrafts:Thisisparticularlysuitedtothe
Appropriatealternativesforclosuremustalsobe
closureofskindeficitsover thedistallimbswhere
considered intheevent theresectionhastobemore
thereisalackofadjacentskinandaxialorisland
flapsarenotpossible.Thesetechniqueswillbe
closuretechniquesareused inveterinaryoncology
duetothefactthatifelaboratecutaneousrecon-
theestablishmentof agoodrecipientgranulationbed.
structivetechniquesareused,thereispotentialfor
verywidetumourrecurrencewithincompleteresec-
Localtissueaugmentation:Omentumcanbe
tion.Tominimizethispotentialforseeding,separate
tunnelled,afterappropriateextension,tomostareas
instrumentsshouldbeusedforthereconstructive
of thebodytoprovideextratissuetoallowclosureof
partoftheprocedure.
53
Chapter6Principles of oncological surgery
Cytoreductionofthetumourmass
Ifadjunctivetherapiesareusedpreoperatively,
Insomecircumstances,definitiveexcisionalcurative
thesurgicalresectionshouldbeplannedtoremove
surgeryforsolid tumoursisnotpossible.Theneed to
allneoplasticcells,i.e.tobe definitiveexcisional sur-
preservevital structures(centralnervous system,
gery.Anexampleofthiswouldbe the‘downstaging
bladder,nasal sinuses)canoftenpreclude complete
of grade Il or Ill MCTswithchemotherapyprior to
excision.Also,second attemptsatcompletesurgical
definitive surgical excision.Theuse ofchemotherapy
excisionofatumourmaybedifficultduetodistorted
todownstagetumoursinhumanmedicineiscom-
anatomyorlackofresectabletissue.Certaintumour
monplace,e.g.forhepatictumours.
typesorgradesareassociatedwithsignificantrates
of localrecurrenceevenafterradicalsurgery,and
Palliativesurgery
resectionofsuchtumours
shouldalwaysbe
Asfarasisknown,animalshaveno comprehension
regardedasincomplete.
of theexpectedfuture.Therefore,itisperfectlyreas-
Such‘cytoreductive’surgery（reducing thenum-
onabletoconsiderperformingproceduresthatmark-
bersoftumourcellspresent)isnotfailedsurgery.
edlyimprovequalityof lifebyrovidingpainrelir
Therationalebehindcytoreductivesurgeryisthatit
relievingpoor function,despite thepresence of un-
isappliedincombinationwithothertreatmentmodal-
resolvedsystemicneoplasticdisease.Inpalliativesur-
itiessuchaslocalorsystemicchemotherapy,radio-
gery,the overriding consideration should be the
therapyorhyperthermiatotrytoachieveacureor
qualityoflife,notthequantityof lifethatisexpected.
improvediseasecontrol.Ingeneral,radiotherapyis
Therearemany situationsinwhich comparatively
oftenusedasadjunctivetherapytoachievelocaldis-
simplesurgicalproceduresprovidethepatientwitha
ease control(softtissue sarcomas and MCTs)and
worthwhileimprovementinqualityoflifedespitea
chemotherapyisusedtoinfluenceprogressionof
poorlong-termprognosis.Examplesof thisinclude:
metastatic disease(OsAs and haemangiosarco-
mas).Cytoreductivesurgeryimprovestheefficiency
Limbamputationforosteoscaromacausing
of theseadjunctivetherapiesbyreducingthenum-
lameness andpain
bersof malignant cellstobe treated.Suchamulti-
Splenectomyforableedinghaemangiosarcoma
modaltherapyistheoptimalformoftreatmentfor
Oralresectionsforamalignantmelanoma or
limb soft-tissue sarcomas,e.g.the combination of
haemangiosarcomacausingdysphagia
surgicalresectionandradiotherapy.Anotherexam-
Tracheostomyforlaryngealmalignancy
pleisthelocalresectionofappendicularOSAand
Removalof largeulceratedpainfulmammary
theuseofanallograftduringalimb-sparingproce-
carcinomas
durefordistalradial OSAinthedog;inthiscasethe
Placementofapermanentcystostomycatheter
tumourresection is regarded as incomplete,the
torelieveurineoutflowobstructionindogswith
microscopicdiseaseleftbehind istreatedwitha
transitional cellcarcinoma(Smithetal.,1995;
slow-release form ofcisplatin(Straw et al.,1994;
Beck et al.,2007).
Dawe,2007;Withrowetal.,2004)andotherchemo-
Therisksandbenefitsmustalwaysbeweighed
therapyisusedforthesystemicmetastasis.
and patients selected carefully.Another emerging
Adjunctivetherapiessuchaschemotherapyor
branchistheincreasinguseofminimallyinvasive
interventionalradiologytechniquesforplacementof
theyaremoreeffectiveduetothesmallnumbersof
palliativevascular,urethralandtrachealstentsfor
cellstobesterilized.However,someveterinaryoncol-
managementofobstructivediseaseprocesses.
ogistsprefertousesuchradiationtherapypreopera-
tively,becausethescatteredperipheralcellsthatthey
Surgical emergencies
are aiming tokill arebestoxygenated at thistime and
Surgicalemergenciesarerelatively common in small
oxygenationofthesetissuesmaybecompromised
aftersurgery(seeChapter8).Postoperativeradiation
animal cancerpatientsandmayinclude:
necessitatesradiation of the entire surgicalscar,
Pericardialeffusionandtamponade
whichusuallyresultsinalargerfieldthanpreopera-
Respiratorydistress
tiveradiation.Thisissuehasnotyetbeenresolved
Abdominalhaemorrhage
Urogenital orgastrointestinalobstructionor
operativelycomesdowntopersonalpreference.
Radiation therapy can be used intra-operatively
perforation
Pathological fracture.
afterremovalofthetumourwhencloseaccesstothe
affectedareaisrequiredduetoproblemsofdamag-
Thesepatients usuallyrequire emergency stabili-
ingsurroundingvitalstructuresifpostoperativeradi-
zation,andthentheethical questionofwhethersur-
ationtherapyisused.Oneexampleofthis
IS
intraoperativeradiationtherapyforbladdercarcin-
addressed.Immediate surgery，prior to definitive
omas.Anotherexampleisalimb-sparingprocedure,
diagnosis,maybeindicatedinsomecasesbutmust
wherethebonetissuecontainingOSAisflipped’out
be followedby appropriatepostoperative care.Very
often such surgeries are palliative only,such as
and fixation inplace(Liptaket al.,2004a;Boston et
resectionofbleedingsplenichaemangiosarcomas,
al.,2007).ln thisway,the tumour cells canbe killed
hepatic tumours,resection of ulcerated orobstruc-
andhostboneretained,andalso thelimb‘spared”
tivegastrointestinalneoplasmsthathavealready
ratherthanamputated.
metastasized,ortheplacementofapermanent
54
Chapter 6Principles of oncological surgery
cystostomycatheterobviating theneedforimmedi-
alcohol mixture)is sufficient;indeed,vigorous scrub-
ateeuthanasiainanimalswithadvancedurethralor
bingofskinoverlyingtumourshasbeenassociated
bladdercancer.Other surgical procedures include
withincreasedmetastasisinlaboratorymice.
emergencytracheostomyforimmediatepalliationof
Similarly,vigorouspalpationoftumourspriortosur-
life-threateningupperrespiratory tractobstructions
geryisnotadvocated，assurfaceinjury,epeciallyo
priortofullevaluationoftheextentoftheobstructive
intra-abdominal tumours,maypotentiateseedingof
massandpossibledefinitiveorpalliativeexcision.
neoplasticcellsorruptureand haemorrhage.
Occasionally,surgeryisrequired todeal with
Oncologicalsurgeryofteninvolvesoperatingon
complicationsofradiationorchemotherapy,e.g.treat-
patientsthathaveoneormoreofthepatientfactors
mentoftissuenecrosisresultingfromextravasated
thathavebeenshowntoincreasethechanceof
chemotherapeuticagentsorradiation-inducedtissue
postoperativeinfection.Theseinclude:
necrosis,orfibrosisand subsequent strictureof hol-
Oldage
lowviscera.
Poornutritional status
Support surgeries
·
Obesity
Supportsurgeriesincludethevariousmethodsof
·
Endocrine disease
providing
nutritionalsupport
(oesophagostomy
·
Hypoxaemia
tubes,gastrostomy tubes,enterostomy tubes)(see
Thepresenceofremoteinfection
alsoChapter10)andtheimplantationoflong-term
·
Corticosteroid therapy
centralcathetersorvascularaccessports
for
Immunocompromise
repeatedadministrationofchemotherapeuticagents
Bowelobstruction
orfortherepeatedadministrationofanaesthetic
Thrombocytopenia
agentsforhyperfractionatedradiotherapyregimens
Cardiovasculardisease
(e.g.radiotherapy three to five times aweek).They
Poor blood supply to the surgical field.
alsoincludetheplacementofcystostomytubesfor
Theinfectionratesfollowingoncologicalsurgery
temporaryurinarydiversionwhilelocalradiation
treatmentofurethraltumoursiscarriedout.
havebeenshowntobesignificantlyhigher thanfor
othersurgicalproceduresinboththeveterinaryand
Surgicaltreatmentofmetastaticdisease
humanfields.Thepresenceofcancerisnotitselfa
Inhumanmedicine,ithasbeendocumentedthatsur-
riskfactor,butsuchpatientsareoftenatriskofsur-
vivalratesforpatientswherelungmetastaseshave
gicalwoundinfectionforthereasonsoutlinedabove.
beenresectedaresimilartosurvivalratesforpatients
Carefulplanningforpharmacologicalpreventionor
whohaveprimarylung tumoursresected.Human
treatmentofinfectionwillmaximizethechancesofa
patientsareselectedformetastatectomy:whenthe
successful surgery.
primarytumourhasbeencontrolled;whenthereisa
Differentclassesofantibioticskillorganismsin
solitarymetastasisormetastasesconfinedtoone
verydifferentwaysandtheappropriatedosesched-
lobeof thelung;wheretherehasbeennolocal recur-
ulesvarygreatly.Forexample,thebeta-lactamsand
renceoftheprimarytumourfollowingtreatment;
amoxicillin/clavulanateexhibit time-dependentkilling
wherethereisnoextrapulmonaryspread;andwhere
andshouldbegiven atdosestomaintainconcentra-
thereisnocirculatoryorrespiratoryinsufficiency.
tionsabove theminimuminhibitoryconcentration
Inveterinarymedicine,thesurgical treatmentof
(MIC)forthewholeoperativeperiod.This may mean
metastaticnoduleshasbeensuggestedinselected
patients,althoughlarge-scaleevaluationislimited
contrast,the aminoglycosides and quinolones(e.g.
(O'Brien etal.,1993;Liptaketal.,2004b).The care-
enrofloxacin)require ahighpeakconcentration,
fulselectionofpotentialpatientsisimportantandthe
whichdeterminesbacterialkilling,and thenaperiod
basic criteria that have been suggested (Gilson,
of low concentration tore-establishorganism sensi-
1998)are that:
tivity.Thusthegoal insurgicalprophylaxis isforthe
organismsinthesurgicalfieldtoencounterjustone
·Theprimarytumourmustbecontrolled
largedoseoftheaminoglycosideorquinolonedur-
Thepatient musthavehadaprolongeddisease-
ing theoperativeperiod.
freeintervalfromthetimeoftreatmentofthe
Thetimingofantibioticprophylaxisiscrucial.
primarytumour(>300days)
Increasedratesofinfectionareobservedifpreopera-
Thepatientmusthave<3metastaticnodules
tiveantibiotictherapyisinitiatedtooearly,orcontin-
Themetastasismusthavealongtumour
uedfortoolongpostoperatively.Thebestresultsare
doublingtime(>30days).
seenwhenantibiotictherapybeginsnomorethan2
hoursbeforethesurgicalprocedure and continuesfor
nomorethan24hoursafterthesurgicalprocedure.
Considerations foroncological
surgery
Postoperativecare
Preoperative preparation
Analgesia
Thepatient shouldbegenerouslyclippedtofacilitate
Specificanti-cancer treatments suchas surgical
effectivepreparationandalsotoallowforchangesin
resectionwillofteneliminateorreduceveryeffec-
the surgical plan during surgery.Gentle cleaning
tivelytheincidenceandseverityofthepainassoci-
usingeffectiveskinpreparations(e.g.chlorhexidine/
atedwithaneoplasticdisease(seealsoChapter
55
Chapter6Principlesof oncological surgery
11).However, the surgical procedures are often
pre-(wherelicensed)orpostoperativeNSAIDther-
extensiveandcaninvolvereconstructiveprocedures
apyshouldbe used.
withthenecessityforprovisionofeffectiveanalgesic
Localanaestheticsshouldalwaysbeusedif
regimens-atleastinthe shorttomedium term.
possible,as local infiltration,regional blocks or as
Analgesiacanhelptopreventsecondaryadverse
partofanepidural.lfusedforlocalinfiltration,care
effectsofpostoperativepain,suchasincreasedlev-
mustbeexercisednottodistorttissuearchitecture
elsofcatabolichormones,prolongedrecovery,and
andnormalfascialplanesintheareaofsurgery.
increasedskeletalandsmoothmuscletone,aswel
Figure6.11summarizesananalgesicapproachto
asthesufferingcausedbythepainitself.Additionally,
effectiveperioperativeanalgesiaincancerpatients
patients,an approach that makes the mostof pre-
maypreventchronicpostoperativepain-apheno-
emptive analgesia.
menonthatisbecomingincreasinglyrecognized in
Ofinterestistherecentfinding thattheprovision
humanmedicine.Itis thoughttooccurdue to the
ofanalgesicssignificantlyreducesthetumour-
superimpositionofacutepainonchronicpain.
promoting effects ofundergoing andrecovering
Inlinewith current thinking,theprevention of
from surgery（Page et al.,2001).Undergoing sur-
postoperativepainshouldstartpreoperatively,with
geryiswellknowntoresult inthesuppressionof
effective dosesof multipleclassesof analgesics(e.g.
several immune functions,including natural killer
opioid plusNSAID).lf elective surgery fora painful
(NK)cell activity inboth animals(Sandoval et al.,
neoplasticlesionisplanned,itisprobablybeneficial
1996)and humans (Kutza et al.,1997).The reduc-
toprovideeffectiveanalgesictherapyforseveral
tionintumour-promotingeffectsofsurgerybyan-
dayspriortosurgicalinterventioninordertomini-
algesicsseems tobeduetothealleviationof
mizecentralsensitization.Thiscouldeasilybepro-
pain-induced reducedNKcellfunction(Page et al.,
videdwithNSAIDtherapy.Asthesurgeryplanned
2001).So theprovisionofadequatepainmanage-
becomesmoreextensive,thedosesofopioidsused
mentmaybeprotectiveagainstmetastaticsequelae
(e.g.buprenorphine,morphine)shouldincreaseand
in clinical patients.
All preoperativeanalgesicsshouldbegivenata
time andat adosetoprovidepre-emptive
Painmanagementintheimmediatepostoperativeperiodis
Monitorpainmanagementat
analgesiaat thetime surgerystarts
home.lnvolve andempower
人
managementat thistimedecreasesthelengthandseverityof
theownertoensureoptimum
postoperative pain over the following days.This immediate
painrelief,andminimal side
Anaesthetic premedication
postoperativepainmanagementshouldbestartedbeforethe
effects
（pioidlph-agnist
animalecmepainfulshulbpre-mtiv
Intensivepainmanagemente.ginjctableIDspod
alpha-2agonists,localanaesthetic（unlessusingawound
analgesiccatheterketamie
Epidural
Nerveblocks
PREM
TEDICATION
ANAESTHESIA
IMMEDIATEPOSTOPERATIVE
EXTENDEDPOSTOPERATIVEPERIOD/
PERIOD
ATHOME
SURGERY
Anaestheticinduction
Painmanngrr
opioidstransdermalopioidstransdermallocal
±analgesics
anaestheticsoraMDAantagonists(amantadne）,
Adjust timing to
Considergivingintraoperative
need therapyforseveral weeks.Analgesiaat thistme
allow analgesic
opioidsktaminealphanist,
isnecessarytooptimizerehabilition
component to be
lidocaine
mosteffective during
Intraoperativeopioidsanddrugssuchasketamine
surgery
helpprovide greaterprotection againstwind-up'due to
surgicalstlationeciallyinlongureri
OR
Give analgesics
treatmentsstartobecomelesseffective
separatelytoprovide
intraoperative
Inject wound bedandsubcutaneousspacewithlocalanaestheti.
coverage
Considerplacementofawoundanalgesiacathetertoadminister
localanaestheticintothewound followingsurgery
6.11
Summaryofoptionsforananalgesicapproachtoperioperativepainmanagement inoncologicalpatients.
56
Chapter6
Principlesofoncologicalsurgery
Monitoringandfluidtherapy
Inthepostoperativeperiod,sensiblemonitoringof
cardiopulmonaryparametersandmajororganfunc-
tionisrequiredtopreventthedevelopmentofpoten-
tiallylife-threateningcomplications.Theprovisionof
effectivefluidtherapyintheimmediatepostoperative
periodandtheinstigationoforalorenteralnutrition
areparticularlyimportant.Thesefactorsassume
greaterimportanceinmanyoncologicalpatientswho
maybeolderand/ordebilitated.Monitoringwillbe
dictatedbythetypesofrecognizedspecificcompli-
cationsthatcanoccurfollowingagivenprocedure.
(a)
Marginevaluation
Alltissueresectedatsurgerymustbesubmittedfor
histopathological analysisforevaluationof thesurgi-
cal margins,the mitoticindex,presenceofnecrosis,
vascularorlymphaticinvasionandthegradeor
degreeofdifferentiationofthetumour(seealso
Chapter3).Such information isused toprovide the
ownerwiththemaximumpossibledetailregarding
prognosis.Followingresection,themarginsofinter-
estshouldbeclearlyidentifiedinordertotargetthe
microscopicevaluationofthetissue.It isoftendiffi-
cult for the surgeon to orient a piece of tissue that
hasjustbeenresected,soonecanimaginehowdif-
ficultitcanbeforthepathologist,afterthetissuehas
beensittinginformalinforacoupleofdays.Agood
plantofollowis:
(b)
1.Laythespecimenoutinthepositionitwasinthe
6.12
Priortosubmitting anytissuetoapathologist,
patient.
suturescanbeused to'reconstruct'the
2.
Use suturesto'reconstruct'the specimen,e.g.to
specimen(e.g.toreplace displaced muscle inits original
replacedisplacedmuscleinitsoriginal invivo
invivoposition）.(a)The underlyinglatissimus dorsi
position(Figure6.12).
muscletendedto'slip'offthespecimen,exposingthe
ventral partof themass.(b)Themuscle was resected as
3.
Decidewheretheresectionmarginwasclosest
theuninvolvedventral margin to thismass.
tothegrosstumourandmarkthatmargin.
4.
Markothermarginsthatneedtobeevaluated
(e.g.lateral,deep)(Figure 6.13).
5.
Drawapictureofthespecimenonthe
histopathologicalsubmissionform,andalsoa
diagramtoindicatewheretheresectionwas
performed.Alsoindicatewherethetumourwas
whatmarginsareinked，andwithwhatcolours.
MarginsshouldbetaggedorpaintedwithIndian
inkorspecifictissuedyesimmediatelyaftersurgery，
sothatiftumourcellsarefoundinparticularmargins
furthersurgeryoradjunctivetherapysuchas
7
2
3
4
5
radiotherapycanbeplannedoptimally.Thepainting
ofparticularmarginsofaresectedmasswithIndian
1
2
inkisparticularlyuseful,asareas thatthesurgeon
maybesuspiciousofasbeing‘dirty'canbe
6.13
Inthislipresection,thedeepmedialmargins
havebeeninkedyellowtoallowthepathologist
misinterpretation(see alsoChapter2).Anotherway
toorient thesectionssothathe/shecancommentonhow
ofassessingmarginsistosubmitsamplesoftissue
farawayanyneoplasticcellsarefromtheinkedmargins.
fromaspectsoftheremainingtissuebedfor
evaluationofwhetherornottherearetumourcells
Thereisconsiderabledebateregardingwhatis
present.Suchfollow-upofcasesisatime-
consideredtobean‘acceptable'cleanmargindis-
tancefromthetissueedgetotumourcells.Forexam-
[Editors'note:Therearedifferingopinionsonthe
ple,inhumans,the surgical margin status following
bestwaytomarkmargins;itisbesttoconsultthe
breast-conservingsurgeryisconsidered thestrong-
pathologylaboratoryastotheirpreferredmethod.]
estpredictor forlocalfailure/recurrence.European
57
Chapter6Principlesofoncological surgery
radiationoncologistsrequirethatthecleanmarginbe
andradiofrequencythermalablationreadilyavaila-
>5mmtobeconsiderednegative,whereasinmany
bleaswell asendoscopicsurgeryandrobotictech-
othercountriesacleanmarginisconsidered tobe
nology.Reconstructiveoptions areincreasing,with
gainedwhentherearenotumourcellsontheinked
tissuesandorgansbeingengineered inlaborato-
margin,regardlessofhowclosetumour cells are to
riesfortransplantation.
the margin(Taghianet al.,2005).
Postoperativeappearance
Referencesandfurtherreading
Sometimessurgerycanproduceacureinananimal
sufferingfrom solidneoplasia,but onlywith signifi-
BeckAL,Grierson JM,Ogden DM.Hamilton MH and LipscombVJ
(2007)Outcome of and complicationsassociatedwithtube
cant alterationofitsappearance.Such cosmetic
cystostomyin dogsandcats:76cases(1995-2006）.Journalof the
changescanbedistressingtolookatinitially,butitis
AmericanVeterinaryMedicalAssociation230,1184-1189
worthrememberingthatanimalsdonotappeartobe
Boston SE,DuerrF,Bacon Netal.(2007)Intraoperative radiation for
limbsparingof thedistalaspectof theradiuswithout transcarpal
asconcernedabouttheirappearanceasweare.
platinginfivedogs.VeterinarySurgery36.314-323
Potentially,ntherightcase,if theprinciplesofonco-
logical surgeryare adhered to,a curecanbepro-
osteosarcomawithultrasound-guidedfine-needleaspiration：36
cases.JournalofSmallAnimalPractice48,145-150
duced,perioperativemorbiditycanbeminimizedand
DaweJ(2007)Osteosarcomaina 6-year-old Newfoundland dog:limb-
theanimal canmaintainexcellentfunction.Examples
sparingsurgeryandcisplatinchemotherapy.CanadianVeterinary
ofsuch surgeriesare theradicalhead surgeries
Journa/48,1169-1171
FulcherRP,Ludwig LL,BergmanPJ etal.(2006)Evaluation of a two-
(Figure6.14)andwhenconsideringthesecases the
centimeterlateralsurgicalmarginforexcisionofgrade|andgrade
ownersneedtobeinformedoftheexpectedvisual
Icutaneousmastcell tumors in dogs.Journal of theAmerican
VeterinaryMedicalAssociation228210-215
outcome.Thismaybedemonstrated usingpicturesof
Gilson SD (1998）Principles of surgery for cancer pallation and
similarcasesandbyenlistingtheassistanceofown-
treatmentofmetastases.Clinical TechniquesinSmall Animal
erswithanimalsthathaveundergonesuchsurgeries.
Practice13,65-69
dorsimyocutaneousflapfor one-stagereconstruction of the
thoracicwallafterenblocresectionofprimaryribchondrosarcoma
infivedogs.VeterinarySurgery36587-592
Krag D（200o）Sentinel lymphnode biopsy for the detectionof
metastases.CancerJourna/6（Suppl.2),S121-124
KrickEL,BilingsAPShoferFSWatanabeSandSorenmoKU（2009）
Cytological lymphnode evaluationindogswithmastcell tumours:
associationwithgrade andsurvival.VeterinaryandComparative
Oncology7,130-138
Kutza J,GratzI,Afshar M and Murasko DM（1997)The effects of
naturalkillercellactivityof humans.AnesthesiaandAnalgesia85,
918-923
Liptak JM,Dernell WS,Lascelles BD et al.(2004a) Intraoperative
extracorporealirradiationforlimbsparingin13dogs.Veterinary
Surgery33446-456
LiptakJM,Dernell WS,Rizzo SA et al.(2008)Reconstruction of chest
walldefectsafterrib tumorresection:a comparisonof autogenous,
prosthetic,and composite techniques in 44 dogs.Veterinary
Surgery37,479-487
LiptakJM,MonnetE,DernellWSandWithrowSJ(2004b)Pulmonary
metastatectomyinthemanagementof fourdogswithhypertrophic
osteopathy.VeterinaryandComparativeOncology2,1-12
MatthiesenDT,ClarkGN,OrsherRJetal.（1992）Enblocresectionof
MooresAandWilliamsJM(2009)BSAvAManualofCanine andFeline
WoundManagement
and Reconstruction,2ndedn.BSAVA
6.14
Ownersshouldbefullyinformedof the
Publications,Gloucester
expected appearanceof theirpetfollowing
OBrien MG,Straw RC.Withrow SJ et al.（1993)Resectionof
pulmonarymetastases in canine osteosarcoma:36cases(1983-
informedof theexpectedappearance,andwasvery
1992).VeterinarySurgery22,105-109
satisfiedwiththetumour-curingsurgeryperformed
Page GG,Blakely WP and Ben-Eliyahu S (2001)Evidence that
postoperativepainisamediatorof the tumor-promotingeffectsof
(radical nosectomy forScC).
surgery inrats.Pain90,191-199
PereiraCTLuizavarroMaqusFWiliamsJWladmreMarin
Future directions
andPrimo Bombonato P（2008)99mTc-labeled dextran for
mammarylymphoscintigraphy indogs.VeterinaryRadiologyand
Ultrasound49,487-491
Atpresent,surgicalexcisionremainsthedominant
Sandoval BA,RobinsonAV,Sulaiman TT,ShenkRRand StellatoTA
modalityofcurativetherapy.Someofthepreviously
(1996)Openversuslaparoscopic surgery:acomparison of natural
heldpreconceptionsregardingwhatispossiblefor
antitumoral cellularimmunityinasmall animalmodel.American
Journalof Surgery62,625-630
patientsareevaporatingasclients'willingnessto
SchneiderR,DornCRandTaylorDO（1969）Factorsinfluencingcanine
pursue more extensive surgeryincreases,along
mammarycancerdevelopmentandpostsurgical survival.Journal
of theNationalCancerInstiture43.1249-1261
withtheirexpectations.Increasinglyinnovative
Simpson AM,Ludwig LL, Newman SJ et al.(2004)Evaluation of
waysarebeingfoundtocombinecurrentlyavailable
surgicalmarginsrequiredforcompleteexcisionof cutaneousmast
treatmentmodalitiessuchaschemoembolization,
celltumorsindogs.Journalof theAmericanVeterinaryMedical
Associaton224,236-240
receptor-targetedradiotherapy,
regional/isolated
Smith JD,Stone EA andGilson SD.（1995)Placementof apermanent
chemotherapyperfusionandhyperthermiawithsur-
gery.There ismovement towardsmoreminimally
withtransitionalcellcarcinoma.Journalof theAmericanVeterinary
MedicalAss0ciation206,496-499
invasiveandinterventional techniques,withethanol
Straw RC,Withrow SJ,Douple EB et al.（1994)Effects of cis
58
Chapter6Principlesofoncological surgery
diamminedichloroplatinumllreleased fromD,L-polylacticacid
VeterinaryRadiologyandUltrasound43.432-441
Weisse C,ShoferFS and SorenmoK(2002)Recurrence rates and
OrthopaedicResearch12,871-877
sitesfor gradell canine cutaneous mastcell tumors following
Taghian A,Mohiuddin M,Jagsi Ret al.(2005)Current perceptions
completesurgicalexcision.JournaloftheAmericanAnimal
regardingsurgicalmarginstatusafterbreast-conserving therapy:
HospitalAssociation38,71-73
resultsofasurvey.AnnalsofSurgery241629-639
WithrowSJ,LiptakJM，StrawRCetal.(2004)Biodegradablecisplatin
Tang J,Li W,LuFet al.(2009) Comparison of gray-scale contrast-
polymerin limb-sparing surgeryforcanineosteosarcoma.Annals
enhanced ultrasonographywithcontrast-enhanced computed
ofSurgicalOncology11,705-713
tomographyindifferentgradingofblunthepaticandsplenictrauma:
WithrowSJ andVailDM(2007)WithrowandMacEwen'sSmallAnimal
ananimalexperiment.Ultrasound inMedicineandBiology35,
Clinicalncology4thedn.ElsevierSaundersEdinburgh
566-575
ZekasLJ,CrawfordJTandO'BrienRT(2005)Computed tomography-
VirkusWW,MarshallD,EnnekingWFandScarboroughMT（2002）The
guidedfine-needleaspirateandtissue-corebiopsyofintrathoracic
effectofcontaminatedsurgicalmarginsrevisited.Clinical
lesionsinthirtydogsandcats.VeterinaryRadiologyand
OrthopaedicsandRelatedResearch397,89-94
Ultrasound46,200-204
WallackST,WisnerER,WernerJA etal.(2002）Accuracyof magnetic
Zitelli JA,Brown CD and Hanusa BH(1997) Surgical margins for
resonanceimagingforestimatingintramedullaryosteosarcoma
excisionofprimarycutaneousmelanoma.Journalof theAmerican
extentinpre-operativeplanningofcaninelimb-salvageprocedures.
AcademyofDermatology37,422-429
59
Princi
les of chemotherapy
Susan E. Lana and Jane M. Dobson
Introduction
Ownersshouldbemadeawareof thepossible
timecommitmentandcostsinvolvedintreatment.
Chemotherapyisacommontreatmentmodalityin
Ownersshouldbegivendetailedoralandwritten
veterinarycancermedicine.Whetherusedaloneor
informationaboutthecancertreatment
asanadjunctto surgeryorradiation,new drugs,
recommendedfortheirpetandshouldbeinstructed
combinationsandmethodsofdeliveryareconstantly
aboutpotentialsideeffectsandwhattodoif toxicity
beingexplored.Inordertousechemotherapysuc-
occursathome.Theyshouldalsobeadvisedof
cessfullytheclinicianmustbeawareofsomebasic
thepotential risksof handlingcytotoxicdrugsand
principles,the potential side effects of the drugs
excretafromanimalsreceivingsuchagents.
usedandthetechniquesforadministeringthem.
Withadequateinformationandunderstanding,
ownersarebetterabletomaketreatmentchoices
Generalprinciplesandconsiderations
thatarerightfortheirpetandthemselvesandwillbe
Patientfactors
satisfiedwiththosechoicesregardlessoftheout-
Prior to initiation of chemotherapy, several patient
come.Theultimategoalofcancertreatmentforthe
factorsmustbeconsidered.
clientandveterinarysurgeonshouldbetoimprove
qualityof lifeandoverallsurvivalforthepatient.
Mostimportantly,anaccuratehistological
diagnosismustbemade.
Indications
Thebiological behaviouroftheparticularcancer
Chemotherapy is indicated for treatmentof tumours
inquestionmustbeunderstoodinorderto
knowntobe chemosensitive,including:
determinewhetherchemotherapyisappropriate.
Forsomecancertypes,suchasalow-grade
Haemopoieticmalignancies(leukaemia,
fibrosarcomaofthedistalextremity,thediseaseis
lymphoma,multiplemyeloma)
confinedtothelocalareaandhasaverylow
Highlymetastaticmalignancies(suchasOSA
probabilityofmetastasis;therefore,chemotherapy
andhaemangiosarcoma).
isnotindicated.Inothercancertypes,such as
osteosarcoma(OsA),whichdisplays ahighly
Chemotherapyiscommonlyusedasaprimary
metastaticbehaviour,chemotherapyhasbeen
treatmentforinduction,consolidation and,in some
showntoextendthedisease-freeinterval.
Thestageof thedisease.(Wherein thebodyis
cases,maintenance of remission in haemopoietic
the cancer?)
malignancies.Chemotherapyagainstsolidtumours
Thepatient'sgeneralhealthstatus,presenceof
suchasOSAisoftenused inanadjuvantsetting
concurrentdiseaseconditions,andabilityto
afterprimarytumourtreatmenttoeradicateoccult
toleratepotentialtoxicity.Althoughchemotherapy
micrometastaticdisease.Neoadjuvant therapy(using
isgenerallywelltoleratedinveterinarypatients,
chemotherapyprior todefinitivetreatment)iscom-
thereisthepotentialforsideeffects.lfan animal
monplace inhumanmedicinebuthasnotbeen
hasunderlyingrenal,hepaticorcardiac
widelyappliedinveterinarymedicine.Commonterms
dysfunction,theriskoftoxicitymaybealtered,
areexplained inFigure7.1.
and thechemotherapyprotocol mayneedtobe
adjusted toserve theneedsof thespecificpatient.
Doseandtiming
Inorderforachemotherapydrugtobeeffectiveit
Ownerfactors
mustreachthecellinquestionandmustexertatoxic
Severalownerfactorsmustalsobeconsideredprior
effectwithin the cell;the cellmustbe susceptible to
to initiating chemotherapy.
thedrugofinterestandresistancemustnothave
developed.Allthesepharmacokineticandpharmaco-
Ownersshouldhaveathoroughunderstandingof
dynamicfactorsmaybeinfluencedbythedose
theirpet'sdisease,including expectedprognosis
given,thetimingofadministrationandthemecha-
andoutcome.
nismofactionofaparticularchemotherapyagent.
60
Chapter7Principles of chemotherapy
Singleagenttreatment:AshypothesizedbyGoldie
Term
Definition
etal.(1982),when tumours become clinically
Remission
Lackof clinicalevidence of tumour.Aremissionmay
detectable(10cells) theyareheterogenousand
be complete（CR)with no evidence of disease,or
alreadycontainapopulationofdrug-resistant
partial(PR)with>50%reductionin tumourvolume
clones.Singleagenttherapyhas thepotentialto
andnonewlesionsdeveloping
resultinanapparentclinicalresponsebutultimate
Induction
Aphaseof chemotherapyin which thegoalisto
tumourprogressionduetosurvival andproliferation
induceremission.Thisphaseusuallyinvolvesa
of the drug-resistant clones.
moreintensetherapy（shorterdosinginterval/drug
combinations)
Multipledrugprotocols:Several‘rules'shouldbe
Aphaseof treatment in whichdrugsare
followedwhenusingmultipledrugprotocols:
Consolidation
administeredinordertoimprove clinicalresponse
byreducingmicroscopicdiseasethatmaystill be
Eachdrugshouldhavesomeefficacyalone
present afterthe patient isalreadyinremission
against thetumourtargeted
Overlappingtoxicitiesshouldbeavoidedordrugs
Maintenance
Thephaseof the drugprotocol used tokeepa
patient inremission.Oftenlessintense than
mustbescheduledtocompensateforthis
previousinduction therapy.Theindicationfor
Maximumdosesshouldbeusedwhenpossible
maintenance therapyisdependent onthetypeof
Drugswithdifferentmechanismsofaction
cancerbeing treated
againstneoplasticcellsshouldbecombined to
Treatmentused tore-induceremissionaftera
maximizethenumberofcellskilled.
Rescue
(salvage)
patient failsapreviousprotocoland thedisease
therapy
returnsclinically
Dosing
Theappropriatedoseofanydrugshouldbethe
Adjuvant
Chemotherapyusedaftersurgeryorradiation
maximumtolerateddosegivenattheshortesttreat-
therapytodelayrecurrenceordistantmetastasis
mentinterval,whilestillmaintaininganacceptable
Neoadjuvant
Chemotherapyused todecreasethebulkof the
toxicityprofile.Chemotherapydrugsareoftendosed
primarytumourpriortoothertreatmentssuchas
on thebasisofbodysurfacearea(BSA)insquare
surgery orradiation
metres (m²).Using this dosage scheme,however,
Commontermsused inchemotherapy
smalleranimals(<10kg)oftenshowincreasedtoxic-
7.1
protocols.
itytocertaindrugs,suchasdoxorubicin.Figures7.3
and7.4showtheconversionofweighttoBSAfor
Singleversusmultipledrugs
dogs andcats,respectively.Detailsofspecificdrug
Chemotherapeuticagentscanbeusedaloneorin
dosagesareincludedlaterinthechapter,aswell as
combination.The advantages and disadvantages of
recommendationsfor those drugswhereadose
single andmultipleprotocolsarelisted inFigure7.2.
reductionisindicatedforsmalleranimals.
Single agent treatment
Multipleagent protocols
Advantages
Disadvantages
Advantages
Disadvantages
Decreased cost
Decreased efficacy
Greater efficacy
Increased cost
Decreasedriskof toxicity
Lackof tumourcontrolossiblydue
Drugresistance slowerto
Increasedriskof toxicity
Decreased timeinhospital
to expansionof drug-resistant clones
develop
Increased time spentat veterinaryclinic
7.2
Singleversusmultiple drugprotocols.
Weight
BSA
Weight
BSA
Weight
BSA
Weight
BSA
Weight
BSA
(kg)
(w)
(kg)
(eu)
(6x)
(2w)
(kg)
(m2)
(6x)
(m2)
11.0
0.500
21.0
0.769
31.0
0.997
41.0
1.201
2.0
0.160
12.0
0.529
22.0
0.785
32.0
1.018
42.0
1.220
3.0
0.210
13.0
0.553
23.0
0.817
33.0
1.029
43.0
1.240
4.0
0.255
14.0
0.581
24.0
0.840
34.0
1.060
44.0
1.259
5.0
0.295
15.0
0.608
25.0
0.864
35.0
1.081
45.0
1.278
6.0
0.333
16.0
0.641
26.0
0.886
36.0
1.101
46.0
1.297
7.0
0.370
17.0
0.668
27.0
0.909
37.0
1,121
47.0
1.302
8.0
0.404
18.0
0.694
28.0
0.931
38.0
1.142
48.0
1.334
9.0
0.437
19.0
0.719
29.0
0.953
39.0
1.162
49.0
1.352
10.0
0.469
20.0
0.744
30.0
0.975
40.0
1.181
50.0
1.371
7.3
Conversion chartforweight tobody surfacearea(BSA)indogs.
61
Chapter7
Principlesofchemotherapy
Weight
BSA
Weight
BSA
Weight
BSA
Weight
BSA
Weight
BSA
(kg)
(w)
(kg)
(m²)
(kg)
()
(kg)
(m²)
(kg)
(m²)
3.2
0.217
5.2
0.300
7.2
0.373
9.2
0.439
1.4
0.125
3.4
0.226
5.4
0.307
7.4
0.380
9.4
0.445
1.6
0.137
3.6
0.235
5.6
0.315
7.6
0.387
9.6
0.452
1.8
0.148
3.8
0.244
5.8
0.323
7.8
0.393
9.8
0.458
2.0
0.159
4.0
0.252
6.0
0.330
8.0
0.400
10.0
0.464
2.2
0.169
4.2
0.260
6.2
0.337
8.2
0.407
2.4
0.179
4.4
0.269
6.4
0.345
8.4
0.413
2.6
0.189
4.6
0.277
6.6
0.352
8.6
0.420
2.8
0.199
4.8
0.285
6.8
0.360
8.8
0.426
3.0
0.208
5.0
0.292
7.0
0.366
9.0
0.433
7.4
Thewayinwhichdrugsaremetabolizedand
Metronomicdosing:Adifferentscheduleoftreat-
excretedfromthebodymustalsobetakeninto
ment currentlybeing investigated ismetronomic
account,ascompromisedfunctionoftheliverorkid-
dosing,orlowdoses ofdrugsgivencontinually.
neysmayleadtoincreasedtoxicityordecreased
Theseregimesuselowerdosesofcytotoxicagents
efficacyofcertaindrugs.Anexampleofthisis
(e.g.cyclophosphamide)ina continuous schedule,
cyclophosphamide，whichmustbemetabolizedin
insteadofpulsedmaximallytolerateddoses.
theliverinordertobeactive.Anotherexampleis
Targeted therapieswithspecificmechanismsof
thepotentialnephrotoxicityofcisplatin:thisdrug
actionarealsobeingstudiedincombinationwith
shouldbeusedwithcautioninanimalswithrenal
low-dosecytotoxicdrugs.Theexact mechanismof
disease.Doseadjustmentguidelinesused
in
actionofthislow-doseapproachisunknown,
humansbasedoncreatinineclearanceorbilirubin
thoughmodulationofangiogenicpathwaysoralter-
concentrationsarenotwellstandardizedinveteri-
ingimmuneeffectorcellsaretwooftheproposed
narymedicine.Astudyevaluating theeffectofglo-
mechanisms(Gately andKerbel,2001).Metronomic
merularfiltrationrate(GFR)onpharmacodynamic
dosingregimenshaveshownpromiseinanimal
endpointsincatsreceivingastandardizeddoseof
modelsandinhumanclinical trials.Veterinarytrials
carboplatinshowedthatdecreasesinneutrophil
havebeenreported,but exact drug combinations,
countweredirectlyrelatedtotheareaunderthe
dosesandefficacyofthisapproacharenotwell
curve（AuC);clearance of carboplatin and a tar-
substantiatedatthistime(Lanaetal.,2007;Elmslie
getedAUCcouldbe predictedbasedonGFR
etal.,2008).
(Bailey etal.,2004).The authorsproposed that dos-
ingforindividualizedclearanceofthedrugcould
Otherdeliverysystems:Theefficacyofadrugis
possiblytranslateintogreaterdoseintensity,accept-
relatedtothelengthoftimeacancercellisexposed
abletoxicityandultimatelyimprovedoutcome.The
tothedrug,whilethetoxicityisrelatedtothepeak
routineclinical applicationofsuchanapproachis
serumconcentration.Alternativedeliverymethods
questionablebutithighlightsthefactthatpharmaco-
arebeingdevisedtoincrease thetimeacellis
kineticandpharmacodynamicvariabilitybetween
exposedtoadrugandtolessenthepeakconcen-
patientscanbegreat.
trations.Examplesofthisincludesustainedrelease
Timing
lateddrugs.Other methods of delivery such as
The timingof administrationof chemotherapy drugs
intracavitary
orintratumoral
administrationare
isveryimportant.Ideally,drugs should be given
designedtogivehigherconcentrations tothe
atintervalstoallowformaximumtumourcelldeath
tumourcellswhiledecreasingsystemicexposure
butadequaterecoveryofnormalcellpopulations
and toxicity.
(e.g.bone marrow,gastrointestinal tract).For this
reason,manychemotherapeuticagentsareadmin-
Drugresistance
istered inapulsedfashion.Formyelosuppressive
Drugresistance is often the ultimatereason for
drugssuchasdoxorubicinandcyclophosphamide,
treatmentfailureanddeath.Currentlythereare
thewhitebloodcellcounttypicallyreachesanadir
severalknownmechanismsofdrugresistance
at7-10daysfollowingadministrationofmaximally
(Figure7.5),including decreased uptake of the drug,
tolerateddosesandhasrecoveredbyday21,
alteredaffinityofthedrugforthetarget,increased
hencethecommonlyused3-weekcyclesof
inactivationofthedrugbythebodyandincreased
treatment.
removalofthedrugfromthecell.
62
Chapter7
Principlesofchemotherapy
Mechanism of resistance
Drugs possiblyaffected
Decreased druguptake
Methotrexate
Decreased drugactivation
Cytarabinemethotrexate
Increased drug target
5-Fluorouracilmethotrexate
Altered drug target
Etoposidedoxorubicinmthotrexat
Increaseddetoxification(increasedglutathioneorglutathionetransferase)
Alkylating agents
Enhanced DNArepair
Alkylatingagentlatinumderivativitrsor
DefectiverecognitionofDNAadducts
Cisplatin
Increased drugefflux
Doxorubicin,tposidevincaalkaloidspaclitaxl
Defectivecheckpointfunctionand/orapoptosis
Most anti-cancer drugs
7.5
Mechanismsof drugresistance.
Thislastmechanismhasbeenoneof thebest
preparation and administration(Conner et al.,1999;
characterizedandinvolvesexpressionoftheMDR-1
Sessink and Bos,1999).
gene,which encodes for P-170 membrane glyco-
Exposurecanoccurinseveralways:
protein.Thisglycoproteinworksasaneffluxpumpto
Inhalationofaerosolofdrugduringmixingor
removexenobioticsfromthecell.Asmanycytotoxic
administration
drugs are substratesfor thispump,developmentof
Absorptionthroughtheskin
resistancetoonedrug throughthismechanismcan
Ingestionthroughcontactwith contaminated food
conferresistancetodifferentdrugstowhichthecell
orother objects(e.g.cigarettes)
hasnotbeen exposed.Othermembraneproteins
Accidental inoculation.
such asMRP(multidrugresistance protein)have
alsobeenidentifiedwithrespecttothisphenomenon.
Itisessentialthatemployeesareinformedofthe
Anotherreasonfordrugresistanceisthesup-
risksofworkingwithcytotoxicdrugsandthesafety
pressionorinactivationofapoptoticorcell-damage
precautions/procedures thatmustbe takentomini-
controlpathways,whichoccursduringtheprocessof
mize exposure.Practices using cytotoxic drugs
carcinogenesis in many tumours.Apoptosis (pro-
shoulddevelopandimplementasetofLocalRules
grammedcelldeath)isacommonpathwaymediat-
or‘Guidelines'for handling cytotoxic drugs in the
ingcelldeathinresponsetomanycytotoxicagents.
practice,as outlined inFigure 7.6.Safetyprecau-
Upregulationofbcl-2orinactivationofp53are
tionsarelisted inFigure7.7.
examplesofgeneticchangesthatcouldcontributeto
drugresistance.
Asresearch
inthis field progresses,it is
Allemployeesmustbeinformedof therisksof workingwith
becomingobviousthatdrugresistanceisoftena
cytotoxic drugs.
complexprocess,involvingseveral mechanismsthat
mayoccurinseriesorinparallel.Becauseofthis,
equipment tominimizeriskof cytotoxicexposure.
Theremustbeaprocedureandspecifiedequipmentforhandling
strategiesaimedatblockingonespecificpathway
（preparationandadministration）of cytotoxicdrugstominimize
areoftenclinicallyunrewarding.Althoughworkis
riskof exposure.
ongoingwithseveral‘anti-resistance’compounds,
Theremustbeaclearprocedureand adequatematerialsfor
definitiveresultsdonotyetwarrantincorporating
cleaning spillageof cytotoxic agents.
these agentsintostandardprotocols.
Allareaswherecytotoxicdrugsarehandledorusedmustbe
clearlyidentifiedaccesstosuchareasshoudberestrictd
Preparationandsafehandling
beforeuse forotherpurposes.
Withtheincreasinguseofchemotherapydrugsin
Theremustbeaclearprocedurefordisposalofallcontaminated
veterinarypractice,moremembersoftheveterinary
(andpotentiallycontaminated)materialsinaccordancewithLocal
healthcareteamareatriskofexposuretothese
Authority Regulations.
compounds.This includes
veterinarysurgeons,
Thereshouldbeaprotocolforcleaningfacilitieswherecytotoxic
drugs are used.
nurses,animal technicians,cleaners,and pet
·Pregnant women should not handle cytotoxic drugs.
ownersandtheirfamilies.Cytotoxicdrugshave
activitythatmaycausemutagenic,carcinogenicand
DetailedGuidelinesforpreventingoccupationalandenvironmental
teratogeniceffects.Studiesconcerningoccupational
exposuretocytotoxicdrugsinveterinarymedicinehavebeen
exposureinthehumancancerfieldhaveshown
preparedbytheEuropeanCollegeofVeterinaryInternalMedicine
changesintheamountsofmutagensintheurineof
andmaybedownloaded from theirwebsite(www.ecvim-ca.org)
employeessampled,aswellasdegreesofwork
surfacecontaminationinareasofchemotherapy
7.6
General guidelinesforhandlingcytotoxicdrugs.
63
Chapter7Principlesof chemotherapy
class-llverticalflowcontainmenthoodFigure7.8a).if thisisnot
possiblenthepracticesetingdrusshoudbepreparedina
low-trafficareaawayfromdoorswindowsordraughts.lastic
shieldcanbeused toprotect thepersonpreparingthedrugs.
Preferablyaclosed-systemdrugprotectivedeviceshouldbe
used,asdiscussed below.
Agowwithlongsleevescuffsandaosed frontmadf
materiawithlwmabilityhouldbewrecialid
a
cuffof thegownStandardsurgicalglovesarenotadequate
Ifasafetycabinetisnotavailable,theuseofadust-andmist
aerosolsisrecommended.Aregularsurgicalmask isnot
acceptable.
Topreventformationfarosolshydrophobicfilesr
chemotherapypinscanbe used toprevent pressurebuild-upina
bottleAfltereedlecanalsobeusedtopreventaerosol
exposure(Figure7.8b).
b）
Luer-Loksyringesshouldalobeused topreventaccidental
separationof theneedlefromthe syringeorchemo-pin.
Allinravenouslinesshouldbeprimedpriortoadditionof
cytotoxicagents to the infusion bag.
Afterpreparationicompletedugsshouldbeplacedinaclealy
tothe areaforadministrationto thepatient.
Materiastdsaddafprrationgringea）
biohazardwasteeedlesshouldbeplacedinaseparate
designatedsharpscontainerTopreventacidentalnoculation
recapping of needlesshould beavoided.
7.7
Safetyprecautionsforhandlingcytotoxicdrugs.
7.9
PhaSealsystemcomponents:(a)protective
cap.whichisfixedtothepharmaceutical bottle;
(b)injectorLuer,whichconsistsofanencapsulated
speciallygroundcannula,usedinbothpreparationand
administration.(c)Administrationtothepatient.
whichpreventsaerosol leakage.Secondly,allcom-
ponentsarefittedwithsealingmembranesthatare
connectedtogether,andtransferiscarriedoutviaa
specialcannula.Whenthecomponentsaresepa-
rated the membranes seal completely,preventing
anyleakage.Whilethissystemhasreducedexpo-
suredramaticallyitshouldnotbeusedasthesole
(a
(b)
meanstopreventcontamination:personalprotective
Equipmentusedtominimizeoccupational
garmentsandglovesarestillrecommended.
7.8
exposuretochemotherapyagents.
Commonsensealsoplaysaroleinminimizing
(a)Biological safetycabinet.(b)Chemotherapypinused
exposure.Handsshouldbewashedbeforeandafter
toprevent aerosolizationofanydrug.
anyprocedurethatinvolvesachemotherapeutic
agent.Anotherwaytodecreasechemotherapyexpo-
Closed systems
sureisforalocalhumanhospitalordrugsupplierto
Closed-system drug transfer devicesmechanically
preparethedrugsfortheveterinarypractice.
prohibit theescapeofhazardousdrugorvapour
concentrationsoutside the system.Thefirston the
Spillageand accidentprocedures
market was thePhaSealsystem(Figure7.9),which
Cytotoxic spillkits(Figure7.10)should be available
hasbeenshowninnumerousstudiestoreduce
intheareasofdrugpreparationandadministration
exposuretobothpersonnelhandlingdrugsandenvi-
andinthewardwhereanyanimalishospitalized,to
ronmental surfaces(Wicket al.,2003;Jorgensen et
preventandcontaincontaminationintheeventof
al,2008).The system has two unique qualities.
spillageoraccidents.Theproceduresthatshould be
Firstly,whenairorliquidisinjectedintothebottlethe
followedintheeventofaccidentalspillageorcon-
pressureisequalizedviaexpansionofthebladder,
taminationareoutlined inFigure7.11.
64
Chapter7Principles of chemotherapy
Disposableprotective gownx2
Cytotoxicdrug
Period of risk(human data)
。
Disposablechemotherapyglovesx2pairs
Disposable shoe coversx2pairs
5-Fluorouracil
3days
Fullfacerespiratorand fiters
Carboplatin
5days
.
pH5 soap tablet
Sealable plasticbags
ChemosorbTMpads
Chlorambucil
2days
Absorbent disposabletowels
Cisplatin
8days
7.10
Contentsof a spill kit forcytotoxicdrugs.
Cyclophosphamide
4days
Cytarabine
3days
Event
Procedure
Doxorubicin
7 days
Spillage of
1.Callforassistance and warn others.
Gemcitabine
7days
cytotoxic drugs
2.Fullpersonal protective clothing should be
worn (including fullfacerespiratorand
Lomustine
3days
protective shoe coverings).
3.
Use dry-absorbent towelsto absorb anyfluid.
Mitoxantrone
8days
4.
Cleancontaminatedarea with70%alcohol
and dry tissue three times.
Vincristine
3days
5.Dispose of alcontaminated materialas
cytotoxic waste.
Vinblastine
3days
Contamination
Rinse withlargeamountsof waterandwash with
7.12
Riskperiodinhumanpatientsafterlastdrug
of skin
administration.No similardata are availablein
soap
veterinarymedicine.
Contamination
1.Seek help.
ofeyes
2.
Remove contact lenses(if worn).
3.Rinse eye(s） with large amounts of water;use
Drug administration
eye washfacilityif available forat least20
minutes.
Oralmedication
4.Consult a doctor.
Whenadministeringoralmedication,protective
glovesshouldbewornandhandsshouldbe
All accidentsshouldbereportedaccordingtolocal HealthandSafety
washedafteradministration.Tabletscanbegiven
regulations
normally,butitisimportant to ensure that the
7.11
Proceduresintheeventof accidental spillage
patient(especiallycats)hasswallowedthe medica-
or contamination.
tion.Asyringefullofwaterfollowingadministration
canbehelpful.Itmaybeeasiertoadministertablets
todogsinasmallamountoffood,whichtheycan
Nursingcareofanimalsthathavereceived
beobservedtoswallow.
cytotoxicdrugs
Anotherimportantaspectoforalmedicationisto
Excreta（saliva,urine,vomit,faeces)of treated ani-
avoidbreakingorsplittingpills.Doingsocanlead to
malsmaycontaintracesofdrugsortheirmetabol-
increasedexposurethroughdustanddebris.It may
itesandarethereforeapotentialrisk.Thereisvery
benecessarytoalterthedosescheduleorhave
littleinformationavailablefortheperiodofriskin
drugsspeciallycompoundedbyapharmacy.
animals;human data arepresented inFigure7.12.
Intramuscular,subcutaneousorintralesional
Specialwardsordesignatedkennelsshouldbe
administration
usedforthehospitalizationofanimalstreated
Intramuscular
andsubcutaneousinjectionsare
withcytotoxicdrugs,withclearidentificationof
administeredinthenormalfashionwhilewearing
the agentsused.
protective gloves.After insertion of theneedle，the
Whilstanimalsarehospitalizedduringtheperiod
syringemustbecheckedforbloodtomakesurethat
ofrisk,personalprotectiveclothingshouldbe
avesselhasnotbeenenteredinadvertentlyandthat
used byall thosetaking careof the animal.
thedrugisnotgivenintravenously.Intralesional
Allmaterialsthathavebeenincontactwiththe
chemotherapyisoftenadministered inasuspending
animalshouldberegardedaspotentially
agentsuchasoiloranothervehicle.Becausethere
contaminated.
isagreaterpotentialforleakingfromtheinjection
Allwasteshouldbedisposedofascytotoxic
site,protectivegloves,achemotherapypreparation
waste.
gownandprotectiveeyewearshouldbeworn.lfsig-
nificant leaking does occur,the areas should be
Whenanimalsaredischargedfromhospitalor
swabbedandcleanedandthematerialsdisposedof
treatedasoutpatients,ownersshouldbeadvisedof
as chemotherapywaste.
thepotentialrisktotheirownhealthandenviron-
mentfromcontaminatedurineandfaeces.They
Intravenousadministration
shouldbeadvised toweargloveswhencleaningup
Whilemanychemotherapydrugsareadministered
urineorfaecesandtoavoidbeinglickedbytheirpet
intravenously,someof themarevesicantsorirri-
(paying specialattention to children).
tants.Becauseof this,everyattempt mustbemade
65
Chapter7Principlesofchemotherapy
toensurethattheveinsusedarecaredforand
4.Duringadministrationof the drug,thepatientis
thatcathetersareplacedascleanlyandatrauma-
monitoredforadversereactionandextravasation.
ticallyaspossible.Peripheralveins shouldbe
Thesiteshouldbevisualizedandnotcoveredby
avoidedforroutinebloodcollectioninoncology
layersofbandagematerial.
patients,andthejugular veinusedinstead.
5.Upon completionof theinfusion,the catheteris
Peripheralveinsarechosenforintravenouschemo-
flushedwithatleast10mlofnon-heparinized
therapyadministrationbecauseof theeaseofmoni-
salinetoensurethatthecatheterandmale
toringforextravasations.lt is goodpracticeto
adapterorhubhavenoresidualdrugpresent.
alternateandrecordtheveinsbeingusedtoallow
Allmaterialsshouldbediscardedintoappropriate
themtorecoverbetweentreatments.
chemotherapywastecontainers.
Drugsareusuallyadministeredwithanindwelling
7.
Accuraterecordkeepingforeachtreatmentis
catheterwhenthevolumeis>3mlortheinfusionis
essential,includingdrug,dose,veinused,
not a bolus injection （Figure 7.13a).For small-
administratorandanyadverseeventsordose
volume bolus injections （suchas vincristine),a
reductionsrequired.
butterflycathetermaybeused(Figure7.13b).
Intracavitaryadministration
7.13
agent(cisplatin,carboplatin)shouldbeadministered
(a)Mostcytotoxicdrugsare
intoabodycavity（thoraxorabdomen)，especially
administeredviaacleanly
whenamalignanteffusionispresent.
placedintravenouscatheter.
(b)Small volumesof drug
Forinstillationintothechestcavity:
givenasaboluscanbe
giventhroughabutterfly
Thepatientisplacedinlateralrecumbency
catheter.This dog is
andtheinjectionsiteisasepticallyprepared.
receivingvincristineintoa
Theright sideispreferredforinjection.
lateral saphenousvein.
Aridgedplasticintravenouscannula is
insertedbetweentheribsandflushedwithat
least12mlofsalinetoensurepatency.
Ifresistanceorexcessivepatientdiscomfortis
noted,thecannulashouldberemoved anda
newone inserted.
Forabdominaladministration:
Thepatient isplacedindorsalrecumbency
andamidlinesitecaudaltotheumbilicusis
prepared.Thissiteischosentoavoid the
(a)
spleen.Itisadvisabletoallowthepatientto
emptythebladderpriortotheprocedureto
reduceriskof bladderpuncture.
A catheterisplacedasdescribed above.
Oncepatencyisdetermined,thefluid lineis
attachedandthedrugisadministered.The
maximumvolumeforthedogis1litre/m²ineither
cavity(Mooreetal.,1991).Forthecat,maximum
volumesof60mlforthechestcavityand250ml
fortheabdominalcavityhavebeen
recommended(OgilvieandMoore,2001b).
Afteradministrationthepatientshouldbeallowed
tomovearoundinordertodistributethefluid
throughout the cavity.
(b)
Becauseasubstantialamountofthedrugdoseis
likelytobeabsorbedsystemically,monitoringand
administrationguidelinesforeachdrugstillapply.
Theprocedureforintravenousadministrationofa
chemotherapydrugisasfollows:
WARNING
Cats are not toreceive cisplatin by anyroute
1.Priorto administration,the siteisclipped and
and saline diuresismust still accompanycisplatin
asepticallyprepared.
administration in dogs.
2.If thevenipuncture wasnot‘clean'，a differentsite
shouldbeattempted.
3.Afterplacement,the cathetershould beflushed
Toxicity
withatleast10mlofnon-heparinizedsalineto
Manychemotherapydrugshave thepotential to
ensurepatency.Heparinizedsaline isavoided as
causeacuteorlatetreatment-relatedsideeffects.
heparincancauseprecipitationofsomedrugs
Discussedbelowaresomeofthemorecommon
(e.g.doxorubicin).
toxicitiesthatcanaffectveterinarycancerpatients.
66
Chapter7Principlesofchemotherapy
Bonemarrowsuppression
possibleifvomitinghasbeenoccurring.Diagnostic
Thebonemarrowissensitivetothetoxiceffectsof
tests,includingCBC,plateletcount,biochemicalpro
chemotherapyduetoitshighgrowthfractionand
fileandurinalysis,should beperformed.Otherpro-
mitoticrate.Becausethenormalbonemarrow
cedures such as chestradiography,urine culture or
transit timesand circulatinghalf-lives of eachcell
abdominocentesis,shouldbecarriedoutifindicated，
linearedifferent,neutropenia typicallyoccursfirst,
looking for sitesof infection.Blood cultures should
followedbythrombocytopenia.Anaemiaassociated
beconsidered,thoughthelikelihoodofobtaininga
withchemotherapyisrarelymanifestclinicallyinthe
positiveresultislow.Atleasttwoorthreebloodsam-
dog and cat.
plesshouldbetakenaseptically,30minutesapart.
Thepatientshouldbecarefullyevaluatedforother
Neutropenia:Neutropeniaisthedose-limitingtoxic-
sites of infection such as pyoderma,surgical
ityof manyfrequentlyusedchemotherapeuticagents.
wounds,cellulitis,or radiation treatment sites for
Mildneutropeniaiscommonandoftennotaclinical
acute effects.lfa likely area is found,samples
problem,butsevereneutropeniacanbecomplicated
shouldbeobtainedforculture.
bysepsisandmaybelife-threatening.Theneutro-
Treatmentshouldconsistofsupportivecarewith
penic nadir is usually 7-10 days for most drugs,
intravenousfluidsandempiricbroad-spectrum
althougheachpatientwillhavesomevariability
antibiotictherapy:
depending on the drugsbeing given,dose,route of
administrationand time sincelasttreatment.Most
Anyelectrolyteabnormalitiesandhydration
combinationdrugprotocolsareestablished
to
deficitsshouldbecorrected.Strictaseptic
accountforadequatebonemarrowrecoverybetween
techniqueshouldbeusedwhenplacing and
treatments.Monitoringpatientswithacompleteblood
handlingintravenouscatheters
count(CBC)isnecessaryprior to eachchemother-
Appropriate antibioticchoicesincludea
apytreatment.Treatmentshouldbedelayedifabso-
combinationofapenicillinorcephalosporinplus
luteneutrophilcountsare<2.0-2.5×10%/.Inmost
anaminoglycoside.Careshouldbetakenwhen
casesofmildneutropenia,the countswill increase in
administeringaminoglycosidesinpatientswith
3-4daysandtreatmentcanthenbereinstituted.
renalcompromiseordehydration.lf
Patientswithabsoluteneutrophilcounts>1.5x
aminoglycosidesarenotanappropriatechoicefor
10%/lareusuallynon-febrileandasymptomatic.They
thepatient,asecond-generationcephalosporin,
shouldbemonitoredathomeforanydeteriorationin
suchascefoxitin,oracombinationofampicillin
theircondition(Figure7.14).Prophylacticantibiotics
andafluoroquinolone,suchasenrofloxacin,can
withagentssuchastrimethoprim/sulphonamides
alsobe used(Figure 7.15)
Antibiotictherapyshouldbealteredaccordingto
given to guard against infection.When absolute
sensitivityindicatedbyanycultureresults
countsdropbelow1.0x10%/l,theriskofdeveloping
Carefulmonitoringofallbodysystemsand
sepsisrises.Ifsignificant neutropenia has devel-
responsetotherapyisnecessaryfora
opedafterchemotherapy,thenextdose（once the
successfuloutcome
neutrophil count is sufficientlyhigh)should be
Filgrastim(granulocytecolonystimulatingfactor,
reducedby20-25%.
G-CSF)canalsobegiventoincreasethe
Theneutropenicpatientthatpresentsasfebrile
neutrophilcount.Ithasaveryquickandprofound
andpossiblysepticisatrueemergency.Themost
effectofenhancingbonemarrowrecoveryafter
likelysourceofinfectionisbacterialtranslocationof
chemotherapyinsult.Onlyahumanrecombinant
the patient's own gastrointestinal flora,released
productisavailablecommerciallyandthereis
whenthenormalmucosalbarrierisdamagedbythe
potential forcross-reactiveantibodydevelopment.
chemotherapy.Clinically,patients thatare severely
Becauseof this,itsroutineuseiscontroversial.
neutropenicmaynothaveall thesignsof infection,
Theauthordoesnotrecommend itsusein
duetothelackofcellstoproduceaninflammatory
afebrilepatientsorprophylactically.lfusedin
response.Othersignswill include lethargy,collapse,
febrileneutropenicpatients,thedoseis2.5-10
anorexiaandgeneral malaise.Gastrointestinal signs
μg/kg s.c.q24h.Oneor two doses are often all
maybepresentormayhaveprecededtheneutro-
thatisnecessarytoimproveneutrophilcounts
penic episode,and aspiration pneumonia is also
dramatically.
Absolute neutrophil
Isafever
Isthe patient showing
Treatment
count(cells/ul)
present?
clinical signs?
<2000
No
No
Delay chemotherapy.No antibiotics needed
<1000
No
No
Delaychemotherapy.Instituteprophylacticantibiotics.Monitorat homefordeclinein
condition
<2000
Yes
No
Delaychemotherapy.lnstituteantibiotics.Monitorcloselyathome
<1000
Yes
Yes
Delaychemotherapyandhospitaliewithintensivemonitoring.Giveintravenous
antibiotics
7.14
67
Chapter7Principlesofchemotherapy
Stoolscanbeloose,wateryorconsistentwith
Dose
haemorrhagiccolitis,especiallyafterdoxorubicin
Trimethoprim/sulphonamide
15mg/kg orallyq12h
administration
Cefalexin
11-22mg/kg orally q8h
Ifseveregastrointestinal toxicityispresent,
bacterial translocationandsepsisarepossible
Cefoxitin
22mg/kgi.v.q8h
sequelaeduetothelossofthenormalmucosal
Ampicillin
22mg/kgi.v.q8h
integrity
5-10mg/kgorallyori.v.q12h
Nauseaandvomitingusuallybegin48hoursafter
Enrofloxicin
drugadministration.Diarrhoeawill lagbehind
Antibioticscommonlyusedinveterinary
7.15
slightly.
oncology.
Treatmentforchemotherapy-inducedgastrointes-
With early and aggressive intervention,most
febrileneutropenic
chemotherapypatientswill
affected.Mildsignscanusuallybemanagedbywith-
respondtotreatment,butasmallproportionwill die.
holdingfoodandwaterifvomiting,andprovidingan
Chemotherapyshouldbewithhelduntil thepatient
anti-emetic.Offeringsmallamountsofwateranda
andbonemarrowhaverecoveredandthenreinsti-
blanddietevery3-4hoursoncevomitinghas
tutedatareduced dose.
stoppedisthenindicated.
Significantgastrointestinaltoxicitywhichlastsfor
Thrombocytopenia:Thrombocytopeniaassociated
>36-48hours and doesnot respond to oral anti-
withchemotherapyisrarelyclinically significant and
emetictherapyshouldbetreatedaggressively.
doesnotoftenresultinbleeding.lfcountsare<50x
Supportivecarewithintravenousfluidsincluding
10%/,administration of bone marrow suppressive
rehydrationandreplacing continued losses,along
drugscanbedelayeduntilcountsrise.
withcorrectionofelectrolyteabnormalities,isimpor-
Gastrointestinaltoxicity
tant.PerformingaCBCandbiochemicalprofileis
Themostcommonproblemobservedbypetowners
alsoprudentforseverelyillpatients,tomonitor the
isgastrointestinal toxicity.Vomitingcanoccuracutely,
possibleneutropeniaorsepsisthatmayalsooccur
within6-12hoursofdrugadministration,ormore
concurrently.lfgastrointestinaleffectsafterchemo-
commonlyisdelayed,occurring24-48hoursafter
therapyadministrationaresevere,institutingprophy-
administration,orlater.Inveterinarymedicine,most
lacticanti-emetictherapyorachemotherapydose
chemotherapy drugs cause delayedemesis,the
reductionmaybeindicated.
most notable exception being cisplatin,which will
Anynauseaorvomitingsecondarytochemo-
causevomitingwithin thefirst6hoursof infusion.In
therapyshouldbetreatedwithanti-emetics（Figure
onestudyoftumour-bearingdogsreceivingcisplatin,
7.16).
27of41dogs（66%)vomited(Knappetal.,1988)
Themechanism
of
chemotherapy-induced
Drug
Dose
nauseaandvomitingiscomplex.Theemeticcentre
Metoclopramide
0.2-0.4mg/kg orally q6-8h
of thebrainisinthemedullaandreceivesinputfrom
or1-2mg/kg/day CRIiv.
several sources,including thechemoreceptortrigger
zone(CRTZ)in the fourthventricle,thecerebral cor-
Chlorpromazine
0.5mg/kgi.m.or s.c.q6-8h
tex,peripheralreceptorsinthegutandthevestibular
Butorphanol
0.1-0.4mg/kg i.m.,i.v.ors.c.
system.Theseareasare influenced bycholinergic,
Ondansetron
serotonin (5HT-3),histaminergic and adrenergic
0.1mg/kgi.v.or orallyq12h
receptors,which are themselves influenced
Dolasetron
0.6-3mg/kgiv.q24h
by
certaindrugs.TheCRTZisactivated bychemical
Maropitant
1mg/kg s.c.q24h for5days or
stimuliandisavitalpartofchemotherapy-induced
2mg/kg orallyq24hfor5days
nausea andvomiting.Peripheralreceptorscanbe
activateddirectlybychemotherapyorbysubstances
Anti-emeticscommonlyused inveterinary
7.16
oncology.
releasedfromcellselsewhere in the gut.Signals
fromtheseperipheralreceptorsascendtotheemetic
centreviathevagusnerveandotherautonomic
Metoclopramideisoneofthemostcommonly
afferent pathways.In humans,influence from the
usedanti-emeticsinveterinarymedicine.lts
cerebralcortexcontributestochemotherapyemesis
effectisbothcentral,intheCRTZasa dopamine
muchmoresothaninveterinarymedicine.Stimuli
antagonist,andperipheral,viaincreasinglower
fromthesehighercentresarelikelyresponsiblefor
oesophagealsphinctertoneandrelaxingthe
'anticipatory'vomitingandnausea.Inputfromthe
pylorus.Metoclopramideiscontraindicated in
vestibularcentreprobablyhasminimal influenceon
gastrointestinalobstruction.
chemotherapy-inducedemesis.
Chlorpromazineiscommonlyusedformild
Clinicalsignsseenwithgastrointestinaltoxicity
nausea.It workscentrally in the CRTZ.It canbe
arevariable:
administeredintramuscularlyorsubcutaneously.
A suppositoryform isalsoavailable.
Anorexiaalone,occasionalvomitingorpersistent
Butorphanolhasbeenusedtoreducenausea
vomitingaccompaniedbydehydration,depression
andvomiting，particularlywithcisplatin
andelectrolyteabnormalitiesmaybeseen
chemotherapy.
68
Chapter7Principlesofchemotherapy
(a)
b
(C)
(a）Alopeciainapoodlefollowingtreatmentwithdoxorubicin.(b)Alopecia,includingwhiskerloss,inacatwith
7.17
lymphoma treatedwithcyclophosphamideandvincristine.(e)Thecat'shairregrewafterdiscontinuationof
treatment.
Serotoninantagonistsareveryeffective anti-
Cisplatin
emeticscurrentlybeingusedinhuman and
Dactinomycin
veterinaryoncology.Theyinhibit the5HT-3
Daunorubicin
(5hydroxytryptamine)receptorintheCRTZas
Doxorubicin
。
wellasinthegutafferents.Ondansetron is
Etoposide
availableinanoralorinjectableformulation.lf
Mithramycin
givenintravenously,itshouldbegivenover25
。
Mitoxantrone
minutesordilutedin0.9%sodiumchloride.
Vinblastine
Dolasetronisalsoused.
Vincristine
Maropitantisaneurokininreceptorantagonist
7.18
Chemotherapeuticagentsthatarevesicants
thatblocksthe actionofsubstancePinthe
and irritants.
centralnervoussystem.Itisaveterinaryproduct
andcomesinanoralandinjectable
(subcutaneous)formulation.Currentlabel
indicationsaretotreatacutenauseaforuseprior
toorsubsequenttochemotherapyadministration
forupto5consecutivedays.
Alopecia
Alopeciaordelayedhairgrowthcanoccur(Figure
7.17)but is not a universal phenomenon.In the dog，
severealopeciaisbreed-dependent,typicallyoccur-
ringinbreedswithcontinuallygrowinghaircoatssuch
asPoodles,OldEnglishSheepdogsandsomeof the
terrierbreeds.Inotherbreeds,hairmaybeslowto
regrow inareasthathave beenshaved,ormay
becomesparse.Hairusuallygrowsbackafterchemo-
therapyisdiscontinuedandinsomecasesmayreturn
withanalteredconsistencyorcolour.Catsrarely
developseverealopeciabutwill losetheirwhiskers.
Extravasation
Somechemotherapeuticagentsarevesicantsand
caninducealocaltissueirritationornecrosisifthey
leakoutoftheveinorareextravasated.Inveterinary
a
(b)
medicine,themost common agents that causethis
7.19
(a)Atissuereactionfollowingvincristine
reactionarevincristine,vinblastineanddoxorubicin
extravasationand(b)thehealedareaseveral
(Figure 7.18).
months later.
Theseverityofthereactionisdependentonthe
agentandtheamountthatleaksintothetissues.
Ifanextravasationissuspected,thedruginfusion
Clinicalsignsassociatedwithextravasationinclude
shouldbestoppedandanydrugremaininginthe
pain,erythema,moistdermatitisandnecrosisofthe
cathetershouldbeaspiratedback,alongwith
area(Figure 7.19).These signs are often not im-
several millilitresofbloodifpossible.
mediateandmayoccur1-7daysafteradministration
Standardwoundmanagementtechniques(dress-
ofvincristineorvinblastineandupto7-10daysafter
ings,bandaging,paincontrol)areusedtomanage
doxorubicin.lfanextravasationreactionoccurs,tissue
mild tomoderatereactions,whileseverereactions
sloughingmayfollow.
mayrequiresurgicaldebridementandskingrafting.
69
Chapter7Principlesof chemotherapy
Anecdotal informationexistsconcerningtheuse
ofotheragentstotreatanimmediateextravasation,
andminimalclinicalinformationastotheireffective-
nessexistsinveterinarymedicine.
Guidelinesborrowedfromthehumanexperience
fordoxorubicinincludeapplyingcoldpacks
intermittentlyforupto12hours.Dexrazoxane,a
free-radicalscavengerusedtoprevent
doxorubicin-induced cardiomyopathy,hasbeen
reportedtoreduceextravasationreactionsif
givenshortlyaftertheevent(within3hours) in
peopleand anecdotallyinveterinarypatients.Ten
timesthedoxorubicindoseisgivenintravenously
la
within3hoursand againat12and24hours.
TopicallyappliedDMSOhasalsobeenadvocated
(ThammandVail,2007).
Forvincaalkaloidextravasation,heatisapplied
forseveralhours.Infiltratinghyaluronidase(1ml
forevery1mlextravasated)intotheareahas
beenrecommended(Spugnini,2002).
Extravasationisapreventablecomplicationif
drugsareadministeredaccordingtosuggested
guidelinesby appropriatelyskilledstaff.Accurate
record keeping of chemotherapy administration,
includingwhichveinisused,isalsoimportantto
helptotrackextravasationreactions.
Allergicreactions
7.20
Hypersensitivityreactionduringdoxorubicin
Agentsmostcommonlyassociatedwithhypersensi-
administration inaBloodhound.Note(a)the
oedema around theeyesand(b) swelling,redness and
tivityreactionsinclude crisantaspase(L-asparginase)
indurationof the lips.
anddoxorubicin,whilereactionstoetoposideand
paclitaxelhavebeenlinkedtothesolventsforthese
compounds(cremophorEL,polysorbate80).
Ifnecessary,giveintravenousfluidsand
Carefulpatientmonitoringisrecommended
adrenaline(epinephrine)(0.1-0.3mlofa1:1000
duringandimmediatelyafterdrugadministration.
solution i.v.)
Clinical signs of hypersensitivityreactions in dogs
Give additional supportivecare.
include urticaria,erythema,restlessness,vomiting，
headshakingandoedemaofthehead,especially
Cardiactoxicity
theeyelidsand lips（Figure7.20).Severereactions
Cardiotoxicityattributedtochemotherapyadminis-
maylead tohypotensionandcirculatorycollapse.In
trationisusuallyassociatedwithdoxorubicininthe
cats,the signs can be similar but cats may also
dog.Otherdrugs,particularly other anthracyclines
exhibitrespiratorysignssuchasdyspnoeaoropen-
suchasdaunorubicin,areassociatedwithcardiac
mouthbreathing.
toxicityinhumansbutarenotwidelyusedinveteri-
Thelikelihoodofhavingareactioninpatients
narymedicine.
receiving crisantaspase increases after repeated
Therearebothacuteandchronicformsofdoxo-
doses.Intramuscularadministrationdecreases the
rubicincardiotoxicity.Theacuteformmanifestsas
chanceofreactionwhencomparedwiththeintra-
arrhythmiasthatoccurduringorsoonafteradminis-
peritonealorintravenousroute.Doxorubicinadminis-
trationofthedrug;thesearetransient.Thechronic
trationcaninducemastcelldegranulation,whichwill
andmorecommonformoftoxicityresultsindilated
contributetoahypersensitivityreaction.Slowingthe
cardiomyopathyandpossiblecongestiveheartfailure
infusion，and/orpretreatingwithanH-1blocker
which isnotreversible.Inhumans,cumulative doses
（diphenhydramine，1-2mg/kgi.m.,30minutesprior
>550mg/m²havebeenshowntocausetoxicityinup
toinfusion)and corticosteroid（dexamethasone,
to30%ofthepatientsstudied,whileonly1-5%of
0.5-1mg/kgi.v.),can eliminate orlessen the effect.
thosewhoreceivedacumulativedose<5o0mg/m²
Treatmentofanaphylacticorotherhypersensitiv-
developedcardiotoxicity.Inthedog,cumulativedoses
ityreactionstochemotherapydrugsisthesameas
between180and240mg/m²areconsideredsafe,
foranyotherdrug.lfareactionis apparent:
althoughtoxicityhasbeenreportedinsmallnumbers
ofcases at lowerdoses.Incats,dosesof300mg/m²
Discontinueinfusionif stillinprogress
givenexperimentallytonon-tumour-bearingcats
AdministerH-1blockers(diphenhydramine,
resulted innoclinical heartdisease;however,histo-
0.2-0.5mg/kgi.m.)anddexamethasone
pathologicalchangesconsistentwithdamagewere
(0.5-2 mg/kg i.v.)
present inallheartsexamined(O'Keefeet al.,1993).
70
Chapter7Principles of chemotherapy
The mechanism of cardiac damage associated
Improvementhasbeenreportedinasmallnumberof
withdoxorubicinadministrationislikelytobedueto
dogs whenintravesicular DMSO(25-50%)solution
theformationoffreeradicalsandtheoxidative
hasbeenused(Kisseberthand MacEwan,2001),but
damagethatsubsequentlyoccurs.Cardiactissue
nostudiesoflargenumbersofdogsareavailable.
hasrelativelylowlevelsofseveralprotective
Todecreasethelikelihoodofsterilehaem-
enzymessuchascatalase,whencompared with
orrhagic cystitisdeveloping,several strategiescan
othertissues.Histologically,changesconsistentwith
beemployed.Treating with furosemide(1mg/kg)
degenerationandatrophyofcardiacmyocyteswith
prior tointravenouscyclophosphamideadministra-
myofibrillarloss,cytoplasmicvacuolizationandcell
tionhasbeenshowntodecreasetheincidenceof
lysiscanbeobserved,aswellasfibrosis.
occurrence(Charney et al.,2003).Giving the oral
Diagnosingdoxorubicin toxicityprior toclinical
medicationfirstthinginthemorninginordertoallow
signsofcongestiveheartdiseasecanbedifficultdue
forbladderemptyingthroughoutthedayisoftenrec-
tothelackofsensitivityoftestsused.Tachy-
ommended.Saltingfoodoradministeringprednisone
arrhythmiasareoftennotedfirst,followedbyecho-
topromotediuresishavealsobeenadvocated.
cardiographic changes.Nuclear scintigraphy and
endomyocardialbiopsiesarethemostsensitivetests
patientsistogive thedrug2-mercaptoethanesul-
usedinhumansbutarenotpractical inmostveteri-
fonate (MESNA)concurrently with cyclophospha-
naryclinicalsettings.Workisbeing done inboth
mideorifosfamide.Thisworksbybindingacrolein
humansanddogstoidentifybiochemicalmarkers,
andinactivatingitstoxiceffectsonthebladder
suchascardiactroponinsoratrialnatriureticpeptide
mucosa,allowingforhigherdosesof thechemother-
(ANP),thatmay providea more convenient way to
apeuticagents.In the dog,administering MESNA
monitoranddiagnosethistoxicity.
withifosfamidehasbeenshowntomitigatethecysti-
Treatmentfordoxorubicin-inducedcardiomyo-
tisnormally seen(Rassnicket al.,2000).
pathyisthesameasforanyothertypeof
Rarely,transitionalcellcarcinomaofthebladder
cardiomyopathy.
hasbeenassociatedwithchroniccyclophospha-
Preventionofthistoxicitycanbeapproachedin
mide use.
variousways:
Nephrotoxicity
Usecautionindogsthathaveriskfactorssuch
Thekidneysaretheeliminationpathwayformany
asabreedpredispositionforcardiomyopathy，or
drugsandtheirmetabolitesandthereforearepoten-
previousorconcurrentthoracicradiation
tiallysusceptibletotoxicity.Cisplatin,methotrexate
Breedspredisposedtocardiomyopathyshould
haveanechocardiogrampriortobeginning
(intermediateand high dose)and,in the cat,doxo-
rubicinare themostcommonlyuseddrugsthatcan
therapy.lfabnormalitiesarefound,theriskversus
benefitofdoxorubicintherapymustbeweighed
leadtonephrotoxicity.Priortoadministering these
drugs,renal function shouldbe screenedusingcre-
carefully
atininelevel,BUN and urinalysis.Pre-existing renal
Manipulationofthechemotherapydrugitself is
diseaseisafactorthatwillpredisposeapatientto
alsopossible.Byincreasinginfusiontime the
furthernephrotoxicity.
peakplasmalevelsarereduced,whichcan
Incats,doxorubicinhasbeenreported tocause
decreasethecardiotoxiceffects.Liposomal
azotaemiaandreducedurinespecificgravityinboth
formulationsofdoxorubicinhavebeendeveloped
tumour-bearingandnormalanimalsreceivinghigh
andarelesscardiotoxic
cumulativedosesofthedrug.
。
Theconcurrentuseofdexrazoxanehasbeen
In thedog,cisplatinisthemostcommonlyused
showninbothhumansanddogstoreduce
nephrotoxicdrug.Within48hoursofadministration,
cardiotoxicity significantly.Itactsasaniron
80-90%of thedrug isexcreted intheurine.Cisplatin
chelatorandultimatelydecreasestheformation
containsheavymetalandcanresultinadecreasing
ofreactiveoxygenspecies.Otherantioxidant
glomerularfiltrationrateaswellasdamagetothe
drugsstudiedhavenotbeenpromising
If thepatienthasunderlyingheartdisease,other
tubules.Becausecisplatinislesstoxicinahighchlor-
ideenvironment,saline diuresis must accompany
drugscanbe substituted ifpossible.
cisplatinadministration.Severalprotocolsexistfor
Cystitis
this,ranging intime from4to24hours.The author
Sterilehaemorrhagiccystitisisapotentialsideeffect
currentlyrecommendsa4-hourprotocol,involving3
ofcyclophosphamideandifosfamideinthedogand,
hoursofnormalsalineatarateof25ml/kg/hour,
rarely,inthecat.Itusuallyoccurswithchronicuse
followedbya20-minutecisplatininfusion,followed
but canhappenacutely.Thiscystitisisdue to the
byanadditionalhourofsalineatthepreviousrate.
toxiceffectsofacrolein(ametaboliteofcyclophos-
Othertechniquesthathavebeenstudiedinclude
phamide)onthebladdermucosa.
administering hypertonic saline,mannitol,orusing
Clinical signs include haematuria,dysuria and pol-
drugssuchasamiphostine,buttheiruseinaclinical
lakiuria.Urinecultureshouldbeperformedtoruleout
settingremainstobeseen.
secondaryinfectionsbutresultsareusuallynegative.
Treatmentincludesfirstdiscontinuingtheoffend-
Neurotoxicity
ingdrug.Secondly,prophylacticantibioticstoprevent
Neurotoxicityisrareinsmallanimal oncologypatients.
infection andanti-inflammatory drugs canbegiven,
Thedrugsmostcommonlyassociatedwiththis
althoughsymptomscanpersistforseveralweeks.
includethevinca alkaloids,cisplatinand5-fluorouracil.
71
Chapter7Principlesofchemotherapy
Vincristineisreportedtocauseperipheralneuro-
commonplace, and has greatly reduced the inci-
pathyin thedog,whichmaymanifestashindlimb
denceandmorbidityassociatedwiththissyndrome.
weakness.Inhumans,vincristine cancauseperiph-
Allopurinolworksbypreventingtheaccumulationof
eral,centralorautonomiceffectsandoccursmost
uricacid byblockingxanthineoxidase.Itsuse for
oftenwithhigh,repetitive dose therapy.The most
ATLSinveterinarymedicinehasbeeninfrequent.
commonandinitialsignofvincristineneurotoxicityin
humanpatientsisdepressionofdeeptendonreflexes
Pulmonarytoxicity
andparaesthesiaofthedistalextremities,whichmay
Bleomycinhasbeenassociatedwithseverepulmon-
progresstoinvolvetheentirehandorfoot.Thistoxic-
aryfibrosis.Incats,evenatlowdoses,cisplatincan
ityisusuallyclinicallyreversedoncetherapyisdis-
induceaseverepulmonaryoedemaandpleuraleffu-
continued.Vincristineis alsoreported tocause
sionthatisoftenfatal.Becauseofthis,cisplatinis
transientileusandconstipationinveterinarypatients.
contraindicated in cats.Lomustine(CCNU) is also
Cisplatinhasbeenreported tocause cortical
reported tocausepulmonarytoxicity,butitisnot
blindness athighdosesintwodogs(Kisseberthand
commonlyreportedinveterinarymedicine.
MacEwan,2001).In humans,ototoxicity and deaf-
humansmanydrugshavebeenassociatedwithpul-
ness,peripheral neuropathy,cortical blindness and
monarytoxicity.
seizureshave allbeenreported.Clinical signs can
persistforyearsafterdiscontinuationoftherapy.In
veterinarypatients,cisplatinneurotoxicityisrareand
Drugs
isnotaswellcharacterized.
Generalmechanismofaction
5-Fluorouracilhasbeenshowntocauserapid
severe neurological signs in cats,including cere-
Chemotherapydrugscausecelldamageineithera
cellcyclephase-specificmannerora cellcycle
bellar ataxia,hyperexcitability,grossdysmetria and
death.For thisreason,5-fluorouracilis contra-
phasenon-specific manner.Alltissues throughout
indicatedincats.Dogscanalsodevelopsignsbut
thebody（bothnormalandtumourtissues)contain
cellsthatareactivelydividingaswellascells that
theyareusuallylesssevere.
arequiescent.Thephasesof thecellcycleare:
Acutetumourlysissyndrome
G1:aperiodofRNAandproteinsynthesis
Acute tumourlysis syndrome(ATLS)isanoncologi-
S:theperiod ofDNAsynthesis
·
G2:aperiodofRNAandproteinsynthesis
nantcellsinresponsetochemotherapy.
The
M:theperiodwhenmitosisoccurs
resultantreleaseofintracellularproductsandions
G0:aperiodofcellrest.
intothecirculationexceedstheexcretorycapacityof
thekidneys,resulting in electrolyte abnormalities
Chemotherapy drugs can damage DNA and
andmetabolicderangementsthatcanbelife-threat-
preventcellularreplicationand/orinduceapoptosis,
ening.Inhumanmedicine,ATLSisoftenmostasso-
or theycanworkduringaspecificphaseofthecell
ciatedwithchemoresponsivediseasessuchas
cycle,suchasmitosis,andpreventthecompletionof
haematological malignancies (lymphoma,leukae-
thatprocess.
mias)andrarelywithsolidtumours（Altman,2001).
Listedbelowaccordingtoclassaredrugscom-
Inveterinarymedicine,ATLSisrarebuthasbeen
monlyused inveterinaryoncology.Thisisnot meant
reportedinlymphomapatientstreatedwithchemo-
tobeanall-inclusivelist.Informationaboutspecific
therapyand/orradiationtherapy.Patientsathighrisk
combinationprotocolsanddrugsforspecificdisease
usuallyhaveadvanceddisease,largetumour
statescanbefoundinotherchaptersinthisbook.
burdens,aredehydrated,mayhaveunderlyingrenal
diseaseandundergoarapidresponsetotherapy.
Alkylating agents
Resultingelectrolyte abnormalitiesincludehyperkal-
Alkylatingagentsallactbycross-linkingDNAafter
aemia,hyperphosphataemia,andassociatedhypocal-
insertionofanalkylgroupandareconsideredcell
caemiaandmetabolicacidosisduetoreleaseof
cyclenon-specific.Thereare severalclasses of
intracellularcontents.Additionally,rapidlydividingcan-
alkylating agents,including the nitrogen mustards
cercellscontainhighamountsofnucleicacidpurines.
(cyclophosphamide，chlorambucil,melphalan)and
Normallythesepurinesarecatabolizedtouricacid
thenitrosoureas(carmustine,lomustine),that are
andexcretedrenally.Whenlargeamounts
are
commonlyused inveterinarymedicine.
released during massive celldeath,the excretory
capacityoftherenaltubuleisexceededandhyperuric-
aemiaoccurs.Ultimatelypatientsmaydevelopacute
Formulation:Cyclosphosphamideisavailableasan
renalfailure,primarilyduetouricacidprecipitation.
injectabledrugandoraltablets.
Clinicalsigns thatmayoccurincludeacute
depression,bradycardia(hyperkalaemia),vomiting,
Mechanismofaction:Cyclosphosphamideworksin
diarrhoea,
cardiovascular
collapseandshock.
thesamewayastheotheralkylatingagents,butit
Successful management of these patients includes
mustbemetabolizedinthelivertotheactiveform.
recognitionofthesyndromeandpromptaggressive
Excretionisprimarilythroughtherenalsystem.
fluid therapywithcorrectionofelectrolyteandmeta-
bolic abnormalities.In humans,treatment with
Doseandadministration:Injectablecyclophospha-
allopurinoltopreventATLSinhigh-riskpatientsis
mideisreconstitutedwithsterilewaterandused
72
Chapter7Principlesof chemotherapy
within24hoursifstoredatroomtemperatureor
Toxicity:Toxicitycanincludebonemarrowtoxicity
within6daysifstoredintherefrigerator.Thetablets
withmyelosuppressionand,withchronicuse,
mustnotbesplit,becauseofvariationindrugdistri-
thrombocytopenia.Alopeciaispossible.
butionthroughoutthetabletandchemotherapysafe
handlingguidelines.Thedoserangeis200-300mg/
Indications:Melphalanismostcommonlyused in
m²givenevery3weeksformostapplications.When
multiplemyeloma,butitsusehasbeenreportedin
usingoral medication,the dosemustbeadjusted in
othersolidtumours.
considerationofthetabletsizesavailable.Inaddition,
the total dose istypicallygivenoveraperiodof 3-4
Ifosfamide
days.Asanexample,apatientrequiring 180mg
shouldreceive175mgtotaldose,witha50mgtablet
Formulation:lfosfamideisavailableasaninjection,
givenondays1,2and3,anda25mg tabletgiven
packagedwith2-mercaptoethanesulfonate(MESNA),
a mandatoryuroprotectiveproduct.
Toxicity:Bone marrow suppression(neutropenia,
Mechanismofaction:lfosfamideworksasthe
thrombocytopenia)withthenadiraround7days,
otheralkylatingagents.
gastrointestinalsideeffectsandalopeciaareall
possible.Sterilehaemorrhagiccystitiscanoccur.If
Doseandadministration:350-375mg/m²i.v.given
every3weeks.Fluiddiuresisisalsorecommended,
cystitisoccurs,thedrug shouldbediscontinued and
chlorambucilormelphalanmaybesubstituted.
toprevent haemorrhagiccystitis,aswell asconcur-
rentadministrationoftheuroprotectantMESNA（at
Indications:Cyclophosphamideisacommonlyused
20%of theifosfamidedoseandgivenatthesame
druginmanymultipledrugprotocolsforlymphoma,
time,andagain2and5hoursafterwards).
leukaemiasandvarioussarcomasandcarcinomas.
Toxicity:Toxicreactionsincludesterilehaemorr-
Chlorambucil
hagiccystitis(morelikely thanwithcyclophospha-
mide);2-mercaptoethanesulfonate shouldalwaysbe
Formulation:Chlorambucilisavailableastablets.
given.Aswithcyclophosphamide,bonemarrowsup-
pression is alsoseen.
Mechanismofaction:Chlorambucilworksasother
alkylatingagentsandmustbemetabolizedtothe
Indications:Inveterinarymedicine,ifosfamidehas
activeformbytheliver.Itisexcretedasinactive
beenusedinvarioustumourswithvariedresponse
metabolitesintheurineandfaeces.
andiscurrentlybeinginvestigated.
Doseand administration:Thedosevariesdepend-
Busulfan
ingontheprotocolusedanddiseasebeingtreated:
0.1mg/kg,2-8mg/m²q24-48h,orpulsed dosing
Formulation:Busulfanisavailableastablets.
giveninplaceofcyclophosphamide1.4mg/kgorally
at once.Tablets must notbebroken,so dose may
Mechanismofaction:Busulfanworksastheother
alkylatingagents,and iswellabsorbedorally.
needtobeadjusted.
Toxicity:Thisdrugisverywelltolerated.Toxicitycan
Doseandadministration:2mg/m²orallyq24h.
include:mildgastrointestinaltoxicity;bonemarrow
suppression,usuallylateinthecourseoftreatment
Toxicity:Bonemarrowsuppressioncanoccur,both
myelosuppression and thrombocytopenia,which
(2-3weeks);rare cerebellartoxicity athigh doses.
Alopecia israre.
maybeprolonged.Pulmonaryfibrosishasbeen
reportedinhumanpatients.
Indications:Chlorambucilisusedforthetreatment
oflymphoma,chroniclymphocyticleukaemia and
Indications:Busulfanisused inchronicmyelogen-
multiplemyeloma.
ousorgranulocyticleukaemia.
Lomustine (CcNU)
Melphalan
Formulation:Melphalan isavailableasaninjection
Formulation:Lomustineisavailableascapsules.
andasoral tablets.
Mechanismofaction:Lomustineworksas the
Mechanismofaction:Melphalanworksasthe
otheralkylating agents.Becauseit ishighlylipophilic,
otheralkylating agents.
itwillpenetrateintothecentralnervoussystem.
Doseandadministration:Thereareseveral dosing
Doseand administration:The dose indogsis
schemes.Formultiplemyeloma,forexample:0.1mg/
60-90mg/m²orallyevery3weeks;incats,thedose
kgorallyq24hfor10days,thenthedoseisreduced
is50-60mg/m²every5-6weeks.
to0.05mg/kgq48hasmaintenancetherapy.Pulsed
therapyisalsousedatadoseof7mg/m²orallyq24h
Toxicity:Bonemarrowcanbeaffected,withacute
for5days,repeatedevery3weeks.
myelosuppressionoccurringat7-10days;thismay
73
Chapter7Principlesofchemotherapy
besevereandcanalsobedelayedandcumulative
thefaecesinanon-activeform;severeliverdysfunc
withadditionalthrombocytopenia.Hepatotoxicityhas
tionmayresultindecreasedmetabolismand
alsobeenseen.Pulmonaryfibrosishas been
increased toxicity.
reported in the cat.
Doseandadministration:Thedoserangeis0.5-
Indications:Lomustineisused forlymphoma,par-
0.75mg/m²i.v.weeklyorincycleaspartofa
ticularlythe cutaneouspresentation,andmastcell
combinationchemotherapyprotocol.Thevolume
disease.lItisalsousedforbraintumoursduetothe
administeredistypicallysmall(1ml)andisgiven as
abilitytocrosstheblood-brainbarrier.
anintravenousbolus.Vincristine isavesicant and
careshouldbetakenwithcatheterplacement.
Dacarbazine
Toxicity:Atissuereactionwilloccurifextravasated
Formulation:Dacarbazine
isavailable
as
an
duringadministration.Othertoxicitiesincludealope-
injectable.
cia,gastrointestinal toxicity（including constipation)
Mechanismofaction:Dacarbazineworksasthe
andperipheralneuropathy（rare).Myelosuppression
isconsideredminimal,althoughitcanoccurif
otheralkylatingagents，butmayactviaother
vincristine isused insome drugcombinations.
mechanisms
Doseandadministration:200mg/m²asaslow
Indications:Vincristineisused inmultipledrug
intravenousbolusgivenoncedailyfor5days,
combinationprotocols forlymphoma,leukaemias,
sarcomasand mastcell tumours(MCTs).Vincristine
repeatedevery3weeks.ltcanalsobegivenonce
willcure90%oftransmissiblevenerealtumours
asaslowintravenousinfusionover4hoursata
inanaverageof3.3doses.Thisdrugwillalso
dose of1000mg/m².
causeprematurereleaseofplateletsfrommega-
Toxicity:Theremaybebonemarrowsuppression,
of thrombocytopenia.
alopecia.It isalsoavesicant.
Vinblastine
Indications:Dacarbazineisprimarilyusedin
Formulation:Vinblastineisavailableasaninjection.
lymphomarescueprotocols.
Mechanismofaction:Thedrugbindstothe
Carmustine
mitoticspindleandpreventsassembly.Vinblastine
Formulation:Carmustineisavailableasaninjec-
ismetabolizedintheliverandexcretedinthebile/
tion.Drug-impregnatedwafersarealsoavailablefor
faeces.Significantliverdysfunctioncanresult in
useinthebrainforlocal therapy.
increasedtoxicity.
Mechanismofaction:Carmustineworksas the
Doseandadministration:2mg/m²i.v.weekly,oras
otheralkylating agents.Likelomustine,thisdrug also
directedbythespecificprotocol.
hasgreatpenetrationintothecentral nervoussystem.
Toxicity:
Vinblastine
causes
myelosuppression
Doseandadministration:50mg/m²i.v.over15-20
(nadirat 4-9days),alopecia,mild gastrointestinal
minutes,every6weeks.
toxicity,andisavesicantthatwillcauseatissue
reactionifadministeredperivascularly.Neurotoxicity
Toxicity:Carmustinemaycauseseveredelayed
isreportedbutisusuallymildandlesscommonthat
myelosuppression;nausea andvomiting canalso
thatseenwithvincristine.
occur.Carmustineisassociatedwithpulmonary
fibrosisinhumanpatients.
Indications:Vinblastineisusedformastcell
diseaseand lymphoma.
Indications:Carmustineisprimarilyusedforbrain
tumoursinveterinarymedicine.
Anti-metabolites
Anti-metabolitesworkbyinterferingwiththebiosyn-
Plantalkaloids
thesisofnucleicacidsbysubstitutingfornormal
Plant (vinca)alkaloids are derived from the peri-
metabolitesandinhibitingnormalenzymaticreac-
winkleplant.Theybindtothemicrotubuleassembly
tions.They are typically cell cycle-specific.
andpreventnormalformationandfunctionofthe
mitotic spindle,resulting in arrest of cell division.
Methotrexate
Thesedrugsarecellcycle-specific.
Formulation:Methotrexateisavailableastablets
Vincristine
and an injection.
Formulation:Vincristineisavailableforinjection.
Mechanismofaction:Methotrexateinhibitsthe
conversionoffolicacidtotetrahydrofolicacidby
Mechanismofaction:Vincristineinhibitsmicro-
bindingtotheenzymedihydrofolatereductase.This
tubuleassembly.Itisexcretedbytheliverinto
inhibitsthymidineandpurinesynthesis,whichare
74
Chapter7Principlesofchemotherapy
essentialforDNAreplication.Methotrexateispar-
Indications:Cytarabineisusedinlymphoma(espe-
tiallymetabolizedbygastrointestinalfloraafteroral
ciallywithCNSinvolvement)andsomeleukaemias
administration.After absorption,it is metabolized in
(myelogenous).
theliverandexcretedintheurine.
Gemcitabine
Doseandadministration:0.6-0.8mg/kgi.v.or
orally;2.5mg/m²orallyi.v.,i.m.ors.c.,q24h,or as
Formulation:Gemcitabineisavailableasan
partofacombinationchemotherapyprotocol.High-
injection.
dosemethotrexatewithleucovorinrescueisusedin
humanpatientsbutisrarelyusedinveterinary
Mechanismofaction:Gemcitabineisadeoxy-
medicineduetotheexpenseandintensivemonitor-
cytidineanalogue,theactivemetaboliteof which
isincorporated into DNA,resulting in inhibition
ingrequired.
ofsynthesis.
Toxicity:Gastrointestinaltoxicity(vomiting,anorexia,
diarrhoea),myelosuppression(nadir 6-9 days),alo-
Doseandadministration:Themaximallytolerated
pecia,renaltoxicityandhepatotoxicitymaybeseen.
dose(MTD)indogsand theappropriatedoseinter-
valhaveyettobedetermined.300mg/m²i.v.given
Indications:Methotrexateisused incombination
onceweeklyfor3or4weekshasbeensafelyused
protocols totreatlymphoma,Sertoli cell tumours
in thedog.Otherdosingregimensreported include
andOSA.
675mg/m²givenevery2weeks.Itcanbeused in
cats,butmostreportsevaluateconcurrentradiation
5-Fluorouracil
treatmentsotheMTDhasnotbeenestablished.
Formulation:5-Fluorouracilisavailableasan
Toxicity:Myelosuppression is thedose-limiting
injectionand1%or2%topicalcreams/ointments
toxicity，andgastrointestinaltoxicitycanoccur.
Mechanismofaction:5-Fluorouracilismetabolized
Indications:Inhumans,gemcitabinehasbeenused
intoanucleotidewhichisincorporatedintoRNA;this
successfullyin lung cancer,pancreatic cancer and
subsequentlyaltersDNAsynthesis.
bladdercancer,aswellasseveralothercarcinomas.
Itsspectrumofactivityhasnotbeendeterminedin
Doseandadministration:5-Fluorouracilisapplied
veterinarymedicine.
topicallywithminimalsystemicabsorption.Intra-
venoususehasbeenreportedatadoseof150
Anti-tumourantibiotics
mg/m²onceweekly.Thisdrugalsopenetrates the
Anti-tumour antibioticsformstablecomplexesand
central nervoussystem.
intercalatewithDNA,preventingDNAandRNAsyn-
thesis.Thisclassof drugsis cellcyclenon-specific.
Toxicity:Severe fatal toxicity occursincats;
5-fluorouracil shouldneverbeused incats.Other
Doxorubicin
effectsinclude
gastrointestinal
toxicity,
myelo-
suppressionandmilderneurotoxicityindogs.
Formulation:Doxorubicinisavailableasan
injection.
Indications:5-Fluorouracilhasbeenusedforvari-
oussarcomasandcarcinomaswithvariablesuccess.
Mechanismofaction:Thisanthracyclineantibiotic
hasseveralmechanismsofaction.It intercalates
Cytarabine (cytosine arabinoside)
DNA,promotesfree-radical formation andinhibits
topoisomeraseenzymesrequiredforDNAreplication.
Formulation:Cytarabineisavailable as aninjection.
Doseandadministration:In the dog,the dose is
Mechanismofaction:Cytarabineisapyrimidine
30mg/m²i.v.givenevery2-3weeks,dependingon
analoguethatinhibitsDNAsynthesis,possiblyinhib-
thediseasebeing treatedandotherdrugsbeing
iting DNApolymerase.This drug is cellcycle-
used.Insmallerdogs（<10kg)thedose isreduced
specific (killing cells undergoing DNA synthesis
to1mg/kgduetoanincreaseintoxicitywhendosed
(Sphase)).It reaches therapeutic concentrations in
onabodysurfaceareabasis.Catsarealsodosed at
thecerebrospinalfluid.Thecirculatinghalf-lifeinthe
1mg/kg.Thedrug isdilutedinsaline toavolumeof
dog isvery short.
35-150 ml,depending on the size of the patient.
Doxorubicinisadministeredthroughanintravenous
Doseandadministration:Dosingrangesfroma
catheterplacedwithouttraumatizingthevein,
constant rate infusionof100mg/m²i.v.q24hfor3-4
because thedrugisavesicant.A20-30minute
days,tohigherpulsed dosing,150 mg/m²s.c.twice
infusionisrecommended.
dailyfor2daysor600mg/m²i.v.ors.c.onceweekly.
Constant-rateinfusionisidealbutnotalways
Toxicity:Myelosuppression(nadir at 7-10days),
clinicallypractical.
alopecia,gastrointestinaltoxicity(particularlyhaem-
orrhagic colitis),allergicreaction,tissue reactionif
Toxicity:Cytarabine may cause gastrointestinal
givenperivascularlyandauniquecumulativecar-
symptoms,alopecia andmyelosuppression.
diactoxicityareallpossible.Renal toxicityhasbeen
75
Chapter7Principlesofchemotherapy
reported(especiallyincats)and is thoughttobe
tissue irritation(mild)ifextravasationoccurs.Cardio-
cumulative.
toxicityand allergicreactionsarenotcommon.
Indications:Thisdrughasawiderangeofreported
Indications:Mitoxantronehasbeenused
for
anti-tumouractivity.Itiscommonlyusedtotreat
lymphomaasarescueorasasubstitutefor
lymphoma,leukaemias,OsA,haemangiosarcoma,
doxorubicin,aswell asfortransitionalcellcarcinoma
mammaryadenocarcinomaandavarietyofother
andsquamouscellcarcinoma(ScC).
tumourtypes.
Dactinomycin (Actinomycin D)
Comment:Dexrazoxanecanbeusedasa
cardioprotectantwithdoxorubicinadministration.Itis
Formulation:Dactinomycinisavailableasa0.5mg
availablein250mgand500mgvials.Thedoseis
vialofpowderforreconstitution.
basedontheamountofdoxorubicingiven.The
recommendedratiois10:1,forexampleif30mgof
Mechanismofaction:Dactinomycinworksby
doxorubicinisgiven,then300mgofdexrazoxaneis
intercalation
of
DNA,
whichpreventsprotein
needed.Thedrugisgivenbyslowintravenousbolus,
synthesis.Excretion is throughurine andfaeces.
30minutespriortodoxorubicinadministration.
Doseandadministration:Thedoserangeis0.5-
Epirubicin
0.9mg/m²i.v.given every 2-3weeks.It is diluted in
25-150mlof0.9%salineandgivenover20-30
Formulation:Epirubicinisavailableasaninjection.
minutes.Acleanstickcathetershouldbeused.
Mechanismofaction:Thisissimilartotheactionof
Toxicity:Toxicitymaycausegastrointestinalsigns
doxorubicin,
includingintercalatingDNAand
(infrequent),alopecia,myelosuppression(nadir7-10
inhibiting topoisomeraseenzymesrequiredforDNA
days)andtissuereactionifgivenperivascularly.
replication.
Dose and administration:In the dog,the dose is
Indications:Dactinomycinisusedinplaceof
doxorubicin inmultiple drugprotocolsfor lymphoma,
30mg/m²i.v.givenevery3weeks.Insmallerdogs
asarescueagentforlymphoma,andreportedina
varietyofothercancerswithvariablesuccess.
increaseintoxicitywhendosedonabodysurface
area basis.Cats are also dosed at 1 mg/kg.The drug
Miscellaneousagents
isdilutedinsalinetoavolumeof35-150ml,
dependingonthesizeof thepatient.
Cisplatin
Toxicity:Myelosuppression(nadir at 7-10 days),
Formulation:Cisplatin is available as an injection.
alopecia,gastrointestinal toxicity,allergic reaction
andatissuereactionifgivenperivascularlyareall
Mechanismofaction:Cisplatinisaheavymetal
possible.Althoughcardiactoxicityislessofaprob-
that binds to DNA, causing intra-and interstrand
lemthanwithdoxorubicin,ithasbeenreportedand
cross-links,preventingprotein synthesis.Thisdrugis
socautionmustbeexercisedifepirubicinisused in
excretedbythekidneys.
patientswithpre-existingheartdisease.
Doseand administration:Thedoserangeis50-70
Indications:Epirubicinhasthesameclinicalindica-
mg/m²i.v.every3weeks.Salinediuresismust be
tions as doxorubicin;however,it is most frequently
givenconcurrently.Theauthorrecommendsa4-hour
usedfortreatmentoflymphomaandleukaemias.
protocolusingafluidrateof25ml/kg/hourfor3
hours, followed by a 20-minute drug infusion,
Mitoxantrone
followedbyanadditionalhourofsalinediuresisatthe
Formulation:Mitoxantroneisavailableasan
previousfluidrate.Anti-emeticsshouldbeconsidered
tocombatacutenauseaandvomiting thatwilloccur.
injection.
Cisplatincanalsobeusedintracavitarily.
Mechanism ofaction:This is a syntheticanti-
tumourantibioticwhosemechanismofactionisby
Toxicity:Nephrotoxicityisthereasonfordiuresis
inhibitionof topoisomerasellenzymes.
duringadministration.Gastrointestinaltoxicitymani-
festedby acute emesis is common.Myelosup-
Doseandadministration:Inthedog,itisgivenata
pressionwithbothneutropeniaandthrombocyto-
doseof5.5mg/m²i.v.onceevery3weeks.Inthecat,
peniaisalsopossible,witha bimodalnadirat 6
thedose is6.5mg/m²i.v.onceevery3weeks.The
and15days.Alopeciacanoccur.Cisplatincauses
fatalpulmonaryoedemaandpleuraleffusionincats.
over15-20minutesthrougha catheter placed
Theuseofcisplatiniscontraindicatedincatsby
withouttraumatizingthevein.
anyroute!
Toxicity:Myelosuppression(nadir at7-10days)is
Indications:CisplatinhasshownefficacyforOSA,
thedose-limitingtoxicity.Gastrointestinaltoxicitymay
SCC,mesothelioma,bladder tumours and other
occurbutisusuallymild.Alsoseenarealopecia and
carcinomas.
76
Chapter7Principlesofchemotherapy
Carboplatin
thediseaserespondstotreatment.Catsshouldbe
given10mg/kgorallydaily,decreasingtoevery
Formulation:
Carboplatinisavailableasan
otherdayasdiseaseresponds.
injection.
Toxicity:Sideeffectsincludemyelosuppression and
Mechanismofaction:Thisdrugisaheavymetal
gastrointestinal toxicity. Sloughing of toenails has
thatworks,likecisplatin,bybindingbetweenand
beenreported inthe dog.
withinDNAstrands.It isexcretedbythekidneys.
Indications:Hydroxycarbamideisusedforpoly-
Doseand administration:Thedosefordogsis300
cythaemiaveraandmyelogenousorbasophilic
mg/m²i.v.,over5-10minutes,givenevery3weeks.
leukaemia.
Itsuseissafeinthecatandthedoserangeis200-
250mg/m²i.v.given every3weeks.
Toxicity:Carboplatinisnotasnephrotoxicascis-
Formulation:Piroxicamisavailableascapsules.
platinanddiuresisisnotrequired.Itisexcretedin
thekidneysandcautionshouldbeusedinpatients
Mechanismofaction:Piroxicamisanon-steroidal
anti-inflammatorydrug(NSAID).Inadditiontohaving
withrenalcompromise.Gastrointestinaltoxicityis
possiblebutacuteemesisisrare.Myelosuppression
anti-inflammatoryeffects,itisthoughttohave anti-
iscommon,withthenadirbeingreportedinthedog
tumoureffectsthroughpossiblecyclo-oxygenase-2
at 11-14days,and14-21days inthecat.
(COX-2) inhibition.
Indications:Carboplatinhasbeenused success-
Doseandadministration:Thedose indogs is0.3
fullyforOSAindogsandispresumed tohaveasim-
mg/kgorallydailyoreveryotherday.Thesamedose
hasbeenused incats,but usually on an every-
ilarspectrumof actionascisplatin.
other-dayschedule.Piroxicamcancausesignificant
Paclitaxel
gastrointestinal bleeding,and the newer Cox-2
specificNSAIDsmaybea safer choice.Accurate
Formulation:Paclitaxel isavailableasaninjection.
dosingisimportanttoavoidtoxicityandcapsulescan
bereadilyformulated.Liquidpreparationshaveques-
Mechanismofaction:Thetaxanesbindtothe
tionablestability(particularlyaqueouspreparations).
microtubularassemblyandpreventitsdisassembly,
therebyinhibitingthecompletionofmitosis.These
Toxicity:Thespectrumoftoxicitymirrorsthatof
drugs are cell cycle-specific.
otherNSAIDs.Gastrointestinal toxicities including
ulcerationare possible,as wellasrenaltoxicity.
Doseandadministration:Inthedog,adoseof
Gastrointestinalprotectantscanbeusedconcur-
135mg/m²i.v.byslowinfusiongivenevery3weeks
rentlybutarenotusuallyneededroutinelyindogs.
hasbeenshowntobetolerated.Thedoseinthe
Combiningpiroxicamwithotherrenaltoxinsorulcer-
cat,which isunder investigation,is 5mg/kg i.v.
promotingdrugsshouldbeavoided.
every3weeks.
Indications:Piroxicamisusedfortransitionalcell
Toxicity:Paclitaxelis dissolved incremophorEL,
carcinoma ofthe bladder,SCCandasananti-
whichcausessignificanthypersensitivityreactionsin
inflammatoryforpaincontrol.
dogs.Premedicationwithdiphenhydramine(4mg/kg
i.m.),cimetidine (4mg/kg i.v.),and dexamethasone
Prednisone or prednisolone
SP(2mg/kg i.v.)given 30minutesprior to infusion
willhelptoprevent thisreaction.Othertoxicities
Formulation:Theseareavailableastabletsand
includemyelosuppression(nadirat3-5days)and
injections.
raregastrointestinal toxicity.
Mechanism ofaction:Prednisoneand predniso-
loneactasahormonethatbindstoreceptorsinthe
Indications:Paclitaxelhasbeenusedtotreatmam-
marycarcinomaandsomesarcomaswithvariable
nucleusandinhibitsDNAsynthesis.
success.
Doseandadministration:Thedoseisvariable
dependingontheprotocolusedanddiseasebeing
treated.Ageneral anti-tumour dose is1-2mg/kg
Formulation:Hydroxycarbamideisavailableas
daily.
capsules.
Toxicity:Sideeffectsincludeiatrogenichyperadreno-
Mechanismofaction:Hydroxycarbamideinhibits
corticism,polyuria and polydypsia,hepatomegaly,
theconversionofribonucleotidestodeoxyribo-
hair loss,muscle wasting,gastrointestinal ulceration
nucleotidesthroughthedestructionofribonucleoside
andpanting.
diphosphatereductase.
Indications:Prednisone andprednisolonehave
Dose and administration:In dogs,the dose is50
anti-tumouractivity against lymphoma,MCTs,leuk-
aemiasandplasmacelltumours.Otherindications
77
Chapter7Principlesofchemotherapy
includesymptomatictreatmentofoedemaand
actsasadrugbarrierforcertaintissuessuchasthe
hyperinsulinismassociatedwithinsulinoma.
brain,testisandplacenta.Whenthisproteinisnot
functional,drugs that are substrates forP-gp are not
excretednormally,leadingtoincreaseddrugexpos-
ureandincreasedclinical toxicity.Chemotherapeutic
Formulation:Thisisavailableasa10,000IUvialfor
drugsthataresubstratesforP-gpincludethevinca
reconstitution.
alkaloids,doxorubicin,dactinomycinand thetaxanes
(Mealey,2004).Dogs that arehomozygous orhave
Mechanismofaction:Crisantaspaseisanenzyme
themutationintwoallelesare1o0timesassuscepti-
derivedfromabacterium.Itinhibitstheenzyme
bleaswild-typedogstodevelopingivermectin-
asparaginesynthetaseanddepletesthetumourcell
inducedneurological toxicity.Thismutationoccurs
ofasparagine.Itisaforeignproteinandantibodies
mostcommonlyinherdingbreedsandseveralstud-
willformtoit,leadingtoresistance.
ieshavebeenreportedlookingattheincidenceof
mutationamongstvariousbreedsoriginatingfrom
Doseand administration:400IU/kgi.m.or s.c.;or
variouscountries.Arecentstudylookingatbreed
10,00oIU/m²i.m.ors.c..Intramuscularadministra-
distributionofthepolymorphisminover5000dogs
tionhasbeenshowntocauselessanaphylaxisthan
thathadsamplessubmittedfortestingfoundcollies
intraperitoneal dosing.After drug administration,
andAustralianShepherdDogstobeaffectedmost
patientsshouldbeobservedfor20-30minutesfor
commonly.Inthecolliesthefrequencyofmutmut
possibleanaphylaxis.
allelicstatuswas35%withmut/wt frequencyof42%.
AustralianShepherdDogswere 10%mutmutand
Toxicity:Anaphylaxisisreportedwithrepeateddos
37%mut/wt.This studyalsoidentified German
ing.Rare toxicitiesinclude myelosuppression,pan-
ShepherdDogswith themutation;and a surprising
creatitis anddisseminated intravascularcoagulation.
numberofmixed-breeddogsthatdidnotappearto
beofherdingdogmixalsohad themutation(Mealey
Indications:Crisantaspaseisused inmultipledrug
and Meurs,2008).Where a patient is scheduled to
protocolsforthetreatmentoflymphoma.
undergochemotherapywithP-gpsubstrate drugs,
testingshouldbeconsidered if thepatientisofa
breedthathasbeenreportedtohaveahighfre-
Newfrontiers
quencyofmutation inthisgene.If thepatientis
Pharmacogenetics
homozygous,thesedrugsshouldbe avoidedorused
withextremecautiontopreventunacceptabletoxicity.
Inter-individualvariabilityinpharmacokineticand
pharmacodynamicparametersisaresultofseveral
Targeted therapy
influences,includinggeneticpolymorphismsindrug
Targetedtherapyisanotherexpandingtreatment
metabolizingenzymes,transporters,ordrugtargets.
area(seeChapter 9).Identificationof signaltrans-
Thisvariabilityleadstothedifferencesinefficacy
ductionpathwaysthatdrivecellularproliferationhas
andtoxicitythatareseenbetweenpatientstreated
led to the discovery of many potential‘drugable”
withthesamedrugsforthesamedisease.
targets.
Pharmacogeneticsis thestudyof thegeneticpoly-
One suchgroupofmoleculesis thetyrosine
morphismsthatdetermineanindividual'sresponse
kinaseswhich,whenactivatedbymutation,resultin
todrugs.Anticancer drugsoftenundergobiotrans-
aberrant cellgrowth (Griffin,2001).A disease in
formationordetoxificationbyenzymesystemsthat
humanmedicineinwhichthistypeofmutation is
areknowninhumanstobeareasofgeneticpoly-
important ischronicmyelogenousleukaemia,where
morphism,potentiallyleadingtoincreasedtoxicityor
thereciprocaltranslocationofchromosomes9and
decreasedefficacy(Nagasubramanianetal.,2003).
22resultsinthebcr-abloncogenicproduct.Oneof
Inveterinarymedicinelessisknownaboutspecific
thefirst targetedagents successfullydeveloped,
geneticdifferences,althoughbreeddifferenceswith
imatinibmesylate,disrupts this importantpathway.
respecttosensitivitytodifferentdrugsarewelldocu-
mented.Inordertoimprovetheabilitytoaddress
unexpectedandexcitingresponseswithrefractory
thisissue theAnimalPharmaceuticsandTechnology
disease.Thisagentisnowpartof thestandardof
FocusGroupoftheAmericanAssociation
of
careforthis disease.
Pharmaceutical Scientists (AAPS)developed
a
Inveterinarymedicineanexcellentexampleof
workinggrouptoexaminebreed-specificdifferences
targetedtherapyhavingaclinicalimpactonhowdis-
inmetabolism that could alterdrug disposition.A
easewillbetreatedlieswithcaninemastcell
recentreviewarticle
summarizestheirfindings
tumours(MCTs).Studies have shown that20-30%
(Fleischeretal.,2008).
ofcanineMCTsexpressamutatedformofthe
receptortyrosinekinaseKiT,whichisinvolvedincell
MDR1mutationsandbreedpredispositionto
growthanddifferentiation.Several invitroandinvivo
toxicity
proof-of-conceptstudieshavebeenpublishedshow-
Aclinicallyapplicablepharmacogeneticsexamplein
ingactivityof targeted tyrosinekinase-inhibiting
veterinaryoncologyisamutationintheABCB-1(for-
compounds(Londonet al.2003;Gleixner et al.,
merlyMDR1)genewhichencodesforthedrug trans-
2007).
Results
ofadouble-blindrandomized
port protein,P-glycoprotein (P-gp).P-gp effectively
placebo-controlledphaseIllclinicaltrialwere
78
Chapter7Principlesofchemotherapy
reported byHahnetal.(2008),whoevaluated the
Goldie JH,Coldman AJand Gudauskas GA（1982) Rationale for the
efficacyofthedrugmasitinib,aselectiveinhibitorof
useof alternatingnon-cross-resistantchemotherapy.Cancer
KIT.Thetreatmentwaswelltoleratedandresultedin
TreatmentReports66,439-449
GrifinJ(2001)The biologyofsignal transductioninhibition:basic
anoverallincreaseintimetoprogression,aneffect
science to novel therapies.Seminars in Oncology 28(suppl.17)
thatwasmorepronouncedinpatientswhowere
HahnKA,OgilvieG,RuskTetal.(2008）Masitinibissafeandeffective
3-8
givenmasitinibasa front-line therapy.Theycon-
forthetreatmentofcaninemastcelltumors.JournalofVeterinary
cludedthatthistargetedtherapywassafeandeffec-
InternalMedicine22,1301-1309
Jones A and HunterAL(1998)New developments in angiogenesis:a
tiveatdelayingtumourprogressionindogswith
majormechanismfortumorgrowthand targetfortherapy.The
recurrentornon-resectablegradeIlor Illnon-meta-
CancerJournalfromScientificAmerican4209-217
Jorgenson JA.Spivey SM,Au C et al. (2008)Contamination
static MCTs.Masitinib(Masivet,AB Science)and
toceranibphosphate （Palladia,Pfizer)have both
drugs.HospitalPharmacy43.732-727
recentlybeenauthorizedfortreatmentofcanine
Kaufman DCand Chabner BA(2001)Clinical strategies for cancer
treatment:the roleof drugs.In:CancerChemotherapyand
BiotherapyrinlandracticerddndAharl
treatmentofothertumourtypes.
pp.1-16.Lippincott,Philadelphia
Basedonresultsinhuman trials,itisclearthat
KeefeDL(20o1）Anthracyclineinduced cardiomyopathy.Seminars in
Oncology28（suppl.12）.2-7
targetedtherapiesaresusceptibletothedevelop-
KisseberthWCand MacEwen EG(2001)Complicationsof cancerand
ment of resistance.lIt isunlikely that these agentswill
itstreatment.In:SmallAnimai ClinicalOncology.3rdedn,ed.SJ
replacestandardchemotherapy,buttheyarelikelyto
Withrowetal.198-219.WBSaunderPhiladephia
KnappDW,RichardsonRC,BonneyPLetal.（1988）Cisplatintherapyin
beusedincombinationwithotherdrugstoachieve
41dogswithmalignant tumors.JournalofVeterinary Internal
bettertumourcontrol.
Medicine2,41-46
KosarekCE,KisseberthWC,GallantSLand CoutoCG(2005)Clinical
malignancies.JournalofVeterinaryInternalMedicine19,81-86
Lana SE,UrenL,Plaza Set al.(2007)Comparison of continuous low
Referencesandfurtherreading
dose
oral
chemotherapy
withconventionaldoxorubicin
chemotherapy for adjuvant therapy ofhemangiosarcomain dogs.
AltmanA(20o1)Acutetumorlysissyndrome.SeminarsinOncology28
JournalofVeterinaryInternalMedicine21764-769
(suppl.5）,3-8
London CA,Hannah AL,Zadovoskaya R et al.(2003)PhaseIdose
Bailey DB,RassnickKM,ErbHNetal.(2004)Effectsof glomerular
escalating studyofSU11654,a smallmoleculereceptor tyrosine
filtrationrateonclearanceandmylotoxicityofcarboplatinincats
kinaseinhibitorindogswithspontaneousmalignancies.Clinical
withtumors.AmericanJournalofVeterinaryResearch65,1502-
CancerResearch9,2755-2768
1507
Mauldin GE,Fox PR,Patnaik AK et al.（1992) Doxorubicin-induced
Charney SC,Bergman PJ,Hohenhaus AE and McKnight JA (2003)
cardiotoxicosis:clinicalfeaturesin32dogs.JournalofVeterinary
Riskfactorsforsterilehemorrhagiccystitisindogswithlymphoma
InternalMedicine6,82-88
receivingcyclophosphamidewithorwithout
concurrent
MealeyKL(2004）Therapeuticimplicationsof theMDR-1gene.Journal
administration of furosemide:216cases（1990-1996).Journal of
ofVeterinaryPharmacologyandTherapeutics27,257-264
theAmericanVeterinaryMedicineAssociation222,1388-1393
MealeyKLand MeursKM(2008)Breed distributionof the ABCB1-
ChuE and DeVita VT (2001)Principlesof cancer management:
1deltapolymorphism（multidrug
sensitivity)
sbopbuowe
chemotherapy.In:CancerPrinciplesandPracticeofOncology.6th
undergoingABCB1phenotyping.
JournaloftheAmerican
edn,edTDVitatalp.289306.ippincotPhiladlhia
VeterinaryMedicalAssociation233921-924
ChunR,GarrettLD andVailDM(2001)Cancerchemotherapy.In:Smal
Moore AS,Kirk C and Cardona A（1991)Intracavitary cisplatin
Animal ClinicalOncology3rdedn,ed.SJWithrowetal.,p.92
chemotherapyexperienceinsixdogs.JournalofVeterinaryInternal
118.WBSaundersPhiladelphia
Medicine5,227-231
Clifford CA and Sorenmo K（1999)Doxorubicin cardiotoxicity:current
Nagasubramanian
R
InnocentiFandRatainMJ(2003)
concepts in pathogenesis, cardioprotection and screening.
PharmacogeneticsincancertreatmentAnnualReviewof Medicine
VeterinaryCancerSocietyNewsletter23,1-5
54,437-452
Conner TH,Anderson RW,Sessink PJ,BroadfieldLand Power LA
OgilvieGKand MooreAS(2001a)Chemotherapy-properties,uses
（1999)Surface contamination with antineoplastic agents in six
andpatientmanagement.In:FelineOncology,ed.GKOgilvieetal
cancer treatment centers in Canada and theUnited States.
pp.62-76.VerinaryearningSystms,Trenton,NwJersy
AmericanJournalofHealthSystem-Pharmacy56.1427-1432
Ogilvie GKandMooreAS(2001b)Drughanding andadministration.ln:
DickinsonKLandOgilvie GK(1995) Safehandling and administration
FelineOncology,ed.GKOgilvieetal,pp.53-61.Veterinary
of chemotherapeutic agents inveterinary medicine.In:Current
LearningystmsTrentonwe
VeterinaryTherapyXllSmallAnimalPracticeed.RWKirketal,
OKeefeDASisson DD,Gelberg HB,Shaeffer DJandKrawiec DR
pp.475-478.WBSaundersPhiladelphia
(1993)Systemictoxicityassociatedwithdoxorubicinadministration
ElmslieREand Dow SW(200o)Gene therapy forcancer.In:Current
incats.ournalofVeterinaryIntrnalMedcine709317
VeterinaryThrapyXilmallnimalPracticedJBonagurap
Rassnick KM,Frimberger AE,Wood CA et al.(20oo)Evaluation of
493-498.WBSaunders,Philadelphia
ifosfamidefor treatmentofvariouscanineneoplasms.Journalof
Elmslie RE,GlawePandDow SW(2008)Metronomic therapy with
VeterinaryInternalMedicine14,271-276
cyclophosphamideandproxicameffectivelydelays
SessinkPJand BosRP(1999)Drugs hazardous to healthcare workers.
Evaluationofmethodsformonitoringoccupationalexposure to
sarcomas.JournalofVeterinaryInternalMedicine22,1373-1379
cytostaticdrugs.DrugSafety20,347-359
Fleischer S,Sharkey M,Mealey K,Ostrander EA and Martinez M
Spugnini EP(2002)Use of hyaluronase
forthetreatmentof
(2008) Pharmacogenetic and metabolic differencesbetween dog
extravasation ofchemotherapeuticagents in six dogs.Journal of
breeds:theirimpactoncaninemedicineand theuseof the dogas
theAmericanVeterinaryMedicalAssociation221,1437-1440
apreclinicalanimalmodel.TheAAPSJourna/10,110-119
Tannock IF and Goldenberg GJ （1998)Drug resistance and
Folkman J.(1997)Antiangiogenic therapy.In:Cancer:Principles and
experimental chemotherapy.In:The BasicScience of Oncology.
Practiceofncology5thedn,edTDevitaetal,p.3075-3085.
3rdedn,ed.IFTannocketal.,pp.392-419.McGraw-Hill,NewYork
Lippincott,Philadelphia
GatelySandKerbelR(20o1)Antiangiogenic scheduling of lower dose
managingadverseeffects.Journalof theAmericanAnimalHospital
cancerchemotherapy.CancerJournal7,427-436
Association43,1-7
Gleixner KV,RebuzziL,Mayerhofer Met al.(2007) Synergistic
WickC,SlawsonMH,JorgensonJAandTyerLS(2003）Usingaclosed
antiproliferativeeffectsofKIT tyrosine kinase inhibitors on
systemprotective device toreducepersonnelexposure to
neoplasticcaninemastcells.Experimental Hematology24,1510-
antineoplasticagents.AmericanJournalofHealth-System
1521
Pharmacy60,2314-2320
79
Principles of radiation therapy
AmyF.PruittandDonaldE.Thrall
Introduction
prohibitedbypreviouslyadministeredtherapy.A
tumourrecurringaftersurgerymaybemoredifficult
Whenconsideringtreatmentoptionsforasolid
toreturn surgicallytomicroscopicdisease.Often
tumour,oftenthefirstchoiceistousea singlemodal-
recurrenttumours willrequirea second excision,
ity,commonlysurgery.Althoughmanysolid tumours
resultinginradiationfieldsthatarelargerthanthey
canbecuredwithsurgery,inothersitisimpossibleto
wouldhavebeenhadmarginsbeenassessedand
obtain tumour-free margins.In these patients,dis-
postoperativeradiationusedinitially.Also,recurrent
ease-freeintervalorsurvivalcanoftenbeextended
tumours are oftenmore aggressive inbehaviour
withacombinationofsurgeryandradiationtherapy.
thantheinitial tumour,givingrisetocellscapable
Thebestchanceofachievingtumourcureis
ofmetastasisandacquiringresistancetodrugs
alwayswithalogical,preplannedapproach,particu-
andradiation.For thesereasons,it is critical that
larlywhendualormultimodaltreatmenttherapyis
thefirsttherapyappliedtoasolidtumourbethe
indicatedasthefirsttreatment.Anyconcernthatsur-
optimal therapy.
gerymaynotachievecompleteexcisionwarrants
consultationwithbothasurgeonandradiationonco-
logistbeforeinitiatingtreatment.Thecombinationof
Indicationsforradiationtherapy
surgery toreducethetumourvolume(preferably to
microscopiclevels)followedbyradiationtherapyto
Generally,radiationtherapyhas thebestchanceof
treatremainingdiseaseisaveryeffectivetreatment
leadingtocureorlong-termremissionwhenused
optionandcanprovidelong-termcontrolinsitua-
forlocalizedmicroscopicdisease.Fortumourshav-
tionswhereneithermodalityaloneissufficientto
ingahighmetastaticpotential,adjuvantchemother-
accomplish thatgoal.Foroptimaloutcomewhen
apyshouldalsobeconsidered.Volumeisthe
combiningsurgeryandradiationtherapy,thorough
biggestfactornegativelyaffectingtumourresponse
preplanningandcommunicationarerequiredamong
toradiationtherapyand,as describedabove,for
all involved aswellasadherencetogoodoncologi-
mostsolidtumoursthebestapproachisacombina-
cal surgical principles.
tionof surgeryandradiation.However,there are
Radiationtherapymaybeadministeredpreopera-
someindicationswherethetumourisnotamenable
tivelyorpostoperatively，andthedecisiononwhich
tosurgicalresectionduetotheanatomicalsite.
sequencetousedependsontumourtype,sizeand/
Theseincludeintranasaltumours,fixed thyroidcar-
orlocation.Fortumourswherecompartmentalresec-
cinomas and brain tumours.In these instances,
tionistheoreticallypossible,preoperativeradiationis
thereisusuallyasmallchancethatradiationwill
favouredastheradiationfieldistypicallysmallerand
lead tolong-term tumour control.Definitivetreat-
thetumourmaybecomeeasiertoexcise.Whenusing
mentofthesetumoursisacceptableprovidedthat
postoperativeirradiation,carefulpresurgicalplanning
theexpectationsareclear.Rarely,radiationtherapy
willdecreasethechanceofradiationtherapycompli-
alonewillbeeffectiveformacroscopictumoursthat
cations.Poorly thought out surgery may leave large
arefairlyradiosensitiveandnotamenabletocom-
scarsorscarorientationsandlocationsthatcanpre-
pleteorpartialresection;examplesincludeacan-
ventorhindertheabilitytoadministerasubsequent
thomatous epulis（alsoreferredtoasbasalcell
courseofradiationtherapysafelyandeffectivelyif
carcinomaandacanthomatous ameloblastoma),
surgicalexcisionisincomplete.Thisemphasizesthe
small(1-2cm)oralcarcinomas,smallgradellmast
needformeaningfulpretreatmentcommunication
celltumoursandtransmissiblevenereal tumours.
betweenthesurgeonandradiationoncologist.
Permanentorlong-termlocalcontrolofvarious
Definitiveandpalliativeintent
solidtumoursmaybeachievedwiththecombina-
Radiationtherapycanbe deliveredwith either
tionofsurgeryandradiation.Commontumours
curative(definitive)orpalliativeintent:
wherethisapproachisapplicableincludegradeIl
caninemastcelltumoursandcanineandfelinesoft
Definitivecancertherapy:Canalsobereferred
?
tissuesarcomas.
toas'curativeintent'therapy.It is a treatment
Theabilitytoachievetumourcontrolorcure
plandesignedpotentiallytocurecancer,using
forarecurrenttumourmaybecompromisedor
oneoracombinationoftreatmentmodalities
80
Chapter8Principlesof radiation therapy
Palliativecancertherapy:Treatmentspecifically
excessivedamagetothesurroundingnormal
directedtohelptoimprovetheclinicalsigns
tissues.To achieve this goal,the total dose of
associatedwithanincurablecancer.Theprimary
radiationis divided intomultiple,smaller fractions,
objectiveofpalliativecareistoimprovethe
withtotaldosesof48-60Gyusuallydeliveredusing
patient'squalityof life.
16-25separatedailyfractionsof 2.5-3Gy.
Radiationtherapyisadministeredinthisway
Curativeradiationtherapy
becausehighertotaldosescanbegivenwithless
Withdefinitiveintent,thegoalistodeliverthemaxi-
riskoflateeffectswhendividedintosmallerdose
mallytoleratedradiationdoseandtoachieveperma-
fractions,andhighertotaldosesareassociatedwith
nent tumour control,or the longest remission
improved tumour control.Fractionating the dose
possible.Thisrequires prescribinga more aggres-
alsoallowsforproliferativerecoveryofnormaltissue
intheradiationfieldastheradiationtherapy
mentof acutesideeffects.
progresses.
Incontemporaryradiationtherapypractices,
Palliativeradiationtherapy
dailyfractionationusingrelativelysmalldosesper
Palliativeradiationtherapyhasaroleinveterinary
fraction(≤3Gy)isstandardpractice and it isdifficult
medicineforthepurposeofrelievingpainorclinical
tojustifydeviating fromthisprescription.Large
signsofanincurabletumour.Thegoalofpalliative
dosesperfractionwillpreferentiallydamageslowly
radiationtherapyforanincurablecancerisnotlong-
proliferatingnormaltissueswithnobenefitto
termcontrolbuttoimprovethequalityoflifeofthe
tumourcontrol.Whileslowlydividingcellsappearto
patientbydecreasinganydistressingclinicalsymp-
besomewhat lesssensitivetosmall dosesofradia-
tomsassociatedwiththetumour.
tionthanthemorerapidlydividingcells,theysustain
Palliativeradiationtherapyofteninvolvesusing
morerelativedamageifradiationisdeliveredin
thesimplestradiationschedulethatwillgivethe
larger dosesperfraction.Thus,the chance thata
maximumreliefwiththeleastmorbidityandcost.
seriousnormaltissuecomplicationwilldevelopis
Thus,mostpalliativeprotocolsuselowertotaldoses
notonlyadirectfunctionofthetotalradiationdose,
andahigherdoseperfractiontoavoidacute
butalsoofthesizeofeachofthefractionswherein
radiationsideeffectsandprolongedhospitalization.
thetotal doseisadministered.
Palliativeprescriptionsarenotintendedforthesake
ofconvenience,ortoaddressfinancial limitations.
Dosedistribution
Itisimportanttoestablishandcommunicatethe
Whenadministeringradiationtherapy,tumourvol-
goalofpalliativeradiationtherapytotheowner.
umesaredefinedtoincludeallknowngrossdisease
Althoughprolongationof lifeisnotagoaloftruepal-
plusamarginofadjacentnormaltissuethatisatrisk
liative radiation therapy,successfulpalliation can
forsuspectedmicroscopictumourextension.ltisthe
lead to increased survival.As such,the choice of
responseoftheadjacentnormaltissuethatlimitsthe
radiationprescriptionforpalliativetreatmentsisnot
amountofradiationthatcanbeadministeredsafely.
trivial andtheuseoflargedosesperfractionforpal-
Mostcontemporaryradiationtreatmentsare
liativeradiationtherapydoeshavesomedrawbacks.
plannedbasedoncomputermodellingofdose
Theriskfordevelopmentofseriouslatesideeffects
distributionincomputed tomography(CT)imagesof
inpatientsreceivinglargedosesper fractionis
the tumourregion(Shiranetal.,2006).Avarietyof
increased if theylivelonger than expected.Also,if
proprietaryprogramsareavailableforthispurpose.
thetumourrespondsmorefavourablythanexpected
Thishighlydetailedanatomicalbasisofradiation
tothepalliativetreatment,theadministrationofaddi-
planningallowsoptimizationoftheradiationdose
tionalradiationiscomplicatedbythelargedosesper
distributioninthetumour,andsparing ofnormal
fractionused intheinitial prescription.
tissue(Figure8.1).Due tothe importance ofpatient
positioningforradiationtherapyadministration,itis
importantthataradiationoncologistbeintimately
Principlesofradiation therapy
involvedwithacquisitionoftheCTimagesusedfor
radiationplanning.
lonizingradiationkills cellsbyproducing chemical
damage inDNA,whicheventuallyleadstocell
Equipment
death.ThelesionsinDNApreventnormalreplication
butdonotleadtoimmediatecelldeath.Radiation
Thoughadetaileddiscussionofthephysicsof
radiationtherapyisbeyondthescopeof thischapter,
damageismanifestedwhentheirradiatedcells
somepreliminary information isprovided.Modern
attempt todivide.Tissueresponses toradiation
veterinaryradiationtherapyisbasedaroundtheuse
therapyareclassifiedasacuteandlateeffects:
ofalinearacceleratorthatcangeneratehigh-
·Acuteeffectsoccurinboththetumourand
energyX-rayssuitablefortreatmentoftumourslying
proliferatingnormaltissues
deeptothesurface,andgenerationofelectronsfor
Lateeffectsoccurinslowlyproliferatingor
treatmentofverysuperficial tumoursintheskin.This
non-proliferatingnormal tissues.
equipmenthasreplaced theuseofcobaltmachines
andorthovoltageX-raymachines.
Fractionation
Cobaltmachinesused thephotonsarisingfrom
Thegoalofradiationtherapyistodestroythe
radioactivedecayof 6oCofortreatment.Although
reproductivecapacity
ofthe
tumour
without
thesephotonswereofrelativelyhighenergy，cobalt
81
Chapter 8Principles of radiation therapy
linearaccelerator.Therefore,theyweresuitedmainly
fortreatmentofsuperficial lesions.Thecomplications
associatedwithorthovoltageuseweremorefre-
quentandmoreseverethanencounteredwhen
usingalinearaccelerator.Theelectron-generating
capabilityoflinearacceleratorsreplacestheneedto
useorthovoltageX-raymachinestotreatverysuper-
ficialtumours.
Acuteand lateradiationeffects
Figure8.2isacompilationofpotentialacuteandlate
radiation-inducedtissue/organsideeffects.
Acuteeffects
Regularlydividing tissues,such as skin and
8.1
Sagittal CTimageof thecaudal abdomenofa
mucosa,arereferredtoasacutelyrespondingnor-
dogwithanincompletelyresectedanal sac
tumour(nogrosstumourispresent) andregional lymph
maltissues.Acuteeffectsthatdevelopinthesetis-
nodemetastasis.Thegreenstepped linesrepresenta
suesasaresultofradiationtherapyareobserved
radiationfieldconfiguredusingamultileafcollimator(see
duringorshortlyaftercompletionofradiationther-
text).Computersoftwareenablesradiationdosestobe
apy.Manifestationofradiationinjuryinacutely
estimatedonce a treatment configurationischosen.Inthis
respondingnormaltissuesisduetodepletionof
imagethewhite,purpleandyellowlinesrepresentthe
stem cells,with failure tomaintain the functional
peripheryof areasreceiving at least49,48and47Gy
respectively.Byassessingradiation doseinthetumour
cellcompartmentthatisthepopulationofdifferen-
andadjacentnormal tissue,thetreatmentconfiguration
tiatedcellsthatprovidefunctionofthetissueat
can be optimized.
risk.Radiationdoseintensity(theamountofradia-
tiondeliveredperunitoftime)isdirectlyassociated
sourcesrequiredperiodicreplacementandthedose
withthedevelopmentandseverityofacuteradia-
fall-offattheedgeofthetreatmentfieldwasquite
tion effects.
broad,leadingtoirradiationofmorenormal tissue
Acuteeffectsinproliferatingtissuesmaycause
thannecessaryanduncertaintiesintreatment
discomfortandrequiresupportivetherapy.However,
planning.Unfortunately，theriseof terrorismin the
worldresultedingreatlyincreasedregulatorycontrol
cantconsequencesandrarelylimitsadministration
oftheselargeradiationsources,whichcomplicated
oftheprescribeddose.Attemptingtoavoidacute
maintainingsuchequipment.
reactionsbyalteringtheradiationscheduleshould
Orthovoltagemachinesarenearlyobsoletein
be
discouraged,because it willresult in the
veterinaryradiationtherapy.Thesemachinesoper-
decreasedefficacyof thetreatment.Givinglessradi-
atemuchlikeadiagnosticX-raymachine,producing
ationdoseorirradiatingoveraprotractedperiodof
timetodecreaseacutereactionswillalsosparethe
geticastheradiationcomingfromacobaltunitora
tumour,leadingtodecreasedtumourcontrol.
Tissue/organ/region
Acute effects
Late effects
Skin
Epidermis:erythema,drydesquamation,
Dermifbrsinratun-lngerlangtasiala
moist desquamation(see Figure8.3ab)
leucotrichia,hyperpigmentation（seeFigure8.3c)
Oral cavity
Mucositis(seeFigure 8.4)
Ucerattradinrosirdnt
Salivary gland
Xerostomia
Nasal cavity
Mucositisnasal discharg
Osteoradionecrosischronicnasaldischarge
Eye
Conjunctivitis,cornealulcer,uveitis
Cataatnjtii
Ear
Otitismedia
Brainand spinal cord
Infarction,necrosis
Cervical region
Oesophagis,tracheitis
Oesophagealulcerationandstricturehypothyroidism
Thoracicregion
Chronicpneumonitiericarditisancardiis
Kidney
Chronicnephrosclerosis
Pelvicregion
Colititisehritiprstatis
Bladdntricntsisrtn
colitis
8.2
Potentialacuteandlateradiation-inducedtissue/organsideeffects.
82
Chapter8Principlesof radiation therapy
Skin
veterinarymedicine.Thereisalackofwelldesigned
Acuteradiationsideeffectstotheskinarecommon
studiesinbothhumanandveterinarymedicineto
indogsbutlesscommonincats.Radiation-induced
evaluatetheeffectivenessof thesetopicaltherapies.
skinsideeffectsmanifestinitiallyasslighterythema
Inarecentreviewof54privateanduniversityteach-
andcanprogresstodrydesquamationormoistde-
ingveterinaryhospitals（FlynnandLurie,2007),the
squamation(Figure8.3).Acute skinside effects are
mostcommonoptionsoutof25differenttopical
usuallyworseifthetreatedsiteincludesskinthatis
therapiesreportedincludedaloevera-basedlotions
subject tofriction,such asthe axilla orgroinregions.
orsilversulfadiazinecream.
Itsoccurrenceisalsoworseinparticularlysensitive
Irradiationofthepawresultsinpainfulsloughing
areas,includingtheperianalregionandpaws.
ofpadsandlossofnails.Oral analgesicsalonemay
Skin sideeffectscan persistfor several weeks
notbesufficientforadequatepaincontrolandoften
followingcompletionoftherapy,withthetreatedarea
thepatientwillbenefitfromlocalnerveblocks.
usuallyhealed3-6weeksaftertreatmentcomple-
tion.Treatment ismainlysupportivewithgentle
Mucosa
cleansing/soakingoftheareawithmildsoap(dilute
Ifareasofmucosaareincludedintheradiationfield,
nolvasanorchlorhexidinesolution)andprescription
themostsignificantacutesideeffectismucositis
ofanti-inflammatory(NSAIDsor corticosteroids),
（Figure8.4),whichoften developsmidwaythrough
analgesicandantibioticmedications.Aftercleansing,
therapy.Mucositiscanbepatchyinitsdistributionor
theradiationsiteshouldbegentlyblotteddry(not
canprogressestoaconfluentmucositis.
rubbed)witha soft,clean towel.Thepreventionof
Treatmentconsistsofsupportivecarewithgentle
self-traumabytheuseofElizabethancollarsorother
cleansing/rinsingoftheareaandprescriptionofanti-
devicesusedtopreventaccesstothesiteisof
inflammatory,antibioticandanalgesicmedications.
utmost importance.
Topical analgesicsinclude2%lidocainegel and‘mira-
Alargenumberofointmentsandcreamshave
cle’mouthwashformulationsthattypicallyinclude
beenusedforthepreventionandmanagement
somecombination of lidocaine,benzocaine,diphen-
ofacuteradiationskinsideeffectsinhumanand
hydramine,kaolin,milkofmagnesiaand/orsucralfate
(a)
(b
(c)
Radiationsideeffectsseenintheskin.(a)Markedconfluentmoistdesquamationof theskinseenneartheend
8.3
ofradiationtherapy.(b)Mildpatchydesquamationof theskinseenat theendofradiationtherapy.
(c)Permanentalopeciaand hyperpigmentationof theskinafterdefinitiveradiationtherapy.
b)
8.4
Acuteradiationsideeffectsseenintheoral
(a)
cavity.(a)Oral mucositisof thecaudaltongue.
(b)Oralmucositisof thebuccal mucosa.
83
Chapter8Principlesofradiationtherapy
mayreduceneovascularization.Radiationdecreases
andSonis,2007).At North CarolinaState University,
theabilityoffibroblaststomultiplyanddecreasestheir
aformulationofdiphenhydramine2.5mg/ml,Maalox
productionofcollagen,orresultsinproductionofcoll-
suspensionandlidocaine2%gelcompoundedin
woundhealing (Tibbs,1997).The force required to
mucositis.Also,if the oral cavity is involved,it is
breakapartahealinglinearsurgical incisioncanbe
importanttomaintainadequatehydrationandnutri-
directlymeasuredbythewoundburstingstrength
tion,whichmaynecessitate the placementofa
(WBS),whichhasbeenshowntobereduced after
temporarygastrostomyoroesophagostomytube.
radiation therapy(Bernsteinetal.,1993).
Iftheperianalregionisintheradiation field,
mucositiscanmakedefecationverypainfulandmay
Delayedeffects
A woundproduced in tissue that was irradiated
requiretheplacementofalumbosacralepidural
catheterforconstantrateinfusionofanalgesics.
monthsorevenyearsprioralsoexhibitsaltered
woundhealingcapacity,thoughlesspronounced.
Lateeffects
Delayedeffectstotheskinandsubcutaneoustis-
Tissuessuchasbrain,spinalcord andbone thato
suesduetofibroblastinjuryincludeatrophy,contrac
notdivideregularlyarereferredtoaslate-
tionandfibrosis.Theskin andsubcutaneoustissues
respondingnormal tissues.Thesetissues willnot
becomeatrophicandlesspliablethannormal,while
expressradiationinjuryuntilmanymonthsoryears
reducedvascularityandtissuehypoxiacanimpair
afterbeingirradiated.Intissueswherecellsdivide
normalwoundhealingresponseandpredisposeto
onlyrarely,cellulardamageremainslatentforalong
bacterial infection(Tibbs,1997).
periodof timeandisrevealedslowly.
Surgical complications
In late-responding normal tissues,the develop-
mentandseverityoflateradiationeffectsarenot
Occasionally,theneedtoperformasurgicalproce-
relatedtothetimeoverwhichtheradiationisgiven,
dureinpreviouslyirradiatedtissuearises.Thesafety
ofsuchaproceduredependsonanumberoffac-
butratherareafunctionoftheindividualfractionsize
and thetotal dose.Thelarger thefraction size,the
tors,includingthesizeoftheoriginal treatmentfield,
loweristhetotaldoserequiredtoproduceserious
thetotaldosedelivered,thefractionsizeused,the
complications.Radiationinjuryinlate-respondingtis-
timebetweencompletionofradiationtherapyand
sues maymanifest as fibrosis,vascular damage，
theplanned surgery，andtheinherenttissuerepair
characteristicsof theindividualpatient.Thereareno
demyelinationornecrosis.
Lateradiationeffectslimitthedosethatcanbe
hardandfastrulesgoverningwhethersurgerywill
betolerated.Negativeriskfactorsarealargeradia-
givensafelybecausetheyareprogressive,oftennot
treatableandadverselyaffecttheanimal'squalityof
tionfield,ahightotal dose,alargefractionsize and
a shorttimebetweenradiationandsurgery.Ingen-
life.Late-respondingnormal tissues are therefore
referredtoasthedose-limitingtissues.Necrosisor
eral,surgerycanbetoleratedintissuethathasbeen
fibrosisofcriticalnon-proliferatingtissuessuchas
irradiatedto48Gyin3Gyfractions,evenwhenthe
thebraininalcordreartcanbelife-threatning
surgeryandradiationareincloseproximity.
andshouldbeavoidedifatallpossible.
Whenconsideringtheeffectofradiationon
Ingeneral,radiationdosesareselectedthatoffer
woundhealing,anotherissueisthetypeofsurgery
thegreatestchanceoftumourcontrolwithsome
itself.Large,extensivesurgeryrequireshealingofa
acceptablefinitebutsmall（<5%)probabilityof
largerwound.Also,scarsunderincreasedtensionin
seriousnormal tissuecomplication.
irradiatedtissuearelikelytobeatahigherriskof
havingwoundhealingcomplicationsthanifinnon-
Implicationsforwoundhealing
irradiatedtissue.
Radiationcreatesbothacuteanddelayedeffectsto
theskinandsubcutaneoustissueswithinthe
Tumourradiationresponsiveness
radiationfieldandtheseeffectshaveimplicationsfor
surgical woundhealing.
Tumourresponsetoradiationtherapycanvary
Acuteeffects
dependingonspecies,tumourhistology,tumourloca-
Acutely，radiationproducesdegenerativechangesin
tion,volume andhistopathological grade.Figures8.5
basementmembranes,increasesvascularpermeabil-
and8.6showsomeof thereportedresultsfortumours
ity,canresultinvasculaturestasisorthrombosisand
commonlyiradiatedindogsandcats,respectively.
Tumourtype
Numberof
Treatments
Results
Reference
patients
Mast celltumour (MCT)
32
Surgery and megavoltage
94%1year disease-free interval.86%
Al-Sarraf et al.
Gradell
radiation
2-5 years disease-freeinterval
(1996)
Stage0
37
Surgery and orthovoltageor
97%1year disease-free interval.93%3
Frimbergeret
megavoltageradiation
years disease-free interval
al.(1997)
8.5
Some of thereportedresultsfortumourscommonlyirradiated indogs.(continues)
84
Chapter8Principlesofradiationtherapy
Tumour type
Numberof
Treatments
Results
Reference
patients
MCT
56
35/56surgery andmegavoltage
32.7months overallmedian disease-free
LaDue et al.
GradeI-ll(mostlygradeIl)
radiation
interval:12monthsifmeasurable disease,
(8661)
Stage1
21/56megavoltageradiation
54monthsifmicroscopic
MCT
19
Surgery andmegavoltage
40.7monthsmediandisease-free survival
Chaffin and
GradeI-Il(mostly gradeIl)
radiationtoprimarytumourand
Thrall(2002)
Stage2
metastatic lymph node.
Prednisone 18/19
MCT
31
Surgery and megavoltage
Mediandurationofcontrolandsurvival
Hahn et al.
GradeIl
radiation
27.7months and28monthsrespectively
(2004)
StageO
Softissue sarcomas
48
Surgery and megavoltage
35.5monthsmediandisease-freeinterval
McKnight et al.
radiation
(2000)
37
Surgery and megavoltage
61monthsmedian survival.Mediantime
Forrest etal.
radiation
to localrecurrence>2years
(2000)
29
Megavoltageradiationandlocal
14.5monthsmediantime to local failure
Thrall et al.
hyperthermia
(966)
122
Megavoltageradiationandlocal
Median durationof local control1.9years
Thrall etal.
hyperthermia (low dose and
in high hyperthermia dose group;1.2
(2005)
high dose hyperthermia)
years inlowhyperthermia dose group
Infitrative lipoma
13
Megavoltageradiation
40monthsmedian survival.Macroscopic
McEntee et al.
(4microscopic;
disease:2/9completeresponse,2/9
(2000)
9macroscopic
partialresponse,4/9stabledisease
Osteosarcoma
14
Definitivemegavoltage
6.9months median survival
Walteret al.
radiationmediantotaldos7
(2005)
Gy,andchemotherapy
95
Palliativemegavoltageradiation,
4months median survival.74%pain
Ramirez et al.
16or30Gy，±chemotherapy
relief response-2.5-4monthsreported
(1999)
Nasal cavity tumours
77
Definitivemegavoltage
9-13monthsmedian survival
Theon et al.
and
radiationmost totaldoss
(1993);LaDue
130
48-57Gy
56
Palliativemegavoltageradiation,
4.9-7monthsmedian survival
Mellanby et al.
and
total dose24-36Gy
(2002b);Gieger
48
51
Megavoltageradiationand
15.6monthsmedian survival
Lana et al.
slow-releasecisplatin
(2004
Nasal planum squamouscell
8
Orthovoltageradiation
6months median survival.2.9months
Thrall and
carcinoma
mean time to failure
Adams(1982)
3
Surgery and megavoltage
2months stabledisease,thenprogressive
Rogers et al.
radiation
disease
11
Surgeryand hypofractionated
9weeksmedian time torecurrence,
Lascelles et al.
radiation;7/11or
whatevertreatment
(2000)
hypofractionatedradiation
alone;4/11
Oral tumours:acanthomatous
39
Orthovoltageradiation
37-47.5monthsmedian survival
Thrall(1984)
epulis
57
Megavoltageradiation
39.8monthsmedian time to firstevent
McEntee etal.
(2004)
Oral tumours:melanoma
38
Megavoltageradiation
8monthsmedian survival
Theonet al.
(1997)
140
Megavoltage radiation:
5monthsmediantimetofirstevent,
Proulx etal.
3different protocols30-57Gy
7monthsmedian survival.Riskfactors
(2003)
（RFs）identified:1-0RFmedian survival
11-21months;3-2RFsmedian survival
3-5months
8.5
(continued)Some of thereportedresultsfortumourscommonly irradiated indogs.(continues)
85
Chapter8Principlesofradiationtherapy
Tumourtype
Numberof
Treatments
Results
Reference
patients
Oral tumours:squamouscell
14
Megavoltageradiation
12and15monthsmediandisease-free
LaDue-Milleret
carcinoma(SCC)
interval andsurvival,respectively
al.(1996)
39
Megavoltageradiation
36monthsmedianprogression-free
Theonet al.
survival
(1997)
Oral tumours:SCC-tonsillar
8
Surgery+megavoltage
75%localdiseasecontrolbut5months
MacMillan et al.
radiation or surgery,
median survival
(1982)
megavoltageradiation+
chemotherapy
6
9monthsmedian survival
Brooks et al.
(1988)
Oral tumours:SCC-tongue
11
Orthovoltageradiationandlocal
4monthsmedian survival
Becket al.
hyperthermia
(1986)
Oral tumours:fibrosarcoma
8
Megavoltageradiation
18monthsmedian survival
Ciekot etal.
(1994)
28
Megavoltageradiation
26monthsmediandisease-freeinterval
Theon et al.
(1997)
Thyroid carcinoma
25
Megavoltageradiation
45monthsmeanprogression-free
Theon et al.
survival;median notreached
(2000)
Timetomaxtumour sizereduction≥8
months
Salivarygland carcinoma
6
Surgery and megavoltage
18monthsmedian survival
Hammeret al.
radiation
(2001)
Apocrine gland anal sac
15-27
Megavoltageradiation±surgery
18-31.5monthsmedian survival
Turekelal.
adenocarcinoma
±chemotherapy
(2003)
Williamsetal.
(2003)
Intracranialtumours:pituitary
13-19
 Megavoltage radiation 
13-46monthsmedian survival
Theon and
macroadenoma
Feldman(1998)
Kent et al.
(2007)
Intracranial tumours:
20-31
Surgery and megavoltage
16.5-30months median survival
Theon et al.
meningioma
radiation
(2000)
Axlund et al.
(2002)
Intracranial tumours:
29-46
Megavoltage radiation
8-23monthsmedian survival
Spugnini etal.
mixed (no histopathology)
(2000)
Bleyet al.
(2005)
Spinalcord tumours:mostly
6-9
Surgery and megavoltage
17 to~36monthsmedian survival
Siegel et al.
meningiomas
radiation
(1996)
Petersenetal.
(2008)
Transitional cellcarcinoma
10
Palliativeradiation and
10.7monthsmediansurvival;22%partial
Poirieret al.
(TCC),bladder
mitoxantrone and piroxicam
responseand90%clinicalimprovement
(2004)
BladderTCCandprostatic
10
Definitive radiation alone
7-8monthsmedian survival
Authors'
Ca/TCC
experience
Thymoma
17
Megavoltageradiation
8.2monthsmedian survival
Smithet al.
(2001)
Transmissiblevenereal
Variable
Variablebutorthovoltagr
24-25monthsmedian disease-free
Thrall and
tumour
megavoltageradiation themost
intervaland survival
Adams(1982)
commonmethod
Rogers etal.
(1998)
8.5
(continued)Someof thereportedresultsfortumourscommonlyirradiated indogs.
86
Chapter8Principlesofradiationtherapy
Tumourtype
Patient
Treatments
Results
Reference
number
Injection site
92
Megavoltageradiation
19.2monthsmediantime tofirst event(recurrence,
Kobayashi et al.
sarcomas
followedby surgery±
metastasis,ordeath）.32.4monthsif complete
(2002)
chemotherapy
excisionversus9.7monthsif incomplete
18
Surgeryfollowedby
21.7monthsmedian disease-free interval
Bregazzi et al.
megavoltageradiationand
(2001)
chemotherapy
76
13.3monthsmediandisease-freeinterval
Cohen et al.(2001)
Oral squamouscell
Variable
Radiation:orthovoltageor
2-6monthsmedian survival
Postorino et al.
carcinoma(ScC)
megavoltage,palliativeor
(1993);Jones et al.
definitive±surgery±
(2003);Fidel etal.
chemotherapy
(2007)
Nasal planum SCC
90
Orthovoltageradiation
16.5monthsmedianprogression-free survival
Theon et al.(1995)
12
Orthovoltageradiation
13.6monthsdisease-freeinterval
Melzer et al.(2006)
Nasal cavity tumours,
8-16
Megavoltageradiation
11-13monthsmedian survival
Theon et al.(1994);
non-lymphoid
Mellanbyetal.
(2002a)
Salivary gland tumour
30
Surgery andmegavoltage
17monthsmediansurvival
Hammeretal.
radiation
(2001)
Thymoma
Megavoltageradiation
23.6monthsmedian survival
Smith et al.(2001)
Pituitary
8
Megavoltageradiation
17.4monthsmedian survival.Endocrine disorder
Mayer et al.(2006)
macroadenoma
improved within1-5months
8.6
Someof thereportedresultsfortumourscommonlyirradiatedincats.
Futuredirections
Althoughconsiderableprogresshasbeenmadein
optimizingtheresponseoftumoursinanimalsto
radiationtreatment,manysolidtumoursstillrecur
followingradiation therapy.This may be due to
insufficientkillingoftumourclonogensduetoinad-
equateradiationdose,ortobiologicalcharacteris-
ticsofthetumourthatrenderitradioresistant.New
directionsinveterinaryoncologyareaimedateach
of theseproblems.
Conformalradiationdosedelivery
Withregardtoinadequatetumourradiationdose,
effortisbeingdirectedtowardsmakingtheradiation
dosedeliverymoreconformal.Thisimpliestailoring
theshapeoftheradiationdosedistributiontothe
shapeof thetumour,toallowhighertumourdosesto
begivenwithnoincreasedrisk,orperhapsevena
8.7
Portalradiographofadogbeing treatedforan
analsaccarcinoma.Thetreatmentfield,
decreasedrisk,ofnormaltissuecomplications.
configuredbyamultileafcollimator,isshown
Akeycomponentofconformalradiationdose
superimposedonadigitallyreconstructedradiographof
deliveryisthemultileafcollimator.Whereasuntil
thecaudalabdomen.Thefieldisrelativelylargeinthe
nowthecollimatorofatherapeuticphotonbeamhas
regionof theprimarytumour,butthenbecomesmore
essentiallybeenidenticaltothatofadiagnostic
conformal fortreatmentofregional lymphnodes,sparing
X-raymachine,withXandYleaves thatcanbe
theventral colonwalland thecaudaequina.Shapinga
adjustedtocreaterectangulartreatmentfields,new
fieldthisextensivelyisessentiallyimpossiblewithoutuse
ofamultileafcollimator.Thisisthesamefieldshownin
collimatorsarecomposedof multipleleaflets-upto
Figure 8.1.
60oneachoftwosides-thatallowcreationof
irregularlyshapedphotonbeamsthattailorthe
shapeoftheradiationdosemorecloselytothe
computingtheradiationdosethatresultsfrom
shapeof the tumour(Figure8.7).
preselectedradiationfieldshapesandsizes,as
Also,software used forradiationplanningis
illustratedinFigure8.1,softwarecannowprescribe
undergoingextensivemodification.Ratherthan
thesizeandshapeofmultiplephotonbeams,all
87
Chapter8Principlesofradiationtherapy
configuredwithamultileafcollimator,andthedose
Nuclearradiation therapy
tobedeliveredfromeachbeam,tooptimizetumour
radiation dose.Thus,software has gone from a
Brachytherapy
reporting tool toaprescribing tool.This typeof
Brachytherapyistheimplantationofradioactive
radiationdoseprescription,basedoncomputerized
sourcesdirectlyinto thetissue.Thesesourcesmay
iterationsoftreatmentdelivery,iscalledintensity-
remaininplacepermanently，orberemovedaftera
modulatedradiationtherapy.IMRTcanultimately
certaindoseisdelivered.
leadtoanincreaseinthedosedeliveredtothe
Brachytherapyisnotdiscussedhereindetail,as
tumour with noincrease,or possibly evena
itreallyhasnoapplicationforcompanionanimal
decrease,inthedosedeliveredtothenormal tissue.
radiationtherapy.ltisonlyusefulfor treatmentof
Dose escalation using this method may lead to
small localizedtumours,asthe dosefall-offatthe
improvedtumourcontrolandvariousstudiesare
edgeoftheimplantisveryrapid.Therearenosites
underwaytestingthisnewdosedeliverymethodina
indogsorcatswherebrachytherapyisthepreferred
varietyofcanineandfelinetumours.
modality.Thisisincontrast tohumans,wherehighly
localizedtumoursoftheprostateglandandcervix
Tumourbiology
canbeeffectivelytreatedusingbrachytherapy.
Modulating the biologyof the tumour to augment
Inlargeanimalswhereaccesstoalinear
radiationtherapyisanexcitingnewdirectionforvet-
acceleratorisproblematic,anddailyanaesthesiais
erinaryoncology.Fulldiscussionofthis topic is
not possible,small superficial tumours,such as
beyondthescopeofthischapter,butthefollowingis
incompletelyresectedperiocularcarcinomas,canbe
abriefdescriptionofsomeselectedapproachesto
effectivelytreatedwithbrachytherapy.
sensitize tumourcellswithnovelanticancer thera-
piesdirected atspecificmoleculartargets.Therapid
Internalradiotherapy
advancesinmolecularoncologyhaveoffered
Inadditiontobrachytherapyinternalradiotherapy
remarkableinsightsintothemolecularbasisofbio-
canbeachievedbyinjectionofasmallradioactive
logicalfactorsthatinfluencetheresponseoftumour
sourcethatseeksout thetargetarea.
cellstoradiationandcanguidethemodernmolecu-
larradiationoncologisttoidentifynovelagentsthat
lodine-131
canmodulatetumourresponsetoirradiation.
131lodine iscommonlyused totreat thyroid cancer in
peopleandhasbeensuccessfullyusedforthetreat-
EGFVEGFinhibition
ment of hyperthyroidism incats.Treatmentwith
Agreatdealofworkhasbeendirectedatdevelop-
iodine-131canbeparticularlyusefulforcatswhen
inginhibitorsofdifferentcomponentsofcellsignal
thereisbilateralthyroidinvolvementorectopicthy-
transductionpathwaysandangiogenesis.Epidermal
roidtissue,orwiththerarecaseofthyroidcar-
growthfactor(EGF)andvascularendothelialgrowth
cinoma.Inoneretrospectivestudywith524
factor(VEGF)signallingpathways areupregulated
hyperthyroidcatstreatedwithiodine-131,overall
inmanytumourtypes.InhibitionofEGFreceptor
response totreatmentwas consideredgoodin
andVEGFhasbeenshown tobeeffectivein
94.2%ofthecatsandmediansurvival timeinthe
increasingtheradiationresponsivenessofneoplas-
catswas2.0years.Thepercentageofcatsalive 1,
ticcellsbothinvitroandinhumantrials.Integrating
2,and3yearsaftertreatmentwas89,72,and52%,
targetedtherapiesagainst theEGFreceptorand
respectively(Peterson andBecker,1995).
angiogenesispathwaysintostandardradiationtreat-
Lessisknownabouttheuseofiodine-131in
mentparadigmsmaybebeneficialfortreating
dogswiththyroidtumours.Resultsfromoneretro-
caninepatientswithtumoursshowntoover-express
spectivestudysuggestedthatiodine-131therapy
EGFreceptorandVEGF.
mayresultinprolongedsurvival timesindogswith
non-resectablethyroid tumours,regardlessofserum
Dosepainting
thyroxine concentrationprior totreatment(54%of
Thereisamounting interest inintegratingbiological
thedogswerehyperthyroid)(Turreletal.,2006b).
information(factorsthatinfluencetreatmentoutcome
suchastumourproliferationandhypoxia)intoradia-
Samarium-153
tiontreatmentplanningforthepurposeoftargeting
153Samarium is another isotope used in internal radi-
radiation-resistantregionsinside thetumour.One
otherapy asa palliative therapy.It is effective in
relievingthepainofmetastaticcancerlesionstothe
with aprocedure calleddosepainting.Dosepainting
bone inhuman medicine.Results from a recent
reliesonnon-invasivebiologicalimaging suchas
studyevaluatingitsusein35dogswithprimary
positronemission tomography,functional magnetic
bonetumourssuggestthatsamarium-153lexi-
resonanceimagingandmagneticresonancespec-
dronammaybeusefulinveterinarymedicineforthe
troscopytoobtainathree-dimensionaldistributionof
palliationofbonepain(Barnardetal.,2007).
tumourfactorsthatmayinfluenceradiationresponse.
This isthenused toguidefocal doseescalationto
Plesiotherapy
radioresistant regionswithinthe tumour.Image-
Plesiotherapy involves the direct therapeutic applica-
guidedbiologicaldoseescalationmaysignificantly
tionofaradiationsourceontoanareaofpathology.
increasetheprobabilityoftumourcontroland
Theuseof strontium-90(9Sr)inthiswayhasbeen
decreasenormal tissuetoxicity.
successfullyemployedfortreatmentofsuperficial
88
Chapter8Principlesofradiationtherapy
felinenasalplanumsquamouscellcarcinoma.One
HammerA,GetzyD,OgilvieGetal.2001）Salivaryglandneoplasiain
thedogandcat：survivaltimesandprognosticfactors.Journalof
went9Srplesiotherapyreported that98%hada
theAmericanAnimal HospitalAssociation37,478-482
Hammond GM,Gordon IK.Theon AP et al.(2007) Evaluation of
responsetotreatmentand88%hadacomplete
strontiumSr90forthe treatmentof superficial squamouscell
response.Reported medianprogression free sur-
carcinoma of the nasal planum in cats:49 cases（1990-2006).
Journalof theAmericanVeterinaryMedicalAssociation231,736-
vival timewas1,710 days(Hammondetal.,2007).
HeadKW,ElseRWandDubielzigRR(2002）Tumoursofthealimentary
741
Irradiationwith9Srhasalsobeenevaluatedin
tract.In:TumoursnDomesticAnimals4thedned.DJMeutenp
thetreatmentof54cutaneousmastcelltumoursin
401-481.lowaStateUniversityPress,lowa
35cats.Treatmentresultedinlocaltumourcontrol in
Jones PD,de Lorimier LP,Kitchell BEet al.(2003)Gemcitabine as a
53of54(98%)tumourswithamedianfollow-uptime
radiosensitizer for nonresectable feline oral squamous cell
of783daysaftertreatment(Turreletal.,2006a).
carcinoma.Journalof theAmericanAnimalHospitalAssociation
39,463-467
Lesionstreated withSrplesiotherapy should be
Kent MS,BommaritoD,Feldman Eet al.(2007)Survival,neurologic
verysuperficial,sinceitseffectivetreatmentdepthis
response,and prognostic factors in dogs with pituitary masses
onlyacoupleofmillimetres.
VeterinaryInternalMedicine21,1027-1033
Kobayashi T，Hauck ML,Dodge R et al.(2002)Preoperative
radiotherapyforvaccineassociatedsarcomain92cats.Veterinary
RadiologyandUitrasound43,473-479
Referencesandfurtherreading
LaDue TA,DodgeR,PageRLetal.（1999）Factorsinfluencing survival
afterradiotherapyofnasaltumours
in130dogs.Veterinary
Al-SarrafR,MauldinGN,PatnaikAKetal.（1996)Aprospective study
RadiologyandUitrasound40312-317
ofradiationtherapyforthetreatmentofgrade2mastcelltumours
LaDue T.Price GS,Dodge R et al.（1998）Radiation therapy for
in32dogs.JournalofVetrinaryInternaMedicine10376378
incompletelyresected canine mast
tcelltumours.Veterinary
Axlund TW,McGlasson MLand Smith AN(2002) Surgery alone orin
RadiologyandItrasound39572
combinationwithradiationtherapyfortreatmentofintracranial
LaDue-MillerTPriceGS,PageRLetal.1996）Radiotherapyofcanin
meningiomas in dogs:31cases (1989-2002）. Journal of the
non-tonsillarsquamouscellcarcinoma.VeterinaryRadiologyand
AmericanVeterinaryMedicalAssociation2211597-1600
UItrasound37,74-77
Barnard SM,Zuber RMand Moore AS(2007)Samarium Sm 153
LanaSE,DernellWS,LaffertyMHetal.(2004)Useof radiation anda
lexidronamforthepalliativetreatmentofdogswithprimarybone
slow-releasecisplatin formulation for treatmentofcaninenasal
tumours:35 cases （1999-2005）.Journal of the American
tumours.VeterinaryRadiologyandUltrasound45577-581
VeterinaryMedicalAssociation230,1877-1881
Lascelles BD,Parry AT, Stidworthy MF et al.(2000) Squamous cell
Beck ER,Withrow SJ,McChesney AEetal.（1986)Canine tongue
carcinomaofthenasalplanumin17dogs.VeterinaryRecord147,
tumours:a retrospectivereviewof57cases.Journalof the
MacMilanR,WithrowSJandGilleteEL（1982)Surgeryandregional
473-476
AmericanAnimalHospitalAssociation22,525-532
Bernstein EF,Salomon GD,HarisiadisLet al.(1993）Collagen gene
irradiation for treatment of canine tonsillar squamous cell
expressionandwoundstrengthinnormalandradiation-impaired
carcinoma:aretrospectivereviewofeightcases.Journalof the
wounds.JournalofDermatologySurgeryandOncology19,564
AmericanAnimal HospitalAssociation18.311-314
570
Mayer MN,Greco DS and LaRue SM(2006) Outcomes of pituitary
BleyCR,SumovaA,RoosMetal.(2005）Irradiationof braintumoursin
tumourirradiationincats.JournalofVeterinaryInternalMedicine
dogswithneurologicdisease.JournalofVeterinaryInternal
20,1151-1154
Medicine19,849854
McEntee MC,Page RL,Mauldin GNetal.(200o)Resultsof irradiation
Bregazzi VS,LaRue SM,McNiel Eet al.(2001)Treatment with a
ofinfitrativelipomain13dogs.VeterinaryRadiologyand
andradiationaloneforcatswithvaccine-associatedsarcomas:25
McEntee MC,Page RL.Theon APet al.(2004） Malignant tumour
cases(1995-2000).Journalof the AmericanVeterinary Medical
Association218,547-550
VeterinaryRadiologyandUltrasound45357-361
Brooks MB,MatusRE,LeiferCEet al.(1988)Chemotherapy versus
McKnight JA,Mauldin GN,McEntee MC et al.(200o)Radiation
chemotherapy plus radiotherapy inthe treatment of tonsillar
treatmentforincompletelyresectedsoft-tissuesarcomasindogs.
squamouscellcarcinomainthedog.JournalofVeterinaryInternal
Journalof theAmericanVeterinaryMedicalAssociation217,205-
Medicine2,206-211
210
ChafinKandThrallDE(2002)Resultsofradiation therapy in19dogs
McLeodDA andThrallDE（1989)Thecombinationof surgery and
withcutaneousmastcelltumourandregionallymphnode
radiationinthetreatmentofcancer.Areview.VeterinarySurgery
metastasis.VeterinaryRadiologyandUltrasound43392-395
18,1-6
Ciekot PA,Powers BE,Withrow SJ etal.(1994）Histologically low-
MellanbyRJ,HerrtageMEandDobsonJM(2002a)Long-termoutcome
grade,yetbiologicallyhigh-grade,fibrosarcomasof themandible
ofeightcatswithnon-lymphoproliferativenasaltumourstreated by
and maxil in dogs:25 cases (（1982-1991）.Journal of the
megavoltageradiotherapy.JournalofFelineMedicineandSurgery
AmericanVeterinaryMedicalAssociation204,610-615
4,77-81
Cohen M,Wright JC,BrawnerWRet al.(2001)Use of surgery and
Mellanby RJ,Stevenson RK,Herrtage MEetal.(2002b)Long-term
electron beam irradiation,with or without chemotherapy.for
outcomeof56dogswithnasaltumourstreatedwithfourdosesof
(1996-2000).Journalof theAmericanVeterinaryMedical
257
Association219,1582-1589
MelzerK,GuscettiFRohrerBleyCetal.(2006)Ki7reactivity innasal
Fidel JL,SellonRK,HoustonRKetal.(2007)Anine-dayaccelerated
radiationprotocolforfelinesquamous
scellcarcinoma.Veterinary
electronbeamradiationtherapy.JournalofVeterinaryInternal
RadiologyandUltrasound48,482-485
Medicine20.676-681
Flynn AK and Lurie DM(2007) Canine acute radiation dermatitis,a
Petersen SA,Sturges BK,Dickkenson PJ et al. (2008) Canine
survey of current managementpractices in NorthAmerica.
intraspinalmeningiomas:imagingfeatures,histopathologic
VeterinaryandComparativeOncology5,197-207
classification,andlong-termoutcomein34dogs.Journal of
ForrestJ,ChunRAdamsWMetal.(200o）Postoperativeradiotherapy
VeterinaryInternalMedicine22,946-953
forcaninesoftissue sarcoma.JournalofVeterinaryInternal
PetersonMEandBeckerDV（1995)Radioiodine treatmentof524cats
Medicine14,578-582
withhyperthyroidism.Journalof theAmericanVeterinaryMedical
FrimbergerAE,Moore AS,LaRue SMetal.(1997)Radiotherapy of
Association207,1422-1428
incompletelyresectedmoderatelydifferentiatedmastcelltumours
PoirierVJ,ForrestJ,AdamsWMetal.(2004）Piroxicammitoxantrone
inthedog:37cases(1989-1993).Journalof theAmericanAnimal
andcoarsefractionradiotherapyforthetreatmentoftransitional
HospitalAssociation33,320-324
cellcarcinomaof thebladderin 10dogs:apilotstudy.Journalof
GiegerTassnick,SiegelSetal.(008）Palliationoflinical signsin
theAmericanAnimalHospitalAssociation40,131-136
48dogswithnasalcarcinomastreatedwithcoarse-fraction
Postorino NC,TurrelJMand Withrow SJ （1993)Oral squamous cell
radiationtherapy.JournaloftheAmericanAnimalHospital
carcinoma in thecat.Journalof theAmericanAnimal Hospital
Association44,116-123
Association29,438-441
HahnKA,King GKandCarrerasJK(2004）Efficacyof radiationtherapy
Proulx DR,Ruslander DM,Dodge R et al.(2003)A retrospective
analysisof140dogswithoralmelanoma treatedwithexternal
cases（1987-1998).Journalof theAmericanVeterinaryMedical
beamradiation.VeterinaryRadiologyandUltrasound44,352-359
Association224,79-82
RamirezODodgeRK,PageRLetal.(1999）Pallitiveradiotherapyf
89
Chapter8Principles of radiation therapy
appendicularosteosarcomain95dogs.VeterinaryRadiologyand
MedicalAssociation204,78-83
Ultrasound40,517-522
Theon AP,RodriguezC,Griffy S et al.（1997)Analysis of prognostic
Rogers KS.Helman RG and Walker MA （1995) Squamous cell
factorsandpatternsoffailureindogswithmalignantoraltumours
carcinomaof the canine nasal planum:eight cases(1988-1994).
treatedwithmegavoltageirradiation.JournaloftheAmerican
Journalof theAmericanAnimalHospitalAssociation31373-378
VeterinaryMedicalAssociation210,778784
RogersKS,WalkerMA and Dillon HB(1998)Transmissible venereal
ThrallDE(1982)Orthovoltageradiotherapyof canine transmissible
tumour:aretrospective studyof29cases.Journalof theAmerican
venerealtumours.VeterinaryRadiology23,217-219
Animal HospitalAssociation34.463-470
Shiran MR,Proctor NJ,Howgate EM et al.(2006)Prediction of
in39dogs.Journalof theAmericanVeterinaryMedicalAssociation
metabolic drug clearanceinhumans:invitro-invivo extrapolation
184,826-829
vsallometricscaling.Xenobiotica36,567-580
ThrallDE and AdamsWM(1982)Radiotherapy of squamous cell
SiegelS,KornegayJNandThrallDE（1996)Postoperativeirradiationf
carcinoma of thecaninenasalplane.VeterinaryRadiology23,
spinalcordtumoursin9dogs.VeterinaryRadiologyand
193-195
UItrasound37,150-153
ThrallDE,LaRue SM,YuDet al.(2005)Thermal dose isrelated to
SmithANWrightJC,BrawnerWRetal.2001）Radiationtherapyinthe
durationoflocalcontrolincaninesarcomastreatedwith
treatment ofcanineand feline thymomas:aretrospective study
thermoradiotherapy.ClinicalCancerResearch11,5206-5214
(1985-1999).Journalof theAmericanAnimalHospitalAssociation
ThrallDE,PrescottDM，SamulskiTVetal.(1996)Radiationplusocal
37,489-496
hyperthermiaversusradiation plusthe combinationof local and
Spugnini EP,Thrall DE,Price GS et al.(20oo）Primary irradiation of
whole-bodyhyperthermiaincaninesarcomas.InternationalJournal
canineintracranialmasses.VeterinaryRadiologyandUitrasound
ofRadiationOncology.BiologyandPhysics34,1087-1096
41,377-380
TibbsMK(1997)Woundhealing followingradiationtherapy:areview.
TheonAPandFeldmanEC（1998)Megavoltage irradiationofpituitary
RadiotherapyandOncology42,99-106
macrotumoursin dogswithneurologic signs.Journalofthe
Treister N and Sonis S(2007)Mucositis:biology and management.
AmericanVeterinaryMedicalAssociation213,225-231
CurrentOpinioninOtolaryngologyandHeadandNeckSurgery15,
TheonAP,LecouteurRA,Carr EAetal.(20oo)Influence of tumourcell
123-129
proliferation and sex-hormone receptors on effectiveness of
Turek MM,Forrest LJ.Adams WM et al.(2003) Postoperative
radiationtherapyfordogswithincompletelyresectedmeningiomas.
radiotherapyandmitoxantroneforanal sacadenocarcinoma inthe
Journalof theAmericanVeterinaryMedicalAssociation216,701-
dog:15cases(1991-2001).VeterinaryandComparativeOncology
707
1,94-104
TheonAP,MadewellBR,HarbMFetal.（1993）Megavoltage irradiation
Turrel JM,FarrellyJ,Page RLetal.(2006a)Evaluation of strontium90
ofneoplasms of thenasalandparanasalcavities in77dogs
irradiationintreatmentof cutaneousmastcelltumoursincats:35
Journalof theAmericanVeterinaryMedicalAssociation2021469
cases（1992-2002）.Journalof theAmericanVeterinaryMedical
1475
Association226,898-901
Theon AP,Madewell BR,ShearnVIet al.（1995）Prognostic factors
Turrel JM,McEnteeMC,Burke BPetal.(2006b)Sodium iodide131
associatedwithradiotherapyofsquamouscellcarcinomaofthe
nasalplanumincats.Journalof theAmericanVeterinaryMedical
(1990-2003).JournaloftheAmericanVeterinaryMedical
Association206,991-996
Association229,542-548
Theon APMarks SL,Feldman ESetal.(2ooo)Prognosticfactorsand
WalterCU,DernellWS,aRueSMetal.2005)Curativeintentradiaton
patternsoftreatmentfailureindogswithunresectable
therapyasatreatmentmodalityforappendicularandaxial
differentiatedthyroidcarcinomastreated
withmegavoltage
osteosarcoma:apreliminaryretrospectiveevaluationof14dogs
irradiation.JournaloftheAmericanVeterinaryMedicalAssociation
withthedisease.VeterinaryandComparativeOncology317
216,1775-1779
WilamsLE,GliatoJM.Dodge RKetal.(2003）Carcinoma of the
Theon AP,Peaston AE,Madewell BR et al.（1994) Irradiation of
apocrine glands of the anal sac in dogs:113cases(1985-1995).
nonlymphoproliferativeneoplasmsofthenasalcavityand
JournaloftheAmericanVeterinaryMedicalAssociation223825-
paranasal sinusesin16cats.Journalof theAmericanVeterinary
831
06
Therapies of the future
StuartC.Helfand
Introduction
explain cancer cellproliferation,microenvironment
interactions,metastasis,apoptosis andangiogene-
Advancesinmolecularbiology,immunologyandcell
sis.Membranereceptorsactingasswitchesturned
biologyhavegreatlyexpandedourunderstandingof
onbyextracellularligandsinitiatecomplexintracell-
abnormalitiesunderlyingmalignancy.Aclearer
ularsignallingcascadesthataffect expressionof
understandingofthesubcellularandgenetic
various cellular proteins,promoting proliferation,
derangementsthatleadtomalignanttransformation,
apoptosis,or stress responses.Development of
coupledwithincreasedawarenessoftheroleofthe
drugsthatcaninterruptgrowthsignalsoractivate
tumourmicroenvironment,havegraduallyrevealed
apoptoticpathwaysisofhighpriority.Somedrugs
anarrayofpotentialtargetswithincancercellsthat
havemadetheirwaytothehumanoncologyclinic
mayofferopportunitiesfor therapeuticintervention.
andhavebeenhighlysuccessful,suchastyrosine
Incontrasttothe‘slashandburn’effectsassociated
kinase inhibitors(e.g.imatinib,dasatinib).Still other
withtraditionalchemotherapythatinterferewithDNA
newapproachesseektoregulateepigeneticevents,
synthesis,mitosis,DNAintegrityandproteinsynthe
suchasmodulatinggene transcriptionbyhistone
sisindiscriminately,thenewanticanceragentsinthe
deacetylaseinhibitors.
therapeuticpipelinearedesignedtoexploitspecific
Themajorparadigmswitchtowardsagentsthat
andpotentiallyvulnerabletargetswithinthetumour
target antigens,receptors and signalling kinases
cellormicroenvironment.
holdsenormouspromise.Redundantandoverlapping
Thediscoveryofproteinsthatmediatecellular
signallingcascadesoffermanypivotalandhub-like
cross-talkandintracellularsignallinghashelpedto
targetscommon tomultiplepathways(Figure9.1).A
KIT
PDGFR
VEGFR
EGFR
Met
Integrins
F
P
Ak
HIF-1a
AngiogenesisAnti-apoptosis
Proliferation
Migration
(survival)
9.1
Cellsignallingpathwaysassociatedwithfeaturesofmalignancy.Thisisasimplifiedschematicofsomeof the
kinases andmembraneadhesionmolecules(integrins)interactwithextracellularligandsthat triggerpropagationof signals
withinthecell.DependentdownstreamsignallingpartnersultimatelyactivatetranscriptionfactorsthataffectDNA
91
Chapter9Therapiesof thefuture
numberoftargetingstrategieshavebeenpursued.
subjectedtorigorousconfirmationthatcomparable
Theseinclude:small moleculesthatselectivelybindto
targetsarepresentinanimalcancersanddrugsbind
andblockfunctionofsignallingmolecules intracellu-
totargetsthatareeffectiveatclinicallyachievable
larly:andmonoclonalantibodiesthataccomplisha
concentrations.lt maynotbeappropriatetoprescribe
similarresultbybindingtogrowthfactorreceptorson
new,expensiveandpotentiallytoxicagentsforpet
thecellsurfaceandcompetewithstimulatoryligands
animalsuntilpreclinical validationisconfirmed.For
foraccessto thereceptor(seeFigure9.2).Antibodies
example,rituximab,amonoclonalantibodyoftre-
canalsomediateanumberofimmunologicalfunc-
mendousbenefitforthetreatmentofhumanB-cell
tionstoxictothecancercell(Weineret al.,2009)
lymphoma,hasnoroleinveterinaryclinicaloncology
Aseeminglyendlessarrayofpotentialcancertar-
becauseitdoesnotrecognizeacomparableepitope
getshasemerged,stimulatingamultitudeofpreclini-
of theCD20 targetincaninelymphoma(Jubalaet al.,
calstudiesexaminingnoveltargetingstrategies.
2005;Impellizeriet al.,2006).
Universal antigens,such as telomerase (a protein that
However,veterinaryoncologymaybenefitfroma
confersimmortalitytomanytypesoftumourcells),
‘coattails'effectduetoanoverflowofnovelideas
canserveasanimmunological targetusingavaccine
associatedwithrobustdevelopmenteffortsinhuman
strategy(BeattyandVonderheide,2008).Otherinno-
oncology.Thedevelopmentofagentsthatblocksig-
vationshavebeenproposedsuchastargeting
nal transductionmediatedbytyrosinekinasesisthe
non-neoplasticproteinswithinthe tumourmicroenvi-
bestexampleand theintroductionoftyrosinekinase
ronment of mostmalignancies.Forexample,targeting
inhibitors toveterinary oncology signaisthe dawn of
adhesionmoleculesexpressedonendothelialcellsof
anewdayincancertherapeuticsforpetanimals.
thenewbloodvesselswithinthetumourmilieu,such
asavβsintegrin(Dickerson etal.,2004;Caiand Chen,
2006;Tucker,2006;Sun et al.,2009),can be anti-
Tyrosinekinaseinhibitors
angiogenicaswellasbeingamorestabletargetin
Nearly100tyrosinekinaseshavebeenidentifiedin
contrasttomutatingtargetsexpressedbyunstable
thehumankinome.Itislikelythatasimilarnumber
tumourcells.Hopes forcancer immunotherapy,the
existsinveterinaryspecies.These proteins are
ultimateformoftargeting,continuetobehighasa
responsiblefortransmittingsignalsfromtheextra-
betterunderstandingandmasteryofthecomplexities
cellularenvironment,startingwiththeactivationof
of theimmuneresponsearerevealed(Mohebtashet
receptor tyrosinekinases thatspan thecellmem-
al.,2009).Indeed,veterinarymedicinewasthefirstto
brane(Figure9.2).Thesein turn transducesignals
bringacommercialcancervaccinetotheoncology
intracellularlytotriggeractivationofcytoplasmic
clinic(Bergman et al.,2003,2006).
tyrosinekinasesalongverticalandhorizontalaxes
Ultimately,it islikelythattrulysuccessfulcancer
within the cell.Signalsarepurposeful and control
therapywillemploycombinationsofstrategiesthat
gene expression that promotes growth,survival,
maximize synergisticeffects.Learning what they
angiogenesis and motility(seeFigure9.1).
maylooklikewillrequirearigorousmethodicalpro-
Activationconfersconformational changeassoci-
cessasthepracticeofveterinaryoncologygainsa
solidunderstanding of howindividual drugswork,
atedwithphosphorylationoftyrosineresiduesinthe
kinasedomainthatactivatedownstreamsignalling
whatcanbeexpectedfromthem,andwhatarethe
partners ina cascading chainreaction.Inhealth,
clinicallyrelevanttoxicities.
ligandsbindspecificallytotheiruniquereceptors
andinitiatethesignallingcascade.
Thechallengetoveterinaryoncology
Activatingmutationsimpartinggain-of-functionto
Thereisgreatenthusiasmfordevelopingtargeted
tyrosinekinaseshavenowbeenrecognizedin
therapyforthetreatmentofhumancancerpatients
numerousmalignanciesandcompriseasteadily
andexcitementalsorunshighinveterinaryoncology.
asthe‘cancerkinome'thatcanbetargetedindividu-
lengesthatmayultimatelylimittheuseofnewstrat-
allyandcollectively.Theprototypicalcancertyrosine
egiesinveterinarycancerpatients.
kinaseistheillegitimatebcr-ablfusionproteinassoci-
Not theleastoftheseisthehighcostassociated
atedwithchronicmyelogenousleukaemiainhumans
withnewdrugdevelopment.Developmentcostsulti-
(Ben-Neriah et al.,1986).This kinase is constantly
matelypassedontoconsumersmaybeprohibitive
activatedandisresponsibleforuncontrolledtrigger-
forpetowners.Thisproblemiscomplicatedby the
ingofproliferationsignals.
relativepaucityofbiotechnologycompaniesdedi-
catedtodevelopmentofnewoncologydrugsforthe
Caninemastcell tumours:c-kitmutations
veterinarymarket.Given theirlikelyexpense,new
andKIT targeting
agentsmustmeetexpectationstomaintainenthusi-
asmforcontinueddevelopment.Thus,amodicumof
Targetingtyrosinekinases
cautioniswarrantedasweembarkonaneweraof
Imatinib,developedandvalidatedasaneffective
cancertreatment.
drug for humanchronicmyelogenousleukaemia
Furthermore,therehasalwaysbeena tendency
patients(Drukeret al.,2006),wasthefirsttyrosine
toextrapolatenewdevelopmentsforhumanhealth
kinaseinhibitortoenterclinicalpracticeandrepre-
directlyintoveterinarypractice.Whilechemothera-
sentedamilestone incancertherapy.Thisdrugcom-
peuticagentshaveforthemostpartbeenamenable
petes withadenosine triphosphate (ATP) for the
tothiswayof thinking,targetedagentsneed tobe
phosphorylation-bindingpocketinthebcr-ablkinase
92
Chapter9
Therapiesofthefuture
9.2
resultinexcessivestimulationwhen ligand（lig)intheextracellularenvironmentbindsandactivates(i.e.
phosphorylates,P)largenumbersofreceptorsthat inturnpromotecellgrowthandmalignantbehaviour(left).Alternatively
activatingmutationsintheregulatoryjuxtamembranedomain（red/whitestar,left）accountforautophosphorylationof the
canblockligandbindingbycompetitiveinhibitionandextinguishgenerationofstimulatorysignals(centre).Small
molecules(tyrosinekinaseinhibitors,TKi)thatcompetefortheATPbindingpocketinthereceptor'scytoplasmicdomain
domain,therebyinterruptingconstitutivesignalsorig-
Therevelationofligand-independentKITauto-
inatingfromthiskinase.lmatinibalsoprovedtobe
phosphorylationincaninemastcellc-kitmutantshas
effectiveinsuppressingseveralothermutatedtyro-
notonlyshedlightonthepathogenesisofcanine
sinekinases in human cancer,includingin gastro-
mastcellcancer,buthasalsolaid thefoundation
intestinal stromal tumours(GIST)(Dematteo etal.,
forrationallydesignedtargeteddrugtherapywith
2009).A mutation in canine chronicmyelogenous
tyrosinekinaseinhibitorsthatspecificallyblock
leukaemiacomparabletobcr-ablinhumanleukae-
KITphosphorylation.
miahasbeenrecognizedinveterinarymedicine，
suggesting that similar opportunitieswith tyrosine
Toceranib
kinaseinhibitorsareofemergingimportanceinvet-
Theattractivenessoftargetingc-kit incanineMCTs
erinaryoncology(BreenandModiano,2008).
wasfurthersubstantiatedbydemonstrationofacti-
To thisend,activating mutationsinthereceptor
vatedKITinvivoincanineMCTsandthecapacityof
tyrosinekinasec-kithavebeenextensivelyinvesti-
anoveltyrosinekinaseinhibitor,SU11654,toinhibit
gated inmalignantcaninemastcells.Sinceexpres-
KITphosphorylationinvivoin thetumour-bearing
sionof c-kitbymalignantcaninemastcellswasfirst
dogs(Pryeretal.,2003).
reported(Londonetal.,1996),arepeatablepattern
Coincidentwiththisstudy,aphaseItrialwascon-
ofmutationsinexons11and12ofcaninec-kit in
ductedindogswithvariousmalignancieswith
malignantmastcellshasbeendemonstrated
SU11654(London et al.,2003),which is an indo-
(Londonetal.,1999).Mutations comprisingrepeats
linonepurportedtoinhibitactivationofagroupof
ofsmallstretchesofDNA(internal tandemduplica-
structurallyrelatedreceptor tyrosinekinases,includ-
tions)withinthenegativeregulatorycodingregion
ingKiT,platelet-derivedgrowthfactorreceptor
ofthec-kitjuxtamembranedomainhavebeenmost
(PDGFR),vascularendothelialgrowthfactorreceptor
commonlyreported.c-kitjuxtamembranemutations
(VEGFR)andfibroblastgrowthfactorreceptor
confergain-of-functionactivityresultinginconstitu-
(FGFR),bycompetitive inhibitionof ATPbinding to
tiveKITphosphorylationintheabsenceofligand
eachreceptor'scatalyticdomainwithinthecytoplasm.
binding.AdditionalsitesofKITmutationassociated
Thistrialprovidedusefulcluesthattyrosine
withgain-of-functionhavebeendescribedinexons
kinaseinhibitortreatmentof dogswithMCTs,espe-
8and9incaninemastcelltumours(MCTs)(Letard
cially thosebearingthejuxtamembraneKiTmuta-
et al.,2008).KITactivation(i.e.phosphorylation)is
tion,canarresttumourgrowthandinduceclinically
anearlyeventinthepropagationofintracellular
meaningfulremission(i.e.9of 11dogs)at clinically
signalling thatculminatesinDNAreplicationand
achievabledoseswithonlymodest toxicity.Dogs
cell division.
withMCTslackingc-kitmutationsshowedalower
93
Chapter9Therapiesof thefuture
responserate(2of 11dogs).Inaddition,responses
Masitinibshouldprovideveterinaryoncologywith
ofmetastaticcarcinomaandsarcomaweredocu-
a uniqueperspectiveinthatitisoneoffew(perhaps
mentedinasmallnumberoftreateddogs,notably
theonly)tyrosinekinaseinhibitorstodatetobemar-
completeresolutionofpulmonarymetastases.
ketedbothforhumanandcaninecancerpatients.
Thepreclinical studiesofSU11654culminated in
Giventheimprovementintumourcontrol indogs
2009followingalargefieldtrialof thedrug（London
withMCTstreatedwithmasitinibasfirst-linetherapy.
etal.,2009),withthelaunchofPalladia（toceranib
phosphate，formerly knownas SU11654,Pfizer
tyrosinekinaseinhibitorswithwhichtotreatcanine
Animal Health).Thisproduct heralded a newera in
MCTsthatarenotcurablewithsurgeryalone.
veterinaryoncologyandrepresentsanothermile-
Furthermore,although masitinib'spatent claim is as
stone inhow(mastcell)cancerwill be treated in
aKIT inhibitor,developers of this drug have pre-
veterinaryoncology.
senteddatasupportingactivityofmasitinibagainst
Responsesofc-kitmutantnegative tumours
severalothertyrosinekinases,includingPDGFR.
thoughnotasrobustasmutants,hasbeenattributed
todrugeffectson thetumour microenvironment,
Future useofKITinhibitors
Anotherstudydocumentedabenefitofimatinibin
interruptionof VEGFR-2andPDGFR-β signallingby
the treatmentof canine MCTs(Isotani etal.,2008);
angiogenicendothelialcellsrecruitedinresponseto
and itspotential tocontrolmastocytosisinhuman
tumour stimuli.Alternative explanations couldbe
patientshasbeendescribed(Droogendijk et al.,
directinhibitionofsignallingtriggeredbyactivating
2006).Aswasseenwithmasitinibandtoceranib,
mutationsinexons8or9（Letardetal.,2008)that
responsesweregreaterindogswithKITmutations
werenotreportedaspartofthestudy.Theoverall
inexon11,thoughtheauthorsobservedobjective
biological response rate(i.e.completeresponders,
responsestoimatinibbytumourslackingKiTmuta-
partialresponders,stabledisease)was60%.
tionsinexon 11(Isotanietal.,2008).Taken together,
Withmoreclinicalxperienceitwilleintresting
abenefitofKITinhibitorsforthetreatmentofcanine
toseetherolefortoceranibinthemanagementof
MCTs has clearlybeenestablished,making future
caninecancerasitwilllikelyhavevalueinavariety
useof thesedrugsawelcomeadditiontothethera-
of tumours.Forexample,toceranibappearsactive
peutictoolboxformastcellcancerindogs.Hopefully,
againstcanineGiSTwhenjuxtamembranedomain
theseagentswillliveuptoexpectationsasmore
c-kit mutations are present (CA London,2009,per-
experienceisgainedwiththemeithersinglyorin
combinationwithchemotherapeuticagents.
sonalcommunication)andtheresultsofthephase1
trialsupportcontinued investigationofefficacyin
Felinemastcelltumours
caninesofttissuesarcoma andmammarycarcinoma.
Comparedwithcaninemastcell cancer,therearefar
Masitinib
fewerstudiesdocumentingKITjuxtamembrane
Masitinibmesylate,anothernewlyavailablecompeti-
mutationsinfelineMCTs.Anearlierstudydidnot
tiveinhibitorofKiT,hasshownefficacyinmediating
findactivatingc-kitmutations inmalignantfeline
mastcells comprising the neoplastic infiltratesof
biologicaleffectsthatslowedgrowthofcanineMCTs
excisedspleensfromcatswithsplenicmastocytosis
andimprovedsurvivaltimeofdogswithgradelland
Illtumours(Hahn et al.,2008).Its benefit to dogs
(Danketal.,2002).Nevertheless,a rolefortyrosine
kinaseinhibitorsintreatingfelinecancerislikelyand
withnon-resectabletumourshasbeendocumented:
ac-kitinternal tandemduplicationassociatedwith
dogswithMCTs expressingKITmutations lived
systemicmastcellcancerinacathasbeen
more thantwiceaslongasdidplacebo-treateddogs
described (Isotani et al.,2006).Seemingly thismuta-
bearingMCTswithKITmutations（417vs.242days)
tion,located within thefifthimmunoglobulin-like
whenmasitinibwasadministeredasfirst-linether-
domainofc-kit,inducedcellularactivation(andpro-
apy.Therewasasignificantprolongationinthetime
liferation)astheaffectedcatreportedlyexperienced
totumourprogressioncomparedwithplacebowhen
completeresolutionofclinicallydetectabletumourin
masitinibwasgiventodogswithMCTsastheinitial
response to treatmentwith imatinib(lsotani et al.,
treatment（175vs.78days)（Hahnetal.,2008).This
2006).Resultsof a smallphaseItrialof imatinibin
benefitwasobservedindependentlyofthemuta-
catswithvariousmalignanciesreportedlowtoxicity,
tional statusof KITamongst MCTs,suggesting,as
but theonecatwithmastcellcancerin thisreport
observedwithtoceranib，thatmasitinibimpactson
didnotrespondtotreatment(Lachowicz et al.,
thetumour'sextracellularmicroenvironment.
2005).TheroleofKITinhibitioninmanagement of
Masitinibhasreceivedapproval inEurope(bythe
felineMCTsawaitsfurtherclarificationbut,giventhe
EuropeanMedicinesAgency,Masivet,ABScience).
report by Isotani et al.(2006),it seems likely that
At thetimeof thiswriting,itisnearingapprovalinthe
somecatswillbenefitfromKITinhibitors.
United States(Kinavet,ABScience)foruse in dogs
with grade Il and Ill MCTs.The same drug isunder
Platelet-derivedgrowthfactor
developmentforvarioushumancancersaswell.For
receptor-beta(PDGFR-β)
example,masitinibexhibitedgreaterinvitroactivity
PDGFR-β,another receptor tyrosine kinase,struc-
andselectivitythanimatinibforhumanwild-type
turallyrelatedtoKIT,appearstobeinvolvedinthe
GISTaswellasGISTwithKITmutationsinthe
malignanttransformationoffelineinjectionsitesar-
juxtamembraneregion(Buietal.,2007).
coma (feline ISS).Inhibition of PDGFR-β signalling
94
Chapter9Therapiesofthefuture
by tyrosinekinase inhibitorsmayrepresentanovel
Cetuximab
treatmentoption for thismalignancy.Specifically,
Cetuximab(Erbitux,ImCloneSystemsIncorporated，
drugssuchasimatinib,toceranibandmasitinibare
alsoknownasC225)isahumanizedmurinelgG1
competitiveinhibitorsofATPbindingtotheactivation
monoclonalantibodythatbindstotheextracellular
sites ofthe splitreceptor tyrosinekinasefamily,
domainofhumanEGFR.Ithasbeenapprovedfor
whichincludesKIT,PDGFR-β,andVEGFR-2.
treatmentofhumanheadandneckSCCincombina-
Asmentionedearlier,oneproposedexplanation
tionwithradiotherapyforadvancedtumoursand asa
forclinicalimprovementofMCTsnegativeforactivat-
singleagentforincurablerecurrent/metastaticdis-
ingKITmutationsissuppressionofPDGFR-βsignal-
ease （Mehra et al.,2008;Harari et al.,2009).
linginangiogenicendothelialcellswithinthetumour
Importantly,itseffectiveness isindependentof muta-
microenvironmentbytyrosinekinaseinhibitors.
tionalstatusofEGFR.Thismaybedueinparttoan
PDGFR-βisa signallingmoleculewidelyexpressed
antibody-dependentcellularcytotoxicity(ADcC)
bymesenchymal cells (Heldin and Westermark,
mechanismmediatedbynaturalkillercellsbindingto
antibodyattachedtotheEGFR(Lopez-Albaiteroet
themalignantfibroblastscomprising thesarcoma
al.,2009).
(Hendrick,1999).The anti-PDGFR-β activity
of
Theauthorandcolleaguesexaminedbindingof
imatinibappearstoinhibit theconstitutivephospho-
cetuximabtoarchivedfelineoralSCCbiopsysam-
rylationofPDGFR-βinculturedfelineISScelllines
ples.Immunohistochemical stainingrevealedstrong
(Katayama etal.,2004).Furthermore,imatinibwas
bindingofcetuximabtothreeofthreeseparatefeline
capableof suppressing invitro growthof feline ISS,
oralSCCbiopsy samples（Figure9.3),indicating the
presumably
duetointerruptionofmitogenic
PDGFR-β signaltransduction;the effect wasbest
demonstratedwhenimatinibwascombinedwithtra-
ditional chemotherapeutic agents(i.e.doxorubicin,
carboplatin)(Katayama etal.,2004)giving clues to
itsoptimal usageinclinicallyaffectedcats.
Epidermalgrowthfactorreceptor(EGFR)
Opportunitiesaboundfordevelopingtyrosinekinase
inhibitorsforveterinarypatients.Targetingsignal
cancers;andasmoreabnormalitiesareidentifiedin
theseproteinsin cancer cells,expanded interest in
useofspecificallytargetedtyrosinekinaseinhibitors
canbeexpected.
cetuximab
As anexample,feline oral squamouscellcarci-
noma,themostcommonoralmalignancyin thecat,
remainsa highlyaggressiveinfitrativeneoplasm that
isnoteasilyeradicateddespiteradicalsurgicalinter-
ventionandradiationtherapy(Northrupetal.,2006;
Fideletal.,2007).TheidentificationofEGFR,another
receptortyrosinekinase,onfelineoralsquamouscell
carcinoma (SCC) biopsy samples (Looper et al,
2006),providesa compellingrationale toevaluate
inhibitorsofEGFRsignallinginthistumour.Inhumans
withheadandnecksquamouscellcarcinoma,the
tyrosinekinaseinhibitorerlotinib（Tarceva，Genen-
tech/OSIintheUS,Rocheelsewhere)hasshowneffi-
cacy inpreclinical studies(Chinnaiyan etal.,2005;
AhmedandCohen,2007;Thomasetal.,2007).
control
BecauseithasbeendifficulttodemonstrateEGFR
activatingmutationsinthesepatients(Lemos-
9.3
FelineoralSCCsexpressEGFR.Positively
Gonzalez etal.,2007),the role oftyrosine kinase
stainingfelineScCcellsfromtheoralcavity
inhibitorsinthemanagementofthiscancerisun-
appearbrown（left)afterbindingcetuximab,amonoclonal
antibodythatrecognizesEFGR.Anirrelevantantibodywas
certainsince thegreatesteffectof thesedrugsis
used onthecontrol tissue（right),followed bythereagents
usuallyseenintumourswithconstitutivekinase
neededtogeneratethebrowncolour(immunoperoxidase
activationsecondary tomutation.However,
over-
methodology).Control tissueswerecounterstainedwith
expressionofEGFRinhumanheadandneckSCC
haematoxylin.WidespreadEGFRexpressionbyfelineoral
alsoleadstooncogenesisduetoligandhyperstimu-
SCC,demonstratedbystrongcetuximabbinding,
lationofreceptorsthattriggermitogenicresponses
suggestsapossibleroleforcetuximabinthetreatmentof
catswiththismalignancy.Humanswithoral SCCare
(Sun etal.,2009).As shown inFigure9.2,monoclonal
routinelytreatedwiththecombinationofcetuximaband
antibodiesthatcompetewithligandforbindingtothe
radiationtherapy.(Immunohistochemistrykindlyprovided
extracellulardomainofreceptortyrosinekinases
byEricArmstronginthelaboratory of DrPaul Harari,
provide analternative strategy to inhibit signalling.
UniversityofWisconsin-Madison,Madison,Wisconsin)
95
Chapter9Therapiesofthefuture
potential tousethisantibodyincats.Whetheranti-
acommonbeliefthat‘theimmunesystemcanbe
bodybindingissufficienttoblockEGFbinding is
trainedtorecognizecancerasbeingsomethingfor-
unknownandtheabilityoffelineFcreceptorstotrig-
eignand dangerous'(Wolchok,2007).
gercytotoxicresponsesinnaturalkillercellsbybind-
Theoverridingchallengein‘training'theimmune
ingahumanFcendpresentincetuximabawaits
systemtorecognizeandmountanti-tumour
clarification.Caninenaturalkiller cells mediate
responsesistheneedtobreakimmunetolerance.
potentADcCwithachimerized antibody(i.e.human
Furthermore,itisnotenoughfortheimmunesystem
Fcend)(Helfand etal.,1994)and soperhaps feline
merelytorecognizetumourcells;theimmune
cells can too.
responseneedstotriggercytotoxicityofclinicalsig-
nificancetobeofvaluetocancerpatients.
Hepatocytegrowthfactor(HGF)andc-Met
During the ontogenyof theT-cellrepertoire,primi-
Itislikelythattyrosinekinaseinhibitorswillbeused
tiveTlymphocytesthatexhibit thecapacitytorecog-
forothertumoursinveterinaryoncologyasmoreof
nizeselfantigensarecarefullydeletedtoprevent
theintricaciesofsignal transductionandtheproto-
autoimmunetissuedestruction.Withtheexceptionof
oncogenes that encodesignallingmolecules are
someviral-inducedtumours,cancercellsareusually
revealed.In the future,therewill likelybeeffortsto
immunologicallyindistinguishablefromnormaltissue
inhibit signalling throughc-Met,a receptortyrosine
kinaseactivatedbyhepatocytegrowthfactor (HGF)
bindingligandthathasbeenimplicatedinhuman
Malignantcells,however,mayover-expressantigens
head andneckSCC(Seiwertetal.,2009)andvari-
compared with normalcounterparts,，providinga
ousothercarcinomas.Afunctionalgermlinemuta-
potential therapeuticwindowforimmuneintervention.
tionincanineMetthathasbeendescribedin
Theimmunesystemisbasicallycomposedof
Rottweilersmaycontributetotumorigenesisinthis
immune cells,antibodies,antigens and regulators
breed(Liaoetal.,2006),providing arationale to
andsostrategiestomanipulateimmuneresponses
exploreMettargetinginthisbreed.Thepotentialfora
needtowork throughthesecompartments.Just
Met/HGFautophosphorylationloophasbeenshown
whatarethemosteffectiveapproachesisstill an
foranumberofculturedcaninecancercell linesand
unansweredquestion.Nosimplemeansforidentifi-
a tyrosinekinaseinhibitorpartiallyblockedphospho-
cationofantigensthatcanbetargetedincancer
rylationofkeysignallingmolecules,functionandpro-
cellshasemerged.Whichimmunecellsshouldbe
liferationofosteosarcomaandmelanomacellsin
stimulated,howtoprovidestimulatory signals,and
vitro(Liaoetal.,2005).The author's laboratoryhas
howimmunostimulatoryfactorsarebestdelivered
beeninterestedintheroleoftyrosinekinaseabnor-
remainsomeofthemajorquestionsincancer
malitiesincaninehaemangiosarcoma;preliminary
immunotherapy.Despite thechallenges,continually
datasuggestthat therewillbeanopportunityto
expandingknowledgeoftheworkingsoftheimmune
impactonthiscancerwithtyrosinekinaseinhibitors.
systempresentnovelopportunitiesforimmuneinter-
vention.Whiletheimmunesystemcanmediatepow-
Anoteofcaution
erfulresponsestocancer,responsesarelimitedby
thefinitenatureoftheimmunesystem-implying
hasyettogainextensiveexperiencewithtyrosine
thatimmunotherapymaybemosteffectiveinthe
kinaseinhibitortherapeutics.Whilethepromiseof this
minimalresidualdiseasesetting.
approachisobvious,theotherpartofthestorydeals
withdevelopmentofresistance.Thoughstunning
Cancervaccines
improvementswithtyrosinekinaseinhibitorstrategies
Whereas
earlier
immunotherapy
approaches
havebeenreported inhumanswithleukaemia,head
focusedonprovidingmoreT-cellhelpintheformof
andneck ScC andbreast cancer,to namea few,
exogenouslyadministeredcytokinesornon-specific
drugresistanceisoftenseenwithchronictreatment.
activatorsoftumoricidalmacrophages,thereisnow
Thisreflectstheaddictionofcancercellstoutilize
moreemphasisondevelopingcancer‘vaccines'
alternativekinasesignallingpathwaysinpromoting
thathelp theimmunesystemtorecognize tumour
cellgrowth and survival (Benavente etal.,2009).
cellsin theface ofdisease.Traditionalvaccines
Overcomingresistancetotyrosinekinaseinhibitors
usedinveterinarymedicineareintendedtoprevent
willbeoneof thebiggestchallengesfortheseagents
infectiousdiseasebystimulatingimmuneresponses
tomeet theirfullpotential.
toimmunizingantigensassociatedwithapathogen
priortoinfection.Cancervaccinesdifferinthatthey
aregivenafteracancerdiagnosis,buttheyaresimi-
Immunotherapy
larinregardtothegoalofelicitingaspecific
immuneresponse.
Thedreamofenlistingthepatient'simmunesystem
tohelptofightcancerhasnevergoneaway.
Antigenpresentation
Harnessingthebody'sown immunedefencesfor
Antigenpresentationinitiatestheimmuneresponse
cancercellsurveillanceandannihilationisthemost
andanumberofnovelapproachesdesignedtoiso-
targetedformoftherapy.Inadditiontobeinghighly
late,activate and prime antigen-presenting cells
selectivefortheirtargets,immunecellscirculateand
(APCs)（e.g.dendritic cells,B-cells)with tumouranti-
arelong-lived;thusthesustained interestinfocusing
genhavebeendescribedintheveterinaryliterature
theseresponsesagainstcancercells.Thereremains
(Figure 9.4).
96
Chapter9Therapiesof thefuture
Strategy
Goal
Method
References
Vaccine
Provide tumourantigen
Allotumourcell vaccine
U'Ren et al.(2007)
Xenotumourvaccine（melanoma,cDNA)
Bergman et al.(2003)
Celltherapy
Antigen-presentingcells
Adeno-DCmelanoma(xenoantigen-loaded
Gyorffy et al.(2005)
(dendritic cells(DCs),
antigen-presenting cells)
B-lymphocytes)
ExvivoDCculture
Catchpole etal.(2002);Wang et al.(2007)
DC-allotumourfusion
Bird et al.(2008)
TumourRNA-transfectedCD40-activated
Mason et al.(2008)
B-cells
Humoral
Target immunodominant
Single-chainfragmentvariabletargeting
Mason（2009,personal communication）
tumourantigens
systems(haemangiosarcoma)
Reverse endogenous
Depleteregulatory
Metronomicchemotherapy
Elmslie et al.(2008)
suppressed anti-tumour
T-lymphocytes(Tregs)
CD25+CD4FoxP3+T-lymphocytedepletion
immunity
Biller etal(2007);ONeiletal.(2009)
9.4
Immuneresponses triggered byAPCsoffer the
dog'smelanomacells.Thevaccinecanbeeffective
potentialofaholistic,physiologicalimmune
againstmetastasiswhengiventoappropriate-stage
responsethatcanengageavarietyofeffectormech-
dogswithoralmelanoma;completelocalcontrolof
anisms.RecruitingAPCsasa meanstoinduce anti-
oralmalignantmelanomaisrecommendedbefore
tumourresponseofferspromiseandisanareaof
vaccineadministration.
greatinterestinhumancancerimmunotherapy.
Thisisasophisticatedapproachtomelanoma
One distinctdrawbackto thistypeofcell therapy
immunotherapyinthedog,butit isonlyabeginning
is theneed togeneratelargenumbersofautologous
becausenotalldogsbenefitfromit(eventhosewith
dendriticorotherAPCsinthelaboratory,whichcan
theappropriateclinical stagemelanoma)and the
be laborious,time consuming and expensive.The
needtoobtainlocalcontrolfirstsignificantlyaddsto
approachesofBirdetal.(2008)andMasonet al.
costandmorbidity.Perhapsfuturemodificationsof
(2008)arenoteworthy fortheiruse ofallogeneic
theapproachmayalsocontainimmunostimulatory
establishedcellinesderivedfrommalignantAPCsso
genesthatcanprovideadditionalhelptoresponding
thattheproblemofautologouscellexpansionwas
dendritic cells and T-cells,enhancing the anti-
avoided.Masonetal.actuallyusedagenetically
melanomaimmuneresponse.
modified xenogeneic(human)B-cell line topresent
antigen.Bothstudiesdocumentedinvivogeneration
RegulatoryT-cells(Tregs)
of tumourantigen-specificT-cell immuneresponsesin
Therecentreportofincreasednumbersofregula-
dogs(normal and tumour-bearing)followingimmuni-
toryT-cells(Tregs)in canine cancerpatients(O'Neill
zationwiththerespectiveAPCsthathadbeenmodi-
etal.,2009)promises tobeadiscovery thatwill
fiedtopresenttumour antigen.While theseresults
areencouraging,demonstrationofinvivoanti-tumour
immunomodulatory,ostensiblypromotingself-toler-
activityorimprovedsurvivaltimeintumour-bearing
ancebyactingasnegativeregulatorsofimmune
dogsgivenAPCtherapyhasyettobereported.
responses and inflammation (Lu and Rudensky,
2009).Increased numbers of Tregs in thetumour
Melanomavaccine
microenvironmentcanbedeleteriousbyhindering
In2007,thecommercialreleaseofacDNAmela-
developmentofaneffectiveanti-tumourimmune
nomavaccinefordogsmarkedanewerainveteri-
response(BeyerandSchultze2009).
naryimmuno-oncology.Thisisamilestonebecauseit
TherapeutictargetingofTregsprovidesanoppor-
wasthefirstlicensedcancervaccineforanyspecies
tunitytosignificantlyimprovetheeffectivenessof
andemploysacutting-edgegenetransferstrategy
anti-tumourimmune
responses
(Banhamand
tostimulateanimmuneresponse.Thisisaxeno-
Pulford,2009;Zhang et al.,2009).This effect was
vaccine,becauseit contains cDNA that codesfor
showninseveralanimalmodelsthatdemonstrated
human tyrosinase,anenzymepresentinpigmented
enhancementoftheTh1cell-mediatedanti-tumour
cellsthatisneededformelaninsynthesis.Expression
immuneresponseandimprovedsurvival timein
ofhumantyrosinasebydogcellsproducesaprotein
foreigntothecanineimmunesystemthatcanstim-
(Nair et al.,2007;Banham and Pulford,2009).As
moreinformationaboutTregsinanimalsbecomes
available,strategiestodepletethesecellsinveteri-
havethepotentialtoelicitabystandereffectagainst
narycancerpatientsseemlikely，asthisisanovel
endogenouscaninetyrosinaseassociatedwiththe
andpromisingidea.
97
Chapter9
Therapiesof thefuture
Photodynamic therapy
inconsequential,photodynamictherapymayoneday
findaroleasanalternativeforradiotherapyforsome
Photodynamic therapy has beenon the fringesof
cancersinveterinaryoncology.
veterinaryoncologyfor20years.Itisaveryspecial-
izedformofcancertreatmentthatemploysboth
physical (i.e.laser energy) and chemical means(i.e.
Other novel approaches
photosensitizingdrugs)toelicit tumoricidaleffects.
Thespecializednatureofthismodalityhaslikelycon-
Therearemanyotherinterestingnovelapproaches
tributedtoitslimitedaccessibilityandintermittent
underinvestigation,toomanytoelaborateherebut
advancesinveterinarymedicine.Yet,intherightsitu-
someareattractingattentionforveterinaryoncology
ations,resultscanbedramaticforsuperficialtumours
andseveralarementionedhereforcompleteness.
thatarereadilyaccessibletolaserirradiation.
Theyrepresentabroadrangeofstrategies,each
Inphotodynamic therapy,aphotosensitizingchemi-
intendedtotakeadvantageofapotentiallyvulnera-
bletarget incancercellsortocorrectaknownonco-
isadministered(intravenously,orally,ortopically)and
genictransformation.
laserlightofanappropriatewavelengththatisexcita-
torytothephotosensitizerisdirectedontothetumour.
Mammaliantargetofrapamycin(mToR)
Growingneoplasticcellsaccumulatemoreporphyrins
Figure 9.1 (see earlier) is a greatly simplified sche-
thannormal tissue，providingatherapeuticwindow.
maticofsomesignallingpathwaysusedbycellsfor
Porphyrinexcitationbylaserlightgeneratesreactive
survival,growth,and proliferation.Ofconsiderable
oxygenspeciesandfreeradicalsthatdamageintracel-
interestasatargetisthePI3kinase/Akt/mTORaxis.
lularorganellesand triggersapoptosis.Italsoinduces
Thisisacomplexpathwaythatinteractswithother
anti-angiogenic
and
immunomodulatory
effects
signallingcascadesandisimportantforcellularregu-
(Ortner,2009).Issues pertaining to optimizing photo-
lationofgrowthandmetabolism.Thepathwayisacti-
sensitizationagents,routeofphotosensitizeradminis-
vatedinavarietyofcancers.InhibitorsofmTOR
tration,depthofpenetrationoflaserenergy,timingof
(mammaliantargetofrapamycin)areinvariousphase
laserexcitationandaccesstotissuepresentthe
I/lltrialsforvarioushumancancers.Severalreportsin
importantchallengestodevelopmentof thismodality.
theveterinaryliteraturesuggestthattargetingmTOR
Superficial tumours,especiallythose of theskin,
maybeimportantinsomecaninecancers(Gordonet
obviouslylendthemselvesmorereadilytophoto-
al.,2008;Kent et al.,2009).Given the association of
thePI3kinase/Akt/mTORpathwaywithsomany
irradiation.Incatswithsolar-inducedSCCofthe
humancancersanditsapparentinvolvementin
nasal planum,for example,responses have been
canine cancer,mTORtargeting(aswellasPI3kinase
impressivealthoughrelapsesarecommon,probably
andAkttargeting)appearstoofferanimportant
duetoinadequacyofexposureofdeeplyseated
opportunityfordevelopmentofneweffectivetherapies
tumourcellstosurfacelasertreatment.Onereport
inveterinaryoncologyandbearsfollowing.
indicatedaremarkable96%responserateofcats
withnasalplanumSCCtophotodynamictherapyand
Histonedeacetylase
mostwereconsideredcompleteclinicalremissions
Interest in histone deacetylase(HDAC)inhibitors in
(Bexfield etal.,2008).Earlyrelapseswereaproblem,
veterinarymedicinewassparkedfollowingacase
however,asthemedianremissiontimewasreported
reportoflong-termsurvivalofadogwithsplenic
tobe 157days.Highly invasive tumours arereport-
haemangiosarcomatreatedwiththeHDACinhibitor
edlyfarlessresponsive(Ferreiraetal.,2009).Newer
suberoylanilidehydroxamicacid(SAHA,alsoknown
photosensitizingagentsmayprovidebetterresults
asvorinostat,Zolinza)(Cohen et al.,2004).Histones
(Buchholz et al.,2007).
areintegraltothesupercoilingofDNAandacetyl
Thereisincreasing interestintheuseofphoto-
groupsonhistoneshelptheDNAwrappedaround
dynamictherapyfortumoursthatmayrequiresurgical
themtobeaccessibletotranscriptionfactorsand
accessfordirectingthelaserlightontothetumour.
DNAreadingenzymes;decreasedacetylationresults
For example,severalrecentreportssupport theuse
inDNAthatisoverlywoundandcannotuncoiltobe
ofintraoperativephotodynamictherapyfortreatment
read.Excessive,unregulatedhistonedeacetylationin
of thecanineprostate(Lucroy etal.,2003a;Huanget
cancercellshinderstranscriptionof importantregula-
al.,2005;Moore etal.,2008),and thepotential for
torygenes,someofwhicharethoughttocodefor
treatmentofcaninebladdercancerhasalsoattracted
proteinsthatinhibit cellgrowth(i.e.tumour suppres-
attention(Lucroy et al.,2003b).Several investigators
sor genes).Development of HDACinhibitors contin-
reportedpositiveresultsusingphotodynamictherapy
uestobeapriorityinhumanoncology，especially
for thetreatmentofcaninenasaltumours(Lucroyet
sincevorinostatwasapprovedfortreatment
tof
al.,2003c;Osakiet al.,2009).
humancutaneousT-celllymphomain2007(Mannet
Astheveterinaryprofessiongainsmoreexperi-
al,2007).Preclinical studies in the dog suggest that
encewithphotodynamictherapy,itisanichemodal-
HDACinhibitorsmaybeuseful invariouscancers
itythatmayevolveintoavaluableadjunctto
(Kisseberth etal.,2008).
resectabletumoursthatcannotbeirradiatedorman-
Angiogenesis
agedeffectivelybyothermeans.Althoughthecosts
Angiogenesisistheformationofnewbloodvessels
of laserinstrumentationandphotosensitizersarenot
fromexistingonesanditsinhibitionisagoalof
98
Chapter9Therapiesof thefuture
contemporarycancer therapy.Tumourcellsplayan
Impressiveresultswerereportedindogswithoral
activeroleinprovidingthestimulithatmature
melanomagivenFasLbyintratumoralinjection
endothelialcellsrequiretobecomemitogenically
（Bianco et al.,2003).The convenience of direct
active andgenerate tumourneovasculature.While
injection intoaccessible tumours is attractive,but
somedrugsarespecificallydevelopedtoinhibitangio-
noveldeliverymethods,suchasuseofadenovirus,
genesis as their primary function,others mediate
couldextendutilityof the concept.Kolluriet al.
anti-angiogeniceffectsincombinationwithadditional
(2008)described thepotentialtouseaderivativeof
activities.Forexample,HDACinhibitorshave shown
the anti-apoptoticprotein,Bcl-2,to turn Bcl-2into a
anti-angiogenicactivitybyalteringpatternsofgene
proapoptotictrigger.Converting apowerfulanti-
expression to favour an anti-angiogenic effect(Liang
apoptotic protein suchas Bcl-2,considered the
etal.,2006).Likewise,receptor tyrosine kinase
antidote toapoptosis'(Hockenbery etal.,1991),into
inhibitorsreportedlymediateanti-angiogeniceffects
acellulardeathtriggerisahighlyinnovativeconcept,
bysuppressingPDGFRandVEGFRsignal trans-
giventhatmanytumoursensuretheirlongevityby
ductionthatisstimulatoryto angiogenesis.Thereare
upregulation ofBcl-2.
alsobeginning tobestudiesinveterinarymedicineof
agentsspecificallydevelopedforanti-angiogenic
activity,suchasthrombospondinanalogues(Rusket
Conclusion
al.,2006a,b)
Advancesinmolecularbiology,immunologyandcel-
Transcriptionalgenesilencing
lulartechniqueshaveresultedinrapidproliferationof
Transcriptional gene silencing due toDNA hyper-
potentialtargetsforcancertherapy.Thewillingness
methylationhasemergedasanimportanttargetin
ofpharmaceuticalcompaniestodevelopsomenovel
drugconceptsintoclinicallyavailablemedicinesfor
thetreatmentofcancerinpetanimalsisagiantstep
certainDNAnucleotides,e.g.methylation
of
forwardforveterinaryoncology.Despiteexcitingpre-
cytosines,that areotherwise present inanun-
clinicaldata,validationofnewagentsmustcome
mutatedDNAsequencecanresultingenesilencing
fromthoughtfullydesignedclinicaltrialsinveterinary
andcanbeanimportantcauseofcancer.Asmore is
cancerpatients.In thefuture,we canexpect towit-
learned about this,correcting transforming epi-
nessavailabilityofnotonlymoredrugsagainstvali-
geneticeventsincancer,suchasthatdocumented
incanine lymphoma(Bryanet al.,2008)will likely
discoveriesthattodaycanonlybeimagined.
becomeanimportantfocusoffuture therapy.
Heatshockproteins
Referencesandfurtherreading
Heatshockproteins(molecularchaperones thatpro-
Ahmed SM and Cohen EE (2007) Treatment of squamous cell
tectandshuttlevariouscellularproteinswithinthe
carcinomaofthe headandneckin themetastaticandrefractory
cell)havebeenrecognizedasvulnerabletargetsin
malignancy.Incapacitatingheatshockproteinscan
molecule epidermalgrowthfactorreceptor kinase inhibitors.
CurrentCancerDrugTargets7,666-673
havearippleeffectandcanbeameanstosuppress
Banham AH andPulfordK(2009)Therapeutic targeting ofFOXP3-
functionoftransportedclientproteinsimportantin
positiveregulatoryT cells usinga FOxP3peptidevaccine
WO2008081581.ExpertOpiniononTherapeuticPatents191023
cancer.Forexample,some oncogenicmutantforms
ofKITinmalignant caninemastcells that are
1028
BeattyGLandVonderheideRH(2008)Telomeraseasauniversaltumor
resistanttotyrosinekinase inhibitorscanbesup-
antigenforcancervaccinesExpertReviewofVaccines7,881-887
Ben-NeriahY.Daley GQ,Mes-Masson AM et al.(1986) The chronic
pressedbytargetingaKiT-associatedheatshock
myelogenousleukemia-specificP210proteinistheproductof the
protein,Hsp90,thatresultsinproteasomal degrada-
bcr/ablhybridgene.Science233.212-214
tionof the oncogenicKITclientprotein,causing cell
BenaventeSHuangSArmstrongEAetal.(009）Establishmentand
characterization ofamodel of acquiredresistance toepidermal
growth inhibitionand apoptosis(Linet al.,2008).
growthfactorreceptor targetingagents
inhuman cancer cells.
Recentinvitrostudiesofcanineosteosarcoma
ClinicalCancerResearch15,1585-1592
demonstratedeffectivenessofaheatshockprotein
Bergman PJ,Camps-Palau MA,McKnight, JA et al.（2006)
DevelopmentofaxenogeneicDNAvaccineprogramforcanine
inhibitoragainstcanineosteosarcomagrowthandit
malignantmelanoma at theAnimal Medical Center.Vaccine24,
washighlyeffectiveincausingtumourregressionin
4582-4585
BergmanPJ,McKnightJ,NovosadAetal.(2003)Long-term survivalof
a canineosteosarcomaxenograftmodel(McCleese
dogswithadvancedmalignant melanoma afterDNAvaccination
et al.,2009).Thisfieldisrapidly growing inhuman
withxenogeneichuman tyrosinase:aphaseItrial.ClinicalCancer
oncologyandislikelytotakeonmoreimportancein
BexfieldNH,StellAJ,GearRNetal.(2008)Photodynamictherapyof
veterinaryoncology.
superficial nasal planum squamous cellcarcinomas in cats:55
cases.JournalofVeterinaryInternalMedicine22,1385-1389
Apoptosis
BeyerMandSchultzeJL(2009)RegulatoryTcells:majorplayersinthe
tumormicroenvironment.Current Pharmaceutical Design 15,
Onefinalinterestingideaworthmentioningis the
1879-1892
developmentofapproachesthatdirectlyserveas
Bianco SR,SunJ,Fosmire SPetal.(2003）Enhancing antimelanoma
apoptoticcelltriggers.Whileapoptosisisaterminal
immuneresponses through apoptosis.Cancer Gene Therapy 10,
726-736
eventinmanycancerstrategies,severalarebeing
BillerBJ,ElmslieRE,BurnettRCet al.(2007) UseofFoxP3expression
examinedforthecapacitytodirectlyactivatecellular
toidentifyregulatoryTcellsinhealthy dogs anddogswithcancer.
VeterinarylmmunologyandImmunopathology116.68-78
deathdomainssuchasthattriggeredbytheinter-
Bird RC,Deinnocentes P,LenzSet al.(2008)An allogeneic hybrid-cell
actionofFas ligand(FasL)with endogenous Fas.
fusionvaccineagainstcaninemammarycancerVeterinary
99
Chapter9
Therapiesofthefuture
Immunologyandlmmunopathology123.289-304
HuangZ,Chen Q,LuckDetal.(2005)Studies of avascular-acting
BreenMandModianoJF(2008）Evolutionarilyconservedcytogenetic
photosensitizer,Pd-bacteriopheophorbide （Tookad）.in normal
canine prostateandspontaneouscanineprostate cancer.Lasersin
and hisbestfriend sharemore than companionship.Chromosome
SurgeryandMedicine36,390-397
Research16,145-154
Impellizeri JA,Howell K, McKeever KP et al. (2006) The role of
BryanJN,TaylorKH,HenryCJetal.(2008）DNAmethylationincancer:
rituximabin the treatmentofcanine lymphoma:anexvivo
techniquesandpreliminaryevidenceofhypermethylationincanine
evaluaton.Vrinaryourna1755558
lymphoma.CancerTherapy6（A-2),137-148
IsotaniM,IshidaN,TominagaMetal.(2008）Effectof tyrosinekinase
BuchholzJ,Wergin M,Walt Hetal.(2007）Photodynamic therapy of
felinecutaneoussquamous cellcarcinoma usinganewly
ofVeterinaryIntrnalMedicine22,985-988
developedliposomalphotosensitizer:preliminaryresults
IsotaniMTamuraKYagiharaHetal.(2006）Idntificationofac-kitxon
8internaltandemduplicationinafelinemastcelltumorcaseandits
Medicine21,770-775
Bui BN,BlayJ,DuffaudFetal.(2007)Preliminaryefficacyandsafety
Veterinarylmmunologyandlmmunopathology114,168-172
resultsofMasitinibadministered,front linein patients with
Jubala CM,WojcieszynJW.ValliVEetal.(2005)CD20expressionin
advancedGIST.AphaselIstudy.JournalofClinicalOncology
normal canine B cells and in caninenon-Hodgkin lymphoma.
25(18S),10025
VeterinaryPathology42.468-476
Cai WandChenX(2006)Anti-angiogeniccancer therapy based on
KatayamaR,HuelsmeyerMKMarrAKetal.(2004）Imatinibmesylate
integrinalpha-vbeta-3antagonism.AnticancerAgentsinMedicinal
inhibitsplatelet-derivedgrowthfactoractivityandincreases
Chemistry6,407-428
chemosensitivityin felinevaccine-associatedsarcoma.Cancer
Catchpole B,StellAJ,and Dobson JM(2002) Generation of blood-
ChemotherapyandPharmacology54,25-33
deriveddendriticcellsin dogswithoralmalignant melanoma.
Kent MS,Collins CJ and Ye F（2009)Activation of the AKT and
JournalfComparativePathology126238-4
mammaliantargetofrapamycinpathwaysandtheinhibitoryeffects
Chinnaiyan P,Huang S,Vallabhaneni Getal.(2005） Mechanisms of
ofrapamycinon thosepathwaysin caninemalignantmelanoma
enhancedradiationresponsefollowingepidermalgrowthfactor
cell lines.AmericanJournalofVeterinaryResearch70,263-269
receptor signalinginhibition by erlotinib（Tarceva）.Cancer
KisseberthWC,MurahariS,LondonCAtal.(2008)Evaluationf the
Research653328-3335
effects ofhistone deacetylase inhibitors on cells from canine
Cohen LA,Powers B,Amin S et al.(2004)Treatment of canine
cancercell lines.AmericanJournalofVeterinaryResearch69,
haemangiosarcoma with
suberoylanilidehydroxamicacid,a
938-945
histone deacetylase
inhibitorVeterinaryandComparative
Kolluri SK,ZhuX,ZhouXet al.(2008)A shortNur77-derived peptide
Oncology2,243-248
convertsBc-2fromaprotectortoakiller.CancerCell14,285-298
DankG,ChienMB,andLondonCA(2002）Activatingmutationsin the
Lachowicz JL,Post GS,and Brodsky E(2005)A phase Iclinical trial
catalyticor juxtamembrane domainofc-kit insplenicmastcell
tumorsofcats.AmericanJournalofVeterinaryResearch63.1129-
JournalofVeterinaryInternalMedicine19.860-864
1133
Lemos-GonzalezYPaezdelaCadenaM,Rodriguez-BerrocalFJtal.
Dematteo RP, Ballman KV,Antonescu CR et al.(2009)Adjuvant
(2007）AbsenceofactivatingmutationsintheEGFRkinase domain
imatinibmesylate
afterresectionoflocalised,primary
inSpanish headandneck cancerpatients.Tumour Biology 28,
gastrointestinal stromal tumour:arandomised,double-blind，
273-279
placebo-controlled trial.Lancet373,1097-1104
LetardS,angHanssensKetal.(08）Gain-offunctionmutationsn
DickersonEB,AkhtarN,SteinbergHetal.（2004)Enhancementof the
theextracellulardomainofKiTarecommonincaninemastcell
antiangiogenicactivityofinterleukin-12bypeptidetargeteddelivery
tumors.MolecularCancerResearch6,1137-1145
of the cytokine toalpha-vbeta-3integrin.MolecularCancer
Liang D,KongXand Sang N(2006)Effectsofhistone deacetylase
Research2,663-673
inhibitorsonHIF-1.CellCycle5,2430-2435
Droogendijk HJ,Kluin-Nelemans HJ,van Doormaal JJ et al.(2006)
Liao AT,McMahon M and London C (2005）Characterization,
Imatinibmesylateinthetreatmentof systemicmastocytosis:a
expressionand function ofc-Metincanine spontaneouscancers.
phaselltrial.Cancer107,345-351
VeterinaryandComparativeOncology36172
Druker BJ,Guilhot F,OBrien SGet al.(2006)Five-year follow-up of
LiaoAT,McMahon Mand LondonCA(2006)Identificationof a novel
patientsreceivingimatinibforchronicmyeloidleukemia.New
germlineMETmutationindogs.AnimalGenetics37,248-252
EnglandJournalofMedicine355,2408-2417
LinTY,BearM,DuZetal.(2008）Thenovel HSP90inhibitorSTA-9090
Elmslie RE,GlawePand DowSW(2008)Metronomic therapy with
cyclophosphamideandpiroxicameffectivelydelaystumor
mastcelltumors.ExperimentalHematology36,1266-1277
recurrence in dogs with incompletelyresected soft tissue
London CA,Galli SJ,Yuuki Tet al.(1999)Spontaneous canine mast
sarcomas.JournalofVeterinaryInternalMedicine22,1373-1379
cell tumorsexpress tandemduplicationsintheproto-oncogene
FerreiraI,Rahal SC,Rocha NSetal.(2009)Hematoporphyrin-based
c-kit.ExperimentalHematology27,689-697
photodynamictherapyfor cutaneoussquamouscellcarcinoma in
London CA,Hannah AL,Zadovoskaya Retal.(2003)Phase|dose-
cats.VeterinaryDermatology20,174-178
escalatingstudyofSu11654,asmallmoleculereceptortyrosine
Fidel JL,Sellon RK.Houston RKet al.(2007)Anine-day accelerated
kinaseinhibitor,indogswithspontaneousmalignancies.Clinical
radiationprotocolforfelinesquamouscellcarcinoma.Veterinary
CancerResearch9,2755-2768
RadiologyandUItrasound48482-485
LondonCA,KisseberthWC,GalliSJetal.（1996）Expressionof stem
Gordon IK,YeF,andKent MS (2008)Evaluation of themammalian
cell factor receptor （c-kit) by the malignant mast cells from
spontaneouscanine mast cell tumours.JournalofComparative
expressionandcellularproliferationinosteosarcomacellsfrom
Pathology115,399-414
dogs.AmericanJournalofVeterinaryResearch69,1079-1084
London C,Malpas PB,Wood-Follis SL et al. (2009) Multi-center,
Gyorfy S.Rodriguez-Lecompte JC,Woods JP et al.(2005)Bone
placebo-controlled,double-blind,
randomizedstudyoforal
marrow-deriveddendriticcellvaccinationofdogswithnaturally
toceranib phosphate （SU11654),a receptor tyrosine kinase
occurringmelanomabyusinghuman gp100 antigen.Journal of
inhibitor,for thetreatmentof dogswithrecurrent（eitherlocalor
VeterinaryInternalMedicine19,56-63
distant)mastcelltumorfollowingsurgicalexcision.ClinicalCancer
HahnKA,OgilvieG,RuskTetal.(2008）Masitinibissafeandeffective
Research15.3856-3865
forthetreatmentofcaninemastcelltumors.JournalofVeterinary
LooperJS,MalarkeyDE,RuslanderDetal.(2006)Epidermal growth
InternalMedicine22,1301-1309
factorreceptorexpressioninfelineoralsquamouscellcarcinomas.
Harari PM,Wheeler DL and Grandis JR (2009) Molecular target
VeterinaryandComparativeOncology4,33-40
approaches in headandneck cancer:epidermal growth factor
Lopez-AlbaiteroA,LeeSC,MorganSetal.(2009）Roleofpolymorphic
FcgammareceptorlllaandEGFRexpressionlevelincetuximab
HeldinCHandWestermarkB（1999)Mechanismofactionandinvivo
mediatedNKcelldependentinvitrocytotoxicityofheadandneck
roleofplatelet-derived growthfactor.PhysiologicalReviews79,
squamous
cell
carcinoma
cells.
Cancer
Immunology
1283-1316
Immunotherapy58,1853-1862
HelfandSC,Soergel SA.DonnerRLetal.(1994）Potential to involve
LuLFand RudenskyA(2009)Molecularorchestrationof differentiation
multiple effector cellswithhumanrecombinant interleukin-2and
andfunctionofregulatoryTcells.GenesandDevelopment23
antiganglioside monoclonalantibodies in a canine malignant
1270-1282
melanomaimmunotherapymodel.JournalofImmunotherapywith
Lucroy MD,Bowles MH,Higbee RG et al.(2003a)Photodynamic
EmphasisonTumorlmmunology16,188-197
therapyforprostaticcarcinoma inadog.JournalofVeterinary
Hendrick MJ (1999)Feline vaccine-associated sarcomas.Cancer
InternalMedicine17,235-237
Investigation17,273-277
LucroyMD,RidgwayTD,PeavyGMetal.(2003b）Preclinicalevaluation
Hockenbery DM，ZutterM,Hickey Wet al.（1991)BCL2protein is
of5-aminolevulinicacid-basedphotodynamic therapy forcanine
topographicallyrestrictedintissuescharacterizedbyapoptoticcell
transitionalcellcarcinoma.VeterinaryandComparativeOncology
death.Proceedingsof theNationalAcademyofScienceof the
1,76-85
UnitedStatesofAmerica88,6961-6965
Lucroy,MD,Long KR,BlaikMA etal.(2003c)Photodynamic therapy for
100
Chapter9
Therapiesof thefuture
the treatment of intranasaltumors in3dogs and1cat.Journal of
SU11654:inhibition of KIT phosphorylation in canine mast cell
VeterinaryInternalMedicine17,727-729
tumors.ClinicalCancerResearch9,5729-5734
Mann BS,JohnsonJR,CohenMSetal.2007)FDAapproval summary:
Rusk A,Cozzi E,Stebbins M et al.(2006a）Cooperative activity of
vorinostat for treatmentofadvancedprimary cutaneousT-cell
cytotoxicchemotherapywithantiangiogenic thrombospondin-l
lymphoma.Oncologist12,1247-1252
peptides,ABT-526inpetdogswithrelapsedlymphoma.Clinical
Mason NJ,Coughlin CM,Overley Bet al.(2008）RNA-loaded CD40-
CancerResearch127456-7464
activatedBcellsstimulate antigen-specificT-cellresponsesindogs
RuskA,McKeeganE,HavivFet al.(2006b）Preclinical evaluationof
withspontaneouslymphoma.GeneTherapy15,955-965
antiangiogenic thrombospondin-1peptide mimetics,ABT-526and
McCleese JK,Bear MD,Fossey SL et al.(2009)The novel HSP90
ABT-510,in companion dogs withnaturally occurring cancers.
ClinicalCancerResearch12.7444-7455
cellines.nternationalJournalofCancerEpubJune19,2009
SeiwertTY,JagadeeswaranR,FaoroLetal.(2009)TheMETrectr
Mehra R,Cohen RBand BurtnessBA(2008)The role of cetuximab for
tyrosinekinaseisapotentialnovel therapeutictargetforheadand
the treatment of squamouscellcarcinoma of the head andneck.
necksquamouscellcarcinoma.CancerResearch69,3021-3031
ClinicalAdvancesinHematologyandOncology6,742-750
Sun Q,Ming L.Thomas SM et al.(2009)PUMA mediates EGFR
Mohebtash M,Gulley JL,Madan RA et al.(2009)Cancer vaccines:
tyrosinekinaseinhibitor-inducedapoptosisinheadandneck
current directions andperspectives in prostate cancer.Current
cancercells.Oncogene28,2348-2357
OpinioninMolecularTherapeutics113136.
Thomas F,Rochaix P.Benlyazid A et al.(2007) Pilot study of
MooreRB,XiaoZ,OwenRJetal.(2008)Photodynamictherapy of the
neoadjuvant treatmentwitherlotinibinnonmetastaticheadand
canineprostate:intra-arterialdrug delivery.Cardiovascularand
neck squamous cell carcinoma.Clinical Cancer Research 13,
InterventionalRadiology31164176
7086-7092
NairS,BoczkowskiDFassnachtMetal.2007)Vaccinationagainstth
TuckerGC(2006)Integrins:moleculartargetsincancertherapy.Current
OncologyReports8,96-103
immunity.CancerResearch67,371-380
U'Ren LW,BillerBJ,Elmslie REet al.(2007)Evaluation of anovel
NorthrupNC,SeltingKA,RassnickKMetal.(2006）.Outcomesof cats
tumor vaccine in dogs with hemangiosarcoma.Journalof
withoraltumorstreatedwithmandibulectomy:42cases.Journalof
VeterinaryIntrnalMedicine21113-120
theAmericanAnimalHospitalAssociation42,350-369.
Wang YS,Chi KH,Liao KW et al.(2007) Characterization of canine
ONeilGuthBilleBtal209）Changeinregulatryellin
dogswithcancerandassociationswith tumor type.Journal of
differentiation.CanadianJournalofVeterinaryResearch71,165-
VeterinaryInternaMedicine23875-881
174
Ortner MA(2009)Photodynamic therapy
forcholangiocarcinoma:
Weiner LM.Dhodapkar MV and Ferrone S(2009)Monoclonal
overviewandnewdevelopments.
CurrentOpinionin
antibodiesforcancerimmunotherapy.Lancet373,1033-1040
Gastroenterology25（5),466-471
LehrerNewsHour(www.pbs.org/newshour/bb/science/jan-june07/
photodynamic therapy usingbenzoporphyrin derivative monoacid
cancer_03-15.html)
ringA(BPD-MA）in14dogswithoralandnasaltumors.Journalof
Zhang Y,Wang L,Li D et al.(2009)Taming regulatory T cellsby
VeterinaryMedicalScience71125-132
autologousTcellimmunization:apotentialnewstrategyforcancer
PryerNK,Lee LB,Zadovaskaya R et al.(2003）Proof of target for
immunetherapy.lnternationallmmunopharmacology9,593-595
101
Principles of nutritionfor the
cancer patient
Korinn E.Saker
Introduction
resultsincelldeath innormalcells,but the tumour
cellhasacquiredtheabilitytoescapethisfate.The
Tumours,notunlikeaparasite,liveinoronahostand
mechanismsthattumourcellshaveacquiredforsur-
obtaintheirnourishmentfromthehostorganism.The
vivalarevaried（ArgilesandAzcon,1988;Spitzet
unfortunatehostsuffersfromconsequencesofmalnu-
al.,2000)and include:
tritionandorganmalfunctionassociatedwithtumour
growthand metastasis.Tumour-hostcompetitionfor
Anacceleratedrateofglycolysisenabledby
energysubstratesisongoing,withsurvival theend-
unhamperedglucoseuptakeintotransformed
point.Anoverviewofnutrientutilizationbyboth
cells
tumourandhostwillhelptoelucidatetherationale
Promotionofmetabolicinefficiencyinthehost
behindnutritionalsupportstrategiesforthecancer
vialactateconversiontoglucosebywayofthe
patienttoprolongsurvivalandmaximizequalityof life.
Coricycle
Todate,themajorityofinvestigationsinto
Reductionof mitochondrial numberintumour
tumour-hostnutrientinteractionsinveterinary
cells,forcing/promotinganaerobicglycolysisas
patientshavebeenfocusedonthemetaboliceffects
thepredominantenergypathway
ofmulticentriclymphoma,tumoursof the gastro-
Detoxificationof intracellularoxidants(i.e.
intestinal tractandsolidnasaltumours.Themecha-
hydroperoxides),renderingtumourcellsresistant
nismofnutrientutilizationbymanysolidtumoursin
tooxidant-inducedcytotoxicity.
canine andfelinecompanionsisnotaswelldocu-
mentedasinhumanpatientswithwidespreaddis-
Thisglucose-dependentstateofmosttumour
ease.Therefore,notunlikeothermedical scenarios
cellssuggestsapotentialtargetforinhibitingtumour
itisnecessarytocombinethedocumentedknowl-
cell growth.
edgebasefromhumanandveterinaryoncology
researchtodevisenutritionalsupportplansfor
Protein(aminoacid)metabolism
patientswithavarietyof neoplasticdiseases.Asthe
Tumourshavetheabilitytoactasanitrogensink,
knowledgebaseinveterinarymedicinedevelops,
wherebyaminoacidsareretainedandusedforoxi-
nutritionalmanagementofcancerpatientswill
dationandproteinsynthesisintransformedcells.
becomemorerefined.
The synthesis of extracellular protein (i.e.hor-
mones)isreduced while enzymescatalysing syn-
thesisofpurinesandpyrimidinestopromotecell
Metabolismof energy substratesby
proliferationareincreased.Additionally,thetumour
thetumourcell
canmodifyproteinsynthesisand/ordegradationin
normalcells,whichresultsinanalteredproteinsta-
Glucosemetabolism
tusof thehost(i.e.clinical hypoalbuminaemia)and
Energyproductionstartsin thecytoplasmof thecell
increased productionofectopichormones (i.e.
withanaerobicglycolysisandendsinthemitochon-
ACTH,parathyroid hormone and growth factors)
driaof the cellwithelectron transportchain（ETC)
(Argiles andAzcon,1988).
production ofadenosine triphosphate（ATP)under
Althoughallaminoacidsareinvolvedinprotein
aerobic conditions.Under normal circumstances,
synthesis inbothnormal and transformed cells,spe-
glucoseismetabolizedtopyruvate,whichisshuffled
cificaminoacidshavebeenidentifiedasessential
intothe Krebs（tricarboxylic acid,TCA)cycle for
fortumourgrowthincertaincancer-bearingstates
metabolism.TCAcyclesubstratesarethenutilized in
(Mackenzie and Baracos,2004;Muscaritoli et al.,
theETCforrespiratorymetabolism(oxidativephos-
2004).Glutamine,a conditionally essential amino
phorylation)toATP(energy).
Whencomparedwithanuntransformed(normal)
source for intestinal mucosal cells,is considered,
cell,thetumourcellhasadistinctive,alteredmetab-
alongwithglucose,tobeamajorcompoundcontrib-
olismthatallowsittoexhibitincreasedglycolysis
uting totheenergyneedsofmosttumourcells.An
andpentosephosphatecycleactivity,whiledemon-
understandingoftheselectaminoacidutilizationby
stratingreducedratesofrespiration.Thisdysregula-
transformedcells(Figure10.1)canhelptoelucidate
tionbetweenglycolyticmetabolismandrespiration
dietaryproteinstrategiesthatpromotehostsurvival.
102
Chapter1oPrinciplesofnutritionforthecancerpatient
withinthesolidtumourcategory，aminoacidprofiles
Function
Amino acid(s)
varywithspecificity/locationof thetumour(i.e.lung,
Protein synthesis
All
breast,hepatocelllular, squamous cell.Clearly,
matchingaminoacidprofilestospecifictumoursand
ATPproduction
Glutamine
malignancies,alongwithdifferentiatingwhetherthe
Glucose production
Alaninetniring
aminoacidimbalanceprimarilyimpactstumour
metabolismorsystemicmetabolicchangesin the
Nucleotide synthesis
Glutamine
host,requiresfurtherinvestigationtoenablepractical
feeding application.
Polyamine synthesis
Arginine,ornithine
Nitric oxide synthesis
Arginine
Tumourversushostsurvival
Methyl group transfer
Methionine
Generaltumour-hostinteraction
Serotonin synthesis
Tryptophan
Thepresenceofatumourresultsinalterationsof
metabolisminthehost.Thesealterationscanbe
10.1
Functionsof amino acidsin tumourcells.
appreciatedat twolevels.
Thetumoursuccessfullydrainsthehost'sdietary
Lipidmetabolism
supplyofmetabolitesand trophicfactors,causing
Therole of lipids as an energy substratefortumour
thehosttoshiftintothe'starvation'and'anoxia'
cellsisnotaswelldefinedastheroleofglucoseand
mode,utilizingbodystoresoffatandproteinfor
aminoacids.Fattyacids arepresented to,taken up
neededenergy.Asbodyreservescontinueto
byandutilizedbythetumourcell,invarying
diminish,acachexicconditionensues,whichcan
degrees,tosupportmetabolicneeds.Atleastone
rapidlyprogresstoseveremalnutrition,multiple
reportedmechanismtopromotelipidutilizationisan
organfailure anddeath.
up-regulation of lipoprotein lipase(LPL)production.
Thetumourcandecreasedifferentiationof
Thisisakeyenzymeinpromotingentryoffatty
certainhostcells.Thisaltered differentiationcan
acidsintothetumourcellformetabolism.Thesefind-
resultinachangeinenzymesensitivityto
ings,alongwithearlierreportedstudiesindicatingde
hormone signals,disturbingthefeedback
novosynthesis(lipogenesis)offattyacidsinspecific
systemsthatcoordinateendocrinegland activity
tumourcelltypes(Herberet al.,1985;Argilesand
inthehost,thereforeadverselyinfluencing
Azcon,1988),support theimplicationof lipidutiliza
energyhomeostasis.
tionasametabolicsubstrateincertaintumourcells.
Inregardtonormalcellenergymetabolism,
Effectsoftumoursonthehost:cancer
ketonebodiesproducedfromfattyacidoxidation
cachexia
provideanalternativefuelsourceinscenariosof
Tumoursappeartohaveatwo-prongedsurvival
inadequateglucose,suchasinthecaseofsimple
mechanism:
starvation.Informationelucidating theroleofketone
Thetumourcellmustobtainnutrientstoprovideit
bodies(acetoacetateandβ-hydroxybutyrate)by the
withthenecessaryfuelforgrowth,asdescribed
cancercell islimited.
above
Tumourssecreteavarietyofcachexia-promoting
Metabolicsubstrateneedsandtumour
compounds,whichhastenamalnourishedstate
type
in thehost(patient),eventuallyresulting in death.
Dependingontheparticulartumourgrowthpattern,
cancer cells preferentiallyutilize glucose,amino
Studies inhuman and animal models,aswell as
observations in clinical veterinary cases,suggest
theirenergyorbiosyntheticneeds.Lipidsare most
that thedepletionofbodyfatcanbedisproportionate
efficientlyutilizedbyveryslow-growing tumours,
toproteinlossandmayaccountforthemajorityof
relyingalmostentirelyonmitochondrialATPasan
initialweightlossseenincancer-bearingpatients
energy source forgrowth.Incontrast,the energy
(Kalantar-Zadeh et al.,2007;Skipworth et al.,2007).
Inthefirststagesoftumourgrowth,alipolyticfactor
erentiallymetbyglucoseoxidation.Tumourgrowth
issecretedbythetumour,whichisassociatedwith
doesaffecttheplasmaaminoacidprofileofpatients
lipidmobilizationfromadiposestoresandsome
based on tumourtype,the stage of diseaseprogres-
degreeofthymicinvolution.Theresultanthyperlipi-
sionand concurrentphysiological state(Muscaritoli
daemia inthehost,inconjunctionwiththetumour-
etal.,2004).The nutritionalrelevance of altered
induced hypoglycaemic environment,triggers the
aminoacidprofilesinthecancerpatientisunder
metabolicmachineryresponsible foroxidationof
investigation.Originalstudiesbasedonpatientswith
fattyacids as an alternative energy source for the
cancerofvaryingoriginsreportedaconsistent
hostinplaceofglucosemetabolism.Whilemobilized
reductioningluconeogenicaminoacids(GAAs)and
freefattyacidsareoxidizedtoketonebodiesvia
normalorincreasedconcentrationofbranched-chain
betaoxidationintheliver,theglycerolcomponentof
amino acids (BCAAs).More recent studies have
themobilizedtriglycerideisutilizedasaglucogenic
identifiedthatspecificaminoacidsarepreferentially
substratewithinhepatocytes.Theseenergy-requiring
utilizedbysolidversushaematological malignancies;
processeshelptoexplainthefatdepletion,
103
Chapter1oPrinciplesofnutritionforthecancerpatient
enhancedgluconeogenesisandoverallnegative
therapieswilldiminishapatient'sabilityto
energybalanceincancerpatients.
prehend,cheworswallowfood,whereasa
Whetherthecachexiaisfullyaccountedforby
pancreatectomymayresult intheonsetof
inadequate energy intake and increased energy
diabetesmellitus.
expenditureisstilunclear;buttheincreaseduncoup-
lingofoxidativephosphorylationassociatedwiththis
Individuallythetreatmentmodalitiesarereported
imbalanceofenergyhomeostasisinthehostsup-
toadverselyinfluencemetabolicandfunctional
portsthecachexicstate.Likewise,up-regulationof the
aspectsofthepatient.Whenutilizingamultimodality
ubiquitin-proteosomepathway
(UPP)incancer
approach,theadversesequelaeoftenbecomemag-
patientspromotes cachexia.TheUPPis themajor
nified,putting thepatient athigherriskformalnutri-
non-lysosomalprocessresponsibleforthebreakdown
tionand itsconsequencesifnotaddressedinan
ofmostshort-andlong-livedproteinsinmammalian
appropriateandtimelymanner.
cells.Theubiquinationprocessassociated with can-
cercachexiaiscontrolledbysulphatedglycoproteins
Nutritional supportfor the host
producedbycachexia-inducingtumours(Ciechanover
etal,2000).Anexampleisproteolysis-inducingfactor
Goalsofnutritionalsupport
(PIF),which hasbeen found in the urine of weight-
Inthecancerpatient,thegoalsofnutritionalsupport
losingpatientswithgastrointestinal tumours(Cabal-
and thefeedingplanwillbedynamicandtherefore
Manzano et al.,2001).PIF is also thought to be
subjecttorevisionbasedonsequentialpatient
involvedintheinflammatoryresponseofcachexia,
assessments.Generalgoalsforeverypatientshould
leadingtoincreasedtumourproductionandsecretion
target:
ofinterleukins(IL-6,IL-8)and C-reactive protein
(Cabal-Manzanoet al.,2001;McMilan,2009).
Optimizingqualityof life
Ultimately,theincreasedrateofproteincatabolism,
Maintainingareasonablyoptimalbodycondition
Preventing metabolic complications from feeding
increasedrequirementformediatorproduction,
increased urinary and gastrointestinal losses,and
Feedingviathegastrointestinal tract whenever
proteinlosstotumourcellspromotesanegativenitro-
possible
gen(protein)balance in the patient.This protein-
Slowingtheonsetandprogressionofcachexia
deficientstateadverselyinfluencesimmunecellfunc-
Replacingnutrient lossesassociatedwiththe
tion,woundhealingandoverallstrengthofthepatient.
diseaseprocessand/oranti-cancertreatments.
Assessmentofeachpatientwillallowfor these
Anti-cancertreatmenteffectsonthehost
Multimodal therapy (combinations of surgery,chemo-
generalgoalstobetailoredtofocusonthespecific
therapy,radiation therapy,mmunotherapy,hyr-
needsofthepatientanddeterminetheappropriate
nutritional supportoptions.Asin thecase ofany
thermia,etc.)for veterinary cancer patients is
terminaldisease state,treatmentandassociated
consideredthecurrentstandardofcare.Eachtreat-
mentmodalitypresentssystemicand/orsite-specific
managementoptionsrangefromchoosingnointer-
ventiontochoosingeverypossibleintervention
biological alterationsthataffectthepatient'srecovery
modalitycurrentlyavailable.Nutritionalsupport
andqualityof life.
guidelinescanbeprovidedacrossthiscontinuumof
Acuteandchroniceffectsofradiationtherapy
diseasemanagementscenarios.
associatedwiththehead/neckregioncanbe
Acaregivermaychoosetotakenospecificaction
appreciatedasmucositis(Ogilvie,2006;Keefeet
(NA) in regard to nutritional support for a pet diag-
al.,2007;SakerandSelting,2009),drymouth，
nosedwithcancer,and thiswouldbeconsidereda
dentaldisease,oralteredsmellandtaste(see
feedingapproach.Basically thismeanstheyhave
Chapter8).Radiationtreatmentof the abdominal
decidedtoletthepeteatwhateveritwilleat,when-
regioncanresultinnausea,vomitingand
everithastheinterestineating.In thisscenario,rea
diarrhoeaasacuteeffects.Inchronicsituations,
sonablerecommendationswouldbetoavoidoffering
intestinalobstruction,fistulaformationorchronic
foodsthatcontainnoxiousorharmfulingredients
enteritismaybeobserved.
andensurethatthereisplentyoffreshwateravaila-
Althoughchemotherapyisutilizedasatreatment
bleatall times.Thenextfeeding approachfornutri-
fornumerous tumourtypes and locations,
tionalsupportfocuseseffortsonoptimizingvoluntary
commonsequelaeofchemotherapyinclude
intake(vi)soastoprovidethepet'sdailyenergy
gastrointestinal sideeffects(seeChapter7).
requirementandaddressspecificnutrientsofcon-
Effectsthatmayhavenutritionalimplications
cernbased onthepet'sclinicalcondition.Thelast
includedecreasedappetite,alterationsinsmell/
feedingapproachfornutritionalsupportisassisted
taste,foodaversions,nausea,vomiting,
feeding (AF),a more aggressive approach tonutri-
diarrhoea,constipationandinflammationofthe
ent delivery.TheAFapproachrangesfrom thevery
oropharyngealregion(SakerandSelting,2009).
simpletechniqueofhandorsyringefeedingtothe
Theeffectsofsurgicalinterventiononcancer
morecomplextechniqueofparenteralfeeding.Both
patients,althoughsite-specific,caninfluence
VIandAFaremostsuccessfulwhenanutritional
overallnutrientutilizationandmetabolicdisease
assessmentofthepatientisperformedpriorto
stateof thepatient(Bozzettiet al.,2007;Saker
developingacomprehensivefeedingplan.Figure
andSelting,2009).Forexample,someoral
10.2summarizesthesefeedingapproaches.
104
Chapter1oPrinciplesofnutritionforthecancerpatient
Feeding approach
Requirements
Practical recommendations
No specific action NA)
Allowthepatienttoeatwhateveriwilleatwhenever
Avoidoffering foods thatcontainnoxiousorharmful
it willeat
ingredients.Ensureplentyoffreshwaterisavailable
Optimize voluntary intake(VI)
Ensure thepatient'sdailyenergyrequirementsare
Calculatedailyenergy/nutrientrequirements.ldentifyand
met and addressspecificnutrients of concern
feedappropriatediettype/amount.Monitordailyintake
Assisted feeding (AF)
Ensurethepatient'sdailyenergyrequirementsare
Handorringfding,tubefedingrparentral
met andaddressspecificnutrientsof concern
feeding
10.2
Optionsfornutritional supportof thecancerpatient:feedingapproaches.
Nutritional assessment
risk for complications,and assumes the‘at risk
The AmericanCollegeofVeterinaryNutrition sug-
patientwillbenefitfromappropriatenutritional
gestsanintegratedapproachtopatientnutritional
support(Detsky et al.,1987).SGA involves identify-
assessmentreferredtoasthe iterativeprocess
ingthecauseofthemalnourishedstateandthe
(Thatcheretal.,2004),whichincludesassessmentof:
categories include:
Thepatient
Maldigestionoffood
The food (diet)
Malabsorptionof the ingesta
Thefeedingmethod.
Decreased intake of food(calories).
Thisapproachhelpstoensureacompleteand
Thisassessmenttechniqueincludescorrelations
accuratenutritional assessmentofeachpatient.
betweenmalnutritionwithspecificorganfunction
andalterationsinbodyweight/composition,aswell
Patient assessment
as identifyinghowthediseaseprocessinfluences
Intheiterativeapproach,assessmentof thepatient
thepatient'snutrientrequirements.
is based on:
SGAcanbeadaptedtothecancerpatientby
focusingmorespecificallyon:
Physicalexamination
Clinicalhistory
Bodyconditionandweightchanges
Dietaryhistory
?
Voluntarydietintake
Routine diagnostics(CBC,chemistry profile,
SignsofGlintoleranceassociatedwiththe
urinalysis)
cancerorthetreatment
Otherpertinentdiagnostics.
Functional capacityof thepatient.
Translatingthepatientassessmentdatainto
Thefindings ofclinical,historicalandphysical
ausefulinformationbasefordevelopinganappro-
assessmentcanbetranslatedintooneofthree
priatefeedingplancanbequitedauntingforpracti-
nutritional statuscategories(Figure 10.3):
tionersnottrainedinclinicalnutrition.Tosimplify
。
Well nourished
this process,a modification of the subjective
Borderline,oratriskofbecomingmalnourished
global assessment(SGA)technique common to
Significantlymalnourished.
humanmedicinecanbeused.TheSGA technique
isbased
onusingclinicalhistoryandphysical
Categorystandingisusedtoindicatewhich
examinationparameterstoidentifypatientsat
feedingapproachwillmostbenefitthepatient.
Category
Definition
Criteria
Suggested feeding approach
Well nourished
Consistentintakeof dailyenergyneeds
Weightmaintenance
VI
Maintain optimal(ornearoptimal） BCS
Musclemass score 2-3
Normal serum albumin
No change in BW
No nutrient losses
2
Borderline malnourished
Inconsistentintakeof dailyenergyneeds
Weight lossof<10%
VIand/orAF
BCSvariable
Musclemass score1-2
Normal tomildhypoalbuminaemia
Undesired weight loss
Moderatbnrlldrinss（idareii
regurgitation,urinary)
10.3
Nutritional statuscategories.BCS,body condition score;RER,resting energyrequirement.(continues)
105
Chapter1oPrinciplesofnutritionforthecancerpatient
Category
Definition
Criteria
Suggested feeding approach
3
Significantlymalnourished
Daily energy intake66%RER
Weight loss≥10%
AF
PoorBCS（<2.5/5or3/9)
Moderatetoseverehypoalbuminaemia
Musclemass score0-1
Undesired/uncontrolledweight loss
Ongoing,uncontrolled nutrient losses
10.3
(continued)Nutritional statuscategories.BCS,bodyconditionscore;RER,restingenergyrequirement.
Bodyconditionandweightchanges:Current
70×BW(kg)0.75kcal/day
bodyweightiseasilydetermined，but justasimpor-
tantisthehistoryandtimeframeofweightchange.
or
Accuratereportingofweightusingthesamescales
[BW(kg)×30]+70kcal/day
andascaleofappropriatesensitivityisideal.The
morerapidtheweightloss,themorelikelyitistobe
associatedwith lossof leanmusclemass(LMM)ver-
This is aninterspecies equation,makingit
susfattissue,althoughbotharedocumentedinthe
relevantforboth
canineandfelinepatients.
cancercachexiasyndrome.Closephysicalexamina-
Dependingonthepatient'sclinicalconditionatthe
tionwillrevealthepresenceofascitesoroedema,
timeof diagnosis and theplanfortreatment(general,
bothofwhichwillobscuretruebodyweight,aswell
chemotherapy,
radiation),
hospitalizedcancer
ascompositionofLMMversusfattissue.Therateof
patientsshouldbereceivingaminimumof66%of
leantissuecatabolism(breakdown)isinverselycor-
RERcalories,andinsomeinstancesadetermined
relatedwithsurvival.
percentagegreaterthanRERcalories.
During the physical examination,an assessment
AccuratedeterminationofDERfortheveterinary
ofbodyconditionandassignmentofabodycondi-
cancerpatientisstilla challenge.The following
tionscore（BCS)（ona5-pointor9-pointscale)is
DERcalculationshouldbeusedasastarting
useful forcurrentandfutureassessment.Current
point,butsincebedsidecalorimetryisnotfeasiblein
BCSsystemsarebasedonsubjectiveevaluationof
pets,reassessment of the patientatregularinter-
fat tissue covering ribs,tail-base,backbone,and
valswillhelptodeterminewhetheradjustmentsto
DER are necessary.
2004).AssignmentofaBCSequal to1indicates an
emaciatedcondition,usingeitherthe5or9scoring
For dogs:
scale.Conversely，aBCSassignmentof5/5or9/9
DERcanine=RER atoptimal Bwx(1.6 to3.0) kcal/day
indicatesextremeobesity.Anoptimalbodycondition
For cats:
wouldbescored3/5or4.5-5/9.Withpractice，
DERteline = RER atoptimal Bw ×(1.2 to 2.5) kcal/day
assigningaBCStoadogorcatcanbedonewith
highaccuracy.Cancerpatients,especiallycats,have
averyhighincidenceofmusclewastingintheface
DERaccountsfordailycalorieneedsthatare
ofadequateorexcessivefatstores.Therefore,it is
associatedwithfooddigestion,activity,thermoregu-
imperativetoevaluatemusclemasssubjectively
lationandmaintenanceofleanbodymass.Itshould
berememberedthat thecachexicpatienthasa
alongwiththetraditional BCSsystems(Figure10.4).
appreciated,due to rapidly ongoing catabolism,
Score
Criteria
increasedrespiratoryefforts,excessiveproductionof
0
Severepronouncedmusclewastingover scapulae,
cytokinesandtheinfluenceofdrugmetabolismon
skull or wings of the ilum
liverandcardiacfunction
TosimplifytheDERcalculationsforacancer
1
Moderatemusclewastingovertheseareas
patient,whileusingtheaboveequationsasastart-
2
Mildmuscle wasting
ingpointitshouldberealizedthatadjustmentswill
Normalmusclemassoverthese areas
probablybenecessarytooptimizecalorieintakefor
3
eachpatient.Intheauthor'sexperienceoffeeding
10.4
Themuscle mass scoring system.
thecachexiccancerpatient,manycases benefit
fromanincreaseinDERofuptotwo-fold inorderto
matchtheirdailycalorieexpenditureadequately.
Voluntarydietaryintake:Thevoluntarydietary
DERfactorsfordogsareconsistentlyhigherthanfor
intakemustbeevaluatedagainstadailycaloricgoal
cats,basedonthemoresedentarylifestyleofcats
calculated asrestingenergyrequirement(RER)of
compared tomost dogs.
thepatientwhilehospitalizedanddailyenergy
requirement(DER)whenmanagedathome.
Signsofintoleranceandfunctionalcapacity:
RER isbasedonbodyweight(BW)andis
Assessmentofthepatientwithregardtothetwo
calculatedas:
remainingSGAfocusareas-signsofGlintolerance
106
Chapter1oPrinciplesofnutritionforthecancerpatient
associatedwiththecancerorthecancertreatment;
Fatandfattyacids:Omega-3fattyacid(n-3FA)
and thefunctionalcapacityof thepatient-canfurther
metabolites,eicosapentaenoicacid(EPA)and doco-
helptoclarifywhichnutritionsupportcategorybest
sahexaenoicacid(DHA)havebeenreportedashav-
describeseachpatient.Thiscategorization,alongwith
inganti-tumorigenic andanti-cachexic functions.
considerationof thepatient'scancerdiagnosis,stage,
Severalmechanismsofn-3FAandtumourgrowth
treatmentprotocolandprognosis,willaidinidentify-
suppressionhavebeenidentified.Omega-3FAcan
ingthemostbeneficialfeedingapproach.
competitivelydown-regulatethen-6metabolitesand
Althoughthe'goldenrule'innutritionalsupportfor
up-regulate EPA and DHA,minimizing the angio-
anyspecies isto“feed thegutwheneverpossible'，
genesis-promotingeffectsofpro-inflammatoryeicosa-
gutfunction and tolerancelevel,patient metabolic
noids (Cowing and Saker,2001;Saker,2006;
Grimble,2007).EPAandDHAhavebeenshown to
totalcalorieseitherprovidedortoleratedviathe
stimulateprogrammedcelldeath,inducedifferentia-
enteralroute,inwhichcaseacombinationofnutrient
tionandinhibitcellproliferationbydown-regulating
delivery methods,alsoutilizing theparenteral route,
NFkB,Bcl-2and MAPK mechanisms in specific
isindicated.
tumourcells（Cowing andSaker,2001;Saker,2006)
Canine andfelinestudiesindicatethatboththe
Diet
essentialfattyacidratio(n-6:n-3)and thetotaln-3
Dietassessmentisthenextcomponentoftheitera-
FAconcentrationinthedietinfluencesthetumour
tiveprocessapproachtoacomprehensivenutritional
cell.Dietaryrecommendationsbasedonresearch
assessment.Choosingappropriatedietoptions
associatedwiththecommercialcaninecancerdiet
involvesmatchingthespecificnutrientanddietchar-
acteristicneedsofthepatientwithwhatthedietpro-
andfelinenutritioncancerstudiessuggest337mg
EPA/DHAper100kcalandann-6:n-3ratioof1:1to
vides.Ingeneral,dietoptionsthathelptominimize
2.5:1aseffective feeding guidelines.
gastric/intestinalcomplicationsandmaximizenutri-
entdigestionandabsorptioninthepresenceof
Protein:Itistheexperience-basedopinionofthis
eitherongoingtumourcelldevelopmentordestruc-
authorthatdietaryproteinlevelsshouldbebasedon
tionoftumourcellsviachemotherapyand/orradia-
thefollowingconsiderations(inthisorder):
tionwouldbepreferred.
Despite thecurrentunderstanding ofnutrient
1.Proteintoleranceof thepatient
accretionandmetabolismofmacronutrientsby
2.Currentproteinstatus,immunocompetenceand
tumourcells,thereislimitedscientificallyfounded
bodycondition
informationavailableregardingcancerdietsforpets.
3.Tumour type.
Todate,thefocusfornutritionalrecommendations
appearstobebasedonresearchusingthecanine
Gl lymphoma model(Saker and Selting,2009)and
Ongoingkidneyorliverdysfunctionwithassoci-
atedclinical consequencesshould takeprecedence
extrapolationfromnutritional interventionstudiesfor
overalteredproteinrequirementsdue totumour-
human cancerpatients,resultinginlittleconsensus
patient competition.Accordingly,excessive protein
ofappropriatedietaryrecommendationsforveteri-
lossesduetorelatedorunrelatedmalabsorptive/
narycancerpatients.Dietchoicesshouldbemade
maldigestivedisorderswillincreasepatientprotein
basedonadesiredanti-tumourgrowthnutrientpro-
fileandthenutrientsneededtoaddressanti-cancer
requirementsabove cancerneeds alone.
Caninelymphoma studies suggestincreased
treatmentsequelaeexperiencedbythepatient.
arginineand/orglutamineasbeneficialforwound
Carbohydrate:Fromastrictlytumour-growthper-
healing,enhancedimmunefunctionand Glentero-
spective,
dietary
carbohydrate
restriction
and
cytenourishmentassociatedwithanti-cancertreat-
omega-3fattyacidsupplementationarenutritional
mentprotocols.Conversely,theseaminoacidsare
managementfocisupportedbymultipleinvitroand
invivoanimalstudies.Glucose deprivationcauses
and synthesis ofnucleotides,nitricoxide andpoly-
cytotoxicityinmultiplehumantumourcelllines,
amines in tumour cells(Muscaritoli et al.,2004).
including fibroblasts,aorta,colonand breast cells,
Supplementationto thepatientmaysimultaneously
andstudiesindicatethattransformedcellsappearto
promote tumour growth.Thisiswhere timing is
bemoresusceptibletoglucosedeprivation-induced
important:deliveryoftherapeuticlevelsofarginine
cytotoxicity thanmatched untransformedcells(Spitz
and/orglutamineimmediatelyfollowingachemo-
etal.,20oo).Basedonstudiesutilizing the canineGI
therapy,radiationorsurgicalprocedurewouldseem-
lymphomamodel,dietarycarbohydratecalories
inglybenefitthepatientbyminimizingcomplications
shouldberestrictedandfatcaloriesincreased,butit
associatedwithanti-cancertreatment,yetprovidelit-
shouldbeborneinmind that thisdietaryrecommen-
tleornobenefittothedeadordyingtumour.
idlygrowing,poorlydifferentiatedtumour types
Antioxidants:Asimilarrationalemayapplytodiet-
utilize glucose oxidation,whichsuggests thata
aryantioxidantsandcancer.Studieshaveshown
carbohydrate-restricteddietwillsloworminimize
thatglucosemetabolismisrelatedtothemetabolic
tumourgrowth.Conversely，slower-growingwell dif-
detoxificationofintracellularhydroperoxidesformed
ferentiatedtumoursrelyonmitochondrialATP,which
asaconsequenceofcellularoxidativemetabolism;
therefore,glucosedeprivationtotumourcellsfrom
influencetumourgrowth.
dietarycarbohydraterestrictioninthehostlimits
107
Chapter1oPrinciplesofnutritionforthecancerpatient
hydroperoxidedetoxificationintumourcells,render-
syringefeedingtodietdeliveryviaafeedingtube.
ingthemmoresusceptibletooxidant-inducedcyto-
Feedingtubeplacementisrecommendedforthe
toxicity （Spitz et al.,2000).Dietary antioxidant
cancerpatientwhenhandorsyringefeedingisno
longer toleratedorfeasible.Thedecisionregarding
speciesinbothnormal and transformedcells,pre-
tubetypeandlocationofplacementwilldependon:
ventingtumourcelldevitalizationanddestruction.
Targetedantioxidantdeliveryfollowingananti-
AmountoffunctionalGltract
cancertreatmentwouldspecificallyprovideprotec-
Lengthof timeAFisrequired
tiontonormalcellsagainstsecretorysubstances
Whetherat-homeorhospitalizedfeeding
fromtumourcellsandfromdamagingreactiveoxi-
Availabilityofresources(i.e.equipment,technical
dantspeciesderivedfromtreatmentprotocolsand
experience).
damaged ordyingcells.Numerousantioxidantprod-
uctsarereadilyavailable.VitaminEprotectslipidcell
During short-termhospitalization,hand feeding，
membranesthroughfree-radicalscavengingandthe
syringefeedingand/orsupplementaldietdeliveryvia
succinateanda-tocopherolacetateformshavebeen
naso-oesophagealtubeareappropriateoptions.If
reportedas
having
anti-proliferative
activity.
aninconsistentappetiteisexpectedathome,place-
Additionally,bothvitaminsEandCreportedlyinhibit
mentofanoesophagostomyorgastrostomytube
nitrozationreactionsthatcan inducecancers(Saker
shouldbeconsideredpriortohospitaldischargefor
and Selting,2009).Specific trace minerals,flavo-
easeofat-homesupplementalassistedfeeding.
noidsandothervitaminsaredescribedashaving
Detailedguidelinesfortubeplacementandmanage-
anti-cancer activity,butevidence-basedresearchfor
mentcanbefoundintheBSAVAManualofCanine
veterinarycancerpatientsisnotavailable.
andFelineRehabilitation,SupportiveandPalliative
Care.Figure 10.5summarizestubetypes,recom-
Thefeedingmethod
mendedfeedingmethod，anddietform(s)forenteral
Assessmentoffeedingmethodisthefinalcompo-
assistedfeeding.
nentofacomprehensivenutritionalassessment
Parenteralfeedingisreservedforhospitalized
approach.
patientsthatrequireeithertemporaryavoidanceof
theenteralfeedingrouteorsupplementalnutrient
Voluntary
intake:
The
leasti
invasive,
most
delivery.Thefeedingapproachdoesnothaveto
physiological feeding approach isVI.The diet should
beaneither/orapproach.Inmanysituationsacom-
beoffered,primarily,nameal-feedingmanner,with
binationofVlandAForcombiningenteralwith
calculatedRERorDERdividedbetweenmultiple
parenteralAFisindicatedandextremelybeneficial
mealseachday.Thisallowsformoreaccurate
forthepatient.
monitoringofcalculatedversusactualfoodintake.In
thecasewherebodyconditionispoor,appetiteis
Feedingplan
stillgoodandViistolerated,acombinationofmeal
Basicstepstodevelopingafeedingplanbasedon
andfree-choicefeedingcanoptimizemaintenanceof
nutritionalstatus category(seeFigure10.3)are as
desiredbodycondition.
follows.
Assistedfeeding:Ifapatientcannotorwillnot
Category1:wellnourishedpatient
consumedesired
caloriesvoluntarilyandina
1.
Calculaterequiredkcal/dayasRER
currentBw,then
consistent manner,then AF is indicated.Enteral
DERusing RERx1.6(canine) or RERx1.2
assistedfeedingmethodsrangefromhandor
(feline).
Tube type and size
Use
Sedation/anaesthesia requirements
Feeding
Diet type
method
Orogastric
Ultra-short term(1-2days)
±Sedation
B
L,CB
16-20Fr
In-hospital use
Naso-oesophageal
Short term(3-7days)
±Sedation.Topicalanaestheticrequired
CRI,B
In-hospitalorat-home use
<
5-10Fr
Oesophagostomy
Weeks toseveralmonths
General anaesthesia required
CRIB
L,CB
14-19Fr
In-hospital orat-homeuse
Gastrostomy
Weekstoyears
General anaesthesiarequired forsurgical,
CRI,B
L,CB
18-28Fr
In-hospitai orat-home use
endoscopic ornon-endoscopic placement
Enterostomy
Short term
General anaesthesia required-surgical
CRI
L
5-8Fr
In-hospital use
placement
10.5
Feedingtubesforcanineandfelinepatients.TheenterostomytubeiscommonlyreferredtoasaJ-tube,as
placement isin thejejunum.AJ-tubecanalsobeplacedasaJ-thru-G'tubetoaccessboththeuppersmall
intestineandstomachasneededforfeedingand/orresidualmonitoring.B,bolusfeeding:CB,canneddietblendedwitha
liquid(waterorliquiddiet);CRI,constant-rateinfusion;L,commercialliquiddiet.
108
Chapter1oPrinciplesofnutritionforthecancerpatient
2.Identifylow-carbohydrate（<8gCHO/100kcal),
7.
Offerfreshdietpriortoascheduledtubefeeding
increased-fatdiet(>4.5g fat/100kcal)enriched in
if notvomiting.
omega-3fattyacidsandhighlydigestible(low
8.Monitratudeappetitodyweigh changs
crudefibrecontent).Considerdietcategoriesas:
conditionandnutrientlosses,daily;monitor
.
Commercialcancermanagementdiet
proteinandelectrolytestatusasindicatedby
i.
Growthdiets,kittenorpuppy
clinicalpicture.
ii.Canineperformancediets(fordogsonly)
iv.Fish-based diets,canine orfeline.
Roadblocksto adequate nutritional
3.
Minimizedietaryandsupplementalantioxidant
support
intakeduringanti-cancertreatment.
Foodaversionsarenotanuncommonsequel toanti-
4.
Feedtwicetothreetimesperday.
cancertreatmentsandtoaprogressingdiseasestate
5.Monitorappetite,bodyweight and condition and
ingeneral.Theveterinarypatientmayassociatenau-
nutrient losses,daily.
sea,pain,oroveralldiscomfortwiththeactofeating，
orsimplywith thesightorscentof food(Michel and
Category2:borderlinemalnourishedpatient
Sorenmo,2008).Clinical signs associated withfood
1.
CalculateRERoptimal Bw,thenDERusingRERx
aversioninclude:initialinterestinfoodfollowedby
(1.6to3.0)(canine)orRERx(1.2to2.5)(feline)
refusal aftersmelling ortasting thefood;salivation;
2.
Identify appropriatedietnutrientprofile(see
repeatedswallowingorturningawayfromfoodwhen
Category1).Considerdietcategoriesas:
offered;and distancingfromthefeedingbowl.
Commercialcancermanagementdiet
ii.
Feline diabetes management diet (for dog or
Alteringtheflavour/scent,textureandtemperature
cat)
of thefoodmayenticethepatienttoeat.
ii.Kitten growthdiet(fordog orcat)
Presentationofsomeuniquefoodstuffmay
IV.
Canineperformancediets(fordogsonly)
interest thepatient andjump-startvoluntaryfood
V.F
Fish-based diets,canineorfeline
intake.
vi.Veterinaryandhumanliquiddiets.
Theuseof appetite-stimulating drugsin
3.Avoiddietaryandsupplemental antioxidant intake
conjunctionwithdietchangeandpalliative
during anti-cancertreatment.
medicationstodecreasenauseamaypromote
4.
Feed twotofourtimesperday.
andsustainappropriatecaloricintake.
5.Ifdailyvoluntarycalorieintakeislessthan
Iffoodaversionbehaviourpersistswithresultant
calculatedRERoptimalw,initiateassistedfeeding
weightloss,anassistedfeedingapproachshould
（i.e.hand,syringe,ortubefeeding)toensure
beinitiated.
deliveryofRER(minimally)andDER(optimally)
tocoverdailycaloricdeficit.
Non-compliancewithdietaryandfeeding
6.Monitorappetite,bodyweightchanges/condition
guidelines canbea multifactorial issue,involving
andnutrientlosses,daily.Proteinandelectrolyte
thepatient,caregiverand/orattendingveterinary
statusasindicatedbyclinicalpicture.
surgeon:
Notethatlimitedveterinaryliquiddietsare
Istherecommendeddietunavailable?
availablethatmatchdesirednutrientprofileandthat
Isthecaregiverunabletoadheretothe
humanliquiddietsmayrequiresupplementationwith
recommendedfeedingschedule?
selectaminoacidsandlinoleicacidbasedon
Doesthecaregiverhavereservationsaboutdiet
essentialnutrientsofthepatient.
Istherepoordietacceptance and/ortoleranceby
Category3:malnourishedpatient
thepatient?
1.
CalculateRERcurent Bwforin-hospitalfeeding;
Are thenutritionsupportrecommendations
RERoptimal w for at-home feeding.
unclear?
2.CalculateDERusing RERx(1.6to3.0)(canine)
orRERx(1.2to2.5)(feline)forhome feeding.
Identificationoftheseissuescanhelptorectify
3.Choose assisted feeding method(i.e.syringe,
any non-compliance.
tube,parenteral orcombination):
Enteralfeedingcontraindicatedifpatient
exhibiting chronicvomiting orregurgitation;
Summary
utilizeparenteral option
ii.Parenteraladmixturesformulatedtomatch
Theprinciplesofnutritionalsupportfortheveterinary
patient'sspecificnutrient needs.
cancerpatientcanbesummarizedasfollows.
4.Identifyenteraldietbasedonnutrientprofile(see
Categories1and2)andfeedingtubesize/
Evaluationofgrowthcharacteristicsofthetumour
location(seeFigure 10.5).
helpstotargetspecificnutrientutilizationby
5.Avoiddietaryandsupplemental antioxidant intake
tumourcells,allowingforefficaciousanti-tumour
duringanti-cancertreatment.
nutritional support.
6.
.Feedingfrequencyasconstant-rateinfusionor
A comprehensivenutritional assessment
bolusschedule:followappropriatetubefeeding
identifiesspecificnutrientneedsandDERfor
and tubemaintenanceprotocols.
eachpatient.
109
Chapter1oPrinciplesofnutritionforthecancerpatient
Usenutritional statuscategorycriteriatodirect
131,1125-1128
theapproachtofeeding.
DetskyAS,McLaughlinJR,BakerJPeta.（1987)Whatissubjective
globalassessmentofnutritionalsupport?JournalofParenteraland
Minimizethecaloriecontributionfromsoluble
EnteralNutrition11,8-13
carbohydrates;target an n-6:n-3FAratio(2.5:1to
Grimble RF(2007) Immunomodulatory impactof dietary lipids.Clinical
1:1)byincreasing EPA/DHAsources such as
NutritionHighlights32-7
Herber D.Byerly LO andChlebowskiRT（1985)Metabolic
menhaden fishoil.
abnormalitiesinthecancerpatient.Cancer55225-232
Dietaryproteinintakecalculationsshouldreflect
JohnenH,LinS,KuffnerTtal.(2007）Tumour-inducedanorexiaand
weight lossaremediatedbytheTGF-beta superfamilycytokine
patientneedsandtolerancelevel.
MIC-1.NatureMedicine13,1333-1340
。
Timeantioxidantsupplementationwithanti-
Kalantar-ZadehK,Horwich TB,OeropoulosA etal.(2007)Risk factor
cancertreatments.
paradoxinwasting diseases.CurrentOpinioninClinical Nutrition
Utilizeassistedfeedingaloneorincombination
andMetabolicCare10,433-442
KeefeDMassiasG,ONeilLetal.2007)Severemucositishowcan
withvoluntaryintakeasneeded.
nutritionhelp?CurrentOpinioninClinicalNutritionandMetabolic
Despitebestintentionstofeed ananti-tumour
Care5,627-631
Mackenzie M and BaracosVE(2004)Cancer-associated cachexia:
diet,thebiggestnutritional impactonsurvival is
alteredmetabolismofproteinandaminoacids.In:Metabolicand
consistentintakeofadequatecalories.
TherapeuticAspectsofAminoAcidsinClinicalNutrition，2ndedn
ed.LCCyoberp339354RCPressBocaRatonlorida
Marks DL,LingNandCone RD(2001）Roleof thecentral melancortin
Althoughfeedingprotocolstargetedtopreventor
systemincachexia.CancerResearch61,1432-1438
cure cancer wouldbe ideal,the presentstate of
McMillan DC (2009) Systemic inflammation,nutritional status and
veterinarynutritional oncologyrealisticallyisfocused
survivalinpatientswithcancer.CurrentOpinioninClinicalNutrition
andMetabolicCare12,223-226
ondevelopmentoffeedingprotocolstocomplement
Michel KE and Sorenmo KU (2008)Nutritional status of cats with
anti-cancertreatmentmodalities.Asstudiescontinue
cancer:nutritionalevaluation
andrecommendations.
In:
EncyclopediaofFeleClinicautritnstdndibota
torevealthemechanismsoftumourcellmetabolism
pp.385-402.RoyalCanin/AniwaSAS,Aimargues,France
andvariedhostresponsestotumourcellgrowth,
Muscaritoli M,Fanelli FR,Meguid MM et al.(2004)Amino acid
feedingprotocolscanmakethetransitionfrom
requirement in cancer.In:MetabolicandTherapeuticAspects of
AminoAcidsinClinical Nutrition,2ndedn,ed.LCCynober,pp.
management topreventionandpossiblycure.
689-704.CRCPress,BocaRaton,Florida
Ogilvie GK(2006)Amazingadvances inveterinaryoncology today.
VeterinaryForumJuly,39-46
Referencesandfurtherreading
Saker KE(2006)Clinicalvalue of fatty acids for our feline friends
ProceedingsofHil'sGlobalSymposiumonFelineCarepp.2834
Saker KE and Selting KA(2009)Cancer.In:Small Animal Clinical
ArgilesJMand AzconJ (1988)The metabolicenvironment of cancer.
Nutrition，5thedn,ed.MHand etal.,pp.587-607.Mark Morris
MolecularandCellularBiochemistry813-17
Institute,Topeka,Kansas
BingCand TrayhurnP(2008)Regulationof adipose tissuemetabolism
SkipworthRJC,StewartGD,DejongCHCetal.(2007)Pathophysiology
incancercachexia.CurrentOpinioninClinicalNutritionand
ofcancer cachexia:muchmorethan host-tumourinteraction?
MetabolicCare11201-207
ClinicalNutrition83,667-676
BozzettiFGianottiL,BragaMetal.(007）Postoperativecomplications
SpitzDR,SimJE,RidnourLAetal.(200o)Glucose deprivation-induced
ingastrointestinalcancerpatients:thejointroleofthenutritional
oxidative stress in human tumour cells.A fundamental defect in
statusandthenutritionalsupport.Clinica/Nutrition6,698709
metabolism?Annalsof theNewYorkAcademyof Sciences899,
349-362
Proteolysisinducingfactorisexpressedin tumoursofpatientswith
ThatcherCD,Hand MS and Remillard RL(2004) Smallanimal clinical
gastrointestinalcancersandcorrelateswithweight loss.British
nutrition:aniterativeprocess.In:SmallAnimalClinicalNutrition,
Journalof Cancer94,1599-1601
4thedn,d.MHandtal,pp19MarkMorrisnstituteTopa
CiechanoverA,OrianA andSchwartz AL(20oo)Ubiquitin-mediated
Kansas
proteolysis:biological regulation via destruction.Bioessays 22,
WatsonPandChan DL(2010)Principlesof clinicalnutrition.In:BSAVA
442-451
ManualofCanineandFelineRehabilitation,Supportiveand
Cowing BEand Saker KE(2001)Polyunsaturated fatty acids and
PaliativeCare:CaseStudiesinPatientManagementdSindy
andPWatson,pp.42-59.BSAVAPublicationsGloucester
110
Relief of chronic cancer pa
BrianJ.Trumpatoriand B.DuncanX.Lascelles
Introduction
AAHA/AAFPPainManagement Guidelineslist
oncologicalpainasafrequentlyoverlookedsource
Inhumanmedicinethereisasignificantamountof
ofpain.
interestincancerpain,bothinitsneurobiologyandin
Barrierstoeffectivecancerpaincontrolin
novelmethodstoalleviateit.However,littleisknown
animalsprobablyinclude:
about therelationshipbetweenpainandcancer in
animals.Yoxall(1978) stated:lt is surprising,for
Lackof appreciationthatmanycancersare
instance,howmuchadog'squalityoflife,observed
associatedwithsignificantpain
bytheowner,maybeimprovedbytheadministration
Overlyfocusingontreatingthecancerandnot
ofasimpleanalgesicifthedogissufferingfroma
present-moment'qualityof lifeofthepatient
tumour,which althoughpainless onpalpation,may
Inabilitytoassesspainincancerpatients
becausingconsiderablechronicpain.Despite this
Lackofknowledgeofdrugs,drugtherapy
statement,andthefactthatobviouspainassociated
combinationandotherpain-relievingtechniques
withspecifictumourssuchasosteosarcomahas
Lackofcommunicationwithclientsandlackof
beenemphasizedforalongtimeasadiagnosticcri-
involvementofclientsintheassessmentand
terion,thereisacompleteabsence ofcontrolled
treatmentphases
studies specificallyinvestigating theoccurrenceof
Underuseofnursingstaffforassessment and
cancerpainincompanionanimalsandarelativelack
re-evaluationofpain incancerpatients.
ofstudiesspecificallyinvestigatingthealleviationof
paininanimalssuffering fromcancer.
Thischapterdealswith theassessmentand
Giventhelackofanimalclinicalstudies,theinfor-
treatmentofchroniccancerpainindogsandcats.
mationinthischaptercannotbebasedonpeer-
Thecontrolofperioperativepainincancerpatients
reviewedinvestigations.Rather,itisacombinationof
isveryimportant(see‘Relationshipbetweencancer
theauthors'experienceandtheexperienceofothers
andpain')andreadersareencouragedtoreferto
whoareheavilyinvolvedinthetreatmentofanimal
appropriatetextsforinformationonperioperative
cancerpatients.Itis alsobasedonconsidered
paincontrolandalsotoChapter6,whichoutlines
extrapolationsfromhumanmedicineandfromveteri-
theprinciplesofperioperativeanalgesia.
naryresearchinother chronicallypainfulconditions,
suchasosteoarthritis.
Itisestimatedthatcancerpaincouldbeman-
How common is cancerpain in dogs
agedeffectivelyinupto90%of humanpatientswith
and cats?
problemsrelatedtohealthcare
professionals,
AsdiscussedinChapter1,theavailableinformation
patientsandhealthcaresystemsleadtofrequent
indicatesthatcancerhasasignificantprevalence
undertreatingofcancerpain.Thesamedrugs and
within thepetpopulation.Thenextquestion that has
techniquesrecommended foruse in humanscan
tobe asked is:“How painful is cancer？Not all
probablybeused togoodeffect inanimals.
tumoursarepainful,andtheamountofpainislikely
Therearenoestimatesforthenumbersofani-
tovaryconsiderablyfromoneanimaltoanother,
malswithcancerpainthatreceiveanalgesicther-
evenwithsimilartumourtypes.Theauthors'experi-
apy,norforhoweffectivethat therapyis.At thetime
ence,andthe experienceofothers,would suggest
thepreviouseditionofthismanualwaspublished，
that,using a conservativeestimate,30%of tumours
surveysintotheuseofanalgesicsintheperiopera-
areassociatedwithsomedegreeofpain.Tumours
tivesettingfoundthatsignificantnumbersofani-
mostlikelytobeassociatedwithpainincludethose
malswerenotreceivinganalgesicdrugs.Since that
at the following sites:oral cavity;bone;urogenital
time,significantimprovementshavebeenmadewith
tract;eyes;nose;liver;gastrointestinal tract;and skin
regardtotheidentificationandmanagementofpain.
(Figure 11.1).That the figure of 30%is conservative
Asaresult,preventing andmanaging pain has
issuggestedbylookingatthefiguresfromhuman
becomeafundamentalpartofhowveterinary
medicine:painisexperiencedby20-50%ofpatients
patientsare cared for.Inspiteofthis,thereis still
whenthelesionisdiagnosed,bynearlyhalfofall
room for furtherimprovement.The most recent
patientsinactive treatment,andbyupto90%of
111
Chapter11
Reliefofchroniccancerpain
Tumour category
Notes
Tumours involving bone
Primarybonetumours（bothof theappendicularandaxialskeleton）andmetastasistobonearepainfulJustasin
exception
Central nervous system
Extraduraltumoursthatexpandandputpressureonneuraltissueareoftenassociatedwithpainbuttumours
tumours
originating fromwithin theneural tissue areoftennotassociatedwithpainuntilateroninthecourseof disease.In
animals also suffer suchheadaches
Gastrointestinaltumours
Inflammatorymammary
Thisformofmammarycancerisverypainfulinhumans.Dogswiththisformofmammarycancerappeartoexhibit
carcinoma
obvious signsof pain
Genitourinary tract tumours
Prostatetumours
Prostatictumoursappeartobeparticularlypainfulespeciallyif localmetastasistoboneispresent
Oraland pharangeal tumours
relativelynon-ainfulumoursinvolvingbonerthatarerowingwithinthetissuesof themaxillaormandibleappear
tobesignifiantlymorepainfulSoftisuetumoursof thepharynxandcaudaloralcavityareparticularlypainfl
Intranasal tumours
Painprobablyresultsbothfromthedestructionof turbinatesandfromthedestructionofboneof thenasalcavity
Invasivesofttissuesarcomas
TheaggressiveinjectionsitesarcomasISs）incatsareparticularlypainfultheapparentizeofthelesiont
non-invasivesoftssuesarcomasthatarepressingonnervesandothersensitivestructureswillbepainfulOneform
Invasive cutaneoustumours
Especially those that areulcerative
Liverand biliary tumours
EspeciallythosethatareexpansilstretchingthelivrcapsuleExpansilelivertumoursarereportedtobepainulin
humans
Disseminated intrathoracic
and intra-abdominal tumours,
abdominallocalanaestheti）canmarkedlymrovetheanimalsdmeanourandthusutasnhumansitappears
e.g.mesothelioma,malignant
that disseminatedneoplasiaof thesecavitiesisassociatedwithsignificantpain
histiocytosis
Lung tumours
Howevereveninthoseanimals,theprovisionofananalgesiccanoftenmprovedemeanour
Pain following surgical
Painwellbeyond thepostoperativeperiodoccursinanimalsthathaveundergonesurgery.Mostoftenitisassociated
removal ofa tumour
withtumourrecurrencebut truephantompain（suchasphantomlimbpain）thatisnotassociatedwithtumour
recurrencedoes appeartoexistinanimals
11.1
Tumoursthatareprobablyassociatedwithpaininveterinarypatients.Inmanyof theseit isdifficult forthe
veterinarysurgeontoappreciatethatpainmaybepresent.However,theadministrationofananalgesicto
animalssufferingfromtheseconditionsisreportedbyownerstoresultinanimprovementindemeanour.Inthefaceof lack
of evidenceto thecontraryit issuggested that thisimprovement indemeanourisduetothealleviationofpain.
patientswithfaradvancedorterminalcancer.In
veterinarysurgeonistoalleviatesufferingand
humansanoverallaverageofabout70%ofpatients
maintainthewelfareof theanimalsintheircare.
withadvancedcancersufferpain.Muchof thisisdue
Intermsofanimalwelfare,fivefreedoms,initially
tometastasisofbreast andprostatecancertobone.
proposedbytheBrambellCommitteeinreferenceto
Inadditiontopaincausedbythetumouritself,pain
farmedanimals,mayequallybeappliedtothe
incancerpatientscanalsobecausedbychemo-
contextofcompanionanimals.Theyare:
therapy，radiationtherapyorsurgery(perioperative
pain,postoperative pain,and conditions such as
Freedomfromhungerandthirst
'phantomlimb'pain)andbyconcurrentnon-cancerous
·
Freedomfromphysicalandthermaldiscomfort
disease,mostnotablyosteoarthritis.
·
Freedomfrompain,injury,anddisease
。
Freedomtoexpressnormalbehaviour
Freedomfromfearanddistress.
Theimportanceofalleviatingpain
Thus,pain is one aspect that is considered to
The
alleviation
pain
is
important
from
compromisewelfare.Superimposedonthisshould
physiological andbiologicalstandpoints,aswell as
beaconsiderationof theseverityanddurationof the
fromanethicalpointofview.Theroleofthe
painfor theindividualpatient.Thegreater the
112
Chapter11Reliefofchroniccancerpain
duration of pain,such as in longstanding painful
perform particular functions?)components.It can
cancers,thegreateristhecompromiseofwelfare.
result fromobvious causes(e.g.ulcerated skin
However,itmustalsoberememberedthatanimals,
tumour)andlastanexpectedtimeperiod.However,
asfarasweknow,havenoabilitytojudgethefuture
in many cases (e.g.post-amputation pain),the pain
andsounrelievedpainatamomentintimemaybe
persistsaftertheoriginalpainfulcancerhasbeen
asignificantwelfarecompromise,evenif thepainis
removedorsurgicalwoundappearstobehealed.
goingtosubsideoverthesubsequentseveral days.
In thepast,painhasoftenbeencategorized as
Theapproachtothecancerpatientshouldbe
‘acute'or‘chronic'basedsolelyonduration-the
onethatconsidersallaspectsofwelfare.Inmany
latterarbitrarilybeingpainthatlastsmorethan3-6
cases,cancerpainisremovedwithtreatmentofthe
months-but it isnowaccepted that thismaynotbe
cancer.Incaseswhereownersdonotwant definitive
a helpful classification.It hasbeensuggested that
treatment,orwheredefinitivetreatmentisnotpossi-
thetermsadaptiveandmaladaptivebeadopted.
bleandownersdonotwanttoelectforeuthanasia,
pain control is important. With the increasing
Adaptivepainreferstoanormalresponseto
demand forhospice'typecareforpets,paincontrol
tissue damageand involvesan inflammatory
isanaspectevery
yveterinarysurgeonshould
component (e.g.a surgical incision).It is
becomefamiliarwith.
reversible overanexpected,relatively short,
Themajorityofveterinarysurgeonsprobably
timeperiod.
agreethatitis'right'toalleviatethepainassociated
Maladaptivepainresultsfromchangesinthe
withcancer,andmostofthelackoftreatmentor
spinalcordandbrain thatresult inabnormal
under-treatmentofcancerpainprobablystemsfrom
sensoryprocessing,and isusuallypersistent.
alackofknowledge,lackofrecognitionofpainand
lackofre-evaluationofpatients.Itdoesnotusually
stemfromalackofconcern.
Maladaptivepaincanresultfrompoorlytreated
adaptivepainandcanoccurquicklyinsomecircum-
Additionaleffectsofanalgesics
stances.Untilproven otherwise,cancerpain should
Physiologically,pain caninducea stressresponse,
beconsideredmaladaptive,withbothperipheraland
withelevationsin‘stresshormones'（aldosterone,
centralchangesinthepainprocessingsystemcon-
angiotensin ll,antidiuretic hormone,adrenocortico-
tributingtothepain,inadditiontonoxiousinputfrom
tropichormone,catecholamines,cortisol and renin)
thecancerorpathologicalarea.
anddecreasesinotherhormones(insulinand testos-
Ideally,painwouldbeclassifiedbytheunderly-
terone).Thesechangesresult inacatabolic state,
ingmechanism:forexample,inflammatoryorneuro-
withmuscleproteincatabolism.Astressresponse
pathic.However,manydiseasesareassociatedwith
canresultindecreasedhealingandcanalso
overlapping“forms'ofpain.Takenonestepfurther,
adverselyaffectthecardiopulmonaryandgastro-
painoccurringindifferentdiseasesorconditions
intestinal systems.Such systems are stressed
wouldbefurtherclassifiedbytheunderlyingmecha-
alreadybythepresenceofcancer.Ofinterestisthe
nismsin thatparticulardisease,andevenpatient.
findingthattheprovisionofanalgesicssignificantly
Thiscouldbereferredtoastheneurobiologicalsig-
reducesthetumour-promotingeffectsofundergoing
natureofpaininaparticulardiseaseorpatient.
Knowingthiswouldbetterguidethepractitionerin
knowntoresult inthesuppressionofseveralimmune
thechoiceof treatment.Forexample,adiagnosisof
functions,including natural killer (Nk) cellactivity,
‘cancer'pain is not very helpful,since the cause
probablyasaresultofreleasedsubstancessuchas
couldbemechanicalcompressionofa nerve,
catecholamines andprostaglandins.Thissuppression
inflammationfrom tissuenecrosis,mechanical dis-
ofNKcellactivitycanenhancemetastasis.The
tensionofanorganorneuropathicpain,oracombi-
reductionofthetumour-promotingeffectsofsurgery
nationof these.Adiagnosisofosteosarcoma
byanalgesicsseemstobeduetothealleviationof
bonepain'withtheassociatedknowledgeof the up-
pain-inducedreducedNKcellfunction,butitislikely
regulationofperipheralTRPV1andASiCreceptors,
thathithertounrecognizedfactorsotherthanimmune
andcentralCox-2enzyme,isfarmoreinformative
cells also play a role (Page et al.,2001).Thus,the
intermsofguidingclinicaltreatment.Withoutthis
provisionofadequateperioperativepainmanage-
information,treatmentisempirical-perhapsbetter
mentinoncologicalsurgerymaybeprotective
termedhitormiss'
againstmetastaticsequelaeinclinicalpatients(Bar-
Akeyfeatureofmaladaptivepainiscentralsen-
Yosefet al.,2001;Benishet al.,2008).It may alsobe
sitization-changes in thecentralnervoussystem
thatthetreatmentofchronicpain,oftenassociated
(anywherefrom thedorsalrootganglionrostrally)
withcancer,issomewhatprotectiveagainstmeta-
thatarelikelyinitiatedbycellular‘wind-up'andresult
stasisandpossiblythelocalextensionofcancer.
inamplificationandfacilitationofnociceptivesignal
generation and transmission(Figure 11.2).A cancer
thatisassociatedwithpain(suchasanosteosarc-
Classification ofcancer pain
oma)resultsinabarrageofsensoryinformation
goingintothespinalcordintheareaofthedorsal
Painisamultifactorialexperiencewithsensory(the
horn.As theproblemprogresses,peripheral sensiti-
sensation),affective/emotional (how it makes the
zationdevelopsandincreasestheamountofnox-
subject feel)and functional (can the subject still
iousstimuligoingintothe spinalcordandCNS.
113
Chapter11Reliefofchroniccancerpain
11.2
Peripheraland
central sensitization
and cancer pain.(a) In the
normalanimal,noxious stimuli
(redarrows)aretransmitted
via thespinalcordtothe
brainandperceivedbythe
brain aspainful.Non-noxious
stimuli(blue arrows)travel
Innocuous stimuli
throughthesystemandare
perceivedbythebrain as
non-painful stimuli.(b)A
cancerthatisassociatedwith
painresults inabarrage of
sensoryinformationgoing
intothespinal cordinthe
Noxious stimuli
areaofthedorsalhorn.
Peripheral sensitization
develops(see textfor
details),makingiteasierfora
signal toget throughandbe
Brief noxiousstimulusat theperiphery
perceived aspainful
(hyperalgesia).Also,usually
(a)
innocuousstimuliarefeltas
painful(blue arrowinto spinal
cordbecomesaredarrowto
thebrain).These changes are
knownascentral
hypersensitivity.
(c）Occasionally,after
resolution of theinitiating
problem(e.g.amputationfor
limbosteosarcoma)
behaviourindicativeofpain
Innocuous stimuli
remainsorrecurs.Thismay
beduetotheestablishment
of'paingenerator'centres.
Noxious stimuli
CNS sensitization
Tumour
(b)
Innocuous stimuli
Possiblepaingeneration sitesin
maladaptivepain
CNS sensitization
(c)
114
Chapter11Reliefofchroniccancerpain
Fromthispointanumberofprocesses takeplace,
Behavioural changes
including:rostraltransmissionofthenoxiousstimu-
Themainstayofpainassessmentincatsanddogs
lus(perceived as‘pain');activationofreceptorson
sufferingfromcancerislikelytobechangesin
dorsalhornneurons(e.g.NMDA receptors);and the
behaviour.Figure11.3outlinesbehavioursthatare
inductionoflonger-termchangeswithintheprimary
probablyindicative,incertain situations,ofpain.The
afferent fibre and theCNS(e.g.sodium channel,opi-
mainpointtorememberisthatanychangein
oidreceptor,serotinergicandnoradrenergic
behaviourcanbeassociatedwithpain.
changes).Theseresult inmodulationofnociceptive
informationprocessingwithinthespinal cord.The
Behaviour
Notes
endresultofthesechangesisaheightenedactivity
andresponsiveness ofthe spinal cord,making it
Vocalization
Althoughoftenthoughtofasassociatedwithpain,
easierforasignaltogetthroughandbeperceived
vocalizationisrareinresponse tochronicpainin
as painful (hyperalgesia).In addition,stimuli that
dogs andcats.Occasionally theremaybe hissing,
plaintivemiaowingorpurringncatsorwhiningin
wouldnotnormallyhavebeenfeltaspainful(both
dogs.Ownersaremorelikelytoreporthese
fromthesiteofsurgeryandfromotherareas)are
behaviours,astheyareseldomseenin the clinic
perceived aspainful(allodynia).Thesechangesare
Facial
Headhunglow,squintedeyesincatswiththeeyes
knownascentralhypersensitivity.Inpatientsexperi-
expression
drawntogetherbyafurrowed foreheadSad”
encinglong-lastingpersistentpain,asis the case
expressionindogs,headcarried low
withmanytypesofcancer,peripheralorcentralsen-
sitizationmaycontributetothefurtherdevelopment
Activity
Less activity than normal;decreased jumping:less
playing;lessventuring outside;less willing togoon
ofpain,separatefromtheinitial incitingcause,and
walks（dogs）;stiff gaitaleredgaitrlmeness
shouldbeconsideredinpatientswithpainthatis
canbeassociatedwithgeneralizedpanbutmore
unresponsivetofirst-lineorconventionalanalgesics.
oftenassociatedwithlimborjointpainslowtorise
Occasionally,afterresolutionoftheinitiatingprob
and getmovingafterrest(osteoarthritis-which is
lem(e.g.amputation for limbosteosarcoma),behav-
oftenconcurrentlypresent)
iourindicativeofpainremainsorrecurs.Thismaybe
Respiration
Maybeelevated withcancerpain
duetotheestablishmentofpaingenerator'centres
Attitude
(Figure 11.2c),probablyresulting from changes simi-
Any changeinbehaviourcanbeassociated with
painsuhashitrtuenagreiv
lartothosedescribedforcentralsensitization.There
dullness,shyness,'clinginess
ismuchdebateastowherethese‘generators'are,
andindeedtheymayexistatmultiplelevels.These
Appetite
Oftendecreased withchronicpain;tartarbuild-up
generators'are thoughttoberesponsibleforsyn-
ononesideof dentalarcaderelativetoothercan
indicatechronicoralpain;droppingof foodcanbe
dromessuchas‘phantom limb'pain.
indicativeofintra-oralpain
Earlyinterventionisrecommendedtolimit
cellularwind-upandpreventcentral sensitization.
Urinaryand
Failure touseliterbox(cats);urinating and
bowelhabits
defecating inside（dogs)
Grooming
Failuretgroomeciallywithchroni
Assessmentofcancer pain
canbe dueto eitherpainful oral lesionor
generalizedpain
Itislikelythatthetoleranceofpaininveterinary
Response to
One of thebestwaystodiagnoseandmonitor
patientsvariesgreatlyfromindividualtoindividual,as
palpation
pain.Paincanbeelicitedbypalpationofaffcted
itdoesinhumans.Coupledwiththeinnateabilityof
arearmanpulatnfafctdareah
dogsand,particularly,catstomasksignificant dis-
exacerbateslow-gradepaintoproducetransient
easeandprobablypain,thismakesitverydifficultto
severepainmanifestedasaversionresponse
from animal,i.e.animalattempts to escape
assesspain.Becausethereisnoobviousexternal
procedrrwriissrit
injury,itisoftendifficultforsomecliniciansandown-
inferred whenthisoccurs
erstoappreciatethatmanycancersareassociated
Posture
withpain.Failureofthepractitionertoassesspain
Unusualposturecanbeanearlyindicatorof the
presence of pain
adequately,bothinitiallyandthroughoutcancertreat-
ment,islikelyamajorcontributortounder-treatment,
Self-
Lickingatanareae.gjintwithostartrits
asitisdifficulttoassessbehaviourandefficacyof
traumatization
bonewithprmarybonecancerabdomenwith
intra-abdominal cancer)can indicate pain;
treatmentifabaselineisnotestablishedearlyon.
scratching canindicate pain(e.g.scratchingat
Unfortunately,littleworkhasbeencarriedoutonthe
cutaneoustumourscratchingandbitingatflank
assessmentofcancerpainincatsordogs.
with prostaticorcolonicneoplasia;scratchingat
area thathasreceivedradiationtherapy).Pulling
Physiologicalparameters
out ofhairorfurcanindicatepaininthatareaof
Physiological
variables
such
asheartrate,
thebodyatorbelowthe surface(e.g.hairpulling
respiratoryrate,temperature andpupil size have
at flankincatswithrenal tumours).Licking atan
beenshowntobeunreliablemeasuresofacute
areacanalsobeindicativeofneuropathicpainor
neurogenicpain;e.g.afterradiation therapyofa
limbconstantlickingattheareaormoredistl
unlikelytobeusefulinchronicpainstates.These
partsof limbmayindicateneuropathicpain
variablesareaffectedbypsychologicalfactors,
11.3
Behavioursthatmaybeseenincancer-
diseasestatesanddrugs,andthuscannotberelied
associatedorcancertherapy-associatedpain
upontodeterminewhetherananimal isinpain.
and other chronicpain incats and dogs.
115
Chapter11Reliefofchroniccancerpain
Tobe able toassesspain,theveterinarysur-
withatumour.Painmaybeelicitedbypalpationofa
geonneedstohaveabasicunderstandingofnor-
tumour,whichexacerbateslow-gradepaintopro-
mal behaviour in the species.Ideally,they should
ducetransientseverepain.Thisismanifested asan
haveknowledgeoftheindividualanimal'snormal
aversionresponse from theanimal,i.e.thecator
behaviour.This isnotpossible inmost cases and so
dogattempts toescape theprocedure，oryowls,
thebestpeopletoassesstheanimal'sbehaviour
cries,hisses or bites.Pain is inferred when this
aretheowners.Theveterinarysurgeonmustwork
occursanditcanthereforebeassumedthatthe
closelywiththeownertoassessthelevelofpain
tumourispainful.Whileitisimpossibletobesure
presentattheinitialevaluationandalsoduring
thattheintensityofthereactiontomanipulationis
there-evaluationsthatmusttakeplacethroughout
trulyrepresentativeoftheseverityofthepainfeltby
treatment.Ownersmaynotbeabletoassessthe
theanimal intheabsenceofstimulation,itshould be
levelofpainitselfbuttheyareusuallyableto
assumed thatpainispresentandstepsshouldbe
assess'qualityof life'.
takentoalleviateit.
Theefficacy ofanalgesictreatments,whether
Spontaneousbehaviours
drugsoradjunctivetherapiessuchasacupuncture,
It isimportant to assessspontaneousbehaviours.
shouldbemonitoredusingpalpationandmanipula-
tion.Also,it is important to assess cancerpatients
·Animals thatareinpain,especiallypain
fornon-cancerousrelatedpainfulconditions,suchas
associatedwiththemusculoskeletalsystem,do
osteoarthritis,and tomonitor thepainassociated
notmovearoundasmuchastheydidpriortothe
withthese.
pain.Becausecatsself-regulateexerciseandare
notgenerallytakenforwalksasdogs are,thisis
Response toanalgesic therapy
more difficult toassessincats.
Anotherverygoodwaytodeterminewhetheracat
Jumping,climbingandplayingareallactivities
ordogisinpainistoexamine itsresponseto
thatcanbedecreasedwhenpainispresent,
analgesictherapy.Bothspontaneousand inducedor
eitherlocalizedmusculoskeletalpain,localized
reactivebehavioursareassessed.Theowner'sinput
painnotassociatedwiththemusculoskeletal
here is vital,and assessing the response to
system,ormoregeneralizedpain.
analgesictherapyisacentralpartoftailoring
In cats,grooming isoftendecreased.Thiscanbe
effectivetreatmenttotheindividualanimal.
evaluatedbyexaminingtheconditionofthecoat.
In dogs,inparticular,attentionispaidtopainful
Health-relatedqualityoflifeassessment
areas,indicatedbylickingatsuchareas.
Overthepasttwodecades,therehasbeen
Bothcatsanddogsinpainhavedecreased
considerablefocusonassessmentofqualityof life
appetites,butdrinkingisusuallyunaffected
(QoL) in human medicine.In humans,cancer pain
unlessthepain issevere.
hasbeenshowntointerferesignificantlywithmany
aspects of daily life, thus altering overall QoL.A
Localizedpaincanresult inspecificsigns:
varietyoftoolshavebeendevelopedandvalidated
whichhaveproveduseful inassessingtheimpact
·Localizedjointboneorsofttissuepainwillresult
that specificdiseases,including cancer,haveona
inlameness,musclewastageoralteredgait
patient'sQoL.Qualityof lifeismostoftenmeasured
Oralpaincanresultinanunevenappearanceto
onthebasisofapatient'sresponsestoquestionsin
tartarbuild-uponteeth,withmoretartarbeing
theformofastructuredquestionnaire.
foundonthepainfulside,andcanalsoresult in
Though still in its relative infancy, there isa
problemswitheatingoranorexia.
growinginterestindevelopingsimilartoolsfor
assessingtheimpactofcertaindiseasesontheQoL
Theseareexamplesofcluestothepossible
ofanimals.Anadditionalchallengeencounteredin
presenceofpain,whichmaybedetectedonclinical
veterinarymedicineisthatassessmentsofQoL
examination.
mustbeprovidedbyaproxyinformant,typicallythe
The
problem
with
assessingspontaneous
ownerorprimarycaregiver-asituationsimilarto
behavioursisthattherearemanyfactorsreleased
assessmentof QoL inhumanneonates,mentally
bythetumouritselfthatcanresultindepressionand
disabledpatientsorthosewhoareseverelyill.
lethargy andsoaltered behaviours arenotalways
TheimpactofcancerpainonQoLindogshas
associatedwithpain.Forexample,lymphomaalso
oftenresultsinanorexia,butprobablydoesnotoften
questionnaire,demonstratingasignificantlylower
havea significantpaincomponent.Theanorexia in
QoLinanimalswithsignsofpainfromcancerwhen
thiscaseispossiblyduetomanyfactors,including
comparedwithhealthyanimalsorthosewithchronic
substances producedby the tumour itself.Also,
skin disease (Yazbek and Fantoni,2005).Other
authorshavereported theuseofquestionnairesto
producepain(e.g.hyperthyroidism).
assess the impact of chronic diseases,including
osteoarthritis(Hudsonetal.,2004;Wiseman-Orret
Inducedorreactivebehaviours
al,2004,2006;Brown etal.,2007,2009;Hielm-
Duringclinicalexaminationit isroutinetouseelicita-
Bjorkmanetal.,2009),spinal cord injuries（Budke
tionofpainasamarkerofpathology.Thesame
etal.,2008)and heart disease（Freeman et al.
approachshouldbeusedtoassesspainassociated
2005),onthequalityof lifeinanimals.While these
116
Chapter11Reliefofchroniccancerpain
toolsareunlikelytoreplaceclinicalevaluation,they
4.Deliverthetherapyinalogicalcoordinated
representyetanotheroptionforassessmentof
mannerandexplaincarefullytotheownerabout
patientswithchronicallypainfulconditions-mal-
anypossiblesideeffects.
adaptivepain.Theseinstrumentscanservebotha
5.Empowerclientstoparticipateactivelyintheir
discriminativeandevaluativefunction:theycan
pet'streatment;askforfeedbackand updateson
identifyanabsoluteQoLscoreataparticularpoint
howthetherapyisworking.
intime,aswellas determineanychanges that
occurasaresultofdiseaseprogressionortreat-
ment.Though notyetevaluated in animals,it has
Principles of drug therapy
beendemonstratedinhumansthatQoLscorescan
independentlypredictsurvivaltimeforpatientswith
Drugsarethemainstayofcancerpainmanagement,
a varietyof typesof cancer.
althoughnon-drugadjunctivetherapiesarebecom-
ingrecognizedasincreasinglyimportant.It iscur-
rentlyunknownwhichoftheapproachesoutlined
Anapproach tocancerpain
belowismostappropriate;indeed,oneapproach
management
maybebestatonestageof thedisease,andthe
otherlateron.
Althoughdrugtreatmentisthemainstayofcancer
paintreatment(see below),adjunctive non-drug
The‘analgesicladder
therapiessuchasacupunctureplayanimportant
TheWorldHealthOrganizationhasoutlinedagen-
roleinpainmanagementofthecancerpatient.It
eralapproachtothemanagementofcancerpain
must alsoberemembered thatsurgery(seeChapter
6)andradiationtherapy(seeChapter8)havevery
analgesics:
importantrolesinthemanagementofcancerpain
throughtreatmentorpalliationofthedisease.
Non-opioid analgesics(e.g.non-steroidal anti-
Abasicapproachtocancerpainmanagement
inflammatorydrugs(NSAIDs),acetaminophen)
couldbesummarizedasfollows.
Weakopioiddrugs(e.g.codeine)
Strong opioid drugs(e.g.morphine)
1.Assessthepain.Askfortheowner'sperceptions
Adjuvantdrugs(e.g.corticosteroids,tricyclic
of thepainpresentorofanycompromiseof the
antidepressants,anticonvulsants,N-methyl
animal'squalityof life.
D-aspartate(NMDA)antagonists).
2.
Believetheowner.Theownerseesthepetevery
dayinitsownenvironmentandknowswhen
This‘analgesicladder'（Figure 11.4)was devel-
alterationsinbehaviouroccur.Theownercan
opedonthepremisethathealthcareprofessionals
rarelysuggestdiagnoses,buttheydoknowwhen
shouldlearnhowtouseafewdrugswell.ltisbased
somethingiswrongandwhentheirpetisinpain,
onthreesteppedlevelsof treatmentintensity:
justasamotherknowswhensomething iswrong
withherchild.
Sometypesofpainrespond tonon-opioid
3.Choose appropriate therapy depending on the
therapyalone
stageof thedisease.Anythingotherthanmild
Painofagreaterintensitycanberelievedwith
painshouldbetreatedwithmore thanoneclass
thecombinationofanon-opioidandaweak'
ofanalgesic,orananalgesicdrug combinedwith
non-drugadjunctivetherapy.Alsoconsider
Moreseverepainrequirestheadditionofa
concurrentproblemsanddrugtherapy;beaware
higherdoseofopioid,andtheuseofastrong
ofpotentialdrug interactions.
opioidthatistitratedtothepainpresent.
Strong opioid
±Non-opioid
Weakopioid
±Adjuvant
±Non-opioid
Non-opioid
±Adjuvant
±Adjuvant
Paindue
Pain persisting
Painpersisting
?Freedomfrom
tocancer
orincreasing
orincreasing
cancerpain
11.4
TheWHOanalgesicladder'for the treatment ofcancerpain.
117
Chapter11Reliefofchroniccancerpain
Atanyof these threelevels,adjunctiveanalge-
beingadministered,and thenumberofclasses of
sicscanbeused toaugmentanalgesia.This
analgesicdrugsbeing used,canbedecreased.This
approachisasoundonewherethepainisinitiallyat
approachistermed(bythisauthorandothers)the
arelativelylowlevelandgraduallybecomesmore
analgesicreversepyramidapproach.
severe.However,therearetwoproblemswiththe
Themostimportantaspecttorememberinthe
useoftheWHOanalgesicladderinveterinarymedi-
treatmentofcancerpainisthat,forthemajorityof
cine.Thefirstisthatthereisverylittleinformation
situations,multimodal therapy(i.e.concurrentuse of
fromhumanmedicine,andvirtuallynonefromveteri-
more than oneclassof drug)isrequiredforsuccess-
narymedicine,onwhichdrugsaremosteffectivefor
ful alleviationof thepain.The theorybehind a multi-
whichparticular typesofcancerpain(seelater).It
modalapproachtothemanagementofcancerpain
maywellbethatso-calledfourthtier'drugsmightbe
stemsfromtheunderstandingthatpaintransmission
mosteffectiveforaparticularconditionandtherefore
involvesavarietyofdifferentpathways,mechanisms
bestusedupfront.Thiscommentrelatesbacktothe
andtransmittersystemsanditisunlikelythatasin-
gleclassofanalgesicwillprovidecompletepain
entcancerpains.The second problem is thatsuch
control.Multimodal approachescombineseveral
anapproachisnotsosuitedtopatientsthatpresent
drugswithdifferingmechanismsofactiontoaffect
initiallywithsignificant toseverepain.
theperception,transmissionandmodulationofpain.
Themultimodal approach
Inadditiontoprovidingmorecompletepaincon-
trol,anothermajoradvantageof thisapproachisthe
Manyveterinarycancerpatientspresentatan
abilitytoreducethedose,andthereforethepotential
advancedstageofdiseaseandthusarealreadyin
fortheoccurrenceofsideeffectsassociatedwith
pain.Oncepainhasbeenpresent foraperiod of
eachindividualdrug.This isespeciallyimportant
time,changes have taken place in the central
whenconsideringtheriskofadverseeventswith
nervoussystemthatalterthewaypainsignalsare
certain medications(e.g.NSAIDs)or the perception
processed:maladaptive pain(seeabove).Asa
of ownerstotheuntowardeffectsofothers(opioids).
result,theCNSofpatientsexperiencingmaladaptive
painmaybemore sensitive toadditionalpainful
Choiceofdrugs
stimuli.The clinicalimplications of this central
Aswebegintoembraceamechanisticapproachto
hypersensitivityare that,once‘pain'isestablished,
pain,weunderstandthatdifferentmechanismsmight
analgesic drugs,fora given dose,are muchless
underliepainassociatedwithdifferenttumours，or
effective(i.e.pain ismore difficult to control);and the
differenttumoursversusotherlong-termpaincondi-
‘pain’feltbytheanimalisgreater.Clinicalcancer
tions,such as osteoarthritis.The result isthe need
painisacombinationofcentralhypersensitivityand
fortreatmentsgearedtowardtheindividualpatient's
peripheralhypersensitivityandcanbeconsidered
specificneedsand theuseofasingleclassofan-
maladaptivepaininmostcases.Bothperipheral and
algesicforeverypatientwouldbeinappropriate
centralhypersensitivityareprobablywellestablished
However,multimodaltherapycanhavenegativeside
inmostveterinarypatientswithpainfulcancers.The
effectsassociatedwithitandthesehavenotbeen
implicationofthisisthatthepainismoredifficultto
definedinveterinarymedicine.Drugs thatcanbe
treat(duetotheestablishedchangesatthe
usedforchroniccancerpainmanagementareout-
peripheryand in thecentral nervoussystem)and
linedinFigures11.5and11.6.Thefollowingnotes
thusamultimodaldrugtherapyapproachshouldbe
arenotacomprehensiveappraisalofeachclassof
employed（usingdrugsf
fromseveraldifferent
drug,butarepointers to theiruseforcancerpain.
classes).Once the pain is minimized,and central
Figure11.7outlinesadecision-making treefor the
changes are partiallyreversed, the amounts of drugs
processof treating cancerpain indogsandcats.
Dose in dogs
Comments
Paracetamol
10-15mg/kgorallyq8hfor5days
Seems tobeassociated withfewerGI sideeffectsthan'regular'NSAIDs.Not noted tobe
Long-term therapy:upto10mg/kg
associated withrenaltoxicity.Toxicitynotevaluated clinically indogs.Canbecombined with
q12h
regularDsineverecancerinbutcominatinnotevalatedfortxity
Paracetamol+
Dosebased on10-15mg/kgof
Sedationcanbe seenassideeffect
codeine
paracetamol-correspond to
codeine at 2mg/kg
Amantadine
4.0-5.0mg/kg orally q24h
Loosestools and excessGI gascanbeseenat higher dosesfora fewdays.Should notbe
interactions
Amitriptyline
0.5-2.0mg/kg orally q24h
Aspirin
10mg/kg orallyq12h
CausessignificantlymoreGl ulceration thanapproved NSAIDs.Donotuseneartimeof
surgeryduetoinhibitionof plateletfunction
Butorphanol
0.2-0.5mg/kg orally up to q8h
Mayproducesedation at higherdoses.Nota verypredictable analgesic,and best when
used in combination(e.g.with NSAIDs)
Analgesicsthatmaybeconsideredforalleviationof chroniccancerpainindogs.Note thatnone of thedrugsis
11.5
authorized forthisuse.(continues)
?
118
Chapter11Reliefofchroniccancerpain
Dose in dogs
Comments
Codeine
0.5-2.0mg/kgorallyq12h
Sedationcanbe seen at higher doses
Carprofen
2mg/kgorallyq12hor4mg/kg
orallyq24h
Deracoxib
1-2mg/kgorallyq24h
(Only available in the US)
Etodolac
5-15mg/kg orally q24h
(Onlyavailable in the US)
Fentanyl,
2-5μg/kg/h
Canbeveryusefulshortterm.Usefulnesslimitedduetoneedtochangepatchevery45
transdermal
days and expense involved
Firocoxib
5mg/kgq24h
Gabapentin
10mg/kg orallyq12h
Notevaluatedforanalgesiceffectsbutappearstobeusefulforcertainneuropathicpain
e.gaflmbamtationrvrootmourinthrcanceinnlingr
damage).Besteffectsseen when used in combination(e.g.with NSAIDs orparacetamol)
Glucosamine and
13-15mg/kgchondroitin sulphate
Oftennotconsideredforcancerpain.Mildanti-inflammatoryandanalgesiceffects.
chondroitin sulphate
orallyq24h
Preparations withavocado-soyaunsaponifiablesmaybemoreeffective asmild analgesics
Meloxicam
0.2mg/kg orally day1,then0.1mg/
kgq24h
Morphine,liquid
0.2-0.5mg/kgorallyq6-8h
CanbeusefulfordosingsmallerdogswheretabletsnotsuitableSedationand（particularly)
constnidfsenissf
Morphine,sustained
0.5-3.0mg/kg orally q8-12h
Doses>0.5-1.0mg/kgareoftenassociated withunacceptableconstipationaccordingto
release
Pamidronate
1-1.5mg/kg slowlyiv.q-5wks
Inhibitsosteoclastactivityandprovidesanalgesiaincasessuffering fromprimaryor
metastaticbonetumourcausingosteolysis
Piroxicam
0.3mg/kg orallyq24-48h
Polysulphated
5mg/kgi.m.twice weekly,then
Hasnteenevauatdfraceinmayprvidemilanagicefctugst
glycosaminoglycan
onceamonth
notused incancerpatientswithhaemostaticdisorders
Prednisolone
0.25-1mg/kg orallyq12-24h;taper
DonotueconcurrentlywithNSAIDs.Canbeparticularlyusefulinprovidinganalgesia
toq48hif possibleafter14days
Robenacoxib
1mg/kg
Tepoxalin
10mg/kgq24h
Tramadol
4-5mg/kg oralyq8-12h
Not evaluated forefficacyor toxicity indogsbut appearstobeusefuladjunctive analgesic
(when combinede.g.acetaminophen orNSAIDs).Notecommentsin text about GI ulceration
Vedaprofen
0.5mg/kgq24h
11.5
(continued)Analgesicsthatmaybeconsidered foralleviationofchroniccancerpainindogs.Note thatnone of
the drugsisauthorized forthis use.
Cat dose
Notes
Paracetamol
Contraindicated
Contraindicated-small dosescausedeath in cats
(acetaminophen)
Amantadine
3.0-5.0mg/kg orally q24h
Notevaluatedfortoxicitybutwetoleratedindogsandhumanswithoccasionaside
chroniccancerpainconditions.The100mgcapsulesneed tobere-compounded forcats
(can be done using amantadine powder)
Amitriptyline
0.5-2.0mg/kg orally q24h
Appearstobewelltolerated forupto12monthsof dailyadministration.Hasbeenused for
cysticcalculiwereobservedduringtreatmentinsomecats.Maybeusefuladditionto
NSAIDsfortreatment ofcancerpainconditions
Aspirin
10mg/kg orallyq48h
Cancause significantgastrointestinalulceration
Buprenorphine
0.02mg/kg sublingual q8-12h
Sublingualroutenotresentedbycatsmaybegodwaytoprovidepostperative
long-termadministrationeseciallyincombinationwithotherdrugs
Suggesteddosagesof analgesicsthatmightbeconsideredforthealleviationofcancerpainincats.Notethat
11.6
noneof theseisauthorizedinanycountry forthetreatmentofcancerpaininthecat;some areapprovedfor
fromtheseThedosagesgivencomefromtheauthorsexperienceandthatofothersworkingintheareaofclinicalcancer
pain control.(continues)
119
Chapter11
Reliefofchroniccancerpain
Drug
Cat dose
Notes
Butorphanol
0.2-1.0mg/kg orally qh
One studysuggestsoralbutorphanolaftersurgerymaybebeneficial.Generaly
usefulaspartofmultimodalapproachtocancerpaintherapy
Carprofen
Not enoughdatato enable
recommendationsfor
long-termadministration
Etodolac
Not enough datato enable
recommendations
Fentanyl,transdermal
2-5μg/kg/h
Patchesmayprovide7daysanalgesiainsomecases.Followingremovalat3days
decayinplasma levelsisslow
Firocoxib
Not enough data to enable
recommendations
anti-pyrexiaeffects inpyrexiamodel
Flunixin meglumine
1mg/kgorallyq24hfor7days
Dailydosingfordaysresultsinincreasedrateofmetabolismofdrug.iseinliver
Gabapentin
10mg/kgq12h
Glucosamine/chondroitin
Approx15mg/kgchondroitin
Appeartoproducemildanti-inflammatoryandanalgesiceffectsincatsmorepredictably
sulphate combinations
sulphate orallyq12-24h
than in dogs
Glucosamine/chondroitin
Labelled dose
ThispreparationhasonlyjustbecomeavailablebutadditionofsDasuquinapear
sulphate combination with
to boost analgesiceffects of Glu/Cho4
avocado-soya extracts
Ketoprofen
1.0mg/kg orally q24h;
maximum5days
treatments.Hasalsobeenusedat1mg/kgq3dlongterm.Anotherapproachhasbeen0.5
mg/kgq24hfordaysweekdaysfollwedbyodrugoverweekendandthisireeated
Meloxicam
0.1mg/kg orally on day1,
Particularlywellreceivedbycatsduetoformulationashoneysyrup.Dropformulation
followedby0.05mg/kg
makesit very easyto decreasedosegradually and accurately.Meloxicam shouldbe dosed
orally q24h for4 days,
then 0.05mg/kgq48h
SuggesteddosingregimennotevaluatedforclinicaltoxicityApprovalgainedinEurope
thereafter,or0.025mg/kg
(June 2007）forlong-term（unlimited）use ofmeloxicam incat at 0.1mg/kg onday1,
q24h
followedby0.05mg/kgq24hformusculoskeletalpain
Morphine,oralliqud
0.2-0.5mg/kg orallyq6-8h
Bestcompoundedintopalatableflavouredsyrupbutcatusuallystronglyresentthis
medication.Morphinemaynoteaseffectiveincatsas indogs
Morphineralsustnd
Tabletstoolargefordosing
release
cats
Piroxicam
0.2-0.3mg/cat orally q24h
piroxicamtoleratedwellincatswithcancerwithmain sideeffectsGsigns
Polysulphated
5mg/kg s.c.twiceweekly for4
Noevidence-asedmedicinethatitprovideanyffectbutanecdotalinformaton
glycosaminoglycans
weeks;then once weekly for4
suggests efficacy in some cancerpain
weeks;thenoncemonthly
(other suggested regimens call
foronceweeklyinjectionsfor4
weeks,thenoncemonthly)
Prednisolone
0.5-1.0mg/kg orallyq24h
administration
Robenacoxib
1-2mg/kg q24h forup to6
Shorthalflife(1-2hours） incatDemonstratestissue selectity
days
Tepoxalin
Not enough data to enable
recommendations
Tolfenamicacid
4mg/kgorallyq24hfor3days
Recentobjectivemeasurementsdemonstrate analgesiaincatwhenadministered
max
perioperatively
Tramadol
1-2mg/kgq12-24h
Recentstudiesindicatemetabolismof tramadolslowerincatthandogandproductionf
M1metabolitverymuchgreatereadingtogreatertndencytoeepioid-isi
effects
Vedaprofen
0.5mg/kgq24h for3 days
postoperativepainfollowingovariohysterectomy
11.6
approvedforinflammatoryorpainfulconditionsinthecatincertaincountries,anddosesforthecontrolofcancerpainare
clinical cancerpain control.
120
Chapter11Reliefofchroniccancerpain
Assessmentofcancerpatient
Reassess
atregular
intervals
Functional
Behavioural
Palpation
assessment
assessment
Pain unrelated
Cancerpain
Nopain
tocancer
Treat as
AnalgesicLadder or
appropriate
ReversePyramid approach
Initiate base (NSAID;
Adjunctive drugs and
Switchbase
steroid;paracetamol)
therapiesto consider
±adjunctive
addingintothe
initial therapy:
Nutraceuticals
Sideeffects
NMDA antagonists
Reassessment
TCAS
Not
Gabapentin
efficacious
Tramadol
Painpersists
Steroids(notwith
NSAIDs)
Paracetamol
Othertreatments
Transdermal opioids
Initiatemultipleadjunctive
to consider:
treatments
Oralopioids
IV'desensitization
Bisphosphonates
therapy'
Transdermal local
Radiationtreatment
anaesthetic
Reassessment
Surgical resection
(ifresponseispoor,
Epidural catheter
consideralteringdoses
Neurolytic(chemical or
where possible,OR,
surgical)procedures
Painpersists
consider72hoursof
'desensitizationtherapy"
Neuroablative
[IVopioid,lidocaine
techniques
andketaminel)
Painpersistsorsideeffects
unacceptablewhenrelief
obtained
Consider euthanasia
11.7
Decision-makingtreeforthetreatmentofcancerpainincatsanddogs.Thisshouldbeconsideredasaguide
painassociatedwithosteosarcomawithanNsAlDandpalliativeradiationbeforemoving tootheradjunctivedrugs.
Non-steroidal anti-inflammatorydrugs
increaseinactivitywasduetothedenovosynthesis
Newimpetustothefieldsofanalgesiaandinflam-
ofnewCoXprotein.Shortlyafterthis,theinducible
mationresearchwasprovidedbythefindingthatthe
COXproteinwascharacterizedasadistinctisoform
cyclo-oxygenase enzyme(Cox)exists in(atleast)
of cyclo-oxygenase, cox-2,and was shown to be
twodifferentforms.ItwasfoundthatCoxactivity
encodedbyadifferentgenefromthatproducingthe
wasstimulatedbybacterialendotoxinandthatthis
constitutive enzyme,renamed Cox-1.Thus,there
121
Chapter11Reliefofchroniccancerpain
arenowknowntobetwotypesofcyclo-oxygenase
ThechoiceofNSAIDsavailablecanbebewilder-
enzyme，oneproducing‘essentialprostaglandins'
ing,andcontinuestoincrease,buttherearea few
(e.g.prostaglandins that areinvolved inmaintaining
keypointstonote.
mucosal integrityof thestomach)onaminute-to-
minutebasis,andavnotherthatisactivatedbytissue
Onapopulationbasis,allNSAIDsareequally
traumaandresultsintheproductionofinflammatory
efficaciousinrelievingpainassociatedwith
orpain-mediating’prostaglandins.However,it isnot
osteoarthritis,butforagivenpatientonedrugs
assimpleasCOx-1being‘good’andCOx-2“bad”，
oftenmoreeffectivethananotherdrug.Thisis
asCox-2hasbeenshowntobeexpressedconstitu-
probablyevenmoretrueforcancerpain,where
tivelyincertaintissues,suchasthecaninekidney
themechanismsofpainmaybeverydifferent
andcaninegastrointestinaltract(Wootenetal.,
fromonepatienttoanother.
2008)andmayplayaroleinprotectionandhealing
Gastrointestinalsideeffectsassociatedwith
ofgastricandduodenal mucosa(Goodmanet al.,
NSAIDusemaybemorecommonwithdrugsthat
2009).So,although theorywould suggest that selec-
preferentiallyblockCOx-1overCOX-2,but
tiveorspecificCox-2inhibitorsmightbeassociated
COX-2selectivedrugsmaydelayorinhibit the
withfewergastrointestinalsideeffectsthananon-
healingof gastricerosionsandulcers.
selectivedrug,thishasnotyetbeenprovedinveteri-
Thereisnodifferenceinrenaltoxicitybetween
COX-1selective drugs andCOx-2selective
narymedicine.Additionally,ifgastroduodenal
ulceration ispresent,selective or specific Cox-2
drugs.BothCOx-1andCOx-2areconstitutively
inhibitorsmayinterferewithhealing.Theclinical sig-
expressedinthekidney.
nificanceof thishasnotbeendefined.Theorywould
LivertoxicitywithNSAIDsisanidiosyncratic
alsosuggestthatCox-2selectivedrugsarenotany
eventthatcanhappenwithanyNSAID.
safertothekidneythanarethenon-selectivedrugs.
Thetotal levelofsideeffectsseenwiththe
Again,widespreadclinical experience indogsis
differentNSAIDsisprobablythesame,butthe
required to substantiate this,though the COx-2
typeofsideeffectsseenwithdifferentNSAIDs
selectivedrugsusedinhumanshavebeenfoundto
appearstodiffer.
beassociatedwithasimilarincidenceofrenaltoxic-
Thus,veterinarysurgeonsshouldstarttreatment
ityastraditionalNSAIDs.
NSAIDsare themostwidelyusedanalgesic
usinganNSAIDwithwhichtheyarecomfortable,
andpossiblyconsidertheaspectofCox-2inhibition
drugsinhumanandveterinarymedicineandthe
orpublishedworkdemonstratingananti-cancer
mainstayfortreatmentof long-standingpain,espe-
effectof aparticularNSAID.
ciallyinosteoarthritis.Theyhavebothcentralanal-
gesicandperipheralanti-inflammatoryeffects.When
Monitoring:If thedrug is effective,it should be
combinedwithothermedications，suchasopioids,
continued.lf not,therapy should be switched to
theyexhibita synergistic effect,allowingfor the
anotherNSAID.Thepatientshouldbemonitoredfor
reductionindose,andintheory thepotentialforthe
toxicity.This consists of twoaspects:
developmentofadverseeffectsassociated.They
shouldbeconsideredasacomponentofamulti-
Informingtheownerofpotentialtoxicityandwhat
modalpainmanagementplaninpatientsforwhich
signstowatchfor(lethargy,depression,vomiting
thereisnotaspecificcontraindicationtoadministra-
melaena,increasedwateringestion)
tion(e.g.renal,hepaticor gastrointestinal disease;
Regularbloodwork(andurinalysis)toevaluate
concurrent steroid administration).
renalfunction（urea,creatinine,urine specific
Apartfromtheconcernoverside effectspro-
gravity)andliverfunction(alkalinephosphatase
ducedbyNSAIDs,discussionofCOXenzymeshas
andalanineaminotransferaseand,ifthese
furtherrelevancetocancerpaintherapy.Ofparticu-
enzymesareraised,bileacids).Abaseline
larinterestincancerpainmanagementisthefinding
shouldbeobtainedwhentherapyisinitiated and
that NSAIDs that inhibit COX-2may not only produce
parametersmonitoredonaregularbasis
painalleviationincancerpainstatesbutalsodem-
thereafter.Therearenoguidelinesonthis,but
onstrate anti-tumoureffects.Inrecentyears,there
theauthorrepeatstheevaluationafter2-4
hasbeenaconsiderableamountofresearchpub-
weeks,andthenat2-4-monthlyintervalsas
lishedregardingtheexpressionofCox-2and/or
dictatedbytheindividualpatientandclient.This
PGE2byavarietyofepithelialandnon-epithelial
re-evaluationisdonemorefrequentlyifmultiple
tumours,including canine transitional cell,prostatic
drugs areused,as thereisnoinformation on
andrenal carcinoma,osteosarcoma,oraland cuta-
clinicaltoxicityassociatedwithcombinationsof
neous squamous cell carcinomas,oral melanoma
analgesicsadministered chronically.Caution
and colorectaladenocarcinoma.Incats,both oral
shouldbe used when administering any NSAID
squamouscellcarcinomaandtransitionalcellcarcin-
todogswithrenal disease;paracetamolmaybea
omashavebeenreportedtoexpresstheCox-2
good alternativeinthesecases.
enzyme(Spugnini etal.,2005;Hayes,2007).These
findingshaveresultedininterest intheclinical useof
NSAIDSincats:NSAIDsareconsideredpotentially
NSAIDsasacomponentoftreatment for these
moretoxictocatsthantodogsorhumans.
tumours,particularlynowwiththewidespreadavail-
Interestingly,thereseemstobesignificantvariation
abilityofCOx-2selectiveorspecificinhibitors.
amongindividualcatsinthemetabolismofNSAIDs
122
Chapter11Reliefofchroniccancerpain
andalsoinconsistentvariationintherateofmeta-
what seemsa‘peripheral’problem,suchas many
bolismofdifferentNSAIDScomparedwithother
cancers,centrally acting analgesics can be very
species.TheuseofNSAIDsincatshasbeencom-
effective.Althoughhighlytoxicin thecat(evenin
prehensivelyreviewed(Lascellesetal.,2007)and
smallquantities)itcanbeeffectivelyusedindogsfor
pertinentdevelopmentssincethatpublicationarethe
paincontrol.Nostudiesoftoxicityindogshavebeen
approval inEuropeandothercountries(including
done,butiftoxicityisseenitwillprobablyaffectthe
Australia)ofmeloxicamtotreatchronicmusculoskel-
gastrointestinal system and,inlargerdoses,theliver.
etalpain.Anadditionaldevelopmentisthatthefirst
Itcanbeusedonitsownorinapreparationcom-
coxib class of NSAIDs,robenacoxib,has been
binedwithcodeineandisinitiallydosedatabout
grantedapproval inEuropeforuseincats.
10-15mg/kgq12h.Theauthoroftenusesitas the
CatsaremoresensitivetoNSAIDsthanaredogs
first lineofanalgesictherapyindogswithrenalcom-
andsomonitoringshouldprobablybecarriedout
promisewhereNSAIDs cannotbeused,orindogs
morefrequently thanindogs.Therearenoguide-
that appeartobeotherwiseintoleranttoNSAIDs(e.g.
linesfor monitoring catsreceiving chronicNSAID
vomiting orgastrointestinal ulceration).
administration.Theauthorsconsideritveryimpor-
tanttomonitor thesepatientsclosely,andsuggest
Opioids
thefollowing:
Inhumans,opioids represent the primary class of
analgesicsformanagementofmoderatetosevere
Abiochemistrypanel,packedcellvolume,total
cancer pain.Many veterinary surgeons,however,
proteinassayandurinalysismeasurementsprior
maybeunfamiliarwiththeuseofopioidsoutsidethe
tostartingtheNSAID
perioperativeperiod.Opioidsactatall levelsofthe
Re-evaluationat1week,4weeksandevery46
painpathway-peripherally,and centrally at the
weeksthereafter.
spinalcordandbrain.Opioidreceptorsinteract
positivelywithotheranalgesicsystemssuchasthe
Thisshouldbedoneinconjunctionwithcontinual
NMDAandalpha-2receptorsandthereforecanbea
reassessmentofthepatientsothatthedosecanbe
veryeffectivepartofthemanagementofcancerpain
tapereddowntothesmallesteffectiveamountas
aspartofamultimodalapproach.
soonaspossible.Althoughdecreasingspecificgrav-
Opioidsmaybeclassified aspureμ-agonists(e.g.
ityisnotanearlyindicatorofrenaldiseaseincatsas
morphine，hydromorphone,oxymorphone,fentanyl,
itisinthedog,butisratheralatephenomenon,urin-
codeine,meperidine),partial agonistsorK-agonist/
alysisshouldstillbeperformedonaregularbasis.
μ-antagonists.Pureμ-agonists are thought to pro-
Decreasingthedrugdosetothelowesteffective
ducethemostcompleteanalgesia.Buprenorphine is
amountisprobablyaveryimportantfactorinlimiting
a commonlyusedpartial μ-agonist.Butorphanol is an
clinical toxicityofNSAIDsinthecat.Thesesugges-
exampleofaK-agonist/u-antagonistand isgenerally
tionsarebasedonverylimitedinformationthatthe
regarded asaweak analgesicdrug;assuch,itsuse
authorshavegatheredonthetoxicityofNSAIDsin
in treatingcancerpainislimited.
cats.Ownersshouldbeinformed aboutthepossibil-
Most commonly,pure μ-agonists are givenby
ityof toxicity andgiventhesignstolookfor.
injection,butoralepiduralandtransdermalroutesof
administrationmayalsobeused.
AdditionaldrugsforusewithNSAIDs:Ifpain
reliefwithNSAIDsisinadequate,otherdrugscanbe
Oralroute:Oralopioidmedicationssuchascodeine
administeredinconjunctionwiththem.Agentsthat
codeine-combination drugs(such as paracetamol
canbeused include:paracetamol;fentanylpatches;
plus codeine),morphine,methadone orbutorphanol
amantadine (an NMDA antagonist);anticonvulsants/
canbeadministeredtodogs,butverylittleisknown
calcium channel modulators,such as gabapentin;
abouttheirefficacybythisroute.Whengivenorally,
and tricyclic antidepressants,such as amitriptyline.
opioidsaresubjecttoahighfirstpass'effectin the
Transdermal lidocainepatchescanbeusedtotreat
liver;publishedstudieshavedemonstratedthatoral
localizedpainanditisbelievedthattheymaypro-
morphineandmethadonearenotwell absorbed in
videreliefinsomemaladaptivepainstates.These
thedog,whichmaylimittheireffectivenessclinically
canallbecombinedwithNSAIDs.However,thetox-
(Kukanichetal.,2005ab).However,unpublished data
icityrelatedtosuchpolypharmacyhasnotbeen
suggest that other oral opioids (suchas codeine)
definedandcliniciansareadvised tomonitorcare-
maybeabsorbedintothesystemiccirculationand
fullyfor side effects.
thushavetheopportunityofbeingeffective.
Paracetamol
Transdermalroute:Transdermaldeliveryofopioids
Paracetamol(acetaminophen)isanon-acidNSAID;
hasbecomeanincreasinglypopularmethod for
manyauthoritiesdonotconsideritanNSAIDasit
managingboth acute and chronicpain inhumans.In
probablyactsthroughdifferentmechanisms.
animals,transdermaldeliveryofopioidsavoidsthe
Although itsmechanismofactionispoorlyunder-
hepaticfirst-passmetabolismassociatedwithoral
stood，itislikelythatitactsthroughseveralcentral
opioids.Theprimaryuseoftransdermalopioidshas
mechanisms,possiblyincludinginhibitionoftheactiv-
beenforthetreatmentofacutepostoperativepain.
ityofasplicevariantofCox-1andbyactingthrough
Fentanyl istheonlyopioidmedicationforwhichstud-
theendogenouscannabinoidsystem.Withanymal-
ieshavedemonstratedeffectivetransdermaldelivery
adaptivepain,therearealwaysCNSchanges,sofor
andresultinganalgesiainanimals.Fentanylpatches
123
Chapter11Reliefofchroniccancerpain
require12-24hourstotakeeffectandlastaslong
thattheplacementofafentanylpatchprovidessuffi-
as4days.Analgesiaachievedfollowingfentanyl
cient analgesia.Animalswithfentanylpatches
patchplacementaloneisgenerallymildtomoderate,
shouldberegularlyassessedandsupplemental
butincasesofmoreseverepainitmayallowfor
analgesicsshouldbeprovided if necessary.Recently
reductioninthedosesofadjuvantmedications.
publisheddataevaluatingtheanalgesiceffectof
Morerecently,transdermalbuprenorphinepatches
transdermalbuprenorphineincatsfailedtodemon-
havebeen introducedinhumansforuseinavariety
strateasignificantanti-nociceptivebenefit(Murrellet
ofchronicpainconditions,includingcancerpain and
al.,2007).
chronicneuropathicpain.Therearecurrentlynodata
tosupport theuseof thesepatchesfordogs.
NMDAantagonists
Itisofnote thatnoneof thesedrugshasbeen
The N-methyl D-aspartatereceptor appears tobe
fullyevaluatedforclinicaltoxicitywhenadministered
centraltotheinductionandmaintenanceofcentral
inthelongterm,norforefficacyagainstcancerpain
sensitization,andtheuseofNMDAreceptorantago-
inthedogorcat.It isimportant torealizethatdosing
nistswouldappeartoofferbenefitinthetreatmentof
mustbedoneonanindividual basis,and adjustment
painwherecentralsensitizationhasbecomeestab-
of thedosetoproduceanalgesiawithoutundesirable
lished(i.e.especiallymaladaptivepain).
sideeffectsrequiresexcellentinteractionandcom-
Ketamine,tiletamine,dextromethorphan,meman-
municationwithclients.
tadineandamantadinepossessNMDAantagonist
properties,among otheractions.Dogsmaynotmake
Epiduralroute:Inadditiontotherouteslisted
theactivemetaboliteafteradministrationofdextro-
above,opioidsmaybeadministeredviatheepidural
methorphan,whichprobablynegatesitsuseindogs
route,either asa singleperioperativeinjection,or
for chronic pain (Kukanich and Papich,2004b).
followingtheplacementofanepiduralcatheterfor
Studieshavesuggestedabenefitofusingketamine
continuous infusion following surgery or asa
perioperativelyinlowdoses.
componentofhospice-typecare.
Amantadinehasbeenusedforthetreatmentof
neuropathicpaininhumans.It doesnothavethe
Sideeffects:Sideeffectsofopioids caninclude
undesirablesideeffectsassociatedwithketamine
diarrhoea,vomiting,constipationwithlong-termuse
administration.Theauthorshavebeenusingaman-
andoccasionallysedation.lt isveryoftentheconsti-
tadineoverthepastfewyearsasanadjunctivedrug
pation,and occasionally the sedation seen,that
(usuallytogetherwithanNSAiD)forthealleviation
ownersseemtoobjecttomost,especiallywiththe
of cancer pain.Recent data suggest that it appears
administrationoforalopioids.
toaugmentpainreliefindogswithosteoarthritis,
withalowincidenceofsideeffects(mainlyagitation
Opioidsincats:There is currentlynoinformation
anddiarrhoeaoverthefirstfewdaysofadministra-
onthelong-termuseofopioidsforpaininthecat.
tion)(Lascelles etal.,2008).This work suggested
Interestingly,thereseemstobesignificantindividual
thatitmaytakeupto2weekstoseethefulleffect
variationinthelevelofanalgesiaobtainedwithcer-
andsoitmaybeadrugtostartearlierratherthan
tainopioids,especially morphineandbutorphanol,in
laterincancerpaintreatment.Amantadineshould
the acutesetting.Buprenorphine appearstoproduce
probablynotbeused inpatientswithcongestive
predictableanalgesiawhengivensublinguallyinthe
heartfailure,norinpatientsonselegiline,sertraline
cat（Robertsonet al.,2005).Comparedwith
or tricyclic antidepressants.
humans,thesublingual route appears more effective
Thedevelopmentof
fmorespecificNMDA
in cats;thismaybearesultof differencesinioniza-
antagonistsisanexcitingareaofresearch,butthe
tioninthealkalineenvironment(pH8-9)of thecat's
developmentofclinicallyusefulandtargeted
mouthcompared with thatofhumans(pH6.5-7).
antagonistsishamperedbythefactthattheNMDA
Sublingualadministrationofbuprenorphineiswell
receptorisknowntoexistinnumerousformswhich
acceptedbycats,withnoresentmentorsalivation
maychangerapidlyfollowingnociceptiveinput.
andsothereisnoneedtocompound theinjectable
Additionally，theformand quantityofthespecific
solution.Basedon clinicalfeedbackfromowners,
NMDAreceptormaydiffer significantlyfromone
thisisaveryacceptabletechniqueforthemtoper-
painful condition to thenext.
formathomeandtheauthorshavefounditusefulto
usesublingualbuprenorphineinthemanagementof
Combination analgesics
certaintypesofcancerpaininthecat.However,
Tramadolisacentrallyactinganalgesicwithcomplex
someownersdonotlikethebehaviouralchangesit
interactions
between
opiate,
adrenergic
and
caninduceincats(euphoria)nor the dilatedpupils.
serotonergicreceptors.Opioidreceptors arewell
Inaddition,inappetencecanoccurafterseveral days
knowntobeinvolvedinpainstates,andthe
oftreatment.Sometimesslightlylowerdosescan
descendingserotonergicsystemisknowntobeone
overcometheseproblems.
of thebody'sendogenous'analgesic'mechanisms.In
Thepharmacodynamicsandkinetics of trans-
humans,clinicalresponsetotramadol isdetermined
dermalfentanylhavebeenevaluatedinthecatand
byitsmetabolism,primarilydue to theanalgesic
thismethodofdeliveryhasprovenefficacyforrou-
effectsof itsmetabolites.Hepaticdemethylationof
tineperioperativeanalgesia.Significantvariationsin
tramadolproducesthemajoractivemetabolite,
plasmaconcentrationsoffentanylhavebeen
O-desmethyltramadol(M1),which isreported tobe
reported,however,andit should notbepresumed
200timesmorepotentattheu-receptorthan the
124
Chapter11Reliefofchroniccancerpain
parentdrug,whichhasaweakaffinityfortheopioid
toother medications.These drugs are most com-
receptors.Boththeparentdrugandmetaboliteexist
monlyadministeredintravenouslyandaregenerally
asaracemicmixture,anddifferentmetabolites
usedasacomponentofamultimodalperioperative
interactdifferentlywiththetargetreceptors
painmanagementplan.Inaddition to theintra-
(Kukanich andPapich,2004a).
venousroute,a2-agonistmaybeadministeredvia
Pharmacokineticstudieshavebeenperformedin
epiduralinjection（incombination withmorphine
both dogs and cats (Kukanich and Papich,2004a;
and/oralocalanaesthetic),intra-articularly,orasa
Pypendop and llkiw,2008)and have suggested
componentofaperipheralnerveblock.Theiruse
sufficientabsorptionoftheoralformandplasma
perioperativelymayhelptopreventlong-termpost-
levelsthataresimilartothoseachievedinhumans,
operativepainorneuropathicpain.
withasignificantlyshortereliminationhalf-life.
Plasmaeliminationhalf-lifeoftheM1metaboliteis
Anticonvulsantdrugs
longerincatsthanindogs,possiblyduetocats'poor
In humans many anticonvulsants,such as car-
abilitytoglucuronidatecompounds.Morerecent
bamazepine,
phenytoin,
baclofen
and，
more
pharmacokineticdatacall intoquestiontheamount
recently,gabapentin,have been used to treat
of theM1metabolitethatisformedindogsfollowing
chronic pain,including
neuropathicpainand
intravenous(McMillan et al.,2008)andoral(Giorgi
chemotherapy-induced
peripheral
neuropathies.
etal.,2009b)administration and,asaresult,calls
Gabapentinand themorerecentlyintroducedpre-
intoquestiontheeffectivenessoftramadolasan
gabalinappeartobeamongthemosteffective
analgesicinanimals.Veryfewstudieshavebeen
drugsavailableforneuropathicpain,buthavealso
performedassessingtheanalgesiceffectoftramadol
beendemonstratedtobeeffectivewhenusedto
inthedogorcatandnonehaveevaluateditsusein
treatacutepostoperativepain.Whiletheexact
treatingmusculoskeletal orcancerpain.Inveterinary
mechanismof actionof thesedrugs isunclear,one
medicine,the standard oral formulation is most
commonlyprescribed;
and
basedonrecent
effect isbybinding tothealpha-2-deltaproteinsub-
pharmacokineticdata,it appearsthattheextended-
unit of voltage-gated calcium channels,thereby
releaseformulationdoesnotallowforonce-daily
reducingexcitatoryneurotransmitterreleasethrough
dosing,as inhumans(Giorgietal.,2009ab).
channel modulationorchannel trafficking.
Tramadolhasnotbeenevaluatedfortoxicityin
Indogs,although thereisconsiderableinforma-
thedogorcatandalmostnothingisknownabout
tionongabapentindisposition(Vollmeretal.,1986;
thesideeffectswhentramadoliscombinedwith
Radulovicetal.,1995)andsomeinformationonits
otherdrugsinhumanorveterinarypatients.Arecent
useasananticonvulsant(Platt etal.,2006),there
studyinhumansfoundthat,forpatientshospitalized
isasyetnoinformationonitsuseforpaincontrol.
for pepticulcer treatment,tramadoluse prior to
Veryrecently,informationonthekineticsofgaba-
admissionwasassociatedwithagreaterriskofmor-
pentin incatshasbecome available（unpublished)
talitythanwasNSAIDusepriortoadmission.
buttherearenoscientificpublicationsdemonstrat-
Additionally,mortalitywas2.02-and1.41-foldhigher
ingitsefficacyforlong-termpain inthis species.
in these groups of patients,respectively, than in
While the indicationsforgabapentin(andpregaba-
patientswhousedneither tramadolnorNSAIDs
lin)are atpresentunclearinveterinarypatients,
（Torring et al.,2008).The authors of that study sug-
theydo appear tobeuseful for cancer pain in
gestedthatthismaybeduetotheabilityoftramadol
somepatientsandareprobablyparticularlyeffec-
tomaskvisceralpainassociatedwithgastrointesti-
tiveincancers thathave some neurogenicor
nalirritationandperforation.However,arecentstudy
nerve destruction component.The authors start at
evaluating theanalgesiceffectsofvariousdosesof
10mg/kgtwicedaily.
rofecoxibandtramadol,bothaloneand incombina-
tion,found that themostanalgesiccombinationof
Tricyclicantidepressants
tramadolandrofecoxibproducedgastricinjuryin
Tricyclicantidepressantshavebeenusedformany
ratsthatwasmoreseverethanwitheitherdrug
yearsforthetreatmentofchronicpainsyndromesin
alone(Garcia-Hernandezetal.,2007).The cause of
humansandarebecomingwidelyusedforthemod-
this injury isunknownbut thesedatadosuggest
ulationofbehaviouraldisordersinanimals.Within
that,undercertaincircumstances,cautionmayneed
the central nervous system,there are descending
tobeexercisedwhencombiningNSAIDsandtrama-
inhibitoryserotonergicandnoradrenergicpathways
dol.However,there arenodatafrom dogs or cats,
thatreducepaintransmissionin the spinalcord.
andotherdataontramadolsuggestprotective
Tricyclic antidepressants,such as amitriptyline,clo-
effectsonthegastrointestinaltract.
mipramine,fluoxetine,imipramine,maprotiline and
paroxetine,primarilyinhibit thereuptakeofvarious
α2-Agonists
monoamines(serotonin forclomipramine,fluoxetine
Thisclassofdrugsexertsanalgesicandsedative
and paroxetine;noradrenaline forimipramine,ami-
effectsbyinteractionwiththea-adrenergicrecep-
triptyline and maprotiline).Tricyclicantidepressants
torsinthedorsalhornofthespinalcordandwithin
canalsointeractdirectlywith5HTandperipheral
thebrainstem.Thoughnotcommonlyusedasfirst-
noradrenergicreceptors andmay also contribute
lineanalgesics,drugs suchasmedetomidine,deto-
otheractionssuchasvoltage-gatedsodiumchannel
midineanddexmedetomidinehavethepotentialto
blockadeandreductioninperipheralPGE-likeactiv-
provideexcellentanalgesiawhenusedasanadjunct
ityortumournecrosisfactor(TNF)production.
125
Chapter11Reliefofchroniccancerpain
Thesedrugshavebeenusedinhumansforthe
painful stimulus,itispossible theymayhaveanalge-
treatmentofchronicandneuropathicpainatdoses
sicactionsduetothesystemicabsorptionoflido-
considerablylowerthanthoseusedtotreatdepres-
caine.Humanpatientsdonotreportalossof
sion.Severalrecentsystematicreviewsofthe
sensitivityornumbness.Whilethemechanismofthis
humanliteratureconfirmtheefficacyofantidepres-
differentialblockadeisnotcompletelyunderstood,it
sant medications(specifically tricyclic antidepres-
hasbeensuggestedthatthelidocainepatchdelivers
sants)in treating certain chronic pain conditions
adequateamountsofdrugtoblocksmall,injuredor
such asneuropathicpain,fibromyalgia,lowerback
dysfunctionalpainfibres,whilelargemyelinatedA-β
painandheadaches.Theauthorsofthesestudies
sensoryfibresareunaffected.Studieshavebeen
identifythat,eveninhumanmedicine,thereisarela-
performedevaluatingthekineticsoflidocaine
tivelackofcontrolledclinicaltrialsspecificallyevalu-
absorbedfrompatchesappliedtodogsandcats
atingtheefficacyofantidepressantsintreating
(Weilandetal.,2006;Koetal.,2007,2008;Weilet
cancerpain,withtheexceptionoftwostudiesdem-
al,2007).Peakplasmaconcentrationsof lidocaine
onstratingalackofefficacyinthetreatmentof
wereobtained10-24hoursafterapplicationindogs
chemotherapy-inducedperipheral neuropathy.
andat65hours after application incats.Theresults
Giventhepossibilitythatmanybehaviouraldis-
of these studies indicate that,as inhumans,sys-
ordersareinfactduetochronicpain,tricyclicanti-
temicabsorptionof lidocainefrom thepatchismini-
depressantsmaynotbedirectlyaffectingbehaviour
mal.Peakplasmaconcentrations wereover100
butratherpain itself,resultinginbehavioural modifi-
timesbelowthelevelreportedtoinduceneurological
cation.Theopposite argument could alsobemade.lt
signsand10timesbelowthelevelreportedtoresult
isnotunrealistictoassumethat,althoughmorediffi-
inmyocardialdepressionindogs,and25 times
cult toappreciate or evaluate,chronicpainful condi-
lowerthanthatobservedfollowinganintravenous
tionsmayalsoaffectmoodorbehaviourinveterinary
injectionoflidocaine(2mg/kg)incats(Weilandet
patients，andthesymptomatictreatmentofbehav-
al.,2006;Ko etal.,2007,2008).Potentialsystemic
iouralalterationsmay,inturn,givetheappearancef
toxicityassociatedwithlidocaineadministration
a decreaseinpainasperceivedbytheowner.
including bradycardia,hypotension,cardiac arrest,
Thetricyclicantidepressantamitriptylineappears
muscleorfacialtwitching,tremors,seizures,nausea
tobeeffectiveinthecatforpainalleviationininter-
andvomitingwerenotnotedinanystudy.
stitialcystitisandmanypractitionersarereportingeffi-
Whiledosingguidelineshavebeen suggested
cacyinotherchronicallypainfulconditionsinthecat,
(Weil etal.,2007),there have been nopublished
includingosteoarthritis.Amitriptylinehasbeenused
reportsevaluatingtheanalgesicefficacyoflidocaine
dailyforperiodsupto1yearforinterstitialcystitis
patchesinveterinarypatients.Basedontheauthors'
andfewsideeffectshavebeenreported.Theauthor
experience,catsappeartobeparticularlysensitive
hasusedamitriptylineinthecatforcancerpainwith
totheeffectsoflidocaineandcareshouldbe
someencouragingresults.lt shouldprobablynotbe
exercisedif lidocainepatchesareutilized.
usedconcurrentlywithotherdrugsthatmodifythe
serotonergicsystem,suchasamantadineortrama-
Steroids
dol,untilmoreisknownaboutdruginteractions.
Steroidshaveamildanalgesicactionandcanalso
produceastateofeuphoria;theyareoftenusedfor
Sodiumchannelblockade
thesereasonstopalliatecancerandcancerpainin
Alterationsinthelevelofexpression,cellularlocali-
catsanddogs.Theyshouldnotbe usedconcurrently
zationanddistributionofsodiumchannelsareseen
withNSAIDs,because theriskof side effects is
inmanypainstates.Theseaberrantlyexpressed
increaseddramatically.
sodiumchannelsresultinhyperexcitabilityand
ectopicactivityinperipheralandcentralnervesthat
Bisphosphonatesandothertargetedtherapies
encodenociceptiveinformation.Lowdosesof lido-
forskeletalneoplasia
caineandothersodium-channelblockersreadily
Malignantbonediseasecreatesauniquepainstate,
blocktheseaberrantlyexpressedsodiumchannels,
withaneurobiologicalsignaturedistinctfromthatof
producingpainrelief.
inflammatoryandneuropathicpain.Bonepain
Sodiumchannelblockersmaybeadministered
inducedbyprimaryormetastaticbonetumoursis
orally,intravenously,intrathecallyorasacomponent
ofaperipheralnerveorplexusblock.Althoughnota
latedosteoclastactivityandactivationofnociceptors
convenientmodeofdeliveryforveterinarypatients
byprostaglandins,cytokinesandhydrogenions.
unlesshospitalized,low-doseintravenouslidocaine
Therapiesthatblockosteoclastactivityandaimto
hasprovedaseffectiveasothercommonlyused
preventboneresorptionnotonlyhavethepotential
medications for treatment ofneuropathicpainin
toreducebonepainmarkedly,butmayalsomitigate
humansand theauthorsusesuchanapproachto
otherskeletalcomplicationsassociatedwithneo-
'down-regulate'centralsensitizationinveterinary
plastic conditions,including pathological fractures
cancerpatients.
andhypercalcaemiaof malignancy(Fanet al.,2007).
Thereisincreasinginterestintheuseof
Bisphosphonatesare syntheticanaloguesof
transdermallidocainepatchesfortreatment
of
pyrophosphatewhoseprimaryeffectistoinhibit
chronicneurologicalandosteoarthriticpain
in
osteoclastactivity.Afteradministration,bisphospho-
humans.Although most recommendations suggest
natesaccumulateinareasofbonethataremore
thatthepatchesbeplacedclosetothesiteofthe
metabolicallyactive,suchas trabecular bone,
126
Chapter11Reliefofchroniccancerpain
growingbone,andareasofosteolysisandrepair.
effectandananalgesiceffect.Theauthorshave
Followingosteoclast-mediatedboneresorption,bis-
foundthemtobeofbenefitinthealleviationofcan-
phosphonatesarereleasedfromhydroxyapatiteand
cerpainbutonlywhenusedaspartofamultimodal
thendisruptcellularfunctions,resultinginosteoclast
approach.Theanalgesiceffectappearstobemore
death.Oral absorptionofbisphosphonatestends to
predictable in cats thanindogs,and the authors
bepoorandintravenousdosingisthepreferred
prefercombinationsofglucosamineandchondroitin
routeofadministration.
sulphatewithavocado-soyaunsaponifiables.
While most reports suggest that these drugs are
relatively non-toxic,adverse effects have been
Radiationtherapy
reportedandincludeoesophagealandgastrointesti-
Radiation therapy isa useful tool inthepalliationof
nal tractirritation(following oral dosing),nephrotoxic-
certaincancerpain.However,radiationpainisa
ity(followingintravenousadministration),electrolyte
recognizedsideeffectofradiationtreatmentof
abnormalitiesand acute-phasereactions(Milneret
tumoursinanimals,and thepainassociatedwiththis
al.,2004).
isextremelydifficulttocontrol.Chapter8gives
Inadditiontotheinhibitoryeffectsofbisphospho-
detailedinformationontopicalmixturesthatcanbe
natesonosteoclasts,reports suggest that theymay
usefulindecreasingradiation-associatedpain.The
alsoexert directeffectsoncancer cells,including
authorsrecommend
anaggressivemultimodal
canineosteosarcomaandfibrosarcomalines,
analgesicdrugapproachthatisinstigatedearlyin
throughavarietyofdifferentmechanisms.Several
patientsundergoingradiationtherapy.
studieshavedemonstratedbeneficialeffectsofintra-
venouspamidronateforthetreatmentofmalignant
Acupuncture
osteolysisandpainassociatedwithprimaryandsec-
Therearenopublishedstudiesontheuseofnon-
ondary bone neoplasms（Fan etal.,2005，2007，
drug therapy（apartfromsurgeryandradiation)for
2008,2009).Thesestudieshavecollectivelydemon-
thealleviationofcancerpain.Fromveterinary clinical
stratedareductioninfocalbonelysisandan
experience,oneofthemostuseful adjunctstodrug
improvementinbothsubjectiveandobjectivemeas-
therapyappearstobeacupuncture.Placementof
uresofpainandlamenessindogswithavarietyof
needlesatspecificacupuncturepointscanrelieve
tumours.As is the case in humans,however,the
painthroughseveralmechanisms.
additionofpamidronatetostandardpalliativethera-
pies(radiation,chemotherapy)doesnotappear to
Acupuncturemaydecreasemusclespasms
improvethedurationofpaincontrolindogswith
whenneedlesareinserted intopressurepoints.
osteosarcoma,though there is evidence that the
Lackofspasmsconsiderablyincreasespatient
degreeofpainalleviationmaybegreater(Fanet al.,
comfort.Musclespasmsareoftenpresent in
2009).Pamidronatemaybeadministeredatadose
cancerpatientswithpain,duetoalteredgaitfrom
of1-2mg/kgasa 2-4-hour infusion（dilutedin
apainful limb,oralteredgaitfromconcurrent
saline)andrepeatedat intervalsof3-5weeks.
osteoarthritis.
Otherexamplesofbisphosphonatesthatcanbe
Acupuncturecanalsoinduce thereleaseofa
usedindogsareclodronate,aledronate
and
varietyofneurotransmitters,whichcanaffectthe
zoledronate （Tomlin etal.,20o0;de Lorimier and
processingofthepainimpulse.
Fan,2005;Martin-Jimenezetal.,2007;Fan et al.,
2008;Wypijet al.,2008).
Acupuncturecanbeprovidedthroughsimplenee-
Samarium-153isaradioisotopethathasbeen
dleplacement,orbyneedleplacementcombined
evaluatedforuseinbothhumansanddogs(Milneret
withelectrical stimulation(ofhighor lowfrequency,
al,1998).Whenadministeredas153Sm-lexidronam,
thecompoundconcentratesinareasofincreased
stimulation).Resultsofa studybyCulpetal.(2005)
osteoblasticactivityandbindstohydroxyapatitecrys-
demonstratedaweakanalgesiceffectofelectro-
tals,whichallowsfortargetedtherapyofbone
acupunctureinanaesthetizedpatientsasevaluated
tumours.Betadecayof theisotopeisreportedto
byareductionintheMACof inhaledanaesthetic
resultinbothtissue-destructive andtherapeutic
agent.Morerecentdata utilizingarodent model sug-
effects.Themostcommonadverseeffectreportedin
gestedthatelectroacupuncturemayhavebeneficial
bothhumansanddogsismyelosupressionresulting
effectsintreatmentofpainassociatedwithbonecan-
inthrombocytopeniaandleucopenia.Whiletheuse
cer（Zhang etal.,2007,2008).In contrast,Kapatkin
of153Sm-lexidronam inveterinary medicine is still
etal.(2006)foundnobenefitofelectroacupuncture
limited,resultsofarecent studydemonstrated an
ontheseverityoflamenessinagroupofdogswith
improvement inlameness scores in 63%of dogs,
osteoarthritis.It islikelythat thebenefitsofacupunc-
turearevariableandspecifictothetypeanddegree
liationofpainindogswithbonetumoursinwhich
ofpain that isexperienced.
curative-intenttreatmentisnotpursued(Barnardet
Arecentsystematicreviewoftheuseofacu-
al,2007).Furtherresearch isneeded todetermine
punctureinveterinarymedicineconcluded thatthe
theultimaterolethatthistherapymayplay.
evidencefortheeffectivenessindomesticanimals
Nutraceuticals
torecommendorreject itsuse intreating anycondi-
Theseareoftenusedinosteoarthritisandthereis
tion'(Habacher et al.,2006).The authors did sug-
evidencethattheyprovideamildanti-inflammatory
gestthatthedataregardingthealleviationof
127
Chapter11Reliefofchroniccancerpain
cutaneouspainwereencouragingandwarranted
Brown DC,Boston RC,Coyne JC andFarrar JT（2007)Development
furtherinvestigationutilizingmorerigorousinvestiga-
andpsychometric testingof aninstrument designed tomeasure
chronicpainin dogswithosteoarthritis.AmericanJournalof
tivemethods
VeterinaryResearch68,631-637
Inadditiontopotentialanalgesiceffects
BrownDC,BostonR,CoyneJCandFarrarJT(2009）Anovelapproach
to the useof animalsin studiesofpain:validation of the canine
brief paininventoryincanine bone cancer.PainMedicine10.133-
alleviatenauseainducedby theadministrationof
142
certainchemotherapeuticoranalgesicdrugs.
Brown DC,ladarola MJ,Perkowski SZet al.(2005)Physiologic and
antinociceptiveeffectsof intrathecalresiniferatoxinina canine
bonecancermodel.Anesthesiology103,1052-1059
Budke CM.Levine JM,Kerwin SCet al.(2008)Evaluation ofa
Thefuture:towardsamechanistic
questionnaire forobtainingowner-perceived,weightedquality-of-
lifeassessmentsfordogswithspinalcordinjuries.Journalof the
understandingofcancerpain
AmericanVeterinaryMedicalAssociation233,925-930
CulpLB,Skarda RTand MuirWW(2005)Comparisons of the effectsof
Overthepastfewyears,ithasbecomeevidentthat
acupuncture,electroacupuncture,and transcutaneous cranial
electrical stimulationonthe minimumalveolarconcentrationof
thepaintransmissionsystem isplastic,i.e.italtersin
isofluraneindogs.AmericanJournalofVeterinaryResearch66
responsetoinputs.It is alsobecoming understood
1364-1370
deLorimierLPand Fan TM(2005)Bonemetabolic effects of single-
that thisplasticityresultsinauniqueneurobiological
dosezoledronateinhealthydogs.JournalofVeterinaryInternal
signaturewithin theperipheralandcentralnervous
Medicine19,924-927
systemforeachpainful disease.Readingandunder-
Fan
TM,Charney SC,de Lorimier LP et al.(2009)Double-blind
placebo-controlledtrialofadjuvantpamidronatewithpalliative
standingtheindividualneurobiologicalsignaturesfor
differentdiseaseprocessesshouldallownovel,tar-
osteosarcomabonepain.JournalofVeterinary InternalMedicine
getedandmoreeffectivetreatmentstobeestab-
23,152-160
FanTM,de LorimierLP,Charney SCand HintermeisterJG(2005)
lished.This approach should alsoallowfora more
Evaluationof intravenouspamidronateadministrationin33cancer-
informedchoicetobemaderegardingwhichofthe
bearingdogswithprimaryorsecondaryboneinvolvement.Journal
of VeterinaryInternalMedicine19,74-80
currentlyavailabledrugsmightbemosteffective.
Itmaysurprisereadersthatonlyinthepast10
yearshasthefirstrelevantmodelofcancerpain
malignantosteolysis.JournalofVeterinaryInternalMedicine22
380-387
beenestablishedinrats:anosteosarcomamodel.
FanTMdeLorimierPODel-AndersonK,Lacoste HIandCharey
Prior tothis,evaluationofmechanisms andtreat-
appendicularosteosarcomabonepain.JournalofVeterinary
mentswasundertakeninvariouschronicpainmod-
InternalMedicine21,431-439
elssuchas sciaticnerveligation,or injection of
FreemanLM,RushJE,FarabaughAEandMustA(2005)Development
chronicirritants-modelsthatdidnotinvolvecancer.
andevaluationofaquestionnaireforassessinghealth-related
Theestablishmentofmorerecentmodels,such as
VeterinaryMedicalAss0ciation226,1864-1868
theosteosarcomapainmodel,haveshownthatthe
Garcia-HernandezL,Deciga-CamposM,Guevara-LopezUandLopez
neurobiologicalsignatureofpaininclinicallyrelevant
Munoz FJ (2007)Co-administration of rofecoxib and tramadol
resultsinadditiveor sub-additiveinteractionduring arthritic
modelsisverydifferentfromthatintheoldermodels
nociceptioninrat.PharmacologyBiochemistryandBehaviour87，
ofchronicpain.
331-340
GiorgiMDelCarloS,SaccomanniGetal.(2009a)Biopharmaceutical
Thenewapproachofusingclinicallyrelevant
profileoftramadolinthedog.
VeterinaryResearch
modelshasallowedtargetedpaintreatmentstobe
Communications33(Suppl.1),189-192
GiorgiM,SaccomanniG,Lebkowska-WieruszewskaBandKowalski
developed.Suchmodelswillalsoallowforthe
(2009b)Pharmacokinetic evaluation of tramadol and itsmajor
screeningofthepotentialefficacyofothernovel
metabolitesaftersingleoralsustainedtabletadministrationinthe
treatments,such asselective neuroablation tech-
dog:apilotstudVerinayourna180253-255
GoodmanL,Torres B,Punke Jetal.(2009）Effects of firocoxib and
niques.Recentlypublishedresearchhasdemon-
tepoxalinonhealinginacaninegastricmucosal injury model.
stratedverypromisingresultsutilizingsuchnovel
JournalofVeterinaryInternalMedicine23,56-62
approachesassubstanceP-saporinandresinifera-
Habacher G,Pittler MH and Ernst E(2006) Effectiveness of
toxinfor thetreatmentofchronicpain.Thesesub-
acupunctureinveterinarymedicine:systematicreview.Journalof
HayesA(2007)Cancer.cyclo-oxygenaseandnonsteroidalanti-
VeterinaryInternalMedicine20,480-488
stances,when administered intrathecally,induce
selectivedestructionorinactivationofneurons
inflammatorydrugs;canwecombine all three?Veterinary and
Comparative Oncology5,1-13
involvedinpaintransmission,resultinginprolonged
Hielm-Bjorkman AK,Rita Hand Tulamo RM (2009)Psychometric
analgesiainpatientsinwhichconventionalanalge-
testingof theHelsinki chronicpain indexby completionofa
sics are ineffective.The effectiveness of such
questionnaireinFinnishbyownersofdogswithchronic signsof
paincausedbyosteoarthritis.AmericanJournalofVeterinary
approacheshasbeendemonstratedindogswith
Research70.727-734
osteosarcomaof thelimbs(Brownetal.,2005)
Hudson JT, Slater MR.Taylor L,Scott HM and Kerwin SC(2004)
questionnaire for use inassessingpainandlameness in dogs.
AmericanJournalofVeterinaryResearch65,1634-1643
Referencesandfurtherreading
Kapatkin AS, Tomasic M, Beech J et al. （2006) Effects of
electrostimulated acupunctureongroundreaction forcesandpain
scoresindogswithchronicelbowjointarthritis.Journalof
Bar-Yosef S,Melamed R,Page GG et al.(2001）Attenuation of the
AmericanVeterinaryMedicalAssociation2281350-1354
Ko
J,Weil A,MaxwellL,Kitao T and Haydon T（2007)Plasma
Anesthesiology94,1066-1073
concentrationsoflidocainein dogs following lidocaine patch
Barnard SM,Zuber RMand Moore AS(2007)Samarium Sm 153
application.Journalof theAmericanAnimalHospitalAssociation
lexidronamforthepalliativetreatmentofdogswithprimarybone
43,280-283
tumors:35cases(1999-2005).Journalof theAmericanVeterinary
KoJC,MaxwellLK,Abbo LA andWeilAB(2008)Pharmacokineticsof
MedicalAssociation230,1877-1881
BenishM,BartallGoldfarbYetal.(2008）Perioperativeuseofbeta-
lidocainefollowingtheapplicationof5%lidocainepatchestocats.
JournalofVeterinaryPharmacologyandThrapeutics3135937
blockersandCox-2inhibitorsmay improve immunecompetence
Kukanich B,Lascelles BD,Aman AM.Mealey KL and Papich MG
andreducetheriskof tumormetastasis.AnnalsofSurgical
3A
Oncology15,2042-2052
p-glycoproteinandgastricacidsecretionontheoralboavailability
128
Chapter11Reliefofchroniccancerpain
ofmethadoneindogs.JournalofVeterinaryPharmacologyand
MetabolismandDisposition23,441-448
Therapeutics28,461-466
RobertsonSA,Lascelles BD,TaylorPMandSearJW(2005)PK-PD
KukanichB,LascellesBD andPapich MG(2005)Pharmacokinetics of
modelingofbuprenorphinein cats:intravenousandoral
morphine andplasma concentrationsofmorphine-6-glucuronide
transmucosaladministration.JournalofVeterinaryPharmacology
followingmorphineadministrationtodogs.JournalofVeterinary
andTherapeutics28,453-460
Spugnini EP.Porrello A， Citro G and Baldi A (2005)COX-2
overexpression in canine tumors:potential therapeutic targetsin
themetaboliteO-desmethyitramadolindogs.JournalofVeterinary
PharmacologyandTherapeutics27,239-246
Tomlin JL,SturgeonC,Pead MJand MuirP(20oo)Use of the
KukanichBandPapichMG（2004b)Plasmaprofileand
bisphosphonate drug alendronate forpalliativemanagement of
pharmacokineticsofdextromethorphanafterintravenousandoral
osteosarcomaintwodogs.VeterinaryRecord147,129-132
administrationinhealthydogs.JournalofVeterinaryPharmacology
Torring ML,RisA,ChristensenSetal.(2008）Perforatedpepticulcer
andTherapeutics27,337-341
andshort-termmortalityamongtramadolusers.BritishJournalof
Lascelles BD, Court MH,Hardie EM and Robertson SA (2007)
ClinicalPharmacology65565572
Nonsteroidalanti-inflammatory drugsincats:areview.Veterinary
VollmerKO,vonHodenbergAandKolleEU(1986)Pharmacokinetics
AnesthesiaandAnalgesia34,228-250
andmetabolism
ofgabapentin
inrat,dogandman.
Lascelles BD, Gaynor JS, Smith ES et al.(2008)Amantadine in a
Arzneimitelforschung36830-839
multimodalanalgesicregimenforalleviationofrefractory
WeilAB,KoJand Inoue T(2007)The use of lidocaine patches.
osteoarthritispainindogs.JournalofVeterinaryInternalMedicine
CompendiumContinuingEducationforVeterinarians29,208-210
22,53-59
212,214-216
Lindley Sand TaylorP(201o) Chronicpain.In:BSAVA Manual of
Weiland L,Croubels S,BaertKet al.(2006)Pharmacokinetics ofa
CanineandFelineRehabilitation,SupportiveandPalliativeCare:
lidocainepatch5%indogs.JournalofVeterinaryMedicine.A,
CaseStudiesinPatientManagementedSLindleyandPWatson,
Physiology.Pathology.ClinicalMedicine53.34-39
pp.42-59.BSAVAPublications,Gloucester
Wiseman-OrrML,NolanAM,ReidJandScottEM(2004)Development
Martin-Jimenez T,De Lorimier LP,Fan TM and Freise KJ (2007)
ofaquestionnaire tomeasure the effectsof chronicpainonhealth-
Pharmacokineticsandpharmacodynamicsofasingledoseof
relatedqualityof lifeindogs.AmericanJournalofVeterinary
zoledronateinhealthydogs.JournalofVeterinaryPharmacology
Research65,1077-1084
andTherapeutics30,492-495
Wiseman-OrrML,ScottEM,ReidJandNolanAM(2006）Validationof
McMillanCJ,LivingstonA,ClarkCRetal.(2008）Pharmacokineticsof
astructuredquestionnaireasaninstrumenttomeasurechronic
intravenoustramadolindogs.CanadianJournalofVeterinary
painindogsonthebasisofeffectsonhealth-relatedqualityof life.
Research72,325-331
AmericanJournalofVeterinaryResearch671826-1836
Milner RJ.Dormehl 1.Louw WK and Croft S（1998）Targeted
Wooten JG,Blikslager AT,Ryan KA et al.(2008)Cyclooxygenase
radiotherapywithSm-153-EDTMPinnine casesofcanineprimary
bonetumours.Journalof theSouthAfricanVeterinaryAssociation
69,12-17
inflammatorydrugs.AmericanJournalofVeterinaryResearch69,
MilnerRJ,Farese J,Henry CJet al.(2004)Bisphosphonates and
457-464
cancer.JournalofVeterinaryInternalMedicine18597-604
WypiJM,FanTM,FredricksonRLetal.(2008）Invivoandinvitro
MurrellJC,RobertsonSA,TaylorPMetal.(2007)Useof a transdermal
cats.JournalofVeterinaryInternalMedicine22,158-163
andpharmacodynamicdata.VeterinaryRecord160,578-583
YazbekKV andFantoniDT(2005)Validityofahealth-relatedquality-of-
Page GG,Blakely WP and Ben-Eliyahu S (2001)Evidence that
postoperativepainisamediatorof the tumor-promoting effectsof
of theAmericanVeterinaryMedicalAssociation226.1354-1358
surgeryinrats.Pain90,191-199
YoxallAT（1978)Pain in small animals-itsrecognition andcontrol.
PlattSRAdamsVGarosiSetal.(006）Treatmentwithgabapentinf
JournalofSmallAnimalPractice19,423-438
11dogswithrefractoryidiopathicepilepsy.VeterinaryRecord159
ZhangRX,LiALiuBetal.(2007）Electroacupunctureatenuatesbone
881-884
cancerpainand inhibitsspinal interleukin-1betaexpression ina
Pypendop BHand llkiwJE(2008)Pharmacokineticsof tramadol,and
ratmodel.AnesthesiaandAnalgesia105,1482-1488
itsmetaboliteO-desmethyl-tramadolincats.JournalofVeterinary
Zhang RX,LiA,Liu Bet al.(2008） Electroacupuncture attenuates
PharmacologyandTherapeutics315259
bone-cancer-induced
hyperalgesiaandinhibitsspinal
Radulovic LL,Turck D,von Hodenberg A et al.（1995）Disposition of
preprodynorphinexpressioninarat model.EuropeanJournalof
gabapentin (neurontin）in mice,rats,dogs，and monkeys.Drug
Pain12,870-878
129
Tumoursoftheskinand
subcutaneous tissues
LauraBlackwood
Introduction
Neithercytologynorhistopathologyis100%sen-
sitiveor specificinthediagnosisofskintumours,
Tumoursoftheskinandsubcutaneoustissues
thoughhistopathologyremainsthegoldstandard.
accountforapproximatelyone-thirdoftumoursin
Cytologywill usuallydifferentiatebetweenneoplastic
dogs andone-quarterof tumoursincats.Most skin
andinflammatorylesions,anddeterminewhether
andsubcutaneoustumoursinthedogarebenign
tumoursaremalignantorbenign.Itwillbroadly
(70-80%),but themajorityoffeline tumours（50-
ascertaintumour type(epithelial,mesenchymal,
65%)aremalignant.Mosttumoursareprimaryand
roundcellormelanocytictumour)butnotexacthisto-
metastaticlesionsareuncommon.
genesis;for example,sarcoma maybe diagnosed，
Based on pathological submissions,mast cell
tumours(MCTs)are thecommonestskin tumours
Cytologicalsamplescontainfewercellsthanbiopsy
indogs,but benignlesionsare also common(lipo-
samplesandthesemaynotberepresentativeofthe
mas,benignepithelial tumours,papillomas).Incats,
wholelesion;furthermore,tissuearchitecturecannot
basal cell tumours, squamous cell carcinomas,
beappreciated.Thereare otherpitfalls:dysplastic
MCTsandfibrosarcomasare commonest,though
epithelialormesenchymal cellsmaymimicneoplas-
historicallybasal celltumourshaveprobablybeen
ticchangeandthisisparticularlyproblematicwhere
over-diagnosed.
thereisinflammation.However,aspiratesareeasyto
Manynon-neoplasticskinlesionscanmimic
perform,oflowcostandyieldrapidresults.
tumours,especially ifproliferative or ulcerated.
Histopathologycanalsobelimitedbysmallor
Examplesinclude:
non-representative
samples.
When
harvesting
incisionalbiopsies:
Eosinophilicgranulomacomplex
Fleaallergicdermatitis
Avoidulceratedandnecroticareas
Mycoses
Donotincrease thesurgicalfieldbysampling at
Poxvirus
thejunctionofnormalandneoplastictissue
Dermatophytoses
Planthebiopsysitesothattheentirebiopsytract
Autoimmune disease.
canberesectedatdefinitivesurgery.
Excisionalbiopsy
Approach to thepatient
Excisionalbiopsyiswidelyused inthemanagement
ofskin tumours.Oftenthisisappropriate and suc-
Clinicalandhistoricalfeatureshelptorefinedifferen-
cessful,particularly in dogs,where many skin
tialdiagnoses for skinlesions,particularlywhen
tumoursarebenign.It islesssuccessful intheman-
therearenon-neoplasticdifferentials.Clinicalfea-
agementofsubcutaneoustumours.Inaminorityof
turestypicalofamalignanttumourincluderapid
cases,thisinterventioncanhavedisastrousconse-
growth,fixation,invasionintodeeptissuesorover-
quencesforthefuturemanagementofthecaseand
lying skin,ulceration,or poorly defined margins.
theopportunityforcurativetreatmentcanbelost
Clinical criteria cansuggest thatalesionismalig-
forever.Thismostoftenoccurs wherethereis
nant,but apparentlyless aggressive behaviour
incompleteexcisionofsofttissuesarcomasor
shouldnotresultinthelesionbeing assumedtobe
MCTs.The difficulty in achieving a complete ex-
benign.Aggressivemesenchymaltumours
may
appearwelldemarcatedduetopseudocapsulefor-
largesurgerieshavebeenperformedand/orcom-
mation,and MCTscanmimicmanybenignlesions,
plexclosuremethodsused.
including lipomas.
Excisionalbiopsyisappropriatewhereadequate
Tumoursoftheskinandsubcutisareseldom
excisionislikelytobeachievedbysimplesurgery.
imaged,butmagneticresonanceimagingorcom-
Thisdecisionisbestmadeinthelightofadiagnosis
putedtomographycaninformsurgicalplanningfor
based onfine-needleaspiration(FNA)rather thanon
sarcomas.Ultrasonographycanhelptoconfirmthat
clinicalcriteriaalone.Theownershouldunderstand
alesionis a lipoma(becauseof thedistinctecho-
thatfurthersurgerymayberecommendedonthe
genicityof fat)，orguideaspirationorbiopsy.
130
Chapter12
Tumoursof theskinandsubcutaneoustissues
wholespecimenmustbesubmittedtothepatholo-
nodesshouldalsobeaspiratedinpatientsknownor
gistfordiagnosisandassessmentofmarginsof
suspectedtohavehighlymalignanttumoursandin
excision.Benignproliferativeepithelialtumourshave
allcasesofMCT.Metastasesmaybefoundinnodes
arelativelydistinctiveappearanceandexcisional
thatarepalpablynormal.
biopsyisjustifiable inthesecases,asthereisahigh
Further tumour staging,to assess fordistant
likelihoodthattheclinicaldiagnosisiscorrect,but
metastatic spread,is appropriate for malignant
careshouldbe takenwheresquamouscellcarci-
nomaisadifferential diagnosis.
type.
Clinicalfeaturesthatsuggestexcisionalbiopsyof
acutaneousorsubcutaneousmasswouldbe
inappropriateinclude:
Solitaryskintumours
Rapidlygrowing mass
Dermatopathologistsarekeentoclassifytumours
Illl-definedorpoorlydemarcatedlesion(Figure
accurately,butthecelloforiginofsomedermal
12.1)
tumourshasbeendifficulttodetermine.Terminology
Peritumoraloedemaorerythema
haschangedashistochemistryandimmunohisto-
Ulcerationof overlyingskin
chemistryhavealloweddeterminationofthetruecell
Injectionsitemassesincats
oforiginoftumours.Alargenumberofdifferent
·
FNA suspicion of softissue sarcoma orMCT
termsareused,particularlyforepithelialtumours,as
Non-diagnosticFNA:
theepitheliumhasmanydifferentcellsandcomplex
。
Nocellsharvested(commoninsarcomas)
adnexalstructures.
。
Verybloodysample,orhaemorrhageonly
Hamartomasandnaevialsocauseconfusion.
(maybeseeninMCTsandsomesarcomas)
Hamartomasarebenignnodulescreatedbydis-
Haemorrhage andeosiniphils(suspiciousfor
organizedovergrowthofmaturecellsandtissues
MCT)
normallyfound intheaffectedarea.Hamartomais
thepreferredtermfor thesetumour-likemalforma-
Anulcerated
tions，whether congenital or acquired.Naevus
12.1
rapidly
impliescongenital origin.
growingandpoorly
Mostsolitaryskintumoursindogsarisefrom
demarcatedskinmass
the epithelial tissues,including the adnexae,but
onamiddle-aged
tumoursmayarisefrommesenchymaltissues,neu-
crossbred dog.
Aspirationof thislesion
ral tissue,melanocytes,histiocytes,mast cells and
toachievea diagnosis
lymphoid cells.
prior to surgery is
recommended.
Epithelialtumours
The common epithelial tumours(andpseudonyms)
aresummarized in Figures 12.2,12.6,12.9 and
12.10.Epithelial tumours include epidermal,follicu-
lar,sebaceous and sweat gland tumours.Non-
neoplasticmasslesionsthatmaymimictumoursare
includedwhererelevant.
Stagingformetastases
Epidermaltumours
Localandregionallymphnodesshouldbeevaluated
Epidermal tumoursaresummarized inFigure12.2.
bypalpation.Nodes thatareabnormal insize or
Oncologically,thesquamouscellcarcinomagroupis
textureshouldbeaspirated;andapparentlynormal
most important.
Lesions(and
Signalment/predisposition
Predilection site
Clinical features
Possible treatment
pseudonyms)
comments
Dermoid cyst
Rhodesian Ridgeback
Dorsal midline
Congenita lesions where
Surgicalexcision(if
thereisafocalreduplication
required)
of the entire skinstructure.
Dermal or s.c.mass,central
pore,hairmayprotrude.
May bemultiple
Squamouspapilloma
None
Face,lst,
Delicatefimbriated
Surgicalexcision(if
(misnomerfibrous
conjunctiva
pedunculated mass
required)
papilloma)
12.2
Epidermal tumours and tumour-like lesions indogs and cats.(continues)
131
Chapter12
Tumoursoftheskinandsubcutaneoustissues
Lesions(and
Signalment/predisposition
Predilection site
Clinical features
Possible treatment
pseudonyms)
comments
Viral papilloma
Dogs<3years old.Whippet,
Haired skin or
Mainlyexophyticwart-like
Usuallyregress
Bernese MountainDog,lrish
mucosa(oral,
fimbriatedhyperkeratotic
Settera
eyelids,nasal
lesions.Rarelyinverted
Cockr
planum)
Viral plaque (canine
YoungadultugMiniaur
Ventral abdomen,
Flat wart,maybe
May progress to
pigmented viral plaque,
Schnauzer,BostonTerrierFrench
thorax,mediallegs
pigmented
malignancyespeciallyin
verruca plana,
Bulldog
(dogs only)
cats(may precede SCC)
epidermodysplasia
verruciformis)
Actinic keratosis (actinic
Sunny climate,highalttude,owr
Pinna,nose and
Plaque-like orpapillated
See text
carcinomansituolar
latitude,aridenvironment.White
eyelids of cats.
lesion.Scalycrusty
keratosiskeratinocti
catsdogswiththin/hitehaircoat
Ventralabdomen
intradermal neoplasia)
andmedial thighin
sbop
Multifocal SCC in situ
Olderanimals
Any site
Multifocalavilyru
May progress to squamous
(Bowenoid carcinoma in
plaquesandverricose
cellcarcinoma orbasalcell
situ,Bowen's disease,
lesions.Maybepigmented.
carcinoma.
multicentric
Seetext:Bowenoid should
papillomavirus induced
not be used toreferto
SCCin situ)
multicentric disease
Squamous cell
Sunnyclmatehighaltitudewr
Pinna,nose and
Plaque-likerpapillated
Surgical excision,
carcinoma
latitude,aridenvironment.White
eyelids of cats.
scalyrustyratrifmr
radiotherapyphotodynamic
cats,dogswiththin/whitehaircoat
Ventral abdomen
ulceratedmass,papillaryor
therapy (see text)
andmedial thighin
fungiformmass.Often
sbop
indurated
Basal cell carcinoma
UVexposure ariskfactorforBCC
Nose,face and ears
Indurated plaques,
Surgical excision
(basal cell epithelioma)
inhumansbutnot provenin dogs
of cat.
umbilicated nodules,
and cats.Mean ageof catswith
Trunk of dogs
alopecia,crusting,
BCC is10years.Older dogs
pigmentation
12.2
(continued)Epidermal tumoursand tumour-like lesionsindogsand cats.
Feline actinickeratosis
It isproposed thatactinickeratosis(Ak)isrenamed
keratinocyticintradermalneoplasiaoractiniccarcin-
omainsitu,asitisanearlyformofsquamouscell
carcinoma(SCC)in situ (i.e.non-invasive).Many of
themolecularandgeneticlesionsfoundinSCCare
alsofound inAK,andmanyAKlesionsprogressto
SCC,sobothbasicscienceand clinical experience
support this.
Aetiology,pathogenesisand
predispositions:
TheaetiologyandriskfactorsforAKincatsarethe
sameasforScC,and thelesionsoccuratthesame
12.3
Actinicdermatosisaffecting thepinnaeofa
sites (see below).
middle-agedfemaleneuteredDSHcat.
(Courtesy of TNuttall)
Clinical presentation:Clinically,theselesionsare
scaly,crusty,scabbyplaque-likeorpapillatedlesions
thereisinterventionbeforethelesionceasestobe
(Figure 12.3).
surgically curable.
Treatment:Surgicalexcisionisgenerallycurative.
Squamouscellcarcinoma
Alternativetreatmentsincludephotodynamictherapy
Squamouscellcarcinomaisthecommonestmalig-
orimiquimod(seebelow).
nant skin tumourin cats（upto50%of skin tumours)
and thesecond commonestindogs(upto20%of
Prognosis:TheprognosisforAKisvariable.
skin tumours).
Althoughthediseasecourseisoftenverylong,
lesionscanprogress throughSCCinsitutofull-
Aetiology,pathogenesis and predispositions:
blownSCC,andearlierinterventionismorelikelyto
ThewidevariationinreportedincidenceofSCCis
achievecure.Activemonitoring isonlyappropriateif
largelydependentongeographicalfactorsreflecting
132
Chapter12
Tumoursoftheskinandsubcutaneoustissues
ultraviolet(Uv)exposure(aridclimate,lowerlatitude
Presentationandclinical signs:In cats,tumours
and higheraltitudewillincreaserisk).UV-relatedp53
tend to arise on the nasal planum,pinnae（Figure
mutationshavebeenidentifiedinfelinetumours.
12.4)and eyelids.In dogs,the ventralabdomen,
Patientriskfactorsarewhitehaircoatincatsand
flanksandmedialthighsaremostcommonly
shortorwhite/piebaldventralhaircoatindogs.White
affected.SCCsareoftenplaque-like,ormayform
catshave13timestheriskofdevelopingSCCthan
ulcerated,crateriform orfungiformmasses.Crusting
catswithanyothercoatcolour.Papillomavirusmay
andulcerationarecommonandtheremaybeasso-
have an aetiological role,and SCC has been
reportedafter thermal injury.Tumoursofthenasal
(thickenedorhardened),especiallywheretherehas
planumindogsarethoughttobeassociatedwith
beenchronicAK.
chronicinflammationratherthanUvexposure.
DogswithSCCof thenailbedusuallypresent
Caninenail-bedSCCiscommonestinlargedogs
withasingleswollendeformeddigitwithorwithout
withdark/blackhaircoats.Nail-bedSCCisuncom-
lossofthenail.Althoughlesionsareusuallysolitary,
mon incats.
multipledigitscanbeaffectedsynchronouslyor
Oldercats(median11years)anddogs(median
metachronously (e.g.in Giant Schnauzers).Meta-
10years)tend tobeaffected.
stasistoregional lymphnodesiscommonanddis-
tantmetastasis occurs inup to 30%of cases.
Tumoursofthenasalplanumindogsareulcerated
lesions(Figure 12.5) andare aggressively locally
invasive,oftenwithnodalmetastases.
MultifocalSCCmayoccurinbothdogsandcats.
Indogs,multiple lesions have been reported
affectingrelativelythin-hairedareasofpale-skinned
dogs chronically exposed to sunlight.In cats,
multiplelesionsarecommon,affectingearandnose,
synchronouslyorsequentially;andSCC,SCCinsitu
andAKmaycoexist.MultifocallesionsofSCCin
situmayhistologicallyresembleBowen'sdiseasein
(b)
a)
(G)
SCCinthreelight-coatedDSHcats.Invasive
b
12.4
erosivelesions areseenaffecting(a)pinnae,
Rhinarial SCC in dogs.(a) Untreated lesion in a
(b)foreheadand(c)therhinarium.Therhinarial tumouris
12.5
7-year-oldmaleGoldenRetriever.(b)Recurrent
apostsurgicalrecurrence.(Photograph(b)courtesy of
tumourina10-year-oldneuteredmaleGoldenRetriever
CGaskell)
4monthsaftersurgeryandradiotherapy.
133
Chapter12
2Tumoursof theskinandsubcutaneoustissues
humans,but this is most often a solitary tumour,
Prognosis:TheprognosisforfelineSCCisvariable
associated withsunlight exposure,whichrarely
butforScCinsitu thediseasecoursemaybelong.
progressestoinvasion.TheuseofBowen'sdisease
ForinvasiveSCC,theprognosisislargelydictatedby
asa termformulticentricSCCinsituisdiscouraged.
theefficacyof local treatment.Wheresurgeryisused，
thisdependsupontheabilitytoachievecomplete
Clinicalapproachandmanagement:Biopsyis
excision.Histologicaldegreeofdifferentiationisalso
requiredfordiagnosisandlocal lymphnodesshould
associatedwithprognosisincats:poorlydifferentiated
beevaluated.ForbothSCCinsituandinvasive
SCCisassociatedwithshortsurvival times(median3
SCC,eveninmultiple sites,treatment options are
months)whereasmediansurvival times(MSTs)may
surgical excision,radiotherapy (strontium plesio-
be>1yearwithwelldifferentiatedtumours.Rhinarial
therapy,orelectronbeamororthovoltageexternal
SCCindogscarriesapoorprognosis.
SCCoftheoralcavityisdiscussedinChapter
RadiationtherapyandPDTaremostappropriatefor
15a.
earlydisease,andinvasiveorextensivedisease
usuallyrequiressurgicalmanagement.
Basal cellcarcinoma
Earlyfelinerhinarial (oreartiporeyelid)SCC
Beforeitwaspossibletoconfirmthediagnosiswith
generallyrespondswell toradiation therapy.PDT
cytokeratinimmunostaining,basalcell carcinomas
mayalsobe appropriateforsuperficiallesions,but
(BCCs)were over-diagnosed.Many tumoursprevi-
recurrenceiscommon.Eitherradiotherapy orPDT
ouslyclassifiedasBCCweretrichoblastomasor
mayachievelong-termcontrolafterasingletreat-
sweatglandtumours.Inthecat,themajorityof
mentinverysuperficial lesions.Topical imiquimod
tumours diagnosedas BCCwerebenignsweat
hasalsobeenreportedtoproduceclinicalremission.
glandadenomas,withfewcarcinomasortrueBCCs.
For invasive tumours,surgical excision is the treat-
TrueBcCsareuncommon,andoflowmalignancy.
mentof choice(seeChapter18).
Theyaredescribed inFigure12.2,above.
CaninerhinarialScChasarapidlyprogressive
clinicalcoursecharacterizedbylocalinfiltration,
Folliculartumours
rapidrecurrenceaftersurgery and/orradiotherapy,
Folliculartumours aresummarized inFigure12.6.As
andlocal/regional metastaticdisease.
thereisarelativelylargenumberoffolliculartissues
Localfailureratherthanmetastaticdiseaseisthe
andtumoursarecompound,i.e.originatefrommore
mostcommoncauseofdeathinpatientswithSCc.
thanonetissue(supposedlyduetothecloseonto-
Thereisnoprovenroleforsystemicchemotherapy.
genyoftissues),thereisaverycomplexhistological
Intra-lesionalchemotherapy(5-fluorouracilandcispla-
classificationsystemforthesecommontumoursand
tin,neitherofwhichcanbeusedsystemicallyincats)
Figure12.6includesnotesonorigin.Manyofthese
hasbeendescribedwith30-64%responserates.
behaveclinicallyinasimilarmanner.Althougheach
individualsubtypeisnotverycommon,overallfollic-
lationtoavoidsystemictoxicityandisrarelyused.
ulartumoursarerelativelycommonindogs.
Lesions(and
Tissue of origin
Signalment
Predilection site
Clinical features
Possible
pseudonyms)
predispositions
treatment
Follicular
Hair follicle
Single nodule ormultiple
Surgical excisionif
hamartoma
(non-neoplastic
grouped plaques or small
required
(follicularnaevus)
malformation)
nodules,orange peel
skin',thickbrush-like
hairs
Fibroadnexal
Possible
Possible association
Pressure points,
Solitary firmmass,
Surgicalexcisionif
hamartoma
malformationsof
withtrauma/scarring
interdigital space（or
polypoid or dome-shaped,
required
(fibroadnexal
folliculosebaceous
Large breed dogs
any site)
may be alopecic
dysplasia/focal
units and/or dermal
adnexal dysplasia)
collagen
Follicularcyst
Boxer,Shih-Tzu,
May occurat pressure
Solitary,frm,intrademal
Surgicalexcisionif
Miniature Schnauzer,
pointsorin scars
or s.c.nodule.Alopecic.
required
Old English Sheepdog
because of follicular
Oftenappearblack/white/
entrapment
yellow.Mayhavecentral
pore(±protrudingkeratin)
Dilated pore（pore of
Proliferative variant
Oldercats
Head and neck
Solitaryfirmmasscenral
Surgical excisionif
Winer)
of follicular cyst
keratinprotrusion
required
Trichofolliculoma
Probablyaform of
Solitary or dome-shaped
Surgicalexcision if
hamartoma,
nodulewitha central
required
resemblingentire
pore/depression
follicular/folliculo-
sebaceous unit
12.6
Folliculartumours and tumour-likelesionsin cats and dogs.(continues)
134
Chapter 12
Tumoursoftheskinandsubcutaneoustissues
Lesions(and
Tissue of origin
Signalment
Predilection site
Clinical features
Possible
pseudonyms)
predispositions
treatment
Trichoepithelioma
Benign neoplasm
Common in dogs,
Tailin cat
Round to oval dermal
Surgical excision if
that differentiates
uncommon in cats.
nodules to subcutaneous
required
towardsall three
BassettBullMastiff
masses.Alopecia or
NB:infitrative
segments of the hair
English Springer
ulceration if large.
trichoepithelioma
follicle
Spaniel,Golden
(Occasionally multiple)
shouldbe
Retriever,Gordon
considered
Setter,Standard
malignant(see
Poodle
text)
Infundibular
Notreallyan
Norwegian EIkhound,
Solitary ormultiple
Surgical excisionif
keratinizing
epithelioma;benign
Lhasa Apso,
partially alopecic dermal
required
acanthoma
follicular lesion
Pekingese,Yorkshire
nodules.Mayhavecentral
(intracutaneous
Terrier,German
pore withprotruding
cornifying
Shepherd Dog
keratin.Maybemultiple in
epithelioma)
Norwegian EIkhound,
Lhasa Apso
Tricholemmoma
Benigntumourof
Rare.Olderanimals
Firm circumscribed
Surgical excisionif
the outerroot
solitarynodule
required
sheath of hair follicle
Pilomatrixoma
Benigntumour
Uncommon in dogs
Legs and trunk
Solitaryfirm well
Surgicalexcisionif
(pilomatrixoma,
arising from follicular
（but seen in Poodle,
circumscribed dome to
required
calcifying
matrixorhairbulb
Kerry Blue,Old
plaque-like mass
epithelioma)
English Sheepdog,
Soft-coated Wheaten
Terrier,Bouvier de
Flandres,Bichon
Frise,Schnauzer,
Basset).Continuously
growingcoatmay
predispose.Rare in
cats
Trichoblastoma
Benign tumour
Common in dogs
Base of ear in dogs
Solitary firm domeor
Surgical excisionif
(basal cell tumour)
derived follicular
(Poodle,Cocker
head/cranial halfof
polypoid nodules,
required
stem cells
Spaniel),reasonably
body in cats
alopecia orulceration（if
common in cats
large)
Malignant
Malignant tumour
Large,poorly
Surgical excision
trichoepithelioma
withmatrical and
circumscribed often
(matricalcarcinoma,
innerrootsheath
plaque-likemasses.
infiltrative
features
Alopecia orulceration
epithelioma,
common
follicularcarcinoma)
Malignant
Mayarisefrom
Rare,dog only
Large,poorly
Surgical excision
pilomatrixoma
pilomatrixoma(not
circumscribed often
(matrical carcinoma,
proven in animals)
plaque-likemasses.
pilomatrix
Alopecia or ulcerationif
carcinoma)
large
12.6
(continued)Follicular tumoursand tumour-like lesions incats and dogs.
Mostfolliculartumours are solitary,firm,well cir-
Sebaceoustumours
cumscribed cutaneousnodules,which maybe alo-
Likefolliculartumours,thereisacomplexclassification
pecic.Themajorityarebenignandcanbecured by
system forsebaceous tumours,but most are benign
and simple tomanage.Nodular sebaceous hyper-
behaviour suggests a moremalignant variant.In par-
plasia (senile sebaceous hyperplasia)（Figure 12.7)
ticular,invasive trichoepitheliomas aremalignant
accounts for25%of non-malignant skinmassesin
ratherthanbenign.Malignantlesionsrequiremore
dogsandupto11%ofnon-malignant skinlesions in
aggressiveinvestigation,treatment andactivemoni-
cats.Sebaceousadenomas(Figure 12.8)(benignneo-
toring.For malignant follicular tumours（or benign
plasmsofcombinedglandularandductalorigin)are
tumours causing a clinical problem),surgical exci-
alsorelativelycommon,accountingforabout6-7%of
sionisthe treatmentofchoice.Radiationtherapy
skintumours indogsand2-4%incats.However,this
maybeofbenefitfornon-resectableorresidual
groupincludesperianalglandtumours,whichmaybe
malignant disease,but there are fewdata.There is
aggressivelymalignant.Featuresof theselesionsand
noprovenroleforsystemicchemotherapy.
sebaceoustumoursaresummarized inFigure12.9.
135
Chapter12Tumoursoftheskinandsubcutaneoustissues
Truesebaceouscystsarerareindogsandvery
12.7
rareincats.Follicularcystsareoftenerroneously
Nodular sebaceous
calledsebaceouscystsbecauseof theirgrumous
hyperplasia onthe
medialaspectof
keratinaceouscontents,but sebumisawhitemilky
liquid.
theelbowofan
8-year-oldmale
Weimaraner.
Sebaceousepitheliomas
Thesecontroversialtumoursmaypossesslow
malignantpotential,andhavea tendencytorecur
afterincomplete/marginalexcision.Histologically,itis
difficulttodifferentiateatrueepitheliomafromits
malignantvariant.If thetumourappearsclinically
malignant (large mass,infiltrative margins,rapid
proliferation)itshouldbetreatedasmalignantin
spiteoftheapparentlybenignhistological diagnosis.
12.8
Treatmentisbysurgicalexcision.
Sebaceous
adenomaonthe
Sebaceouscarcinomas
dorsumof thehead
Thesearelocallyaggressivetumoursthatshow
of an11-year-old
local/regionalmetastaticbehaviourbutrarelydistant
neuteredfemale
metastases.Treatmentissurgicalexcision:radiother-
StandardPoodle.
apy canbeused to treatresidual diseaseornodal
metastases,buttherearefewdataonoutcome.
Perianalglandtumours
hepatoid glands,
whicharemodifiedsebaceous
glandsfoundintheskinoftheperianalarea,
Lesions(and
Signalment or other predisposition
Predilection
Clinical features
Possibletreatment
pseudonyms)
site
comments
Sebaceous duct
Rarendgveryan
Eyelid:
Small nodules
Surgical excisionif
cyst
meibomian cyst
required
Nodular sebaceous
Poodln
Dorsal head,
Wartywithawaxyorpearly
Aspiration can be
hyperplasia(senile
TerrierWhnr
ears,face,neck
alopecic surface.Dome-shapedor
difficultasmasses often
sebaceous
papillatdpaleorlowywit
very small.Notreatment
hyperplasia)
usuallyrequired
Sebaceous
Solitary alopecic nodule
Variant of fibroadnexal
hamartoma
hamartoma
Sebaceous
CockerpanielSiberianHusky
Head,any site
Dome-shaped orpapillated
Surgical excisionif
adenoma
MiniatureoodeCoonhoundamyed
noduleyellowopalescentr
required
BeagleDahhundPrsana
pigmented,maybealopecicr
ulcerated
Sebaceous
Common in dogs(Cocker Spanieland
Head,ears,
Firmnodularplaqueorfungiform
Surgical excision if
epithelioma
otherspredisposed tosebaceous
dorsum
massefenlceratdma
required
adenoma),rareincats
pigmented
Sebaceous
CockerSpaniel,CavalierKingCharles
Head
Ofenarecnd
Surgical excision(see
carcinoma
Spanotishrrierrian
ulcerated
text)
Perianal gland
Dogsnlyldr（8yarslu）mstl
Perianal skin,
Nodularpoloidoranulr
Hormonal(castration,or
adenoma(hepatoid
male male to female ratio at least3:1,
tail,prepuce,
masses.Rubberyfirm texturemay
delmadinone acetate).
gland adenoma
and neutered femaletoentirefemale
thigh
ulcerate
Surgical excision may
perianal gland
ratio3:1).CockerSpaniel,Samoyed,
beindicatedumay
adenoma)
SiberianHusky,EnglishBulldog,Beagle
facilitatedbyprior
crossbreeds
hormonal therapy
Perianal gland
As adenomas
As adenomas
epithelioma
Perianal gland
GermanShepherdDogArcticCircle
Mainly perianal,
Nodular,polypoidoranular
Seetext
carcinoma
breeds
occasionally tail
masses.Rubbery firm texture.
orprepuce
Oftenpoorlydemarcatedmay
ulcerate
12.9
Sebaceoustumoursin dogs and cats.
136
chapter12Tumoursoftheskinandsubcutaneoustissues
proximal thirdofthe tail,dorsallumbosacralarea,
Sweatglandtumours
and lateral totheprepuce.Indogs,theseandrogen-
SweatglandtumoursaresummarizedinFigure
dependentglandsarelargerandmoreextensivein
12.10.Overrecentyearspathologistshaveintro-
adultmalesthaninfemales.Therearenohepatoid
ducedmorepreciseclassificationofthesetumours
glands in cats.
andfoundthatmanytumourspreviouslyclassified
asbasal cellcarcinomasincatsareinfactapocrine
Perianalglandadenomasaccountforupto
ductularadenomas(60%)ortrichoblastomas(40%).
18%ofcanine skintumours(perianalgland
Boththesetumoursarebenign.
epitheliomasaresometimesreportedby
Apocrinecarcinomasaccount for0.6-2.2%of
pathologistsandshouldbeapproached as
canineskintumoursand2.5-3.6%ofcatskin
adenomas).Featuresaresummarizedin
tumours.Theycanbeclassifiedintodifferent
Figure 12.9
histological subtypes,butthe clinical value of this is
Perianalglandcarcinomasarerelatively
unclear.Thedegreeofmalignancymaycorrelate
uncommon,representing0.25-2.6%of skin
withthedegreeofdifferentiation.Thesetumoursare
tumoursubmissions.Theirfeaturesare
locallyinvasive,withvariablemetastaticpotential.
summarized inFigure12.9.
Overall,themetastaticrateislowandsotreatment
isusuallyfocusedontheprimarytumour.Surgery is
Welldifferentiatedtumoursaremanagedinthe
themainstayoftherapy,withadjunctiveradiotherapy
samewayasadenomas.Poorlydifferentiated
usedforresidualdisease.
tumourstendtoshowaggressivebehaviour,pre-
sentingaslargepoorlycircumscribedlesions,which
metastasizeearlyinthediseasecourse.Aggressive
Mesenchymaltumours
carcinomasareoftenandrogen-independent.
Surgicalexcisionisthetreatmentofchoicebut
Mesenchymal tumoursaresummarizedinFigure
completeexcisionmaynotbefeasible:adjunctive
12.11anddiscussed indetail inChapter 14.
radiotherapymaybeusedinthesecases.Thereare
Caninenodulardermatofibrosisisabenignskin
limiteddataonchemotherapy,butthereareanec-
lesion,butisassociatedwithrenalepithelialtumours
dotalreportsoflong-termsurvivalafterchemother-
(including cystadenocarcinoma,cystadenoma)or
apy(usingtheVACregime)forindividualpatients.
cysts,or less commonly uterine leiomyoma.The
Histopathologicalgradeispredictiveof behaviour.
renallesionsareoftenmulticentricandbilateraland
Lesions(and pseudonyms)
Signalment orother
Predilection site
Clinical features
Possible treatment
predisposition
comments
Apocrine cyst(sweat gland
Old English Sheepdog,
Head,neck,legs,
Bullousnodules withbluishor
Surgical excisionif
cystepitrichial weatgland
WeimaranerPersian
dorsal trunk in dogs.
reddishcontentsvisible through
required
cyst)
Earcanal incats
alopecicskinWelldinedns
orfluctuant
Apocrine cystomatosis
Rare in dogs,uncommon
Headand neck in
Multipleclustersofdilatedsweat
Surgical excisionif
incats
dogs.Ear canal or
glandsftenlookblue/blackon
required
pinnaincats
cats
Apocrine cystadenoma
Great Pyrenean,Chow
Head,neckdorsumn
As apocrine cyst
Surgical excisionif
(sweat gland cystadenoma,
Chow,Malamute,ld
dogs.Head in cats
required
apocrine hidrocystoma)
EnglishhpdogPsin
cat
Apocrine secretory adenoma
Great Pyrenean,Chow
Head,neck,dorsumin
Wellcircumscribedfirmor
Surgical excisionif
(sweat gland adenoma/
Chow,Malamute,Old
dogs.Head in cats
fluctuant dermal nodules
required
epitrichial sweat gland
English sheepdog
adenoma)
Apocrine ductal adenoma
Rare in dogs,more
Head and neck
Circumscribed dermal or s.c.
Surgical excisionif
(ductular sweat gland
common in cats.
nodules;may be alopecic and
required
adenomabasaloidsweat
PitbullTerrierldEnglish
blue-black-brown;canbe
glandadenoma,nodular
Sheepdog,English
ulcerated
hidroadenoma)
Springer Spaniel
Apocrine secretory
Older cats and dogs.
Legs of dogs or cats;
Solitaryltuanma
Surgical excision
adenocarcinoma
Coonhound,Norwegan
head,abdomen and
poorlydemarcated,alopecic,
EIkhoundSamesea
chin of cats
ulcerated
Apocrineductularcarcinoma
Incidence unclear.
Legs of dogs or cats,
Solitrylt
Surgical excision
(ductular sweat gland
Older cats and dogs.
head and abdomen of
poorly demarcated,alopecic,
adenocarciomamalignant
Coonhound,Norwegian
cats
ulcerated
nodularhidradenoma,
Elkhound and Siamesecat
hidradenocarcinoma)
12.10
Sweatglandtumours indogs andcats.
137
Chapter12
2Tumoursoftheskinandsubcutaneoustissues
Lesions(and
Signalment
Predilection site
Clinical features
Possibletreatment/
pseudonyms)
predispositions
comments
Collagenous hamartoma
Relatively common in dogs
Head,neck,
Small solitary dome-shaped firm
May bediagnosed as
proximallimbs
nodule.Maybe alopecic,
fibroma.Managementis
hyperpigmented
the same:surgical excision
Caninenodular
German ShepherdDog
Legs,earsead
Firmwellcircumscribed nodulesin
InGerman Shepherd Dogs
dermatofibrosis
（rare inherited autosomal
dermisorsubcutis,thickened
associated withrenal
recessivedisorder)middle
overlying skin,hyperpigmentation,
tumours and cysts
aged and older
ulcerationmaybealopeic
Acrochordon
Common in dogs
Trunk,pressure
Solitaryrll
(acrochordonous
points
filformwiththickenedalpecicand
plaque,skin tag,
orpigmented epidermis
fibroepithelialpolyp,
fibromatouspolyp,
fibromatousplaque)
Dermatofibroma
Usually lessthan5years
Head
Solitary circumscribed dermal nodule
Maybereactiverather
old(dog orcat)
with alopecia and thickened
than benign tumour:either
epidermis
wayura
Nodular fascitis
Uncommon:young dogs
Any
Poorlydemarcatedmassmaybe
Surgicalexcisioncurative
(notcats)
attached todeepfascia
Fibroma
Quiteuncommon,middle
Head and limbs
Solitary rubbery circumscribed mass.
Surgical excision if
aged andolderdogs
Alopeciaandatrophyofoverlying
required
dermis
Fibrosarcoma
GordonSetter,Goln
Trunk and limbs,
Firmporlyircumscrbdma
See text and Chapter14
RetrieverrishWolfhund,
feline injection sites
multilobular.Alopecia/ulcerationcan
Dobermann,Brittany
occur
Spaniel
Myxoma/myxofibroma
Trunk orlimbs
Softmassfenilldefin
Can be difficult to
differentiatehistologically
frommyxofibrosarcoma
Feline sarcoid
Rural catsonlymainly
Philtrum,nares,lip,
Solitaryormultiplenodules
Locally invasive,commonly
youngmales.
digit,tail
recurafterexcision
Papillomavirus induced
Angiomatosis
Progressive forminyoung
Digits,feet,limbs
Darkredmaculesandpatcheswith
Progressive forminyoung
tomiddle-aged dogs or
(any).Also scrotal
irregularmargins
dogs dificult tomanage,
cats,scrotalforminolder
type
scrotal typelessrapidly
sbop
progressive
Haemangioma
Many(short-haired,
Solar-induced on
Solitarywellcircumscribedmeaty
Infiltrativelesionsdifficult
light-coated dogs
glabrous skin areas
masses,maybered toblack/bluish.
toexcise surgically
vulnerable to solar
in dogs.Infiltrative
Arise in dermis or subcutis
induced)
haemangiomas in
subcutaneousfat
on trunk/proximal
limbs.Head,legs,
abdomen incats
Lymphangiomatosis/
Rare;young animals
?Inguinalregion
Poorly demarcatedfluctuant swelling
Probablymainly congenital
lymphangioma
withulcers/draining tracts
malformation
Haemangiosarcoma
Uncommon.Older dogs
Ventral abdomen,
ll-definedred todarkblueplaquesor
Surgical excision.
and cats.Dogs with thin
groin, aila, any.
noduleaifrd
Generallylessmetastatic
hair coat (Whippets).In
Limbs and head in
growingMaybe sof/sny
thanvisceralcounterparts,
dogs may arise from
cats
resemblinghaematoma
but still cause death due to
transformationof
local or distant disease.ln
haemangiomas whichare
cats,recurrencemore
UVinduced
common thanmetastases.
Valueof chemotherapy
unclear(see text).
(Lymphangiosarcomas
behave similarly,butmay
bemoremetastatic)
12.11
Mesenchymal tumours of the skin and subcutaneous tissue indogs andcats.(continues)
138
Chapter12
Tumoursof theskinandsubcutaneoustissues
Lesions(and
Signalment
Predilection site
Clinical features
Possible treatment/
pseudonyms)
predispositions
comments
Haemangiopericytoma
Dogs onlysuallyolder.
Trunk orlimbs
Solitary deep dermal ors.c.
Surgical excision（see text)
Possiblefemale
multlobularmasses.Oftenadherent
predisposition
todeep structures.Overlying skin
maybealopcic,uratd
hyperpigmented
Lipoma
Common in dogs.All
Trunk and limbs
Wellcircumscribed,freelymobilesoft
Surgical excisionif
breeds,olderage
masses.
required
Infiltrative lipoma
Uncommonindogsraren
Neck,trunk,legs
Largepoorly defined deep
May bedifficult toexcise.
cats.LabradorRetriever,
subcutaneous and intramuscular
Possiblerole foradjunctive
Standard Schnauzer,
lesions
radiotherapy
Dobermann
Liposarcoma
Older dogs.Possble
Axial region,
Variablycircumsribedsofttofm
Surgical excision(see text)
predisposition inSheltie,
proximallimb
Beagle.Rare in cats
Leiomyoma
Rare
Vulva,perineum,
Solitarywellcircumscribedfirm
Surgical excision
groin,head,
masses
dorsum
Leiomyosarcoma
Rare
Perineum,trunk,
Small non-ulcerated dermal masses
Surgical excision
legs,face,
(generallylowmetastatic
extremities
potential)
Rhabdomyosarcoma
Rare
Feline injection site
Firmpoorlydemarcatedmultlobular
Surgicalexcision
s.c.mass,adhered tounderlying
(generally lowmetastatic
tissue,skin
potential)
Benignperipheral nerve
Uncommonoldercatsand
Trunk,distal limbin
Circumscribed lobulated cutaneous
Recurrence common after
sheathtumour
sbop
dogs,head and
or subcutaneous mass
incomplete excision
(schwannoma,
neckin cats
neurofibroma)
Malignant peripheral
Uncommonoldercatsand
Trunk,distallimbin
Circumscribed lobulated cutaneous
Surgical excision
nerve sheathtumour
sbop
dogs,headand
or subcutaneous mass.Poorly
(generally lowmetastatic
(malignant
neck incats
circumscribedadheredtounderlying
potentialbut someae
schwannoma)
tissue,skin
metastatic especially in
younger patients)
12.11
(continued)Mesenchymal tumoursof the skin andsubcutaneoustissueindogs andcats.aSeetextre
classification andnomenclatureof thesetumours.
metastasesoccurin20%ofcases.The syndromeis
inheritedinGermanShepherdDogsbutcanoccurin
otherbreeds.
Themostcommonlydiagnosedsofttissuesarco-
masoftheskinandsubcutisarefibrosarcoma
(Figure12.12)andhaemangiopericytoma(peripheral
nervesheathtumour)(Figure12.13).Fibrosarcomas
accountfor15-17%offelineskintumours
in
cats and about1.5%indogs.Historically,haemangio-
pericytomasaccountforabout7%ofcanineskin
tumoursandabout 13%ofmesenchymal tumours.
Recentlyithasbeensuggestedthatmanytumours
previouslydiagnosedashaemangiopericytomasare
infactperipheral nervesheathtumours(thereiscur-
Becauseoftheconflictingterminology,somepatholo-
gistsprefer tocalltheselow-gradespindlecell
tumours.Forthesofttissuesarcomas,histological
gradeisprognosticformetastaticpotential.
Forallsofttissuesarcomas,treatmentisbywide
orcompartmentalexcisionand thefirstsurgeryis
Recurrent fibrosarcoma(suspected injection-
themostlikelytoachieveacure:excisionalbiopsyis
sitesarcoma)afterattemptedexcisionalbiopsy
notrecommended.Reportedrecurrenceratefor
ina 10-year-oldDSHcat.
139
Chapter12Tumoursof theskinandsubcutaneoustissues
Celltype
Phenotype
Phenotype
Disease state
(6op)
(cat)
Macrophage
CD45
Haemophagocytic
(fromblood
CD18
histiocytic
monocytes)
CD11d
sarcoma
MCHCII
CD68
Dendritic cell
CD45
CD18
Canine cutaneous
(from
CD18
CD1
histiocytoma
CD34-positive
CD1
MHCII
(CD14-ve)
haemopoietic
CD11c
Cutaneousor
stem cells)
CD11b
systemic
MCHCII
histiocyosis
ICAM1
(CD14+ve)
CD14
Histiocytic
sarcoma(CD14
Langerhans'cell
E-cadherin
Canine cutaneous
(epithelial
histiocytoma
dendriticcell)
12.14
Cellsgivingrisetohistiocytictumoursand
Haemangiopericytomaof thecraniolateral
reactive histiocytoses incats and dogs.
12.13
elbowofa9-year-oldneuteredcrossbredbitch.
Theproximallimbisa commonsitefor thesetumours.
Presentationand clinical signs:Commonsitesare
head,ears,neck and extremities.Clinically,CCHs
canine skinandsubcutaneoussarcomasis34%and
arerapidlygrowing dome-shapedorplaque-like(or
for feline sarcomas in excess of 70%,illustrating
button-like)masses,which are often alopecic or
both the dificully in treating these tumoursand
ulcerated(Figure12.15).
consequences
fo
inappropriate
management.
Radiationtherapycanbeusedasanadjunctivether-
ofmetastaticdisease in high-grade tumours.The
management of soft tissue sarcomas(including
feline injectionsitesarcomas)isdiscussedin
Chapter14.
Roundcell tumours
Cutaneousround cell tumours include mast cell,
lymphoidand histiocytictumours,and plasmacyt-
oma.Mast cell tumours are discussed on pages
142-150.
Histiocytictumours
12.15
Histiocytomaontheearofa4-year-oldmale
Histiocytes
Boxer.(Courtesy of T.Nuttall)
are
either
macrophages(antigen-
processing)or dendritic(antigen-presenting) cells.
Thephenotypesof thesecells,and thetumoursthat
Approach,managementand prognosis:Diag-
arise from them,aresummarized inFigure 12.14.
nosis is usually easily achievedbyFNA.Tumours
Conditionsthatusuallypresentasmultiplelesions
mayoftenresolvespontaneously(evenifmultiple).
(cutaneous and systemichistiocytosis,malignant
Langerhans'cellsmaymigratetothedraininglymph
histiocytosis)arediscussed inthe sectiononmulti-
node,resultinginlymphadenopathy,whichwillalso
focal skin tumours,below.
regress.Surgicalexcisionmayberequiredforprob-
lematiclesions,orwherecytologydoesnotyielda
Canine cutaneous histiocytoma(CCH)
definitivediagnosis.
CCHisacommon,benigntumour,accountingforup
to 14%of canine skin tumours.
Benignfibroushistiocytoma
Benignfibroushistiocytomas（reactivefibrohistiocytic
Aetiology,pathogenesis and predispositions:
nodule,juvenilexanthogranuloma,fibroxanthoma)are
Thesetumoursarethoughttoarisefromthe
uncommontumoursindogs,clinicallysimilartoCCH.
epidermal Langerhans'cells.CCH mainly affects
dogslessthan3yearsofage,butanyagemaybe
Aetiology,pathogenesis and predispositions:
affected.Boxers,Dachshunds,Cocker Spaniels and
Thesemayrepresentreactivehistiocyticprolifera-
Bull Terriersarepredisposed.
tionsratherthantruetumours.Theyaffectyoung
140
Chapter12
Tumoursof theskinandsubcutaneoustissues
dogs(2-4years)ofany breed,but Colliesand
StandardPoodlesmaybepredisposed.Olderani-
GoldenRetrieversmaydevelopmultiplelesions.
malsareusuallyaffected.
Presentationandclinicalsigns:Animalsmaypre-
Presentation and clinicalsigns:Plasma cell
sentwithsolitaryormultiplelesionsontheface,legs
tumours are usually sessile,firm,raised dermal
andscrotum.Lesions arefirmwell circumscribedder-
masses,which maybe alopecic.Commonlocations
malnoduleswithnormaloralopecicoverlyingskin.
indogs are thepinnae，lips,digits,chin,legs,trunk
andoralcavity;mucosallesionsusuallyhavean
Clinical approach,managementandprognosis:
intactsurfaceepitheliumandareeitherpeduncu-
Biopsyisrequiredfordiagnosisandtheselesionsare
latedorhaveabroadbase.Incats,similarsitesare
characterizedbyaswirlingstromaembeddedinthe
affectedbutalsothetailandlesionsmaybemore
histiocyticandinflammatorycellpopulation.Surgical
likelytoreflectsystemicdisease(plasmacellmye-
excisionisrecommended.Inmultiplefibroushistio-
loma,see Chapter19).
cytoma,lesionsmayalsorespond toimmunosup-
pression(oral or intralesionalglucocorticoids).The
Clinical approach,management and prognosis:
prognosis is good.
Indogs,mostlesionsarebenignand canbecured
bysurgical excision.Wherethisisimpossible,radia-
Histiocyticsarcoma
tiontherapymaybeused.Aminorityaremetastatic
Localizedhistiocyticsarcomaisafocalsofttissue
(initiallytoregionalnodes)andinfrequentlypatients
tumour.Pathologistsarenowdiagnosinghistiocytic
presentwithmultiplecutaneouslesions.Thereisno
sarcomaswithincreasing frequency,butimmuno-
definedroleforchemotherapy.
histochemistryisoftenrequiredforabsoluteconfir-
mation.Most tumourswillbepositiveforCD18,as
wellasCD45andCD11c.Fascinisalsousedbutis
Melanocytictumours
notfullyvalidatedinthedog.Flat-coatedRetrievers
andRottweilersarepredisposed.
Lentiges
Lentigesarebenignproliferationsofmelanocytes,
Presentation andclinical signs:Dogsmostoften
common in dogs and cats.
presentwitharapidlygrowingfirmsofttissuemass,
whichmaybeill-definedandusuallyinfiltratesadja-
Presentationandclinicalsigns:Lentigesaresmall
cent tissues.Anysite canbe affected,but subcuta-
（<5mm),welldemarcated，black,macularorslightly
neouslesionsare common.
raised,smooth,well circumscribed lesions.In dogs,
theyoccuralmostexclusivelyonthenipplesofolder
Clinicalapproachandmanagement:Theseare
animals,while in cats they affect the lips,eyelid
managedinasimilarwaytoothersofttissuesarco-
margins,nasalplanumandpinnaeandoftenarise in
mas(seeChapter14).Primarytumoursarepossibly
moreradiosensitivethanothermesenchymal
younganimals.
tumours.However,thesetumourstendtobehighly
metastaticandmany
oncologistsrecommend
Managementandprognosis:No treatment
is
required.
These
adjunctive chemotherapy.Lomustine(CCNU)is cur-
lesionsdonottransformto
malignancy.
rentlythedrugofchoice.Theremaybearolefor
PEG-encapsulateddoxorubicin.
Cutaneousmelanoma
Prognosis:MSTsaftersurgeryalone arein the
Indogs,two-thirds ofcutaneous melanomasare
regionof5months，butmultimodalitytherapymay
benign（melanocytoma)and one-third malignant.
improve survival.
Malignanttransformationofbenignlesionsisthought
tooccuroccasionally.Incats,cutaneousmelanomas
Felinehistiocyticsarcoma
arerare,but at leasthalf aremalignant.
Therearefewdataonhistiocyticsarcomaincats,
thoughitmaybethatlocalizedhistiocyticsarcomas
Aetiology,pathogenesisandpredispositions:
havebeendiagnosedasmesenchymal tumoursin
Canineand feline cutaneousmelanomasarenot
thought to be UV-linked.Dogs withheavily pig-
thepast.Mostcasesintheliteraturehavedissemi-
nateddiseaseratherthancutaneousorsubcutane-
mented skinandcatswithblackor greyhair coats
ous lesions,and the prognosisispoor.
aremostatrisk.Anyageof animal maybeaffected,
but most animals are older(8-12years).
Plasmacelltumours
Cutaneousplasmacytoma/plasmacelltumours
Presentationand clinicalsigns:Melanocytic
accountforabout1.5%ofallcanineskintumours
tumourscanoccuranywhereonthebody.Tumours
andmostoftenariseasasolitarymass,thoughmul-
ofthenailbedandmucocutaneousjunctions（and
tiplemassesmayoccur.
oralmucosa)areoftenmalignant,whilelesionson
hairedskinaremorelikelybenign.Benign lesions
Aetiology,pathogenesis and predispositions:
aremostoftenfoundontheheadincats,andonthe
Theaetiologyisunknown.CockerSpaniels,Airedale
heador trunkindogs.Predilectionsitesformalig-
Terriers,Kerry Blue Terriers,Scottish Terriersand
nanttumoursarelips,eyelidsandlegs(including nail
141
Chapter12Tumoursoftheskinandsubcutaneoustissues
beds) in dogs,and head,trunk and tail in cats.
Mastcelltumours
Benignmelanomasareusuallywellcircumscribed,
pigmented,alopecicnodules(smooth topapillated,
MCTsindogs
sessile,plaque-like orpedunculated).Most melano-
MCTsaccount for7-21%of skin tumoursindogs,
masareatleastpartiallypigmented.Ulcerationand
withanestimatedannualincidenceof90-129per
infiltrationarecommoninmalignanttumours.
100,0o0dogs.MCTsshowvariablebiologicalbehav-
iour.Metastaticratesof10%to>95%arereported,
Clinicalapproach,managementandprognosis:
andoutcomecorrelatesbroadlywithhistopathologi-
Malignantmelanomapatientsshouldhavestagingto
calgrade（Figure 12.16).These tumours can be
detect localandregionallymphnodemetastases,
anddistantmetastases.
itytherapy.Treatmentmaybecompromisedbyalack
Treatment issurgical excision,but overallcure
of a diagnosis prior to therapy.
ratein dogs isonly35%,whichis at oddswith the
reportedrateofmalignancy.Wherecompleteexci-
Aetiology,pathogenesisandpredilections:The
sionofmalignancyisimpossible,radiotherapymay
aetiologyisunknown.Aroleforchronicinflammation
beofbenefit.Thereisnoprovenroleforchemother-
hasbeensuggested,butthereislittleevidenceto
apyandthemelanomavaccinehasnotbeenevalu-
support this.
ated inthesepatients.
TheaverageageofdogswithMCTsis8years.
Thereisarelativelycomplexsystemofhistologi-
Any agemaybeaffected,but patientsunder4years
cal classificationformelanomasbuttypeisnotof
arelesscommon.Manybreeds arepredisposed;
prognosticrelevance.Highermitoticindexpredicts
breedandsitepredispositionsaresummarizedin
moremalignantbehaviour，asdootherproliferation
Figure12.17.Therelativeriskis16.7forBoxersand
markers(Ki67andPCNAexpression).
8forBostonTerriers.
Grade
Frequency
Metastatic
Recurrence
Recommended treatment
Prognosis
of diagnosis
potential
potential
Well differentiated/
<10%
Low
Surgical excision
Unlikely to cause death（up to
Gradel
7-12%)
Intermediategradel
50%ormore
5-22%
Variable
Surgicalexcision.Consider
May cause death(17-56%)
Gradell
radiotherapyifcompleteexcision
duetolocal treatment failureor
impossible ornodalmetastases;
metastaticdisease
considerchemotherapyif MI>5
Poorly differentiated/
>80%
High
Chemotherapy;multimodality therapy
Likely tobecause of death
Grade Ill
12.16
Summaryof caninemastcelltumoursbyhistopathologicalgrade.
Breed
Predisposed sites
Other features
AmericanBull Terrier
Hindlimb
AustralianCattleDog
Beagle
BostonTerrier
Hindlimb
Boxer
Hindlimb
Highproportionofgradelrlltumourspredisposedtoultipletumours
Bulldog(American and English)
Bullmastiff
Dachshund
FoxTerrier
Golden Retriever
Predisposed tomultiple tumours
Labrador Retriever
?Highproportionofgradelltumourspredisposedtomultipletumours
Pug
Hindlimb
Rhodesian Ridgeback
Tail
Schnauzer
Sharpei
Highproportionof high-grade tumours(especially USpopulation)
Staffordshire Bull Terrier
Weimaraner
Predisposedtomultipletumours
12.17
Dog breed and sitepredispositionsformastcell tumours.
142
Chapter12
Tumoursof theskinandsubcutaneoustissues
Presentationandclinicalsigns:Mostdogspre-
sentwithacutaneousorsubcutaneousmass.
Althoughtumoursaremuchmorecommonlysolitary
rather than multicentric,sequential or synchronous
developmentofMCTsiscommon.
MCTsmaydevelopanywhereonthebodyand
may be cutaneous(dermal)or subcutaneous.Of
cutaneous MCTs,50-60% arise on the trunk,
25-40%ontheextremitiesand10%onthehead
andneck.Thescrotum,perineum,backandtailare
lesscommonlyaffected.
Occasionally,tumours occur inextracutaneous
sites:the conjunctiva,or mucosa of thenasophar-
ynx,larynx or oral cavity,Gl tract orurinary tract.
SpinalMCTisalsoreported.Visceralorsystemic
mastocytosisisdescribed,butmostoften occurs
wherethereisdisseminationfromanaggressivepri-
marycutaneoustumour.IsolatedvisceralMCTsand
primarymastcell leukaemiasareveryrare indogs.
MCTsareoftenerythematousoroedematous
(Figure 12.18)and maybe alopecic,but theirreputa-
tionasgreatimitatorsiswelldeservedandthey
haveawidevarietyofclinicalappearances（Figure
12.19).Soft cutaneous or subcutaneous masses
maymimiclipomas.Lackofinvestigationcanresult
inlatepresentationofpatientswithmoreadvanced
diseasethat isclinicallydifficulttomanage.
ThegrossappearanceofMCTsdoescorrelateto
12.19
MCTaffecting theseconddigitof theforelimbof
someextentwithhistologicalgradeandatumour
amiddle-aged crossbreddog.Differential
that appears aggressive is almost certainly aggres-
diagnosesforthisswollendigitwouldincludeinfectious
causes(nail-bed infection) and SCC.
sive.However,a tumour that appears quiescent
shouldnotbeassumedtobebenign.Theclinical
featuresof aggressiveMCTsare:
Rapidgrowth
Local irritationandinflammation
Localinfiltration/poordemarcationfromadjacent
tissues
Ulceration
Satellitenodules(Figure 12.20).
Patientsmayalsopresentwithurticarialswelling
ordiffuseoedema/inflammation（Figure12.21)which
maymimiccellulitisoracrallickdermatitis.
12.20
Satellitenodulesandpartial wounddehiscence
MCTonthethoracicwallofa6-year-old
after incompleteexcisionofagradeIll MCTina
12.18
neuteredcrossbredbitch,showing local
2-year-oldmale Bulldog.The satellitenodulescanbe
erythema andoedema.
seen distal to thewound.
143
Chapter12
Tumoursoftheskinandsubcutaneoustissues
Systemically,histamine release canresult in
gastrointestinalulceration（
(due toH2 receptor
stimulationbyhistamine,
hyperacidity,vascular
damageandhypermotility).Ulceration is found in
35-83%ofdogswithMCTsatnecropsyandis
associatedmorecommonly
withhigher-grade
tumoursorlarge-volumedisease.Systemicrelease
ofotherfactorscanresult inso-calledflashing syn-
dromes'collapseoranaphylacticshock.
Clinicalapproach:FNA
correctly
diagnoses
92-96%ofMCTs.Mastcellgranulesoccasionallydo
notstainwellwithrapidmodifiedRomanowsky-type
stains,butthisisuncommonandmaybeovercome
byalonger fixationinalcohol.Althoughaccurate
cytological grading is notpossible,particularly for
gradeIandlltumours,poorlydifferentiatedtumours
maybesuspectedbasedoncytologicalfeatures.
Theapproachtoamassconfirmedcytologicallyto
beamast cell tumour isoutlined inFigure 12.23.
Histopathologyisrequiredforgrading.
Imagingmayassistassessmentoftheextentof
the primary tumour;for example，an ultrasound
examinationmayallowappreciationthatthemass
invadesintothemusclelayerdeeptothetumour.
Metastasis is to the local lymph nodes,then
spleen,liverorothervisceral organs.Theminimum
recommendedtumourstagingisaspirationoflocal
lymphnodes(evenifpalpablynormal)and abdomi-
nalultrasonography to assesstheliverand spleen.
12.21
Extensiveoedemaandswellingaroundthe
Cytologicalevaluationoflocalnodesisthemost
IMCTfromtheflankofa6-year-oldmaleBulldog.There
importanttest.Diagnosisofmetastasescanbediffi-
isdiffuseswellingovertheleftlateralabdomenextending
cult,becausenormalmastcellsmaymigratetothe
fromthelastribtotheflankfoldand,distally,downtheleft
nodeduetochemotaxis.Ithasbeensuggested that
hindlimbto thestifle.
if>3%ofcellsaremastcells,metastasisshouldbe
diagnosed,butusing thiscriteriaupto25%of nor-
Complicationsresultingfromthereleaseofbio-
mal lymphnodeswouldbepositive.Thepresenceof
activesubstancesfromMCTsoccurinuptohalfof
abnormalmastcellsoraggregatedcellsisconsist-
dogswithMCTs.Localeffects ofdegranulation
entwithmetastases.
includeerythema,inflammationandhost irritation,
Aspirationofultrasonographicallynormalspleens
local haemorrhageandpoorwoundhealing(Figure
isa low-yieldprocedure,butintheauthor'sexperi-
12.22).
encetumourmetastasesmaybediagnosedin
cantfor theindividualpatient.Forhigh-grade
tumours,aspirationof thespleenisrecommended.
PulmonarymetastasesareuncommoninMCTs
butthoracicradiographsmaybeindicatedtoevaluate
stitialinfiltrate.Theymayalsobeofvaluewherethere
isasuspicionofconcurrentdiseaseortoruleout
othersignificantpathologyinolderpatientsbefore
expensiveand involvedtreatment isundertaken(for
example,surgeryfollowedbyradiationtherapy).
Examiningbuffycoatsmearsfromperipheral
bloodisnotrecommended,becausemastcellsare
foundmorefrequentlyinanimalswithinflammatory
diseasethaninthosewithMCTs.Thevastmajority
ofdogswithMCTsdonothavemalignantmastcells
intheircirculationorbonemarrowandthisisvery
unlikelyinpatientswithoutdisseminateddisease.
Bonemarrowaspirationshouldthusbereservedfor
Woundbreakdownfollowingsurgicalremovalof
animalswithvisceralanddisseminateddisease,
agradelllMCTfromthethighofa5-year-old
althoughtheirpoorprognosismightrendertheinfor-
neuteredBulldogbitch.
mationof littleclinicalvalue.
144
Chapter12
Tumoursoftheskinandsubcutaneoustissues
FNA of mass diagnosesMCT
Cytology suggests highgrade
Gradeunknown
Yes
Clinicalindicationsofmalignancy?
LymphnodeFNA
±Adominal ultrasonography
ematology/bie
hemistry
outcome
No
Excise
Neoadjunctivechemotherapy
Multimodalitytherapy
OR
Histopathology
Palliativetherapy
OR
Grade andmargins
12.23
Approachto caninepatientsdiagnosedwithMCTsonthebasisof cytology.
DecisionmakinginMCTtreatmentisoutlinedin
havesuggestedthatwide surgicalmarginsmay
Figure 12.24.
notbenecessaryforsuccessfulmanagementof
grade|and IlMCTsupto5cmdiameter,and
Surgery:Surgeryis thetreatmentofchoicefor
suggest2cmlateralmarginsandadeepmargin
primarygrade|orIlMCTs.Theacceptedubiqui-
ofonefascialplaneasstandard.A2cm/one
tousdogmaforMCTremovalhasbeenmarginsof
facialplaneoptionhasnotbeenevaluatedfor
3cmintwoplanes,andremovalofonefascial
tumours>5cmandwillbeinadequateinmost
planedeeptothetumour.However,recentstudies
gradeIll tumours.
MCTbiopsysubmittedforhistology
Gradelor Grade ll tumour
Grade ll tumour or Gradell
with high MI or metastases
Iswide surgical excisionpossible?
Iswide surgical excision
possible/indicated?
No
Yes
Yes
No
Neoadjuvant chemotherapy
WIDESURGICAL
Neoadjuvant chemotherapy
OR
EXCISION
Cytoreductive surgery and
s
OR
radiotherapy(refer)
radiotherapy(refer)
Palliativetherapy
OR
Histopathology
Palliativechemotherapy
OR
Grade Ill tumour or Gradell
with high Mi or metastases
Complete surgicalmargins?
Complete surgicalmargins?
YesNoornarrow
YesNoornarrow
Follow-upfor12-18
Second surgery?
Adjunctive therapy:
Adjunctivetherapy:
months
OR
Chemotherapy
Radiotherapy
Radiotherapy
(Radiotherapyof
Chemotherapy
OR
nodal metastases)
Closemonitoring
12.24
Approachto treatmentofcanineMCTs.
145
Chapter12Tumoursof theskinandsubcutaneoustissues
Radiationtherapy:Radiationtherapyiswidelyused
surgeryalone,evenwhenhistological marginsare
inthetreatmentofMCTs,mostoftenasapostoper-
incomplete;forexample，onerecentstudyreported
ativeadjunctivetherapy.Thisisbestachievedwhere
23%recurrencerateof incompletelyexcisedgradell
radiationisplannedfromthebeginning,ratherthan
tumours(Seguinet al.,2006).Adjuvantradiation ther-
asanafterthoughtfollowinginadequatesurgery.
apy for intermediategradeMCTsresults in a 1-2-
Radiationtherapyisavoidedasasoletherapywhere
yeardisease-freeinterval in81-95%of cases,and
thereisbulkydisease,duetotheriskofradiation-
disease-freeintervalsof40monthshavebeen
inducedmastcelldegranulationandserioussys-
reportedfordogswithgradeI/lltumourswithregional
temiceffects:fatalitieshavebeenreported.Where
lymphnodemetastasestreatedwithsurgeryand
thereisgrossdisease,neoadjuvantchemotherapyor
radiation.Manydifferentfractionationregimesare
prednisolonewillreducetheriskofsignificant
reported and theidealprotocol isunknown.
degranulationevents.
Inordertomaximizethechancesofagoodout-
Traditionalchemotherapy:Chemotherapyisused
come,accuraterecordingofthepresurgical tumour
wheresystemic(ratherthanlocoregional)therapyis
isrequired.Ideally,metal surgicalclips should be
requiredtotreatdisseminated,non-resectableand
placed atthesurgicalmargins:thesecanbevisual-
high-grade tumours.Chemotherapyis also some-
izedbyportalimagingandmayalsohelptoreduce
timesusedforresidualmicroscopicdiseasewhere
thechanceofageographicalmiss,particularlyon
radiationtherapyisnotavailable.
thetrunkandbodywallwheretheremaybepost-
Forgradell tumourswithahighmitoticindex,
surgical tissuemigration.Theuseofadvancement
grade lll tumoursor tumourswherethepathologist
flapsandgraftingtechniquesmayincreasethefield
suggestsgradeI/llfeatures,chemotherapyisused
sizefortreatmentandresultinadelayinstarting
todelayorpreventmetastaticdisease(inadditionto
radiationtherapybecauseofdelayedwoundhealing
surgical treatmentof theprimarysite).Goodout-
orwoundbreakdown,andasimplesurgerywithpri-
comeshavebeenreportedinthissetting,withall
maryclosuremaybepreferablewhenpostoperative
patientsaliveat3yearsinonestudy(Thammetal.,
radiationtherapyisplanned.
2006),though overalltheprognosis isnot as good
Onthelimbs,a stripofskinmustbe excluded
for all high-grade cases.
fromtheradiationfieldtopreventlatelymphoedema
Oftenfirstlinetherapyisvinblastineandpredni-
duetodamagetothelymphatics.Thismeansthat
solone,andsecond linelomustine.Protocolsalter-
thewholecircumferenceofthelimbcannotbeirradi-
natingvinblastineand lomustinearealsoused.The
ated,limitingmargins,andwhereradiationistobe
commonestprotocolsaresummarized inFigure
usedpostsurgicallyobliqueandtransverseincisions
12.25.Goodresponseratesarereportedwithcom-
shouldbeavoided.
binedvinblastine,cyclophosphamideandpredniso-
Radiationtherapycanalsobeusedtotreatlocal/
lone,buttheadditionalpotentialtoxicitywithout
regional nodalmetastases.
TheprognosisforMCTstreatedwithsurgeryand
hasnotbecomeestablished.Thereisonlyanecdotal
radiationisgood,butthelitratureisdifficulttointr-
evidencetosupporttheuseofotherchemothera-
pret,giventhelowrateofrecurrencereportedwith
peuticagentsinthetreatmentofcanineMCTs.
as
Published response
Protocol
Comment/toxicity
References
rate(measurable
disease,completeand
partial responses)
Vinblastine and
47%
Vinblastine 2mg/m²i.v.weeklyfor4
6-20%toxicity:myelosuppression
Thamm etal.
prednisolone
weeksthenfortnightlyfor4further
andGl toxicity
(1999,2006);
treatments
Canroll vinblastineout to6months
Vickeryetal.
Prednisolone2mg/kgorallyq24hfor
Dose escalation of vinblastinemay
(2008)
one week,then1mg/kgq24h for2
bepossible in some cases
weeks,then1mg/kgq48h
Lomustine
44%
70mg/m²orallyq21d for4cycles
Lomustine is associated with
Rassnicket
myelosuppression,Gland
al.(1999)
hepatotoxicity
Toxicityof longer-termmonotherapy
unknownif lomustine continued
Lomustine often used asrescue
therapyaftervinblastine and
prednisolone
Vinblastine/lomustine
Not published
Vinblastine2mg/m²i.v.week1,then
Protocol continues for6months
Welle etal.
andprednisolone
every4thweek
(2008)
(alternating vinblastine/
Lomustine70mg/m²orally week3,
lomustine,one
thenevery4th week
treatmentq14d)
Prednisolone0.5mg/kgorallyq24h
12.25
Most commonly used chemotherapy protocolsforcanine MCTs.(continues)
1
146
Chapter12Tumoursoftheskinandsubcutaneoustissues
Drugs
Published response
Protocol
Comment/toxicity
References
rate(measurable
disease,completeand
partial responses)
Vinblastine/lomustine
57%overalresponse
Vinblastine2mg/m²i.v.week1,then
Planned protocol4-6cycles
Cooper et al.
(alternating vinblastine/
rate
every4thweek
Toxicityin54%ofcasesmainly
(2009)
lomustine,one
Lomustine60mg/m²orallyweek3,
myelosuppression
treatmentq14d)
thenevery4thweek
Vinblastine,
64%overallresponse
Vinblastine 2-2.2mg/m²i.v.every3
Protocol continues for6months
Camps-Palau
cyclophosphamide,
weeks
11-14%neutropenia
et al.(2007)
prednisolone
Cyclophosphamide200-250mg/m²
i.v.ororallyday8of 21-daycycle
Prednisolone1mg/kgorallyq24h
taperedanddiscontinuedover24-32
weeks
Chlorambucil/
38%overallresponse
Chlorambucil5mg/m²orallyq48h
No toxicity
Tayloret al.
prednisolone
rate
Prednisolone40mg/m²orallyq24h
(2009)
for 14 days then20mg/m²q48h
12.25
(continued)Most commonlyused chemotherapyprotocolsforcanine MCTs
Neo-adjunctivechemotherapy,priortosurgeryor
tumour.H2antagonistssuchascimetidine(licensed
radiotherapywilloftenresultinconsolidationofthe
intheUk),ranitidineandfamotidinearevaluable
tumourmassandimprovethelikelihoodofachieving
treatmentsforpatientswithgastrointestinalsigns
completeexcision,ormakeiteasierandsaferto
associatedwiththeirtumour,or inasymptomatic
irradiatethemass.
patients attimesofrisk,e.g.when onhigh-dose
Informationontheuseofcytotoxicdrugsisgiven
prednisolone,orduringandsoonafterradiationther-
inChapter7.Lomustineshouldbeusedwithcare:
apy.Sucralfate is also of benefit.H1antagonists(e.g.
onerecentstudyreportedfatalityintwoof12dogs
chlorpheniramine)areseldomrequiredonacontinu-
withmast celltumours,duetohepatotoxicity
ingbasisbutareoftenrecommendpriortomanipu-
(Hosoya et al.,2009).
lationofthetumour,forexampleduringplanned
cytoreductivesurgery,orradiotherapy.
Tyrosinekinaseinhibitors:Activationof theKIT
receptortyrosinekinase(TK)isassociatedwiththe
Othertreatments:Localintralesionaltherapyofpri-
developmentofcanineMCTs.Activation isusually
maryMCTshasbeendescribed,usingintralesional
dueto geneticmutations in the c-kit gene,which
corticosteroidsordeionizedwater,orbrachytherapy
resultinligand-independentincreasedcellprolifera-
(radioactive
implants),
with
variable
results.
tion,and also alterations in migration,maturation
Experimentaltreatmentwithanimmunomodulatory
andsurvivalcharacteristics(seeChapter9formore
compoundbasedonhumanchorionicgonadotrophin
details).Approximately 15-40%ofcanineMCTs
andbacillusCalmette-Guerinhasresultedin
harbourc-kit mutations.Mutations are more fre-
responses in28%of treated dogs(Henry etal.,2007).
quentlyfoundinhighergradetumours,andcorrelate
with apoorerprognosis.
PrognosticindicatorsforMCTs:Themostimpor-
Recently,interesthasfocusedontyrosinekinase
inhibitors(TKis)fortumoursbearing c-kit mutations,
tant prognostic factor is histological grade.The
Patnaik system （based on extent,cellularity,cell
and theTKisinvestigatedsofar(masitinibmesylate
and toceranib phosphate（SU11654)have most
morphologyandnuclearfeatures)isthemostwidely
effectinMCTswithc-kitmutations.Bothagentshave
used.Ithassomelimitations,particularlyindealing
beenusedwithoutunacceptabletoxicityindogs,and
withwelldifferentiatedsubcutaneoustumoursor
superficialdermal tumours（wherecytologicaland
controlledstudies
have
demonstrated
tumour
architectural featuresresult in conflictinggrading),
response（toceranib)anddelayedtime toprogres-
sionand increased survival（masitinib,toceranib) in
andsuffersfromsubjectivityresultinginvariation
selected grade Ilor llMCTs（Hahn et al.,2008;
betweenpathologistsingrading.Nevertheless,
London et al.,2009).Interestingly,some tumours
PatnaikgradeI(welldifferentiated),grade Il(inter-
withwild type(normal)c-kitrespond to thesedrugs,
mediategrade)andgradeIll(poorlydifferentiated)
probablybecausethesemoleculesalsoinhibitother
tumoursdifferwidelyintheirclinicalbehaviourand
TKs.Theseeffectsalsoexplaintheadverseeffects
dictatedifferenttreatmentandprognosis.Manystud-
seenwith theseagents.TKlsrepresentanexciting
ieshaveconfirmed thebehaviourofgradeI（good)
developmentin thetreatmentofcanineMCTsbut
andgradell(bad)tumours,butforgradeIltumours
ourunderstandingoftheirroleiscurrentlylimited
traditionalhistologicalgradingisoflimitedvalue，
andmuchworkremainstobedone.
becauseitdoesnotidentifythosetumoursthatare
likelytometastasize.
Supportivetherapy:PatientswithMCTsmustbe
Clinicalfactorsmaybeofprognosticrelevance
treatedforsystemicsignsassociatedwiththe
and aresummarized inFigure12.26.
147
Chapter12
Tumoursof theskinandsubcutaneoustissues
Tumour features
Tumourstageisprognostic,withmoreadvanced
diseasegenerallyhavingapoorerprognosis.Grade
Rapid tumourgrowth
Iltumourswith metastasesarecontroversial,as
Largetumour size
Ulceration
improvedsurvivaltimesforthesepatientscompared
Erythema
withhistoricalreports.TheWHOstagingsystemfor
Irritation
MCTsis shown inFigure 12.27,butunfortunately
Thesefeaturesmostoftenassociated withhigher-gradetumours
stageandprognosisdonotcorrelatedirectlyinall
clinical situations.
Systemic signs
Proliferation indices such asmitotic index(MI),
Gastrointestinal signs
argyrophilicnucleolar organizerregions（AgNORs),
Flashing syndromes
Ki67 and proliferating cellnuclear antigen(PCNA)
Anaphylaxis
mayofferprognosticinformation.These tests are
Thesefeaturesmostoftenassociated withhigher-gradetumours
summarizedinFigure12.28.Mlhasbeenshown to
beausefulprognosticindicator:inonerecentstudy,
Tumour site
MSTfordogswitha tumourwithMls5per10high
Nailbed
powerfieldswas70monthscomparedwith2months
Oral cavity
whereMlwas>5,irrespectiveofgrade(Romansiket
Muzzle
al,2007).Thisis supported by early work showing
Inguinal
thatpatientswithtumourswithamitoticindexof10or
Preputial
morehadasurvival timeofonly11weeks(Bostocket
Perineal
Mucocutaneous junctions
al.,1989).Acut-offMIof7rather than5hasbeen
proposed (Elston et al.,2009),but further work
LiteraturecontradictoryDiferencesprobablymultifctoriaand
exploringoutcomeforpatientsreceivingadjunctive
therapyon thebasisofMI isrequired.Theimpact of
high-grade tumoursin some sites
MIonlikelihoodofrecurrenceisunclear.However,itis
Factorsindicatingpoorprognosisindogswith
12.26
ausefulmarkerthatcanbedeterminedinmostcases
MCTs.
by standard histopathology.
Stage
Description
0
Onetumourincompletelyexcisedfromthedermisdentifiedhistologicallywithoutregionalymphnodeinvolvement
a.Without systemic signs
b.With systemic signs
Onetumourconfined tothedermis,withoutregional lymphnodeinvolvement
a.Without systemic signs
b.With systemic signs
Onetumourconfinedtothedermiswithregionallymphnodeinvolvement
a.Without systemic signs
b.With systemic signs
a.Without systemic signs
b.With systemic signs
IV
Anytumourwithdistantmetastasisorrecurrence withmetastasis(includingbloodorbonemarrowinvolvement)
12.27
World HealthOrganizationstagingsystemforcanineMCTs.
Marker
Significance
Comment
Mitotic index(MI)
>5prognosticforreducedsurvivalindependentofgrade.Notproventopredict
Usefulstanbcard
forrecurrence
on routine histological sections.
Someauthorsrecommend7as
cut-off rather than5
Argyrophilicnucleolar
HigherAgNORcountsassociatedwithincreased likelihoodof death,recurrence
Notindependentof histological
organizer regions(AgNORs)
andmetastasis
grade
Ki67
HighKi67expression（scores>1.8)associated withincreasedmortality,
Usefulifavailableasprven
recurrence andmetastasis.Prognosticfactorindependent ofhistologicalgrade
independent of grade
Proliferating cell nuclear
IncreasedPCNAexpressionassociatedwithincreasedmortality.Not
Not independentof histological
antigen (PCNA)
consistently withincreasedriskofrecurrenceormetastasis
grade
12.28
Markersof proliferation andMCTprognosisindogs.
148
Chapter12Tumoursoftheskinandsubcutaneoustissues
Marginsofexcision:Some studieshaveques-
tionedwhetherthereisanyprognosticvalueincom-
pleteversusincomplete
marginsforMCTs.
Certainly,ina significantproportion of tumours
（probably25%ormore)withincompleteornarrow
margins,enblocresectionof the scarrevealsno
mastcells,andonerecentstudyreportedonly23%
recurrencerate ofincompletelyexcisedgradell
tumours(Seguin etal.,2006).Thismayreflecteither
thatthemastcellsseenatthemarginswerenot
neoplastic,orthat theimmune systemhaderadi-
catedmicroscopicdisease.Thedifficultiesin
assessing margins arise because MCTsrelease
factorsthatarechemotacticfornormalinflammatory
mastcells,andwhile thetumourcellsinhigh-grade
tumoursarereadilydifferentiatedfromnormalcells,
thoseingradeIandlltumoursaremoredifficultto
differentiate fromnormalmastcells.Recurrence
mayoccurevenwheremarginshavebeenreported
ascomplete（localfailureratesof5-11%are
reportedinthissituation)butismorelikelywhere
marginsareincompleteornarrow.
Wheremarginsareincompleteornarrowand
thereismacroscopicresidualdisease,recurrenceor
metastasis,clearlyawaitandsee'approachisnot
appropriateandwherepossibledefinitivesurgery
shouldbeperformed.Insiteswheresurgicalexci-
sionisdifficulttoachieve,neo-adjunctivechemo-
therapy（usually vinblastine andprednisolone，or
prednisolonealone)mayfacilitateacompleteexci-
sion,orpostoperativeradiotherapymaybeusedto
dealwithresidualdisease.RecurrentMCTscarrya
poorerprognosis.
Forgrade|andmostgradelltumourswhere
(q)
incompletemarginsarereportedbutthereisno
grossdiseaseandthewoundhashealedunevent-
fully,theoptionsaretoperformanenblocexcision
of thescar(preferred)ormonitorthesiteandresect
recurrentdiseasewithadequatemarginsassoonas
this is detected.lf the second surgery achieves clean
margins,noadjunctivetherapyisgiven.
DogswithmultipleMCTs
Upto44%ofdogscuredofapreviousMCTwill
develop further MCTs,and some dogs（probably
>20%)developmultipleMCTseitherwithinarela-
tivelyshorttimeframeorsequentiallythroughout
theirlifetime,particularlyGoldenRetrieversandpos-
siblyLabradorRetrievers,WeimaranersandBoxers.
Theseanimalsdonotexperienceshortersurvival
thanthosewithsolitarytumoursofthesamegrade,
asthetumoursrepresentdenovolesionsratherthan
d
metastaticdisease.Thereisnoevidencethatthese
12.29
MetastasesfromapoorlydifferentiatedMCTin
dogs respond to systemic therapy,nor does sys-
a 6-year-oldneuteredfemaleBoxer.Theprimary
temictherapypreventthedevelopmentoffurtherde
tumouraffectedtheleftupperlip(a)and therewas
markedenlargementof theleftsubmandibularlymph
novo lesions.Cutaneous metastases from MCTs
nodeduetometastasis.Erythematouscutaneous
tendtobeseenonlyinassociationwithaggressive
metastaticlesions affected theskinof(b)thelimbsand
high-gradetumoursandaremultiple,rapidlygrowing
(c)theventrum,and therewereulceratedlesions(d)on
and often ulcerated(Figure 12.29).
themedial thigh.
MCTsincats
Aetiology,pathogenesisandpredisposition:Cats
MCTsarerelativelycommon incats(8-15%ofskin
withMCTareusuallyover4yearsofage,withan
tumours)butarepoorlyunderstood.Most are
averageof9-11years.Apredispositionisreported
consideredbenignandwelldifferentiated.
inSiamesecats.
149
Chapter12
2Tumoursof theskinandsubcutaneoustissues
Clinicalpresentationandapproach:Mostoften
'Histiocytic'MCTs
MCTspresent as discrete firm alopecic nodules,
So-calledhistiocyticMCTsarenotofhistiocyticori-
whichmaybepaleor tanincolour.Lesionsmaybe
ginandarebestdescribedasatypicalpoorlygranu-
solitaryormultiple（approximately25%aremultiple
lated MCTs.Thesetumoursmostoftenpresentin
atpresentation).Distantmetastasis is uncommon.
youngcats(6weeks to 4years).Again,Siamese
Predilectionsitesarethehead(Figure 12.30),limbs
catsarepredisposed.Theseoftenpresentasmulti-
and tail.Cats can developcutaneousmetastases
plediscreterelativelywellcircumscribedsubcutane-
fromvisceralMCTsandanimalspresenting with
ousnodules.Lesionsmaybegroupedtogether.The
multiplenodules(orpalpableabdominalabnormali-
headisapredilectionsite.These lesions may
ties)shouldalwaysbeclinicallystaged.
regressspontaneously,suggestingareactiverather
than truly neoplasticprocess.
Spontaneousregression mayoccur,and steroid
therapydoesnot enhancethis.The prognosis is
generallygood.
Multifocalneoplasticskin disease
Multifocalneoplasticskindiseaseisanuncommon
presentationindogs andcats andmustbedifferenti-
ated from non-neoplastic disease （Figure 12.31).
Diagnosis isoftenchallenging andneoplasiaisnot
suspecteduntilmore commondifferentialshave
DiffuseMCTaffecting the upper lipof an
beenexcluded.Neoplasticskindisease tendsto
11-year-old maleDSHcat.(Courtesy of IGrant)
affectolder animals and,unlike allergicand endo-
crineskindisease,itisrarelysymmetrical indistribu-
Treatmentandprognosis:Thetreatmentofchoice
tion.Infrequently，animals may present withmulti-
forfelineMCTissurgicalexcision.Tumoursdescribed
focalvariantsoftumoursthatareusuallysolitary:
histologicallyasdiffuserequirewidermarginsthan
thesearesummarized inFigure12.32.
thosedescribed ascompact.Thereisnoprovenrole
Animalswithmultifocalneoplasiamaypresent
forchemotherapy，but vinblastine,chlorambuciland
withmultiplecutaneousmasses,nodulesorplaques.
lomustineare
reported.Prednisoloneisoften
Lesionsmay also be erythematous,exfoliative，
included.Therearelimiteddataonradiationtherapy.
ulceratedandcrustedandinsomecasespruritic.
Histopathological gradingusing
Patnaik-type
Mucocutaneouslesionsarerelativelycommonin
criteriadoesnotpredict
prognosis.Histological
canineepitheliotrophiclymphoma.
classificationas compact or diffuse tumoursis
Diagnosisdependsoncytologicalorhistological
useful:compactmastocytictumoursarecommonest
(70-85%),are minimally invasive and donot meta-
evaluationshouldbecarriedoutasindicatedbythe
stasize;butdiffusetumoursarelocallyinvasiveand
tumourtype.
commonly havelocoregional metastases (5-10%).
Managementisoftendifficultandtheprognosis
Proliferationmarkersmay offer some indication
for multifocal skinneoplasia is generally guarded to
ofprognosis
poor.
Type
Neoplastic
Non-neoplastic
Multiple cutaneous
Lymphoma:
Infectious granulomas
masses,nodules or
Non-epitheliotrophic lymphoma（D,C)
Bacterial (D,C)
plaques
Epitheliotrophiclymphoma(D,C)
Mycobacterial (D,C)
Histiocytic disease：
Fungal(D,C)
Malignant histiocytosis(D,C)
Hypersensitivity:
(Multiple fibrous histiocytoma)（D）
Eosinophilic granulomas/furunculosis(arthropod bites)(D,C)
Others:
Immune-mediated:
Multiple mast cell tumours（D,C)
Sterile nodular panniculitis (D,C)
Multile squamouscell carcinoma/SCC in situ(C)
Juvenile cellitis and lymphadenitis(D)
Multiplefibrosarcoma(C)
Sterilenodular granuloma/pyogranuloma(D)
Cutaneous metastatic disease (D,C)
Plasma cell pododermatitis(C)
Parasitic granulomas(D,C)
Histiocytic disease:
·Cutaneous histiocytosis(D)
Systemichistiocytosis(D)
Multiple naevi/cysts（D)
12.31
Differential diagnosisof presentations of multifocal skinneoplasia in dogs(D)andcats(C).(continues)
150
Chapter12Tumoursoftheskinandsubcutaneoustissues
Type
Neoplastic
Non-neoplastic
Erythematous,
Lymphoma:
Hypersensitivity:
exfoliative,alopecic
Epitheliotrophic(D,C)
Flea allergic dermatitis（D.C)
and pruriticlesions
(Non-epitheliotrophic)(D,C)
Adversefood reaction（D,C)
Squamous cell carcinoma（C,D)
Atopy (D.C)
Contact allergic/irritant dermatitis (D,C)
Ectoparasites:
Sarcoptes(D.C)
Cheyletiella(D,C)
Otodectes(D,C)
Lice(D,C)
Harvest mites(D.C)
Demodex(D,C)
Notoedres(C)
Immune-mediated:
Pemphigus complex（D,C)
Cutaneous lupus erythematosus(D,C)
Infectious:
Pyoderma/bacterial folliculitis(D,C)
Dermatophytosis(D,C)
Malassezia(D,C)
Poxvirus(C)
Eosinophilicgranuloma complex（C)
Psychogenic alopecia(C)
Mucocutaneous
Lymphoma:
Immune-mediated:
lesionsand
.
Epitheliotrophic(D,C)
Pemphigus complex(D,C)
multifocal facial
(Non-epitheliotrophic)（D,C)
Cutaneous lupus erythematosus(D,C)
ulcerations
Squamous cell carcinoma(D,C)
Drug eruptions(D.C)
Hypersensitivity:
Eosinophilicgranuloma complex(C)
Drug eruptions(D,C)
Infectious:
Pyoderma/bacterial folliclitis (D,C)
Candidiasis(D,C)
（Subcutaneous and deepfungalinfections)(D,C)
（Toxic epidermal necrolysis)（D)
(Erythemamultiforme)(D)
12.31
(continued)Differential diagnosisof presentations of multifocal skinneoplasia indogs(D)and cats(C).
Tumour(species)
Breed or sexpredisposition
Predilection site
Clinical features
Possible treatment
Infundibularkeratinizing
Norwegiankhundrry
Any
Multiplepartialyalopecicdermal
Isotretinoin1-2mg/kg/day
acanthoma(intracutaneous
BlueTerrer,hasa
nodules.Mayhavecentral pore
cornifying epithelioma)(D)
withprotrudingkeratin
Squamouscell carcinoma
Older
Digits,lips,
Proliferativeerosiveorulcerated
Surgicalexcision;radiation
(C,D)
externalnares
lesions
therapy (see text)
Lipoma(D,C)
(?Overweight female)
Any
Soft tofirm slow-growing
Surgical excision
subcutaneousmasses
Haemangiosarcoma(D)
German Shepherd Dog
Any
Poorlycircumscribednvasive,
Surgical excision
friable,rapidlygrowing
Adjunctive chemotherapy
Fibrosarcoma(C)
Multiplefibrosarcomasonly
Any
Firmpaleaidlygwing,
Biopsy toconfirmdiagnosis
seen inyoung cats
infitrative orulceratedcutaneous
clinicalstagingifappropriate.
concurrentlyinfected with
and subcutaneous masses
Diseaseprogressionrapidno
FeLVandfelinesarcoma
successful treatment
virus:rare
Perianal gland adenoma（D)
Male
Perianal region,
Wellcircumscribednodulesmay
Surgical excision
SamoyedCockerSpaniel,
perineum,tail,
ulcerate
Castration/hormonaltherapy
Bulldog,Beagle
prepuce,thigh
Perianal gland
Male
Perianal
Poorly circumscribedinvasive
Surgical excision
adenocarcinoma(D)
massesoftenulceratd
?Efficacyofradiationtherapyl
chemotherapy
Histiocytoma(D)
Often young (<3years)
Head,limbs,ft
Wellcircumscribednodulemay
May spontaneouslyregress
BoxerBuldog,Dobermann,
be hairlessmayucerate
Surgical excision
Dachshund
12.32
Tumoursthatmostcommonlypresentassolitarylesionsbutmaypresent inmultifocal formsindogs(D)and
cats(C).Casesmustbeapproachedonanindividual basisand treated asindicatedbytheirclinical
circumstances.(continues)
151
Chapter12
Tumoursoftheskinandsubcutaneoustissues
Tumour(species)
Breed orsexpredisposition
Predilection site
Clinical features
Possible treatment
Sebaceous adenoma/
Older dogs
Any,head,face
Dome-shaped orpapillated
Surgical excision
epithelioma tumours(D)
CockeranieKerrylu
nodulefungiformmassyellow
Terrier,BostonTrr,
opalescent orpigmentedmay
BeagleBassetHound
be alopecic orulcerated
Dachshund,SierianHusky
MiniaturePoodle,
Coonhound,Samoyed,
Persian cats
Plasmacell tumour
Any,
Well circumscribedusually
Clinical staging toruleout
plasmacytoma(D)
mucocutaneous
non-ulcerated masses
cutaneous involvementin
junctions
multiplemyeloma.Surgical
excision,radiotherapy（no
proven chemotherapy)
Trichoepithelioma(D,C)
Basset HoundCocker
Dorsallumbar
Wellcircumscribed intradermal
Surgicalexcision
Spaniel,German Shepherd
and lateral
nodules
Dog,Golden Retriever
thoracic
12.32
(D)andcats(C).Casesmustbeapproachedonanindividualbasisand treatedasindicatedbytheirclinical
circumstances.
Primarycutaneouslymphoma
Epitheliotrophiclymphoma(mycosis fungoides)
Cutaneouslymphomasaccountforonly3-8%of
ischaracterizedbyinfiltrationofneoplasticmemory
caninelymphomas（1%ofcanine skintumours)and
T
cellsintothe
epidermis,Pautrier'smicro-
<3%offelinelymphomas(2.8%of felineskin
abscesses(focalaccumulationsoftumourcells)and
tumours).Primary cutaneouslymphomasare clas-
tropismoftumourcellsforadnexalstructures
sifiedhistologicallyaseitherepitheliotrophicornon-
(Figure12.33).In humans,epitheliotrophiclym-
epitheliotrophic,dependingonwhethertheneoplastic
phoma isfurther classified asinFigure 12.34,butin
infiltrationisepidermal（epitheliotrophic)ordermal
dogs thesesub-classificationsaremoreuseful to
(non-epitheliotrophic).Epitheliotrophiclymphoma
is
pathologists thanclinicians.Theclassicalmycosis
more commonthannon-epitheliotrophicindogs,and
fungoidesformiscommonestindogs.
extremelyrareincats.Non-epitheliotrophiclymphoma
Non-epitheliotrophiclymphoma ischaracterized
islesscommonthanepitheliotrophiclymphomain
byadiffuseinfiltrationofneoplasticlymphoidcellsin
dogs,butmorecommonincats,thoughrare.
thedermis,whichmayextendintotheepidermis.
12.33
Epitheliotrophiclymphoma.Thedistributionof thetumourcellinfiltrateintheepidermisandaround thehair
follicle isevidentonlowandhighpower.(a)H&E;x20originalmagnification;(b)H&E,x100original
magnification.(Courtesy of A Jefferies)
Form ofepitheliotrophic
Subclassification
Characteristics(based on human data)
sboa
lymphoma
Mycosis fungoides (MF)
Classic
Oftencharacterizedbyorderlyprogression through
Commonest formbutodisti
eczematoustoplaqueto tumourstage
progression through stages
D'emblee
Sudden-onset nodularform withnopre-tumourstage
Clinicallyrecognized indogs
Pagetoid reticulosis(PR)
Woringer-Kolopp
Localizedoften slowlyprogressive
One suspected casereport
Ketron-Goodman
Generalized form;differentiatedfromMFbyhistology
One casereport
Sezary syndrome
Characterized bycirculatingneoplasticcells
Rare in dogs
12.34
Clinicopathological classificationofepitheliotrophiclymphomainhumans,andrelevancetodogs.
152
Chapter 12
Tumoursof theskinandsubcutaneoustissues
Aetiology,pathogenesisandpredispositions:The
aetiologyofepitheliotrophiclymphomaisunknown.
Chronic inflammation has been proposed as a pos-
sibleriskfactorindogs.Chronicactivation and stimu-
lationofTlymphocytesbypersistentenvironmental
antigensorabnormalitiesinLangerhans'cellfunction
mayresultinclonalexpansionofactivatedlympho-
cytesgivingrisetolymphoma.However,thereisno
clearevidencetosupport thisindogs.
The
epitheliotrophiclymphomas
areT-cell
tumours.In both humans and dogs,these are
tumoursof thememory subpopulationofTcellsbut
indogsthetumourcellshavedifferentclusterofdiffer-
generearrangementsthan inhumans,suggesting a
a
different molecular pathogenesis.Most (but not all)
non-epitheliotrophiclymphomasindogsandcatsare
alsoofT-cellorigin.Althoughcatswiththiscutaneous
lymphomaareusuallyFeLV-negativeonp27enzyme-
linked immunosorbent assay(ELISA),tumour tissue
maytestpositiveforfelineleukaemiavirusantigenby
immunohistochemistryorintegratedretroviralele-
mentsonpolymerase chainreaction(PCR),support-
ing thehit and run'theory of FeLV oncogenesis.
Thereissuggestedbreedpredispositionforepi-
theliotrophiclymphoma inCocker Spaniels and
Boxers,butno sexpredisposition.Olderdogs tend
tobeaffected(meanage 8-11years).Non-
epitheliotrophiclymphomamaybemorecommonin
Boxers,St Bernards,BassetHounds,Irish Setters,
CockerSpaniels,German Shepherd Dogs,Golden
(b)
RetrieversandScottishTerriers.
12.35
(a)A14-year-oldneuteredmalecrossbreddog
withcutaneouslymphomawithmarkedpruritus
Clinical signs:Cutaneous lymphoma can mimic
andscaling.(b)Aproliferatingerythematousscaling
ulceratedlesioninanelderlypruriticcrossbreddogwith
many dermatides.In humans,there is a classical
epitheliotrophiclymphoma.(b,Courtesyof L.Buckley)
step-by-stepprogressionofepitheliotrophiclym-
phomafrompremycotic/eczematoustoplaqueto
tumourstage.Dogsmaypresentwithlesionstypical
of anyorall stages.Clinical features include:
Exfoliativeerythroderma,i.e.erythema,scaling,
withorwithoutlossofpigmentationandalopecia
(Figure12.35),which isoftenpruritic
Mucocutaneouserythema,infiltration,
depigmentation,alopecia orulceration;multiple
orsolitarypatches,plaques,ornodularmasses,
whichmaybescaly,crustyorerythematous
(Figure12.36)
Infiltrativeorulcerativeoralmucosaldisease
(Figure12.37b,c).
Overall, erythema is present in about 80%of
cases;plaques,scalesand/ornoduleseach in60%
ofcases;and erosions,ulceration,crusting,mucosal
involvementandprurituseachinabout40%of
cases.Morethanoneformoflesionmaybepresent
inthesamepatientandinvolvementofthemuco-
cutaneous junctions(especially lips)andoral cavity
(a)
iscommon.Perioculartissuesmayalsobeaffected.
Diseaseprogression tolocalandregionallymph
Mucocutaneouslesions in canine
epitheliotrophiclymphoma.(a)Thedogshown
nodesiscommonindogsandsystemicinvolvement
inFigure12.35a,displayingperianal cutaneousand
ofother lymphoid tissues may occur,resulting in
mucocutaneous erythema and ulceration,alongwith
lymphadenopathyandclinicalsignsassociatedwith
faecal staining duetopain(hewouldnotallowtheowners
disseminatedlymphoproliferativedisease.
toclean the area).(continues)
153
Chapter12Tumoursoftheskinandsubcutaneoustissues
(continued)
Mucocutaneouslesions
incanineepitheliotrophic
lymphoma.
(b)Epitheliotrophic
lymphomaonthemuzzle
ofamiddle-aged
crossbred dog.(c) Lip
lesionina9-year-old
femaleShetland
Sheepdog.
(c)
(a)
b)
12.37
Epitheliotrophiclymphomainan8-year-oldneuteredcrossbredbitch.(a)Araisedreddenedplaque-likelesion
Clinical signsofnon-epitheliotrophiclymphoma
Clinical approach:Diagnosiscanonlybeconfirmed
include:
bybiopsy，wherethemicroscopicdistributionofthe
neoplastic cells can be appreciated,though the
Generalizedormultifocal nodulardisease(Figure
presenceofalymphoproliferativeneoplasmmaybe
12.38)
apparentoncytology.
Systemicinvolvementandsignsofgeneralized
Clinicalstagingandpre-treatmentevaluation
lymphoproliferativedisease(lesionsprogress
shouldbecarriedoutaswithotherlymphoma
rapidlyandtheclinicalcourseisshort).
patients(seeChapter19).
Exfoliativeerythrodermaispresentinonlya
Management:Systemiccombinationchemotherapy
minorityofcasesandpruritusisrare.Hypercalcaemia
(seeChapter19)canbeusedtotreatanimalswith
mayberelativelycommoninnon-epitheliotrophiclym-
cutaneous lymphoma,but response rates are
phoma,soanimalsmayhavea historyofpolyuria/
generallylowandmedianremissionsof 1-11
polydipsia,gastrointestinal signs and muscleweak-
months in dogs arereported,though there are
ness(see Chapters4and19).
occasional long-termsurvivors.Thereisnoproven
advantageofonecombinationprotocoloverany
otherforthisformoflymphoma，butsingleagent
lomustinehasbeenreportedtohavehighresponse
rates(around 80%)as aprimary orrescue drug.
Long-termfollow-updata arelackingandcaremust
be takenwhenusinglomustine.Catsrespond less
favourablythandogstochemotherapy.
Inhumanmedicine,interferonalpha2b（IFN)has
beenusedincombinationwithlocalradiation
therapy，photodynamictherapyor retinoid therapy.
Interferonisthoughttoactasabiologicalresponse
modifierandtoup-regulatethehost'simmune
responseagainstthe tumour.Currently,recombinant
humanIFNisavailablebutnotlicensedforanimal
Non-epitheliotrophiclymphoma inadog,
use:it hasbeen used offlabel in both cats and dogs
12.38
showingmultipleraisednodularlesionsonthe
andclinicalresponseinepitheliotrophiclymphoma is
dorsum.(Courtesy of JDobson)
reported.However,relatively rapid induction of
154
Chapter12
Tumoursof theskinandsubcutaneoustissues
antibodiestothisforeignproteinmaylimit itslong-
Multifocalhistiocyticdisease
termvalue.
Therearethreeformsofmulticentrichistiocyticdis-
Retinoids(isotretinoin,etretinate)are vitamin A
ease in dogs:cutaneous,systemicand malignant
analoguesthathavebeenreportedtoproduceclini-
(alsoknown as disseminated histiocytic sarcoma).
calimprovementinupto50%ofcutaneouslym-
Malignanthistiocytosishasrecentlybeendescribed
phomapatients,thoughpatientsmay showonly an
incats,buttheformsdescribed hererelatetodogs.
ameliorationofclinicalsignsratherthanameasur-
Cutaneousand systemichistiocytosesarereactive
able tumourresponse.Theyaremost commonly
histiocytoses,whichresultfromreactiveproliferation
used inconjunctionwithcorticosteroidsorother
ofdermaldendriticantigen-presentingcells asa
treatments.Isotretinoinisusedfordogsat1-2mg/
consequence of immunodysregulation(see Figure
12.14)ratherthanneoplasticconditions.
2-3mg/kgq24h.Caremustbetakenwhenhandling
Diagnosisofhistiocyticdiseaserequirescytologi-
theseagents as they arepowerful teratogens,and
calorhistological(andoccasionallyimmmunohisto-
patientsshouldbemonitoredforadverseeffects.
logical)examinationofcells.The differentiation
Lymphoproliferativediseasesareveryradiosensi-
betweensystemic
and
malignant histiocytosis
tiveandradiotherapymaybeusedtotreat(forexam-
dependsonevaluationofcellularmorphology:in
ple)problematicoral lesions,tofacilitate longer
malignant histiocytosis,the cells have features of
survivalwithabetterqualityof life,butthegeneral-
malignancy,while theinfiltrates in systemichistio-
izednatureofthediseasemeansthatradiationis
cytosis are of apparently non-malignant cells.Inboth
notasuitabledefinitivetherapyformostpatients.
systemicand malignanthistiocytosis,erythrophago-
cytosismaybeaprominentfeature.
Prognosis:Theprognosisforcutaneouslymphoma
Itisimportanttostage theseanimals clinically,
isguarded,withMSTsmeasured intermsofmonths,
especiallytodifferentiatecutaneousfromsystemic
thoughtheremaybeindividuallonger-termsurvi-
histiocytosis.Thoroughclinicalexamination,imaging,
vors.Localizedformsofepitheliotrophiclymphoma,
haematology,biochemistryandbonemarrowaspira-
involvingthelipsororalcavity,maycarryamore
tionarerecommended.
favourableprognosis.Theselesionsmayrespond
verywelltosurgicalmanagementorradiationther-
Cutaneous histiocytosis
apy,whichhavethepotentialtobecurativeintruly
Aetiologyandpredispositions:Thisreactive
localizeddisease.S
Sadly,solitary or localized
conditionarisesduetodysregulationofLangerhans
tumoursareuncommon.
cells(see Figure 12.14).Cutaneous histiocytosis
Secondary cutaneous lymphoma
mayaffectanyageorbreed,butcolliesandspaniels
seempredisposed.
Lymphoma arising in anothersite(multicentric,cranial
mediastinal,alimentaryor extranodal)may dissemi-
Presentation and clinical signs:Dogspresentwith
nate to the skin during disease progression,giving
multiple cutaneousnodules,whichareoftendepig-
rise toso-calledsecondarycutaneouslymphoma.
mented.Predilectionsites are theface(bridgeof the
Lesionsmaytake anyof theformsdescribedabove.
nose,noseandmuzzle),ears,neck,trunk,perineum
Cutaneousinvolvementshouldbeconfirmed
andscrotum.Lesions are restricted to the skin.
cytologicallyorhistologically.Theimmunophenotype
Thereisnolymphnodeorsystemicinvolvement.
reflectsthatoftheoriginaltumour,sothatmoreB-cell
Occasionally,involvementofthenasalmucosaemay
tumoursmaybefound.Theanimal shouldbeappro-
produceinspiratorystridororsneezing,butinvolve-
priatelyevaluatedforanyrescuetherapyconsidered.
mentofothermucosal surfacesisuncommon.
Treatmentisverydifficult,astheseanimalshave
usuallybeenextensivelypretreatedwithcombination
Managementandprognosis:Theprognosisisvari-
chemotherapyandoftenexhibitmultidrugresistance.
ableandtreatmentshouldberegardedaspalliative
Localradiotherapymaybeconsideredforproblem-
ratherthancurative.Theclinical coursemaywaxand
aticlesions,where appropriate，but many animals
wane,butaround50%of dogswillhaveapartialor
havegeneralizedrelapseandrapidlyprogressive
completeresponse toimmunosuppressive cortico-
disseminateddisease.
steroids.Responders canoftenbeweanedoff
Theprognosisforsecondarycutaneouslymph-
therapy.Azathioprineorciclosporinmaybeofvalue
oma isveryguarded.
inrefractory cases(Figure 12.39).
Drug
Dose
Side effects
Notes
Prednisolone
2-4mg/kgq24h tapering to lowest
latrogenichyperadrenocorticism;Gleffects；
Steroid sideeffectsoftenunderestimated
effective doseq48h
(pancreatitis)
Azathioprine
2mg/kg q24h for7 days,thenq48h
Myelosuppression;mild GI signs;
Monitorhaematologyformyelosuppression.
(pancreatitis)
Cytotoxicdrugappropriatehandlingrequired
Ciclosporin
Atopica5mg/kgq24h,thentapered
Vomiting,diarrhoea（usuallytransient;
Atopicanotauthorized forusefor
to lowest effective doseq48h
anorexia;gingival hyperplasia;changesin
immunosuppressionortreatmentof histiocytic
haircoat;muscle cramps,weakness
disordersbuthas licenceforatopyindogs
12.39
Immunomodulatory therapiesused inmultifocal skindisease indogs.
155
Chapter12Tumoursoftheskinandsubcutaneoustissues
Systemichistiocytosis
Aetiology,pathogenesisandpredisposition:This
reactivehistiocytosisarisesduetodysregulationof
interstitial dendriticcells.
InBerneseMountainDogs,thereisa polygenic
inheritabletraitandmalesareover-represented.
Systemichistiocytosishadbeenreportedinother
breeds,includingtheRottweilerandGoldenRetriever.
Presentationandclinicalsigns:Cutaneous
lesionsarecommonbutmanynon-cutaneoussites
maybeaffected,includingmucocutaneousjunctions,
the ocular and nasal mucosa,lymph nodes,liver,
spleen,lung and bone marrow （Figure 12.40).
Presentationdependson theorgansinvolvedand
12.41
Ocularinvolvementinsystemichistiocytosis,
clinical signsinclude anorexia,weightloss,cutane-
withconjunctival involvementanddiffuse
infiltrateresulting inuveitis-likesigns.
ousnodules,stertorousrespirationandscrotalder-
matitis.Cutaneousnodules areagainoftenfoundon
theface,muzzleandaround thenares.Ocularand
Management:Systemichistiocytosisisgenerally
periocularinfiltratesmayresultinpresentationwith
slowlyprogressivewithawaxingandwaningclinical
ocularorperiocularsignssuchasintractablechemo-
course,whichmakesitdifficulttoassesstheimpact
sisorepiscleritis(Figure 12.41).
oftreatmentondiseaseprogression.Corticosteroid
therapyaloneisseldomsufficientandtheadditionof
otherimmunosuppressivetherapyisoftenrequired
(seeFigure12.39).Dogsmaybeweaned off therapy,
butrelapseiscommonandtheconditionoften
becomesrefractory.Manychemotherapeuticdrugs
havebeenused,includingvirtuallyalloftheagents
usedagainstlymphoma,buttheprotracted andfluctu-
atingnatureof thediseasecoursemakesassessment
ofresponsedifficult.Oculardiseasemaybenefitfrom
topical corticosteroids,butmayberefractory.
Prognosis:Theprognosisforsystemichistiocytosis
isguarded,withmostanimals succumbingtodis-
easeprogressioneventually,orinsomecasesthe
developmentofmalignanthistiocytosis.
Disseminated histiocyticsarcoma,malignant
histiocytosis,haemophagocytichistiocytic
sarcoma
Thesearetrulyneoplasticconditions.Inmalignant
histiocytosis(MH)and disseminated histiocyticsar-
coma,tumoursarise fromdendriticcells（CD18,45
and11c-positive),whileinhaemophagocytichistio-
cyticsarcoma thereisastronghaemophagocytic
componentand thecelloforiginisthoughttobethe
CD11d-positivemacrophage.Clinical features,breed
predispositionandclinicalcoursearesimilarandthe
prognosisisequallydismal.
Aetiologyandpredisposition:Thisdiseaseaffects
predominantly Bernese Mountain Dogs,in which
thereisapoorlydefinedpolygenicmodeofinherit-
ance,andMHaccountsforupto25%oftumoursin
thisbreed.Thereisamalepredisposition.Flat-coated
Retrievers,GoldenRetrievers andRottweilersare
alsopredisposed,thoughitoccursinotherbreeds.
12.40
Systemichistiocytosisina5-year-oldmale
BerneseMountainDog.Lateraland
Presentationandclinicalsigns:Multipleorgans
dorsoventral thoracicradiographsshowconsolidationof
areaffected(spleen,liver,lymphnodes,lungs,bone
therightmiddlelunglobe,resultinginairbronchograms.
marrow,kidneys)and theremaybecutaneousor
FNAof thelesionrevealedaninfiltrateofhistiocyticcells.
subcutaneouslesions,thoughthese are often less
156
Chapter12
Tumoursof theskinandsubcutaneoustissues
clinicallysignificant.Dogspresentwithvagueclini-
calsignsreferabletotheorgansinvolved,including
anorexia,weight loss,anaemia,dyspnoea and
coughing.There is oftenpallor,lymphadenopathy
andhepaticorsplenicenlargement.Anaemiamay
beduetodestructionofredcellsinhaemophago-
cytichistiocyticsarcoma,andbonemarrowinfiltra-
tionmayresultinneutropeniaorthrombocytopenia.
Animalsmaypresentwithlamenessorneurological
signsduetotheinfiltrationinjointsor thecentral
nervoussystem.
Managementandprognosis:Malignanthistiocyto-
siscarriesagraveprognosis:treatmentrarelyresults
inasustainedresponse,asthediseasedoesnot
cylines and lomustinehave been used).Successful
treatmentofdogswithahumancytotoxicT-cell line
hasbeenreported(Visonneauet al.,1997),buthas
notprovedrepeatableandhasnotbecomean
establishedtherapy.Short-termmaintenancewith
matchedbloodtransfusionsandcorticosteroidsmay
bepossible in somecases.
Felineprogressivedendriticcell
histiocytosis
Thisisaprogressiveproliferationofnon-Langerhans'
dendriticcells.Asmallnumberofreportsdescribe
thedevelopmentofmultipleintradermal nodulesover
aprotracted time course in cats.Distribution is usu-
allygeneralizedbutoftenstartsontheheadand
neck,or mayberegional(e.g.one limb).There isno
documentedtreatmentandcatsmayprogressto
aggressivefelinedisseminatedhistiocyticsarcoma/
malignanthistiocytosis.Catswithtrulymalignanthis-
12.42
Lung-digit syndromeinanelderlyneutered
tiocytosismaypresentwithanaemia,andspleno-
femaleDSHcat.Onthelateralthoracic
radiograph,apartiallymineralizedsofttissuemassisseen
megalymaybeprominent.
inthecaudodorsal lungfield,whichwasconfirmedonFNA
Metastatic digit tumours in cats:lung-
tobeacarcinoma.Thedorsopalmarviewof theforepaw
showsextensivesofttissueswellingonthemedialaspect,
digitsyndrome
withirregularnewboneformationonthephalangesand
Thisisasyndrometypicallyassociatedwithprimary
metacarpi,accompaniedbyosteolysis.Theselesions
lung tumours(ScC,bronchogenic carcinoma,pulm-
representmetastaticcarcinoma.(Courtesyof SCorr)
onarycarcinoma)thatmetastasizetothedigits.
Cutaneousmetastases
Presentationandclinicalsigns:Thereisdigital
Thedevelopmentofcutaneousmetastaticdisease
pain,swellingandulcerationand thenailmaybe
maybeseenwithanymalignancyandhasbeen
lost.Catsareusuallylame,orreluctantorunableto
reportedinawidevarietyoftumours,including
mammaryadenocarcinomainthecat,poorlydiffer-
andthelesionsmaybeasymmetric.Furthermeta-
entiatedsofttissuesarcomas,osteosarcoma,malig
staticlesionsmaybefoundinlymphnodesand
nantmelanoma,aggressivemammarycarcinomas
othersites.
andseminomaindogsandMCTsinbothspecies.
Cutaneousinvolvementmayalsobeseeninlympho-
Clinicalapproach:Thoracicradiographyshouldbe
proliferativedisease.
carriedouttoidentify theprimarylesion（Figure
12.42).Radiographyof thepedallesions showssoft
Presentationandclinicalsigns:There isusuallya
tissueswelling,lysis of thedistalphalanges and
sometimesirregularnewboneformation.FNAof the
animalspresentwiththemetastaticdisease.Lesions
pulmonarymassanddigitallesionswilloftenconfirm
areveryvariableinappearance,butmaybenodular,
thediagnosis，thoughbiopsyof thedigitallesions
erythematous,orulcerated(Figure12.43).
mayberequiredinsomecases.
Clinical approach,management andprognosis:
Managementandprognosis:Thereisno
BiopsyorFNAisrequiredfor diagnosis.Thereis
successfultreatmentandtheprognosisforthese
generallynoeffectivetherapyandtheprognosisis
catsishopeless.
grave.
157
Chapter12
Tumoursoftheskinandsubcutaneoustissues
Cooper M,TsaiXand Bennett P (2009)Combination CCNU and
vinblastine chemotherapyforcanine mastcelltumours:57cases.
VeterinaryandComparativeOncology7,196-206
Dobson JM and Scase TJ (2007)Advances in the diagnosis and
management of cutaneousmastcell tumours in dogs.Journal of
SmallAnimalPractice48,424-431
ElstonLB,SueiroFAR,CavalcantiJNand MetzeK(2009)Letterto the
editor.Theimportance of themitoticindexasaprognosticfactorfor
survivalofcaninemastcelltumours:avalidationstudy.Veterinary
Pathology46,362-365
Fontaine J,Bovens C,Bettenay S and Mueller RS (2009)Canine
cutaneous epitheliotrophicT-cell lymphoma:areview.Veterinary
andComparativeOncology7,1-14
GrossTL,Ihrke PJ,Walder EJandAffolterVK(2005）Section two:
(a)
neoplasmsandothertumors.In:SkinDiseasesof theDogandCat:
ClinicalandHistopathologicDiagnosis,2nd edn，pp.561-893.
Blackwell Science,Oxford.
HahnKA,OglivieG,RuskTtal.(208）Masitinibssafeandefctive
forthetreatmentofcaninemastcelltumors.JournalofVeterinary
HenryCJ,DowningS,Rosenthal RCetal.(2007)Evaluationofanovel
InternalMedicine22,1301-1309
immunomodulatorcomposedofhuman chorionicgonadotropin and
bacillusCalmette-Guerinfor treatmentofcaninemastcell tumours
inclinicallyaffecteddogs.AmericanJournalofVeterinaryResearch
68,1246-1251
Hosoya K,Kisseberth WC,Alvarez FJ et al.(2009)Adjuvant CCNU
(lomustine)andprednisone chemotherapyfordogswith
incompletelyexcisedgrade2mastcelltumors.Journalof the
AmericanAnimalHospitalAssociation45.14-18
London CA,Malpas PB,Wood-Follis SL et al.(2009) Multi-center,
placebo-controlled,double-blind,
randomizedstudyoforal
toceranib phosphate （SU11654),a receptor tyrosine kinase
inhibitor,forthetreatmentofdogswithrecurrent（eitherlocal or
(b)
distantmastcelltumorfollowingsurgicalexcision.ClinicalCancer
Research15,3856-3865
Murphy S(2006a)Skin neoplasia in smallanimals.2.Common feline
tumours.InPractice28,320-325
Murphy S(2006b)Skin neoplasia in smallanimals.3.Common canine
tumours.InPractice28,398-402
MurphyS,SparkesAH,SmithKC,BlundenASandBrearleyMJ(2004）
Relationships between thehistological grade ofcutaneousmast
resection.VeterinaryRecord154.743-746
PadgettGA,MadewellBR,KellerET,JodarLand Packard M(1995)
InheritanceofhistiocytosisinBernesemountain dogs.Journalof
SmallAnimalPractice36,93-98
RassnickKM,MooreAS.WilliamsLEetal.(1999)Treatmentof canine
mast celltumourswithCCNU（lomustine).Journal ofVeterinary
InternalMedicine13,601605
Romansik EM,Reilly CM,KassPH,MoorePFandLondon CA(2007)
Mitoticindexispredictivefor survival forcanine cutaneousmast
celltumours.VeterinaryPathology44,335-341
Seguin B,Besancon MF,McCallan JLet al.(2006)Recurrence rate，
(c)
clinical outcome,and cellular proliferation indices as prognostic
12.43
Cutaneousmetastases.(a)An inflamed and
mast celltumours:28dogs(1994-2002).JournalofVeterinary
ulceratedpreputial metastaticlesionfrom(b)a
InternalMedicine20,933-940
primaryanaplasticsarcoma on thebridgeof thenose ina
TaylorF,GearR,HoatherTand DobsonJ(2009)Chlorambucil and
prednisolonechemotherapy fordogswithinoperablemastcell
4-year-old maleGoldenRetriever.(c)Metastasesfroma
tumours:21cases.JournalofSmallAnimalPractice50,284-289
visceralhaemangiosarcoma(thepurplishlesionsvisiblein
Thamm DH,Maudlin EA and VailDM （1999)Prednisolone and
theclippedarea) inan elderlycrossbreddog.
vinblastine chemotherapy for canine mast celltumor-41cases
(1992-97)JournalofVeterinaryInternalMedicine13,491-497
Thamm DH,Turek MM andVail DM(2006) Outcomeandprognostic
factorsfollowingadjuvantprednisone/vinblastinechemotherapyfor
high-riskcaninemastcelltumour:61Cases.Journal ofVeterinary
MedicalScience68,581-587
Referencesandfurtherreading
vinblastineforthetreatmentofcaninemastcelltumour.Veterinary
Bostock DE,Crocker J,Harris K and SmithP （1989）Nucleolar
andComparativeOncology6.111-119
organiserregionsasindicators ofpost-surgical prognosisin canine
Visonneau S,Cesano A,Tran T,Jeglum KA and Santoli D （1997)
spontaneousmastcelltumours.BritishJournalofCancer59,915-
Successful treatment of canine malignant histiocytosis with the
918
Camps-Palau MA,Leibman NF,Elmslie Ret al.(2007)Treatment of
T-cellineTALL-104.ClinicalCancerResearch3,1789-1797
canine mast cell tumours withvinblastine,cyclophosphamide and
WelleMM,Bley CR,Howard Jand RufenachtsS(2008)Canine mast
prednisone:35cases(1997-2004).Veterinary andComparative
cell tumours:a review of the pathogenesis,clinical features,
Oncology5.156-167
pathologyand treatment.VeterinaryDermatology19.321-339
158
system
WilliamS.Dernell
Introduction
aggressivenessmakes successful treatmentand
follow-up challenging.
Osteosarcoma(OSA)isbyfarthemostcommon
This chapter will focus on thediagnosis,treat-
primarybonetumourindogs,accountingforupto
mentandfollow-upofappendicularOsA,because
85%ofmalignanciesoriginatingintheskeleton.
ofitsprominenceamongbonemalignancies.Axial
PrimaryOSAaccountsforapproximately5%ofall
OSAandlesscommonbonetumourswillbedis-
caninetumoursandthusthepractitionercanexpect
cussedbriefly，primarilyinlightoftheirdifferences
toseethistumourwithsomeregularity.Although
to appendicular OSA
thediagnosisandtreatmentarestraightforward,
Figures 13.1and 13.2list the differential diagno-
due tosomewhatlimited options，its biological
ses，
clinicalandradiographicfeatures,biological
Tumourtype
Clinical features
Radiographic features
Biological behaviour
Treatment options
Osteosarcoma:
Appendicular skeleton,
Lysisunorganizdprista
90%micrometastaticat
Surgery with adjuvant
endosteal
metaphyseal locations
responseosteoidproduction
presentation
chemotherapy
Osteosarcoma:
Appendicularoraxial
Bonesurfacelesion withcortical
Locally invasive and
Surgery withadjuvant
periosteal
skeleton
destruction
presumed highlymetastatic
chemotherapy
Osteosarcoma:
Appendicular oraxial
Osseous lesion adjacent to bone.
Minimallynvasivevariabe
Surgical resection
parostealorjuxtacortical
skeleton
No cortical destruction
(low)metastasis
Chondrosarcoma
Primarily flat bones
Blasticwithfeaturesfwr
Localyinvasivemoderat
Surgical resection
(skull)
growth
metastasis
Haemangiosarcoma
Appendicular skeleton,
Lysis
90%micrometastaticat
Surgery with adjuvant
variable locations
presentation
chemotherapy
Fibrosarcoma
Appendicular
Lysis without osteoid production
Locallyinvasivew
Surgical resection
moderatemetastasis
Multilobular
Flat bones,primarily
Lobularosteoid/fibroustissue
Lowtomoderateinvasion,
Surgical resection
osteochondrosarcoma
skull
popcorn ball'appearance
lowmetastasis
Bone cysts:aneurysmal,
Metaphyseal locations,
Thinnedcortices,cystic
Non-invasive,benignan
Surgical curettage with
truecysteudocyt
long bones
appearancmayxi
recur
filing or stabilization
Multiplecartilaginous
Any skeletal site,
Circumscribed bonymasson
Benignrraf
None,or surgical
exostoses
especiallyvertebrae
surface
debulking
Osteoma
Flat bonesprimarly
Dense,blasticresponse,smooth
Non-invasive
None,or surgical
skull
borders
debulking
13.1
Featuresof themostcommontumoursof theskeletal systemof thedog.
Tumourtype
Clinical features
Radiographic features
Biological behaviour
Treatment options
Osteosarcoma
Appendicularor axial
Oftenjuxtacorticalorparosteal
Moderatelocalinvasionlow
Surgical resection,
skeetonrible
metastasis
adjuvant chemotherapy
foraxiallesions
Multiple cartilaginous
Any skeletal site,
Circumscribed bonymass on
Local invasion,malignant
None or surgical
exostoses
especiallyvertebrae
surfacelocaldestructin
transformation
removal forpalliation
FeLV-positive
Chondrosarcoma,
Asfor dogs (seeFigure
As for dogs (seeFigure 13.1)
Rare,assumedasfordogs
As for dogs (seeFigure
haemangiosarcoma,
13.1)
(see Figure 13.1)
13.1)
fibrosarcoma
13.2
Featuresof themostcommontumoursof theskeletalsystemof thecat.
159
Chapter13Tumoursoftheskeletalsystem
behaviourandtreatmentoptionsforthemostcom-
Aetiology,pathology andnatural
montumoursoftheskeletalsystemforthedogand
behaviour
cat,respectively.Figure 13.1alsoincludesbenign
TheaetiologyofcanineOSAisgenerallyunknown.A
lesionsthatmaypresentasimilarradiographic
simplistictheoryproposesthatmultipleminortrauma
appearance.
andsubsequentinjurytosensitivecellsinthephyseal
regionmay occur inlarge,fast-growingdogs.
.This
Osteosarcoma in dogs
increasingtheprobabilityforthedevelopmentofa
mutantlineageandsubsequenttumourformation.
Incidenceandriskfactors
TherearereportsofOsAassociatedwithmetallic
OSAisestimatedtooccurinover8000dogseach
implantsusedforfracturerepair,chronicosteomyelitis
yearintheUnitedStates.Itislargelyadiseaseof
andwithfracturesinwhichnointernalrepairwas
middle-agedtoolderdogs,withamedianageof7
used（Figure13.3).Exposuretoionizingradiationcan
years.Thereisawiderangeinageofonset,witha
induceOsA.Anychronicinflammatoryprocessmay
smallpeakinincidenceat18-24months.
causesarcomaformation,andOsAisoneof thehis-
OSA is classically a cancer of large and giant
tologicaltumourtypesreportedwithvaccine-associ-
breeds.Increasing weight and,more specifically,
atedsarcomasincats.OSAshavebeenconcurrently
heightappeartobethemostpredictivefactorsin
seenindogswithboneinfarcts,butitisnotclear
thedog.ThebreedsmostatriskareStBernard，
whetherthereisanycausalrelationship.
Great Dane,Irish Setter,Dobermann,German
Shepherd Dogand Golden Retriever.The overall
male/femaleratioofOsAappearstobefairlyequal,
withareportedslightlyincreasedincidencein
males.IntheRottweiler,maleandfemaledogsthat
underwentgonadectomybefore1yearofagehad
anapproximately1in4lifetimeriskforbonesar-
comaandweresignificantlymorelikelytodevelop
bonesarcoma thandogsthatweresexuallyintact
(Cooley et al.,2002).There was a highly significant
inversedose-responserelationshipbetweendura-
tionoflifetimegonadalexposureandincidencerate
ofbone sarcoma,independentofadult height or
bodyweight.
Overall,approximately 75%ofOSAoccursin
the appendicular skeleton,with theremainder occ-
urringintheaxial skeleton.Themetaphyseal region
oflongbonesisthemostcommonprimary site,
withfrontlimbsaffectedtwiceasoftenasrearlimbs
andthedistalradiusandproximalhumerusbeing
thetwomostcommonlocations.ItisrareforOSA
tobelocated inbonesadjacenttotheelbow,but
thereisonereportof12caseslocatedattheproxi-
malradiusor distal humerus(Liptak et al.,2004).
Noprognosticdifferencein thesecasesascom-
paredwithmorecommonappendicularsiteswas
found.Intherearlimbs,tumoursarefairlyevenly
distributedbetweenthedistalfemur,distaltibiaand
proximal tibia,withtheproximal femura slightly
lesscommonsite.PrimaryOSAdistaltotheante-
13.3
Lateralradiographofahumeralosteosarcoma
brachiocarpalandtarsocruraljointsisrelativelyrare
arisinginassociationwithlongstandinginternal
in dogs.
fixationforfracturerepair.
Inastudyof116casesofcanineprimaryOSAin
theaxialskeletonitwasreportedthat27%were
Therehasrecentlybeenaflurryofexperimental
locatedinthemandible,22%in themaxilla,15%in
workandclinicaldatatosupportmoleculargenetic
the spine,14%inthecranium，10%inribs,9%in the
nasalcavityorparanasalsinusesand6%inthepel-
someofthemolecularandgeneticfactorsthathave
vis(Heyman etal.,1992).Documentablemulticentric
beenimplicatedintheformationorprogressionof
OSAatthetimeof initialdiagnosisoccursin<10%
OSA.Asfurtherresearchoutlinesthe details,these
of allcases.
featuresmayproveuseful inaugmentingthepresent
Osteosarcomaofextraskeletalsitesisrare,but
clinical techniques indiagnosis,prognosis and treat-
primaryOsAhasbeenreportedinmammarytissue,
mentoptions.Many similarapproachesarebeing
subcutanouisue,ln,bwllivr,kidny
investigatedand,inlimitedincidences，beingapplied
ticle,vagina,eye,gastricligamentandadrenalgland.
forothercancerdiseasesinpeople and animals.
160
Chapter13
Tumoursoftheskeletalsystem
Factor
Comments
Prognostic relevance
p53
Mutatedand/orover-expressedinseveralinvestigations
Expressionpredictiveofoutcome（related
through MDR1)
IGF-1/IGF-1R
May contribute to themalignant phenotype
HGF/c-Met
May contribute to themalignant phenotype
erbB-2/HER-2
Over-expressed in several canineOSA cellines
PTEN
Mutatedordown-regulatedinhighpercentageofcanineOSAcellines
sis/PDGF
Over-expressed in some canine cellines
Matrixmetalloproteinases
Over-expressed in canine OSAcellines
Ezrin
Amembrane-cytoskeletonlinkerassociatedwiththemetastatic
Expressionpredictiveofmetastasisand
phenotype in canine OSA
survival
COX-2
Expressionup-regulated in some canineOSA:prognosticin some
Highexpressionpredictiveofpooroutcome
investigtnn
Angiogenic factors
VEGFmeasurableinplasmaof dogs withOSA;angiostatinpresent in
urine of dogs withOSA
Telomerasereverse
Up-regulated in some canine OSA
transcriptase gene
13.4
MolecularandgeneticfactorsassociatedwithOSA indogs.(AdaptedwithpermissionfromDernelletal.,2006)
OSAusuallyoriginatesfromelementswithinthe
occur.Rarely,OSAwill crossajoint surface.Although
medullary canal ofbones(intraosseousOSA).There
<15%ofdogshaveradiographicallydetectablepul-
arerareformsthatoriginatefromtheoutsidesurface
monaryorosseousmetastasisatpresentation,
ofbones:periostealandparosteal (juxtacortical),the
approximately90%willdiewithmetastaticdisease,
behaviourofwhichisdescribedinFigure13.1.
usuallytothelungs,within1yearwhenamputationis
OSAisamalignantmesenchymaltumour
of
theonlytreatment.Metastasis via thehaemato-
primitivebone cells.Thesecellsproduce anextra-
genousrouteismostcommon,butonrareoccasions
cellularmatrixofosteoidandthepresence
of
extensiontoregionallymphnodesmayoccur.
tumourosteoidisthebasisforthehistologicaldiag-
Althoughthelungisthemostcommonlyreportedsite
nosisdifferentiatingOSAfromothersarcomasof
formetastasis,tumourspreadtobonesorothersoft
bone.Thehistologicalpatternmayvarybetween
tissuesitesoccurswithsomefrequency.Anincrease
tumours,or evenwithin the same tumour.Small
intheincidenceofbonemetastasisfollowingsystemic
biopsysamplesmayleadtomisdiagnosessuchas
chemotherapyhasbeendocumentedinhumansand
chondrosarcoma,fibrosarcoma,haemangiosarcoma
issuspectedindogs.Somedifferencesinmetastatic
orsimplyreactivebone,dependingon the section
behaviourhavebeenobservedbasedontheanatomi-
sampled.It isimportanttoobtainhistologicalanaly-
callocationoftheprimaryOSAsite.Forexample，
sisoftheentiretumourfollowingdefinitiveexcision
mandibularOSA,and toadegreeothercalvarium
toconfirm the diagnosis.In addition,alkaline phos-
locations,mayhavealessaggressivemetastaticbe-
phatasestaininghasbeenshowntoaid indifferenti-
haviour,butcontradictoryevidenceexists（Strawet
atingOSApathologicallyfromotherconnective
al.,1992;Dickerson et al.,2001).
tissuetumours.
Therearemanyhistological subclassificationsof
Historyand clinical signs
OSAbasedonthetypeandamountofmatrixand
DogswithOSAofappendicularsitesgenerallypre-
characteristics of the cells,including osteoblastic,
sentwithlamenessorswelling(orboth)at theprimary
chondroblastic,fibroblastic,poorlydifferentiatedand
site.Sometimesthereisahistoryofmildtraumajust
telangiectatic OSA(avascular subtype).In dogs,it
priortotheonsetoflamenessandthiscanoftenlead
hasnotbeenwellestablishedthatthereisadiffer-
tomisdiagnosisas another orthopaedicinjury.The
enceinthebiologicalbehaviourofthedifferent
painislikelyduetomicrofracturesordisruptionofthe
histological subclassifications;however,histological
periosteuminducedbyosteolysisofcortical bonewith
grade,based on microscopicfeatures,maybe pre-
tumourextensionfrom themedullarycanal.There
dictive for systemicbehaviour(metastasis).Newer
maybeanoticeableresponsetorestandanalgesics,
techniques designed torecognizemolecularor
butrecurrenceofsignsshouldpromptfurtherevalua-
geneticalterationsarebeingevaluatedtodetermine
tion.Asthelamenessworsens,amoderatelyfirmto
theirpotential useinpredictingbehaviourofOSA.
OSAhasveryaggressivelocaleffectsandcauses
marysite.Dogsmaypresentwithacuteseverelame-
lysisand/orproductionofbone(seeFigure13.5).The
ness associated withpathological fractures,though
localdiseaseisusuallyattendedbysofttissueswell-
pathologicalfracturesaccountfor<3%ofallfractures
ing.Pathologicalfractureoftheaffectedbonecan
seen(Boulay et al.,1987).
161
Chapter13
3Tumoursoftheskeletalsystem
ThesignsassociatedwithaxialskeletalOSAare
thefinetrabecularpatterninthemetaphysis,a
site-dependent,ingeneralpresenting with swelling
vaguetransitionzoneat theperipheryof themedul-
andpainassociatedwithfunctionoftheaffectedsite.
laryextentof thelesion(ratherthanasharpsclero-
Dogsrarelyhaverespiratorysignsasthefirstclinical
ticmargin)orareasoffinepunctatelysis.Anyone
evidenceofpulmonarymetastasis;rather,their first
orcombinationsof thesechangesmaybeseen，
signsareusuallyvague.Withradiographicallydetect-
depending on the size,histological subtype,loca-
ablepulmonarymetastasisdogsmayremainasymp-
tionanddurationof thelesion.
tomatic for many months,but mostdogs develop
ApresumptivediagnosisofOSAcanbemade
decreasedappetitesandnon-specificsignssuchas
basedonsignalment,history,physicalexamination
malaisewithin1month.Hypertrophicosteopathymay
andradiographicfindings.Differentialdiagnosesof
developindogswithpulmonarymetastasis.
lytic,proliferativeor mixed-patternaggressivebone
lesionsidentifiedonradiographsinclude:otherpri-
Clinicalapproach
marybonetumours;metastaticbonecancer;multiple
Ingeneral,the basicapproach to dogs with sus-
myeloma orlymphoma ofbone;systemicmycosis
pectedOsAisaphysicalexamination,radiography,
withbonylocalization;andbacterialosteomyelitis.In
biopsyanddiscussionoftreatmentoptions.Inaddi-
caseswherethe travelorclinicalhistorymightsup-
tion,dueconsiderationshouldbegiventoobtaining
port thepossibilityofosteomyelitis,abiopsywithsub-
blood work,thoracicradiography,abdominalultra-
missionforhistologyandculturemaybewarranted.
sonography and urinalysis,depending on the sus-
pectedhealthstatusofthepatientandthepossible
Cytology:Althoughcytologyhasnothistorically
orintendedtreatment.
beenthoughttobedefinitivefordiagnosis,recent
Radiology:Initialevaluationoftheprimarysite
evidencewouldsupporttheuseoffine-needleaspi-
involvesinterpretationoflateralandcraniocaudal
ratecytologyinthepreoperativediagnosisofOSA.
Evenif it isnotdiagnostic,itmaysupport thetenta
lesionsoccurringinsitesotherthaninthe appendic-
tivediagnosisand,combinedwithclinical features
ularskeleton.
andradiographicappearance,theremaybeenough
Theoverallradiographicabnormalityofbone
confidenceinthediagnosistomoveforwardwithdis-
variesfrommostlybonelysistoalmostentirely
cussionof treatmentoptions.
osteoblasticor osteogenicchanges(Figure 13.5).
Slightdifferencesexistinthetechniqueofobtain-
Thereisoftensofttissueextensionwithanobvious
ingsamplesaswellastheinterpretationofresults.
softtissue swelling,and newbone（tumourbone)
Sincethepresenceoftumourosteoidisthehallmark
mayformintheseareasinapalisadingpatternper-
featureofadefinitivediagnosis,samplesobtained
pendiculartoorradiatingfromtheaxisofthecortex
('sun-burst'effect).As tumour invades the cortex,
tion)aspirationareoftenmoresuccessfulthanthose
theperiosteumiselevatedandnewboneislaid
obtainedwithsmaller-boreneedles,withorwithout
downbythecambiumlayer,providingatriangular
aspiration.Because bone lesions are often more
depositionofdensenewboneonthecortexatthe
painfulthansoft tissuemassesandaslarger-bore
peripheryofthelesion.Thisperiostealnewbone
needlesaremoreoftenused,theuseofsystemic
hasbeencalled‘Codman's triangle'but thisisnot
analgesicsisindicatedforpatientcomfortandto
pathognomonicforOSA.Osteosarcomadoesnot
assureadequatesampling.
directly crossarticularcartilage,butthe tumours
Specificcytological criteriainsupportofadefini-
mayextendintoperiarticularsofttissues,andadja-
tivediagnosishavebeendescribed(Reinhardtetal.,
centbonesareatriskbyextension.Otherradio-
2005).Inthemajorityofcases,the cytologicaldiagno-
graphicchanges thatcanattend OSAare lossof
sis,ifmade,willbesarcoma,suggestiveofA.his
(a)
(b)
13.5
(a)LongitudinallysplitspecimenofdistalradialOsAinadog,showingcortical destruction,
soft tissue andosteoidneoplasticcomponents.(b)Dorsopalmarradiographofasimilarlesion.Radiographic
featuresinclude:Codman'striangle;cortical lysis;lossof trabecularpatterninthemetaphases;and tumourbone extension
intothesoft tissuesina'sunburst'pattern
162
Chapter13Tumoursof theskeletalsystem
diagnosiswithsupportingclinicalandradiographic
Forbonebiopsy（Figure 13.6),thecentreof the
evidencemaybeconsidereddefinitive,dependingon
radiographiclesionischosenforsampling.Biopsy at
theindividualcase.lffurtherconfirmationisrequired,
thelesionperipherywilloftenresultinsamplingthe
additional staining,suchaswithbonealkalinephos-
reactivebonesurroundingthetumourgrowth.lfthere
phatase,may increase the specificityof theresults.
isapossibilityoflimbsparing,additionalconsidera-
Negative cytologicalresultsdonotnecessarily indi-
tionsexist(seelater).
catethatOsAisnotpresent.
Materialforcultureandcytologymaybetaken
from thesamplespriortofixation.Generally,halfof
Tissuebiopsy:Iftheclinicalandradiographicfea-
eachsampleisputinforcultureandhalfforhistology.
turesaretypical forOSA,especiallywhenthereis
It iscrucial tothesuccessofalimb-sparingsurgery
littlepossibilityoffungalorbacterialinfection,andif
thatthebiopsyprocedureisplannedandperformed
theclientiswillingfortreatmenttobebasedonthe
carefullywithcloseattentiontoasepsis,haemostasis
presumptive diagnosis，confirmation ofhistological
andwound closure.The skin incisionfor thebiopsy
diagnosisfollowingsurgicaltreatmentoflocaldis-
mustbesmallandplacedsothatitcanbecom-
ease(amputationor limb sparing)can be consid-
pletelyexcisedwiththetumouratlimbsparingwith-
ered.Ifhistologicalconfirmationisneededpriorto
outcompromising theprocedure.Fluoroscopyor
treatmentintervention,atissuebiopsyisindicated.
advancedimaging(computedtomography)canassist
Bonebiopsymaybeperformedasanopeninci-
inobtainingneedle-corebiopsysamplesofsus-
sional,closedneedleortrephinebiopsy.Theadvan-
pectedbonelesions,especiallyforaxialsites.
tageoftheopentechniquesisthatalargesampleof
tissueisprocured,whichpresumablyimprovesthe
Stagingandpatientassessment:Examinationfor
likelihoodofestablishinganaccuratehistologicaldiag-
evidenceofapparentspreadofOSAisessential,
nosis.This advantagemaybeoutweighedbythedis-
sincethepresenceofdetectablemetastasesisthe
advantagesofanoperativeprocedureandriskof
singlemostimportantprognosticindicator.Regional
postsurgicalcomplications,includingpathologicalfrac-
lymphnodesshouldbepalpatedandfine-needle
ture.Thisunderscoressomeof theadvantages ofa
cytologyperformedonanyenlargednode.
closedbiopsyusingaJamshidiorsimilartypeofbone
Althoughsomecontroversyexists,itisstillconsid-
marrowbiopsyneedle.Needlebiopsyhasanaccuracy
eredimportantbymostoncologiststohavethree
rateof91.9%fordetecting tumourversusotherdis-
radiographicviewsofthethorax,includingbothright
ordersandan82.3%accuracyratefordiagnosisof
andleftlateralviews.Pulmonarymetastasesfrom
specifictumoursubtype(Powerset al.,1988).
OSA are generally of a sof tissue density and cannot
①
(iv)
(a)
(b)
(C)
(d)
13.6
(a)TheJamshidibone biopsyneedle:(i)cannula and screw-oncap;(i) taperedpoint:;(ii)pointed stylet to
advancecannulathroughsofttissues;and(iv)probetoexpel specimenfromcannula.(b)Withthestyletlocked
inplace,thecannulaisadvanced throughthesofttissueuntilboneisreached.Theinsetisaclose-upviewshowingstylet
againstbone cortex.(c)Thestyletisremoved and thebonecortexpenetratedwiththecannula.The cannulaiswithdrawn
and theprocedurerepeatedwithredirectionof theinstrument toobtainmultiplecoresamples.(d)Theprobeisthen
insertedretrogradeintothetipof thecannulatoexpelthespecimenthroughthebase(inset).(Reproduced fromBSAvA
GuidetoProceduresinSmali AnimalPractice)
163
Chapter13Tumoursof theskeletalsystem
bedetectedradiographicallyuntilthenodulesare
CTormagneticresonanceimaging(MRI) canalso
6-8mmindiameter(Figure13.7).It isrelativelyrare
beusedtostagelocaldisease,especiallyforaxial
（<10%ofdogs)todetectpulmonary metastaticdis-
tumoursitesorforplanninglimb-sparingresection
easeatthetimeofdiagnosisbut,todate,treatment
margins.Inone study,MRIwasmore accuratethan
recommendationsandprognosesarebasedonthe
plainradiographsorCTinpredictinglengthof tumour
resultsofplainradiographs.Computed tomography
involvementforappendicularcanineOsA(Wallacket
(CT)mayincreasethenumberofdogsdetectedwith
al.,2002).
lunglesionsatpresentationbutisnotwidelyused in
Thepatient'soverallhealthstatusrequirescareful
veterinarypatients,duetoavailabilityandcostcon-
assessment.Advancingyearsdonotprecludetreat-
straints.Inaddition,thesensitivityofCTmayresultin
ment,butprolonged anaesthesiaandchemotherapy
anumberoffalse-positiveresults.
maynotbetoleratedindogswithorgancompromise.
Particularattentiontothecardiovascularsystemis
important.Coexisting cardiomyopathy or any degree
ofheartfailuremayleadtoseriouscomplications,
particularlyduring fluid diuresis,anaesthesia or
administrationofcertainchemotherapyagents.
Management
TreatmentoptionsforappendicularOSAandthepre-
dictedoutcomearelistedinFigure13.9.Occultmeta-
staticdiseaseispresentinapproximately90%of
dogsatpresentationandmediansurvivalisonly3-4
monthsifamputationistheonlytreatment;therefore,
someformofsystemictherapyisnecessaryifsurvival
istobeimproved.Withnotreatment at all,thecondi-
Lateralthoracicradiographshowingmultiple
tionbecomesverypainfulbecauseofextensivede-
13.7
soft-tissuedensemetastaticosteosarcoma
structionofboneandsurroundingtissuebyprimary
lesions.
tumours,andmostownerselectforeuthanasia for
theirpetssoonafterdiagnosisifnotreatment isgiven.
Sitesofbonemetastasismaybedetectedbya
carefulorthopaedicexamination,bonesurveyradio-
Surgery
graphs or nuclear scintigraphy(Figure 13.8).Due to
Surgicaloptionsforprimarybonetumoursatdiffer-
thelowincidenceofscintigraphiclesionsinmost
entanatomical sitesaresetoutinFigure13.10.
casesof OsA,theusefulnessofnuclearscintigraphy
Amputationoftheaffectedlimbisthestandard
(bonescan)forclinical stagingof dogswithOSAis
treatmentforcanineappendicularOSA.Evenlarge-
somewhatcontroversial.Inonestudyof70patients,
andgiant-breeddogscanfunctionwellafterlimb
scintigraphywasnotsuccessful indetectingmeta-
amputationandmostownersarepleasedwiththeir
static or synchronous lesions (Lamb et al.,1990).
pets'mobilityandqualityof lifeaftersurgery.Pre-
Anotherstudyfoundsecondary sitesconsidered
existingdegenerativejointdiseaseatthelevelfound
highly suspect of bony metastasis in 7.8%of (399)
inmostolderlarge-breeddogsisrarelyacontraindi-
cases;however,most suspected lesions were not
cationforamputation.Mostdogswillreadilycompen-
subjectedtohistologicalconfirmation(Jankowski et
sate;althoughtheosteoarthritismayprogressmore
al.,2001).Scintigraphycanalsobeused toevaluate
thedegreeofboneinvolvementfromaprimarybone
clinicalproblem.Severepre-existingorthopaedicor
tumour,withscintigraphyoverestimatingthelengthof
neurologicalconditionsmaycausepoorresultsin
OSAdisease in limb-sparepatientsby30%,allowing
somecases,and carefulpreoperativeexaminationis
foradequaterequiredmargindefinition(Leibmanet
important.
al.,2001).
Itisgenerallyrecommendedtoperformacom-
pleteforequarteramputationforforelimblesions
andacoxofemoraldisarticulationamputationfor
hindleglesions.This levelofamputationassures
completelocaldiseaseremovalandalsoresultsin
amorecosmeticandfunctionaloutcome;and the
moreaggressiveamputationsreducetheweightto
becarriedbytheanimal.Forproximalfemoral
lesions,acompleteamputationandenblocacetab-
ulectomyisrecommendedtoobtainproximalsoft
tissue margins.
Surgeryalonemustbeconsideredpalliativefor
OSA,buta study demonstrated significantmprove-
Scintigraphicviewofanosteosarcomapatient
mentinsurvivaltimesfordogsundergoingamputa-
13.8
followingtechnetium99Mhydroxymethylene
tionincomparisonwithdogsundergoingnotreatment
diphosphonateinjection.Increaseduptakeisnoted inthe
(Zachoset al.,1999),possibly due to thepain-alleviat-
sternumand10thrib,suggestiveofbonemetastases.
ing nature of surgery.
164
Chapter13
Tumoursof theskeletalsystem
Treatment option
Methods
Median
Mode of failure
Approximate cost
Comments
survival
(based on survival times)
Painmanagement
NSAIDS
Leg pain,lameness,
$100-S200
Often used in conjunction
Narcotics
pathological fracture
with other treatments
"Local'analgesics
Palliativeradiation
Megavoltage photons
2-6months
Leg pain,lameness,
$600-S800
Addition of(platinum)
Strontiumor
pathological fracture
chemotherapyimproves
samarium
Metastasis(lung) late
response
Surgery alone
Amputation
3-6months
Lung metastases
$1500
Potential complicationsof
Limb sparing
$3500-S5000
limb sparingmake this
option questionable
withoutadjuvant therapy
Radiation and
Fractionated
6-12months
Lung metastases
$4000-S8000
Data(immature) from one
chemotherapy
megavoltage with
(estimate)
(cost dependent on
platinum
chemotherapyregimen)
chemotherapy
Amputationand
Cisplatin,carboplatin,
10-14months
Lung orbone
$2500-$5000
Limb sparing may be an
chemotherapy
doxorubicin or
metastases
(cost dependent on
option in selected cases
combinations
chemotherapyregimen)
Limb sparing and
Cisplatin,carboplatin,
12-16months
Lung or bone
S5000-$10,000
Survivalimproved indogs
chemotherapy
doxorubicinor
metastases
(cost dependent on
with postoperative
combinations
chemotherapyregimen)
infection of allografts
(Lascelles et al,2005)
13.9
Treatmentoptionsandpredictedoutcomeforcanineappendicularosteosarcoma.Approximatecostbasedon
TheColoradoStateUniversityVeterinaryTeachingHospital in2002.
Site
Treatment options
Comments
Humerus,
Amputation
GenerallyhighcomplicationrateforlimbsparingDiaphyseal
femur,tibia
Limbsparingin limitedcases
possibleforproximal femorallesions.Intraoperative
extracorporalradiationtechniquemayapply
Radius
Amputation
Can combine radius/ulnaresection(graft radiusonly)
Limbsparing(allograft;endosteal prosthesis;intercalarybonegraft;
ulnartranspositionbone transportosteogenesispasteurized
autograft;intraoperativeextracorporalradiationtherapy)
UIna
Amputation
Oftendoesnotrequire allograftreconstruction
UInectomy
Scapula
Amputation
Proximallesionsbest.Complete scapulectomy described
Scapulectomy
Pelvis
Pelvectomywithorwithoutamputation
Lateralportionof sacrumcanbeexcised.Mayincludebody
wall
Metacarpus/
Amputation
Limb-sparing functiondependent onbone(s）involved
metatarsus
Localresection
Mandible
Mandibulectomy
Oftenrequirsttammandiuletmilaralyit
4thpremolar
Maxilla/orbit
Maxillectomy
Limitedbymidlinepalateorcranial vaultinvasion.Combined
Orbitectomy
approachmayassist exposure
Calvarium
Resection±radiation
Resection dependenton venous sinusinvolvement
Vertebrae
Decompression（palliative)±radiation/chemotherapy
Vertebrectomytechniquesnotwelldeveloped.Limited local
disease control
Rib
Ribresection
Requiresremovalofadditional cranialandcaudalrib
13.10
165
Chapter13Tumoursof theskeletalsystem
Limbsparing
avoidcompromiseoftheresectionwithpotential
Insomeinstances,limbsparing(limb salvage)may
seedingofthetissuesinvolvedin thebiopsy.Care
beconsideredandmaybepreferredtoamputationfor
mustbetakentoavoidcontactingtheulnawhensam-
functionalorcosmeticreasons.Exampleswouldin-
pling theradius(ortoavoid theradiuswhensampling
cludeextremelylargeorobesedogsorthosewith
theulna),to prevent iatrogenic tumour seeding.
concurrent(severe)orthopaedicorneurological dis-
Discussionofbiopsytechniquewith thesurgeonor
ease.Todate,themajorityoflimb-sparingprocedures
centreperformingthelimb-sparingsurgerymaybe
havebeenperformedbecauseofownerreluctanceto
warranted.
amputate.
Experiencehasassistedincaseselectionoflimb-
Limb-sparingsurgeryaimstoprovideafunctional
sparingcandidateswithahigherlikelihoodofshort-
pain-freelimbforthepatientafterremovalofthe
and long-termsuccess.Dogswithtumourconfinedto
localdisease.Theboneorjointremovedismost
onesite,with<50%ofthelengthoftheboneradio-
oftenreplacedbyanallograft,butnewertechniques
graphicallyaffected，arepotentialcandidates.Length
arebeinginvestigated.Functionfollowinglimbspar-
involvementof>50%makesimplantfixationtothe
inghasbeengood inmostpatients.Thereisnosig-
remaininghostbonemoredifficult,potentiallyincreas-
nificantdifferenceinsurvivalratesfordogstreated
ing thechanceoforthopaedicfailure.
withamputationandcisplatincomparedwithdogs
Asmalltomoderatesofttissuecomponentispre-
treatedwithlimbsparingand cisplatin(Figure13.11).
ferredwhenconsideringlimbsparing.Tumourresec-
tionislesssuccessful incasespresentingwithlarge
Caseselection:Althoughlimbsparingdoesnotcom-
softtissuecomponents,duetotheincreasedchance
promisepatientsurvivalwhencomparedwithamputa-
oftumourseedingoftheoperativesite.Preoperative
tion,thecomplicationrateishigh.Tumourrecurrence,
down-staging，usingcombinationsofchemotherapy
deepinfectionsandotherproblemsthatarerareafter
andradiation,canbeconsideredinselectpatients.
amputationarenotuncommonafterlimb-sparing
Optimaloutcomeaftertraditionallimbsparingof
operations.Thecostandownercommitmentforlimb
metaphyseallesionshasbeenlimitedtodistalradial
sparingislargewhencomparedwithamputationand
thesefactorscanmultiplyexponentiallyifcomplica-
malhumeralanddistaltibialsiteshasresultedinpoor
tionsoccur.Forthesereasons,limbsparing cannotbe
functionandincreasedcomplications,primarilydueto
consideredasthetreatmentofchoiceforlocaldis-
theneedforarthrodesisofhigh-motionjoints.Since
easecontrolinmostcasesofappendicularbone
functionaloutcomeforamputeesisgenerallygood,
tumours.Ownersmustbethoroughlyinformedofall
withalowcomplicationrate,thisispresentlyrecom-
factorsinvolvedwithlimbsparingbeforethatcommit-
mended(withexceptions)fortumoursitesother than
ment ismade.
distalradiusorulna.Limbsparingatothersitesmay
Ifbiopsyisperformed,planningthebiopsytech-
becomeapplicableasthetechnologyfortotaljoint
niquewithspecificattentiontothesiteisessential to
replacementimproves.Proximalfemoralsiteshave
avoidcompromiseof limbsparing(seealsosection
beentreatedwithresectionfollowedbyproximalfem-
onbiopsy,above).Boththe skinincisionand biopsy
oralallograftplacementandtotalhiparthroplasty
tractmustberemoved atthedefinitivelimbsparingto
(Figure13.13).
1.00
0.75
ility
Limbsparing
?
0.50
Survi
Amputation
0.25
0.00-
0
100
200
300
400
500
600
700
800
Time (days)
13.11
chemotherapy.Nosignificantdifferenceisevidentinsurvivalbetweenthetwosurgeries.(Reprintedwith
permissionfromStrawandWithrow,1992)
166
Chapter13
Tumoursoftheskeletalsystem
Siteof tumour
No.of cases
13.14
Distal radius
297
Lateralradiographicview
aftermetal implant
Proximal humerus
27
placementandcarpal
46
arthrodesisforadistalradial
UIna
osteosarcoma inadog.
Femur
6
Tibia
15
Metacarpus
7
Scapula
22
Carpus
1
13.12
Limb-sparing treatmentsatColoradoState
Universityfrom1975to2002.(Adaptedwith
permissionfromDernell,2002)
13.13
Lateral andcraniocaudalradiographicviews
Autogenousreplacementinvolvesreplacement
followinglimbsparingforaproximalfemoral
of theresectedbonespecimenaftereitherheat
OSAresectedwithallograftfixationandtotalhip
(autoclave) sterilizationorhigh-doseradiation
replacement.
sterilizationofthetumourtissue.Onlyafew
reportsexistofthisapproach,theprimary
complicationbeingorthopaedicfailuresecondary
Limb-sparingtechniquesfordistalradialOSA:
tocollapseof thetumourboneimplant(Morello
Thefollowingarethecurrentoptionsforlimb-sparing
etal.,2003).
techniques(followingtumourresection)forthedistal
Vascularizedulnartranspositioninvolvesthe
radialsite.
rotationofavascularizedportionoftheipsilateral
ulna into the(radial) defect.Theprimary
Boneallograftreplacementisthetraditional
advantageof thistechniqueistherapidrepair
method of limbsparing indogs.Followinga
andremodellingof thevascularizedbone.The
marginalresectionof thetumourbone,abone
primarydisadvantageisthesmallerimplantsize
allograft(eitherbankedfrompreviousharvestor
withincreasedriskofpostoperativefailure
purchasedfromabank)isfitted tothedefectand
(Seguin et al.,2003).
securedusingaboneplateand including
Bone transportosteogenesisinvolvesthe
arthrodesisof the adjacentjoint.Thistechnique
applicationofdistractionosteogenesistofillthe
hasbeenappliedtonumeroustumourlocations,
defectcreatedbytheresection.Theprimary
withthedistalradiusbeingthemostcommonand
advantageof thetechniqueistheautogenous
thesiteresultinginthebestoutcome(LaRueet
natureofthereplacementbone.Theprimary
al.,1986).
disadvantageisthelong-termapplicationof
Metalimplantutilizesacommerciallyavailable
externalskeletalfixationdevices(Ehrhartetal.,
metalimplanttoreplacethebonedefectwith
2002).
compositestabilizationsimilartothatof the
Intraoperativeextracorporalradiationinvolves
allografttechnique.Theprimaryadvantageisthat
high-doseradiationof thebone insitu,which
thistechniqueavoidstheneedforallograft
sterilizesthetumourwhilesparingjointtissues
procurement(and/orstorage).Theprimary
andsubsequentfunction(theprimary
disadvantageisthelackofautogenousrepair
advantage).Thistechniqueismost applicablefor
andreplacementandthepermanentrelianceon
high-motionjointsandtheprimarycomplication is
the(metal)implantsforweightbearing(Figure
orthopaedicfailurefollowingimplantcollapse
13.14)(Liptak et al.,2004).
(Figure 13.15)(Liptaket al.,2004).
167
Chapter13
Tumoursoftheskeletalsystem
13.16
PreoperativeradiographofOSAof theproximal
scapula.
ectomy.Contraindicationstoscapulectomyinclude
diseasethatextendsbeyond theintrinsicmuscula-
tureofthescapulaordistaltothescapulohumeral
13.15
Postoperativelateralandcraniocaudal
joint.Reconstructioninvolvesreattachmentofdor-
surgerywithintraoperativeradiationforadistaltibial
sal muscles toventralmusclesormusclereattach-
osteosarcoma inadog.（Reprinted fromDernell,2002,
menttotheremainingscapularboneorproximal
withpermissionofWBSaunders,Philadelphia)
humerus.Functionisgenerallygoodafterpostoper-
ativerehabilitation,thoughamechanical limpoften
Otherlimb-sparingsites:Fordistalulnarsites,an
persistsduetoincreaseddorsalmotionofthelimb
ulnectomyisgenerallyperformedwithoutallograft
inreference tothebodywall.Physiotherapyis
replacement.Salvageofthestyloidprocessisrec-
importantafterscapulectomytomaintainmuscle
ommended,ifpossible,withfixationoftheremaining
massandtofacilitatefibroustissueformation,limb
styloid tothedistalradius.Ifthe styloidprocessis
supportandarapidreturntofunction.
removed,reconstructionofthelateral jointshouldbe
Pelviclesionsusuallyrequirepelvectomywith
attempted.Moreproximal tumoursaremoredifficult,
hindlimbamputation,butincertainlocations,andwith
duetothecloseassociationofthetwobonesatthe
small low-gradelesions,internalpelvectomyandlimb
levelof theinterosseousligament,andamputationis
sparingcanbeconsidered.Obtainingwidemargins
generallyrecommended.Return tonormal function
foraggressivemalignanciesoftennecessitatesampu-
afterulnectomyisgenerallyrapidandcomplete
tationwithpelvectomy.
within2-4weeks.
Metatarsalandmetacarpallocationscanbe
Techniquesforlimbsparingindogswithhumeral
treatedwithlocalresectionsoramputation.Proximally
andtibiallesionshavebeendescribed,butahigh
locatedlesionsaremoredifficulttoresectcompletely，
failurerateprecludesrecommendation toconsider
duetotheproximityofadjacentbones.Experienceat
salvageofthesesites,unlesstheyoccurinthedia-
ColoradoStateUniversitywouldsupportremovalofa
physis.Newer techniquesforlimbsparing,involving
singleboneor thecentral twobonesinmostdogs
intraoperativeradiationof thetumourbone,are
withgoodfunctionaloutcome.Insmalldogs,removal
beingevaluatedwithanemphasisonmaintaining
ofthemedialorlateraltwobonescanresultinnormal
jointfunction.Althoughthesetechniquesshowprom-
function.Resectiontothisextenthasnotbeen
ise,evaluationispreliminary.Ownerswhodesire
attemptedinlargerdogs.
limb-sparingoptionsforsitesotherthandistalradius
orulnacanbeconsideredonacase-by-casebasis.
Postsurgicalpatientfollow-uptherapy:Theshort-
Discussion with,orreferral to,a centre performing
termsurvivalwithsurgeryalonesupportstheneed
limb-sparingproceduresisrecommendedinthese
forfollow-up systemic therapy(see below).Overall,
circumstances.Theauthorhasexperiencewith two
limbfunctionhasbeensatisfactory,withapproxi-
casesoflimbsalvageinvolvingproximalfemoral
mately80%ofdogsexperiencinggoodtoexcellent
resection,allograft replacement andtotalhip
limbfunction.
replacement(seeFigure13.13).
Immediatepostoperativerecommendationsin-
Scapularlesions(Figure 13.16)canbe treated
cludefrequentbandagechangesandcontinuation
withamputationorwithpartialorcompletescapul-
ofprophylacticantibioticsuntilsystemicadjuvant
168
Chapter13
3Tumoursoftheskeletalsystem
chemotherapyiscompleted.Recommendedfollow-
growthfactor-1)incombinationwithcarboplatinin
OSAdogsfollowingamputationhasshownthatlower
intervalstoevaluateforhealing,localtumourrecur-
IGF-1hasminimalenhancementofsurvival time
renceandinfectionaswellasdistantmetastasis.
(Khannaetal.,2002).
Themajorcomplicationsrelated tosurgeryare
Anumberofreportshaveevaluated thepotential
recurrentlocaldiseaseandinfection.Theincidence
therapeutic effects ofbisphosphonatesfor canine
oflocalrecurrencerangesfrom20%to30%.Local
OSAinvitroandinvivo.Bothcytotoxicandcytostatic
tumourrecurrencecanbedifficulttodifferentiate
effectswereseenincanineOsAcellinesexposed to
frominfectionradiographicallyorclinicallyandso
pamidronate,alendronateandzoledronate invitroina
cytologicalor histologicalconfirmationisrecom-
dose-dependent manner(Poirieretal.,2003;Farese
mended.Localdiseasecontrolcanbeimprovedby
et al.,2004;Ashton et al.,2005).Additionally,surro-
pretreatmentdown-staging(discussed above).When
gatebiologicalactivitywasshowninvivofollowing
aprolonged-releaseformofcisplatinisimplantedat
thetimeoftumourremovaltheincidenceoflocal
pamidronate administrationindogswithgrosspri-
recurrencedropsto10%.Somedogscanhavetheir
maryOSAasassessedbyreductioninurinary
locallyrecurrentdiseaseresectedenblocandremain
N-telopeptideexcretionandenhancedbonemineral
disease-freeforanextendedperiod,butrecurrence
density(dual-energyX-ray absorptiometry)（Fan et
generallywarrantsamputationfordiseasecontrol.
al,2005).Whether the invitroand surrogate invivo
Inonestudy，40%ofdogsdevelopedinfections
effectstranslateintosurvivaladvantagesindogswith
involvingtheallograftboneplacementforlimbspar-
OSAawaitsinvestigationwithcontrolledclinicaltrials.
ing.Systemicantibiotics control themajorityof
Ina prospectiverandomized clinical trial using
infectionswithorwithout local antibiotic(antibiotic-
dogswithnaturallyoccurringappendicularOSA,the
impregnatedPMMAbeads)implantation.However,
therapeuticpotentialofdexniguldipine,aninhibitorof
amputationmayberequiredinasmallnumberof
protein-kinase-C(apotent stimulatorof tumour cell
dogswithuncontrolled infections.
proliferation),wasevaluated.Dogstreatedwithdex-
Anunexpectedfindinghasbeenthatdogswith
niguldipineorcisplatinhadlongermedianremission
allograftinfectionsexperienceastatisticallysignifi-
duration and survival time thanuntreated dogs,but
cantprolongationofoverallsurvivaltimescompared
dexniguldipine-treateddogshadashortersurvival
withdogswithlimbsparingwithoutinfectedallo-
time than cisplatin-treated dogs(Hahn et al.,1997).
grafts(Lascelles et al.,2009).The reason for this is
Thecombinationofdexniguldipineandchemother-
unclearbutcouldberelatedtoactivationofimmune
apyhasnotbeeninvestigated indogs.
effectorcells and a responseto cytokines,such as
interleukinsortumournecrosisfactor,elaborated in
Chemotherapy:Figure13.17listscommonly
thefaceofchronicbacterial infection.
Additionalcomplicationsfollowinglimbsparing
reportedadjuvantchemotherapyprotocolsandout-
includeimplantfailure,suchasplatefractureorscrew
come fordogsfollowingamputationforOSA(see
pullout.Theserareoccurrencesaredealtwithona
Chapter9formoredetaileddiscussions).
case-by-casebasis.
Cisplatinhasbeendemonstratedtoimprovesur-
vivalindogswithOSAafteramputation.Theredoes
Surgical approach atothersites:Mandibulectomy
notappeartobeasignificantinfluenceof thetiming of
andmaxillectomyareappropriatesurgeriesforbone
cisplatinchemotherapy(orwithotherchemotherapeu-
tumourprimariesoforal sites.Tumoursofperiorbital
sitescanberemovedbyorbitectomy.Ribtumours
atelypostoperativelyorafteradelayofupto14days
canberemovedbythoracicwallresectionand
postoperatively.ltseemsreasonable,however,torec
reconstruction.
ommendtheearliestpossibleadministrationofchemo-
VertebralOSAsitesarethemostdifficultwith
therapy,whichisusuallyat the timeofamputation.
respecttoadequatetreatmentoflocaldisease.
Therecommendeddoseforcisplatinis70mg/m²
Techniquesofcompletevertebrectomyarenotwell
bodysurfacearea.Salinediuresishelpstoprevent
established inveterinarymedicine,and surgeryis
nephrotoxicity,whichis dose-limiting.Most studies
oftenanattempttodecompressdogswithneurologi-
involvethetargetedadministrationoffourdosesof
cal deficitsand toobtainadiagnosis.Presentrecom-
cisplatin;theadministrationofmorethanfourdoses
mendationsaretoperformsurgeryincasesthat
appears to increase the incidence of (renal) toxicity.
requiredecompression(withorwithoutstabilization)
Carboplatinisa second-generationplatinum
andinstituteradiationtherapyandchemotherapy.
compound thatislessnephrotoxicthancisplatinand
Adjuvanttreatment
canbegivenwithoutdiuresiswithapparentlysimilar
anti-tumour effects ascisplatin.One multi-institu-
Immunotherapy:Liposome/MTP-PE(LMTP-PE),a
tionalstudyhassupporteditsefficacyagainstcanine
syntheticanalogueofafragmentofMycobacterium
OSA.Moreevaluationsare ongoing.The drug can
cellwall,hasbeenshowntoactivatemacrophages
begivenatamputationandinsubsequent21-day
todestroymalignantcells.Ithasbeenstudied in
cyclesprovidedthatperipheralbloodcountsand
dogs and positive effects on prolonging survival
renal functionremainadequate.Thedoserecom-
werefound.
mendedforuseindogsis300mg/m²administered
every3weeks,withatargetoffourtreatments,but
Moleculartargetedtherapy:Acombinationofa
themaximumtoleratedcumulativedosehasnot
growthhormone(GH)inhibitor(tolower insulin-like
beendescribed.
169
Chapter13
Tumoursoftheskeletalsystem
Drug and no.of
Dosage/regimen
Disease-free
Survival range
Comments
References
dogs in study
range
Cisplatin(n=26)
70mg/m²i.v.on two
Median
At1year:38-43%
No significantdifferencebetween
Strawet al.,
occasionsevery21days
177-226
At2years:16-18%
survivaldatafordogsgiven
1991
days
Median262-282
cisplatinbefore amputation
days
comparedwiththose treatedafter
amputation
Cisplatin（n=22;
60mg/m²i.v.on1 to6
Notreported
At1year:45.5%
Apparent increase in treatment
Berg et al.,
some dogs treated
occasionsevery2day
At2years:20.9%
failures duetobonemetastases
1992
with limbsparing)
Median325days
Cisplatin (n=11)
40-50mg/m²i.v.on2to6
Median165
Median300days
Shapiro et al.,
occasionsevery28days
days
1988
Cisplatin(n=15)
50mg/m²i.v.on2
Not reported
At1year:30%
Thompson
occasions,2and7weeks
Median290days
andFugent,
afteramputation
1992
Cisplatin (n=16)
50mg/m²i.v.onup to9
Notreported
At1year:62%
Trend fordogsreceivinghigher
Kraegelet al.,
occasionsvery28day
Median413days
cumulativedosesofcisplatinto
1991
have longersurvivaltimes
Carboplatin(n=48)
300mg/m²on4occasions,
Median257
At1year:35.4%
Maximumtoleratedcumulative
Bergmanet
every21days
days
Median321days
dosehasnotbeendescribedfor
al.,1996
sbop
Doxorubicin(n=35)
30mg/m²on5occasions,
Notreported
At1year：50.5%
Percentage necrosisof tumour
Berget al,
every2weeks
At2years:9.7%
predictedsurvival
1995
Median366days
Doxorubicin and
Doxorubicin at 30mg/m²i.v.
Median210
At1year:37%
No significantdiferencefound
Mauldinet al.
cisplatinalternating
on day1and cisplatinat60
days
Median300days
betweensurvivaldatafromthis
1988
sequentially(n=19)
mg/m²i.v.onday21,cycle
study and froma single-agent
repeatedoncein21days
cisplatin study
Doxorubicin and
Doxorubicinat15-20mg/
Not reported
At1year:48%
Twenty-two casesof dose
Berget al.,
cisplatin concurrent
m²followed in2hoursby
At2years:28%
reduction.Nodifferencein
1997
(n=102)
cisplatin at 60mg/m²
Median345days
postoperativeversuspreoperative
chemotherapy
Doxorubicin and
Cisplatin at 50mg/m²on
Median470
Median540days
Small sample size.Anothertrial
Chun et al.,
cisplatin concurrent
day1and doxorubicin at
days
lookingat similarprotocolwith
2000;
(n=14)
15mg/m²on day 2
highercisplatin dosing（60mg/m²)
DeRegiset
and doxorubicin(25mg/m²)was
al.,2003
associated with unacceptable
toxicity
Doxorubicin and
Carboplatinat 300mg/m²
Median227
At1year:48%
Includesbothamputationand
Kent et al.,
carboplatin
onday1and doxorubicin at
days
At2years:18%
limb-salvage therapiesforthe
2004
alternating
30mg/m²on day 21,
Median320days
primary tumour
sequentially(n=32)
alternatingat3-week
intervalsfor3cycles（6total
treatments)
Doxorubicin and
Carboplatin at 175mg/m²
Median195
Median235days
The combination at these
Bailey et al.,
carboplatin
onday1and doxorubicinat
days
dosageswaswell tolerated in
2003
concurrent (n=24)
15mg/m²on day2,every3
mostcases
weeksfor4treatments
Lobaplatin
35mg/m²every 3weeks for
At1year:
At1year:31.8%
No need fordiureses with this
Kirpenstejinet
4treatments
21.8%
platinum analogue
al.,1999
OPLA-Pt(n=37)
80mg/m²implanted at time
Median256
At1year:41.2%
Newtrialsongoing withinjectable
Withrowetal.,
of amputation
days
Median278days
polymercontaining cisplatin
1995
13.17
CommonlyusedadjuvantchemotherapyagentsandsurvivaloutcomefordogswithOsAwhereamputationhas
theseprotocolsincludelargenumbersofdogs andfewercomparetreatmentprotocolsinarandomizedprospective
fashion;thereforeevaluationsofefficacybetweenthevariousprotocolsaresubjecttobiasandshouldbecomparedwith
caution.(AdaptedwithpermissionfromDernelletal.,2006)
170
Chapter13Tumoursof theskeletalsystem
Lobaplatinisanew third-generationplatinum
135daysaftertreatmentwasrelativelyshortand
compound.Inanadjuvantstudyof28dogstreated
localdiseaserecurrenceratherthanmetastasiswas
with35mg/m²every3weeksforfourtreatments,the
theusual causeofdeath(Dernelletal.,2000).
drugwaswelltolerated.However,thosepatientshad
a32%1-yearsurvivalrate-lessthanthatseenin
Stereotacticradiosurgeryorintensitymodulated
radiation
therapy:
Stereotactic
radiosurgery
historicalsetsofdogstreatedwithcarboplatinorcis-
platin(Kirpensteijnetal.,1999).
(gammaknifetherapy)hasbeenperformedasa
meansof limb-salvagesurgeryin11dogs(Fareseet
Doxorubicinhadapoorresponseasasingle
al.,2004).In some cases,carboplatin was used
agent inanolderreportof16dogswithOSA.Inthat
studydoxorubicinwasgivenintravenouslyatados-
immediatelypriortotreatmentforitsradiosensitizing
potentialinadditiontoitsconventionalcytotoxic
ageof30mg/m²every3weeks,beginning3weeks
qualities.Impressively,overallmediansurvivalwas
after surgery.Ina morerecent study，doxorubicin
363daysinthisseries,albeitnumbersarestillsmall.
wasgivenatthesamedosagebutevery2weeksfor
Advantagesof thistechnique include thenormal
fivetreatmentsto35dogswithappendicularOSA
tissue-sparingeffectsthatstereotacticradiation
(Bergetal.,1995).The 1-and2-yearsurvivalrates
potentiallyprovidesandtheabilitytoavoidsurgery.
were50.5%and 9.7%,respectively.Nodifference
Disadvantagesarethat thetechniqueinvolvesequip-
wasfoundbetweendogstreatedpriortoorimmedi-
mentthatisnottypicallyavailabletoveterinary
atelyfollowingamputation.Subsequenttrialshave
surgeons.
supportedtheefficacydataoftheselaterstudies.
Intensitymodulatedradiation therapy(IMRT)isa
Itwouldseemreasonablethatcombinationsof
meansofpreciselydeliveringradiationtherapyto
cisplatinorcarboplatinanddoxorubicin-drugs
tumourswhileconformallyavoidingnormaltissues.A
showntobeefficaciousalonewhichworkbydiffer-
formof IMRT,Tomotherapy,utilizesa marriageofa
entcytotoxicmechanisms-couldfurtherimprove
CTscanandalinearacceleratorandhasbeeninves-
survival times.Todate,however,results donot sup-
tigatedindogswithOSAanddogswithnasal
portincreasedresponseoutcomeforcombination
tumours(Forrestetal.,2004).While suchtechniques
therapywhencomparedwithsingle-agentplatinum
areinvestigationalindogsatpresent,theywould
compounds.Reportsofrecentevaluationsofcombi-
allowdeliveryofsignificantdosesofradiationtherapy
nationprotocolsalternatingcisplatinorcarboplatin
thattheoreticallycouldbelocallycurativewhilespar-
withdoxorubicinaresummarized inFigure13.17.
ingnormalstructures.
Radiation
Radioisotopes:Thebone-seekingradioisotope
samarium-153-ethylenediaminetetramethylenephos-
Thecombinationofexternalbeamradiationtherapy
phonate (153samarium-EDTMP)has been used to
and limbsparinghasbeendescribed(Thrallet al.,
treatOSAindogs andhumans.Inhighdoses,samar-
1990;Withrowetal.,1993).Itappearsthatradiation
iumhasbeenshowntodeliverlocally20to200Gyof
therapycancauseconsiderablenecrosisofprimary
radiationtonormal bone andOsA tumours,respec-
OSAindogs.In thismanner,radiationcanbeused in
tively.TheefficacyofsamariumincanineOSA
anefforttodownstagetheprimarytumourtoimprove
patientshasbeenreported(Milneretal.,1998;Aaset
thesuccessof local diseasecontrol followingremoval.
al.,1999).Studieson theefficacy of samarium for
At present,the roleofradiation therapy used to
OSAindogsindicatethattumourdosesequivalent to
20Gymaybedeposited incanineOSAsusinglowto
apy,isunclear.Currently,radiation therapy in dogs
moderatedosesofsamarium,andtheratiobetween
withappendicularOsAisprimarilyreservedforpallia-
tumourdoseanddosetosurroundingtissues
is
tionofbonepain(seelater).Asaprimary therapy,a
favourable.The treatmentprovides painreliefin
mediansurvivaltimeof209dayshasbeenreported
caninepatientsandinsomecasestumourgrowth
in14dogswithappendicularOSAtreatedwithfrac-
delaybutisnotcurative.
tionatedhigh-doseradiation(mediandoseof57Gy)
Isolatedlimbperfusion
totheirprimarytumourandsystemicchemotherapy
Isolationof limbcirculationandperfusionwithchemo-
for micrometastasis(Walter et al.,2005).Similar
therapyhasbeenusedinpeoplewithsarcomasand
resultsareseeninpeoplewithextremityOSAtreated
melanomasasasoletreatmentortodownstagelocal
withhigh-doseradiationwithandwithoutsurgical
diseaseandallowlimbsparing.Isolatedlimbper-
stabilization.
fusion(ILP)allowsdelivery ofhigh concentrationsof
Radiationtherapylikelyplaysaroleinthetreat-
chemotherapyaswellasdeliveryofcompoundsthat
mentofOSAofvertebrae.Inaseriesof14dogs
arepoorlytoleratedsystemically.Varyingdegreesof
withvertebralOSAtreatedbetween1986and1995.
localtoxicityarereported，dependingonthedrugs
12hadsurgerytodecompressthespinalcord,
，7
used.Successfuluseof ILPincanineOSAhasbeen
weretreatedwithOPLA-Ptimplantedinadistant
reported (Van Ginkelet al.,1995).ILP may be a
intramuscularsiteand11weregivenintravenous
methodtofacilitate therapeuticdrugconcentrationsin
cisplatin.Ninedogsweretreatedwithfractionated
primarytumoursforpreoperativedownstagingpriorto
externalbeamradiationtherapy.Alldogshadsur-
limbsalvage.Currentlyinvestigationsarebeingcon-
gery,radiation therapyorboth，whilenodog was
ducteddeliveringtheradioisotopesamariumathigh
treatedwithchemotherapyalone.Fourdogs
im-
dosesusingILPindogstoassesswhetheraclinically
provedneurologically,fourdogsworsenedand six
meaningfulpercentagenecrosiscanbeachieved
dogsremainedthesame.Themediansurvivalof
priortoprimarytumourremoval.
171
Chapter13Tumoursof theskeletalsystem
Follow-up and prognosis after curative
dogswithoutnodal spread(Hillersetal.,2005).
intenttherapy
Indogs,ithasnotbeenwellestablishedthatthere
Oncesurgeryandadjuvanttherapyarecompleted,
isadifferenceinthebiologicalbehaviourofthediffer-
follow-upincludesphysicalexaminationandthoracic
ent histological subclassifications,but histological
radiographstoassessformetastases,recommended
grade,based on microscopic features,has been
at3-monthlyintervals.Nuclearscintigraphycanbe
showntobepotentiallypredictiveforsystemicbehav-
used for screeningfor suspiciousbonelesions,with
iour(metastasis)(Kirpensteijin et al.,1999).
follow-upradiographs.Clientsmayconsiderfollow-up
Elevatedalkalinephosphatasehasbeenassoci-
academic,butearly detectionofmetastasis(orother,
atedwithapoorerprognosisfordogswithappendic-
non-tumour disease)canassist treatmenteffective-
ularOSA.Apreoperativeelevationofeitherthetotal
ness.In addition,the data gathered onresponse to
(serum)or bone isoenzyme is associated witha
treatmentprotocolsareinvaluableinimprovingthe
shorterdisease-freeintervalandsurvival.Inone
overalltreatmentsuccessofthedisease.Withradio-
study,dogsthathadelevatedpreoperativevalues
graphicallydetectablepulmonarymetastasisdogs
thatdidnotreturntonormalwithin40daysfollowing
mayremainasymptomaticformanymonths,butmost
surgicalremovaloftheprimarylesionalsofailedear-
dogsdevelopdecreasedappetitesandnon-specific
lierfrom disease(Ehrhartetal.,1998)(Figure 13.18).
signssuch asmalaisewithin1month.Hypertrophic
Ariseinserumalkalinephosphataseaftertreatment
hasbeenshowntopredictpulmonarymetastaticfail-
metastasisandmaybethecauseof theprimarypre-
ure,indicatingthatitcouldbeusedtoscreenpatients
senting complaint.
forpendingmetastasistoassistpre-emptivetreat-
Inamulti-institutionalstudyof162dogswith
ment decisions(Dye et al.,2001).
appendicularOSAtreatedwithamputationalone,
dogsyoungerthan5yearsofagehadworsesurvival
rates than older dogs （Spodnick et al.,1992).
0.9
0.9
Additionalstudieshaverelatedlargetumoursizeand
bu!
0.8
0.8
humeral locationtopooroutcome.Theonlyanatomi-
vivi
calsitethathasanimprovedoutcomeisthemandi-
0.7
0.7
ble:dogswithOSAofthemandibletreatedwith
ns
0.6
0.6
mandibulectomyalonehada1-yearsurvivalrateof
uo
0.5
0.5
71%in one study(Straw et al.,1996).In contrast,
E
0.4
0.4
maxillaryOsAhasdemonstratedamediansurvivalof
Propor
0.3
0.3
5monthsfollowing maxillectomy(Hardyetal.,1967;
Schwarz et al,1991;Wallaceet al.,1992).A study
0.2
0.2
evaluatingresponsetotreatmentfororbitalOSA
0.1
0.1
reportedlong-termsurvivalfollowingcompletesurgi-
0
0
calexcision(Hendrixand Gelatt,2000).
OSA of the canine scapulahasbeenreported to
0
200
400
600
800
1000
haveapoorprognosiswhentreatedwithsurgery
Time (days)
andchemotherapy(Hammeretal.,1995;Troutetal.,
1995).SurvivalofdogswithOSAdistaltotheante-
BoneAP≤23IU/
BoneAP>23IU/
(a)
brachiocarpalortarsocruraljointswassomewhat
longer(medianof466days)thansurvivalofdogs
withOSAofmorecommonappendicularsites,but
1
OSAin these sitesisaggressive witha high potential
formetastasis(Gamblinetal.,1995).
0.8
0.8
Althoughvertebral OSAisuncommon,reported
casesindicateanaggressivelocalandsystemic
0.6
0.6
behaviour.In15dogstreatedwithacombinationof
surgery,radiationandchemotherapy,themediansur-
0.4
0.4
vival was4months(Dernell etal.,2000).
ForOSA originating from flat bones,smalldog
0.2
0.2
sizeandcapacityforthelesiontobeexcisedcom-
pletelywerepositiveprognosticindicators.Extra-
skeletal(soft tissue)OSAsites also appeartohave
0
aggressivesystemicbehaviour thatbenefitsfrom
0
500
1000
1500
adjuvanttherapyfollowingsurgicalresection.Whilst
Time(days)
therearedifferencesindiseasedistributionand
prevalence,documentationofimprovedsurvivalfor
TotalAPs110IU/TotalAP>110IU/
smalldogswithOSAislacking.
(b)
Anegativeprognosiscanalsobepredictedbya
higher tumourgrade(Kirpensteijnet al.,2002).Dogs
13.18
(a)Relationofdisease-freeinterval indogs
treatedforOSAandpreoperativebonealkaline
presentedwithstage Ill disease(measurablemetas-
phosphataselevels.(b)Relationof survival outcomeof
tases)haveaverypoorprognosisanddogswith
dogstreatedforOSAandpreoperativeserumalkaline
lymphnodemetastasishadshort survivalswitha
phosphatase levels.(Reprinted withpermissionfrom
medianofonly59days,comparedwith318daysfor
Ehrhart et al.,1998)
172
Chapter13
3Tumoursof theskeletalsystem
Metastaticdiseaseanditstreatment
difficultintermsoftryingtoestablishthetrueinci-
Theusualcauseofdeathinhumansanddogsfollow-
denceofthedifferenttypesofprimarybonetumours
ingamputationasthesoletreatmentforOSAisdif-
anditunderscorestheimportanceofevaluatingthe
fusepulmonary metastasis.Thereisareportof 36
entireexcisedspecimentovalidatethepreoperative
dogstreatedwithpulmonarymetastasectomyfor
biopsy.Thisisalsotrueincaseswheretheinitial
OSA（O'Brienetal.,1993).Based on this study,the
biopsymightindicatelow-gradedisease.
criteriaestablishedforcaseselectionforpulmonary
PrimarybonetumoursotherthanOSAmakeup
metastasectomyinordertomaximizetheprobability
5-10%ofbonemalignanciesindogsand include
of longsurvivalperiodsare：
chondrosarcomas,haemangiosarcomas,fibrosarco-
mas,lymphomasand myelomas.
。
Primarytumourincompleteremission,preferably
foralongrelapse-freeinterval(>300days)
Chondrosarcoma
Oneortwonodulesvisibleonplainthoracic
Chondrosarcoma(CSA)isthesecond mostcommon
radiographs
primary tumourofboneinhumansanddogs,and
Canceronlyfoundinthelung
accountsforapproximately5-10%ofallcaninepri-
Perhapslongdoublingtime(>30days)withno
marybonetumours.CSAoccursmostcommonlyin
newvisiblelesionswithinthistime.
flatbones,withthenasal cavityasthemostcommon
site.
Metastasectomymaybeindicatedfordogswith
CSAsarecharacterizedhistologicallybyanaplas-
solitarybonemetastasesandnoevidenceofcancer
ticcartilagecellsthatelaborateacartilaginousmatrix.
elsewhere,butthesubsequentdisease-freeintervalis
Theaetiologyisgenerallyunknown,thoughCSAcan
generallyshort.
ariseindogswithpre-existingmultiplecartilaginous
Cisplatin,doxorubicinandmitoxantronechemo-
exostosis.CSAisgenerallyconsideredtobeslowto
therapyappeartobeineffectiveforthetreatmentof
metastasize.Tumour locationratherthanhistological
measurablemetastaticOsAinthedog,butmayslow
grade maybeprognostic,buthistological gradehas
theprogressionofdisease(Ogilvie etal.,1993).A
beenfoundtobeimportantforpredictingsurvivalfor
numberofpotentialtargetedtherapieshavebeen
tumoursofthesameanatomicalsiteoforigin.The
established for metastatic OSA,including inhalant
reportedmediansurvivalofdogswithnasalCSA
Il-2,doxorubricin,paclitaxel andgemcitabine,anda
rangesfrom210daysto580dayswithradiationther-
liposome-DNAcomplexthatcodesforIL-2(Khanna
apy,orrhinotomyandradiationtherapy，orrhinotomy
etal.,1996,1997;Micheau et al.,1997;Hershey et
alone.Metastaticdiseaseisnota featureofnasal
al,1999;Poulaki et al.,2001;Khanna and Vail,
CSA in dogs.
2003;KoshkinaandKleinerman,2005).
ThereportedmediansurvivalfordogswithCSAof
ribsvarieswidely,butappearstobeprolonged(upto
Palliativetreatment
1000 days)following curative-intentresection.The
Analternativetocurative-intenttreatmentistotreat
mediansurvivalfordogswithCSAof longboneswas
metastaticbonelesionswithpalliativeradiation.
201daysinonereportofsevendogstreatedwith
Variousprotocols havebeenreported,mostusing
amputationwithorwithoutadjuvantchemotherapy
largerfractionsizes(6-10Gy)withone,twoorthree
and540daysinanotherstudyoffivedogstreated
treatmentsover time.Over70%ofdogsrespond
withamputationalone.Deathwasusuallyassociated
positively（improvementinclinicalevidenceofpain
withmetastaticdisease.Responsetochemotherapy
and lameness)for 2-4 months.Unfortunately,the
isnotknownforcanineCSA.Basedonthetreatment
lesionsusuallybecomesymptomaticagainwithin
successofnasalCSA,adjuvantradiationtherapycan
2-4monthsafterradiation.Addingadditionalfrac-
beutilized forincompletely resected lesions,but
tionsbeyondthree(course)fractionshasbeensuc-
cessfulforfurthertemporarypainreliefinafew
responsedataarelacking.
dogs,butthepotential formarkedacuteradiation
Haemangiosarcoma
toxicityisincreased.Radiopharmaceuticals(suchas
strontiumandsamarium)havealsobeenusedto
Primaryhaemangiosarcoma(HSA)of bone israre
andprobablyaccountsfor<5%ofallbonetumours.
palliatepainfrommetastaticbonecancerinpeople.
Thisdiseasegenerallyaffectsmiddle-agedtoolder
Asmentioned above,153samarium-EDTMPisaradi-
opharmaceuticalthathasbeenusedtotreatmeta-
dogsandcanoccurindogsofanysize.Similarto
OSA,itisahighlymetastatictumourandvirtuallyall
staticandprimarybonetumoursindogs(Lattimeret
al.,1990).Othertherapiestopalliatethepainassoci-
dogsaffectedwill developmeasurablemetastaticdis-
atedwithOSAarediscussedinChapter11.
easewithin6monthsofdiagnosiswithoutadjuvant
therapy.Metastasescanbewidelyspreadthroughout
organs such aslungs,liver,spleen,heart,skeletal
Otherprimarybonetumoursofdogs
muscles,kidney and brain,and also other bones.
Dogscanpresentwithmultiplelesions,makingitdif-
Whenonlysmallamountsofbiopsytissueareevalu-
ficult todetermine thesiteofprimarydisease.
ateditcanbedifficulttodistinguishchondroblastic
Histologically,HSAiscomposedofhighlyanaplas-
OSAfromchondrosarcoma,orfibroblasticOSAfrom
ticmesenchymalcellswhichareprecursorstovascu-
fibrosarcoma,ortelangiectaticOsAfromhaemangio-
larendothelium.Thecellsarearrangedinchords
sarcoma.This makes interpretationofolderreports
173
Chapter13Tumoursoftheskeletalsystem
appeartobeformingvascularchannelsorsinuses
Cellularpleomorphismandnumerousmitoticfigures
arefeaturesofthishighlymalignantdisease.Thereis
profoundbonelysisand themalignantcellsaggres-
sivelyinvadeadjacentnormalstructures.Thelesion
maybeconfusedwithtelangiectaticOSA,especiallyif
thediagnosisisbasedonsmall tissuesamples.Often
thedominantradiographicfeatureislysis.
IfHSAis diagnosed,the dogmust be thoroughly
stagedwiththoracicandabdominal films,bonesur-
graphicevaluation,particularlyoftheheartand
abdominal organs.RightatrialHSAmaybepresent
withoutclinicalorradiographicsignsofpericardial
13.19
T2(left)and T1（right)MR imagesof a
effusion.Theprognosisispoor andevendogswith
multilobularosteochondrosarcomaarisingfrom
HSAclinicallyconfinedto onebonysitehavea
thecalvariuminadog.Thesetumourshaveagranular
<10%probabilityofsurviving1yearif thetumour
appearanceonradiography,oftenreferredtoas
canbecompletelyexcised.Cyclophosphamide,vin-
'popcorn-ball.
cristineanddoxorubicinhavebeenusedincombina-
obtainhistologicallycompleteresection.Lesionsof
tionasanadjuvantprotocolandthereportedmedian
thecraniumwillofteninvadeintothecalvarium,dis-
survivalofdogswithnon-skeletalHSAis172days
(Hammeretal.,1991;Ogilvieetal.,1996).
placingbraintissuecausingcentralnervoussystem
signs,but thesetumours arerarelyinvasiveinto
Fibrosarcoma
brain.Craniectomywilloftenresultinrapidrecovery
Primaryfibrosarcoma（FSA)ofboneisararetumour
and hasthepotentialforlong-termremission.
indogsandprobablyaccountsfor<5%ofallcanine
Theroleofchemotherapyandradiationtherapyin
primarybone tumours.Thedifficulty indistinguishing
themanagementofMLOisnotwelldefined.
FSAfrom fibroblasticOSA histologicallyrenders
studyofthistumourproblematic.Forexample,ina
studyof 11dogs thought tohaveFSA,thehistologi-
Metastatic tumoursofbone
cal diagnosiswaschangedtoOSAinsixdogsupon
review(Wesselhoeft et al.,1991).Histological charac-
Almostanymalignanttumourcanmetastasizeto
teristicsofFSAhavebeendescribedasinterwoven
bonevia thehaematogenousroute.Thelumbarverte-
bundlesof fibroblastswithinacollagenmatrixperme-
brae,femur,humerus,riband pelvis are common
sitesforprimarybonetumourmetastasisaswellas
atingcancellousandcortical bonebutnotassociated
fromthecommonurogenitalmalignanciessuchas
withosteoidproducedbythetumourcells.
Completesurgicalresectionoftheprimarylesion
prostate,bladder,urethral and mammary cancer.
isrecommendedfordogswithFSAclinicallycon-
Metastaticlesionsinlongbonesfrequentlyaffectthe
fined totheprimarysite.Thistreatmentmaybecura-
diaphysis,probablybecauseoftheproximitytothe
tive,butmetastaticpotentialmaybevariable.Data
nutrientforamen.Nuclearscintigraphyisaverysensi-
ontheefficacyofadjuvanttherapyarelackingdueto
tivetechniquetodetecttheusualmultiplesitesof
therarenatureof thedisease.
bone metastasis.
Multilobularosteochondrosarcoma
Multilobular osteochondrosarcoma(MLO)
isan
Primarybonetumoursofcats
uncommontumourindogsthatgenerallyarisesfrom
theskull.Thesetumourshaveacharacteristicradio-
Incidenceandrisk
Cancerinvolvingfelinebonesisrare.Anestimateof
graphicappearance:generallythebordersofthe
theincidenceofallbonetumoursincatsis4.9per
tumouraresharplydemarcated,withlimitedlysisof
adjacentbone,andthereisacoarsegranularmineral
100,000 (Dorn et al.,1968).Up to 90%of bone
densitythroughout(Figure13.19).
tumoursincatsarehistologicallymalignant.Inone
Histologicallythesetumoursarecomposedof mul-
tiplelobuleseachcentredonacoreofcartilaginous
and40of90wereaxial(Heldmannetal.,2000).
orbonymatrixthatissurroundedbyathinlayerof
OSAaccountsfor70-80%ofallprimarymalig-
spindlecells.Inonereportof39dogs,slightlyfewer
nantbonecancerincats.Thediseasediffersfrom
than50%ofdogshadlocaltumourrecurrencefollow-
thatindogsinthattheprimarylesionsoccurmore
ingresectionatamediantimeofapproximately800
ofteninhindlimbsincatsand thediseaseisfarless
days(Dernellet al.,1998a).A little overhalf the dogs
metastatic.OSAgenerallyaffects bothmale and
developedslowlyprogressivemetastasesaftertreat-
femaleoldercatsbuttheagerangeofreportedcases
ment,withamediantimetometastasisof542days.
islarge(1-20years).
Themediansurvivaltimewasalso800days.
Multiple cartilaginous exostosis(MCE)isadis-
Localtumourexcisionappearstoofferagood
ease thatoccurs afterskeletal maturityincats.Thisis
opportunityforlong-term tumourcontrol,partially
incontrasttodogs,whereexostosesdevelopbefore
predictedbyhistologicalgradeandtheabilityto
closureof growthplates.Also in contrast todogs,the
174
Chapter13Tumoursoftheskeletalsystem
lesionsseldomaffectlongbonesincats,arerarely
poorerprognosis,presumablyduetoincreaseddiffi-
symmetricalandareprobablyofviralratherthan
cultyof localresectionandcontrol.Axialsitesarebest
familialorigin.Theredoesnotappeartobeanybreed
treatedwithcombinationtherapy，andchemotherapy
orsexpredisposition.Affectedcatsrangeinagefrom
hasshownasurvivaladvantageinthesecases
1.3to8years(mean3.2years).Virtuallyallcatswith
(Heldmann etal.,2000).
multiplecartilaginousexostosiswilltestpositivefor
CatswithMCEhavea guardedprognosis.Lesions
theFeLVvirus.Thisdiseasehas anaggressive
mayberemovedsurgicallyforpalliation,butlocal
natural behaviour.
recurrencesarecommonornewpainfuldebilitating
lesionsmayoccur.Noreliablyeffectivetreatmentis
Pathologyand natural behaviour
knownforthisconditionincats.
AhistologicalfeatureofsomefelineOSAcasesis
thepresenceofmultinucleategiantcells,whichmay
References
benumerous.Reactiveandremnanthostboneare
oftenpresentinspecimens.Tumoursareseentobe
AasM,MoeLandGamlemH（1999）Internalradionuclidetherapyof
invasive,butsomesurrounding softtissuemaybe
primaryosteosarcoma in dogs,using 153Sm-ethylene-diamino-
tetramethylene-phosphonate(EDTMP).Clinical CancerResearch
compressedrather thaninfiltrated.Thereis often
5,3148s-3152s
variationofthehistologicalappearancewithinthe
AshtonJA,FareseJPMilnerRJ,Lee-AmbroseLMandvan GilderJM
tumour,withsomeportionshavingmorefibrosarco-
(2005)Investigationof theeffectofpamidronatedisodiumonthein
vitroviabilityofosteosarcomacellsfromdogs.AmericanJournalof
matousappearanceandothersmorecartilaginous.
VeterinaryResearch66,885-891
Someauthorshavedescribedsubtypesthatresem-
Bailey D.ErbH,Williams L,Ruslander D and Hauck M(2003)
Carboplatinanddoxorubicin combination chemotherapy forthe
ble those seenin dogs,but these features do not
treatmentofappendicularosteosarcomainthedog.Journalof
appeartoconferanyprognosticpredictivevalue.
VeterinaryInternalMedicine17,199-205
OSAincatsismoreoftenof thejuxtacortical
BergJ,Gebhard MCandRandWM（1997)Effectof timingon
postoperative
chemotherapy
on
survivalofdogswith
（parosteal)type.Inarecentlargecase study，56of
osteosarcoma.Cancer79,1343-1350
146caseswereextraskeletalinoriginwiththemost
BergJ,Weinstein MJ,SchellingSHandRandWM(1992)Treatmentof
dogswithosteosarcoma byadministrationofcisplatinafter
common sitebeingintrascapular(Heldmann et al,
amputationorlimb-sparing surgery:22cases（1987-1990)Journal
2000).In this subset,vaccination at thesitewas con-
oftheAmericanVeterinaryMedicalAssociation200,2005-2008
BergJ,WeinsteinMJ,SpringfieldDSandRandWM（1995)Response
sideredapredisposingfactor.Nomentionwasmade
doxorubicin.JournaloftheAmericanVeterinaryMedical
incomparisonwithskeletalsites.
Association206,1555-1560
BergmanPJ,MacEwen EG,Kurzman IDetal.（1996)Amputation and
Historyand clinical signs
（1991-1993）JournalofVeterinarynternalMedicine107681
Bitetto WV.Patnaik AK, Schrader SC and Mooney SC （1987)
ThemostcommonsignsofOSAaredeformityand
Osteosarcoma in cats:22 cases(1974-1984）.Journal of the
lameness,dependingonthelocationofthelesion.
AmericanVeterinaryMedicalAssociation190.91-93
Boulay JP,WallaceLJ andLipowitzAJ(1987)Pathologicfractureof
Thelesionsmayappearradiographicallysimilarto
longbonesinthedog.Journalof theAmericanAnimal Hospital
OSAindogs,or canarise from theperiosteal sur-
Association23,297-303
face(juxtacortical OSA).It israre for cats tohave
ChunR,Kurzman ID,Couto Getal.(200o)Cisplatin and doxorubicin
combinationchemotherapyforthetreatmentofcanine
metastaticOSA.
osteosarcoma:apilotstudy.JournalofVeterinaryInternalMedicine
Catswithvirallyassociatedmultiplecartilaginous
14,495-498
Cooley DM，Beranek BC,Schlittler DL et al.(2002) Endogenous
exostosishaverapidlyprogressingconspicuoushard
gonadal hormone exposureandbone sarcoma risk.Cancer
swellingsoveraffectedsites,causingpainandlossof
function.Commonsitesforlesiondevelopmentarethe
Davis GJ,Kapatkin AS,Craig LE,Heins GS and Wortman JA (2002)
Comparisonofradiography,computed tomographyandmagnetic
scapula,vertebraeandmandible,butanybonecan
resonanceimagingforevaluationofappendicularosteosarcomain
becomeaffected.Radiographically thelesions are
dogs.JournaloftheAmericanVeterinaryMedicalAssociation220,
1171-1176
eithersessileorpedunculateprotuberancesfrombone
DeRegisCJ,Moore AS,RandWMand BergJ(2003）Cisplatin and
surfaceswithindistinctborders.Theremaybealossof
doxorubicin toxicosis in dogswithosteosarcoma.Journal of
VeterinaryInternaMdicn17668673
smoothcontourwithevidenceoflysis,particularlyif
DernellWS(2002)Limbsparing surgeryfordogswithboneneoplasia.
thereismalignanttransformation.
In:TextbookfmallnimaSurgeryrdedndDMSlatr
2272-2285.WBSaunders,Philadelphia
DernellWS,EhrhartNP,StrawRCandVailDM(2006)Tumoursof the
Diagnosticwork-up,therapy and
skeletalsystem.In:SmallAnimalClinicalOncology4thedned.J
prognosis
WithrowandDMVai.540582.WBSaunders,Philadelphia
Dernell WS,Straw RC.Cooper MF et al.（1998a) Multilobular
BothOSAandMCEmaybesuspectedfromtheradi-
osteochondrosarcomain 39 dogs:1979-1993.Journal of the
ographicappearance of the lesions,andMCEfrom
AmericanAnimalHospitalAssociation34,11-18
DernellWSVanVechtenBJ,StrawRCetal.(20oo)Outcomefollowing
theFeLVstatusof thecat.Definitivediagnosisiscon-
treatmentforvertebral tumorsin20dogs(1986-1995).Journalof
firmedbyhistopathological evaluation.
theAmericanAnimalHospitalAssociation36,245-251
IncatswithOSAofalimbwheretherearenoclin-
DernellWS,WithrowSJ,StrawRCetal.(1998b)Clinicalresponse to
antibioticimpregnatedpolymethylmethacrylatebeadimplantation
icallydetectablemetastaticlesions,amputationalone
ofdogswithsevere infections after limbsparing with allograft
maybecurative.Intwostudiesof15cats,themedian
replacement -18 cases （1994-1996).Veterinary Comparative
OrthopedicsandTraumatology11,9499
survivalafteramputationalonewas24and44
DickersonME,PageRL,LaDueTA etal.(2001)Retrospective analysis
months（Turreland Pool,1982;Bitetto etal.,1987).
ofaxialskeletonosteosarcomain22largebreeddogs.Journalof
Themetastaticpotential ismuchlessthanfor the
VeterinaryInternalMedicine15120-124
DornCR,Taylor DONand SchneiderR（1968）Survey of animal
samediseaseindogsorhumans.Axialsitescarrya
neoplasms inAlameda and Contra Costa Counties,California.ll.
175
Chapter13Tumoursoftheskeletalsystem
CancermorbidityindogsandcatsfromAlamedaCounty.Journal
carboplatin aloneindogswithnaturallyoccurring osteosarcoma:
of theNationalCancerInstitute40.307-318
evaluationofinsulin-likegrowthfactorsuppression
and
DowS,Elmslie R,Kurzman|etal.(2005）Phase|study of liposome-
chemotherapy.ClinicalCancerResearch8,2406-2412
DNA complexesencoding the interleukin-2gene in dogswith
Khanna Cand Vail DM(2003)Targeting the lung:preclinical and
osteosarcoma lung metastases.Human GeneTherapy 16.937-
comparativeevaluationofanticanceraerosolsindogs
with
946
naturallyoccurringcancers.CurrentCancerDrugTargets3,265-
DyeTL,Kristal OMDernellWSetal.(2001）Alkalinephosphataseasa
273
predictorofcanineosteosarcoma metastasis.Proceedingsofthe
Khanna C,WanX,Bose Set al.(2004)The membrane-cytoskeleton
VeterinarancerocietstnuaMetingBatonougeA
linkerezrin isnecessary for osteosarcoma metastasis.Nature
75(abstract)
Medicine10,182-186
Ehrhart N.Dernell WS.Hoffmann WE et al.(1998)Prognostic
Kirpenstejn J,Kik M,Rutterman GRand Teske E(2002)Prognostic
significanceofanewhistologicgrading system for canine
withappendicularosteosarcoma:75cases（1990-1996).Journalof
osteosarcoma.VeterinaryPathology39,240-246
theAmericanVeterinaryMedicalAssociation213,1002-1006
Kirpensteijin J,Steinheimer D,Park RD et al.（1998）Comparison of
EhrhartN,EurellJC,TommasiniMetal.(2002）Theeffectsof cisplatin
cemented andnon-cemented allograftsforlimbsparingprocedures
onbonetransportosteogenesis.AmericanJournalofVeterinary
indogswithosteosarcomaofthedistalradius.Veterinary
Research63.703-711
ComparativeOrthopedicsandTraumatology11,178-184
FanTM,deLorimier LP,Charney SCand Hintermeister JG(2005)
KirpensteijinJ,TeskeE,KlennerTH,KikMandRutterman GR（1999）
Evaluationof intravenouspamidronateadministrationin33cancer-
Surgeryandloboplatinchemotherapyfor treatmentof canine
bearingdogswithprimaryorsecondaryboneinvolvement.Journal
appendicularosteosarcoma.VeterinarySurgery28,396（abstract)
ofVeterinaryInternalMedicine19,74-80
Koshkina NV andKleinerman ES(2005)Aerosol gemcitabine inhibits
FareseJPAshtonJ,MilnerRmbroseLLandVanGilderJ（2004）Th
thegrowthofprimaryosteosarcomaandosteosarcomalung
effectof thebisphosphonatealendronateonviabilityof canine
metastases.InternationalJournalofCancer116,458-463
osteosarcoma cellsinvitro.InVitroCellularandDevelopmental
Kraegel SA,MadewellBRandSimonsonE（1991)Osteogenicsarcoma
Biology-Anima/40.113-117
and cisplatin chemotherapy in dogs:16 cases （1986-1989).
Farese JP,Milner R.Thompson MS et al.(2004)Stereotactic
Journalof theAmericanVeterinaryMedicalAssociation199.1057-
radiosurgeryfortreatmentofosteosarcomasinvolvingthedistal
1059
portionsof the limbsindogs.JournaloftheAmericanVeterinary
LambCR(1987)Bone scintigraphy in small animals.Journal of the
MedicalAss0ciation225,1548,1567-1572
AmericanVeterinaryMedicalAssociation191.1616-1622
Forrest LJ, Mackie TR, Ruchala K et al.（2004） The utility of
LambCR,BergJand BengstonAE(1990)Preoperativemeasurement
megavoltage computed tomography
imagesfromahelical
ofcanine primary bone tumors,using radiography and bone
tomotherapysystemforsetupverificationpurposes.International
scintigraphy.JournaloftheAmericanVeterinaryMedical
JournalofRadiationOncologyBiologyPhysics601639-1644
Association196.1474-1478
GamblinRM,StrawRC,PowersBEetal.（1995）Primaryosteosarcoma
LaRue SM,Withrow SJ andWrigley RH (1986)Radiographicbone
surveysintheevaluationof primarybone tumorsindogs.Journal
(1980-1992).Journalof theAmericanAnimalHospitalAssociation
of theAmericanVeterinaryMedicalAssociation188.514-516
31,86-91
LascellesBDX,DernellWS,CorreaMTetal.(2005)Improved survival
Hahn KA,Legendre AM and Schuller HM （1997)Amputation and
associatedwithpostoperativewoundinfectionindogstreatedwith
limb-salvage surgeryfor osteosarcoma.Annals of Surgical
dexniguldipineastreatmentforcanine appendicularosteosarcoma.
Oncology12,1073-1083
JournalofCancerResearchandClinicalOncology123,34-38
HammerAS,CoutoCG.FilppiJ,GetzyD and ShankK（1991）Efficacy
Lattimer JC,Corwin LA,Stapleton Jet al.（1990) Clinical and
andtoxicityfACchmtherapvicristinedoxorubiinand
clinicopathologicresponse of canine bone tumor patients to
treatmentwithsamarium-153-EDTMP.JournalofNuclearMedicine
cyclophosphamide)indogswithhemangiosarcoma.Journalof
VeterinaryInternalMedicine5,160-166
31,1316-1324
Hammer AS.Weeren FR.Weisbrode SEand Padgett SL （1995)
Leibman N,KuntzCA,Steyn Pet al.(2001)The measurement of the
Prognosticfactors in dogswith osteosarcomasof theflator
proximal extentof canine osteosarcoma of the distal radiususing
irregularbones.JournaloftheAmericanAnimalHospital
radiography,nuclear scintigraphy andhistopathology.Veterinary
Association31,321-326
Surgery30,240-245
Hardy WD,Brodey RS and Riser WH (1967)Osteosarcoma of the
LiptakJM,DernellWS,StrawRCetal.(2004)Proximal radialanddistal
humeralosteosarcomain12dogs.Journalof theAmericanAnimal
canineskull.Journalof theAmericanVeterinaryRadiologySociety
HospitalAssociation40.461-467
8,5-9
MauldinGN,MatusREandWithrowSJ(1988)Canineosteosarcoma
Heldmann E,AndersonMA,Sweet D andWagner-Mann CC(2000)
Feline osteosarcoma:145 cases (1990-1995）.Journal of the
treatmentbyamputationversusamputationandadjuvant
chemotherapyusingdoxorubicinandcisplatin.Journalof
AmericanAnimalHospitalAssociation36,518-521
HendrixDVandGelattKN(20oo)Diagnosistreatmentandoutcome of
VeterinaryInternalMedicine2,177-180
MicheauO,SolaryE,HammannA,MartinFandDimanche-Boitrel MT
orbitalneoplasiaindogs:aretrospectivestudyof44cases.Journal
(1997)Sensitizationofcancercellstreatedwithcytotoxic drugsto
ofSmallAnimalPractice41,105-108
fas-mediatedcytotoxicity.JournaloftheNationalCancerInstitute
Hershey AE,Kurzman ID,Forrest LJ et al.（1999)Inhalation
89,783-789
Milner RJ,Dormehl 1.LouwWKand Croft S（1998） Targeted
proofofprincipleusingdogswithspontaneouslyoccurringtumors
radiotherapywithSm-153-EDTMPinnine casesof canineprimary
asamodel.ClinicalCancerResearch5,2653-2659
HeymanSJ,DiefenderferDL,Goldschmidt MHandNewton CD（1992)
bonetumours.Journalof theSouthAfricanVeterinaryAssociation
69,12-17
Canineaxial skeletalosteosarcomaaretrospectivestudyof116
MorelloE,Vasconi E,MartanoM,Peirone Band BuraccoP(2003)
cases（1986to1989).Veterinary Surgery21.304-310
Pasteurized tumoral autograft and adjuvant chemotherapy for the
HillersKR,DernellWS.LaffertyMHIWithrowSJandLanaSE(2005)
treatment ofcaninedistalradialosteosarcoma:13cases.
Incidence andprognosticimportanceof lymphnodemetastasesin
VeterinarySurgery32,539-544
Mullins MN,Lana SE,Dernell WS et al.(2004) Cyclooxygenase-2
JournalofAmericanVeterinaryMedicalAssociation226,1364
expressionin canine appendicular osteosarcomas.Journalof
1367
JankowskiMK,SteynPF,LanaSEetal.(2001)Clinical sensitivityand
VeterinaryInternalMedicine18,859-865
O'Brien MG.Straw RC.Withrow SJ et al.（1993)Resectionof
specificityofnuclear scanning with99mTc-HDPfor osseous
pulmonarymetastases in canine osteosarcoma:36 cases(1983-
metastasisin dogs with osteosarcoma.Proceedings of the
1992).VeterinarySurgery22,105-109
VeterinaryCancerocit2stAnnualMeetingBatnRougeA
OBrien MG,Withrow SJ,StrawRC.Powers BEandKirpensteijnJ
35(abstract)
(1996)Totalandpartialorbitectomyforthe treatmentofperiorbital
Kent MS,Strom A,London CA and Seguin B（2004）Alternating
tumorsin23dogs and6cats.VeterinarySurgery25,471-479
carboplatinanddoxorubicin asadjunctivechemotherapy
yto
Ogilvie GK,KrawiecDRandGelberg HB（1988)Evaluation of a short-
or
limb-sparingsurgeryinthetreatment
of
term saline diuresisprotocol for the administrationof cisplatin.
appendicularosteosarcomaindogs.JournalofVeterinaryInternal
AmericanJournalofVeterinaryResearch491076-1078
Medicine18,540-544
Ogilvie GK,Powers BE,Mallinckrodt CH and Withrow SJ （1996)
KhannaC,Anderson PM,HaszDEet al.（1997）Interleukin-2liposome
Surgery and doxorubicin in dogswithhemangiosarcoma.Journal
inhalationtherapyissafe andeffectivefordogswithspontaneous
ofVeterinaryIntenalMedicine10379-384
osteosarcomametastases.Cancer791409-1421
Ogilvie GK,StrawRC,JamesonVJet al.（1993）Evaluationof single
Khanna C,Hasz DE,Klausner JS and Anderson PM（1996)Aerosol
agentchemotherapyforthetreatmentofclinicallyevident
deliveryofinterleukin2liposomesisnontoxicandbiologically
osteosarcoma metastasis in dogs（1987-1991).Journal of the
effective:canine studies.ClinicalCancerResearch2721-734
AmericanVeterinaryMedicalAssociation202304-306
KhannaC,PrehnJ,JacobSetal.(2002)Arandomizedcontrolled trial
PoirierVJ,Huelsmeyer MK,Kurzman ID,Thamm DH andVail DM
ofoctreotidepamoate long-actingreleaseandcarboplatinversus
(2003)The bisphosphonates alendronate andzoledronate are
176
Chapter13
Tumoursoftheskeletalsystem
inhibitorsof canine andhumanosteosarcoma cellgrowthinvitro.
theAmericanVeterinaryMedicalAssociation207,585-587
VeterinaryComparativeOncology1,207-215
Turrel JMandPool RR（1982)Primary bone tumors in the cat:a
Poulaki V,Mitsiades CSandMitsiadesN(2001)TheroleofFas and
retrospectivestudyof15catsandaliteraturereview.Veterinary
FasLasmediatorsofanticancer chemotherapy.DrugResistance
Radiology23,152-166
Update4,233-242
Van GinkelRJ,Hoekstra HJ,MeutstegeFJetal.(1995)Hyperthermic
Powers BE,LaRue SM,WithrowSJ,StrawRCand RichterSL（1988）
isolatedregionalperfusionwithcisplatininthe localtreatmentof
Jamshidineedle biopsy for diagnosisofbonelesions in smal
spontaneous canine osteosarcoma:assessment of short-term
animals.JournaloftheAmericanVeterinaryMedicalAssociation
effects.JournalofSurgicalOncology59,169-176
193,205-210
ReinhardtS,StockhausC,TeskeE,RudolphRand BrunnbergL(2005)
VasseurP(1987)Limbpreservationindogswithprimarybone tumors.
VeterinaryClinicsoforthAmerica1789993
dogs.Journal ofSmallAnimalPractice46.65-70
VignoliM,Ohlerth S,RossiFetal.(2004)Computed tomography-
SchwarzPD,WithrowSJ,Curtis CR,Powers BEandStrawRC（1991)
guidedfine-needleaspiration andtissuecorebiopsyofbone
lesionsinsmallanimals.VeterinaryRadiologyandUltrasound45.
dogs.JournaloftheAmericanAnimalHospitalAssociation27
125-130
617-624
WallaceJ,MatthiesenDTandPatnaikAK（1992)Hemimaxillectomy for
Seguin B,Walsh PJ,Mason DR et al.(2003)Use of an ipsilateral
thetreatment of oral tumors in69dogs.VeterinarySurgery21,
337-341
of thedistalradius indogs:ananatomicandclinical study.
WallackST,WisnerER,WernerJAetal.(2002）Accuracyofmagnetic
VeterinarySurgery32,6979
ShapiroW,FossumTWandKitchellBE(1988)Useof cisplatin for the
extentinpre-operativeplanningofcaninelimb-salvageprocedures.
treatmentofappendicularosteosarcoma indogs.Journalof the
VeterinaryRadiologyandUItrasound43432-441
AmericanVeterinaryMedicalAssociation4507-511
WalterWS,DernellSM,LaRueSEetal.(2005)Curative-intentradiation
SpodnickGJ,BergRJ,RandWMetal.（1992）Prognosisfordogswith
therapyasatreatmentmodalityfor appendicular andaxial
appendicularosteosarcoma treatedby amputationalone:162
cases(1978-1988).Journalof theAmericanVeterinary Medical
osteosarcoma:apreliminaryretrospectiveevaluationof14dogs
with thedisease.Veterinary andComparativeOncology3,1-7
Association200,995-999
WesselhoeftAblinL,BergJandSchelling SH(1991)Fibrosarcoma in
StrawRC,Powers BE,KlausnerJet al.（1996)Canine mandibular
osteosarcoma:51cases,(1980-1992).Journalof theAmerican
the canine appendicularskeleton.Journalof theAmericanAnimal
AnimalHospitalAssociation32,257-262
HospitalAssociation27,303-309
Straw RC and Withrow SJ(1992) Limb-sparing surgery versus
WithrowSJ,StrawRC,BrekkeJHetal.(1995)Slowrelease adjuvant
amputationfordogswithbonetumors.VeterinaryClinicsofNorth
cisplatinfortreatmentofmetastaticcanineosteosarcoma.
America26,135-143
EuropeanJournalofExperimentalMusculoskeletalResearch4,
Straw RC.Withrow SJ and Powers BE （1992) Partial or total
105-110
WithrowSJ,ThrallDE,StrawRCetal.（1993)Intra-arterialcisplatinwith
twocats.VeterinarySurgery21,183-188
orwithoutradiationinlimb-sparingforcanineosteosarcoma.
StrawRC,WithrowSJ,RichterSLetal.(1991)Amputationandcislatin
Cancer71,2484-2490
fortreatmentofcanineosteosarcoma.JournalofVeterinary
YazawaM,OkudaM,KanayaNetal.(2003）Molecularcloningof the
InternalMedicine5205-210
caninetelomerasereverse transcriptasegene anditsexpressionin
Thompson JPandFugent MJ (1992)Journal of theAmerican
neoplasticandnon-neoplasticcells.AmericanJournalofVeterinary
VeterinaryMedicalAssociation200,531-533
Research64,1395-1400
ThrallDE,WithrowSJ,Powers BEet al.(1990)Radiotherapyprior to
Zachos TA,Chiaramonte D,
DiResta GR et al.(1999)Canine
osteosarcoma:treatment with surgery,chemotherapy and/or
responseassay.InternationalJournalofRadiationOncology
radiation therapy,the Animal MedicalCenter experience.
BiologyPhysics18,1354-1357
TroutNJ,Pavletic MMandKrausKH(1995）Partial scapulectomy for
ProceedingsoftheVeterinaryCancerSociety,19thAnnual
Meeting,WoodsHole,MA,12（abstract)
management of sarcomasin three dogsand twocats.Journal of
177
Soft tissue sarcomas
Nicholas Bacon
Introduction
havesimilarbiologicalbehaviour,theyareoften
treatedasone.Sometumoursofmesodermbehave
Soft tissue sarcoma(STS)isa catch-allclassifica-
inamuchmoreaggressiveandlesspredictable
tionreferringtotumoursthatarisefromtheembry-
fashionandhaveamuchhigherrateofmetastasis.
onicmesoderm and,assuch,canoccuranywherein
ThesetendnottobeincludedinSTS;examples
thebody.Thetermismostcommonlyusedinrefer-
includevisceral haemangiosarcoma(Chapter19b),
encetosubcutaneoustissues,withothersitessuch
chondrosarcoma,andosteosarcoma(Chapter13).
as thealimentaryandurogenital tractsbeingless
frequentlyaffected.Thisvariabledistributionleadsto
hugerangeofhistopathologicalsubtypes.
Aetiologyandpathogenesis
Generally，theyare classifiedbyhistopathologyor
immunohistochemistryaccordingtothepresumed
Manysubcutaneoussofttissuelesionsarebenignor
celloforigin,suchasfibrosarcoma（FSA),peripheral
inflammatory,butSTSscomprise15%ofallskinand
nerve sheathtumour(PNST),myxosarcoma,liposarc
subcutaneous tumoursindogsand 7-9%incats
oma,orleiomyosarcoma（Figure 14.1).Sometimes
(TheilenandMadewell,1979;Milleretal.,1991).No
thesedistinctionsarenotclearandthegeneric
consistentsexorbreedpredispositionindogshas
termssofttissuesarcomaandspindiecellsarcoma
beenfound,althoughspayedfemaleswereover-
areemployed.Astumourswithinthisgrouptend to
represented inone study(Baker-Gabbet al.,2003).
Middle-agedtoolddogsofmediumtolargebreeds
Benign
seemtobemostcommonlyaffected.WhileSTSs
Malignant
areless commonincats,there has beenan
Liposarcoma
Lipoma
increaseinthenumberoffelinesarcomassince
1991,particularlyatanatomicalsitesusedforvacci-
Fibrosarcoma
Fibroma
nation.Thiswascoincidentwiththeshiftfrommodi-
Haemangiosarcoma
Haemangioma
fiedlivetokilledrabiesvaccineproducts.Linkswith
Myxosarcoma
Myxoma
felineleukaemiavirusvaccines,vaccinationforother
felineinfectiousdiseasesandnon-vaccineinjections
Peripheral nerve sheath tumours
Neurofibroma
(PNSTs）including:
ingeneralhavealsobeendescribed.
Haemangiopericytoma
Neurofibrosarcoma
Malignant schwannoma
Presentation and clinicalsigns
Lymphangiosarcoma
Lymphangioma
History
Epidermal inclusioncyst
ManySTSsare detectedwhenstill small,butare
oftennotinvestigatedastheownerorclinician
Collagenous naevi
assumes themtobebenign.Theyare typicallynon-
Malignant fibrous histiocytoma (MFH)
painfulmassesand,althoughtheymaybefirmand
attachedtodeepertissues,manyaresoftand
Histiocytic sarcoma
Histiocytoma
mobile,mimicking lipomasorotherbenignmasses.
Injection-associated sarcomas in cats:
Haemangiopericytomasinparticularareslowgrow-
Fibrosarcoma
ing,andmaycontainfluidpockets creating‘soft
Osteosarcoma
spots'onpalpation.
Leiomyosarcoma
Leiomyoma
AstudyofinsureddogsintheUKidentifiedlipo-
masin318per100,000dogs,withSTSat142per
Gastrointestinal stromal tumour(GIST)
100,000 (Dobson et al.,2002).It is this greater inci-
Rhabdomyosarcoma
Rhabdomyoma
denceofbenignlipomasthatleadstoincorrect
assumptionsthatsoftsubcutaneousmassesarenot
Synovial cell sarcoma
malignantandthusmanymalignant tumoursgo
14.1
undiagnoseduntil they change their behaviour,
Benign andmalignantsoft tissue tumours.
causeclinicalsignsorcauseconcernfortheowner.
178
Chapter14Softtissuesarcomas
Ahistoryofamassonthebodywallorextremities
Avascularresponse(newbloodvessels)
(Figure 14.2)slowlygrowingoverseveralyearsis
Mesenchymalresponse(tophysical presenceof
notuncommon
thetumourand abnormal localtissueforces)
Aninflammatoryresponse(tonecrosisor
haemorrhage).
Thisreactivezonemaybe fractionsofamilli-
metrewideinsmalllow-gradetumours,but signifi-
cantlywiderinrapidly
expandinghigh-grade
tumours.The zonecreatesavisibleandpalpable
‘edge'tothe tumour,mimicking a fascialplane,but
microscopicallyorimmunohistochemicallyit isa
three-dimensionalhalo'ofmalignancy.Dissections
within thereactivezone(i.e.'shelling out)are there-
foremarginal excisions;these commonlyresult in
tumourcellsextendingtotheedgesoftheresected
tissue,or satellitedeposits of tumourcellsinthe
reactivezonebeingleftinthewound.
14.2
Softtissuesarcomaseventuallyinvadethe
Pseudocapsule
Reactivezone
promptsveterinaryattention,aswiththislong-standing
STS of the pinna.
Feline injection-site sarcomas (IsSs) are seen
Muscle
Tumour
2-10monthsaftervaccinationandareonaverage
23cminvolumeonpalpationatdiagnosis(McEntee
andSamii,2000),oftenwithahistoryofrapidgrowth
(Figure 14.3).Most resolve in30-90days.Only those
Satellitetumour
Skipmetastasis
thatpersistlongerthan3monthsshouldbeinvesti-
14.4
Thereactivezonecontainssatellitedepositsof
gatedandpossiblyremoved.
cancer cells.These microscopictumours are
easilyleftbehind inthewoundifamarginalexcisionis
performedbypeeling themassout.
STSspresentasnon-painful massesonthe trunk
orextremities.Astheygrow,theyinvadetheskinand
deepertissue,causingthemtobecomemorefixed
andoftensuperficiallyulceratedorinfected(Figure
14.5).Whensarcomasareconfinedwithinanatomi-
cal spaces,patientspresentwithsignsofpain dueto
increased
compartmental
pressure.
Examples
include STSs contained within muscle bellies,or
expansileintermusculartumourscompressingneuro-
vascular structures(e.g.thigh masses compressing
thesciaticnerve).
14.3
Feline injectionsitesarcomas(ISSs)typically
occurovertheinterscapular areaorbodywall.
Toachieveacure,3cmmarginsandaresectionofat
leastoneuninvolvedfascialplanebelow/aroundthe
tumour isrecommended at thefirstsurgery.
Clinical signs
STSsaretypicallyinthesubcutaneousspaceandthe
skinoverlyingthemassisoftenfreelymobile.Many
STSsfeelencapsulatedanddistinctfromsurrounding
tissues.Thisisbecausetheyaresurroundedbya
pseudocapsule,whichcreatesaneasyplaneofcleav-
agebetweentumourandsurroundingtissues,allow-
ing themassestobe'shelledout'.Thepseudocapsule
arisesbecauseexpandingtumoursarehistologically
14.5
Thisslow-growingaxillarygradeISTSinan
surroundedbyapoorlydefinedreactivezone（Figure
elderlyRottweilerhadbeenpresentfor6years,
14.4),consisting of some orall of:
but wasbeginning tointerferewithwalking.
179
Chapter14Softtissuesarcomas
FelineISSshistoricallyariseinpopularinjection
oftenonlyconfirmthatthemassisofsofttissue
sitessuchasthedorsal interscapulararea.Recent
density(Figure 14.6).
workhasshownthat,followingpublicationofvaccine
Ultrasonography(especiallyDoppler)canbeuse-
guidelinesinthemid1990srecommendingvaccina-
ful toascertaindegreeoflocalvascularity,butcross-
tionintheextremities(toallowforamputationshould
sectional imaging-computed tomography(CT)or
a tumour arise),tumours are now arising with
magnetic resonance imaging (MRl) - is the imaging
increasingfrequencyinthehindlimbsandcaudal
methodofchoice,ifavailable，and istypicallysup-
flank（thelatterlikelydue tomisplacedinjections
portiveofthediagnosis,inadditiontoidentifying
designedforthepelviclimbsinsittingcats)(Shawet
accuratelytherelationshipofthemasstolocalvital
al,2009).FelineISSsarelocallyinvasive withan
structures.WhereasMRIistraditionallyregardedas
infiltrativegrowthpatternandwillregrowfollowing
superiorforsofttissue detail,CT(especiallycontrast
inadequatesurgery.Thereareoftencentrallylocated
CT)offersafast,simpleandaccuratealternativefor
micro-ormacro-abscessesgivingrise toa cystic
allbut the most complex STSs(Figure 14.7).It is
centre,yielding fluidonfine-needleaspiration(FNA).
Clinical approach
DiagnosticinvestigationofapossibleSTShasthree
aims:
Todiagnosethetumouraccuratelybefore
treatment
Todefinetheanatomicalrelationsof theprimary
tumourtosurroundingstructuresforsurgeryand/
orradiationplanning
Toidentifythepresenceorabsenceof metastatic
disease.
Biopsy
Fine-needleaspiration
FNAisoflimitedvalueindiagnosingSTS,because
cellsdonotexfoliateeasilyandclinicalpathologists
finditdifficulttodeterminewhetherthereiscancer
presentornotbasedononlyafewcells.However,
fine-needleaspirateshaveanimportantroleinruling
outothersubcutaneousdifferentials,such aslipo-
14.6
Plainradiographsof theextremitieswillshow
mas,mastcelltumoursorinflammatory lesions,all
themasstobeofsofttissueratherthanfat
ofwhichexfoliatecellseasily.Inauniversitysetting，
density,as in thisSTS of the caudal thigh.
fine-needleaspiratesofSTSsyieldedacorrectdiag-
nosis in62.5%cases,werenon-diagnostic in22.5%
cases,andanincorrectdiagnosiswasmadein15%
(Baker-Gabb et al.,2003).If an aspirate of a sub-
cutaneousmassfailstoyieldmanycellsontheslide,
theindexofsuspicionforanSTSshouldberaised
andshouldpromptacorebiopsy.
Corebiopsy
Percutaneous core biopsies(e.g.Tru-cut) are possi-
Ilium
blythebesttechniqueforsafelyachievinganaccu-
ratediagnosisandcaneasilybeperformedwith
local anaesthesiaandsedation.Tru-cutbiopsieswill
Myxos
reliablydifferentiatebenignfrommalignantdisease
na
andinmostcaseswillalsogiveagoodindicationof
grade.Thesimplicityandaccuracyofcorebiopsyfor
STSmeansthatincisionalbiopsiesareinfrequently
indicated,thereforeavoiding theaddedconcernsof
locationanddirectionofscar,andtumourdissemina-
tionfrompost-incisional biopsyhaematoma.
Evaluationofprimarytumourand
14.7
ContrastCTshowingagradellmyxosarcoma
possible metastasis
of theproximal right thighina dog.The close
anatomicalrelationshipwithboththefemurandpelvis
Radiographsofthemass
mayyieldsome
shows thatamputationalonewouldnotcurethisdog:
information regarding local behaviour (especially
hemipelvectomytoremovetheiliumwouldalsobe
whetherinvasionofunderlyingboneisevident),，but
necessary.
180
Chapter14Soft tissuesarcomas
oftencheaperthanMRl,ismoreintuitivetointerpret
14.8
ifinexperienced(astheimagesarevery similar to
conventionalradiographs)andit has theadded
GradeIPNSTover
advantagethatimagingthethoraxformetastaticdis-
thehockinan
elderlyGerman
easecaneasilybeperformed atthesametime.
ShepherdDog.
STSsmetastasizehaematogenously andlym-
phaticinvolvement isunusual.Anyfirm,irregularor
enlargedregionallymphnodesshouldbeevaluated
byFNA,Tru-cutbiopsy orexcisional biopsy.
Histologicalgrading
STSsare graded intolow(1),intermediate(ll)and
high (ll),taking into account histological features
suchasmitoticrate,extentofnecrosis,cellular dif-
ferentiationand cellular pleomorphism.Gradingof
STSindogsisconsideredmoreimportantforprog-
nosisthanthe cellof origin,becausegrade signifi
cantlyaffectslikelihoodofmetastasis(Powerset al,
1995;Kuntzet al.,1997).Reported metastaticrates
for the dogare:grade1,13%;gradell,7%;and
Patientswillpresentwithmusclewasting,single
grade lll,41%(Kuntz et al,1997).
forelimblamenessandoftenafirmpainfulmass
Silverstaining techniqueshavedemonstrated
deepin the axilla,or justanadversereaction to
thatincreasedAgNORcountintissuespecimensis
axillapalpation.Becauseofthecommonoccurrence
a significant prognostic indicatorfor decreased sur-
ofelbowandshoulderjointdiseaseleadingtolame-
vival time(Etingeretal.,2006).Onthestrengthof
ness,manyof thesetumoursgoundiagnosed for
this,AgNORsmaybecomepartofroutineevaluation
severalmonths.Electromyography todemonstrate
muscledenervationandCTorMRItoplansurgery
Gradeplaysanimportantroleintumoursofthe
arerecommended.Manycaseshave spinal cord
upperlimb,chestwallandflankwherewideexci-
invasion,andamputationcombinedwithalamin-
sions with tumour-free marginscanbe taken,but
ectomymaybenecessary.
mayhavealesserrolewhentumoursinvolve the
Invasionintothespinalcordisalsopossiblein
head and neck,retroperitoneum or distal limbs,
cats,but much less common than in dogs,repre-
wherespecificanatomicalrestraintsatthesesites
senting<5%of cases(Marioni-Henry et al.,2008).
preventwidecurative-intentexcision.Intheseloca-
tionstheamountoftumourexcisedorexcisablemay
Fibrosarcoma(FSA)
provetobemoreimportant thangrade.
Originating from neoplasticfibroblasts,fibrosarco-
mashavealow-moderatemetastaticrate.They
occurmost commonly on the flanks(dermal,sub-
Histological subtypes
cutaneousanddeepfascia)andoralcavity（see
Chapter15a).Non-oralFSAsbehavelikeSTSs.
Peripheralnervesheath tumour(PNST)
A specifictypeofFSA,thehi-lo，isencountered
andhaemangiopericytoma
inthe mouth ofyoung dogs,commonlyGolden
Thislargegroupoftumourscontainsneurofibrosarc-
Retrievers.Thisisabiologicallyhigh-gradebuthisto-
omasandmalignantschwannomasinadditionto
logicallylow-gradetumour,i.e.thebiopsy canbe
PNSTs.Somewhat contentiously,haemangioperi-
misleadingintermsofclinicalbehaviourandprogno-
cytomasarealsoincluded underPNSTs.Mosthaem-
sis.Aggressive surgical excision and fractionated
angiopericytomasdonotstainwithS100(markerfor
radiation therapyofa‘hi-lo'may stillresultinlocal
recurrenceand/ordistantmetastasis.
placehaemangiopericytomasinaseparategroupof
FSAinthecatiscoveredasaseparatecondition
“low-grade spindle cell tumours.However, recent
(see‘Felinesarcomas',below).
cytomasarelessfrequentandmoremalignantthan
Myxosarcoma
previouslybelieved(Avallone etal.,2007).Together,
Amesenchymalmalignancycharacterizedbythe
thesetumourstendtobelocallyinvasivebutmetasta-
production ofmucinous matrix,myxosarcoma can
sizerarely,especiallyhaemangiopericytomas.
PNSTsarisepredominantlyinthedistalextremi-
tionedandthetumoursaregenerallysoftertothe
tiesandtheycanbecomelargeandadherentto
touchthanotherSTSs.Otherwise theybehavebio-
theoverlyingskin(Figure 14.8).Infiltrationbetween
logicallyinasimilarfashiontootherSTSs.
theflexorandextensortendonsiscommon,making
manyoftheseexcisionsmarginalatbest,leaving
Rhabdomyosarcoma
residual tumour disease behind.These tumours
An STS originating from striated skeletal muscle,
canalsobederivedfromperipheralnervesclose
rhabdomyosarcomacommonlyarisesinthehead
tothe spinal column,most commonlyinthe
andneck,includingthe tongue,pharynx,larynxand
brachialplexus.
trachea.Tumourshavealsobeenreportedin the
181
Chapter14Softtissuesarcomas
urethra,bladderand cardiac muscle.Occasionally
drainingmesentericlymphnodesshouldbe
felineinjectionsitesarcomaswilldifferentiateinto
carefullyinspected,andbiopsysamplestaken,or
rhabdomyosarcoma.Manyrhabdomyosarcomasare
removediffirmorenlarged.
lowgrade,especiallyinthelarynx,anddifferentiation
Leiomyosarcomaoftheoesophaguspresents
fromrhabdomyomamaybedifficult.Treatment
lateinthecourseof thediseasebutappearsto
optionsaresimilar to thoseforotherSTSs,though
belowgradeandhasbeentreatedwithmarginal
marginalexcisionoflow-gradetumoursintheneck
excisionwithlong-termresolutionofclinicalsigns
mayresult inlongdisease-freeintervals.
(Farese etal.,2007).
Leiomyosarcomainthevaginamaybemanaged
Synovialcellsarcoma
byepisiotomyandresection,andoccasionally
Arising within joints,synovial cell sarcoma isa
totalvaginectomyifextensivediseaseispresent.
locallyaggressivetumourandthereforetypically
Paraneoplastichypoglycaemiahasbeen
painful.Bonedestructionisseenradiographically
associatedwithleiomyosarcoma.
inmanycasesbut isnotalwayspresent.Metastatic
rate ishigh,withupto22%of dogshavingmeta-
GISTsarisefrom theinterstitialcellsofCajal
stases atpresentation(Vail etal.,1994).Thestifle
(ICC),whicharepacemakercellsbelieved tocoordi-
isthemostcommonlyaffectedjointbutanycan
nateperistalsisintheintestinal tract.TheyareSTSs
be involved.
thatarise solelywithintheintestinaltract,most
Synovial cellsarcomasareunlikeotherSTSsin
frequently the caecum （see also Chapter 15)
that lymphnode involvement isfrequentlyencoun-
AppearingsimilartoleiomyosarcomaonH&Ehisto-
teredandstagingshouldincludeFNAofthedraining
pathology,they have subtleimmunohistochemical
lymphnodealongwithchestradiographs.Itis
differences(GISTsexpressCD117),butthishasnot
thought thatthis isfoundbecausemany‘synovial
beenshowntotranslateintoadifferentprognosis.
cellsarcomas'areactuallyahistiocyticvarietyof
Studieshaveshownnosignificantdifferencein
sarcoma.Immunohistochemical stainingfor cyto-
survivalbetweentumoursubtypesorwhether the
keratin,CD18,and smoothmuscleactin isrecom-
tumouris smallintestinal orcaecal.Animportant
mendedtomakethediagnosisofeithersynovialcell
difference,however,is that dogs with GiSTsare
sarcomaorhistiocyticsarcoma,andtherebypredict
significantlymorelikelytobeolder,andtopresent
thebehaviourofsynovial tumoursindogs.
withcaecalperforationandsepticperitonitis,than
Anyefforttopreservethejointbyincompletesur-
dogswithintestinalleiomyosarcomas,andthismight
gicalexcisiontypicallyresultsinrapidlocalregrowth
result in GiSTs having ahigher perioperative
andprogressionofdiseaseandpain.Attemptsto
mortality(Maas etal.,2007;Russellet al.,2007).
predictoutcomeintermsofgrade,cytokeratinstain-
ingandepitheloidversushistiocytictumourshave
Adiposetumours
beenlargely inconclusive.Themost importantprog-
nostic factors are cleanwide excision(typically
Lipoma
amputation),lackof metastasis at time of surgery
Lipomaisawellcircumscribedsoftmasswithina
and histological type.Inone study,theaverage sur-
thincapsuleandcanoccasionallygrowto
vivaltimewas31.8monthsfordogswithsynovial
considerablesize.Althoughthesubcutaneoussiteis
cellsarcoma,5.3monthsfordogswithhistiocytic
themostcommon,lipomashavebeendiagnosedin
sarcoma,30.7monthsfordogswithsynovialmyx-
thethoracicandabdominal cavitiesandpelviccanal.
omaand3.5monthsfordogswithothersarcomas
Indicationsforremovalincludesuddenrapidgrowth,
(Craig et al.,2002).
recentchangeintexture,causing clinical signsdue
Onepoorlyunderstoodphenomenonseenwith
toits space occupyingnature,botheringthe animal,
synovialcellsarcomainparticularisthatofpossible
bothering the owner,or interfering withnormal
(butunlikely)localrecurrence at theamputationsite
function.Lipomasincatsarerare.
andowners shouldbe warned of this.Again,this
maywellbedueto thepresence,inthose cases,of
Infiltrativelipoma
thehistiocyticsarcoma.
Mostcommonlyreported inthelimbsandflank,and
occasionally associated with joints,infiltrative lip-
Leiomyosarcomaandgastrointestinal
omasare poorlydemarcatedtumours,withthe
stromaltumours(GiSTs)
macroscopicappearanceofmaturefat,butmicro-
Leiomyosarcomaisa tumourarisingfromsmooth
scopicallythefatinfiltratesmusclefibres.Thereisno
musclecellsand ispredominantlyfoundinthewalls
obvioustumourcapsuleandCTorMRl isnecessary
ofthe alimentary andurogenital tract,whereit
toadequatelyplansurgeryandidentifypotential
resultsinclinical signsduetoitsphysicalpresence
risks(McEnteeandThrall,2001).Infiltrationbetween
(luminalobstruction/organdeviation),orthrough
musclebelliesandaroundneurovascularstructures
ulceration(vaginal bleeding,melaena).Rarelyit may
makes surgery anintra-lesional dissection(Figure
involveoverlyingsubcutaneousspacesorskin.
14.9).Cobaltradiation therapyhasbeenusedwith
some success tocontrollocaldisease following
Small-intestinal leiomyosarcomatreatedby
debulking surgery,witha median survival of 40
resectionanastomosiswith3-5cmmargins
months reported (McEntee et al.,20o0).These
usuallyresults intumour-free margins,but the
tumoursdonotmetastasize.
182
Chapter14Soft tissuesarcomas
Infiltrating fat
sparselyhaired dogs(Beagle,white Bulldog,English
UIna
PointerandDalmatian)havealsobeenreportedas
Muscl
predisposedtothedevelopmentofcutaneousand
Radius
subcutaneous HSA.It ispossible that unpigmented
skinincatsmayalsobepredisposedtodeveloping
dermal HSA.It hasbeen suggested that cutaneous
haemangiomasmayundergomalignanttransforma-
tiontoHSA,but thisappearsless likelywith thesub-
cutaneousform.
Indogs,most cutaneous HSAsarewelldefined
superficialmassesthatareamenabletolocalexcision
and thatmetastasize slowly,ifatall.Subcutaneous
HSAtendstobeamorelocallyinvasive,problematic
tumour.Infiltrative tumours，plus those with hypo-
(a)
dermalormuscularinvolvement,seemtohaveahigh
recurrencerateand incidenceofmetastasis.
Incats,dermal and subcutaneous HSAs are
morecommonthanthevisceralformandaretreated
primarilybysurgery.Attainingatumour-freemargin
followingsurgeryismorelikelywithawelldefined
dermalmassandthistranslatesintoalongerrecur-
rence-free interval,whereasmarginsofnormal tis-
suecanbedifficulttoidentifywithsubcutaneous
HSA because of localized bleeding and bruising.
Inone study 50%catswithsubcutaneous HSA
suffered local recurrencefollowing surgery,while
noneofthecatswithdermalHSAhadrecurrence
(Johannes et al.,2007).Subcutaneous HSA is par-
ticularlydifficulttomanagewhenitarisesinthe
ventral（Figure 14.10)oringuinalareasasthese
(b）
tumoursareoftentoolargetotreatbythetimeof
14.9
Infiltrativelipoma.(a) CTimages show an area
diagnosis(McAbee et al.,2005).Ahigh mitotic count
of fatdensitypushingbetweenthemusclesof
(>3/10hpfs) isassociatedwithapoorersurvival in
therightlimb.(b)Intra-lesionalexcision.Umbilical tape
cats(Johannes et al.,2007).It is likely that themeta-
can be seenretracting andprotecting anerve.Gross
tumourwillbeleftbehind andpostoperativeradiation
staticrateoffelinesubcutaneousHSAishigherthan
shouldbeconsidered.
previouslythought(Krajeet al.,1999).
Liposarcoma
Amalignantmesenchymaltumourderivedfromadi-
pocytes,liposarcomacanoccurequallyontheflanks
and thelimbsandoccasionallyinbodycavities.The
tumoursarelocallyinvasiveandmediansizeatpres-
entationis4cm.Recentworkhasindicatedthattheir
metastaticpotentialmaybelowerthanpreviously
believed.Awideexcisionisassociatedwitha
mediansurvivalof1188days,comparedwith649
daysfora marginalexcision(Baezetal.,2004).
Haemangiosarcoma
VisceralHSA
HSAismostoftenconsideredavisceraldisease,
withinternalorganssuchasthespleen,liverand
heartbeingcommonlyaffected.It isahighlymalig-
nanttumour,withdeathtypicallyoccurringwithin6
months throughwidespread systemicmetastases,
14.10
SubcutaneousHSAof theventral neckina cat.
despite theuseofchemotherapy(seeChapter19).
Chestradiographsrevealeddisseminated
metastaticdisease.
DermalandsubcutaneousHSA
DermalHSAisbiologicallymuchmorebenign than
Radiationtherapyforunresectableorincom-
theaggressivevisceralform.It isreportedmorefre-
pletelyexciseddermal orsubcutaneousHSAhas
quentlyinbreedssuchaslrishWolfhound,Whippet,
beenpoorlyreportedindogsandcats.Arecent
Saluki,Bloodhound andpointers.Lightlypigmented,
reportdescribedtheuseofpalliativeradiationto
183
Chapter14Softtissuesarcomas
treatnon-splenicHSA indogs:20patientswere
givendosesofeither6or8Gytoamaximumof
spleen.RottweilerandGoldenRetrieverarethe
24Gy;a subjectivereductionin tumour sizewas
breedsmorecommonlyaffected(Goldschmidtand
seenin70%anda completeresponseseenin20%,
Hendrick,2002).Long-term local control is possible
but the median survival time(MST)was only95
withsurgeryalone,orcombinedwithradiation
days(Hillers et al.,2007).Chemotherapy for sub-
(McKnight et al.,2000).
cutaneoustumourshasbeendescribed,withcom-
monlyusedagents being doxorubicin,vincristine
Felinesarcomas
and cyclophosphamide,butthereislittleevidenceto
Three typesof sarcoma areseenincats:viral-
show anybenefit.
induced;non-viral non-vaccine;and injection site
AlthoughtheprognosisfordermalHSAinboth
sarcoma.
dogsandcatsisgood,nodifferenceinoverallsur-
vival indogshasbeenfoundbetweenvisceraland
Viral-induced(felinesarcomavirus,FesV)
subcutaneousHSA,whereas incats the subcutane-
Theseareseenincatsalsopositiveforfelineleuk-
ousformislessaggressivethanthevisceralform
aemia virus （FeLV).FeSVoncogenes transform
(Sorenmo et al.,1993;Johannes etal.,2007).Stage
fibroblastsandproduce FSA.Thesearerare,
1HSA（tumour<5cm,doesnotinvadebeyondder-
accounting for 2%of FSA;they are seen inyoung
mis)hasalongMSTwithsurgeryaloneof780days
catsandaretypicallymulticentric.Arapiddoubling
indogs and36months incats.Stage2(invades
time （12-72 hours) is possible. Surgery will not
subcutaneous tissue)andstage3(invadesadjacent
benefit thesepatients.
muscle)carryapoorerprognosis.
Non-viral,non-vaccine
Lymphangiosarcoma
Usuallyseeninoldercats,thesesarcomasaffectthe
InadditiontobehavinglikeanySTSwhereolder
head,neckandextremities（Figure14.11).
patientsaremoreatrisk,lymphangiosarcomas can
alsoaffectyoungerdogsandcats,oftenwithsoft
fluctuantswellingsarisingalongtheventralbody
wall,theinguinalareaoraround theproximal thigh.
Themassesaresoftandeasilycompressible,some-
timesadoptingthefeelofbubble-wrap'.Cleartrans-
udatecanbeeasilyexpressedfromanyskin
puncture（e.g.throughaneedle tract forTru-cut
biopsy).Duetoanatomicallocation,oftenwideexci-
sionmeansamputationandreconstructionwith
myocutaneousflaps.Theprognosis isguarded due
toriskfor localrecurrenceattheamputation site,
andreportedlyincreasedriskofmetastasis.Thereis
noknownbenefittogivingchemotherapy.
Histiocyticsarcoma
Arisingfrommyeloiddendriticcells,theseraremalig-
14.11
Fibrosarcomaontherostraledgeof thepinnain
nant tumours behave like otherSTSs,buttend to
anelderlycat.Thiswastreatedby3cm
havea highermetastaticpotential (see later).They
excision,pinnectomyandtotalearcanalablation,and
should notbeconfused withhistiocytomas(benign
closedwithasingle-pedicleadvancementflapfromthe
cutaneousroundcelltumoursoftenseeninjuvenile
dorsalneck.
dogs thatcanundergospontaneousregression
within3months).Histiocyticsarcomasarelocalized
Feline injection site sarcoma (Iss)
massesarisinginthe subcutaneous tissues,butpri-
Feline ISS(seeFigure 14.3)is alsoreferred to as
marytumoursaffectingjointshavealsobeen
vaccine-associatedsarcomainsomepartsofthe
described(Craiget al.,2002).They are locallyinva-
world.Thisis dueto theprovenstatisticallinkto
sive tumours,aregraded according toSTSguide-
vaccinationinjections,particularlyFeLVandrabies
linesandareprimarilytreatedsurgically.
virusvaccines,enhancing theriskofISSby2-5-fold.
Theymayrepresentanearlyformofthedissemi-
Catsareyoungerthanthoseinthenon-vaccinesar-
nateddisease,malignanthistiocytosis,whichisarap
comagroup.Thereisanincreasedriskwithincreas-
idlyprogressivesystemicformmostcommonlyseen
ingnumberofvaccinations,andwithrepeated
intheBerneseMountainDog:Rottweilerandretriev-
vaccinationat the same site （Kass et al.,1993,
ersarealsoaffected.Dogswithdisseminateddisease
2003).Tumours usually arise2-10 months aftervac-
presentwithanorexia,weightlossandoftenpulmo-
cination,anda riskof0.32sarcomas/10,000doses
narysignsandarepoorlyresponsivetotherapy.It
givenhasbeenreported (GobarandKass,2002)
carriesagraveprognosis(FulmerandMauldin,2007).
However,ISSshavealsobeenseenfollowingother
injections in cats.
Malignantfibroushistiocytoma(MFH)
ISSsaremostlyfibrosarcomas,butrhabdomyo-
Theseareoftenconfusedwithhistiocyticsarcomas,
sarcoma,osteosarcoma,chondrosarcoma etc.are
butarea separatememberoftheSTSfamily,
alsoseen.MSTsforcatswithFSAorPNSTare
184
Chapter14Softtissuesarcomas
significantlylongerthanmediantimeforcatswith
Marginsforsurgicalresection
MFH(Dillonetal.,2005).Aninflammatoryreactive
OurunderstandingofmarginsforexcisingSTSsis
granuloma isseen11.8times/10,000dosesofvac-
basedonEnneking'spioneeringworkinmusculo-
cineincats,butit isnotnecessarytoremove these
skeletal tumours inhumans,whereby he classified
massesunlessmalignantbehaviourisapparentor
resectionmarginsasintralesional/intracapsular,mar-
theypersistover3months(GobarandKass,2002).
ginal,wideorradical(Enneking etal.,1980).
ISSsarenotlinkedtoFeLVorFIVinfection,butthe
aluminiumadjuvantmayplayaroleincarcinogene-
Anintracapsularmarginisachievedby
sis,asmight theinflammationinduced byanycom-
piecemealremoval('debulking')ofalesionfrom
ponent of the injectate.
withinthecapsule.Thisisalsoused if the
ISSsaregradedfromI(leastaggressive)toIll
capsuleisaccidentallyenteredduring dissection
（mostmalignant)dependingonmitoticindex,differ-
asthesurgicalfieldisnowcontaminated.Gross
entiationandnecrosis.Multinucleatedgiantcellsare
and/ormicroscopicdiseaseremains.Examples
seeninthemoremalignanttumours,andmosthave
includeincisionalbiopsyandinfiltrativelipomas
peritumoral lymphocyteinflammationandincreased
(seeFigure 14.9b).
vasculardensity.Recentevidencehassuggested
Amarginalmarginisachievedbyan
thata higher grade (i.e.grade lll) is associated
extracapsulardissectionthroughthereactive
withanincreasedriskofmetastasis(Romanelliet
zonearound theSTS.Classicallytheseare
al.,2008).
termed'shell-outs'andinvolvepeelingthemass
outfromitstissuebedandofflocalattachments.
Bothbenignandmalignantlesionsmayhave
Managementandprognosis
extracapsularmicroextensionsofdisease
microsatellites（inthereactive zone),and'skip
Surgicalresectionisthemosteffectivetreatmentfor
metastasesofhigh-gradelesions(innormal)
primarylocalizedSTSs,astheyarerelativelychemo-
tissueof thesame compartment；seeFigure
insensitive,andradiotherapyismore effective at
14.4).Thesehaveimplicationsformarginal
treatingmicroscopicdiseasethanunresectablegross
excisionsintermsofpotentialforlocalrecurrence
disease.Theaimofcurative-intent surgeryisto
（Figure14.13)
widelyexcisetheprimary tumour(3cmwideand3
Awidemarginisachievedbyenblocremovalof
cm orafascialplanedeep)andachievehistopatho-
thelesion,itscapsule and thesurrounding
logicalmarginsclearof tumourcells(Figure14.12).
reactivezonebutalwaysworkinginnormal
uncontaminatedtissuewithinthecompartmentof
thelesion.Non-neoplastic,non-reactive
intracompartmentalnormaltissueisleftatthe
marginsand thereisthepossibilityof‘skip
metastasesarisingintheremainingportionofthe
compartment(e.g.high-grade STS).
Aradicalmarginremovesthelesion,reactive
zoneandallthetissueoftheassociated
compartment.Thereisnopotentialforresidual
neoplasmlocally.Thetypicalexampleis
amputation,alongwithvariantssuchas
hemipelvectomy.
14.12
GradeISTSofthelateralstifle.Anoutlineofthe
subcutaneousmassisdrawn,followedbya
cm skinmargin.Thistypeof preoperativeplanning helps
inchoosingreconstructiveoptionsbeforeexcising the
tumourenbloc.
Thegreatvariationinpossiblelocation,factored
withvariablesizeandgrade,canpresentsignificant
problemswhendesigningatreatmentplananditis
complicatedbyanatomicalconstraints,theneed to
maintainlocalfunction,biological characteristicsof
thetumour,andlength andcost of surgery and
reconstruction.Wheneverconcernsexistaboutthe
feasibilityofasinglecurativeexcisionduetothesite
14.13
Amarginalexcisionof themassshowninFigure
orsizeof themass,it isbest toconsult witha
14.5.The deepmargin of themasswaspeeled
off thepectoral muscles.Residual disease was assumed.
radiation oncologistprior to definitive surgery，as
Giventhe ageof thedogand theslow-growing historyof
preoperativeradiationtosterilizethetumouredges
themass,theowneroptedforaconservativepalliative
mayallowforasmallersurgerytobeperformed.
surgerytoimprovequalityof life.
185
Chapter14Softtissuesarcomas
Upperlimb
ratioofatleast1partmassto10partsformalin.On
Theabundanceofskinontheneckandflanksof
processingand interpretation,inkedmarginsassistin
mostpatientsmeans thatwideresectionsofthe
orientationoftheresectedtissue.Additionally,identi-
upperlimborflankarepossibleandcomplexrecon-
fying tumourcellsininkedtissuerepresentstumour
structivetechniquesareoftenonlyindicatedinawk-
at thewoundedge,andsoanincompleteexcision.
wardanatomicallocations,forexamplearoundthe
Largertissue masses may need tobebread-loafed”
perineum.Radiationhasaveryvaluableroleif
priortofixing,astheformalincannot diffusetoatis-
incompletemarginsarefoundandiffurtherrevision
sue depth of >1cm.Alternatively, some surgeons
surgeryisdeclined.Becauseextensivereconstruc-
prefertotiesmallsutureknotsatlocationswhere
tionsresultinoftenverylargeradiationfieldsbeing
concernexistsoverthewidthofthenormaltissue
requiredpostoperativelyiftheresectionwasincom-
margin，toencouragethepathologisttoexamine
plete,complicatedandextensivereconstructive
these areas morecritically.
techniquesareingeneralavoidedwherepossible
until thecompletenessofresectionisknown.lt must
TreatmentofextremitySTS
berememberedthatradiationintheareaoftheaxial
Treatmentoptionsforahistologicallydiagnosed
skeletoncanhavelatesideeffects.
extremitySTSinclude:
Distallimb
Amputation
Inthedistallimbs(at/belowthestifleandat/below
Curative-intentexcisionplusradiationif
theelbow),whereawide surgical marginof skin is
tumourcellsextendtotheedgeofresected
usuallyonlyachievableusingfreeskingraftsorvari-
tissuemicroscopically(seenotesaboveon
ousskinflaps,optionssuchasamputationormar-
extensivereconstruction)
ginalresectionandradiationaretheprimary
Preoperativeradiationtosterilizetissuearound
methodsof tumourcontrol.Bothoptionshavedraw-
thetumour,withmarginalexcisionof mass4
backsinterms of altered function,morbidityand
weekslater
cost.Whereasamputationcouldbeexpectedtocure
Plannedmarginalexcisionof mass,then
apatient,thelimbmightbesparedwithmarginal
postoperativeradiationtosterilizeresidual
excisionoftheSTSandradiation,butthisiscostly
tumourinthewoundbed2weekslater
andresultsinalocalrecurrencerateof19-35%.
Skin-sparingsurgery-plannedmarginal
excisiontomicroscopicdisease,includingfascia
Tissue slip
wherepossible,butensuringwoundcanbe
Following someresections it can be seen that the
closedwithoutadvancedreconstruction.
variouscomponentsoftheresectedtissuemoveover
each other(slip).For example,thetissues deep toa
The firstfouroptionsarecurative-intentplans
and local recurrence isunlikely.Skin-sparing surgery
thebaseof thetumour.Inordertogetaccurateinfor-
isapalliativeplan,andtheowneracceptsthatlocal
mationfrom an examinationofmargins,manysur-
recurrence is a possibility. For many geriatric
geonssuggestreconstructingtheresectedtissueinto
patientswithlow-gradeSTS,thisisaviableoption
theposition and formpresent in theanimal.Thisis
withtheexpectationthat thepatientwilldieof
doneusingsuturesthroughthevariouslayersatthe
somethingelsebeforethetumourhasachanceto
margins.Edgesoftheresected tissue(skinmargin
recurormetastasize.
anddeepmargin)shouldthenbeidentifiedbypaint-
ingwitha thinlayerofIndiaink(Figure 14.14),left to
Plannedmarginalexcision
dry，and thenplaced into10%formalintofix,ata
Without presurgical biopsies,inadvertent shell-out
proceduresonmassesassumed tobebenign that
subsequentlyturnouttobemalignantrepresentan
unfortunatelycommonbuteasilyavoidableclinical
scenario.Thedifferencebetweenplannedand
unplannedmarginal excisionsisasfollows.
Inplannedmarginalexcisions,typicallyinthe
distalextremities,thesurgeonhasperformeda
biopsyofthemassandisawarethatthesurgery
isanincompleteexcisionofanSTS.Local
recurrenceisanticipatedandsothesurgeon
attemptswhereverpossibletoworkoutsidethe
pseudocapsuletoexcisetheinfiltrationofthe
tumourintothesurroundingtissues.Wide
marginsarenotpossiblewithoutreconstructive
14.14
Toprevent'tissueslip'，thedeepfasciais
techniques(whichhavebeendiscussed and
suturedto theskinedgetoensure thatinkdoes
not'under-run'thefascial layer,givingmisleadingresults
declinedbytheowner)andsotheaimisto
ontumourmargins.Athinlayerof Indiaink(coloursother
remove asmuchtumouraspossible,butstill
thanredrecommended)isappliedtothecutsurfaceswith
close theskinoverthewound.This skin-sparing
a cottonbud.
surgerymaystillinvolveexcisingfasciabeneath
186
Chapter14Softtissuesarcomas
themass.Atsomepointduring thesurgerythe
15%(Figure 14.16).Tumour maybe found in only
pseudocapsuleisentered(normallywhen
22%ofresectedscarsonhistopathologybut its
peelingtumouroffskin)andsothesurgeryis
classifiedasmarginal.Arecurrencerateindogs
havelocalrecurrence(Baconet al.,2007).
of11%forthistechniquehasbeenreported
whenperformedbyexperiencedsurgeonsandall
STSs were grade I (Stefanello et al.,2008).
Anunplannedmarginalexcisionisatrue
‘shell-out',workinginthepseudocapsuleof an
unknownmass.Fasciaisnot taken,and small
macroscopicdiseasemayremain.Asno
attemptismadetoreducethechanceof
recurrencebywiderdissection,local recurrence
isconsideredlikely.
Incompleteexcision
IffacedwithanincompletelyexcisedSTS(so-called
‘dirty margins'),treatment options include:ampu-
tation(if on a limb);postoperativeradiation;re-
excision;or'waitandsee'
14.16
A'dirty’scarovertheelbowof adogisbeing
Amputation(ifonalimb):Thisshouldbelocally
excisedwith3cmmargins.Theantebrachial
curative,assuming the scarandprevious tumour-
fascia(inforceps) is forming thedeepmargin.The
contaminatedsurgicalwoundarenotenteredduring
residual tumourwascompletelyexcised.
amputation.Theriskofmetastasisremains.
Waitandsee:Formanyownersthisisanunder-
Postoperativeradiationtosterilizetumourbed:
standablechoice.Thefailurerateformarginalexci-
Severalstudieshavereportedtheresultsofadjunc-
sions in dogs is historically quotedas 60-70%，
tiveradiotherapyinthemanagementofSTSwith
basedonworkperformed20-30yearsagoongrade
surgicallyincompletemarginsanditssuccesshas
Illsarcomaswithunknownmarginstatus,butmuch
generallybeenmeasuredbyitslongoverallsurvival
haschangedsinceintermsofunderstandingtumour
times.The effectonlocal tumour control,however,
biologyandespeciallyearlierinterventionbyowners.
hasbeenvariable,with recurrence rates ranging
MarginalexcisionofgradeIsarcomasmayhavea
between 17%and31%(Figure14.15)(Forrestet al.,
localrecurrencerateaslowas11%,andsotherate
2000;McKnight et al.,2000).
forgradelltumoursislikelytobesomewhere
between11%and70%
14.15
Recurrence of
anSTSin the
Chemotherapy
radiationfieldonthe
STSs are not considered chemosensitive.It is
antebrachiumofadog.
known that>40%of dogswithgradeIllSTSwill
developdistantmetastaticdisease （Kuntz etal.,
1997)andso theadditionofconventionalchemo-
therapydrugstotrytocontrol thissystemicspread
issensible.Littleevidenceexists,however,toshow
abeneficialeffectofchemotherapyonoverallsur-
vival.Doxorubicinasasingleagentfailedto
improvedisease-freeintervaloroverallsurvivalin
dogs with grade IllSTS （Selting et al.,2005).
Recentworkfollowingdogswithincompletely
excisedSTSreceivingdailyoral low-dosecyclo-
phosphamide(10mg/m²)and full-dosepiroxicam
(0.3mg/kg)showed ittobeveryeffectiveatdelay-
inglocalrecurrencecomparedwithacontrolpopu-
lationandcouldbeconsidered indogswithdirty”
wounds(Elmslieetal.,2008).
Radiotherapy
Useofradiotherapyasasoletreatmentforunre-
Re-excisionofscarwithlocalclosuretech-
sectableSTShasreceivedrecentattention.Astudy
niques:Even inthedistal limbs,wherethereis little
ofdogswithmacroscopicSTSreceivingfourfrac-
availablesofttissue,re-excisionofthescarwithas
tionsofradiation（totaldose32Gy)inapalliative
wideamarginaspossible(still toclose thewound
settingshowedthatthetreatmentwaswelltoler-
primarily)canresultincleanmarginsofexcisionin
ated,withanoverallresponserateof50%,butthis
over90%ofcasesandalocalrecurrencerateof
wasashort-lived improvementasmediantimeto
187
Chapter14Soft tissuesarcomas
progression was 155 days(Lawrence et al.,2008).
SurgeryforfelineIss
Cobaltradiationwasadministeredinthreefractions
Thegeneralapproachofsurgicalmargins2-3cm
(total dose 24 Gy)to dogs with non-resectable STS,
wideandonefascialplanedeeptothetumourbed
andmediantimetoprogressionwas263days
hasbeenadoptedforISSincats,buteven thismay
(Plavecetal.,2006)
notbeadequateconsideringhistoricalratesoflocal
recurrence.Some surgeons are suggesting more rad-
ManagementoffelineIss
icalmethods,includingsurgicalmarginsof≥3cmand
Thepresenceof metastasishasbeenshowntosig-
1-2fascialplanesdeeptothetumour,alongwithpar-
nificantlydecrease survival timeincatswithISS
tialscapulectomy,osteotomyof spinousprocesses
(Cohen et al.,2001;Sorensen et al.,2004),under-
(Figure14.18)orhemipelvectomy whenindicated
lyingtheimportanceofpreoperativestagingpriorto
(Cohen et al.,2001;Seguin,2002;Kobayashi et al,
2002;Daviset al.,2007;Romanelliet al.,2008)
minimum andcross-sectional imagingsuch ascon-
trastCTorMRlisrecommendedtodelineatethe
tumour.From apractical pointofview,theveteri-
narysurgeonwhoislikelytoperform thesurgery
should ensurethatthecatisplaced inanappropri-
atenormalanatomical positionduring cross-
thetumourandanatomicallandmarkscanbe
assessed accurately.Thisaidsinsurgicalplanning
(Figure 14.17).Palpationmay suggest a discrete
mass,butpost-contrast CT often shows the true
extentofinfiltrative disease,whichcannotbe
appreciatedbyfeelalone.Radicalfirstexcisionof
ISSyieldedsignificantlylongermediantimetofirst
sion(79 days)(Hershey et al.,2000).MST is signif-
14.18
Usingbonecutterstocut thedorsal spinous
icantlylongerincatswithtumours<2cmin
processes ina cat during ISSresection.The
diametercomparedwiththosewithtumours2cm
surgeon ismovingfromcranialtocaudal.Thedorsal border
indiameter(Dillonetal.,2005).
of thescapulaintheforeground has alsobeenresected.
Locationof tumour
Leg
Other
Proximal
Distal
CT
CT
Resectablewith
Notresectable
widemargins
withwidemargins
Hemipelvectomy
Disarticulation
Resect3-5cm
Preoperative
Amputation
margins
radiation48Gy
Resect3-5cm
Histopathology
Histopathology
Histopathology
margins
Postoperative
Histopathology
radiation54-57Gy
Adjuvanttherapy
Radiation±
Consider
Adjuvant
chemotherapy
chemotherapy
chemotherapy
14.17
Treatment planning infelineISS.
188
Chapter14Softtissuesarcomas
Currently,theVaccine-AssociatedSarcomaTask
surgery，radiation(pre-orpostoperative)andchemo-
Forcerecommendsmultimodaltreatment,including
therapy.Ratesof metastasisrange from 5.6%to
22.5%(Cohenet al.,2001;Kobayashietal.,2002;
planes,withmentionofuseof3-5cmsurgicalmar-
Poirieretal.,2002;Romanellietal.,2008).
gins for excision(VASTF,2005).When such large
Pulmonary metastasis is most commonly reported,
surgeriesareperformed,epiduralanalgesia,local
withothersitesincludingregional lymphnodes,skin,
tissueinfiltrationwithbupivacaineprior toclosure，
intestine,spleen,epidural and cularinfiltration,or
anda constantrate infusion(CRl)offentanyl,orfen-
multi-organ involvement （Hershey et al.,2000;
tanyl patches,should beused.
Kobayashiet al.,2002;Cohenet al.,2003;Chang et
al.,2006).
ChemotherapyforfelineISS
AlthoughthereareisolatedreportsofISSresponding
PreventionoffelineISS
todrugs such as doxorubicin,cyclophosphamide，
Preventivemeasuresinclude:
mitoxantroneandcarboplatin,thereislittleevidence
inlargernumbersofcatswithISSthatadjuvant
Not over-vaccinating
chemotherapyimprovesoverallsurvival(Bregazziet
Keepingdetailedvaccinationrecords
al.,2001;Martano et al.,2005).However,it may
Vaccinatinginlocationsthatcanbeeasily
delaylocalrecurrenceincatsalsoreceivingcurative
resected in thefuture(e.g.mid-distalthigh,
intentradiation therapy(Hahnet al.,2007).
treatablebyamputation)
Excisingorbiopsyingvaccine-sitereactionsthat:
RadiationtherapyforfelineISs
。
Persistover4months
AlthoughISSresponsetoexternalbeamradiation
Are>2cmindiameter
canbeunpredictable,itplaysanimportantrolein
Increaseinsize1monthaftervaccination
largefixedtumourswhereCTshowsthatachieving
(Hershey et al.,2000).
tumour-freemarginsbysurgeryalonewillbedifficult.
Preoperativeradiationwillsterilizethereactive
Referencesandfurtherreading
zoneandsurrounding'clean'tissuesandsoallow
forapotentiallysmallerresectiontobe
Al-SarrafR(1998)Update onfelinevaccine-associated fibrosarcomas.
VeterinaryMedicine93,729-735
performed.
Avallone G,Helmbold P,Caniatti M et al.(2007) The spectrum of
Postoperativeradiationcanbeusedwhena
canine cutaneous perivascular wall
tumours:morphologic.
curative-intent surgeryhasbeen unsuccessful
phenotypicandclinical characterization.VeterinaryPathology44,
607-620
andresidualtumourdiseaseremains(see
Figure 14.17).
excisionafterrecentinadequateresectionofsoftissuesarcomas
indogs:41cases(1999-2004).Journalof theAmericanVeterinary
Theorientationof thescarisanimportantfactor
MedicalAss0ciation230,548-554
BaezJ,HendrickM,ShoferFetal.(2004)Liposarcomas in dogs:56
inlimitingradiationsideeffects:ascarinthemidline
cases(1989-2000)Journalof theAmericanVeterinaryMedical
paralleltothespinewillresult inminimal dosetothe
Association224,887-891
Baker-Gabb M,Hunt GBandFrance MP(2003)Soft tissue sarcomas
spinal cord,asthebeamscanbe targeted from lat-
andmastcelltumours in dogs;clinical behaviourandresponse to
erallyto'skyline'thescar.lf thescarrunsperpendic-
surgery.AustralianVeterinaryJournal81,732-738
ulartothespineandextendsdownoverthethoracic
BanerjiNandKanjilal S.(2006)Somatic alterationsof thep53 tumor
suppressorgene invaccine-associatedfeline sarcoma.American
wallonbothsides,thenthereisamuchgreaterrisk
JournalofVeterinaryResearch67,1766-1772
ofincludingthespinalcordwithintheplannedtreat-
BregazziVS,LaRue SM,McNiel Eet al.(2001）Treatment with a
mentvolume.
andradiationaloneforcatswithvaccine-associatedsarcomas:25
Thepostoperative treatmentisstarted10-14
cases(1995-2000).Journalof theAmericanVeterinaryMedical
daysaftersurgerywhenthesurgicalsitehasalready
Association218,547-550
Chang HW,Ho SY, Lo HF et al. (2006) Vaccine-associated
healed.lfradiationisgivenpreoperatively,thedose
isoftenlowertoavoidoverlydamagingtheskinand
metastasisinacat.VeterinaryPathology4355-58
CohenM,SartinEAWhitleyEMetal.(2003）Ocularmetastasisofa
soreducetheriskofcreatinganon-healingwound
vaccine-associatedfibrosarcoma
inacat.Veterinaryand
following surgery.
ComparativeOncology1,232-240
CohenM,WrightJC,BrawnerWRetal.(2001）Useof surgeryand
Prognosis:Usingpreoperativecobalt60incombi-
electronbeamirradiation,with
orwithout chemotherapy，for
treatmentofvaccine-associated
sarcomas in cats:78 cases
nationwithsurgery,mediantimetorecurrencewas
(1996-2000).Journal of theAmerican VeterinaryMedical
2.7yearsfollowingcompleteexcisionand0.8years
Association219,1582-1589
Craig LE, Julian ME and
ifincompletely excised(Kobayashi et al.,2002).
Ferracone JD(2002)The diagnosis and
prognosisof synovialtumorsindogs:35cases.Veterinary
Surgeryfollowedbymegavoltageradiationgave
Pathology39,66-73
mediansurvivalsof23-24months,buttimetorecur-
CroninK,Page RL,Spodnick Getal.(1998）Radiation therapy and
renceandsurvivalweredecreasedwhentimeto
Ultrasound95156
surgeryandstartingradiationwasincreased
DavidsonEB,Gregory CRandKassPH(1997)Surgicalexcisionof soft
(Bregazzi et al.,2001;Cohen et al.,2001).
tissuefibrosarcomasincats.VeterinarySurgery26,265-269
DavisKM,Hardie EM,Lascelles BDetal.(2007)Feline fibrosarcoma:
Reportedratesoflocalrecurrencerangefrom
perioperativemanagement.Compendium:ContinuingEducationfor
25%to60%(Kobayashiet al.,2002;Martanoet al.,
Veterinarians29,712-729
2005;BanerjiandKanjlal,2006;Hahn et al.,2007;
DernellWS,WithrowSJ,KuntzCAetal.(1998)Principlesof treatment
forsoft tissuesarcoma.ClinicalTechniquesinSmallAnimal
Romanellietal.,2008)aftervariouscombinationsof
Practice13,59-64
189
Chapter14Softtissuesarcomas
DillonCJ,MauldinGNandBaerKE(2005)Outcomefollowing surgical
Maas CPHJ,Ter HaarG,Van der GaagIetal.(2007)Reclassification
removalofnonvisceralsofttissue sarcomas incats:42cases
（1992-2000)Journalof theAmericanVeterinaryMedical
clinical,histologicandimmunohistochemicalevaluation.Veterinary
Association227,1955-1957
Surgery36,302-313
DobsonJM,SamuelS,MilstinHetal.(2002)Canineneoplasiainthe
Macy DWand HendrickMJ(1996）Thepotential roleof inflammation in
UK:estimatesof incidenceratesfromapopulationof insureddogs.
the development ofpostvaccinal sarcomas in cats.Veterinary
Journalof SmallAnimalPractice43.240-246
Clinicsof NorthAmerica:SmallAnimalPractise26103-109
Doddy FD.Glickman LT,Glickman NWet al.（1996)Feline
Marioni-HenryK,VanWinkleTJandSmith SH(2008)Tumorsaffecting
fibrosarcomas atvaccination sites andnon-vaccination sites.
the spinal cord of cats:85cases (1980-2005) Journal of the
JournalofComparativePathology114165-174
AmericanVeterinaryMedicalAssociation232,237-243
ElmslieRE,GlawePandDow SW(2008)Metronomictherapywith
MartanoM,MorelloM,UghettoMetal.(2005)Surgery alone versus
cyclophosphamideandpiroxicameffectivelydelays
surgeryanddoxorubicinforthetreatmentoffelineinjection-site
recurrenceindogs withincompletelyresectedsoft
tissue
sarcomas:areporton69cases.TheVetJourna/170,84-90
sarcomas.JournalofVeterinaryInternalMedicine22,1373-1379
McAbee KP,Ludwig LL,Bergman PJ et al.(2005）Feline cutaneous
Enneking WF,SpanierSSandGoodman MA（1980)A system for the
hemangiosarcoma:aretrospective study of 18cases(1998-2003).
surgicalstagingofmusculoskeletalsarcoma.ClinicalOrthopaedics
Journalof theAmericanAnimalHospitalsAssociation41110-116
and RelatedResearch153,106-120
McEntee MCandThrall DE(2001)Computed tomographicimaging of
EttingerS,ScaseTandOberthalerK（2006）Associationofargyrophilic
infitrativelipomain22dogs.VeterinaryRadiologyandUltrasound
nucleolar organizing regions,Ki-67,and proliferating cell nuclear
42,221-225
antigenscoreswithhistologicgradeandsurvivalindogswithsoft
McEnteeMC,PageRL,Mauldin GNetal.(200o）Resultsof irradiation
tissue sarcomas:60cases（1996-2002).Journalof theAmerican
ofinfiltrativelipomain13dogs.VeterinaryRadiologyand
VeterinaryMedicalAss0ciation228,1053-1062
Ultrasound41.554-556
Farese JP, Bacon NJ. Ehrhart NP et al. (2007) Oesophageal
McEntee MC and Samii VF (20oo) The utilityof contrast enhanced
leiomyosarcomaindogs:surgicalmanagementandclinical
computedtomographyinfelinevaccineassociatedsarcomas:35
outcomeof fourcases.Veterinary andComparative Oncology6
cases[abstract].VeterinaryRadiologyandUltrasound41,575
31-38
McKnight JA,Mauldin GN,McEntee MC et al.（2000) Radiation
ForrestLJ,ChunR,AdamsWMetal.(20oo）Postoperativeradiotherapy
treatmentforincompletelyresectedsoft-tissuesarcomasindogs
forcaninesofttissue sarcoma.JournalofVeterinaryInternal
Journalof theAmericanVeterinaryMedicalAssociation217205-
Medicine14,578-582
Fulmer AK and Mauldin GE(2007) Canine histiocytic neoplasia:an
210
MillerMAlsonSLurkJRtal.（199）Cutaneousneoplasiain340
overview.CanadianVeterinaryJournal48,1041-1050
cats.VeterinaryPathology28,389-395
PlavecT,KesslerM，Kandel Betal.(2006)Palliative radiotherapy as
vaccination practices,postvaccinal reactions,and vaccine site-
treatment fornon-resectable soft tissuesarcomasin the dog-a
associatedsarcomasincats.Journalof theAmericanVeterinary
reportof15cases.VterinaryComparativeOncology498-103
MedicalAssociation220,1477-1482
Poirier VJ,Thamm DH,KurzmanID et al.(2002)Liposome-
Goldschmidt MHand HendrickMJ(2002)Tumors of the skin and soft
encapsulated doxorubicin(Doxil)anddoxorubicinin the treatment
tissues.In:TumorsnDomesticAnimals,4thedn,ed.DJMeuten,
ofvaccine-associated sarcoma incats.JournalofVeterinary
pp.89-91.lowaStateUnivPressAmesowa
InternalMedicine16726731
HahnK,EndicottM,KingGetal.(2007）Evaluationofradiotherapy
Powers BE,Hoopes PJ and Ehrhart EJ （1995) Tumor diagnosis,
aloneorincombinationwithdoxorubicin chemotherapy for the
gradingandstaging.SeminarsinVeterinaryMedicineandSurgery
treatmentofcatswithincompletelyexcisedsoftissuesarcomas:
10,158-167
71cases(1989-1999).Journalof theAmericanVeterinaryMedical
Romanelli G,Marconato L,Olivero D et al. (2008) Analysis of
Association231,742-745
prognosticfactorsassociatedwithinjection-sitesarcomas incats:
Hargis AM,Ihrke PJ,Spangler WL et al.（1992)A retrospective
57cases(2001-2007）.Journalof theAmericanVeterinaryMedical
clinicopathological
Association232,1193-1199
hemangiomas andhemangiosarcomas.VeterinaryPathology 29,
Russell KN, Mehler SJ, Skorupski KA et al. (2007) Clinical and
316-328
immunohistochemicaldifferentiationof gastrointestinal stromal
HendrickMJ,ShoferFS,GoldschmidtMH etal.（1994）Comparisonof
tumors from leiomyosarcomas in dogs:42cases(1990-2003).
Journalof theVeterinaryMedicalAssociation230,1329-1333
vaccination sitesincats:239cases(1991-1992).Journalof the
SeguinB(2002)Injection sitesarcomasincats.ClinicalTechniques in
AmericanVeterinaryMedicalAssociation205,1425-1429
SmallAnimalPractice17,168-173
Hershey AE,Sorenmo KU,Hendrick MJ et al.(20oo)Prognosis for
SeltingKA,PowersBEandThompsonLJ(2005)Outcomeof dogs with
presumedfelinevaccine-associatedsarcomaafterexcision:61
high-gradesofttissuesarcomastreatedwithandwithoutadjuvant
cases(1986-1996).Journalof theAmericanVeterinaryMedical
doxorubicin chemotherapy:39cases(1996-2004).Journalof the
Association216,58-61
AmericanVeterinaryMedicalAssociation227.1442-1448
HillersKR,Lana SE,Fuller CR et al.（2007)Effects of palliative
Shaw SC,Kent MS,Gordon IK et al. (2009) Temporal changes in
characteristics of injection-site sarcomas incats;392cases(1990-
oftheAmericanAnimalHospitalAssociation43,187-192
2006).JournaloftheAmericanVeterinaryMedicalAssociation234
JohannesCMHenryCJandTurnquistSE(2007）Hemangiosarcomain
376-380
cats:53cases（1992-2002）JournaloftheAmericanVeterinary
Sorenmo KU,Jeglum KA and Helfand SC (1993) Chemotherapy of
MedicalAss0ciation231,1851-1856
caninehemangiosarcomawithdoxorubicinandcyclophosphamide.
Kass PH,Barnes WG,Spangler WL et al.（1993) Epidemiologic
JournalofVeterinaryInternalMedicine1993370-376
evidenceforacausalrelationbetweenvaccinationand
Sorensen KC,KitchellBE,Schaeffer DJetal.(2004)Expression of
fibrosarcoma tumorigenesisincats.Journalof theAmerican
matrix metalloproteinases in feline vaccine site-associated
VeterinaryMedicalAss0ciation203,396-405
sarcomas.AmericanJournalofVeterinaryResearch65,373-379
Kass PH，SpanglerWL,Hendrick MJ et al.(2003）Multicenter case
StefanelloD,MorelloE,Roccabianca Petal.(2008）Marginal excision
controlstudyofrisk factorsassociatedwithdevelopment of
of low-grade spindlecellsarcomaofcanineextremities:35dogs
vaccine-associated sarcomas incats.Journalof theAmerican
(1996-2006).VeterinarySurgery37,461-465
VeterinaryMedicalAssociation223,1283-1292
Theilen GH and MadewellBR（1979)Tumours of the skin and
Kobayashi T,Hauck ML,Dodge R et al.(2002) Preoperative
subcutaneoustissues.In:VeterinaryCancerMedicine,ed.GH
radiotherapyforvaccineassociatedsarcomain92cats.Veterinary
Theilen and BR Madewell,pp. 123-191.Lea and Febiger,
RadiologyandUltrasound43,473-479
Philadelphia
Kraje AC,Mears EA.Hahn KA et al.(1999) Unusual metastatic
Vaccine-Associated Feline Sarcoma TaskForce (2005) The current
understandingandmanagementofvaccine-associatedsarcomas
orvisceralhemangiosarcoma.Journalof theAmericanVeterinary
incats.JournaloftheAmericanVeterinaryMedicalAssociation
MedicalAssociation214,670-672
226,1821-1842
KuntzCADernellWSPowersBEetal.（1997)Prognosticfactorsfor
Vail DM,PowersBE,Getzy DMet al.（1994）Evaluationofprognostic
surgical treatment of soft-tissue sarcomas in dogs:75 cases
factors for dogs with synovial sarcoma:36 cases（1986-1991).
(1986-1996).JournaloftheAmericanVeterinaryMedical
Journalof theAmericanVeterinaryMedicalAssociation205,1300-
Association211,1147-1151
1307
LawrenceJ,Forrest L,AdamsWet al.(2008)Four-fractionradiation
Ward H,Fox LE,Calderwood-Mays MB et al.(1994)Cutaneous
therapyformacroscopicsofttissue sarcomasin 16dogs.Journal
hemangiosarcoma in25 dogs:aretrospective study.Journal of
oftheAmericanVeterinaryMedicalAssociation44.100-108
VeterinaryInternalMedicine8,345-348
190
Oraltumours
B.Duncan X. Lascelles
Introduction
mostcommonoropharyngealcancerincatsandthe
mostfrequentlydiagnosedtumourin thetongueof
Oraltumoursarecommoninbothcatsanddogs,
dogs.Asummaryofthecommonoral tumoursis
withcancersoftheoralcavityaccountingfor
giveninFigure15.1.Oral tumourscannotbedistin-
3-12%and 6%of alltumours in thesespecies,
guished by appearance alone(Figure 15.2),empha-
respectively.
sizingtheimportanceofbiopsyearlyintheevaluation
Themostcommonmalignanttumoursoftheman-
of oral masses.
dibleandmaxilla indogs are,indescendingorder,
malignant melanoma,squamous cell carcinoma
Itisimportanttorememberthatbenigntumours
(SCC)and fibrosarcoma（FSA).Other malignantoral
areprobablyatleastascommonasmalignant
tumoursincludeosteosarcoma(OsA),chondrosarc-
tumours in thedog,and sobiopsy is always indi-
oma,anaplasticsarcoma,multilobularosteochondro-
catedpriortoanydefinitivetreatment.Benign
sarcoma,intraosseous carcinoma,myxosarcoma,
tumours include the‘epulis'group,aswellasviral
haemangiosarcoma,lymphoma,mast cell tumour
papillomatosis,ameloblastoma andnon-neoplastic
(MCT),and transmissiblevenerealtumour.SCCisthe
gingivalhyperplasia.
sboa
Cats
Malignant
Squamous cell
Fibrosarcoma
Epulides
Squamous cell
Fibrosarcoma
melanoma
carcinoma
carcinoma
Frequency(of all
15-20%
8-15%
5-12%
40-50%
70-80%
15-20%
oral tumours)
Average age
12
8-10
7-9
Variable
10-12
10
(years)at
presentation
Sexpredisposition
Male(slight)
None
Male
None
None
None
Animal size
Smaller
Larger
Larger
None
no data
no data
Sitesof
Gingiva
Rostral mandible
Maxillary gingiva
Rostral mandible
Tongue
Gingiva
predilection
Buccal and labial
Hard palate
Pharynx
mucosa
Tonsils
Lymphnode
Common
Rare(<40%)
Occasional
None
Rare
Rare
metastasis
(40-75%)
Tonsillar SCCup
(10-30%)
to73%
Distant metastasis
Common
Rare(<35%)
Occasional
None
Rare
Rare(<20%)
(15-90%)
(0-70%)
Gross appearance
Pigmented (67%)
Red;cauliflower,
Flat,firm,
Variable
Proliferative;
Firm
oramelanotic
ulcerated
ulcerated
ulcerated
(33%);ulcerated
Boneinvolvement
Common(60%)
Common(80%)
Common
Common
Common
Common
(60-70%)
(80-100%）with
acanthomatous;
doesnotoccur
withfibrous and
ossifying types
15.1
Summaryofpresentationof commonoral tumoursinthedog andcat.
191
Chapter15aOraltumours
a
(d)
(b)
(e)
15.2
Oral tumourscannotbedistinguished fromeachotherbasedonappearance alone:(a,b)squamous cell
carcinoma;(c)melanoma:(d)fibrosarcoma:(e)mastcelltumour.
Tumourtypesandbehaviour
melanomasrepresentuptoone-thirdofalloral
melanomasindogs.Underlyingmelanomacanbe
Oraltumoursindogs
presentwithareturnedhistopathologicaldiagnosisof
undifferentiatedoranaplasticsarcoma,orevenof
Malignantmelanoma
epithelial cancer.lf theclinician issuspiciousof this,
Incontrasttoothermalignantoraltumours,malignant
melanAisanimmunohistochemicalstainwithahigh
melanomatendstooccurinsmallerbreedsaswell
assomelargebreeds,withanaverageageof11
sensitivityandspecificityforthediagnosisofmelan-
years.Cocker Spaniel,MiniaturePoodle,Anatolian
omaindogsandcanbeusedalongwithS100and
Sheepdog,GordonSetter,ChowChowand Golden
HMB45todifferentiatemelanomafromotherpoorly
Retrieverareover-represented.Malignantmelanoma
differentiatedoraltumours(seealsoChapter2).
can be difficult to diagnose if the tumour orbiopsy
Melanomaoftheoralcavityisahighlymalignant
sectiondoesnot containmelanin;amelanotic
tumourthatfrequentlymetastasizes(reportedinup
192
Chapter15aOraltumours
to80%ofdogs).Themetastaticratedependson
manyofthefibromatousandossifyingtypesbeing
site,sizeandstage.Malignantmelanomaisahighly
derivedfromthegingiva.Acanthomatousepulishas
immunogenictumour,andmolecularapproachesto
beenreferredtoasbasalcellcarcinomaand,more
treatment,particularlygeneticimmunotherapy,isan
recently，asacanthomatousameloblastoma,although
activeareaofresearchandtreatment.
thetermacanthomatousepulisisstillused.
Adamantinomaisanothertermthathasalsobeen
Squamouscellcarcinoma
usedforeitherameloblastomaoracanthomatous
SCCisthesecondmostcommonoraltumourin
ameloblastoma.
dogsandfrequentlyinvadesbone.Themetastatic
Acanthomatousepulisisabenigntumourbut
ratefornon-tonsillarSCCindogsisapproximately
withanaggressivelocalbehaviourandfrequent
20%,but themetastaticriskis site-dependent,with
invasionintoboneoftheunderlyingmandibleor
rostraltumourshavingalowmetastaticrateandthe
maxilla.Therostralmandibleisthemostcommon
caudaltongueand tonsilhavingahighmetastatic
site.Theydonot metastasize.Acanthomatousepulis
potential.Thetonsillarandlingualsitesarethemost
isthepreferredterm,butsomepathologistswillrefer
importantnon-gingivalsitesin thedog.Tonsillar
to these tumoursbyotherterms(see above).
lesionsmetastasize totheregional(retropharyngeal)
Fibromatousandossifyingepulidesarebenign
nodes inalmost allcases.Distant metastasis may
oral tumoursthat,unlikeacanthomatousepulides,do
developinpatientsthatsurviveforlonger.
nottendtoinvadeintounderlyingbone.Theyare
slow-growing,firmmassesandareusuallycovered
Fibrosarcoma
byintactepithelium.Ossifyingepulidesusuallyhave
OralFSAisthethirdmostcommonoraltumourin
abroadbaseof attachmentandarelesspeduncu-
dogs.lttendstooccurinlargebreeds,particularly
latedthanfibromatousepulides.Thesetwoepulides
theGoldenandLabradorRetriever,withamedian
ageof about8years,and theremaybeamalepre-
absenceofbonewithinthetumour.
disposition.OralFSAmayappearsurprisinglybenign
histologicallyand,evenwith large biopsy samples,
Oraltumoursincats
thepathologistwilloftendiagnosefibromaor‘low-
gradeFSA'Thissyndrome,whichiscommononthe
hardpalateandmaxillaryarcadebetweenthe
Squamouscellcarcinoma
SCCis themostcommonoral tumourincats.
canineandcarnassial teethof large-breeddogs,has
Reportedriskfactorsforthedevelopmentoforal
beentermedhistologicallylow-gradebutbiologically
SCCincludefleacollars,highintakeofeithercanned
high-grade'FSA(Ciekot et al.,1994).Treatment
shouldbeaggressive,especiallyif thecancerisrap-
foodingeneralorcannedtunafishspecifically,and
idlygrowing,recurrentorinvadingbone.FSAisvery
exposuretohousehold smoke(Bertone etal.,2003).
locally invasive,butmetastasizes to thelungsand,
Boneinvasionisfrequentand isusuallysevereand
occasionally,regional lymphnodesin<30%of dogs.
extensive.Paraneoplastichypercalcaemiahasbeen
reportedintwocatswithoralScC.Themetastatic
Osteosarcoma
rateinthecatisunknown,sincesofewcatshave
OSAofaxialsitesislesscommonthanappendicular
theirlocaldiseasecontrolledtoallowobservationof
OSA(axialrepresents approximately 25%ofall
thelong-termmetastaticpotential.
OSA),andabout25%ofaxialOSAsoccurinthe
mandibleandmaxilla.Theprognosisfordogswith
Odontogenictumours
Theseoriginatefromepithelialcellsof thedental lam-
larOsAbecauseofalowermetastaticpotential,but
ina,andaccount forupto2.4%ofallfeline oral
thisfindingiscontroversial.
tumours.Theyarebroadlyclassifiedintotwogroups
dependingonwhetherthetumoursareabletoinduce
Epulides
astromalreaction-inductive and non-inductive.
Epulidesarerelativelycommonindogs.Epulidesare
Inductiveodontogenictumoursincludeameloblastic
benigngingivalproliferationsarisingfromtheperio-
fibroma,dentinoma,andameloblastic,complexand
dontal ligamentandappearsimilartogingivalhyper-
compoundodontomas.Ameloblastomasandcalcify-
plasia.Ingeneral,fourtypesofepulideshavebeen
ingepithelialodontogenictumoursareexamplesof
described inthedog:fibromatous;ossifying;acanth-
non-inductiveodontogenictumours.
omatous;andgiantcell.However,thenomenclature is
Inductivefibroameloblastomaisthemostcommon
confusing,andvaried,andtheclinicianisencouraged
odontogenic tumourin cats,occurring in cats less
tospeakdirectlytothepathologistifthereareany
than18monthsofageandoftenintheregionof the
upper canine teethandmaxilla.Radiographically,
referstoanytumourthatarisesfromthegingivabut
therearevaryingdegreesofbonedestruction,pro-
foralongtimehasbeenusedtodesignatetumours
duction,andexpansionofthemandibularormaxillary
thatarisefromtheperiodontal ligament.Thesewere
bones.Smallerlesionsaretreatedwithsurgical
furtherdescribedasbeingoneof threemainforms-
debulking andcryosurgeryorpremaxillectomy.Larger
fibromatous，ossifying or acanthomatous.However,
lesionswillrespondtoradiation.Withaggressivelocal
morerecentlyithasbeenshownthatsomeofthese
treatment,controlratesaregood andmetastasishas
tumoursdonotinvolvetheperiodontal ligament,with
not beenreported.
193
Chapter15aOraltumours
Eosinophilicgranuloma
necrosisandinflammation.Alargeincisionalbiopsy
Eosinophilicgranuloma(rodentulcer orindolent
isrecommended.Cauteryshouldonlybeusedfor
ulcer)occursmorecommonlyinfemalethaninmale
haemostasisafterbladeincisionorpunchbiopsy，so
cats,withameanageof5years.Theaetiologyis
asnottodamagethespecimen.Caremustbetaken
unknown.Anyoralsiteisatriskbutthetumouris
nottocontaminatenormal tissuethatcannotbe
mostcommonontheupperlipnearthemidline.The
removedwithsurgeryorincludedintheradiation
historyisusually thatof a slowlyprogressive(months
field.lf thelesionissmallandanexcisional biopsyis
toyears)erosionof thelip.Biopsyisoftennecessary
performed,detailednotesshouldberecordedabout
todifferentiatetheconditionfromtruecancers.Care
exactlywherethesamplewastakenfrom(possibly
shouldbetakentoruleoutanyunderlyinghypersen-
sitivityasacause.Varioustreatmentshavebeenpro-
therapythatisrequiredcanbetargetedtothecor-
posed,including:oral prednisone（1-2mg/kg q12h
rectarea.
for30days)orsubcutaneousmethylprednisolone(20
mg/cat every 2weeks);megestrol;hypoallergenic
Clinicalstaging
diets;radiation therapy;surgery;immunomodulation;
or cryosurgery.Theprognosisforcompleteandper-
Local tumourimaging:Regionalradiographsof the
manentrecoveryisfair,andrarecasesmayundergo
skull,ordentalfilms,canbeuseful indelineatingthe
spontaneousregression.
extentofdisease,butbonelysisisnotradiograph-
icallyevidentuntil40%ormoreofthecortexis
Othertumourtypes
destroyedandhenceapparentlynormalradiographs
donot exclude bone invasion.Advanced imaging
OralFSAisthesecondmostcommonoraltumourin
modalitiesarenowwidelyavailableandtheseare
catsbutverylittleisreportedonitsbiological behav-
recommendedforimagingoforaltumours,particu-
iour.Epulideshavealsobeenreportedincats.The
larlytumoursarising fromthe maxilla,palateand
mostcommonare thefibromatousandgiantcell
caudal mandible.Computed tomography(CT) scans
epulides;acanthomatousandossifyingepulidesare
aregenerallypreferredtomagneticresonanceimag-
rareincats.
ing(MRl)becauseofsuperiorbonedetail,butboth
CTandMRIprovidemoreinformationon thelocal
extentofthetumourthanregionalradiographs.This
Presentation and clinical signs
informationisimportantforplanning thedefinitive
surgicalprocedure(orradiationtherapyif indicated).
Mostcatsanddogswithoralcancerpresentwitha
massin themouthnoticedby theowner.Cancerin
Regionallymphnodes:Regionallymphnodes
thecaudalpharynx,however,israrelyseenbythe
shouldbecarefullypalpatedforenlargementorasym-
owner,and theanimalisoftenpresentedatalater
metry.However,cautionshould beexercisedwhen
stageofdisease,whichresultsinfeweroptionsfor
makingclinical judgementsbasedonpalpationalone,
treatment.Theanimalmaypresentwith signs of
aslymphnodesizeisnotanaccuratepredictorof
hypersalivation,exophthalmos or facial swelling,
metastasis.Inonestudyof100dogswithoralmelan-
epistaxis,weight loss,halitosis,bloody oral dis-
oma,40%ofdogswithnormalsizedlymphnodes
charge,dysphagia orpainonopening themouth,or
hadmetastasisand49%ofdogswithenlargedlymph
occasionallycervical lymphadenopathy(especiallyin
nodesdidnot(WilliamsandPacker,2003).
SCCof the tonsil).Loose teeth,especially in an ani-
Furthermore,theregional lymph nodes include the
malwithgenerallygooddentition,maybeindicative
mandibular,parotidandmedialretropharyngeallymph
ofunderlying neoplastic bone lysis,especially in
nodes.Enblocresectionof theregional lymphnodes
cats.Acompleteexaminationoftheoralcavitydur-
hasbeendescribedand,althoughthe therapeutic
ingannualhealthchecksisrecommendedtoscreen
benefitofthisapproachisunknown,itmayprovide
fororopharyngeal masses,asthismaypermitearlier
valuable staging information(Herring et al.,2002;
diagnosis,bettertreatmentandimprovedprognosis.
Smith,1995).
Distantmetastasis:Three-viewthoracicradio-
Clinicalapproach
graphs(rightandleftlateralplusdorsoventralorven-
Diagnosis and clinical staging
evaluateanimalsforthoracicmetastasis;rightand
leftlateralviewsaretheminimumrequirement.
Biopsy
HelicalCTscansshouldbeconsideredforanimals
Biopsy isrequired for definitive diagnosis andwill
withhighlymetastatictumourtypes,suchasoral
assisttheclinicianindeterminingbiologicalbehav-
malignant melanoma,since CT scans are signifi-
iourandprognosis.Indeed,theauthorrecommends
cantlymoresensitivethanradiographsfordetecting
biopsybeforeanyotherstaging,asthetumourtype
pulmonarymetastaticlesions.
willinfluencethestagingrequired.Touchoraspira-
tioncytologypreparationsare usuallynotrewarding,
Based on these steps, oral tumours are then
andcanresultinanincorrectdiagnosissincemany
clinicallystagedaccording totheWorldHealth
oraltumoursareassociatedwithahighdegreeof
Organization(WHO) staging scheme(Figure 15.3).
194
Chapter15aOraltumours
T-Primary tumour
Surgery
Surgicalexcisionisthemostcommonlyusedmodal-
Tis
Tumour in situ
ityfortreatmentofthelocaloraltumour,andsurgical
T1
Tumour2cmindiameteratgreatestdimension
approachdependsontumourtypeandlocation.
Exceptforfibromatousandossifying epulides,the
T1a
Withoutevidenceof boneinvasion
majorityoftumours involving themandible,maxilla
T1b
Withevidenceof boneinvasion
andhardpalatehavesomeunderlyingboneinvolve-
T2
Tumour2-4cmindiameteratgreatestdimension
ment,andsurgicalresectionof theseshould include
bonymarginstoincreasethelikelihoodofcomplete
T2a
Withoutevidenceof boneinvasion
excision.Radicalsurgeriessuchasmandibulectomy
T2b
Withevidenceof boneinvasion
andmaxillectomyarewelltoleratedbycatsanddogs
(see Chapter 13).Theseprocedures areindicated
T3
Tumour>4cmindiameteratgreatest dimension
fororaltumoursinvolvingthemandibleandmaxilla,
T3a
Withoutevidenceofboneinvasion
particularlylesionswithextensiveboneinvasionand
T3b
With evidenceof boneinvasion
tumourtypesthathavepoorsensitivitytoradiation
therapy.
N-Regional lymph node status
Adetailedknowledgeoftheregionalanatomyis
NO
Nometastasistoregionallymphnodes
importantforasuccessfuloutcomeandtominimize
theriskof complications.The anatomy shouldbere-
N1
Movable ipsilaterallymphnodes
viewedpriortosurgery，incombinationwitheither
N1a
No evidence of lymph nodemetastasis
CTorMRl imagesof thepatient,toplanthesurgical
Evidenceof lymphnodemetastasis
approach,resectionandreconstruction.Catand dog
N1b
skullsshouldbeavailableforintraoperativeorienta-
N2
Movablecontralaterallymphnodes
tion andplanning.
N2a
No evidence of lymph nodemetastasis
Effectivepainmanagementisofparamountimpor-
Evidence of lymph nodemetastasis
tanceinanysurgery(seeChapters6and11).
N2b
M-Distant metastasis
Margins
No distantmetastasis
Minimummarginsofatleast2cm,andpreferably3
MO
cm,havebeenrecommendedformalignantcancers
M1
Distantmetastasis[specify sites]
such as SCC,malignant melanoma and fibrosar-
(a)TNM classification.
coma in the dog,but this is unrealistic in most
cases.It isthe author'sopinion that mostof thepub-
T1
NO,N1a,N2a
MO
lishedworkhasinvolvedmarginsof0.5-1.0cm
(seebelow).Likewise,it has been suggested that
T2
MO
SCC in thecat shouldbetreated with surgical
NO,N1a,N2a
margins>2cmbecauseofhighlocalrecurrence
II
T3
NO,N1a,N2a
MO
rates.Thisisnotusuallyrealistic;suchmarginsmay
AnyT
N1b
MO
notbepossiblewithoutsignificantmorbidity
becauseoftheextentofthetumour.Whilesuchrec-
IV
AnyT
N2b,N3
MO
ommendedmarginswouldbelikelytoimprove
AnyT
AnyN
M1
tumourcontrol,therealityisthatthereportedout-
(b) Stage grouping.
comesoforalsurgeryforneoplasiaarebasedon
narrowermargins-approximatelyafullcentimetre
Clinical staging（TNM)oforal tumoursindogs
ofnormal tissue beyond the gross margin.
15.3
and cats.
Therefore,although wider marginsmayresult in
longerdisease-freeintervals,aworkinggoalof1cm
iswhattheclinicianshouldstrivefor:a1cmmargin
ofnormaltissuebeyondeitherthegrosslyvisible
tumourortheextentof thetumourasdeterminedby
Management
imaging,whicheverisgreater,isrecommendedfor
Clinical serieshavebeenreportedofover500 dogs
malignantoral tumours.Forbenigntumours,a mar-
withvariousoralmalignancies,treatedwitheither
ginof0.5-1.0cmisrecommended.
mandibulectomyormaxillectomy.Themajorityof
theseweretreatedwithsurgeryalone,indicatingthe
Instrumentsandsuturematerials
importantrolesurgeryplaysinthemanagementof
Anoscillatingsawispreferredformandibularosteot-
oraltumours.Othersurgicalproceduresincludehard
omies, although pneumatic burrs,Gigli wire and
palateresectionandpartial/totalglossectomy.In
bonecutterscanalsobeused.Osteotomesshould
general,maxillofacialsurgeryshouldbereferredto
beavoidedforallnon-symphysealmandibularosteo-
aspecialist veterinary surgeon.Detailed surgical
tomiesbecauseof theriskofboneshattering.
approachesaredescribedandillustratedinother
Monofilament absorbable suturematerial(e.g.
books,includingtheBSAVAManual of Canineand
FelineHead,NeckandThoracicSurgery.
defectsbecauseitmaintainsadequatetensile
195
Chapter15aOraltumours
strengthforprolongedperiodsandisrelativelyinert,
Outcome
whichminimizesmucosalirritationandinflammation.
Over85%ofownersaresatisfiedwiththepostopera-
Two-layerclosureispreferredtoone-layerclosure
tivecosmeticandfunctionalresultsintermsofeat-
becauseofareducedriskofincisionaldehiscence.
ing,drinkingand abilitytoholdobjectsinthemouth
Suturematerialshouldbepassedthroughbonetun-
(Lascelles etal.,2003;Northrupetal.,2006).Results
nelsifpossible,particularlyinthehardpalateand
shouldbediscussedwithowners,preferablyusing
maxilla,becauseofincreasedholdingpowercom-
representativepostoperativeimages(e.g.Figures
paredtosofttissue(Figure15.4).
15.5to15.8)priortoobtainingconsentforsurgical
a
(b)
15.4
dehiscencecanbedecreasedbyusingholesdrilled inbonyedgesthroughwhichtosecuresutures.
(b)Closureof thedefecthasbeencompleted usingatwo-layerclosure.Polydioxanonehasbeenusedtoclosetheoral
resultsina longer-lastingsuture anddecreased dehiscence.
15.5
(a)The24-hour
postoperative
appearanceof thedog
undergoing surgeryin
Figure 15.4.The
reconstructionhas
resultedinamedial
'puckering'of the lip.
Thiswill relaxtoacertain
extent,and isless
apparentashairgrows
back.(b) In this German
ShepherdDogmedial
deviation of thecaudal lip
occurreddueto
reconstructionofalarge
defectcreatedfollowinga
caudalmaxillectomyfor
OSAperformed usinga
(a)
（b）
combinedapproach.
(b)
(c)
15.6
(a)Completeexcisionofarelativelysmall,low-gradeFSAusingfull thicknessresectionof thecaudal hard
palate.(b)Reconstructionwasperformedusingalabialmucosalflap,and theclosureof thisdefectresulted in
dimpling'of thelateral face.(c)Headandnecksurgeryreadilyresultsinswelling.
196
Chapter15aOraltumours
treatment.Thecosmeticappearanceisusuallyvery
goodfollowingmostmandibulectomyandmaxillec-
tomyprocedures,butcanbe challengingwithaggres-
sivebilateralrostralmandibulectomiesandradical
maxillectomies(Lascellesetal.,2003).
Complications
Bloodlossandhypotensionarethemostcommon
intraoperativecomplications,
particularly
during
caudalmaxillectomy
(Lascelles
et
al.,
2003).
Postoperativecomplications
are
uncommonbut
includeincisional
dehiscence
(Figure
15.9)，
epistaxis,increasedsalivation,mandibulardrift and
Postoperativeappearancecanbedramatically
malocclusion,anddifficultyprehendingfood.Enteral
15.7
alteredfollowingradicaloral surgery,suchasin
feedingtubesarenotusuallyrequiredfollowingoral
thisdogwithabilateralrostralmandibulectomytothe
surgery in dogs,but arerecommended for cats
levelof the3rdpremolar.However,functioninthisdog
treatedwithanytypeofmandibulectomyaseating
wasexcellent.Duringsurgery,carewastakentoavoid the
canbedifficultfor2-4monthsfollowingsurgery
hypoglossalnerve toavoid anyfunctional compromiseof
(Figure 15.10).
the tongue.
15.9
Dehiscence can occur following oral surgery.It
isminimizedbyadheringtoappropriate
surgical principlesandbyminimizing tension.Pre-or
postoperativeradiationtherapyincreasesthechanceof
dehiscenceoccurring,asin thepatient shownhere.In this
case,multiplesurgicalattemptstoclosethesmall
oronasalfistulawereunsuccessful,andsoa'nasalseptal
button'wasplaced toplug'thefistula.Thiswasa
laterofdiseaseunrelatedtotheoral tumour.
(b)
15.8
Thisdogunderwentresectionof thezygomatic
arch,verticalramusandcaudal maxillaanda
partialorbitectomy(includingorbitalcontents)fora
low-grademultilobularosteochondrosarcoma.Duetothe
extentofsurgeryandsomepostoperativebleeding.the
immediatepostoperativeappearanceof thedog(a)is
startling.Notethe analgesiccatheteronthelateralaspect
iskeptmaximallycomfortablepostoperatively.Owners
shouldbeover-warned about thepostoperativealteration
15.10
Althoughdogsgenerallyfunctionextremelywell
of theirpet'sfeatures.(b)Afterseveralweeks,however,
afterradicalresections,catstendnottofunction
theappearanceof thedogisveryreasonable.Partof the
aswell,andfeedingtubesshouldalwaysbeplacedafter
pigmentedtissuearoundtheeyelidhadbeenleftinplace
radicaloralsurgery.Ownersshouldbewarnedthatcats
asthiswasconsideredcosmeticallymoreacceptableto
maynotlearntoeatontheirown,andmayrequiretheir
theowneranddid notcompromise theresection.
ownerstogroomthem.
197
Chapter15aOraltumours
Multimodalmanagement
such asblepharitis,conjunctivitis,keratitis anduve-
itis.Acutesideeffectsofcoarsefractionationareless
Radiationtherapy
severethanwithfull-courseprotocols.Latecompli-
Thiscanbeeffectiveforlocoregionalcontroloforal
cations arerare（<5%ofcases)but caninclude
tumours.It canbeusedasaprimarytreatment,with
permanent alopecia （Figure 15.11),skin fibrosis，
palliativeorcurativeintent,orasanadjunct for
bonenecrosisandoronasal fistula formation,devel-
incompletelyresectedtumoursor
thosewithan
aggressivelocalbehaviour,e.g.oralFSA.Malignant
field,keratoconjunctivitis sicca,cataract formation
melanoma,canine oral scC,
andsomebenign
andocularatrophy(seeChapter8).
tumours,such asthe acanthomatous epulides,are
knowntoberesponsivetoradiation,andradiation
Chemotherapy
therapycanbeconsideredintheprimarytreatment
Themajorproblemwithmostoraltumoursiscontrol
of these tumours （although surgery is still the
oflocaldisease.Chemotherapywouldbeindicated
treatmentofchoiceduetotheriskofosteonecrosis
forsometumoursinprinciplebecauseoftheirhigh
developingfollowingradiationtreatment).
metastatic potential (e.g.oral melanoma in dogs,
For canineoral SCC,dental tumours andFSA,
tonsillarSCCincats anddogs)butchemosensitivity
dailyandalternate-dayprotocols
have
been
is low.
described，consistingof2.7-4.2Gyperfractionwith
ExpressionofCox-2hasbeennoted infeline
a totaldoserangingfrom48to57Gy.Tumourcon-
oral tumours（mainly SCC)（Hayes et al.,2006;
trolisbetterforsmallerlesions（T1andT2tumours)
DiBernardietal.,，
2007)butnon-steroidalanti-
treatedwithradiationalone.Localtumourcontrol
inflammatory drugs (NSAIDs)such as piroxicam
andsurvivaltimecanbeimprovedbycombining
havenotbeeneffective in themanagementof
radiationtherapywithsurgery,especiallyfortumours
SCC incatsinpreliminaryunpublished studies.
consideredtoberadiation-resistant,suchascanine
Piroxicam does have some effect against oral
oralFSAandfelineoral SCC.Radiationsensitizers,
SCC indogs and thisresponserateis improved
suchas etanidazole and gemcitabine,havebeen
whenpiroxicamiscombinedwithcisplatin(Boriaet
suggestedtoresultinimprovedresponseratesin
al.,2004).
catswithoralScC,andplatinumdrugshavebeen
usedasradiationsensitizersindogswithoralmel-
Immunotherapy
anoma(Jonesetal.,2003,Proulxetal.,2003),but
Malignantmelanoma isahighlyimmunogenictumour.
theirtruebenefit iscontroversial.
Theuseof immunotherapy agents andbiological
Oralmelanomaisresponsivetocoarsefractiona-
responsemodifiers isanemergingandexciting
tionprotocols.Inhumanpatientsdoses>4Gyper
approachfortheadjunctivemanagementofdogswith
fractionarerecommended,asresponseratesare
oralmelanoma.Biological responsemodifiers,such
significantlybetterwithfractions>8Gycomparedto
asCorynebacteriumparvumandliposomemuramyl
<4Gy.However,in one study of dogswith oral mela
tripeptide
phosphatidylethanolamine
（L-MTP-PE)
nomathatcomparedtwohypofractionatedprotocols
haveshownencouragingresultscompared tocontrol
of9-10Gyperfractionwithafullyfractionatedpro-
groups in controlled clinical studies.Others,such as
tocolof2-4Gyperfraction,therewerenosignificant
bacillusCalmette-Guerin(BCG)andlevamisole,how-
differencesineitherlocalrecurrenceratesorsurvival
ever,havefailedtoimprovesurvival timesindogswith
time(Proulxet al.,2003).Coarsefractionationoforal
malignant melanoma.
melanomahasbeendescribedinafewcatswith
Geneticimmunotherapyisanactiveareaof
limited success,including one complete response
researchandcurrentapproacheshaveresultedin
and twopartialresponses.
significantimprovementsinlocalcontrolratesand
Acuteradiationsideeffectsarecommonbutself-
survival times.Theseapproaches include:systemic
limiting.Theyincludealopeciaandmoistdesquama-
administrationofinterleukin-2(IL-2)andtumour
tion,oral mucositis,dysphagia and ocular changes
necrosis factor （TNF);autologous vaccines from
15.11
Radiationoforal
tumourscanresult
insideeffects.Thesetwo
dogsshowpermanent
alopeciain theradiationfield.
198
Chapter15aOraltumours
irradiatedtumourcellstransfectedwithhumanrecom-
androstral locationarefavourableprognosticfactors.
binant(hr)granulocyte-macrophage colony-stimulat-
Intwostudiesof142dogstreatedwitheitherman-
ing factor(GM-CSF)-a potent haemopoieticand
dibulectomyormaxillectomy,tumour-relateddeaths
proinflammatorycytokine;directinjectionofDNAinto
were10-21timesmorelikelywithmalignanttumors,
tumourstoinduceexpressionofstaphylococcal enter-
upto5timesmorelikelywithtumourslocatedcaudal
otoxinB(asuperantigen)incombinationwitheither
tothecanine teeth,and2-4timesmorelikely follow-
GM-CSForIL-2;andDNAvaccinationwithmurineor
ingincompleteresection(Schwarzetal.1991a,b).
humantyrosinase,whichcanresultincytotoxicand
Fibrosarcomahas ahighlocalrecurrence rate,
T-cell responses,withorwithouthrGM-CSF.
whereasmelanomaiscontrolledlocallyin75%of
Preliminary results suggest immunotherapeutic
casesbutmetastaticdiseasecausedthedeathof
approaches,incombinationwitheithersurgeryand/
mostdogs.lmprovedexposureofthetumourtobe
orradiationtherapy，arepromisinginthemanage-
resectedappears toresultinimprovedoutcome
mentoforalmelanoma.ADNAvaccinewithhuman
(Lascellesetal.,2003).
tyrosineisnowcommerciallyavailable(under
restricted licence)for theadjunctive treatmentof
Withradiationtherapy
dogswithcompletelyexcisedoralmalignantmelan-
Fordogstreatedwithmegavoltageradiation,tumour
oma(see Chapter9).
sizeis themostimportantfactorinlocal tumour
controlforbothbenignandmalignantoral tumours.
Localrecurrenceisreported inupto30%ofcases
Prognosis
and,compared to T1 tumours（<2cm diameter),
recurrenceisthreetimesmorelikelyinT2tumours
Figure 15.12 summarizes prognostic data for the
(2-4cmdiameter)anduptoeight timesmorelikely
commonmalignantoraltumoursindogsandcats.
inT3tumours(>4cmdiameter).Tumoursize isalso
associatedwithsurvivalindogswithmalignantoral
Withsurgicaltreatment
tumours,with3-yearprogression-freesurvivalrates
Overallthelowestratesoflocal tumourrecurrence
of55%,32%and 20%forT1,T2andT3tumours,
andbestsurvivaltimesarereportedindogswith
respectively.
acanthomatous epulisandSCC,whileFSAand
malignantmelanomaareassociatedwiththepoorest
Tumoursofthetongue
results (Kosovskyet al.,1991;Schwarz et al.,
Theprognosisfortonguetumoursappearstodepend
1991a,b;Wallace et al,1992a,b).Most of these
onthe site,typeandgradeofcancer.Inarecent
reportssuggestthathistologicallycompleteresection
retrospectivestudy42casesoflingualtumoursin
Dogs
Cats
Malignant
Squamous cell
Fibrosarcoma
Epulides
Squamous cell
Fibrosarcoma
melanoma
carcinoma
carcinoma
Responseto
Fair to good
Good
Fair to good
Excellent
Poor
Fair
surgery:
Localrecurrence
0-60%
0-50%
30-60%
0-10%
nodata
nodata
MST
5-17months
9-26months
10-12months
>28-64months
45days
no data
1-yearsurvival
20-35%
60-90%
20-50%
70-100%
<10%
no data
rate
Response to
Good
Good
Poortofair
Excellent
Poor
Poor
radation
therapy:
MST
4-12months
16-36months
7-26months
37+months
90days
no data
1-yearsurvival
35-70%
70%
77%
85%
40days
no data
rate
Optimal therapy
Surgery and/or
Surgery and/or
Surgeryand/or
Surgery
Surgeryand/or
Surgery and/or
radiation±
radiation
radiation
radiation±
radiation
immunotherapy
sensitizer
Overall
Poor to fair
Moderate togood
Moderate to good
Excellent
Poor
Fair
prognosis
Causeofdeath
Distantmetastasis
Local disease or
Local disease
Rarelytumour-
Local disease
Local disease
distant metastasis
related
15.12
199
Chapter15a
Oraltumours
15.13
Subtotalglossectomyperformedforamalignantmelanomaof thetongue.Histologically,completeresectionwas
dogswere evaluated(Syrcleetal.,2008):27(64%)
plete surgicalresection,witha25%metastaticrate
weremalignantand 15(36%)werebenign.Theover-
incompletelyexcisedtumoursand75%following
allmedian survival time(MST)fordogswithbenign
incompleteresection;metastasisisalsomorelikely
tumourswas>1607days,comparedto286daysfor
withhigherhistologicalgrade.Thereisnoknown
malignant tumours.Complete resection（Figure
effectivechemotherapy
treatmentformetastatic
15.13),small tumour size and and benign tumours
disease.Tumourlocation appearstohaveprognostic
wereassociatedwithincreasedsurvival.Short-term
significance,astheoutcomefordogswithmandibular
multilobularosteochondrosarcomaissignificantly
ismanddehiscence.Long-termmorbidityincluded
betterthanfortumoursatothersites.
minorchanges ineatinganddrinking habits.
Multilobularosteochondrosarcoma
Referencesandfurtherreading
Multilobularosteochondrosarcomaisaninfrequently
Bertone ER,Snyder LAand MooreAS(2003)Environmental and
diagnosedbonyandcartilaginoustumour,whichusu-
lifestyleriskfactorsfororalsquamouscellcarcinomaindomestic
allyarisesfromthecanineskull,including themandi-
cats.JournalfVerinaryIntrnalMdiine17557-2
ble,maxillaandhardpalate.Surgeryisrecommended
Boria,PA,Murry DJ,Bennett PFetal.(2004)Evaluationofcisplatin
combinedwithpiroxicam for thetreatmentoforalmalignant
formanagementofthelocaltumour,althoughthere
melanoma andoral squamous cellcarcinomaindogs.Journal of
areanecdotalreportsthatmultilobularosteochondro-
theAmericanVeterinaryMedicalAssociation224,388-394
sarcomamay alsoberesponsive toradiation therapy.
grade,yetbiologicallyhigh-grade,fibrosarcomasofthemandible
Theoverallrateoflocalrecurrencefollowingsurgical
and maxilla in dogs:25 cases （1982-1991）.Journal of the
resectionisabout50%andisdependentoncom-
AmericanVeterinaryMedicalAssociation15,610-615
DiBernardi L,Dore M,Davis JA et al.(2007) Study of feline oral
pletenessofsurgicalresectionandhistologicalgrade.
squamous cell carcinoma:potential target for cyclooxygenase
Themediandisease-freeintervalforcompletely
inhibitor treatment.ProstaglandinsLeukotrienesandEssential
resectedmultilobularosteochondrosarcomaisalmost
FattyAcids76,245-250
HayesA,ScaseTMillerJetal.(2006）COX-1andCOx-2expressionin
4years,andsignificantlybetterthanthe11months
felineoral squamouscell carcinoma.JournalofComparative
reportedforincompletelyexcisedtumours.Thelocal
Pathology135,93-99
recurrencerateissignificantlyworsewithhigher
HerringES,SmithMMandRobertsonJL(2002）Lymphnode stagingof
oralandmaxillofacialneoplasmsin31dogsandcats.Journalof
grade.Thetumourhasamoderatemetastaticpoten-
VeterinaryDentistry19,122-126
tial,particularlytothelungs,whichisgrade-depend
Jones PD,de Lorimier LP,Kitchell BE and Losonsky JM(2003)
entbutusuallyoccurslateinthecourseofdisease.
Gemcitabineasaradiosensitizer fornonresectablefeline oral
squamouscellcarcinoma.Journalof theAmericanAnimal Hospital
Metastasisissignificantlymorelikelyfollowing incom-
Association39.463-467
200
Chapter15aOraltumours
Kosovsky JK,Matthiesen DT,Marretta SM and Patnaik AK(1991)
SchwarzPD,WithrowSJ,CurtisCR,PowersBEandStrawRC（1991b）
Resultsofpartialmandibulectomyforthetreatmentoforaltumors
Partialmaxillaryresectionasa treatmentfororalcancerin61
in142dogs.VeterinarySurgery20,397-401
dogs.Journalof the AmericanAnimal HospitalAssociation27.
Lascelles BD,Thomson MJ,Dernell WS et al.(2003)Combined
617-624
dorsolateraland intraoralapproachfortheresectionof tumorsof
themaxillainthedog.Journalof theAmericanAnimalHospital
maxillofacialneoplasmsindogs.JournaloftheAmericanAnimal
Association39,294-305
HospitalAssociation31514518
Syrcle JA.Bonczynski J.Monette S and Bergman PJ (2008)
NorthrupNC,Selting KA,RassnickKMet al.(2006)Outcomes of cats
withoraltumorstreatedwithmandibulectomy:42cases.Journalof
Retrospectiveevaluationoflingualtumorsin42dogs:1999-2005.
theAmericanAnimal HospitalAssociation42,350-360
JournaloftheAmericanAnimalHospitalAssociation44,308-319
WallaceJ,MatthiesenDTandPatnaikAK（1992)Hemimaxillectomy for
Proulx DR,Ruslander DM,Dodge RKet al.(2003)A retrospective
analysisof140dogswithoralmelanoma treatedwithexternal
341
beamradiation.VeterinaryRadiologyandUltrasound44.352-359
WilliamsLEandPacker RA(2003)Associationbetween lymphnode
SchwarzP,Withrow S,CurtisC,Powers B and StrawR（1991a)
Mandibularresectionasa treatment fororalcancerin81dogs.
cases（1987-2001）.Journalof theAmericanVeterinaryMedical
Journalof theAmericanAnimalHospitalAssociation27,601-610
Association222,1234-1236
201
Tumours of the salivary glands
BrianJ.TrumpatoriandRichardA.S.White
Introduction
respectively,at the timeof initial diagnosis(Hammer
etal.,2001).
Tumoursofthesalivaryglandsareunusualinthe
dog,withanoverallincidencereportedas0.2%
（KoestnerandBuerger,1965;Carberryetal.,1987;
Presentation and clinical signs
Spangler and Culbertson,1991;Head et al.,
2003).Inareportofhistologicalevaluationofsali-
Themostcommonpresentingsignforsalivarygland
varytissuefrombothdogsandcats,30%ofthe
tumoursisapalpablemassnoticedbytheowner
245submissions were neoplastic(Spangler and
(Figures 15.14and 15.15).The mass is normally
Culbertson,1991).The mean age of affected dogs
non-painfulandthepatientisotherwiseasympto-
andcatsisabove10years.Spanielswerereported
matic.Thelocationoftheswellingmayvarydepend-
tobeatgreaterriskthanother breeds(Karbe
ingonthegland involvedandmaybelocatedatthe
andSchiefer,1967)but subsequentstudieshave
cranioventralcervicalregion(mandibular,sublingual
notsubstantiatedthis.Tumoursatthissiteare
glands),baseoftheear（parotidgland),upperlipor
equallyuncommoninthecat,althoughonereport
maxilla(zygomaticgland),or within themucosa of
indicatesthatSiamesemaybeover-represented,
theupper lipor tongue(accessory salivary tissue).
suggestingapossible
breed
predisposition
Alternatively,theremaybeahistoryofrapidlydevel-
(Hammeretal.,2001).
opingsalivarymucocelescausedbyerosionor
Allmajorglandsmaybeaffected,buttheman-
obstructionof the salivary duct(Stubbsetal.,1996).
dibularandparotidglandsappeartobemost
Halitosisanddysphagiamaybeseeninpatients
frequentlyinvolved.Tumoursmayalsobederived
withlargemassesthathaveintra-oralinvolvement.
fromtheminorsalivaryglandsscatteredthrough-
Tumoursofthezygomaticglandusuallypresent
outthemucosaofthetongueandorpharyngeal
withexophthalmos.Differentialdiagnosesforsali-
surfaces.
varyglandmassesorenlargementincludemuco-
Salivaryglandtumourscanbeeitherbenignor
celes,abscesses,sialadenitis,sialadenosis,necro
malignant,withmostofepithelial
originand
tizingsialometaplasia,obstructivesialolithiasisand
malignantinnature.Benign salivary tumoursare
regionallymphadenopathy.Cats arereportedto
veryunusual;theyincludeadenomaandlipoma
presentwithmoreadvancedlesionsthandogs
(Stubbs etal.,1996;Brown etal.,1997;Shimoyama
(Hammeretal.,2001).
et al.,2006).
Mostmalignantsalivarytumoursinthedogand
catare simple adenocarcinomas(Hammeretal.,
2001).Otherlessimportanthistological typesinclude
squamous cellcarcinoma,basal celladenocarcin-
oma,mast cell tumours,osteosarcoma,malignant
fibrous histiocytoma,malignant myoepithelioma,
oncocytoma,carcinomaexpleomorphicadenoma,
carcinosarcoma（malignantmixedtumour)and
complex,anaplastic,mucoepidermoid orclear cell
carcinomas.Someobscuretumoursofcomplex
originmayrequireimmunohistochemicaltechniques
toidentifykeratinorvimentinexpressionformore
accurate typing(Perez-Martinezet al.,2000).
Salivaryglandtumoursmaybelocallyinvasive
and locoregional lymphnodemetastasisiscommon
inbothdogs and cats.Distant metastasisisless
commonandmaybeslowertodevelop.Reported
sites of distant metastasis include,eyes,lung
kidneys and bone.In one study,17%and8%of
15.14
Tumourof themandibularsalivaryglandwith
dogshadlymphnodeanddistantmetastasis,
associatedmucocele.
202
Chapter15b
Tumoursof thesalivaryglands
Earlydiagnosisandtreatmentarereportedto
improvesurvival timessignificantlyindogs(Hammer
etal.,2001).Fine-needleaspiration(FNA)of thepri-
marymassisrecommendedtodifferentiateneoplas-
ticfromnon-neoplasticdiseaseandhasbeen
reportedforthediagnosisofadenocarcinomainthe
dog(Militernoetal.,2005).If this doesnotprovide
thenecessaryanswer,incisionalwedgebiopsycan
beperformedtoobtainadefinitivediagnosis.
However,thesurgeonshouldensure that the surgi-
calincisionispositionedwithinthefieldofsubse-
quent resection.In some cases, tumour-like (but
non-neoplastic)lesions suchas necrotizing sialo-
metaplasiamaybedifficulttodifferentiatefromneo-
plasiaevenwiththeaidofhistopathology(Militerno
et al.,2005).
Theregional lymphnodesshouldbeexamined
initiallyusing palpationand FNA,but subsequent
imagingprocedures(CT,MRl)mayreveal enlarge-
mentofregionallymphnodesnotreadilyaccessible
bypalpation.Asearchfordistantmetastaticdisease
thatincludesthoracicradiographsandabdominal
15.15
Tumourof theparotidsalivarygland.Surgical
ultrasonographyshouldbemade,butinviewofthe
biopsyrevealedthemasstobean
widedistributionofpotentialtargettissuesitmaybe
adenocarcinoma.
difficult toruleoutsecondarytumoursentirely.
Clinicalapproach
Management
Primarylesionsshouldbecarefullypalpatedto
assess theirinfiltration intolocal tissues.Theman-
Surgery
dibularandsublingualglandsareeasytopalpate,
Aggressive surgicalresectionis the treatmentof
butthemarginsoftheparotidglandaremorediffuse
choiceforbenignandnon-metastasizedsalivary
and,therefore，difficult to assess.Assessment of
tumours.Duetotheinvasivenatureofmostmalig-
zygomaticlesionsbypalpationisnotnormallypossi-
nantsalivaryneoplasms,andthecloseassociation
ble，duetotheir locationwithintheorbit.Plainfilm
withvital structuresof theheadandneck,wideexci-
sionmaynotbepossibleinmanycases.Tumoursof
centosseous structuresordistortionofregional
themandibularandsublingualchainarenormally
anatomy,butaloneitisgenerallyinsufficientforeval-
amenabletoconventionalsialoadenectomy,although
uationofextentorinvasiveness.
thereislittletissueavailablefortheresectionofaddi-
Diagnosticimaging （Figure 15.16),particularly
tionalmarginsofsurrounding tissue.Several differ-
ultrasonographicexamination,maybehelpfulinfur-
entsurgical techniquesmaybeused.
therassessmentofthemass.Whensurgical man-
agementiscontemplated,it maybeappropriate to
Mandibular/sublingualsialoadenectomy
considercontrast-enhanced CTorMRI of theregion
toassessinvolvementof theinfiltrationofsurround-
Lateralapproach:Thelateralapproachgivesmore
ingsoft tissuestructures.
immediateaccesstothemandibularandintracapsu-
larsublingualglandsthantheventralapproach,butit
isrestrictedinitsexposureofthemorerostralpor-
tionof thesublingual chain.
1.Positionthedoginlateralrecumbencywitha
packplaced underthecervical spine.
2.
Makeacurvedskinincisioncaudalto,but
followingtheangleof,themandible.
3.
Split theplatysma(panniculus)muscleinthe
directionofitsfibres,allowingthelinguofacial and
maxillaryveinstobeidentified.
4.
Isolatethecapsuleofthemandibularglandfrom
the surrounding connective tissue;it should
remainintactthroughoutthedissection.
5.
Ligatevesselsonthemedialaspectof thegland.
6.
Applytractiontothemandibularglandandduct;
thiswillelevatethesublingualchainfrombelow
15.16
Sialogramofaparotid adenocarcinoma.
thedigastricusmuscle.Small arteryforcepscan
203
Chapter15bTumoursofthesalivaryglands
beplacedoneafteranothertohelptoelevatethe
Zygomaticsialoadenectomy
duct,whichmaybesectionedwithoutligation
oncetheoralmucosaisreached.
1.
Approachzygomaticlesionsviaaskinincision
madealongthedorsalbrimof thezygoma.
Ventralapproach:Themajoradvantageofthis
2.
Reflecttheorbitalfasciadorsallyandthe
approachistheexcellentaccessitprovidestothe
massetermuscleventrally.
rostralportion ofthe sublingual chain(Ritter et al.,
3.It may be necessary to resect the zygoma and
2006).
replaceitlater,ortocutadorsalwindow'inthe
bonetoexposethegland intheorbit.
1.Position the dog indorsal recumbency.
4.
Tumoursof theglandcannormallybeeasily
2.Makeanincisionmedialtothemandibleand
dissected,althoughitissometimesdifficultto
lateraltothelarynxtopermitthemandibular
distinguishthetumourfromsurroundingorbitalfat.
gland tobeidentified.
Replaceordiscardthesectionedzygoma.
3.Thecapsuleof themandibularglandshould
6.Repair the periosteum and close the skin.
remainintact(asfaraspossible)whilethe
sublingualglandisdissectedrostrally.The
Othermodalities
salivarychainrunsventraltothedigastricus
Although radiation therapy(Evans and Thrall,1983;
muscleandmustbepassedbeneaththismuscle
Carberryetal.,1987)andchemotherapy(Hammer
during thedissection.
etal.,2001)havebothbeenusedinthetreatmentof
4.Identifytherostralcomponentof thechainby
salivarytumours,toofewcaseshavebeenreported
tractiononthedistalsectionandresectbyblunt
toallowanysignificantconclusionsregarding
dissection.
efficacytobedrawn.
Parotidsialoadenectomy
Resectionofthenormalparotidglandisadifficult
Prognosis
andprolongedprocedurethatiscomplicatedbyits
indistinctmarginsandtheproximityofthefacial
Theprognosisforsalivaryglandtumoursisvariable
nerve.Fragmentsoftheglandarefrequentlyleftin
andislikelytobeworseinpatientswithadvanced
situ,duetothedifficultyofrecognizingthelimitsof
diseaseorinthoseforwhichcompletesurgicalexci-
thesalivary tissue.Furthermore，goodmarginsof
sioncannotbeperformed.Therearefewreportsof
normaltissueareveryrarelyavailable（Figure
survivaldataforlargenumbersofsalivarytumours.
15.17).Removal ofparotidgland tumours is,there-
Clinicalexperience based on small numbers
of
fore,somethingofa surgicalchallenge.Resection of
caseswouldseemtoindicatethatincompleteresec-
thefacialnerveisapossiblecomplication.
tionaloneislikelytoresultinlocalrecurrence;how-
Thedifficultyofachieving
sufficient
surgical
ever,incompleteresectionfollowedbyradiation
marginshasledtotheexplorationofradiation
therapymayresultinacceptablelocalcontroland
therapyasapostoperativeadjuvantforparotid
long-termsurvival.Histopathological featureswere
lesions(Evans andThrall,1983).
notfoundtobeofprognosticimportanceinone
study(Hammeretal.,2001),although clinical stage
waspredictive.TheMSTsfordogsandcatswithsal-
ivarymalignancieshavebeenreportedas550days
and516days,respectively(Hammeret al.,2001).In
anotherstudyofsixdogswithsalivarycarcinomasin
particular,theMSTwas74days,withalldogseven-
tuallydevelopingpulmonarymetastaticdisease
(Hahn and Nolan,1997).
References and furtherreading
Brown PJ.LuckeVM.Sozmen MandWyattJM（1997)Lipomatous
infitrationofthecaninesalivarygland.JournalofSmallAnimal
Practice38,234-236
Carberry CA,Flanders JA,AndersonWIand Harvey HJ （1987)Mast
celltumourinthemandibular salivaryglandinadog.Cornell
Vetrinaran77-
Evans SMand ThrallDE(1983)Postoperative orthovoltage radiation
therapyofparotidglandadenocarcinomainthreedogs.Journalof
theAmericanVeterinaryMedicalAssociation182,993-994
glandneoplasms.Proceedings,AmericanCollegeofVeterinary
RadiologyandVeterinaryCancerSociety
HammerA,GetzyD,OgilivieGetal.2001)Salivaryglandeoplasiain
15.17
Parotidsalivaryglandfromthedogshownin
thedogandcat:survivaltimesandprognosticfactors.Journalof
Figure15.15,afterresectionof te
theAmericanAnimalHospitalAssociation37,478-482
Head KW,Cullen JM,Dubielzig RR et al.(2003)Histological
adenocarcinoma.Thedissectioniscomplexandthereare
classification of salivary gland tumors of domesticanimals.In:
minimal surgical marginsavailable.
HistologicalClassificationofTumorsoftheAlimentarySystemof
204
Chapter15b
Tumoursof thesalivaryglands
DomesticAnimals,2ndSeries,Vol.10.pp.58-72.ArmedForces
VeterinaryPathology37,350-353
InstituteofPathology,AmericanRegistryofPathologyandThe
Ritter MJ,vonPfeil DJF,Hauptman JGandWalshaw R（2006)
WorldHealthOrganizationCollaboratingCenterforWorldwide
Mandibularand sublingual sialoceles in the dog:aretrospective
ReferenceonComparativeOncologyWashington
evaluationof41cases,using theventralapproachfortreatment.
NewZealandVeterinaryJournal54,333-337
carnivores.VeterinaryJourna8212-215
Shimoyama Y,Yamashita K,Ohmachi Tet al.(2006）Pleomorphic
KoestnerAandBuergerL(1965)Primary neoplasmsof the salivary
adenomaofthesalivaryglandintwodogs.JournalofComparative
glandsinanimalscomparedtosimiliartumorsinman.Veterinary
Pathology134,254-259
Pathology2.201-226
MiliternoG,BazzoRandMarcatoPS(2005)Cytological diagnosisof
and cats:245cases（1985-1988)Journal oftheAmerican
mandibularsalivaryglandadenocarcinomainadog.Journalof
VeterinaryMedicalAssociation198,465-469
VeterinaryMedicine,SeriesA52,514516
Stubbs WP,Voges AK.Shiroma JT and Wolf J（1996）What is
Perez-MartinezC,Garcia FernandezRA,ReyesAvilaLEetal.(2000)
yourdiagnosis？Infiltrativelipomawithchronicsalivary duct
Malignant fibroushistiocytoma(giantcelltype)associatedwitha
obstruction.JournaloftheAmericanVeterinaryMedical
malignant mixedcell tumor in the salivaryglandofadog.
Association209,55-56
205
Tumours of the c
oeso
BrianJ.TrumpatoriandRichardA.S.White
Introduction
thebeetle;thismay thenbeingestedby thedog
directlyortheremaybeaparatenichostsuchasa
Primarytumoursoftheoesophagusareextremely
snake orrat.Oncein theprimaryhost,the larvae
rare in both dogs and cats.In Europe,primary
migratewithin3weeksthroughthestomachwallto
oesophagealneoplasiaissorarethatitisdifficultto
thearterialsupplyandthencetothethoracicaorta,
assessitstruerateofoccurrence.Inregionsofthe
wheretheyremainfor2-3months.Thelarvae then
worldwhereoesophagealsarcomaoccurssecond-
movetotheoesophagealwall,wheretheybecome
arytoinfestationwiththeparasiteSpirocercalupi,
surroundedbyacysticgranulomatousnoduleand
theincidenceisstillreportedtobeonly0.5%ofall
also become sexually mature.These granulomas
tumours,making S.lupi-associated sarcomas the
communicatewiththeoesophageal lumenviafistu-
majorcauseofoesophagealneoplasia.
lae,throughwhicheggspassperiodicallyintotheali-
Ingeneral,mostoesophagealtumoursarelocally
mentary tract.
invasiveandmetastasizebyhaematogenous,lym-
S.lupimaydamageavarietyoftissuesalongits
phaticordirectextension.
migratorytract.Injurytotheaorticwallmaypromote
Primarytumoursofthe.canineoesophagusare
thedevelopmentofaneurysms,potentiallyleadingto
mostcommonlymalignant.Theyincludesquamous
rupture of thevessel.Gastrointestinalgranulomas
cellcarcinoma(SCC),osteosarcoma(OSA),fibro-
mayalsorupture,withfatal consequences.Oesopha
sarcoma(FSA)and leiomyosarcoma(Campbelland
gealorpulmonarylesionscangiverisetoneoplastic
Pirie,1965;CarbandGoodman,1973；Ridgewayand
lesions,whichare usually sarcomas.Occasionally,
Suter,1979;McCawet al.,1980;Farese etal.,2008)
patientsmaydevelophypertrophicpulmonaryosteo-
SarcomasassociatedwithSpirocercainfectionare
pathysecondarytothoracicoesophageal orpulmon-
mostcommonlyOSA,followedbyFSAandundiffer-
arylesions,andsignsof thismayprecedethose
entiatedsarcoma.Theseparticular tumourshave
associatedwiththeprimarysite.
beenreported tooccurmorecommonlyinthebitch
(Ranen et al,2008).In the cat, SCC has been
unclear duetotheirrarity,althoughingestion of
reportedtooccurinthemid-thoracicoesophagus,
carcinogens has been shownexperimentallyto
mostcommonlyinqueens.Metastaticdiseasefrom
induce cancerindogs(Sasakiet al.,1984).
malignantlesionsmaybefoundintheregionalnodes
orlungs,aswell asinvariousabdominal organs.
Benign tumours,including leiomyomas
and
Presentationandclinicalsigns
plasmacytomas,are encounteredinfrequentlyand
aremostcommonlylocatedattheterminaloesopha-
Importantsignsassociatedwithoesophagealneo-
gusandgastriccardiaatthelevelofthelower
plasiareflectluminalobstructionandincludedys-
oesophageal sphincter.
phagia,discomfortonswallowing,regurgitationand
Secondaryinvasionof theoesophagusissome-
aspiration.Weightlossandcoughareseeninmore
timesencountered inassociationwithcervicalperi-
advancedcases.Patientsmaybepresentedforthe
oesophageal tumours（e.g.thyroid)orwith tumours
investigationoforthopaedicsignsorlamenesswhen
of themediastinumandthorax(e.g.thymoma,heart
affectedbyhypertrophic pulmonary osteopathy
base,lung).
associatedwithS.lupi-inducedlesions.Clinico-
pathologicalchangesassociatedwithS.lupi infec-
Aetiologyandpathogenesis
tionincludenon-regenerativeanaemia,neutrophilic
leucocytosis,hyperproteinaemiaandelevatedalka-
OesophagealtumoursassociatedwithSpirocerca
linephosphatase(Mylonakisetal.,2006).Arecent
lupi infectionareencounteredinareasoftheworld
retrospectivestudycomparingbenignandmalignant
wheretheparasiteisendemic;thisincludespartsof
lesionsassociatedwithS.lupiinfectionfoundthat
the south-easternUSA,Africa,Israel,Turkey,India,
anaemiaandleucocytosisweremoreseverewith
PakistanandareasofAsia.Dogsinfestedwith the
malignant thanwithbenigntumours.Additionally,
parasitepass embryonatedeggs intheirfaeces,
olderdogs,spayed females,and thosewithhyper-
whichare theningestedby dung-eatingbeetles.The
trophicosteopathyweremorelikelytohavemalig-
eggsdeveloptoaninfectivethirdstageandencystin
nanttumours(Dviretal.,2008)
206
Chapter15cTumoursof theoesophagus
Clinical approach
Advancedimaging
Advanced imagingmodalities includingCTandMRI
Radiography
shouldbeconsideredinpatientssuspectedofhav-
Radiographic investigation is indicated in patients
ingmalignantdisease，todetermine theextentof
withregurgitationordysphagiaandinallpatients
localinvasionandtoevaluateforregionalanddis-
presenting withhypertrophic osteopathy.Thoracic
tantmetastases.Intheeventthatattemptstoobtain
viewsmaydemonstrateasofttissuemasswithinthe
abiopsysampleviaendoscopyareunsuccessful,
thorax,thepresenceofanabnormalgasshadow
cervical,thoracicorabdominalexplorationmaybe
withintheoesophageallumen,dilatationofthe
requiredforconfirmationof thediagnosis.
oesophagusproximal tothemass,orcompressionof
the oesophageal lumen.
Other
MassesassociatedwithS.lupi usuallyaffectthe
If infectionwithSpirocercalupiissuspected,afaecal
terminalportionoftheoesophagusbutcranially
analysisshouldbeperformed.
locatedmasseshavealsobeendescribed(Dviret
al.,2001).Spondylitis of the thoracicvertebrae is
considered apathognomonicfinding forS.lupi infec-
Management
tion,theunderlying pathogenesis of which is
Medicalmanagement
unknown.Aorticmineralizationsecondarytosmall
OesophagealgranulomasassociatedwithS.lupimay
aneurysmscanalsobeidentifiedincasesofS.lupi
progresstomalignantdisease;theyarereportedto
infection.Secondaryconditionsincludingtrachealor
respondwelltotreatmentwithoraldoramectin(Berry,
bronchial displacement,pleural effusion,aspiration
2000;vanderMerweetal.,2008).Theuseofchemo-
pneumonia,mediastinitis and pneumothorax may
therapyfortreatmentofoesophagealsarcomahas
alsobeidentified.
notbeenclinicallyevaluatedbutinonerecentreport
Positivecontrastradiographic(Figure15.18)and/
thehistologicalscoresof lungmetastasesinseveral
orfluoroscopicevaluationstudiesoftheupper
dogsreceivingdoxorubicinforoesophagealsarco-
gastrointestinal tractwillhelptoidentifythelevel,
maswerenotedtobesignificantlylowerthanthose
locationandnatureofthelesionandhighlightthe
oftheprimarytumoursatthetimeofnecropsy,
mass.The lungs,mediastinal and bronchial lymph
suggestingthattheroleofchemotherapydeserves
nodesshouldalsobeevaluatedradiographicallyfor
furtherevaluation(Ranenet al.,2008).
evidenceofsecondarydisease.
Similarly,theroleofradiationtherapyiscurrently
unknown,butitisfeltthatitwouldbeoflimitedvalue
duetothepotentialforundesirableeffectstothe
surrounding structures.Palliativetreatmenttypically
includesnutritionalsupportviaoesophagostomyor
gastrostomytubefeeding.
Surgery
Accesstotheoesophagusisobtainedviacervicall
midlineincisionorintercostal thoracotomy.Insome
casesbenignsmoothmuscletumoursmaybe
removedatthoracotomy,ifthereisminimaldistur-
banceof themucosalsurface （Figure 15.19).
15.18
Lateralthoracicradiographdemonstrating
compressionof thedistal oesophagus
associatedwithprimaryoesophageal leiomyoma.
Endoscopy
Directobservationandbiopsyofthemasscanbe
achievedusing oesophagoscopy.Most malignant
lesionsappearulcerated.Rarebenignlesionsmay
beasymptomatic,andcomparativelylargelesions
maybedetectedincidentally.
Abiopsysamplemaybetakenusingendoscopy:
malignantlesionsmaybeamenabletohavingasam-
pletakenfrom theirulceratedsurface.Toensurea
representativesample,severalspecimensshouldbe
obtained,asulceratedmassesoftencontainareasof
inflammationandnecrosisonhistopathology.When
theluminalsurfaceisintact(asmaybethecasewith
smooth musclelesions),obtainingarepresentative
15.19
Resectionofoesophageal leiomyomavia
biopsysampleviaendoscopycanbedifficult.
thoracotomy.O,oesophagus;T,tumourmass.
207
Chapter15cTumoursof theoesophagus
Exposureofcaudal lesionsvialateralthoracotomyis
rubicin(plus carboplatin in 1case).
normally excellent,whilemid-thoracic sections are
Thelong-termdevelopmentofmetastaticdisease
more difficult to access. In some cases of benign
fromoesophageal malignanciesisnotwellrecorded,
smoothmuscletumours,completeexcisionmaybe
but in the report byRanenet al.(2008)53%of dogs
performedviathoracotomyorcoeliotomy.
undergoingnecropsydemonstratedvariousabdomi-
Incontrast,however,because of the advanced
nalorganmetastases（renal,stomach,spleen,pan-
nature ofdisease atpresentation,patients
with
creas,adrenal,heart,tongue and lymphnode)and
malignantlesionsrarelyrepresentrealisticsurgical
pulmonarymetastasis.Localrecurrencewasnoted
candidates.Intrathoracicresectionsareoftenmade
intwoof threedogsthathadundergoneresectionof
moredifficultbypoorsurgicalexposure,theneedto
theprimarytumour.
resectalargesegmentofoesophagusandthe
Tumours arising
fromperi-oesophagealstruc-
resultantdefectinoesophageallength.The major
turesmaybeamenabletomanagement,inwhich
complicationofsuchresectionsistensionacrossthe
case the outlok isnormally dependent ontheprog-
anastomosissite,leading todehiscenceand infec-
nosisfortheprimarytumour.
tion.Avarietyofsolutionshavebeendescribedin
ordertorecruitorsubstitutetissueforreconstruction,
includingpatchingofdeficitswithpericardium,vas-
Referencesandfurtherreading
cularized intercostalmuscle,orpackingwithomen-
tum,and theuse of Gortex stents（Straw etal.,
BerryWL(200o)Spirocercalupi esophagealgranulomasin7dogs:
1987).Replacementbymicrovascularanastomosis
resolutionaftertreatmentwithdoramectin.JournalofVeterinary
usingjejunumorcolonhasbeendescribed
for
InternalMedicine14.609
CampbellJandPirie H(1965)Leiomyoma of the oesophagus ina dog.
oesophageal tumours in human patients,but has
VeterinaryRecord77,624
onlyrarelybeenreportedinsmallanimals(Gregory
CarbA and GoodmanD（1973)Oesophageal carcinoma in the dog.
etal.,1988;Kuzma et al.,1989).Expandable
JournalofSmallAnimalPractice14,91
Dvir E,Kirberger RM and Malleczek D (2001）Radiographic and
chrome/cobaltstentshavealsobeenusedasatem-
computedtomographic changes and clinicalpresentationof
porarypalliativemeasure inhumans tomaintain
spirocercosisinthedog.VeterinaryRadiologyandUltrasound42,
119-129
oesophagealpatency.Advancementofthestomach
DvirE,KirbergerRM,MukoreraVet al.(2008）Clinical diferentiation
through thediaphragmorthecreationofaniso-or
betweendogswithbenignandmalignantspirocercosis.Veterinary
antiperistalticgastrictubemaybeusedforresection
Parasitology155,80-88
oflesionsaffectingthedistaloesophagusorcardia.
Farese JP, Bacon NJ, Ehrhart NP et al.(2008) Oesophageal
leiomyosarcoma in dogs:surgical management and clinical
outcomeoffourcases.Veterinary andComparativeOncology6,
31-38
Prognosis
Gregory CR,Gourley IM,Bruyette DS and Schulz LJ （1988）Free
The prognosis forbenign smooth muscle tumours of
dog.JournaloftheAmericanVeterinaryMedicalAssociation193,
230-232
the oesophagus is excellent (Hamilton,1994;Rolfe,
HamiltonTA and CarpenterJL(1994)Oesophagealplasmacytoma ina
1994).However,the outlook forprimarymalignan-
dog.Journalof theAmericanVeterinaryMedicalAssociation204.
1210-1211
cieshas historicallybeenconsidereduniversally
Kuzma AB,Holmberg DL,Miller CW,BarkerIand Roth J (（1989)
poor,sinceadequate surgicalresectionandrecon-
Esophagealreplacementin thedogbymicrovascular colon
structionisrarelyfeasible.
transfer.VeterinarySurgery18,439-445
McCawD,PrattMandWalshawR（1980)Squamouscellcarcinomaof
Inareportofsixdogstreatedbypartialoeso-
theoesophagusin thedog.Journal of theAmericanAnimal
phagectomy for Spirocerca-associated sarcomas,
HospitalAssociation16,561-563
theMSTwas267days;fiveofthesixdogsalso
Mylonakis M,Rallis T,Koutinas AFetal.(2006)Clinical signs and
receivedconcurrentchemotherapywithdoxorubicin
clinicopathologicabnormalitiesin dogs with clinical spirocercosis:
39cases(1996-2004)Journalof theAmericanVeterinaryMedical
（Ranen etal.,2004a,b).
Association228,1063-1067
Morerecently,theoutcomeofmarginalresection
RanenE,DankG,LavyEetal.(2008）Oesophageal sarcomasin dogs:
histologicaland clinicalevaluation.TheVeterinaryJourna/178,78
oflow-gradeoesophagealleiomyosarcomaswas
84
reportedinfourdogs.lnthreeof thesedogs,tumour
Ranen E,Lavy E,Aizenburg1et al.(2004a)Spirocercosis-associated
margins were considered‘dirty';in the fourth,the
esophageal sarcomas in dogs:aretrospective study of 17cases
（1997-2003）.VeterinaryParasitology119,209-221
marginswerecleanbutclose.Twoofthedogsdied
Ranen E,ShamirMH,ShaharRetal.(2004b)Partial esophagectomy
fromcausesunrelatedtotheirneoplasmand the
withsinglelayerclosurefortreatmentofesophagealsarcomasin6
remaining two were alive at 388 and 405 days,
dogs.VeterinarySurgery33,428-434
Ridgeway RL and SuterPF(1979) Clinical andradiographic signs in
respectively,demonstrating the potential for
pro-
primaryandmetastaticesophagealneoplasmsof thedog.Journal
longedsurvivalwithmarginalresectionofmalignant
of theAmericanVeterinaryMedicalAssociation174,700-704
smoothmuscletumours(Fareseetal.,2008).
Rolfe DS,Twedt DCand Seim HB（1994) Chronic regurgitation or
Ahistologicalgradingschemehasrecentlybeen
vomitingcausedbyoesophageal leiomyoma inthreedogs.Journal
of theAmericanAnimalHospitalAssociation30,425-430
proposedforoesophagealsarcomasbutinareport
Sasaki O,SaitoT,Matsukuchi T et al.（1984) Endoscopic study of
of32dogs(Ranenetal.,2008)therewasnoappar-
chronological changesleadingtocancerintheesophagusofdogs
entcorrelationnotedbetweensurvivalandgradeor
inducedbyN-ethyl-N-nitro-N-nitrosoguanidine.Gastroenterology
Japan19,456-463
tumourtype.Atotalof19dogsunderwentsurgery.
StrawRC,Tomlinson JL,Constantinescu G,TurkMAMand Hogan PM
TheMSTforthe10dogsthatsurvivedtheimmedi-
(1987)Use of a vascular skeletal muscle graft for canine
esophageareconstructionVeterinarySurgery16155-156
atepostoperativeperiodwas278days;6ofthose
van derMerweLL,KirbergerRM,Clift S etal.(2008)Spirocerca lupi
casesreceivedadjuvantchemotherapywithdoxo-
infectionin thedog:areview.TheVeterinaryJourna/176,294-309
208
Tumours of the stomach
JonathanBrayandRetoNeiger
Introduction
Tumourbehaviour
Neoplasiaofthestomachisuncommoninthedog,
Carcinomas
accountingfor<1%of alltumours.Most stomach
Histologically,carcinomas can be subclassified into
tumoursaremalignant,andadenocarcinomarepre
signet ring cellcarcinoma,undifferentiated carcin-
sents themajority(42-72%)ofcases.Other malig-
oma,tubularadenocarcinoma andscirrhous adeno-
nanttumourtypesthathavebeenreportedindogs
carcinoma,buttheclinicalbehaviouroftheseisvery
includefibrosarcoma,leiomyosarcomaandlympho-
similar.Carcinomasinfiltratethegastricmucosaand
sarcoma.Benign tumours(leiomyoma,most com-
extend intosubmucosa,muscularis andserosa.This
monly)havealsobeenrecorded,andmayoccurat
resultsinaverytough,scirhouslesionthatissome-
thecardiaorcaudaloesophagealregion.Avarietyof
timescalled alinitisplastica'becauseof itsnon-dis-
othersporadictumourshavebeenreported,includ-
tensiblenature.Later,acentralulceriscommonly
ingplasmacytoma,polyps,squamouscellcarcinoma
found.At the time ofdiagnosis,mostgastriccarcino-
andcarcinoid tumours(from the enterochromaffin
mashavespreadtotheregional lymphnodes,lung,
cells).Althoughtumoursofthestomachmayarise
liverandspleen.
anywhere,sitesofpredilectioninclude theincisure
Adenomas
angularisandthepyloricantrum.
In the cat,B-lymphocyticlymphoma is themost
Adenomatouspolypscancauseoutflowobstruction
common tumourofthestomach;affectedcatsare
duetothe closeproximitytothepylorus.In humans,
typicallynegativeforfelineleukaemiavirus.
theyareconsidered tobepremalignantlesions.
Lymphomas
Gastriclymphomasarisefromthesubmucosaor
Aetiologyandpredispositions
fromthemucosa-associatedlymphoidtissue
(MALT).They canbe either diffusely infiltrative or
Helicobacterpylori infectionhasbeenstrongly
localized,ormay be seen aspartof more general-
associatedwithdevelopmentofgastricadenocarcin-
ized lymphoma.
omaand.mucosal-associatedlymphoidtissue
(MALT) lymphoma in humans.In dogs,there is no
Mesenchymaltumours
indication thatgastricHelicobacterspp.arean
Mesenchymaltumourscanbedividedintogastro-
increasedriskfactorforgastrictumours.However,a
intestinalstromaltumours(GiSTs)and leiomyomas
study in cats suggested that Helicobacter spp.
onthebasisofhistologicalfeaturesandcell
mightberesponsible
forMALT
lymphomas
differentiation.
(Bridgefordetal.,2008).
InhumansGiSTsarisefromtheinterstitialcells
Inhumans,avarietyofdietarysubstanceshave
ofCajal.Theyconstitutethemajorityofmesenchy-
beenimplicatedasriskfactorsinthedevelopmentof
maltumoursofthegastrointestinaltractandcan
gastric tumours,e.g. salt, starch, mycotoxins and
occur anywhere,though are most commonin the
polycyclichydrocarbonsfound insmokedmeatand
stomachandsmall intestine.GiSTshaveaspectrum
fish.Experimentalstudiesshowed thatlong-term
fromsmallbenigntumourstofranklymalignantsarc-
administrationofnitrosaminescaninducecarcin-
omas.They typically expressKIT(CD117).In dogs,
omasinthedog.Duodenogastricrefluxhasbeen
GISTsseemtooccurmorecommonlyin thecolon
showntobeariskfactorforgastriccancerina
andsmallintestine,whereasonly19%of themare
murine model.
located inthestomach.
Somebreedpredispositionsarenoted.Belgian
Leiomyomasarecomposedofwelldifferentiated
Shepherd Dogs have a higher than average
smoothmusclecellsthataretypicallypositivefor
incidenceofgastriccarcinomaand thedisease
smoothmuscleactinanddesmin,markersfordiffer-
seems tohave aheritable component (h2=0.09
entiation.These tumours arenegative for CD117and
±0.02).Collies and Staffordshire Bull Terriers are
typically have anindolent clinicalcourse.Indogs,
alsoreportedtobeatincreasedriskofgastric
leiomyomaoccursmostcommonlyinthestomachof
carcinoma.
geriatricanimals,withapredilectionformales.
209
Chapter15dTumoursof thestomach
Presentation and clinicalsigns
isalsoimportanttocheckforevidenceofregional
lymphnodeenlargementormoredistantmetastasis
Patientswithgastriccancertypicallypresentwitha
tootherabdominalorgans,especiallytheliver.When
historyofchronicvomiting,butmayotherwiseappear
anobviouslesionisevidentwithultrasound,itmay
tobehealthy.Thevomitingmaybeintermittentand
bepossibletoobtainguidedaspirationsamplesfor
cytologicalevaluation.
foodatatimewhenthestomachwouldnormallycon-
Flexiblegastroscopypermits directvisualization
sidered tobeempty(6-8hours after feeding).The
ofandbiopsyfromthegastricmucosalsurface,and
historyisusuallychronic,withsignsdevelopinginsid-
isperhapsthemosteffectivemethodforidentifyinga
iouslyoveraperiodofweeksormonths.Insome
lesion affecting the stomach lumen.Gross findings
patients,fresh or digested blood (haematemesis)
mayincludeaproliferativemassonthemucosalwall
maybeseeninthevomitusonoccasion.
ofthestomachoradeepulcerationofthemucosal
Theremaybeweightlossinchroniccasesdueto
surface(Figure 15.21).More subtle changes may
a combination ofpoor digestion，anorexia,protein
occurwithlymphoma,withthemucosal surface
andbloodlossfromtheulcer,andcancercachexia.
developingageneralisedsmoothorlightlycobble-
Metastatic diseasemayresult inother systemic
stoned appearance.
abnormalities.
Clinicalapproach
Diagnosis
Confirmationofthediagnosisofgastricneoplasia
requiresrulingoutmetabolicorconcurrentdisease
usingphysicalexamination,haematologyand bio-
chemistry.Rarelyisphysicalexaminationandabdomi-
nalpalpationofbenefit.Becausethestomachis
completelyprotectedbythecostal arch,mostdogs
mayhavenodetectableabnormalitiesonphysical
examination,thoughsome cranial abdominal pain
maybeevident inlatestages.
Imaging
a
Plainradiographsareofteninsensitivetothesubtle
changesassociatedwithgastricneoplasiabutmay
behelpfulto assessother abdominalorgans.In
somecases,however,plainfilmsmaydemonstratea
markedlydistendedstomach,withcaudalextension
ofthe gastric fundus and body，and increased
dimensionofthepylorusifoutflowobstructionis
present.Positivecontraststudiesmaydemonstrate
fillingdefects.Fluoroscopyisusefulinevaluating
gastricperistalsisandpyloricsphincterfunction.
Ultrasonographyismorehelpfulthanradiography
andmayshowthickeninganddisruptionofthe
normal layering of the gastricwall(Figure 15.20).It
(b)
15.21
(a)Endoscopicviewofagastricmassshown
bybiopsytobe aplasmacytoma.(Reproduced
fromBSAvAManualofCanineandFeline
Gastroenterology,2ndedn)(b)Endoscopicviewofa
gastric adenocarcinoma.(Courtesy of EHall)
Histology
Duetothesuperficialnecrosisandinflammation
thatisoftenassociatedwithmalignantlesions,it
isimportanttoperformmultiplebiopsiesinorder
toobtain representative neoplastic tissue.Taking
samplesfromulcerated,necroticorhaemorrhagic
areasshouldbeavoided.False-negativehistopatho-
Ultrasound imageshowingmarkedlythickened
logicalresults arenotuncommon.The clinician
15.20
gastricmucosaandlossof thetypicalmucosal
shouldendeavourtotakemultiplesamplesfrom
layerduetolymphomaina10-year-oldLabrador
severallocationsaboutthelesiontoimprovediag-
Retriever.(Courtesy of PMantis)
nosticaccuracy.
210
Chapter15d
Tumoursofthestomach
Staging
Benignneoplasmsanddiscretetumourslocated
Stagingofgastrictumoursismainlydonebydiag
inthefundusorbodyofthestomachcanoftenbe
nosticimaging (ultrasonography,thoracicradio-
excisedcompletely,butthesurgeonmusttrytotake
adequatemargins(atleast1-2cmofnormaltissue
gastric adenocarcinomas(Figure 15.22)suggests
beyondobviouslyabnormaltissue)toensuregood
that theremightbeaworseprognosisfor local infil-
long-termsurvival.Partialgastrectomyisindicatedif
trationand metastaticdisease.Nohistologicalgrad-
a largesectionof thefundusisinvolved.
ingsystemisused.Gastriclymphomasarestaged
Radiation therapy
asdescribed inChapter19.
Radiationtherapyforgastrictumoursisnotwell
toleratedinsmallanimals,duetothesensitivityof
T-Primary tumour
thegastrointestinaltractandtheassociatedorgans
TO
No evidence of primary tumour
toradiationtoxicity.
T1
Tumour not invading serosa
Chemotherapy
T2
Tumour invading serosa
Cytotoxicdrug therapyforgastriccarcinomashas
notbeen seen tobeeffective indogs andcats.In
T3
Tumourinvadingneighbouring structures
humanmedicine,intraperitoneal5-fluorouracilorcis-
N-Regional lymph node status
platinplusintravenous5-fluorouracil hasbeen used,
but with littlesuccess.
NO
No evidenceof lymph node involvement
Treatmentofgastriclymphomas
N1
Regionallymphnodesinvolved
Gastriclymphomasareonlytreatedsurgicallyifper-
N2
Distant lymphnodes involved
forationislikelywithoutsurgicalintervention.They
areusuallytreatedwithastandardchemotherapy
M-Distant metastasis
MO
No evidence of distantmetastasis
partialresectionoflocalizedlymphomaisprognosti-
cally advantageous isnot known.Eradicationof
M1
Distant metastasis detected
H.pylorioftenreversesMALTlymphoma inhuman
15.22
WHOclassificationofgastrictumours.
patients,butitisunclearwhether eradicationof
Helicobacterspp.inanimalswithlymphomamight
haveasimilareffect.
Management
Prognosis
Surgery
Ingeneral theprognosisforgastrictumours ispoor.
For gastric neoplasia (except gastric lymphoma),
The MST for gastric adenocarcinoma is 2 months,
widesurgicalresectionisindicated.Due tothe
despitesurgicalexcisionofthetumour;veryrare
insidiousandnon-specificnatureoftheclinical
cases may survive longer(3 years).Incontrast,
signs,malignantgastrictumourscanbeofconsider-
leiomyosarcomashaveabetterprognosisif theycan
ablesizeandmayhavealreadymetastasizedprior
beresectedcompletelyandnocomplicationsarise
tosurgery.In thesepatients,tumourresectionwould
during thepostoperativeperiod;forpatientswho
requireextensivereconstructivesurgery.End-to-end
survivetheimmediatesurgicalintervention(2
gastroentericre-anastomosiswithagastroduoden-
weeks),the MST is 12months (Kapatkin et al.,
ostomy(BilrothI;seeBSAVAManualofCanineand
1992).Leiomyomasandotherbenigntumourshave
FelineAbdominalSurgery)canbeusedif the
agoodprognosisaftercompleteresection,with the
tumourinvolvesonlypartsoftheantrum/pylorus.
possibilityof thediseasebeingcured.Theprognosis
Unfortunately,in many patients,the tumour is so
forgastric lymphomasin dogs ispoor,significantly
advancedthatsurgicalexcisionisprecluded.
Extensive surgery,suchas a gastrojejunostomy
worsethanthatof multicentriclymphoma.
(BilrothIl),whichissometimesperformed
in
humans,results in high morbidity indogs and
shouldbeperformedonlyinexceptionalcases.
Referencesandfurtherreading
Survivaltimesareextremelypoor(14days,onaver-
Bridgeford EC,Marini RP,Feng Yet al.(2008)Gastric Helicobacter
age)andthepost-surgical courseis complicated
speciesasacauseof felinegastriclymphoma:aviablehypothesis.
withahighmorbidity.Whilsttotalgastrectomyhas
beendescribed,itisalsoassociatedwithnumerous
Kapatkin AS,Mullen HS,Matthiesen DT and Patnaik AK （1992)
Leiomyosarcoma indogs:44cases（1983-1988).Journalof the
complicationsandconsiderablemorbidity.
AmericanVeterinaryMedicalAssociation201,1077-1079
211
Tumours of the small intestines
B.DuncanX.Lascellesand RichardA.S.White
Introduction
youngerdogs,withameanageof7years.There is
predilectionforthemale;nobreedpredisposition
Most intestinal tumoursinsmallanimalsaremalig-
hasbeenrecorded.
nant,withadenocarcinomabeing mostcommon in
Thecauseof mostsmall intestinal tumours inthe
thedog，and lymphoma mostcommon in the cat.
dogremainsunclear.Diethasbeendemonstratedto
Tumoursof thelargeintestinearemorecommon,
haveanimportantcausalrelationshipinseveral
withtherectumconsideredtobethemostcommon
typesofhumanintestinal cancer,butitsroleinani-
site(seeChapter15f).
mal tumoursis uncertain.
Thedog
The cat
Thesmall intestinesareanuncommonsiteofneo-
Intestinaltumoursarealsounusualinthecat;the
plasia in the dog and account for<1.0% of all malig-
meanageofaffectedanimalsis11years.
nanttumours.The jejunum,ileum and caecum are
Lymphomaisbyfarthemostcommon typeof
reportedtobethemostcommonsites,and the
tumourinthesmall intestine,withthejejunumand
importanthistological typesincludeadenocarcin-
ileumbeinginvolvedmostfrequently.Lesionsof
oma,gastrointestinalstromaltumours(GiSTs),leio-
small intestinallymphomainthecatmaybesolitary
myosarcoma,leiomyomaand lymphoma(Birchardet
ordiffuse.Mesentericlymphnodeinvolvementis
al.,1986;Maasetal.,2007).
commonly foundwithdiffuselesions;somereports
Halfofallgastrointestinaltumoursinthedogare
alsosuggestthatrenal involvementiscommon(Turk
adenocarcinomas;thereisameanageof9yearsat
etal.,1981).Fewer than25%ofcatswithsmall
presentation.Collies,German Shepherd Dogs and
intestinallymphomaarefoundtobepositivefor
Boxersmaybeatincreasedriskforthisdisease;
felineleukaemiavirus.
malesarealsoatincreasedrisk.Adenocarcinomas
Mastcell tumours(MCTs)areoccasionallyfound
causeluminalobstruction:usuallythroughdevelop-
in the small intestine of older cats(mean age 13
mentinanannularpatternofgrowth,therebycaus
years).Intestinal MCTsin catsbehave aggressively
ing constriction of the bowel;or,less commonly,
andcommonlymetastasizetothemesentericlymph
throughintraluminalintrusion.Histological classifica-
nodes,theliver,the spleen and other sites.
tionintoacinar,solid,mucinousandpapillarygroups
Adenomatouspolypshavebeenrecordedinthe
hasbeenlinkedwiththepatternofgrowth.Bothlym-
duodenum of oriental cats(MacDonald et al.,1993).
phaticandvascularmetastasesmaydevelopfrom
Adenocarcinomasarereportedtobefound inthe
adenocarcinomasandcanbefoundin themesen-
ileumandileocaecalregion,althoughonereport
tericlymphnodes,peritoneal cavity,omentum,liver,
indicatesthejejunumtobethemoreimportantsite
kidneys and lungs.
(Kosovsky etal.,1988).The Siamese is reported to
Recently,ithasbeenrecognized that tumours
beatincreasedriskforadenocarcinomas.Metastatic
previouslyclassifiedasleiomyosarcomasandleio-
spreadatthetimeofdiagnosisisseeninthree-
myomasmayinfactbeGiSTs.Thisnewinformation
quartersofcats，andtransabdominalspreadgiving
regarding classificationmayhelpdefine improved
risetoinvasionofadjacentabdominalorgansis
treatmentsin thefuture,thoughonerecentstudy
commonlyencountered(Figure15.23).
concluded thattherewerenosignificantdifferences
insurvivalforthesethreetumourtypes,histological
orimmunohistochemical characteristics(Maaset
Presentation andclinicalsigns
al.,2007).In general,these tumour types affect
slightly older dogs（10-11years);there is no
Theclinical signsofsmallintestinalneoplasiaare
reportedbreedpredisposition.Whenthesetumours
variedandnon-specific.
Discretelesions (e.g.
occur inthe small intestine,they tend to develop
adenocarcinomas)areoftenannularandcommonly
secondarydiseasemoreslowly;althoughnodal dis-
giverisetosignsofobstruction,includingvomiting,
easemayoccur,thediseaseisoftenlessaggres-
anorexia,abdominalpainandweightloss.Melaena,
sivethanadenocarcinoma.
diarrhoeaandmicrocyticnormochromicanaemia
Lymphomaaccountsforapproximately10%ofall
maybeseeninpatientswithulceratedlesions.A
gastrointestinalcaninemalignanciesandaffects
palpableabdominalmassispresentinsomecases.
212
Chapter15eTumoursofthesmall intestines
Thickeningof the intestinal wallandreduction in
luminaldiameter
Ulcerationof theintestinal wall.
Ultrasonographicexamination is often helpful,
bothfordetectingmasslesionsandforproviding an
appreciationof increasedbowel wall thickness.It
mayalsoshowalossoflayeringoftheintestinalwall
in thecaseof infiltrativetumourssuchaslymphoma.
However,arecentreportof idiopathiceosinophilic
massesof the gastrointestinal tract indogs high-
lightedthatdiffusethickeningcanbeseenwithnon-
neoplastic disease(Lylesetal.,2009).Involvement
ofother abdominal sites,resulting in mesenteric
lymphadenopathy,hepatomegalyor splenomegaly
mayalsobereadilyidentified.Ultrasound-guidedfine
15.23
Laparotomyinacatwithwhatwasfoundtobe
metastaticadenocarcinomaspreadingtothe
needleaspiratescanberetrievedfromintestinal
spleen,liverand local lymphnodes.Followingresection of
sitesandfromotherabdominalorgans,suchasthe
theintestinal massandsplenectomy,thecatsurvived
liverand thespleen.
another 14monthswithnoother treatment.
Coeliotomy and biopsy
Theonsetofclinicalsignsisoftenchronicand
Definitive diagnosis and clinical staging of small
insidiousovermanyweeks,althoughacutepresenta-
intestinal tumoursmaybeachievedatcoeliotomy.
tionofanimalswithcompleteobstruction,orperfor-
The mesentericlymphnodesand,inparticular,the
ation that has led to peritonitis,is possible.These
livershouldbecarefullyinspectedforanyevidence
signsmaybeseenwitheitherbenignormalignant
ofmetastaticdiseasebeforeresectionisattempted.
lesions.Onerecentstudyof smoothmuscletumours
Suspectedmetastaticdiseaseshouldpromptbiopsy.
indogsfound thatdogswithcaecaltumourswere
Apositivebiopsyresultdoesnotprecludereason-
morelikelytopresentwithperforationandperitonitis
ablesurvivalfollowingresectionoftheprimary
thanwhenthetumourwaslocatedmoreproximally
lesion,andsuspectedmetastaticdiseaseisrarelya
in the smallintestines(Maas et al.,2007).
compellingreasontocease treatmentatthisstage
Diffuse or infiltrating tumours (e.g.lymphoma)
ofevaluation,butbiopsyresultsmaybeinformation
tendtocauselessacutesignsandmaycausemore
ownerswould likeinordertodecidewhethertopro-
chronic signs of malabsorption,weight loss,hypo-
ceed further.
proteinaemiaorintermittentdiarrhoea(duetoaltered
Coeliotomyis alsoindicatedinthecaseof
motilitypatterns).
infiltratingtumoursofthesmallintestinetopermit
Involvementofmesentericlymphnodesmay
multiplebiopsiestobetakenforconfirmationofthe
resultinobstructed lymphaticdrainageandlymph-
diagnosis.Biopsy sites should becarefullyclosed
angiectasia.
andomentalpatchesapplied.
Rarely,tumoursmayreleasebiologicallyactive
agents such ashistamine (e.g.MCTs),which may
giverisetocutaneouschangesoracutediarrhoea.
Management
Surgery
Clinicalapproach
Theextentof theresectionnecessaryforremovalof
theprimarylesionshouldbeassessed following
In allcases of small intestinalneoplasia,a thorough
biopsy;surgical techniqueiscovered in theBSAVA
evaluationofallsignsassociatedwiththedisease
ManualofCanineandFelineAbdominalSurgery.In
（e.g.anaemia,hypoproteinaemia,occult faecal
most instances,wide local resection with margins
blood)shouldbecombinedwithasearchforregional
extending2-4cmoneithersideof thetumourcanbe
anddistant metastaticdisease.Biochemicalinvesti-
performedby
enterectomy
andanastomosis.
gationsmayrevealelectrolyteabnormalitiesresult-
Resectionsshouldbeperformedbetweenbowel
ingfromintestinalobstructionorlowserumprotein
clamps（Figure 15.24)(orwithanassistant's fingers
levelsresultingfrominfiltratingtumours.
actingtoclampthebowel)andextendedthroughthe
supporting mesentery.Where appropriate,regional
Imaging
lymphnodesshouldbeincludedinanenblocresec-
Diagnosticimagingisthemosteffectivediagnostic
tion.Thisisnotpossibleandshouldnotbeattempted
tool fortheidentificationofneoplasticlesionsofthe
whenaffectedlymphnodesareintimatelyinvolved
small intestines.Commonradiological signs associ-
withmesentericvesselssupplyingunaffectedpartsof
atedwithsmallintestinalneoplasia include:
thebowel.Enblocresectionofthiskind ispossible
withmoreaggressiveresectionsoftheiliocaecocolic
Signsofileusassociatedwithluminalobstruction
junction area.Mesenteric vessels supplying the
Anabnormal transit time(increased or
affectedsegmentofbowelshouldbeligated,aswell
decreased)
as thevesselssupplyingthemesentericbordersof
213
Chapter15e
Tumoursofthesmallintestines
Thetypeofsuturepatternusedforbowelanasto-
mosesinthedogandcatisprobablybestlimitedto
asimpleapproximatingtype.Thesimpleinterrupted
patternisanon-crushing technique thatcausesmin-
imaltissueischaemiaattheanastomoticsite.This
techniquecallsforaccurateandatraumaticplace-
mentofthesuturesandappositionofthetwoseg-
mentsofbowelinagentlemanner.Thisis
technicallysimpleandisrecommendedforgeneral
useinallanastomoses in small animals.Crushing
techniquesresultinmorelocal ischaemia thansim-
pleinterrupted sutures,butarereportedto allow
morerapidmucosalregenerationandlessscarfor-
mation(Brown,2003).The twotechniquesprovide
similar immediateresistance toburstingpressure,
andtheirlong-termhealingresultsshowlittlediffer-
ence.Theuseofa continuoussuturepattern has
beendescribed;thisresultsinlessmucosaleversion
andmorepreciseappositionof thesubmucosal layer
thaninterruptedpatterns(Weismanetal.,1999)
(a)
Thechoiceofsuturematerial tendstobeamat-
terfortheindividualsurgeon.Syntheticabsorbable
materialswillfaroutlastthehealingperiodandthere
isnoindication,evenincachexichypoproteinaemic
cancer patients,touse permanentmaterials.The
useofmonofilamentsuturematerialsratherthan
braidedmaterialsisconsideredtoresultinless
trauma totheintestineas thesutureispassed
throughit,andtoprovidelessriskofbacterialwick-
ing'fromthelumen.Conversely,however,itisworth
bearinginmindthatbraidedmaterialsallowforsub-
stantiallygreaterknot stability.Since manymore
patientsexperiencepostoperativecomplications
throughdehiscenceoftheanastomosisthanever
succumbtoinfectionresultingfrombacterialmigra-
tionalongsuturematerial,thismaybethemore
compellingargument.
Anastomosisusing surgical stapling instruments
isundoubtedlya muchlesstime-consumingoption,
althoughitismoreexpensive.Goodoutcomeshave
been reported in clinical cases (White，2008),
althoughonly5of those15casesunderwentresec-
tionandanastomosisforintestinaltumours.
Irrespectiveofthesuturematerialandpattern
chosen for the anastomosis,meticulous care in
techniqueisveryimportant.Ischaemicdamageisan
(c)
importantfactorleadingtofailureofthesurgery.
Once the intestinal anastomosis iscomplete,the
15.24
Resectionandanastomosisofan
supportingmesentery shouldbe carefullyrepaired to
adenocarcinomainthemid intestineofacat.
(a)Themesentericvessels areligated.(b)Theresection
ensurethatincarcerationcannotoccur.
iscomplete.Anastomosisisinitiatedbyplacing the
Onlyrarelyistheresectioncompromisedbylack
mesentericand antimesenteric sutures.Note theDoyen
ofadjacent normaltissue,but small intestinal sur-
forcepsinplace-oftenthesearetoolargeforsmaller
gerymaybebesetbyavarietyof otherproblems:
animals,and anassistant'sclampedfingersworkbetter.
(c)Resectedspecimen.Notethatthemarginofgrossly
Duodenal lesionsmaybecomplicatedbythe
normaltissueontheleftisconsideredbarelysufficient
(1.5 cm）.
problemsinherentinpreservingthebiliaryand
pancreaticducts,andmarginsmayneedtobe
thetwoendstobeanastomosed.Thesevessels
modifiedtoaccommodatethis
shouldbecarefullylookedfor;iftheyarenotligated，
Adhesionsassociatedwithtumourgrowthare
significantbleeding canoccur following surgery.
commonandmayrequireextensiveresectionof
Somesurgeonsprefertoresectanyevertingmucosa
involvedmesentery
toensureaccurateappositionofthetwocutends
Perforationsofneoplasticbowelmaybe
although,withpractice,thisisrarelyimportant.
encounteredwithresultinglocalizedor,
214
Chapter15eTumoursofthesmallintestines
occasionally,generalized,peritonitisandmay
following surgical resection (Maas et al.,2007).
requiretheuseofperitoneal lavageand
Following excision,1-and2-yearrecurrence-free
drainageprocedures.
periodswere80%and 67%for smallintestinal
tumours.Nodifference in survivalwasnoted for
Resectionandanastomosisisassociatedwitha
tumourtype,location,histologicalgradeorimmuno-
riskofdehiscence.Onestudyevaluated115cases
histochemical characteristics.This is similartoprevi-
of intestinal anastomosis in dogsandcats andcon-
ousreports of gastrointestinalleiomyosarcomas
cluded thatpreoperativefactorssignificantlyassoci-
(Cohen et al.,2003).
atedwithdevelopmentofanastomoticleakagein
Inonereportofsmallintestinaladenocarcinoma
dogsincludedpreoperativeperitonitis,lowserum
in thecat,twodistinctsurvivalgroupswerenoted:
albumin concentration,neutrophilia,and the pres-
about50%diedwithin2weeksofsurgery,whilethe
enceofanintestinal foreignbody(Ralphsetal.,
averagesurvivaltimeforthosecatssurvivinglonger
2003).Subsequentworkfound hypoproteinaemia not
was 15months(Kosovsky et al.,1988).Extended
tobeariskfactor(Shalesetal.2005).Discriminant
survival(MST 12months)was seenin some cats
analysisshowedthatdogswithtwoormoreofthe
withdetectablenodaldiseaseatsurgery，suggesting
followingfactorswerepredictedtodevelopanasto-
thatadvanceddiseaseisnotnecessarilyconsistent
moticleakage:preoperativeperitonitis;intestinalfor-
withagraveprognosis.High-gradesmall intestinal
eignbody;lowserumalbuminconcentration.Dogs
lymphoma thatisnotamenabletosurgicalresection
withgastrointestinaltumoursrarelypresentforfor-
maybetreatedmedicallywithcytotoxicdrugs,
eignbodies,buttheotherfactorsarelikelysignifi-
butwithlittleexpectationoflong-termsurvival.Few
cant riskfactorsincancercases.
catsexperienceremissionsfor>6months.Catswith
low-grade,diffusealimentarylymphomaoftenres-
Chemotherapy
pondfavourablytochemotherapyandachievelong
Whilesomelymphomalesionsofthesmallintestine
periods of remission.
aresufficientlylocalizedtoallowsurgicalresection,
manyintestinal lymphomasaremoresuitable to
chemotherapeuticmanagement.However,in the
Referencesandfurtherreading
treatmentoflargemasses(especiallyin thelarge
BirchardSJ,CoutoCGandJohnsonS（1986)Non-lymphoidintestinal
bowel),aggressive cytotoxic therapy can result in
neoplasiain32dogsand14cats.Journalof theAmericanAnimal
rapidperforationoftheintestine.Intheseinstances,
HospitalAssociation22,533-537
surgicalresectionorcytoreductivesurgerypriorto
Brown DC(2003)Smallintestines.In:Textbookof SmallAnimal
SurgryrddindDatBadshilad
medicaltherapyispreferred,toreducetheriskof
Cohen M.Post GS and Wright JC (2003)Gastrointestinal
thiscomplication.
Variousprotocolshavebeen
leiomyosarcomain14dogs.JournalofVeterinaryInternalMedicine
reportedforthetreatmentofsmallintestinallym-
17,107-110
KosovskyJG,Matthiesen DIandPatnaikAK（1988)Small intestinal
phomaincats(seeChapter19a).Theuseofchemo-
adenocarcinomaincats:32cases.JournaloftheAmerican
therapyforothersmall
intestinalneoplasia
is
VeterinaryMedicalAssociation192,233-235
LylesSE,Panciera DL,Saunders GKandLeibMS(2009) Idiopathic
unproven insmall animals.
eosinophilicmassesof thegastrointestinal tractindogs.Journalof
VeterinaryInternalMedicine23,818-823
Radiationtherapy
Maas CP,ter Haar G,van der GaagIand Kirpensteijin J (2007)
Radiotherapy hasvery limited application in the
Reclassification of small intestinal andcecal smooth muscle
tumorsin72dogs:clinical,histologic,andimmunohistochemical
managementofsmall intestinalmalignancybecause
evaluation.VeterinarySurgery36,302-313
ofthedifficultyofirradiatingtheaffectedareaaccu-
MacDonaldJM,Mullen HSandMoroffSD(1993)Adenomatouspolyps
oftheduodenum in cats:18cases（1985-1990).Journalofthe
ratelyusingexternalbeamtherapyandthehighrisk
RalphsSCJessenRandLipowitzJ2003Riskfactorsforleakage
AmericanVeterinaryMedicalAssociation202,647-651
ofradiation-associatedcomplicationssuchasperfo-
followingintestinal anastomosis in dogs and cats:115cases
rationand adhesions.
(1991-2000).JournaloftheAmericanVeterinaryMedical
Association223,73-77
ShalesCJ,WarrenJ,AndersonDM,BainesSJandWhiteRAS(2005)
Complicationsfollowingfull-thicknesssmall intestinalbiopsyin66
Prognosis
dogs:aretrospective study.Journal ofSmallAnimalPractice46,
317-321
Inthedog,wideresectionofwelldifferentiated,non-
Turk MAM,Gallina AM and Russel TS (1981)Non-hemopoietic
metastasizedsmall intestinaladenocarcinomaspro-
gastrointestinalneoplasiaincats.VeterinaryPathology18,614-
620
videsafavourableprognosis;localrecurrenceor
Weisman DL,Sweak DD,Birchard SJ and Zweigart SL （1999)
secondaryextensionofthediseaseisunlikely.
However,lesions that havemetastasizeddonot
interruptedpatternforentericclosureindogsandcats:83cases
（1991-1997）.Journalof theAmericanVeterinaryMedical
have the same favourable prognosis.Small intestinal
Association214,1507
White RN(2008)Modified functionalend-to-end stapled intestinal
leiomyomas,leiomyosarcomas andGiSTshave
anastomosis:techniqueandclinicalresults in15dogs.Journalof
beenfound tobeassociatedwithagoodprognosis
SmallAnimalPractice49,274-281
215
Tumoursofthecolonand
rectum
JonathanBray
Introduction
Althoughcancerofthegastrointestinaltractindogs
Normal epithelium
andcatsisuncommon,themajorityoftumoursthat
Loss of APC
dooccurwilldevelopwithintherectumorcolonof
thedog.Tumoursof thelargeintestinerepresent
36-60%ofallgastrointestinalneoplasmsinthe
Hyperplasticepithelium
dog,and10-15%of all feline gastrointestinal neo-
DNA hypomethylation
plasms.Tumoursaremorelikelytoaffecttheolder
animal,withmaleanimalsmoreatriskofdevelop-
Earlyadenoma
ingcarcinoma.Polypsoccurwithequalfrequencyin
malesandfemales.ColliesandGermanShepherd
Activation of K-ras
Dogshaveanincreasedprevalenceofcarcinoma,
asdoestheSiamesecat.Histological tumour types
Intermediateadenoma
include epithelial,mesenchymal,neuroendocrine
androundcell.
Lossof 18q TSG
Lateadenoma
Aetiology
Inhumans,nearly800,oo0new colorectal cancer
Lossofp53
casesarebelievedtooccurgloballyeveryyear.
Carcinoma
Colorectalcanceraccountsforapproximately10%of
allincidentcancers.Theannualworldwidemortality
ratefromcolorectalcancerisestimatedatnearly
450,0oo.IntheUSA,colorectalcanceraccountsfor
Invasionandmetastasis
nearly10%ofcancermortality.Themajorityofcolo-
rectalcancerinhumansisanage-relateddisease,
andsporadiccolorectalcancerincreasesdramati-
15.25
Thestepwiseprogressionofcancer
callyabovetheageof45-50yearsforallgroups.In
developmentforproceedingfromdysplasiato
humans,a geneticpredisposition tocolorectal can-
anoutright invasivemalignantneoplasmhasbeenwell
ceriswellrecognized,andsome familylinesinherit
describedinhumans.Geneticand environmental factors
conspiretochange thenormal mucosatoapremalignant
genemutationsthatmaketheirlikelihoodofdevelop-
adenomatouspolypandontoafrankcolorectalcancer
ingcolorectalcancer almostinevitable（e.g.APC
overthecourseofmanyyears.
gene).For the majority of the population,however,
theaetiologyofcolorectalcanceriscomplex,and
involvesinterplayofenvironmentalandgeneticfac-
characteristicswithhumandisease.Allcolorectal
tors.Obesityandtotalcaloricintakeareindependent
adenomasandabout50%ofallcarcinomasindogs
riskfactorsforcolorectalcancer,asrevealedby
demonstrateincreasedB-cateninactivity.Basedon
cohort andcase-controlstudies.Ingestionofred
theresultsofonestudy,however,malignantprogres-
meatbutnotwhitemeatisassociatedwithan
sionin canineintestinaltumoursdoes.notappearto
increasedcolorectalcancerrisk.Ithasbeenesta-
bedependentonalossofE-cadherinorB-catenin
blishedthatgeneticandenvironmentalfactorswill
expression,norisit stronglyassociatedwithover-
conspiretochange thenormalmucosatoapre-
expressionofp53.Positivestainingforincreased
malignantadenomatouspolypandthentoafrank
p53expressionwasobservedinabout44%of
colorectalcanceroverthecourseofmanyyears
tumour types,including hyperplasticpolyps (50%),
(Figure 15.25).
adenomas(48%),carcinoma in situ(41%),adeno-
Asimilarlevelofmoleculardetailhasnotbeen
carcinomas(75%),and invasive carcinomas(35%).
elucidatedinsmallanimalpatientstoindicate
However,therewasnosignificantrelationbetween
whethertheprogressionofcolorectalcancershares
MSTandp53immunoreactivity.
216
Chapter15fTumoursofthecolonandrectum
Tumourtypes
Epithelialtumours
Polyps
Adenomatouspolypsareanon-neoplasticcondition
thatmaybedetectedoccasionally,mainlyinthedog.
Theyareusuallylocatedattheanorectaljunction,but
maybefoundseveralcentimetreswithintherectum.
Althoughbenigninbehaviour,manyhaveevidenceof
earlymalignanttransformationonhistologicalassess-
ment.Thecharacteristicfeatureofpolypoiddiseaseis
theabsenceofinvasionbeneaththelaminamuscula-
risonbiopsy,sogrossevaluationaloneisinsufficient
toachievea diagnosis.Polypsmaybe singleormulti-
ple,andareusuallypedunculated fromthemucosal
15.26
Sessilemucosalcarcinomainadog.
surface.Occasionally,a thickcarpet’ofsessilepoly-
poidtissuemaybefoundextendingavariablelength
tumoursmaybeirregularandulcerated,butthereis
aboutthecircumferenceoftherectalwall.
frequentlynointraluminal'mass'evidentand themis-
diagnosisofstricturemaythereforebemade.
Carcinoma
Colorectalcarcinomaisamalignanttumour,with
Carcinomaisthemostcommonlyencountered
metastasis toregionalnodes and lung(andother
tumouraffectingthecolorectalregionofthedog.It
sites)occurring.Directextensionofdisease through
mayoccuranywherealong thelengthofthecolon,
theserosaofthecolonintotheabdominalcavitycan
thoughamid-rectallocationismostcommon.
also occur(Figure 15.27).
Histological descriptionsincludeadeno-(gland-form-
ing),mucinous,signet ring and undifferentiated or
Mesenchymaltumours
solidforms.Grossly,thetumourmaybeintraluminal
Leiomyomasarebenigntumoursofsmoothmuscle
(pedunculated,frequentlymultiple,usuallyulcerated;
cellsbetweentheserosaandsubmucosaandform
Figure15.26)orannular.Withprogressiveinvasion
extraluminalmasses.Theycangrowtoaconsider-
about thecircumference ofthe rectum,annular
ablesizebeforetheycauserecognizableclinical
lesionswillultimatelycausecircumferentialnarrow-
signs.Signs areusuallydueto thephysicalsize of
ingofthecolon.Themucosalsurfaceofannular
themasscausingocclusionof theintestinal lumen.
Lymphnode
Serosa
Muscle
Mucosa
Stage0
Stagel
Stagell
StageIl
StageIv
15.27
Epithelialcolorectal tumoursdevelopinitiallyonthesurfaceof themucosaandarethusamenabletolocal
resectionwithamarginofsurroundingmucosa,providedthereissufficientlocaltissueavailableforclosure.
Colorectalcarcinomashowsmalignantpotential toinvadedeeperintotheunderlyingtissues.Oncethetumourhas
invadedthroughthesubmucosa,full-thicknessresectionof therectalwall willbenecessarytoachieveadequatelocal
management.
217
Chapter15fTumoursofthecolonandrectum
Insevencasesofcolorectalleiomyoma,twowere
asymptomaticatthetimeoftumourdetectionand
fiveshowed clinicalsignssuchas tenesmusor
abnormal stoolformation.Themucosa over the
tumourusuallyremainsintactandsoulcerationand
haemorrhageareuncommon.
Inhumans,mosttumourspreviouslydiagnosed as
leiomyosarcomaarenowclassifiedasgastrointestinal
stromal tumours(GiSTs),whicharebelieved toarise
fromthecellsofCajalandarecharacterizedbyhigh
vimentinimmunoreactivity,lowalphasmoothmuscle
actinreactivityandexpressionofthereceptortyrosine
kinaseKIT(CD117).GISTshavebeenrecognized in
the dog(see Chapter15d).
Roundcell tumours
Lymphoma tends to affect the small intestine(see
Chapter15e)ofbothcatsanddogsmorecommonly
15.28
Asmostcolorectal tumoursoccurinthelastfew
than the colorectalregion.Extramedullaryplasma-
centimetresof the colon,itisusuallypossibleto
cytomascanoccurrarelyinthecolorectalregion.
assess thelesionwithrigidproctoscopy or(ashere)by
Theyareusuallysolitarywithnosystemicsigns.
gentle eversionof therectal mucosa.
evacuationofstoolusingawarmwaterenemamay
Presentationand clinicalsigns
berequired,dependingonthelocationof themass.
The size,location,distributionand appearanceof
Clinicalsignsrelatetothephysicalpresenceofthe
thelesionshouldbenoted.
mass,the effects ofmucosal ulceration,and pain
Abdominalandthoracicradiographsshouldalso
associatedwithtumourinfiltrationintotheintestinal
beobtained.Althoughtheyareunlikelytoreveal
musclewall.Becausethesurfaceofthemassis
muchmorphologicalinformationonanintraluminal
likelytobefriable,frankbloodmaybeseenonthe
mass,theradiographscanbeassessedforevidence
surfaceof thestool,orthedogmaybleedspontane-
of tumourextension(localizedperitonitis)ormetasta-
ouslyfromtherectum.Occasionally,theownermay
sis(enlarged sublumbarnodes,presenceof thoracic
reportavisiblemassprotrudingfromtheanusdur-
lesions).
ing defecation,and constipation.Additional signs
Ultrasonography is probably themost effective
that may occurincludeanorexia,weight loss,vomit-
andleastinvasivediagnosticmodalityavailableto
ing,and diarrhoea.
detectandevaluatemasseswithintheintestinal
tract.Thelimitationwithcolorectalmasses,however,
is their caudal location,andtheinability to scan
Clinical approach
beyond thepubicbrim.Pararectal scanningmay
provideareasonableacousticwindow,butoverall
Becausesomeof theclinicalsignsdescribedare
evaluationofthelastfewcentimetresoftherectum
similartothosereportedforinflammatoryorobstruc-
ispoor.Ultrasonographicfeaturesofcertaintumours
tivedisease，acareful investigationisessentialto
may assist in diagnosis:
differentiatethetwo.Duetothenon-specificnature
oftheclinical signs,diagnosisofacolorectalcancer
Transmuralthickening,withthelossofnormal
isoftenmadeverylateinthecourseofdisease.
gastrointestinalwalllayering,ischaracteristicof
Earlydiagnosisandpromptmanagementofmost
intestinaladenocarcinoma（Figure15.29)
colorectal cancers,particularlyepithelial cancer,is
Leiomyosarcomashavebeenreportedtohavean
morelikelytobeassociatedwithagoodclinical
eccentricgrowthpattern,withalackofregional
outcome.
lymphadenopathy.Whenthelesionextendsover
4cminlength,thepresenceof poorlyechogenic
Physicalexamination
cavitiesiscommon
Acompletephysicalexaminationisimportant.Rectal
Transmural circumferentialthickeningwith
examinationshouldalwaysbeperformed,as the
completelossof layering,associatedwith
majorityofcolorectaltumoursarewithindigitalreach.
moderateorseverelymphadenopathy,hasbeen
Itmaybepossibletoprolapse themassforvisual
reportedforfeline andcaninelymphoma.
inspection inthe sedatedanimal(Figure 15.28).The
presenceofapainful,circumferential strictureshould
Ultrasonographymayalsoassistindetermining
promptconsiderationofannularcarcinoma.
theextentofalesionandthusinsurgicalplanning.
TheuseofCTorMRIhasnotbeenspecifically
Imaging
describedincolorectalcancerinthedogor cat,
Rigidproctoscopyorendoscopy(performedunder
althoughitmaybeofvaluetoassesstheextentand
generalanaesthesia)willenableamoredetailed
local invasivenessof largeintrapelvicstromal tumours
inspectionofthecolorectalcanal.Preoperative
toassist surgical planning(Figure 15.30).
218
Chapter15fTumoursofthecolonandrectum
parenchymalorganssuchaslung and liver),adeno-
carcinomaalsohasatendencytoinvadethrough
thelayersof theintestine.Onceit hasinvaded through
theserosa,it may continue toprogressby trans-
coelomicspread.
Riskfactors
Thereareseveralfactorsassociatedwiththeanatomy
andfunctionofthecolonthatpredisposeittosignifi-
cantoperativeandpostoperativecomplications.
Manyof thetumoursthatoccurwithintherectum
arelocatedwithinthelast6cmofthebowel.
Surgicalaccesstothislocationcanbeimpeded
bythepelvis.Avarietyofsurgicalrouteshave
15.29
Transmural thickeningwiththelossofnormal
beendescribedthatfacilitateaccessbut,in
gastrointestinalwall layering ischaracteristicof
intestinal adenocarcinoma.A large intraluminalmass is
almostallcases,theworkingroomforthe
alsoevident.
surgeonisgreatlyconstrained.
Preservationof continenceisasignificant
challengewheneversurgeryiscontemplated on
theterminalrectum.Sphinctercontinencecan
usuallyberetainedprovidedashort cuff(1-1.5
cm)ofrectalmuscularisandtheexternalanal
sphincterispreserved.Inaddition,during
7（2）
dissection,itisvitaltoprotectthepelvicplexus,
pudendalnervesandrectalnerves,bystaying as
closetotherectalserosaaspossible.Whenever
afull-thicknessresectionoftherectumis
contemplated,itislikelythatsomeorallofthese
elementswillbedisruptedwhichcanresultin
profoundpostoperativeincontinence.
Postoperativetenesmusandpostoperative
scarringcanbeaprobleminsomepatients,
particularlywhenthelumenissmall.Thiscan
AT2-weightedsagittal imageofalargerectal
alsocomplicatesurgicalrecoveryinsomecases.
15.30
leiomyoma.Thesizeof themassmade
Thebacterialcontentof thecolonishighand
evaluationofresectabilitydifficultonpalpable
surgicalstimulationofthecolonresultsinahigh
characteristics alone.Theinformationobtainedby
levelofcollagenaseactivity.Thiseffectively
imagingin this case indicated that the masswas not
prolongs the‘lagphase'of healing to5-7days
invasiveintosurrounding structures,andsurgery（viaa
combined dorsal rectal and abdominal approach)
postoperativelybeforegainsintensilestrengthof
proceeded uneventfully.
thewound areseen.Thiscanresultina
weakenedsuturelineandsubsequent
Biopsy
dehiscenceifanysurgicalerrorshavebeen
Incisionalbiopsyshouldbeperformedonanylesions
made.Excessivetissuetrauma,vascular
thatarepresent.Biopsysamplesshould includethe
compromiseorstrangulationof tissueswith
submucosallayertoallowthepathologisttoassessthe
suture,maypotentiatetheriskofdehiscence.
extentoftumourinvasion;thesmallsamplesobtained
Surgicalstrategies
usingendoscopicforcepsmaythusfailtoreveal the
Surgicaloptionsformanagementofcolorectal
trueinvasivepotentialofmanylargecolorectalmasses.
tumourswillbedictatedbythelocationandbiologi-
Ultrasoundcanbeusefultoguidebiopsyofintestinal
massesand enlargedlymphnodes,fortumourdiagno-
calbehaviourofthemassandbyconsiderations
sisand stagingpurposes.
regardingpostoperativecomplications(seeabove).
Typically,thereisatrade-offbetweenanaggressive
'curativeintentresectionwithahigherrateof
Management
potentialcomplications,and amore conservative
Surgery
management.Underlying any decisionregarding
Surgicalexcisionis thetreatmentofchoicefor all
surgicaldoseisthefundamentalissuethatmost
colorectallesionsotherthanlymphoma.Theextent
colorectal tumourswillbemalignantandthusmay
ofsurgeryrequiredwillbeindicatedbythetumour
alreadyhaveescapedanyhopeofcurativeman-
diagnosis.Recommendedmarginsforresectionvary
agement,regardlessoftheextentofsurgicalinter-
from1-2cmforrectalpolypstoaminimumof2-8
vention.Beingcertainof tumourstageis,therefore,
cmformalignancies.Aswell ashaving apotential to
spread toregional lymphnodes(andthencetoother
atedwithahighriskofpostoperativecomplications.
219
Chapter15fTumoursofthecolonandrectum
Surgicalstrategies described for themanage-
shouldbemadewithoneortwolayersofsimple
mentofcolorectalcancermaybedividedintothose
interruptedsutures.
wheretheresectionisperformedentirelywithinthe
Colonicresection and anastomoses:For
lumenoftherectum(so-calledintraluminal)and
lesionslocatedwithinthecolonoratthe
thosewherefull-thicknessresectionand anastomo-
colorectaljunction,aventralmidlinelaparotomy
sisof thecolon isperformed.Furtherinformationon
combinedwithapubicosteotomy/symphysiotomy
manyofthesetechniquesisavailableintheBSAVA
canbeperformed.Thisaccessprovides
ManualofCanineandFelineAbdominalSurgery.
opportunityforextensiveresectionofcolonic
lesionsandallowsamoreconventionalend-to-
Intraluminalprocedures:Intraluminalprocedures
end anastomosis(EEA)tobeperformed.Surgical
onlyenableresectionofthemucosaandsubmucosal
accessremainslimitedandtheuseofEEA
liningof therectum,andarethusmostappropriatefor
staplingequipmentcanthereforebehelpfulto
lesionsarisingfromthemucosalsurface(i.e.epithelial
performtheanastomosissafely.
tumours,<Stage 2).Once the tumourhas invaded
intothemuscularwalloftherectum,intraluminal sur-
Colostomy:Inhumans,theuseofcolostomysys-
geryisunlikelytoprovidecurativetumourcontrol.
temsisrelativelycommonplacetoovercomethe
inevitableconsequencesofextensiveresectionof
Rectalpull-out,ormucosaleversion:Asimple
colorectalcanceraffectingthedistalsectionsofthe
andeffectivetechniqueformanagementofmost
largebowel.Colostomyprovidesthepatientwithan
solitarybenignlesions(e.g.pedunculated
abilitytomanagetheirtoiletfunctionsinahygienic
masses)only.The mucosal liningisprogressively
andaccessiblemannerfollowingresectionofthe
evertedfromtheanus,usingatraumaticforceps,
distal sectionsof thecolon.Inveterinarypatients,
until themassandasectionofsurrounding
theuseofcolostomyfollowingcolorectalresections
mucosacanbereadilyviewed.Thetissuesare
hasbeenisolatedtoasmallnumberofpatients.
maintainedinanexteriorizedpositionusingstay
Stomamanagementinhumanpatientscanbea
sutures.Aresectionof themassisthen
majorconsiderationandhasbeenassociatedwith
performed,tryingtomaintainabout1-2cm
significantreductioninqualityoflifeoutcomesin
marginsabouttheedgeofthegrosslyvisible
affectedpatients.Itisunclearwhetherthisstrategy
mass.Resectionoccursatthelevelofthe
hasarealisticroleinveterinarypatients.
muscularis,withnoattempttoachieveadeeper
margin.Primaryreconstructionofthemucosal
Pararectal lesions:Thedorsal approachtotherec-
defectisperformedusingsimpleinterrupted
tumandpelviccanalprovidesaccesstothedorsal
absorbablesuturematerial.Theuseofstapling
pelviccanal,andlesionswithinthecaudalandmid-
equipmenthasalsobeendescribedtoenable
dlerectum.Access for manipulation is limited,and
rapidbuteffectiveresectionandclosureof the
performanceofanastomosescanbedifficult.Ahigh
defect.
incidenceofcomplicationsisreported(20%,mostly
Transanalendoscopictreatment:Removalof
infection),duetothehighpotential forcontamination
polypoidmasseswithelectrocauteryhasbeen
andlimiteddrainagefromthisregion.
describedfortumoursaffecting2-13cmof the
Chemotherapy
rectalmucosal length(Holt,2007).
Apart from lymphoma,most colorectal tumours
Full-thicknessresectionandanastomosis:
respondpoorlytoconventionalchemotherapy.
Doxorubicinhasbeenshowntoimprovesurvival in
Rectal'pull-through'resection:Therectumis
catswithcolonicadenocarcinoma(MST280days
evertedandseveralstaysuturesareplaced
versus56dayswithoutchemotherapy;Slawienski
thoughtherectumcranialtothemucocutaneous
etal.,1997).Veryfewotherstudiesexisttodeter-
junction.Therectalwall isthencircumferentially
minebenefitfromadjuvantchemotherapyfollowing
transected,leavingthestaysuturesattachedto
resectionof intestinaltumoursindogsandcats.
themostcranialsectionoftheresectedbowelto
Theuseofanti-inflammatorydrugsfortheman-
enablemanipulation.Aminimumof1-1.5cmof
agementandpreventionofcolorectalcancer has
normaldistalrectumshouldremainattachedto
beenreportedincreasinglyinbothhumanandveteri-
theanalringdistallyinordertopreserve
naryfields.lthasbeensuggestedthatthedrugsexert
continence.Therectumismobilizedbycontinuing
adirectantineoplasticactivityviainhibitionofCox-2
bluntdissectionalong its adventitial surface,
receptors.However,despiteclearevidenceforpro-
extendingasfarcraniallyasthecranialrectal
apoptoticand antiproliferativeeffectsintumours,the
arteryifrequired.Aftersufficientcoloncranialto
mechanismbywhichNSAIDscauseprotectiveand
thelesionisidentified,theabnormaltissueand
directantitumoureffectsisstilltobedetermined.In
1-2cmofnormaltissueproximalanddistalto
vitrostudieswithbothpiroxicamandmeloxicamhave
thelesionisexcisedandtherectalends
suggested thattheconcentrationsrequiredtoobtain
anastomosed.Theanastomosiscanbe
significantcytotoxiceffectsappearhigherthancould
performed instagesbyincisingasectionof the
beachievedinvivothroughregularsystemicdelivery
rectumandsuturingthecorrespondingnormal
atrecommendeddosesandintervalsofbothdrugs.
tissuetothedistalrectalcuffleftatthe
Topically applied medicationmay,however,enable
mucocutaneousjunction.The anastomosis
highlocaldrugconcentrationstobeachievedwithout
220
Chapter15fTumoursofthecolonandrectum
systemictoxicitybeingaconcern.Theuseofpiroxi-
Rectalpull-through
cam suppositories(0.3mg/kg)has been shown to
Resultsfor thisprocedurewerefirstdescribedby
providesignificantpalliativebenefitforpatientswith
White and Gorman(1987),whoreportedresults for
colorectaladenocarcinoma(Knottenbelt etal.,2000),
ninedogswithepithelial tumoursaffectingthecolo-
withexcellentcontrolofclinicalsigns,whilstsystemic
rectalregion.Twodogsdiedintheimmediatepost-
piroxicamatsimilardoseswasassociatedwitha
operativeperiod,butsevendogsremainedaliveat
undesirablerateofrenalandgastrointestinalcompli-
thecloseofthestudy,withfollow-uptimesranging
cations.Topicaltreatmentcanalsoreducethebulk
from8to20months.Twodogsdevelopedlocal
andfriabilityoftherectalmasssupportingadirect
recurrences(at3and 11months followingsurgery)
antineoplasticpropertyofthedrug.Anecdotalbenefit
andonedogdevelopedalocallymphnodemeta-
hasbeenreportedforsystemicmeloxicambutlarge
stasis.Resectionoftheserecurrentlesionspermitted
clinicalstudieshavenotbeenreported.
furtherpalliationofsignsandprolongedsurvival.
Severalcasesdevelopedpostoperativestenosisof
thecolorectalrepair,whichwasmanaged
Prognosis
by
bougienagedilation.Faecalincontinence was not
Epithelialtumours
reportedinanydog,thoughresectionwaslimitedto
thelast6cmof theterminalrectum.
Theprognosisforpatientswithcolorectalcanceris
influencedsignificantlybytumourtype,size,location
Morerecently,Morello etal.(2008)reported
andclinical stage.However,irespectiveofthe can-
resultsfor11dogswithextensivepull-throughresec-
certypebeingtreated,long-termsurvivalhasbeen
tionsforcolorectaladenocarcinomaandinsitucarcin-
showntobesignificantlyinfluencedbytheabilityto
oma.Anabdominalapproachwascombinedwitha
achieveacleansurgicalmargin.Becausethereisa
transanalresectioninfourpatientstoenableremoval
varied‘menu’oftreatmentoptions,thechoiceof
oftumourslocatedinthemid-cranialregionofthe
techniquefortumourmanagementmustweighup
rectum to thelevelofthedescendingcolon.Mean
theprospectofachievingacompletesurgicalresec-
disease-freeandoverallsurvivaltimeswere44.3and
tion,againstthepotential complications associated
44.6months,respectively,indicating thatprolonged
withthechosenapproach.
survivaltimesarepossiblewithcompleteenbloc
resection.Incontinence occurred in twodogsfora
Rectaleversion
period of 1-5months after surgery.Two dogs devel-
Duetolimitedaccessandtheconservativismof
opedfatalcomplicationsinthepostoperativeperiod.
resection,mucosaleversionwastraditionallyreserved
for localized benign lesions.However,in 2006,
Colonicresection(pubicsymphysiotomy)
Danovaetal.describedtheresultsfor23dogswitha
Therearelimitedclinicalreportsontheoutcomefol-
varietyofprimaryrectaltumours,includingadenocar-
lowingresectionofadenocarcinomaviathisroute.
cinoma,adenomatous polyps and plasmacytoma.
YoonandMann(2008)reportednopostoperative
Incompletemicroscopicmarginswereobtainedfora
ambulatory
complications
associatedwiththe
mucinouscarcinoma inonedog,butnotumourrecur-
approach through thepubis.Neurological complica-
rencewasrecordedinthisdog38monthsafterresec-
tions(faecal/urinary)were notreported inthesmall
tion.Tumourrecurrenceoccurredintwodogs16and
numberofcasesintheir study,butfollow-uptimes
24 months after the original surgery, despite appar-
weretooshortinthisstudytocommentonlong-term
entlycleanhistologicalmargins.Resectionswere
outcome.Resectionmarginswerenotdescribed.
repeatedinthesetwodogs,providingfurtherdisease-
freeintervalsof86and14months,respectively.For
Mesenchymaltumours
the 18dogsfollowedupinthispaper(meanfollow-up
Theprognosisforleiomyomafollowingresectionis
33months,range 5-84 months),a disease-free
considered tobevery good,with‘curative'manage-
intervalof 34.8months(range 5-84months)was
ment likelyinthemajorityofcases.Becausethe
reported.Halfofthedogsdiedforreasonsunrelated
tumouristypicallynon-invasive,itusually‘shells-out
totheircancer.Complicationswereobservedin10
fromthewalloftheintestine.Malignantleiomyosar-
dogsbutwerelimitedtorectalbleedingandmild
comamayoccur,whichmaydemonstrateahigher
tenesmus,whichresolved spontaneously within7
potentialfor metastasis(upto30%);furtherclinical
days.Woundinfections,rectalstricture orfaecal
dataonthistumourtypearelimited,however.
incontinencewerenotobserved.Theresultsofthis
Roundcell tumours
effectivesolutionformanynon-infiltrativelesions
Theprognosisforplasmacytomasisusuallyexcel-
affectingthecaudalrectal lumen.
lentfollowingexcision,providedtumour-freemargins
Transanalcautery
havebeenobtained.Repeatsurgeryshouldbecon-
Theuseoftransanalcauterywasdescribedin13
sideredifincompletemarginsareobtained.Where
dogsbyHolt(2007).Fiveanimalswerecuredof their
further surgery is not possible,adjunctive chemo-
disease,withfollow-uprangingfrom1.3to5.5years,
therapy（with melphalan)may be considered.The
whilst threedogshad theirclinicalsignssuccessfully
patientshouldbemonitoredforevidenceoflocal
palliatedfor19monthsto4years.Unfortunately,fatal
recurrence,ordevelopmentofmultiplemyelomain
complicationsoccurredinthreedogsduetorectal
thefuture.
perforationandperitonitis.
Detailsforlymphomaarecovered inChapter19a.
221
Chapter15fTumoursofthecolonandrectum
References and furtherreading
throughrectal amputationfortreatmentofcolorectal carcinoma in
11dogs.Veterinary Surgery37,420-426
Slawienski MJ,Mauldin GE,Mauldin GN and Patnaik AK（1997)
Danova NA,Robles-Emanuelli JC and Bjorling DE (2006) Surgical
excisionofprimary caninerectal tumorsbyananalapproachin
Malignant colonicneoplasia in cats:46cases(1990-1996).Journal
of theAmericanVeterinaryMedicalAssociation211878-881
twenty-threedogs.VeterinarySurgery35,337-340
White RAS and Gorman NT （1987)The clinical diagnosis and
HoltPE(2007)Evaluation of transanalendoscopictreatment of benign
managementofrectalandpararectal tumours inthedog.Journal
caninerectal neoplasia.JournalofSmallAnimalPractice48,17-
ofSmallAnimalPractice28,87-107
25
WilliamsJMandNilesJD(2005)BSAVAManual ofCanineandFeline
KnottenbeltCM,SimpsonJW.TaskerSetal.(20oo)Preliminaryclinical
AbdominalSurgery.BSAVAPublications,Gloucester
observationsontheuseofpiroxicamin themanagementofrectal
YoonHYandMannFA(2008)Bilateral pubicand ischial osteotomyfor
tubulopapillarypolyps.JournalofSmallAnimalPractice41393-
surgical management of caudal colonic andrectal masses in six
397
dogsandacat.JournaloftheAmericanVeterinaryMedical
Morello EA.Martano M,Squassino Cet al.(2008)Transanal pull-
Association232,1016-1020
222
Tumours oftheperianalregion
JonathanBray
Introduction
Analsacapocrineadenocarcinoma
Tumoursarisingfromtheanal sacareuncommonbut
Almostanytumourcan affect thetissuesof theperi-
thisisanimportanttumourduetoitspropensityfor
anal area,including lymphoma,soft tissue sarco-
invasivenessandrapidmetastasistoregional lymph
mas,rhabdomyosarcoma,squamouscellcarcinoma,
nodes.Recent largepopulationstudiesof apocrine
melanomaandmastcelltumours.However,tumours
glandadenocarcinomahavecompletelyrevisedpre-
ofeitherthesebaceousortheapocrineglandsof the
viousknowledgeofthisdisease.Althoughoriginally
analsacareuniquetothearea.Featuresoftheir
consideredtooccuralmostexclusivelyintheolder
clinicalbehaviour,treatmentandprognosisrequire
(>10years)femaledog,largerstudieshaverevealed
special attention.
no apparent sexbias.Apossiblehigherbreed inci-
dencehasbeennotedin theEnglishCockerSpaniel
(witha heritablerisk inthisbreedsuspectedby
Tumourtypesandbehaviour
Polton(2008)),and also in the Labrador Retriever,
Perianalsebaceousadenomaand
GermanShepherdDog,GoldenRetriever,Cavalier
adenocarcinoma
King Charles Spaniel,SpringerSpanieland Border
Tumours derived from the sebaceous(circumanal)
Collie.Tumours are commonlyrecognized in the
glandsareoneofthemostcommonskintumoursin
olderdog(medianage 11.5years)although theinci-
thedog.Benigncircumanaladenomasaremore
denceoftumourintheseagegroupsisnodifferentto
typical,while malignantadenocarcinomasareless
thatofothertumourtypes.
prevalent,representing just3-17%of allperianal
Analsacadenocarcinoma isanaggressive
tumours.Ineithercase,tumoursmaybe single or
tumour in thedog,withapproximately36-96%of
multiple,and may be found wherever circumanal
casesdemonstratingmetastasistotheregional node
gland tissueislocated （Figure 15.31).Thehairless
at the timeofpresentation.Thesenodalmetastases
area of theanal ring is themost commonsite,but
arefrequentlymultipleandmayextendthelengthof
tumoursatthebaseofthetail,prepuceandventral
the sublumbar chain.Inmany cases,the bulkof
midlinehavebeenrecorded.
metastaticdiseaseisconsiderablygreater thanthe
Metastasisisnotuncommonwithmalignant
primarylesion.
lesions;about 13%of caseswillhave positive
Paraneoplastic
hypercalcaemiaisreportedin
regionalnodesatthetimeofpresentation.Metastasis
25-53%ofcases.Hypercalcaemiaoccursdue to
tootherorgans,ncluding thelung,israre.
overproductionand
secretionofaparathyroid
Hormonal dependencyoftheperianalglandshas
hormone-related peptide(PTHrP)by the neoplastic
beendemonstrated byvarious authors,as these
cells.The serumcalciumconcentrationindogswith
tumoursoccurprimarilyintheintactmaledog.
analsac adenocarcinoma hasa significantlinear
Adenomasmaybehormonallyresponsiveandwill
correlation with the serumPTHrPconcentration.The
oftenregresscompletelyfollowingcastrationalone.
geneticmutationresponsibleforPTHrP synthesisand
secretioninneoplasticcellshasnotbeen identified.
15.31
Circumanalgland
Presentation and clinicalsigns
tumoursare
typicallysessile
Perianalsebaceousadenomaand
massesarising
adenocarcinoma
fromanywherein
Benigntumoursaretypicallyslow-growing,andmay
thecutaneous
zoneoftheanus.
remain small,discrete and clinically asymptomatic
for long periods.Nevertheless,periods of rapid
growtharenotuncommonandadenomascanattain
aconsiderablesize insomecases.Theiraverage
diameteris0.5-3.0cmandthelesionsaregenerally
wellcircumscribed.Benignlesionsmayulcerateand
becomeinfected-possiblyresultingintheiracute
223
Chapter 15g
Tumoursof theperianalregion
presentation-but arerarelyadherentor fixedto
Distinguishingbetweenbenignandmalignant
surroundingstructures.
Malignantlesionsmay
diseaseis important,asthetumour formshavea
diffuselyinfiltratetheanalareaandwillbeadherent
verydifferentbiologicalbehaviourandpatientout-
todeepertissuesonpalpation;theirrateofgrowth
come.Cytologyhasnotbeenfoundtobereliablein
tendstobefasterandtheyarefrequentlyassociated
differentiatingperianalglandadenomafromperianal
withclinical signsofdyschezia and analpain.
glandadenocarcinoma.
Analsacapocrineadenocarcinoma
Analsacapocrineadenocarcinoma
Tumoursmaybedetectedforavarietyofreasons,
Bloodtests,combinedwithameasure ofionized
althoughfrequently(40%)they mayberecognized
bloodcalcium,areimportant to determine the
incidentallyduringroutineexamination.Themajority
patient'sgeneralhealthstatus.Confirmationofclini-
cal diagnosiscanusualybeachievedbycytologyof
showingevidenceofillhealth.Perianalswellingand/
afine-needleaspiratefrom theenlargedperianal
orfaecaltenesmusarethemostcommonsigns,and
mass(Figure 15.33).
Othersignscanincludepolyuria/polydipsia,hindlimb
relatetothesizeofthetumourorwhetherparaneo-
plastichypercalcaemiaispresent.Carefulrectalpal-
pationisnecessaryasupto50%of tumoursarenot
detectableonexternalexaminationalone.However,
tumoursizecanbeconsiderable（Figure15.32),with
someextendingroundmorethan50%oftheanalcir-
cumference.Duringrectalassessment it maybepos-
sibletodetectlymphadenopathyoftheiliaclymph
nodes.
15.32
15.33
Thisfine-needle aspiratefromthemassin
Analsac
Figure15.32showsthat thisisanepithelial
adenocarcinomas
tumourwithobviousfeaturesofmalignancy.(Diff-Quik,
canbeverylarge.
original magnificationX40)
Paperstripshave
beenusedto
Staging
outline the sizeof
themassonthis
Diagnosticevaluationofanalsacadenocarcinoma
dog.
requiresaccuratestagingof thediseaseand assess-
mentofthesystemiceffectsofhypercalcaemia，if
present.Thesizeoftheprimarytumourshouldbe
measuredwithcalipers,especiallywhenitislarge
as thismay have an influenceon prognosis.The
extentoflocal invasion,including itsdegreeoflocal
fixationandproximitytotherectalwall,willalso
assistevaluationofsurgicalrisk.Atumourstaging
Paraneoplastichypercalcaemia,originallyconsid-
system proposed byPolton and Brearley(2007)
eredacommonoccurrencewiththistumour,isnow
(Figure15.34)hasbeenshown todemonstratesta-
shown tobelesscommon（20%)thanoriginally
tisticallysignificantrelevance toclinicaldecision-
suspected.Presenting signsare usually thoseof
making.TheWHOstaging scheme for analsac
hypercalcaemia andinclude anorexia,polydipsia,
adenocarcinoma is presented inFigure15.35.
polyuria,depression,weaknessandweightloss.
Thetumourislikelytohavemetastasizedtothe
regional iliacandsublumbarlymphnodesin>50%of
cases.Rarelyis thefullextentoflymphadenopathy
Clinicalapproach
evidentonphysicalexaminationalone.Caudal
abdominal radiography is alsoinsensitive,with>60%
Perianal sebaceousadenoma and
of lesionsfailingtobedetected(Figure15.36).
adenocarcinoma
Afullabdominalultrasoundexaminationisessen-
Preoperativeevaluationshouldincludea thorough
tialtoquantifytheextentofdiseasepresent.
digitalandrectalexaminationofthemassto
Lymphadenopathymayappearasmultiplediscrete
determineitssize,anddegreeofinfiltrationintothe
masses,locatedadjacenttotheiliacbifurcation,and
surroundingtissues;the sublumbarnodes should
canextendoneithersideoftheaorta/venacavato
alsobecarefullyevaluated.
Caudal abdominal
thelevelof thekidneys.Confluentmasses,especially
radiographyand,ifpossible,ultrasoundexamination
whenthereisevidenceofinvasionintothesublum-
ofthesublumbarnodesshouldbeperformedif
barmuscles,presentdifficultiesforsurgicalresection.
adenocarcinomaissuspected.Asmostaffected
Advancedcoaxialimagingmayalsobeused
patientsareelderly,aroutinegeriatricwork-upis
torevealtheextentoflymphnodeinvolvement
essentialpriortoanaesthesia.
(Figure 15.37).
224
Chapter 15g
Tumoursof theperianal region
Clinical
T-
N-
M-
Median
stage
tumour
metastasis
survival
time(MST)
Stage1
<2.5cm
None
None
>1205days
max
diameter
Stage2
>2.5cm
None
None
>722days
max
diameter
Stage3a
AnyT
Present
None
448-492
(<4.5cm
days
max
diameter)
Stage3b
AnyT
Present
None
294-335
(>4.5cm
days
max
diameter)
Stage4
AnyT
AnyN
Present
71-82days
15.34
Clinical stagingsystemforanalsac
adenocarcinomaproposedbyPoltonand
Brearley(2007).
T-Primary tumour
Tis
Preinvasive carcinoma（carcinoma in situ)
No evidence of tumour
T1
2cmmaxdiametersuperficialorexophytic
15.36
Althoughradiographsof thesublumbarspine
T2
2.5cmmaximumdiameter,orwithinvasionof
arenotalwayssensitive enoughtoreveal thefull
the subcutis,irrespectiveof size
extentoflymphnodeinvolvement,thesetworadiographs
bothshowobviouslymphnodeenlargement.
T3
Tumourinvadingotherstructures suchasfascia,
musclenrarl
N-Regional lymph nodes
2ML/KGOMNIPAQUE
NO
Noevidenceofregional lymphnodeinvolvement
Se:105/7
lm:148/238
Acq.Tm10:21:49.17763
Movableipsilateral nodes
Ax1223.0
N1
512×512
a-Nodesnotconsidered to contain growth
STD
b-Nodes considered to contain growth
N2
Movablecontralateralorbilateralnodes
a-Nodesnotconsidered to containgrowth
b-Nodesconsidered to containgrowth
120.0kV
N3
Fixed nodes
90.0mA
3.0mm/0.0.1
M-Distant metastasis
TiltO.0
DCM/Lin:DCM/IdID
MO
Noevidence of distant metastasis
N:400L:40
A
DFOV:25.6×25.6cm
15.37
Althoughnot an essential diagnostictool,
M1
Distant metastasis detected
coaxial imagingcanprovideverydetailed
informationontheextentanddiscretenessof the
15.35
WHOTNMclassificationforcaninetumoursof
metastaticburden.Thiscomputedtomography'slice'
epidermalordermalorigin(excluding
revealsa largeclusterof lymphnodeenlargementsabout
lymphosarcoma andmastocytoma).
the iliacbifurcation.
225
Chapter15gTumoursof theperianalregion
Thoracicradiographymayrevealevidenceofpul-
Analsacapocrineadenocarcinoma
monarymetastasis（Figure 15.38)inupto20%of
Avarietyoftherapeuticoptionsexist,dependingon
cases.Dogswithevidenceofpulmonarymetastasis
thesizeandstageof thetumour,thephysical status
haveasignificantlyshortersurvivalfollowingtreat-
of thepatient,andtheavailabilityofadjunctivethera-
ment,thanthosewhodonot.
peuticmodalities.Surgical resectionof thetumour,
combinedwithmetastatectomywherenecessary,
hasbeenassociatedwithgoodlong-termsurvival.
Most authorshavenotshown anystatisticallysignifi-
cantdifferenceinsurvivaltimebetweendogstreated
withsurgeryalone,radiationtherapyalone,surgery
andradiotherapy，surgeryandchemotherapy，ora
combinationofsurgery,chemotherapyandradiother-
apy.However,strictinterpretationofthesefindingsis
difficultduetothesmallnumbersineachstudy,the
heterogeneityofthepopulationsstudied,anddiffer-
encesinchemotherapyadministered.Williamsetal.
(2003)demonstrated that therewas asurvival
geryaspartoftheirtreatment.PoltonandBrearley
(2007)considered that chemotherapymaybeof
greatestbenefitforStage3btumours.
15.38
Thoracicmetastasisdetectedradiographically
Local surgery
inadogwithanalsacapocrine
Tumoursarisefromtheapocrinecomponentofthe
adenocarcinoma.
analsacglandslocatedadjacenttotheanalsac,
andextendvariablyintothesurroundingconnective
tissues.Thelumenoftheanalsacistypicallynot
infiltratedbythetumourbutmaybecompressedby
Management
thesurroundinggrowth.Thetumoursareoftenhighly
infiltrative.Marginal excisionof the tumour（Figure
Perianalsebaceousadenomaand
15.39) is advised,as attemptsatwide surgical exci-
adenocarcinoma
sionaremorelikelytoinducecomplicationssuchas
faecal incontinence.Occasionally,invasion by the
Adenomas
tumourintotherectalwallmaynecessitatepartial
Themajority(95%)ofadenomascanbemanaged
resectionof themucosaatthissite,withsubsequent
bycastrationalone.Attemptstoresectthetumour
primaryclosureof theluminaldefect.Wherethe
itselfareoftencomplicatedbyitsfriablecharacter,
tumourisverylarge,surgicalmanagementcanbe
resulting inhaemorrhageandunnecessarysurgical
complicatedandthecaseshouldbediscussedwith
trauma.Theresponse to castrationisusuallybrisk
someoneexperiencedwiththistypeofsurgery.For
and themassshouldbeconsiderablysmallerand
theselargermasses,particularcaremustbetaken
lessfriablebythetimeofsutureremoval.Surgical
toclosetheconsiderabledeadspacethatdevelops
resectionmaybenecessaryfortumoursinfemales,
inthepararectalfossatopreventredundancyinthe
fortumoursthatpersistfollowingcastration,forlarge
rectalwall.
uncomfortabletumours,orwhentheownersdonot
consenttocastration.Pre-treatmentwithanti-testo-
steronemedicationsmayreduce thesizeofmassto
limit thesurgical interventionnecessary.
Adenocarcinomas
Surgicalresectionofadenocarcinomasisoftendiffi-
cultduetothediffuselyinfiltrativenatureofthe
tumour.They donot respond to castration.Local
recurrence is common,asmost‘shell-outresections
areincomplete.Forthisreason,if malignancy issus
toensurethemassisremovedwithadequatemar-
gins.Adjunctiveradiotherapyfollowingcytoreductive
rarelycurative.Regional lymphnodeexcisionshould
beconsideredif metastaticdiseaseissuspected.
Thedevelopmentofregionalordistantmetasta-
15.39
Surgical managementof theanal sacmass
requiresgentleexcisionabouttheinfiltrative
sismaytakeseveralyears.Numerouspalliativelocal
borderof themass,takingcarenot todamage
surgeriescanthereforebejustifiediflocalrecur-
remaininganal sphinctermuscle,neuralelementsand
renceoccurs.
therectalwall.
226
Chapter 15g
Tumoursof theperianalregion
Metastatectomy
notoccur,thepatientmaybe sufficiently‘down-
Abdominalexplorationandsublumbarlymphaden-
staged'tobecomeamoresuitablesurgicalcandi-
ectomyshouldbeperformedinallcaseswhere
date.Bennettetal.(2002)reportedMSTsofabout
lymphnodemetastases have beendetected,to
7-8months(Figure15.41).
reducetumourburden.lfpelviclymphadenopathyis
present,theseglandsmaybebetterapproachedvia
Number
Response to
Number
a dorsal rectaldissection.
treatment
showing that
Exposureofthesublumbarfossaisachievedby
treated
response
utilizingtheduodenalorcolicmanoeuvreandpack-
Cisplatin
13
PR
4(31%)
ingintestinalcontentwithmoistenedlaparotomy
sponges.The enlargedlymphnodesarenormally
SD
1(8%)
palpableastheyextendalongtheaortaandvena
PD
8(61%)
cava and theiriliacbifurcations.Massesaretypically
discreteandcanberemovedfromtheirfascialbed
Carboplatin
3
PR
1(33%)
withgentledissection（Figure15.40).Careisrequired
SD
2(67%)
toensureallenlargedlymphnodesareremoved;in
somecasestheremaybeasmanyas9-12separate
Doxorubicin
4
SD
2(50%)
nodes.Whenthey areconfluent,withinvasioninto
PD
2(50%)
thesublumbarmuscles,attemptstoremovethemare
Dactinomycin
4
PD
4(100%)
illadvised,duetothepotentialforneurological injury,
haemorrhageandothercomplications.
5-Fluorouracil
2
PD
2(100%)
Mithramycin
PD
1(100%)
Vincristine and
1
PD
1(100%)
cyclophosphamide
Melphalan
PD
1(100%)
Epirubicin
PD
1(100%)
Mitoxantrone
PD
1(100%)
15.41
Responsestochemotherapyindogswithanal
sacadenocarcinoma.PR=partial remission
(250%reduction in tumour size):SD= stable disease
(<50%change in size of tumour withina1-month period);
PD=progressivedisease(≥50%increase intumoursize
withinonetreatmentperiod,oranynewtumourlesions).
(DatafromBennettetal.,2002)
15.40
Removalofsublumbarlymphnodedeposits
requirescarefuldissectionofthelymphnode
swellingsfromthesublumbarfascia.Themedianiliac
Radiotherapy
arteryisvisibletowardsthebottomof thesurgicalfield.The
The role of radiotherapy in themanagement of anal
suctiontipissittingontopof theenlarged lymphnode.
sacadenocarcinomaisunclear,withinsufficientdata
availabletovalidateitsuse.Adjuvantfractionated
Thecloseproximitytomajorvesselsandthe
radiotherapyinassociationwitheithersurgeryor
expansile,confluentnatureof thelymphadenopathy
mitoxantrone chemotherapyhas been shownto
indicatesthatsurgical managementofmetastaticdis-
provideprolonged tumourcontrol.
easeshouldonlybeundertakenbysurgeonsexperi-
encedwith thistypeofprocedure.Mostanimalsare
Palliativecare
inclinicallygoodhealthdespitetheirtumourburden,
Wherespecifictumourtreatmentisdeclinedbythe
soexposingthemtounnecessarysurgicalriskasa
owners,palliative medical managementmaybeof
resultofsurgical inexperienceisnotjustifiable.
value.Palliativemanagementisdirectedattheman-
agementoffaecaltenesmus,usinglaxatives and
Chemotherapy
otherdietaryaids,oratlimiting theeffectsofhyper-
Avarietyofchemotherapeuticagentshavebeen
calcaemiawithacombinationofshort-termintra-
describedforthemanagementofanalsacadeno-
venousfluids,prednisoloneandfurosemide.Survival
carcinoma,withtreatmentemployedeitherasthe
timesbetween2daysand9months(MST8.7
primarymodalityor,morecommonly，asanadjunct
months;95%confidenceintervals3.6-9.6 months)
tosurgery.Asaprimary treatment,no significant dif
wereachievedin10dogsmanaged inthiswayalone.
ferenceshavebeenidentifiedbetweendifferent
drugsorcombinationprotocols,thoughpatientnum-
Repeatedmetastatectomy
bersarelow.
Followinginitial lymphadenectomy,somepatientscan
PoltonandBrearley(2007)intimated thatneo-
developfurtherlymphnodeenlargements.Repeated
adjuvanttreatmentwithcarboplatinmightbeuseful
exploratorylaparotomytoextirpategrosslyevident
atreducingtumourvolumeandshouldthereforebe
tumourcanbeeffectiveinthesepatientstocontinue
consideredforhigher-stagepresentationsinparticu-
palliationoftheirdisease.Becausesurgeryisassoci-
lar.Inthiscontext,evenifcompleteremissiondoes
atedwithcomparativelylowmorbidity，somepatients
227
Chapter15g
Tumoursoftheperianalregion
ApartfromBennettetal.(2002),whodescribeda
duringtheirlifetime.Alimitingfactorwithsubsequent
45%localrecurrencerate,tumourrecurrenceasa
surgeries isthematureperivascularfibrosisthat
causeofdeathisrarelyreported,evenwith
developsasaconsequenceofpreviousdissection
conservativesurgery.
events，combinedwithprogressiveinvasionofthe
tumourintotheunderlyingmusculatureandperivas-
Hypercalcaemia
cularstroma.Whenthemetastaticlesionsareconflu-
Signsassociatedwithhypercalcaemiashouldresolve
entandnot amenabletodebulking,orwhen
quickly(1-2days)ifall tumourisremoved.Persis-
extirpationmaybeassociatedwithlife-threatening
tence,orrecurrence,ofhypercalcaemiaisindicative
haemorrhagefromtheaorta,venacavaorassociated
ofmetastaticdisease.Williamsetal.(2003)identified
vasculature,theprocedureshouldbeabandoned.
thepresenceofhypercalcaemiaasbeingasignifi-
cant(p=0.002)independentpredictorof survival,
with MSTs of 256days for hypercalcaemic dogs,
Prognosis
comparedwith584daysfornormocalcaemicdogs.
However,thesefindingsarenotsupportedbyother
Perianalsebaceousadenomaand
studies.Polton(2008)considered that hypercalcae-
adenocarcinoma
miapersewasnotanindependentriskfactor,but
Theprognosisforadenomasisexcellent.
wasaconfoundingeffectduetoclinicalstage.
Theprognosisforadenocarcinoma isunfavour-
ableduetolocalrecurrenceandmetastasis.Survival
Tumoursize
timesof>2yearshavebeenrecordedin70%of
Thesizeoftheprimarytumourmaybeaninde-
patientsthatwerenode-negativeatthetimeofthe
pendentpredictorofsurvival.TheMSTfordogswith
initial surgery.
tumours≥10cm²was292days,comparedwith584
days for smaller tumours(p=0.04).It is possible
Analsacapocrineadenocarcinoma
thatlargetumoursizemaypresentanobstacleto
Previously,agrave prognosiswas givenfordogswith
managementduetoconcernsregardingcomplica-
thisdisease,withsurvival timesof<12months.
tions,butwhere surgeryisperformed by experi-
However,recentworksuggeststhatgood tumour
enced specialist soft tissue surgeons suchrisks
controlispossibleinmanyanimals,evenwhenmeta-
seemtobeminimal.Neoadjuvantchemotherapy
staticspreadtoregional lymphnodesispresent.
maybeaconsiderationtoattemptreductionin
tumourvolumewhentheinitialtumoursizepresents
Williamsetal.(2003)reportedanMSTof544
a surgical concern.
days(range0-1873days)forallpatients,
regardlessoftreatmentmethod,witha37%
Recurrences
probabilityofsurviving2yearsormore.
Tumourrecurrenceshouldbeconsideredinevitable
PoltonandBrearley(2007)reportedMSTsof
inalmostallcasesofanal sacadenocarcinoma,with
479-508days,withclosecorrelationofsurvival
tumourbeingconsideredthecauseofdeathin
timeswithclinicalstagedetermination.Removal
almostallclinical studies.Tumourrecurrenceshould
ofmetastaticlymphnodeswasstatistically
besuspectedwheneverhypercalcaemia-related
associatedwithimprovedsurvival.
polyuria/polydipsiarecurs,orwhenfaecaltenesmus
Emms(2005)reported anMSTof20months
recurs.Othersignsofdistantmetastaticdiseasemay
(range5-42months)butdidnotidentifyany
alsooccur(e.g.exerciseintoleranceor dyspnoea
differenceinsurvivalbetweendogswithdiffering
withpulmonarymetastasis).
stagedisease(i.e.thosewithsublumbarlymph
nodemetastasiscomparedtothosewithout).
Hobsonetal.(2006)describedsurvivalinone
Referencesandfurtherreading
dogfor50monthsafterdiagnosisbyperforming
repeatedmetastatectomyonfourfurther
BennettPF,DeNicola DB,BonneyP.GlickmanNWandKnapp DW
(2002)Canine analsacadenocarcinomas:clinical presentation and
occasionsafteroriginalmanagement.
response totherapy.JournalofVeterinary InternalMedicine16,
Theimportanceofmetastatectomyinimproving
100-104
survivalwasalsoillustratedbyBennettetal.
Emms SG(2005)Anal sactumoursof the dog and theirresponse to
(2002),whoreporteda poorerMSTof8.7
cytoreductive surgery andchemotherapy.Australian Veterinary
Journa/83,340-343
months(range2days to41months).
HobsonPBrownMRandRogersS(2006）Surgeryofmetastaticanal
sacadenocarcinomainfivedogs.Veterinary Surgery35267-270
Lymphadenectomywasuncommonlyperformed
Polton G (2008)Analsacgland carcinoma in cocker spaniels.
in thisstudy(36%),eventhoughregional lymph
VeterinaryRecord163,608
nodeenlargementswerepresentin91%of
Polton GA and Brearley MJ(2007)Clinical stage,therapy and
prognosisin canine analsac gland carcinoma.Journalof
patientsundergoing surgery.Ahighlocal
VeterinaryInternalMedicine21,274-280
recurrencefollowingresectionwasalsocommon,
WilliamsLE,GliattoJM.Dodge RKet al.(2003)Carcinoma of the
whichmayhavehadanimpactonoverallsurvival
apocrine glands of the anal sac in dogs:113 cases(1985-1995).
figuresin the study.
JournaloftheAmericanVeterinaryMedicalAssociation223,825-
831
228
Tumours of the liver
JonathanBray
Introduction
Tumour typesandbehaviour
Theliveristhelargestparenchymousorganinthe
There arefour general tissue types fromwhich pri-
bodyandreceivesbloodfrombothportalandsys-
maryhepatictumoursmaybe derived:hepato-
temicsources.Possiblybecause of these factors,
cellular;bile duct;neuroendocrine (carcinoid);and
46%ofalltumoursthatoccurintheliverofthedog
mesenchymal.Almostirrespectiveoforigin,aprim-
areof metastaticorigin（Figure 15.42).Inone study,
aryhepatictumourmaydevelopaccordingtothree
uptoa thirdofalldogswithamalignantprimary
morphological subtypes:massive;nodular;ordiffuse:
tumourhadevidenceofliverinvolvementonpost-
mortemexamination;thiscontrastswiththelungs,
Massiveisdefinedasalargesolitarymass
whichmaybeinvolvedinjust24%ofcases.
confinedtooneliverlobe
Haemopoietictumourtypesaccountforuptotwo-
Nodulartumoursaremultifocalandmayinvolve
thirds ofall metastases,followed by an approxi-
multiplelobes
matelyequalamountofepithelialandmesenchymal
Diffusediseaseincludesmultifocalorcoalescing
tumours.
nodulesaffectingall lobes,oftencausing
effacementofnormalhepaticparenchyma.
Animportantdifferentialforalllivermassesis
nodular hyperplasia（Figure 15.43),which may be
found in 15-60%ofgeriatricdogs.Lesionscanbe
solitaryormultiple,andrangefrom0.1to5cmin
diameter.Theyaredifficulttodifferentiatefromother
hepatictumours;biopsyistherefore important.
15.42
Widespreadmetastaticdepositsintheliverofa
12-year-oldRhodesianRidgebackwitha
splenichaemangiosarcoma.
Primarytumoursoftheliverarelesscommon
andaccountfor0.6-1.3%ofcaninetumoursand
1.0-2.3%of allfeline tumours.In the dog,approxi-
15.43
Nodularhyperplasia inan8-year-oldSpringer
mately25%ofalllivertumoursareofprimary
Spaniel.This conditionis animportant
(hepaticorbiliarytissue)origin,25%areofhaemo-
differentialforall livermasses.
poieticoriginandalmost50%aremetastatic.Inthe
cat,haemopoietic tumours(principallylymphoma)
Hepatocellulartumours
predominate,representing75%ofalllivertumoursin
Hepatocellulartumoursincludehepatocellularcarci-
this species.
noma(HcC),hepatocellular adenoma and hepato-
Hepaticneoplasiaismostcommoninthegeriatric
blastoma.HCC is themost common hepatic
patient,withthemeanageofoccurrencebeing10-11
neoplasminthedogandmayaccountforupto48%
years.In onestudy,cats withmalignanthepatic
ofallcasesofprimaryhepatictumours.Morph-
massesweresignificantlyyoungerthanthosewith
ologically,over two-thirds ofHCCs are massive
benignmasses.
(Figure 15.44),with theremaindereither diffuseor
229
Chapter15h
Tumoursof theliver
aremorecommonindogs,whereasthereisaneven
distributionof intrahepaticandextrahepatictumoursin
cats.Themorphological distributionincludesmassive
(37-46%),nodular(upto54%),anddiffuse(17-54%)
forms.Metastasisisreported tobeashighas88%in
dogs and78%incats,occurring mostoftenin the
regional lymphnodes,lungsorperitoneum.
Benignadenomaaffectingthebileducthavealso
beencalledbiliaryorhepatobiliarycystadenomas,
due to their cystic appearance （Figure 15.46).Bile
ductadenomasmayaccountfor>50%ofallfeline
primaryhepatictumours，affectingmainlydomestic
short-hairedcatsover10yearsofage.Theytypically
donotcauseclinicalsignsuntiltheyarelarge
enoughtocompressadjacenttissues.
15.44
Themassiveformofhepatocellularcarcinoma
ina dog.
nodular.Metastasisismorecommonwithnodularor
diffuse HCC (93%and 100%,，respectively)，whilst
solitarytumoursarethoughtnottohavesuchahigh
rateofmetastaticspread(0-37%).
Hepatocellularadenomas(hepatomas)aretypi-
rarelycauseclinical signs.They canbeseen inthe
living animal,however,asmultiplenodulesorpedun-
culated masses,and distinguishing them from a
moregeneralizedmetastaticdiseaseistherefore
important.Somesolitaryadenomascanattainacon-
siderablesize,wheretheirencroachmentonother
organscanresult innon-specificclinical signs.Large
adenomasmaybefriable,withintermittentbleeding
fromthesurfacecausinganaemiaandhaemorrhagic
ascites.In cats,hepatocellular adenoma occurs
more frequently thanHCC.
Bileducttumours
15.46
Benignadenomaof thebileduct(hepatobiliary
cystadenoma)inadog,showing thecystic
Carcinomaofthebileduct(biliarycarcinomaorchol-
appearance.(Courtesy of JuliusLiptak)
angiocellularcarcinoma;Figure 15.45)is themost
commonmalignantnon-haemopoietichepatictumour
Neuroendocrine tumours
incatsand thesecondmostcommon indogs.These
Neuroendocrine tumours,also known as hepatic
tumoursprincipallyarisefromintrahepaticbileduct
carcinoids,are infrequently reported in dogs and
epithelium,although they canoccur in the extra-
cats.Arising fromneuroectodermal cells,they are
hepaticbileductsorgallbladder.Intrahepatictumours
embryologicallysimilartothecellsresponsiblefor
insulinomasandgastrinomas.They tendtooccur at
ayoungeragethanotherhepatictumours(7years
versus 10years).Carcinoidshaveanaggressive
biologicalbehaviourandarenotusuallysurgically
resectable,as themajorityaremorphologically
diffuse.
Mesenchymaltumours
Primarytumoursofmesenchymaloriginarerarein
dogsandcats.Themostcommonprimarysarcomas
areleiomyosarcoma,haemangiosarcomaandfibro-
sarcoma.Othersarcomasincluderhabdomyosar-
coma,liposarcoma,osteosarcoma and malignant
mesenchymoma.Males appear predisposed,but
thereisnoknownbreedassociation.Massiveand
nodularmorphologyhavebeenreportedin33%and
Carcinomaofthebileduct,acommon
67%of cases,respectively.Diffusedisease hasnot
15.45
malignantnon-haemopoietichepatictumourin
beenreported.Sarcomasareaggressivebiologically
dogs.(Courtesy of Julius Liptak)
withmetastasisreportedin86-100%ofcases.
230
Chapter15hTumoursof theliver
Presentationandclinicalsigns
Amildhypoglycaemiamaybedetectedinabout
20%of cases.A more markedparaneoplastichypo-
Clinicalsignsassociatedwithhepatictumoursare
glycaemia,causing weakness and seizures,has
frequentlyvague and non-specific.Many animals（up
beenreportedwithbothbenignandmalignant
to50%ofcatsand25%ofdogs)maybecompletely
hepatic neoplasms.Typically, the tumour in these
asymptomatic,with aliver tumour identifiedonly
caseshasbeenverylargeandreadilypalpable.
duringaninvestigationforraised liverenzymes.When
Hypoglycaemiamayoccurasaresultof inefficient
clinical signsdooccur,theymayrelatetothephysical
glucoseutilizationbythelarge tumour,releaseofan
presenceof themassitselformaybeaconsequence
insulin-likesubstancebythe tumouror failureof
ofhepatobiliarydamage or failure.Inappetence,
hepatic gluconeogenesis.
intermittentvomitingordiarrhoea,polyuria/polydipsia，
Whilstliverfunctiontestsareabletoindicatethe
lethargyand weight loss are amongst the signsmore
relativedegreeofhepatocellularinjury,biliarystasis
commonlydescribed.Ascites,jaundiceandweakness
ormetabolicdysfunction,theyareinadequateforthe
maybeseenlesscommonly.
establishmentofanaetiological diagnosis,specific
therapy orprognosis.
Clinicalapproach
Imaging
Plainabdominalradiographsprovidelittlespecific
Physicalexamination
informationonhepaticneoplasiaapartfromoffering
Physicalexaminationcanbeunremarkableinmany
evidenceforhepatomegalyorthepresenceofasoft
cases.Becausetheliverisborderedby thecostal
tissuemasswithinthecranialabdomen.Ascitesmay
arch,changesmaynotbepalpableunless theliver
beseenonoccasion.Thoracicradiographyshould
hasbecomesignificantlyenlarged.
beconsideredtoexcludemetastaticdisease.
By contrast,abdominal ultrasonography is a useful
Haematologyandbiochemistry
andconvenientmethodforestablishingthepresence
Abnormalitiesonaroutinebloodscreenarefre-
ofahepaticmassandforpotentiallycharacterizingits
morphological extent （solitary，nodular,difuse)，its
evenifthehaematologicalandserumbiochemical
relationship toadjacent structures,the presence of
changesarenon-specificforaparticulardiseasepro-
metastaticdisease,andfordetectingsubtlevolumes
cess.Leucocytosis,anaemiaand thrombocytosismay
ofascites.However,ultrasonographyisrarelyeffective
occur in50-75%of animalswith liver masses.The
indeterminingthespecificpathology thatispresent,
leucocytosismaybeaconsequenceofperitumoral
asmanybenignandmalignantmassessharesimilar
inflammationandnecrosisoflargemasseswhose
sonographicfeatures.Fordiffusehepaticdisease,the
growthhasexceededthebloodsupply.Mildanaemia
overallaccuracyofultrasonographicdiagnosisalone
(usuallynormocytic,normochromicandnon-regener-
was<40%indogs and<60%forcats(Feeneyet al.
ative)may occur due to chronic disease,iron defi-
2008).Fornodular disease,it isgenerallyaccepted
ciencyor redcell sequestration.Thrombocytosisis
thatbenignandmalignantdiseasecannotbereliably
seeninupto50%ofpatientswithamassiveHCC.
differentiatedusingconventionalultrasoundimaging
Anaemiaand thrombocytopeniamaybeseenin
alone.Diagnosis isbestachieved using ultrasound to
patients with primary or metastatic haemangiosar-
guidepercutaneouscollectionofspecimensforcyto-
comaoftheliver,probablyasaconsequenceof
logicalorhistologicalassessment.Thedevelopment
occulthaemorrhage.Clottingabnormalitiesarea
ofcontrastharmonicultrasoundhasenabledbetter
potentialconsequenceofallliverdiseases,even
accuracyindistinguishingbenignandmalignantnod-
ulesinthedogbutrequiresspecializedequipment
hepaticfailurehasoccurredasaconsequenceofdif-
andmicrobubblecontrastagents.
fuse disease.Assessmentof clotting times should
Advancedimagingtechniquessuchascomputed
alwaysbeperformedpriortoperforminginvasivepro-
ceduresontheliver.Dogswithhaemangiosarcomaof
surpassed ultrasonographyas thetoolsofchoicefor
theliverareatriskofdevelopingdisseminatedintra-
evaluationofhumanpatientswithfocalhepatic
vascularcoagulation(DIC)
lesions,with MRI being the preferred modality for
Elevationsinliverenzymesareobservedcom-
accuratelycharacterizingthepathologicalnatureof
monlyinanimalswithlivertumoursasaconse-
hepaticlesions.Therearefewveterinarystudiescom-
quenceofhepatocellulardamageandbiliarystasis.
paringthesemodalities,andavailabilityislikelytolimit
Asa generalrule,there isno correlationbetween
theselectioninmostcases.However,MRlprovides
thetypeandmagnitudeofenzymeelevationanda
superiorsoft tissuecontrast(Figure15.47)and isthus
specific underlying hepatobiliary disease.However,
likelytogivebetterlesiondetection,quantificationand
someauthorshavereportedelevationsinalanine
localizationcomparedtoothermodalities.Inone
aminotransferase (ALT)and alkaline phosphatase
study,MRIwasabletodetermine theextentandloca-
(ALP)withprimaryhepatictumours,whilstaspartate
tionofthehepaticlesiontoallowareliableassess-
aminotransferase(AsT)andbilirubinaremorecom-
mentofthesurgicalresectabilityofaspecificlesion,
monlyelevatedwithmetastaticdisease.Additionally,
andpermitteddifferentiationofmetastatichepatic
anAST:ALTratioof<1isconsistentwithHCCorbile
tumour from HCC（Clifford et al.,2004).Thus,MRI
ductcarcinoma,whilstahigherratioismorelikely
withneuroendocrineormesenchymaltumours.
patientswithbenignorunresectablelesions.
231
Chapter15h
Tumoursoftheliver
15.48
Laparoscopycanprovideaneffectivestrategy
forobtainingvisuallyguidedbiopsyspecimens
fromtheliverwhenpatientfactorsorthelocationof the
tumourprecludestheuseofultrasound-guided
percutaneous techniques.
15.47
AT1-weighteddorsal MRimageof thetumour
mass shown inFigure15.44.Suchimages
needleallowsfortargetedsamplestobecollected
providegoodanatomical informationandhelpguidea
fromthemid-parenchymalregionoftheliver,while
decisiononwhethersurgicalresectionispossible,based
largermid-parenchymalsamplescanbeobtained
on the involvement of thehilarregion.
withtheuseofasterilecutaneousbiopsypunch
(Figure15.49).Post-biopsyhaemorrhagewiththese
Biopsy
methodscanbebriskbutisfrequentlyself-limiting.
Therearemanydifferentlesionsthatcanaffectthe
Bleeding maybe stopped byplugging the defect with
liverbutthatarenotdiagnosableonevaluationof
a piece of haemostatic sponge,ora smallpiece of
grey-scaleultrasonographyor
CT/MRI
"alone.
omentum.Attemptstosuturethedefectclosedare
Collectionofa tissuespecimenisthereforeessential
likelytoresultinmoredisruptiontotheliverparen-
toensurethatfutureinterventionforthepatientis
chyma andfurtherbleeding.
basedonobjectiveinformation.
Cytologicalorhistopathologicalevaluationisthe
mostimportantprocedureinobtaininganaccurate
aetiologicaldiagnosisofhepaticdisease.Thediag-
nosticaccuracyofultrasound-guidedaspirationcyto-
logyis only about 60%,though this is better for
diffuseinfiltrativediseasesuchaslymphomainthe
cat.Improved diagnostic accuracy(90%)can be
obtainedwithTru-cutbiopsy.Withcarefulpreparation,
complicationsassociatedwithhepaticbiopsyshould
beminimal.Clottingparametersshouldbeassessed
inallpatientsundergoingTru-cutbiopsyoftheliver.
General anaesthesiaorprofoundsedative techniques
shouldbeusedtopreventpatientmovementduring
needle placement.Follow-up imaging several hours
afterbiopsycollectionshouldalsoberoutinetohelp
detectocculthaemorrhageatthebiopsysite.
Mortalitydirectlyattributedtoultrasound-guided
hepaticbiopsyhasbeenreportedtobe<3.5%.
However,in90%ofcasesbiopsymaterialprovided
critical diagnosticinformation.
Wherepatientsafetyorthelocationofthetumour
precludestheuseofultrasound-guidedpercutaneous
techniques,laparoscopy（Figure 15.48)providesan
effectiveandlessinvasivestrategythanopensurgery
toobtainvisuallyguidedbiopsyspecimens,andpro-
videsreasonablecontrolofbleeding.Mortalityrates
followinglaparoscopicbiopsyarereported tobe1.4%.
If liverpathologyisidentifiedatthetimeofexplor-
15.49
During exploratorylaparotomy.largermid-
parenchymal samplescanbeobtainedwith the
atory surgery,collectionofbiopsy specimensisa
useof a sterile cutaneousbiopsypunch.Anybleeding
straightforwardprocesswithfewsignificantrisks,pro-
may be stopped by plugging thedefect withapiece of
videdadequatecareistaken.TheuseofaTru-cut
haemostatic sponge.(continues)
232
Chapter15hTumoursof theliver
palliationofclinicalsignsby,forexample:removalof
denof paraneoplastic effects(e.g insulinoma);or
reducing thepotential forlife-threateninghaemor-
rhage.Because surgical risks for hepatic mass
resection(especiallyright-sided lesions)canbesig-
nificant,it behovesthecliniciantopursuenon-inva-
sivediagnosticmethodstoassessthepatientasto
theirsuitabilityforsurgery.Preoperativepreparation
ofpatientsforliverlobectomyincludescorrectionof
potentialabnormalitiessuchasdehydration,anae-
mia,and clottingfactordeficiencies.
Anaestheticconsiderations
Ascitesoralargehepaticmassmaycausehypoven-
tilationundergeneralanaesthesia.Increased intra-
abdominalpressuremayrestrictmovementofthe
diaphragmandthethoracicandabdominalmuscula-
ture,limiting lung expansion.Consciouspatients are
oftenabletotolerateandcompensateforsuch
restrictions,butonceundergeneral anaesthesiathey
becomeunable tobreathevoluntarily.Preoperative
abdominocentesis may,therefore,benefit patients
withmassiveascites.Inpatientswithlargeintra-
abdominal masses,positioning thepatientonatilted
tablewiththeheadslightlyelevatedmayalsohelp
reducerestrictionofdiaphragmaticmovement.ltis
15.49
(continued)Duringexploratorylaparotomy.
desirableinthesecasestotryandexteriorizethe
largermid-parenchymalsamplescanbe
tumourearlyinthecourseofthesurgerytominimize
obtainedwiththeuseofasterilecutaneousbiopsypunch.
compression of thevena cava.
Anybleedingmaybestoppedbyplugging thedefectwith
apieceof haemostaticsponge.
Surgical strategies
Liverlobectomyismostcommonlyperformedfor
Slightlylargersamplesofhepatictissuecanbe
obtainedfromthetipsofthenarrowlobes.Aloopof
removalofmasslesions.Lobectomymaybepartial
absorbablesuturematerialisplacedaroundthe
orcomplete,andmaybeperformedbyseveral differ-
lobe,slightlyproximal tothetissuetobesampled.
enttechniques(seeBSAVAManualofCanineand
FelineAbdominalSurgery).
Post-biopsyhaemorrhageusuallyresultsfrom
ligaturefailureandisrarelydirectlyattributabletoa
coagulopathy.Significanthaemorrhage shouldbe
Partiallobectomymaybeperformedbyplacing
controlledwithsurgicalexplorationandtreatment.
overlappingrowsoffull-thicknesshorizontal
SerialmeasurementsofPCVandtotalplasma
mattresssuturesproximaltothelesionand
proteinswillallowmonitoringofapatient'scondition
excisingthediseasedtissuejustdistal tothe
incasesofsuspectedhaemorrhage.
sutured margin.
Anothertechniqueisfingerfractionationofthe
parenchymaproximaltoalesion,followedby
Management
handorautomatedligationofvessels.
Haemoclipsmayslipoff largevessels;therefore,
Surgery
theyshouldnotbereliedonasasolemethodof
Surgicalresectionistherecommendedtreatmentin
ligation,especiallyif thevesselsareverylarge.
allcasesofsolitaryhepatictumours,withadecision
Inarecentstudy,apre-tiedsutureloopsystem
tooperatebasedmainlyonthepotentialforresect-
(SurgiTieTM)wasassociatedwithfewer
ability(and the presence ofmetastaticlesions)
complicationsthanothermethodsduringpartial
ratherthantheunderlyingpathologicaldiagnosis
hepatectomyinexperimentalpatients.
alone.Thispointemphasizes theimportance of
Skeletonizationand individuallyclippingvessels
advancedimagingmodalitiessuchasMRIinthe
had thehighest blood loss(Risselada et al.,in
presurgical investigationof livertumourstoprovidea
press).
basisforreliable triageof thepatient.Surgeryis
Tumoursaffectingtherightorcentraldivisionsof
rarelyanoptionformostnodularordiffusehepatobil-
the liverpresentmoreofachallenge,asthe
iarytumoursastheytendtoaffectseverallobesand
caudalvenacavaisburiedwithinthe
completesurgical extirpationisimpossible.However,
parenchymaof theliverandismoresusceptible
localizedresectionofprimaryormetastaticnodules
toinjury during dissection.
maybeconsideredifsuchinterventioncanbe
Surgicalstaplingdevicesmaybeused,butthe
achievedsimplyandislikelytoprovideeffective
hepaticparenchymaisgenerallythickerthanthe
233
Chapter15hTumoursoftheliver
openingofthejaws,andhaemostasismaynotbe
influenceonoutcomeforpatientsthatsurvivedthe
optimalwithdouble-rowed('non-vascular)
surgery.Local recurrencefollowing surgeryfor HCC
staplingsystems.Bleedingfromaliverlobe
isuncommon(0-13%)andalthoughmetastaticdis-
stumpfollowinglobectomywithaTA55stapler
easehasbeendocumentedinuptoa thirdofdogs
canbeverysignificantandpotentially
withHCC,clinicalreports suggestthat metastasisis
life-threatening.
uncommoninsurgicallymanagedpatientsandmost
Tumoursencroachingonthehilusofthelivercan
deathsareunrelatedtotheHCC.
sometimesbedifficulttoresectcleanlyusing
staplingtechniques.Theparenchymaof theright
Biliarytumours
lateral liverlobeandcaudateprocessofthe
Forbileductadenoma(biliarycystadenoma)in the
caudatelobeenvelopthevenacava,which
cat,liverlobectomyisrecommendedifthelesionis
makesvisualizationof thehepaticveinstothese
solitaryorifamultifocallesionisconfinedtooneor
lobesimpossibleuntilsomeparenchymal
twolobesonly.lfcompleteresectionisachieved,the
dissectionhasbeencompleted.Forthese
prognosisisgoodwithnolocalrecurrenceormalig-
reasons,arecentlydescribedmethodforhilar
nant transformationreported.
liverresectionhassignificantbenefitsandshould
Forsolitarybiliarycarcinomalesionsin thedog
be themethodofchoicewhenconsidering
andcat,liverlobectomyisrecommendedtopalliate
surgicalmanagementof livertumours(Coveyet
clinical signs.However,survivaltimesremainpoorif
al.,2009).Withthismethod,ligationof individual
thereisdevelopmentoflocallyrecurrentormeta-
vesselsandbiliaryductscanbeperformedto
staticdiseasewithin6monthsofsurgery.
helpminimizethepotentialforlife-threatening
blood lossaswell asimprovethelikelihood of
Neuroendocrinetumours
obtainingcleansurgical margins.
Most carcinoidshavean aggressivebiological behav-
iourandrarely,ifever,present asa solitarylesion.
Chemotherapy
The prognosis ispoor,andmetastasis toregional
Chemotherapyhasshownlimitedefficacyintheman-
lymph nodes,peritoneum and lungs has usually
occurredbythetimeofdiagnosis.
metastaticlivertumours.Adjuvantchemotherapymay
beaconsiderationforhaemangiosarcomaoftheliver
Mesenchymal tumours
ifcompleteresectionoftheprimarymasshasbeen
Liverlobectomymaybeattemptedforsolitarylesions
accomplished.Lymphomaofthelivermaybeman-
agedwithsystemicchemotherapy(seeChapter19).
vention tobeprudent.Thisstrategymayprovide
palliationofspace-occupyingeffectsofthelesion,or
preventcatastrophichaemorrhage fromoccurring.
Prognosis
However,developmentofmetastaticdiseaseremains
The prognosis for all primary or metastatic liver
aconcernandconsiderationofadjuvantchemother-
tumourswheresurgicalresectionisnotpossibleis
apyisappropriate.
generallypoor,withsurvivaltimesfollowingpresen-
tationinfluencedbytheclinicalstatusofthepatient
andthesuccessofanypalliativeinterventions
Referencesandfurtherreading
directedatimprovingappetite,hydrationorgeneral
Bigge LA,Brown DJ,Pennick DG (2001)Correlation between
comfort.Incatswithbiliarycarcinoma,diffuseintra-
peritonealcarcinomatosisisoftenpresentat thetime
guidedbiopsies:434cases（1993-1996).Journalof theAmerican
AnimalHospitalAssociation37,228-233
ofdiagnosisin67-80%ofcases.Whensurgical
CliffordCA,PretoriusES,Weisse Cetal.(2004）Magneticresonance
resectionofasolitaryhepatobiliarymassispossible,
imagingof focalsplenicandhepaticlesionsinthedog.Journalof
CoveyJL,DegnerDAJacksonAH,HofelingADandWalshawR（2009）
antsofhepaticcancerissignificantlyenhanced.
HilarlivrresectionindgsVetrinarySurgery38104111
Feeney DA,AndersonKL,ZieglerLEetal.(2008)Statisticalrelevance
Hepatocellularcarcinoma
ofultrasonographic criteria in the assessment of diffuse liver
diseaseindogsandcats.AmericanJournalofVeterinaryResearch
Surgical managementistherecommendedstrategy
69,212-221
forallpatientswithsolitarymassiveHCC.In one
LiptakJM,DernellWS,Monnet Eetal.(2004）Massive hepatocellular
studyevaluatingoutcomefordogswithmassive
carcinomaindogs:48cases（1992-2002).Journalof theAmerican
HCC,dogstreatedconservativelywere15.4times
VeterinaryMedicalAss0ciation225,1225-1230
RisseladaM,Ellison GWBaconNJetal.(inres)Comarisonof5
morelikelytodiefromtumour-relatedcausesthan
surgical techniquesforpartial liverlobectomyin thedogfor
intraoperativebloodlossandsurgicaltime.VeterinarySurgery
reducedmediansurvivaltime (270daysversus
dogsandcat56casesVrinaryClinicalPathology303538
>1460days)(Liptaketal.,2004).Whilst tumour loca-
Wang KY,Panciera DL,A-RukibatRKandRadiZA(2004）Accuracyof
tionmayincreasetherisksassociatedwithsurgery
findings indogs and cats:97cases（1990-2000).Journalof the
(e.g.right-sided lesions), tumour location had no
AmericanVeterinaryMedicalAssociation2247578
234
Tumours of the exocrine
pancreas
Brian J. Trumpatori and Reto Neiger
Introduction
sinusesduetosteatitis,havebeenreportedincats
anddogswithmalignantpancreaticneoplasms
Cancersoftheexocrinepancreasareextremelyrare
（Brownet al.,1994;Pascaltenorioetal.,1997);
in dogs andcats,accounting for<3%of allabdomi-
following successfulsurgical resection,the alopecia
nal neoplasms in dogs;incats,theincidenceiseven
mayresolvebutcanthenreturnuponregrowthof
lower.Inonestudyevaluatingultrasonographyfor
thecarcinoma(Taskeret al.,1999).
pancreaticneoplasiainthedog,only1of16tum-
ourswasofexocrine origin,withtheremainder
eitherendocrineormetastaticinnature(Lambetal.,
Clinical approach
1995).Usuallyolderanimalsareaffected(meanage
10.5years);and there is possibly an increasedpre-
Diagnosisofexocrinepancreaticneoplasiais
valenceinbitches.Theremaybeabreedpredis-
challenging,due to non-specific or absent clinical
positioninCocker Spaniels,
，AiredaleTerriers,
signs and clinicopathological changes.The final
LabradorRetrieversandBoxers.
diagnosisisusuallymadebyexploratorylaparotomy.
Almostalltumoursoftheexocrinepancreasare
Histopathologicalconfirmationofaneoplasm
is
epithelial,with adenocarcinomas(most common)
important,as chronic pancreatitis canmimica
arisingfromeitheracinarorductcells.Otherreported
pancreatictumourclinically.
non-endocrinetumourtypesincludesquamouscell
carcinoma,lymphoma,lymphangiosarcoma,spindle-
Haematologyandbiochemistry
cellsarcomaandvariousmetastaticneoplasms
(Hecht etal.,2007).Earlymetastasis isvery common
non-specific butmay showaneutrophilia due to
andispresumedtohaveoccurredatthetimeof
inflammationandanon-regenerativeanaemiadueto
diagnosis,mostly intoregional lymph nodes,liver,
chronic disease.Increased serum amylase and
omentum,peritoneum,diaphragm,lung and bones.
lipaseareinconsistentlyseen,whileincreased alka-
Otherreportedsitesincludetheheart,thyroidglands,
linephosphataseandbilirubincanbefoundincases
central nervoussystem,adrenalsandovaries
ofcholestasis.In severe cases,signs ofexocrine
Benign conditionssuchasnodularhyperplasia,
pancreaticinsufficiency maybeidentified（Bright,
pancreaticpseudocysts,abcessationandadenomas
1985).
havebeenreportedascommon,andsometimes
incidentalfindings(VanEnkevort et al.,1999).
Cytology
Tumoursoftheendocrinepancreasaredis-
Aspirationofperitonealeffusion,ifpresent,mayre
cussed inChapter20.
veal thepresenceofneoplasticcellsoncytological
evaluation.
Presentationand clinical signs
Imaging
Plainabdominal radiographsmayreveal a mass in
Clinicalsigns arenon-specificand includeweight
therightcranialabdomenordecreasedcontrastser-
loss,anorexia,depression and vomiting.lf biliary
osal detail incases with ascites(Hecht et al.,2007).
obstructionorhepaticmetastasisispresent,animals
Abnormalgastricmotilityor,infrequently,invasionor
maybecomejaundiced.Rarely，signsmightbedue
compressionoftheduodenummaybeseenonbar-
todiabetesmellitusandexocrinepancreaticinsuffi-
iumcontrastseries.
ciency,causedbycompletedestructionofthepan-
creaticparenchyma.Ascitescanbepresentifthere
andisthemostcommonmodalityusedtoevaluate
ismetastaticspreadintotheperitoneum.
thepancreasindogsandcats.Atumourof thepan-
Abdominalpainoranabdominalmassmaybe
creasmaybeseenasanill-definedhypoechoic
foundonphysicalexamination.Incasesofdestruc-
massbetween theduodenumand stomach(Figure
tionof thepancreaswithnecrotizing steatitis,the
15.50).Thearea might alsoshowmixedechogenic-
animal canpresentwithsignsofan'acuteabdomen'.
ityif steatitisispresent.However,differentiation
Dermatological signs,suchas paraneoplastic alo-
betweenpancreatitisornodularhyperplasiaand
peciaorsubcutaneousswellingswithdischarging
pancreatictumoursisnormallyimpossibleultrasono-
235
Chapter15iTumoursoftheexocrinepancreas
graphically(Bennett et al.,2001;Hechtet al.,2007)
helpful insurgicalplanning,andmayprovideinforma-
Potentialchallengestodiagnosticimagingofpancre-
tionaboutthestatusofregional lymphnodesandthe
aticneoplasmsincludemassesarisingfromadjacent
presenceofabdominalmetastaticdisease.
structures,the presenceofconcurrent pancreatitis,
Theuseofmagneticresonanceimagingforthe
abnormal lymphnodesincloseproximitytothepan-
diagnosisofbenignandmalignantpancreaticdisease
creasandthesimilarappearanceofmanypancre-
iscommoninhumans,buthasnotyetbeenreported
atic diseases,making definitive diagnosisdifficult
inveterinarymedicine.
(Hecht and Henry,2007).In a recent imaging study
ofpancreatic disease incats,the onlyultrasono-
graphicallyuniquefeatureofmalignantdiseasewas
Managementandprognosis
thepresenceofasinglenoduleoramassexceeding
2cminat leastonedimension;however,theauthors
Sincemosttumoursoftheexocrinepancreashave
notedasignificantoverlapbetweentheappearance
eithermetastasizedbythetimeofdiagnosisor
ofnodularhyperplasiaandneoplasia(Hecht et al.,
becomelocallyinvasive,extensiveorheroic'surgery
2007).Whilehelpfulultrasonography ishighly oper-
isoftencontraindicated.Completepancreatectomy
ator-dependent.Lymphaticdrainageofthepancreas
orpancreaticoduodenectomyispossible，butboth
isprovided by the splenic,hepatic,pancreaticoduo-
carryahighriskofmorbidityandmortality.Toallevi-
denal andjejunal lymphnodes,eachofwhichdrains
ateclinical signs,apalliativegastrointestinalbypass
additional organs,makingaccurate assessmentof
isanoption.Mostpatientsbenefitfromtheplace-
metastatic disease difficult (Robben etal.,2005;
mentofajejunostomyorgastrostomyfeedingtube.
Hecht and Henry,2007).The usefulness of ultra-
Radiationandchemotherapyhavebeenshowntobe
sound-guidedFNA to diagnosepancreatic tumours
ineffectiveforpancreatictumours.
hasnotbeenreported.
Theprognosisforcanceroftheexocrinepan-
creasindogsandcatsisgrave,withasurvival time
ofbetween3and90days.
Referencesandfurtherreading
Bennett PF,Hahn KA,
ToalRLand Legendre AM（2001)
Ultrasonographicand cytopathological
diagnosisofexocrine
pancreaticcarcinoma inthedogandcat.Journalof theAmerican
Animal HospitalAssociation37,466-473
Bright JM（1985)Pancreatic adenocarcinoma in a dog with
maldigestionsyndrome.JournaloftheAmericanVeterinary
MedicalAss0ciation187,420-421
BrownPJ,MasonKV,MerrettDJ,MirchandaniSandMillerRI（1994）
Multifocalnecrotizingsteatitisassociatedwithpancreatic
carcinomain3dogs.JournalofSmallAnimalPractice35,129-132
HechtSand HenryG(2007)Sonographicevaluationof thenormaland
abnormalpancreas.ClinicalTechniquesinSmallAnimalPractice
22,115-121
Hecht S,Penninck DG and Keating JH (2007) Imaging findings in
pancreaticneoplasiaandnodularhyperplasiain19cats.Veterinary
RadiologyandUltrasound48,45-50
15.50
Ultrasonographicappearanceofa
Lamb CR,SimpsonKW,Boswood Aand MatthewmanLA（1995)
hyperechogenicpancreaswitha1.3cm
Ultrasonographyofpancreaticneoplasiainthedog:aretrospective
hypoechogenicnodule(arrowed) in an 11-year-old
reviewof16cases.VeterinaryRecord137,65-68
PascaltenorioA,Olivry T,Gross TL,Atlee BA and Ihrke PJ (1997)
AmericanCockerSpaniel.The dogwaseuthanaseddue
Paraneoplasticalopeciaassociatedwithinternalmalignanciesin
tooesophagealrupture,andapancreaticadenomaand
thecat.VeterinaryDermatology8,47-52
chronicpancreatitiswerefoundon histopathology.
Tasker S,Griffon DJ,Nuttal TJ and Hill PB (1999) Resolution of
(Courtesy of J Lang)
paraneoplasticalopecia followingsurgicalremovalofacarcinoma
inacat.JournalofSmallAnimalPractice40,16-19
Robben JH,Pollak YW,Kirpensteijn Jet al.(2005)Comparison of
Theuseofcomputedtomographyforevaluationof
ultrasonography,computedtomography,and single-photon
thecanineandfelinepancreashasbeenreportedfor
emissioncomputed tomographyforthedetectionandlocalization
ofcanine insulinoma.JournalofVeterinary InternalMedicine19
otherconditionssuchaspancreatitisandendocrine
15-22
neoplasia.Whiletheuseofadvancedimagingmodali-
Van Enkevort BA,O'Brien RT and Young KM（1999)Pancreatic
tieshasnotbeenspecificallyreportedfordiagnosisof
pseudocystsin4dogsand2cats:ultrasonographicand
clinicopathologicfindings.JournalofVeterinaryInternalMedicine
exocrineneoplasiaofthepancreas,CTislikelytobe
13,309-313
236
Tumours of the mammary
HenrikvonEuler
Caninemammarytumours
consumptionofhomemademealshavebeenassoci-
atedwithincreasedriskofdevelopingMT.
Generalconsiderations
Mammary tumours(MTs)are the most common
Pathogenesis
typeofneoplasia inentirefemaledogs,represent-
Thecaninemammarytumourmodel supportsthe
ingapproximately50%ofalltumoursreported,
ideaoftheneoplasticprogressionasacontinuum
althoughrecentlyquoted tobeashighas70%of al
frompreneoplasticlesionstofullyinvasivecarcin-
cancer types(Merlo etal.,2008).Bitches are 62
omas,asalso describedinhumanbreastcancer
timesmorelikelytodevelopmammarygland
(Antuofermo etal.,2007;Sorenmoetal.,2009).This
tumoursthanmale dogs,inwhichmammary
implies adenosis,sclerosing adenosis,intraductal
tumoursarepredominantlybenign.
papilloma,sclerosingpapilloma,ductal hyperplasia,
ThecanineMTmalignancyrateisabout50%
atypicalductalhyperplasiaandductalcarcinomain
andhalfofthesewillmetastasize.Meanageofonset
situ.Malignantfociarealso foundinotherwise
ofMTis approximately8years.Dobsonetal.(2002)
benign tumours.Large tumours (longer growing
reportedastandardizedincidencerateforMTof
time)aremoreoftenofamalignantphenotypeand
205/100,000dogs/year,basedonadefinedpopula-
carryaworseprognosis;sexhormonereceptorsta-
tion of insured dogs in the UK.
tuschangeswithincreased malignancy;andfinally
InaSwedishstudybasedonaninsureddog
multipletumoursinthesameindividualoftencarrya
populationof80,000femaledogs,theoverall MT
differenthistopathologicalgrade.
ratewas154dogsayearatrisk(DYAR)(Egenvallet
al.,2005).Theincidence increasedwithageandvar-
Histopathological classification
iedbybreed,from319DYARintheEnglishSpringer
The
highly
detailed
current
World
Health
Spaniel toonly5DYARintheRough-HairedCollie，
Organization(WHO)histological classification sys
clearlyshowingbothhigh-riskandpotentiallypre-
temaimstostandardizeterminologyandnomencla-
ventive(genetic)phenotypes.High-riskbreedsvary,
tureofcanineMTsinternationally(Misdorpetal.
dependingonstudyandgeographical location.Toy
1999)(Figure 16.1).With the abundance of different
and Miniature Poodles,English Springer Spaniel,
malignant typesit maybehard togetaclinicallyrel-
Brittany Spaniel,Cocker Spaniel,
Puli,
English
evantoverview,butitdoesshowhowanaccurate
Setter,pointers,German Shepherd Dog,Maltese,
histopathologicaldiagnosiscanaidinprognosisand
YorkshireTerrierandDachshundhaveallbeen
definetreatmentoptionsandapproaches.Ingeneral
reportedtobepredisposed
thereisafavourableprognosisforbenigntumours
Itiswellestablishedthatsexhormonestimulation
aswell asfor'unclassified’types.
increases theriskof mammary tumoursindogs,as
TheWHOclassificationfollowsthededifferentia-
wellasother
species
（including
humans).
tionprocess,starting with the malignant tumours
Ovariohysterectomypriorto2yearsofagegreatly
mostcloselyresemblingthenormalstructureof the
reducestheriskofmammarytumours.Thereisno
protectiveeffect,however,forbitchesthatarespayed
tiatedtumourswithnoglandularstructure.Ithas
after thesecondheat.Ovariectomybeforethefirst
beenshownthatprognosisiscloselycorrelatedwith
oestrusreducestheriskofmammaryneoplasiato
thelevelofdifferentiation.Thisisveryimportantto
0.5%oftheriskinintactbitches;ovariectomyafterthe
recognizeina clinicalsituation,so that prognosis
firstoestrusreduces therisk to8%.Althoughdis-
andtreatmentplanningmaybecommunicatedmore
puted，theimportanceoftimingofspayingonsurvival
easily(Figure 16.2).
ofdogswithMTshasbeenclaimed(Sorenmoet al.,
2000):bitchesthatwerespayedless than2years
Themalignanttumourswiththebestprognosis
beforeMTsurgery hada significantly longer overall
consistofhighlydifferentiatedglandularstructure
survivalcomparedwithintactbitchesandthosethat
withsecretoryepitheliumcontainingalveoli,tubuli
werespayedmorethan2yearsbeforeMTtreatment.
andmyoepithelium.Thesetumoursareclassified
Thesedataarecontradictedbyotherstudiesshowing
ascomplexadenocarcinomas.Theyseldom
noclinicalbenefitwithovariohysterectomyat(orin
metastasizeandwithcompleteexcisionthe
prognosisisusually good.
237
Chapter16
Tumoursof themammaryglands
Ifthemyoepithelialcellsareabsentthetumours
Malignant tumours
arecalledsimpleadenocarcinomas,often
dividedintoalveolar,tubular,tubuloalveolar,
Non-infitrating(in situ)carcinomas
papillaryorpapillary-cysticadenocarcinomas.
Complexcarcinoma
·Simple carcinoma:
Thesetumoursareinvasiveandcanleadto
oTubulopapillary carcinoma
distantspread.lfthishasnotoccurred,surgical
removalstillgivesafairprognosis.
0Solid carcinoma
oAnaplastic carcinoma
If the tumourislacking luminal structures,itis
describedassolidcarcinoma.Thistypeismore
Special types of carcinoma:
invasiveand ispronetometastasizeearly.The
oSpindlecell carcinoma
prognosis ismoreguarded.
oSquamous cellcarcinoma
Themostpoorlydifferentiatedneoplasms,witha
oMucinous carcinoma
heterogenicdisorganizedtissueappearance,are
oLipid-rich carcinoma
the mostmalignant(Figure16.3).These tumours
Sarcoma:
areoftencalled anaplasticandhaveastrong
oFibrosarcoma
oOsteosarcoma
tendencytoinvadelymphandbloodvessels.The
oOther sarcomas
invasionofcutaneouslymphvesselsmakesthe
Carcinosarcoma
skinappearinflamed,thustheclinical descriptive
terminflammatory'adenocarcinoma.The
Carcinomaorsarcoma inbenigntumour
prognosisforthesepatientsisalwayspoor,even
Benign tumours
withradicalsurgery.TheyaretermedstageIV
accordingtotheclinical stagingscheme（Figure
Adenoma:
16.4)(Owen,1980;seealsoChapter3).
oSimple adenoma
Squamouscellcarcinomainthemammary
oComplexadenoma
glandissometimesseenandcarriesagrave
0Basaloid adenoma
prognosis,oftenmetastasizingearlytoregional
Fibroadenoma
lymph nodes.
Benignmixed tumour
Theincidenceofsarcomasvariesbetween
Duct papilloma
studies,butiscommonly5-10%.Themajority
areprimaryextraskeletalosteosarcomas(Figure
Unclassified
16.5).orfibrosarcomasThese alwayscarrya
poorprognosisand75%of thesarcomasgive
Duct hyperplasia
risetometastases,mostcommonlythrough
Lobular hyperplasia
haematogenousspread.Themammarygland is
Cyst
thesecondmostcommonplaceforprimary
Ductectasia
osteosarcomasinintactfemalesaftertheskeletal
Localfibrosis
manifestation,andtheybehavejustas
Gynaecomastia
malignantly.Iftherearemalignantneoplastic
cellsofbothepithelial andmesenchymalorigin
Histologicalclassificationofcaninemammary
16.1
(veryrare)thetumouriscalled carcinosarcoma.
tumours.(Adapted fromMisdorpetal.,1999)
TheseMTsarealwaysveryaggressiveandhave
a similarprognosistotheanaplasticcarcinomas.
Positive factors
Smallbreeds（reportedtohavemorebenigntumours)
Expressestrogenandprogesteroereepor
Male （reported to havemorebenigntumours)
Negativefactors
Tumour>3cmdiameter
Ulcerationor fixation
Lymph nodes involved
Distant metastasis present
Donot expressoestrogen and progesteronereceptors
Histologicalsubtype（carcinoma-poorlydiferentiatedsmle
solidanastimatryarnmrm
Vascular or lymphatic invasion
Indexofproliferation：highAgNORKi-67orPCNAcounthigh
16.3
Histologicalspecimenshowing skininfitration
p53genemutationorDNAaneuploidy
andneoplasticthrombiandskinulcerationin an
anaplasticcarcinoma.（OriginalmagnificationX100)
Prognosticfactorsinvolvedincaninemammary
(CourtesyofDrArmanShokraiNational Veterinary
16.2
glandtumours.
Institute,Uppsala,Sweden)
238
Chapter16Tumoursofthemammaryglands
Sexhormonereceptorstatus:Themostobvious
T-primary tumour size
markeristheexpressionofsexhormonereceptors:
T1
<3cmmaximumdiameter
oestrogenreceptor(ER)andprogesteronereceptor
(PR).There isacleartendency towardsworseprog-
T2
3-5cmmaximumdiameter
T3
>5 cmmaximumdiameter
expressionofERsandPRs.Thismightexplainthe
T4
Inflammatorycarcinoma
poorresultsof ovariohysterectomyinconjunction
withmastectomy.Moreover,themetastasesrarely
N-regional lymphnode status
expressERsorPRs.Sexual hormones,and inpar-
NO
Nometastasis
ticularprogestins,arebelievedtoactviaactivationof
growthhormone(GH)(van GarderenandSchalken
N1
Metastasis toipsilateral node
2002).Progestin-inducedbiosynthesisofGHoccurs
N2
Metastasistocontralaterallymphnode
inthecaninemammaryglandtissueandiscrucial
forthenormalcyclicaldevelopmentofthemammary
M-distant metastasis
gland,butmayalsopromotemammarytumorigene-
MO
No distant metastasis
sisbystimulatingproliferationof susceptible，and
sometimestransformed,epithelial cells.Asthepres-
M1
Distant metastasis
enceofPRoftenisreducedorevenlostduring
(a)TNMclassification.Evidenceof lymphnode
malignant transformation,the GHstimulation may
involvementbaseduponcytologicalorhistological
alsoactindependentlyofsexualhormones.
analysis.
T1
NO
MO
Mitoticindex:Highermitoticindicesrecordedwith
either the proliferation marker Ki-67，argyrophilic
Ⅱ
T0-1
N1
MO
T2
NO-1
MO
theproliferationthepooreristheprognosisandthe
T3
Nx
MO
Tx
N2
MO
paranetal.,2006)
IV
Tx
Nx
M1
HER-2/neuexpression:Humanepidermalgrowth
T4
Nx
Mx
factorreceptor2(HER-2/neu)-positivecaninemam-
marytumoursareassociatedwithindicatorsofpoor
(b) Stage grouping.
prognosis such as histological grade lll,invasive
16.4
Clinicalstagingofcaninemalignantmammary
typeofgrowth,simplehistologicaltypeandabsence
tumours.(ModifiedfromOwen,1980)
ofsteroidhormonereceptor.Thesefindingsarein
agreementwiththoseobservedinhumanbreastcar-
cinoma,asover-expressionof HER-2alsoassoci-
ateswithfeaturesindicativeofworseprognosis.
BRCA1:Lossofnuclearexpressionofthecellcycle
regulatingphosphoproteinBRCA1correlateswith
highKi-67proliferationandER-negativetumours.
ThereductionandaberrantdistributionofBRCA1in
caninemammary tumoursaresignificantlyassoci-
atedwithmalignantcharacteristics.
p53:Probablythebestknown tumoursuppressor
geneisp53,whichisakeyplayerincellcycle
regulation.Alterationsinp53havebeenreportedin
16.5
Osteosarcomainan8-year-old intactfemale
canine tumours,as both somatic andgerm-line
Bichon Havanais.
mutations.Manystudieshavealsoindicated thatp53
mutationisassociatedwithprogressionandpredicts
Immunohistochemistry
increasedmalignantpotentialandworseprognosis
Inparallelwithbreastcancerinhumans,therehave
in canine mammarytumours(Wakuiet al.,2001)
beenseveralreportsshowingthebenefitofpredict-
ingprognosiswithdifferentimmunohistochemistry
E-cadherin:Cadherins,andparticularlyE-cadherin
markers.Prognosticmarkersinclude:
(E-cad),a calcium-dependent epithelialcelladhe-
sionmolecule,areimportantduringembryonic
Sexhormonereceptorstatus
developmentandforthemaintenanceofadulttissue
Mitoticindex(AgNOR,Ki-67andPCNA)
architecture.Thereductionorlossof E-cad hasbeen
HER-2/neuexpression
associatedwithtumourdedifferentiation,invasive-
BRCA1
nessandmetastaticpropensityandhasbeencorre-
p53
latedwithasignificantlyshorteroverallsurvivaland
E-cadherin.
。
disease-freeperiod(Gamaetal.,2008).
239
Chapter16
Tumoursof themammaryglands
Cytology
Mostcarcinomasmetastasizethroughlymphatic
Althoughaspirationcytologyiseasytoperform,
spread.The twocaudalglands（4-5)communicate
aspiratesofamammarytumourunfortunatelyhave
withthesuperficial inguinal lymphnode,whereasthe
littlevalueinpredictingmalignancyindogs（Figure
twocranial glands（1-2)communicatewiththe
16.6).Thisisprobablyduetothehighlyvariable
axillarynode.Mammarycarcinomasthatoccurinthe
morphologyofthenormal caninemammarycellsin
inguinal(5)gland may showretrograde metastasis
differentstagesof theoestrouscycle.Thenormal
via thelymphaticplexusinthesubcutisoftheinner
proliferationandinvolutionoftheglandgiveriseto
thighto thepopliteallymphnodes.Thethirdgland
usuallydrainsvia theinguinal route,but mayalso
totic.However,occult tumours,such as mastocyt-
drainviatheaxillary.Palpationoftheregionallymph
omas,malignantlymphomas and melanomas,can
nodesshouldalwaysbeperformed,asdetected
beverifiedbythissimplediagnostictool.Inthese
lymphnodemetastasiscarriesaworseprognosis.lf
casesitwillsuggest other stagingprocedures as
nodes are enlarged,
anaspirationshouldbe
wellastreatmentregimens.
performedtodetectmetastasisoncytologypriorto
surgical planning.
Thesecondmostcommonorganformetastasisis
thelungs.In25%of the carcinomas and in the major-
ityof the sarcomas,pulmonarymetastasisusually
occurs as the disease progresses (Figure 16.7).
Three-viewchestradiographyisrecommended,
althougharecentstudyon375MTsshowedlow
metastases in dogs(Djupsjobacka and Eksell,2003).
Itwasfoundthatthechanceofdetectingthoracic
metastaseswasonly3%indogsyoungerthan8
yearswithatumoursizeof1cm.Inthesecases
abdominal ultrasonography,screening for example
thesuperficialinguinalandthemedialiliaclymph
nodes,mightbemoreappropriatetodetectpossible
metastasisearlier(Nymanetal.,2005).
16.6
Cytological specimenfromadogwith
tubulopapillary adenocarcinoma.Cytology is
rarelyhelpful inconfirmingdegreeofmalignancyortype
incaninemammaryglandtumours,butinflammation,
hyperplasiaandnon-mammaryglandmalignanciescan
oftenbedifferentiated.Aswithothercarcinomas,features
ofmalignancyincludeanisokaryosis,anisocytosis,
increasedbasophilia,cellularpiling,and largeprominent
and/ormultiplenucleoli.Sometimesacinar structurescan
be seen.(Original magnificationX100)
Clinical staging
Clinical staging （see Chapter 3)is important in
determiningprognosis.Bitcheswithhigh-stage dis-
easeaccording to theWHOTNM stagingcriteria
（see Figure 16.4)carry a poor prognosis.Thus
DX
treatmentplanningshouldalwaysrelyonaproper
Multiplemetastasesin thelungsof adogwith
stagingprocedure.
16.7
adenocarcinoma simplex.(Courtesy of the
Thegeneralphysicalexaminationwillascertain
Divisionof DiagnosticImaging,UniversitySmallAnimal
whetherthetumourismobileinthemammarytissue
Hospital,Uppsala,Sweden)
orinfiltrative involvingtheadjacentskinortheunder-
lyingfascia,oreven theabdominalwall,whichhas
Otherorgans/systemsreported toharbourMT
been shown to imply amore guarded prognosis.lf
metastasisare the liver,kidneys,spleen,skeleton
mammaryhyperplasiaispresentthismaybeasign
(Figure 16.8),central nervous system and pleura.
ofpseudopregnancybutmayalsoindicatethepres-
Occasionalcasesofretrogrademetastaticspreadby
enceofahormone-producingovarian tumour.In
mammarycarcinomastothevaginahavealsobeen
moremalignantlesionstheremaybeerythemaof
reported inbitches.Althoughrarely abnormal,it is
theskin,elevatedtemperatureandsometimesulcer-
prudenttoperformhaematology,biochemistryand
ationandlymphoedema,allofwhicharefeaturesof
urinalysisbefore surgery,asdogswithmammary
themost aggressivecaninemammary tumour,ana-
tumoursareoftenolderandmaycarryundetected
plastic(inflammatory)carcinoma,inwhichsurvival is
concomitantdiseasesimportant forplanning the
anaesthetic procedure.Finally,hypocalcaemiais
Tumoursizeisasignificantparameterpredicting
reportedasbeinga（rare)paraneoplasticfindingin
clinicaloutcome,accordingtoTNM.
canineMTs.
240
Chapter16
Tumoursof themammaryglands
Surgery
ThetreatmentofchoiceforcanineMTsissurgery，
theextentideallybeingguidedbyclinicalstageand
histologicalgrade.The different typesofsurgery
proposedfordefinedtumourcharacteristicsare
shown inFigure 16.10.
Type of surgery
Tumour characteristics
Lumpectomy orpartial
<0.5cmin diameter
mammectomy
Simplemastectomy
Tumour involvescentral areasor
majorityof the gland
Regional mastectomy
Multiple tumoursinadjacent glandsor
tumourlocatedbetweentwoglands
Radical mastectomy
Several tumoursthroughout thechain
Skeletal metastasisismuchmorefrequentin
Staged bilateral
Multiple tumours inbothchains
16.8
humanswithbreastcancerthanincanine
mastectomy
mammarytumours.Thisscintigraphyexamination
16.10
Recommendedsurgeryforcaninemammary
anaplasticcarcinoma.(Courtesyof theDivisionof
tumoursofdifferent locationandextent.
Diagnostic Imaging,UniversitySmallAnimal Hospital,
Uppsala,Sweden)
Itisimportanttobearinmindthatoverallsurvival
is(surprisingly)notinfluencedbytheextentof the
Managementandprognosis
surgicalprocedure.Ifthesurgerydoesnotobtain
Amanagementflowchartforbothcanineandfeline
cleanmargins,the outcomeis alwaysworse.The
MTs is given inFigure 16.9.
chosensurgicalprocedureshouldalwaysaim to
16.9
An approachto
Massinthemammarygland
managementof
canineand
feline
Surgical
candidate?
Yes
No
mammary
tumours.
Curativeintentsurgery
Palliativemedicaltreatment
Chemotherapy
NSAIDS
Tumour size
<0.5cm
<3cm
>3cm
orMultiple tumours
or Positive lymphnodes
orFeline
Excisional biopsy
Wideregionalexcision
Unilateral total
mastectomy
orStagedbilateral
mastectomy
Histopathology
Benign tumour
Stage>ll
Considersecond
Sarcomaor
orStage|andIl
orFeline
Nofurthertreatment
carcinosarcoma
Consider adjuvant
chemotherapy
Anaplasticcarcinoma
chemotherapy
Consideradjuvant
chemotherapy
241
Chapter16Tumoursofthemammaryglands
obtainfreesurgicalmarginswithasuggestedmargin
Themostcommonlyuseddrugsinhumanbreast
of2cmofgrosslynormal tissue.
cancerare cyclophosphamide,doxorubicin,gemcit-
Delayingsurgeryisnotadvisable,astumoursize
abine and taxanes.These have allbeenused in
isasignificantprognosticmarker.Tumours<1cm in
caninemammary tumours.Bitcheswithmalignant
diameterhaveafavourableoverallsurvival;tumours
tumourstreatedwith5-fluorouracilandcyclophos-
2-3cmindiameterstillhavea fairprognosis,with
phamidewerereportedtorespondfavourablywhen
reportedoverallsurvivalof22months.Conversely,
treatedinanadjuvantpostoperativesettingcom-
theoutcomeismoreguardedfortumours>3cm,
paredwithbitchestreatedbysurgeryalone.More
withreportedsurvivaltimesofapproximately1year
recently，12bitcheswithinvasivemammarygland
after surgery（Philibert et al.,2003).All tumours
tumoursweretreatedwithdoxorubicinordocetaxel
>0.5cmindiametershouldbeexcisedandsubmit-
after mastectomy;however,theoutcome was not
tedforhistopathologicalreview.lfthetumourhasa
significantlyimprovedbychemotherapy(Simonet
highgradeorisreportedtohaveincompletemar-
al,2006).Inaprospective clinical trial(Marconatoet
gins,newand moreaggressive surgery should be
al,2008)inwhichdogswithaggressivemammary
performedassoonaspossible.
carcinomaofclinicalstagesIVandVweretreated
withsurgicalexcision（n=9)orwithsurgery and
Mammectomymaybeperformedif thetumouris
adjuvantweeklygemcitabine(n=10)forat leastfour
small(>0.5cm indiameter).Anysignsof fixation
cyclesatadoseof800mg/m²,therewerenosignifi-
toskinorunderlyingfascia should increasethe
cantdifferencesbetweenthegroups oneither
response oroverall survival.However,in thedogs
amountoftissueexcised,toobtaintumour-free
margins.Mammectomymayoftenbemore
receiving adjuvantchemotherapy,the number of
complicatedtoperformthanamoreextensive
gemcitabinetreatmentswaspositivelycorrelated
withoverallsurvival.
regional mastectomy.
Basedonthelymphaticdrainage,regional
mastectomiesaregenerallyrecommendedto
Radiotherapy
includeeitherglands1-3orglands4-5.Inthe
Althoughcurrentlyconsideredstate-of-the-arttreat-
caseoftumoursingland3,anapproachwhere
mentincertainsubtypesofhumanbreastcancer,
atleastresectionofonenormalglandflanking
adjuvantradiationtherapyhasnotshownanybene-
theaffectedpartisrecommended.
fitscomparedwithsurgeryalone indogs.Anecdotal
Themost radicalapproachwith a unilateral total
casereportsdescribepalliativeprotocols(8Gyin
mastectomy,includingallglandsandthe
2-3fractions)innon-resectabledisease.Largerpro-
superficial lymphnode(theaxillarylymphnodeis
spectivetrialsareneededtodeterminethepotential
onlyresectedifpalpablyenlargedorproven
roleofradiationtherapyforcaninemammary
cytologicallypositive),isrecommendedifseveral
tumours.However,the anatomical locationof the
tumoursarepresent.Thiswillalsodecreasethe
mammaryglandsleadstoahighriskofinducing
riskoftumourrecurrenceinunaffectedglands.
radiation therapy sideeffects,preferentiallyin the
Ifabilateralmastectomyisneeded,thisshould
gastrointestinal tract.
beperformedasastagedprocedure at least3
weeksapart,toallowwoundhealingandskin
Hormonaltherapy
relaxation.Thisistodecrease theriskof
Earlyspayingpreventsthedevelopmentofmam-
increasedpost-surgeryintra-abdominalpressure,
maryneoplasms.Mostavailableliteraturestatesthat
discomfortandwounddehiscence.
spayinglateroratthetimeofmastectomyhasno
impactonoverallsurvival.InwomenwithBRCA
Adjuvanttherapy
mutations,postpubertal oophorectomy significantly
Althoughcommoninhumanbreastcancerand
decreasestheriskofdevelopingbreastcancerinthe
proventoincreaseprogression-freesurvival aswell
subsequent15years,particularlyifperformedbefore
asoverallsurvival inwomen,theuseofchemother-
40yearsofage.Currentstudieswithinthedog
apy,hormonetherapy,immuno-and/orradiotherapy
indogshasshownlitleclinicalbenefitcompared
ingthebenefitsofsexhormoneablationwithina
withsurgeryalone.However,it isobviousthat ina
subsetofdogswithmammaryneoplasia.
certainsubsetofmalignanttumoursthecurrentsur-
Anti-oestrogenssuchas tamoxifenhavebeen
gicaltreatmentisclearlyinsufficientforlong-term
testedbothinvitroandinvivoindogswithmam-
survivalandhencecallsfornewtreatment
marytumours.Theadjuvantanti-tumouractivity
modalities.
seeninwomenwithbreastcancerhasnotbeen
reproduced in the canine trials.Mostofthedogs
Chemotherapy
hadtostopmedicationprematurelyduetooestro-
Adjunct chemotherapy(see Chapter 7)incanine
genic sideeffectssuchasvulvularswelling,vaginal
mammarytumourshasyettobeprovenasbenefi-
discharge,incontinence，urinary tract infection,
cialasitisinhumanbreastcancer.ltispossiblethat
stumppyometra,signsofoestrusand thusahigher
small sample size,retrospective studies and the
interest frommaledogs (Morris et al.,1993).
largenumberofbenigntumourshavemadeithard
Simultaneously,the anti-tumoureffectsweremar-
toshowanysignificantbenefitscomparedwithsur-
ginal.Currently,the use of tamoxifen cannot be
gery alone.
advised indogs.
242
Chapter16
Tumoursof themammaryglands
Comparativemedicine andgenetics
SiameseandDomesticShort-haircatsare
reportedtohaveahigherincidenceratethanother
Genearrays
breeds.FortheSiamesecatatwo-foldincreasein
Theparticularlyhighdiseaseincidencereportedin
riskcomparedwithotherbreedsisreported.
certain canine breeds suggests a significant genetic
Mammaryneoplasiahasbeenreportedincats
component.The identificationofgeneticriskfactors
from9monthsto23yearsofage,withameanage
iscritical toimprovementsinprevention,diagnosis
ofoccurrenceof 10-12years.Siamesecatsare
andtreatmentofthesetumours.
reportedtohaveaslightlyearlieronset.Asindogs,
Inrecentyears there hasbeensignificantpro-
themajorityofaffectedcatsareintactfemales,
gressindevelopingthetoolsandreagentsneces-
althoughmammaryneoplasiaisalsoseeninlate-
sary to analyse the canine genome.This has
spayed females and,rarely,inmalecats.Incontrast
culminated inahigh-qualitydraftgenomesequence,
tomaledogs,themajorityofthemammarytumours
singlenucleotidepolymorphism(SNP)map and an
foundinmalecatsaremalignant.Themeanage
SNP array for genome-wide association (GWA)
at tumour diagnosis,around 13 years,is also
analysis(Lindblad-Toh et al.,2005;Karlsson et al.,
slightlyhigherthanthatreportedinqueens
2007).These toolsprovide anunprecedented oppor-
(Skorupski et al.,2005).
tunity tocharacterizethegeneticinfluences
in
caninediseasessuchascancer,eventuallyallowing
Hormonal importance
explorationofmoreeffectivetherapies.
Hormonalinfluenceisalsoreportedtobepartofthe
pathogenesisinfelinemammarytumours.Theriskof
ExpressionanalysisincanineMT
developingmammarytumoursisseventimeshigher
cDNAmicroarrayshavebeenused toprofile the
inintactthaninoophorectomizedcats.Arecent
geneexpressionpatternsofnearlyallmajortumours
reportstated thatcatsspayedpriorto6monthsof
inhumans-includingbreast cancer-and have
ageandcatsspayedbetween6monthsand1year
changedthewaytheyarediagnosed,classifiedand
of agehadonly9%and14%,respectively,of therisk
treated.In contrast,very few expression studies
ofdevelopingMTcomparedwithintactcats(Overley
havebeenpublished on canine MTs,mostfocusing
etal.,2005).Noprotective effectof spaying was
onsingle,orinthebestcaseahandfulof,predeter-
seenif thiswasperformedafter2yearsofage.
mined transcripts (Kumaraguruparan et al.,2006).
Therearemanyreportsontheroleoftestoster-
Althoughhighly interesting,research onjust a few
one，oestrogenandprogesteronereceptorsinthe
genesatatimerisksbeingbiased,ascancer isa
developmentof felineMTs.There is a strongassoci-
complex disease.A multimarkercDNAmicroarray
ationbetweentheprioruseofprogesterone-like
studyfound31over-expressedgenesoutof174
drugsandthedevelopmentofbenignandmalignant
tested,basedonahumanbreastcancercDNAarray
MTs.Melengestrolacetate(MGA),apotent synthetic
(von Euler et al.,2005).Among the genes over-
progestin,hasbeenusedasa contraceptiveinzoo
expressed,manywereassociatedwithsimilarfind-
felids,andmammarygland carcinomashavebeen
ingsinhumanbreastcancer.Thesefindingswere
linked to this treatment.In one study,90%ofzoo
confirmed in a dog-specific cDNA array in 2008
felidswithmammarytumourshadbeentreatedwith
wheredifferentcaninemammarytumourcelllines
MGA(McAloose et al.,2007).
were investigated(Raoetal.,2008).
Only10%offelinemammarytumoursare
With thehigh homology of the doggenometo the
reportedtoexpressoestrogenreceptors,farlower
human counterpart(higherthan,forexample,mouse
thanindogs andhumans.Thisreflects thehigher
versushuman),moleculargeneticand clinical com
percentageof malignanttumoursseeninthecat,as
parisonsareundertaken.In thepost-genomicera
therate of tumour cellsstainingpositive forsteroid
techniquesthatreflectgeneexpressionareused as
receptorsdecreaseswithincreasedmalignancy(de
powerfultools,forexampletodetectmolecularsub-
lasMulas et al.,2000).
classification in tumours.It ishoped that thismay
alsobeuseful incomparisonstoenhancetheunder-
standingoftumorigenesisandmetastaticpathways
Clinicalpresentation
inbothdogs andhumans.
Mammarytumoursincatscanoccurassingleor
multiplemasses inoneormanyglands simultan-
eously.Thetumoursaregenerallyconsideredtobe
Felinemammary tumours
equallylocatedinthecranial(axillary)orthecaudal
(inguinal)glands.Most tumours present as a firm,
General considerations
welldefinedmassonpalpation,buttheymayalsobe
Mammarytumoursincatsaremoreoftenmalignant
soft or ill-defined and infitrative. More aggressive
thaninthedog.Thefrequencyofmalignancyis
typesoftenadheretotheskinandtotheabdominal
reportedtobeatleast80%.Mammarytumoursare
wallandmaybeulcerated.
thethirdmostcommoncancer,outnumberedonlyby
The aggressive nature also reflects the high
haemopoietic neoplasms and skin tumours.There
frequencyoflymphaticandlymphnodeinvasion,
arefewreportsonincidencecomparedwithdogs
visibleatnecropsy.Themetastaticrateishighand
and humans,butapproximately20%of tumoursin
occursmostlyintheregionallymphnodesand
thefemale catconsist ofmammary tumours-half
lungs.Metastases to the liver, skeleton,pleura,
theincidencereported in humans and dogs.
spleenandkidneyshaveallbeenreported.
243
Chapter16
Tumoursof themammaryglands
Histopathology
Themostcommonhistological classificationisadeno-
carcinoma,accountingfor>85%oftumours.Themost
commonsubtypesaretubular,tubulopapillary，solidr
cribriform.Othermalignanttumourslessfrequently
reported are sarcomas,mucinous carcinomas,duct
papillomas
and
adenosquamous
carcinomas.
Complexcarcinomasshowingabiphasicnature,with
bothneoplasticepithelialandmyoepithelialcells,are
reportedtobelessaggressive,withabetterprogno-
sisandalsooccurringatayoungeragethanother
feline mammary carcinomas (Seixas et al.,2008).
Vascularinvasionand,toanevenhigher degree，
(a)
lymphaticinvasionmaybepresentuponhistological
examinationandareofprognosticsignificanceas
they suggest metastaticpropensity.Therarebenign
mammaryglanddysplasiasareimportantasdifferen-
tialdiagnosesandbecausetheymaypresentasa
severeclinicalcondition.
Hyperplasias
Non-inflammatoryhyperplasiaisgenerallyeither
（6）
lobularhyperplasiaorfibroepithelialhyperplasia.
Lobularhyperplasia:Lobularhyperplasiaoccurs
infrequentlyaspalpablemassesinoneormore
glands.Ithasbeenreportedincatsfrom1to14
yearsofage(median8years).Mostreportsarefrom
intactfemales.Themostcommontypeoflobular
hyperplasiainvolvesoneormoreenlargedlobules
withacysticordilatedductalcomponent.Mammary
hyperplasiamayalsoonrareoccasionssignifythe
presenceofahormone-producingovariantumour.
Fibroepithelialorfibroadenomatoushyperplasia:
Thiswillusuallyoccurinyoung,cyclingorpregnant
queens.It is a benign,non-neoplasticlesion associ-
atedwithprogesteronestimuli.Apartfromendo-
genousprogesteroneproduction,it is also seen in
(a)Mammaryfibroadenomatoushyperplasiain
16.11
oldintactfemalesand inmalesgivenmegestrol.
a4-year-oldDSHqueen(afterprogestin
treatment).Multiplehyperplasticglandsarebilaterally
Clinically,mostaffectedcatsexhibitmammary
significantlyenlargedwithoedemaandulcerationof the
glandhyperplasia1-2weeksaftertheirfirstoestrus
skinin thefirst twocranialglands.(b)Macroscopically
or2-6 weeksafter exogenously administered
thetumourismultinodularandlightyellow.
megestrol.Theglands aregenerallysignificantly
(c)Histopathologyshowsanetlikepatternbuilding up
enlargedwitharapidclinicalonset.Theskinis
epithelial ducts.（H&E,orginal magnificationX100)（b,c
sometimeserythematousandcanbecomenecrotic
courtesyofErikaKarlstam,NationalVeterinaryInstitute，
(Figure 16.11a).Also oedema of the skin and sub-
Uppsala,Sweden)
cutis，and of both hindlegs,may be present.This
conditioncaneasilybeconfusedwithanacutemas-
symptomsmaytaketimetoresolve.Othertreat-
titisorafast-growingmalignant tumour.Theheat
mentswithvariableresultsarediuretics,corticoster-
andpainpresentuponpalpationgenerallyseenat
oids,testosteroneand aglepristone.Inseverecases
mastitistogetherwithdiscomfortarerarelypresent
theskinmaybeulceratedandlocalizedorsystemic
tothesameextentinfibroadenomatoushyperplasia.
infectionmayoccur.Inthiscasegeneralsupportive
Moreover,amalignanttumourisseldomasfast
careandantibioticsshouldbegiven.
growingandtheanamnesisofrecentprogesterone
Iftheglandsare stillgreatlyenlarged,ovario-
administration,orayounganimaland theinvolve-
hysterectomythroughaflankincisionshouldbeper-
mentofmanyglandsortheentiremammarychain,
formedinsteadofviaalineaalbaincision.
helpstodistinguishthisbenignconditionfromarap-
idlyevolvingmalignancy.Anincisionalbiopsyisgen-
Clinicalstaging
erally diagnostic(Figure 16.11b,c).
Ofspecificimportancewhenstagingfelinemam-
As theseconditions arethoughttobeassociated
mary tumour(seeChapter3) is to describe thepri-
withhormonalstimulationoftheglandulartissue，
mary tumour(defineT) andevaluatethepresenceof
ovariohysterectomyornon-renewalofprogesterone
metastasis(define M).Forthe primary tumour,num-
treatmentisgenerallycurative,though theclinical
beroftumours,size（ofprognosticsignificanceonits
244
Chapter16Tumoursofthemammaryglands
own),locationandsignsofinfiltrativegrowth(fixation
themostcommonlyencountered.Vaguesignsof
toskin/underlyingfascia)shouldbeexamined.
metastaticdiseaseshouldnotdelaytreatment,due
Regional lymphnodes(define N)should beexam-
tothedisease'saggressivenature.
ined forsignsof metastasis(Figure 16.12).Enlarged
Becauseofthehighrateofmalignanttumours,
lymphnodes,especiallytheaxillarynodes,should
anaggressiveapproachismandatoryto achieve
beaspiratedpriortosurgerytodecidewhetherto
diagnosisviahistopathologicalexaminationatthe
includetheminthemastectomy.
timeofmastectomy.Apre-surgical biopsyisnot
advisable.Asin thedog,cytology is seldomrecom-
T-primary tumour size
mendedbeforesurgery,butmayofcoursebeuseful
toruleoutnon-mammarymalignanciesorinflamma-
T1
<1cmmaximumdiameter
tory conditions.lf these are present,cytological
examinationshouldbeperformedfrompleuraleffu-
T2
1-3cmmaximum diameter
sionif thecathasatumourinthemammarygland,
T3
>3cmmaximumdiameter
tolookformalignantcells.
T4
Inflammatory carcinoma
Managementandprognosis
N-regional lymph node status
Surgeryisthepreferredtherapyforfelinemammary
gland tumours(see Figure 16.9).Since there isa
NO
No metastasis
highfrequencyofmalignanttumoursthatsignificantly
N1
Metastasisto ipsilateral node
reducetimetoprogression andoverallsurvival,adju-
vant therapy(e.g.chemotherapyandradiationther-
N2
Metastasistocontralateral lymphnode
apy)issuggested indefinedcases.There areno
M-distant metastasis
majorprospectivetrialstoverifythesuperiorityof
certainchemotherapyprotocols;thusthereisaneed
MO
No distant metastasis
forsuchstudiestobeconducted.Prognosticmarkers
M1
Distantmetastasis
thatmayprovetobemorefrequentlyaddressedin
thefuture are HER2/neu,immunohistochemical
(a)TNMclassification.Evidenceof lymphnode
expressionoftopoisomerasell-betabindingprotein1
(TopBP1),vascular endothelial growth factor(VEGF)
analysis.
and the expression of cyclo-oxygenase 2(COx-2)
T1
NO
MO
receptors(Morris et al.,2008).
TO-1
N1
MO
Surgery
Asthetimefromfirstoccurrencetoveterinary
T2
NO-1
MO
examinationmaybeexcessivelylong，thesurgeon
T3
Nx
MO
oftenfacesalargeinfiltrativetumourthatwill
diminishtheprobabilityoftumourremovalwithclean
X1
N2
MO
margins.ltisreportedthatunilateralmastectomy
IV
Tx
Nx
M1
significantly
decreasesthe
degreeoflocal
recurrencecomparedwithlumpectomy.Hencea
T4
Nx
Mx
moreradicalapproachisrecommendedinfeline
(b) Stage grouping.
mammarytumourscomparedwiththeircanine
Clinicalstagingof felinemalignantmammary
counterparts.Catswithtumours<2cmhavebeen
16.12
tumours.(Modified fromOwen,1980)
reportedtosurvive>3years,whilecatswithtumours
>3cmwill survive<12monthsdespitesurgery.
Thecathasfourpairsofmammaryglands:the
AlthoughaminimumdatabaseofCBC,biochem-
twocranialpairsdraintotheaxillarylymphnode,
istryprofileandurinalysisisgenerallyunremarkable
whilethetwocaudalpairsdraintothesuperficial
infelineMT,itisnecessarytoruleoutotherconcom-
inguinal node.Unlike inthedog,thereissometimes
itantdisease.Thoracicradiographs,both right and
communicationbetweenthetwomammarychains,
leftlateralandventrodorsalviews,should
be
across the midline.Thus,staged bilateral mastec-
obtainedtolookformetastasis.Signsofmetastasis
tomyisrecommended,performed3-4weeksapart
aresmalltolargenodularopacities,butalsomiliary
toallowhealingandrelaxationofstretchedskin.
pleural lesionsthatmayproduceprominentmalig-
Simultaneous
bilateralmastectomyshould
be
nant effusions.Both bronchialand sternal lymph
avoided,asmoststudiesreportnosignificantbenefit
nodeenlargementmaybesignsofmetastatic
inoverallsurvivalandtheprocedurewillmostlikely
spread.Inthegeriatricpatientchangesarenormally
causeunnecessarypostoperativediscomfortand
present in thelungs and pleura.Thisalongside
increasetheriskofwounddehiscence.Additionally，
inactiveinflammatorylesionsmayconfuseinthe
worriesaboutclosureofthewoundoftenresultina
evaluationofchestradiographs.Abdominalradio-
compromisedresectionsurgery.Ifthetumourhas
graphsmaybevaluablefordetectionofiliaclymph
invadedtheabdominalmusculaturetheexcision
node enlargement in caudal tumours.Abdominal
mustincludeaportionoftheabdominalwalland
reconstructionwithmeshmaybenecessarytopre-
metastasis,althoughthoracicmetastasisisgenerally
ventincreasingintra-abdominalpressuretoomuch.
245
Chapter16Tumoursofthemammaryglands
The superficial inguinallymphnodeisalmost
days,while cats with pulmonary metastasis pro-
invariablyexcisedalongwiththecaudalgland.The
gressedatamedianof183days.Theworstprogno-
axillarynodeshouldonlyberemovedifproventobe
metastaticbycytologypreoperatively，asthereisno
anaplastichigh-grade histological subtype,staying
evidencethatprophylacticremovalofthisnodewill
freeofdisease115and95days,respectively,despite
provideabetteroutcome.
adjuvantchemotherapy.Almosthalf thegrouphada
Itiscrucialtostressthatseparatemammary
DFIof 4yearsor longer(41.5%),clearly indicating a
massesonthesameanimal maybeofdifferenthisto-
possibilityfortreatingselectedcasesoffelinemam-
logical types,asindogs.Thereforeallmasses should
marytumourswithadjuvantdoxorubicin.Themost
beexcised(using separate instruments)andsubmit-
commonreasonsfordiscontinuingdoxorubicin
tedforhistopathologicalexamination.Itisimportant
includedprogressivedisease(7.5%)and thedevel-
toensurethateachmasscanbeindividuallydistin-
opment of renal disease(4.5%).
guishedwhenthepathologicalreportreturns.
Themajorsideeffectswiththeseprotocolshave
Simultaneousovariohysterectomyhasnotbeen
beenanorexiaandmildmyelosuppression.Reducing
proventodecreaseincidenceofrecurrenceorpro-
the
doseofdoxorubicin
or
substitutingwith
moteoverallsurvivalbenefits.Itwillpreventuterine
mitoxantronemaylimittoxicitytoanacceptablelevel.
disease (e.g.pyometra,metritis)and significantly
Doxorubicincan benephrotoxictothe cat,though
decreasefemalehormonalinfluenceonexisting
thisis considered uncommon.Prospective studies
lesions.lt isprimarilyperformedinthecaseoffeline
using
combined
adjuvant
chemotherapy
and
fibroadenomatoushyperplasia,andisoftenfollowed
mastectomyinthecathaveyettobeperformed.
byregressionofhyperplastictissue.It is important
torememberthatthisbenignconditionoften
resolvesspontaneouslywithinacoupleofweeks,
Referencesand furtherreading
whetheranovariohysterectomyisperformedornot.
Theriskofrelapsedoes,however,decreasefollow
AntuofermoE,MillerMA,PirinoSetal.(20o7)Spontaneousmammary
intraepitheliallesionsindogs-amodelof breastcancer.Cancer
ingovariohysterectomy.
EpidemiologyBiomarkersandPrevention16,2247-2256
de
lasMulas JM,van Niel M,Millan Yet al.（20oo)Immuno-
Radiationtherapy
histochemical analysisofestrogenreceptors infelinemammary
gland benign and malignant lesions:comparisonwithbiochemical
Thereisnoevidencethatradiotherapyisbeneficial
assay.DomesticAnimal Endocrinology18,111-125
inimproving clinicaloutcomeinfelinemammary
Djupsjobacka A and EksellP(2003）Frequencyofradiographically
detectedpulmonarymetastasesinbitcheswithmammarygland
tumours comparedwithsurgeryalone，andit is
neoplasia.EuropeanJournalofCompanionAnimalPractice13
seldomused inanadjuvantsetting.
149-155
DobsonJM,Samuel S,MilsteinHetal.(2002)Canine neoplasiainth
UK:estimatesof incidenceratesfromapopulationof insureddogs.
Chemotherapy
JournalofSmallAnimalPractice43,240-246
Becauseoftheaggressivenatureoffelinemammary
EgenvallA,Bonnett BN,Ohagen Pet al.(2005） Incidence of and
tumourswithsignificantlyreducedoverallsurvival if
insuredfemaledogsinSwedenfrom1995to2002.Preventive
tumoursizeexceeds3cm,therehavebeenmany
VeterinaryMedicine69,109-127
attemptstouseadjuvantchemotherapy(seeChapter
Gama A,ParedesJ,GartnerFet al.(2008）Expression of E-cadherin,
7)followingsurgeryorsometimesastheonlytherapy
P-cadherin and beta-catenin in canine malignant mammary
tumoursinrelationtoclinicopathologicalparameters,proliferation
innon-resectablecases.Drugsusedaloneorincom-
andsurvival.VeterinaryJourna/177,45-53
bination are:doxorubicin,carboplatin,cyclophospha-
Karlsson EK,Baranowskal,WadeCMetal.(2007)Eficientmapping of
mendeliantraitsindogsthroughgenome-wideassociation.Nature
mideandmitoxantrone.
Genetics39,1321-1328
Insmallerstudiesithasbeenreportedthatdoxo-
rubicinalone,orincombinationwithcyclophospha-
canines:immunohistochemical analysis of PCNA, Bcl-2,p53,
cytokeratinandERinmammary tumours.ResearchinVeterinary
mide,hasresulted inpartial responses in cats with
Science81,218-224
non-resectablelocaldiseaseordistantmetastasis,
Lindblad-Toh K,Wade CM,Mikelsen TS et al. (2005) Genome
sequence，comparative analysis andhaplotype structure of the
andithasefficacyagainstmacroscopicfelinemam-
domesticdog.Nature438,803-819
mary carcinomas(Stolwijketal.,1989).
Marconato LLorenzo RM,AbramoF et al.(2008）Adjuvant
Inalargerretrospectivemulticentrestudyon67
gemcitabineafter surgicalremovalofaggressive malignant
mammarytumoursindogs.VeterinaryandComparativeOncology
catswithhistologicallyconfirmedmammarygland
6,90-101
adenocarcinomastreatedwithadjunctivedoxorubicin
McAloose D,Munson Land Naydan DK(2007)Histologicfeatures of
atadoseof1mg/kgintravenouslyevery3weeksfor
mammarycarcinomasinzoofelidstreatedwithmelengestrol
acetate（MGA)contraceptives.VeterinaryPathology44,320-326
amaximumoffivetreatments,oruntilthecatdevel-
MerloDF,Rossi L,PellegrinoCet al.(2008)Cancer incidence in pet
opedprogressivediseaseorconcurrentillness,itwas
dogs:findingsof theAnimal TumorRegistry ofGenoa,Italy.Journal
shownthatcatsthatcompletedtheadjunctivedoxo-
ofVeterinaryInternalMedicine22,976-984
MisdorpW,ElseRW,HellmenEetal.（1999）.Histologicalclassification
rubicinprotocolhad significantly improved survival
ofmammarytumorsof thedogandcat.WHOInternational
(Novosad et al.,2006).The mediansurvival timeof
HistologicalClassificationofTumorsinDomesticAnimals.Armed
ForcesInstitute of Pathology.WashingtonDC
catsthatreceivedsurgeryanddoxorubicinwas448
MorrisJS,DobsonJMand Bostock DE（1993）Useof tamoxifenin the
days,while themedian disease-free interval(DFI)
controlof canine mammaryneoplasia.VeterinaryRecord 133
was255days.PrognosticfactorsforDFIapartfrom
539-542
Morris JS,Nixon C,Bruck A et al.(20o8)Immunohistochemical
completionofchemotherapywere:tumourvolume,
histological subtype,developmentof metastaticdis-
histologicalgrade,Ki67,Ealphaandp53.VeterinaryJourna175
easeandlocationofmetastaticdisease.Catswith
218-226
Novosad CA,Bergman PJ,O'Brien MG et al.(2006) Retrospective
lymphnodemetastasishadamedianDFIof1,122
evaluationofadjunctivedoxorubicinfor the treatmentoffeline
246
Chapter16
Tumoursof themammaryglands
mammaryglandadenocarcinoma:67cases.Journalofthe
Medicine20,1184-1190
AmericanAnimalHospitalAssociation42,110-120
SkorupskiKA,OverlyB,ShoferFSetal.(2005）Clinicalcharacteristis
NymanHT,KristensenAT,Skovgaard IMetal.(2005）Characterization
ofmammarycarcinomainmalecats.JournalofVeterinaryInternal
ofnormalandabnormal caninesuperficiallymphnodesusinggray-
Medicine19,52-55
scale B-mode,color flow mapping.power,and spectral Doppler
SorenmoKU,ShoferFSandGoldschmidtMH(20oo）Effectofspaying
ultrasonography:amultivariatestudyVeterinaryRadiologyand
andtimingofspayingonsurvivalofdogswithmammary
UItrasound46,404-410
Overley B.Shofer FS,Goldschmidt MH et al.(2005)Association
Sorenmo KU,Kristiansen VM,Cofone MA et al.(2009)Canine
betweenovariohysterectomyandfelinemammary carcinoma.
mammary gland tumours;ahistological continuum frombenign to
JournalofVeterinaryInternalMedicine19560-563
malignant:clinicalandhistopathologicalevidence.Veterinaryand
OwenLN（1980)TNMClassificationofTumoursinDomesticAnimals.
ComparativeOncology7（3),162-172
WorldHealthOrganization,Geneva
StolwijkJA,Minke JM,Rutteman GRet al.（1989)Feline mammary
PhilibertJC,Snyder PW,Glickman Net al.(2003)Influence of host
carcinomasasamodel forhuman breastcancer.ll.Comparisonof
invivoandinvitroadriamycinsensitivity.AnticancerResearch9,
JournalofVeterinaryInternalMedicine17,102-106
1045-1048
Rao NA,van Wolferen ME,van den Ham Ret al.（2008） cDNA
vanGarderenEandSchalkenJA(2002)Morphogenic and tumorigenic
microarrayprofilesofcaninemammarytumourcellinesreveal
potentialsofthemammarygrowthhormone/growthhormone
deregulatedpathwayspertaining totheirphenotype.Animal
receptorsystem.MolecularandCellularEndocrinology197,153-
Genetics39,333-345
165
SeixasF,Palmeira C,Pires MA etal.(2008)Are complexcarcinoma of
von EulerH,Khoshnoud R,HeQetal.(2005）Time-dependent RNA
degradationaffecting cDNA array quality in spontaneous canine
identical tumours?Comparisonofclinicopathologicfeatures,DNA
tumours sampled using standard surgicalprocedures.International
ploidyandfollowup.ResearchinVeterinaryScience84,428-433
JournalofMolecularMedicine16,979-985
SimonD,SchoenrockD.BaumgartnerWetal.(2006）Postoperative
Wakui S,MutoT,YokooKetal.(2001)Prognostic statusofp53gene
adjuvant treatment of invasivemalignantmammaryglandtumorsin
mutationincaninemammary carcinoma.AnticancerResearch21,
dogswithdoxorubicinanddocetaxel.JournalofVeterinaryInternal
611-616
247
Tumours of the urogenital
system
RobertN.WhiteandMalcolmBrearley
Tumours of thekidney
Generalconsiderations
PrimarytumoursofthekidneyarelistedinFigure
17.1.Thekidneysarerelativelycommonsitesfor
developmentofmetastases,butprimarytumoursof
thekidneyareuncommoninboththedogandcat.
Theyaccountforonly1.7%and2.5%ofalldogand
cat tumours,respectively (Crow,1985).In the dog,
adenocarcinomaisthemostfrequentprimarytumour
Benign
Adenoma
Fibroma
Haemangioma
.
Interstitialcelltumour
Leiomyoma
Transitionalcell papilloma
Malignant
Adenocarcinoma/carcinoma
Fibrosarcoma
Haemangiosarcoma
Leiomyosarcoma
Nephroblastoma
Transitional cellcarcinoma
17.2
Intra-operativeviewofanephroblastomaof the
Lymphoma
right kidney.
17.1
Primary tumoursof thekidney.
muscle,cartilageandboneatvariousstagesof
differentiation.
typeanditismostcommonlyseeninmiddle-aged
andolderdogs.Malesaremorefrequentlyaffected
Presentationandclinicalsigns
thanfemales.In thecat,lymphoma isthemostcom-
Primarytumoursof thekidneyareusuallysolitary
monrenaltumour;itmaybeprimaryorsecondary.
andunilateral,whereasmetastatictumoursarecom-
Thereisnosexpredispositionforfelinerenallym-
monlymultipleandbilateral.Bilateralrenalcyst-
phoma;itismostfrequentlyreportedinindividualsof
adenocarcinomaisararetumourreportedinthe
6-7yearsof age.AlthoughFeLVinfectionisconsid-
GermanShepherdDogaspartofasyndromeasso-
eredariskfactorforthedevelopmentofrenallym-
ciatedwithnodulardermatofibrosisanduterinepol-
phoma in the cat,reports suggest that only25-50%
yps (Moe and Lium, 1997).
ofaffectedindividualsareFeLV-positive.Aswiththe
Classically,specificclinical signsassociatedwith
dog,renal carcinomas(tubular and tubulopapillary)
renal tumoursinclude:
arethemostfrequentlydiagnosedprimaryrenal neo-
plasm in the cat(Henry etal.,1999).
Palpablerenal mass（thereisoftenbilateralrenal
Nephroblastoma(Wilm'stumour;embryonal
enlargementinacatwithrenallymphoma)
nephroma;Figure17.2)isanembryomaandoccurs
Intermittentorpersistenthaematuriathroughout
most frequentlyinyoung dogs,oftenlessthan1
urination
yearof age(meanage 4years).The tumourmay be
Abdominaldistension
present in only one pole of an affected kidney.
Abdominaldiscomfort
Histologically,itmaydemonstrateprimitiveepithelial
Developmentofpelviclimboedemawhen
andmesenchymaltissuessuchasvestigial tubules,
lymphaticdrainageiscompromised.
248
Chapter17Tumoursof theurogenitalsystem
Inmanyinstances,the clinical signs are notso
acontralateral'normalkidneypossessesadequate
welldefinedandonlyvaguesignsofillnesssuchas
excretoryfunctionforanindividualtofunctionnor-
anorexia,depression,weightlossandlethargymay
mallyfollowinganelectivenephrectomy.
bepresent.Signsofovertrenalfailurearerarelypre-
sent unless there issevere,bilateralinvolvement
Management
(e.g.in renal lymphoma in the cat)or the otherkid-
neyiscompromisedbyanon-neoplasticprocess.
Surgery
Inthemajorityofanimalswithaunilateralrenal
Clinical approach
tumourandnoevidenceofmetastaticdisease,the
treatmentofchoiceisureteronephrectomy.Thepro-
Bloodsamples
cedureissimilar tothatdescribedforureterone-
Completebloodprofileswillbeunremarkableinmany
phrectomy forotherconditions.Whenremovinga
neoplastickidneyit is important tominimize the
cases.
handling of theaffected structures,sincehandling
mayinduceintravascularseedingofthetumour.
?
Inindividualswithhaematuriatheremaybe
Similarly,it is importanttoisolatethebloodsupply
evidenceofaregenerativeanaemia.
toandfromtheaffectedkidneyasearlyaspossible
Polycythaemiaveramayoccurasa
during the resection.ldeally,the renal capsule
paraneoplasticsyndromeinsomecasesofrenal
shouldberemovedintactwiththekidneytomini-
carcinomawherethetumourautonomously
mizethepotentialspreadoftumourcellswithinthe
produceserythropoietin.
peritonealcavity.Someembryonal tumoursmay
Renalserumbiochemistryresultswillmostlybe
achieveamassivesizepriortodetectionandresec-
normalunlessthereisseverebilateralrenal
tion.Thesheervolumeofsuchtumourswillmake
involvement.
theuseofascrubbedsurgical assistantimperative.
Hypercalcaemiamayoccasionallybeseenasa
Manyrenaltumoursarereadilyamenableto
paraneoplasticsyndrome.
resection,butsome carcinomasmaydemonstrate
Allcatswithsuspectedrenal lymphomashould
local invasionintoneighbouring structuressuch as
betestedforFeLVstatus.
theinfrarenalvena cava.Thesecasesmayprove to
besurgicallydemandingandmayrequiretheplace-
Urinalysis
mentofautologousvenousorprostheticvascular
Neoplastic cells may occasionally be seen on cyto-
grafts.
logicalexaminationofurinesediment,buturinalysis
isgenerallyunrewardingwhenlookingforthepres-
Radiotherapyandchemotherapy
enceoftumourcells.Proteinuriaisacommonfind-
Theconsequencesof local intraperitonealorganradi-
ingandhaematuriamaybeobservedinindividuals
ationdamagemeanthatradiotherapyis,ingeneral,
sufferingfrominvasive,destructivetumourssuchas
notusedinthemanagementofrenal tumoursinthe
haemangiosarcomaandrenalcarcinoma.
dog and cat.
Combinationchemotherapyis thetreatmentof
choiceinindividualswithrenal lymphomaasthecon-
Imagingtechniques
Renaltumoursthatdemonstraterenomegalymaybe
ditioniscommonlybilateraland/orgeneralized.
Standard protocols,as discussed in Chapter 19a,
detectableonplainsurveyabdominalradiographs.
maybeused.Theresponse isoftennotasgoodas
Assessmentofrenalfunctionandintraparenchymal
thatseenwithotherformsoflymphoma.Foranimals
architecturemaybeenhancedbyperformingintra-
withunilateralrenal lymphoma theremaybearole
fornephrectomy.Unfortunately,itmaynotbepossible
Inmost instances,the use of ultrasonography will
toprovethatonlyonekidneyisaffected;therefore
complementorsupersedetheseradiographicinves-
mostauthoritieswouldadvocatetheuseofchemo-
tigations.Renal ultrasonography allowsrenalarchi-
therapyinallcaseswithrenal lymphoma.Adjunctive
tecturetobeassessed inanon-invasivemannerand
chemotherapymaybeconsideredincaseswithnon-
itenablesaccuratepercutaneousfine-needleaspira-
resectableor resected non-lymphoid tumours,but
tion（FNA)orneedlebiopsyofanyabnormalstruc-
objectiveevidenceforaresponseislacking.
alsoallowtheassessmentoflocaltumourinvasion
Prognosis
intoadjacentvascularstructuressuchasthevena
The prognosis for the majority of renal tumours
cava.
remainspoorbecauseoftheirinvasivenatureand
Moreadvancedmethodsofinvestigationinclude
hightendencyformetastasispriortodetectionand
magneticresonance imaging(MRl)and computed
treatment.Survivaltimesforrenalcarcinomafollow-
ingureteronephrectomyareconsideredtobe6-12
assessmentofrenalfunctionandglomerularfiltra-
monthsonaverage.Nephroblastomacarriesabetter
tionrate(GFR).These techniques are becoming
prognosisand,withadequatesurgicalexcision,many
morewidelyavailableandwilloftenprovideunparal-
casesmaybecured.Renal lymphomaappears to
leledinformationforthesurgicalplanningofcases
respondlesswelltochemotherapythandoother
withlocalvascularinvasion.Scintigraphyorexcretion
formsoflymphoma;long-termremissionandsurvival
arerarelyachieved.
249
Chapter17
7Tumoursof theurogenitalsystem
Tumoursoftheureter
kidney.Percutaneous ultrasound-assisted biopsy
maybepossible,butinmanyinstances theureteral
General considerations
tumourwillprovetoosmallforabiopsytobeper-
TheprimarytumoursoftheureterarelistedinFigure
formedsafelyandaccuratelybythistechnique.
17.3.Tumoursoftheuretersareextremelyrareinthe
dogandcat.Theuretercanbethesiteofaprimary
Management
neoplasmoritmaybeinvadedbylocalspreadfrom
Ingeneral,thetreatmentofchoicefortumoursof the
aninvasivetumouraffectingitsassociatedkidney.
ureterthathavenotmetastasizedorinvadedlocallyis
ureteronephrectomy.Thefunctionofthecontralateral
Benign
kidneyshouldbeassessedpriortoperformingthis
Leiomyoma
surgery.Incaseswherecontralateralkidneyfunction
isconsideredcompromised,itmayprovenecessary
Malignant
toperformalocalresectionoftheaffectedportionof
Leiomyosarcoma
theureterfollowedbyend-to-endureteralanastomo-
Transitional cell carcinoma
sis.Insome instancestheassociatedkidneymustbe
transposedcaudally,toensurethatnounduetension
17.3
Primarytumoursof theureter.
isplacedon the anastomosissutureline.
Presentationandclinicalsigns
Therearenoreportsontheuseofchemother-
apyorradiotherapyinthemanagementofureteral
Thenarrowdiameteroftheuretermeansthatevena
tumours.
smalltumourmayresultinobstructiontourineflow
andthedevelopmentofproximalhydroureterand
Prognosis
hydronephrosis.These,along with unilateral renal
Mostrecognizedureteraltumoursaremalignantand
compromise,mayresult in clinical signs.However,
sothepresenceoflocalinvasionand/ormetastasis
thefunctionalcapacityoftheunaffectedcontralateral
makes the prognosis for this condition poor.The
kidneymeansthatsignsofrenal failureareoften
resectionofabenigntumourcarriesthepossibilityof
masked andnotdetected.Signs are,therefore,often
complete cure.
non-specificand includelowerbackpain,stiffness
andlethargy.
Tumoursoftheurinarybladder
Clinical approach
General considerations
Bloodsamples
TumoursoftheurinarybladderarelistedinFigure
Acompletebloodprofilerevealsnospecifichaemato-
17.5.Tumoursofthebladderarethemostcommon
logicalorbiochemicalchangesinindividualswitha
formofcanceraffectingtheurinarytractinthedog
ureteraltumour.
Afterrenal lymphoma,bladdercanceristhesecond
mostcommonlocationforcanceroftheurinarytract
Imagingtechniques
inthe cat.In both species,however,the bladder is
Investigationofureteralabnormalitiesshouldinclude
stillanuncommonsiteforcancerdevelopment,with
contrastradiographic studies;plain surveyradio-
afrequencyoflessthan1%ofalltumoursinthedog
graphsrarelyallow theureterstobedefined.
andwithanevenlowerfrequencyinthecat（Crow,
PerformingIvuwillallowpreciseassessmentofthe
1985).Inthedog,bladdercancerismorecommon in
intraluminalureteralstructure tobemade（Figure
bitchesand themeanageatpresentationisapproxi-
17.4).Bothlateralandventrodorsalviewsshouldbe
mately10years.Certainbreeds,includingtheWest
obtainedatvarioustimepointsfollowingtheadminis-
HighlandWhiteTerrier,JackRussellTerrier,Beagle
trationoftheintravenouscontrastmedium.Ifmalig-
andScottishTerrier,maybemoreatrisk.In thecat,
nancyissuspected,thoracicradiographsshouldbe
thediseaseappearstohavenobreedpredilection,
obtained forstaging.
butisseenwithgreatestfrequencyinagedmales
Ultrasonographymayalsobeusedtoassessthe
(mean 9-10 years).
structureoftheaffectedureterand itsassociated
Benign
Leiomyoma
Fibroma
Haemangioma
Maignant
Transitional cellcarcinoma（commonest)
Lymphoma
Leiomyosarcoma
Haemangiosarcoma
Undifferentiated carcinoma
.
Squamouscell carcinoma
Rhabdomyosarcoma(embryonal)
17.4
Intravenousurogramrevealingthepresenceof
Fibrosarcoma
fillingdefects inthe ureterof acat(arrowed).
Excisional surgery(nephrectomy andureterectomy)and
Adenocarcinoma
histopathologyconfirmed thelesiontobeaureteral
17.5
Tumoursof theurinarybladder.
carcinoma.
250
Chapter17Tumoursoftheurogenitalsystem
Themajorityofbladdertumoursinboththedog
haematuria,theremaybeevidenceofaregenera-
(97%of cases)and cat(80%ofcases)are malignant
tiveornon-regenerativeanaemia.
andepithelialinorigin,themostfrequentbeingtransi-
tionalcellcarcinoma(TcC).Tumoursmostcommonly
Urinalysis
arisefromthetrigoneregionofthebladder.TCCis
Urinalysis,urinecultureandantibioticsensitivitytest-
ingshouldbeperformedinallcasesofsuspected
bladdertumour.Tominimize theriskofseedingneo-
tate,vagina,uterusorrectum.Thistumouriscapable
plasticcells,itisadvisabletoobtaina urinesample
ofbothlocal(hypogastric andmedial iliaclymph
byfreecatch’rather thanconventionalcystocente
nodes)and distant (liver,lungs,spleen)metastasis
sis.Insomecases,cytologicalexaminationofurine
andmetastases maybepresent inupto50%of
sedimentwillreveal thepresenceofpleomorphic
cases at thetime of diagnosis.
tumourcells.Unfortunatelythisisnotalwaysreliable,
Ithasbeenhypothesizedthatthedifferencein
assomebladdertumours,especiallysarcomas,do
prevalenceofbladderneoplasiabetweenthedogand
notexfoliatewell,leadingtoafalse-negativeresult
thecatisrelatedtodifferencesinmetabolismof tryp-
Careshouldbetakentoavoidconfusingneoplastic
tophananditscarcinogenicintermediarymetabolites.
Althoughdogsexcreteappreciablequantitiesoftryp-
tophanmetabolitesintheirurine,caturineisalmost
ciatedwithabenigncystitis.Aurinedipsticktestis
availableforthedetectionofbladdertumourantigen
devoidofthesesubstances.Theprolonged exposure
of thebladdermucosa tosuchcarcinogenic sub-
indogs,butcare shouldbe takenininterpreting the
stancesmaybeimportantinthedevelopmentofblad-
resultsinthe faceofhaematuriaandproteinuria,
derneoplasia.
whenfalse-positiveresultsarenotuncommon.
Presentationandclinicalsigns
Cytology
Allepithelialbladdertumoursmaybesolitaryormul-
FNAofbladderwalllesionsmaybeattemptedunder
tipleandappearaspapillaryornon-papillary(Figure
ultrasoundguidanceand thismethodofdiagnosisis
17.6)growths.Mesenchymal tumoursaremost likely
advocatedbysome.However,in thecaseof TCC
tobelocallyinvasive,althoughsome,suchashaem-
especially,thereisaseriousriskofseedingtumour
angiosarcoma,arelikelytoexhibitmetastasis.
cellsalongtheneedletract(intotheperitonealcavity
andtheabdominal wall),andalternativemethodsof
collecting tissue,via cystoscopy or using a blind
cathetersuctiontechnique,maybesafer.
Imagingtechniques
Contrastradiographyandultrasonographyareuseful
techniquesforinvestigationofsuspectedbladderneo-
plasia.Ultrasonographylendsitselfparticularlywellto
investigationofthebladdersincethelumengenerally
contains urine,allowing for good transmission of
soundandthegenerationofclearultrasound images.
Mucosalabnormalitiesattheinterfacebetweenthe
CystotomyforpartialexcisionofalargeTCC.
intraluminalfluidandsofttissuestructuresofthewall
17.6
Thepresentingclinical signswerehaematuria,
willbemostclearlyvisualized;thetechniquewillalso
dysuriaandintermittentstranguria.
allowtheextentoflocalinvasiontobeassessed
Bladdertumoursoftenshowclinicalsignsconsist-
(Figure 17.7).Whenbladderurinevolume islowit
entwithcystitis,including：
mayprovehelpfultodistendthestructurewiththe
administrationofsaline.
Dysuria
.
Haematuria
ELADDER
。
Pollakiuria(increased frequencyof micturition).
These clinical signs may showa temporary
response to symptomatic therapy,but invariably
returneitherwhilsttheanimalisstillbeingmedicated
oronce therapyhasbeenstopped.Therecurrent
natureof thesesignsshouldalertthecliniciantothe
possibilityofunderlyingbladderneoplasia.
Clinical approach
Bloodsamples
Complete blood profiles will,in many cases,be
Ultrasound imageofabladderwithaTCC
unremarkable.Inindividualssufferingfromchronic
17.7
(arrowed)at thelevel of the trigone.
251
Chapter17Tumoursof theurogenitalsystem
Plainradiographsofthebladderwilloftenbe
reducetumourload.Themucosaisapproachedviaa
unremarkable,butinsomecircumstancestheymay
cystotomyandtheaffectedportionisundermined
indicateachangeinbladdershapeorposition.
superficial tothesubmucosa,allowing themucosa to
Contrastradiographyisconsiderablymoreinforma-
be‘peeled’away.Ideally,the remaining mucosa
tive.Negative contrast studies(pneumocystogram)
shouldbeusedtoclosethemucosaldefectthathas
willoftenindicatethepresenceofanintraluminal
beencreated.Alternatively,thedefectcanbeleftto
massoranirregularmucosalsurfaceconsistent
closebysecondintentiongranulation,epithelialization
witha tumour.Mostinformationcanbegainedby
andcontraction.Thispalliativeoperationisnotwithout
obtainingadoublecontrastcystogram.Theaddition
potentiallyseriouscomplications,butincertaincases
ofasmallvolumeofpositivecontrastpriortoinfla-
mayreduceclinicalsignsandincreasetheeffective-
tionwithairwilloftenhighlightthepresenceofan
nessofadjunctivechemotherapybyreducingtumour
epithelial abnormality(Figure17.8).
targetvolume.
Totalcystectomy:Thereareanumberofexperimen-
talandclinicalreportsdescribingtotalcystectomyin
thedog.Toperformsuchsurgeryrequirestheureters
tobeimplantedintoadistantsitethatwillallowun-
impededurinetoflowfromtheirassociatedkidneys.A
numberofimplantationsiteshavebeendescribed;
theseinclude thecolon,theurethra and thepassage
of theuretersthroughtheabdominalwallwithcutane-
ousstoma formation.Thecoloncannotberecom-
mendedasasite,becauseimplantationresultsinthe
developmentofpyelonephritisand/orfaecalinconti-
nence.Bothurethralandcutaneousimplantationsites
Doublecontrastcystogramdemonstratinga
17.8
resultinurinaryincontinenceandthepossibledevel-
mass(arrowed)associatedwiththedorsal
opmentofanascendingpyelonephritis.Althoughin
bladderwall.Theurothelium appears smooth,suggesting
manyinstances theincontinencemaybemanaged
that themassmightbemesenchymalandnotepithelial in
origin.Thesefindings may alsobe suggestive of abenign
with theuseof disposablechildren'snappies,theethi-
rather thanamalignanttumour.
calimplicationsandhighpatientmorbidityofsuch
proceduresshouldnotbeunderestimated.
Management
Cutaneouscystostomy:Thecreationofaperma-
Ideally,completestagingshouldbeundertakenprior
nentcutaneous cystostomyhasbeendescribedin
toanyintervention.Bothregionalanddistantmeta-
dogswithstranguriaassociatedwithinoperableblad-
stasesarenotuncommon inindividualssuffering
dertumours.Theavailabilityofone-wayvalvesmanu-
frommalignantbladderneoplasiaandthefindingof
facturedfrombiologicallyinertmaterialshasallowed
metastaticdiseasewillsignificantly influencehow
permanentcystotomysites tobecreatedwithout
theconditionismanagedandwhat thelikelyout-
associatedurinary incontinence.Experience would
comeofmanagementwillbe.Treatmentisunlikelyto
suggestthatthedevelopmentofascendinginfections
affectmetastaticrateoralterdiseaseprogressionor
withinabladderiscommonfollowingtheplacementof
survival timesoncegrossmetastasisisdetected.
suchadeviceandagain,tsadvisedthatsuchsurgi
Surgery
calproceduresshouldbeundertakenwithcaution.
Theaimsofsurgeryshouldbeclearlydefinedatthe
Tumourresection:Resectionofmesenchymal
outset:istheprocedurebeingundertakeninan
tumoursthatcanbecompletelyexcised(apexand
attempt tocuretheindividual,oristheproposedsur-
bodytumours)andbenigntumoursmayprovemore
rewarding（Figure 17.9).Some two-thirds of the
naryobstruction?
bladderbodymayberesectedwithoutsignificantly
Partialcystectomy:Surgicaltherapyforthemajority
affectingbladderfunction.
ofTcCsisoftenunrewarding,since themostcom-
monsiteforthesetumours isat thetrigone.Although
itmaybepossibletoperformapartialcystectomy，
includingtransectionof theureters and theirre-
implantationintotheapexof thebladder,theremoval
ofthe trigonewilltypicallyresultinurinaryinconti-
nence.Themultipleanddiffusenatureofmanyepi-
thelial tumoursmakesmarginassessmentdifficult,
andlocalrecurrencefollowingapparentlysuccessful
resectioniscommon.
Submucosalresection:Inselectcasesofextensive
Intra-operativeviewofasmoothnon-infiltrative
diseasewherepartialcystectomyisnotconsidered
17.9
mesenchymal massassociatedwiththedorsal
feasible,orincaseswheretheTCCinvolvesthetrig-
bladderwall.The grossfindingswereconsidered
oneand/orperi-ureteralregions,submucosalresec-
consistentwithabenigntumour.Histopathologyconfirmed
tionofthesuperficialtumourmaybeperformedto
themasstobealeiomyoma.
252
Chapter17Tumoursoftheurogenitalsystem
Medicaltherapy
inthedogareofepithelialoriginandincludeTCC
Non-resectableTcCshavebeenmanagedmedically
and squamous cell carcinoma (ScC).In the dog.
withthenon-steroidalanti-inflammatorydrugpiroxi-
tumoursoftheurethrapresentlesscommonlythan
cam(0.3mg/kg orally q24h).It is thought that COx-2
thoseof thebladder.Urethral tumoursareconsidered
inhibitionisinvolvedintumourresponse，andother
extremelyrareincats.
morepotentCox-2inhibitorsmayprovideasimilar
Themeanage of dogs with urethral tumours is10
effect.Inonestudy,partialorcompleteremissionwas
yearsandthereisapredilectionforurethral tumour
notedin6of34dogs;manyotherdogssubjectively
developmentinthebitch.TCCmostcommonlyaffects
hadanimprovedqualityof life，despitelackoftumour
theproximal thirdof theurethra,whereasSCCpre-
remission(Knapp et al.,1994).Other non-selective
dominatesinthedistalportionoftheurethraandure-
COx-2inhibitorsappearaseffectiveaspiroxicam;
thral tubercle.Both tumours arehighly malignant,
thisappliestomeloxicam(personalobservation)and
showinglocalinvasion throughtheurethralwall,ure-
firocoxib.
thral luminalobstructionandmetastasistobothlocal
Improvedremissionratesandremissiontimes
lymphnodesandlocalpelvicorgans.
maybeachieved inasubsetofpatientsbycombin-
ingCOx-2inhibitorswithplatinum-basedchemother-
Presentationandclinical signs
apyand,toagreaterextent,mitoxantrone.However,
Clinicalsignsassociatedwithurethraltumours
thereareconflictingreportsintheliteratureandthe
include:
benefitof thesetherapiesisstill underinvestigation.
Therehavebeenreportsthatlocallyapplied
Dysuria
interleukin-2maybeofvalueinthemanagementof
caninebladdertumours,butthesehavenotyetbeen
Haematuria
Pollakiuria
substantiated inpublishedclinical trials.
Stranguria(in advanced cases).
Prognosis
Theprognosisformostmalignant tumoursof epithe-
Signsmaybeverysimilartothoseseenwith
bladdernecktumours.Inearlydisease,signsmay
lialoriginispoorbecauseoftheirdiffuse,some
belesspronouncedandarelikelytobethoseofan
times multiple and infiltrative nature.Also,their
tendencytodevelopatthetrigonalregionofthe
unresponsive cystitis and/or urethritis.
bladderoftenmakestheminoperable.Survivaltime
followingexcisionofbladdercarcinomasisusually
Clinical approach
lessthan6months.Mesenchymal tumourscarrya
Physicalexamination
andareamenabletosurgicalexcision.Theprogno-
Themajorityofurethral tumours,especiallythosesit-
sisforbenigntumoursof thebladderdependson
uatedwithinthedistalurethra,willbepalpableeither
thesiteofgrowth;inmanyinstances,surgicalresec
pervaginumorperrectum.Theymaybedetected as
tionwill provecurative.
adiscretemassoramorediffuseswellingwithinthe
urethralwall.Palpationpervaginummayalsoindi-
catethepresenceof local infiltrationintotheadjacent
Tumoursoftheurethra
ventralvaginalwall.
Generalconsiderations
Blood samples
TumoursoftheurethraarelistedinFigure17.10.
A completebloodprofilewill reveal no abnormalities
Infiltrativeurethral diseaseisuncommonindogsand
cats;neoplasiaandgranulomatousurethritisarethe
associatedspecificallywithurethralneoplasia.
twoconditionsmostfrequentlydescribed(Matthiesen
andMoroff,1989).Thecommonesturethraltumours
Urinalysis
Althoughurinalysiswillcommonlyfail toreveal the
Benign
presenceofneoplasticcells,itmayindicatethepres-
enceofproteinuriaand haematuria.Urine should
·Adenoma
alsobesubmittedforcultureandsensitivitytesting.
Fibroma
Theurinesamplemaybeobtainedbycystocentesis,
Leiomyoma
butitwouldbesafertoobtainthesamplebyfree
Myxoma
catch'if thediagnosisisindoubt and thereisapos-
Papilloma
sibilityof thepresenceofbladdertumour.
Malignant
Transitional cellcarcinoma(commonest)
Imagingtechniques
Adenocarcinoma
Furtherinvestigationsofananimalwithclinicalsigns
.
Haemangiosarcoma
indicativeof lowerurinarytractdiseaseshouldinclude
Rhabdomyosarcoma
alowerurinarytractradiographic study.Themost
Myxosarcoma
valuableinformationregardingthepresenceandsize
Squamous cell carcinoma
ofaurethral tumourwilloftenbeobtainedbyperform-
17.10
ingretrogradepositivecontrasturethrographyor
Tumoursof the urethra.
vaginourethrography(Figure 17.11).
253
Chapter17Tumoursof theurogenital system
Biopsy
It isimportanttoobtainbiopsymaterialfrom aninfil-
trativeurethrallesionforhistologicaldiagnosisof
tumourtypeanddistinctionfromthenon-neoplastic
conditionofgranulomatousurethritis.Adequate
biopsymaterialcanoftenbeobtainedbyapplying
negativepressurewithasyringetoaurinarycathe-
ter thathasbeenplacedwithinthevicinityofthe
urethrallesion.Thesamplesobtainedwilloftenbe
largeenoughtobesubmittedforhistopathological
examination.
Management
17.11
Retrogradepositivecontrastvaginourethrogram
ofabitchwithhaematuria anddysuria.Thereis
Surgery
afillingdefectwithinthedistal urethra(arrowed)
Inanimalswithurethraltumoursthatshownoevi-
consistentwithaurethraltumour.Exfoliative
denceoflocal ordistantmetastasis,it maybepossi-
histopathology confirmed thelesion tobeaTCC.The
bletoresect thetumoursurgically.Inthemaledog,
bitchsubsequentlyunderwentsuccessfultumour
resectionandreconstructivevaginourethroplasty.
ingapenileamputationandscrotalorperinealure-
Enlarged regional lymph nodes（medialiliac,
throstomy.Small,proximal tumoursmaybeamenable
tolocalurethralexcisionandend-to-endanastomo-
sacralandhypogastricnodes)mayindicatethepres-
sis.In the bitch,successful management of both
enceoflocalmetastasis.Thoracicradiographsshould
beobtainedtoruleoutthepresenceofdistantlung
benignandmalignanttumoursaffecting thedistal
urethraandurethral tuberclehasbeendescribed
metastasis.Thelowerurinarytractradiographicstudy
willrequiretheurethrainboththedogandthebitchto
(Whiteetal.,1996).Upto50%ofthedistalurethra
becatheterized.Thiswillprovideinformationregard-
canberemovedandrepairedbyperformingavagino-
ingthesiteanddegreeofurethralconstriction.Aure-
thrallesionmaycausecompleteobstructionofthe
postoperatively.Inboththedogandthebitch,access
lumenandsomakeitimpossibletopassaurethral
totheintrapelvicurethrarequireseitherpubicsym-
cathetersafely.Insuchcases,urinecanberemoved
physectomyorsagittalpubicosteotomy.Proximal
tumoursclosetothebladderneckareoftenmoredif-
fromthebladderbyintermittentcystocentesisorauri-
narydiversionproceduresuchasatubecystostomy.
ficulttoremove.In the dog,intraprostaticurethral
Inthebitch,thevestibule,urethraltubercle,vestib
tumourswillrequireprostatectomy,resultingalmost
ulovaginaljunctionandvaginashouldbeexamined
invariablyinpostoperativeurinaryincontinence.
visuallywith the aidof a scope(Figure17.12)orspec-
Aswithcertaininoperablebladdertumours,the
ulum(inmanyinstances,theuseofasimpleoto-
creationofapermanentcutaneouscystotomyutiliz-
scopewillprovideasatisfactoryview).Thisprocedure
ingsomeformofbiologicallyinertone-wayvalvecan
maywellbeperformedatthesametimeastheplace
beconsideredinindividualswithurethral tumours
mentofaurethralcatheter.
showingsignsofseveredysuriaorstranguria.
Chronicascendinginfectionsofthebladderarecom-
monfollowingthistypeofsurgeryand theimplica-
tionsforthewelfareofthepatientshouldbe
consideredbeforesuchsurgeryisembarkedupon.
Alternatively，therecentavailabilityofsuitablysized
metallicstentshasledtotheirpalliativeuseinthe
managementofmalignanturethralobstructionsin
dogs(Weisseet al.,2006).Theiruseremainscontro-
versialasthetreatmentisonlypalliativeandmaybe
associatedwithsignificantcomplications suchas
severe incontinenceandstent migration.
Radiotherapyandchemotherapy
Urethral tumours are,ingeneral,notresponsiveto
eitherradiotherapyorchemotherapy.Sideeffects
associatedwithradiationoftheintrapelvicstructures
andbladderaregenerallyunacceptable.Theuseof
COx-2inhibitorspluschemotherapymayhavearole
intheshort-termmanagementofurethral tumours,
butevidenceofefficacyislackingatpresent.
17.12
Examinationoftheurethraltubercleand
vestibulovaginaljunctionwiththeaidofarigid
endoscope.Asoft fleshy masscanbeseenprotruding
Prognosis
fromtheurethralorifice.Pinchbiopsiesconfirmedthe
Theprognosisforthemajorityofmalignanturethral
masstobeaurethralTCC.
tumoursispoor,sincemostwillnotbeamenableto
254
Chapter17Tumoursoftheurogenitalsystem
surgicalresectionbythetimetheyarerecognized.In
Malignantsurfaceepithelialtumoursoftenmeta-
contrast,theprognosisforexcisablebenigntumours
stasizetoboththelungsandneighbouring abdominal
suchastheleiomyomaisveryfavourable.
organssuchasthekidneys,omentum,liverandpara
aorticlymph nodes.They canseed cancer cells
throughouttheperitonealand，sometimes,thepleural
Tumoursoftheovary
cavities,resulting inthe conditionofcarcinomatosis.
Lymphaticobstructionmayresultinthedevelopment
Generalconsiderations
ofaperitoneal and/orpleuraleffusion.
TumoursoftheovaryarelistedinFigure17.13and
arerareinboththedogandcat.Theyaccountforless
than 1.2%and3.6%of allneoplasms in thedog and
Gonadostromal tumours
cat,respectively.Areasonfortheirinfrequentrecogni-
Gonadostromaltumoursincludethebenignthecoma
tionisthatmanybitchesandqueensundergoovario-
andluteomaandthemostlymalignantgranulosacell
hysterectomyatayoungage.Affectedindividualsare
tumour.Granulosacelltumouristhemostcommon
mostfrequentlyolder,nulliparousindividuals,buttra
ovariantumourinqueens.Inbitches,itisseenwitha
tomawilloftenoccurinyoungeranimals.Reported
similarfrequency tosurfaceepithelialtumours.
tumourtypesrelatetothetissuetypesfoundinthe
Granulosacelltumoursaremostcommonlyunilat-
normalovary.
eralandspherical,withasmoothsurface.Theymay
containbothsolidandpolycysticareas.Although
Tumour site
Benign
Malignant
some maybebenign,itisbesttoconsiderthat all
aremalignantuntilprovenotherwise.Malignant
Surface epithelial
Cystadenoma
Cystadenocarcinoma
formsmay metastasize tolocal(kidney,omentum,
tumours
Papillaryadenoma
Papillary
liverandabdominallymphnodes)anddistant
(40-50%of cases)
adenocarcinoma
(lungs)sites.Peritoneal seeding(carcinomatosis) is
Undifferentiated
carcinoma
alsopossible.Granulosa cell tumourscanbehormo-
nally active,producing oestrogen.
Gonadostromal
Thecoma
Granulosa celltumour
Thecomaandluteomaareextremelyrareinboth
tissuetumours
Luteoma
bitchesandqueens.
(35-50%ofcases)
Germcelltumours
Teratoma
Dysgerminoma
Germcelltumours
(6-20%of cases)
Teratoma
Germcelltumoursincludedysgerminomaandtera-
Carcinoma
toma;bothtumoursareuncommon.Dysgerminoma
Tumoursof the ovary.
isanalogoustotesticularseminomainthemaledog
17.13
arisingfromundifferentiatedgermcells.Thistumour
oftenattainsalargesizeandhasasmooth,lobu-
Surfaceepithelialtumours
lated surface.Metastasis toregional lymphnodes
Surfaceepithelialtumoursincludecystadenoma/
andadjacentabdominalstructuresoccursinupto
adenocarcinoma andpapillaryadenoma/adenocarci-
30%ofcases.
noma.These tumoursareveryrare inqueens,but
Teratomaiscommonlywelldifferentiatedand
accountforapproximatelyhalfofovariantumours
benign,thoughmalignantformshavebeenreported
seeninbitches.Theymaybeunilateralorbilateral
inbothbitchesandqueens.Teratoma isoftencom-
andcanvaryconsiderablyinsize.Capillaryorcystic
posedoftissuesfromtwoorthreegerminallayers
(Figure 17.14) formsofbothbenignand malignant
including bone,cartilage，glandular epithelium or
surfaceepithelialneoplasmsarerecognized.
brain.
Presentationand clinicalsigns
The clinical signs of ovarian tumours in entirebitches
areextremelyvariable,buttheycaninclude:
Pyometra
Abnormaloestrus
Vaginaldischarge
Secondarysexorganchange
Lumbarpain
Thepresenceofanabdominal mass
Anenlargedabdomen(frommassand/or
effusion)
Lethargy
Weight loss orweight gain.
Manytumoursareclinicallysilentandaredis-
A cysticadenocarcinomaofanovaryfollowing
coveredasanincidentalfindingatthetimeofcoeli-
17.14
ovariohysterectomyinabitch.
otomyforwhatwasthoughttobearoutine
255
Chapter17
Tumoursof theurogenitalsystem
ovariohysterectomy.Anovariantumourshouldbe
Management
suspectedinanysexuallyintactfemaledogorcat
withahistoryofabnormaloestrus.
Surgery
Animalswithgranulosacelltumourmayshow
Incasesofbenignovariantumours,orinthosewith
clinicalsignsrelated tooestrogensecretion:
noevidenceofmetastasis,thesurgicalremovalofthe
affectedovaryisthetreatmentofchoice.Inmost
Abnormaloestrus(oftenprolonged)
instances,thismeans performing an ovariohyster-
Bilateralalopecia
ectomy,butleavingasingleovaryanduterusforthe
。
Mammaryhyperplasia
purposesoffuturebreedingisapossibilityinsome
Cysticendometrialhyperplasia/pyometra
cases.Inindividualsdemonstratingcysticendometrial
Vaginal discharge
hyperplasiaorpyometra,itisadvisabletoperforma
Swollenvulva
completeovariohysterectomy.
Attractivenesstomaledogs
Myelosuppression(rare).
Radiotherapyandchemotherapy
Radiotherapyisrarelyindicatedinthemanagement
Clinical approach
ofovarianneoplasia.Primarytumoursarebestman-
agedsurgicallyandradiationtherapyformetastatic
Physical examination
spread israrelysafeorfeasible.
Abdominal palpationmay suggest thepresenceof a
Similarly,theredoesnotappeartobearolefor
chemotherapyinthemanagementofprimaryovar-
massintheregionofthekidneys.Ovariantumours
ianneoplasia.Incaseswithmetastaticspreadand
willoftenbemoremobileonpalpationthantumours
of thekidney.
peritonealcarcinomatosis,however,theremaybea
roleforperitoneallavageorsystemictherapywith
platinum-basedchemotherapeuticagents.Theeffi-
Blood samples
cacyofthesetreatmentshasnotbeenconfirmed.
Nospecificchangesonacompletebloodprofile
arereportedinbitchesorqueenswithovarian
Prognosis
tumours.Inrare caseswhere hyperoestrogenism
Followingovariectomy or ovariohysterectomy,the
leadstomyelosuppression,haematologicalabnor-
prognosisforbenignovariantumoursisextremely
malities mayincludeanaemia,thrombocytopenia
good.Malignanttumourscarryaguardedprognosis
and neutropenia.
andtheprognosisfor individualswithsignificant
metastasisorcarcinomatosisisgrave.
Imagingtechniques
Plain abdominal radiographsmay suggest thepres-
enceofasofttissuemassadjacenttoeithertheright
Tumoursoftheuterusandcervix
enceofaperitonealeffusion,whichwillcomplicate
Generalconsiderations
theassessmentofabdominalsofttissuestructures.
Tumoursof theuterus(Figure17.15)arerareinboth
Teratomasmaydemonstrateareasofmineralization
thedogandcat.Theyhavenoknownaetiologyand
and/or odontogenesis.Thoracicradiographs should
theymostcommonlyoccurintheolderindividual.In
beobtainedforassessmentofpulmonarymetastasis.
thebitch,benign tumours occur withgreatest fre-
Abdominalultrasonographyisusefulinthe
quency.Malignanttumours,althoughstillveryuncom-
assessmentoftheprimaryovarianmassanditcan
mon,areseenmorefrequentlyinqueens.
alsobeused intheassessmentofperitonealeffu-
Theleiomyomaisthemostcommonbenignuter-
sion,localmetastasisandthepresence ofdiffuse
inetumour inbothbitches(Figure 17.16)and
carcinomatosis.
queens.Benigntumoursoftendevelopasmultiple
nodules in theuterine wall.Benignmesenchymal
Cytology
tumoursarenon-invasiveandslowgrowing.An
Incaseswithperitonealeffusion,abdominocentesis
associationbetweenbenignuterinetumourdevelop-
willallowsamplesoffluidtobeobtainedforcytologi-
mentandbothnodulardermatofibrosisandrenal
cal interpretation.Inmostinstances,analysisreveals
onlythepresenceofamodified transudate,butsedi-
Benign
mentexaminationmayconfirmthepresenceof
Fibroma
tumourcellsinindividualswithmetastaticspread.
Fibroleiomyoma
Leiomyoma
Biopsy
Adenoma
Whena largeprimary tumour is detected,it may
provepossibletoperformeitheradirectFNAora
Malignant
directcorebiopsy.Withsmallertumours,itiseasier
Fibrosarcoma
andsafertoperformsimilarbiopsieswiththeaidof
Leiomyosarcoma
ultrasound guidance.Insomeinstances(forexample,
Adenocarcinoma
whenthetumourisdiscoveredasanincidentalfind-
Lymphoma
ingatcoeliotomy)diagnosiswillbemadeonexci-
sional(ovariectomy)biopsy.
17.15
Tumours of themesosalpinx,uterus and cervix.
256
Chapter17Tumoursoftheurogenitalsystem
Abdominalultrasonographyisusefulinthe
assessmentofuterine tumours.Thetechnique wil
alsoallowfortheassessmentofpyometraand
abdominalmetastaticspread.Ultrasound-guidedfine-
needleaspiratesmaybeobtained,butinthemajority
ofcasesfurtherassessment isbestmadeat thetime
ofexploratorycoeliotomy.
Management
Thetreatmentofchoiceforthemajorityofuterine
orcervicaltumourswhichdemonstratenoevidence
ofmetastasisisovariohysterectomy.Atpresent,
thereappearstobenoroleforradiotherapyinthe
managementofuterine tumours.Similarly,therole
ofchemotherapyinthemanagementofbothpri-
Aleiomyomawithintherightuterinehorn.The
maryandsecondarytumoursoftheuterushasyet
17.16
tumourwasfound asanincidental findingina
tobeestablished.
10-year-oldbitchundergoing ovariohysterectomy.
Prognosis
cystadenocarcinomaappearstoexistintheGerman
Followingovariohysterectomy,theprognosisfor the
Shepherd Dog (Moe and Lium,1997).A recent
majorityofuterinetumoursinthedogisgood,since
reporthasdescribedaleiomyomainthemesosal-
most tumours proveto be benign.Inthecat,the
pinxofa terrierbitch(Ekeretal.,2006).
prognosisisworse,becauseadenocarcinomaisthe
Ofthemalignantuterinetumours,themostfre-
mostfrequentlyencounteredtumourandmetastasis
quentlyreportedistheadenocarcinomaarisingfrom
islikelytohaveoccurredbythetimeofdiagnosis.
theendometrium.This tumourismorecommon in
queensthaninbitches.It demonstratesbothlocal
invasionandmetastasis.Metastasiscanbewide-
Tumoursofthevaginaandvulva
spreadandhasbeenreportedinlocal lymphnodes,
otherabdominalorgans,thelung，theeye and the
Generalconsiderations
brain.Malignantmesenchymaltumoursoftheuterus
Tumoursofthevaginaandvulvaarelisted inFigure
areoccasionallyreported,especiallyinqueens,but
17.17.Excludingmammaryglandneoplasia,vaginal,
inbothspeciestheyareconsideredveryrare.
vestibularandvulvaltumoursarethemostcommon
tumoursofthereproductivetractinthebitch.Tumours
Presentationandclinicalsigns
at thesesitesarerareinqueens.Ingeneral,benign
The clinical signs associated with uterine tumours are
mesenchymal vaginaltumours,such asleiomyoma,
oftennon-specificand infact,inmanyinstances,the
affect entire,aged bitches(mean age 10-11years),
tumourisidentifiedasanincidentalfindingatthetime
whereasthelipoma affectsslightlyyoungerindividu-
ofexploratorycoeliotomy.Anabdominalmassmaybe
als(meanage6years).Themajorityoftumoursare
palpableandoccasionallyavaginal dischargemaybe
seeninnulliparousindividuals.
noted.Theremaybesignsoflumbarand/orabdomi-
Benign smoothmuscletumoursaccountfor
nal discomfort.Inconsistent signs such as lethargy,
approximately80-90%ofvaginalandvulvaltumours
malaise,anorexiaandcachexiamayalsobepresent.
reportedinbitches.Thegrowthofmanyofthese
benignsmoothmuscletumoursisassociatedwiththe
Clinical approach
ovariansecretionofoestrogen.Therefore,unlessthe
Physicalexamination
Abdominalpalpationmaydetectthepresenceofa
Benign
masswithinthemidtocaudal abdomen.
Leiomyoma
Fibroma
Blood samples
No specific changes on a complete blood profile are
Fibroleiomyoma
Lipoma
reportedinbitchesorqueenswithovariantumours.
Aneutrophiliawithleftshiftmaybeseeninindividu-
Malignant
alswithaconcurrentpyometra.
Leiomyosarcoma
Imagingtechniques
Adenocarcinoma
Plainabdominalradiographsmayconfirmthepres-
Transmissiblevenerealtumour
enceofasoft tissuemassconsistentwithanenlarge-
Squamouscellcarcinoma
mentof theuterus.Inindividualswithaconcurrent
Haemangiosarcoma
Osteosarcoma
pyometra,theremaybeevidenceofgeneralizeduter-
Mastcelltumour
ineenlargement.Thoracicradiographsshouldbe
obtainedtoassessthepresenceofpulmonary
17.17
Tumoursof thevaginaandvulva.
metastasis.
257
Chapter17Tumoursof theurogenitalsystem
bitchisreceivingexogenousoestrogens,it is very
Clinicalsignsassociatedwithvaginaltumoursare
unusual tofindsuchtumoursinananimal thathas
variable,butaremostlyrelatedtothesizeandposi-
undergoneovariectomyorovariohysterectomy.
tionof themass:
Themostcommonlyreportedmalignanttumour
ofthevaginaandvulvaistheleiomyosarcoma.
Bulgingof theperineum
Thesetumoursarelocallyinvasiveandalsoshow
Prolapseof tumourtissuefromthevulva
local anddistantmetastasis.Similartothemaledog,
Dysuria
transmissiblevenerealtumour(TVT)tendstoaffect
Stranguria
youngersexuallyactivebreedingbitches.TVTis
Haematuria
seenmorecommonlyinfemalesthaninmales.
Vulvalbleedingand/ordischarge
Inadditionto thetumourslisted inFigure17.17,
Faecaltenesmus
thevulvallabiacanbeassociatedwithanyformof
Constipation
cutaneous tumour,particularlyScCand mast cell
Obstructiontocopulationinentirefemales.
tumours (MCT).
Clinical approach
Presentationandclinicalsigns
Benignsmoothmuscle tumoursmaypresentas
Physical examination
eitherextraluminalorintraluminalforms.Extraluminal
Clinical historyandclinical signsatpresentationwill
tumoursaremostlywellencapsulatedandtheir
oftensuggestthepresenceofavaginal/vestibular
growthresultsinanoticeableperinealswelling
mass.Preliminaryexaminationofthevaginacanbe
(Figure 17.18).Intraluminal tumours tend to be
achievedwithdigitalpalpationviatherectumorthe
attachedtothewallofthevestibuleorvaginabya
vagina.
thinpedicle.Theyareoftenovoidandfirm,andtheir
pedicleattachmentallowsthemtoprotrudefromthe
Blood samples
vulva.Largeintraluminaltumoursmaybecome
Nospecificchangesonacompletebloodprofile
traumatizedoedematousand infected.heirappear-
arereportedindogsorcatswithvaginal/vestibular
ancemaybesimilartothatofvaginaloedema
tumours.Aneutrophiliawithleftshiftmaybeseen
(hyperplasia),although this isa conditionof younger,
inindividualswithaconcurrentsecondaryvaginitis
entirefemalesandisassociatedwithoestrus.Itisnot
orpyometra.
unusualformammaryglandtumours,ovariancysts
andcysticendometrialhyperplasiatobeseencon-
Imagingtechniques
currentlywiththedevelopmentofsmoothmuscle
Plaincaudalabdominalradiographsmaysuggest
tumoursof thevagina.
thepresenceof an intrapelvicsoft tissue mass,but
theywillrarelyconfirmthetrueextentorpositionof
the lesion.Findings suggestive of a vaginal mass
includeelevationorcompressionoftherectum,
cranioventraldisplacementofthebladder,andfaecal
orurinaryretention.Plain films can be used to
assesspossiblemetastasistoregional lymphnodes
(medial iliac,sacral and hypogastricnodes).Contrast
radiographic studies(includingpositive contrastret-
rogradevaginourethrography)andMRI orCT imag-
ingwillprovidethemostinformationregardingthe
positionandextentoftheprimarytumour.Inthe
caseofmalignanttumours,thoracicfilmsshouldbe
obtainedtoinvestigatethepresenceofpulmonary
metastasis.
Theintrapelvicpositionofmostvaginal tumours
makes meaningful ultrasonographic assessment
difficult.
Endoscopy
Endoscopicexaminationofthevaginawillallowthe
extentofthetumourtobeassessedandmayaid in
theretrievaloffine-needleaspirateorcorebiopsy
material.
Histology
Definitivediagnosiscanonlybemadeonhistological
examinationofexcisedtissuesamples.Sincethe
majorityofvaginaltumoursinthedogarebenign,
manyauthoritiessuggestthatdefinitivediagnosiscan
Perinealswellingassociatedwithbenign
bemadebyexaminationofmaterialremovedduring
17.18
vaginal leiomyomainabitch.
surgicalexcisionof thetumour.
258
Chapter17Tumours of theurogenital system
Management
Tumour site
Benign
Malignant
Surgery
Gonadostromal
Interstitialcell
Sertolicelltumour
Forbenignandmalignanttumourswithnoevidence
tissue tumours
(Leydig)tumour
ofmetastasis,the treatmentof choice is surgical
Germ cell tumours
Teratoma
Seminoma
excision.Surgeryofteninvolvesadorsalepisiotomy
andcareshouldalwaysbetakentorecognizeand
17.19
Tumoursof thetesticle.
preservetheurethral tubercle(catheterizationof this
structure prior to surgery is recommended).The
strongassociationofmostvaginaltumourswiththe
tumourmaybelessprevalent(Griecoetal.,2008).lt
secretionofoestrogensuggeststhattumour
hasalsobeensuggested that,asreported inhumans,
resectionshouldbecombinedwithovariectomyor
testiculartumoursindogshaveincreasedinpreva-
ovariohysterectomy.
Removalofthesource
of
lenceduring thelast40years.Thecauseforsuchan
oestrogen
production
should
minimize
the
increaseremainsunclearbuttheroleofenvironmen-
recurrence of these oestrogen-influenced tumours.
talpollutantshasbeen implicated inhumans.Many
Malignantvaginalcarcinomaswilloftenprovevery
olderdogsdemonstratethepresenceofmultiple
challenging toremove,sincetheyarerarely wel
tumoursinoneorbothof thetesticles.
circumscribed.
In thenormalanimal,interstitial(Leydig)cellsare
responsiblefortheproductionoftestosterone.lthas
Radiotherapyandchemotherapy
beensuggestedthatinterstitialcelltumoursresultin
Radiotherapyisrarelyindicatedinthemanagement
theproductionofexcesstestosteroneleadingtothe
ofvaginal tumours,but may be usefulinthe
developmentofperianaladenomas,perinealhernia-
managementofSCCorMCTsinvolving thevulva.In
tionandbenignprostatichyperplasia.Infact,tumours
mostinstances,radiationtherapyisutilizedwhere
derivedfromthiscelllinedonotshowautonomous
completesurgicalexcisioncannotbeachieved.TVTs
secretionoftestosteroneandmanyauthoritiesbelieve
arealsoverysensitivetoradiationtherapyandcan
thattheseconditionsareencounteredwithequalfre-
oftenbetreatedsuccessfullywithlow-dosage
quencyinthenormal maledog.Sertolicelltumours
radiation(15Gy).
willoften produce excess oestrogen,causing the
Thereislittleinformationavailableregardingthe
developmentoffeminizationsyndromeandsquamous
metaplasiaoftheprostate.Seminomasofthetesticle
nantvaginalorvulval tumours.ltdoesnotappearto
beindicated inthemanagementofbenign tumours,
mentoffeminizationsyndrome.
where surgicalexcisioncanbemosteffective.An
Testicularneoplasmsarerarelyseeninthecat
exceptiontothisisTVT.Weeklyadministrationofvin-
andthis,inpart,isrelatedtothepracticeofelective
cristinesulphateatadosageof0.5mg/m²willoften
castrationofanymale that isnottobeused asastud
resultinacompletecureafter4-6weeksof
cat.Althoughcryptorchidismdoesoccurintomcats,
treatment.
it does not appear tobe a risk factorfor the develop-
mentoftesticulartumours.
Prognosis
Cryptorchidismpredisposestothedevelopmentof
Followingsurgicalresectioncombinedwithovario-
Sertolicelltumoursandseminomas.Theabdominal
hysterectomy,theprognosisforbenignvaginal and
oringuinalpositioningofthetestisinsuchindividuals
vulval tumours is good.In contrast, the high likeli-
maintainsthestructureatanabnormallyhightemper-
hoodoflocalrecurrenceandmetastasisformalig-
ature,leadingtodamagetospermatogeniccellsand
nanttumourssuchasadenocarcinomaandScC
possibleneoplastictransformation.
makestheirprognosisguardedtopoor.
Thescrotummaybe affected byany typeof skin
tumour.Tumoursmostcommonlyassociatedwiththis
siteareMCTsandmelanomas.
Tumoursofthetesticle
Generalconsiderations
Presentation and clinical signs
Testiculartumoursarecommoninthemaledogand
Sertoli cell tumours and,occasionally,seminomas
representapproximately75%ofalltumoursinvolving
maycausethe developmentoffeminizationsyn-
thereproductivetractof themaledog.Nobreedpre-
drome.Theclinicalsignsassociatedwithfeminiza-
dispositionforthedevelopmentoftesticulartumours
tionsyndromeduetooestrogensecretionare:
hasbeenrecognized.Tumoursareusuallyseen in
dogsolderthan10years,but thedevelopmentof
Bilaterallysymmetrical alopecia
tumoursincryptorchidanimalsislikelytooccurearl-
Reducedlibido
ier.Cryptorchiddogsarestatedtohaveupto20-fold
Attractivenesstoothermaledogs
increasedriskoftesticularneoplasia.
Pendulousprepuce
Thethreemostcommontumourtypesseeninthe
。
Gynaecomastia(mammaryenlargement,nipple
dogare the interstitialcell tumour,seminoma and
elongation)
Sertoli cell tumours(Figure 17.19).Recent studies
Atrophyofunaffectedtesticle
suggestthattheinterstitialcelltumourandseminoma
Myelosuppression(anaemia,neutropeniaand
occurwiththesamefrequency,thoughtheSertolicell
thrombocytopenia).
259
Chapter17
Tumoursoftheurogenitalsystem
Clinical approach
Radiotherapyandchemotherapy
Inthemajorityofanimals,thepresenceofatesticular
Thereisonlylimitedinformationavailableontheuse
tumourwillbediscoveredonpalpationofanenlarged
ofradiotherapyorchemotherapyinthemanagement
testicleortesticularmassonroutineexamination.In
oftesticular tumours.Reasonsinclude thefactthat
someanimals,signsoffeminizationsyndrome will
primarytumourscanbesoeffectivelymanagedsur-
suggest the presence of an oestrogen-producing tes-
gically,secondarytumourswillrarelybesituatedata
ticulartumour.Inanapparentlycastrateddogshow-
siteamenabletoradiationtherapyandreported
ingsignsoffeminization,carefulexaminationofthe
chemotherapyforthemanagementofsecondarytes-
animal'srecordsshouldbemadetoensurethatthe
ticulartumourshasdemonstratedlittlebeneficial
possibilityofcryptorchidismcanbeexcludeddefini-
effect.Interestingly,inhumans,platinum-based(cispl-
tively.lf thereisanydoubtaboutthedog'scastration
atin)chemotherapyprotocolshaveprovedtobevery
history，cryptorchidismshouldbeconsideredalikely
effectiveinthemanagementofgermcelltesticular
possibility.
tumours and theuseof theseagentsforthemanage-
mentoftesticulartumoursinthedogandcatmight
Management
warrantfurtherinvestigation.
Surgery
Prognosis
Thetreatmentofchoiceinthemajorityofanimals
The prognosisforthemajorityof testicular tumours is
withtesticular tumours iscastration(orchiectomy).
consideredgoodfollowingtheirremovalbycastra-
Sincethemajorityofcaninetesticulartumoursdem-
tion.Inindividualswithmetastaticdiseasetheprog-
onstratealowmetastaticpotential,removalofthe
nosis islessfavourable.Theworstprognosis isoften
testicleswilloftenprovecurative.It issuggested that
seeninindividualsdemonstratingmyelosuppression
thecastrationprocedureshouldbeperformedusing
associatedwithfeminizationsyndrome.Following
a‘closed’ratherthanan‘open'technique sincethis
removalofSertolicelltumoursinanimalswithmyelo-
willminimizethechanceoftumourcellcontamination
suppression,therateofrecoveryofbonemarrow
of thevaginal tunicandlocal tissues.Undoubtedly,it
functioncanbeveryslow,andtakeupto6months.
issensibletoexciseaslongalengthofspermatic
cordandassociatedspermaticvesselsaspossible,
tominimizethepotential of localtumourextension.
Tumoursofthepenis
Similarly,thetreatmentofchoiceforthemajorityof
Generalconsiderations
individualswithtesticulartumoursassociatedwith
abdominalcryptorchidismisorchiectomyviaamidline
Tumoursof thepenis（Figure 17.21)are,ingeneral,
coeliotomy(Figure 17.20).In these animals the surgi-
rareinboththedogandcat.However,transmissible
calprocedurewillbelessstraightforwardthanascro-
talcastrationandbothinguinalandabdominal
commonconditionincertainpartsoftheworld.
Areaswherethistumourisenzooticincludethe
explorationmayberequired.Inanimalsdemonstrat-
ingfeminizationsyndrome,resolutionofmostofthe
Mediterraneancountries,thesouth-easternUSAand
associated signs willoccur within 6weeks of the
theCaribbean.Apart fromTVT,whichoccursinsex-
removaloftheprimarytumour;bonemarrowrecovery
ually active,younger dogs,the majority ofpenile
may take longer(see below).In some instances,per-
tumoursoccurintheolderdog.Theredoesnot
sistenceoffeminizationsignsmayindicatethepres-
appeartobeanybreedpredispositionfortumour
enceofsecondarygrowthsthatareactivelysecreting
developmentatthissite.TVTistransmittedbytrans-
oestrogen.
plantationof cellsatcoitus.TVTdoesnotcommonly
metastasize,butmaybetransplantedtootherparts
of thebody,suchasthefaceandnose,bygrooming，
lickingandtrauma.Anaffectedindividualwillmount
animmuneresponsetothetumourandthismay
resultintheslowingofitsdevelopmentanditsevent-
ualregression.
InareasoftheworldwhereTVTisnotenzootic,
SCCisthemostcommontumourofthepenisinthe
dog.
Benign
Papiloma
Malignant
Squamouscell carcinoma
Transmissiblevenerealtumour
Haemangiosarcoma
17.20
ASertolicelltumourassociatedwitha
17.21
Tumours of the penis.
cryptorchid testicleinadog.
260
Chapter17Tumoursoftheurogenitalsystem
Theprepucemaybeaffectedbyanytypeofskin
comprehensiveexaminationwillbeachievedinthe
tumour.Tumourscommonlyassociatedwiththisstruc-
sedatedoranaesthetizedanimal.Acarefulexami-
ture includeMCTs,melanomas andperianalgland
nationoflocalinguinallymphnodesshouldbe
adenoma.
undertakenandthepresenceofnodalenlargement
shouldpromptanassessmentforlocalmetastasis.
Presentation and clinical signs
Thoracicradiographycanbeusedtoassessdistant
TVToftenaffectstheglansormorecaudalpenis,and
metastasis.
thetumourcanbevegetative,pedunculated,papillary
ornodularinappearance.Metastasistolocal inguinal
Bloodsamples
lymphnodesandabdominalorganshasbeen
Acompletebloodprofilewillnotdemonstrateany
reportedinsomecases,butthisfindingisconsidered
changesindicativeof thepresenceofatumourof the
unusual.
penis.
SCCof thepenispresentsasanulceratedsessile
lesion,most commonly affecting the glans penis,
Cytology
thoughitcanalsoaffecttheliningoftheprepuce.In
Cytologicalsamplesmaybeobtainedfromanylesion
someinstancesitmayhavethe appearanceofacauli-
usingeitherdirectimpressionsmearsorfine-needle
flower-likegrowth.ScCislocallyinvasiveandmay
aspirates.
spread to thelocal inguinal lymph nodes.Distant
metastasis is also possible in the more aggressive or
Biopsy
advancedcase.
Where
necessary,histologicalsamplesmaybe
Clinicalsignsassociatedwithpeniletumoursare
obtainedbygrab,punchorincisional biopsy.
relatedtolocaltissueirritation,infectionandbleeding:
AdiagnosisofTVTcanbemadeeitheronhisto-
Lickingofprepuceandpenis
pathologyorbychromosomekaryotypicanalysis.
Haemorrhagicand/orpurulent dischargefromthe
Thetumourischaracterizedbyamodalchromo-
somenumberof 59±5,insteadof theusual78
prepuce
Haematuria(maybefrankbloodatbeginning or
found innormal canine cells (Murray et al.,1969). In
endof micturition)
mostinstances,histopathologyinvestigationwill be
sufficientforclinical diagnosticpurposes.
Dysuria
Increasedfrequencyofurination
Management
Phimosis
Paraphimosis(occasionally).
Surgery
Themajorityofpeniletumourswillnotbedis-
Thetreatmentofchoiceforthemajorityofpenile
cerniblewhilst thepenislieswithintheprepuce.
tumours（apart from TVT)is surgicalexcision.In
Skintumoursof theprepuceareoftenobviousas
mostinstances,thiswillinvolveeitherapartialora
discretemasses,butthepresenceof local swelling
totalpenileamputationwithcastrationandthe
andoedemamaymaskthelocationofamastcell
constructionofascrotalurethrostomy（Figure
tumour.
17.23).Adjunctiveradiotherapy for SCCmaybe
consideredpostoperatively.
Clinicalapproach
Obtainingaclinical historythatincludesoneormore
ofthesignslistedaboveshouldalerttheclinicianto
thepossiblepresenceofapeniletumour.
Physicalexamination
Inmostinstances,thepresenceofa tumourwillbe
obviousoncethepenishasbeenfullyextruded
from theprepuce （Figure 17.22).Thiscan usually
beperformed in theconsciousanimal,butamore
17.23
Postoperativephotographof adogfollowing
totalpenileamputationwithcastrationandthe
constructionof a scrotal urethrostomy.
Radiotherapyandchemotherapy
TVTcanbetreatedusingeitherchemotherapyor
radiotherapy.Completeregression(including meta-
staticdiseaseinmostcases)willoccurwithweekly
dosesofvincristinesulphateat0.5mg/m²every7
17.22
Multiplepetechial lesionswithintheepithelium
of the glanspenis.Fullthicknessbiopsy
daysforacourseof4-6weeks.Alternatively,regres-
samplesconfirmed thelesionstobehaemangiosarcoma,
sioncanbeachievedusinglow-doseradiotherapy
necessitating total penile amputation.
(15Gy).
261
Chapter17Tumoursoftheurogenitalsystem
Prognosis
Theneoplasticprostateglandisusuallypainful on
Followingwide-marginexcisionforSCCof thepenis,
bothpalpationof thecaudal abdomenandpalpation
theprognosisisfavourableinthoseanimalswithno
of theglandperrectum.Animalswithbenignpros-
evidenceofeitherlocalordistantmetastasis.Local or
tatichyperplasiararelyshowsuchdiscomfortonpro-
distantmetastasisalwaysremainsapossibility.The
staticpalpation.Inanimalswithaprostatictumour,
prognosisforTVTfollowingeitherchemotherapyor
palpationalsorevealsglandasymmetryandanodu-
radiotherapyisexcellentinthemajorityof individuals.
larconsistency.Itmayalsobepossibletopalpate
enlarged sublumbar (hypogastric and medial iliac)
andpelvic(sacral)lymphnodesthatare suggestive
Tumoursoftheprostategland
oflocalmetastasis.Inanimalswithmetastaticlesions
withinthepelvicbonesorspinetheremaybeclinical
Generalconsiderations
signsofpelviclimbweakness,lamenessand/orneu-
TumoursoftheprostateglandarelistedinFigure
rological deficits.Bonescontainingmetastaticlesions
17.24.Prostaticneoplasiaoccursmostcommonlyin
willbepainfulonmanipulation.
old(meanage 10years),mediumor largebreed
Byfarthecommonestprostatictumourtypeinthe
dogs.Prostatictumours in thedogarealmost invaria-
dog is the adenocarcinoma. This tumour is very
blymalignant,thoughthereareoccasional reportsof
malignantandshowslocalinvasionandearlymeta-
benignprimarytumoursofthegland.Theprostate
stasis.Approximately70%ofcaseswill havemetasta-
mayalsobe thesiteofsecondary,metastatic
sizedbythetimethetumourisdiagnosed.
tumourssuchaslymphomaandperianaladenocarci-
noma.Prostaticneoplasia isanextremelyrarefinding
Clinical approach
inthecat.
Bloodsamples
Benign
Acompletebloodprofilewillnotdemonstrateany
findingsthatarespecificallyconsistentwithatumour
Fibroma
Leiomyoma
of theprostate,althoughmanyindividualswillshowa
Benignprostatichyperplasia
regenerativeornon-regenerativeanaemia,elevations
inbothalkalinephosphataseandalaninetransferase,
Malignant
hypoalbuminaemia,andhypercalcaemia.Inindividu-
alswithintraprostaticurethral obstruction theremay
Adenocarcinoma(commonest)
Leiomyosarcoma
beevidenceofanobstructiverenal failure.
Squamouscell carcinoma
Inhumans,theearlydetectionofprostaticcancer
Transitional cell carcinoma
hasbeenenhancedbythemeasurementofserum
Undifferentiatedcarcinoma
prostatic specific antigen(PSA).This has allowed
Tumoursandtumour-likeenlargementsof the
theearlydiagnosisoforgan-confineddiseasewhich
17.24
prostate gland.
prognosisfora cure.In thedog,prostaticadenocar-
Themalignanttumourarisingfromprostaticglan-
cinomadoesnotappeartobeassociatedwithsignif-
dular tissueisanadenocarcinoma;however,TcC
icantincreasesinPSAandreliableserumorseminal
fromtheprostaticurethracaninvadeintothepros-
plasmamarkershaveasyettobefound.
tate.Differentiationbetweenthese tumourtypescan
beverydifficult onclinicalgrounds;it maybepossi-
Physicalexamination
ble by detailed histopathological assessmentbut
Thedigitalrectalexaminationoftheprostategland
immunohistochemicaltechniquesmayberequired.
isoneofthemostuseful techniquesfordetecting
In theentiremaledog,thecommonestcauseof
prostaticabnormalities.Inthemaledog,theyearly
anenlargedprostate(prostatomegaly)isbenignpro-
check-upexaminationperformedatboostervaccin-
statichyperplasia.Inthecastratedindividual,hyper-
ationshouldalwaysincludeperrectumpalpationof
plasiawillregress;prostatomegalymaysignal the
theprostatetoscreenforthepresenceofearly
presenceofamoreseriousneoplasticcondition.The
prostaticdisease.
relationshipbetween thepresenceofbenignpros-
tatichyperplasiaandthesubsequentdevelopmentof
Imagingtechniques
aprostatictumourremainsunclear,butmostauthori-
Ingeneral,plainradiographyisnotsensitiveinde
tieswouldagreethatthedevelopmentofprostatic
tecting thepresenceofprostaticneoplasia.Prostatic
tumours is not influencedby thesexual integrity of
enlargementwilloftenbedetectableonasurveylat-
thedog;indeed,prostaticcarcinoma maybe more
eralabdominal film,butmanyprostatictumoursdo
common incastrated dogs(Bryanet al.,2007).
notdemonstratesignificantprostatomegaly.Plainradi-
ographsmaybeusefulinassessmentof tumour
Presentationandclinicalsigns
metastasis.Enlarged regional lymph nodes (medial
Prostatictumours oftencause clinical signsconsistent
iliac,sacral and hypogastricnodes),lyticor sclerotic
withlowerurinarytractdisease,includinghaematuria,
bonelesionsinthevertebraeorpelvisand/orpulmo-
dysuria andapurulentpeniledischarge.Inindividuals
narylesionsonthoracicfilmsmayindicate thepres-
witha significantprostatomegaly，theclinicalsigns
enceof tumourmetastasis.
mayincludeconstipationandfaecal tenesmus.
Theuseofnegative(pneumourethrocystogram)
262
Chapter17Tumoursoftheurogenitalsystem
andpositive(retrograde urethrogram)contrast radio-
Management
graphicstudieswilloftenprovideinformationthat
supportsadiagnosisofprostatictumour.Theinva-
Surgery
sivenatureofprostaticcarcinomaoftenresultsin
Althoughmanyofthecurrentlyavailableveterinary
thepresenceofmucosalirregularitywithinthe
surgicaltextbooksstillcarryinformationregardingthe
intraprostaticurethra.Themucosamaybedamaged
techniqueoftotalprostatectomyforthemanagement
tosuchadegreethatcontrastagentcanbeseento
ofprostaticneoplasia,mostauthoritieswouldnow
leak(extravasation)intotheprostaticparenchyma
agree thatveryfewcanineprostatic carcinomas are
(Figure 17.25).
amenabletosurgicalresection.Totalprostatectomy
forthemanagementofcarcinomawillalmostinvaria-
blyresult inunmanageableurinaryincontinence;
thereforethetechniquecannotberecommendedin
themajorityofcases.
Radiotherapyandchemotherapy
Theintraoperativeadministrationofexternalbeam
radiotherapyhasbeenusedasapalliativetreatment
forlocalizedprostatictumours,but thisapproachhas
proved tobeof limited benefit (Turrel,1987).
Prostatic adenocarcinomarespondspoorlyto
chemotherapy.Castrationoradministrationofanti-
androgensisnotconsideredeffectiveinthemanage-
Retrogradepositivecontrasturethrogram
mentofcanineprostatictumourssincemostdevelop
17.25
demonstratinganirregularintraprostaticurethral
independentlyofhormonalstimulation.Althoughthe
useofCOx-2inhibitingdrugssuchaspiroxicamor
parenchyma(arrowed) ina dogwithprostatic
meloxicamdoesnotappeartohaveanyeffecton
adenocarcinoma.
tumourgrowth,theiradministrationisoftenhelpful in
Theuseofultrasonographyisindicatedinany
controllingthediscomfortassociatedwiththisformof
individualwithprostaticdisease.Clearinformation
tumour.In that TCCfromtheprostaticurethracan be
regardingtheinternalstructureoftheglandcanbe
difficult toexclude,itisoftenworth tryingCOx-2
gainednon-invasively,andbiopsysamplestaken
inhibitorsandplatinum-basedtherapybutwithavery
percutaneouslyfromanyrelevantabnormalities.
Ultrasonographywillaid thedifferentiationof other
guardedprognosis.
types ofprostaticpathologysuchas prostatitis,
Prognosis
benignhyperplasia,prostaticcystic diseaseand
Thehighlymalignantnatureof mostprostatictumours
abscessation.
andtheirhightendencytometastasizemakethe
Magneticresonanceimagingandcomputed tom-
ographymaybeconsideredintheinvestigationof
prognosisforthisconditionextremelygrave.When
prostaticdiseaseandtheassessmentof local meta-
dealingwithanindividualwithprostaticdiseaseitis
static spread.In general,however,since surgical
imperativethatthepossibilityofaprostatictumouris
interventionisrarelyindicatedinthemanagementof
excludedearlyinthemanagementof thecase.
canine prostatic cancer,the expense of suchan
investigationisnotwarranted.
Referencesandfurtherreading
Biopsy
Althoughtheinvestigativetestsdescribedwilloften
Bryan JN,Keeler MR,Henry CJ et al.(2007)A population study of
be highly suggestive of a specific prostaticcondition,
neuteringstatus as a risk factor for canine prostate cancer.
Prostate67,1174-1181
confirmationrequiresthemicroscopicexaminationof
eitherabiopsyspecimenoranaspirateofthelesion.
Compendium
onContinuingEducationforthePracticing
Veterinarian7,607-618
Thesearebestobtainedwiththeaidofultrasound
EkerK,SalmanogluMRandVursalSA(2006)Unilateralleiomyoma in
guidance,thoughdirectpalpationoftheglandcanbe
themesosalpinxofadog.Journalof theAmericanAnimal Hospital
achievedinindividualswithmarkedprostatomegaly.
Association42,392-394
GriecoVRiccardiE,GreppiGFetal.2008）Caninetesticulartumours:
Inmost instances,corebiopsies canbeperformed
astudyon232dogs.JournalofComparativePathology1388689
viatheinguinalregion,butitmayprovenecessaryto
Henry CJ,Turnquist SE,Smith Aetal.(1999)Primaryrenal tumours in
cats:19cases （1992-1998).JournalofFeline Medicineand
useaperinealapproachif theprostateispositioned
Surgery1,165-170
withinthepelviccanal.
KnappDW,RichardsonRCandChanTCK(1994)Piroxicam therapy in
Cytologicalmaterialmaybeobtainedbyperform-
34dogswith transitional cellcarcinomaof the urinarybladder.
JournalofVeterinaryInternalMedicine8273-278
ingaurethralwashinconjunctionwithtransrectalpro-
MathiesenDTandMoroffSD(1989）Infitrativeurethraldiseasesinthe
static massage.This technique,although easy to
dog.In:CurrentVeterinaryTherapy,1othedn-SmallAnimal
Practiced.WKirkp.1161-1163BaundersPhiladi
perform,maynotprovideconfirmationofadiagnosis
MoeLand LiumB(1997)Hereditary multifocal cystadenocarcinomas
becauserepresentativecellsmayfailtoexfoliateinto
andnodulardermatofibrosisin51GermanShepherdDogs.
theurethral aspirate.Ifclinical signssuggest apros-
JournalofSmallAnimalPractice38,498-505
MurrayM,JamesHandMartinWJ(1969)A studyof thecytologyand
tatictumour,anegativeresultoncytologicalexamina-
karyotypeofthecaninetransmissiblevenerealtumour.Researchin
tionshouldalwaysbetreatedwithsomescepticism.
VeterinaryScence10565-58
263
Chapter17Tumoursoftheurogenitalsystem
ObradovichJ,WalshawRand GoullaudE（1987)The influenceof
WeisseC,Berent A,Todd K,Clifford Cand Solomon J(2006)
castrationonthe developmentof prostaticcarcinomainthe dog:43
Evaluationofpalliativestentingformanagementofmalignant
cases(1978-1985).Journalof Veterinary InternalMedicine1,183
urethralobstructionsindogs.Journalof theAmericanVeterinary
187
MedicalAssociation229,226-234
Turrel JM（1987)Intraoperativeradiotherapyofcarcinomaof the
WhiteRN,DaviesJVandGregorySP（1996)Vaginourethropexy for
prostateglandintendogs.Journalof theAmericanVeterinary
treatmentof urethralobstructionin thebitch.VeterinarySurgery
MedicalAssociation190,48-52
25,503-510
264
Tumours of the
respl
system and thoracic cav
B.Duncan X. Lascelles and Robert N.White
Tumoursofthenasalplanum
scrapings)isof littleuse,tending toreflect theinflam-
mationthatisinvariablypresent.Duringabiopsyof
Tumoursofthenasalplanumaresummarizedin
thenasalplanum,haemorrhagecanbebriskbutitis
Figure 18.1.
rarelyofconcern;thesiteshouldbeclosedwithtwo
orthreesutures andpressureapplied.
Benign
Metastasistolymphnodesisrare,but alllymph
nodesshouldbepalpatedandaspirated.Regional
Fibroma
radiographyisnotindicatedandmetastasistolung
。
Eosinophilic granuloma
tissue isveryrare.
Haemangioma
Malignant
Imaging
OnceadiagnosisofSCCof thenasalplanumhas
Squamous cellcarcinoma(ScC)
beenmade,thepriorityistoestablishhowfarthedis-
Lymphoma
Fibrosarcoma
easeextendscaudally.Directvisualizationinsidethe
Melanoma
Mastcell tumour
informativeandpalpationisoftenmisleading.
Computed tomography(CT)or,better,magneticreso-
18.1
Tumoursof thenasal planum.SCC isbyfarthe
nanceimaging(MRl)isavaluablediagnostictool to
most commoncancer at this site.
helpdefinetheextentofthedisease,butinvasive
SCCisoftensodiffusethatCTorMRIdoesnot
Presentationandclinicalsigns
Cancerof thenasalplanum israre inthedogbut is
alwaysaccuratelydefinethetrueextentofdisease.
Additionally,evenusingintravenous contrast with
fairlycommoninthecat.Themostcommoncancer
thesetechniquesdoesnotalwaysindicatethefull
ofthenasalplanumisthesquamouscellcarcinoma
extentofthedisease.Whendefiningtherequired
(SCC).In thecat,invasiveSCC isusuallypreceded
byaprotracted diseasecourse(severalmonthsto
gery)itisbettertoerronthesideofoverestimating
years)progressing from solar dermatitis,through
theextentofdisease.
carcinoma in situ,to superficial ScC and then in-
vasiveSCC.
Management and prognosis
Clinically,crusting anderythema areseenfirst,
PreventivemeasuresarelistedinFigure18.2.
then superficial erosions and ulcers and,finally,
deeplyerosivelesions.ThedevelopmentofSCChas
Therapy
Notes
beencorrelatedwithexposuretoultravioletlight(sun-
light)andalackofpigmentprotection(whitehairand
Preventexposure
Limitingexposureto sunlightmayarrest the
non-pigmentednasal planum).Often in cats,eyelid,
to sunlight
couref thpreneolastiprcessand
pre-auricularskinandearpinnalesionswillalsobe
themosteffective preventionforSCC
seenif theseareashavewhitehairandarenotpro-
Tattooing
Ifinfammatinadurationrepreen
tectedwithpigment(seealsoChapter12).
difficultomaintain the tattoo
Clinical approach
Topical sunscreen
Theseareoftenlickedoff
Biopsy
SyntheticvitaminA
Thesemaybeofhelpinreversingorlimiting
derivatives
the growth of preneoplasticlesions
SCCisalocaldisease.Awedgebiopsyshouldbe
performedonerosivelesions.Caremustbetakento
18.2
MeasuresforpreventionofUV-induced
locatethebiopsyinsuchaposition thatanysubse-
squamouscellcarcinomaofnasalplanum.
quentsurgicalresection isnotcompromised,i.e.the
biopsyshouldnotbeplacedinapositionwhere
SCCofthenasalplanumincatsfallsintotwo
resectionofthebiopsytractandthetumourwould
categories fortreatment:superficialandinvasive.
resultinlargermarginsthanifthebiopsytractwere
Canine nasalplanumSCCis invariablyinvasive.
notpresent.Cytologicalexamination(such asof skin
TreatmentoptionsfornasalplanumSCCare:
265
Chapter18
Tumoursoftherespiratorysystemandthoraciccavity
Cryosurgery(cats)
(Hammond et al.,2007).Thehistological diagnosis
Intralesional chemotherapy(cats)
wasSCCin37cats,andSCCinsitu in14cats.
Photodynamic therapy(cats)
Moreapplicationswereusedinlargertumours,and
Radiationtherapy(catsanddogs)
althoughtherewasnosignificantassociationbe-
Strontium-90plesiotherapy(cats)
tweennumberofapplicationsandoverallsurvival
Surgicalresection(cats and dogs).
times,itdid appearthat themore applicationsthat
wererequired,thegreaterwasthechanceofrecur-
SuperficialnasalplanumSCCin thecatcanbe
rence,suggestingthatthistherapymayworkbestfor
managedusinganyoftheoptionslistedabove.The
superficial SCC.
optimal treatmentforinvasiveSCCofthenasalpla-
numincatsanddogshasnotbeensystematically
Surgicalresection
evaluatedbutthediseaseisprobablybestmanaged
Inmanycasessurgeryisthe treatmentofchoice.
using surgery inboth species.
Surgicalresectionofthenasalplanumcanbeper-
formed,withgoodcosmeticresults.Theattainment
Cryosurgery
oftumour-freemarginsinbothcatsanddogs iscor-
Cryosurgeryis thedestructionoftissuebythe
related toprolongedsurvivalandcure(Lanaet al.,
controlleduseoffreezingandthawing.Inonestudy
1997;Lascelles etal.,2000,2004).Theline ofexci-
of90catswithnasalplanumScC,84%weretumour
sionismarkedout（Figure18.3a)and theaffected
freeat12monthsand81%weretumourfreeat36
arearemovedwitha360degreeincision,which
months,thoughmanyrequiredmultipletreatments
extendsdownthroughtheskinand theunderlying
(Clarke,1991).Alater studyincats indicated a73%
rostral turbinates（Figure 18.3b).Indogs,a 1cm
recurrencerateaftercryosurgery(Lana et al.,1997).
marginshouldbeobtained.Incats,a0.5cmmargin
isneededforsuperficiallesions;fordeeperormore
Intralesionalchemotherapy
diffuselesions,a1cmmarginshouldbeobtained.
Intralesionalchemotherapyusingcarboplatinhas
beendescribed,andearlyworksuggesteda70%
responseratewitha30%recurrencerate.Nofurther
workhasbeenperformed,suggesting thatthis ap-
proachisnotpractical onaroutinebasis.
Photodynamictherapy
Severalstudieshavedescribedtheuseofphoto-
dynamic therapy(PDT)for the treatment of feline
SCC.Atopicalphotosensitizer,5-aminolaevulinicacid
(5-ALA),is widely used inhumanSCC treatmentand
hasrecentlybeenevaluatedincatsasasingletopical
treatmentusinghigh-intensitylight-emittingdiodesas
POREX
4715Roosevel Highwa
thelight source(Bexfield et al.,2008).Theresultsindi-
SURGICALINC
08518-696（0）
cated that96%ofsuperficialnasalplanumSCCs
(a)
treatedwithPDTusing topical5-ALArespondedto
therapy,withacompleteresponserateof85%.
Although initial responserateswere encouraging,
PDTdidnotleadtodurableremissionorcure inall
cases,witharecurrencerateof51%atamedianof
157days.
Radiationtherapy
Incats,overall,the literature suggests thatpatients
withsmallvolumesoftumourhavelongerdisease-
freeintervalsandsurvivaltimes.Thedisadvantageof
radiationtherapy istherequirement formultiple treat-
ments.Indogs,radiationtherapydidnotseemtobe
effective(Lascellesetal.,2000).
POREX
4715
Strontium-90plesiotherapy
This involves the direct application ofradioactive
(b)
luululu
strontium(9oSr)to the surfaceof a lesion.The maxi-
18.3
Surgical resection of ScCof thenasal planum.
malradiationdoseisdeliveredtothesurfaceofthe
(a)Forsuperficial lesionsinthecat,amarginof
skinwitharapiddecreaseindosewithdepthbelow
0.5cmofgrosslynormal tissueshouldberesected;for
the surface,such that<10%of the surfacedosepen-
deeperlesions,a1cmmarginofnormaltissueshouldbe
resected.Thisshouldbemarkedoutonthe animal priorto
etratestoadepthof3mm.Of49catsthatunder-
cutting.(b)Inbothcats anddogs,the line of excision is
wentstrontiumplesiotherapy,using1-6applications
markedout,andtheaffectedarearemovedwitha360
atasingletreatmenttimepoint,98%hadaresponse
degreeincisionthatextendsdownthroughtheskin and
totreatmentand88%hadacompleteresponse
the underlying rostral turbinates.(continues)
?
266
Chapter18
Tumoursoftherespiratorysystemandthoraciccavity
interrupted suturesof nylon（Figure 18.3c).In the
authors'experience,a single purse-string suture
resultsinstrictureformationmoreoftenthanusing
simpleinterruptedsuturesof1.5metric(4/0USP)or
1metric(5/0USP)nylontosuturethehairedskinto
thenasal mucosa.Theareawillcrustandscabover
andneedstobekeptcleanbygentledebridement
usingcotton-tipped applicators('cottonbuds')bythe
ownersduringthehealingprocess.Healingis usu-
C
thecosmeticresult is acceptable（Figure18.4).
(continued)Surgical resectionofSCCof the
Occasionally,progressivestrictureformationdevel-
18.3
nasalplanum.(c)Anewnasalorificeiscreated
usinga purse-string suture,or,asinthiscase,
taintumourtissue,furtherresectioncanbecarried
reconstructingtheareawithsimpleinterruptedsutures.
out,orradiationtherapytried.
FormoreinvasiveScCandforotherinvasiveor
Bleedingcanonlybecontrolledoncetheaffected
extensivecancersinvolvingthenasalplateandrost-
tissueisremoved,andacombinationofdirectpres-
ralmaxilla,radicalresectionofthenasalplateand
sureandelectrocauteryisused.Thenasalorifice
rostralmaxillahasbeendescribedandistolerated
canbereconstructedwitheitherasinglepurse-
wellbydogs（Figure18.5)andprobablycats(Figure
string suture,not pulled too tight,or using simple
18.6)(Kirpensteijnet al.,1994).
(a)
(b)
18.4
goodcosmeticresultobtained.
18.5
Appearanceofadog
(a)2weeks after
combinedresection
of thenasalplanum
androstralmaxillato
thelevelofthe
2nd/3rdpremolaras
treatmentfora
fibrosarcomaof the
rostralnasalareaand
(b)14weeks after
surgery.The siteof
surgeryhas healed,
and thecosmetic
appearanceis
acceptable,even
aftersuchradical
surgery.
(a)
(b）
267
chapter18Tumoursoftherespiratorysystemandthoraciccavity
Tumoursofthenasalcavity
Tumoursofthenasalcavityaresummarizedin
Figure 18.7.
Benign
Occasionallybenign sarcomas occur(e.g.chondrosarcoma)
Fibromas
Polyps
Malignant
Carcinomas(adenocarcinoma,squamouscell carcinoma
undiferentiated carcinoma)
Sarcomasfibrosarcomaschondrosarcomasteosarcoma
(a)
undifferentiated sarcoma)
Lymphoma
18.7
Tumoursof thenasal cavity.Carcinomasmake
up about two-thirdsof nasal tumours;sarcomas
comprise themajorityof therest.
Presentationandclinicalsigns
Indogs,two-thirdsof intranasal tumours are carcin-
Nasaltumoursarerelativelyrareindogs,accounting
forabout1%ofalltumours.Incats,themostcommon
formofintranasalneoplasiaislymphoma,withcarci-
nomasbeingthesecondmostcommon.Despitethe
factthatnasal lymphomaisthemostcommonnasal
tumourincats,itisrelativelyrare,accountingfor<1%
ofallfelinetumours.Inbothspecies,carcinomas and
sarcomasoccurinolderanimals.
(q)
Theaveragedurationofclinicalsignsindogswith
nasaltumoursis3monthsandincatsthistimeperiod
18.6
(a)A catwithaninvasive SCCof thenasal
ismorevariable-weekstoyears.Inanolderdog，a
planumundergoingradical nosectomy(allof
thetissuerostral tothe2ndpremolar).(b)Appearanceof
historyofprogressivebutintermittentsignsofsneez-
thesame cat the dayaftersurgery.Note thecrusting
ingandsnorting,unilateralnasaldischargeand/or
around thenewnasalorifice.Thisneedstobegently
epistaxisrogressingtbiateralsignsinraseddi
cleanedforseveral weeksashealingprogresses.Thiscat
ficultyinbreathingandsometimesfacialdeformity,is
alsohad actinicchangeson thetipsof itsearsand these
strongly suggestive ofcancer.Epiphora,dullness and
werealsoremoved.
neurological signsmayalso be seen.Unlike nasal
Prognosis
neoplasmsinthedog,nasal dischargeandepistaxis
Theprognosisforearlynon-invasivediseaseisvery
areless common signs in cats,occurring in only
good,though subsequentdevelopmentofSCCat
aboutone-thirdofthoseaffected.Seizurescanbean
othersitesonthenasalplanumisnotuncommon.
associatedsigninbothspeciesiftheneoplasmhas
Invasivediseasecanbecuredbyappropriatelyagg-
extendedbeyondthecribriformplate.Inbothspecies,
ressive surgery.With surgery('nosectomy'),>80%of
therehasbeenasuggestionthatanimalswithlonger
catswillbealiveandfreeofdiseaseat1year,and
nasalpassagesmayhaveapredispositionfordevel-
median survivaltimes(MSTs)of 22monthshave
opingnasal malignancies.
beenreported(Lanaet al.,1997).Withnosectomy in
Differentialdiagnosesincludebleedingdisorders,
hypertension，fungalrhinitis,
bacterialrhinitis,
medianfollow-uptimes(at whichpoint notumour
immune-mediatedrhinitisandforeignbody.Incats,
recurrencewasseen)havebeenreportedas24and
nasopharyngealpolypshouldalsobeadifferential,
32months;butwhen tumour-freemarginsare not
dependingontheageof thecat.
obtainedSCCinvariablyrecurs,inonestudyatabout
6weeks.Incats,the literature would suggest that
Clinical approach
althoughrecurrenceismorelikelywhencleanresec-
Athoroughclinicalexaminationshouldbeperformed,
tionsarenotobtained,itdoesnotalwayshappen,but
includinganintraoralexamination(lookingfordistor-
thismaybesimplyduetoinsufficientfollow-uptimes.
tionordestructionof thehardpalate).lfepistaxis is
Radiationtherapyisrelativelyineffective,andactive
present,bleedingdisordersshouldberuledoutwith
growthorrecurrenceof tumourstendstooccur8-12
appropriatelaboratorytests.Furtherdiagnosticevalu-
weeksaftertreatment.
ationisthencarriedoutundergeneral anaesthesia.
268
Chapter18
Tumoursoftherespiratorysystemandthoraciccavity
Imaging
Definitivediagnosisrequiresabiopsybutradiographs
shouldbe takenprior tothis（bleedingafter the
biopsyprocedure canobscureintranasal detail).The
most usefulradiographicviewsare:
Ventrodorsalopen-mouth20degreesangled
viewtoimagethenasalcavityandcribriform
plate(ortheintranasalviewwithradiographicfilm
placedwithinthemouthandtheimagetakenin
theDVposition)
Skylineviewof thefrontalsinus.
Turbinatedestructionandreplacementbymateri-
alofsofttissueradiodensitysuggestsatumour,buta
biopsyisrequiredtomakethedefinitivediagnosis.
MRI isaveryuseful tool,bothtohelptodecide
whetherthereistumourpresentandtodelineateits
extent (Figure 18.8). CT is probably the imaging
modalityofchoicebecauseofthehighdefinitionof
Oth
GE VET SCHOOL
P
softtissuewithinthenasalandfrontalsinusesand
18.8
TransverseMRIsectionthroughtheskullofa
adjacentorbit andbrain(Figure18.9).
dog,at thelevelof theeyes,showinga tumour
intheleftnasal cavityandinvading theorbit.
Biopsy
Whilethepatientisstillunderanaesthesiafromits
imaging procedures,rhinoscopy can be used to
visualizethetumourbeforeabiopsyprocedure.
Althoughtissuesamplesarerelativelyeasytoobtain
through most endoscopes,this method is not a
recommendedsamplingprocedureassamples
procuredaregenerallylimitedtothesuperficiallayer
oftissue,dueto the smallsizeof theinstrument.A
nasalbiopsy shouldbecollectedusingaclosed
nasal biopsytechnique-a closedsuctiontechnique,
abone curette,alligator forceps or‘melon-baller
forceps.It doesnotmatterwhichinstrument isused
toprocureasamplebut,whateverthemethod,care
mustbetakentoensurethatthecribriformplateis
notpuncturedandthebrainisnotentered,andthat
alargeenoughsamplefromthecorrectlocationis
obtained.
Thelocationofthesuspectedtumourisread
fromradiographsorCT/MRIimagesandeithera
plasticcannulaor'melonballer'cupforceps(suchas
18.9
CTscanof themid-noseareaof an11-year-old
mareuterinebiopsyforceps)canbeadvancedvia
crossbreddogwithanintranasalchondroblastic
thenostriltowardsthelesion.Priortothis,thebiopsy
osteosarcoma(arrowed).TheCTenablestheextentof the
instrumentshouldbemarkedoffwithtapesothatit
tumourtobedefined and alsoallowsplanningfor
isnotadvancedfurtherthanthedistancefromthetip
radiationtherapy.
of thenares(not therostraledgeofthenasalbone)
tothemedial canthus.Tumourtissueisusuallyvery
soft（not‘crunchy'liketurbinates)and a whiteor
yellowcolour.
Adrenalinecanbeplacedintheexternalnares
Haemorrhagecanbe profuse,butusuallysub-
Intheeventofsignificantbleeding,theunilateral
sidesafterafewminutes.Thefollowingmethodsto
carotidarterycouldbepermanentlyligated.The
dealwithsignificanthaemorrhagemaybeused:
authorshaveneverhadtoresorttothismethod.
Keeptheanimalanaesthetized,orsedatedand
Otherconsiderations
quiet,untilbleedingsubsides
Nasalwashingandbrushcytologyareoflimited
Packthepharynxand therostralnares(in
valueandnotrecommendedasthesolemethodof
anaesthetizedanimals)andletclotsform
diagnosis.
Ifbloodpressureisadequate,small amountsof
Lymphnodemetastasisisusuallypresent in10%
acepromazinecanbeadministered
of casesatthetimeofdiagnosis,but laterinthedis-
Usegauzeswabswithasmall amountof
easeupto40%ofnasaltumoursmaymetastasize
adrenaline(epinephrine)
tolymphnodeand lung.
269
Chapter18Tumoursof therespiratorysystemandthoraciccavity
Managementandprognosis
orwithsurgeryorchemotherapy，is2-5months.
Thisisimprovedtobetween8and25monthswith
Dogs
radiationtherapy,dependingon theprotocolused，
Thetherapyofchoiceindogsisradiationtherapy.
with1-and2-yearsurvivalsofabout40-80%and
withorwithoutaradiosensitizer(e.g.low-dosecispla-
20-40%,respectively(Lana andWithrow,2001).
tin).Most of these tumourspresent latein thedisease
Theprognosisforsarcomasisthoughttobe
slightlybetterthanforcarcinomas;ofthelatter,the
gery.Surgicalcytoreductionisusuallyofnobenefit
adenocarcinomasrespondslightlybetterthanSCC
priortoradiationtherapy(but isnecessarywhenlow-
orundifferentiatedcarcinoma.However,evenifclini-
calsignsresolve,fewdogsare considered cured
makesnodifferencetosurvivalwhenusedonitsown.
andmetastasisismorelikelytobeseeninlonger-
However,abenefitofpre-radiationsurgicalcytoreduc-
survivingpatients.Theuseofplatinumagentsas
tionofchondrosarcomashasbeenshown,presum-
radiationsensitizers improves survival times.The
ablybecausetheseareslow-growingtumours.
combinationofradiationtherapyfollowedbysurgery
Computerizedplanningofradiationtherapyhelps
hasresultedinlongerdisease-freeintervals,butnot
tomaximize thedosetothetumour,whilstsparing
significantly so.
normal tissue(suchaseyes andbrain)as much as
Usingsurgeryfollowedbyradiationtherapy,itwas
possible.Totaldosesof40-57Gyareusually
foundthatdogsthatunderwentbothweresignifi-
administeredin12-19fractionsover3-4weeks
cantlymorelikelytodeveloprhinitisorosteomyelitis
Hypofractionatedradiotherapy(4x8-9Gyfractions)
thandogstreatedwithradiationtherapyalone
hasalsobeenreportedtoprovidegoodpalliation
(Adams et al.,2005).Also noted in the same study
(Mellanbyetal.,2002a).
wasthattherateoflocalrecurrenceofneoplasiawas
Mucositis（reactionof the mucous membranes)
andrhinitisareoftensevereinanimalstreatedwith
notsignificantlydifferentbetweenthetwogroups.
thehigh-dosefractionatedregimens,althoughthisis
However,the2-yearsurvivalratefordogsinthe sur-
notthecaseforpalliativeprotocols.Analgesiaisvery
gerygroupwas69%,comparedwith44%for the
importantoverthe3-4weeksofthesesymptoms.
radiationtherapygroup.
Keratoconjunctivitissicca,corneal ulcersandcataract
Theprognosisforcatswithlymphomaisbetter,
formationcanalloccurifaneyereceivessufficient
withonestudyreportingamediansurvivalof4years
radiation.
incatswithnasallymphomatreatedbyradiation
alone.Non-lymphoidneoplasiasurvivalratesinthe
Cats
catfollowingradiationtherapyappearsimilar
to
Supportivecareisparticularlyimportantincats.Cats
thosein the dog（Theonet al.,1994;Mellanbyet
withnasaltumourshaveareducedabilitytosmell
al.,2002b).
andshouldbetreatedwithappetitestimulantsand
havetheirfoodheatedtoenticethemtoeat.lforal
nutritionisnotofanadequateamount,placementof
Tumoursofthelarynxandtrachea
anenteralfeedingtubeshouldbeconsidered
Cancerof thelarynxortracheaisrareinthedog and
Lymphoma:Incatswithoutsystemicinvolvement,
cat,thoughbothmalignantandbenigntumoursare
radiationtherapycanresultinextendedsurvivaltimes
recognized ateach site（Figures 18.10and 18.11).
ormaybecurative.Animportantprognosticfactor
Malignanttumoursaremorecommonthanbenign
maybethepatient'sFeLVstatus,withFeLV-positive
tumours.There issome confusion over the true
statusbeingassociatedwithpoorsurvivalrates.A
natureoftherhabdomyomaandtheoncocytoma.
recentretrospectivestudyfoundnodifferenceinsur-
vivalbetweencatstreatedwithradiotherapyalone,
chemotherapyalone,oracombinationof thetwo；
Benign
however,therewasasuggestionthathigherdosesof
.
Leiomyoma
radiotherapymaybeassociatedwithlongersurvival.
Lipoma
Whenlookingatdeathscausedbyprogressivedis-
.
Osteochondroma
ease,overallsurvivaltimeswereabout 16months,
Rhabdomyoma
butwhenlooking atdeathsregardlessofcause,over-
Oncocytoma
allsurvivalwas6months.Anaemiawasanegative
Fibropapiloma
prognosticvariable(Haneyetal.,2009).Patientswith
Malignant
systemicdiseaserequirechemotherapy.
Squamous cellcarcinoma
Intranasalcarcinomasandsarcomas:Surgery
Adenocarcinoma
aloneresultsinrelativelyfasttumourrecurrence.The
Poorly differentiatedcarcinoma
Chondrosarcoma
useofradiationtherapy(48Gyandvaryingprotocols
·
inasmallnumberofcats)resulted in1-and2-year
Lymphoma
Malignantmelanoma
survivalratesof44%and17%,withthesideeffects
Mastcelltumour
of radiationtherapyincatsbeinglessthanindogs.
Osteosarcoma
Rhabdomyosarcoma
Prognosis
·Plasma cell tumour
Overall, the prognosis for canine nasal tumours is
18.10
Tumours of the larynx.
verypoor.Themeansurvivaltimewithouttreatment,
270
Chapter 18
3Tumoursof therespiratorysystemandthoraciccavity
instancestheirseveritywillberelatedtothesizeof
Benign
themassinrelationtothesizeofthetracheallumen.
Leiomyoma
Earlyindevelopment,small trachealmasses will
Osteochondroma
oftenproduce no clinical signs whatsoever.These
Osteochondral dysplasia
massesaremostlycoveredwithnormaltracheal
Polyp
mucosaandwillrarelyleadtotheinitiationofa
Malignant
coughreflex.
Adenocarcinoma
Clinical approach
Squamouscell carcinoma
Poorly differentiated carcinoma
Imagingandbiopsy
Chondrosarcoma
Undergeneralanaesthesiathemajorityoflaryngeal
·
Lymphoma
Osteosarcoma
tumourscanbevisualized,and biopsyperformed,
Plasma cell tumour
through themouth(Figure 18.12).Endoscopymay
Mast celltumour
alsobe used.
Rhabdomyosarcoma
18.11
Tumoursof the trachea.
Althoughthesetumoursarisefromdifferentcellines
（rhabdomyoma arises from striated muscle cells,
whereasoncocytomaarises fromepithelialcells
called oncocytes),theycan prove hard to differenti-
atehistologicallyandimmunohistochemistrymaybe
requiredtodifferentiatethetwo.
Presentationandclinicalsigns
Laryngealtumours
In the dog,the clinical signs ofa laryngeal tumour
aremostcommonlyassociatedwithdistortionofthe
laryngealcartilagesandwithprogressivestenosisof
thelaryngeal lumen(rimaglottidis).The signs will
includechangesinvoiceorbarkand,in thoseindi-
vidualswithstenosisof therima glottidis,thepres-
18.12
Intraoralviewofalaryngealadenocarcinomain
enceofstridorousrespiratoryfunction.Aswith the
conditionof idiopathicbilateral laryngeal paralysis,
adog.
thelaryngealstridorwillbeworsenedbyanything
Tracheal tumoursarebestvisualizedintralumi-
causing an increase in respiratory rate,such as
nallywiththeaidofeitherarigidoraflexibleendo-
excitement,pantingandexercise;therefore,individu-
scope(Figure18.13).Certaintracheal tumoursfailto
alswilloftensufferfromexerciseintolerance.
demonstrateanysignificantdegreeofintraluminal
Inthecat,thepresenceofalaryngealtumourwill
protrusion,makingendoscopicbiopsy procedures
commonlyresultinaninabilitytopurraswellasa
impossible,and insuchcases anincisionalorexci-
changeofvoice.Laryngealstridorandexpiratory
sionalbiopsymayhavetobeperformedaspartof
dyspnoealocalizedtothelarynxwillalsooccur,but
surgicalexploration.
thesedentarynatureofmanycatsoftenallowsthese
individualstohidetheobstructiveclinicalsignsuntil
theybecomesevere.
Inbothspecies，advanced laryngeal tumours
may cause pharyngeal signs.
.Thiswillresult in
dysphagia,causedeitherbyinfiltrationofan
aggressivetumourtypeintothelocalpharyngeal
tissuesor,morecommonly,bythesheersizeof the
laryngeal mass.
Trachealtumours
Inboth thedog and the cat,the clinical signs of
trachealtumoursareingeneralassociatedwiththe
space-occupyingnatureof thetumourwithinthe
tracheal lumen.ltis,therefore,notsurprisingthatthe
clinicalsignsseenwithtrachealtumoursinclude
coughing,dyspnoeaandexerciseintolerance.
18.13
Endoscopicviewofa tracheal lymphoma ina
Clinicalsigns areofteninsidious andinmost
cat.
271
Chapter18
3Tumoursoftherespiratorysystemandthoraciccavity
Radiographyof thelarynxisgenerallyunhelpful,
implicationsfortheanimal'swelfareanditslong-term
thoughitmaybeusedtoassesslocal lymphnode
careshouldbediscussedcarefullywiththeowner.
(retropharyngeal)enlargementand theextentofdis-
placementoflocalstructuresintheneckandphar-
Trachealtumours:Trachealtumoursmaybeamen-
yngealregion.Plainradiographsofthecervicaland
able to surgical resection (Figure 18.15).In most
thoracicregionsmaydemonstratethepresenceof
instancesthiswillrequireresectionoftheaffected
intraluminaltrachealnarrowing,whichisoftenasso-
trachealringsfollowedbysubsequentend-to-end
ciatedwiththepresenceofatrachealtumour(Figure
anastomosisoftheseparatedtrachealends.
18.14).Inmany instances,appropriateradiographic
Althoughreportssuggestthatupto30-40%of the
interpretationcanprovedifficultevenwhengood
tracheacanberesectedwithsuccessfulre-anasto-
qualityradiographshavebeenobtained.
mosis,tension-free and thereforecomplication-free
repairismorelikelytobeaccomplishedifnomore
thanfiveorsixringsareresected.Thissurgerywill
beperformedmorereadilywhenthetumouraffects
thecervicaltracheaasopposedtothethoracictra-
chea.Resectionandrepairof the trachealbifurcation
canbeaccomplishedbutistechnicallydemanding
andassociatedwithahighincidenceofcomplica-
tions,suchasair leakage caused bydehiscenceof
theanastomosis.
18.14
Lateralthoracicradiographofacatwitha
trachealchondrosarcoma.Notethediscrete
narrowingof thetracheal lumenat thesiteof thetumour.
Staging
Tumourstaging should beundertakenforboth lym-
phoid andnon-lymphoid tumours.Staging fornon-
lymphoidtumoursshouldincludeevaluationof
regionallymphnodes andlungs formetastasis.
Lymphoidtumourstagingshould alsoincludethor-
aciclymphnode,abdominalorganandbonemarrow
evaluationforevidenceofmetastasis.Catswith
laryngealortracheallymphomashouldalsohave
evaluationoftheirFeLVandFIVstatusperformed.
18.15
Intraoperativeviewof theresectionofa
CT/MRIimagingmaybeusedtoassesstheextent
chondrosarcomainvolvingfourtofiveringsof
andinvasivenessof theprimarytumourandalsocan
theproximal cervical tracheaina cat.
bepartoftheassessmentforlocal/distantmetastatic
disease.
Radiationtherapy
Incaseswithradiosensitivetumourssuchaslym-
Managementandprognosis
phoma,thetreatmentofchoicemayberadiotherapy.
Thiswouldcertainlybethecaseinindividualswith
Surgery
eithernon-resectableradiosensitivetumoursorin
Laryngeal tumours:Thereareanumberofreports
caseswheretheresectionofsuchatumourwaslikely
describingthesuccessfulresectionofbenignlaryn-
toresultinlife-threatening complications.Assuch,the
geal tumourssuchasrhabdomyomas(oncocytomas)
potentialimportanceofobtainingadiagnosison
biopsyisclear.lt isimportant tonotethat,althoughit
Unfortunately,the majority ofmalignant laryngeal
maybetemptingtoadministercorticosteroidsinan
tumoursarenotamenabletolocal laryngealresec-
attempttorelievetherespiratorysigns,thiswilloften
tion.In suchcases,total laryngectomyisrequired to
maskthediagnosisoflymphomaandsoresultina
achieve complete tumourresection.Although this
potentiallyunnecessaryintervention.
techniquecantechnicallybeaccomplished inboththe
dogandthecat,itrepresentsanextremeformof
Chemotherapy
treatmentwhichisassociatedwithmanypotential
Felinelaryngeal lymphomamayalsobe treatedby
complications.Suchsurgeryinvolvestheformationof
chemotherapy，usingprotocolsdescribedinChapter
apermanenttracheostomyandmayresultinvarying
19a.Responseisoftenfavourable.
degreesofpharyngealdysphagia.Therefore,although
thetechnique isdescribedinmanysurgicaltextbooks,
Prognosis
theauthorsconsiderit israrelyindicatedintheman-
Benigntumoursofthelarynxandtracheacarrya
agementof laryngealtumoursinthedogandcat.The
goodprognosisiftheycanbecompletelyexcised
272
Chapter18
Tumoursoftherespiratorysystemandthoraciccavity
surgically.Althoughtherearefewreportsdescribing
<0.5cmdiameterinthecat),itwilloftenproduceno
themanagementofmalignanttumoursaffectingthe
clinicalsignsatall.In these individuals themass
larynxandtrachea,thesiteofdevelopmentofsuch
maybedetectedasanincidentalfindingonasur-
tumoursmakestheirprognosisverypoor,regardless
veythoracicradiographthatwasobtained,forexam-
ple,foranunrelatedcondition.Inanindividualwith
of treatment.
alarger mass,clinical signs including coughing，
lethargy,haemoptysisanddyspnoeamaybeseen.
Tumoursofthelungs
Non-specificsignssuchasanorexia,pyrexia,weight
Primarytumoursofthelungsaresummarizedin
Under certaincircumstances thelungmassmay
Figure 18.16and differential diagnosesfor lung
leadtotheproductionofapleuraleffusionand，
dependingonthetumoursizeandposition,regurgi-
masses aregiven inFigure18.17.
tationmay also occur.
Adenocarcinoma/carcinoma
Inapproximately15%ofdogs,andmorerarelyin
oBronchial gland
thecat,theparaneoplastic syndrome hypertrophic
oBronchogenic
osteopathy(Marie'sdisease)mayoccur.Theunder-
oBronchiolar-alveolar（commonest in both dog and cat)
lyingmechanismfor thisconditionremainsunclear,
Anaplastic carcinoma
oSmall cell
butit is characterizedbypainful,proliferativeperi-
oLarge cell
ostealnewbonegrowthonthedistallimbsassoci-
Squamous cell(epidermoid) carcinoma
atedwitharapidincreaseinperipheralbloodflowto
Sarcomas
thedistalextremities.Thepresenceof lamenessand
Pulmonary lymphomatoid granulomatosis(dog)
painful,non-pittingwarmswellingonthedistal limbs
·Benign tumours(very rare)
shouldalertthecliniciantothepossibilityofhyper-
18.16
Primary tumoursof thelungs.
trophicosteopathy.ltisimportanttonotethatthis
conditionmayresultfromaspace-occupyingmass
ineitherthe thoracicortheabdominalcavities(see
Pulmonary neoplasia
also Chapter4).
Mediastinal neoplasia
Pulmonary abscess
Mediastinal abscess
Clinical approach
。
Pulmonary granuloma
Ideally,adefinitivediagnosis shouldbemadein all
Lung lobe torsion
cases.Despite therationalethat thetreatmentof
Focal pneumonia/consolidation
choiceforanywellcircumscribedconsolidatedlung
18.17
Differential diagnosesforlungmasses.
lesionisitsremovalbytotalorpartiallobectomy,there
isnoreasontoconsiderlungtumoursanydifferent
thananyotherform of cancer;that is,anattemptto
Thelungrepresentsaverycommonsiteforthe
makeadefinitivediagnosisshouldalwaysbemade
developmentofsecondarymetastatictumoursinthe
dogand the cat.Developmentof primary lung
sothataninformeddecisioncanbetakenwithregard
totheappropriatetreatmentofthecondition.Similarly,
tumoursinbothspecies ismuchless common,
tumourstagingshouldbeconsideredmandatory,as
accountingforapproximately1%ofalltumoursinthe
theresultsof thismayhaveadramaticeffectonboth
dogand<0.5%in thecat.Mostprimarylungtumours
aremalignant；sites ofmetastasisincluderegional
（tracheobronchial andsternal)lymphnodes,lung and
apy.Tumourstaginginvolvesdetermining thesizeof
bone.Therateofmetastasisofprimarylungtumours
theprimarytumour,thepresenceorabsenceof local
shouldbeconsideredmoderateatthetimeofdiagno-
(generallytracheobronchial)lymphnodemetastasis
sisandhighlateinthecourseof thedisease.
and/ordistant(lungorbone)metastasis.
Themostcommontypeofprimarylungtumourin
Bloodtesting
bothcats anddogs isthe adenocarcinoma.This
tumourtypemaybeclassifiedasdifferentiatedor
Completebloodprofileswilloftenbeunremarkable,
though hypercalcaemiahasbeenreported insome
undifferentiated(carcinoma)and it mayalsobeclassi-
fiedbyitslocation,withbronchialgland,bronchogenic
cases.
andbronchiolar-alveolar formsbeingrecognized.
Bronchiolar-alveolarcarcinomaisthecommonest
Imaging
Survey thoracicradiographs are still considered the
form,whereasbronchogeniccarcinoma isconsidered
veryrareinthedogandcat.
most reliable formofinvestigation（Figure 18.18).
Otherformsofprimarytumour,suchasScCand
Mostauthoritieswouldconsider thatthreeviewsare
anaplasticcarcinoma(small and large cell),areless
required:bothlateralviewsandtheventrodorsalview.
common.Sarcomas andbenigntumours areconsid-
Goodqualitythoracicradiographsareimportantand
eredextremelyrare.
canbestbeachievedintheanaesthetizedintubated
individual,whereinflatedviewsmaybeobtained.In
Presentationand clinical signs
cases with suspected hypertrophic osteopathy，or
Inmanyindividuals theclinical signsassociated
thosewithsuspected distantbonemetastasis,radio-
withaprimarylungtumourarerelatedtoitssize
graphyoftheabdomen,spineandperipheralappen-
When the mass is small (<2 cm diameter in the dog,
dicularskeleton(Figure18.19) shouldbeperformed.
273
Chapter18
Tumoursof therespiratorysystemandthoraciccavity
CTmaybeused togreateffectfortheassess-
mentofmetastaticlungtumoursinthedog（Figure
18.20)andcat.Infact,CToffersthemostsensitive
methodforthedetectionoflungmetastasisandthe
presenceorabsenceof localtracheobronchial lymph
nodeenlargement.Itshouldbeconsideredsuperior
toplainradiographyandtheimaginginvestigationof
choice,ifcostsandavailabilityallow.
(a)
18.18
Ventrodorsalandlateral thoracicradiographsof
adogwithawellcircumscribedmassintheleft
caudallunglobe.
18.20
(a)Axial CTscanofadogshowingmultiple
18.19
Radiographof thedistal forelimbs,
metastaticlungtumours.(b)Coronal CTscan
demonstratingperiostealnewbone
of thethoraxof thesamedogshowing aprimarylung
characteristicof hypertrophicosteopathy.
tumourandmultiple metastatic lung tumours.
274
Chapter18
Tumoursoftherespiratorysystemandthoraciccavity
Incaseswithmetastaticlung tumours,theloca-
Managementandprognosis
tionof theprimarytumourmayrequirefurthersurvey
Treatmentisbasedonclinicalstageofthedisease
radiographyoradvancedimagingofotherpartsof
and,ideally,ona lesion thathasbeen confirmedto
theanimal'sbody.Diagnosisofdiffusepulmonary
metastasisisoftenpresumed bythepresenceof
onewithonlyapresumeddiagnosis.
multipleconsistent lung lesionsonsurvey thoracic
radiographs,especiallyinindividualswithaconcur-
Surgery
rentorpreviousdiagnosisofamalignanttumourwith
The treatmentofchoiceforsolitaryprimarylung
metastaticpotential.
tumourswithnoevidenceofdistantmetastasisisthe
Ultrasonography
ofpulmonarymassesmay
resectionoftheaffectedlunglobewithconcurrent
provedifficultunlessthetumourislargeandthereis
visualinspectionoftheregionaltracheobronchial
nooverlyingair-filledlung.Incaseswherethelesion
lymphnodes.Inindividualswithpreoperativestaging
isadjacenttothethoracicwall,fine-needleaspirates
suggestiveofregional lymphnodeenlargement,or
orcorebiopsysamplesmaybeobtainedwiththeaid
inindividualsprovingtohavelymphnodeenlarge-
ofultrasoundguidance.Obtainingpercutaneous
mentatthetimeofsurgery，biopsysamplesofthe
offending lymphnodeornodesshouldbesubmitted
biopsysamplescanbeassociatedwithpotentially
forhistopathology.
life-threateningcomplications,includingpneumothor-
Inmostcasesthesurgerycanbeperformedvia
axandinterpleuralhaemorrhage.Atworst,these
lateralintercostal thoracotomy.Insomeinstances,for
techniquesmayactuallyleadtoinappropriate
examplewhencontemplatingremovalofaverylarge
tumour spread by seeding.Theprosandcons of
lungtumourorwherethereisuncertaintyastowhich
obtainingsuchbiopsysamplesshouldbecarefully
lobeisaffected,itmaybetemptingtoconsiderenter-
explainedtotheownerbeforesuchproceduresare
ingthethoraciccavityviaamediansternotomy.
embarked upon.
Althoughalllunglobescanberemovedviathis
Enlargedregionallymphnodesmayalsobe
approach,theirresectionismademoredifficultbythe
detectablewithultrasound.Althoughitmayprove dif-
positionof the dorsally situatedhilarvessels and
ficultorimpossibletoperformabiopsy(tracheobron-
bronchi.Inrare cases,a tumourwithintheperipheral
chial) in these cases,the presence of node
aspectoftherightaccessorylobemayappear,radio-
enlargementisstillprognosticallysignificant andin
graphically,to be within the left caudal lung lobe.
themajorityofcasessuggestsalessfavourable
Althoughnotanidealapproachforsucharesection,it
outcome.
isfeasibletoremovetherightcaudal lunglobeviaa
leftlateral thoracotomy.Manyprimarylungtumours
Bronchoscopy
provereadilyresectableandtheprospectofthoracic
Bronchoscopymaybeperformedtoinvestigatethe
surgerymayseemappealing，butitshouldbeclearly
presenceoflowerairwaydiseasebutitwillcom-
understoodthatsurgeryisbestperformedbyaspe-
monlybelessrewardingintheconfirmationofapri-
cialistwithadequateexpertise,equipmentand
marylungtumour.Itsometimesprovespossibleto
instrumentation.
obtainaspirateand/orgrabbiopsymaterialviabron-
Thereislittledoubt that,withtheadventofsurgi-
calstaplingequipment,thepartialorfulllobectomy
complicationstothosedescribedforultrasonography
procedurecanbeperformedbothmorequickly
andinasimilarwayshouldnotbeundertakenwith-
andmoresafelythanbyconventional techniques.
outcarefulconsiderationandafullyinformedowner.
The thoracoabdominal （TA)stapler that is used
firesadoubleortriplerowofB-shapedstaples
Cytology
(Figure18.21).
Cytologicalexaminationoftracheobronchialwashes
willoftenfailtodetectthepresenceofneoplastic
cells.Similarly,obtainingpleural fluidsamplesinindi-
vidualswithaneffusionwilloftenconfirmthepres
enceofamodifiedtransudatewithoutrevealingthe
presenceofneoplasticcells.
Thoracoscopy
Recentdevelopmentsandthegreateravailabilityof
minimallyinvasivetechniqueshaveconfirmedthat
thoracoscopycannowbeconsideredasafemeans
forbothvisualizationandsafebiopsy ofprimary lung
tumours,regional lymphnodesand lung metastatic
lesions.Asthese techniquesbecomemore widely
available,itislikely thattheirroleintheassessment
andtreatmentoflungtumourswilldevelopfurther,
18.21
Intraoperativeuseofathoracoabdominal
withthepossibilitythatthoracoscopicassessmentwill
staplertoclosethebronchusof therightcaudal
lunglobeinadogpriortoitsexcisionforthemanagement
tumoursinboththedog and thecat.
ofaprimarylung tumour.
275
Chapter18Tumoursof therespiratorysystemandthoraciccavity
Pneumonectomymaybe considered but a lung
Inthedog,thereareseveralfactorsassociated
massshowingthisdegreeofinvolvementcarriesa
withapoorerprognosis.Theseincludealarger
significantlyworseprognosis.
tumoursize(>5cmdiameter),thepresenceofclini-
Local lymphnodesshouldalwaysbeinspected
cal signs,and metastasistoregional lymphnodes.
(Figure 18.22).lf there isevidenceofenlargement,
Well diferentiated(low-grade)tumourshaveabetter
samplesshouldbesubmittedfordiagnostic
survivaltimeanddisease-freeintervalwhencom-
histopathology.
paredwithtumoursthataremoderatelyorpoorlydif-
ferentiated (high-grade).Tumours located centrally or
nosis than those located in theperiphery on thelung.
Thepresenceofpleuraleffusionshould alsobecon-
sideredanegativeprognosticindicator.
Ingeneral,postoperativemeansurvivaltimesfor
solitaryprimarylungtumoursthatdemonstrateno
evidenceofmetastasescanextend to>12months
andcanbe>2yearsinsomecases.On the con-
trary,inindividualsdemonstratingoneormoreof
thenegativeprognosticindicatorsdescribedabove，
themediansurvivalfollowingprimarytumourresec-
tionmaybeonly1-8months.MSTfordogswith
unresectableprimarytumoursisseveralweekstoa
fewmonths.
18.22
Enlargedhilar lymphnodewhichcanbe
Lungtumoursincats
visualizedfollowing theresectionofacaudal
Ingeneral,theclinicalsigns,investigationsandman-
lung lobe ina dog forthemanagement of lungneoplasia.
Nodeenlargementmayrepresentreactivehypertrophyor
agementofprimarylungtumoursaresimilarforboth
metastaticspread of thetumour.
dogsandcats,buttherearesomeinterestingand
specificclinicaldifferencesinthecatthatwarrant
Metastatictumoursareusuallymultipleandrarely
furtherdiscussion.
amenabletosurgery,thoughtheresectionofsolitary
Primarylungtumoursarelesscommoninthecat
slow-growingmetastaseshasbeenattempted.The
than inthedog,but,asinthe dog,pithelial tumours
resectionofosteosarcomalungmetastaseshasbeen
(carcinoma)predominate.The rate of metastasis of
performed inthe dog,but thishasnotbeen shownto
primarytumoursissimilarorpossiblyslightlygreater
produce anysignificantimprovementinlifespan.
thaninthedog;itshouldbeconsideredmoderateto
Histopathologyshouldbeperformed
all
highatthetimeofdiagnosis(unless the tumourwas
on
resectedlesions,asthisinformationcanbeusedto
detectedas anincidental finding).The sites of
type and grade thetumour.
metastasisare similartothoseforthedog(regional
lymph node,lung and bone)but,specifically,cats
Radiationtherapy
sufferingfrompulmonaryepithelialtumoursnot
Radiotherapyisnotundertakeninanimalswitheither
uncommonlyshowmetastaticspread tomultiple
primary or metastaticlung tumours,since thelungs
digits(lung-digit syndrome).
areparticularlyradiosensitivetissuesandaresus-
Likethedog,treatment incatsisbasedonbiopsy
ceptibletoradiationsideeffects.
diagnosisandtheclinicalstageofthedisease.
Surgicalexcisionisthetreatmentofchoiceforsolitary
Chemotherapy
lungtumourswithnometastasis.OverallMSTforcats
withresectableprimarylungtumoursisapproximately
Themajorityofprimarylung tumours(carcinomas)
4monthsaftersurgery;however,individual catscan
arenotparticularlysensitivetochemotherapyand
efficacyisconsideredtobeminimal,exceptforlym-
surviveformuch longer(2-3yearsormore).Like the
dog,apositiveprognosticindicator would be the
phoma.Theuseofadjunctivechemotherapyisde-
resectionofasmalllesioninacatshowingnoclinical
pendentonthepresenceorabsenceofregionaland/
signsinwhichthetumourwasfoundasanincidental
ordistantmetastaticdisease.Thechoiceofagent is
based on the tumour type;for example,carcinoma
finding.Notsurprisingly，poorlydifferentiated tumours
areassociatedwithamuchworseprognosis.The
mayshowapositiveresponseto theadministrationof
benefitofchemotherapyfortheadjunctivemanage-
platinum drugs such as carboplatin,whereas a
mentofgrossprimaryormetastaticdiseaseisnot
short-livedpartialorcompleteremissionispossible
clearlydefinedandinthemajorityofcasesislikelyto
forhistiocyticsarcomafollowingtheadministrationof
haveminimalpositiveeffect.
lomustine(CCNU).
Prognosis
Tumoursofthechestwall
Adenocarcinomaandpapillarycarcinomaofthelung
tend tohaveaslightlybetterprognosis(meansurvival
Primarymesenchymaltumoursof thechestwalland
timeof 19months)thanSCC(mean survival time8
differentialdiagnoses for chestwallmassesare
months)(Mehlaff et al.,1983).
listed inFigures18.23and18.24.
276
Chapter18
Tumoursoftherespiratorysystemandthoraciccavity
theclearestinformationregardingmetastasistothe
Osteosarcoma(mostcommon)
Chondrosarcoma（secondmost common)
lungsandlocal lymphnodes.
Undifferentiated sarcoma
Ultrasonographymaybeused incertain circum-
Fibrosarcoma
stances,butwilloftenprovide littlefurtherinforma-
Haemangiosarcoma
tionthanthatobtainedfromsurveyradiographs.
Haemangiopericytoma
Myxosarcoma
Biopsy
Chondroma
Abiopsyshouldbeperformedonanychestwal
Primarymesenchymal tumoursof thechest
masspriortotreatment.Cellsmaybecollected using
18.23
wall.
fine-needleaspiration,but manymesenchymal
tumoursdonotexfoliatewellandsoitisoftenbetter
toperformacorebiopsy.Surveyradiographsmaybe
Abscess(most common?)
used todecidethesiteofbiopsy.Samplesshouldbe
Neoplasia （benign ormalignant)
Osteomyelitis
.
Fungal infection
tissueswhichwillberemovedshouldsurgical inter-
ventionbeundertaken.
18.24
Differential diagnoses for chest wall masses.
Despiteobtainingcorebiopsysamples,thediffer-
entiationbetweenchondrosarcomaandchondroblas-
Tumoursofthethoracicwallmostcommonly
ticosteosarcomaremainsdifficultinmanycases.In
some instances,the truenatureof thetumour can
involvetheribs,butcanalsooccurinthesternum.
Tumoursof thethoracicwall arerareinthedogand
onlybeascertainedfollowingopenbiopsy.
evenrarerinthecat.Theredoesnotappeartobea
Pleuralfluidsamples
sexpredilectionandmostcasesareseeninmiddle-
Incaseswithpleuraleffusion,samplesof theeffusion
agedtooldindividuals.Large-breeddogsareover-
maybesubmittedforcytology,butthesewilloften
represented.Mostthoracicwalltumours
are
onlyrevealthepresenceofamodifiedtransudate.
mesenchymal inoriginandnearlyallaremalignant.
Presentationand clinicalsigns
Managementandprognosis
The most common clinical sign is a visible mass on
Surgery
thethoracicwall.Tumoursmostfrequentlyoccurat
Thedefinitivetherapyforchestwalltumoursisenbloc
thecostochondraljunction,affecting the sixth,sev-
surgical resection(Figure 18.25).Intercostal thoraco-
enthandeighthribs.Right-and left-sided masses
tomiesshouldbeperformedcranialandcaudaltothe
appeartooccurwithequal frequency.
ribmass,andtheintrathoracicextentof themasscan
Other clinical signsincludelethargy,weightloss,
thenbeascertained.Ideally,atleastonenormal rib
coughing,dyspnoea andlameness(mostassociated
bothcranialandcaudaltothemassshouldbe
withhypertrophicosteopathy).Althoughnotproven,
removed.Allstructuresincontactwiththemass
thereissomesuggestionthatthedevelopmentofa
shouldberesectedwithatleasta3cmmarginof
proportionofthoracicwallsarcomasisassociated
grosslynormal tissue.Atno timeshould thetumour
withaprevioustraumaticepisodetothethoracicwall.
beincised,becausethiswillresultincontaminationof
Clinical approach
thesurgicalbed and,potentially,thethoraciccavity.
Haematology
Completebloodprofilesingeneralprovidelittle
informationofdiagnosticvalue，butaninfectious
process suchas anabscessmaycommonlybe
associatedwithaneutrophiliawithorwithouta
regenerativeleftshift.
Imaging
Goodqualitysurvey thoracicradiographs(atleast
twoorthogonalviews)shouldbeobtained.Thesewill
oftenconfirmtheribwithprimaryinvolvementand
mayalsoprovideinformationonlocal invasioninto
adjacentribs.Manymesenchymal tumoursof therib
willdemonstrate theso-callediceberg'effect,i.e.the
sizeof themassonitsintrapleural aspectwillbesig-
nificantlylargerthanthesizeoftheexternal,lateral
aspectof thegrowth.Insome instances,themass
willbeassociatedwiththepresenceofapleural
effusion.Theeffusionmayrequiredrainagetoallow
18.25
Enblocsurgicalresectionof a chestwall
clearradiographicinterpretation.
chondrosarcoma.Ideally,atleastonenormal rib
bothcranial andcaudal to themassshouldberemoved.
Advanced scanning modalities such as CT will
Thetumour shouldnotbeincisedduring theexcision
oftenprovidegreaterinformationthanthatobtained
surgeryas thismightresult inneoplasticcontaminationof
withsurveyradiographs.CTscanswillalsoprovide
thesurgical site.
277
Chapter18
3Tumoursof therespiratorysystemandthoraciccavity
Afterresection,margins should be marked with
inkorsuturesforevaluationbythehistopathologist.
Haemangiosarcoma(mostcommon)
Chemodectoma(secondmostcommon)
Alternatively,furthersmallsamplesmaybeobtained
Chondroma
fromsiteswithinthesurgicalfieldthatwarranthisto-
Chondrosarcoma
logical assessment.It is theauthors'opinion that,
Fibroma
whendealingwithlargetumours,thismethodof
Fibrosarcoma
assessmentisoftenpreferableandeasiertoperform
Granularcell tumour
thanthatofmarkingthemainmass.
Haemangioma
Myxoma
Whennomorethanthreeribshavebeen
Rhabdomyosarcoma
removed,closurecanoftenbeaccomplishedlocally.
Teratoma
Theremovalofmorethanthreeribswilloften
requiremorecomplicatedclosure techniques,such
18.26
Primary cardiactumoursreported in the dog.
astheuseoflocal muscleflaps(e.g.latissimusdorsi
ordiaphragm)or syntheticmesh.Complicationsof
Haemangiosarcoma（most commonin dogs)
healingassociatedwiththeuseofsyntheticmesh
Lymphoma(most common in cats)
suggestthatitsuseisbestavoidedifpossible.The
Malignantmelanoma
caudalpositionofthemajorityofthoracicmasses
Mammary carcinoma
meansthatsyntheticmeshisrarelyrequiredand
Mastcelltumour
surroundingsofttissuescanbeusedtoclosethe
Pulmonaryadenocarcinoma
Salivary adenocarcinoma
majorityofdefects.Althoughresectionmayberela-
tively straightforward,the techniques required for
Secondarycardiactumoursreportedin thedog
18.27
complication-freethoracicclosurewilloftenrequire
andcat.
considerableexpertise,andsurgicalcasesarethen
Presentationandclinicalsigns
such techniques.
Cardiactumoursareconsidereduncommoninthe
dogandevenmorerareinthecat.Tumoursmaybe
Radiationtherapy
primaryorsecondaryinnatureandmayoccurin
Thesiteandpoorresponseof mosttumoursmake
intracavitary,intramuralorpericardiallocations.The
radiationtherapyoflittleuseintheadjunctiveman-
mostcommoncardiactumourinthedogishaeman-
agement ofthoracicchestwall tumours,but the
giosarcoma,towhich theGermanShepherd Dog
increasingavailabilityoflinearacceleratorswith
appearstobepredisposed.Aorticbodytumours
electronbeamfacilitiesmakestheuseofradiationto
(chemodectomas)represent the secondmost com-
treatchestwalltumoursmorefeasible.
moncardiactumourinthedogand theseappearto
haveapredispositioninolderindividualsofthe
Chemotherapy
brachycephalicbreeds.
Littleinformationisavailableregardingtheeffectsof
Secondarylymphomarepresentsthemostcom-
adjunctivechemotherapy.Itislikelythatthe
montumouraffecting theheartincats.Primaryheart
administration of drugs such as carboplatin,cis-
tumoursareextremelyrareinthisspecies,withonly
platin（doNOTuse incats)and/ordoxorubicinwill
twocasesofchemodectomahavingbeenreported
provideanincreaseindisease-freeintervalsfor
(Tilley et al.,1981).
tumours such as osteosarcoma,chondrosarcoma
Thepericardiummaybea site for the develop-
andhaemangiosarcoma.
mentof both primary(e.g.mesothelioma)and sec-
ondary （e.g.lymphoma)tumours;these arenot
Prognosis
strictlytumoursof theheart.
Theprognosisfollowing surgicalresectionof achest
Thenatureoftheclinicalsignsassociatedwith
wallmassdependsonhistologicaldiagnosisandthe
cardiactumourswilldependtoalargedegreeonthe
completenessofclean surgical margins.Resection
siteof theirdevelopment.Forexample,tumourssuch
ofbenigntumourssuchasthechondromawillcarry
asthechemodectoma,whichcommonlydevelopat
afavourablelong-termprognosisandsurgeryin
thebaseoftheaorta,willgenerallynotaffectcardiac
suchcaseswillbecurative.Conversely,theprogno-
rhythm,butmayresult intheproductionofapericar-
sisfor themajorityofmalignanttumoursispoor.A
dialeffusionleadingtosignsofcardiactamponade
recent studysuggested that theMSTfor animals
and right-sided heart failure.Tumours developing
withosteosarcomawas17weeksandforfibrosar-
withinthecardiacmusclemaywellinterferewiththe
comawas26weeks（Bainesetal.,2002).Abetter
electricalactivityof theheart,leadingtothedevelop-
long-termoutcomewasachievedfollowingthe
mentoflife-threateningdysrhythmias.Intracavitary
resectionofchondrosarcoma,with50%ofanimals
tumoursmayresultinobstructiontobloodflowand
still alive2yearspostoperatively.
thedevelopmentofperipheralorpulmonaryoedema.
Animalssufferingfromhearttumourswill ingen-
eralpresentwithclinicalsignsassociatedwithcardiac
Tumoursoftheheart
dysfunction.Initsmostextremeform thismaymean
thesuddendeathofanindividualfromeitherrupture
Primaryandsecondaryhearttumoursaresummar-
ofthetumourordevelopmentofafatalcardiacdys-
ized inFigures18.26and18.27.
rhythmia.Tumours thatresult in the formationofa
278
Chapter18
Tumoursof therespiratorysystemandthoraciccavity
pericardialeffusion（chemodectoma)orpericardial
ofalteredcomplexamplitudessuggestiveofchamber
enlargementandalsothepresenceofrhythmabnor-
induceclinicalsignsofright-sidedheartfailureinclud-
malitiessuggestiveofafocal disease.Forexample,
ingexerciseintolerance,dyspnoea,syncope,ascites,
thepresenceofapericardialeffusionmayresultin
dysrhythmiasandweightloss.Examinationofthese
theformation ofelectricalalternans,whereas the
presenceofanintramurallesionmayresultinthe
enceofpulsedeficits.
developmentofventricular
prematurecomplexes
Haemangiosarcoma,beingahighlymalignant
(seeBSAVAManual
of
Canine
andFeline
tumour,willcommonlydemonstratewidespreaddis-
CardiorespiratoryMedicine).
seminationbythetimeofclinicalpresentation.This
Cytology
mayresultinthedevelopmentofhaemorrhagicdia-
thesisduetodisseminatedintravascularcoagulation.
Cytologicalanalysisofaneffusionassociatedwitha
cardiactumour(pleuralorpericardial)willcommonly
Clinicalapproach
failto identifythepresence of neoplasticcells，but
Clinical signsareoftennon-specific,since they are
suchanalysismaybeuseful inrulingoutothercauses
relatedtoeithercardiacrhythmdisturbanceorright-
ofeffusionsuch asinfection.
orleft-sidedheart failure.Haemangiosarcomais
mostcommonlyassociatedwithhaemorrhagicperi-
Managementandprognosis
cardialeffusionandcardiac tamponade.Tumours
Surgery
causingobstructiontobloodflowwithintherightor
Themajorityof cardiactumoursarenot amenableto
leftsidesoftheheartmayleadtoclinicalsignssuch
as the presence of a murmur,jugular distension,
surgicalresection.However,therearea numberof
cranialvenacavasyndrome,ascites,pleuraleffusion
cardiac
tumoursfor
whichsurgicalintervention
and/orpulmonaryoedema.
shouldbeconsidered.Theseincludechemodect-
omas,haemangiosarcomas confined to the right
Haematology
atrialappendage（Figure 18.28)andcertainbenign
Completebloodprofileswilloftenbeuninformativebut
intracavitary tumours.
schistocytesoracanthocytesmaybeseenincasesof
haemangiosarcoma(seeChapter 19b).Clotting pro-
filesshouldbeperformedincaseswherehaemangio-
sarcomaissuspected.
Imaging
Surveythoracicradiographsmaybeunrewarding,
butwithcertaintumourstheymayindicatethepres-
enceofcardiomegalyand/orpericardialeffusion.
Radiographicsignsassociatedwithright-orleft-
sidedheartfailuremayalsobepresent,suchaspul-
monaryoedemaincaseswithleft-sidedheartfailure.
ThoracicCTmayprovidevaluableinformationonthe
siteandsizeofatumourassociatedwiththeheart
Intraoperativeviewofarightatrial
18.28
orpericardium.
haemangiosarcoma ina dog.
Inmost instances,theuse of cardiacultrasono-
Surgical intervention for the managementof
graphyrepresentsthemostuseful andleastinvasive
chemodectomasofteninvolvesthecompleteexcision
formof investigation.Echocardiographywillallowthe
ofthetumourfromitspositionattheoriginofthe
accurateinterpretationofmostintracavitary,intra-
greatvessels.Under certaincircumstances(for
muralorpericardial lesions.Ultrasoundexaminations
tumoursdemonstratinglocalinvasionandinfiltration),
willalsoprovideinformationregardingthefeasibility
it isnotpossible toresect the tumour.In these cir-
ofsurgicalexcisionofcertaintumours.Ofgreater
cumstancesaneffectivelong-termmanagementof
significance,considering thatthemajorityofcardiac
thistumourtypecanoftenbeachievedbyperforming
tumourscannotberesected,isthatechocardiogra-
asubtotalpericardiectomy(Ehrhartetal.,2002).
phycanprovideconsiderableinformationregarding
Theresectionofaprimaryhaemangiosarcoma
theeffectsofthetumouronhaemodynamicfunction
associatedwiththerightatriumoftenprovesless
of theheart.Thiscanbeusedtomonitor thepro-
satisfactory.Althoughassessmentmayindicatethat
gressionof thetumour,withorwithouttreatmentinto
the tumouris confined toitsprimaryatrialsite,un-
thelongerterm.
Numerouscontrasttechniquessuch as angiogra-
diagnosedmetastasisprior tosurgicalresection
oftenmeansthatpostoperativesurvivalpriortofatal
phyandpericardiographyhavebeendescribedfor
metastaticgrowthmaybemeasuredonlyinmonths.
theinvestigationofhearttumours.Inmostcircum-
Withtheadventofopenheartsurgeryusingcardi-
stances,thesetechniqueshavebeensupersededby
the useofultrasound examinations.
opulmonarybypass,it isnowpossibletoconsiderthe
removalofslow-growingintracavitarytumours.All
Electrocardiography
formsofcardiacsurgeryrequireconsiderableexper-
Acompletecardiacexaminationshouldincludean
tiseandequipment,andreferralofsuchcasestoa
ECG.Thismaybeused todemonstratethepresence
specialistshouldbeconsideredmandatory.
279
chapter18Tumoursof therespiratorysystemandthoraciccavity
Radiationtherapy
Presentationandclinicalsigns
Littleinformationisavailableregardingtheuseof
Inthemajorityof individuals,clinical signs areasso-
radiotherapyinthetreatmentofcardiactumours.
ciatedwiththepresenceofalargespace-occupying
Radiationmaybeconsideredasapalliativemeas-
massinthecranial mediastinum.Signsofrespiratory
ureinthemanagementofinoperablechemodect-
distress,including coughing,dyspnoea and tachy-
omas(Turrel,1987),butfurtherstudiesarerequired
pnoea,arecommon.Insome instancesthe sizeof
toascertain thetrueefficacyofthistechniquein
themasswillobstructthegreatveinsand lymphatic
smallanimals.
systemwithinthecranialmediastinalspace,leading
totheformationofprecaval syndrome.Thismani-
Chemotherapy
festsitselfwiththedevelopmentofswellingand
Thereisnoevidencethatchemodectomaissensitive
oedematothehead,neckandfrontlegs.
tochemotherapy.Thereareanumberofreports
Thymomasarealsoassociatedwiththeparaneo-
regardingtheuseofchemotherapyinthemanage-
plasticsyndromeofmyastheniagravis.Thiscondition
mentofhaemangiosarcoma.Combination therapy
maybeseen inupto40%ofdogsaffectedby the
withvincristine，doxorubicin andcyclophosphamide
tumourbutappearstobemuchrarerinthecat.
appearstobemosteffective(deMadronet al.,1987).
Myastheniagravisischaracterizedbyageneralmus-
Aswithotherformsofhaemangiosarcoma,theprog-
cleweaknessand,insomeindividuals,thepresence
of megaoesophagus.There also appears to be an
nosisforlong-termresolutionof thediseaseremains
associationbetweenvariousautoimmunediseases,
guarded,regardlessofhowaggressively thecondi-
suchasimmune-mediatedanaemiaandpolymyositis,
tionismanaged.Inmanyindividuals,managementis
andthepresenceofthymoma.Inthecat,anassocia
aimed at controlling the secondary clinical signs
tionhasbeenreportedbetweenexfoliativedermatitis
associatedwithheartfailureand/ordysrhythmia.
and thepresenceof thymoma(Scottetal.,1995).
Prognosis
Clinical approach
Ingeneral theprognosisforcardiactumoursinsmall
Small thymicmasseswilloftenproducenoclinical
animalsispoor.Thisisparticularlythecasewithcar-
signsandmaygounnoticed.Inindividualswithasus
diachaemangiosarcomas,wherethemeansurvival
pectedthymoma,afull clinical examinationshould
timefollowingsurgery(withoutchemotherapy)
is
includethoracicauscultationandanassessmentfor
reported tobeonly4months（Aronsohn,1985).In
thedevelopmentofprecavalsyndrome.Evidenceof
pittingedemaofthehead，neckorfrontlegs,withor
tumourwithpericardiectomyandcombinedchemo-
withoutjugularveindistension,mayindicatethepres-
therapy,theMSTmaybeextendedtobetween5and
enceofalargecranialmediastinal mass.Decreased
8months.
lungsoundsoverthecranialmediastinummayalso
Whiletheprognosisforchemodectomasandmeso-
indicateacranialmediastinalmass.Insome
theliomas ofthepericardiumis guarded,in some
instancesthepresenceofamassatthis sitemay
casesdirectsurgicalresectionorpalliativepericardi-
alter the cardiac axis,resulting in the unusualposi-
tioningofheartsoundsonauscultation.Thoracicper-
ectomymayproduceasignificantdisease-freeinterval
of many months.
cussionofthecranialthoraxmayindicateadullness
consistentwith thepresenceofasofttissuemass.
Tumoursofthethymus
Haematology
Bloodprofileswillgenerallybeunremarkable,though
Thymomas are uncommon tumours inboth the dog
bothleucocytosisand,morerarely,hypercalcaemia
and thecat.Althoughthe thymusgland ismostactive
havebeenreported.
intheyounger individualunder6monthsof age,
Imaging
tumourdevelopmentismostcommonlydiagnosedin
Survey thoracicradiographywill,inmost instances,
olderdogsandcatsover9yearsofage.Moststudies
revealthepresenceofavariablysizedmasswithin
shownosexorbreedpredilection,butmedium-and
thecranial mediastinum(Figure18.30).
large-breeddogsmaybeover-represented.
Allthymomasoriginatefromthymicepithelium,but
manyofthetumoursareinfiltratedtoagreateror
lesserextentbymaturelymphocytes.Whiledifferent
histological celltypesarerecognized,theredoesnot
appeartobeanyprognosticvalueinthisinformation.
Distant metastasisisrarebut mayoccur.
Differential diagnoses for a mass in the cranial
mediastinumarelisted inFigure18.29.
Mediastinal lymphoma（mostcommon)
Thymoma
Tumours of the craniallung lobes
Thyroidhaemorrhageassociatedwithinvolution
Othertumoursof thethyroide.g.thyroidmelanoma
18.29
Differential diagnoses in the dog andcat fora
18.30
Lateral thoracicradiographof adogwith a
masswithinthecranialmediastinum.
cranial mediastinalmass.
280
Chapter 18
Tumoursof therespiratorysystemandthoraciccavity
Radiographicdiagnosismaybeconfusedbya
easiertoestablishapositivediagnosisofmediasti-
pleuraleffusion;anddefinitionofthecardiacsilhou-
nallymphomafollowingtheobservationoflarge
numbersoflymphoblasts.
massandalsobyitsabilitytoinducedisplacementof
localstructures.Inanyindividual thatdemonstrates
Staging
possiblemyastheniagravisand/oroesophagealdys-
Thecanine thymoma canbeclinicallystaged,butthis
function,a lateralthoracicradiograph should
be
canprovedifficulttoaccomplishpriortoexploratory
obtainedof theconsciouspatient toruleoutthepres-
surgerysinceitrequiresassessmentofthetumour
enceofmegaoesophagus.Myastheniagravismaybe
capsule,theassessment of tumour invasioninto
furtherinvestigatedbyassessmentofanti-acetylcho-
adjacenttissuesandthepresenceofmetastasis
linereceptor autoantibody concentrations.Thoracic
(Figure18.32)
CTmayprovidevaluablefurtherinformationand，if
available,maybeconsideredtheradiographicimag-
Description
ing techniqueofchoice（Figure18.31).
Growthcompletelywithinintact thymiccapsule
01101/290
Pericapsulargrowthintomediastinalfat tissue,
adjacent pleura and/orpericardium
川
Invasioninto surrounding organs and/orintrathoracic
metastases
IV
Extrathoracicmetastases
18.32
Clinical staging of thymoma in the dog.
Managementandprognosis
Surgery
Thedefinitivetherapyforthymomaissurgicalresec-
tion(thymectomy).Thesurgicalapproachforthymec-
tomydependsontherelativesizeof themass.Small
massesmaybeapproachedviaanintercostalthora-
cotomy（mostcommonlyfrom theleftside)whilst
175of60
largermassesmayrequireananteriorsternotomy
Post-contrastaxial CTscanof thethymoma
(Figure 18.33).
18.31
withinthecranial thoraxofadog.Thegreat
vessels(white)aredisplacedventrally,whereasthe
18.33
trachea(black)hasbeendisplaced totherightside.
Intraoperative
appearanceofa
Inmost cases,the craniomediastinal mass will
thymomaina
haveobtainedsuchasizethatthecranial lunglobes
crossbreddog.
willbedisplacedinacaudaldirection.Thiswillallow
ultrasonographicassessmentofthemassviaeithera
cranialintercostalora thoracicinletwindow.Although
somethymomasmaycontaincysticcavitiesas
opposed to the more homogenous appearance of
lymphoma,theconsiderable variety of textures
observedmeans thatultrasonography cannotbe
usedasadefinitiveguidetothehistologyofthe
mass.Ultrasonographymaybebestusedtoassess
thedevelopmentofpleuraleffusion,toinvestigatethe
developmentof local invasion,andtoaidinthecol-
lectionofbiopsyoraspiratematerial.
Biopsy
Thedefinitivediagnosisofthymomarequiresbiopsy.
Fine-needleaspiration isconsidered a safe(with the
Theso-calledbenign'thymomasarenon-invasive
aidofultrasoundguidance)andnon-invasive
andwellencapsulated,whereas‘malignantthymo-
methodforobtainingcytologicalmaterial,butresults
maswillbefoundtobeinvadingadjacentstructures.
areoftenveryunreliable.Themajordifferentialdiag-
Metastasisisrare.Itisimportanttoremember,froma
nosisforthymoma,especiallyinthecat,ismediasti-
surgical standpoint,thatthesizeof the thymoma on
nal lymphoma.The epithelial component of the
radiographyand/orultrasoundexaminationimparts
thymomararelyexfoliateswellandsamplestendto
littleinformationregardingwhetherthetumourcanbe
containlargenumbersoflymphocytes,makingtheir
successfullyresectedornot.Approximately70%of
differentiationfromalymphomadifficult.Itisoften
thymomasareresectable,regardlessoftheirsizeat
281
chapter18Tumoursof therespiratorysystemand thoraciccavity
surgery.Surgical debulkingof theunresectableinva-
instancesmaytakemonths.Therefore,if themyasthe-
siveformof thymomaisoftennotverysuccessfuland
nia gravis is complicatedby the presence of mega-
mayleadtoconsiderableintraoperativehaemorrhage
oesophagusitisunlikelythatthedogwillsurvivelong
andpostoperativemorbidity.Asthefeasibilityofcom-
enoughfollowing surgerytoallowanimprovement to
pletetumourresectioncanoftenonlybeassessedat
beseen.Onrareoccasions,myastheniagravis may
the timeofsurgery,it isprudent todiscussthepossi-
developfollowingthymectomy.
bilityofintraoperativeeuthanasiapriortoperforming
Thesurgicalresectionof thymomaincatsappears
theprocedure.
tohavea favourableprognosis.Onestudyreported
In thecat,thymoma ismuchlesscommon than
amediansurvival approaching 2years(Goreset
mediastinal lymphoma.This,and theproblems asso-
al.,1994).
ciatedwithcytologicaldiagnosis,hasledtotheprac-
ticeof treating allcranial mediastinal massesinthe
catwithchemotherapyeffectiveagainstlymphoma.
Mesothelioma
Unfortunately,inthe cases where this treatment
provesineffective,furthersurgical investigationand
Mesothelioma isarare tumour indogsandcats.It
possibleremovalofathymomamaybecompro-
arisesfromtheserosal liningofthebodycavitiesand
soanypartof thebodypossessingaserosal lining
misedduetoprolongedwoundhealingassociated
withtheuseof chemotherapydrugs.Thisgroupof
maybeaffected.Inboththedogandcat,formsaffect-
ingthepleural,pericardialandperitonealcavitiesare
animalspresentsthegeneralpractitionerwithaseri-
the mostcommon.
ousdilemmaanditishighlyrecommendedthat
Ingeneral,theaetiologyofmesotheliomais
advice from，orreferralto,a specialist is sought in
unknown,but dogswiththepleuralform of thedis-
such cases.
easehavebeenshowntohavehigherlevelsof
asbestosintheirlungsthannormalcontrols.Affected
Radiationtherapy
Thereislitteinformationavailableregarding theuse
dogsoftenhaveownerswhohaveoccupationsor
hobbiesinwhichexposuretoasbestosisaknown
ofradiotherapyinthetreatmentofthymoma.Theor-
risk;therefore,exposureto airborneasbestosfibres
etically,radiation therapy mightbe expected to
hasbeen implicatedintheaetiologyofpleural meso-
decrease thelymphoidcomponentof themass.In
thelioma(Glickmanetal.,1983).
verylarge‘unresectable'tumoursitmaybepossible
todownstage(shrink)thetumourusingradiation so
Presentationandclinicalsigns
that itbecomesamenabletosurgicalexcision.
Mesotheliomaclassicallyoccursasadiffusenodular
Chemotherapy
masscoveringthesurfacesof theaffectedbodycav-
ity.Itisahighlyeffusivetumourandtheclinicalsigns
Theuseofchemotherapyinthetreatmentofthy-
aremostcommonlyassociatedwiththeeffusion.For
moma inthedogandcatisunrewarding.Asstated
example:dyspnoeawillbeseeninindividualswitha
above,achemotherapyregime that is effective
pleuraleffusion;cardiac tamponadeandsignsof
againstmediastinallymphomahasbeenusedasa
right-sidedheartfailurewillbeseeninindividuals
meanstodifferentiatethetwotumourtypes.Unlessit
withapericardialeffusion;andabdominaldistension
isabsolutelyclearthattheindividual isnottoundergo
willbeseeninindividualswithaperitonealeffusion.
thymectomy,the consequences of this approach to
thesuccessfuloutcomeofpossiblefuture surgery
Clinical approach
shouldbeclearlyexplainedtotheowner.Similarlyto
Adiagnosisofmesotheliomashouldbeconsidered
radiation,chemotherapy(cyclophosphamide)maybe
inadultdogswithevidenceofachroniceffusivedis-
used toshrinkalarge‘unresectable'tumourso thatit
ease.Themajordifferentialdiagnosesformesotheli-
becomessignificantlysmallerand amenabletosurgi-
omaarelistedinFigure18.34.Establishinga
calresection
definitivediagnosisofmesotheliomamayprovediffi-
cult,sincemesothelial cellscanbeexpectedtopro-
Prognosis
liferateunderanycircumstancethatleadstothe
Theprognosisforthymomadependsonthefeasibility
ofsurgicalresectionand alsothepresenceofpara-
Diseases causing pleural effusion
neoplasticmyasthenia gravis.Inindividuals without
myasthenia gravis and/ormegaoesophagus,theprog-
Haemangiosarcoma
nosis isgood if thetumour canberemoved.Dogs
Pyothorax
Primarypulmonaryneoplasms
withoutmegaoesophagusandwitharesectable
Metastaticcarcinoma
tumourhavebeenreportedtohavean83%1-year
Felineinfectiousperitonitis
survivalrate.Withsurgery,long-termremissionscan
thereforebeexpectedinindividualsinthisgroup.
Diseases causing pericardial efusion
Conversely,the prognosis is poorinindividuals
Idiopathicpericardial efusion
witheitheranon-resectablethymomaorwithevi-
Haemangiosarcoma
denceofmegaoesophagusandmyastheniagravis.
Coagulopathy
Althoughanumberofreportsdescribe theresolution
Pericardial cyst
ofmyastheniagravisfollowingthymectomy,this
18.34
improvementisbynomeanscertainandinmany
Differentialdiagnosesformesothelioma
282
Chapter18
Tumoursoftherespiratorysystemandthoraciccavity
productionofaneffusion.Therefore,thecytological
of the tumour itself (Moore etal.,1991).There are
fewdataavailableregardingtheconsequencesof
proliferationandamalignantmesotheliomaisoften
intracavitaryadministrationofcisplatinintheman-
notpossible.Ingeneral,large samplesofaffected
agementofmesothelioma.Furtherstudiesare
serosaltissuesobtainedviathoracotomyoranopen
requiredbeforethetrueroleof thisdrugcanbedelin-
biopsyarerequiredfordefinitivediagnosis.
eated.Cisplatinmustnotbe administered tocats.
Haematology
Prognosis
Theinterpretationofacompletebloodprofileisoften
Survivalfiguresformesotheliomaaresparseasthe
unrewardinginestablishingadiagnosisof mesotheli-
majorityof animalsareeuthanizedondiagnosis.
omabutmaybehelpful inrulingoutothercausesof
Thelackofaneffectivemethodoftreatment
effusions.
meansthat theprognosisinmostinstancesispoor.
Individualswiththepericardialformofthedisease
Imaging
maybenefitfromapalliativepericardiectomysince
Surveyradiographsofaffectedcavitieswilloftenonly
thiswillpreventtheoccurrenceofclinical signsasso-
indicatethepresenceoffluidwithinthecavity.Films
ciatedwithpericardialeffusion.
takenafterfluiddrainagemayprovidefurtherinfor-
mationbutarestillunlikelytodemonstrateclearlythe
presenceofthetumour.Similarly,ultrasound investi-
Referencesand furtherreading
gationcancommonlybeunrewarding.Thediffuse
Adams WM,Bjorling DE,McAnlty JF et al. (2005) Outcome of
natureofthetumourmakesestablishingadefinitive
acceleratedradiotherapyaloneoracceleratedradiotherapy
ultrasonographicdiagnosisdifficult.
followedbyexenterationofthenasalcavityindogswithintranasal
neoplasia:53cases （1990-2002).Journal of the American
Endoscopyandbiopsy
VeterinaryMedicalAss0ciation227,936-941
AronsohnMG(1985)Cardiachaemangiosarcomainthedog:areview
Theincreasingavailabilityofthoracoscopyandlapa-
of38cases.JournaloftheAmericanVeterinaryMedical
roscopyinsmallanimalsmay allowforalessinvasive
Association187,922-926
Baines SJ,Lewis S and White RAS (2002)Primary thoracic wall
wayofpatientevaluationthanundertakinganopen
tumoursofmesenchymaloriginindogs:aretrospectivestudyof46
biopsy.
cases.VeterinaryRecord150,335-339
Itshouldberememberedthatthisisadisease
BexfieldNH,StellAJ,GearRNandDobsonJM(2008)Photodynamic
therapyofsuperficial nasalplanum squamouscellcarcinomasin
thatcanprovedifficulttodiagnosebyconventional
cats:55cases.JournalofVeterinaryInternalMedicine22,1385-
means.Obtaininga negativeresult onbiopsydoes
1389
Clarke RE(1991)Cryosurgical treatment of cutaneous squamous cell
notalwaysruleoutthepresenceofmesothelioma.
carcinoma.AustralianVeterinaryPractice21,148-153
Theauthorscanrememberanumberofcaseswhere
Closa JM,FontAandMascortJ(1999)Pericardial mesotheliomaina
adefinitivediagnosiswasonlyconfirmedatopen
dog:long-termsurvivalafterpericardiectomyincombinationwith
surgical investigation,or,ofmore concern,on post-
chemotherapy.JournalofSmallAnimalPractice40,383-386
de
Madron E,Helfand SC and Stebbins KE （1987) Use of
mortemexamination.
chemotherapyforthetreatmentof cardiachaemangiosarcoma in
thedog.JournaloftheAmericanVeterinaryMedicalAssociation
Management and prognosis
190,887-891
EhrhartN,EhrhartEJ,WillisJetal.(002）Analysisof factorsaffecting
survival indogswithaorticbodytumours.VeterinarySurgery31,
Surgery
44-48
Thereisatpresentnoeffectivemethodoftreatment
GlickmanLT,DomanskiLM,MaguireTG,DubielzigRRandChurgA
(1983）Mesotheliomainpetdogsassociatedwithexposureof their
formesothelioma.Thediffuseandeffusivenatureof
ownerstoasbestos.EnvironmentalResearch32,305-313
thediseasemeansthatthewholeofanaffectedbody
Gores BR,Berg J,Carpenter JL and Aronsohn MG （1994） Surgical
cavityisconsideredcontaminatedwiththetumour.
treatment of thymoma incats:12cases（1987-1992）.Journal of
theAmericanVeterinaryMedicalAssociation204,1782-1785
Therefore,inmost instancesthe surgicalexcisionof
Hammond GM,Gordon IK,TheonAPandKent MS(2007)Evaluationof
grosslyaffectedserosalsurfacesisof littlebenefit.
strontium Sr 90 for the treatment of superficial squamous cel
Performingapericardiectomymayprovepalliativein
carcinoma of the nasal planum in cats:49 cases (1990-2006),
JournaloftheAmericanVeterinaryMedicalAssociation231,736-
individualswithclinicalsignssuchascardiactampon-
741
HaneySMBeaverLTurelJetal.2009）Survivalanalysisof97cat
adeassociatedwiththepericardialformofthedis-
ease (Closa et al.,1999).
withnasallymphoma:amulti-institutionalretrospectivestudy
（1986-2006）.JournalofVeterinaryInternalMedicine23,287-294
KirpensteijinJ,WithrowSJandStrawRC（1994）Combinedresectionof
Radiationtherapy
thenasalplanumandpremaxilla inthreedogs.VeterinarySurgery
23,341-346
Thediffuseandwidespreadnatureofthediseasepre-
Lana SE,Ogilvie GK,Withrow SJ,Straw RC and RogersKS（1997)
ventstheuseofradiotherapyasatreatmentoption.
Feline cutaneous squamous cellcarcinomaof thenasalplanum
and thepinnae:61cases.Journalof theAmericanAnimal Hospital
Association33,329-332
Chemotherapy
LanaSEandWithrowSJ(2001)Nasaltumors.In:SmallAnimal Clinical
Inhumans,theadministrationofintracavitarycispla-
Oncology.ed.SJWithrow andEG MacEwen,pp.370-377.WB
tinissometimesusedtomanageandslowthepro-
Saunders,Philadelphia
LascellesBD,HendersonRA,SeguinB,LiptakJMandWithrowSJ
gressionof thedisease.Thedrugappearstobewell
toleratedanditsadministrationhasbeenshownto
rostralmaxillofacialneoplasmsinsixdogsandonecat.Journalof
theAmericanAnimalHospitalAssociation40.137-146
decreasetheproductionofthemalignanteffusion.
Lascelles BDX,Parry A,Stidworthy MF,Dobson JM and White RAS
Thistechniquemayhavearoleinthemanagement
(2000) Squamous cellcarcinoma of the canine nasal plate:17
cases(1986-1997）.VeterinaryRecord147,473-476
ofcanine mesothelioma.In the dog,it has been
Mehlaff CJ,Leifer CE,Patnaik AK and Schwarz PD（1983)Surgical
suggestedthatcisplatinmayretardtheprogression
treatmentofprimarypulmonaryneoplasia in15dogs.Journalof
283
Chapter18
Tumoursoftherespiratorysystemandthoraciccavity
theAmericanVeterinaryMedicalAssociation20,799-803
Theon AP.Peaston AE,Madewell BR and Dungworth DL（1994)
MellanbyRJ,HertageMEandDobsonJM(2002b)Long-termoutcome
Irradiationofnon-lymphoproliferativeneoplasmsofthenasalcavity
ofeightcatswithnon-lymphoproliferativenasaltumourstreatedby
megavoltageradiotherapy.JournalofFelineMedicineandSurgery
andparanasalsinusesin16cats.JournaloftheAmerican
VeterinaryMedicalAssociation204,78-83
4,77-81
Tilley LP.Band B,Patnaik AK and Liu SK（1981)Cardiovascular
MellanbyRJ,StevensonRK,HerrtageME,WhiteRASandDobson JM
(2002a)Long-termoutcomeof56dogswithnasaltumourstreated
tumoursin the cat.Journalof theAmericanAnimal Hospital
withfourdosesofradiationat intervalsof7days.Veterinary
Association17,1009-1021
Record151,253-257
TurrelJM(1987)Principlesofradiation therapy.ll.Clinicalapplications.
Moore AS,Kirk C and Cardona A （1991)Intracavitary cisplatin
In:Veterinary CancerMedicine,ed.GHTheilen andBRMadewell,
chemotherapyexperienceinsixdogs.JournalofVeterinaryInternal
pp.148-156.Lea&Febiger,Philadelphia
Medicine5,227-231
WithrowSJ(2001)Tumorsof therespiratory system，In:SmallAnimal
Scott DW,YagerJAand JohnsonKM（1995)Exfoliative dermatitis in
ClinicalOncology,ed.SJWithrowandEGMacEwen,pp.354-377.
association withthymoma inthree cats.FelinePractice23,8-13
WBSaundersPhiladelphia
284
Tumours of the haemopoiet
tic
system
David M.Vail
CanineIymphoma
dogs withlymphoma(Breen andModiano,2008).
Additionalsuggestedaetiologies,albeitweakly
Thelymphomas(malignantlymphomaorlympho-
linked to thisdisease,include:
sarcoma)areadiversegroupofneoplasmsthat
haveincommontheiroriginfromlymphoreticular
Phenoxyaceticacid herbicides(e.g.
cells.Theyareoneofthemostcommonneoplasms
2,4-dichlorophenoxyaceticacid)
seeninthedogandusuallyariseinlymphoid
Exposuretostrongmagneticfields(observedin
tissues such as lymph nodes,spleen and bone
apreliminaryepidemiologicalstudy(Reifetal.,
marrow.However,theymayariseinalmostany
1995))
tissueinthebody,including non-lymphoidsites.The
Impairedimmunefunctionandimmunesystem
annualincidencehasbeenestimatedtorange
alterationssuchasimmune-mediated
between13and24per100,000dogsatrisk
thrombocytopenia
(Backgren,1965;Kaiser,1981),but,as in people，
Living inindustrial areas
thisrateisincreasingannuallyandtheseolderdata
Atopy and cutaneous lymphoma.
likelygreatlyunderestimate the true incidence.A
morerecentstudyfromtheUKshowedaninci-
Classification
dencerateof114per100,000dogsperyear
Lymphomaindogscanbeclassifiedonthebasisof
(Dobson et al.,2002).Middle-aged to olderdogs
anatomicallocationorbyhistological,cytological
(medianage6-9years)areprimarilyaffectedand
andimmunophenotypiccriteria.
genderisnotanimportantrisk factor.Breeds
reported tohaveahigherincidenceincludeBoxer,
Anatomical classification
BullMastiff，Basset Hound,St Bernard,Scottish
Therelativefrequencyofanatomicalsitesand
Terrier,AiredaleTerrierandBulldog,butlymphoma
clinicalcharacteristicsareshowninFigure19.1.The
can occurinanybreed.
mostcommonanatomicalformsoflymphomain
dogs include themulticentric(approximately 80%)
Aetiology
(Figure 19.2),cranial mediastinal (Figure 19.3),
Theaetiologyof caninelymphoma is likelymulti-
cutaneous（Figure 19.4)andgastrointestinal forms.
factorial.Retrovirusinvolvementhasbeensuggested
Primaryextranodal forms,suchasthose occurring in
buthasnotbeenconfirmedindogs.Severalcyto-
the eye,central nervous system,bone,testis and
geneticabnormalitieshavebeencharacterizedin
nasal cavity,arelesscommonlyobserved.
Anatomical
Approximate
Clinical signs
Site-specific diagnostics
Differential diagnosis
location
frequencyof
cases
Multicentric
80%
Painless lymphadenopathy.PU/PDif
Biopsy of affected node:
Disseminated nfctions（e.g.bacterialviral,
(nodal)
accompanyinghypercalcaemia.
FNAor surgical.Staging
ricketsialrasiti,fungalmu
Non-speificsgs（lthargyw
(see text)
mediated disorders(e.g.dermatopathies,
loss,anorexia)maybepresentin
vasculiilyathritu
approximately20%of cases.±Splenic
Tumoursmetastatic to nodes.
and hepaticenlargement
Other haemopoietictumours:(e.g.
leukamiamuilmomaalina
systemichistiocytosis)
Alimentary
7%
Non-specific signsrelated to the Gl
Abdominal imaging
Several primary and secondary enteritides.
tract
tract（viingdiaroeaweigss)
(radiography,
Infitrative enteritis(lymphocyticand
Abdominal masspossibly palpable.
ultrasonography).Biopsy:
plasmacyticenteritis).OtherGl tumours
Thickenedintestinaloopspossibly
ultrasound-guided FNA;
palpable
endoscopic;surgical
full-thickness.Staging
(see text)
19.1
Characteristicsof caninelymphomainvariousanatomical locations.(continues)
285
Chapter19aTumoursof thehaemopoieticsystem
Anatomical
Approximate
Clinical signs
Site-specific diagnostics
Differential diagnosis
location
frequencyof
cases
Cutaneous
6%
Usuallygeneralized butcanbe
Biopsy:multiple dermal
Infectious dermatitis（e.g.advanced
solitary.Non-specific skin changes.
punch.Staging （see text)
pyoderma).Immune-mediateddermatitis
Mayhaveaprogressionfromscaly
(e.g.pemphigus).Othercutaneous
alopeciatothickenederythematous
neoplasms
ulcerative form,toplaque-likelesions
（seeFigure19.4）.Approximately half
arepruritic
Mediastinal
3%
Dyspnoea/tachypnoea dueto
Thoracic radiography.
Othertumours:thymoma,chemodectoma,
space-occupyingmass orpleural
Biopsy:ultrasound or
ultimobranchialcystectopicthyroid
effusion.Precaval syndrome（pitting
CT-guidedFNA or surgical
carcinoma,pleuralcarcinomatoss
oedema of head,neckand forelimbs)
(if not generalized
pulmonary lymphomatoid granulomatosis.
PU/PD secondary to hypercalcaemia
disease).Analysis of
Infectiousdiseasegranulomatousdisease,
pleuralfluid if present.
pyothorax.Miscellaneous:congestiveheart
Staging(see text)
failure,chylothorax,haemothorax
Extranodal
3%
Site-dependent.IncludesCNS,bone,
Imaging of affected site.
Variabledpendingonorgan/systm
heartaavitycuarand
Biopsy:tissueorfluid from
involved
affected site.Staging（see
(x))
19.1
(continued)Characteristicsofcaninelymphoma in various anatomical locations.
(a)
(b)
19.4
Cutaneouslymphoma.(a)Earlylesionwith
scalyalopeciainaGoldenRetriever.
(b)Progressive latelesioninaBulldog showingnodular
disease.
19.2
Generalized non-painful lymphadenopathyis
Histological/immunophenotypical classification
thetypicalpresentationforlymphomaindogs.
Lymphomasarisefromaclonalexpansionoflym-
phoidcellswithdistinctivemorphologicaland
immunophenotypicalfeatures.Manyhistologicalsys-
19.3
temshavebeenusedtoclassifynon-Hodgkin's
Ventrodorsalthoracic
lymphomainhumanpatientsandsomeof thesesys-
radiographofadog
temshavebeenappliedtolymphomainthedog
withcranial
(e.g.WHO,REAL，Kiel,NCI-Working Formulation).
mediastinal
lymphoma.
ThenewestWorldHealthOrganization(WHO)sys-
tem(Valliet al.,2002)is the mostuptodate for
canine tumours.In these systems,tumours are
categorizedaslow,intermediateorhighgrade.The
low-gradelymphomas,composedofsmallcellswith
lowmitoticrate,typicallyprogressslowly;whilethey
arelesschemoresponsivet
thanhigher-grade
tumours,they are associatedwithlong survival
times.Incontrast,intermediate-andhigh-gradelym-
phomaswithahighmitoticrateprogressrapidlybut
aremorelikelytorespondtochemotherapy.
Lymphomacanfurtherbeclassifiedasbeingof
B-cell,T-cellornullcell(neitherBorT) lineage and
this subclassificationisprognosticallyimportant.In
general,most caninelymphoma isofthe B-cell
immunophenotype，withapproximately25-30%
286
Chapter19aTumoursofthehaemopoieticsystem
being of T-cell derivation(Modianoet al.,2005).
orbiopsyisindicatedforcompletestagingandin
Furthermore,T-cell lymphomas tend tobeassoci-
dogswithanaemia,lymphocytosis,peripheral lym-
atedwithhypercalcaemiaandcranialmediastinal
phocyteatypiaorotherperipheralcytopenias.While
involvement.Cutaneouslymphomasaremostlyof
cytologicalassessmentofafine-needleaspirate
T-celloriginandaretermedmycosisfungoidesif
(Figure 19.5)by a trained clinicalpathologist is suc-
theyareepitheliotrophic.Thedevelopmentofmono-
cessfulinmakingadefinitivediagnosisof lymphoma
clonalantibodiestodetectspecificmarkers
on
inmostcases,lymphnodebiopsyispreferred forhis-
caninelymphocyteshasmadeimmunophenotyping
tologicalclassificationand immunophenotyping.Care
oftumoursindogsavailableinmanycommercial
shouldbetakentoavoidlymphnodesfromreactive
laboratories.
areas,suchas the mandibularlymphnodes;the
An updated morphological classification,com-
prescapularorpopliteallymphnodesarepreferable
binedwithimmunohistochemistry,hasbeenshownto
samplingsitesifalsoinvolvedinthediseaseprocess.
provideaclinicallyrelevantclassification,identifying
Ifpossible,the diagnosis should bemade by
sixsubsetsofcaninelymphomathatcorrelatenot
samplingperipheralnodes,avoidingpercutaneous
onlywithclinicalpresentationbutalsowithresponse
biopsyof liverand/orspleen.However,if there isno
totreatmentandprognosis.MostB-celltumourswere
peripheralnodeinvolvement,itisappropriatetotake
classified as centroblastic and polymorphic,but of
biopsysamplesofaffectedtissuesintheabdominal
notewasasmallsubsetofBurkitt-type'lymphomas
cavity.Figure 19.1gives further diagnosticproce-
whichcarriedaverypoorprognosis.Thetwomain
duresthatarespecifictotheanatomicalsiteinvolved.
typesofT-celllymphomawerepleomorphicmixed
and lymphoblastic,both of which were diffuse,but
alsoofnotewasasmallgroupofsmallclear-cell
Tlymphomas,showingaT-zonepatternandwiththe
longestsurvival timeofall(Ponce et al.,2004).This
classificationsystemisbasedonarelativelysmall
numberofcases(n=54)andwillrequirelargernum-
berstoconfirm itsrelevance.
Presentationandclinicalsigns
Clinical signs arevariable and dependon the extent
and locationof the tumour(seeFigure 19.1),but the
typicalpresentationisthatofgeneralizedlymph-
adenopathyasshown inFigure19.2.Lesscommon
presentationsincludecasesconfinedsolelyto the
spleen,orspleenandliver.
Caninelymphomamayalsobeassociatedwith
paraneoplasticsyndromes,themostclinicallysignifi-
cantbeinghypercalcaemia.Approximately15%ofall
dogswithlymphomaandnearly50%ofdogswith
mediastinalinvolvementand/orT-cell immunopheno-
19.5
Fine-needleaspiratefromaperipheral lymph
types present withhypercalcaemia,characterized
node of a dogwithhigh-gradelymphoma.The
clinicallybyanorexia,weightloss,muscleweakness,
normal nodalcellshavebeenreplacedbyamonotonous
populationof immaturelymphoid cells.(Wright's-Giemsa
lethargy,polyuria,polydipsia and,rarely,central
stain;original magnificationX1000)
nervous systemdepressionandcoma.Hyper-
calcaemiaisusuallyrelatedtotheproductionofa
hormone-like
substance,
parathyroidhormone-
Staging
relatedpeptide(PTH-rP),which isproduced by the
Afteradiagnosishasbeenestablished,theextentof
neoplasticcells;itismost commonlyassociatedwith
diseaseshouldbedetermined.AWHOstagingsys-
T-cell lymphoma（Rosoletal.,1992).Otherparaneo-
temisroutinelyusedtostagedogswithlymphoma
plasticsyndromesthatmaybeencountered include
(Figure 19.6).Most dogs(>80%)arepresented in
monoclonal gammopathies,neuropathiesand can-
advanced stages(lll-IV).
cer cachexia (see Chapter 4).Lymphocytosis is
BonemarrowFNAorbiopsyisimportant inclini-
uncommon andoccurs in approximately20%of
calstagingofthepatientwithlymphoma,asitmay
affecteddogs.Thrombocytopeniamaybeseen in
provide
diagnostic
and
prognosticinformation.
30-50%of cases,but spontaneousbleeding is sel-
Thoracicandabdominalradiographsmaybeimpor-
domaclinicalproblem.
tantindeterminingtheextentofinternalinvolvement.
Diagnostic ultrasonography,including ultrasound-
Clinicalapproach
guidedFNAorneedlebiopsy,canbeuseful foreval-
For all dogs suspected ofhavinglymphoma,irre-
uationofinvolvementoftheliver,spleenor
spectiveof theanatomicalsite,thediagnosticevalua-
mesentericlymph nodes.However,if the client is
tionshouldincludeacompletebloodcount(CBCwith
intentonhaving theirdogtreatedirrespectiveof
a differentialcellcount),plateletcount anda serum
stageorprognosis,someorallofthestagingtests
biochemistryprofile(includingserumtotalorionized
maynotbeessentialand treatmentcanbeinitiated
calcium).Bone marrow fine-needleaspiration(FNA)
onceconfirmationofdiagnosisisestablished.
287
Chapter19a
Tumoursof thehaemopoieticsystem
Stage
Criteria
90%indogs treatedwithmulti-agentchemothera-
peuticapproaches.Importantly,clientperceptionof
Single lymph node
a.Without clinicalsignsof disease
generallypositiveandthevastmajorityofclientsfeel
b.With clinical signs of disease
thattreatmentisworthwhileandresultsinimprove-
Multiple lymph nodes inaregional area
a.Without clinical signsof disease
qualityof life（Brondenetal.,2003;Mellanbyet al.,
b.With clinical signs of disease
2003).Unfortunately,most animals eventually suc-
Generalized lymphadenopathy
cumbtorelapseofchemotherapy-resistant,dissemi-
a.Without clinical signsof disease
nated disease.Lymphoma,typicallya systemic
b.With clinical signs of disease
disease,requiresasystemicapproachto therapy
IV
Liverand/orspleeninvolvement(withorwithout stage Ill)
(i.e.chemotherapy).Exceptionstothisincludecases
a.Withoutclinical signsof disease
ofsolitarynodalorsolitaryextranodallymphoma
b.With clinical signsof disease
wherelocal therapy(surgeryorradiation therapy)
Bonemarroworblood involvement and/oranynon-
maybeinitiallyindicated.Intheselattercases,due
V
lymphoid organ(with or without stages I-IV)
diligencetothepossibilityofsystemicspread inthe
a.Without clinical signs of disease
futureisessentialandsystemicchemotherapymay
b.With clinical signs of disease
eventuallyberequired.
WHOclinicalstagingfordomesticanimalswith
19.6
Systemicchemotherapy
lymphoma.
Avarietyofchemotherapeuticprotocolshavebeen
reportedintheveterinaryliterature.Thisprobably
Advanced diagnostictechniques
reflectstheinabilitytoachieveacureinthemajority
Inuncommoncircumstances,routinecytologicaland
ofcases.Whileremissionratesapproach80-90%
histological assessmentsoftissuesorcellularfluids
withavailablecombinationchemotherapyprotocols
areinadequatetoconfirmadiagnosisoflymphoma.
andthequalityoflifeofpatientsisgenerallyvery
When suspicious solid tissues,circulatinglympho-
good during theperiodofremission,themajorityof
cytesandeffusivesamplesincludeamixedcellpop-
dogswilleventuallysuccumbtorelapseoftheir
ulationordonotentirelydiscriminatemalignantfrom
diseaseandofteninamoredrug-resistantform.
benign reactive proliferations,immunophenotypic
Prior to initiating therapy,caregivers should be
characterizationsbyflow cytometricmethods(Lana
informedabouttheadvantagesanddisadvantages
ofseveralchemotherapyoptionsaswellasoverall
prognosisandexpectations.Several factors should
markofmalignancy:themalignantcellpopulation
beconsideredanddiscussed,includingthecostof
theoreticallyshouldbederivedfromexpansionofa
treatment,the timecommitmentrequired,efficacy,
singlemalignantclonecharacterizedbyaparticular
toxicityandtheexperienceoftheclinicianwiththe
DNAregion unique to that tumour.Forexample,ina
protocols in question.
dogwithT-cell lymphoma all themalignantcells
Theavailabilityofgenericdrugshasallowed
shouldcontainthesameDNAsequenceforthevari-
chemotherapyprotocolstobecomeaffordabletomore
ableregionof theT-cellreceptorgene;likewise,ina
clients thanbefore.Ingeneral,combination chemo-
dogwithB-cell lymphoma the malignant lympho-
therapyprotocolsrepresentagreaterexpense,are
cytesshouldhaveidenticalDNAsequencesinthe
moretime-consuming（repeatedvisits,closermonitor-
variableregionoftheimmunoglobulinreceptorgene.
ing)andaremorelikely toresultintoxicity thansim-
Conversely，inbenignreactivelymphocytosisthe
pler single-agent protocols.That being said,as a
cellsarepolyclonalfortheirantigenreceptors.
generalrule,themorecomplexcombinationprotocols
Currently,polymerase chainreaction(PCR)technol-
willresultinlongerremissionandsurvivaldurations.
ogy canbeused toamplify thevariableregionsof
Acompletelistingofallavailableprotocolsfor
theT-celland immunoglobulinreceptorgenesto
dogswithlymphomaisbeyondthescopeof this
detectthepresenceofclonallymphocytepopula-
discussionandthereaderisreferredtoarecent
tionsindogs.Suchassaysofclonalityareapproxi-
review(VailandYoung,2007).Anexampleofthe
mately70-90%sensitive.False-negativeratesof
combinationprotocolusedbytheauthor,aprotocol
approximately5%canoccur.In thesecases,adiag-
commonlyused inEurope,and themostwidelyused
nosisshouldbemadeonlyafter considering the
single-agentprotocolsarepresentedbelow.
resultsofalldiagnosticevaluations,includinghisto-
logical/cytologicalevaluation,immunophenotypingand
Combinationprotocols:Nearlyallcombinationpro-
clonalitystudiesinconjunctionwiththesignalment
tocolsused inveterinarypracticearemodificationsof
andphysical findings.
CHOP'protocolsinitiallydesignedfortreatinghuman
lymphoma.CHOPrepresentscombinationsofcyclo-
Managementandprognosis
phosphamide,doxorubicin (H,hydroxydaunarubicin),
Onceadiagnosisisestablished,untreateddogswill
vincristine（O,Oncovin)andprednisone orpredniso-
generallyliveanaverageof4-6weeks,butseveral
lone(P).Regardlessofwhich CHOP-based protocol
exceptions to this exist, including dogs with low-
isused,responseratesof80-90%canbeexpected
gradetumours.Initiallythemanagementof lymph-
withoverallmedianremissionandsurvivaltimesof
omaisquitegratifying,asresponseratesapproach
approximately8and12months,respectively.
288
Chapter19aTumoursof thehaemopoieticsystem
Approximately25%oftreateddogswillbealive2
shorterprotocolswithoutlong-termmaintenanceare
yearsormoreafterinitiationoftherapy.Response
thenorm(VailandYoung,2007;Simonetal.,2008).
ratesandlengthofresponsecanbemoreindividually
TheauthorcurrentlyprefersamodifiedCHOP
predictedbasedonthepresenceorabsenceofprog-
protocol,asoutlinedinFigure 19.8(UW-Madison-
nosticfactorspresented inFigure19.7.
Short).Chemotherapyis discontinued at 19weeks if
Historically,followinganinductionperiodduring
thedogisincompleteremissionatthattime.After
whichdrugsaregivenweekly,treatmentintervalsare
therapy isdiscontinued,dogs arere-evaluated
slowlyspreadoutanddrugsaregivenlessfrequently
monthlybyphysicalexamination,withspecialatten-
inwhatistermedthemaintenance'phaseofthe
tionbeingpaidtolymphnodesizeor,inthosecases
protocol.Currently,theuse of maintenance chemo-
notinvolvingperipheralnodal disease,attentionto
therapyisnolongerthoughttobebeneficialand
theoriginalanatomicalsiteinvolved.
Factor
Strengthof
Comments
Treatmentweek
Drugs,dosage,route
association
with
1
Vincristine:0.5-0.7mg/m²i.v
prognosis
Prednisone:2mg/kg orally
WHO clinicalstage
Modest
Stagel/l-favourable
Cyclophosphamide:250mg/m²i.v.
StageVwithsignificantbone
Furosemide:1mg/kg i.v.a
marrowinvolvement-
Prednisone:1.5mg/kgorally
unfavourable
WHO clinical
Strong
Substage b (clinicallyil)-
Vincristine:0.5-0.7mg/m²i.v
substage
associated withdecreased
Prednisone:1mg/kg orally
survival
4
Doxorubicin:30mg/m²i.v.
Histopathology
Moderate
High/medium-grade-
Prednisone:0.5mg/kgorally
associated with high
responseratebutreduced
5
Notreatment
survival
Low-grade tumours
6
Vincristine:0.5-0.7mg/m²i.v.
associated withlower
responsetochemotherapy
Cyclophosphamide:250mg/m²i.v
but longer-term survival
Furosemide:1mg/kgi.v.
Immunophenotype
Strong
T-cell phenotypeusually
8
Vincristine:0.5-0.7mg/m²i.v.
associatedwithreduced
survival
96
Doxorubicin:30mg/m²i.v.
Hypercalcaemia
Moderate
Negative factorif associated
10
No treatment
withT-cellsubtype and
reduced renalfunction
11
Vincristine:0.5-0.7mg/m²i.v.
Measuresof
Weak
Contradictoryreportsexist
12
Cyclophosphamide:250mg/m²i.v.
proliferation
Furosemide:1mg/kgi.v.
Prolonged steroid
Moderate
Most reports suggest
pre-treatment
previous steroid use
13
Vincristine:0.5-0.7mg/m²i.v.
shortensresponse durations,
14
Doxorubicin:30mg/m²i.v.
but length of exposure
necessary isunknown
15
No treatment
Presence of
Moderate
Dogs with anaemiaareless
anaemia
likely torespond and
16
Vincristine:0.5-0.7mg/m²i.v.
durationof responseisshort
17
Cyclophosphamide:250mg/m²i.v.
Molecularlevel
Investigations
Examples includeP
Furosemide:1mg/kgi.v.
alterations
continue
glycoproteinexpression,
serumVEGFexpression,
18
Vincristine:0.5-0.7mg/m²i.v.
survivinexression,lama
DNA,circulatingglutathne
19°
Doxorubicin:30mg/m²i.v.
S-transfraseciclan
thymidine kinase
19.8
Universityof Wisconsin-Madison-Short
combinationchemotherapyprotocol fordogs
Cranial
Moderate
Large compilationof cases
with lymphoma.aFurosemideisgivenconcurrentlywith
mediastinal
reports shorterremission
cyclophosphamidetodecreasetheincidenceofsterile
lymphadenopathy
andsurvival durations
haemorrhagiccystitis.lf thepatient isincomplete
Moderate
Diffuse cutaneous and
remissionatweek9,treatmentcontinuestoweek11.f
Anatomical
alimentary,and
thepatient isincompleteremissionatweek19,therapyis
location
discontinued andthedogisrecheckedmonthlyfor
hepatosplenic forms
associated withunfavourable
recurrence.Note:ACBCshouldbeperformed before
eachchemotherapytreatment.If theneutrophil countis
prognosis
<1500cells/ul,theclinicianshouldwait5-7daysandthen
19.7
Factorsknownorsuspectedtoaffectthe
repeat theCBC;the drug is administered if the neutrophil
prognosis indogswith lymphoma.
counthasrisenabove the1500cells/ulcutoff.
289
Chapter19a
Tumoursofthehaemopoieticsystem
Alternativesshouldbeofferedtocaregiverswho
fordogswithlymphoma.Itislessexpensiveand
declinemoreaggressivesystemicchemotherapy.
time-consuming than CHOPorCOPprotocols,and
Theseincludemodificationoftheoriginal COPproto-
ispreferredbytheauthoroverCOPwhenclients
cols,outlined inFigure 19.9,aswellas single-agent
decline fullCHOP-based protocols.Doxorubicin(30
doxorubicin(seebelow).Theseless aggressive pro-
mg/m²,i.v.)isgivenevery3weeksfora totalof five
tocolsgenerallydonotresultinsuchhighresponse
treatments.Thisprotocol results inresponserates of
rates orasdurableremissionlengths as CHOP-
approximately70%andmedianremissionandsur-
based protocols.
vivaltimesof5and7months,respectively.
Advantagesofthisprotocolincludeashortertime
commitment,fewerhospitalvisits,andsideeffects
Protocol
Frequencyof drug delivery
that areonly attributabletoonedrug.
COPhigh dose for dogs
Ifasituationariseswhereclientsoptforonlyoral
medications,thenlomustine（CCNU;70mg/m²orally
Cyclophosphamide
Give onceevery3weeksfor1year.lf
every3weeks)andprednisonetherapycanbe
(250-300mg/m²i.v.or
dogisincompleteremissionat1year,
used,thoughresponse rates and durations are
orally)
decreasetoonceevery4weeksfor6
additionalmonths.Discontinueifanimal
isincompleteremissionat1.5years
doxorubicin(Sauerbrey et al.,2007).
Incaseswhere clientsdecline‘chemotherapy”，
Vincristine
Giveonceaweekfor4doses,thenonce
prednisone/prednisolonealone(2mg/kgorallyevery
(0.75mg/m²i.v.)
every3weeksforayearonthesame
day)willresultinashortremissionofapproximately
dayascyclophosphamide.lf dog isin
1-2months.It isimportant toeducateclients that
completeremissionat1yeardecrease
toonceevery4weeksfor6additional
dogsreceivingsuchtherapyaremorelikelyto
months.Discontinueifanimal isin
developmultipledrugresistanceovertimeand
completeremissionat1.5years
experienceshorterremissionandsurvivaldurations
withcombinationprotocols,shouldmoreaggressive
Prednisone/prednisolone
Givedailyfor22daysthnverytr
(1mg/kg orally)
therapybepursuedatalaterdate.Theearlier that
dayfor1.5years.iscontinuebygradual
tapering over3weeksif animal isin
clientsoptformore aggressivetherapy,themore
completeremission at1.5years
likely is a longer-lastingresponse.
COPlow dose fordogs
Re-induction orrescue therapy:Most dogs expe-
Cyclophosphamide
Giveq48horforthefirst4daysofeach
riencearelapseof theirdiseasefollowing initially
(50mg/m²orally)
week
successful chemotherapy;therecurrentdiseaseis
typicallymoreresistanttotreatmentwithchemo-
Vincristine
Giveq7d
therapeuticagents thanoninitialpresentation.At
(0.5mg/m²i.v.)
thefirstrecurrence,if thepatientisamonthormore
Prednisone/prednisolone
Giveat40mg/m²orallyq24hfor7days
outfromdiscontinuationofinitialinductiontherapy,it
then at 20mg/m²orallyq48h
isrecommendedthatre-inductionbeattemptedby
Maintenance
restartingtheinductionprotocolthatwasinitially
After8weeksofinductioncontinu
COPalternate-week treatment for4
successful.In this scenario,thelikelihoodofa sec-
months,then1weekin3for6months,
ondremission is stillhigh(80-90%);however, the
and reduce to1week in4after1year
lengthofthesecondremissionistypicallyhalfthat
ofthe initial remission,thougha subsetofanimals
COPforcats
willenjoylong-termre-induction.
Cyclophosphamide
Give every3weeksonthedayafter
Ifre-inductionfails(orif theinitialinductionwas
(300mg/m²i.v.)
vincristine.Discontinueifanimalisin
not successful),the use of‘rescue'agentsorproto-
completeremissionat1year
colsmaybeattempted.Rescueagentsaredrugsor
Vincristine
drugcombinationsthatarenotfound instandard
Give q7donweeks1，2,3and4,then
CHOPprotocols and are specifically used in cases
(0.75mg/m²i.v.)
every3weeksthereafterontheday
before cyclophosphamide.Discontinueif
ofdrugresistance.Variousrescueprotocolshave
animalisincompleteremissionat1year
been described (Vail and Young,2007).These
includesingle-agentorcombinationuseoflomus-
Prednisone/prednisolone
Giveq24hfor1year
tine （CCNU),dactinomycin,mitoxantrone，doxo-
(50mg/m²orally)
rubicin（(ifdoxorubicinwasnotpartoftheoriginal
COPprotocolsforlymphomaindogsandcats.
19.9
inductionprotocol),dacarbazine,vinblastine,procar-
aForhigh-doseprotocols,a CBCshould be
bazine andmethclorethamine.The author'spre-
performedpriortoeachcyclophosphamidetreatment.If
ferredfirst-linerescueprotocolisacombinationof
theneutrophilcount is<1500cells/ul,theclinicianshould
lomustine (70 mg/m² orally)and crisantaspase
wait5-7daysandthenrepeattheCBC.Treatmentis
givenif neutrophilsare≥1.5x10/1.Forlow-dose
(L-asparginase)（10,000 units/m² s.c.),given at
continuousprotocols,aCBCshouldbeperformedevery
3-weekintervals.Overallrescueresponseratesof
2-4 weeks,depending on the neutrophil count.
70-80%are expected,but most responses are not
durable,withmediandurations of 1.5-3months.
Doxorubicinsingle-agentprotocol:Doxorubicin
Contactwithanoncologyspecialistshouldberou-
therapyrepresentsthemosteffectiveandcommonly
tineinthesesituations,asnovelandinvestigational
used single-agent chemotherapyprotocol available
protocolsareoftenavailable.
290
Chapter19aTumoursofthehaemopoieticsystem
Treatmentofextranodallymphoma
20yearshavegreatlyimprovedthemanagementof
Ifextranodal involvementispartofamulticentricdis-
this disease.However,newerdrugs，drug delivery
easeprocess,systemictherapiespreviouslydiscus-
sedshouldbeinstituted.However,if theextranodal
neededtocontinuetheseadvances.
siteissolitaryandnotpartofamulticentricpresent-
ation,localtherapymaybeperformedwithout
Thefutureofcaninelymphomatherapy
institutionofchemotherapy.Inthese cases,strict
Basedonthesimilarityofresultsreportedwiththe
adherence to staging diagnostics,including bone
manyvariedcombinationchemotherapyprotocols
currentlyinuse,itappearsthattheveterinaryprofes-
marrowevaluationandradiographicorultrasound
imagingofthethoraxandabdomen,arewarranted
sionhasgoneasfaraspossibleusingavailable
toensurethattheprocessislocalized.Ifthedisease
chemotherapeuticagentsforlymphoma.Allcombina-
isconfinedtoasinglesite,localsurgery and/orradi-
tionprotocolsreportedtodatearehittingthesame
ationtherapyisofteneffective.Clients shouldbe
brickwall:a 10-12-monthmediansurvival time.
forewarnedthat,inthesecases,systemicdiseaseis
Advancesinremissionandsurvivaldurationsawait
likelytooccurmonthstoyearslaterandaregular
thedevelopmentofnewchemotherapeuticdrugs,
recheck schedule shouldbeinstituted.Itis the
novel targetedtherapiessuchastyrosinekinase
author'sopinionthat systemic therapyshouldbe
inhibitors,andaffordableandpracticalmarrowor
withhelduntil systemicdiseaseisdocumented.
stemcell transplant therapies.Inhuman medicine,
thepast10yearshaveheraldedanewstandardof
Treatmentofcutaneouslymphoma
careforB-celllymphomawiththeadventofrituxi-
Cutaneouslymphomacanbesolitaryorgeneralized
mab,acommerciallyavailablemonoclonalantibody
(seeFigure 19.4).Generalized cutaneousepithelio-
thatrecognizesaB-lymphocyteextracytoplasmicsur-
trophiclymphomacanhaveawaxingandwaning
faceantigen(CD20),thatisnowused incombination
courseandisoftennotaschemoresponsiveasis
withstandardchemotherapy.Thisparticularantibody
multicentriclymphoma.Solitarylesionscanbedealt
doesnotrecognizeanexternalantigenoncanine
withby local therapy(seeabove)，but generalized
lymphomacellsand thereforeisineffectiveforther-
casesrequiresystemictherapy.Thecurrentstandard
apy.Theveterinaryprofession awaits the characteri-
ofcareforgeneralizedcutaneouslymphomaisoral
zationanddevelopmentofeffectivemonoclonal
lomustine（70mg/m²orallyq3wk)withorwithout
antibodytherapiesforuseindogsandcats.
prednisoneorprednisolone.Approximately70%of
caseswillrespond,butremissionlengthsofonlya
Felinelymphoma
fewmonths are expected（Risbon etal,2006;
Williamset al.,2006).If thisprotocolisineffective,
Lymphomaaccountsforthemajorityofhaemopoietic
CHOP-basedprotocols canbeattempted.Other
tumoursincats.Asinhumans anddogs,the annual
chemotherapeuticswithreportedactivityagainst
incidenceoflymphomainthespeciesappearstobe
cutaneouslymphomaincludecis-retinoicacidther-
increasinginNorthAmerica,primarilyduetoa rise
apy（Accutane,1-3mg/kg orallyq12h),Doxil（a
inthealimentaryforminoldercats(Louwerenset
liposomeencapsulatedformofdoxorubicin),crisan-
al.,2005).Since theimplementationof felineleukae-
taspaseanddacarbazine.
miavirus(FeLV)containmentandvaccinationproto-
cols,there has been a profound change in the
Prognosis
presentation,signalmentand frequencyofanatomi-
Theprognosisfor dogswith lymphoma isvariable
cal sites in cats.Ingeneral,catsare at risk for a
anddependsonanumberof factors(seeFigure
widerrangeofanatomicalandhistologicalformsof
19.7).The twofactors thatcurrentlyaremostcon-
lymphomathanaredogsand,withtheexceptionof
sistently identified ashaving significantprognostic
low-gradesmallcellvarieties（whicharecommon,
importanceareimmunophenotypeandWHOsub-
particularly in the alimentary form),tend not to
stage.Manyreportshaveconfirmedthatdogswith
respondaswell totreatment.Thatbeingsaid,most
T-cellderivedtumoursareassociatedwithsignifi-
catownerswhoelecttopursuechemotherapyin
cantlyshorterremissionandsurvival durations,butit
theirpetsreportapositiveexperience(Brondenet
isbecomingapparentthattherearesubsetsofB-
al,2003;Tzannes et al.,2008).
andT-celltumours thatdifferintheirresponseto
chemotherapy.DogspresentingwithWHOsubstage
Aetiology
bdisease (i.e.clinicallyill)also tend to dopoorly
Thefelineleukaemiaviruswasthemostcommon
whencomparedwithdogswithsubstageadisease.
causeofhaemopoietictumoursincatspriortowide-
DogswithstageIandstagelldiseasealsohavea
spreaduseofFeLVvaccines.However,only25%or
betterprognosisthanthosedogsinmoreadvanced
lessofcasesareassociatedwithFeLVantigen-
stages (llI, IVand V).
aemia (Vailet al.,1998;Louwerens et al.,2005),
Treatingcaninelymphomacaninitiallybeavery
comparedwith60-70%ofcasespublishedpriorto
rewardingexperienceforthedog,owner
and
vaccineavailability.Otheraetiologiesthathavebeen
veterinarysurgeon.Inmostdogswithlymphoma,
suggested for feline lymphoma include gastric
CHOP-basedchemotherapycaninducean80-90%
Helicobacterinfection(Bridgeford etal.,2008)and
clinicalremissionrateandamediansurvivaltimeof
dietforfelinegastriclymphoma,andenvironmental
approximately 12months,with 25%of patients
tobacco smoke('second-hand”smoke)(Bertone et
survivingfor2years.Theadvancesmadeinthepast
al.,2002).
291
Chapter19aTumoursofthehaemopoieticsystem
Aswouldbepredicted,alongwithashiftaway
Classification
fromFeLVantigen-associatedtumourscameashift
Theclassificationoffelinelymphomainvolvesboth
awayfromtraditionalsignalmentsandtherelative
theanatomicallocation(Figure 19.10)and histo-
frequency of various anatomical sites(Figure 19.10).
logicalandimmunophenotypiccriteria.Themorpho-
Themediastinal form thatoccurs inyounger,FeLV-
logicalcriterionoftheNiHworkingformulationhas
antigenaemiccatsusedtobethemostcommon
beenusedtoclassifymorethan600casesoflym-
anatomicalpresentation,butthealimentaryformin
phoma in cats in NorthAmerica(Valliet al.,2000).
older,FeLV-negativecatshasnowbecomethemost
Low-gradelymphomawasfound in8.6%,intermedi-
commonpresentation.Thereisevidencethatfeline
ate in35.1%andhigh-grade in55.2%of the cases.
immunodeficiencyvirus(Fiv)infectioncanincrease
Ina largegroupcompiled inAustralia,90%ofcases
theincidenceof lymphomaincats,thoughitappears
wereofmediumtohighgradewhenclassifiedina
tohaveanindirectroleintumorigenesis.
similar way (Gabor et al.,1999).More recently,
Anatomical
Relative
Age
Clinical signs
Site-specific
Differential
Immunophenotype
FeLV
site
frequency
class
diagnostictests
diagnosis
status
Alimentary
50-70%
Late
Abdominal massor
Abdominal
Inflammatorybowel
High-grade intestial
Usually
tract
middle
thickened bowel
radiography,
disease.Feline
lymphomaseither
negative
ageto
loops.Weight loss,
ultrasonography.
infectiousperitonitis
T-orB-cell in the
aged
anorexia,vomiting.
Massormesenteric
(FIP).Other
literature.Small-cell
Abdominal
lymph nodeFNA.
intestinal tumours.
low-grade intestinal
distension.
Biopsy:endoscopic
Primaryand
formsare more
Haematochezia.
or fullthickness
secondary enteritis.
likely to beT-cell
Sepsisif bowel is
(intestine)
Hyperthyroidism
perforated
Multicentric
20-30%
Depends
Peripherallymph
Lymphnode
Reactive or
T-cellif FeLV-
About
(nodal)
on
node enlargement.
excisionpreferred
hyperplasticnode
associated.B-cell
one-
FeLV
Often liveror spleen
syndromes.
morelikelyif
thirdare
status
involved(except
Systemic infection.
FeLV-negative.T-cell
positive
Hodgkin's-like).
FIV infection.
rich,B-cellif
Lethargy and
Hodgkin's variant
Hodgkin's-like
depression(except
Hodgkin's-like)
Mediastinal
10-20%
Young
Dyspnoea,
Thoracic
Thymoma.
Generally T-cell
Usually
tachypnoea.
radiographs/CT.
Chylothorax.
positive
Non-compressible
Thoracocentesis
Cardiomyopathy.
thorax.Dullheart
and pleuralfluid
Pyothorax.FIP.
andlung sounds.
analysis.FNA
Mesothelioma.
Rare Horners
cytology or needle
Diaphragmatic
syndrome
biopsyof
hernia
mediastinal mass
Nasal
5-10%
Late
Nasal discharge,
Nasal CT scan.
Rhinitis（bacterialor
Generally B-cell
Usually
middle
sneezing.Dyspnoea.
Nasal biopsyor
fungal).
negative
ageto
Epistaxis.Facial
flush
Inflammatory polyps.
aged
deformity.Epiphora.
Other tumour types.
Exophthalmos
Bleeding diathesis
Renal
5%
Middle
Lethargy,
Abdominal imaging.
Polycystic renal
UsuallyB-cell,
30-50%
aged
depression,weight
Transabdominal
disease.FIP.Acute
howeverT-cell not
loss.Bilateral renal
needle aspiration
renal failure.Other
uncommon
enlargement.
renaltumours
PU/PD.
Neurological signs
(high percentage
haveCNS
involvement)
Spineor
1-3%
Mixed
Thoracolumbar
Spinal radiography,
Trauma.Other
Equallydivided
About
central
myelopathy.
CT,MRI.CSF tap.
tumours.Feline
between B-and
50%are
nervous
Hindlimb weakness,
CT-guided or
infectious peritonitis.
T-cellineages
positive
system
ataxia.Bladder
surgical biopsy
Disc disease.
atonia.Tailflaccidity.
Mycosis.
Central signs if brain
Aorticembolism
involvement
19.10
Characteristicsof felinelymphomainthemorecommonanatomicalsites.FeLV-positivecatstend tobe
younger,and thecancerismorecommonlyofT-cellderivation.
292
Chapter 19a
Tumoursof thehaemopoieticsystem
smallcell low-gradeintestinal lymphoma incats（a
Treatmentweek
Drug,dosageroute
distinctformofalimentarylymphoma)wasreported
tomakeupapproximately13%ofallcasesoflym-
Vincristine:0.5-0.7mg/m2i.v.
phoma in cats (Kiselow et al.,2008).
Crisantaspase:400 U/kg s.c.
Prednisone:2mg/kg orally
Immunophenotypes
2
Cyclophosphamide:200mg/m²i.v.
Inmoststudies,themajorityoflymphomaincatsis
Prednisone:2mg/kg,orally
of theB-cell immunophenotype(approximately75%).
However,the mediastinal,leukaemicand small-cell
3
Vincristine:0.5-0.7mg/m²i.v.
Prednisone:1mg/kg orally
low-gradeintestinalformsaremorelikelytobeof
T-cell derivation.Controversy existsregarding the
4
Doxorubicin:25mg/m²i.v.
immunophenotypeofcatswithhigh-gradealimen-
Prednisone:1mg/kg,orally
tarytractlymphoma.Twolargecompilationsofcases
6
Vincristine:0.5-0.7mg/m²i.v.
foundthatmostarederivedfromB-lymphocytesin
gut-associated lymphoid tissue(Vail et al.,1998;
7b
Cyclophosphamide:200mg/m²i.v
Gabor et al.,1999).In conflict with this,others
8
Vincristine:0.5-0.7mg/m²i.v.
reportedthatthemajorityofalimentarycasessam-
pledwerecomposedprimarilyofTcells(Zwahlenet
gc
Doxorubicin:25mg/m²i.v.
al.,1998).Thismay represent geographical varia-
11
Vincristine:0.5-0.7mg/m²i.v
tions andwill requirefurtherinvestigations.
13
Cyclophosphamide:200mg/m²i.v
Clinicalapproach
Thediagnosticevaluationshouldincludeacomplete
15
Vincristine:0.5-0.7mg/m²i.v.
bloodcount(CBCwithdifferentialcellcount),platelet
17
Doxorubicin:25 mg/m²i.v.
count,aserumchemistryprofileanda testforFeLV
andFIV.BonemarrowFNAorbiopsyisindicated to
19
Vincristine:0.5-0.7mg/m²i.v.
assessthepossibleinvolvementandstagingofthe
21b
Cyclophosphamide:200mg/m²i.v.
extentofdisease.Bonemarrowevaluationisparticu-
larlyindicatedifanaemia,cellularatypiaorleucope-
23
Vincristine:0.5-0.7mg/m²i.v.
nia is present.Furthermore,lymph node or organ
25d
Doxorubicin:25mg/m²i.v.
biopsy,via surgical incision,endoscopy orneedle-
19.11
UniversityofWisconsin-Madisoncombination
corebiopsytoobtaintissueforhistopathological
chemotherapyprotocolforcatswithlymphoma.
evaluationisessentialfordefinitivediagnosis.
aPrednisone(1mg/kgorally)iscontinuedeveryotherday
Unlikewithitscaninecounterpart,FNAaloneofa
fromthispointon.bIfrenal orCNSlymphoma ispresent,
lymphnodeisnotgenerallysufficientinmostcases
substitutecytarabine（600mg/m²s.c.q12h over2days)at
offelinelymphoma,owingtodifficultiesencountered
these treatments.If thepatientisincompleteremission at
indistinguishinglymphomafrombenignhyperplastic
week9,continue toweek11.dlf thepatientisincomplete
lymphnodesyndromesuniquetothespecies.These
remissionatweek25,therapyisdiscontinuedandthecat
isrecheckedmonthlyforrecurrence.Note:ACBCshould
includeidiopathicperipheral lymphadenopathy,plexi-
beperformedbeforeeachchemotherapytreatment.If the
formvascularizationoflymphnodes,andperipheral
neutrophilcount is<1500cells/ul,theclinicianshouldwait
lymphnodehyperplasiaofyoung cats.In these
5-7days and thenrepeat theCBC;the drug is
cases,wholelymphnodeexcisionispreferred，asthe
administeredif theneutrophil counthasrisenabovethe
orientation,invasivenessandarchitecturalabnormali-
1500cel/μl cutoff.
tiesmaybenecessaryfordiagnosis.Additionalsite-
specificdiagnosticproceduresarenotedinFigure
Controversyexistsastotheusefulnessofdoxo-
19.10.Histochemicaland immunohistochemical tech-
rubicinfortreatinglymphoma incats.Catsareless
niquescanalsobeusedtodetermineimmunopheno-
tolerantofdoxorubicinthanaredogsandalower
type,tumourproliferationratesandclonality.
The
dose（either25mg/m²or1mg/kgi.v.)is generally
availabilityof suchanalysisisincreasing,butnone
employed.Several largestudieshaveshownthatthe
hasproved tobeconsistentlyindicativeofoutcome.
additionofdoxorubicintoCOP-basedprotocolshas
shownsuperiorresultstoCOPaloneinthecatand
Chemotherapy
theseCHOP-basedprotocolsarecurrentlyused by
Asforthe dog,most current combination protocols
the author(Mooreetal.,1996;Vailetal.,1998).Two
forintermediateorhigh-gradelymphomaincatsare
smallerstudiesusingsingle-agentdoxorubicindocu-
modificationsofCHOPprotocolsinitiallydesigned
mentedcompleteresponsesinonlyone-quarterto
forhumanoncologicaluse(seebelowforlow-grade
one-halfoftreatedcases;however,youngSiamese
lymphoma treatmentprotocols).The currentprotocol
catswithmediastinallymphomawereover-repre-
inuseattheauthor'spracticeis shown inFigure
sentedinoneofthesestudiesandwouldnotbe
19.11.Thisprotocolisgenerallywelltoleratedand
expectedtorespondwellastheyareusuallypositive
gastrointestinaltoxicityislesscommonthaninthe
forFeLV(Peastonand Maddison,1999;Kristalet al.
dog.As long-termmaintenanceprotocolshavenot
2001).Thatbeingsaid,thereisa subsetofSiamese
beenshowntobesuperiorindogsandhumanswith
catsthatdevelopFeLV-negativemediastinal lymph-
lymphoma,itislikelythatthesameistrueinthecat
oma thathaveamorefavourableprognosis(Teske,
althoughtherearecurrentlynodatatodocument this.
2002).
293
Chapter19aTumoursofthehaemopoieticsystem
AreportinEuropedocumentedresponserates
Completeresponsetotherapy(unfortunatelythis
anddurationswithaCOPcombinationthatrival
cannotbedeterminedpriortotherapy)
thosereported forCHOPinAmericanstudies
Small-celllow-gradehistologies(particularlythe
(Teskeetal.,2002).ldeally,aprospective
alimentaryforms)
randomizedhead-to-headtrialwillbenecessaryto
NegativeFeLVstatus
settle thematter.
Earlyclinical stage
Substage a(however,most cats are substageb)
Reinductionorrescuetherapy
Anatomical location
Ultimately,most cats withlymphoma successfully
Additionofdoxorubicintothetreatmentprotocol.
treatedwithchemotherapyhavearelapseoftheir
disease.Oftenthisrelapse isaccompaniedbysignif-
Unlike in the dog, the T-cell immunophenotype
icantly more drug-resistant disease.Theprinciples
hasnotbeenestablishedasanindependentnega-
discussedabovefordogsalsoapplytocats.
tiveprognosticindex in the cat.Ingeneral,FeLV-
negativecatsthatachieveacompleteresponseon
Radiationtherapy
multi-agentchemotherapyprotocolshaveahighlike-
Radiationtherapyhasbeenusedeffectivelytotreat
lihoodoflong-termsurvival,withapproximately35%
localizedlymphoma incats.Mostcatswillachievea
aliveat18monthsafterdiagnosis.
completeremissionoflocaldiseasefollowingradi-
Theanatomicalsiteof lymphomaincatsalsocan
ationandthismodalityisespeciallyusefulforthe
suggestprognosis.
treatmentofnasal lymphoma.Completeresponse
isusualandmedianremissiondurationsof1-2
Inhigh-gradealimentarylymphoma,median
yearscanbeexpectedinFeLV-negativecatswith
survivalsof7-10monthsareexpectedwith
diseaseconfinedtonasalandparanasalcavities.
chemotherapy thatincludesdoxorubicin.Cats
Thisappearstobesuperiortocatswithnasal
withsmall-cell low-gradealimentarylymphomain
tumourstreatedwithchemotherapyalone,where
generaldomuchbetter(mediansurvivalsof
reportedmedianremissiondurationsare6months
approximately2years).
toayear.lt isofcourseimportant tostagecats
Mediastinal lymphomaisassociatedwiththe
thoroughly,toensurethattheirdiseaseislocalized
poorestprognosis;survivaltimesofapproximately
beforecontemplatinglocal therapyintheabsence
3monthsareexpectedwithchemotherapy.
ofsystemictherapy.Somehaveadvocatedcombi-
Catswithnasal lymphomahavearelativelygood
nationsofbothchemotherapyandradiationtherapy
prognosis,aslocalradiationtherapyresultsin
forcatswithnasaltumours(Sfiligoietal.,2007)but
excellentcontrol,withmediansurvivals
ithasbeentheauthorsexperiencethat,ifdisease
approaching18months.
isconfined tothenasalpassage,systemictherapy
Renal lymphomaisassociatedwithshorter
canbewithhelduntil suchtimeassystemicdisease
survivaltimes,withmediansurvivaltimesranging
isdocumented.
from3to6months.
Fewstudieshavereportedontheresultsofcats
Prognosis
withspinallymphoma,butthereportsthatdo
In general,catswithlymphoma experience lower
existrevealagenerallypoorprognosis,with
responseratesandremissionandsurvivaldura-
mediansurvivalsofonlyafewmonths.
tions than dogs.Completeresponseratesvary
between50and70%followingcombinationchemo-
Hodgkin's-likelymphoma
therapyandoverallmedianremissionandsurvival
AformofHodgkin's-likelymphomahasbeenreported
durationsareapproximately4and7months,
in the cat(Day et al.,1999;Walton and Hendrick,
respectively.However,a significant proportion of
2001).Thisuncommonanddistinct formofnodal
cats(30-35%)thatachieveacompleteresponse
lymphomainvolvessolitaryorregionalnodesofthe
withcombinationchemotherapyenjoylongeroverall
headandneckandhistologicallycloselyresembles
remission and survival times (i.e.>1year).Thus
Hodgkin'slymphomainhumanpatients.Caseshave
initialresponsetotreatmentappearstobeastrong
usuallybeenfoundtobeanimmunophenotypically
prognosticindicator.Additionally,catswithlow-
heterogenousT-cellrich,B-cell lymphoma admixed
gradeintestinal lymphoma(seebelow)enjoy signifi-
withapopulationofbizarregiantormultinucleate
cantlylongerremissions.
cells,andnonehasbeenassociatedwitheitherFeLV
Responseratesandlengthsofresponsevary
orFIv.Littleisknownabouttreatmentoutcomeofthis
accordingtothepresenceorabsenceofseveral
form of nodal lymphoma incats,but the clinical
prognosticfactors.Thewidevariationsinfrequency
course inmostcasesisprolonged.
andthegreatvariabilityofanatomicalformsoflym-
Thetypicalscenarioisthatofasolitarymandi-
phomaencountered incatsmakespecificprognoses
bular (Figure 19.12)or cervical node.Following
moredifficult thanindogs.Most reportshave
staging torule out systemicinvolvement,surgical
excisionoftheaffectednodeofteneffectscontrolfor
response durations and,ingeneral,the number of
severalmonthswhereuponarecurrenceisdiscov-
animalswithanyonespecificanatomicalformistoo
eredinaregionallydrainingnode.It is currently
small for statistical analysistobeuseful.Thatbeing
unknownwhethertheadditionofchemotherapy
said,it appearsthatthefactorsmoststronglyassoci-
at initialdiagnosis incombinationwithnodeextir-
atedwithamorepositiveprognosisincatsare:
pationwillprolongorpreventrecurrence.Eventually,
294
Chapter19a
Tumoursof thehaemopoieticsystem
19.13
Fine-needleaspiratefromtheliverofacatwith
largegranularlymphoma.Thenormal hepatic
architectureiseffacedbyamonotonouspopulationof
immatureLGLs.(Wright's-Giemsa stain;original
19.12
Massivemandibularlymphnodeenlargementin
magnificationX1000).(Courtesy ofKristenFriedrics,
a catwithHodgkin's-likelymphoma.
UniversityofWisconsin-Madison)
chemotherapymaybeindicatedifmultiplenodes
nodes.Mostcasespresentwithextensiontomany
areinvolved,thoughtheresponsivenessof thisform
sites,including liver,lung,myocardium,salivary
of lymphoma incats isnotwellknown atpresent.
gland andspinal cord.Leukaemiahas alsobeen
Occasionally,a moreaggressiveclinical coursehas
reportedwiththisdisease.Affectedcatsare
beenobserved.
generallynegativeforFeLVandFIV.
LGLsmustbedifferentiatedfromseveralother
Small-cellalimentarytractlymphoma
granularcelltypesthatmaybefoundinthesmall
Whilemostalimentarytractformsoflymphomain
intestine,includingtheenterochromaffincells,mast
the cat are of intermediate orhigh grade,a signifi-
cellsandeosinophils.CatswithLGL tumourstend to
cantsubsetof'small-cell'orlow-gradelymphomas
respondpoorlyto chemotherapy,withmedian
havebeenidentifiedandhaveimportanttreatment
survivalofapproximately1.5months,thoughlong-
and prognostic significance.Consequently,a less
termresponseshavebeenoccasionallyreported.
aggressiveapproachtosystemictherapyisrecom-
mendedforcasesofsmall-cell lymphomainvolving
the intestinal tract,liver and mesenteric lymph
nodes.Most cats willrespond wellto oral chlor-
Leukaemiaandmyeloproliferative
ambucil(20mg/m²q2wk)andprednisoneorpredni-
disorders
solone(5mgorallyq24hfor 14days,thenq48h).
Long-term survivalisthenormforthisdisease,with
Leukaemia,whichmaybeclassifiedaslymphoidor
mediansurvivaltypicallyapproaching2years
non-lymphoid,is defined asa neoplasticprolifera-
(Kiselow et al.,2008).
tionofhaemopoieticcellsoriginating within the
bonemarrow.Themyeloproliferativedisorders
Largegranularlymphoma
(MPDs)areagroupof neoplasticdiseasesofbone
Alesscommonlyreportedbutdistinctformofali-
marrowwhereunregulatedproliferationofcells
mentarylymphomahasbeendescribedandisclas-
derivedfromhaemopoieticstemcellsoccurs.These
sifiedaslargegranularlymphoma(LGL)(Wellman
include myeloid,neutrophil,basophil,eosinophil,
et al.,1992;Drobatz et al.,1993;McEntee et al.,
monocyte,lymphoid,megakaryocyte,anderythro-
1993;Darbesetal.,1998;Roccabianca etal.,2006;
cytelineages.The characteristics ofMPDs are
Krick et al.,2008).These tumours represent granu-
shown inFigure19.14.
latedroundcelltumoursandhavebeentermed
TheleukaemiasandMPDscanalsobeclassified
either'globuleleucocytetumours'or“largegranular
accordingtothedegreeofcelldifferentiation:
lymphocytelymphoma'，althoughtheyareprobably
variationsofthesamedisease.Largegranular
Welldifferentiatedleukaemiasareusually
lymphocytes(LGLs)arecharacterizedbyabundant
referredtoaschronicleukaemias
cytoplasmwithprominentazurophilicgranules
Poorlydifferentiatedleukaemiasareusually
(Figure 19.13).This population of cells includes nat-
referredtoasacuteleukaemias.
ural killercells andcytotoxicTcellsbasedonimmuno-
phenotypicanalysis.
Thisdistinctionisveryimportantinthe
Thetumourscommonlyoriginateinthesmall
therapeuticmanagementandprognosisoffelineand
intestine,especiallythejejunumormesentericlymph
canineleukaemias.
295
Chapter 19a
Tumoursof thehaemopoieticsystem
Type
Subtype
Cell lineage
Characteristics
Therapy
Prognosis
Acute
Acutemyelogenous
Myeloblasts
Allarerare.Somemixed
Aggressivechemotherapy
Poor;even with
leukaemia (AML)
formspossible.Rapid disease
to decrease tumour
aggressive
course.Oftenrequire
burden and open up
therapy
Acutemyelomonocytic
Myeloblasts/monoblasts
immunophenotypicand
marrow.Aggressive
remissionsare
leukaemia(AMML)
immunohistochemical
supportivecare for
notdurable
Acutemonocytic
Monoblasts
diagnosis.Accumulations of
infection,
leukaemia(AmoL)
blasts inbonemarrowand/or
thrombocytopenia and
peripheral blood.Clinical
anaemia.Often
Acutemegakaryoblastic
Megakaryoblasts
signsrelatedtomyelophthisis
unrewarding
leukaemia(AmkL)
and resulting cytopenias.
Sepsisorhaemorrhagemay
Erythroleukaemia
Erythroblasts
result
Acute undifferentiated
Untyped precursors
leukaemia
Chronic
Chronicmyelogenous
Neutrophils,late
Excessivedifferentiatedbone
Therapymaynot be
Guarded.
leukaemia(CML)
precursors
marrowcells.Slower,
warranted unless clinical
However,
Primary/essential
insidious disease course.
signs present or
remissionscan
Platelets
Patientscan live formany
significant secondary
be achieved for
thrombocythaemia
months to years.Can
cytopenias.
many monthsor
Basophilic leukaemia
Basophils and precursors
Hydroxycarbonamideis
evenyears
crisis'andrevert toanacute
the drug of choice.
Eosinophilic leukaemia
Eosinophils and
disorderwitharapidclinical
Phlebotomyand
precursors
course
radiophosphorus can also
be used forprimary
Polycythaemia vera
Erythrocytes
erythrocytosis
19.14
Characteristicsofmyeloproliferativedisordersindogs andcats.
Lymphocyticleukaemia
CLLareFeLV-negative.However,there isnoclear
evidenceimplicatingaretroviral causeindogs.
Incidenceandaetiology
Lymphocyticleukaemiaismorecommon thannon-
Pathology
lymphocyticleukaemiaandotherMPDs.The true
InALL,the blast cells always infiltrate the bone
incidenceisnotknown.Themedianageisapproxi-
marrow,resultinginvariabledegreesof anaemia
mately5yearsandmalesmaybeover-represented.
thrombocytopeniaandneutropenia.Infiltrationof the
TheremayalsobeabreedpredilectionforGerman
spleenandliveriscommonandextramedullarysites
Shepherd Dogs.
suchasthenervoussystem,boneandgastrointesti-
Welldifferentiatedorchroniclymphocyticleuk-
naltractmaybeinvolvedaswell.Someanimalsmay
aemia(CLL) isseenlessfrequently thanacutelympho-
havelymphnodeinvolvementanddevelopgeneral-
blastic leukaemia （ALL)（Figure 19.15).The median
izedlymphadenopathy,butthenodal enlargementis
ageforCLLishigher thanforALL（approxmately11
typicallynot marked.
years)and,again,malesareover-represented.
ThelymphocytesofCLLarevirtuallyindistin-
Retroviruseshavebeenimplicated
in
cats:
guishablemorphologicallyfromnormalsmalllympho-
approximatelytwo-thirdsofcatswithALLareFeLV-
cytes.InCLL,the marrowis infiltratedwithmature
antigenaemic（FeLV-positive),while most cats with
lymphocytesandtheextentofmarrowinfiltrationis
generallylessthatthatseenwithALLorMPD.
Despitethewelldifferentiatedappearanceofthe
lymphocytesinCLL,thesecellsfunction abnormally.
SomeanimalswithCLLhaveanaccompanying
monoclonalgammopathy.
Investigationshaveimmunophenotypedcellsfrom
dogswithALLand CLL(Vernau and Moore,1999;
Williams etal.,2008).Interestingly,themajorityof
CLLswereassociatedwithaCD8T-cellphenotype,
whichisdifferenttothecaseinhumanswheremost
CLL are of B-cell derivation.In dogs,the CD34
(a)
(b)
immunophenotypeisthoughttobeamarkerofALL,
19.15
(a)Peripheralbloodsmearfromadogwith
thoughsomeB-andT-cell immunophenotypeshave
acutelymphoblasticleukaemia,showingthe
beendocumented.Mostcasesofdogswithcirculat-
characteristicmorphologicallyimmaturelymphoblasts.
ingB-celllymphoblastslikelyrepresentstageV
(b)Peripheralbloodsmearofadogwithchronic
lymphoma rather than ALL,as they are usually
lymphocyticleukaemia,showingmorphologicallymature
lymphocytes.(Wright's-Giemsa stain,original
associatedwithmarkedperipheral lymphadenopathy
magnificationX100o)(Courtesyof KarenYoung,University
andrespondmuchbettertotreatment thantrueALL.
ofWisconsin-Madison)
ThemajorityofALLincats areofT-cell type.
296
Chapter19aTumoursofthehaemopoieticsystem
Presentation andclinical signs
Infiltrationbecomesmoreextensiveasthedisease
slowlyprogressesandeventuallytheneoplasticcells
Acutelymphoblasticleukaemia:AnimalswithALL
replacenormal marrow.
usuallyhaveahistoryofanorexia,weightloss,poly
AllcatswithleukaemiashouldbetestedforFeLV.
uria/polydipsiaandlethargy.Splenomegalyiscom-
monandotherphysicalabnormalitiesmayinclude
Management
haemorrhage,lymphadenopathyandhepatomegaly.
Anaemia,thrombocytopeniaandanelevatedwhite
Acute
lymphoblasticleukaemia:Likeother
bloodcell(WBC)countarecommonlydetectedona
infiltrativebonemarrowmalignancies,ALLcauses
complete blood count(CBC).The anaemia maybe
morbiditybysuppressingnormalbonemarrow
severeandisusuallycharacterizedasnormocytic
function.
Neutropenia,
thrombocytopenia
and
and normochromic(non-regenerative).WBC counts
anaemiamaybesevere.Patientsneedsupportive
areusuallyelevated,despitethepresenceofaneu-
therapysuchasfreshwholeblood,broad-spectrum
tropenia,owingtoanincreasednumberofcirculat-
antibiotics,fluid therapy and nutritional support.
inglymphoblasts.Somedogsmaybeleucopenic.
Patientsmustbecarefullymonitoredforbleeding
Infiltrationofbonemarrowbyneoplasticlympho-
andthrombosisthatmaysignalthedevelopmentof
blastsmaybeextensivewithresultantdpressionf
disseminatedintravascularcoagulation.The treat-
normalhaemopoieticelements.
thestandard CHOPprotocols(outlined earlier)are
Chronic lymphocytic leukaemia:In CLL，mild
oftenemployed.
lymphadenopathyandmildtomarkedsplenomegaly
may be present.CBC shows that most dogs and
Chroniclymphocyticleukaemia:Becauseofthe
indolentnatureofCLLinmanyanimals,it iscontro-
catsareanaemic（PCV<35%)andmildlythrombo-
cytopenic.TheWBCcount isusually>30×10/but
versialwhetherornotalldogswiththisdisease
canbeashighas>300x10l,owingtoanincrease
shouldbetreated.Theclinicianmayelecttoobserve
thepatientifthediscoveryofCLLisincidentalandif
incirculating maturelymphocytes.Lymphocytosis is
therearenoaccompanyingphysicalorclinicalsigns
usuallypersistentandgranulocytesareusuallypre-
andnosignificanthaematologicalabnormalities.
sent in normal numbers.In some animals,the dis-
Treatmentisgenerallyreservedforthoseanimalsthat
ease isidentifiedincidentallywhilethepatientis
are anaemicor thrombocytopenic,have significant
undergoingevaluationforanotherreason.
excessivelyhighwhitebloodcellcount(lymphocytes
Clinicalapproach
Infiltrationofneoplasticlymphoidcellsintothebone
>100×10%/)
ThetreatmentofchoiceforCLLischlorambucil.
marrowisthehallmarkofbothALLandCLL
Thisisgivenorallyatadoseof 0.2mg/kgor6mg/m²
Therefore,carefulexaminationofperipheral blood
q24hfor7-14daysindogsandcats.Thedosecan
andbonemarrowbyanexperiencedcytopathologist
thenbereducedto0.1mg/kgor3mg/m²q24h.For
isessential inestablishingadiagnosisoflympho-
long-termmaintenance,dosingeveryotherdaymay
cyticleukaemia.
besufficient.Thedoseshouldbeadjusted according
Ifdiagnosticbonemarrowcannotbeobtained
toclinicalresponseandbonemarrowtolerance.The
byaspiration,bonemarrowcorebiopsyshouldbe
anti-tumouractivityofchlorambucilcombinedwith
performed. In ALL,lymphoblasts predominate in
prednisone/prednisoloneisbetterthanthatofchlor-
themarrowandarealsopresentinperipheral blood.
ambucilalone.Whenchlorambucilisnolonger
Inmany cases,these cells cannot be easily dis-
effective,the choice oftreatment is combination
tinguishedfromblastcellsofotherhaemopoietic
chemotherapy,such as theCHOPorCOPprotocols.
lineageswithouttheuseofimmunophenotypic
ThetreatmentofCLLisrarelycurativeandeventually
markeranalysis.Thepresenceof30%ormore
mostpatientsgoontoevolve intoALL.
lymphoblastsinthebonemarrowisconsidered
diagnostic.Approximately10%of ALLcasesare
Prognosis
classified
as'aleukaemic'
leukaemiabecause
In general,the prognosisofALLnthe dogand cats
bonemarrowinfiltrationispresentbutperipherallycir-
poor.The majority of animals do not achieve a com-
culatinglymphoblastsareabsent.ALLmaybefurther
pleteremissionand,when they do,thisisnot long
differentiatedclinicallyfromstageVmulticentric
lasting（<4months).In thedog,cellsize,cellnumber
lymphoma byitsmorerapid progression,lackof
andimmunophenotypecanpredictprognosis:large
significant lymphadenopathy in approximately50%
cellswithCD21expression,counts>30,000/uland
ofcases,poorchemoresponsiveness,shortsurvival
expressionofCD34havebeenassociatedwitha
timesandconfirmationofCD34immunophenotype
more negativeprognosis(Williamsetal.,2008).
(Williams et al.,2008).The infiltration of bone
Asstated earlier,CLLisa slowlyprogressive dis-
marrowbylymphoblastsisaccompaniedbya
ease,andsomeanimalswillnotrequire therapy
decreaseinthemyeloid,erythroidandmegakaryo-
cytic cellines.
nisone therapy,themediansurvival time is approxi-
ThelymphocytesinCLLaresmallmaturecells
mately18monthsaftertheinitiationoftherapy.
thatoccurinexcessivenumbersinbonemarrow
Accuratefiguresonsurvivalarenotavailableinthe
(>30%ofnucleatedcells)earlyin the disease.
cat,asCLLisaveryrarediseaseinthisspecies.
297
Chapter 19a
Tumoursof thehaemopoieticsystem
Non-lymphoidleukaemiasand
Multiplemyeloma
myeloproliferativedisorders
IgM(Waldenstrom's)macroglobulinaemia
Non-lymphoidMPDsarealsoclassifiedaccording to
Solitaryplasmacytoma(includingsolitary
celllineageanddegreeofdifferentiation(i.e.acute
osseousplasmacytomaandextramedullary
or chronic)(seeFigure 19.14).
plasmacytoma).
Acutemyeloproliferativedisorders
Multiplemyelomaisthemostclinicallyimportant
AcuteMPDsarerareinbothdogsandcatsandare
plasma cell neoplasm,based on incidence and
characterizedbytheaccumulationofimmatureblast
severity.
cellsinthebonemarrowandperipheralblood.
Thesecellsmayalsoinfiltrateotherorgans,suchas
Multiplemyeloma
thelymphaticvessels,liver,spleenandcentralnerv-
Multiplemyeloma(MM)represents8%ofallhaemo-
oussystem.TheclinicalcourseoftheacuteMPDsis
poietictumoursinthedog.While theincidencein
rapidandgenerallyfatal,duetothesequelaeof
cats is unknown,it is diagnosed much less fre-
bonemarrow effacement (myelophthisis)by the
quentlyinthisspecies.MMoccursinolderdogs and
immatureblasts;thisleads toprofound anaemia,
cats;nobreedorsexpredilectionhasbeenconsist-
neutropenia and thrombocytopenia.Uncontrolled
entlyreported.
haemorrhageandsepsisarecommonoutcomes.It
Inmostcases,the malignantplasma cellspro-
isoftendifficultorimpossibletoclassifythecell lin-
duceanoverabundanceofasingletypeofor
eageinvolvedbystandardlightmicroscopyalone;
componentof,immunoglobulin,whichisreferredto
immunophenotypic,immunocytochemicalandhisto-
as the M-component.Less commonly,biclonal
chemicaltechniquesareoftennecessarytodeter-
immunoglobulinproductionhasbeenreported.
minethecelloforigin.The classificationof the
TheM-componentcanrepresent anyclassof
variousacuteMPDsbasedon thesetechniquesis
immunoglobulin,oronlyaportionofthemolecule.
beyondthescopeofthischapterandthereaderis
Thismaybe thelightchain(Bence-Jonesprotein)
referredtoarecentreview(VailandYoung,2007).
orheavychain(heavychaindisease')of the
molecule.
Chronicmyeloproliferativedisorders
ChronicMPDsarecharacterizedbyanover-
Aetiology
proliferationofmatureorwelldifferentiatedcellsof
The aetiology of MM is unknown.In humans,
bonemarroworiginsuchaserythrocytes,granulo-
genetic/epigenetic predispositions,viral infections,
cytesorplatelets.Theclinicalcourseofthechronic
chronicimmunestimulationandexposuretocarcino-
MPDscanbeprolongedandtreatmentmaynotbe
genshaveallbeensuggestedascontributingfac-
necessaryintheearlystages.Ultimately，
the
tors.MMhasnotbeenassociatedwitheitherFeLV
proliferatingcellsmayresultinmyelophthisisand
orFiv infectionsincats.
relatedsequelae,orablastcrisis'mayoccurwhere
thechronicMPDshiftstoanimmatureacuteMPD
Pathophysiology
andresultsinarapidandfataloutcome.
Tumourinfiltrationoforgansystems(includingbone
marrow)and/orthepresenceofabnormallyhighcir-
Managementandprognosis
culatingM-componentresultsinawidearrayofpos-
Aswiththelymphoidleukaemias,theprognosisfor
siblepathologicalabnormalitiesandrelatedclinical
animalswithchronicMPDsisbetterthanforthose
syndromes(Matus et al.,1986).Feline myeloma,
withacuteMPDs.TheacuteMPDsrarelyrespondto
sometimesreferredtoas‘myeloma-relateddisor-
availablechemotherapyprotocols;ifthey
do,
ders'whileinvolvingthebonemarrowinthemajority
responsedurationsareshort.Chronicmyelogenous
ofcases,appears toinvolve extramedullary sites
leukaemiaandprimaryerythrocytosis(polycyth-
(e.g.skin,abdominalviscera)more commonly than
aemiavera)canenjoy significantremissionswith
indogs(Hanna,2005;Pateletal.,2005;Melloret
hydroxycarbamide
(hydroxyurea)
chemotherapy.
al.,2006,2008).
Hydroxycarbamideisusedatadoserateof20-50
mg/kgorallyq24hfor10days,andisthenreduced
Presentation and clinical signs
to15mg/kgq24h.Alternatively，polycythaemiavera
ClinicalsignswithMMarevariableandaredueto
canbemanagedwithintermittentphlebotomiesor,if
thewiderangeofpathophysiologicaleffectsoutlined
available,radiophosphorus(32P).
inFigure 19.16.Clinical signsindogswithMM，in
weakness,lameness,bleeding,fundoscopic abnor-
Plasma celltumours
malities,polyuria,polydipsia and CNS deficits.
Anorexiaandweightlossarethemostcommonclini-
Plasmacelltumoursaredefinedasneoplasticprolif-
calsignsinthecatandtheremaybeahistoryof
erationsofcellsoftheB-lymphocyteplasma cellin-
chronicrespiratoryinfections.Skeletal lesionswere
eage.The proliferations are,in most instances,
thought not tooccurcommonlyincats,butmost
monoclonal(i.e.derived from a single cell),as they
recentreportshavefoundthemtobecommon.
typicallyproducehomogenousimmunoglobulin.
Organomegalyduetoorganinfiltrationwithtumour
Plasmacell tumoursinclude:
is frequent.
298
Chapter 19a
Tumoursofthehaemopoieticsystem
Clinical syndrome
Aetiology
Clinical consequences
Frequency
Hyperviscosity
High serumviscosity fromelevatedM-component
Bleeding diathesis.
Dogs:20%
syndrome(HVS)
resultsinudgingfloodnsmallesselinffctiv
Neurological signs.Ophthalmic
Cats:10-25%
deliveryofoxygenandnutrientsandcoagulation
abnormalities.Cardiomyopathy
abnormalities
Hypercalcaemia
Indecreasing orderoflikelihood:productionof
PU/PD.Hypercalcaemic
Dogs:20%
osteoclastactivatingfactororothercytokineselevation
nephrosis.Neurological signs.
Cats:10-20%
ofN-terminalparathyroid hormone-relatedprotein;may
Cardiac arrhythmias
be secondary toassociated renal disease
Renal disease
Canresult fromanyof thefollowing:Bence-Joneslight
Renal failure.
Dogs:30-50%
chain）proteinuria;tumourinfitrationintorenaltissue;
Glomerulonephropathies with
Cats:one-third
hypercalcaemia;amyloidosis;diminishedperfusiondue
proteinuria
to HVS;dehydration;urinary tract infections
Immunocompromised
Depressed normal immunoglobulin levels.Leucopenias
Immune deficiencies lead to
Themajorityof patients are
patient
due tobone marrowinfitration(myelophthisis)
secondary infections
immunocompromisedto some
degree
Anaemia/leucopenia/
Blood loss fromcoagulationdisorders.Anaemia of
Risk of sepsis.Weakness.
Dogs and cats:two-thirds
thrombocytopenia
chronicdisease.Erythrocyte destruction secondaryto
Haemorrhage
anaemic;one-third leucopenic;
HVS.Myelophthisis
one-third thrombocytopenic
Bleeding diathesis
M-componentsmay:inhibit plateletaggregation;
Haemorrhage (epistaxis,
Dogs:about one-third have
releaseplatelet factor-3;absorbminorclottingproteins;
gingiva bleeding).Anaemia.
activebleeding
generate abnormalfibrin polymerization.
Weakness
Cats:10-15%
May alsobe due to:functional decrease incalcium;
thrombocytopenia（myelophthisis);lossof clotting
factorsduetoglomerulonephropathies
Lameness/bone pain
Bone lysissecondary to tumourlysisof long bonesand
Pathological fractures.
Dogs:almost half
vertebrae
Transversemyelopathy dueto
Cats:15-50%
vertebralbodyfracture
19.16
Featuresof clinical syndromes associatedwithmultiplemyeloma indogsandcats.
Clinical approach
AdiagnosisofMMdependsuponthedemonstration
G
of allormostof thefollowing:
Bonemarrowplasmacytosis
Presenceofosteolyticbonelesions
Serumorurinemyelomaproteins(M-component)
Organinfiltrationwithmalignantplasmacytes.
0
0
Intheabsenceofosteolyticbonelesionsor
organinfiltration,adiagnosiscanalsobemade if
marrowplasmacytosis
is
associatedwith
progressiveincrease inM-component.
ACBC,plateletcount,serumbiochemistryprofile
andurinalysisshouldbeperformedinallanimals
suspectedofhavingMMandparticularattention
shouldbepaidtorenalfunctionandserumcalcium
19.17
Serumproteinelectrophoresisfromadogwith
levels.Serum electrophoresis,immunoelectrophor-
multiple myeloma.A,albumin.G,large
M-component spikerepresenting anIgA monocolonal
esisandquantificationdeterminethepresenceofa
gammopathy.
monoclonalgammopathyandcategorizetheclassof
immunoglobulininvolved（Figure 19.17).In thedog,
presenceofBence-Jonesproteinuria;commercial
theM-componentconsistsof IgAorIgGimmunoglob-
urinedipstickmethodsarenotcapableofthis
ulin(theauthor'sexperienceis thatthemajorityare
determination.
IgA),whilethemajorityofcasesreported inthe cat
Definitivediagnosisusuallyrequiresabonemar-
involvelgG.lIfIgMconstitutestheM-component,the
row aspirate（Figure19.18)or core biopsy.Normal
termWaldenstrom'smacroglobulinaemiaisapplied.
marrowcontains<5%plasmacells,whilemyeloma-
Bicolonalgammopathyhasalsobeenreportedin
tousmarrowwilltypicallyhaveamuchgreaternum-
bothspeciesandcryoglobulinaemia（requiring
ber.Marrowinvolvementcanbelocation-dependent
specialized serumcollectiontechniques)hasbeen
andsomemarrowcompartmentsmayappearnor-
reportedoccasionallyindogs.Heatprecipitationand
malcytologically;areaswithobviousradiographic
electrophoresisofurinearenecessarytodetectthe
evidenceofcorticallysisorosteoporosisaremore
299
Chapter 19a
Tumoursofthehaemopoieticsystem
DiseasesyndromesotherthanMMthatcan
beassociatedwithmonoclonalgammopathiesand
shouldbeconsideredinanylistofdifferentials
include:
Otherlymphoreticulartumours(e.g.lymphoma,
CLL,ALL)
Chronic infections(e.g.erhlichiosis,
leishmaniasis,FIP)
Monocolonalgammopathyofunknown
significance(MGUS).
MGUS (benign,essential or idiopathic mono-
clonalgammopathy)isabenignmonoclonalgammo-
pathythatisnotassociatedwithosteolysis，bone
marrowinfiltrationorBence-Jonesproteinuria.
19.18
BonemarrowaspiratefromadogwithMM
showingneareffacementofnormalmarrowby
Management
plasmacellswitheccentricnuclei andpaleperinuclear
Therapy should be directed at both the tumour cell
Golgiareas.(Wright's-Giemsa stain,originalmagnification
massandthesecondarysystemiceffectscausedby
X1000).(CourtesyofKristenFriedrics,University of
theelevatedM-component.
Wisconsin-Madison)
Chemotherapy:Chemotherapyishighlyeffectivein
likelytobeeffaced.Thedegreeofdifferentiationand
reducingmyelomacellburden,relievingbonepain
thereforethemicroscopicappearanceofmalignant
(unless significantpathological fractureispresent),
plasmacellscanvaryfromthatofnormalplasma
initiatingskeletalhealingandreducinglevelsof
cellstothoseinearlystagesofdifferentiation.
serumimmunoglobulinsindogs.Completeelimina-
Thepresenceandextentofosteolyticlesions
tionofneoplasticmyelomacellsisrarelyachieved;
(Figure 19.19)shouldbedeterminedby skeletal sur-
butsignificantdecreaseinthetumourloadis
veyradiography，astheyhavediagnostic,prognostic
achieved,whichsignificantlyextendsboththequality
andtherapeuticimplications.Rarely,biopsyofthese
andquantityofmostpatients'lives.WhileMM
osteolyticlesions(i.e.Jamshidibonecorebiopsy)is
remainsagratifyingdiseasetotreat,eventual
necessary for diagnosis.In macroglobulinaemia,
relapseistobeexpected.
malignantcellsaremorelikelytoinfiltratethespleen,
ThetreatmentofchoiceforMMindogsisacom-
liverandlymphtissuethanbone.Bonesengaged in
active haemopoiesis（e.g.vertebrae,ribs,pelvis,
nisone/prednisolone.
Theinitialstartingdoseof
skullandproximal longbones)aremorecommonly
melphalanis0.1mg/kgorallyq24hfor10days;it is
affected.All animalsshould undergoacarefulfundo-
scopicexamination;abnormalitiesmayincludereti-
Prednisoneisinitiatedatadosageof0.5mg/kgorally
nalhaemorrhage,venousdilatationwithsacculation
q24hfor10days,thenreducedtoeveryotherday
andtortuosity,retinaldetachmentandblindness.
thereafter.Therapyiscontinueduntilclinicalrelapse
occursormelphalan-associatedmyelosuppression,in
particular thrombocytopenia,necessitates adose
reduction or drug holiday. CBC,including platelet
counts,shouldbeperformedevery2weeksfor2
monthsfollowinginitiationoftherapyandmonthly
thereafter.
Analternativepulse-dosingregimenformelpha-
lan（7mg/m²orallyq24hfor5consecutivedays
every3weeks)hasbeenused successfullyina
smallnumberofcaseswhere thrombocytopenia
resultedfromtheuseofmoreconventionalcontinu-
ouslow-dose therapy.Melphalanplusprednisone/
prednisolonehasalsobeenusedincatswithMM,
butresponseratesareloweranddurationsof
response areshorterthanindogs.
Cyclophosphamidehasbeenadvocatedasan
alternativealkylatingagentforthetreatmentofMM,
thoughthereisnoevidencetosuggestthatitis
superiortomelphalan.Intheauthor'spractice,cyclo-
phosphamideislimitedto thosecasespresenting
19.19
Lateral thoracicradiographofadogwithMM,
withseverehypercalcaemiaorwithwidespreadsys-
showingmultipleexpansilelyticlesionsand
pathologicalfracturesintheaxialskeleton,mostapparent
temicinvolvement,whereafaster-actingalkylating
inthespinousprocessesofthevertebraeandina
agentwouldtheoreticallyalleviatesystemiceffects
collapsefractureof thethird thoracicvertebralbody.
morequickly.In those situations,cyclophosphamide
300
Chapter19aTumoursofthehaemopoieticsystem
isgiven atadosageof250mg/m²i.v.once.At the
Rescuetherapy:Rescuetherapyistreatment thatis
sametime,oral melphalantherapyisinitiated.
initiatedwhenmelphalan/prednisonecombinations
Chlorambucil,anotheralkylatingagent,hasalso
eventuallybecomeineffective,orincasesthatare
beenusedsuccessfullyforthetreatmentofIgM
initiallyresistanttostandardtherapy.Theauthorhas
macroglobulinaemiaindogsatadosageof0.2mg/
had,inafewcases,successwithacombinationof
kg orallyq24h.
doxorubicin(30mg/m²i.v.every21days),vincristine
Evaluationsofresponsetotherapyshouldbe
(0.7mg/m²i.v.ondays8and 15)andprednisone
basedonimprovementofclinicalsigns,clinicopatho-
(1.0mg/kg orally q24h),given in21-day cycles.Most
logicalparametersandradiographicimprovementof
skeletallesions.Subjective improvementinbone
althoughtheresponsetendstobeshort lived,lasting
pain,lameness,lethargyandanorexiashouldbeevi-
onlya fewmonths.High-dose cyclophosphamide
dentin2-4weeks.Objectivelaboratoryimprove-
(300mg/m²i.v.every21days)hasalsobeenused
ment,includingreductioninserumimmunoglobulin
withlimitedsuccess.
orBence-Jonesproteinuria,isusuallynoted in4-6
Prognosis
weeks(curiously，aninitial increaseinM-component
Intheshortterm,theprognosisfordogswithMMis
inthefirst2weeksoftreatmenthasbeennotedon
good for initial control of the tumour and a return toa
severaloccasionsbytheauthor).Improvementin
osteolyticbonelesionsmayoccurasearlyasafew
goodqualityof life.Long-termsurvival isusual,witha
weeksintotherapy,butcompleteresolutionofbone
medianof1.5yearsreported,butrecurrenceis
lesionsmaytakemonthsandmayonlybepartial.
expected.Eventually,thetumourisnolongerrespon-
SincecompleteresolutionofMMrarelyoccurs
sivetoavailablechemotherapeuticagentsanddeath
withtherapy，areductioninmeasuredM-component
followsfromrenal failure,sepsisoreuthanasia(due
tointractablebone or spinalpain).Hypercalcaemia,
toatleast50%ofpre-treatmentvalueswouldbe
classifiedas a goodresponse.Quantificationof
Bence-Jonesproteinuriaandextensivebonylysis
serumimmunoglobulinorurineBence-Jonesprotein
areknowntobenegativeindicesinthedog.
shouldbeperformedmonthlyuntilagoodresponse
The prognosis for MM is guarded in cats,as
isnotedandthenevery2-3months.Bonemarrow
responserates anddurationsareless thanthose
aspirationisrepeatedifM-componentlevelsriseorif
reported indogs.Mostcatsrespond to melphalan/
clinicalsignsrecur.Additionally,if cytopenias(partic-
prednisoneor cyclophosphamide-based protocols.
ularly thrombocytopenia)occur during therapy，a
However,responsesarenotlong-lastingandmostani-
bonemarrowaspirateisindicatedtodifferentiate
malssuccumbwithin2-3monthsofdiagnosis,though
betweentumourmyelophthisisandchemotherapy-
somecaseseriesreportmediansurvivalsfrom6to
inducedmyelosupression.
12months(Hanna,2005;Mellor et al.,2006).
Less is understoodabout the prognosis for
Ancillarytreatments:
Hypercalcaemia,hyper-
dogswithIgMmacroglobulinaemia，but long-term
viscositysyndrome(HVS),bleeding diatheses,renal
responsestochlorambucilhaveoccurred.
diseasemmunosuppressionandpathologicalskele
Solitaryplasmacytoma
talfracturesoftencomplicatethepresentationand
Solitary collections
ofmonoclonalplasmacytic
indeed the treatment ofMM.Therapydirectedmore
tumourscanoriginateinboneorsofttissuesandare
specificallyatthesecomplicationsmaybeindicated
referredtoassolitaryosseousplasmacytoma(SOP)
in theshort term.
and extramedullary plasmacytoma(EMP),respec-
tively.The majorityof SOPs eventuallyprogress to
Plasmapheresisisusedformanagingclinically
systemicMM.
significantHVS.Wholebloodiscollectedfromthe
ThebiologicalbehaviourofEMPvarieswithana-
patient,plasmaisseparatedofffromthepacked
tomical location.CutaneousandoralcavityEMPs
cells,and thered cells arethenre-suspended in
aretypicallybenigndisordersinthedog;thereis an
normalsalineandreinfusedbackintothepatient.
exception formultiplecutaneousplasmacytoma,a
Bleedingdiatheseswillusuallyresolvealongwith
rarebiologicallyaggressiveformofthedisease.In
HVS;however,platelet-richplasma transfusions
contrast,non-cutaneousEMPsinparticular alimen-
maybenecessary.
tarytractlocationsareassociatedwithamuchmore
Pathologicalfracturesofweight-bearinglong
aggressivenaturalbehaviourandhavebeen
bonesand/orvertebrae(resultinginspinalcord
reportedtoinvolve the oesophagus,stomachand
compression)mayrequireimmediatesurgical
intestine.Whilebonemarrowinvolvementandgam-
interventioninconjunctionwithsystemic
mopathiesareless commoninthesealimentary
chemotherapy.Orthopaedicstabilizationof
cases,metastasistoassociatedlymphnodesdoes
fracturesandspinalcorddecompressionshould
occur.ColonicEMPtendstobeanexceptiontothe
beundertakenwherenecessary and maybe
rule;itoftenremainssolitaryand isamenabletosur-
followedwithexternalbeamradiotherapy.
gicalresection,withresultinglong-termsurvival.
Radiationtherapycanbeusedfortheinitial
control ofbonepaininlongbones.Theuseof
Presentation and clinical signs
bisphosphonates(e.g.pamidronate,zoledronate)
Clinical signs associatedwithsolitaryplasmacyt-
toinhibitboneresorptioninpatientswithMMis
omasreflecttheanatomicallocationofinvolvement
currentlybeinginvestigatedbutisstill
or,inthoserarecaseswithsignificantelevationsin
controversial.
M-component,hyperviscosity syndromes.SOPis
301
Chapter19a
Tumoursofthehaemopoieticsystem
usuallyassociatedwithpainandlamenessifthe
clinicalandhaematologicalstudy.ActaVeterinariaScandinavica6
appendicularskeletonisaffected,orneurological
Suppl.1
Bertone ER,SnyderLA and Moore AS(2002)Environmental tobacco
signsifvertebraeareinvolved.Themorebenign
smokeandriskofmalignantlymphoma inpetcats.American
cutaneousformofEMPusuallyhasnorelatedclini-
JournalofEpidemiology156,268-273
BreenMandModianoJF(2008）Evolutionarily conservedcytogenetic
cal signs(see Chapter 12).In contrast,alimentary
changes in hematological malignancies of dogs and humans-
EMPoftenpresentswithsignssuggestiveofgastro-
more than companionship.
intestinaldisease.Ataxiaandseizureactivityhave
ChromosomeResearch16,145-154
beenassociatedwithEMPssecondarytotumour-
Bridgeford EC,MariniRP,FengYet al.(2008）GastricHelicobacter
speciesasacause of feline gastriclymphoma:aviablehypothesis.
associatedhypoglycaemia.
Veterinarylmmunologyandlmmunopathology123,106-113
BrondenLB,Rutteman GR,FlagstadAetal.(2003)Studyof dogand
Clinical approach
catownersperceptionsofmedicaltreatmentforcancer.Veterinary
A tissuebiopsyforhistological assessmentisneces-
Record152,77-80
DarbesJ,MazoubBreuWtal.（1998）Largegranularlmphocy
saryforthediagnosisofSOPandEMP.Immuno-
leukemia/lymphomainsixcats.VeterinaryPathology35.370-379
histochemical studiesmaybehelpful inconfirminga
DayMJ,Kyaw-TannerM,SilkstoneMAetal.（1999)T-ce-richBell
diagnosis in morepoorlydifferentiated tumours.In
lymphomainthecat.JournalofComparativePathology120,155-
167
addition,PCRtechniquescanbeused todetermine
Dobson JM,Samuel S,Milstein H,RogersKand Wood JLN (2002)
theclonalityoftheimmunoglobinheavy-chainvaria-
Canine neoplasia in the UK:estimates of incidencerates froma
populationof insured dogs.Journal of SmallAnimalPractice43.
bleregiongene.Thoroughstagingofthedisease is
240-246
requiredinthesecases,includingbonemarrowaspi-
DrobatzKJ（1993)Globuleleukocytetumorinsixcats.Journalof the
ration,serum electrophoresis and skeletal survey
AmericanAnimalHospitalAssociation29,391-397
Gabor LJ,Canfield PJ and MalikR(1999) Immunophenotypic and
radiography,toensurethatthediseaseisconfinedto
a singlesitepriortoinitiationof therapy.
AustralianVeterinaryJournal77436441
HannaF(2005)Multiplemyelomasincats.JournalofFelineMedicine
Management
andSurgery7,275-287
Kaiser HE(1981)Animal neoplasms:a systemicreview.In:Neoplasms
Ifthoroughclinicalstagingfailstoidentifysystemic
-Comparative Pathologyin Animals,Plantsand Man,ed.HE
involvement,animalswithsolitaryformsofplasma
Kaiserpp.747-812.William&WilkinsBaltimore
Kiselow MA,RassnickKM,McDonough SPet al.(2008)Outcomeof
catswith low-gradelymphocyticlymphoma:41cases(1995-2005).
theneedforsystemicchemotherapy.Local therapy
JournalofAmericanVeterinaryMedicalAssociation232,405-410
Krick EL,Litle L,Patel Ret al.(2008）Description of clinical and
therapy;thesemaybeused alone,orin combination.
pathologicalfindings,treatment andoutcome of felinelarge
granular lymphocytelymphoma（1996-2004）.Veterinaryand
AsmostdogswithSOPandnon-cutaneousEMP
ComparativeOncology6,102-110
KristalLanaSE,OgilvieGKetal201）Singleagentchmotherapy
eventuallydevelopsystemicMM,controversyexists
withdoxorubicinforfelinelymphoma:aretrospectivestudyof19
astowhethersystemicchemotherapyshouldbeini-
cases（1994-1997).JournalofVeterinaryInternal Medicine15,
tiatedconcurrentlywithlocaltherapy.Inhuman
125-130
patientswithsolitaryplasmacytomas,systemic
Lana S,Plasa S,Hampe Ket al.(2006) Diagnosis of mediastinal
massesindogsbyflowcytometry.JournalofVeterinaryInternal
Medicine20,1161-1165
beyonddiagnosis,andstudiesrevealthatnobenefit
LouwerensM,LondonCA，PedersenNCetal.(2005）Felinelymphoma
isderivedfromtheinitiationofsystemicchemo-
inthepost-felineleukemiavirusera.JournalofVeterinaryInternal
Medicine19,329-335
therapypriortothedocumentationofsubsequent
MatusRE,LeiferCE,MacEwenEGetal.（1986)Prognosticfactors for
systemicspread.It is theauthor'sopinion that the
multiplemyeloma inthedog.Journalof theAmericanVeterinary
sameapproachshouldbeappliedtoveterinary
MedicalAss0ciation188,1288-1292
McEnteeMF,HortnS,BlueJetal.（1993)Granulatedroundcelltumor
patientsand,followinglocal control,aregularfollow-
of cats.VeterinaryPathology30,195-203
upscheduleshouldbeimplementedinordertorec-
assessmentsoftheir dog's qualityof life during palliative
ognizebothrecurrenceofdiseaseandsystemic
chemotherapyforlymphoma.JournalofSmallAnimalPractice44,
spread.At that time,systemictherapy iswarranted,
100-103
asdescribed aboveforMM.
Mellor PJ,Haugland S,Murphy S et al.(2006) Myeloma-related
disordersincatscommonlypresentasextramedullaryneoplasms
Prognosis
incontrasttomyelomainhumanpatients:24caseswith clinical
follow-up.JournalofVeterinaryInternalMedicine20,1376-1383
Dogswithcutaneousandoralplasmacytomasare
Mellor PJ.Haugland S,Smith KC et al.(2008)Histopathologic,
immunohistochemical,and cytologic analysis of feline myeloma-
existforcutaneousplasmacytomasincatsbut,while
relateddisorders:furtherevidenceforprimaryextramedullary
developmentinthecat.VeterinaryPathology45,159-173
some are controlled with surgicalexcision,the
ModianoJFBreenMBuettRCtal.005）DistinctB-cellandTl
potentialtobeacomponentofwidespreadsystemic
lymphoproliferativediseaseprevalenceamongdog
breeds
indicatesheritablerisk.CancerResearch65,5654-5661
involvement ismorelikely.DogswithSOPorEMPof
Moore AS,Cotter SM,Frimberger AEet al.（1996)A comparison of
doxorubicinandCoPformaintenanceofremissionincatswith
sion,incombination withsystemicchemotherapy
lymphoma.Journalof VeterinaryInternalMedicine10.372-375
Patel RT,CaceresA.FrenchAFet al.(2005）Multiple myeloma in16
oncesystemicdiseaseisdocumented,havesurvival
cats:aretrospective study.VeterinaryClinicalPathology34,341-
timesofmorethan1yearinthemajorityofcases.
PeastonAEand MaddisonJE（1999)Efficacyofdoxorubicinas an
352
inductionagentforcatswithlymphosarcoma.AustralianVeterinary
Referencesandfurtherreading
Journa/77,442-444
PonceF,Magnol J-P,LedieuDetal.(2004）Prognositc significance of
AveryPRandAvery AC(2004)Molecularmethods todistinguish
chemotherapy.VeterinaryJourna/167,158-166
reactiveandneoplasticlymphocyteexpansionsandtheir
Reif JS,LowerKSandOgilvie GK（1995)Residential exposure to
importancein transitionalneoplastic states.Veterinary Clinical
magneticfieldsandriskofcaninelymphoma.AmericanJournalof
Pathology33.196-207
Epidemiology141,352-359
BackgrenAW(1965)Lymphatic leukaemia in dogs.An epizootiological
Risbon RE,de Lorimier LP,Skorupski K et al. (2006) Response of
302
Chapter19a
Tumoursof thehaemopoieticsystem
canineepitheliotropiclymphoma tolomustine (CCNU):a
Vail DM,Moore AS,Ogilvie GKetal.（1998)Feline lymphoma（145
retropective studyof46cases（1999-2004).JournalofVeterinary
cases):proliferationindices,CD3immunoreactivity，andtheir
InternalMedicine20,1389-1397
associationwithprognosisin90cats.JournalofVeterinaryInternal
RoccabiancaPVernauW,CaniattiMetal.(2006)Feline large granular
Medicine12,349-354
lymphocyte(LGL)lymphoma with secondaryleukemia:primary
VailDMandYoung KM(2007)Canine Iymphoma and lymphoid
intestinal originwithpredominanceofa CD3/CD8（alpha)(alpha)
leukemiasIn:malnimalClinicalOncology4thednd
phenotype.VeterinaryPathology4315-28
WithrowandDMVail,pp.699-732.Saunders/Elsevier,StLouis,
RosolTJ.NagodeLA,CoutoCGet al.(1992）Parathyroidhormone
ValliVE,JacobsRM,NorrisAetal.(20oo)Thehistologicclassification
Missouri
withcancer-associatedhypercalcemia.Endocrinology131，1157-
of602 casesof feline lymphoproliferative disease using the
1164
NationalCancerInstituteworkingformulationJournalofVeterinary
Sauerbrey ML,Mullins MN,BanninkEOet al.(2007)Lomustine and
DiagnosticInvestigation12,295-306
prednisone asa first-line treatment fordogswith multicentric
lymphoma:17cases(2004-2005).Journal of theAmerican
HematopoieticTumorsofDomesticAnimals，2ndseries,Volume
VeterinaryMedicalAssociation230,1866-1869
Vlll.ArmedForcesInstituteofPathologyincooperationwiththe
SfiligoiG,Theon APandKent MS(2007)Response of 19catswith
AmericanRegistryofPathologyandTheWorldHealth
nasallymphomatoradiationtherapyandchemotherapy.Veterinary
OrganizationCollaborationCenterforWorldwideReferenceon
RadiologyandUltrasound48,388-393
ComparativeOncology.Washington,D
Simon D,Moreno SN,HirschbergerJet al.(2008)Efficacy of a
VernauWandMoorePF（1999)Animmunophenotypicstudyofcanine
continuousmultiagentchemotherapeuticprotocolversusashort
termsingle-agentprotocolindogswithlymphoma.Journalof the
chainreaction.VeterinaryImmunologyandImmunopathology69,
AmericanVeterinaryMedicalAssociation232,879-885
145-164
Teske E,Sraten GV,van Noort R and Rutteman GR（2002)
WaltonRMand HendrickMJ(2001)Feline Hodgkin's-like lymphoma:20
Chemotherapy
withcyclophosphamide
vincristine
and
cases（1992-1999).VeterinaryPathology38,504-511
prednisolone（CoP)incatswithmalignantlymphoma:newresults
Wellman ML,HammerAS,DiBartola SPet al.（1992)Lymphoma
withanoldprotocol.JournalofVeterinaryInternalMedicine16,
involving large granular lymphocytesincats:11cases(1982-
179-186
1991).Journalof theAmericanVeterinaryMedicalAssociation201
TzannesS,Hammond MF,MurphySetal.(2008)Ownersperception
1265-1269
of theircats'qualityof lifeduringCOPchemotherapyforlymphoma.
Williams LE,Rassnick KM,Power HT et al.(2006)CCNU in the
JournalofFelineMedicineandSurgery10,73-81
treatmentofcanineepitheliotropiclymphoma.JournalofVeterinary
Vail DM(2007a)Feline lymphoma and leukemias.In:Small Animal
InternalMedicine20,136-143
Clinicalncology4thdndWWithowandDMVailpp3
WilliamsMF,AveryAC,Lana SEetal.(2008)Canine
755.Saunders/Elsevier,StLouis,Missouri
lymphoproliferative
diseasecharacterizedbylymphocytosis:
VailDM(2007b)Plasmacelltumors.In:SmallAnimalClinicalOncology,
immunophenotypicmarkersofprognosis.JournalofVeterinary
InternalMedicine22,596-601
ElsevierStLouis,Missouri
ZwahlenCH,LucroyMD,KraegelSAandMadewellBR(1998)Results
VailDM(2007c)Feline lymphoma and leukemias.In:Small Animal
cases(1993-1997）.Journalof theAmericanVeterinary Medical
755.Saunders/ElsevierStouisMissouri
Association213,1144-1149
303
Tumours of the
een
JaneM.Dobson
Introduction
alsorecognizedinthespleenofolderdogs,especially
thoseof theretrieverbreeds(Spangleret al.,1994).
Althoughtumoursofthehaemopoieticsystemoften
Theaetiologyofsplenictumoursisnotknown.
involve the spleen,thisreticuloendothelialorgan is
GermanShepherd Dogs,Golden Retrievers and
alsoanimportantsiteforthedevelopmentofnon-
LabradorRetrieversareover-representedinsome
lymphoidprimarytumoursandasiteformetastasis.
caseseriesandsuchbreedpredispositionsmight
Mostofthesetumoursarecoveredelsewhereinthis
suggestgeneticfactors.Angiogenicgrowthfactors
manual,butsplenichaemangiosarcoma and splenic
arestronglyexpressedinhaemangiosarcoma cells,
sarcomainthedogandvisceralmastcelltumours
implicatingdysregulatedstimulationofoneormore
(MCTs) inthecatwarrantindividual consideration.
ofthesefactorreceptorsintumourdevelopment.
Mutations in the tumour suppressorgene PTEN
havealsobeenimplicatedinthepathogenesisof
Canine splenic tumours
caninehaemangiosarcoma(Dickersonetal.,2005).
Splenomegaly,orasplenicmass,isquiteacommon
Presentationandclinicalsigns
clinical finding in dogs andreports suggest that
Forlow-gradeandbenigntumours,abdominal dis-
43-75%of thesecasesarecausedbyneoplasia
tensionduetotheenlargingtumourmassmaybe
（Freyand Betts,1977;Day etal.,1995).Tumours
thepresenting sign.Alternatively,themassmaybe
affectingthespleenindogsaresummarizedin
detectedduringroutineclinicalexamination,assuch
Figure19.20.
tumourscanreachalargesizewithoutcausingclini-
cal signs.
Primarytumours
Splenicsarcomasmaycausenon-specificsigns
ofmalaise,butarealsooftendetectedonclinical
·Haemangioma
Haemangiosarcoma
Sarcoma(various)
thetimeofexploratorylaparotomy.
Thepresenting signsofsplenichaemangiosar-
Secondary ormulticentric tumours
comamaybedramatic,withacutecollapsefollowing
Lymphoproliferative andmyeloproliferative conditions(e.g.
ruptureof,orbleedingfrom,theprimarymass,lead
lymphoma)
ingtoahaemoperitoneum.Lessspecificsignsof
Malignanthistiocytosis/disseminatedhistiocyticsarcoma
lethargy,weakness,pallor and anorexia may be
Haemangiosarcoma
detectedpriortoamajorabdominalbleed.Some
Mastcell tumour
Othermalignant tumours with widespreadmetastases(e.g.
dogsmayhaveahistoryoftransientperiodsof
weaknessorcollapseinthedaysorweekspreced-
melanoma)
inganacutecollapseanditispostulatedthatthese
Non-neoplastic causes of splenomegaly or splenicmass
episodesrepresentabdominalbleedsfromwhich
Nodularhyperplasia
thedogmayrecoverduetoauto-transfusion.
Haematoma
Haemorrhagicdiathesesduetodisseminatedintra-
Thrombosis andinfarction
vascularcoagulation(DiC)maybeapresentingsign
Congestion
insomecases.However,splenichaemangiosarcoma
Extramedullaryhaemopoiesis
mayalsobedetectedasanincidentalfindinginthe
Torsion
absenceof overt clinical signs.
19.20
Tumours andmassesof thecaninespleen.
Splenicneoplasiamaybeassociatedwith
cardiacdysrhythmiassuchasventricularpremature
contractions.
Haemangiosarcomaisthemostcommon tumour
of thecanine spleen.It affectsolderdogs(9-10
Clinical approach
years)andtheGermanShepherdDogisatgreater
risk than other breeds (Ng and Mills,1985).Non-
Haematology
angiomatous mesenchymal tumours('splenic sar-
Anumberofhaematologicalabnormalitiesmaybe
comaincludinghistiocyticsarcoma-seebelow)are
detectedindogswithsplenichaemangiosarcoma:
304
Chapter19b
Tumoursofthespleen
Anaemia-regenerativeifduetobloodloss;or
Radiographyof thethoraxandultrasonographyof
microangiopathicifduetofragmentationofred
otherabdominalorgans,especiallytheliverandkid-
bloodcellsduringpassagethroughameshwork
neys,areindicated to detectmetastases.
offibrininthemicrovascularnetworkof the
tumour
Cytologyandbiopsy
Acanthocytes(damaged red cells;Figure 19.21)
Fine-needle aspiration （FNA)may assist in cyto-
andschistocytes(redbloodcell fragments)-
logicaldiagnosisincasesofgeneralizedspleno-
highlyindicativeofhaemangiosarcoma
megaly(e.g.associatedwithlymphomaorMCTs in
Thrombocytopenia-may be due to bleeding,
thecat)，orwhere spleniclesions appearsolidon
sequestrationofplateletswithinthe
ultrasonography.
microvascularnetworkofthetumour,orDic.
WARNING
ItisnotadvisabletoattemptFNAincaseswhere
splenic lesions have a vascular appearance on
samples would beof diagnostic quality,asblood
isusually all that is collected from such lesions.
More importantly,the procedure carries a riskof
causinghaemorrhage into the abdomenandpos-
sible seeding of tumourcells.
Splenicbiopsymaybeindicatedincaseswithdif-
fusesplenomegalyormultinodularsplenicdisease.
Needlebiopsy techniquesmaybeused underultra-
soundguidance（though they stillcarryariskof
bleeding),orincisional biopsysamplesmaybe col-
19.21
Theseerythrocytesareacanthocytes,which
lectedatlaparotomy.Thelatterallowsvisualization
haveroundedprojectionsofvariablelengthdue
of thewholespleenandthusbetterselectionofrep-
tomembrane damage.(ModifiedWright's-Giemsa stain,
original magnificationX10oo)(Courtesy of CSommerey.
resentativelesionsforbiopsyspecimens.
ClinicalPathology,DepartmentofVeterinaryMedicine,
Incaseswherethereisadistinctmassinthe
University of Cambridge)
spleen,performinganexcisionalbiopsybysplenec-
tomyispreferable.Notonlyisthistechnicallyeasierto
IncaseswithDlC,clotting studiesrevealabnor-
perform,butitalsoprovidesthepathologistwithsuffi-
malitiesinbothprimaryandsecondaryhaemostasis,
cientmaterial toachievethecorrectdiagnosis.This
fibrindegradationproductsareelevated,andfibrino-
isparticularlyimportantfordifferentiationbetween
genand anti-thrombinlllaredecreased.
splenichaematoma,haemangioma and haemangio-
Ahaemophagocyticvariantofhistiocyticsarcoma
sarcoma.Sufficientmaterialshouldalwaysbepre-
hasbeendescribed thatconsistentlyinvolvesthe
sentedforhistopathology.Eitherthewholespleencan
spleenandisassociatedwithaCoombs'test-
besubmitted,orsections thattheclinicianconsiders
negativeregenerativeanaemia,thrombocytopenia
representative.However,if‘representative'piecesare
andhypoalbuminaemia(Dobsonetal.;2006;Moore
submitted,it isalwaysadvisabletokeeptherestof
etal.,2006).
thespleenincasetheclinicalpicturedoesnotfitwith
the diagnosis.
Imaging
Splenomegalyorasplenicmassmaybedetected
Haemangiosarcomaandhaemangioma
onplainradiographsof theabdomenandthesemay
Haemangiosarcoma is the most important tumour of
alsoshowevidenceofabdominalfluidincaseswith
thecaninespleen.Haemangiomaandhaematoma
haemorrhage.
mayalsoaffectthespleenanditcanbedifficulttodif-
Ultrasonographycanprovideuseful information
ferentiatetheseconditionsclinicallyandhistopath-
about the structureofa splenicmass(ormasses)
ologically，for example,when haemorrhage occurs
anditsrelationshipwithnormalsplenictissue.The
withinahaemangiosarcoma.It maybenecessaryto
vascularnatureofhaemangiosarcomamaybeseen
examinemultiplehistologicalsectionsfromthelesion
asamixedornon-homogenousmasswithecho-
beforeacertaindiagnosiscanbereached.Collapse
lucentareas,incontrasttothemorehomogenous
andpresenceofhaemoperitoneumaresignificantly
denserstructureofnormalspleen.
morecommonindogswithsplenichaemangiosar-
Contrast-enhanced ultrasonography using micro-
coma thanthosewithsplenichaematoma(Prymaket
bubblecontrastmediahasbeenused toimprove
al.,1988)andinonestudydogswithhaemangiosar-
characterizationbetweenbenignandmalignantfocal
comahadlowertotalproteinconcentrationsand
ormultifocal lesions in the spleen（Rossi etal,
plateletcountsthandogswithothersplenicmasses
2008).Contrast-enhanced computed tomography
atthetimeof admission(HammondandPesillo-
canalsoprovidesignificantdifferencesinimaging
Crosby,2008).
characteristicsbetweenbenign
andmalignant
Haemangiomaand haemangiosarcoma（Figure
splenic lesions(Fife et al.,2004).
19.22a)mayeachpresentaseitherasinglemassor
305
Chapter19b
Tumoursofthespleen
T-Primarytumour
TO=No evidence of tumour
T1=Tumour confined to primary site
T2=Tumourconfined to primary sitebut ruptured
T3=Tumourinvading adjacent structures
N-Lymphnodes
NO=No evidence of lymphnode involvement
N1=Regional lymphnode involvment
N2=Distantlymphnode involvement
M-Metastasis
(al
MO=No evidence ofmetastaticdisease
M1=Metastasisinsamebodycavityasprimary tumour
M2=Distant metastasis
Stage grouping
Stage1=TOorT1,NO.MO
StagelI=T1orT2,NOorN1,M1
Stage l=T2orT3,N1orN2,M2
19.23
Clinicalstaging forcanine haemangiosarcoma.
Managementandprognosis
Surgery:Surgicalremovalof thetumourbysplen-
ectomyisthetreatmentofchoiceforsplenichaem-
(b)
angiomaandhaemangiosarcoma.
Preoperative
19.22
(a)Splenichaemangiosarcomaremovedfroma
considerationsincludecorrectionofhaematologicalor
6-year-oldneuteredfemaleMastiff.(b)The
coagulationabnormalitieswithbloodproductsifnec-
primarytumourhasruptured,butsecondarymassescan
essaryandcirculatorysupportwithappropriatefluids.
beseen in the spleen and liver.(CourtesyofDuncan
Lascelles)
Dogsundergoingsplenectomyareatriskofdevelop-
ingventriculararrhythmiasduringandupto24-48
hoursaftersurgeryandshouldbemonitoredbyelec-
multiplenoduleswithin the spleen.Haemangiosar-
duringtheriskperiod.Atthetimeofsplenectomythe
metastasizetothespleen.Itisdebatablewhetherthe
abdomenshouldbeexploredforsignsofmetastases
heartorthespleenisthemorecommonsiteforthe
andanysuspiciouslesionsexcisedandsubmittedfor
developmentofhaemangiosarcomainthedog.In
histopathology.Careshouldbetakentoensure that
somepatientswithwidespreadtumourmetastases,it
vesselsareligatedandligaturesarewellplaced.
isdifficulttobecertainwhichlocationistheprimary
However,care shouldbe takennot toligate the
focus,orwhetherthetumourmightbemulticentric.
branchof thesplenicarterysupplyingthepancreas.
Haemangiosarcoma isahighlymalignanttumour,
withhaematogenousmetastasisoccurringearlyin
Chemotherapy:Postoperativechemotherapyisindi-
thecourseof thedisease（Figure 19.22b).Rupture
oftheprimarytumourcanleadtoacuteandfatal
sionofmicrometastaticdisease.Single-agentor
haemorrhage.Primaryandmetastatictumoursmay
combinationdoxorubicin-basedchemotherapyproto-
beassociatedwithDic.Incontrast,haemangiomaof
colsaremostoftenusedfollowingsplenectomy,but
thespleenisaslowlygrowingtumourthatcanattain
mediansurvivaltimesarerelativelyshort,inthe
largeproportionsbeforediagnosis.Metastasisdoes
orderof141-179daysforcombinationprotocols
notoccur.
（Hammeretal.,1991;Sorenmoetal.,1993),with
<10%ofdogssurviving>12months.Doxorubicin
Staging
usedasasingleagenthasbeenreportedtoachieve
Aclinical stagingsystemforcaninehaemangiosar-
similar survival times(Ogilvie etal.,1996),ashas
coma hasbeendescribed (Figure 19.23).In splenic
low-dosecontinuouschemotherapywithcyclophos-
haemangiosarcoma,theextentofthetumourwithin
phamide，etoposideand piroxicam(Lana et al.,
thespleenisoflessimportancethanwhetherthe
2007).Arecent studyusing epirubicinpostopera-
tumourhasinvaded through the spleniccapsule.
tivelysuggestedthatdogswithstageIdiseasesur-
Nodal metastases are uncommon,butradiography
vivedsignificantlylongerthanthosewitheitherstage
andultrasonographyarerequiredtoevaluatethepa-
Ilorstage lldisease(median345daysversus93
tientforhaematogenousmetastases.
and68days,respectively)(Kimetal.,2007).
306
Chapter19bTumoursof thespleen
Prognosis:The prognosis for dogs withsplenic
withamitoticindex<9showedsignificantlylonger
haemangiosarcomaispoor.Haemangiosarcomatyp-
survivalthanthosewithamitoticindex>9(Spangler
icallymetastasizesearlyinthecourseofthedisease
etal.,1994).
and,inmostcases,micrometastaseswillbepresent
at thetimeofdiagnosisof theprimarytumour.These
Histiocyticsarcoma
Histiocytic
sarcoma
may
be
localized
or
timesfollowingsplenectomy,whichrangefrom19to
disseminated(seeChapter 14)butquitefrequently
86days(Woodet al.,1998).Theownersof dogs
involvesthespleen.Ahaemophagocyticvarianthas
withhaemoperitoneumshouldbeadvised,before
recentlybeendescribed inwhich thespleenis
consistentlyinvolved.Affectedanimalshaveadiffuse
themassisfound tobesplenichaemangiosarcoma.
splenomegalywith ill-definedmasseswithinthe
spleen(Figure 19.24).Lesionsmay alsobe found in
Splenicsarcoma
theliver,lung and bone marrow(Dobson et al.,
Primarytumoursof mesenchymal origin('sarcomas')
2006;Moore et al.,2006).Oncytological
or
mayarisewithin thespleen,givingrise tospleno
histologicalexaminationthemalignanthistiocytes
megalyorasplenicmass.Somesuch tumoursare
showmarkederythrophagia,whichisthecauseof
welldifferentiatedandcanbeclassifiedaccordingto
theaccompanying anaemia(see above),butareas
theirmorphology.However,manylackcleardifferen-
ofextramedullaryhaemopoiesisareoftenfoundin
tiation,leadingtodiagnosesof‘undifferentiatedsar-
the adjacent splenic tissue,which can complicate
coma'.Whenmoredetailedimmunohistochemical
stainingisperformedonthesetumours,it appears
beenshowntoarisefromsplenicredpulpandbone
thatthey,alongwithsplenicfibrosarcomaandleio-
marrowmacrophagesandexpressMHCclasslland
myosarcoma,mighthaveacommonoriginfrom
thebeta2integrinCD11d(Mooreet al.,2006).
smoothmuscleorsplenicmyofibroblasts(Spangler
et al.,1994),though some might nowbe classified
ashistiocyticsarcoma(seebelow)
Primarymesenchymaltumoursofthespleencan
bedividedintothreecategoriesonthebasisoftheir
biologicalbehaviour(Spangleretal.,1994):
Benign,non-invasivetumours(leiomyoma,
lipoma):thesedonotmetastasizeandare
associatedwithlongpatientsurvivaltimes
Intermediatetumours(mesenchymoma):these
haveamediansurvivalperiodof12months
Malignanttumours(fibrosarcoma,
leiomyosarcoma,undifferentiatedsarcoma):
thesetumoursarecapableofmetastasisandare
associatedwithrelativelyshortpostoperative
19.24
Histiocyticsarcomafrom thespleenofa
Flat-coatedRetriever.
survivaltimes(mediansurvival4months;
80-100%mortality after12months).
Managementandprognosis
Management
Inthecasesdescribedtodate theprognosisis
grave,withmostanimalsbeingeuthanized ordying
atthetimeofdiagnosisduetowidespreadmeta-
Surgery:Surgicalremoval ofthetumourbysplenec-
stasis.Caseswherethetumourislocalizedto the
tomyisthetreatmentofchoiceforsplenicsarcoma.
spleenmightbenefitfrompostoperativechemother-
Unfortunately,this is nota curative treatment for
apy.Lomustine (CCNU)has recently been shown to
malignantsplenicsarcomas.
havesomeefficacyintreatmentofhistiocyticsar-
coma(Skorupskiet al.,2007),butno trialshaveyet
Chemotherapy:As withsplenichaemangiosar-
beenconductedtovalidate itsusespecificallyin
coma,postoperativechemotherapywouldbealogi-
splenichistiocyticsarcoma.
caltreatmentfordogswithmalignantsplenic
sarcoma,butlessisknownaboutthechemosensitiv-
ityofsuchtumours.Larger-scaleclinicaltrialsare
Felinesplenictumours
requiredtodefinetheroleofchemotherapyinthe
managementofsuchtumours.
Tumoursof thespleenarelesscommonincatsthan
indogs.Aswithdogsformsofleukaemiaand lym-
Prognosis:Theprognosisformalignantsplenicsar-
phoma may affect the feline spleen,buta splenic
comaispoorandamediansurvival timeof4months
formofmastcelltumour(lymphoreticularorvisceral
hasbeenreported,withmetastasesbeingafrequent
MCT)accountsfor15%of‘splenicdisease'inthecat
reason for euthanasia(Spangler etal.,1994).The
(Spangler and Culbertson,1992).Tumours and
mitoticindexhasbeenshowntobeofprognostic
tumour-likeconditionsofthefelinespleenarelisted
importanceinthisgroupoftumours:thosetumours
inFigure 19.25.
307
Chapter19b
Tumoursof thespleen
splenectomymayinvolvethecat'simmunesystem,
Primary tumours
hencetheuseofpostoperativecorticosteroidsin
Mastcelltumour
these animalsis controversial.
Haemangiosarcoma
Sarcoma(various)
Referencesandfurtherreading
Secondary or multicentric tumours
Brown NO,Patnaik AKand MacEwan EG（1985)
Lymphoproliferativeandmyeloproliferative conditionse.g
Canine
haemangiosarcoma.Journalof theAmericanVeterinaryMedical
lymphoma)
Association1865658
Haemangiosarcoma
Day MJ,LuckeVM and PearsonH （1995）A reviewofpathological
Othermalignant tumours with widespreadmetastases(e.g.
diagnosesmadefrom87caninesplenicbiopsies.JournalofSmall
AnimalPractice36,426-433
adenocarcinoma)
Dickerson EB,Thomas R,Fosmire SP et al.(2005） Mutations of
phosphateand tensinhomologdeletedfrom chromosome10in
Non-neoplastic causes of splenomegaly or splenicmass
caninehaemangiosarcoma.VeterinaryPathology42,618-632
DobsonMVilliersEouloisAetal006）Histiocyticsarcomaf t
Nodular hyperplasia
spleenin flat-coatedretrievers presentingwithregenerative
Haematoma
anaemiaandhypoproteinaemia.VeterinaryRecord158,825-829
Congestion
FifeWD,SamilVF,DrostWT.MatonJSand Hoshaw-WoodardS
Extramedullaryhaemopoiesis
(2004)Comparisonbetweenmalignant andnon-malignant splenic
masses indogsusing contrast-enhancedcomputed tomography.
VeterinaryRadiologyandUItrasound45,289-297
19.25
Tumoursandmassesof thefelinespleen.
FreyAJandBettsCW（1977)Aretrospective surveyofsplenectomyin
thedog.Journal of theAmericanAnimal HospitalAssociation13.
730-734
HammerAS,CoutoCG,Filippi Jet al.（1991）Efficacy and toxicity of
VAC
chemotherapy
(vincristine,
doxorubicin
and
Felinevisceralmastcelltumours
cyclophosphamide)indogswithhaemangiosarcoma.Journal of
VeterinaryIntrnalMedicine5,160-166
TherearethreedistinctformsofMCTincats:
HammondTNandPesillo-Crosby
SA(2008)Prevalenceof
cutaneous(seeChapter 12),intestinal (see Chapter
hemangiosarcoma in anaemicdogs with a splenicmass and
15)andvisceral.Theprincipalsiteofdevelopmentof
hemoperitoneum requiring transfusion:71cases (2003-2005).
Journalof theAmericanVeterinaryMedicalAssociation232,553
thelatteristhespleen,whichaccountsfor>85%of
558
visceralMCTs.Otherorgansandsitesmayhave
Kerline RLand Hendrick MJ(1996)Malignant fibroushistiocytoma and
visceral MCTs, such as the liver,kidney,visceral
malignant histiocytosisinthe dog-convergentordivergent
phenotypicdifferentiation?VeterinaryPathology33.713-716
lymph nodes,
intestine,
bone
marrow
and,
Kim
SE,Liptak JM,Gall TT,Monteith GJand Woods JP （2007)
occasionally,themediastinumandlung.While itis
Epirubicininthe adjuvant treatmentofsplenichaemangiosarcoma
indogs:59cases(1997-2004)Journalof theAmericanVeterinary
possiblefor cutaneousMCTto spread toviscera,
MedicalAssociation231,1550-1557
thisisuncommoninthecat.
Lana S.U'ren L,Plaza S et al.（2007)Continuous low-dose oral
chemotherapyforadjuvant therapyofsplenichaemangiosarcoma
indogs.JournalofVeterinaryInternalMedicine21764-769
Presentation
LiskaWD,MacEwenEGZakiFAandGarveyM（1979）Felinesystemic
Catswithvisceral MCTpresentmostcommonlywith
mastocytosis:areview andresultsofsplenectomy inseven cases
anorexia,chronic vomiting and malaise.This is
Journalof theAmericanAnimalHospitalAssociation15,589-597
MoorePF,AffolterVKandVernauW(2006）Caninehaemophagocytic
thoughttobeduetogastroduodenalulceration
histiocytic
sarcoma:
aproliferativedisorderofCD11d
resultingfromtheeffectsofhistamineongastricH2
macrophages.VeterinaryPathology43,632-645
Ng CYandMillsJN(1985)Clinical andhaematological featuresof
receptors.Gastriculcersmayeventuallyperforate,
haemangiosarcomaindogs.AustralianVeterinaryJournal62,1-4
leadingtoperitonitisanddeath.Splenicrupturehas
Ogilvie GK,Powers BE,Mallinckrodt CH et al.(1996)Surgery and
alsobeenreported.
InternalMedicine6,379-384
Catswithvisceral MCTmaybeanaemic,due to
Prymak C,McKee LJ,Goldschmidt MH and Glickman LT （1988)
bloodlossfromgastricorduodenal ulcersordueto
Epidemiologic,clinicalpathologicandprognosticcharacteristisof
bonemarrowinfiltration.Othercytopeniasmayalso
cases（1985).Journal of the AmericanVeterinaryMedical
occurincaseswith
bone
marrowinfiltration.
Association193,706-712
Circulatingmastcellsmaybeseenonbloodsmears;
RossiF,neVF,VignoliM,LaddagaEandTerragniR.(2008）Uf
contrast-enhancedultrasoundforcharacterizationoffocalsplenic
bonemarrow
aspirationisindicatedincats
lesions.VeterinaryRadiologyandUltrasound49154-164
suspectedofhavingvisceralMCT.
Skorupski KA,Clifford CA,PaoloniMC et al. (2007)CCNU for the
treatmentofdogswithhistiocyticsarcoma.JournalofVeterinary
InternalMedicine21,121-126
Managementandprognosis
SorenmoKU,JeglumKA and Helfand SC(1993)Chemotherapyof
DespitethefactthatcatswithvisceralMCToften
canine
haemangiosarcoma
with
doxorubicin
and
cyclophosphamideJournalofVeterinaryInternaMedicine7370
have signsofsystemicinvolvement,oratleast
376
involvementofotherorgans,splenectomyappearsto
SpanglerWLandCulbertsonMR(1992)Prevalence and typeof splenic
be thetreatmentof choice.
diseasesincats:455cases(1985-1991).Journalof theAmerican
VeterinaryMedicalAssociation201,773-776
TheprognosisforcatswithvisceralMCTisfair
Spangler WL,Culbertson MR and Kass PH （1994)Primary
following splenectomy.In onereportof sevencases,
mesenchymal (nonangiomatous/nonlymphomatous)neoplasms
survivalrangedfrom2to34months,withamedian
occuringinthecaninespleen:anatomicclassification,
of12months.Resolutionofhaematologicalabnor-
survival.VeterinaryPathology31,37-47
malitieswasreportedfollowingsplenectomyinthese
WoodCAMooreAS,GliattoJMetal.（1998）Prognosisfordogswith
StageIorllsplenichaemangiosarcoma treatedbysplenectomy
alone:32cases（1991-1993).JournaloftheAmericanAnimal
1979).It hasbeenpostulated that thisresponseto
HospitalAssociation34,417-421
308
Endocrine tumours
J.CatharineR.Scott-Moncrieff
Introduction
Palpablecervicalmassesarepresent in71%of
cases;cervicalmassesmaybeattached tounder-
Commonendocrinetumoursindogsandcats
lyingoroverlying tissues.
includetumoursofthethyroidgland，parathyroid
gland，pituitarygland，adrenalglandandendocrine
Diagnosis
pancreas(Figure 20.1).
Commonabnormalitiesonbloodtestsaresimilarto
thoseincatswithbenignthyroiddiseaseandinclude
increasedhaematocritandmeancorpuscularvol-
Thyroidglandtumours
ume,a stressleucogram,highliverenzymeactivity,
Themajorityofcasesoffelinehyperthyroidismare
azotaemiaandoccasionallyhypercalcaemia.Radio-
graphicabnormalitiesmayincludecardiomegaly,
duetobenignadenomaoradenomatoushyper-
evidence ofcongestiveheart failure,mediastinal
plasia.Unlikefeline thyroid tumours,mostclinically
masses andevidenceofpulmonarymetastasis.The
significantcanine thyroidtumoursaremalignant
carcinomas.Thediagnosisandtreatmentofbenign
electrocardiogrammayshowincreasedR-wave
functionalfelinethyroidtumourshasbeenexten-
amplitude,tachycardiaandarrhythmias.Echocardio-
sivelyreviewedelsewhere.Thischapterwillfocus
onmalignant thyroidcancersinthecatanddog.
trophy,thickeningoftheinterventricularseptum,and
leftatrialandventriculardilatation.
Thyroidtumoursincats
Themajorityofcatswiththyroidcarcinomahave
Malignantthyroidneoplasiaisdiagnosedinapproxi-
increased basal serum thyroxine(T4)concentra-
mately1-2%ofcasesofcatswithhyperthyroidism
tions.Nodifferenceshavebeenidentifiedin the
(PetersonandBecker,1995).Mostmalignantthyroid
rangeofserumT4concentrationsincatswith
tumoursinthecatarefunctionaltumours,withfollic-
benignandmalignant thyroidtumours.Incatswith
ularcarcinomasbeingmost common.Rarelyare
earlyhyperthyroidism,orthosewithconcurrentdis-
catsdiagnosedwithnon-functionalthyroidtumours.
ease,measurementoffree T4,aT3suppression
Clinicalfeatures
firming thediagnosis.Anon-functional tumour
Agerangesfrom6to18yearsandmalesareover-
shouldbesuspectedifathyroidtumourisidentified
represented.Manycatshaveahistoryofprior thy-
butT4concentrationisnormalandtherearenoclin-
roidectomy.Weight loss,polydipsia and polyuria,
icalsignsofhyperthyroidism.
polyphagiaandhyperactivityarethemostcommon
Nuclearscintigraphyusingsodiumpertechnetate
historical findings.Tachycardia,hyperactivity,heart
isvaluableintheevaluationofcatswithsuspected
murmur,dyspnoea，polypnoea,moist pulmonary
malignant thyroidtumours.Sodiumpertechnetate
ralesandtremorarecommonphysicalexamination
(99mTc)isactivelyconcentrated inallfunctional thy-
findings.Voicechangehasalsobeenreported.
roid tissue.Incats with thyroid carcinoma,a99mTc
Endocrine gland
Benign tumours
Malignant tumours
Thyroid
Thyroidadenoma
Thyroid carcinoma
Parathyroid
Parathyroid adenoma
Parathyroid carcinoma
Pituitary
Adenomaof somatotrophsorcorticotrophs
Pituitary carcinoma
Adrenal
Adrenocorticaladenoma
Adrenocortical carcinoma
Phaeochromocytoma
Endocrinepancreas
Insulinoma
Gastrinoma
20.1
Endocrinetumoursof thedog andcat.
309
Chapter20Endocrinetumours
scanmaydemonstratepatchyorirregularuptakeof
isotope,extensionofisotopeuptakedowntheneck
（Figure 20.2)and into themediastinum,and evi-
denceofdistant metastasis;however,insomecats,
scintigraphicfindingsincarcinomamaybesimilarto
thoseforcatswiththyroidadenomatoushyperplasia
oradenoma.Also,scansthatrevealuptakebymulti-
plemasses inthecervicalregionormassesextend-
ingintothecranialmediastinummaybearesultof
benignectopic tissue.Scintigraphyalone cannot
definitivelydistinguishbetweenadenomatoushyper-
plasiaand thyroidcarcinoma.Bronchogeniccarcin-
omamayhavescintigraphicfindings thatmaybe
confusedwiththoseofthyroidtumours.Non-
functional thyroidtumoursmayormaynottakeup
20.3
Thyroidcarcinoma inacatpriortosurgical
99mTc,depending upon the degree of differentiation
resection.Notethesizeand irregularshapeof
the tumour.
of the tumour.
increasedmitoticratearenotconsistentfeatures.
Featuresthatdistinguishmalignantfrombenign
tumoursincludelocal tissueinvasion,regional lymph
nodeinvolvementanddistantmetastasis.Metastasis
hasbeenreportedtooccurinupto71%offeline
thyroidcarcinomas.
Treatment
Therapeuticoptionsfortreatmentofcatswithhyper-
thyroidismduetobenigndiseaseincludeanti-thyroid
drugs(e.g.methimazole,carbimazole),131iodine（131)
orthyroidectomy.
Anti-thyroiddrugs:Whilecatswiththyroidcarcin-
omamayshowclinicalimprovementwhentreated
withanti-thyroid drugs,thesedrugs arenotrecom-
mendedforseveralreasons.Thyroxineexertsaneg-
ativefeedbackeffectontheanteriorpituitarygland,
resultingindecreasedreleaseofthyroid-stimulating
hormone （TSH).Anti-thyroid drugs may increase
releaseofTSHfromtheanteriorpituitaryglandby
decreasingsecretionofthyroxineandexacerbate
tumourgrowthdue to thetropiceffectsofTSH.
20.2
Ventrodorsalviewfromatechnetiumscanina
Furthermore,anti-thyroid drugsarenotcytotoxicand
catwiththyroidcarcinoma,showingirregular
willslowneitherprogressionoflocaltumourgrowth
uptakeof isotope into three thyroidmasses in thecervical
normetastasistodistantorgans.Theonlyindication
region.
forusinganti-thyroiddrugsinthemanagementof
thyroidcarcinoma isforthepurposeof initial clinical
Definitivediagnosisofthyroidcarcinomarequires
histopathological
examinationofexcisedtissue.
Sincethemajorityoffeline thyroidtumoursare
Betablockers:Betablockerssuchaspropanolol or
benign,thyroidcarcinomamaynotbesuspected on
atenololareusefulinhyperthyroidcatsthatrequire
theinitialevaluation.Factorsthatshouldincreasethe
indexofsuspicionforthyroidcarcinomainclude
therapy.Betablockersdecreasethecardiotoxic
recurrenceofhyperthyroidismafterpreviousthyroid-
effectsofthyroidhormonesbutarecontraindicated
ectomyorradioiodinetherapy,presenceofmultiple
inpatients with overt heart failure,asthma,or
palpable cervical nodules（Figure20.3)and cervical
chronic bronchiolar disease.Atenolol,a beta-1-
nodulesthat arefirmlyattachedtounderlyingor
selective antagonist,maybea saferchoice than
overlyingstructures.Largepalpablethyroidmasses
propranololinpatientswithrespiratorydiseaseand
thatcompresssurroundingstructuresmaybedueto
needstobegivenonlyonce a day.
eitherthyroidcarcinomaorbenignthyroidcyst.
Thyroidcarcinomashould alsobesuspected ifscinti-
Surgery:Thyroidectomyistheinitial treatmentof
graphyrevealsmultipleareasofradionuclideuptake
choiceincatswithsuspected thyroidcarcinoma,
andirregularorpatchyisotopeuptake.
because thediagnosismustbeconfirmedbyhisto-
Cytologicalcharacteristicsareusuallyunhelpful
pathologyandbecausecompleteexcisioncanbe
indifferentiationofbenignfrommalignantthyroid
curative.Thethyroid tumourshouldbecompletely
tumours,because pleomorphism,anaplasia and
excised ifpossible;however,thyroid biopsy,followed
310
Chapter20
Endocrinetumours
sitesofmetastasisincludethebaseoftheheart,
catswithinvasiveorinfiltrativemasses.Preservation
spleen,kidney,bone marrow,prostate，adrenal
of theparathyroidglandsismoredifficultincatswith
gland,bones and spinal cord.
invasive thyroidcarcinomastreatedsurgically,and
postoperativemonitoringofserumcalciumconcen-
Clinicalfeatures
trationsisessentialforcatsundergoingbilateralthy-
Caninethyroidcarcinomasaremostcommoninmid-
roidectomy.Acatexhibitingsignsofhypocalcaemia
dle-agedandolderanimals,withameanageof10
after thyroidectomy(e.g.muscle tremors,tetany，or
years.Breeds atincreasedriskincludeBoxer,
convulsions)shouldbetreatedwithappropriatecal-
BeagleandGoldenRetriever.Clinicalsignsdueto
ciumand vitamin Dsupplementation(seelater for
thepresenceofa space-occupyingcervicalmass
approachtotreatmentofhypocalcaemia).
arethemostcommon.Affecteddogsmayexhibit
Evenifallvisibletumourisremoved,manythy-
dyspnoea,coughing,dysphagia,retching，anorexia,
roidcarcinomaswillrecurwithinweekstomonths.
facial oedema anddysphonia.Other clinical signs
Thus,inhistopathologicallyconfirmed thyroid carcin-
include vomiting,listlessness and weight loss.In
oma,thyroidscintigraphy shouldberepeated 4-8
dogswith functional thyroidtumours,polyuriaand
weeksafterthyroidectomyinordertoevaluatethe
polydipsia,restless behaviour,polyphagia,weight
successofsurgicalremoval.lIftumourrecurrenceis
loss,diarrhoeaand tachycardiamaybeobserved.
confirmed,treatmentwithhigh-dose131isrecom-
Signsofhypothyroidismmaybepresentindogsthat
mended.Following treatment with 131,periodicre-
Physical
examination findings
are
hypothyroid.
evaluationofserumT4concentrationsand
99mTc
includea firm,usuallyasymmetrical massinthecer-
scansshouldbeperformed every3-6months.If
vicalregion（Figure20.4)andoftensubmandibular
recurrenceisnotdetectedinthesefollow-upevalua-
lymphadenopathy.Dyspnoea，cachexia and neck
tionsafter1year,theperiodbetweenevaluations
painoccurlesscommonly.Cardiacarrhythmiasor
canprogressivelybelengthened.
murmursmaybedetectedinhyperthyroiddogs.
lodinetreatment:Treatmentwith1311isindicatedin
catswithnon-resectablethyroidcarcinoma,evidence
ofmetastasis,orrecurrence after thyroidectomy.
Higherdoses（10-30mCi)arerequiredfor thyroid
carcinomathanforadenoma.Acombinationofsurgi-
calresectionandpostoperativetreatmentwithhigh
doses of1311isaneffectiveapproach.Surgical
removalfollowedbyadministrationof30mCi1311in
sevencatswiththyroidcarcinomaresultedinsurvival
timesrangingfrom10to41months,andnoneof the
catsdieddue to thyroidcarcinoma（Guptilletal,
20.4
Alargethyroidcarcinomainvolvingthelarynxin
talizationtoallowtheisotopetimetodecaytoactivity
an8-year-oldneuteredmaleEnglishPointer.
levelscompatiblewithdischargetothehomeenviron-
ment.Themajorityofcatstreatedwithhigherdoses
Diagnosis
of131|becomepermanentlyhypothyroidandrequire
Non-specificabnormalities,suchasmildnormocytic
supplementationwithlevothyroxine.
normochromic anaemia,leucocytosis,mild azotae-
miaandelevationsinserumliverenzymeactivities
Thyroidtumoursindogs
aretypicalfindingsontheminimumbloodworkdata-
Clinicallysignificantcaninethyroidtumoursareusu-
base.Hypercalcaemiahasbeenreportedindogs
ally large,non-functional,unilateral,invasive and
withthyroidcarcinomaandmaybeduetoeither
malignant.Whileone-thirdofallcanine thyroidneo-
concurrentprimaryhyperparathyroidismorapara-
plasmsdetectedatnecropsyaresmalladenomas,
neoplasticphenomenon.Some dogswithprimary
thesebenignlesionsrarelyresultinsignificantclini-
thyroidneoplasiahaveevidenceofotherprimary
calsigns.Malignant thyroid tumours account for
endocrine tumours,inparticularparathyroidtumours
70-100%ofclinicallydetectedthyroidtumoursin
andadrenaltumours.
dogsandmostare carcinomas.Themajorityof
Thoracicandabdominalradiographyandabdom-
affecteddogsareeuthyroid;however,approximately
20%of thyroidcarcinomasarefunctional,producing
monary,hepaticorothervisceralmetastases.Upto
clinicalsignsofhyperthyroidism.Hypothyroidismdue
60%ofdogswiththyroidcarcinomahaveradio-
todestructionofnormalthyroidtissuebythetumour
graphicevidenceofpulmonarymetastasisatthe
hasbeenreportedin6-20%ofmalignantthyroid
timeofdiagnosis.Cervicalultrasonographyand
tumours(Marks et al.,1994;Théonetal.,2000).
computed tomography(CT)maybeuseful in deter-
Mostcaninethyroidcarcinomasarisefromfollicu-
miningtheextentoftumourinvasion.Thyroidtesting
larcells,butparafollicularC-cell(medullary)carcin-
(T4,freeT4,TSH)shouldbeperformed todetermine
omasalsooccur.Caninethyroidcarcinoma
is
thyroidstatus.Increasedserumthyroid hormone
characterizedbylocaltissueinvasionandahighrate
concentrationsduetothepresenceofautoanti-
of metastasis,particularlytothelungs,retropharyn-
bodiestotri-iodothyronine(T3)orT4areanimpor-
geal lymphnodesandtheliver.Otherlesscommon
tantdifferentialforcaninehyperthyroidism.
311
Chapter20Endocrine tumours
Fine-needleaspirationcytologymaybeuseful in
20.5
differentiatinga thyroidtumourfromanabscess,
Ventrodorsalview
cyst,salivarymucocele,orenlargedlymphnode,but
cytologyisnothelpful indefinitivelydifferentiating
fromatechnetium
scan of a dog,
benignfrommalignant thyroidneoplasia.Aspirates
showing
arefrequentlynon-diagnosticduetoperipheral blood
heterogenous
contamination.Use of larger biopsyinstruments,
uptake(shape and
suchasalarge-boreneedleorTru-cutbiopsynee-
density)into a
dle,is not recommended,because most thyroid
thyroid mass.
tumoursarehighlyvascular.Asurgicalbiopsyis
Histopathologyof
the excised mass
necessaryfordifferentiationbetweenathyroidaden-
indicatedthyroid
omaandcarcinoma.lf themass isclearlynotamen-
adenocarcinoma.
able to complete surgical excision,anincisional
wedgebiopsyshouldbeperformed.
Nuclearimagingisuseful inthediagnosticevalu-
ationofdogs withthyroidtumours,andsodium
pertechnetate istheisotopeofchoice.Ina studyof
29dogswiththyroidcarcinoma，99mTcscanswere
abnormal inalldogs(Markset al.,1994)and loca-
tionofthetumouratsurgerycorrelatedwellwith
scintigraphicfindings.Dogswithnon-functional thy-
20.6
roidcarcinomastendtohavepoorlycircumscribed
Ventrodorsalview
heterogenous isotope uptake(Figure 20.5).Dogs
fromatechnetium
withfunctionalcarcinomasusuallyhaveintensewell
scanofa
circumscribedandhomogenousuptakeofisotope
hyperthyroid dog,
on9mTc scan(Figure 20.6). Scintigraphy is no more
showing
sensitivethanthoracicradiographyfordetectionof
homogenous
pulmonarymetastases.
uptake intoa
thyroidmass.
Histopathology of
Treatment
excisedtissuewas
consistentwitha
Surgery:Surgicalresection istheinitial treatmentof
welldifferentiated
choicefordogswiththyroidtumours,regardlessofthe
thyroid carcinoma.
functional statusof thetumour.Thyroidadenomasare
generallywellencapsulatedandmoreamenableto
surgicalresection thanthyroidcarcinomas.Evenif
completeremovalof thetumourisnotpossible,
surgical debulkingprovidestissuesamplesforhisto-
pathologicalevaluationandmayalsoalleviatesome
of the clinical signs(e.g.dyspnoea,dysphagia,dys-
phonia)associatedwiththetumour.Surgeryisbest
performedbyanexperiencedsurgeonbecauseofthe
vascularityofthyroidtumoursandtheriskofdamage
havebeenusedempiricallytotreatthyroidcarcinoma
totherecurrentlaryngealnerves,parathyroidglands
in thedog,withMSTsrangingfrom3to9months.
andmajorbloodvessels.Thyroidtumours thatare
Thereisnostrongevidencebasetosupport theuse
mobileandwellcircumscribed arethebestsurgical
ofchemotherapyforcaninethyroidcarcinoma.
candidates.Successfuloutcomeafter thyroidectomy
hasbeenreportedin20/82ofdogswiththyroidcarci-
Radiotherapy:Externalbeamradiation therapyis
noma(Klein et al.,1995).Dogs werepreselected for
effectiveforlocalcontrolofunresectable thyroid
surgerybasedonthepresenceofafreelymovable
tumours,butisineffectiveinpreventionofmetastatic
massandtheabsenceofevidenceofmetastasis.
disease.An80%1-yearsurvivalratehasbeen
Mediansurvival time(MST)was>36months.Indogs
reportedin25dogswithunresectablethyroidcarcin-
withextensivelocaltumourinfiltrationorwithdistant
omas（Théon,2000);28%ofthedogs developed
metastases,however,surgicalresectionisstrictlypal-
metastasis.Maximalreductionintumoursizereduc-
liative.Whenthetumouris>100cm3,theprobability
tionwasobservedat8-22months.Acutecomplica-
ofmetastasisisextremelylikely，evenifnotclinically
tionsofexternalbeamradiationincludechangesin
apparent.Adjunctive chemotherapy,palliativeradia-
vocalization,dysphagia,skin changes,oesophagitis,
tiontherapy,orradioiodide therapyshouldbeconsid-
pharyngitis,laryngitisandhypothyroidism.
ered in thesepatients.
lodinetreatment:Indogswithunresectablethyroid
Chemotherapy:Chemotherapyaloneisunlikelyto
carcinomasthatconcentrateradioiodinebasedon
resultintotalremissionofthyroidcarcinoma.
nuclearscintigraphy,treatmentwith1311isaviable
Doxorubicin,cisplatinandcombinationtherapyutiliz-
alternativetoexternalbeamirradiation.Inaretro-
ing doxorubicin,cyclophosphamideand vincristine
spectivecaseseriesof39dogswithnon-resectable
312
Chapter20Endocrinetumours
thyroidcarcinomatreatedwith1311,MSTrangedfrom
dogswithPHPTpresentduetoclinicalsignsofuro-
366daysindogswithmetastaticdiseaseto839
lithiasisorurinarytractinfection.Signsdirectly attrib-
days indogswithlocaldisease(Turrelet al.,2006).
utabletohypercalcaemiaoccurin<50%ofaffected
Although50%ofthedogswerehyperthyroid,there
dogs and include polyuria,polydipsia,weakness,
wasnoassociationbetweenthepre-treatmentT4
decreasedactivity,inappetence,weightloss,muscle
concentration and survival.Ina second study,43
atrophy,vomiting,shivering and trembling.Other
rarer manifestationsincludeseizures,lamenessand
to185mCl,eitheraloneorasanadjuncttosurgery
bonepain.Hypercalcaemia isanincidentalfinding in
(Worthetal.,2005).MSTswere 34monthsin the
>30%ofdogswithPHPT.Thephysicalexamination
isusuallynormal.Muscleatrophy,weaknessandthin
thedogstreatedwith1311alone，comparedwith3
body conditionoccurinsomedogs.
months in untreated dogs.These studies suggest
Themostconsistentlaboratory abnormalitiesin
dogswithPHPTarehypercalcaemia,hypophospha-
ablethyroidcarcinomaandthatthebenefitof1311is
taemiaandlowurinespecificgravity(SG).
not limitedtodogswithfunctional thyroid.
Hypercalcaemiamaybemild tomarked,withtotal cal-
cium ranging from 12.1 to23.0mg/dl(3.03-5.75
Prognosis
mmol/l).Mild increasesintotal serumcalciumcon-
Caninethyroidcarcinomahasamuchmoreguarded
centrationsmaybesecondarytohyperalbuminaemia,
prognosisthanfelinethyroidcarcinomaduetothe
becauseapproximately50%oftotalcalciumispro-
propensityforbothlocal tissueinvasion,metastasisto
tein-bound.lonized serum calcium concentration is
distantsitesandrelativeresistanceto1311treatment.
unaffectedbychangesinplasmaproteinconcentra-
tionandisusefulforconfirmationofmildhypercalcae-
mia.ThemajorityofdogswithPHPThaveaserum
Parathyroidglandtumours
phosphorusleveleitherwithinorbelowthereference
range.Mostdogswithprimaryhyperparathyroidism
Parathyroidglandtumourscauseprimaryhyperpara-
haveurineSG<1.030.Renal failureispresentin<4%
thyroidism(PHPT)duetoautonomousproductionof
parathyroidhormone(PTH)byneoplasticparathy-
miatypicallyoccursinconjunctionwithanormalor
roid‘chief”cells.A solitary parathyroid adenoma/
lowphosphorusconcentration.Increasedactivityof
hyperplasiaisthemostcommoncauseofPHPTand
alkalinephosphataseisfoundin40%ofdogswith
parathyroidcarcinoma israre.ExcessPTHsecretion
PHPTsecondarytoosteolysis.Approximately30%of
fromtheparathyroidglandcauseshypercalcaemia
dogs havecysticcalculi(calciumphosphate or cal-
throughdirectandindirectactionsofthehormone.
PTHincreasesrenalconservationofcalciuminthe
ondarytoincreasedglomerularfiltrationofcalcium，
distal tubules and collecting ducts,decreasesproxi-
thoughotherfactorsmayplayarole.
mal tubularresorptionofphosphorusandenhances
osteoclasticactivity,promotingreleaseofcalcium
Diagnosis
and phosphorus from bone.PTH also facilitates
DiagnosisofPHPTisbyrulingoutothermorecom-
renalconversionof25-hydroxycholecalciferol
to
moncausesofhypercalcaemiasuchasnon-parathy-
1,25-dihydroxycholecalciferol.ActivatedvitaminD
roidneoplasia（Figure20.7)（seealsoChapter4),in
increasesintestinalabsorptionofcalciumandphos-
conjunctionwithdocumentationofaninappropriate
phorus.Boneresorption and intestinal absorptionof
PTH concentration(normal orhigh) in thepresence
phosphoruspromoteincreased serumphosphorus
ofhypercalcaemiaandalowornormalserumphos-
concentrations，butthisisinsufficienttocounteract
phorus concentration(Figure20.8).PTH concentra-
renalphosphorusloss,resultingina netdecreasein
tionshouldbebelow thereferencerangeindogs
serum phosphorus concentrations.Increased cal-
withhypercalcaemiaandthusanormalPTHdoes
ciumconcentrationresults inanegativefeedback
not excludePHPT.Inone study,PTH concentrations
effect on PTH secretion,quicklyreturning calcium
werewithinthelaboratoryreferencerangein73%of
levelstonormal.Inanimalswithprimaryhyperpara-
210dogswithPHPT（Feldmanetal.,2005).
thyroidism,neoplasticparathyroid tissue is insensi-
tivetoincreasingserumconcentrationsofcalcium,
Primaryhyperparathyroidism(duetoparathyroid hyperplasia,
andsynthesisandsecretionofPTHcontinues
adenoma,carcinoma)
despitepersistenthypercalcaemia.
Hypercalcaemia of malignancy (lymphoma,apocrinegland
adenocarcinomamutiplemyelomamelanomacarcinomas)
Parathyroid tumours in dogs
Chronicrenal failure
Hypoadrenocorticism
Clinicalfeatures
Vitamin D toxicosis
Nutritional secondaryhyperparathyroidism
Primaryhyperparathyroidismaffectsmainlyolder
Granulomatous diseases(e.g.blastomycosis,histoplasmosis,
dogs.Themeanageofonsetindogsis11years
schistosomiasis)
(range6-17years)andthereisnosexpredisposition
Idiopathichypercalcaemia (cats only)
(Feldmanetal.,2005).Primaryhyperparathyroidism
Haemoconcentration
isinheritedasanautosomaldominanttraitinthe
Laboratoryerror
Keeshond but themutationlocushasnotyetbeen
20.7
Causesof increasedblood calcium levelsin
identified(Goldstein et al.,2007).Fifty percentof
dogs and cats.
313
Chapter20
Endocrinetumours
Serum measurement
Primary hyperparathyroidism
Hypercalcaemia of
Chronic renal failure
HypervitaminosisD
malignancy
Total calcium
↑
↑orNor↓
Nor↑
lonizedcalcium
JON
Phosphorus
JN
Nor
orN
orN
Parathyroid hormone
orN
orN
(PTH)
PTH-related peptide
orN
orN
(PTH-rP)
Vitamin D
orN
Interpretationofdiagnostic testing indogswithhypercalcaemicdisorders.↑=raised;N=normal;
=decreased
Cervical ultrasonographymaybeusefultoconfirm
therapyfailtodecreaseserumcalciumconcentra-
thepresenceofoneormoreenlargedparathyroid
tions effectively，glucocorticoids may beusedto
glandsindogswithsuspectedPHPT.Affecteddogs
decreasecalciumconcentrationsinpatientswithpri-
usuallyhaveoneroundorovalmassincloseassocia-
maryhyperparathyroidism.Glucocorticoidtreatment
tionwithonethyroidlobe.Parathyroidglandtumours
shouldbeavoideduntilalldiagnosticsampleshave
rangingfrom3mmto23mmindiameterhavebeen
beencollected.
identifiedinPHPT(Figure20.9).UItrasoundfindings
correlatewellwithfindingsatsurgery,butultrasound
Surgeryandheatablation:Definitivetherapyby
issubjectiveanddependentontheskilloftheopera-
surgicalparathyroidectomyorultrasound-guided
tor.About10%ofdogswithPHPThavebilateralpara-
heatablationisrecommended,evenindogswith
thyroidgland involvement(Rasoretal.,2007).
mildhypercalcaemia,becausetheseverityofhyper-
calcaemiatendstoworsenwithtimeandbecauseof
theriskofurolithiasis.Tumoursmaybelocated in
eithertheinternalorexternalparathyroidglands.
Bilateraldiseasehasbeenreportedwithprimary
hyperparathyroidism,particularlywithparathyroid
glandhyperplasia.lftheinternalparathyroidglandis
involved,theassociatedthyroidglandshouldalsobe
removed.Ultrasound-guidedheatablationisan
acceptablealternativetoparathyroidectomybut
availabilityoftheequipmentiscurrentlyverylimited
andsuccessishighlydependentupontheskillofthe
operator(Rasor etal.,2007).Chemicalablation
3.0-
lowersuccessrateandthistechniquehaslargely
beenreplacedbytheheatablationtechnique.
20.9
Ultrasoundimageofasingleparathyroidgland
adenoma(arrowed)ina10-year-oldneutered
Treatmentofpostoperative
hypocalcaemia:
maleLong-hairedDachshund.
Becauseof thelowincidence ofmalignancy,the
long-term prognosis inpatientswithPHPT is good
Treatment
withappropriateandearlysurgicaltreatment.The
Treatmentofparathyroidneoplasiashouldinclude
most common andpotentially life-threatening compli-
bothacutemedical managementofhypercalcaemia
cationispostoperativehypocalcaemiaduetoatro-
(ifwarranted)andablationofabnormalparathyroid
phyofnormal parathyroid tissue.Hypocalcaemia
gland tissue.Hypercalcaemia shouldbe treated
typicallyoccursbetween24hoursand6daysafter
medicallyifincreasedserumcalciumconcentrations
surgery.Mildhypocalcaemiawithoutclinicalsignsis
cause clinical signs(see Chapter 4).Parathyroid-
commonanddoesnotrequiretreatment.Clinically
ectomyresultsinlong-termcontrolofhypercalc-
symptomatichypocalcaemiaismostlikelyindogs
aemiaandprovidestissueforadefinitivediagnosis.
thathaveacalciumconcentration>14mg/dl(3.5
mmol/l)priorto surgery,soprophylactictreatment
Diuretictherapy:Correctionoffluiddeficitsand
withcalcitriolandcalciumsupplementationimmedi-
salinediuresiswillpromoterenalexcretionofcal-
atelyfollowingrecoveryfromanaesthesiaisrecom-
cium.Diuretictherapyshouldbeinitiatedonlyafter
mended inthesepatients.
fluid deficitsare corrected.Loop diuretics,such as
Parenteralcalciumsupplementation(10%calcium
furosemide,inhibitcalciumreabsorptioninthethick
gluconateatadoseof0.5-1.5ml/kgasanintrave-
ascendinglimboftheloopofHenle,enhancingcalci-
nousinfusionover10-30minutes)shouldbetheini-
uresis.lfsalinediuresisandconcomitantdiuretic
tialapproachtotreatmentofclinicalhypocalcaemia.
314
Chapter20Endocrinetumours
Electrocardiographicmonitoringisrecommended
Pituitarygland tumours
duringcalciumadministration.Onceserumcalcium
concentrationsareatthelowerendofnormal,treat-
Pituitary tumoursindogsandcatsmaybeeither
mentwithcalcitriolandoralcalciumsupplementation
functionalornon-functional.Functional tumoursmay
shouldbeinitiated;inthemeantimenormocalcaemia
secreteeithergrowthhormone,causingacromegaly，
shouldbemaintainedbyintravenousorsubcutane-
or adrenocorticotrophic hormone (ACTH),causing
ousadministrationofcalciumgluconate（diluted
hyperadrenocorticism(Cushing's disease).
50:50with0.9%sodiumchloride)approximately
every6-8hoursuntilvitaminDandoralcalciumsup-
Felineacromegaly(hypersomatotropism)
plementationbecomeseffective(1-4days).Calcitriol
Acromegalyiscausedbyexcesssecretionofgrowth
hasafastonsetof action(1-4days) and a shorthalf-
hormone(GH) from a pituitary adenoma.Excess
life（<24hours).Therecommendeddoseforcalcitriol
circulatingGHcausesincreasedsecretionof insulin-
inboth thedog andcat is20-30ng(nanograms)
likegrowthfactorI(IGF-1)fromtheliver.Increased
GHcauses insulinresistance,carbohydrate intoler-
perkgperday.Calciumcarbonateistheoralcalcium
preparationofchoicebecauseof itshighconcentra-
ance,hyperglycaemia and diabetes mellitus.The
tionofelementalcalcium.Calciumsupplementation
anaboliceffectsofIGF-1causeproliferationofbone,
shouldprovide50-100mg/kg/dayofelementalcal-
cartilageandsofttissues,withorganomegaly.Feline
cium.Serumcalciumconcentrationsshould bemain-
acromegalyisbelievedtobeararecondition,though
tainedatthelowerendof thenormalrange（8-10
recentstudiessuggestthatitmaybeamorecom-
mg/dl)(2.0-2.5mmol/l).
moncauseofinsulinresistanceindiabeticcatsthan
AftervitaminDandcalciumsupplementation
hasbeenpreviouslyrecognized.
havebeen initiated,serum calciumconcentrations
shouldbemonitoreddailyuntil theystabilizeinthe
Clinicalfeatures
Mostcatswithacromegalyaremiddle-agedorolder
lowerendofthenormalrange;thenweeklyuntila
stabledoseregimenisachieved.Thedoseofvitamin
(median 10years,range 4-17)and90%are male.
Dcanbereduced in25%decrements every2-4
Clinical signs include polyuria,polydipsia,poly-
weeks until vitaminD therapy is completely discon-
phagia (due to insulin-resistant diabetesmellitus),
tinued,withserumcalciumconcentrationsmeasured
largebody size,weightgain(despitepoorglycaemic
aftereachdoseadjustment.Calcium supplementa-
control)andenlargementoftheheadandextremi-
ties（Figures 20.10 and 20.11).Allreported cases
tionmaythenbeslowlywithdrawn.
have hadconcurrentdiabetesmellitus(Niessenet
Themostimportantcomplicationassociatedwith
therapyforhypocalcemiaishypercalcaemia.Owners
al.,2007).Central nervous system signs,including
lethargy,circling,seizuresanddementia,can occur
shouldbeadvisedtowatchforrecurrenceofsignsof
duetoextrasellarexpansionofthepituitarytumour.
hypercalcaemia,such aspolyuria andpolydipsia.lf
hypercalcaemia
occurs,
supplementaltherapy
shouldbediscontinuedimmediatelyandsalinediur-
esisandfurosemidetreatmentshouldbeinstitutedif
hypercalcaemia issevere.Persistentelevationsin
serumcalciumconcentrationsdespitewithdrawalof
vitaminDandcalciumsupplementationsuggest
recurrenceofhyperparathyroidism.
Prognosis
Appropriatemedicalandsurgicalmanagementof
PHPT results in a good to excellent prognosis.Non-
(a)
reversiblerenaldisease,identificationofametastatic
parathyroidcarcinomaandinadequateattentionto
calciumandvitaminDsupplementationarefactors
thatcontributetoalessfavourableoutcome.
Parathyroidtumoursincats
Primaryhyperparathyroidismisrareincats.
Parathyroidadenoma,hyperplasia and carcinoma
haveallbeenreportedincats.Incontrasttodogs
withhyperparathyroidismandhypercalcaemia，the
mostcommonpresentingsignsinthecatareanor-
exia,lethargy and constipation,withpolyuria and
polydipsia occurringless frequently.Theenlarged
parathyroidglandsmaybepalpableinsomecats.
Calciumconcentrationsranging from11.1to22.8
mg/dl(2.8-5.7mmol/)have been reported in cats
(b)
withPHPT.Diagnosisand treatmentofPHPTincats
20.10
A 10-year-oldcastratedmalecat(a)beforeand
aresimilartothosedescribedfordogs.
(b)afterdevelopmentofacromegaly.
315
Chapter20Endocrinetumours
GHorIGF-1shouldbeconfirmedbyeithercontrast-
enhancedCTorMRIofthebrain（Figure20.12)to
documentthepresenceofapituitarymass.Inone
caseofconfirmedacromegaly，acidophilproliferation
withinthepituitaryglanddidnotresultinadetect-
ablemassonCTorMRl.ThusevennegativeMRI
findingsdonotprecludeadiagnosisofacromegaly
(Niessenetal,2007).
P
20.11
An11-year-oldmaleDSHcatwithacromegaly,
demonstratingenlargementof thehead and
mild prognathia inferior.
Physicalexaminationmayrevealabdominalorgano-
megaly,inferiorprognathia,cataracts,clubbedpaws，
broadfacialfeatures,cardiacmurmursorarrhyth-
mias,respiratorystridor,lameness,peripheralneuro-
pathyandcentralneurologicalsignsattributableto
an enlargingpituitarymass.Althoughweight loss
duetopoorlyregulateddiabetesmellitusmayoccur
initially,akeyfindinginacromegaliccatsisweight
gainorastableweightinadiabeticcatwithother
indicatorsofpoorglycaemiccontrol.Somecatswith
fromnormal cats.
20.12
Magneticresonanceimagingstudy
demonstratingapituitarymassinacatwith
Diagnosis
acromegaly.
A tentativediagnosisofacromegalyisbasedonthe
presence of insulin-resistant diabetes mellitus,clini-
Treatment
calsignsandgrowthhormoneandIGF-1concentra-
Treatmentmodalitiesthathavebeeneffectivefor
tions.Themostcommon abnormalitiesonblood and
catswithacromegalyincluderadiationtherapyand
urinetestingarehyperglycaemiaandglucosuria.
hypophysectomy.Radiationtherapymayimprove
Otherlaboratoryabnormalitiesincludehyperpro-
neurological signsincatswithpituitarytumoursand
teinaemia,hypercholesterolaemia and hyperphos-
resultindecreasedinsulinrequirementsordiabetic
phataemia.Mild to severe azotaemia,proteinuria,
remissionincats with acromegaly(Mayeret al.,
increasedliverenzymeactivityanderythrocytosis
2006;Dunning et al.,2009).Unfortunately thecost
mayalso be present.Thoracic radiographs may
andavailabilityofradiationtherapyoftenlimitaccess
revealcardiomegalyorothersignsofcongestive
totreatment.Althoughhypophysectomyisfeasiblein
heartfailureinmoreseverelyaffectedcats.Echo-
cats,itisnotroutinelyperformedinmostpartsof the
cardiographicevaluationmaydemonstratethickening
world.Incatsinwhichdefinitivetreatmentofthe
oftheintraventricularseptumand theleftventricular
tumourisnotpossible,long-termcontrolofclinical
caudal wall.Radiographyofaffectedjointsmayreveal
signsofdiabetesmellitusmaybeachievedusing
evidenceofdegenerativejointdiseasewithosteo-
highdosesof insulin.Becauseof theprofound insu-
phyte formation,soft tissueswellingor joint space
linresistanceassociatedwithacromegaly,hypogly-
collapse.Otherradiographicabnormalities
may
caemiccomplicationsusingthis approach
are
includeorganenlargement(hepatomegalyandreno-
unusual.Meansurvivalof20monthswasreported in
megaly),thickeningof thebonyridges of the calvar-
ium,inferiorprognathismandspondylosisdeformans.
thatonly2catsweretreatedwithradiationtherapy
MeasurementofIGF-1isagoodscreeningtest
(Petersonet al.,1990).Causeofdeath inacromeg-
foracromegaly.Theassayhasaspecificityof92%
aliccatsismostcommonlyduetorenalfailureand/
and sensitivityof 84% （Berg et al.,2007).Some
orcongestiveheartfailure.
poorlycontrolleddiabeticcatshaveincreased IGF-1
concentrations,but in most cases these increases
arenotashighasinthosecatswithdocumented
Hyperadrenocorticism
acromegaly.Mostcatswithacromegalyhave
increasedserumGHconcentration,thoughinsome
Hyperadrenocorticism (Cushing's syndrome)isan
casesGHconcentrationmaybenormal becauseof
endocrinedisordercausedbyoverproductionofcort-
shorthalf-lifeandepisodicsecretion.A tentative
isolfromtheadrenalcortexduetothepresenceof
diagnosisofacromegalybasedonmeasurementof
eitherapituitaryoranadrenalglandtumour.
316
Chapter2oEndocrinetumours
Secretionofcortisolbytheadrenalgland isunder
includereproductiveabnormalities,pulmonarythrom-
thecontrolof thehypothalamic-pituitary-adrenal
boembolism,systemichypertension,proteinuria,
axis.Thehypothalamus produces corticotropin-
increasedsusceptibilitytoinfections(especiallyof the
releasing hormone(CRH)which stimulates the pro-
urinary tract),and insulin resistance.Neurological
ductionofadrenocorticotrophichormone（ACTH)by
abnormalitiesmayincludepseudomyotonia,facial
thepituitarygland.ACTHstimulatestheadrenalcor-
nerve paralysis,and central nervous system signs.
tex toproduce cortisol.Cortisoldecreases ACTH
Stupor,seizures,circling,ataxia,and blindnessare
andCRHproductionby thepituitaryandhypothala-
suggestiveof anenlargingpituitarytumour.
mus bynegative feedback.Inpituitary-dependent
hyperadrenocorticism (PDH),cortisol inhibition is
Diagnosis
inadequatetoinhibittheproductionofACTHbyan
Commonabnormalitiesonbloodtestinginclude
autonomouslyfunctioningpituitary tumour,resulting
leucocytosis,monocytosis,eosinopenia,lympho-
inadrenalhyperplasiaand increasedconcentrations
penia andmildpolycythaemia.Increasedlevelsof
ofplasmacortisol.Withafunctionaladrenal tumour
alkaline phosphatase (ALP)are found in 95%of
(AT),hypercortisolaemia iscaused byincreasedsyn-
dogswithhyperadrenocorticism.
Serumalanine
thesisandsecretionofcortisolbythetumourthatis
aminotransferase （ALT)concentrations are more
nolongerdependentonthepresenceofACTHto
mildlyincreased.Otherbiochemical changesinclude
stimulate cortisolproduction.Thenumerousgluco-
hypercholesterolaemia,hyperglycaemia,hypophos-
neogenic,lipolytic,catabolic,anti-inflammatory and
phataemia,hypernatraemia
andhypokalaemia.
immunosuppressiveeffectsofglucocorticoidsresult
Urinalysismayreveal lowurineSG,glucosuriaand
in theclinicalsignsofhyperadrenocorticism.
evidenceofurinarytract infection.Becauseurinary
tractinfectionmaybeoccult,urinecultureandsen-
Hyperadrenocorticismindogs
sitivityshouldbeperformedroutinelyindogswith
Eightyfivepercentofcasesofcaninehyperadreno-
suspected hyperadrenocorticism.
corticismareduetoPDHand15%areduetoa
Adiagnosisofhyperadrenocorticismshouldbe
functionalAT.Pituitarytumoursareusuallybenign
confirmedbythelow-dosedexamethasonesuppres-
adenomas.Fiftypercentofadrenal tumoursare
sion(LDDS)test,ACTH stimulationtest,orboth.An
benignand50%aremalignant.Dogswithconcur-
increased urine cortisol:creatinine(C:Cr)ratio ina
rentPDHandAThavebeendescribed.
cismisalsoverysupportiveof thediagnosis.PDH
Clinicalfeatures
mustthenbedifferentiatedfromAT,byacombination
Hyperadrenocorticismaffectsmiddle-agedandolder
of the low-and high-dose(HDDS)dexamethasone
dogs.The median age is 11 years.It has been diag-
suppression tests,measurement of endogenous
nosed in numerous breeds,with Poodles,Dachs-
ACTH concentrations,abdominal radiography and
hunds，Beagles,German Shepherd Dogs,Boston
abdominalultrasonography.
TerriersandBoxersbeingover-represented.There
ACTHstimulationtest:Thistestreliesonthe
isaslightlyincreasedpredispositionforfemales
assumptionthathyperplasticorneoplasticadrenals
(55-65%).Largerbreeds maybe affected more fre-
haveabnormallylargereservesofcortisolandthere-
quentlywithATthansmallerbreeds.
forehyper-respondtomaximalstimulationbyACTH
Clinical signsinclude polydipsia,polyuria,poly
(Figure 20.14).Plasma samplesare collectedprior
phagia,hepatomegaly,muscle weakness,panting,
exerciseintolerance,lethargyanddevelopmentofa
pendulousabdomen.Dermatological abnormalities
35
suchasbilaterallysymmetricalalopecia(Figure
20.13),thin skin,easybruising,pyoderma,calcinosis
30
cutis,cutaneoushyperpigmentationand seborrhoea
arealso common.Other clinicalmanifestations
25
20
rtisol
15
Cor
10
0
BeforeACTHcortis
AfterACTHcortisol
Time-
Normal
Addison's
Cushing's
20.13
Apoodleshowingclinical manifestationsof
hyperadrenocorticism.Note thealopecia and
20.14
thin skin.
ACTH stimulationtestresults.
317
Chapter2oEndocrinetumours
to,and 1hourfollowing,administrationof synthetic
non-adrenaldiseasesalsoincrease theC:Crratio
ACTH(5μg/kgi.m.ori.v.).TheACTH stimulation test
andsotheresult shouldbeinterpretedwithcare.In
isabnormal in85-90%ofPDHcasesand in50%of
dogswithapositiveresult,asecondtestshouldbe
AT.TheACTH stimulationtestallowsdifferentiationof
performedtoconfirmthediagnosis.
iatrogenicfromspontaneoushyperadrenocorticism
It isimportanttobeawarethatfalse-positivetest
andislessaffectedbystressandconcurrentdisease
resultsmayoccurwithalladrenalfunctiontests,
thantheLDDStest.TheACTHstimulationtestdoes
especiallyindogswithotherconcurrentillness.
notdistinguishbetweenATandPDH.Becauseofthe
Testingforhyperadrenocorticismshouldonlybeper-
lowsensitivityofthistest,adiagnosisofhyperadreno-
formedindogswithappropriateclinicalsignsthat
corticismshouldnotbeexcludedbasedonanormal
aresystemicallywell.
ACTH stimulation testresult.
TeststodifferentiatePDHfromAT
LDDStest:Thistest ismore sensitiveforhyper-
ThemostusefulendocrinetestsfordistinguishingAT
adrenocorticismand isabnormal in95%ofdogs.lt
fromPDHaretheHDDSandLDDStestsandmeas-
doesnotdistinguishspontaneousfromiatrogenic
urementofendogenousACTHconcentration.
hyperadrenocorticism.Plasma samples are col-
lectedpriortoand8hoursfollowingadministration
LDDSandHDDStests:Thesetestsrelyonthefact
ofdexamethasone(0.01mg/kgi.v.).Anadditional
thatsecretionofcortisolbyadrenaltumoursisun-
samplecollectedat4hoursafterdexamethasone
affectedbyadministrationofdexamethasone,while
administrationmayhelptodifferentiatedogswith
inPDHthepituitaryglandretainssomeresponseto
PDHfromthosewithAT.Administrationofdexa-
thefeedbackeffectsofdexamethasone.Theprotocol
methasone should suppressproduction ofACTH
for the high-dose(HDDS)testis thesame as the
fromthenormalpituitaryanddecreasecortisol
low-dosetestexceptthata4-hourbloodsampleis
secretion(Figure20.15).Suppression persistsin the
notrequiredandthedexamethasonedoseishigher
normaldogfor24-48hours.Sincedexamethasone
(0.1mg/kg).Suppression is defined asa 4-or8-hour
isnotdetectedbytheassayforcortisol,the
plasmacortisolconcentrationafter dexamethasone
decreaseincortisolcanbemeasureddespitedexa-
administration<50%ofthebaselinesample.
methasoneadministration.Adrenaltumoursfunction
Suppressionofcortisol concentrationsisdiagnostic
independentlyofACTH,whileahyperplasticorneo-
forPDH(seeFigure20.15)butlackof suppression
plasticpituitarygland isrelativelyresistanttonega-
isnotdiagnosticforAT,because20%ofPDHcases
tivefeedbackfromcirculatingsteroids.Ineither
failtosuppresswiththehigherdoseofdexametha-
disorder,thereisalackofcortisolsuppression8
sone.Ifsuppression>50%isseenat4or8hourson
hoursafterdexamethasoneadministration.
anLDDS,anHDDStestisunnecessary.
Endogenous ACTHconcentration:Dogswith
9
functionaladrenal tumourshavelowACTHconcen-
8
trations.Levelswithinorabovethereferencerange
7
areconsistentwithadiagnosisofPDH.ACTHcon-
centrationsareloworborderlineinsomedogswith
6
(Ip/6r)
PDH,possibly due toepisodic secretion of ACTH;
5
therefore，a low ACTHconcentrationalone isnot
enoughtoconfirmadiagnosisofadrenaltumour.
tisol
4
ACTHconcentrationsarehigherindogswithlarger
3
pituitarytumoursandthosewithneurologicalsigns
2
(Kipperman etal.,1992;Bosje et al.,2002;Granger
et al.,2005).Endogenous ACTH is susceptible to
1
rapidenzymaticdegradationinvitroandsohandling
F0
recommendationsfromthelaboratoryshouldbe
Time (hours)
followedcarefully.
0
4
8
Imaging:Approximately57%ofadrenaltumoursare
NormalPDH
ATorPDH
identifiedonabdominalradiographyasasofttissue
massoramineralizedopacity，comparedwith72%
20.15
Low-dosedexamethasonesuppressiontest
with ultrasonography(Reusch andFeldman,1991).
results.
Otherradiographicfindingsmayincludehepato-
megaly,osteopenia,dystrophic mineralization and
Urinary cortisol:creatinineratio:TheurineC:Cris
distensionof theurinarybladder.Thoracicradio-
anestimate of24-hourcortisolproduction.The
graphsmayrevealevidenceofmetastasis,pulmon-
measurementismadeonavoidedmorningurine
arythromboembolismormineralization.
samplecollected athome,soitisaveryconvenient
IndogswithPDH,ultrasonographyof the adrenal
initialscreeningtest.TheC:Crratioisasensitivetest
fordiagnosisofhyperadrenocorticismbuthaslow
enlargementoftheadrenalglandswithpreservation
specificity.AC:Crratiowithinthereferencerangeis
ofnormaladrenal architecture(Figure 20.16).The
helpful inrulingouthyperadrenocorticism,butmany
glandsmaynotbeidenticalinsizebutthedifference
318
Chapter20
Endocrinetumours
20.16
Ultrasoundimageof theleftadrenalglandinan
8-year-oldneuteredmaleLabradorwith
pituitary-dependenthyperadrenocorticism.Theadrenal
gland is enlarged(arrowed)but hasnormalarchitecture.
A
inthicknessisusually<5mm（Grootersetal.,1996)
20.18
CTimageofa10-year-oldneuteredfemale
Thesizeoftheadrenalglandsmaybewithinthe
mixed-breeddogwithaleftadrenaltumour.
Notetheadrenal mass(arrowed)medialtotheleftkidney
normalrangeinsomedogswithPDH.Indogswitha
(bright due to contrast medium).
functionaladrenaltumourthereisunilateraladrenal
glandenlargementwithabnormaladrenalgland
architecture （Figure 20.17).Evidenceof tumour
isusedfortreatmentofdogswithpituitarytumours
thrombuswithinthevenacavaisdetectedbyultra-
that are causing neurological signs.
sonography in 11%of dogs withadrenocortical
tumours(Kylesetal.,2003)andevidenceofdistant
Medicalmanagement:Trilostaneisasynthetic
metastasistotheliver,kidneysandotherabdominal
hormonallyinactivesteroidanaloguethatisacom-
organsmaybepresent.Bilateraladrenal tumours
petitiveinhibitorofthe3β-hydroxysteroiddehydro-
genase system (Neiger et al.,2002).Trilostane
indogswithPDHmaycomplicatetheinterpretation
blockssynthesisofanumberofadrenalsteroids,
ofultrasoundfindings.
including cortisol and aldosterone.Trilostane is rap-
idlyabsorbedorallyandsuppressionofplasmacorti-
solconcentrationsis short lived（<20 hours).The
drugiswell tolerated indogsandiseffective incon-
trollingclinicalsignsofhyperadrenocorticisminmost
75-31/1/3/4
patients.Currentrecommendationsareto startata
RTADR
doseof2-6mg/kgq24handthenincreaseor
res
decreasethedosebasedonevaluationofACTH
stimulationtestsperformed4-6hoursafterdrug
administration.Twice-a-daytherapy at lowerdosesof
1-3mg/kgmayresult ingoodcontrolofclinicalsigns
atalowertotaldailydosewithlessriskofadverse
effectsthanhigherdosesadministeredonceaday
(Vaughan et al.,2008).ACTH stimulation testing
shouldbeperformed10,30and90daysafterstart
idID
oftreatmentand30daysaftereachdoseadjust-
ment.Adverseeffectsareusuallymildandself-limit-
20.17
Ultrasound imageof therightadrenalglandofa
5-year-oldneuteredfemaleAustralianShepherd
ingandincludediarrhoea,vomitingandlethargyin
Dogwithbilateraladrenaltumours.Notetherounded
upto63%oftreateddogs.Bothisolatedglucocorti-
appearance(arrowed) and abnormal adrenal architecture.
coiddeficiencyandoverthypoadrenocorticismoccur
occasionallyduetotrilostanetreatmentandinsome
CTisalsoausefultoolforevaluatingtheadrenal
casesresolutionmay takeweekstomonths.Adrenal
glands,especiallyindogswithadrenal tumours
necrosis(possiblysecondary tohighACTHconcen-
(Figure 20.18).MRIorCTof the brainishelpful
trations)maybe thecauseofhypoadrenocorticism
indeterminingpituitarytumoursizeindogswith
insomedogsandtherehavebeenreportsofacute
PDH.Approximately70%ofdogswithPDHhave
deathduringtreatment.
adetectablepituitarytumouronCTorMRI(Bertoy
Mitotane(o,p-DDD)isdirectlycytotoxic tothe
etal.,1995).
zonafasciculataandreticularisoftheadrenalcortex
andhasbeenwidelyprescribedfor themedical
TreatmentofPDH
managementofbothPDHandAT.Treatmentcon-
OptionsfortreatmentofdogswithPDHinclude
sistsofaninductionperiod,typically7-10days,fol-
eithermedicalmanagementwithmitotaneortrilos-
lowedbyalifelongmaintenanceprotocol.Mitotaneis
tane,orsurgical hypophysectomy.Radiationtherapy
initiallyadministeredatadoseof50mg/kgq24h,
319
Chapter2oEndocrinetumours
dividedtwicedailywithfood,whichimprovesintesti-
thatpresentwithsignsofmildneurologicalimpair-
nalabsorption.Commonsideeffectsofmitotane
ment.Likewise, dogs with large tumours have a
includeweakness,vomiting,anorexia,diarrhoeaand
poorerprognosisthandogswithsmallertumours.
ataxia.Thegoalof inductionistodecreaseboth
basalandpost-ACTHplasmacortisolconcentrations
Transphenoidal hypophysectomy:Hypophysec-
towithinnormalrestingranges.TheACTH stimula-
tomyhasbeenusedsuccessfullytotreatPDH in
tiontestisusuallyperformedbetweendays7and10
dogs,butthetechnical expertiserequired limitsthe
of induction,orearlierifclinicalsignsofhyperadreno-
availabilityofthistreatment.In150dogsundergoing
corticismareresolvingorif thedogisexhibiting
hypophysectomy for treatment of PDH,the1-and
signssuggestiveofmitotanetoxicity.lfadogstillhas
2-yearsurvivalrateswere84%and76%,respec-
anexaggeratedresponsetoACTHstimulationafter
tively(Hanson et al.,2005).Complications include
10days of induction therapy,the induction period
procedure-relatedmortality,incompletehypophysec-
shouldbecontinuedforanadditional3-10days,with
tomy,reducedtearproductionandcentraldiabetes
repeatACTHstimulationtestsperformeduntilalow
insipidus.Theprognosisisworsefordogswithlarger
post-ACTH response is achieved. Some dogs with
pituitarytumours.
PDHwill takeconsiderablylongerthan10daysto
Treatmentforadrenal-dependent
achieve thisgoal.
hyperadrenocorticism
Onceadrenocorticalreservehasbeenreduced
satisfactorily,mitotaneisadministeredatamainte-
Adrenalectomy:Surgicaladrenalectomyisthetreat-
nancedoseof50mg/kg/week,dividedintotwoor
mentofchoiceforATsbecauseitcanprovideperma-
moredoses.ACTHstimulationtestsshouldbeper-
nent resolution ofhyperadrenocorticism.However,
formedfollowing1，3and6monthsoftherapy（or
patientselectionisimportant,becauseperioperative
earlier,if necessary)andevery3-6months there-
mortality ishigh(20%)(Kylesetal.,2003;Schwartz
etal.,2008).Adrenalectomyshouldbereservedfor
plasma cortisolconcentrations after ACTHstimu-
patientsthatdonothaveextensivetumourinvasion
lationincreaseabovetherestingrange,themitotane
doseshouldbeincreased.Sideeffectsofmitotane
tated.Presurgicaltreatmentwithmitotaneortrilos-
administrationduring themaintenanceperiodare
similartothoseobservedduring theinduction
severeclinical signsofhyperadrenocorticism.
period.Ifsideeffectsareobserved,temporarydis-
PatientswithATsrequireclosemonitoringduring
continuationofmitotanetherapymaybenecessary
andimmediatelyfollowingsurgeryandmustbe
untiladverseclinicalsignsresolve.
adequatelysupportedwithcareful intravenousfluid
Inaretrospectivestudyofdogstreatedwith
therapy,glucocorticoid supplementation and min-
eithermitotane(n=25)ortrilostane(n=123),long-
eralocorticoidadministrationifnecessary.Without
termsurvivalwasnotstatisticallydifferentbetween
adequateglucocorticoidsupplementation,removalof
the groups(Barkeretal.,2005).MSTin the mitotane
aunilateralATwillresult in life-threateninghypo-
groupwas708days（range 33-1399)andin the
adrenocorticism,becauseofatrophyof thecontra-
trilostanegroupwas662days（range8-1971).Other
lateraladrenalgland.Glucocorticoidreplacement
drugsthathavebeenreportedtobeeffectiveindogs
canbeprovidedwithdexamethasoneadministered
withPDH include ketoconazole,I-deprenyl,retinoic
inintravenousfluidsover6hoursassoonasthe
acid andcabergoline.
tumourisidentified.Alternatively,hydrocortisoneas
a continuousinfusionwillprovideglucocorticoidand
Radiationtherapy:Radiotherapyimprovesoutcome
mineralocorticoid supplementation.Bloodpressure,
indogswithPDHthathaveassociatedneurological
central venous pressure,electrolytes,blood urea
signsduetoapituitary tumour,and indogswith
nitrogenandbloodglucoseshouldbecarefullymoni-
pituitarytumours>0.8-1.0cmindiameter.Neuro-
toredduring andaftersurgery.lfclinicalorlaboratory
logicalabnormalitiesattributedtothepresenceofa
evidenceformineralocorticoiddeficiencyisevident
followingsurgery,mineralocorticoidsupplementation
behaviour,inappetence,obtundation,aggressive-
(desoxycorticosteronepivalateorfludrocortisone
ness,anisocoria,apparent blindness and seizures.
acetate)shouldbeadministered.Aftersurgery,oral
Interestinglythereispoorcorrelationbetweendevel-
supplementationwithprednisonecanbeinitiated
opmentofneurologicalsignsindogswithPDHand
oncethepatient is bright,alert andeating.Gluco-
thepresenceofapituitarytumouronCTorMRI
corticoidandmineralocorticoidsshouldbegradually
scan(Wood et al.,2007).
taperedoverseveral months.
Radiation therapyhasbeenreported toincrease
Theprognosisfordogsundergoingadrenalec-
survivalandimproveneurologicalsignsindogswith
tomyisgoodinthosethatsurvivetheperioperative
pituitarymasses.Complicationsassociatedwithradi-
period.MSTsof690-778dayshavebeenreported
ationtherapyincludealopeciaandleucotrichia.
(Anderson et al.,2001;Schwartzet al.,2008).Dogs
Resolution of associated endocrine signs afterradi-
withATsthatrequireconcurrentnephrectomy
ationtherapyisnotconsistentandmaybedelayed
(Figure 20.19)andcauseintraoperativehaemor-
forseveral months;thereforedogswithPDHmay
rhagehaveaguardedprognosis.Immediatepostop-
needcontinuedmedical treatment.Dogs thatpre-
erativecomplicationssuchasacuterenalfailure,
sent withmore severe neurological impairment(e.g.
pancreatitis，pneumonia,andpulmonaryartery
stupor,seizures)havea worseoutcome thandogs
thromboembolismoccurinupto35%ofpatients.
320
Chapter2oEndocrinetumours
20.20
A13-year-oldneuteredfemaleDSHcatwith
PDH.
20.19
Alarge adrenal massinvadingakidney,seen
afterconcurrentadrenalectomyand
nephrectomy.
Medicalmanagement:Thismaybemoreappropri-
ateforsomedogswithATs,suchasdogswithlarge
tumours,metastatic lesions in the lungs,liver,or
other organs,andseverelydebilitatedpatients.
Dogswith ATs generally improve inresponseto
shrink duringmitotanetreatment.Inmost cases
20.21
Skinlaceration inducedbygrooming ina
higherdosesofmitotanearerequiredtocontrol
10-year-old neuteredmaleDSHcatwithPDH.
clinical signsthanindogswithPDH.Ina studyof
32dogswithATsthatweretreatedwithmitotane，
Diagnosis
theMSTwas12monthsandfinalmaintenance
Theresultsofa CBC,biochemicalpanelandurin-
dosagerangedfrom35to
1275mg/kg/week
alysisareusuallytypicalofcatswithdiabetesmelli-
(Kintzer and Peterson,1994).Some dogs had
tus.IncreasedALPandALT,hypercholesterolaemia,
prolongedsurvivaltimesanddogswithoutmeta-
hyperglycaemiaand lowBUNarecommon.Endo-
staticdiseasesurvivedlonger.Therecommended
crinetestsusedindiagnosisoffelinehyperadreno-
initialinductiondosageis50-75mg/kgq24hfor
corticisminclude theACTH stimulationtest,the
10-14dayswithconcurrentprednisoneadministra-
LDDStestand urineC:Crratio.
tion(0.2mg/kg),followedbyaninitial maintenance
dosageof75-100mg/kg/week.
LDDstest:Thisisthetestofchoicefordiagnosisof
felinehyperadrenocorticismandisperformedusing
Hyperadrenocorticismincats
ahigher doseofdexamethasone(0.1mg/kg i.v.)
thaninthedog.Abaselinebloodsampleiscollected
Clinicalfeatures
andadditionalsamplesarecollectedat4and8
Catswithhyperadrenocorticismaremiddle-agedor
hoursafterdexamethasoneadministration.Cortisol
older(median 10years,range 5-16years)and
concentration willbe suppressed (<1.5μg/dl) (41.4
femalesareslightlyover-represented.Mosthave
nmol/l)at8hoursinnormalcatsbutnotincatswith
diabetesmellitusatthetimeofdiagnosis.Clinical
hyperadrenocorticism.Afewcatswithhyperadreno-
signsincludeinsulin-resistantdiabetesmellitus
corticismwill suppressnormallyon theLDDS.If the
(polyuria,polydipsia,polyphagia,weight loss and
indexofsuspicionforhyperadrenocorticismishigh,
peripheral
neuropathy),
lethargy,
abdominal
asecondtestusingthelowerdoseofdexametha-
enlargementorpot-belliedappearance,
muscle
sone(0.01mg/kg)canbeperformed but some nor-
atrophy,unkempt hair coat (Figure 20.20),bilater-
malcatswillfailtosuppressatthisdose.
allysymmetrical alopecia,cutaneousfragility and
recurrentabscessformation.Thephysicalexamina-
ACTHstimulationtest:Thistestislesssensitive
tionmayreveal hepatomegaly,seborrhoea and
thantheLDDStest.SyntheticACTHisadministered
cutaneouslacerations.Skinfragilitymaybe so
atadoseof125μg/cateitheri.v.ori.m.Samples
severethattearingoftheskinoccursduringroutine
areatbaseline,andthenat30and60minutesafter
grooming （Figure 20.21).Virilization,oestrous
administrationof ACTH.Apost-ACTH cortisolof
behaviourandhyperaldosteronismmayoccurin
>15μg/dl(414nmol/l)ateither30or60minutes
catswithadrenaltumoursthatsecreteadrenalster-
afteradministrationisconsistentwithadiagnosisof
oidsotherthancortisol.
hyperadrenocorticism.
321
Chapter2oEndocrinetumours
C:Crratio:This isa useful screeningtestforhyper-
perioperatively.Catsundergoingbilateraladrenal-
adrenocorticism.UrineformeasurementoftheC:Cr
ectomyorwithevidenceofhypoadrenocorticism
ratioshouldbecollectedathometominimizethe
(hyperkalaemia,hyponatraemia)needsupplemental
influenceof stress.Hyperadrenocorticism isunlikely
mineralocorticoids(desoxycorticosteronepivalateor
if theresultisnormal.Increasedvaluesoccurincats
fludrocortisone).
Postoperative
complications
withhyperadrenocorticism,butincreasesmayalso
include electrolytederangements,skinlacerations,
occur incatswithotherconcurrentillness and so
pancreatitis,hypoglycaemia,pneumonia,sepsisand
additionaltestingshouldbeusedforconfirmation.
venousthrombosis.
Thelong-termprognosisforcatswithhyperadreno-
TeststodifferentiatePDHfromAT
corticismisfairtogoodfollowingadrenalectomy.Of10
PDHoccurs in85%of catswith spontaneoushyper-
catstreatedbyadrenalectomy,3diedwithin5weeks
adrenocorticism,while 15%have functional ATs.
ofsurgeryofcomplicationsassociatedwithsepsisor
Abdominalultrasonographyisthemostusefuldiag-
thromboembolism.Theremaining7survivedamedian
nosticmethodfordifferentiationofPDHfromAT.
of12months(Duesberg et al.,1995).
In equivocal cases,the HDDS test (1 mg/kg)or
measurement of endogenousACTH concentration
Otheradrenalglandtumours
may be helpful.
Non-cortisol-secreting adrenocortical
Treatment
tumours
Unfortunatelymedicalmanagementofhyperadreno-
Insome dogs andcatswithfunctionalATs,adrenal
corticism islesssuccessful in thecat thaninthedog.
steroidhormonesotherthancortisolarethemajor
Moreover,catswithhyperadrenocorticismareoften
secretoryproductsofthetumour.Cortisol concentra-
poorsurgicalcandidates.Thusthelong-termprogno-
tionsarelowanddonotincreaseafterACTHstimu-
sisincatswithhyperadrenocorticismisguarded
lation.Increasedproductionofadrenalsteroidsother
thancortisolmaybeduetodeficienciesofenzymes
Medicalmanagement:Trilostane iscurrently the
involvedinsteroidogenicpathways,duetomutations
mosteffectivedrugformedicalmanagementofcats
inneoplasticadrenal tissue.Cortisol concentrations
withPDH(Neigeretal.,2004).Treatmentwithtrilos-
arehypothesizedtobelowbecauseofsuppression
tanemay improveclinicalsignsbutcatstypically
ofthehypothalamicpituitaryaxisbyelevatedpro-
remaindiabetic.Theeffectivedoseoftrilostane
gestin concentrations.Most reported non-cortisol-
rangesfrom15mgorallyq24hto60mgorallyq12h.
secretingadrenocortical tumoursindogsandcats
ACTHstimulationtestsshouldbeused totitratethe
havebeencarcinomas.
dose,similarto theprotocol fordogs.
Clinicalsignsareusuallyconsistentwithhyper-
Metyrapone，an11b-hydroxylase inhibitor that
adrenocorticism,butsomecasesmaydemonstrate
blockstheconversionof11-deoxycortisoltocortisol,
masculinization,or signs of hyperaldosteronism
hasbeenusedsuccessfullytotreathyperadrenocor-
suchasweakness,hypertensionandhypokalaemia.
ticism inthe cat（Daleyetal.,1993;Mooreetal.,
Adrenocorticaltumoursareusuallyreadilyidentified
2000).Therecommendeddoseis65mg/kgorally
byimaging studies.Endocrinefunction testsdonot
q8-12h.Side effectsinclude depression,tremors,
demonstrate
hypercortisolaemiaandinmost
ataxia,hypocortisolaemiaandseverehypoglycaemia
casestheresponsetoACTHisbelowthereference
(secondarytocontinuationof insulinadministration
range.Hormones thathavebeenreportedtobe
in thefaceofresolvinghyperglycaemia).
increasedindifferentcombinationsinaffecteddogs
Resultsof treatmentwithmitotaneandketocona-
andcatsinclude 17-hydroxyprogesterone,proges-
zolehavebeendisappointing,withpartialresponses
terone,oestradiol,testosterone and androstene-
observed inonlysomecats.
dione.Increasedconcentrationsofaldosteroneand
desoxycorticosterone,either alone in combination
Radiationtherapy:Radiotherapyisanotheroption
withotheradrenalhormones,mayalsooccur.
forcatswithPDH.Resolutionofneurological signs,
Caninephaeochromocytoma
improvedclinical signsandimprovedglycaemicreg-
Phaeochromocytomas arecatecholamine-secreting
ulationhavebeenreportedafterradiationtreatment
tumoursofneuroectoderm-derivedchromaffincells
(Kazer-Hotz,2002;Mayeretal.,2006).Improvement
thatusuallyarisefromtheadrenal medulla.Phaeo-
inendocrinefunctionoccurswithin 1-5monthsof
chromocytomasareuncommoninthedogandrare
completion of radiation therapy.
inthecat.Thecatecholaminesadrenalineandnor-
adrenalinearesynthesizedbythehydroxylationand
Surgery:IncatswithfunctionalATs,adrenalectomy
decarboxylationofphenylalanineandtyrosine.The
isthetreatmentof choice,butinitialmedical treat-
rate-limitingstepinthecatecholaminesyntheticpath-
mentmaybenecessaryinseverelydebilitatedcats.
wayisthehydroxylationoftyrosinebytyrosine
Bilateraladrenalectomyisalsoeffectiveincatswith
hydroxylase.Negativefeedbackinhibitionof theactiv-
PDHthatdonotrespond tomedical therapy.Asin
ityofthisenzymebydopamineandnoradrenaline
dogs,intravenousfluidsupplementationandgluco-
normalycontrolscatecholamineproduction.Thisnor-
corticoidadministrationarevitalforsuccessfulpost-
malcontrolmechanismisdisruptedinanimalswith
operativemanagement.Catswithdiabetesmellitus
phaeochromocytoma,resulting inthe formation and
requirecarefulmanagementofinsulinrequirements
secretionofexcessnoradrenalineand adrenaline.
322
Chapter20Endocrine tumours
Clinicalfeatures
andnormalfunctiontestingoftheadrenalcortex
Phaeochromocytomasusuallyoccurinolderdogs
(ACTHstimulation,LDDSand HDDS tests).Thereis
(mean age 10-12years,range 3-16years).There is
some overlap,however,in the spectrum of clinical
nobreedpredispositionandmalesareslightlyover-
signs,andadrenalfunctiontestsmaybeabnormal in
represented.Clinical signsmaybe due toexcess
dogswith underlying systemicillness(Kaplanet al.,
catecholaminesecretionandactivationofadrenergic
1995).Teststodocumentexcessiveconcentrations
receptors,effects of distant tumour metastases,or
ofcatecholaminesandtheirmetabolitesinthe
tumourinvasionofregionalorgansandthecaudal
plasmaandurinehavenotbeenthoroughlyinvesti-
venacava.
gatedinthedog.Measurementof24-hoursecretion
The onsetand durationofclinicalsignsassoci-
ofurinarycatecholaminesandmetabolitesisthe
atedwithphaeochromocytomaareextremelyvaria-
traditional approachtodiagnosisinhumanmedicine,
bleand clinical signsmaybeacuteorchronic.Dogs
butreferencerangesfordogshavenotbeenestab-
withphaeochromocytomamaydieacutely,orpre-
lished.Referencerangesforurinarycatecholamine
sentincardiovascularcollapseanddieshortlythere-
andratiosofmetanephrinetocreatininehavebeen
after,butinover50%ofdogs thetumourisan
establishedinnormaldogsandshowpromisefor
incidentalfindingduringexploratorylaparotomyorat
diagnosisofphaeochromocytoma.
necropsy (Gilson et al.,1994;Barthez etal.,1997).
Abdominalradiographymayrevealthepresence
Concurrent neoplasia(particularly endocrine neo-
ofalargeadrenalmassorascites.Abdominalultra-
plasia)isdetected inover50%of affecteddogs.
Themostcommonclinical signsareweightloss,
nalmetastasistootherorgans suchas theliver,
anorexia,lethargy，pantingandweakness(Barthez
regional lymphnodes,spleen andkidneys.Invasion
etal.,1997).Weaknessmaybedueeither
to
orencroachmentofthecaudalvenacavaoccursin
adversecardiaceffects(e.g.tachycardiaorarrhyth-
upto50%ofdogswithphaeochromocytoma.CT
mias)from excess catecholamine secretion or to
maybeusefulinidentifying tumourextentand
impairedbloodflowfromtumourinvasionofthecau-
metastasis.Thoracicradiographs shouldbe per-
dalvenacava.Otherclinicalsignsincludeexercise
formedindogswithsuspectedphaeochromocytoma
intolerance,cutaneous flushing,abdominal disten-
toevaluateforcardiacenlargement,thepresence
sion(secondary to ascites or haemoperitoneum),
andseverityofsignscompatiblewithcongestive
polyuria,polydipsia,a palpable abdominal mass,
heart failure(pulmonary oedema,pleural effusion),
dyspnoea,cough,cardiac abnormalities（tachycar-
thesizeofthecaudalvenacava（enlargementmay
dia,arrhythmias,systolicmurmur,signs of conges-
suggestthepresenceofanintracavaltumourthrom-
tive heart failure),pale mucous membranesand
bus),concurrentbronchopneumoniaandpulmonary
acutecollapse.Neurological abnormalities(e.g.seiz-
orcardiacmetastases.Echocardiographymayalso
to
behelpful indocumentingleftventricularhypertro-
metastasisorhypertension-inducedhaemorrhagein
phy ortumour thrombi.
thecentralnervoussystem.Aseverehypertensive
episodemayalsocauseepistaxisorasuddenonset
Treatment
ofblindnessfromretinalhaemorrhageanddetach-
ment.Phaeochromocytomahasbeenreportedinsix
Surgery:Thetreatmentofchoiceforphaeochromo-
dogswithconcurrenthyperadrenocorticism.
cytoma issurgical removal.Evenwithmetastasis,
surgical debulkingmaybebeneficialtoincreasethe
Diagnosis
efficacyofmedicalmanagement.Presurgicaltreat-
Whilesystemichypertensionisconsidered thehall-
mentwiththealpha-1-adrenergicblockingvaso-
marksignofphaeochromocytoma,it maybe epi-
dilatorphenoxybenzamine(0.1-2.5mg/kgq12h)is
sodic.Inonestudyof61dogswithphaeochromo-
associatedwithimprovedperioperativemortalityrate
cytoma,only10of23dogstestedwerehypertensive
(Herrera,2008).Phenoxybenzaminereversesvaso-
(Barthez et al.,1997).Dogswith suspected phaeo-
constrictionandhypovolaemiapriortosurgeryand
chromocytomashouldhaveseveralbloodpressure
controlsfluctuationsofbloodpressureandheartrate
determinationsduring thecourseof thediagnostic
during anaesthesia.Thedoseshould beindividual-
evaluation.Afundicexaminationishelpfultodetect
izedforeachpatientwiththeaimofpreventing
retinal haemorrhagesthatmayhaveoccurredduring
hypertensionwithoutinducinghypotension.
previoushypertensiveepisodes.
Adrenalectomyisbestperformedbyanexperi-
Bloodtestsareoftenunremarkableindogs
encedsurgeonwithaccesstogoodmonitoring
withphaeochromocytoma.ReportedCBCabnor-
equipmentandpostoperativecare.Bloodpressure
malitiesinclude
neutrophilic
leucocytosis,mild
and theelectrocardiogramshouldbemonitoredprior
non-regenerative anaemia,
,ormildhaemoconcen-
toinductionofanaesthesia,throughout the surgical
tration.Serum
biochemical
abnormalities
may
includeelevationsinserumliverenzymeactivities,
period.Hypertensionshouldbecontrolledwithan
mild uraemia,hypercholesterolaemia,proteinuria
alpha-1-adrenergicblockingagent suchasphen-
andhypoalbuminaemia.
tolamine.Cardiacarrhythmiasandseveretachycar-
Apresurgicaldiagnosisisdifficulttoestablish.
diamaybetreatedwithabeta-adrenergicblocking
Phaeochromocytomas
are
distinguished
from
agent,such as propranolol.However,propranolol
adrenocorticaltumoursbasedonthelackofthe
shouldonlybegivenfollowingadministrationofan
characteristicclinicalsignsofhyperadrenocorticism
alpha-1-adrenergic blocker,inorder toprevent
323
Chapter20Endocrinetumours
severehypertensionoccurringsecondarytoblock-
F cells secrete pancreatic polypeptide and fetal
adeofbetareceptor-mediatedvasodilatationofvas-
isletcellssecretegastrin.Pancreaticendocrine
cularsmoothmuscle.Hypotensionmaydevelopafter
tumoursmaysecreteoneormoreofthesespecific
the tumourisremoved;strategiesutilizedtoalleviate
hormones.Pancreaticendocrinetumoursreported in
hypotensioninclude decreasingordiscontinuing
dogsandcatsincludeinsulinomas,gastrinomasand
phentolamine,vascularvolumeexpansionwithan
glucagonomas.(Tumoursof theexocrinepancreas
appropriatecolloidandtreatmentwithdopamine.
arediscussedinChapter15i.)
Manipulationofthetumourmayexacerbatesystemic
hypertensionandsocareshouldbetakenwhen
Canineinsulinoma
handling themass.
Insulinomasarefunctionalinsulin-secretingtumours
of thepancreaticbeta cells.Insulinsecretion isreg-
Medicalmanagement:Ifcompletesurgicalresec-
ulatedprimarilybytheserumglucoseconcentration;
tionof thetumourisnotpossible,orif surgery isnot
as glucose concentrations increase,insulin secre-
anoption,medicalmanagementmay be used to
tionincreases;inresponse,serum glucose concen-
controlsystemicbloodpressureandpreventlife-
trationdecreases
duetoglucoseuptakeby
threateningarrhythmias.Phenoxybenzamineorpra-
peripheral tissuesandglycogenstorage.Asblood
zosinmay beutilized to controlhypertension,and
glucosedecreases inresponsetotheeffectsof
propranololcanbeadministeredtocontroltachycar-
insulin,insulin secretion alsofalls.In thepresence
diaandcardiacarrhythmias.
ofaninsulinoma,insulinsecretionisunresponsive
totheregulatingeffectofserumglucoseconcentra-
Prognosis
tionsand insulinproductioncontinuesinthepres-
Theprognosisforphaeochromocytomaisguarded.
enceofhypoglycaemia.
Morethan50%ofcaninephaeochromocytomasin
onereportweremalignant,withlocal tumourinva-
Clinicalfeatures
sion occurring in 26of 50 dogs（52%),regional
Insulinomaismostcommoninmiddle-agedtoold
lymphnodemetastasisin6of50dogs(12%),and
dogs(averageage9years,range3-15years)and
distant metastasis in12of50dogs(24%)(Gilson et
certainbreedssuchasthePoodle,FoxTerrier,lrish
al.,1994).
Setter,German Shepherd Dog,Boxer,Golden
RetrieverandLabradorRetrieverareover-repre-
Incidentallydiscoveredadrenal masses
sented.Clinical signs result fromhypoglycaemia，
which causes neuroglycopenia,and stimulation of
Withtheincreaseduseofabdominalultrasono-
thesympatheticnervous system，whichresults in
graphyandCTimaging,adrenal massesmaybean
incidental finding.Theapproachtoanincidentally
elevated circulating catecholamine concentrations.
Clinicalsignsaretypicallyepisodicand includesei-
discoveredadrenalmassshouldincludeadetailed
historyandphysicalexaminationtoinvestigatefor
zures,weakness,collapse,ataxia,posteriorparesis,
musclefasciculation，
dementia,polyphagiaand
clinical signs of hyperadrenocorticism,phaeochro-
depression.Physicalexaminationfindingsaregener-
mocytomaorotherneoplasiathatcouldmetastasize
allynon-specific.The most common findings are
totheadrenalgland.Asensitivescreeningtestfor
obesity(duetotheanaboliceffectsofinsulin)and
hyperadrenocorticism,retinalexaminationandmulti-
neurologicalabnormalities.Aperipheral polyneuro-
plebloodpressuremeasurementsshouldbeper-
formed.Thoracicradiographsshouldbeconsidered
pathyindogswithinsulinomahasbeendescribed
andisbelievedtobeaparaneoplasticeffect.
toscreenforneoplasia.Dependingupon thecharac-
teristicsofthemassandtheclinicalfindingsafine-
Diagnosis
needleaspirateofthemassmaybeconsidered.
Basedonthediagnosticevaluationandthe
Hypoglycaemiaisthehallmarksignofinsulinoma.
TheCBCandurinalysisareusuallyunremarkablein
noduleversusadrenal masswithdisruptionofarchi-
animals.Themostcommonfindings arehypoglycae-
tectureandinvasionofvessels),exploratorysurgery
miaandsometimesincreasedserumliverenzyme
activities.Othercauses ofhypoglycaemia in the dog
orcarefulmonitoringofthemassmayberecom-
mended.Thepercentageoftheseincidentallydis-
arelisted inFigure20.22.
problem tumourshasnotbeendefined.Inaddition,
Non-islet-celltumours(hepatic,leiomyomas/leiomyosarcomas,
evidence from human medicine suggests that about
other)
a third of'masses'seen ultrasonographicallyarenot
Hypoadrenocorticism
Hypopituitarism（growthhormoneACTH
Toxicosis(e.g.xylitol)
Sepsis/endotoxaemia
Puppy/toybreed hypoglycaemia
Endocrinecancersofthepancreas
Glycogen storage diseases
Insulin overdose
TheisletsofLangerhansformtheendocrineportion
Invitroconsumption(polycythaemia,leucocytosis）
of thepancreasandsecreteanumberofpolypeptide
Artefactualprolongedstorageportableglumeer
hormones.Beta cells secrete insulin,alpha cells
20.22
Othercauses of hypoglycaemia indogs.
secrete glucagon,delta cells secrete somatostatin,
324
Chapter20Endocrine tumours
Documentation ofhypoglycaemia,neurological
maintenancerate.Higherconcentrationsofdextrose
abnormalitiessecondarytohypoglycaemiaandres-
stimulatethepancreasandexacerbatehypogly-
olutionofclinicalsignsbyfeedingoradministering
caemiaandshouldbeavoided.Dexamethasone
glucoseare suggestiveof insulinoma.Thediagnosis
canusuallybeconfirmedbymeasurementofserum
venous fluidsifnecessary.Thisdosecanbe
insulinconcentrationatatimewhentheserum
repeatedevery12-24hoursasneeded.
glucoseconcentration is<60mg/dl(<3.33mmol/l)
Frequentfeedingofadiethighinfat,proteinand
Iftheseruminsulinconcentrationisinthehigh
complex carbohydrates,but low in simple sugars,
normalrange or abovethe normalrange,this is
maycontrol clinicalsignsforaperiodoftime.Stress
supportive of insulinoma;if theseruminsulincon-
shouldbeminimizedandexerciselimited.Oncefre-
centration is below thenormalreferencerange,
quentfeedingfailstocontrol clinicalsigns,treatment
insulinoma isunlikely.
withglucocorticoidsisnecessary.
Ratiossuchastheamendedinsulin:glucoseratio
havepoorspecificityandmayresultinfalse-positive
Thestartingdoseforprednisoneis0.25mg/kg
results indogs that donot have insulinoma.If the
q12h.Thedoseshouldbetitratedupwardsin
seruminsulinisintheborderlinerange,repeatingthe
ordertocontrol clinical signs asnecessary.
measurementuptofourtimesina24-hourperiod
Thereislittlebenefittoincreasingthedose
maybeuseful.Thisincreasesthe likelihoodofdetect-
>3mg/kg/dose.
ingan insulinpeak.Ifseruminsulinconcentrations
Diazoxideinhibitsinsulinsecretionfromthe
areconsistentlybelow thereferencerangeinthe
pancreas,stimulatesgluconeogenesisand
presenceofhypoglycaemia,othercausesofhypogly-
glycogenolysis,andhasadirectinhibitoryeffect
caemiashouldbeinvestigated.Provocativetests(e.g.
oncellularuptakeofglucose.Thedoseis5-30
glucagon,glucoseand tolbutamidetolerancetests)
mg/kgq12h,startingatthelowerendofthedose
havegenerallybeendisappointingindiagnosing
and increasingasnecessary.Sideeffectsinclude
insulinomainthedogandarenotrecommended.
anorexia,vomiting,diarrhoea,hyperglycaemia,
Thoracicradiographs are usuallynormal indogs
cataracts,tachycardia,bonemarrow
withinsulinoma.Abdominalradiographyandultra-
suppression,hypernatraemia,cardiac
sonographymaybehelpful inidentifyinglargepancre-
arrhythmiasandpancreatitis.
atictumours andmetastaticmasses.Themost
commonsitesofmetastasisincluderegionallymph
Ifclinical signsofhypoglycaemiacannotbecon-
nodesandtheliver.Abdominal radiographyand ultra-
trolledbydextroseandglucocorticoidtreatmenta
sonographyhavepoorsensitivityfordetectionofsmall
glucagonconstant-rateinfusionshouldbeaddedat
pancreaticmassesormetastasisandonly35%of
arate of 5-10 ng/kg/min （Fischer et al.,2000).
insulinomasaredetectedbyabdominalultrasonogra-
Glucagonantagonizesthehypoglycaemiceffectsof
phy.CTismoresensitivefordetectionofpancreatic
insulinbydirectlystimulatinghepaticgluconeogen-
masses,identifyinginonestudy10of14pancreatic
esisandglycogenolysis.Octreotide,a somatostatin
massesthatwereconfirmed asinsulinoma atsurgery
analogue,hasalsobeenused totreatdogswith
insulinoma,but theresultshave beenequivocal.In
falsepositivesformetastaticdisease.
onereport,octreotideatadoseof2-4μg/kgq24h
Somatostatinreceptoractivityisapromisingnew
wasnotefficaciousincontrollingeithertheclinical
areaforthelocalizationofpancreaticandmetastatic
sitesofinsulinomas.Somatostatinreceptorshave
trationsofglucoseandinsulin（Simpsonet al.,
beenidentifiedatthesurfaceofmostneuroendo-
1995),whereasothershavereportedresolutionor
crinecellsandarepresentinabnormaldensityin
improvementofclinicalsignsindogstreatedwith
isletcelltumours.Somatostatinreceptors canbe
octreotideatsimilardoses.Treatmentwithasingle
imagedinvivobymeansofindium111pentetreotide
doseofoctreotide（50microgramss.c.)decreased
(Octeoscan)scintigraphy.Inastudyoffivedogswith
insulinconcentrationsandincreasedbloodglucose
insulinoma,anabnormalfocusofactivitywasidenti-
concentrationsin11dogswithinsulinoma（Robben
fiedin four dogs,withonedog having equivocal
etal.,2006).Octreotide is expensive andmostdogs
results(Garden,2005).
becomerefractoryovertime.
Chemotherapeuticagentssuchasalloxanand
Treatment
streptozocinhavedirecttoxicityforthebetacellsof
thepancreas,butbothdrugs are alsonephrotoxic.
Medicalmanagement:Indicationsformedicalman-
Streptozocin（500mg/m²q3wkcombinedwithadi-
agementofinsulinomaincludestabilizationof
uresisprotocol)is welltolerated in dogsandhas
patientsprior toexploratorysurgery，patientswith
beenassociatedwithresolutionofparaneoplastic
obviousmetastaticdiseaseandpostsurgicalpatients
peripheralneuropathyandreductionsintumoursize
inwhichcompletesurgicalremovalofthetumouror
(Mooreetal.,2002).
metastaseswasnotpossible.Inpatientswithclinical
signsofhypoglycaemia,intravenousglucose should
Surgery:Serum glucose concentrations should be
beadministered(1-5ml50%dextrosei.v.slowly
maintained>40mg/dl(>2.22mmol/l)during surgery
over 10minutes).Ifclinical hypoglycaemiapersists,
byintravenous infusionof 5%dextrose.Thepan-
continuousinfusion of dextrose(2.5-5%dextrose in
creasshouldbecarefullyinspectedforevidenceof
wateri.v.)shouldbeadministeredat112-2timesthe
atumour(Figure20.23).Most dogs have visible
325
Chapter20Endocrinetumours
Caninegastrinoma(Zollinger-Ellison
syndrome)
Pancreaticislet-celltumoursthatsecreteexcessive
amountsofgastrinarereferredtoasgastrinomas.
Affecteddogs have gastricacid hypersecretion,
gastrointestinalulcerationandagastrin-secreting
pancreaticmass.
Clinicalfeatures
Gastrinomasareraretumours indogs.The most
common clinicalsigns arechronicvomiting,diar-
rhoea,anorexia,depression,lethargy and weight
loss.Melaena,haematemesis,haematochezia and
Insulinomaidentified inthepancreasduring
palemucousmembranesmayalsooccursecondary
20.23
surgeryina10-year-oldneuteredmaleGerman
togastrointestinalblood loss.
ShorthairedPointerwithhypoglycaemia.
Diagnosis
The diagnosis is made by documentationof
pancreaticmasses,butafewmayrequiregentlepal-
increasedcirculatinggastrinconcentrationsfollowed
pationoftheorgantoidentifysmalltumours.Minimal
byexploratorylaparotomyandtumourresectionor
handlingofthepancreasisdesirable,inordertopre-
ventpostoperativepancreatitis.Partialpancreatec-
staining arenecessarytoconfirmthediagnosis.
tomyornodulectomyisperformedtoremovethe
affected tissue.
Treatment
Intravenousfluidswithdextroseshouldbecontin-
Surgicalexplorationandpartialpancreatectomyare
uedandoralintakeoffoodandwaterwithheldfor
requiredtoestablishadefinitive diagnosis,resect
24-48 hours following surgery, to minimize risk of
perforatingulcers,manageperitonitis andremoveor
postoperativepancreatitis.If thepatient isnotvomit-
debulk thetumour.（
Gastrinomasaremalignant
ing,gradualintroductionofwaterandablanddiet
tumoursindogs,andsurgeryisusuallyonlypallia-
shouldbeinitiatedafterthisperiod.Otherpotential
tive.Forpatientsinwhichcompletetumourresec-
postoperativecomplicationsarehypoglycaemiaor
tionisnotpossible,hypersecretion ofgastricacid
hyperglycaemia.
Blood
glucose
concentrations
shouldbecontrolledwithdrugsthatdecreasegas-
shouldbeevaluatedtwicedailyforatleast3-4days
tricacid secretion,suchas Hreceptor antagonists
followingsurgery.Transitorydiabetesmellitusmay
(cimetidine，ranitidine，famotidine),proton pump
occurasaresultofatrophyof thenormalbetaislet
inhibitors(omeprazole)and thesomatostatinana-
cells.Insulinadministrationisrecommendedonlyif
logue octreotide.
hyperglycaemiapersistsformore than2-3daysfol-
lowing discontinuationof dextrose.Postoperative
drugofchoiceduetoitslongerdurationofaction
hypoglycaemiashouldbetreatedwiththefeedingof
andmoreeffectiveblockadeofbothbasal andstimu-
smallfrequentmeals.If itpersists,moreaggressive
latedgastricacidsecretion,comparedwithHrecep-
medical therapy should be instituted(see above).
tor
antagonists.Higher dosesof H2receptor
Persistentpostoperativehypoglycaemia suggests
antagonistsmay be necessary to control clinical
thattumourresectionisincompleteandisapoor
signsindogswithgastrinoma.Other drugs,suchas
prognosticindicator.
sucralfateandmisoprostol,mayalsobeofbenefit.
Octreotideblocksgastricacidproductionby
Prognosis
inhibitinggastrinsecretionandbydirectlyinhibiting
Insulinomaisamalignanttumourindogsandthe
parietal cellacid secretion.Octreotide(10-20μg s.c.
long-termprognosisis guarded topoor.Evidence of
q8h)incombinationwithcimetidineandsucralfate
grossmetastasisispresent inatleastone-thirdof
wassuccessfullyusedtotreatadogwithgastrinoma
dogsatthetimeofdiagnosis.Survivaltimesare
thathadfailedtorespondtocimetidineandsucral-
longer fordogs treatedsurgically.Inonestudy,
fatealone.
MSTfordogstreatedsurgicallywaslongerat381
days（range 20-1758days),than for those treated
Prognosis
medically(74days,range8-508days)（Tobinet al.,
Thelong-termprognosisindogswithgastrinomas is
1999),though the dogs in the medical group may
poor due to thehighrate of metastasis at the time of
havereceivedlessaggressive therapy.in another
diagnosis.Althoughcompletesurgicalresectionof
studyof28dogswithinsulinoma,MSTfor19dogs
the tumourmaybeunlikely,aggressiveuseof anti-
treatedwithpartialpancreatectomyandprednisone
secretorydrugssuchasomeprazolemayextend life
and diazoxide was785days(Poltonet al.,2007).
expectancy.
Thelong-termprognosisfordogswithdetectable
metastaticdisease isgenerallyconsideredpoor,
Glucagonoma
butlongsurvivaltimesafteraggressivesurgical
Glucagonoma is a rare islet-cell tumour of the
debulkingofprimaryandmetastaticnoduleshas
pancreas
thatsecretesexcessivequantitiesof
beenreported.
glucagon.Clinicalsignsarehyperkeratosisof the
326
Chapter20
Endocrinetumours
footpads anderythematous,erosive and crusting
Hanson JM,van't Hoofd MM,Voorhout G et al.(2005）Eficacy of
lesionsaffectingthemuzzle,externalgenitalia,peri-
transsphenoidalhypophysectomyin treatmentofdogswith
pituitary-dependenthyperadrenocorticism.JournalofVeterinary
neum andperiocularregion.Necrolytic migratory
InternalMedicine19,687-694
erythemaassociatedwithliverdisease(hepatocuta-
HerreraMA,MehlML,KassPHetal.(2008)Predictive factors and the
effect of phenoxybenzamine on outcome in dogsundergoing
neous syndrome;seeChapter4)isapotential dif-
adrenalectomyforphaeochromocytoma.JournalofVeterinary
ferential diagnosis for the cutaneous changes
InternalMedicine22,1333-1339
reported in dogswithglucagonoma.
Kallet AJ,Richter KP,Feldman EC et al.(1991)Primary hyper-
parathyroidism in cats:seven cases(1984-1989）.Journalof the
Americanof theVeterinaryMedicalAssociation199,1767-1771
KaplanAJ,PetersonMEandKemmpainenRJ(1995)Effectsof disease
Referencesandfurtherreading
ontheresultsofdiagnostictests for use in detecting
hyperadrenocorticismindogs.JournaloftheAmericanVeterinary
AndersonCR,BirchardSJ,PowersBEetal.(2001）Surgical treatment
MedicalAssociation207,445-451
of adrenocortical tumors:21cases(1990-1996).Journal of the
Kaser-HotzB,RohrerCR,Stankeova S et al.(2002)Radiotherapy of
AmericanAnimalHospitalAssociation37,93-97
pituitarytumorsinfivecats.JournalofSmallAnimalPractice43,
Barker EN,CampbellS,TebbAJ etal.(2005)A comparison of the
Kent MS,BommaritoD and Feldman E(2007) Survival,neurologic
303-307
survival timesofdogstreatedwith mitotane or trilostane for
pituitary-dependenthyperadrenocorticism.JournalofVeterinary
response,and prognostic factors in dogs with pituitary masses
InternalMedicine19,810-815
treatedwithradiationtherapyanduntreateddogs.Journalof
BarthezPYMarksSL,WooJetal.（1997）Pheochromocytomaindogs:
VeterinaryInternalMedicine211027-1033
61cases（1984-1995）.JournalofVeterinaryInternalMedicine11.
KintzerPPand Peterson ME(1991)Mitotane (op-DDD) treatment of
272-278
200dogswithpituitary-dependenthyperadrenocorticism.Journal
Berg RIM,NelsonRW,Feldman EC et al.(2007) Serum insulin-like
ofVeterinaryInternalMedicine5,182-190
growthfactor-lconcentrationincatswithdiabetesmelitusand
KintzerPPandPetersonME（1994）Mitotane treatmentof32dogs with
acromegaly.JournalofVeterinaryInternalMedicine21,892-898
cortisol-secretingadrenocorticalneoplasms.Journalofthe
BertoyEHFeldmanEC,NelsonRWetal.（1995）Magneticresonance
AmericanVeterinaryMedicalAssociation20554-61
imagingof thebrainindogswithrecentlydiagnosedbutuntreated
Kipperman BS,Feldman EC,Dybdal NOet al.（1992)Pituitary tumor
pituitary-dependenthyperadrenocorticism.Journal of theAmerican
sizeneurologicsignsandreationtoendocrinetestresultsindog
VeterinaryMedicalAssociation206,651-656
with pituitary-dependent hyperadrenocorticism:43cases（1980-
BertoyEHFeldmanEC,NelsonRWetal.（1996)Oneyearfllow-u
1990).Journalof theAmericanVeterinaryMedicalAssociation201
evaluationofmagneticresonanceimagingof thebrainindogswith
762-767
KleinMK,Powers BE,Withrow SJ etal.（1995)Treatmentof thyroid
VeterinaryMedicalAssociation208,1268-1273
Bosje JT,RijnberkA,Mol JA etal.(2002）Plasma concentrationsof
1989).Journalof theAmericanVeterinaryMedicalAssociation206,
ACTHprecursors correlatewithpituitarysizeandresistance to
1007-1009
dexamethasone indogswithpituitary-dependenthyperadreno-
Kyles AE,Feldman EC,De Cock HEV et al. （2003） Surgical
corticism.DomesticAnimalEndocrinology22,201-210
managementofadrenalgland tumorswithandwithoutassociated
Daley CA，Zerbe CA,SchickRO etal.（1993)Use of metyrapone to
tumor thrombi in dogs:40 cases（1994-2001).Journal of the
AmericanVeterinaryMedicalAssociation223,654-662
cutaneouswounds.Journalof theAmericanVeterinaryMedical
Marks SL,Koblik PD,Hornof WJ et al.（1994）mTc-pertechnetate
Association202,956-960
imagingof thyroid tumorsindogs:29 cases(1980-1992).Journal
Duesberg CA.Feldman EC,Nelson RW et al. (1995） Magnetic
oftheAmericanVeterinaryMedicalAssociation204,756-760
Mayer MN,GrecoDS and LaRue SM(2006)Outcomesof pituitary
Journalof theAmericanVeterinaryMedicalAssociation206,657-
irradiationincats.JournalofVeterinaryInternal Medicine20,
662
1151-1154
Duesberg CA,NelsonRW,Feldman ECetal.（1995)Adrenalectomy for
Moore AS, Nelson RW,Henry CJ et al.(2002) Streptozocin for
treatmentofhyperadrenocorticism incats:10cases（1988-1992)
treatment of pancreaticisletcell tumors in dogs:17cases(1989-
JournaloftheAmericanVeterinaryMedicalAssociation207066
1999).Journalof theAmericanVeterinaryMedicalAssociation221
1070
811-818
Dunning MD,LeatherCA，BexfieldNJetal.(2009）Exogenousinsulin
NeigerR,Ramsey1,OConnorJetal.(2002）Trlostane treatment of78
dogswithpituitarydependenthyperadrenocorticism.Veterinary
diabetesmellitusandacromegaly.JournalofVeterinaryInternal
Record150,799-804
Medicine23,243-249
Neiger RN,Witt AL,Noble A et al. (2004)Trilostane therapy for
Feldman EC,HoarB,PollardRet al.(2005）Pretreatment clinical and
JournalofVeterinaryInternalMedicine18,160-164
cases(1987-2004).Journalof the AmericanVeterinary Medical
Ass0ciation227,756-761
in cats:seven cases （1978-1987). Journal of the American
FeldmanECandNeisonRW(2004)Canine andFeline Endocrinology
VeterinaryMedicalAssociation193,245-250
andRrodutonrddnBaundrhiad
NiessenSJMPetrieG,GaudianoFtal.2007)Felineacrmegaly：n
FischerJR,Smith SA and Harkin KR(200o)Glucagon constant-rate
underdiagnosedendocrinopathy？JournalofVeterinaryInternal
Medicine21,899-905
hypoglycemiccrisis in thedog.Journalof the AmericanAnimal
PetersonMEandBeckerDV(1995）Radioiodine treatmentof524cats
HospitalAssociation36.27-32
withhyperthyroidism.JournaloftheAmericanVeterinaryMedical
Garden OA,Reubi C.Dykes NLet al.(2005） Somatostatin receptor
Association207,1422-1428
imaginginvivobyplanarscintigraphyfaclitatesthediagnosisof
PetersonME,TaylorRS,GrecoDSetal.（1990）Acromegalyin14cats.
canineinsulinomas.JournalofVeterinaryInternalMedicine 19,
JournalofVeterinaryInternalMedicine4,192-201
168-176
PoltonGA,WhiteRN,BrearleyMJetal.(2007）Improved survival ina
GilsonSDWithrowSJ,WheelerSLetal.（1994)Pheochromocytomain
retrospectivecohortof28dogswithinsulinoma.JournalofSmall
50dogs.JournalofVeterinaryInternalMedicine8,228-232
Animal Practice48.151-156
GoldsteinREAtwaterD,CazolliMetal2007）nheritancemodef
RasorL,Pollard R,Feldman EC(2007)Retrospective evaluation of
threetreatmentmethodsforprimaryhyperparathyroidismindogs.
inKeeshonden.JournalofVeterinaryInternalMedicine21,199
Journalof theAmericanAnimalHospitalAssociation437077
203
Reusch CEand Feldman EC(1991)Canine hyperadrenocorticism due
Granger N,de Fornel P,Devauchelle P et al.(2005）Plasma pro-
toadrenocorticalneoplasia.JournalofVeterinaryInternalMedicine
opiomelanocortin,pro-adrenocorticotropinhormone,andpituitary
5,3-10
adenomasizeindogswithCushing'sdiseaseJournalofVeterinary
Robben JH,PollakWEA,KirpensteijinJet al.(2005)Comparisons of
InternalMedicine192328
Grooters AM,Biller DS,Theisen SKet al.(1996)Ultrasonographic
computed tomographyforthe detectionand localizationofcanine
characteristics
of
theadrenal
sbopu！spuej6
with
insulinoma.JournalofVeterinaryInternalMedicine19.15-22
RobbenJHvandenBromWRMolJAetal.（2006）Effectofctreotide
dogs.JournalofVeterinaryInternalMedicine10,110-115
on plasma concentrationsof glucose,insulin,glucagon，growth
GuptillL,Scott-Moncrieff JCR,JanovitzEB etal.(1995)Response to
hormoneandcortisolinhealthydogsanddogswithinsulinoma.
high-doseradioactive iodine administration incatswiththyroid
ResearchinVeterinaryScience80,25-32
carcinoma thathadpreviouslyundergonesurgery.Journalof the
Schwartz P,Kovak JR,Koprowski A et al.(2008)Evaluation of
AmericanVeterinaryMedicalAssociation207,1055-1058
prognosticfactors inthesurgical treatmentofadrenalglandtumors
327
Chapter2oEndocrinetumours
indogs:41cases（1999-2005).Journalof theAmericanVeterinary
Turrel JM,McEntee MC,Burke BPet al.(2006)Sodium iodide 1311
MedicalAssociation232,77-84
treatmentof dogs with nonresectable thyroid tumors:39cases
Simpson KW,Stepien RL,Elwood CMetal.（1995)Evaluation of the
(1990-2003）.JournaloftheAmericanVeterinaryMedical
long-acting somatostatin analogueoctreotideinthemanagement
Association229,542-548
ofinsulinomainthreedogs.JournalofSmallAnimalPractice36,
VaughanMA,Feldman EC,HoarBRetal.(2008）Evaluation of twice-
161-165
daily,lowdosetrilostanetreatmentadministeredorallyindogswith
TheonAPandFeldmanE（1998)Megavoltageirradiationofpituitary
VeterinaryMedicalAssociation232,1321-1328
TheonAPMarksSL,FeldmanESetal.(20oo）Prognosticfactorsand
Pheochromocytoma andhyperadrenocorticismindogs:sixcases
(1981-1992).JournaloftheAmericanVeterinaryMedical
thyroidcarcinomastreatedwithmegavoltageirradiation.Journalof
Association207,322-324
theAmericanVeterinaryMedicalAssociation2161775-1779
Wood FD,PollardRE,Ueling MRet al.(2007)Diagnostic imaging
Tobin RL,NelsonRW,Lucroy MDet al.（1999)Outcomeof surgical
findingsandendocrinetestresultsindogswithpituitary-dependent
versusmedical treatmentof dogswithbetacellneoplasia:39
hyperadrenocorticism that did or didnothave neurologic
cases(1990-1997).Journalof theAmericanVeterinaryMedical
abnormalities.JournaloftheAmericanVeterinaryMedical
Association215,226-230
Association231,1081-1085
Turrel JM,Feldman EC,Nelson RWet al.（1988)Thyroid carcinoma
causing hyperthyroidismincats:14cases（1981-1986).Journalof
forthetreatmentofcaninethyroidcarcinoma.AustralianVeterinary
theAmericanVeterinaryMedicalAssociation193.359-364
Journa/83,208-214
328
Tumours of the nervous system
ChristopherMariani
Introduction
Primarytumours
Tumoursaffectingthenervoussystemmayinvolve
Meningeal tumours:
thecentralnervous system(CNS)(brain and spinal
oMeningioma
。
Granularcell tumours(rare)
cord)or the peripheral nervous system （PNS)
oMeningeal sarcoma(rare)
(peripheral andcranial nerves).Tumours areclassi-
Neuroepithelial tumours:
fiedasprimaryif theyarisefromtissuesorcelltypes
0
Astrocytoma
normallypresentwithinthenervoussystemor
。
Oligodendroglioma
meningealtissues,orsecondaryif theyarisefrom
Choroid plexustumours
。
adjacent structures(e.g.nasal cavity, skull,verte-
Ependymoma
Primitive neuroectodermal tumours(PNETs)
brae)ormetastasizetothenervoussystem.
0
Medulloblastoma(cerebellum only)
Haemopoietictumours:
oLymphoma
Intracranialtumours
oHistiocytic sarcoma
Secondary tumours
IntracranialtumoursarelistedinFigure21.1.
Pituitary tumours:
Tumourtypesandpathogenesis
oPituitary adenoma
Nervoussystemtumoursmaybedescribed asextra-
oPituitary carcinoma
axial(arisingfromoutsidethebrainparenchyma)or
Nasal tumours:
oNasal adenocarcinoma
intra-axial (arising fromwithin the parenchyma).
Skull tumours:
Clinicalsignsrelatedtointracranialtumoursare
oMultilobular tumourof bone
causedbycompressionofnervoustissueandvas-
0
Osteosarcoma
culature,impairedbloodflowtonervoustissue,cere-
Chondrosarcoma
braloedema,haemorrhage,orbydirectinvasionof
Cranial nerve tumours:
brainparenchyma.Theskullofmatureanimalsisa
oPeripheral nerve sheath tumour
rigid,non-expandable compartment.Increasesin tis-
Metastatictumours
sue(tumour)within thiscompartmentincrease the
Non-neoplastic lesions
intracranialpressure (ICP),which causes impaired
Vascularhamartoma
bloodflow,ischaemiaandshiftsinbraintissue.Brain
.
Epidermoiddermoidandarachnoidcysts
herniationunderthetentoriumcerebelliorthrough
Granuloma or abscess
theforamenmagnumleadstocompressionofvital
Encephalitis
midbrain andmedullarycentres,reducedconscious-
Stroke
ness,respiratoryarrestand death.
Classificationof intracranial tumours.
Thechangesthatresultinseizureswithbrain
21.1
aLymphomaand histiocyticsarcomamaybe
tumoursareincompletelyunderstood.Althoughcom-
pressionofnervoustissueandtheresultingchanges
tobraintissue,oroccuraspartofasystemicprocess.
describedaboveareinvolvedinsomecases,other
factorssuchasproliferationofreactiveastrocytes
adjacenttothetumourlikelyplayarole.Systemic
(seeChapter20)arealsocommon.Choroidplexus
metastasisofbraintumoursisrareinsmallanimals,
tumoursoccurwithsomefrequencyandarisefrom
buthasbeenreportedformeningiomas.Spreadof
within theventricularsystem.Round celltumours
tumourcells through the cerebrospinal fluid(CSF)
affecting thebrainofcaninepatientsincludelym-
(dropmetastasis')is seenwith some tumours,not-
phomaandhistiocyticsarcoma(seeChapter19a)
ablychoroidplexuscarcinomas.
Bothmayoccuraspartofasystemicproliferationof
neoplasticcells,asaprimaryCNSneoplasm,orwith
Dogs
secondaryextensionfromanextraduralorextra-
Meningiomasarethemostfrequentlyrecognized
cranialprocess.Commonmetastaticbraintumours
intracranial tumour in dogs,though gliomas(astro-
includehaemangiosarcoma,melanomaandcarcin-
cytomas,oligodendrogliomas)andpituitarytumours
omas(e.g.mammary,prostatic).
329
Chapter21Tumoursof thenervoussystem
Boxers,Boston Terriers,Bulldogs and other
causingseizures.Pituitary tumoursmaybe func-
brachycephalicbreedsfrequentlydevelopgliomas,
tionalornon-functional,withorwithoutassociated
whiledolichocephalicbreedsappeartobeat
endocrinopathies(see Chapter20).These tumours
increasedriskforthedevelopmentofmeningiomas.
oftenexpanddorsallyintothehypothalamusand
PoodlesandDachshundsfrequentlydeveloppituitary
thalamus,causing altered mentation(behavioural
tumours.Bernese Mountain Dogs,Rottweilers,
changes,decreased consciousness,head pressing,
GoldenRetrieversandFlat-coatedRetrieversareat
compulsivepacing)andblindness.
increasedriskforhistiocyticsarcoma,while Golden
Retrieverswereatincreasedriskforchoroidplexus
Cats
tumours inone study(Westworthet al,2008).
Catswithmeningiomastypicallypresentwithaltered
Consistentgenderpredispositionshavenotbeendoc-
mentationandbehavioural changes,whileseizures
umentedindogs.Molecular aberrationscontributing
arerelativelylesscommonthanindogs(Tomeket
tothedevelopment,growthandinvasionofnervous
al.,
2006).Clinicalsignsassociatedwithother
systemtumoursarejustbeginningtobeelucidated in
tumours aresimilartothoseindogs.
dogs.Similar tohumans,recent studies showthat
caninebraintumoursover-expressreceptortyrosine
Clinicalapproach
kinases(Dickinson et al.,2006a)and telomerase
A diagnosis of neoplasia affecting the CNS is often
(Long etal.,2006)andpossessanumberofother
suspectedbasedon theclinical signsandsignal-
geneticaberrationsinvolvedincytoskeletalrearrange-
mentof thepatient,thoughavarietyofotherdisease
mentandcelltransformation（Thomsonetal.,2005).
processes canpresentwithidentical signs.In the
brain,themaindifferentialdiagnosestoconsider
Cats
aremeningoencephalitis,cerebrovascular disease
Meningiomasarethemostfrequentintracranial
(stroke)and idiopathic(genetic)oracquired(crypto-
tumoursincats.Lymphoma(seeChapter 19a)and
genic,probably symptomatic)epilepsy.Inaddition,
pituitary tumours(seeChapter20)alsooccurrela-
althoughthemajorityof intracranial tumoursoccurin
tively commonly（Troxel et al.,2003;Tomek et al.,
olderpatients,thesetumourscandevelopinyoung
2006),
whileastrocytomas,
oligodendrogliomas,
animalsandthisdiagnosisshouldnotbeexcluded
ependymomasandchoroidplexustumoursarerare
basedonage alone.
inthisspecies.Riskfactorshavebeenpoorlydefined
Theinitialdiagnosticplanforanimalswithnervous
incats.Mosttumoursoccurinolderanimals,butcats
systemtumoursusuallyincludesacompleteblood
count (CBC),serum biochemistry and urinalysis.
riskforthedevelopmentofmeningiomasatayoung
Thesetestsrarelyprovidevaluablediagnosticinfor-
age.Male cats seem tobeat increased risk formen-
mationpertainingtothe tumour,butareuseful in
ingiomadevelopment.
detectingcomorbiddisease,whichisimportantfor
anaestheticplanningandmayultimatelyaffectther-
Presentationandclinicalsigns
apy.Exceptionsmaybeseenwithhaematological
Aswithanydiseaseof thenervous system,clinical
malignanciessuchaslymphomaandmultiplemyel-
signsdependonthespecificanatomicalregion
oma,whichmayhaveabnormalitiespresentonblood
affected.Tumoursinvolvingtheforebrainmayleadto
andurinetests.Similarly,thoracicandabdominal
seizures,altered mentation,contralateralproprio-
ceptive deficits,blindness and compulsive circling.
ingcomorbidconditionspriortoanaesthesiaformore
Tumoursinvolving thecerebellummayresultinataxia,
advanceddiagnostics.Althoughnervoussystem
dysmetriaandintentiontremors.Tumoursinvolving
themidbrainormedullamaycausealteredmentation,
organsystems,metastaticdiseaseaffectingboththe
ipsilateralorcontralateralproprioceptivedeficits,tetra-
lungsandnervoussystemisaconcernandanimals
paresis,ataxiaandcranialnervedysfunction.
withnervoussystemtumoursfrequentlyhaveasec-
Commoncranial nervesaffected includetheoculomo-
ondprimarytumourinanotherlocation(Snyderet al.,
tor(mydriasis,ophthalmoplegia),trigeminal(reduced
2006,2008).Specific diagnostic tests available to
facial sensation,atrophy of masticatory muscles),
investigatebraindiseaseincludeimaging,CSFanaly-
facial(droopylip,absentpalpebralreflex)andvestibu-
sis,electrodiagnostictests and cytological or histo-
lar nerves(ataxia,head tilt,nystagmus).Neckpainis
pathologicalexaminationofbiopsiedtissue.
occasionallyseenwithintracranial neoplasia.
Diagnosticimaging
Dogs
Conventionalradiographyisrarelyusefulinthe
Seizuresarethemostcommonclinicalsignassoci-
examinationofbraintumours,althoughtumoursorig-
atedwithbraintumoursinthedogandoftenoccur
inatingfromoradjacenttotheskull thatcausebone
withoutanyaccompanyingneurologicaldeficits.As
lysisorproliferationcanoccasionallybedetected
thetumourincreasesinsize,andwith thedevelop-
(Figure 21.2).Hyperostosisof the skull isfrequently
mentofcerebraloedema,othersignsofintracranial
seenwithmeningiomas,particularlyincats,andcan
dysfunctionmaybenoted.Meningiomasinthedog
sometimesbeappreciatedonplainradiographs.
frequentlyariseintheolfactoryandfrontalregions
Computed tomography(CT)or magneticreso-
andat thecerebellomedullary junction,leading to
nanceimaging(MRi)isrequired toobtainadequate
forebrainandvestibularsignsrespectively.Gliomas
imagingofthebrainparenchyma.CTutilizesX-rays
frequentlyariseinthetemporalorpiriformlobes,
inordertogenerateaseriesoftransverseimagesof
330
Chapter21
Tumoursof thenervoussystem
Acommonfindinginanimalswithbraintumours
isincreasedCSFproteinwithoutelevatedwhite
bloodcell numbers(albuminocytologicaldissoci-
ation).Proteinelevationisoftenmarked inanimals
withchoroidplexustumours,particularlycarcinomas
(Westworth et al.,2008).Pleocytosismaybeseen
withsometumours,notably meningiomas(Dickinson
etal.,2006b)
AlthoughCSFcanbecollectedsafelyinthe
majorityofpatientswithintracranialneoplasia,ani-
malswithincreasedICPmaybeatriskforsudden
changes inpressure gradientsandaccompanying
herniationofbraintissuewiththisprocedure.
Pretreatmentwithmannitolorhypertonicsalineand
21.2
Lateralradiographof theskullofadog
collectionoffluidfromthelumbarcisternmayhelpto
presentedaftertheownernoticedaswellingon
itshead.Notetheproliferativebonylesiononthe
preventcomplicationsassociatedwithCSFcollection,
caudodorsal surfaceof the skull(arrowed).Thefinal
but therisksmaybeconsideredtoogreatinsome
diagnosiswasmultilobulartumourofbone.
patients（e.g.those with stupor,coma,or abnormal
theareaofinterest.Althoughimagequalityvaries
formedpriortoCSFcollectioninordertoidentify
widely,dependingonequipmentandimagingsoft-
existingbrainherniationorotherriskfactors.
ware,MRIisalmostalwayssuperiortoCTin the
imagingoflesionsinvolving thebrain,providing
Electrodiagnostictests
muchbettercontrastbetweendifferentsofttissues
Although
electrodiagnostictestsareusedin-
and highlighting pathological abnormalities.With
frequentlyintheevaluationofanimalswithbrain
bothCTandMRi,imagescanbeobtainedbefore
tumours,theycanprovideafunctionalcorrelationto
andafterintravenouscontrastadministrationtolook
theanatomical informationobtainedfromdiagnostic
forenhancinglesionscharacteristicoftumours.One
imaging.
Brainstemauditoryevokedresponse
particularlimitationofCTis‘beam-hardening'arte-
(BAER)testingmaydemonstratedysfunctionof the
fact,whichisproducedbythethickpetroustemporal
auditorynerve(Vill)oritsascendingpathwaysinthe
bone in small animals,obscuring imaging of the
brainstem.Electromyographyandnerveconduction
adjacentbrainstem.
velocitymaybeusedtoinvestigatetheintegrityof
cranialnerveswithmotorinnervation（Il,v,,,ll,
Cerebrospinal fluid analysis
IX,X,XI,xll).Electroencephalographymay provide
AnalysisofCSFisausefuladjuncttoimaging in
informationregardingseizureactivity，ordysfunction
patientswithbraintumours.Parametersevaluated
ofregionsof thebrainaffectedbyneoplasticdisease.
typicallyincludecellcounts,proteinlevelandcyto-
logy.Adefinitivediagnosisisrarelyobtained,though
Cytologyandhistology
occasionallyneoplasticcells maybe detectedon
Althoughhistologicalexaminationoftumourtissueis
cytological examination (Figure 21.3).This occurs
thegoldstandarddiagnostic technique forintra-
mostfrequentlywithlymphomaandchoroidplexus
cranialtumours,itisperformed less frequentlyin
carcinomas(Westworth et al.,2008).More com-
patientswithintracranialtumoursthaninthosewith
monly,CSFanalysisisusefultosupportoreliminate
neoplasms inother organs.Thisisduetodifficulties
adiagnosis of meningoencephalitis,but interpreta-
withaccessandtheperceivedrisksofobtainingthe
tionmustbemadetogetherwithimagingandinthe
sample.Despite these challenges,a histological
contextofotherpatientinformation.
diagnosisisidealbeforemovingforwardwithexpen-
siveandpotentiallyharmfuldefinitivetherapy.
Optionsforobtainingtissueincluderesectionof
tissuevia anopencraniotomyorcraniectomy，or
biopsyoftissuewithaneedleorsimilardevice.A
biopsysamplemaybeobtainedfreehand'afteranaly-
sisofMRIorCTimages,ormaybeguidedbyavari-
etyofimaging techniques,includingultrasonography
and CT.StereotacticCT-guidedbiopsyofbrainlesions
iscommonlyperformedinhumanpatientswithintra-
cranial lesionsandisavailableforveterinarypatients
at some centres (Koblik et al.,1999).Cytological
analysisofaspirates,touchpreparations,or smear
preparationsfromtumourtissuecanprovidearapid
diagnosis in manycases(Vernauet al.,2001).
21.3
Cytospinpreparationof CSFfromadogwith
CNSlymphomathatwaspresentedfor
seizures.Note thepopulationof largemononuclearcells
Management
consistentwithlymphoblasts.Amitoticfigureis also
Managementofintracranialtumourscanbeaimed
present(arrowed).
ateitherpalliatingclinicalsignsordefinitively
331
Chapter21Tumoursof thenervoussystem
addressingneoplasticdiseasetomaximizesurvival
ulcerationoftheoralcavityorexternalearcanal.In
time.Definitivetherapyforintracranialneoplasms,as
addition,astheCNSisalate-respondingtissue(see
withcancerinotherorgansystems,typicallyinvolves
Chapter8),radiationinjurytothebraincanoccur6
surgery,radiationtherapy,chemotherapy，oracom-
monthsorlongerafterinitiatingtherapy.Theselate
binationofthese.Thetherapeuticplandependson
effectsaremorelikelywithhigherfractiondoses,
the species,signalment,type of tumour,tumour
whichshouldideallybe3Gyorless.Although
location,comorbiddiseaseprocessesandfinancial
orthovoltageprotocolshavebeenutilizedwithsome
concernsof theowner.
acceleratorispreferred.Conformaltherapiessuch
Palliativetherapy
asIMRTandSRShavefewersideeffectsthan
Palliationinvolvestheadministrationofanti-
conventionalradiationtherapy.
convulsantmedicationstocontrolseizuresandof
glucocorticoidstoreducetumour-associatedcerebral
Chemotherapy:Chemotherapyis theleast investi-
oedema.Traditionalanticonvulsantmedications(phe-
gatedofthemajoranti-neoplasticmodalitiesfor
nobarbital,bromide)areusuallyquiteeffectiveincon-
intracranial tumoursinsmallanimals.Fewstudies
trolling seizures,but have substantialside-effect
existanditisdifficulttomakerecommendations,
profiles.Themainadvantageof theneweranticonvul-
consideringthepaucityofefficacydataavailable.
sant medications(levetiracetam,zonisamide,gaba-
Themedicationsmostcommonlyusedarelomustine
pentin,pregabalin)isareductionof sedationand
(CCNU),hydroxycarbamideand cytarabine(Ara-C).
othersideeffects.Althoughexperiencewiththese
drugsassoletherapyinveterinarypatientsislimited,
Meningioma
theymayproveveryusefulinanimalswithbrain
tumourswheresedationmaybecompoundedby
Dogs:Meningiomas arethemostsurgically accessi-
existingmentationimpairment.Glucocorticoidadmin-
bleintracranial tumoursin canine patients,due to
istrationatanti-inflammatorydosesisusually
theirextra-axial location.However,incontrastto
sufficienttoreducethevasogenicoedemaassoci-
felinemeningiomas,
thedemarcationbetween
atedwithintracranialneoplasms,andfewanimals
tumourtissueandnormalbrainisfrequentlydifficult
benefit from higherdoses.
toappreciate.Asaresult,residual tumour tissueis
commonlypresentaftersurgeryandrecurrenceis
Definitivetherapy
frequentwithsurgicaltherapyalone.Althoughstud-
iesarelimited,mostreportsofcaninemeningiomas
Surgery:Anumberof surgicalapproacheshave
treatedwithsurgeryalonedescribemediansurvival
beendevelopedforthetreatmentofintracranialdis-
timesof 1-7months.However,severalrecent stud-
easeinsmallanimals.Extra-axialtumoursonthe
iesdescribingnewersurgicaltechniqueshave
dorsalorlateralsurfacesofthebrainaretheeasiest
reporteddramaticallyimprovedsurvivaltimesasso-
toapproach,while intra-axial,intraventricular and
ciatedwithmorecompletetumourremoval(Grecoet
ventralskull-basetumoursmaybedifficultorimpos
al.,2006;KloppandRa0,2009).
sible toaccess safely.Potentialcomplicationsof
Anumberofstudieshaveexaminedsurvival
intracranialsurgeryincludehaemorrhage,postoper-
timesafterradiationtherapyofbrainmassesindogs,
ativeinfectionandincreasesinICP.Despitethese
withresultstypicallyrangingfromabout1to1.5
risks,surgicalinterventioncanyieldabiopsysample
years.Unfortunately,manyofthesestudiesdidnot
oftumourfordefinitivediagnosis,substantialdebulk-
havehistologicalconfirmationof theneoplasm,and
ingoftumourtissueorachanceforcureinsome
definitivestatementsaboutradiationtherapyforany
instances,andlife-savingreliefofICPelevation in
braintumourinsmallanimalsaredifficulttomake.
certainscenarios.
However,theweightof theevidencesuggestsaben-
eficialeffectofradiationformeningiomasindogs,
Radiationtherapy:Thisisthemostcommonlyutil-
whetherasasoletherapyorasadjunctivetherapy
izedtherapyforsmallanimalswithintracranial
aftersurgicaldebulkingorincompleteexcision.
tumoursandcanbedeliveredinavarietyofways.
Littleinformationisavailabledocumentingthe
Conventionalfractionatedradiotherapyisdelivered
responseofcaninemeningiomastochemotherapeu-
atavarietyofdifferenttimeintervals,dependingon
ticprotocols.Anecdotal successhasbeenreported
facilityandcurativeintent,usuallytoatotaldoseof
withtheuseofhydroxycarbamide，lomustineand
45-55Gy.Moreprecisemodalitiesareavailableat
temozolomide.
some institutionsandincludeintensity-modulated
radiation therapy(IMRT)and stereotactic radio-
Cats:Manymeningiomasincatsareamenableto
surgery(SRS)(Lesteretal.,2001).Both techniques
surgicaltherapy，astheytendtooccurinsuperficial
takeadvantageofadvancedimagingtechniquesto
andeasilyaccessibleareasandareusuallyfairly
deliverlargedosesofradiationtothetumourina
welldemarcatedfromadjacentbraintissue（Figure
highlyconformal manner.InthecaseofSRS,alarge
21.4),facilitating completeremoval.Surgery alone
doseisdeliveredinasinglefraction,whichhascon-
oftenleadstofairlylongsurvivaltimesandmany
siderablebenefitsinveterinarypractice,allowinga
catsdieofunrelatedcauseswithoutsignsoftumour
singleanaestheticepisodefortreatment.
recurrence.Successfuloutcomescanalsobe
Sideeffectsofconventionalradiationtherapy
achievedwithsurgicalexcisionofmultiplemeningi-
include alopecia,leucotrichia,moist dermatitis and
omas(Forterre et al.,2007).Incompletelyresected
332
Chapter21
Tumoursof thenervoussystem
21.4
Meningiomainacat.Transverseplane,post-
contrast,T1-weightedMRimageof thebrainof
21.5
Glioma ina dog.Dorsalplane,post-contrast,
acatpresenting foralteredmentation.Notethelarge,
T1-weightedMRimageof thebrainof a dog
extra-axial contrast-enhancingmass,withabroaddural
presentedwithseizures.Note theintra-axial,ring-
attachment,characteristicofameningioma（arrowed).The
massiscausingcompressionof theventricularsystemand
(arrowed),consistentwithan aggressiveglial celltumour.
deviationof themidlinestructurestothecontralateralside.
Thelesioniscausingamasseffect,withdeviationof the
midlinestructurestowardsthecontralateral side.Thefinal
diagnosiswasanaplasticoligodendroglioma.
tumoursormeningiomasinareasthataremoredif-
ficult to access surgically(e.g.skullbase,ventricle)
may benefit from radiotherqpy.SRS has been
Patientsmay benefit from surgicaldebulking,if
performedsuccessfullyincatswithmeningiomas,
accessible,andadjunctiveradiationtherapy.
butthisexperienceisquitelimitedtodate.There
arenoreportsof-theuseofchemotherapyincats
Cats:Thereisapaucityof dataconcerning therapy
withmeningiomas.
ofthesetumoursinthecatandrecommendations
aregenerallymadebasedonexperiencewithcanine
Neuroepithelialtumours
patients.
Dogs: The intra-axial location of gliomas(Figure
Roundcelltumours
21.5) makes surgicalexcision more challenging,and
Recommendationsforthetherapyof intracranial lym-
phomainveterinarypatientshavenotbeenwidely
intheveterinaryliterature.Surgerymayprovidea
discussed.Beyondobtaining a diagnosis,surgery
definitivediagnosis,but isunlikely toresult incom-
typicallyplaysaminorroleintherapy.Chemotherapy
pleteexcision,andadjunctivetherapyistypicallyrec-
isthecornerstoneoflymphomatherapy(see
ommended.Similartomeningiomas,radiotherapy is
Chapter19a),as theprocess is usuallyassumed to
commonlyusedaloneoraftersurgicaldebulkingof
besystemic.For animalswith CNS involvement,
the tumour.Definitive conclusions are dificult to
inclusionofadrugthatpenetratestheblood-brain
makeinlightofthefrequentlackofahistological
barrierandachieveshighlevelsinthebrainisrec-
diagnosis,thoughmost reportsandanecdotal evi-
ommended.Cytarabinemeetsthesecriteriaandcan
dencesuggestthatradiationtherapyisbeneficial in
beadministered asanintravenousinfusion,subcuta-
thesescenariosandextendssurvival indogswith
neouslyorintrathecally.Radiationtherapymayalso
astrocytomasoroligodendrogliomas.Theroleof
playanimportantroleinpatientswithprimaryCNS
chemotherapyforthesetumoursisvirtuallyunknown,
lymphoma,orinthosewhererapidreductionofthe
butlomustine,carmustine,ortemozolomidemaypro-
sizeof the tumour isdesirabledueto life-threatening
videsomebenefit.
increasesinICP.
Thelocationandvascularnatureofchoroid
Nodataareavailableregardingthetherapyof
plexus tumoursmakesurgicalexcisionchallenging,
intracranial histiocyticsarcoma.Regardlessofloca-
though thishasbeen successful insome cases.Very
tioninthebody,this neoplasm has traditionally
littleinformationisavailableregardingradiotherapy
carried a verypoorprognosis.However,arecent
orchemotherapyforthesetumours.Beforepursuing
studysuggests thatlomustinemaybeefficacious
definitivetherapy，carefulexaminationandadditional
(Skorupskiet al.,2007).Althoughintracranial
imagingof theentireCNSshouldbeconsidered,as
tumourswerenotrepresentedinthisstudy,theabil-
metastasisvia theCSFiscommon.Definitive ther-
ityoflomustinetopenetratetheblood-brainbarrier
apyforothertumoursofneuroepithelialoriginhas
warrantsfurtherinvestigationofthisdrugforintra-
beenrarelydescribedintheveterinaryliterature.
cranial disease.
333
Chapter21
Tumoursof thenervoussystem
Pituitary tumours
Therapyof thefunctionalaspectsofpituitarytumours
isdiscussedinChapter20.Surgicalremovalofthe
pituitaryglandhasbeendescribed indogsandcats,
andisavailableatafewselectspecialtycentres(Meij
etal.,2002).Thisprocedure istypicallyperformedby
accessingtheglandthroughatrans-sphenoidal
approach(ie.through the palate),whichlimits the
size of tumour that can be removed.Thus,many
macroadenomas(Figure21.6)aredificulttoaccess
andremovesurgically.Withtheselimitations,defini-
tivetherapyformostpituitarytumoursinvolvesradia-
21.7
Skull tumourina dog.Transverseplane,
tiontherapy,whichhasbeenshown toimprove
post-contrast,T1-weightedMRimagesof the
survivaltimewhencomparedwithdogsnotreceiving
brainofa dogpresented forseizures.(a)Note thelarge
it (Kent et al.,2007).
spherical contrast-enhancing.extra-axial mass(arrowed).
Thelesioniscausingasubstantial masseffect,with
compressionof thelateralventricleanddeviationof the
midlinetowardsthecontralateral side.Acontrast-
enhancinglesionispresentwithin thetemporal
musculature adjacenttothe intracranial lesion
(arrowhead),suggestive of alesion traversing the skull.
(b)Aftercraniectomyandmassremoval,thebrainhas
returnedtoitsnormalposition,andnovisibletumour
remains.Thefinaldiagnosiswasfibrosarcoma.
Metastatictumours
Humanpatientsoftenundergosurgicalremovalor
targetedradiation therapy(e.g.SRS)of metastatic
brainlesionsinadditiontosystemicchemotherapy.
Thisappearstoprovideaclearbenefitinimproving
clinicalsignsandextendingsurvivalinmany
patients.Althoughsuchapproachesmaybeconsid-
ered,therapyformetastaticCNStumourshasbeen
poorlydocumentedtodateinveterinarymedicine.
Prognosis
Formulatingaprognosisforveterinarypatientswith
Pituitary tumourina dog.Transverseplane,
braintumoursisdifficult,as thereisadearthof
post-contrast,T1-weightedMRimageofa dog
knowledgeconcerningthenaturalhistoryofthese
presentedwith alteredmentation.Note thelargespherical
diseases.Effortsarehinderedbythedelayedrecog-
contrast-enhancingmasslesionthat appearstobe
nitionofamasslesionorfailuretoequateclinical
originatingfromthesellarregion,consistentwitha
signs(particularlyseizures)witha structural brain
pituitary tumour(arrowed).The mass iscompressing the
lesion,thelackofa definitivehistological diagnosis,
thirdventricleandthereismildtomoderatedilatationof
thelateralventricles,consistentwithobstructive
variabletherapeuticprotocolsandthelackofcon-
hydrocephalus(arrowhead).
trolledtrialscomparingdifferenttherapies.However,
some generalstatementsandguidelinescanbe
Tumourswithsecondaryextensionintothe
developed,evenwiththeseshortcomings.
cranialvault
Tumoursoftheskullmaybetreatedsuccessfullyin
Animalswith lesssevere clinical signs(e.g.
some cases with surgicalremoval(Figure 21.7).
intermittentseizureswithanormal interictal
Thesetumoursareoftenclearlydemarcatedfrom
neurologicalexamination,subtleproprioceptive
underlyingbrain,allowingaclearplaneofdissection
deficits)tendtodobetterandsurvivelongerthan
tobedeveloped.Themainlimitingfactoristhesizeof
thosewithmoreextensiveintracranial signs(e.g.
thetumour,as extensive skullinvolvementmay
mentationchanges,altered consciousness,
requirereconstructive surgery(cranioplasty).Incom-
moderatetosevereparesis).
pletelyexcisedtumoursarelikelytobenefitfrom
Animalstreatedwithpalliativetherapy(e.g.
adjunctiveradiationtherapy.Nasal tumoursmaybe
glucocorticoids,anticonvulsants)have shorter
debulkedsurgically,butradiationistypicallyanimpor-
mediansurvivaltimesthanthosetreatedwith
tantpartofdefinitivetherapy.Adjunctivechemother-
definitivetherapy.Thisisusuallyintheorderof
apymaybeuseful inpreventingsystemicmetastases.
1-6months,though longer survival times（up to
Surgical therapyoftumoursofcranialnervesinintra-
severalyears)arepossible.
cranial locations hasbeendescribed,but is techni-
Catswithmeningiomastreatedwithsurgical
callychallengingandrarelyperformed.Someofthese
resectionoftenhavesurvivaltimesof2yearsor
tumoursmaybenefit fromradiotherapy.
longer.Evenifsurgicalresectionisnotcomplete,
334
Chapter21
Tumoursof thenervoussystem
theslow-growingnatureof these tumoursoften
Primary tumours
resultsinthedeathof thecatfromothercauses
beforeintracranial signsrecur.
·Meningeal tumours:
Dogswithmeningiomastreatedwithsurgical
Meningioma
Meningeal sarcoma(rare)
resectionaloneoftenhavesurvival timesinthe
Neuroepithelialtumours:
rangeof3-9months.Deathusuallyoccurs due
。
Astrocytoma
toregrowthoftumour.Completetumourremoval
oOligodendroglioma
mayresult indramaticallyincreasedsurvival.
oEpendymoma
Dogswithmeningiomastreatedwithradiation
Nephroblastoma
aloneoftenhavesurvivaltimesintherangeof
Haemopoietic tumours:
oLymphomaa
7-16months.
Dogswithmeningiomastreatedwithsurgical
Secondary tumours
resectionandadjunctiveradiotherapyhave
Vertebral tumours:
mediansurvivaltimesintherangeof12-28
0Osteosarcoma
months.
oChondrosarcoma
Theprognosisfordogsandcatswithintra-axial
Fibrosarcoma
tumours(e.g.astrocytomas,oligodendrogliomas)
oPlasmacytomaandmultiplemyeloma
isoftenlessfavourable.Althoughdata are
oMetastatic tumours
Peripheral nerve tumours:
lacking,survivaltimesof3-12monthswith
definitiveradiotherapymightbeanticipated.
oPeripheral nerve sheath tumour
Soft tissue sarcomas
Dogswithpituitarytumourstreatedwithradiation
Metastatictumours
therapyhaveprolongedsurvivalwhencompared
with untreated dogs(Kentetal.,2007):survival
Non-neoplastic lesions
timesrangefrom5monthsto4years.
Vascularhamartoma
Theprognosisforanimalswithprimitive
Dermoid or arachnoid cysts
neuroectodermaltumours(PNET)andhistiocytic
Intervertebral discdisease(IVDD)
Syringohydromyelia
sarcomaisgenerallyunfavourable.
Granuloma orabscess
Limited useof SRSindogssuggeststhat it
Myelitis
comparesfavourablywithconventional
Fibrocartilaginous embolism(FCE)
radiotherapyintermsofsurvivaltimes,withfewer
Tumoursinvolving the spinal cord.Aswith
sideeffects.
21.8
intracranial tumours,lymphomamayoccurasa
primaryorsecondaryneoplasm.
Spinalcord tumours
Dogs
Tumourtypesandpathogenesis
The most common tumours causing spinal cord dis-
Tumoursinvolvingthespinal cordcanalsobeclas-
easeinthedogarevertebral tumours,softtissue
sified asprimaryorsecondary（Figure 21.8),
sarcomas,meningiomas,and tumoursoftheperiph-
eralnerveandnerveroot.Commonvertebral
tissueorcreatespinal cordsignsthroughextension
tumours include osteosarcoma,multiple myeloma
fromadjacentanatomicalstructures.Anotheruseful
and metastaticcarcinomas(e.g.prostate,mammary,
classificationsystem isonethatdescribestheana-
squamouscell).Most peripheral nerve and nerve
tomical locationofthetumourrelativetothemenin-
roottumoursinthedogareclassifiedasperipheral
gesandspinalcord.A lesionmaybeextradural,
nervesheathtumours(PNSTs)and typicallydisplay
intraduralbutextramedullary（outsidethespinal
malignantbehaviour.Intramedullary tumoursare
cord),or intramedullary:
uncommonindogs,butincludeastrocytomas,oligo-
Extraduraltumoursmayarisefromthevertebrae,
dendrogliomas,ependymomas,lymphomaandmeta-
adjacentmuscleorothersofttissue,orwithinthe
statictumours.
spinal canal(e.g.lymphoma)
Intradural-extramedullarylesionsmayarisefrom
Cats
themeninges,peripheral nerveornerveroot
Spinalcordtumoursarelesscommonincatsthanin
Intramedullarytumoursincludeastrocytomas,
dogs,but includemanyof the same typesof neo-
oligodendrogliomasandependymomas.
plasm.Lymphomaisrelativelymorecommoninfeline
patientsandmayoccurasanextradural mass,or
Themainclinicalproblemsassociatedwithspinal
maydirectlyinfiltratethenerverootsandspinalcord.
andspinalcordtumoursarepainandmyelopathy.
Painmayresultfrom involvementofthevertebrae,
Presentationand clinical signs
nerve roots and meninges,but is oftennot associ-
Tumoursinvolving thespinalcordcausevarying
atedwithintramedullarylesions.Myelopathymay
degreesofparesisandataxia,
andpossibly
resultfromdirectinvasionofthetumourintothe
decreasedsegmentalspinalreflexesifthebrachial
spinalcordorcompressionofthespinalcordbyan
orlumbarplexuses areinvolved.Spinalpain
is
adjacent tissuemass.Occasionallyhaemorrhage or
commonandmaybetheonlyclinicalsignin
pathologicalfracturesofthevertebraemayoccur
manypatients.Clinicalsigns are typically chronic
secondarytoneoplasticdisease.
andprogressiveinnature,butacutepresentations
335
Chapter21Tumoursof thenervoussystem
canbeseen,particularlywhenassociatedwithsud-
denhaemorrhageorpathologicalfracturesofthe
vertebrae.Achroniclamenesswithsubsequent
developmentofparesisisaclassicpresentation
for PNST,which can invade the spinal cord (dis-
cussedbelow).
Clinicalapproach
Foranimalswithpotentialspinal cordneoplasia,the
(a)
maindifferentialdiagnosesareintervertebraldisc
disease (IVDD),discospondylitis,meningomyelitis
and fibrocartilaginous embolism (FCE).The main
testsavailabletodifferentiatetheseconditionsare
diagnosticimaging,CSFanalysis andelectrodiag-
nosticevaluation.As withintracranialdisease，a
CBC,serumbiochemicalanalysisandurinalysisare
typicallythefirststepsinordertoidentifycomorbid
diseaseandtoevaluatethesuitabilityofthepatient
foranaesthesia,which isrequiredformostneurodi-
agnostictests.Similarly,imagingof thethoracicand
abdominalcavitieswithradiographsandultrasono-
(b)
graphyshouldbeconsideredtoscreenforcomorbid
ormetastaticdisease.
Diagnosticimaging
Conventionalradiographsareusefultovisualizethe
vertebraeandmayshowlyticlesionswithtumours
arisingfromthevertebraeorinvadingfromadjacent
soft tissue structures（Figure 21.9).Rarely,expan-
silespinalcordtumoursmaybeappreciatedby
remodellingandwideningofthevertebralcanal.
(c)
Spinalradiographsarealsouseful toidentifydis-
21.10
Myelographicpatterns of compression.
cospondylitis.However,considerablebony destruc-
(a)Lateralmyelogramof thethoracolumbar
tionmustbepresentbeforeitcanbeappreciated
spineof adogpresentedwithbackpain.Thereis
attenuationof theventral anddorsal contrastcolumns
allowdirectvisualizationof thespinalcord,menin-
(arrowheads),consistentwith anextradural lesion.
ges,ornerveroots.
(b)Lateral myelogramof thethoracolumbarspineofa
dogpresentedwithbackpainandataxia.Thereisafiling
defectinthesubarachnoidspace,characterizedbya
large'golf-tee'appearance（arrowed),consistentwithan
intradural-extramedullarylesion.(e)Lateralmyelogramof
thethoracolumbarspineofadogpresentedwith
paraparesis.Notetheattenuationofboththeventral and
dorsalcontrastcolumns,withapparentexpansionof the
spinalcord andspinalcanal(arrowheads).Thisis
consistentwithanintramedullarylesion.
Lateral thoracolumbarspinalradiographofa
flowwithinthesubarachnoidspace,whichcanbe
21.9
dogpresentedforbackpainandambulatory
impairedbymarkedcompressionoccurringovermul-
paraparesis.Thebodyof thesecondlumbarvertebra
tiplevertebrallevels，contrastleakageintothe epi-
showsreduceddensity,consistentwithbonylysis
duralspace,oroperator inexperience.Inaddition,
(arrowheads).There isan absenceof the thindiscrete
myelographycancauseseizuresorworseningofthe
radiodenselinethatnormallydelineatesthedorsalaspect
spinalcord signs.Asaresultof these limitations,
of thevertebralbodyandthefloorof thespinalcanal
(arrowed).Thefinal diagnosis wasosteosarcoma.
myelographyisbeingsupplantedinmanyspecialty
veterinaryhospitalsbymoreadvanceddiagnostic
Tocompensatefortheshortcomingsinherentin
imagingtechniquessuchasCTandMRI.
conventionalradiography,myelography wasdevel-
CTismuchmoresensitive thanradiographyin
oped,whichinvolvestheinjectionofradiopaquecon-
detectingalterationsintheintegrityofvertebrae
trastmaterial into the subarachnoid space.Lesions
（Figure 21.11)caused by bony or soft tissue
identifiedwithmyelographyaretypicallydescribed
tumours.In addition,CTallows improvedcontrast
as being extradural,intradural-extramedullary,or
betweensofttissuestructuresandsomedegreeof
intramedullary(Figure21.10).Althoughusefultodoc-
visualizationof thespinalcanal.Itcanalsobevery
ument spinalcordcompression,myelographyhasa
usefulaftermyelographytoimprovetheidentification
numberofpotential limitationsandsideeffects.Good
ofsubarachnoidcontrastandtodelineatetheexact
qualityimagesaredependentonadequatecontrast
locationofacompressivelesion.
336
Chapter21
Tumoursof thenervoussystem
or CT)and used toplandefinitive therapy.Insome
cases,laminectomy mayberequired inorder to
obtainadiagnostictissuesample.
Management
Palliativetherapy
Palliativetherapyfortumoursinvolvingthespinal
cordinvolvesthecontrolofpainandreductionof
oedemaandinflammationassociatedwiththe
tumour.Glucocorticoidsmayreduce thevasogenic
oedemaassociatedwithsometumoursandimprove
paresisandotherneurologicalsigns.Areduction in
inflammatorycells,particularlyaroundnerveroots,
mayamelioratethepainassociatedwiththetumour.
Otherpotentiallyusefulmedications include tradi-
tional analgesics suchasnon-steroidal inflamma-
torydrugs(NSAIDs)andopioids,aswellasNMDA
receptor antagonists,bisphosphonates and some
anticonvulsants.
AlthoughNSAIDsandopioidscanbebeneficial in
21.11
TransverseplaneCTimageofalumbarvertebra
alleviatingpainassociatedwithbonesorjoints,they
inadogpresentedforbackpainandataxia.
Notetheobviouslyticlesionof thevertebralbody
oftenfunctionpoorlyinthecontrolofneuropathic
(arrowheads).The massextendsupintothe spinal canal,
pain.Neuropathicpaininvolvesalterationsinmolecu-
and is compressing the spinal cord(arrowed).Thefinal
larstructureandsignallingatthelevelofperipheral
diagnosiswasosteosarcoma.
and central neurons.Gabapentin,pregabalin and
NMDA receptor antagonists (ketamine,amantadine)
MRIisthesinglebestimagingmodalityavailable
mayinterferewiththisaberrantneuronalsignalling
toevaluatespinal corddisease,andallowsvisualiza-
andimprovepaincontrol.Bisphosphanatedrugsare
tionofthespinalcordparenchyma and intramedul-
potentiallyusefuladjunctsinthemanagementoflytic
larylesionsnotdetectablewithothermodalities(see
bonelesions.Tramadol isauniquedrugwithopioid,
Figures 21.12 and 21.13).
noradrenergicandserotonergiceffects.Althoughany
single drugmaybeuseful inpain control,multimodal
Cerebrospinalfluidanalysis
therapyistypicallymoreeffectiveandisusuallyrec-
AlthoughthecollectionandanalysisofCSFrarely
ommended.Finally,palliativeradiationtherapycanbe
providesadefinitivediagnosisofspinalcordneo-
veryeffectiveinthemanagementofspinalpainasso-
plasia,this test is often essential to support the
ciatedwithvertebraltumours.
diagnosisandtoruleoutotherdiseaseprocesses
Definitivetherapy
such asmeningomyelitis.Neoplasticdisease affecting
Therearerelativelylimitedoptionsavailableforthe
thespinalcordoftenresultsinan increasedCSF
definitivetherapyoftumoursinvolvingthespinal
proteinlevelwithanormalcellcountandcytology.A
cord.For most tumours,the treatment is centred
similarpatternisseenwithmanyspinalcorddiseases
aroundsurgicalexcisionordebulking,withorwithout
(e.g.IVDD,FCE),butmeningomyelitistypicallyresults
inpleocytosis.Inrarecasesneoplasticcellsmaybe
adjunctiveradiotherapy.Thespinalcordisrelatively
identifiedoncytologicalexamination.
sensitivetoradiationandcaremustbetakenwhen
irradiating these tumours.Therole of chemotherapy
Electrodiagnostictests
ispoorlydefinedinthemajorityoftheseneoplasms.
Althoughrarelyused intheinvestigationofspinal
Vertebral tumoursandsofttissuesarcomas
corddisease insmallanimals,testssuchasspinal
Tumoursofthevertebraemaybedebulkedsurgi-
evokedpotentials,cord dorsumpotentialsand mag-
cally,whichcanprovidesomeimprovementandtem-
neticmotorevokedpotentialsmaybeusefultodocu-
poraryreliefofclinicalsigns.Mosttumoursoriginate
ment spinal cord dysfunction in some scenarios.
fromthevertebralbody,andalthoughcomplete
Electromyography andother electrodiagnostictech-
removalof this structure(spondylectomy)hasbeen
niquesexaminingperipheralnervefunctionareuse-
described,thisprocedureisextremelychallenging，
ful to investigate peripheral nerve tumours,which
carriesasignificantriskofmortalityand israrelyper-
mayinvadethespinalcord(discussedbelow)
formed.AdjunctiveRTmayprolongthetimeuntil
recurrenceofclinical signs.Softtissuesarcomasare
Cytologyandhistology
managedsimilarly,withdebulking surgeryand
Althoughapresumptivediagnosisofneoplasticdis-
adjunctiveradiotherapy.Roundcelltumoursof the
easemaybemadewithimagingandCSFanalysis,
vertebraearetreateddifferently(seebelow).
histologicalexaminationofatissuesampleofthe
masslesionisidealbeforeinitiatingtreatment.
Roundcell tumours
Samplesofvertebralorparavertebraltumourscan
Plasmacytoma(Figure21.12)andmultiplemyeloma
oftenbeobtainedwithimagingguidance（ultrasound
typicallyarisefromthebonemarrowwithinvertebral
337
Chapter21
Tumoursof thenervoussystem
(a)
21.13
Intramedullaryspinal cordtumourinadog.
Sagittallaneost-contrast,T1-weightedMR
imageof thecervicalspineofadogpresentedfor
tetraparesis.Notethering-enhancing,intramedullarylesion
presentoverthesixthandseventhcervicalvertebrae.The
dog alsohada largepulmonarymass.Final diagnosiswas
(b)
poorlydifferentiatedmetastaticsarcoma.
21.12
Vertebral tumourinacatpresentedforspinal
painandparaparesis.(a)Lateral radiographof
Prognosis
the thoracolumbarspine.Aquestionablelyticlesionis
The prognosis for animalswithneoplasia involving
presentinthebodyof theseventhlumbar(L7)vertebra
(arrowed).(b)Lateralplane,post-contrast,T1-weighted
thespinalcordmustbeconsideredguardedin the
MRimage.Note the obviouscontrast-enhancinglesion
majorityofcases,ascuresareuncommon.Surgical
involvingL7andextendingdorsallyintothespinalcanal
excisionmayprovidelong-termbenefitinmanyani-
(arrowed).Thefinal diagnosiswasplasmacytoma.
malswithmeningiomas,nephroblastomasand low-
gradePNST,withreportedsurvivaltimesin the
rangeof4monthsto4years.Onerecentstudy
bodies,whilelymphoma mayoccurwithinbone，as
foundabenefitofadjunctiveradiotherapyindogs
anextraduralmasswithinthespinal canal,within
nerveroots andmeninges,orasanintramedullary
(Petersen etal.,2008).Catswithmultiple myeloma
mass.Surgerymaybeconsideredforrapidrelief
orlymphomainvolvingthespinalcordhave
a
ofsignsinpatientswithseverecompressivemyel-
guardedprognosis.Dogswithmultiplemyeloma
opathy,butsystemicchemotherapyisthetreatment
haveareasonableprognosiswithsystemicchemo-
ofchoiceformostroundcellneoplasms.Adjunctive
therapyandoftensurvive1-3yearsafterdiagnosis.
radiation therapymaybenefitanimalswithsolitary
lesions.
Peripheralnerve tumours
Meningiomas,peripheralnervesheathtumours
andnephroblastomas
Tumourtypes
Definitive therapyfortheseneoplasmsissimilar
Themajorityofperipheralnervetumoursinsmall
andconsistsofsurgicalexcisionwithorwithout
animals(Figure 21.14)areclassifiedasperipheral
adjunctiveradiationtherapy.
Debulkingof
the
nerve sheathtumours(PNSTs),whichencompasses
tumouroftenimprovesclinicalsigns andthis
improvementmaybesustainedformonths,oreven
Primarytumours
forseveralyears insome cases.Occasionally
tumours maybecompletelyexcised.For incom-
·Peripheral nerve sheath tumour(PNST)
pletely excised tumours,adjunctive radiotherapy
Lymphoma
shouldbeconsidered.
Peripheral neuroblastoma（rare)
Paraganglioma(rare)
Intramedullarytumours
Secondary tumours
Intramedullarytumoursincludeastrocytomas,oligo-
·Soft tissue sarcomas
dendrogliomas,
ependymomas,
lymphomaand
metastatictumours(Figure21.13).Therapyforthese
Non-neoplastic lesions
neoplasmshasbeeninfrequentlydescribedin the
·Neuritis
veterinaryliterature.Surgicaldebulkingofthese
.Myopathy
lesionsisrarelyundertaken,butmaybebeneficialin
Focal neuropathyorradiculopathy:
somecases.Radiationtherapyprovidesalessinva-
0Invertebral disc disease (IVDD)
sivetreatmentthatmaybeusefulforsomepatients.
0Hypothyroidism
Lymphomaisbesttreatedwithsystemicchemo-
21.14
therapywithorwithoutadjunctiveradiotherapy.
Peripheral nerve tumours.
338
Chapter21
Tumoursofthenervoussystem
schwannomas,neurofibromas and neurofibrosar-
comas(Brehm et al.,1995).These tumours affect
large-breeddogsmorefrequentlythansmallbreeds
andarerareincats(Jones et al.,1995).Thebrachial
andlumbarplexusesarecommonsitesofoccur-
rence.Cranialnerveinvolvementisrelativelyuncom-
mon,althoughtrigeminalnerve(CNV)tumoursare
occasionally seen(Bagley et al.,1998).In smallani-
malsPNSTsusuallybehaveaggressively,withlocal
tissueinvasionandmalignanthistology,butsystemic
metastasisisrare.Othertumoursarisingfromwithin
theperipheralnervoussystem,includingparagangli-
omas and peripheral neuroblastomas,havebeen
described,butareveryrare insmallanimals.
Lymphomacanarisefromwithinoraroundperiph-
eralnerves,nerverootsorcranialnerves inboth
dogsandcatsandoccasionallyaffectsmultiple
nervesornerveroots.
Presentationandclinicalsigns
Tumoursinvolvingperipheralnervescauseclinical
21.15
Brachialplexustumourinadog.Transverse
signsreferabletothenerveinvolved,includinglame-
plane,post-contrast,T1-weightedMRimageof
ness,reflex deficits,paresis,reduced muscle tone
thecervicalspine andbrachialplexusofadogpresented
and muscle atrophy(Brehm etal.,1995;Joneset al.,
witha chronicthoraciclimblameness.Note the contrast
enhancementandmarked thickeningof theperipheral
1995).Chronicthoraciclimblamenessisacommon
nerveon the right side(arrowheads).The spine is
presentingcomplaintinlargerdogswithtumours
indicatedbythewhite arrow.Thefinaldiagnosiswas
involvingthebrachialplexus.Althoughosteoarthritis
peripheralnervesheathtumour.
orotherorthopaedic diseaseis oftensuspected，
thesepatientsusuallyhaveapoorresponse
to
NSAIDs.Additional clinical signssuchasatrophyof
contrastmaterialduetotheirintradurallocation.
themusculatureontheaffectedlimbandpainwith
Routineradiographicimagingisusuallyoflimited
deeppalpationoftheaxillaryregionmayincrease
valueinthediagnosisoftheseneoplasms,thoughit
the
suspicionofabrachial
plexus
tumour.
maybehelpfulinrulingoutosteoarthritisortumours
Occasionallyamassmaybepalpatedintheaxillaor
involving thebone.
onrectalexamination.Withtime,invasionof the spi-
nalcordmayoccur,withaccompanyingparesisof
Cerebrospinalfluidanalysis
theaffectedlimbandpelviclimbs.Animalswith
AlthoughCSFanalysisisnormal inanimalswith
trigeminalnervesheathtumoursusuallypresentfor
exclusivePNS
involvement,
peripheralnerve
unilateralatrophyofthemasticatorymuscles.
tumoursinvadingthebrainorspinalcordmayshow
Lymphomamaycauseunilateral orbilateral dysfunc-
CSFchanges,mostcommonlyelevationsinprotein.
tionofsingleormultiplecranialnerves,withoutevi-
AnalysisofCSFshouldbeconsidered iflymphoma
denceofCNSsigns.
isapossibility,asneoplasticlymphocytesmaybe
found insomepatients.
Clinical approach
Focalperipheralnervesignsinanolderanimalare
Electrodiagnostictesting
highlysuggestiveofneoplasticdisease affectingthe
Electromyography(EMG)often shows neuropathic
nerve.Otherpotentialdiagnosesincludeneuritis,myo-
changes inanimalswithPNSTs,whichcanbevery
pathicdisease,orafocalperipheralneuropathyor
helpfulinsupportingthisdiagnosisover other
radiculopathy(e.g.nerverootcompressionsecondary
causesof chroniclameness(e.g.orthopaedicdis-
toIVDDor spondylosisdeformans,hypothyroidism).
ease).However,thisisnotspecificforneoplasiaand
Diagnosticteststoconsiderincludeimagingof the
maybeabnormalwithotherperipheralneuropathies,
affected nerve or bodyregion,electrodiagnostic
althoughfocalinvolvementofasinglelimborcranial
evaluationoftheaffectednerve(s)andmuscle,and
nerveisunusualwiththesediseases.
potentiallynerveandmusclebiopsy.Routineblood
testsshouldbeconsideredtoruleoutmetabolic
Cytologyandhistology
neuropathiesandasapre-anaestheticscreen.
Examinationofmuscleandnervetissuecanbeuse-
fulinconfirmingadiagnosisofperipheralneuro-
Diagnosticimaging
pathyandmaybesupportiveofnon-neoplastic
MRI(Figure 21.15)is thepreferred modality forimag-
neuropathicormyopathicdiseaseinsomecases.
ing theperipheralnerves(Kraft etal.,2007),although
Histologicalconfirmationof the tumour isideal
CTand ultrasonography(Rose etal.,2005)may be
beforeinitiatingdefinitive therapy.Therefore，aninci-
useful insomecases.Myelographymaybeableto
sionalorneedlebiopsyofapalpablemassshould
detecttumoursinvadingthespinalcord,whichoften
beconsideredandmaybeaidedwithultrasound
causeacharacteristic‘golf-tee'appearanceofthe
guidanceinsomecases(daCostaetal.,2008).
339
Chapter21
1Tumoursof thenervoussystem
Management
receptor tyrosine kinases VEGFR-1（FLT-1),VEGFR-2（KDR),
EGFR-1PDGFRa and c-Met in canine primary brain tumours.
Thebestopportunityforlong-termtherapeuticsuc-
VeterinaryandComparativeOncology4132-140
cesswithPNSTsliesincompleteexcisionofthe
Dickinson PJ,Sturges BK,Kass PH et al.(2006b) Characteristics of
neoplasmwith wide margins.Unfortunately,thisis
cisternal
cerebrospinalfluidassociatedwithintracranial
meningiomas in dogs:56cases（1985-2004).Journal of the
oftenimpossiblebythetimea diagnosisismade,as
AmericanVeterinaryMedicalAssociation228,564-567
thesetumourstendtoinvadeproximally,ofteninfil-
Forterre F,TomekA,Konar Met al.(2007） Multiple meningiomas:
tratingmultiplenerverootsandpotentiallyspinal
outcomeinfourcats.JournalofFelineMedicine andSurgery9
cord orbrainstem(Brehm et al.,1995).Asa result,
36-43
aggressivetherapyconsistingoflimbamputation
Greco JJ,Aiken SA,Berg JMet al.(2006）Evaluationof intracranial
withlaminectomyandsectioningofnerverootsat
(1996-2004）.JournaloftheAmericanVeterinaryMedical
thelevelofthemeningesmaybethebestchanceof
Association229,394-400
tumourcure,butisstill unsuccessful insomecases.
JonesBR,AlleyMR,JohnstoneACetal.（1995）Nerve sheathtumours
inthedogandcat.NewZealandVeterinaryJournal43,190-196
Likewise,PNST involving cranial nerves may be
Kent MS,BommaritoD,FeldmanEetal.(2007)Survival,neurologic
addressed successfully withsurgery(Bagley et al.,
response,andprognosticfactorsin dogswithpituitary masses
1998),but suchtreatment isusually extremelychal-
treatedwithradiationtherapyanduntreateddogs.Journalof
VeterinaryInternaMedicine211027-1033
lengingandmaynotbepossibleinmanyanimals.
KloppLSand RaoS(2009)Endoscopic-assistedintracranial tumor
Patientswithincompletetumourexcisionmaybenefit
removal indogsandcats:long-termoutcomeof39cases.Journal
ofVeterinaryInternalMedicine23108-115
from adjunctive RT.
Koblik PD,LeCouteur RA,Higgins RJ et al.（1999)CT-guided brain
Due tothe propensityforrecurrence,palliative
biopsyusingamodifiedPelorus Markll stereotacticsystem:
therapyischosenbymanyclientsandconsists
mainlyofanalgesics.Gabapentin(and likelypregaba-
KraftS,EhrhartEJ,GallDetal.(2007)Magneticresonance imaging
lin),tramadolandamantadinearehelpfuldrugsto
characteristics ofperipheralnerve sheath tumorsof the canine
addressneuropathicpain inthesepatients.Although
48,1-7
NSAIDsareoften ineffective assole therapy,they
Lester NV,Hopkins AL,Bova FJet al.(2001）Radiosurgeryusinga
may providea useful contribution in a multimodal
dogs.Journalof theAmericanVeterinaryMedicalAssociation219,
analgesicprotocol.Lymphomaaffectingperipheralor
1562-1567
cranialnervesmaybenefitfromsystemicchemo-
Long S,Argyle DJ,Nixon Cet al.(2006）Telomerase reverse
therapyandlocalradiationtherapy.
transcriptase(TERT)expression andproliferation incanine brain
tumours.NeuropathologyandAppliedNeurobiology32,662-673
Prognosis
hypophysectomy
for
treatment
ofpituitary-dependent
PNSTsoccurringindistal nervesthatcanbecom-
hyperadrenocorticismindogsandcats.MolecularandCellular
Endocrinology197,89-96
pletelyexcisedmayhaveagoodprognosis.
Petersen SA,SturgesBK,Dickinson PJetal.(2008）Canine intraspinal
However,PNSTsinvolving thebrachial andlumbar
meningiomasimagingfeatureshistopathologicclassification,and
long-termoutcomein34dogs.JournalofVeterinaryInternal
plexuseshaveaguardedprognosis,due totheten-
Medicine22,946-953
dencyforthesetumourstoinvademultiplenerve
Rose S,LongC,Knipe Metal.(2005)Ultrasonographicevaluationof
roots,withresultingdifficultiesincompleteresection
brachialplexustumorsinfivedogs.VeterinaryRadiologyand
Ultrasound46,514-517
（Brehm et al.,1995).Recurrence of signs or the
SkorupskiKA,Clifford CA,PaoloniMC et al.(2007)CCNU for the
developmentofnewspinalcordsignstypically
treatmentofdogswithhistiocyticsarcoma.JournalofVeterinary
occurswithinseveralmonths.Dogswithlymphoma
InternalMedicine21,121-126
SnyderJM,LipitzL,SkorupskiKAetal.(2008)Secondary intracranial
treatedwithchemotherapywithorwithoutlocal
neoplasiainthedog:177cases（1986-2003）.Journalof Veterinary
radiotherapymayhaveareasonableprognosis,with
InternaMedicine22,172-177
SnyderJM,ShofrFS,VanWinkleTJetal.(2006）Canineintracranial
manyanimalssurviving1-2yearsafterdiagnosis.
primaryneoplasia:173cases(1986-2003).JournalofVeterinary
InternalMedicine20,669-675
ThomsonSAMKennerlyE,OlbyNetal.2005）Microarrayanalysisf
Referencesandfurtherreading
canine
centralnervoussystem.VeterinaryPathology42550-558
TomekA,CizinauskasS,DoherrMetal.(2006)Intracranialneoplasia
Bagley RS,Wheeler SJ,KloppLet al.(1998) Clinical features of
in61cats:localisation,tumour types and seizurepatterns.Journal
trigeminalnerve-sheathtumorin10dogs.Journalof theAmerican
ofFelineMedicineandSurgery8,243-253
Animal HospitalAssociation34,19-25
Troxel MT,Vite CH,Van WinkleTJetal.(2003)Feline intracranial
Brehm DM,Vite CH,Steinberg HS et al.（1995)Aretrospective
neoplasia:retrospectivereviewof160cases(1985-2001).Journal
evaluationof51casesofperipheral nervesheathtumorsinthe
ofVeterinaryInternalMedicine17,850-859
dog.Journalof theAmericanAnimalHospitalAssociation31349-
VernauKM,Higgins RJ,BollenAWet al.(2001)Primary canine and
359
felinenervoussystemtumors:intraoperativediagnosisusingthe
daCosta RC,ParentJM,Dobson Hetal.(2008)Ultrasound-guidedfine
smeartechnique.VeterinaryPathology38,47-57
needle aspiration in the diagnosisofperipheralnerve sheath
Westworth DR,DickinsonPJ,VernauWet al.(2008)Choroid plexus
tumors in56dogs（1985-2007).JournalofVeterinary Internal
DickinsonPJ,RobertsBN,HigginsRJetal.(2006a）Expressionof
Medicine22,1157-1165
340
Ocular tumours
David Gould
Introduction
Neoplastic lesionsmay be primary or secondary.
Primarytumoursmayarisefromthebonyorbitalwalls
Inallcasesofocularandperiocular tumours,itis
orfromthesofttissuecontentsoftheorbit.Awide
importanttocarryoutathoroughgeneralphysical
rangeoftumourtypeshasbeenreported.Primary
examinationinadditiontoadetailedophthalmic
tumourstendtobeslowtometastasizebutareoften
examination.Haematologyandserumbiochemistry
locallyinvasive.Secondarytumoursmayenterthe
profilesmaybeindicated.Wheremalignancyissus-
orbitby localextension(e.g.from thenasalcavity,
pected,chestradiographyandabdominalultra-
paranasalsinuses,cranialcavityoralcavityorskinr
sonographyshouldbeperformed.
bymetastaticspread.
Tumoursoftheorbit
General considerations
Neoplasiaisacommoncauseoforbital disease in
Differentialdiagnosis
middle-aged toolder dogs.Theaverageageof
Space-occupyinglesionsoftheorbitmaybeneo-
affecteddogsisaround8yearsandthereisno
plasticornon-neoplastic;Figure22.1lists themajor
apparentbreedorsexpredilection.
differentialdiagnoses.
Orbitalneoplasiaislesscommonincats,although
itremainsasignificantcauseoffelineorbitaldisease.
Theaverageageofaffectedcatsisaround9years;
Primary tumours
againthereisnobreedorsexpredilection.
Inbothdogsandcats>90%oforbital tumours
Osteosarcoma
aremalignant.Indogs,themajorityof orbital
Fibrosarcoma
tumours are primary,whereasin cats secondary
Chondrosarcoma
causespredominate.
Myxosarcoma
Meningioma
Neurofibrosarcoma
Presentation and clinical signs
Adenoma
Exophthalmos(Figure22.2)is the major presenting
Adenocarcinoma
signofan orbitalmass.Associated signs include
Melanoma
reducedgloberetropulsion,awidenedpalpebralfis-
Lipoma
sure,chemosis,exposurekeratitis and epiphora.In
Histiocytoma
Mast cell tumour
caseswherethemassliesoutsidethemusclecone
formed by the retractor bulbi muscles,third-eyelid
Secondary tumours
protrusionand strabismusmaybeseen.If themass
lieswithinthemuscleconeformedbytheretractor
Lymphoma
Squamous cellcarcinoma(ScC)
bulbi muscles,globeprotrusion is axialand third-
Nasal adenocarcinoma
eyelidprotrusionmaybeminimal.
Cerebral meningioma
Secondaryorbitaltumoursthatariseinthe
Non-neoplastic orbital masses
adjacentnasalpassages(e.g.nasaladeno-
carcinoma orsquamouscellcarcinoma,ScC)may
Abscessation
beassociatedwithnasal signs includingsneezing.
Cellulitis
stertor,nasal discharge (Figure 22.3)or epistaxis,
Foreign body
andmayalsobeassociatedwithfacialdistortion.
Pseudotumour
Haemorrhage
Mostorbitaltumoursareslowlyprogressiveand
Zygomaticmucocele
painless.However,some may be associated with
Masticatorymyositis
painduetolocalcompressiveorinflammatory
Extraocularmusclemyositis
effects.Forthisreasonthepresenceorabsenceof
Lacrimal gland cyst
paincannotreliablybeusedtodistinguishanorbital
tumourfromorbitalabscessation(themajorother
22.1
Orbital space-occupyinglesions.
differential diagnosisinexophthalmos).
341
Chapter22Oculartumours
22.4
Papilloedemaduetocompressionof theoptic
nervebyanorbital tumourinadog.Theoptic
nerveheadprotrudesintothevitreous,andtheretinal
bloodvesselscanbeseentochangedirectionasthey
follow itscourse.Theretinaappears outof focusdueto
thenarrowdepthof fieldof thefunduscamera.
Ultrasonography
Orbitalultrasonography is an appropriate first-line
approachforimagingtheorbit.Mostcommonly,real-
timeB-modeultrasonographyisperformedusinga
7.5MHzscanner.This canbedoneona conscious
Leftexophthalmosduetoorbitalmeningiomain
animalviaa transcornealapproach,followingtopical
22.2
a9-year-oldcat.Theexophthalmoswasmost
cornealanaesthesia.
readilyevidentwhenviewedfromabove:notethe
A major limitationof orbital ultrasonographyis
prominentleftcorneashownincomparisonwiththeright
thatitmaynotrevealthetrueextentofthemassor
eye.AnMRIscanshowedthatthetumourinvadedthe
accuratelyidentifyits margins.This isparticularly
orbitfromthebrain.
truefordeeporextensiveorbitaldisease,forexam-
plemassesextendingintracraniallyorintoadjacent
softtissues.Forsuch suspectedcases,advanced
imagingtechniquesaremoreappropriate.
Ultrasound-guided fine-needleaspiration（FNA)
undergeneralanaesthesiamayallowcytological
diagnosisof orbital neoplasia in around50%of
cases.Extremecaremustbetaken during thispro-
ceduretoavoidinadvertenttraumatotheglobe.
Radiography
Skullradiographymay be useful where there is
boneinvolvement.Itshould includetheorbit,nasal
andparanasal sinusesand maxilla.Acombination
oflateral,dorsoventral,ventrodorsal andoblique
viewsisrequired.Askylineviewisusefulwhere
frontal sinusinvolvement issuspected;and a dorso-
22.3
Rightexophthalmosduetonasal
adenocarcinomainvading theorbit.Notethe
ventralintraoralviewisalsousefultoidentifycon-
ipsilateralnasal discharge.
ditionsinvolvingthenasalturbinatebones.However,
thecomplexityofskullanatomyandthesuperim-
Clinicalapproach
posed imagesof itsstructuresmakeinterpretation
Adetailedophthalmicexaminationshouldbeper-
ofradiographicimagesdifficult.Chestradiographyis
formed.Massesthatinvolvecranialnerveswithinthe
indicatedforstagingpurposes.
orbit (ll,Ill,IV,VIand ophthalmicbranch ofV)may
leadtodetectablecranialnervedefectssuchas
Advancedimagingtechniques
blindness,reducedpupillarylightreflexes,abnormal
Magneticresonance imaging(MRl)and computed
globepositionormobility,andreducedcornealsen-
tomography（CT)provideexcellentdetailoforbital
sation.Massesclose to theglobecancauseindenta-
structures.CTprovidesbettervisualizationofbony
tionoftheposteriorsclera,whichmaybevisualized
structures of theorbit,whereas MRIis superior for
byophthalmoscopy.Massesthatimpingeontheoptic
softtissuevisualization.Thesemodalities are indi-
nerve sheath may inducepapilloedema(Figure22.4).
catedwhenultrasonographicresultsareinconclusive,
342
Chapter22
Oculartumours
whenthereisapossibilityofextensiveorbitalorextra-
Non-neoplasticeyelid masses
orbital involvement,orincasesinwhichorbitalsur-
geryistobeconsidered(Dennis,20o0;Boroffka et
Dermoid
al.,2007).
External hordeolum(abscessationorinflammationofZeissor
Moll glands within the eyelid skin)
Managementandprognosis
Internalhordeolum（abscessationofameibomiangland withinthe
palpebral conjunctiva)
Surgicalresection
Chalazion（granulomaformationfollowingruptureofanimpacted
Surgicalresectionisthetreatmentofchoiceforpri-
meibomian gland)
maryorbitaltumours.Smallanddiscretetumoursmay
Meibomiancyst
Cutaneous histiocytosis
beremovedviaanorbitotomy，sothattheglobeand
Nodular fascitis
associatedstructurescanbepreserved(Ramseyand
Cutaneous nodular leishmaniasis
Fox,1997).However,orbitotomyisacomplexsurgical
Erosive eyelid disease thatmaymimicerosiveeyelid tumours
procedureandshouldbeperformedonlybyexperi-
encedsurgeonswithknowledgeoforbitalanatomy
Pemphigus vulgaris
andanappreciationofpotential complications.Large
Pemphiguserythematosus
orinfiltrative tumoursusuallyrequireexenteration
Systemiclupus erythematosus
(removaloftheentireorbitalcontents,including the
Viral blepharitis(felinepoxorfelineherpesvirus-1)
globe).
Feline eosinophilicblepharitis
Secondaryorbitaltumoursingeneralarepoorly
Conditionstobedifferentiatedfromeyelid
amenable to surgicalresection.Thesurgical tech-
22.5
tumours.
niquesofpartialorfullorbitectomyindogsandcats
havebeendescribedandcanresultincomplete
localresection.
Sebaceousgland adenoma(accountingfor60%
ofallcanineeyelidtumours)
Radiotherapy
Benignmelanoma(17%ofcases)
Radiotherapyasasoletreatmentfororbitalneoplasia
Squamouspapilloma(11%of cases).
isnotusuallyperformed,becauseof thesensitivityof
theeyetoradiation.However,it maybeindicated as
Othertumourtypesareuncommonandtogether
adjunctivetherapyfollowingexenteration.Itmayalso
accountfor<10%ofallcanineeyelidneoplasms.
beusedasaprimarytreatmentfornasalorparanasal
However,some of thesemaybemalignant.They
tumourswithorbitalextension,thoughsuchtreatment
include malignant melanoma,sebaceousadenocar-
ispalliativeandisassociatedwithradiation-induced
cinoma,histiocytoma，mast cell tumour (MCT),
oculardamage.
lymphomaandbasalcell tumour.Malignanteyelid
tumoursareusuallylocallyinvasiveratherthanmeta-
Chemotherapy
static.Anexceptiontothisismalignantmelanoma,
Mostorbitaltumoursarenotamenabletochemother-
which may metastasize(Roberts et al.,1986).
apy.Anexceptionisorbital lymphoma,whichmaybe
Incats,eyelidtumoursaremorelikelytobe
responsivetochemotherapeuticagents.
malignant:
Prognosis
SCCisthemostcommoneyelidneoplasm,
Indogs,theprognosisfororbitalneoplasiaisguarded
accounting forupto65%of cases(McLaughlinet
topoor.Inaretrospective studyof44cases,only19%
al.,1993).Majorpredisposingfactorsare
survived for>1year(Hendrixand Gelatt,2000).In
exposuretoultravioletlightandlackofcutaneous
catstheprognosis isgrave:inone study,meansur-
pigmentation.It islocallyinvasiveandlateto
vivaltimefollowingdiagnosisoforbitaltumourwas
metastasize.
just 1.9 months (Gilger et al.,1992).Another study
Othermalignanttumourtypesincatsinclude
reportedameansurvivaltimeof10monthsindogs
fibrosarcoma,adenocarcinoma,lymphomaand
and<1month incats(Attali-Soussay et al.,2001).
haemangiosarcoma.
Benigneyelidmassesincatsincludebasal cell
carcinoma,MCT,papillomaand apocrine
Tumoursoftheeyelid
hidrocystoma.
Differentialdiagnosis
Non-neoplasticeyelidmassesanderosiveeyeliddis-
Presentationandclinicalsigns
easethatmaymimicerosiveeyelidtumoursarelisted
Sebaceousadenomasarisefrom themeibomian
inFigure 22.5.
glandsandpresentasfocalmassesontheeyelid
margin.Theirfrond-like appearancemeans that
Generalconsiderations
theyarecommonlyclinicallymistakenforpapilloma.
Eyelidtumoursareverycommonindogs.Withthe
However,diagnosis is straightforward,because
exceptionofviralpapilloma,theyusuallyaffectdogs
eversionoftheeyelidwillrevealswellingofthemei-
olderthan9years.Eyelidtumoursoccurinfrequently
bomianglandbeneaththepalpebralconjunctiva
incats.
(Figure22.6).They maybeassociatedwithocular
Indogsmosteyelidtumoursarebenign.Thethree
discomfortduetocornealirritation,whichmaylead
most common types are:
tokeratitisandcornealulceration.
343
Chapter22
Oculartumours
22.7
Erosivebasalcellcarcinomaoftherightupper
eyelid ina6-year-oldcat.
22.6
Caninesebaceousadenomaaffectingtheleft
22.8
Mastcelltumourof theleft uppereyelid ina
eyeofan8-year-oldWestHighlandWhite
3-year-old cat.
Terrier.Thistypeof tumourarisesfromthemeibomian
glandopeningontheeyelidmargin.Eversionof theeyelid
revealedswellingof themeibomianglandbeneaththe
palpebral conjunctiva.(Courtesyof SM Crispin)
Other eyelid tumours inbothdogs and catspre-
sent asfocal,erosiveorinfitrativemassesof varying
size(Figures22.7and 22.8).
Apocrinehidrocystomaincatspresentassingle
ormultipleroundpigmentedeyelidmasses,which
maybeunilateralorbilateral(Figure 22.9).Histo-
pathologicalexaminationshows thattheseare
cysticadenomasoftheapocrinesweatglands.
TheyaremorecommoninthePersianandHima-
layanbreeds.
Clinical approach
Inmanycasesapresumptivediagnosisismadeon
clinical examination.Impressionsmearsarepoorly
diagnosticformosteyelidtumours.FNAisusually
more rewarding,though cytology doesnot allow
tumourgrading.Biopsyisthediagnosticmodalityof
choiceandexcisionalbiopsyisusuallypossiblefor
small masses.
Managementandprognosis
Surgicalresection
Surgicalresectionis thetreatmentofchoicefor
mostcasesofeyelidneoplasia.Sincethereisonly
22.9
Multiplebilateralapocrinehidrocystomas
afiniteamountofeyelidmargin,itisadvisableto
affectingthelowereyelidina10-year-old
removeeyelidtumoursatanearlystage,especially
Persian cat.
344
Chapter22Oculartumours
iftheyareenlarging.Preoperativeconsideration
Othermodalities
ofhowtoachieveprimaryclosurefollowingmass
excision is imperative.In dogs,direct primary
Brachytherapyusingradioactivegold9seeds,
closureoftheeyelidmargincanbeachievedfollow-
hasbeenusedsuccessfullyinthetreatmentof
ing removal of up to25%of the eyelid margin.
felineeyelidSCC(HardmanandStanley,2001).
Incats(whichhave more tightlyapposedeyelids)
Carbondioxidelasertherapyhasbeenreported
andindogsinwhich>25%oftheeyelidmargin
fortreatmentofmeibomianglandadenomatain
isremoved,additional reconstructive blepharo-
dogs(Bussieres etal.,2005).
plastytechniquesareusuallyrequiredtoachieve
Photodynamictherapyhasbeenreportedforthe
primaryclosureoftheeyelidmargin.Alargenum-
treatmentofearlysuperficialeyelidScCincats,
beroftechniqueshavebeendescribed;thesemay
although7of11treatedcases(64%)
becomplexanditmaybeadvisabletoseekspe-
subsequentlyrecurred(Stelletal.,2001).
cialistadvice.
Chemotherapy is indicated forlymphoma
Forsmall tumoursinvolvingtheeyelidmargin,a
involvingtheeyelids.Chemotherapymayalsobe
full-thicknesswedgeexcisionisperformed,followed
usefulasanadjuncttosurgicalresectionof
bya two-layer closure.However,benign tumours
MCTs.
involvingonlytheskinandsuperficialsubcutaneous
Histiocytic-typeMCTsincats(inparticularthe
layersmayberemovedbyapartialthicknessexci-
Siamesebreed)mayrequirenotreatment,as
sionthatspares the conjunctival layer(Gelattand
thesetumoursmayregressspontaneously.
Gelatt,2003)
Apocrinehidrocystomaincatsmayrequireno
Themarginofexcisionrequireddependson
treatment,unlessitcauseslocalocularirritation.
tumourtype.Forbenignmassesa1-2mmmarginof
Externalbeamradiotherapyisnotusedinthe
excisionshouldbeachievedwherepossible.Forsus-
treatmentofeyelidneoplasia,becauseof the
pectedmalignantmasses,FNAorbiopsyfollowedby
sensitivityof theeyetoradiation.
histologicaltumourgradingisrecommendedpriorto
surgerytoaidsurgicalplanning.
Prognosis
SurgicalresectionofcanineeyelidMCTsposes
Theprognosisfollowingremovalofbenigneyelid
aparticular problem,sinceit isimpossible to
tumours isvery good,though some （in particular,
achievethe2cmmarginofexcisionrecommended
canine sebaceousadenoma)carrya significantrisk
as surgical treatment for gradeI-ll MCTsof the
oflocalrecurrence.Theprognosisfollowingremoval
skin(Fulcheretal.,2006)withoutlosingeyelidfunc-
ofmalignanteyelidtumoursdependsonthetumour
tion.Surgicalresectionwithaswideamarginof
typeandstageofmalignancy.
excisionaspossiblewhilststillmaintainingeyelid
functionisadvisable.Thiswillusuallyinvolvean
Becauseofitslowrateofmetastasis,early
additionalreconstructiveblepharoplastyprocedure
inbothdogsandcatscarriesafavourable
suchasapedicleadvancementflap,rotationalskin
prognosis.
graft,sliding Z-plasty,full-thicknesslidgraft orlip-
InvasiveScChasa moreguardedprognosis,as
to-lid technique（Petersen-Jones,2002;Gelatt and
itmaybedifficulttoachieveadequatemarginsof
Gelatt,2003).
excision.
Surgerymayalsobecombinedwithadjunctive
Malignantmelanomaof theeyelidsmaybe
treatments suchas chemotherapy in suchcases,
associatedwithmetastaticdiseaseandtherefore
althoughitshouldbenotedthatthereislittlepub-
carriesaguardedprognosisinbothdogs and
lishedinformationontheeffectivenessofchemo-
cats.
therapyintreatmentofMCTsandtodatetreatment
CanineMCTsof theeyelidsshouldcarrya
regimesremainsomewhat empirical(Dobsonand
guardedprognosisinviewof thedifficultyin
Scase,2007).Neoadjuvanttherapywithprednisolone
achievingasatisfactorymarginofexcision,but
maybebeneficialatthissite(Stancliftand Gilson，
publishedfollow-updataonsuchcasesare
2008).For possible chemotherapeutic options,see
scant.
Chapter12.
FelineMCTsareusuallybenignandmayregress
GradeIllMCTsrequireradical surgicalexcision
。
spontaneously,particularlyintheSiamesebreed
includingexenteration.
(Wilcocketal.,1986).
Apocrinehidrocystomas arebenign and carrya
Cryosurgery
goodprognosis,butrecurrenceordevelopment
Cryosurgerymaybeperformedonsmalleyelid
ofmultiplemassesiscommon(Cantaloubeetal.
tumours.Thermalcouplingwithinand adjacenttothe
2004).
massisrecommendedduring thefreezingprocess,
andgenerousapplicationofapetrolatum-based
ocularlubricanttothecornealsurfacepriortotreat-
Tumours ofthe conjunctiva,third
mentwillreducetheriskof iatrogeniccornealfreezing
eyelidandexternalglobe
duringtheprocedure.Instudiescomparingsurgery
andcryosurgeryfortreatmentofeyelidtumours,
Differential diagnosis
recurrencerateswerenotsignificantlydifferentbut
Non-neoplastic masses are listed in Figure 22.10.
cryotherapyledtoearliertumourrecurrence(Roberts
Someexamplesofnon-neoplasticocularsurface
et al.,1986;Collins and Collins,1994)
masses are shown inFigures22.11and 22.12.
345
Chapter22
Oculartumours
Generalconsiderations
Dermoid
Nodular granulomatous episclerokeratitis(NGE)
Tumoursoftheconjunctiva,thirdeyelidorexternal
Necrotizingornon-necrotizing sclerokeratitis
globeareuncommonindogsandcats.Reported
Systemic histiocytosis
typesincludemelanoma,CC,lymphomaMCT,a
Proliferativekeratoconjunctivitis
illoma,adenocarcinoma,haemangioma,haemangio-
Nodular fascitis
sarcoma,fibrosarcoma,histiocytoma,transmissible
。
Idiopathicsterilegranulomatosis
venerealtumour,lobularorbitaladenoma,angioendo
Staphyloma
Subconjunctival orbital fat prolapse
thelioma,angiokeratomaandepithelioma.
Parasiticgranuloma
Becauseofthelargedifferentialdiagnosislist,
Lacrimal gland cyst
biopsyisrecommendedifthereisanydoubtasto
Conjunctival cyst
thenatureof themassunderinvestigation.
Corneal epithelial cyst
lrisprolapse
Presentationand clinicalsigns
Foreign body
Conjunctival andthird-eyelidtumoursusuallypresent
22.10
Non-neoplasticmasses of the conjunctiva,third
asavisiblemassorerosivelesion.Theymaybe
eyelid andglobe.
associatedwithsecondaryconjunctivitisandocular
discharge,whichmaymasktheunderlyingdisease.
Diffuseconjunctival lymphomamaymimicchronic
conjunctivitis （Figure22.13)，as may conjunctival
MCTs.Melanomausuallypresentsasafocal dark
swellingofvaryingsize,mostcommonlyarisingfrom
thelimbusorepibulbarregion（Figure 22.14).
Intraoculartumoursmayextendexternallythrough
the limbustomimiclimbal melanoma(Figure22.15).
(a)
g
22.11
Twoexamplesofagroupof immune-mediated
22.13
Lymphomainfitrating therightdorsalpalpebral
conditionsof thecanineglobe thatmaymimic
conjunctivaina 4-month-oldFeLV-positiveDSH
tumours:(a)nodulargranulomatousepisclerokeratitisina
cat.Thiscondition can mimicchronicconjunctivitis.
4-year-oldEnglishSpringerSpaniel;(b)necrotizing
Conjunctival biopsy is usuallydiagnostic.
sclerokeratitisina2-year-oldGoldenRetrieverDefinitive
diagnosis isbybiopsy.
22.12
Staphylomaaffecting therighteyeof a7-year-
22.14
Canineepibulbarmelanomaina6-year-old
old crossbreed dog.Thisconditionrepresentsa
GoldenRetriever.Epibulbarandlimbal
focalareaofscleral thinningwithexposureof underlying
melanomasinvolvetheepisclera,nottheoverlying
choroidalpigment.Thelesioncanmimicocular
conjunctiva;notehow the conjunctival bloodvesselspass
melanoma.
over the tumour and not intoit.
346
Chapter22Oculartumours
Surgicalexcisionfollowedbycryosurgeryisusu-
allycurative.Laserphotocoagulationhasalsobeen
reported，butrecurrencerateswereslightlyhigher
thanforcombinedexcision/cryosurgery(Sullivanet
al.,1996).
Conjunctival melanoma
Conjunctival melanomaatasitedistanttothelimbus
isuncommon,butisimportanttorecognizebecause
itsbehaviourmaybeaggressive.Inacaseseriesof
12 dogs,local recurrence after excision was
reportedin6casesandmetastasisin2cases
(Collinsetal.,1991).Incats,therehaveonlybeena
fewreportsofconjunctivalmelanoma,butfromthese
reportsitseemstobemalignantin themajorityof
22.15
Canine anterioruvealmelanoma inan8-year-
oldBoxerdog,showingextraocularextension
cases,withlocalrecurrenceanddistantmetastasis
throughthelimbus.lt isimportant todifferentiate thisfrom
likely(Patnaik and Mooney,1988;Cooket al.,1995;
limbalmelanoma.
Schobert and Dubielzig，2008).However,benign
felineconjunctivalmelanomahasbeenreported
Clinical approach
(Payen et al.,2008).
inbothdogsandcats,widesurgical excisionin
Ophthalmicexamination
combinationwithcryosurgeryisadvisedfollowing
Athoroughophthalmicexaminationshouldbeper-
distant staging.
formed.Forlimbal melanoma,this should include
gonioscopy(examinationof theiridocorneal drain-
Conjunctival orthird-eyelidMCT
ageangle)tocheckfor intraocular involvement.
In dogs,casereportsofconjunctival MCTsindicate
Gonioscopyisaspecialisttechniqueandreferralto
aveterinaryophthalmologistshouldbeconsidered
(Johnson et al.,1988).A recent retrospective study
insuch cases.
of35conjunctivalMCTsindogsindicatedabreed
predispositionintheLabradorRetriever.Around90%
Imaging
ofthetumoursweregradeIorll,andfollow-updata
Ocularandorbitalultrasonographyisindicatedif
upto24monthsshowed thatnodogsdiedofMCT-
localinvasionof tissuesis suspected.Chestradio-
related disease(Fifeetal.,2007).
graphyisindicated for conjunctivalor third-eyelid
A single report of a third-eyelidMCT in a cat
tumoursifthereisapossibilityofmalignantdisease.
Diagnosticimagingisnotusuallyindicatedforcanine
excisionwascurative(Larocca,2000).
limbalmelanoma.However,thoracicradiographyand
Third-eyelidadenocarcinoma
felinelimbalmelanomainviewofthepossibilityof
Thetreatmentofchoiceisremovaloftheentirethird
distantmetastasis.
eyelid,becauseof theriskoflocal invasion.lf the
tumourhasinvadedtheorbit,exenterationisrequired.
Biopsy
Biopsyisindicatedinmost cases.It is particularly
Squamouscell carcinoma
usefultodistinguishneoplasiafrominflammatory
Accuratedeterminationoftumourmarginsisimpor-
conditionssuchasnodulargranulomatousepisclero-
tant,becauseSCCof thethirdeyelidorconjunctivais
keratitis.Forsmallmasses,excisionalbiopsyisoften
oftenassociatedwithextensionfromtheeyelids,and
possible.
thetumourmayalsoinvadeinto theorbit.Surgical
excision,possiblyincombinationwithothermodali-
Managementandprognosis
ties,maybeindicated.lflocal invasionisextensive，
exenterationmaybeindicated.
Limbalandepibulbarmelanomas
Indogs,limbal or epibulbar melanoma isnearly
Prognosis
alwaysbenign.GermanShepherdDogsmaybepre-
disposed.In cats,limbal melanoma is also usually
Third-eyelidadenocarcinomaandScCare
benign,althoughmetastatic
diseasehasbeen
locallyinvasive,ratherthanmetastatic,andhave
reported(Day and Lucke,1995;Betton et al.,1999)
agoodprognosisif treatedearly(Wilcockand
Inmiddle-agedtoolderdogs,inwhichthesetumours
Peiffer,1988).
MCTsof theconjunctivaorthirdeyelidindogs
besufficient.Inyoungdogs,however,limbalorepibul-
andcatsseemtocarryagoodprognosis
barmelanomamaygrowrapidlyandthereforeearly
followinglocalexcision(Gilgeret al.,2007).
treatmentisrecommended.Likewise,incats(inwhich
Limbal melanomaindogshasagoodprognosis
thetumourmaybemalignant)，earlyinterventionis
followingsurgicalremoval.Incatstheprognosis
advisable.
is alsogoodbut it shouldbeborneinmind that
347
Chapter22Oculartumours
distantmetastasishasbeendocumentedinthis
arepredisposed.Adenomasarewelldifferentiated,
species(Day andLucke,1995;Bettonet al,
slowgrowingand,althoughtheymayinfiltratethecil-
1999).
iarybodyoririsstroma,donotinvade thesclera.
Conjunctivalmelanomahasaguardedprognosis
Adenocarcinomasarelesswelldifferentiated,show
indogsandapoorprognosisincats,inviewof
increasednumbersofmitoticfiguresandarelocally
theriskof localrecurrenceandofmetastasis
invasive.Themetastaticpotentialofbothadenoma
(Collins et al.,1991;Patnaik and Mooney,1998).
andadenocarcinomaisextremelylow,butmetasta-
sistothelungshasbeendocumentedonoccasion.
Medulloepitheliomaarisingfromtheundifferenti-
Intraoculartumours
atednon-pigmentedepitheliumof theciliarybody
hasbeenreported(Klostermanetal.,2006).
Differential diagnosis
Non-neoplasticintraocularmassesarelisted inFigure
Sarcoma
22.16.
Intraocularsarcomaisthesecondmostcommonpri-
maryintraoculartumourofcatsafteranterioruveal
Benign irispigmentation
melanoma.Previousoculartraumaisamajorpredis-
Ocularmelanosis
posingfactor(Dubielzig et al.,1990).Oldercatsare
Foreign body
mostatriskandthetimefromtraumaticinjuryto
Uveal cyst
Inflammatorymasses
diagnosisofsarcomaaverages5years.Secondary
uveitisorglaucomaiscommon.Thetumourishighly
22.16
Non-neoplasticintraocularmasses.
malignantandbothlocal invasionandmetastatic
diseasearecommon.
Generalconsiderations
Glioma
Intraoculartumoursmaybeprimaryorsecondary.
Non-neuronal CNStissuetumoursreportedtoinvolve
Thetwomostcommonprimarytumourtypesare
theretinaoropticnerveheadincludeastrocytoma
uvealmelanomaandiridociliaryepithelialtumour.
and oligodendroglioma(Naranjo etal.,2008).The
Otherprimarytumoursarerarebutreportedtypes
metastaticpotential islow.
include sarcoma (cats only),medulloepithelioma,
Secondarytumours
astrocytoma,glioma,ciliarybodyhaemangioma,iridal
Withtheexceptionoflymphoma,secondaryintra-
haemangiosarcoma,
，iridalleiomyosarcoma,
iridal
myxoidleiomyoma,primaryocularosteosarcomaand
oculartumoursareuncommon.Theymayinvadethe
eyebyhaematogenousspreadorbylocalextension.
anterioruvealspindle-celltumour.
Localextensionisrare,becausethetoughfibrouscoat
Themostcommonsecondaryintraoculartumour
islymphoma(seeChapter
Othertypes
oftheglobeoffersaformidablephysicalbarrier,but
19a).
intracranialtumourssuchasmeningiomamayinvade
reported include haemangiosarcoma,
metastatic
theposteriorsegmentviatheopticnervesheath.
adenocarcinoma,metastaticcarcinoma,metastatic
Haematogenousspread accountsformostsecondary
melanoma,
malignant
histiocytosis,
seminoma,
tumours and these includelymphoma,haemangio-
transmissible venereal tumour,sarcoma,fibrosar-
coma,rhabdomyosarcoma,
phaeochromocytoma
sarcoma,carcinoma/adenocarcinoma,osteosarcoma
andoralmalignantmelanoma,amongstothers.Inone
andhistiocyticsarcoma.
study,37%ofdogswithlymphomahadocular
Uvealmelanoma
involvement,makingoculardiseasethesecondmost
Melanomaisthemostcommonprimaryintraocular
commonpresentingsignoflymphomaafterlymph-
adenopathy(Krohneetal.,1994).
tumourof dogs andcats.Itusuallyarisesfrom the
anterior uveal tract(irisor ciliarybody);choroidal
Presentation and clinical signs
melanomaisrare.Inbothspecies,olderanimalsare
All intraoculartumours,whetherbenignormalignant,
mostcommonlyaffected.Abreedpredispositionin
maycausesevereintraocularpathologyduetospace-
LabradorRetrieversandPersiancatshasbeen
occupyingeffects,localinfiltrationandreleaseoflocal
suggested,thoughthisremainsunproven.
immunogenicandangiogenicfactors.Commoncom-
Thebehaviourofanterioruvealmelanomaisdif-
plicationsincludeintraocularhaemorrhage,uveitis,ret-
ferent indogsand cats.Themajorityof canineante-
inaldetachmentandglaucoma.Thepresenceofthese
rioruvealmelanomasarebenignandonlyaround
maymasktheunderlyingtumour.
5%metastasize.Nonetheless,evenbenign melan-
omas may belocally invasive(Giuliano et al.,1999).
Melanoma
Incontrast,feline anterioruveal melanoma isvery
Canineanterioruvealmelanomaaffectingtheirisusu-
aggressive,withlocal invasionandmetastasisthe
allypresentsasadiscretenodularmassonthesurface
norm.Ithasareportedmetastaticrateofupto63%
of theiris(Figure22.17).Secondary changes such as
(Patnaikand Mooney,1988).
haemorrhage,uveitis,retinal detachment and glau-
comaarecommonandmaymasktheunderlying
Iridociliaryepithelialtumours
tumour.Differentialdiagnosisincludesbenignirismela-
Ciliarybodyadenomaandadenocarcinomaarethe
nosisand anterior uveal cyst（Figure22.18).In the
nextmostcommonprimaryintraoculartumoursof
CairnTerrieramajordifferentialdiagnosisisdiffuse
dogs,butarerareincats.Middle-agedtoolderdogs
ocularmelanosis(Petersen-Jones et al,2007,2008).
348
Chapter22Oculartumours
Benign
22.17
22.20
anterior
uvealmelanoma
Benignocular
affecting theirisin
melanosisina
a7-year-old
4-year-old cat.
crossbreed dog.
22.18
Anterior
uveal
cyst ina 4-year-
Iridociliaryepithelialtumours
oldcrossbreed
Theseusuallypresentaspinkorredintraocular
dog.Trans-
illumination using
massesthatmayprotrudethroughordistortthepupil
(Figure 22.21).Occasionally pigmented iridociliary
focal illumination
demonstratesits
tumoursareencounteredthatmaymimicanterior
cystic nature.
uvealmelanoma （Figure 22.22).Secondaryintra-
ocularchangessuchashaemorrhage,uveitis,retinal
detachmentandglaucomamayoccur.
Felineirismelanoma usuallypresentsaspro-
gressive diffuse infiltrationof the iris（Figure22.19)
rather thananodularmass.Themaindifferential
diagnosesarebenignirismelanosis（Figure22.20)
andchronicuveitis,and itmaybeimpossibletodis-
tinguish theseconditionsby clinicalexamination
alone.Clues thatapigmented irislesionmaybe
neoplasticinclude:
22.21
Ciliarybodyadenoma ina10-year-oldWest
Progressiveand insidious irispigmentation
HighlandWhiteTerrier.Themassprotrudes
lris thickening
throughanddistortsthepupilmediallyInthiscaseA
。
of themassallowedcytological diagnosis.
Increasedintraocularpressurerelativetothe
contralateraleye
Abnormalitiesinpupilsizeormotility
22.22
Pigmentsheddingintotheanteriorchamber
Rarely.pigmented
whenviewedbyaslit-lamp
iridociliary
Pigment invasionof the iridocorneal drainage
tumoursare seen
anglewhenviewedbygonioscopy.
thatmaymimic
anterioruveal
melanoma.In this
11-year-old
StaffordshireBull
Terrier,ophthalmic
examination
suggested an iris
melanoma.
However,
histopathological
examination
following
enucleation
revealeda
Anterioruvealmelanoma ina14-year-oldcat.
pigmented
22.19
iridociliarytumour.
Notethepupildistortion andpigmentdeposition
ontheanteriorlenscapsule,bothofwhichimplypotential
(below,courtesy
malignancy.Thickeningof theiriswasalsoevidenton
of JMould)
slit-lampexamination,andtheintraocularpressurewas
elevatedrelativetothecontralateraleye.Inaddition,
gonioscopyrevealedprogressionof thepigmented
tumourtowardstheiridocornealdrainageangle(see
Figure 22.26).
349
Chapter22
Oculartumours
Retinaltumours
tonometryorreboundtonometry（e.g.usinga
Primarytumoursof theretina,choroidoropticnerve
TonopenorTonovet,respectively)arethemostaccu-
areveryrare.
ratemethods inveterinary patients.Whenmeasuring
intraocularpressures,leftandrighteyesshouldbe
Secondarytumours
compared.if thereisadifferenceinintraocularpres-
Thesemaypresentasbilateraloculardiseaseor
sureof8mmHgormore,thismaybeconsidered
concurrent systemic disease.Uveitis,intraocular
significant(Ollivieretal.,2007).
haemorrhageandsecondaryglaucomaarecommon
Gonioscopydescribes theexaminationofthe
andmaymask theunderlyingtumour.Incaninelym-
iridocornealdrainageangle.Foranatomicalreasons,
phoma,neoplasticlymphocytes may infiltrate the
directvisualizationofthedrainageangleisdifficult
cornea,creatingacharacteristicdensewhite circum-
andavarietyofgoniolenseshavebeendevelopedto
cornealband(Figure22.23).
facilitateexamination(Figure22.25).Thegoniolens
isplacedonthecornealsurfacefollowingapplication
oftopicalanaesthesiaandthedrainageangleisthen
visualizedthroughthegoniolenswiththeaidofaslit-
lamp(Figure22.26).Gonioscopyisaspecialisttech-
niqueandreferraltoaveterinaryophthalmologist
trainedinitsuseisrecommended.Followinggonio-
scopy,itisimportanttodilate thepupilwithamydri-
aticandexaminetheposteriorsegmentindetail.
Multicentriclymphoma causing anterioruveitis
USASUSSMW
22.23
ina5-year-oldLabradorRetriever.Inthiscase
chronicuveitishascausedextensiveadhesionsbetween
theirisandlenscapsule,leading toirisbombeand
secondaryglaucoma.Notethedensewhite circumcorneal
band.
Clinicalapproach
22.25
Barkan-Lovac,KoeppeandSussman
Ophthalmicexamination
goniolenses.
Acompleteophthalmicexaminationshouldbeper-
formed,including tonometrytomeasuretheintra-
ocularpressureandgonioscopytoexamine the
iridocornealdrainageangle.Thesetwodiagnostic
techniquesareespeciallyimportantintheinvesti-
gationof anterioruveal melanomas,whichmay
invadetheiridocornealdrainageangleandcause
secondaryglaucoma.
Tonometryshouldbeperformedwithminimal
restraint.Particularcaremustbetakentoavoidpres-
sureon thepatient'sneck,sinceobstructionof the
jugularveinswilltransientlyraise intraocularpres-
sure.Thepatient shouldbe conscious,standing orin
sternal recumbency（Figure22.24).Applanation
Gonioscopy of the eye shown inFigure22.19
using aKoeppegoniolensrevealedpigmented
tissueextendingtowardsthepectinatefibresof the
iridocorneal drainageangle.
Haematology/serumbiochemistry
Thisisgenerallynotindicatedin theinvestigationof
intraoculartumours,exceptwhensecondaryneopla-
siaissuspected(inparticular,lymphoma).
Diagnosticimaging
Ocularultrasonographyisindicatedforallintraocular
22.24
Tonometryusinganapplanationtonometer.
Caremustbetakentoavoidpressure on the
tumoursinordertoassessthesizeandlocationof
neck,asthiscanartificiallyelevateintraocularpressure
theintraocularmass.Thoracicandabdominalradio-
readings.
graphyandabdominal ultrasonographyare indicated
350
Chapter22Oculartumours
formalignantneoplasia.MRIor CTscanning maybe
techniquescanbeusedtodifferentiateprimaryepi-
helpfulindeterminingtheextentoflocallyinvasive
thelialtumoursfromsecondarymetastaticdisease
tumours(inparticular,feline intraocularsarcoma).
(Dubielzig et al.,1998).
Aqueocentesis
Managementandprognosis
Cytologyofanaqueocentesissamplemaybediag-
nosticforocularlymphoma,butisnothelpfulinthe
Surgery
diagnosisofotherintraoculartumoursascellshed-
Surgicalexcisionispossible for some smalliris
ding intotheaqueoushumourisusuallyminimal.The
tumours,butexperienceofintraocularsurgeryand
techniqueshouldbeperformedundersterilesurgical
access towet-field cauteryisrequired.Inmany
conditionswiththepatientundergeneral anaesthesia
casesenucleationisindicated.Followingremoval,all
andwiththeaidofastronglightsource.A25-27G
tumour tissueshouldbesubmittedforhistopatho-
needleattachedtoa1mlsyringeispassedviathe
logicalevaluation.
limbusintotheanteriorchamber(Figure22.27).Fine
tissueforcepsarerequiredtostabilizetheglobedur-
Othermodalities
ingpassageoftheneedle.Magnificationintheform
ofsurgicalheadloupesaidsvisualizationduringthe
Regularmonitoringofcanineprimaryintraocular
procedure,andextremecaremustbetakentoavoid
tumoursmaybesufficientinviewoftheirbenign
iatrogenicdamagetotheirisorlens.A0.2mlsample
behaviour.Enucleationshouldbeconsideredif
ofaqueoushumourisslowlyandcarefullywithdrawn
theyprogress to cause localmass effects such
andplacedinanEDTAtube.Ifcytologicalexamina-
asglaucoma,orifmalignancyissuspected.
tionisnottobeperformedimmediately，adropoffor-
Diodelaserphotocoagulationhasbeenusedto
malininthecollectiontubewillaidcellpreservation.
treatpresumedirismelanomaindogs(Cookand
Becauseoftherelativelylowcellyieldfromasample
Wilkie,1999).Thishasthemajorbenefitof
ofaqueoushumour,cytospinanalysisfollowingcol-
preservingtheglobeandvisionandmaybe
lectionofthesampleisrecommendedpriortocyto
useful inthe early stagesof disease.Todate,
logicalexamination.
therearenopublishedreportsofitsuseinthe
treatmentoffelineanterioruvealmelanoma.
Radiationtherapymayhaveapalliativerolein
advancedocularsarcoma.
Chemotherapyisindicatedforlymphomawith
ocularinvolvement.
Prognosis
Prognosis dependsontumourtype and species.
Generally,canineprimaryintraoculartumours
carryaverygoodprognosisfollowingremoval
thoughhistologicallymalignantanterioruveal
melanomaisassociatedwithashorterlife
expectancy(Giuliano et al.,1999).
Felineanterioruvealmelanomacarriesa
22.27
Aqueocentesis technique.Thiscan aid
guardedprognosis,withashortenedlife
diagnosisofocularlymphomawhensuggestive
expectancyandahighriskofmetastaticdisease
anteriorsegmentsignssuchasanterioruveitisare
tolungsand liver(Patnaik and Mooney,1988;
present.lt israrelyusefulfordiagnosisofothertumour
types,sincethereisminimalcellsheddingfrommost
Kalishmanet al.,1998).
typesof anteriorsegmenttumours.
Felineintraocularsarcomacarriesaverypoor
prognosis,withmortalityrateexceeding90%
Biopsy/FNA
(Peiffer et al.,1999).
FNAofanteriorsegmenttumoursisnotroutinely
Indogs,lymphomawithocularinvolvement
performed,becauseit hasalowdiagnosticyield.
carriesapoorprognosis.Ocularinvolvement in
Furthermore,the technique carriesa riskof severe
animalswithlymphomaindicatesstageV
intraocularcomplicationssuchashaemorrhageand
disease,anddogspresentingwithocular
traumaticlensrupture.Biopsyofanteriorsegment
involvementhavealifeexpectancythatis
tumoursisperformedoccasionally,butwet-fieldcau-
60-70%of thatofdogspresentingwithoutocular
tery isrequired because of the high risk of intra-
signs (Krohne et al.,1994).
ocularhaemorrhage;onlycliniciansexperienced in
intraocularsurgeryshouldperformthistechnique.
Histopathologicalexaminationofexcisedtumour
Ocularparaneoplastic signs
tissuegivesaguidetoitsmalignantpotential.For
anterioruvealmelanoma,mitoticindexisthemost
Paraneoplasticsignswithintheeyemaybeseenwith
reliableindicatorofmalignancyinbothdogsand
someextraoculartumours;therefore,acompleteoph-
cats （Bussanich et al.,1987;Day and Lucke,
thalmicexaminationiswarrantedinallcaseswhere
1995).Forepithelial tumours,specialized staining
neoplasia is suspected.
351
Chapter22Oculartumours
Multiplemyelomamaycauseserum
JournaloftheAmericanVeterinaryMedicalAssociation230,
hyperviscosity.
671-680
Brightman AH,OgilvieGKand Tompkins M（1986)Ocular disease in
Examinationof theretinalbloodvesselsmay
FeLV-positive cats:11cases（1981-1986).Journalof theAmerican
demonstrategrosslydilatedandtortuousretinal
VeterinaryMedicalAssociation198,1049-1051
BrooksDE（1999)Ocularimaging.In:Textbookof Veterinary
bloodvessels.Intraretinalhaemorrhageand
retinaldetachmentmayalsobeobserved.
WilkinsPhiladelphia
Braintumoursmaycausevisualdeficitsorcranial
Bussanich NM,Dolman PJ,RootmanJand Dolman CL（1987)Canine
uvealmelanomas:seriesandliteraturereview.Journalof the
nerve abnormalities,dependingontheirlocation.
AmericanAnimalHospitalAssociation23,415-422
Braintumoursmayalsobeassociatedwith
BussieresMKrohne SG,StilesJandTownsendWM(2005）Theuseof
swellingof theopticnervehead(papilloedema),
dogs.Journalof theAmericanAnimalHospitalAssociation41
duetoraisedintracranialpressure（Figure22.28).
227-234
Uveitismaybeseeninavarietyofsystemic
CantaloubeB,Raymond-Letron|andRegnierA(2004)Multipleeyelid
tumours,inparticularlymphoma.
intwoPersiancats.Veterinary
Ophthalmology7,121-125
Feline leukaemiavirus(FeLV)maycause
Cassotis NJ. Dubielzig RR,Gilger BC and Davidson MG （1999)
abnormalitiesinpupil shape(D-shapedpupil)
Angioinvasivepulmonary carcinomawithposterior segment
metastasisinfourcatsVeterinaryOphthalmology2125-131
duetoinfiltrationoftumourcellsintothe
ChaitmanJ,van derWoerdtAandBartickTE（1999)Multiple eyelid
oculomotornerveoriris.FeLVinfectionmayalso
cystsresemblingapocrinehidrocystomasinthreePersiancatsand
beassociatedwithnystagmus,intraretinal
haemorrhageandanterioruveitis(Brightmanet
behaviour and histological characteristics of canine conjunctival
al.,1986).
melanoma.
Progress
Veterinary
andComparative
Incats,theeyeappearstobeapreferentialsite
Ophthalmology3,135-139
CollinsLLandCollinsBK(1994)Excisionandcryosurgicalablationof
formetastasisofprimarylungcarcinoma,ina
severeperiocularpapillomatosisinadog.JournaloftheAmerican
similarwaythatmetastasistothedigitshasbeen
VeterinaryMedicalAss0ciation204,881-885
documented insuchtumours.Tumourcellsmay
CookCSandWilkie DA(1999)Treatment ofpresumedirismelanoma in
dogsbydiodelaserphotocoagulation.VeterinaryOphthalmology2.
blockend-stagebloodvesselswithinthechoroid,
217-225
leadingtoanischaemicchorioretinopathy.The
CookCS,RosenkrantzWandPeifferRL(1995)Malignantmelanomaof
theconjunctivainacat.Journalof theAmericanVeterinaryMedical
resultantchorioretinalnecrosisgivesa
Association186,505-506
characteristicophthalmoscopicappearanceof
DayMJand LuckeVM(1995)Melanocyticneoplasia inthecat.Journal
areasoftandiscolorationinthetapetalfundus
ofSmallAnimalPractice36,207-213
Dennis R(20oo)Use of magnetic resonance imaging for the
(Cassotis et al.,1999).The tumourcellsinfiltrate
investigationoforbitaldiseaseinsmallanimals.JournalofSmall
notonlythebloodvesselsbutalsoallintraocular
AnimalPractice41,145-155
surfaces,yetinterestinglytheydonotform
Dobson JM and Scase TJ (2007) Advances in the diagnosis and
managementofcutaneousmastcelltumours indogs.Journalof
discretemassesinanyof thesesites(Mouldand
SmallAnimalPractice48,424-431
Billson,2002).
Dubielzig RR,Everitt J,Shadduck JA et al.（1990) Clinical and
morphological featuresofpost traumaticocular sarcomas incats.
VeterinaryPathology27,62-65
DubielzigRR,Steinberg H,GarvinH,DeehrAJandFischerB（1998）
Iridociliary epithelialtumoursin 100 dogs and17cats:a
morphologicalstudy.VeterinaryOphthalmology1,223-231
Fife MM, Blocker T,Dubielzig RR,Fife T and Dunn K (2007)
Retrospective evaluationof canine conjunctival mastcelltumours.
ACVO2007AbstractsVeterinaryOphthalmology10398
centimeterlateralsurgicalmarginforexcisionof gradeIandgrade
I cutaneousmastcelltumoursindogs.Journal of theAmerican
VeterinaryMedicalAssociation228,210-215
GelattKNandGelattJP(2003)Surgeryof the eyelids.In:SmallAnimal
74-124.ButterworthHeinemann,Edinburgh
GilgerBC,BentleyEandOllivierFJ(2007)Diseasesandsurgeryof the
caninecorneaandsclera.In:VeterinaryOphthalmology，4thedn，
ed.KNGelattpp.690752.BlackwellPublishing,Ameslowa
GilgerBC,McLaughlin SA,Whitley RDand WrightJC（1992)Orbital
neoplasmsincats:21cases(1974-1990).Journalof theAmerican
VeterinaryMedicalAssociation20110831086
Giuliano EA,ChappellR,Fischer B and Dubielzig RR （1999)A
matchedobservational
studyofcaninesurvivalwithprimary
Papilloedema inassociationwithanintracranial
22.28
intraocular melanocyticneoplasia.VeterinaryOphthalmology2.
massina12-year-oldWestHighlandWhite
185-190
Terrier.
Glaze MB and GelattKN(1999)Feline ophthalmology.In:Textbook of
VeterinaryOphthalmology,3rdedn,ed.KNGelatt,pp.997-1052.
WilliamandWikinhilad
Referencesandfurtherreading
GrahnBH,PeifferRL,Cullen CLandHainesDM(2006)Classification
offelineintraocularneoplasmsbasedonmorphology.
Attali-SoussayK,Jegou JPandClerc B(2001)Retrobulbar tumors in
histochemicalstaining.andimmunohistochemicallabeling.
dogsandcats:25cases.VeterinaryOphthalmology4,19-27
VeterinaryOphthalmology9,395-403
Betton A,Healy LN,English RVand Bunch SE（1999)Atypical limbal
HardmanCandStanleyR(2001) Radioactivegold-198seedsforthe
melanomainacat.JournalofVeterinaryInternalMedicine13,
treatmentof squamouscellcarcinoma in the eyelidofacat.
379-381
AustralianVetrinaryJourna7960408
Billson M,Miler-Michau T,Mould JRBand Davidson MG (2006)
HeadrickJF,BentleyEand Dubielzig RR(2004）Canine lobularorbital
Idiopathicsclerosingpseudotumour in seven cats.Veterinary
adenoma:areportof15caseswithdistinctivefeatures.Veterinary
Ophthalmology9,45-51
Ophthalmology7,47-51
Boroffka SAED,Verbruggen A-M,Grinwis GCM,Voorhout G and
HendrixDVH(1999)Diseases and surgery of the canine conjunctiva.In:
Barthez PY(2007)Assessment ofultrasonography and computed
TextbookfVetrinaryOphthalmology3rdednedNGelattp
619-634.WilliamsandWilkinsPhiladelphia
352
Chapter22
Oculartumours
Hendrix DVH(2007)Diseases and surgery of the canine anterioruvea.
Payen G,Estrada M,Clerc B and Chahory S (2008)A case of
In:TextbookofVeterinaryOphthalmology4thedn,ed.KNGelatt，
conjunctivalmelanoma ina cat.VeterinaryOphthalmology 11.
pp.812-858.BlackwellPublishing.Ames,lowa
401-405
HendrixDVHandGelattKN(200o)Diagnosis,treatmentandoutcome
Peiffer RL,Wilcock BP,Dubielzig RR,Render JA and Whiteley HE
oforbitalneoplasia indogs:aretrospective studyof44 cases.
(1999)Fundamentals of veterinary ophthalmicpathology.
In：
JournalofSmallAnimalPractice41,105-108
TextbookofVeterinaryOphthalmology.3rdednedKNGelattp
JohnsonBW,BrightmanAHandWhiteleyHE（1988)Conjunctival mast
355-425.Williams andWilkins,Philadelphia
cell tumourintwodogs.Journalof theAmericanAnimalHospital
Petersen-Jones SM(2002) The eyelids and nictitating membrane.In:
Association37.557-562
BSAVA ManualofSmallAnimal Ophthalmology2ndedn，ed.S
Kalishman JB,ChappellR,Flood LA and Dubielzig RR（1998）A
Petersen-Jones and S Crispin,pp 78-104.BSAVA Publications,
matchedobservationalstudyofsurvivalincatswithenucleation
duetodiffuseirismelanoma.VeterinaryOphthalmology12529
Gloucester
KernTJ(1985)Orbital neoplasia in23dogs.Journalof theAmerican
Petersen-JonesSM,ForcierJandMentzerAL(2007)Ocularmelanosis
VeterinaryMedicalAssociation186,489-491
in theCairnTerrier:clinicaldescriptionandinvestigationofmodeof
inheritance.VeterinaryOphthalmology10（Supplement1）,63-69
KlostermanE,Coliz
CMH,
ChandlerHLet
al.(2006)
Petersen-Jones SM.Mentzer AL,Dubielzig RR et al. (2008)Ocular
Immunohistochemical
properties
of
ocular
adenomas,
adenocarcinomas
medulloepitheliomas.
Veterinary
melanosisin theCairnTerrier:histopathological descriptionof the
and
Ophthalmology9,387-394
condition,andimmunohistological
and
ultrastructural
Kneissl S,Konar M.Fuchs-Baumgartinger A and Nell B (2007)
characterizationofthecharacteristic
pigment-laden cells.
Magneticresonanceimagingfeaturesoforbitalinflammationwith
VeterinaryOphthalmology11260-268
intracranialextensioninfourdogs.VeterinaryRadiologyand
RamseyDTandFoxDB(1997)Surgery of the orbit.Veterinary Clinics
Ultrasound48,403-408
ofNorthAmerica,SmallAnimal Practice27,1215-1264
Krohne SG,Henderson NM,Richardson RCand Vestre WA（1994)
Roberts SM,Severin GA and Lavach JD （1986)Prevalence and
Prevalenceofocularinvolvementindogswithmulticentric
lymphoma:prospective evaluationof94cases.Veterinary and
1983).Journalof theAmericanVeterinaryMedicalAssociation189,
ComparativeOphthalmology4.127-135
1355-1359
Larocca RD (20oo)Eosinophilic conjunctivitis,herpesvirus andmast
Schobert CSand Dubielzig RR(2008)Feline conjunctival melanoma:
celltumorof thethirdeyelidinacat.VeterinaryOphthalmology3
histopathologicalcharacteristics and clinicaloutcomes.ACvO2008
221-225
Abstracts.VeterinaryOphthalmology11415
Mason DR,Lamb CR and McLellan GJ (2001)Ultrasonographic
StadesFCand Gelatt KN(2007)Diseases and surgeryof the canine
findingsin50dogswithretrobulbardisease.Journalof the
eyelid.In:VeterinaryOphthalmology4thedn,ed.KNGelattpp.
AmericanAnimal HospitalAssociation37.557-562
563-317.BlackwellPublishing,Ames,lowa
Mauldin EA.Deehr AJ.HertzkeDand Dubielzig RR(2000)Canine
Stanclift RM and Gilson SD(2008)Evaluation of neoadjuvant
orbitalmeningiomas:areviewof22cases.Veterinary
prednisoloneadministration and surgical excision in treatment of
Ophthalmology3,11-16
caninemastcell tumours.Journalof theAmericanVeterinary
McLaughlinSAWhitlyRD,GilgerBC,WrightJCandLindleyDM
MedicalAssociation232,53-62
(1993)Eyelid neoplasmsincats:areview of demographic data.
StellAJ,DobsonJMandLangmackK(2001)Photodynamic therapy of
Journalof theAmericanAnimalHospitalAssociation29,63-67
feline squamous cellcarcinoma using topical 5-aminolaevulinic
Proceedings,45thAnnualCongress,
acid.Journal ofSmallAnimalPractice42,164-169
BSAVAScientific
StilesJandTownsendWM(2007)Felineophthalmology.In:Veterinary
Birmingham,p.614
Naranjo C,Dubielzig R and Friedrichs KR (2007) Canine ocular
Ophthalmology4thedn,ed.KNGelatt,pp.1095-1164.Blackwell
PublishingAmeslowa
histiocyticsarcoma.VeterinaryOphthalmology10,178-185
NaranjoC.Schobert CandDubielzigR(2008）Canineoculargliomas:
Sullian TC.Nasisse MP, Davidson MG and Glover TL （1996)
aretrospectivestudyVeterinaryOphthalmology1135632
Photocoagulationoflimbal melanoma in dogsandcats:15cases
Narfstrom Kand Petersen-Jones S(2007)Diseases of the canine
（1989-1993).Journalof theAmericanVeterinaryMedical
ocularfundus.In:Veterinary Ophthalmology.4th edn，ed.KN
Association208,891-894
WilcockBP（1993）Theeyeandear.ln:PathologyofDomesticAnimals
Gelatt,pp.944-1025.BlackwellPublishing,Ames,lowa
OBrienMG,WithrowSJ,StrawRC,PosersBEandKirpensteinK
4thedn,ed.KVFJubb etal.pp.441-529.AcademicPress,San
(1996)Totalandpartialorbitectomyforthe treatmentofperiorbital
WilcockBPand PeifferR(1988)Adenocarcinoma of the glandof the
Diego
tumoursin24dogsand6cats:aretrospective study.Veterinary
Surgery25,471-479
thirdeyelidinsevendogs.Journalof theAmericanVeterinary
OllivierFJ,PlummerCEandBareKP(2007）Ophthalmicexamination
MedicalAssociation193,1549-1550
and diagnostics.Part 1:The eye examination and diagnostic
Wilcock BP,Yager JA and ZinkMC（1986)The morphology and
procedures.In:TextbookofVeterinaryOphthalmology.4thedn，ed.
behaviouroffelinecutaneousmastocytomas.VeterinaryPathology
KNGelatt,pp.812-858.BlackwellPublishingAmeslowa
23,320-324
PatnaikAKand MooneyS（1988)Feline melanoma:a comparative
WilliamsLW,GelattKNandGwinRM(1981)Ophthalmicneoplasmsin
studyfcularralanddemaneoplasms.VetrinaryPathlogy
thecat.JournaloftheAmericanAnimalHospitalAssociation17,
25,105-112
999-1008
353
Pagenumbersinitalicsrefertofigures
Amelanoticmelanoma,immunohistochemistry17
Ameloblastoma,surgicalmargins 48
Amitriptyline,pain control
Acanthocytes305
in cats 119,126
Acanthomatousepulis
in dogs118
indogs193
Anaemia34
radiotherapy85
Analsacgland tumours
Acrochordon138
breedpredispositions223
Acromegaly,incats315-16
chemotherapy227
Actinickeratosis,in cats 132
cytology224
ActinomycinDseeDactinomycin
histology22
Acupuncture 127-8
imaging 225-6
Acutelymphoblasticleukaemia296,297
metastasis 227,228
Acutemyeloproliferativedisorders298
presentationand clinical signs224
Acute tumourlysissyndrome72
prognosis228
Adaptivepain113
radiotherapy86
Adenocarcinoma
staging224
analsacgland 223,224-6,227,228
surgery226-7
gastric210
tumourtypes223
intestinal213,214,219
Analgesia
laryngeal271
acupuncture 127-8
mammary240
approach 117-18,121
nasal342
drugs 118-120,121-7
ovarian255
ethical considerations 112-13
perianalgland 137,223,224,226,227
models128
prostate263
salivary gland 203,204
nutraceuticals 127
pre/postoperative55-6
thyroid312
Adenoma
(see also specific agents)
Angiomatosis138
biliary230
eyelid344
Anti-angiogenic therapy98-9
gastric209
Antibiotics
hepatocellular230
anti-tumouragents 75-6
during chemotherapy67,68
mammary22
ocular349
preoperative55
perianalgland 137,223,224,226,227
Anticonvulsants,analgesia 125
prevalence indogs3
Anti-emetics68
Adenomatous polyps,colorectal 217
Anti-metabolites74-5
Adrenalglandtumours
(seealsoindividualdrugs)
and hyperadrenocorticism317-22
Antioxidants 108
non-cortisol-secreting322
Apocrine tumours137
phaeochromocytoma 322-4
eyelid344
AgNORs 18,148
Apoptosis99
Alkylating agents 72-4
Aqueocentesis 351
(see alsoindividual drugs)
Argyrophilicnucleolarorganizerregions(AgNORs)
Alopecia
18,148
duringchemotherapy69
L-AsparginaseseeCrisantaspase
paraneoplastic37
Aspirin,pain control
Amantadine,paincontrol 124
in cats119
in cats119
indogs118
in dogs118
Azathioprine,inmultifocal skin disease,dogs 155
354
Index
Basal cellcarcinoma
Carcinoma
oral,surgicalmargins 48
analsacgland22
skin 132,134
biiary230
Benignfibroushistiocytoma 140-1
colorectal217
Bileduct tumours
gastric209
andpain112
hepatocellular 230,232
prognosis 234
immunohistochemistry17
tumourtypes230
mammary238
(seealsospecifictumours)
salivarygland,radiotherapy86
Biopsy
thyroid
bone163
incats310
bonemarrow10
in dogs 311,312
colorectal219
radiotherapy86
liver232
ureter250
nasal cavity269
Cardiomyopathy,during chemotherapy70-1
nasalplanum265
Carmustine,drug profile 74
ocular351
Carprofen,pain control
oesophagus 207
in cats120
oral194
in dogs119
ovary256
CCNUseeLomustine
penis261
CD3,as tumourmarker 16,17
preoperative46
CD18,astumourmarker 16,17
principles 46-8
CD79a,astumourmarker 16,17
prostate263
CD117seeKIT
Cetuximab
skin 130-1
small intestine213
infelinesquamouscellcarcinoma95-6
Chemotherapy
soft tissue sarcomas180
administration 65-6
spleen305
alkylating agents 72-4
surgical techniques 10-12
antibiotics 75-6
thymus281
anti-metabolites74-5
urethra254
dosing 61-2
Bisphosphonates,inpaincontrol 126-7
indications60
BladderseeUrinarybladder
mechanism of action72
Bodyconditionscoring106
nursing care65
Bone
owner/patientfactors60
biopsy 163
pharmacogenetics78
cysts159
preparationandsafehandling63-5
tumours 159-60
resistance 62-3
pain112
singleversusmultipleagents61
(seealsospecifictumours)
targetedtherapy78-9
Bonemarrow
terminology61
sampling 9-10
toxicity 66-72
suppressionbychemotherapy67-8
tyrosinekinase inhibitors78-9
inTNM staging 28,29
(seealsoindividualdrugsandtumours)
Brachytherapy88
Chestwalltumours277-8
Buprenorphine，pain control in cats 119
Chlorambucil
Busulfan,drug profile 73
drug profile73
Butorphanol
inleukaemia297
as anti-emetic68
inmastcelltumours147
paincontrol
inmultiplemyeloma301
in cats120
Chlorpromazine,asanti-emetic 68
in dogs 118
Chondrosarcoma
chestwall277
in dogs 159,173
Cachexia 38,103-4
tracheal,cat 272
CancerseeNeoplasia,Tumourandspecifictumours
CHOPprotocols
Caninecutaneoushistiocytoma 140
forcats293
Caninenodulardermatofibrosis138
for dogs288-9
Carbohydratemetabolismincancerpatients107
Choroid plexustumours,indogs333
Carboplatin
Chroniclymphocyticleukaemia296,297
inanalsacadenocarcinoma227
Chronicmyeloproliferativedisorders298
drugprofile77
Ciclosporin,inmultifocal skin disease,dogs 155
inosteosarcoma,dogs 169,170
Circumanalgland tumour223
Carcinoids,hepatic 230
(seealsoPerianalglandtumours)
355
Index
Cisplatin
Deracoxib,paincontrolindogs119
inanalsacadenocarcinoma227
Dermatitis,paraneoplastic37
drug profile76
Dermatofibroma 138
inosteosarcoma,dogs 169,170
Dermoid cyst131
resistance 63
Desmin,astumourmarker 16
toxicity 62,68,71,72
Disseminatedhistiocyticsarcoma156-7
c-kit mutations 93,94
Disseminated intravascularcoagulation(DiC),
Clinicalstaging
paraneoplastic35-6
procedures29
Dolasetron,as anti-emetic68
TNM classification 23-7,29
tumourbiology/behaviour20-1
Doxorubicin
inanalsacadenocarcinoma227
(seealsospecifictumours)
Coagulationdisorders,paraneoplastic35-6
drug profile75-6
inlymphoma 289,290,293
Codeine,paincontrol indogs 119
Collagenoushamartomas138
inmultiplemyeloma301
Colorectal tumours
inosteosarcoma,dogs 170,171
aetiologyanddevelopment216
resistance 63
biopsy219
insplenichaemangioma/haemiangiosarcoma,
chemotherapy220-1
dogs306
clinicalapproach 218-19
toxicity 69,70,71
epithelial tumours 217,221
Dysplasia1
imaging218-19
mesenchymaltumours217-18,221
presentationandclinicalsigns218
Endocrinetumours309
prognosis221
(seealsospecificglandsand tumours)
prophylactic surgery46
Endoscopy
roundcelltumours218,221
biopsy12
surgery219-20
gastrictumours210
(seealsospecifictumours)
oesophageal tumours207
Colostomy221
Eosinophilic granuloma,incats 194
Computed tomography(CT),inTNMstaging 27,29
Epidermalgrowthfactorreceptor(EGFR)
(seealsospecifictumours)
Conjunctival tumours346-7
antibodies 95-6
inhibition,andradiotherapy88
COPprotocol290
Crisantaspase
Epirubicin
inanalsacadenocarcinoma227
drugprofile78
inlymphoma293
drug profile76
toxicity70
insplenichaemangioma/haemiangiosarcoma,
Cyclophosphamide
dogs306
inanal sacadenocarcinoma227
Epitheliotrophiclymphoma 152,153,154
drug profile72-3
Epulides,in dogs 191,193,199
in lymphoma 289,290,293
Erythrocytosis,paraneoplastic34
inmastcell tumours 147
Ethicalconsiderations 40-3
inmultiplemyeloma 300,301
Etodolac,pain control
toxicity 69,71
incats120
Cystitisduringchemotherapy71
indogs119
Cysts
Etoposide,resistance 63
bone159
Euthanasia 40,41
dermoid131
ExcisionseeSurgery
follicular134
Exophthalmos342
Cytarabine
Eyelidtumours
drug profile75
presentation and clinical signs343-4
resistance63
prognosis345
Cytokeratin,as tumour marker 16,17
Cytology
surgery345
cancer diagnosis6-7
specimen submission 10
techniques 7-9
Fattyacidrequirementsincancerpatients107
(seealsospecifictumours)
Feedingplansforcancerpatients108
CytosinearabinosideseeCytarabine
Feeding tubes 108-9,197
Cytospin preparations9
Feline sarcoid 138
Fentanyl,pain control
in cats 120,124
Dacarbazine,drug profile74
in dogs 119,123-4
Dactinomycin
Fibroadnexalhamartoma134
inanal sacadenocarcinoma227
Fibroma,skin 138
drugprofile76
Fibromatous epulides,in dogs 193
356
Index
Fibrosarcoma 181
Haemangioma
bone 159,174
skin138
immunohistochemistry17
Haemangiopericytoma181
oral
skin 139,140
in dogs193
Haemangiosarcoma
presentation 91
atrial,dog 279
prognosis199
bone 159,173-4
radiotherapy86
penile261
skin 138,139,151
skin 138,151,183-4
Filgrastim,during chemotherapy 67
spleen,metastasisindogs 4
Fine-needle aspiration,technique 8-9
Haemophagocytichistiocyticsarcoma 156-7
Firocoxib,pain control
Hamartomas 131
incats 120
Hearttumours
indogs119
clinicalapproach/signs278-9
Flunixinmeglumine,pain control incats 120
imaging279
5-Fluorouracil
prognosis280
inanalsacadenocarcinoma227
surgery279-80
drugprofile75
Heat shockproteins99
resistance 63
Helicobacterpylori,and stomachtumours209
toxicity72
Hepatic tumours
Follicular cyst 134
bile duct tumours230
Follicularhamartoma134
biopsy 232-3
Food aversion 109
chemotherapy234
Furosemide,inCHOPprotocol 289
clinicalapproach231-3
hepatocellular229-30
imaging231-2
Gabapentin,pain control 125
mesenchymal 230
incats120
neuroendocrine 230
indogs119
presentation andclinical signs231
Gastrictumours
prognosis 234
aetiology209
surgery233-4
breedpredispositions209
Hepatobiliary cystadenoma 230
chemotherapy211
Hepatocellularadenoma230
diagnosis210
Hepatocellularcarcinoma 230,232,234
presentationand clinical signs210
Hepatocyte growth factor(HGF)96
prognosis211
“Histiocytic'mastcelltumours150
radiotherapy211
Histiocytic sarcoma 141,184
staging211
disseminated 156-7
surgery211
haemophagocytic 156-7
types209
immunohistochemistry17
(seealsospecifictumours)
intracranial333
Gastrinoma,indogs 326
splenic307
Gastrointestinal stromal tumours(GISTs)182
Histiocytoma 140
colorectal218
multifocal 151
gastric209
prevalence,in dogs3
Gastrointestinal system
Histiocytosis
toxicityduringchemotherapy68-9
cutaneous155
tumours,pain 112
malignant 156-7
(seealsospecificorgansandtumours)
systemic 156
Gastrointestinal ulceration36
Histology
Gemcitabine, drug profile75
cancer diagnosis7
Glialfibrillaryacidicprotein(GFAP),，astumour
sample submission 12-14
marker16
Histone deacetylase98
Glioma
Hodgkin’s-like lymphoma,in cats294-5
in dogs333
Hospice care 41
ocular348
Hydroxycarbamide
Glucagonoma 326-7
drugprofile77
Glucosamine/chondroitinsulphate,paincontrol
inmyeloproliferativedisorders298
incats120
HydroxyureaseeHydroxycarbamide
in dogs119
Hyperadrenocorticism
Glucosemetabolismof tumourcells102
incats321-2
Grabbiopsy 12
indogs317-21
Grading,andtumourmarkers
18
asparaneoplasticsyndrome33
(see also specifictumours)
Hyperalgesia 115
357
Index
Hypercalcaemia30-3
Largegranularlymphoma,incats295
inanalsacadenocarcinoma228
Laryngeal tumours
inhyperparathyroidismindogs313-14
clinical approach271-2
Hyperparathyroidism,indogs313
prognosis 272-3
Hyperplasia1
radiotherapy272
Hyperproteinaemia36
staging272
Hypersensitivityreactions,duringchemotherapy70
surgery272
Hyperthyroidism
Leiomyoma
incats 309-11
colorectal217-18,219
in dogs 311-13
gastric209
Hypertrophicosteopathy38
oesophageal 207,208
Hypocalcaemia,postoperative314-15
skin 139
Hypoglycaemia 33
andhepatictumours231
uterine257
and insulinoma,indogs 3245
vagina258
Hypothyroidism
Leiomyosarcoma 182
skin 139
incats311
Lentiges 141
in dogs 311,312
Leucocytosis,paraneoplastic 34
Leukaemia
Ifosfamide
lymphocytic 296-7
drugprofile73
non-lymphoid 298
toxicity71
Lidocainepatches 126
Imatinib,infelinemastcelltumours93-4
Lipidmetabolismof tumourcells103
Immune-mediatedhaemolyticanaemia34
Lipoma 182
Immunohistochemistry
infiltrative 182-3
technique 16
radiotherapy85
tumourmarkers 16-18
prevalence,in dogs 3,178
Immunotherapy5,96-7
skin 139,151
(seealsospecifictumours)
Liposarcoma 183
Impression smears8
skin 139
Infundibularkeratinizingacanthoma135,151
LiverseeHepatictumours
Injectionsitesarcoma,incats
Lobaplatin,inosteosarcoma,dogs 170,171
clinical signs 179-80
Lomustine(CCNU)
histological types 184-5
drug profile73-4
prophylacticsurgery46
inmastcelltumours146-7
radiotherapy87,189
Lung tumours
Insulinoma,in dogs
bronchoscopy275
clinical approach 324-5
incats276
treatment325-6
chemotherapy276
IntestineseeColorectal tumours,Smallintestinal
cytology275
tumours
imaging273-5
Intracranialtumours
metastatic 27,240,274
chemotherapy332
pain112
clinical approach330-1
CSF analysis331
presentation and clinical signs273
prognosis276
imaging330-1
thoracoscopy275
palliativecare332
surgery 275-6
presentationandclinical signs330
Lung-digit syndrome 157
prognosis 334-5
Lymph nodes
radiotherapy86,332
surgery332
clinicalassessment25-6
tumourtypesandpathogenesis329-330
inoral tumours194
lodine-131,radiotherapy88,311
removal52
Iridociliaryepithelial tumours348,349
Lymphangioma/lymphangiomatosis,skin138
Lymphangiosarcoma 184
Lymphoma
Ketoprofen,pain controlin cats 120
incats
Ki67
aetiology291-2
andprognosisinmastcelltumours148
chemotherapy 293-4
in tumourgrading18
classification292-3
Kidney seeRenal tumours
clinical approach 293
KIT
conjunctival 346
targetedtherapy92-4
Hodgkin's-like 294-5
astumourmarker 16,91
largegranular295
(seealsoTyrosinekinaseinhibitors)
nasal270
358
Index
prognosis294
eyelid344
radiotherapy294
visceral308
small-cellalimentary tract295
cytology7
tracheal271
indogs
cutaneous 152-5
aetiology andpathogenesis142
in dogs
breedpredilections 142
aetiology285
chemotherapy 92-4,146-7
chemotherapy288-90
clinicalapproach/signs 143-5
classification 285-7
grading142
clinical approach287-8
multiple149
cutaneous286
prevalence3
cytology287,331
prognosticfactors 147-9
mediastinal286
radiotherapy146
ocular350
staging 148
presentationand clinical signs287
surgery 145
prevalence3
margins 149
prognosis 289,291
histology7
staging287-8
ocular347
gastric 209,211
radiotherapy84-5
immunohistochemistry17
surgery45
intracranial333
margins 48,49,50
Mac387,as tumourmarker 16
MelanA,astumourmarker 16,17
Macroadenoma,pituitary25
Melanocytictumours141-2
radiotherapy86,87
Magneticresonance imaging,inTNM staging 25,29
Melanoma
cutaneous 141-2
Maladaptivepain 113-15
Malignancy
ocular346,347,348-9
oral
features21
malignant,metastasisindogs4
mechanisms 21-3,91
Malignant fibroushistiocytoma(MFH)184
radiotherapy85
vaccine97
Malignantmelanoma,oral,dogs 191,192-3,199
Meloxicam,pain control
Mammaliantargetofrapamycin(mTOR)91,98
Mammarygland tumours
incats120
in dogs119
incats
Melphalan
chemotherapy246
inanalsacadenocarcinoma227
hyperplasias 244
presentation and clinical signs243-4
drugprofile73
staging 244-5
inmultiplemyeloma300
Meningioma
surgery245-6
in dogs
in cats 332-3
chemotherapy242
in dogs332
cytology240
radiotherapy86
genetics243
Mesothelioma282-3
hormonal therapy242
c-Met mutations96
Metastases
immunohistochemistry239
metastasis 240-1
inbone241
prevalence3
clinicalassessment26-7
progesteronereceptors46
indigits157
prognosticfactors238
inlung 27,173,240,274
prophylacticneutering45-6
mechanism 22,23
radiotherapy242
in skin 157-8
tumourtypes237-8
in spinalcord 338
staging239
surgery55
surgery241-2
(seealsospecificprimarytumours)
histology 7, 22
Methotrexate
pain112
drug profile74-5
Mandibular salivarygland tumour202
resistance 63
MarginsseeSurgery
Methylprednisolone,ineosinophilicgranuloma194
Maropitant,asanti-emetic 68,69
Metoclopramide,asanti-emetic68
in caninemastcelltumours 93-4
Metyrapone,nhyperadrenocortism,cats322
Masitinib,in caninemast cell tumours 93-4
Microangiopathichaemolyticanaemia34
Mast cell tumours
Mithramycin,inanal sacadenocarcinoma227
incats149-50
Mitotane,inhyperadrenocortism,dogs 319-20,321
chemotherapy94
Mitoticindex148
359
Index
Mitoxantrone
pain112
inanalsacadenocarcinoma227
peripheral nerves338-40
drugprofile76
spinalcord 335-8
Morphine，pain control
(see alsospecifictumours)
incats120
Neurotoxicity,during chemotherapy71-2
indogs119
Neutering,tumourprophylaxis45-6
MRI seeMagneticresonanceimaging
Neutropenia,in chemotherapy 67-8
Mucositisinradiotherapy83-4
NMDA antagonists,analgesia 124
Multifocal neoplasticskindisease
Nodulardermatofibrosis36-7
cutaneouslymphoma 152-5
Nodularfasciitis 138
differential diagnosis 150-2
Nodulargranulomatousepisclerokeratitis346
felineprogressivedendriticcellhistiocytosis157
Non-steroidalanti-inflammatory drugs(NSAIDs),
lung-digit syndrome 157
analgesia 121-2
multifocalhistiocytic disease155-7
Nosectomy
Multilobularosteochondrosarcoma200
in cats267
in dogs 159,174
in dogs 58,267
skull331
Nutraceuticals 107-8
Multiplecartilaginousexostosis
Nutritionalassessmentofcancerpatients105-7
in cats 159,174-5
Nutritional supportforcancerpatients104-9
indogs159
postoperative,cat 197
Multiplemyeloma
chemotherapy 300-1
clinicalapproach299-300
Oculartumours
presentationandclinical signs298-9
conjunctiva/thirdeyelid/externalglobe345-8
prognosis301
eyelid343-5
Myasthenia gravis 37
intraocular348-51
Myelophthisis 34
orbit341-3
Myeloproliferative disorders295-6
(seealsospecifictumours)
(seealsoLeukaemia)
Odontogenictumours,incats193
Myxoma/myxofibroma138
Oesophagealtumours
Myxosarcoma 181
aetiology206
clinical signs/approach 206-7
endoscopy207
Naevi 131
medicalmanagement207
Nasalcavitytumours
prognosis208
biopsy269
radiography207
imaging269
surgery207-8
pain112
Oestrogenreceptorsinmammarytumours,dogs239
presentationand clinical signs268
Ondansetron,asanti-emetic68,69
prognosis 270
Opioids,analgesia 123-4
radiotherapy 85,87,270
OPLA-Pt,inosteosarcoma,dogs 170,171
supportive care in cats 270
Oraltumours
Nasal planum tumours
biopsy 194
biopsy265
in cats 193-4
cryosurgery266
chemotherapy198
imaging265
clinicalfeatures
191,192,194
photodynamictherapy266
in dogs 192-3
plesiotherapy266
imaging194
presentationandclinical signs265
immunotherapy198-9
prognosis268
metastasis 194
radiotherapy 85,87
pain112
surgery266-8
prognosis 199-200
TNM staging,cat 28
radiotherapy85-6,87,198
(see alsospecifictumours)
staging 194-5
Necrotizingsclerokeratitis346
surgery195-7
Needlecorebiopsy 11-12
(seealsospecifictumours)
Neoplasia
Orchidectomy,tumour prophylaxis 46
definition1
Ossifyingepulides,ndogs193
mechanisms 1-2
Osteocalcin,astumourmarker 17
Nephroblastoma248
Osteoma,in dogs 159
Nephrotoxicity,during chemotherapy71
Osteosarcoma
Nervesheathtumours139
in cats 159,174-5
Nervous systemtumours
indogs
intracranial 329-35
aetiology and pathology160-1
360
Index
biopsy 163
Paraneoplasticsyndromes
chemotherapy 169-71
cachexia38
clinical approach 161-4
cutaneous 36-7
cytology 162-3
endocrine 30-4
immunotherapy169
gastrointestinal 36
incidence andriskfactors160
haematological/haemostatic34-6
intranasal269
hypertrophicosteopathy38
metastasis 4,173
neuromuscular37
oral193
ocular351-2
palliative care 173
renal36
prevalence3
pyrexia38
prognosis 172
(seealsospecificconditions)
radiology162
Parathyroidgland tumours
radiotherapy171
incats315
spinal336,337
indogs
staging 163-4
clinical approach313-14
surgery 164-9
treatment314-15
immunohistochemistry17
Parathyroid hormone-relatedprotein(PTHrp)assay 31
pain controlmodel 128
Parotidsalivaryglandadenocarcinoma203,204
radiotherapy85
Pathologyreport 15
surgicalmargins48
PCNA(proliferatingcellnuclearantigen)18
Pemphigus,paraneoplastic,indogs 37
Ovarian tumours255-6
Ovariectomy/ovariohysterectomy,
Peniletumours
clinical approach/signs 260-1
tumourprophylaxis45-6
management261
prognosis262
Paclitaxel
Perianal gland tumours
chemotherapy227
drug profile77
clinicalapproach224-6
resistance63
Pain
metastasis 226,227
assessment 115-17
multifocal 151
presentation and clinical signs 136-7,223-4
incidence 111-12
prognosis228
management
radiotherapy227
acupuncture 127-8
surgery226-7
‘analgesic ladder117-18
Peripheralnerve tumours
analgesics used incats119-120
clinical approach339
analgesics used in dogs118-119
management andprognosis340
anticonvulsants 125
tumourtypes338
bisphosphonates 126-7
Peripheralnervesheathtumours181
combination analgesics 124
brachialplexus339
multimodalapproach118
Peripheral neuropathy,paraneoplastic37
NMDA antagonists 124
Peripheralodontogenicfibroma,surgical margins48
NSAIDs 121-3
Phaeochromocytoma,in dogs322-4
nutraceuticals 127
Photodynamictherapy98
opioids 123-4
(seealsospecifictumours)
sodiumchannel blockade126
Pilomatrixoma 135
steroids 126
Pinch biopsy 12
tricyclicantidepressants 125-6
Piroxicam
(seealsospecificanalgesics)
drugprofile77
andstress113
paincontrol
types 113-15
in cats120
Palliative care 40
indogs119
(seealsospecifictumours)
Pituitarygland tumours315-16,334
Pamidronate,paincontrol in dogs 119
MRI25,334
Pancreatictumours
radiotherapy 86,87
clinicalapproach/signs235-6
Plasmacelltumours 141,151,298-302
endocrine 324-7
(seealsospecifictumours)
managementandprognosis236
Plasmacytoma301-2
ultrasonography 235-6
spinal338
(seealsospecifictumours)
Platelet-derivedgrowthfactorreceptor-beta
Pancytopenia,paraneoplastic35
(PDGFR-β),inhibition 94-5
Papilloedema,dog 342,352
Plesiotherapy 88-9
Paracetamol,paincontrol in dogs 118,123
Pleural fluid,cytospin9
361
Index
Polycythaemia,paraneoplastic34
S100,as tumourmarker 16,17
Polyps,colorectal 217
Salivarygland tumours
Polysulphatedglycosaminoglycans,paincontrol
clinical approach203
incats120
presentationandclinicalsigns202
in dogs119
prognosis204
Prednisolone/prednisone
radiotherapy85,87
drug profile77-8
surgery203-4
ineosinophilicgranuloma194
Samarium-153,radiotherapy88
in lymphoma 289,290,293
inosteosarcoma,dogs 171
inmastcell tumours146-7
Samarium-153-lexidronam,analgesia127
inmultifocal skin disease,dogs 155
Sarcomas
inmultiplemyeloma300,301
incats 184-5(seealsoInjectionsitesarcoma)
paincontrol
immunohistochemistry17
incats120
ocular348
indogs119
Progesteronereceptors,inmammarytumours,dogs
splenic307
surgical margins 45
239
Scintigraphy,inTNM staging27,29
Progressive dendritic cellhistiocytosis,incats 157
(seealsospecifictumours)
andprognosisinmastcelltumours148
Sebaceoustumours 135-6
Proliferatingcell nuclear antigen(PCNA),
intumourgrading18
multifocal151
Prostategland tumours262-3
Sertolicelltumour260
pain112
SIADH33-4
Sialoadenectomy203-4
(seealsospecifictumours)
Prostaticcarcinoma
Skeletal tumoursseeBonetumours
cytology7
Skintumours
radiotherapy86
biopsy130-1
Protein
clinical approach 130-1
metabolismof tumourcells102-3
epithelial131-7
requirementsincancerpatients107
mast cell tumours
Protein-losingnephropathy36
in cats 149-50
Proto-oncogenes 2
in dogs 142-9
PTHrp assay31
melanocytic 141-2
Pulmonarytoxicityduringchemotherapy72
mesenchymal 137-40
(seealsoLung tumours)
metastasis 131,157-8
Punch biopsy 11
multifocal 150-8
Pyrexia,paraneoplastic38
round cell 140-1
solitary 131
staging 131
Qualityof life42,116-17
(seealsospecifictumours)
Skull tumours334
Small intestinetumours
RadiationtherapyseeRadiotherapy
incats212
RadiographyinTNM staging 27,29
chemotherapy215
(see alsospecifictumours)
clinical approach213
Radiotherapy
coeliotomy andbiopsy213
curativeversuspalliative81
indogs212
dosedistribution/fractionation81
imaging213
dosepainting88
presentationand clinical signs212-13
equipment81-2
prognosis 215
futuredevelopments87-9
radiotherapy215
indications 80-1
surgery213-15
internal 88
Small-cellalimentarytract lymphoma,incats295
pain127
Sodiumchannel blockers,analgesia126
results 84-7
side effects 82-4,104,198
Soft tissuesarcoma
aetiology and pathogenesis178
and surgery54
(seealsospecifictumours)
biopsy180
Renal tumours
chemotherapy 187,189
clinicalsigns/approach248-9
clinical approach 180-1
managementandprognosis249
clinical signs
179-80
Rhabdomyosarcoma 181-2
grading181
skin139
histological subtypes 181-5
Robenacoxib,pain control
history 178-9
incats120
pain112
indogs119
prevalence in dogs3
362
Index
radiotherapy 85,187-8,189
of metastases55
surgery 185-7,188-9
palliative54
(seealsospecifictumourtypes)
postoperativeappearance58
Spinal cord tumours
postoperative care55-7
clinical approach336-7
preoperativeplanning/preparation44-5,55
myelography336
primary44
palliative care337
prophylactic 45-6
presentation and clinical signs335-6
reconstruction 52-3
radiotherapy85
revision45
treatment337-8
tumourtypesandpathogenesis335
technique51-2
Spindle cellsarcoma,surgicalmargins48
(seealsoBiopsy andspecifictumours)
Spirocercalupi,andoesophagealtumours206,207
Sweatgland tumours137
Splenichaemangiosarcoma/haemangioma,indogs4,
Synaptophysin,as tumourmarker 16
306-7
Synovialcell sarcoma182
Splenic sarcoma,in dogs 307
immunohistochemistry17
Splenictumours
incats307-8
indogs
Tepoxalin，pain control
clinicalapproach 304-5
incats120
presentation and clinicalsigns304
in dogs119
(see alsospecifictumours)
Testicular tumours
Squamouscellcarcinoma
management260
clinicalapproach/management134
presentationandclinicalsigns259-60
immunotherapy95-6
prognosis260
multifocal151
prophylactic neutering46
nasalplanum 133
Thrombocytopenia
clinical approach 265
in chemotherapy68
cryosurgery266
paraneoplastic 34-5
photodynamic therapy266
Thrombocytosis,paraneoplastic35
Thymoma
prognosis268
chemotherapy282
radiotherapy85,87,266
clinical signs/approach280-1
surgery266-8
TNM staging,cat 28
prognosis282
radiotherapy 86,87
oral
staging281
incats193
surgery281-2
indogs193
Thyroidglandtumours
presentation91
incats
prognosis199
clinicalapproach309-10
radiotherapy 85,87
treatment310-11
presentation and clinical signs 133-4
indogs
prophylacticsurgery46
clinical approach311-12
surgical margins48
treatment312-13
Squamouspapilloma 131
TNMclassification,principles23-7
Staging see Clinical staging and specifictumours
(seealsoClinical stagingandspecifictumours)
Staphyloma346
Toceranib(SU11654)
Stereotacticradiosurgerynosteosarcoma,dogs71
in canine mastcelltumours 93-4,147
Sterilehaemorrhagiccystitisduringchemotherapy70
Tolfenamicacid,paincontrolincats 120
Stomachsee Gastric
Tongue tumours199-200
Strontium-90,radiotherapy88-9
Tracheal tumours
Superficialnecrolyticdermatitis37
clinical approach 271-2
Surgery
prognosis 272-3
closure53
radiotherapy272
cytoreductive54
staging272
diagnosis andstaging46-8
surgery272
effects onhostnutrition104
Tramadol,pain control 124-5
emergencies54-5
incats120
excision 48-54
indogs119
futuredirections 58
Transcriptional gene slicing99
indications 44-5
Transitionalcellcarcinoma
limb-sparing techniques 167-8
prostate,radiotherapy 86
lymphnodes52
urethra254
margins 45,48-51
urinarybladder251
sample submission 13-15,57-8
radiotherapy86
363
Index
Transmissiblevenerealtumour,radiotherapy86
Vaccinesforcancer96-7
Tregs(regulatoryT-cells),inimmunotherapy 97
Vaginaltumours
Trichoblastoma 135
clinicalapproach258
Trichoepithelioma 135,151
management259
Trichofolliculoma 134
presentation andclinical signs 257-8
Tricholemmoma135
prognosis 259
Tricyclicantidepressants,analgesia 125-6
prophylacticovariectomy46
Trilostane
Vascularendothelialgrowthfactorreceptor(VEGFR)
inhyperadrenocortism
inhibition94
incats322
andradiotherapy88
in dogs319
Vedaprofen,paincontrol
Tumour
incats120
biology/behaviour20-1
in dogs119
definition1
Vertebraltumours,surgery337
development 1-2
Vimentin,astumourmarker16,17
markers
Vinblastine
immunohistochemistry16-17
drug profile74
and treatment 18
inmastcelltumours146-7
metabolism 102-3
Vincristine
suppressor genes2
inanalsacadenocarcinoma227
(seealsospecifictumours)
drugprofile74
Tyrosinekinase inhibitors 5,18,78-9,92-6
extravasation69
inmastcell tumours147
in lymphoma 289,290,293
(seealso specific agents)
inmultiplemyeloma301
toxicity 69,72
Viral papilloma132
UItrasonography,inTNM staging 24,26,27,29
Viralplaque132
(seealsospecifictumours)
Vomiting duringchemotherapy68
Ureteraltumours250
Urethral tumours
clinical approach 253-4
Wisconsin-Madisonchemotherapyprotocols
prognosis 254-5
for cats293
surgery254
for dogs289
Urinarybladdertumours
Wounds
clinical approach 251-2
dehiscence 196,197
medicaltherapy253
healing,radiotherapyeffects84
presentation and clinical signs250-1
reconstruction52-3
prognosis 253
radiotherapy86
surgery252
Zollinger-Ellisonsyndrome,indogs326
ultrasonography24
Urogenital tract tumours,pain 112
(seealsospecificorgansandtumours)
Uterinetumours256-7
364